{"initialLink":"https://academic.oup.com/HTTPHandlers/Sigma/LoginHandler.ashx?error=login_required&state=997b234e-ba15-464c-af78-0244a94fea51redirecturl%3Dhttpszazjzjacademiczwoupzwcomzjjcemzjarticlezj102zj11zj3869zj4157558","sanitizedLink":"https://academic.oup.com/HTTPHandlers/Sigma/LoginHandler.ashx?error=login_required&state=997b234e-ba15-464c-af78-0244a94fea51redirecturl%3Dhttpszazjzjacademiczwoupzwcomzjjcemzjarticlezj102zj11zj3869zj4157558","finalLink":"https://academic.oup.com/jcem/article/102/11/3869/4157558","htmlEmbed":"<script>window.contexterSetup=window.contexterSetup||function(){window.contexterSetupComplete=!0;class ContexterLink extends HTMLAnchorElement{constructor(){super()}connectedCallback(){this.setAttribute(\"target\",\"_blank\")}}customElements.define(\"contexter-link\",ContexterLink,{extends:\"a\"}),customElements.define(\"contexter-inner\",class extends HTMLElement{constructor(){super()}attributeChangedCallback(name,oldValue,newValue){}connectedCallback(){this.className=\"contexter-box__inner\"}}),customElements.define(\"contexter-thumbnail\",class extends HTMLElement{constructor(){super()}attributeChangedCallback(name,oldValue,newValue){}connectedCallback(){this.className=\"contexter-box__thumbnail\"}}),customElements.define(\"contexter-byline\",class extends HTMLElement{constructor(){super()}attributeChangedCallback(name,oldValue,newValue){}connectedCallback(){this.className=\"contexter-box__byline\"}}),customElements.define(\"contexter-keywordset\",class extends HTMLElement{constructor(){super()}attributeChangedCallback(name,oldValue,newValue){}connectedCallback(){this.className=\"contexter-box__keywordset\"}}),customElements.define(\"contexter-linkset\",class extends HTMLElement{constructor(){super()}attributeChangedCallback(name,oldValue,newValue){}connectedCallback(){this.className=\"contexter-box__linkset\"}}),customElements.define(\"contexter-meta\",class extends HTMLElement{constructor(){super()}attributeChangedCallback(name,oldValue,newValue){}connectedCallback(){this.className=\"contexter-box__meta\"}}),customElements.define(\"contexter-summary\",class extends HTMLElement{constructor(){super()}attributeChangedCallback(name,oldValue,newValue){}connectedCallback(){this.className=\"p-summary entry-summary\"}}),customElements.define(\"contexter-box-head\",class extends HTMLElement{constructor(){super()}connectedCallback(){this.className=\"contexter-box__head\"}}),customElements.define(\"contexter-box-inner\",class extends HTMLElement{constructor(){super()}connectedCallback(){}});class ContexterBox extends HTMLElement{constructor(){super(),this.first=!0,this.shadow=this.attachShadow({mode:\"open\"})}connectedCallback(){if(this.first){this.first=!1;var style=document.createElement(\"style\"),lightDomStyle=(style.innerHTML=`:host {--background: #f5f6f7;--border: darkblue;--blue: #0000ee;--font-color: black;--inner-border: black;font-family: Franklin,Arial,Helvetica,sans-serif;font-size: 14px;background: var(--background);width: 600px;color: var(--font-color);min-height: 90px;display: block;padding: 8px;border: 1px solid var(--border);cursor: pointer;box-sizing: border-box;margin: 6px;contain: content;margin: 6px auto;}// can only select top-level nodes with slotted::slotted(*) {max-width: 100%;display:block;}::slotted([slot=thumbnail]) {max-width: 100%;display:block;}::slotted([slot=header]) {width: 100%;font-size: 1.25rem;font-weight: bold;display:block;margin-bottom: 6px;}::slotted([slot=author]) {max-width: 50%;font-size: 12px;display:inline-block;float: left;}::slotted([slot=time]) {max-width: 50%;font-size: 12px;display:inline-block;float: right;}::slotted([slot=summary]) {width: 100%;margin-top: 6px;padding: 10px 2px;border-top: 1px solid var(--inner-border);font-size: 15px;display:inline-block;margin-bottom: 6px;}contexter-meta {height: auto;margin-bottom: 4px;width: 100%;display: grid;position: relative;min-height: 16px;grid-template-columns: repeat(2, 1fr);}::slotted([slot=keywords]) {width: 80%;padding: 2px 4px;border-top: 1px solid var(--inner-border);font-size: 11px;display: block;float: right;font-style: italic;text-align: right;grid-column: 2/2;grid-row: 1;align-self: end;justify-self: end;}::slotted([slot=keywords]):empty {border-top: 0px solid var(--inner-border);}::slotted([slot=archive-link]) {font-size: 1em;display: inline;}::slotted([slot=archive-link])::after {content: \"|\";display: inline;color: var(--font-color);text-decoration: none;margin: 0 .5em;}::slotted([slot=read-link]) {font-size: 1em;display: inline;}contexter-linkset {width: 80%;padding: 2px 4px;font-size: 13px;float: left;font-weight: bold;grid-row: 1;grid-column: 1/2;align-self: end;justify-self: start;}/* Extra small devices (phones, 600px and down) */@media only screen and (max-width: 600px) {:host {width: 310px;}}/* Small devices (portrait tablets and large phones, 600px and up) */@media only screen and (min-width: 600px) {...}/* Medium devices (landscape tablets, 768px and up) */@media only screen and (min-width: 768px) {...}/* Large devices (laptops/desktops, 992px and up) */@media only screen and (min-width: 992px) {...}/* Extra large devices (large laptops and desktops, 1200px and up) */@media only screen and (min-width: 1200px) {...}@media (prefers-color-scheme: dark){:host {--background: #354150;--border: #1f2b37;--blue: #55b0ff;--font-color: #ffffff;--inner-border: #787a7c;background: var(--background);border: 1px solid var(--border)}}`,document.createElement(\"style\"));lightDomStyle.innerHTML=`contexter-box {contain: content;}contexter-box .read-link {font-weight: bold;}contexter-box a {color: #0000ee;}contexter-box img {width: 100%;border: 0;padding: 0;margin: 0;}/* Extra small devices (phones, 600px and down) */@media only screen and (max-width: 600px) {...}/* Small devices (portrait tablets and large phones, 600px and up) */@media only screen and (min-width: 600px) {...}/* Medium devices (landscape tablets, 768px and up) */@media only screen and (min-width: 768px) {...}/* Large devices (laptops/desktops, 992px and up) */@media only screen and (min-width: 992px) {...}/* Extra large devices (large laptops and desktops, 1200px and up) */@media only screen and (min-width: 1200px) {...}@media (prefers-color-scheme: dark){contexter-box a {color: #55b0ff;}}`,this.appendChild(lightDomStyle),this.shadow.appendChild(style);const innerContainer=document.createElement(\"contexter-box-inner\"),innerSlotThumbnail=(this.shadow.appendChild(innerContainer),document.createElement(\"slot\")),innerSlotHeader=(innerSlotThumbnail.name=\"thumbnail\",innerContainer.appendChild(innerSlotThumbnail),document.createElement(\"slot\")),innerSlotAuthor=(innerSlotHeader.name=\"header\",innerContainer.appendChild(innerSlotHeader),document.createElement(\"slot\")),innerSlotTime=(innerSlotAuthor.name=\"author\",innerContainer.appendChild(innerSlotAuthor),document.createElement(\"slot\")),innerSlotSummary=(innerSlotTime.name=\"time\",innerContainer.appendChild(innerSlotTime),document.createElement(\"slot\")),metaContainer=(innerSlotSummary.name=\"summary\",innerContainer.appendChild(innerSlotSummary),document.createElement(\"contexter-meta\")),innerSlotInfo=(innerContainer.appendChild(metaContainer),document.createElement(\"slot\")),linkContainer=(innerSlotInfo.name=\"keywords\",metaContainer.appendChild(innerSlotInfo),document.createElement(\"contexter-linkset\")),innerSlotArchiveLink=(metaContainer.appendChild(linkContainer),document.createElement(\"slot\")),innerSlotReadLink=(innerSlotArchiveLink.name=\"archive-link\",linkContainer.appendChild(innerSlotArchiveLink),document.createElement(\"slot\"));innerSlotReadLink.name=\"read-link\",linkContainer.appendChild(innerSlotReadLink),this.className=\"contexter-box\",this.onclick=e=>{if(!e.target.className.includes(\"read-link\")&&!e.target.className.includes(\"title-link\")){const mainLinks=this.querySelectorAll(\"a.main-link\");mainLinks[0].click()}}}}}customElements.define(\"contexter-box\",ContexterBox)},window.contexterSetupComplete||window.contexterSetup();</script><contexter-box class=\"link-card h-entry hentry\" itemscope=\"\" itemtype=\"https://schema.org/CreativeWork\"><contexter-thumbnail class=\"thumbnail\" slot=\"thumbnail\"><img src=\"https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/jcem/Issue/102/11/3/m_cover.jpeg?Expires=1722615010&Signature=1k7bdN9ysp1LbHC-WdBQCSB9w8IJRIodgVWnNGaQKp-lm55NjCUmXT-ebEQE8BKCj0sUH8aEsUBVOtouS8VC7sh7HG57Tbp2yIbki2yS~-gqF-1v4W3Z47djZeV7~dq0rcxoC0KNK8WANS~xjFZiksUkRE3VNS3is720fTWOzh-7TaPOTYIJAR1jIBaA6FOvhheUPLurGmssKN5Sq3FKiA2m689PMATqMf8vcthKlm6VYS5I3Be~7TQavbvcGzgTAWVqvhX1ikdnhh~ceGtNIDGAJZiLJCIaXjcSc4~HVWKslGdO6tJg71lTWN-8vZ4d~RhJV7hLXDiqXH5rw~06eA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA\" alt=\"\" itemprop=\"image\" /></contexter-thumbnail><contexter-box-head slot=\"header\" class=\"p-name entry-title\" itemprop=\"headline\"><contexter-box-head slot=\"header\" class=\"p-name entry-title\" itemprop=\"headline\"><a is=\"contexter-link\" href=\"https://academic.oup.com/jcem/article/102/11/3869/4157558\" itemprop=\"url\">Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society* Clinical Practice Guideline</a></contexter-box-head></contexter-box-head><time class=\"dt-published published\" slot=\"time\" itemprop=\"datePublished\" datetime=\"2017-09-13T00:00:00.000Z\">8/12/2017</time><contexter-summary class=\"p-summary entry-summary\" itemprop=\"abstract\" slot=\"summary\"><p>Gender affirmation is multidisciplinary treatment. Gender-dysphoric/gender-incongruent persons seek and/or are referred to endocrinologists to develop the physi</p></contexter-summary><contexter-keywordset itemprop=\"keywords\" slot=\"keywords\"></contexter-keywordset><a is=\"contexter-link\" href=\"https://academic.oup.com/jcem/article/102/11/3869/4157558\" class=\"read-link main-link\" itemprop=\"sameAs\" slot=\"read-link\">Read</a></contexter-box>","linkId":"0ae930de1ff32fbecad8dd8f081a822d6e503468","data":{"originalLink":"https://academic.oup.com/HTTPHandlers/Sigma/LoginHandler.ashx?error=login_required&state=997b234e-ba15-464c-af78-0244a94fea51redirecturl%3Dhttpszazjzjacademiczwoupzwcomzjjcemzjarticlezj102zj11zj3869zj4157558","sanitizedLink":"https://academic.oup.com/HTTPHandlers/Sigma/LoginHandler.ashx?error=login_required&state=997b234e-ba15-464c-af78-0244a94fea51redirecturl%3Dhttpszazjzjacademiczwoupzwcomzjjcemzjarticlezj102zj11zj3869zj4157558","canonical":"https://academic.oup.com/jcem/article/102/11/3869/4157558","htmlText":"\r\n\r\n\r\n<!DOCTYPE html>\r\n<html lang=\"en\" class=\"no-js\">\r\n\r\n<head>\r\n                <title>Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society* Clinical Practice Guideline | The Journal of Clinical Endocrinology & Metabolism | Oxford Academic</title>\r\n\r\n    <script src=\"https://ajax.googleapis.com/ajax/libs/jquery/2.2.4/jquery.min.js\" type=\"text/javascript\"></script>\n<script>window.jQuery || document.write('<script src=\"//oup.silverchair-cdn.com/Themes/Silver/app/js/jquery.2.2.4.min.js\" type=\"text/javascript\">\\x3C/script>')</script>\n<script src=\"//oup.silverchair-cdn.com/Themes/Silver/app/vendor/v-637926276336137318/jquery-migrate-1.4.1.min.js\" type=\"text/javascript\"></script>    <meta name=\"viewport\" content=\"width=device-width, initial-scale=1, maximum-scale=10\" />\r\n\r\n    \r\n    <meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\r\n    <meta http-equiv=\"X-UA-Compatible\" content=\"IE=Edge\" /><script type=\"text/javascript\">window.NREUM||(NREUM={});NREUM.info = {\"beacon\":\"bam.nr-data.net\",\"errorBeacon\":\"bam.nr-data.net\",\"licenseKey\":\"8d76ca6f26\",\"applicationID\":\"220513093\",\"transactionName\":\"ZQBRMkVUCEtRVkINXlxKfjB0GiltYGVXA1RxCl0SRVoKVFVHGSVDRgxQClI=\",\"queueTime\":0,\"applicationTime\":3533,\"agent\":\"\",\"atts\":\"\"}</script><script type=\"text/javascript\">(window.NREUM||(NREUM={})).init={privacy:{cookies_enabled:true},ajax:{deny_list:[\"bam.nr-data.net\"]}};(window.NREUM||(NREUM={})).loader_config={xpid:\"XAYBV15WGwECVFRTBAEOVQ==\",licenseKey:\"8d76ca6f26\",applicationID:\"220513093\"};window.NREUM||(NREUM={}),__nr_require=function(t,e,n){function r(n){if(!e[n]){var i=e[n]={exports:{}};t[n][0].call(i.exports,function(e){var i=t[n][1][e];return r(i||e)},i,i.exports)}return e[n].exports}if(\"function\"==typeof __nr_require)return __nr_require;for(var i=0;i<n.length;i++)r(n[i]);return r}({1:[function(t,e,n){function r(t){try{s.console&&console.log(t)}catch(e){}}var i,o=t(\"ee\"),a=t(27),s={};try{i=localStorage.getItem(\"__nr_flags\").split(\",\"),console&&\"function\"==typeof console.log&&(s.console=!0,i.indexOf(\"dev\")!==-1&&(s.dev=!0),i.indexOf(\"nr_dev\")!==-1&&(s.nrDev=!0))}catch(c){}s.nrDev&&o.on(\"internal-error\",function(t){r(t.stack)}),s.dev&&o.on(\"fn-err\",function(t,e,n){r(n.stack)}),s.dev&&(r(\"NR AGENT IN DEVELOPMENT MODE\"),r(\"flags: \"+a(s,function(t,e){return t}).join(\", \")))},{}],2:[function(t,e,n){function r(t,e,n,r,s){try{p?p-=1:i(s||new UncaughtException(t,e,n),!0)}catch(f){try{o(\"ierr\",[f,c.now(),!0])}catch(d){}}return\"function\"==typeof u&&u.apply(this,a(arguments))}function UncaughtException(t,e,n){this.message=t||\"Uncaught error with no additional information\",this.sourceURL=e,this.line=n}function i(t,e){var n=e?null:c.now();o(\"err\",[t,n])}var o=t(\"handle\"),a=t(28),s=t(\"ee\"),c=t(\"loader\"),f=t(\"gos\"),u=window.onerror,d=!1,l=\"nr@seenError\";if(!c.disabled){var p=0;c.features.err=!0,t(1),window.onerror=r;try{throw new Error}catch(h){\"stack\"in h&&(t(10),t(9),\"addEventListener\"in window&&t(6),c.xhrWrappable&&t(11),d=!0)}s.on(\"fn-start\",function(t,e,n){d&&(p+=1)}),s.on(\"fn-err\",function(t,e,n){d&&!n[l]&&(f(n,l,function(){return!0}),this.thrown=!0,i(n))}),s.on(\"fn-end\",function(){d&&!this.thrown&&p>0&&(p-=1)}),s.on(\"internal-error\",function(t){o(\"ierr\",[t,c.now(),!0])})}},{}],3:[function(t,e,n){var r=t(\"loader\");r.disabled||(r.features.ins=!0)},{}],4:[function(t,e,n){function r(){var t=new PerformanceObserver(function(t,e){var n=t.getEntries();s(v,[n])});try{t.observe({entryTypes:[\"resource\"]})}catch(e){}}function i(t){if(s(v,[window.performance.getEntriesByType(w)]),window.performance[\"c\"+l])try{window.performance[h](m,i,!1)}catch(t){}else try{window.performance[h](\"webkit\"+m,i,!1)}catch(t){}}function o(t){}if(window.performance&&window.performance.timing&&window.performance.getEntriesByType){var a=t(\"ee\"),s=t(\"handle\"),c=t(10),f=t(9),u=t(5),d=t(19),l=\"learResourceTimings\",p=\"addEventListener\",h=\"removeEventListener\",m=\"resourcetimingbufferfull\",v=\"bstResource\",w=\"resource\",g=\"-start\",y=\"-end\",x=\"fn\"+g,b=\"fn\"+y,E=\"bstTimer\",R=\"pushState\",S=t(\"loader\");if(!S.disabled){S.features.stn=!0,t(8),\"addEventListener\"in window&&t(6);var O=NREUM.o.EV;a.on(x,function(t,e){var n=t[0];n instanceof O&&(this.bstStart=S.now())}),a.on(b,function(t,e){var n=t[0];n instanceof O&&s(\"bst\",[n,e,this.bstStart,S.now()])}),c.on(x,function(t,e,n){this.bstStart=S.now(),this.bstType=n}),c.on(b,function(t,e){s(E,[e,this.bstStart,S.now(),this.bstType])}),f.on(x,function(){this.bstStart=S.now()}),f.on(b,function(t,e){s(E,[e,this.bstStart,S.now(),\"requestAnimationFrame\"])}),a.on(R+g,function(t){this.time=S.now(),this.startPath=location.pathname+location.hash}),a.on(R+y,function(t){s(\"bstHist\",[location.pathname+location.hash,this.startPath,this.time])}),u()?(s(v,[window.performance.getEntriesByType(\"resource\")]),r()):p in window.performance&&(window.performance[\"c\"+l]?window.performance[p](m,i,d(!1)):window.performance[p](\"webkit\"+m,i,d(!1))),document[p](\"scroll\",o,d(!1)),document[p](\"keypress\",o,d(!1)),document[p](\"click\",o,d(!1))}}},{}],5:[function(t,e,n){e.exports=function(){return\"PerformanceObserver\"in window&&\"function\"==typeof window.PerformanceObserver}},{}],6:[function(t,e,n){function r(t){for(var e=t;e&&!e.hasOwnProperty(u);)e=Object.getPrototypeOf(e);e&&i(e)}function i(t){s.inPlace(t,[u,d],\"-\",o)}function o(t,e){return t[1]}var a=t(\"ee\").get(\"events\"),s=t(\"wrap-function\")(a,!0),c=t(\"gos\"),f=XMLHttpRequest,u=\"addEventListener\",d=\"removeEventListener\";e.exports=a,\"getPrototypeOf\"in Object?(r(document),r(window),r(f.prototype)):f.prototype.hasOwnProperty(u)&&(i(window),i(f.prototype)),a.on(u+\"-start\",function(t,e){var n=t[1];if(null!==n&&(\"function\"==typeof n||\"object\"==typeof n)){var r=c(n,\"nr@wrapped\",function(){function t(){if(\"function\"==typeof n.handleEvent)return n.handleEvent.apply(n,arguments)}var e={object:t,\"function\":n}[typeof n];return e?s(e,\"fn-\",null,e.name||\"anonymous\"):n});this.wrapped=t[1]=r}}),a.on(d+\"-start\",function(t){t[1]=this.wrapped||t[1]})},{}],7:[function(t,e,n){function r(t,e,n){var r=t[e];\"function\"==typeof r&&(t[e]=function(){var t=o(arguments),e={};i.emit(n+\"before-start\",[t],e);var a;e[m]&&e[m].dt&&(a=e[m].dt);var s=r.apply(this,t);return i.emit(n+\"start\",[t,a],s),s.then(function(t){return i.emit(n+\"end\",[null,t],s),t},function(t){throw i.emit(n+\"end\",[t],s),t})})}var i=t(\"ee\").get(\"fetch\"),o=t(28),a=t(27);e.exports=i;var s=window,c=\"fetch-\",f=c+\"body-\",u=[\"arrayBuffer\",\"blob\",\"json\",\"text\",\"formData\"],d=s.Request,l=s.Response,p=s.fetch,h=\"prototype\",m=\"nr@context\";d&&l&&p&&(a(u,function(t,e){r(d[h],e,f),r(l[h],e,f)}),r(s,\"fetch\",c),i.on(c+\"end\",function(t,e){var n=this;if(e){var r=e.headers.get(\"content-length\");null!==r&&(n.rxSize=r),i.emit(c+\"done\",[null,e],n)}else i.emit(c+\"done\",[t],n)}))},{}],8:[function(t,e,n){var r=t(\"ee\").get(\"history\"),i=t(\"wrap-function\")(r);e.exports=r;var o=window.history&&window.history.constructor&&window.history.constructor.prototype,a=window.history;o&&o.pushState&&o.replaceState&&(a=o),i.inPlace(a,[\"pushState\",\"replaceState\"],\"-\")},{}],9:[function(t,e,n){var r=t(\"ee\").get(\"raf\"),i=t(\"wrap-function\")(r),o=\"equestAnimationFrame\";e.exports=r,i.inPlace(window,[\"r\"+o,\"mozR\"+o,\"webkitR\"+o,\"msR\"+o],\"raf-\"),r.on(\"raf-start\",function(t){t[0]=i(t[0],\"fn-\")})},{}],10:[function(t,e,n){function r(t,e,n){t[0]=a(t[0],\"fn-\",null,n)}function i(t,e,n){this.method=n,this.timerDuration=isNaN(t[1])?0:+t[1],t[0]=a(t[0],\"fn-\",this,n)}var o=t(\"ee\").get(\"timer\"),a=t(\"wrap-function\")(o),s=\"setTimeout\",c=\"setInterval\",f=\"clearTimeout\",u=\"-start\",d=\"-\";e.exports=o,a.inPlace(window,[s,\"setImmediate\"],s+d),a.inPlace(window,[c],c+d),a.inPlace(window,[f,\"clearImmediate\"],f+d),o.on(c+u,r),o.on(s+u,i)},{}],11:[function(t,e,n){function r(t,e){d.inPlace(e,[\"onreadystatechange\"],\"fn-\",s)}function i(){var t=this,e=u.context(t);t.readyState>3&&!e.resolved&&(e.resolved=!0,u.emit(\"xhr-resolved\",[],t)),d.inPlace(t,y,\"fn-\",s)}function o(t){x.push(t),m&&(E?E.then(a):w?w(a):(R=-R,S.data=R))}function a(){for(var t=0;t<x.length;t++)r([],x[t]);x.length&&(x=[])}function s(t,e){return e}function c(t,e){for(var n in t)e[n]=t[n];return e}t(6);var f=t(\"ee\"),u=f.get(\"xhr\"),d=t(\"wrap-function\")(u),l=t(19),p=NREUM.o,h=p.XHR,m=p.MO,v=p.PR,w=p.SI,g=\"readystatechange\",y=[\"onload\",\"onerror\",\"onabort\",\"onloadstart\",\"onloadend\",\"onprogress\",\"ontimeout\"],x=[];e.exports=u;var b=window.XMLHttpRequest=function(t){var e=new h(t);try{u.emit(\"new-xhr\",[e],e),e.addEventListener(g,i,l(!1))}catch(n){try{u.emit(\"internal-error\",[n])}catch(r){}}return e};if(c(h,b),b.prototype=h.prototype,d.inPlace(b.prototype,[\"open\",\"send\"],\"-xhr-\",s),u.on(\"send-xhr-start\",function(t,e){r(t,e),o(e)}),u.on(\"open-xhr-start\",r),m){var E=v&&v.resolve();if(!w&&!v){var R=1,S=document.createTextNode(R);new m(a).observe(S,{characterData:!0})}}else f.on(\"fn-end\",function(t){t[0]&&t[0].type===g||a()})},{}],12:[function(t,e,n){function r(t){if(!s(t))return null;var e=window.NREUM;if(!e.loader_config)return null;var n=(e.loader_config.accountID||\"\").toString()||null,r=(e.loader_config.agentID||\"\").toString()||null,f=(e.loader_config.trustKey||\"\").toString()||null;if(!n||!r)return null;var h=p.generateSpanId(),m=p.generateTraceId(),v=Date.now(),w={spanId:h,traceId:m,timestamp:v};return(t.sameOrigin||c(t)&&l())&&(w.traceContextParentHeader=i(h,m),w.traceContextStateHeader=o(h,v,n,r,f)),(t.sameOrigin&&!u()||!t.sameOrigin&&c(t)&&d())&&(w.newrelicHeader=a(h,m,v,n,r,f)),w}function i(t,e){return\"00-\"+e+\"-\"+t+\"-01\"}function o(t,e,n,r,i){var o=0,a=\"\",s=1,c=\"\",f=\"\";return i+\"@nr=\"+o+\"-\"+s+\"-\"+n+\"-\"+r+\"-\"+t+\"-\"+a+\"-\"+c+\"-\"+f+\"-\"+e}function a(t,e,n,r,i,o){var a=\"btoa\"in window&&\"function\"==typeof window.btoa;if(!a)return null;var s={v:[0,1],d:{ty:\"Browser\",ac:r,ap:i,id:t,tr:e,ti:n}};return o&&r!==o&&(s.d.tk=o),btoa(JSON.stringify(s))}function s(t){return f()&&c(t)}function c(t){var e=!1,n={};if(\"init\"in NREUM&&\"distributed_tracing\"in NREUM.init&&(n=NREUM.init.distributed_tracing),t.sameOrigin)e=!0;else if(n.allowed_origins instanceof Array)for(var r=0;r<n.allowed_origins.length;r++){var i=h(n.allowed_origins[r]);if(t.hostname===i.hostname&&t.protocol===i.protocol&&t.port===i.port){e=!0;break}}return e}function f(){return\"init\"in NREUM&&\"distributed_tracing\"in NREUM.init&&!!NREUM.init.distributed_tracing.enabled}function u(){return\"init\"in NREUM&&\"distributed_tracing\"in NREUM.init&&!!NREUM.init.distributed_tracing.exclude_newrelic_header}function d(){return\"init\"in NREUM&&\"distributed_tracing\"in NREUM.init&&NREUM.init.distributed_tracing.cors_use_newrelic_header!==!1}function l(){return\"init\"in NREUM&&\"distributed_tracing\"in NREUM.init&&!!NREUM.init.distributed_tracing.cors_use_tracecontext_headers}var p=t(24),h=t(14);e.exports={generateTracePayload:r,shouldGenerateTrace:s}},{}],13:[function(t,e,n){function r(t){var e=this.params,n=this.metrics;if(!this.ended){this.ended=!0;for(var r=0;r<l;r++)t.removeEventListener(d[r],this.listener,!1);return e.protocol&&\"data\"===e.protocol?void g(\"Ajax/DataUrl/Excluded\"):void(e.aborted||(n.duration=a.now()-this.startTime,this.loadCaptureCalled||4!==t.readyState?null==e.status&&(e.status=0):o(this,t),n.cbTime=this.cbTime,s(\"xhr\",[e,n,this.startTime,this.endTime,\"xhr\"],this)))}}function i(t,e){var n=c(e),r=t.params;r.hostname=n.hostname,r.port=n.port,r.protocol=n.protocol,r.host=n.hostname+\":\"+n.port,r.pathname=n.pathname,t.parsedOrigin=n,t.sameOrigin=n.sameOrigin}function o(t,e){t.params.status=e.status;var n=v(e,t.lastSize);if(n&&(t.metrics.rxSize=n),t.sameOrigin){var r=e.getResponseHeader(\"X-NewRelic-App-Data\");r&&(t.params.cat=r.split(\", \").pop())}t.loadCaptureCalled=!0}var a=t(\"loader\");if(a.xhrWrappable&&!a.disabled){var s=t(\"handle\"),c=t(14),f=t(12).generateTracePayload,u=t(\"ee\"),d=[\"load\",\"error\",\"abort\",\"timeout\"],l=d.length,p=t(\"id\"),h=t(20),m=t(18),v=t(15),w=t(19),g=t(21).recordSupportability,y=NREUM.o.REQ,x=window.XMLHttpRequest;a.features.xhr=!0,t(11),t(7),u.on(\"new-xhr\",function(t){var e=this;e.totalCbs=0,e.called=0,e.cbTime=0,e.end=r,e.ended=!1,e.xhrGuids={},e.lastSize=null,e.loadCaptureCalled=!1,e.params=this.params||{},e.metrics=this.metrics||{},t.addEventListener(\"load\",function(n){o(e,t)},w(!1)),h&&(h>34||h<10)||t.addEventListener(\"progress\",function(t){e.lastSize=t.loaded},w(!1))}),u.on(\"open-xhr-start\",function(t){this.params={method:t[0]},i(this,t[1]),this.metrics={}}),u.on(\"open-xhr-end\",function(t,e){\"loader_config\"in NREUM&&\"xpid\"in NREUM.loader_config&&this.sameOrigin&&e.setRequestHeader(\"X-NewRelic-ID\",NREUM.loader_config.xpid);var n=f(this.parsedOrigin);if(n){var r=!1;n.newrelicHeader&&(e.setRequestHeader(\"newrelic\",n.newrelicHeader),r=!0),n.traceContextParentHeader&&(e.setRequestHeader(\"traceparent\",n.traceContextParentHeader),n.traceContextStateHeader&&e.setRequestHeader(\"tracestate\",n.traceContextStateHeader),r=!0),r&&(this.dt=n)}}),u.on(\"send-xhr-start\",function(t,e){var n=this.metrics,r=t[0],i=this;if(n&&r){var o=m(r);o&&(n.txSize=o)}this.startTime=a.now(),this.listener=function(t){try{\"abort\"!==t.type||i.loadCaptureCalled||(i.params.aborted=!0),(\"load\"!==t.type||i.called===i.totalCbs&&(i.onloadCalled||\"function\"!=typeof e.onload))&&i.end(e)}catch(n){try{u.emit(\"internal-error\",[n])}catch(r){}}};for(var s=0;s<l;s++)e.addEventListener(d[s],this.listener,w(!1))}),u.on(\"xhr-cb-time\",function(t,e,n){this.cbTime+=t,e?this.onloadCalled=!0:this.called+=1,this.called!==this.totalCbs||!this.onloadCalled&&\"function\"==typeof n.onload||this.end(n)}),u.on(\"xhr-load-added\",function(t,e){var n=\"\"+p(t)+!!e;this.xhrGuids&&!this.xhrGuids[n]&&(this.xhrGuids[n]=!0,this.totalCbs+=1)}),u.on(\"xhr-load-removed\",function(t,e){var n=\"\"+p(t)+!!e;this.xhrGuids&&this.xhrGuids[n]&&(delete this.xhrGuids[n],this.totalCbs-=1)}),u.on(\"xhr-resolved\",function(){this.endTime=a.now()}),u.on(\"addEventListener-end\",function(t,e){e instanceof x&&\"load\"===t[0]&&u.emit(\"xhr-load-added\",[t[1],t[2]],e)}),u.on(\"removeEventListener-end\",function(t,e){e instanceof x&&\"load\"===t[0]&&u.emit(\"xhr-load-removed\",[t[1],t[2]],e)}),u.on(\"fn-start\",function(t,e,n){e instanceof x&&(\"onload\"===n&&(this.onload=!0),(\"load\"===(t[0]&&t[0].type)||this.onload)&&(this.xhrCbStart=a.now()))}),u.on(\"fn-end\",function(t,e){this.xhrCbStart&&u.emit(\"xhr-cb-time\",[a.now()-this.xhrCbStart,this.onload,e],e)}),u.on(\"fetch-before-start\",function(t){function e(t,e){var n=!1;return e.newrelicHeader&&(t.set(\"newrelic\",e.newrelicHeader),n=!0),e.traceContextParentHeader&&(t.set(\"traceparent\",e.traceContextParentHeader),e.traceContextStateHeader&&t.set(\"tracestate\",e.traceContextStateHeader),n=!0),n}var n,r=t[1]||{};\"string\"==typeof t[0]?n=t[0]:t[0]&&t[0].url?n=t[0].url:window.URL&&t[0]&&t[0]instanceof URL&&(n=t[0].href),n&&(this.parsedOrigin=c(n),this.sameOrigin=this.parsedOrigin.sameOrigin);var i=f(this.parsedOrigin);if(i&&(i.newrelicHeader||i.traceContextParentHeader))if(\"string\"==typeof t[0]||window.URL&&t[0]&&t[0]instanceof URL){var o={};for(var a in r)o[a]=r[a];o.headers=new Headers(r.headers||{}),e(o.headers,i)&&(this.dt=i),t.length>1?t[1]=o:t.push(o)}else t[0]&&t[0].headers&&e(t[0].headers,i)&&(this.dt=i)}),u.on(\"fetch-start\",function(t,e){this.params={},this.metrics={},this.startTime=a.now(),this.dt=e,t.length>=1&&(this.target=t[0]),t.length>=2&&(this.opts=t[1]);var n,r=this.opts||{},o=this.target;if(\"string\"==typeof o?n=o:\"object\"==typeof o&&o instanceof y?n=o.url:window.URL&&\"object\"==typeof o&&o instanceof URL&&(n=o.href),i(this,n),\"data\"!==this.params.protocol){var s=(\"\"+(o&&o instanceof y&&o.method||r.method||\"GET\")).toUpperCase();this.params.method=s,this.txSize=m(r.body)||0}}),u.on(\"fetch-done\",function(t,e){if(this.endTime=a.now(),this.params||(this.params={}),\"data\"===this.params.protocol)return void g(\"Ajax/DataUrl/Excluded\");this.params.status=e?e.status:0;var n;\"string\"==typeof this.rxSize&&this.rxSize.length>0&&(n=+this.rxSize);var r={txSize:this.txSize,rxSize:n,duration:a.now()-this.startTime};s(\"xhr\",[this.params,r,this.startTime,this.endTime,\"fetch\"],this)})}},{}],14:[function(t,e,n){var r={};e.exports=function(t){if(t in r)return r[t];if(0===(t||\"\").indexOf(\"data:\"))return{protocol:\"data\"};var e=document.createElement(\"a\"),n=window.location,i={};e.href=t,i.port=e.port;var o=e.href.split(\"://\");!i.port&&o[1]&&(i.port=o[1].split(\"/\")[0].split(\"@\").pop().split(\":\")[1]),i.port&&\"0\"!==i.port||(i.port=\"https\"===o[0]?\"443\":\"80\"),i.hostname=e.hostname||n.hostname,i.pathname=e.pathname,i.protocol=o[0],\"/\"!==i.pathname.charAt(0)&&(i.pathname=\"/\"+i.pathname);var a=!e.protocol||\":\"===e.protocol||e.protocol===n.protocol,s=e.hostname===document.domain&&e.port===n.port;return i.sameOrigin=a&&(!e.hostname||s),\"/\"===i.pathname&&(r[t]=i),i}},{}],15:[function(t,e,n){function r(t,e){var n=t.responseType;return\"json\"===n&&null!==e?e:\"arraybuffer\"===n||\"blob\"===n||\"json\"===n?i(t.response):\"text\"===n||\"\"===n||void 0===n?i(t.responseText):void 0}var i=t(18);e.exports=r},{}],16:[function(t,e,n){function r(){}function i(t,e,n,r){return function(){return u.recordSupportability(\"API/\"+e+\"/called\"),o(t+e,[f.now()].concat(s(arguments)),n?null:this,r),n?void 0:this}}var o=t(\"handle\"),a=t(27),s=t(28),c=t(\"ee\").get(\"tracer\"),f=t(\"loader\"),u=t(21),d=NREUM;\"undefined\"==typeof window.newrelic&&(newrelic=d);var l=[\"setPageViewName\",\"setCustomAttribute\",\"setErrorHandler\",\"finished\",\"addToTrace\",\"inlineHit\",\"addRelease\"],p=\"api-\",h=p+\"ixn-\";a(l,function(t,e){d[e]=i(p,e,!0,\"api\")}),d.addPageAction=i(p,\"addPageAction\",!0),d.setCurrentRouteName=i(p,\"routeName\",!0),e.exports=newrelic,d.interaction=function(){return(new r).get()};var m=r.prototype={createTracer:function(t,e){var n={},r=this,i=\"function\"==typeof e;return o(h+\"tracer\",[f.now(),t,n],r),function(){if(c.emit((i?\"\":\"no-\")+\"fn-start\",[f.now(),r,i],n),i)try{return e.apply(this,arguments)}catch(t){throw c.emit(\"fn-err\",[arguments,this,t],n),t}finally{c.emit(\"fn-end\",[f.now()],n)}}}};a(\"actionText,setName,setAttribute,save,ignore,onEnd,getContext,end,get\".split(\",\"),function(t,e){m[e]=i(h,e)}),newrelic.noticeError=function(t,e){\"string\"==typeof t&&(t=new Error(t)),u.recordSupportability(\"API/noticeError/called\"),o(\"err\",[t,f.now(),!1,e])}},{}],17:[function(t,e,n){function r(t){if(NREUM.init){for(var e=NREUM.init,n=t.split(\".\"),r=0;r<n.length-1;r++)if(e=e[n[r]],\"object\"!=typeof e)return;return e=e[n[n.length-1]]}}e.exports={getConfiguration:r}},{}],18:[function(t,e,n){e.exports=function(t){if(\"string\"==typeof t&&t.length)return t.length;if(\"object\"==typeof t){if(\"undefined\"!=typeof ArrayBuffer&&t instanceof ArrayBuffer&&t.byteLength)return t.byteLength;if(\"undefined\"!=typeof Blob&&t instanceof Blob&&t.size)return t.size;if(!(\"undefined\"!=typeof FormData&&t instanceof FormData))try{return JSON.stringify(t).length}catch(e){return}}}},{}],19:[function(t,e,n){var r=!1;try{var i=Object.defineProperty({},\"passive\",{get:function(){r=!0}});window.addEventListener(\"testPassive\",null,i),window.removeEventListener(\"testPassive\",null,i)}catch(o){}e.exports=function(t){return r?{passive:!0,capture:!!t}:!!t}},{}],20:[function(t,e,n){var r=0,i=navigator.userAgent.match(/Firefox[\\/\\s](\\d+\\.\\d+)/);i&&(r=+i[1]),e.exports=r},{}],21:[function(t,e,n){function r(t,e){var n=[a,t,{name:t},e];return o(\"storeMetric\",n,null,\"api\"),n}function i(t,e){var n=[s,t,{name:t},e];return o(\"storeEventMetrics\",n,null,\"api\"),n}var o=t(\"handle\"),a=\"sm\",s=\"cm\";e.exports={constants:{SUPPORTABILITY_METRIC:a,CUSTOM_METRIC:s},recordSupportability:r,recordCustom:i}},{}],22:[function(t,e,n){function r(){return s.exists&&performance.now?Math.round(performance.now()):(o=Math.max((new Date).getTime(),o))-a}function i(){return o}var o=(new Date).getTime(),a=o,s=t(29);e.exports=r,e.exports.offset=a,e.exports.getLastTimestamp=i},{}],23:[function(t,e,n){function r(t,e){var n=t.getEntries();n.forEach(function(t){\"first-paint\"===t.name?p(\"timing\",[\"fp\",Math.floor(t.startTime)]):\"first-contentful-paint\"===t.name&&p(\"timing\",[\"fcp\",Math.floor(t.startTime)])})}function i(t,e){var n=t.getEntries();if(n.length>0){var r=n[n.length-1];if(f&&f<r.startTime)return;var i=[r],o=a({});o&&i.push(o),p(\"lcp\",i)}}function o(t){t.getEntries().forEach(function(t){t.hadRecentInput||p(\"cls\",[t])})}function a(t){var e=navigator.connection||navigator.mozConnection||navigator.webkitConnection;if(e)return e.type&&(t[\"net-type\"]=e.type),e.effectiveType&&(t[\"net-etype\"]=e.effectiveType),e.rtt&&(t[\"net-rtt\"]=e.rtt),e.downlink&&(t[\"net-dlink\"]=e.downlink),t}function s(t){if(t instanceof w&&!y){var e=Math.round(t.timeStamp),n={type:t.type};a(n),e<=h.now()?n.fid=h.now()-e:e>h.offset&&e<=Date.now()?(e-=h.offset,n.fid=h.now()-e):e=h.now(),y=!0,p(\"timing\",[\"fi\",e,n])}}function c(t){\"hidden\"===t&&(f=h.now(),p(\"pageHide\",[f]))}if(!(\"init\"in NREUM&&\"page_view_timing\"in NREUM.init&&\"enabled\"in NREUM.init.page_view_timing&&NREUM.init.page_view_timing.enabled===!1)){var f,u,d,l,p=t(\"handle\"),h=t(\"loader\"),m=t(26),v=t(19),w=NREUM.o.EV;if(\"PerformanceObserver\"in window&&\"function\"==typeof window.PerformanceObserver){u=new PerformanceObserver(r);try{u.observe({entryTypes:[\"paint\"]})}catch(g){}d=new PerformanceObserver(i);try{d.observe({entryTypes:[\"largest-contentful-paint\"]})}catch(g){}l=new PerformanceObserver(o);try{l.observe({type:\"layout-shift\",buffered:!0})}catch(g){}}if(\"addEventListener\"in document){var y=!1,x=[\"click\",\"keydown\",\"mousedown\",\"pointerdown\",\"touchstart\"];x.forEach(function(t){document.addEventListener(t,s,v(!1))})}m(c)}},{}],24:[function(t,e,n){function r(){function t(){return e?15&e[n++]:16*Math.random()|0}var e=null,n=0,r=window.crypto||window.msCrypto;r&&r.getRandomValues&&(e=r.getRandomValues(new Uint8Array(31)));for(var i,o=\"xxxxxxxx-xxxx-4xxx-yxxx-xxxxxxxxxxxx\",a=\"\",s=0;s<o.length;s++)i=o[s],\"x\"===i?a+=t().toString(16):\"y\"===i?(i=3&t()|8,a+=i.toString(16)):a+=i;return a}function i(){return a(16)}function o(){return a(32)}function a(t){function e(){return n?15&n[r++]:16*Math.random()|0}var n=null,r=0,i=window.crypto||window.msCrypto;i&&i.getRandomValues&&Uint8Array&&(n=i.getRandomValues(new Uint8Array(t)));for(var o=[],a=0;a<t;a++)o.push(e().toString(16));return o.join(\"\")}e.exports={generateUuid:r,generateSpanId:i,generateTraceId:o}},{}],25:[function(t,e,n){function r(t,e){if(!i)return!1;if(t!==i)return!1;if(!e)return!0;if(!o)return!1;for(var n=o.split(\".\"),r=e.split(\".\"),a=0;a<r.length;a++)if(r[a]!==n[a])return!1;return!0}var i=null,o=null,a=/Version\\/(\\S+)\\s+Safari/;if(navigator.userAgent){var s=navigator.userAgent,c=s.match(a);c&&s.indexOf(\"Chrome\")===-1&&s.indexOf(\"Chromium\")===-1&&(i=\"Safari\",o=c[1])}e.exports={agent:i,version:o,match:r}},{}],26:[function(t,e,n){function r(t){function e(){t(s&&document[s]?document[s]:document[o]?\"hidden\":\"visible\")}\"addEventListener\"in document&&a&&document.addEventListener(a,e,i(!1))}var i=t(19);e.exports=r;var o,a,s;\"undefined\"!=typeof document.hidden?(o=\"hidden\",a=\"visibilitychange\",s=\"visibilityState\"):\"undefined\"!=typeof document.msHidden?(o=\"msHidden\",a=\"msvisibilitychange\"):\"undefined\"!=typeof document.webkitHidden&&(o=\"webkitHidden\",a=\"webkitvisibilitychange\",s=\"webkitVisibilityState\")},{}],27:[function(t,e,n){function r(t,e){var n=[],r=\"\",o=0;for(r in t)i.call(t,r)&&(n[o]=e(r,t[r]),o+=1);return n}var i=Object.prototype.hasOwnProperty;e.exports=r},{}],28:[function(t,e,n){function r(t,e,n){e||(e=0),\"undefined\"==typeof n&&(n=t?t.length:0);for(var r=-1,i=n-e||0,o=Array(i<0?0:i);++r<i;)o[r]=t[e+r];return o}e.exports=r},{}],29:[function(t,e,n){e.exports={exists:\"undefined\"!=typeof window.performance&&window.performance.timing&&\"undefined\"!=typeof window.performance.timing.navigationStart}},{}],ee:[function(t,e,n){function r(){}function i(t){function e(t){return t&&t instanceof r?t:t?f(t,c,a):a()}function n(n,r,i,o,a){if(a!==!1&&(a=!0),!p.aborted||o){t&&a&&t(n,r,i);for(var s=e(i),c=m(n),f=c.length,u=0;u<f;u++)c[u].apply(s,r);var l=d[y[n]];return l&&l.push([x,n,r,s]),s}}function o(t,e){g[t]=m(t).concat(e)}function h(t,e){var n=g[t];if(n)for(var r=0;r<n.length;r++)n[r]===e&&n.splice(r,1)}function m(t){return g[t]||[]}function v(t){return l[t]=l[t]||i(n)}function w(t,e){p.aborted||u(t,function(t,n){e=e||\"feature\",y[n]=e,e in d||(d[e]=[])})}var g={},y={},x={on:o,addEventListener:o,removeEventListener:h,emit:n,get:v,listeners:m,context:e,buffer:w,abort:s,aborted:!1};return x}function o(t){return f(t,c,a)}function a(){return new r}function s(){(d.api||d.feature)&&(p.aborted=!0,d=p.backlog={})}var c=\"nr@context\",f=t(\"gos\"),u=t(27),d={},l={},p=e.exports=i();e.exports.getOrSetContext=o,p.backlog=d},{}],gos:[function(t,e,n){function r(t,e,n){if(i.call(t,e))return t[e];var r=n();if(Object.defineProperty&&Object.keys)try{return Object.defineProperty(t,e,{value:r,writable:!0,enumerable:!1}),r}catch(o){}return t[e]=r,r}var i=Object.prototype.hasOwnProperty;e.exports=r},{}],handle:[function(t,e,n){function r(t,e,n,r){i.buffer([t],r),i.emit(t,e,n)}var i=t(\"ee\").get(\"handle\");e.exports=r,r.ee=i},{}],id:[function(t,e,n){function r(t){var e=typeof t;return!t||\"object\"!==e&&\"function\"!==e?-1:t===window?0:a(t,o,function(){return i++})}var i=1,o=\"nr@id\",a=t(\"gos\");e.exports=r},{}],loader:[function(t,e,n){function r(){if(!O++){var t=S.info=NREUM.info,e=m.getElementsByTagName(\"script\")[0];if(setTimeout(f.abort,3e4),!(t&&t.licenseKey&&t.applicationID&&e))return f.abort();c(E,function(e,n){t[e]||(t[e]=n)});var n=a();s(\"mark\",[\"onload\",n+S.offset],null,\"api\"),s(\"timing\",[\"load\",n]);var r=m.createElement(\"script\");0===t.agent.indexOf(\"http://\")||0===t.agent.indexOf(\"https://\")?r.src=t.agent:r.src=p+\"://\"+t.agent,e.parentNode.insertBefore(r,e)}}function i(){\"complete\"===m.readyState&&o()}function o(){s(\"mark\",[\"domContent\",a()+S.offset],null,\"api\")}var a=t(22),s=t(\"handle\"),c=t(27),f=t(\"ee\"),u=t(25),d=t(17),l=t(19),p=d.getConfiguration(\"ssl\")===!1?\"http\":\"https\",h=window,m=h.document,v=\"addEventListener\",w=\"attachEvent\",g=h.XMLHttpRequest,y=g&&g.prototype,x=!1;NREUM.o={ST:setTimeout,SI:h.setImmediate,CT:clearTimeout,XHR:g,REQ:h.Request,EV:h.Event,PR:h.Promise,MO:h.MutationObserver};var b=\"\"+location,E={beacon:\"bam.nr-data.net\",errorBeacon:\"bam.nr-data.net\",agent:\"js-agent.newrelic.com/nr-1216.min.js\"},R=g&&y&&y[v]&&!/CriOS/.test(navigator.userAgent),S=e.exports={offset:a.getLastTimestamp(),now:a,origin:b,features:{},xhrWrappable:R,userAgent:u,disabled:x};if(!x){t(16),t(23),m[v]?(m[v](\"DOMContentLoaded\",o,l(!1)),h[v](\"load\",r,l(!1))):(m[w](\"onreadystatechange\",i),h[w](\"onload\",r)),s(\"mark\",[\"firstbyte\",a.getLastTimestamp()],null,\"api\");var O=0}},{}],\"wrap-function\":[function(t,e,n){function r(t,e){function n(e,n,r,c,f){function nrWrapper(){var o,a,u,l;try{a=this,o=d(arguments),u=\"function\"==typeof r?r(o,a):r||{}}catch(p){i([p,\"\",[o,a,c],u],t)}s(n+\"start\",[o,a,c],u,f);try{return l=e.apply(a,o)}catch(h){throw s(n+\"err\",[o,a,h],u,f),h}finally{s(n+\"end\",[o,a,l],u,f)}}return a(e)?e:(n||(n=\"\"),nrWrapper[l]=e,o(e,nrWrapper,t),nrWrapper)}function r(t,e,r,i,o){r||(r=\"\");var s,c,f,u=\"-\"===r.charAt(0);for(f=0;f<e.length;f++)c=e[f],s=t[c],a(s)||(t[c]=n(s,u?c+r:r,i,c,o))}function s(n,r,o,a){if(!h||e){var s=h;h=!0;try{t.emit(n,r,o,e,a)}catch(c){i([c,n,r,o],t)}h=s}}return t||(t=u),n.inPlace=r,n.flag=l,n}function i(t,e){e||(e=u);try{e.emit(\"internal-error\",t)}catch(n){}}function o(t,e,n){if(Object.defineProperty&&Object.keys)try{var r=Object.keys(t);return r.forEach(function(n){Object.defineProperty(e,n,{get:function(){return t[n]},set:function(e){return t[n]=e,e}})}),e}catch(o){i([o],n)}for(var a in t)p.call(t,a)&&(e[a]=t[a]);return e}function a(t){return!(t&&t instanceof Function&&t.apply&&!t[l])}function s(t,e){var n=e(t);return n[l]=t,o(t,n,u),n}function c(t,e,n){var r=t[e];t[e]=s(r,n)}function f(){for(var t=arguments.length,e=new Array(t),n=0;n<t;++n)e[n]=arguments[n];return e}var u=t(\"ee\"),d=t(28),l=\"nr@original\",p=Object.prototype.hasOwnProperty,h=!1;e.exports=r,e.exports.wrapFunction=s,e.exports.wrapInPlace=c,e.exports.argsToArray=f},{}]},{},[\"loader\",2,13,4,3]);</script>\r\n    <!-- Turn off telephone number detection. -->\r\n    <meta name=\"format-detection\" content=\"telephone=no\" />\r\n\r\n<!-- Bookmark Icons -->\n  <link rel=\"apple-touch-icon\" sizes=\"180x180\" href=\"//oup.silverchair-cdn.com/UI/app/img/v-637926275900268789/apple-touch-icon.png\">\n  <link rel=\"icon\" type=\"image/png\" href=\"//oup.silverchair-cdn.com/UI/app/img/v-637926275900268789/favicon-32x32.png\" sizes=\"32x32\">\n  <link rel=\"icon\" type=\"image/png\" href=\"//oup.silverchair-cdn.com/UI/app/img/v-637926275900268789/favicon-16x16.png\" sizes=\"16x16\">\n  <link rel=\"mask-icon\" href=\"//oup.silverchair-cdn.com/UI/app/img/v-637926275900418809/safari-pinned-tab.svg\" color=\"#5bbad5\">\n  <link rel=\"icon\" href=\"//oup.silverchair-cdn.com/UI/app/img/v-637926275900268789/favicon.ico\">\n  <link rel=\"manifest\" href=\"//oup.silverchair-cdn.com/UI/app/img/v-637926275900318925/manifest.json\">\n  <meta name=\"msapplication-config\" content=\"//oup.silverchair-cdn.com/UI/app/img/v-637926275900268789/browserconfig.xml\">\n  <meta name=\"theme-color\" content=\"#002f65\">\n\r\n\r\n    \r\n\r\n\r\n\r\n\r\n<link rel=\"stylesheet\" type=\"text/css\" href=\"//oup.silverchair-cdn.com/UI/app/fonts/icons.css\" />\r\n\r\n<link rel=\"stylesheet\" type=\"text/css\" href=\"//oup.silverchair-cdn.com/Themes/Client/app/css/v-637941262613747852/site.min.css\" />\r\n\r\n        <link rel=\"stylesheet\" type=\"text/css\" href=\"//oup.silverchair-cdn.com/Themes/Client/app/vendor/oupCookiePolicy/css/v-637926275899768865/jquery.fancybox-1.3.4_1.css\" />\r\n        <link rel=\"stylesheet\" type=\"text/css\" href=\"//oup.silverchair-cdn.com/Themes/Client/app/vendor/jscrollpane/v-637926275899718819/jscrollpane.css\" />\r\n        <link rel=\"stylesheet\" type=\"text/css\" href=\"//oup.silverchair-cdn.com/Themes/Client/app/vendor/jquery.tablesorter/v-637926275899718819/theme.default.css\" />\r\n\r\n    <link rel=\"stylesheet\" type=\"text/css\" href=\"https://fonts.googleapis.com/css?family=Merriweather:300,400,400italic,700,700italic|Source+Sans+Pro:400,400italic,700,700italic\" />\r\n\r\n\r\n        <link href=//oup.silverchair-cdn.com/data/SiteBuilderAssetsOriginals/Live/CSS/journals/global.css rel=\"stylesheet\" type=\"text/css\" />\r\n                <link href=//oup.silverchair-cdn.com/data/SiteBuilderAssets/Live/CSS/jcem/Site-478814713.css rel=\"stylesheet\" type=\"text/css\" />\r\n\r\n\n\n    <script> var dataLayer = [{\"event_type\":\"full-text\",\"supplier_tag\":\"SC_Journals\",\"object_type\":\"Article\",\"siteid\":\"jcem\",\"authzrequired\":\"false\",\"doi\":\"10.1210/jc.2017-01658\"}]; </script>\n            <script>\r\n                (function (w, d, s, l, i) {\r\n                    w[l] = w[l] || []; w[l].push({\r\n                        'gtm.start':\r\n                            new Date().getTime(), event: 'gtm.js'\r\n                    }); var f = d.getElementsByTagName(s)[0],\r\n                        j = d.createElement(s), dl = l != 'dataLayer' ? '&l=' + l : ''; j.async = true; j.src =\r\n                        'https://www.googletagmanager.com/gtm.js?id=' + i + dl; f.parentNode.insertBefore(j, f);\r\n                })(window, document, 'script', 'dataLayer', 'GTM-W6DD7HV');\r\n            </script>\r\n\r\n    \r\n\r\n        <script type=\"text/javascript\">\r\n            var App = App || {};\r\n            App.LoginUserInfo = {\r\n                isInstLoggedIn: 0,\r\n                isIndividualLoggedIn: 0\r\n            };\r\n\r\n            App.CurrentSubdomain = 'jcem';\r\n            App.SiteURL = 'academic.oup.com/jcem';\r\n        </script>\r\n    \r\n    \r\n    <link href=\"https://cdn.jsdelivr.net/chartist.js/latest/chartist.min.css\" rel=\"stylesheet\" type=\"text/css\" />\r\n    <script type=\"application/ld+json\">\r\n        {\"@context\":\"https://schema.org\",\"@type\":\"ScholarlyArticle\",\"@id\":\"https://academic.oup.com/jcem/article/102/11/3869/4157558\",\"name\":\"Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society* Clinical Practice Guideline\",\"datePublished\":\"2017-09-13\",\"isPartOf\":{\"@id\":\"https://academic.oup.com/jcem/jcem/issue/102/11\",\"@type\":\"PublicationIssue\",\"issueNumber\":\"11\",\"datePublished\":\"2017-11-01\",\"isPartOf\":{\"@id\":\"https://academic.oup.com/jcem/jcem\",\"@type\":\"Periodical\",\"name\":\"The Journal of Clinical Endocrinology & Metabolism\",\"issn\":[\"1945-7197\"]}},\"url\":\"https://dx.doi.org/10.1210/jc.2017-01658\",\"inLanguage\":\"en\",\"copyrightHolder\":\"Oxford University Press\",\"copyrightYear\":\"2022\",\"publisher\":\"Oxford University Press\",\"sameAs\":\"\",\"author\":[{\"name\":\"Hembree, Wylie C\",\"affiliation\":\"1 New York Presbyterian Hospital, Columbia University Medical Center, New York, New York 10032 (Retired)\",\"@type\":\"Person\"},{\"name\":\"Cohen-Kettenis, Peggy T\",\"affiliation\":\"2 VU University Medical Center, 1007 MB Amsterdam, Netherlands (Retired)\",\"@type\":\"Person\"},{\"name\":\"Gooren, Louis\",\"affiliation\":\"3 VU University Medical Center, 1007 MB Amsterdam, Netherlands (Retired)\",\"@type\":\"Person\"},{\"name\":\"Hannema, Sabine E\",\"affiliation\":\"4 Leiden University Medical Center, 2300 RC Leiden, Netherlands\",\"@type\":\"Person\"},{\"name\":\"Meyer, Walter J\",\"affiliation\":\"5 University of Texas Medical Branch, Galveston, Texas 77555\",\"@type\":\"Person\"},{\"name\":\"Murad, M Hassan\",\"affiliation\":\"6 Mayo Clinic Evidence-Based Practice Center, Rochester, Minnesota 55905\",\"@type\":\"Person\"},{\"name\":\"Rosenthal, Stephen M\",\"affiliation\":\"7 University of California San Francisco, Benioff Children’s Hospital, San Francisco, California 94143\",\"@type\":\"Person\"},{\"name\":\"Safer, Joshua D\",\"affiliation\":\"8 Boston University School of Medicine, Boston, Massachusetts 02118\",\"@type\":\"Person\"},{\"name\":\"Tangpricha, Vin\",\"affiliation\":\"9 Emory University School of Medicine and the Atlanta VA Medical Center, Atlanta, Georgia 30322\",\"@type\":\"Person\"},{\"name\":\"T’Sjoen, Guy G\",\"affiliation\":\"10 Ghent University Hospital, 9000 Ghent, Belgium\",\"@type\":\"Person\"}],\"description\":\"Gender affirmation is multidisciplinary treatment. Gender-dysphoric/gender-incongruent persons seek and/or are referred to endocrinologists to develop the physi\",\"pageStart\":\"3869\",\"pageEnd\":\"3903\",\"siteName\":\"OUP Academic\",\"thumbnailURL\":\"https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/jcem/Issue/102/11/3/m_cover.jpeg?Expires=1722615010&Signature=1k7bdN9ysp1LbHC-WdBQCSB9w8IJRIodgVWnNGaQKp-lm55NjCUmXT-ebEQE8BKCj0sUH8aEsUBVOtouS8VC7sh7HG57Tbp2yIbki2yS~-gqF-1v4W3Z47djZeV7~dq0rcxoC0KNK8WANS~xjFZiksUkRE3VNS3is720fTWOzh-7TaPOTYIJAR1jIBaA6FOvhheUPLurGmssKN5Sq3FKiA2m689PMATqMf8vcthKlm6VYS5I3Be~7TQavbvcGzgTAWVqvhX1ikdnhh~ceGtNIDGAJZiLJCIaXjcSc4~HVWKslGdO6tJg71lTWN-8vZ4d~RhJV7hLXDiqXH5rw~06eA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA\",\"headline\":\"Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society* Clinical Practice Guideline\",\"image\":\"https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/jcem/Issue/102/11/3/m_cover.jpeg?Expires=1722615010&Signature=1k7bdN9ysp1LbHC-WdBQCSB9w8IJRIodgVWnNGaQKp-lm55NjCUmXT-ebEQE8BKCj0sUH8aEsUBVOtouS8VC7sh7HG57Tbp2yIbki2yS~-gqF-1v4W3Z47djZeV7~dq0rcxoC0KNK8WANS~xjFZiksUkRE3VNS3is720fTWOzh-7TaPOTYIJAR1jIBaA6FOvhheUPLurGmssKN5Sq3FKiA2m689PMATqMf8vcthKlm6VYS5I3Be~7TQavbvcGzgTAWVqvhX1ikdnhh~ceGtNIDGAJZiLJCIaXjcSc4~HVWKslGdO6tJg71lTWN-8vZ4d~RhJV7hLXDiqXH5rw~06eA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA\",\"image:alt\":\"Issue Cover\"}\r\n    </script>\r\n        <meta property=\"og:site_name\" content=\"OUP Academic\"/>\r\n        <meta property=\"og:type\" content=\"article\"/>\r\n        <meta property=\"og:title\" content=\"Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society* Clinical Practice Guideline\"/>\r\n        <meta property=\"og:description\" content=\"Gender affirmation is multidisciplinary treatment. Gender-dysphoric/gender-incongruent persons seek and/or are referred to endocrinologists to develop the physi\"/>\r\n        <meta property=\"og:url\" content=\"https://academic.oup.com/jcem/article/102/11/3869/4157558\"/>\r\n        <meta property=\"og:updated_time\" content=\"2017-09-13\"/>\r\n        <meta property=\"og:image\" content=\"https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/jcem/Issue/102/11/3/m_cover.jpeg?Expires=1722615010&amp;Signature=1k7bdN9ysp1LbHC-WdBQCSB9w8IJRIodgVWnNGaQKp-lm55NjCUmXT-ebEQE8BKCj0sUH8aEsUBVOtouS8VC7sh7HG57Tbp2yIbki2yS~-gqF-1v4W3Z47djZeV7~dq0rcxoC0KNK8WANS~xjFZiksUkRE3VNS3is720fTWOzh-7TaPOTYIJAR1jIBaA6FOvhheUPLurGmssKN5Sq3FKiA2m689PMATqMf8vcthKlm6VYS5I3Be~7TQavbvcGzgTAWVqvhX1ikdnhh~ceGtNIDGAJZiLJCIaXjcSc4~HVWKslGdO6tJg71lTWN-8vZ4d~RhJV7hLXDiqXH5rw~06eA__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA\"/>\r\n        <meta property=\"og:image:url\" content=\"https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/jcem/Issue/102/11/3/m_cover.jpeg?Expires=1722615010&amp;Signature=1k7bdN9ysp1LbHC-WdBQCSB9w8IJRIodgVWnNGaQKp-lm55NjCUmXT-ebEQE8BKCj0sUH8aEsUBVOtouS8VC7sh7HG57Tbp2yIbki2yS~-gqF-1v4W3Z47djZeV7~dq0rcxoC0KNK8WANS~xjFZiksUkRE3VNS3is720fTWOzh-7TaPOTYIJAR1jIBaA6FOvhheUPLurGmssKN5Sq3FKiA2m689PMATqMf8vcthKlm6VYS5I3Be~7TQavbvcGzgTAWVqvhX1ikdnhh~ceGtNIDGAJZiLJCIaXjcSc4~HVWKslGdO6tJg71lTWN-8vZ4d~RhJV7hLXDiqXH5rw~06eA__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA\"/>\r\n        <meta property=\"og:image:secure_url\" content=\"https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/jcem/Issue/102/11/3/m_cover.jpeg?Expires=1722615010&amp;Signature=1k7bdN9ysp1LbHC-WdBQCSB9w8IJRIodgVWnNGaQKp-lm55NjCUmXT-ebEQE8BKCj0sUH8aEsUBVOtouS8VC7sh7HG57Tbp2yIbki2yS~-gqF-1v4W3Z47djZeV7~dq0rcxoC0KNK8WANS~xjFZiksUkRE3VNS3is720fTWOzh-7TaPOTYIJAR1jIBaA6FOvhheUPLurGmssKN5Sq3FKiA2m689PMATqMf8vcthKlm6VYS5I3Be~7TQavbvcGzgTAWVqvhX1ikdnhh~ceGtNIDGAJZiLJCIaXjcSc4~HVWKslGdO6tJg71lTWN-8vZ4d~RhJV7hLXDiqXH5rw~06eA__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA\"/>\r\n        <meta property=\"og:image:alt\" content=\"Issue Cover\"/>\r\n<meta name=\"citation_author\" content=\"Hembree, Wylie C\" /><meta name=\"citation_author_institution\" content=\"New York Presbyterian Hospital, Columbia University Medical Center, New York, New York 10032 (Retired)\" /><meta name=\"citation_author\" content=\"Cohen-Kettenis, Peggy T\" /><meta name=\"citation_author_institution\" content=\"VU University Medical Center, 1007 MB Amsterdam, Netherlands (Retired)\" /><meta name=\"citation_author\" content=\"Gooren, Louis\" /><meta name=\"citation_author_institution\" content=\"VU University Medical Center, 1007 MB Amsterdam, Netherlands (Retired)\" /><meta name=\"citation_author\" content=\"Hannema, Sabine E\" /><meta name=\"citation_author_institution\" content=\"Leiden University Medical Center, 2300 RC Leiden, Netherlands\" /><meta name=\"citation_author\" content=\"Meyer, Walter J\" /><meta name=\"citation_author_institution\" content=\"University of Texas Medical Branch, Galveston, Texas 77555\" /><meta name=\"citation_author\" content=\"Murad, M Hassan\" /><meta name=\"citation_author_institution\" content=\"Mayo Clinic Evidence-Based Practice Center, Rochester, Minnesota 55905\" /><meta name=\"citation_author\" content=\"Rosenthal, Stephen M\" /><meta name=\"citation_author_institution\" content=\"University of California San Francisco, Benioff Children’s Hospital, San Francisco, California 94143\" /><meta name=\"citation_author\" content=\"Safer, Joshua D\" /><meta name=\"citation_author_institution\" content=\"Boston University School of Medicine, Boston, Massachusetts 02118\" /><meta name=\"citation_author\" content=\"Tangpricha, Vin\" /><meta name=\"citation_author_institution\" content=\"Emory University School of Medicine and the Atlanta VA Medical Center, Atlanta, Georgia 30322\" /><meta name=\"citation_author\" content=\"T’Sjoen, Guy G\" /><meta name=\"citation_author_institution\" content=\"Ghent University Hospital, 9000 Ghent, Belgium\" /><meta name=\"citation_title\" content=\"Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society Clinical Practice Guideline\" /><meta name=\"citation_firstpage\" content=\"3869\" /><meta name=\"citation_lastpage\" content=\"3903\" /><meta name=\"citation_doi\" content=\"10.1210/jc.2017-01658\" /><meta name=\"citation_journal_title\" content=\"The Journal of Clinical Endocrinology & Metabolism\" /><meta name=\"citation_journal_abbrev\" content=\"J Clin Endocrinol Metab\" /><meta name=\"citation_volume\" content=\"102\" /><meta name=\"citation_issue\" content=\"11\" /><meta name=\"citation_publication_date\" content=\"2017/11/01\" /><meta name=\"citation_issn\" content=\"0021-972X\" /><meta name=\"citation_publisher\" content=\"Oxford Academic\" /><meta name=\"citation_reference\" content=\"citation_title=Grading quality of evidence and strength of recommendations; citation_author=GRADE Working Group; citation_author=Atkins  D; citation_author=Best  D; citation_author=Briss  PA; citation_author=Eccles  M; citation_author=Falck-Ytter  Y; citation_author=Flottorp  S; citation_author=Guyatt  GH; citation_author=Harbour  RT; citation_author=Haugh  MC; citation_author=Henry  D; citation_author=Hill  S; citation_author=Jaeschke  R; citation_author=Leng  G; citation_author=Liberati  A; citation_author=Magrini  N; citation_author=Mason  J; citation_author=Middleton  P; citation_author=Mrukowicz  J; citation_author=O’Connell  D; citation_author=Oxman  AD; citation_author=Phillips  B; citation_author=Schünemann  HJ; citation_author=Edejer  T; citation_author=Varonen  H; citation_author=Vist  GE; citation_author=Williams  JW; citation_author=Zaza  S;  citation_journal_title=BMJ;  citation_year=2004;  citation_volume=328;  citation_issue=7454;  citation_pages=1490\" /><meta name=\"citation_reference\" content=\"citation_title=A case for clarity, consistency, and helpfulness: state-of-the-art clinical practice guidelines in endocrinology using the grading of recommendations, assessment, development, and evaluation system; citation_author=Swiglo  BA; citation_author=Murad  MH; citation_author=Schünemann  HJ; citation_author=Kunz  R; citation_author=Vigersky  RA; citation_author=Guyatt  GH; citation_author=Montori  VM;  citation_journal_title=J Clin Endocrinol Metab;  citation_year=2008;  citation_volume=93;  citation_issue=3;  citation_pages=666-673; \" /><meta name=\"citation_reference\" content=\"citation_title=Transsexualism in history; citation_author=Bullough  VL;  citation_journal_title=Arch Sex Behav;  citation_year=1975;  citation_volume=4;  citation_issue=5;  citation_pages=561-571; \" /><meta name=\"citation_reference\" content=\"citation_title=The transsexual phenomenon; citation_author=Benjamin  H;  citation_journal_title=Trans N Y Acad Sci;  citation_year=1967;  citation_volume=29;  citation_issue=4;  citation_pages=428-430; \" /><meta name=\"citation_reference\" content=\" Meyerowitz J. How Sex Changed: A History of Transsexuality in the United States. Cambridge, MA: Harvard University Press ; 2002. \" /><meta name=\"citation_reference\" content=\"  Hirschfeld M.   Was muss das Volk vom Dritten Geschlecht wissen. Verlag Max Spohr, Leipzig; 1901.  \" /><meta name=\"citation_reference\" content=\"citation_title=Editorial: Gender dysphoria syndrome—the conceptualization that liberalizes indications for total gender reorientation and implies a broadly based multi-dimensional rehabilitative regimen; citation_author=Fisk  NM;  citation_journal_title=West J Med;  citation_year=1974;  citation_volume=120;  citation_issue=5;  citation_pages=386-391; \" /><meta name=\"citation_reference\" content=\" Diamond L. Transgender experience and identity. In: Schwartz SJ, Luyckx K, Vignoles VL, eds. Handbook of Identity Theory and Research. New York, NY: Springer;  2011 : 629 – 647. \" /><meta name=\"citation_reference\" content=\"  Queen C, Schimel L  , eds. PoMoSexuals: Challenging Assumptions About Gender and Sexuality. San Francisco, CA: Cleis Press; 1997. \" /><meta name=\"citation_reference\" content=\"citation_title=Alternating gender incongruity: a new neuropsychiatric syndrome providing insight into the dynamic plasticity of brain-sex; citation_author=Case  LK; citation_author=Ramachandran  VS;  citation_journal_title=Med Hypotheses;  citation_year=2012;  citation_volume=78;  citation_issue=5;  citation_pages=626-631; \" /><meta name=\"citation_reference\" content=\"citation_title=Gender identity disorder outside the binary: when gender identity disorder-not otherwise specified is not good enough; citation_author=Johnson  TW; citation_author=Wassersug  RJ;  citation_journal_title=Arch Sex Behav;  citation_year=2010;  citation_volume=39;  citation_issue=3;  citation_pages=597-598; \" /><meta name=\"citation_reference\" content=\"citation_title=Impact of androgen deprivation therapy on sexual function: a response; citation_author=Wibowo  E; citation_author=Wassersug  R; citation_author=Warkentin  K; citation_author=Walker  L; citation_author=Robinson  J; citation_author=Brotto  L; citation_author=Johnson  T;  citation_journal_title=Asian J Androl;  citation_year=2012;  citation_volume=14;  citation_issue=5;  citation_pages=793-794; \" /><meta name=\"citation_reference\" content=\"Pasquesoone V. 7 countries giving transgender people fundamental rights the U.S. still won’t. 2014. Available at: https://mic.com/articles/87149/7-countries-giving-transgender-people-fundamental-rights-the-u-s-still-won-t. Accessed 26 August 2016. \" /><meta name=\"citation_reference\" content=\" American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Arlington, VA: American Psychiatric Association Publishing. \" /><meta name=\"citation_reference\" content=\"citation_title=Minding the body: situating gender identity diagnoses in the ICD-11; citation_author=Drescher  J; citation_author=Cohen-Kettenis  P; citation_author=Winter  S;  citation_journal_title=Int Rev Psychiatry;  citation_year=2012;  citation_volume=24;  citation_issue=6;  citation_pages=568-577; \" /><meta name=\"citation_reference\" content=\" World Professional Association for Transgender Health. Standards of care for the health of transsexual, transgender, and gender nonconforming people. Available at:http://www.wpath.org/site_page.cfm?pk_association_webpage_menu=1351&amp;pk_association_webpage=3926. Accessed 1 September 2017. \" /><meta name=\"citation_reference\" content=\"citation_title=A European network for the investigation of gender incongruence: the ENIGI initiative; citation_author=Kreukels  BP; citation_author=Haraldsen  IR; citation_author=De Cuypere  G; citation_author=Richter-Appelt  H; citation_author=Gijs  L; citation_author=Cohen-Kettenis  PT;  citation_journal_title=Eur Psychiatry;  citation_year=2012;  citation_volume=27;  citation_issue=6;  citation_pages=445-450; \" /><meta name=\"citation_reference\" content=\"citation_title=A European network for the investigation of gender incongruence: endocrine part; citation_author=Dekker  MJ; citation_author=Wierckx  K; citation_author=Van Caenegem  E; citation_author=Klaver  M; citation_author=Kreukels  BP; citation_author=Elaut  E; citation_author=Fisher  AD; citation_author=van Trotsenburg  MA; citation_author=Schreiner  T; citation_author=den Heijer  M; citation_author=T’Sjoen  G;  citation_journal_title=J Sex Med;  citation_year=2016;  citation_volume=13;  citation_issue=6;  citation_pages=994-999; \" /><meta name=\"citation_reference\" content=\"citation_title=Gender development; citation_author=Ruble  DN; citation_author=Martin  CL; citation_author=Berenbaum  SA; citation_author=Damon  WL; citation_author=Lerner  RM; citation_author=Eisenberg  N; citation_publisher=Wiley, New York, NY;  citation_title=Handbook of Child Psychology: Social, Emotional, and Personality Development;  citation_year=2006;  citation_volume=Vol. 3;  citation_pages=858-931; \" /><meta name=\"citation_reference\" content=\"citation_title=Gender identity development in adolescence; citation_author=Steensma  TD; citation_author=Kreukels  BP; citation_author=de Vries  AL; citation_author=Cohen-Kettenis  PT;  citation_journal_title=Horm Behav;  citation_year=2013;  citation_volume=64;  citation_issue=2;  citation_pages=288-297; \" /><meta name=\"citation_reference\" content=\"citation_title=Approach to the patient: transgender youth: endocrine considerations; citation_author=Rosenthal  SM;  citation_journal_title=J Clin Endocrinol Metab;  citation_year=2014;  citation_volume=99;  citation_issue=12;  citation_pages=4379-4389; \" /><meta name=\"citation_reference\" content=\"citation_title=Evidence supporting the biologic nature of gender identity; citation_author=Saraswat  A; citation_author=Weinand  JD; citation_author=Safer  JD;  citation_journal_title=Endocr Pract;  citation_year=2015;  citation_volume=21;  citation_issue=2;  citation_pages=199-204; \" /><meta name=\"citation_reference\" content=\"citation_title=The biology of human psychosexual differentiation; citation_author=Gooren  L;  citation_journal_title=Horm Behav;  citation_year=2006;  citation_volume=50;  citation_issue=4;  citation_pages=589-601; \" /><meta name=\"citation_reference\" content=\"citation_title=Gender development and sexuality in disorders of sex development; citation_author=Berenbaum  SA; citation_author=Meyer-Bahlburg  HF;  citation_journal_title=Horm Metab Res;  citation_year=2015;  citation_volume=47;  citation_issue=5;  citation_pages=361-366; \" /><meta name=\"citation_reference\" content=\"citation_title=Gender dysphoria and gender change in chromosomal females with congenital adrenal hyperplasia; citation_author=Dessens  AB; citation_author=Slijper  FME; citation_author=Drop  SLS;  citation_journal_title=Arch Sex Behav;  citation_year=2005;  citation_volume=34;  citation_issue=4;  citation_pages=389-397; \" /><meta name=\"citation_reference\" content=\"citation_title=Gender development in women with congenital adrenal hyperplasia as a function of disorder severity; citation_author=Meyer-Bahlburg  HFL; citation_author=Dolezal  C; citation_author=Baker  SW; citation_author=Ehrhardt  AA; citation_author=New  MI;  citation_journal_title=Arch Sex Behav;  citation_year=2006;  citation_volume=35;  citation_issue=6;  citation_pages=667-684; \" /><meta name=\"citation_reference\" content=\"citation_title=Gender role behavior, sexuality, and psychosocial adaptation in women with congenital adrenal hyperplasia due to CYP21A2 deficiency; citation_author=Frisén  L; citation_author=Nordenström  A; citation_author=Falhammar  H; citation_author=Filipsson  H; citation_author=Holmdahl  G; citation_author=Janson  PO; citation_author=Thorén  M; citation_author=Hagenfeldt  K; citation_author=Möller  A; citation_author=Nordenskjöld  A;  citation_journal_title=J Clin Endocrinol Metab;  citation_year=2009;  citation_volume=94;  citation_issue=9;  citation_pages=3432-3439; \" /><meta name=\"citation_reference\" content=\"citation_title=Prenatal androgenization affects gender-related behavior but not gender identity in 5–12-year-old girls with congenital adrenal hyperplasia; citation_author=Meyer-Bahlburg  HFL; citation_author=Dolezal  C; citation_author=Baker  SW; citation_author=Carlson  AD; citation_author=Obeid  JS; citation_author=New  MI;  citation_journal_title=Arch Sex Behav;  citation_year=2004;  citation_volume=33;  citation_issue=2;  citation_pages=97-104; \" /><meta name=\"citation_reference\" content=\"citation_title=Gender change in 46,XY persons with 5α-reductase-2 deficiency and 17β-hydroxysteroid dehydrogenase-3 deficiency; citation_author=Cohen-Kettenis  PT;  citation_journal_title=Arch Sex Behav;  citation_year=2005;  citation_volume=34;  citation_issue=4;  citation_pages=399-410; \" /><meta name=\"citation_reference\" content=\"citation_title=Discordant sexual identity in some genetic males with cloacal exstrophy assigned to female sex at birth; citation_author=Reiner  WG; citation_author=Gearhart  JP;  citation_journal_title=N Engl J Med;  citation_year=2004;  citation_volume=350;  citation_issue=4;  citation_pages=333-341; \" /><meta name=\"citation_reference\" content=\"citation_title=Gender identity outcome in female-raised 46,XY persons with penile agenesis, cloacal exstrophy of the bladder, or penile ablation; citation_author=Meyer-Bahlburg  HFL;  citation_journal_title=Arch Sex Behav;  citation_year=2005;  citation_volume=34;  citation_issue=4;  citation_pages=423-438; \" /><meta name=\"citation_reference\" content=\"citation_title=The heritability of gender identity disorder in a child and adolescent twin sample; citation_author=Coolidge  FL; citation_author=Thede  LL; citation_author=Young  SE;  citation_journal_title=Behav Genet;  citation_year=2002;  citation_volume=32;  citation_issue=4;  citation_pages=251-257; \" /><meta name=\"citation_reference\" content=\"citation_title=Gender identity disorder in twins: a review of the case report literature; citation_author=Heylens  G; citation_author=De Cuypere  G; citation_author=Zucker  KJ; citation_author=Schelfaut  C; citation_author=Elaut  E; citation_author=Vanden Bossche  H; citation_author=De Baere  E; citation_author=T’Sjoen  G;  citation_journal_title=J Sex Med;  citation_year=2012;  citation_volume=9;  citation_issue=3;  citation_pages=751-757; \" /><meta name=\"citation_reference\" content=\"citation_title=Association study of ERβ, AR, and CYP19A1 genes and MtF transsexualism; citation_author=Fernández  R; citation_author=Esteva  I; citation_author=Gómez-Gil  E; citation_author=Rumbo  T; citation_author=Almaraz  MC; citation_author=Roda  E; citation_author=Haro-Mora  J-J; citation_author=Guillamón  A; citation_author=Pásaro  E;  citation_journal_title=J Sex Med;  citation_year=2014;  citation_volume=11;  citation_issue=12;  citation_pages=2986-2994; \" /><meta name=\"citation_reference\" content=\"citation_title=Sex steroid-related genes and male-to-female transsexualism; citation_author=Henningsson  S; citation_author=Westberg  L; citation_author=Nilsson  S; citation_author=Lundström  B; citation_author=Ekselius  L; citation_author=Bodlund  O; citation_author=Lindström  E; citation_author=Hellstrand  M; citation_author=Rosmond  R; citation_author=Eriksson  E; citation_author=Landén  M;  citation_journal_title=Psychoneuroendocrinology;  citation_year=2005;  citation_volume=30;  citation_issue=7;  citation_pages=657-664; \" /><meta name=\"citation_reference\" content=\"citation_title=Androgen receptor repeat length polymorphism associated with male-to-female transsexualism; citation_author=Hare  L; citation_author=Bernard  P; citation_author=Sánchez  FJ; citation_author=Baird  PN; citation_author=Vilain  E; citation_author=Kennedy  T; citation_author=Harley  VR;  citation_journal_title=Biol Psychiatry;  citation_year=2009;  citation_volume=65;  citation_issue=1;  citation_pages=93-96; \" /><meta name=\"citation_reference\" content=\"citation_title=Hormone and genetic study in male to female transsexual patients; citation_author=Lombardo  F; citation_author=Toselli  L; citation_author=Grassetti  D; citation_author=Paoli  D; citation_author=Masciandaro  P; citation_author=Valentini  F; citation_author=Lenzi  A; citation_author=Gandini  L;  citation_journal_title=J Endocrinol Invest;  citation_year=2013;  citation_volume=36;  citation_issue=8;  citation_pages=550-557; \" /><meta name=\"citation_reference\" content=\"citation_title=Association study of gender identity disorder and sex hormone-related genes; citation_author=Ujike  H; citation_author=Otani  K; citation_author=Nakatsuka  M; citation_author=Ishii  K; citation_author=Sasaki  A; citation_author=Oishi  T; citation_author=Sato  T; citation_author=Okahisa  Y; citation_author=Matsumoto  Y; citation_author=Namba  Y; citation_author=Kimata  Y; citation_author=Kuroda  S;  citation_journal_title=Prog Neuropsychopharmacol Biol Psychiatry;  citation_year=2009;  citation_volume=33;  citation_issue=7;  citation_pages=1241-1244; \" /><meta name=\"citation_reference\" content=\"citation_title=Neuroimaging studies in people with gender incongruence; citation_author=Kreukels  BP; citation_author=Guillamon  A;  citation_journal_title=Int Rev Psychiatry;  citation_year=2016;  citation_volume=28;  citation_issue=1;  citation_pages=120-128; \" /><meta name=\"citation_reference\" content=\"citation_title=Desisting and persisting gender dysphoria after childhood: a qualitative follow-up study; citation_author=Steensma  TD; citation_author=Biemond  R; citation_author=de Boer  F; citation_author=Cohen-Kettenis  PT;  citation_journal_title=Clin Child Psychol Psychiatry;  citation_year=2011;  citation_volume=16;  citation_issue=4;  citation_pages=499-516; \" /><meta name=\"citation_reference\" content=\"citation_title=Psychosexual outcome of gender-dysphoric children; citation_author=Wallien  MSC; citation_author=Cohen-Kettenis  PT;  citation_journal_title=J Am Acad Child Adolesc Psychiatry;  citation_year=2008;  citation_volume=47;  citation_issue=12;  citation_pages=1413-1423; \" /><meta name=\"citation_reference\" content=\"citation_title=Factors associated with desistence and persistence of childhood gender dysphoria: a quantitative follow-up study; citation_author=Steensma  TD; citation_author=McGuire  JK; citation_author=Kreukels  BPC; citation_author=Beekman  AJ; citation_author=Cohen-Kettenis  PT;  citation_journal_title=J Am Acad Child Adolesc Psychiatry;  citation_year=2013;  citation_volume=52;  citation_issue=6;  citation_pages=582-590; \" /><meta name=\"citation_reference\" content=\"citation_title=Demographic characteristics, social competence, and behavior problems in children with gender identity disorder: a cross-national, cross-clinic comparative analysis; citation_author=Cohen-Kettenis  PT; citation_author=Owen  A; citation_author=Kaijser  VG; citation_author=Bradley  SJ; citation_author=Zucker  KJ;  citation_journal_title=J Abnorm Child Psychol;  citation_year=2003;  citation_volume=31;  citation_issue=1;  citation_pages=41-53; \" /><meta name=\"citation_reference\" content=\"citation_title=Mental health and gender dysphoria: a review of the literature; citation_author=Dhejne  C; citation_author=Van Vlerken  R; citation_author=Heylens  G; citation_author=Arcelus  J;  citation_journal_title=Int Rev Psychiatry;  citation_year=2016;  citation_volume=28;  citation_issue=1;  citation_pages=44-57; \" /><meta name=\"citation_reference\" content=\"citation_title=Traits of autism spectrum disorders in adults with gender dysphoria; citation_author=Pasterski  V; citation_author=Gilligan  L; citation_author=Curtis  R;  citation_journal_title=Arch Sex Behav;  citation_year=2014;  citation_volume=43;  citation_issue=2;  citation_pages=387-393; \" /><meta name=\"citation_reference\" content=\"citation_title=Children and adolescents with gender identity disorder referred to a pediatric medical center; citation_author=Spack  NP; citation_author=Edwards-Leeper  L; citation_author=Feldman  HA; citation_author=Leibowitz  S; citation_author=Mandel  F; citation_author=Diamond  DA; citation_author=Vance  SR;  citation_journal_title=Pediatrics;  citation_year=2012;  citation_volume=129;  citation_issue=3;  citation_pages=418-425; \" /><meta name=\"citation_reference\" content=\"citation_title=Factors predicting psychiatric co-morbidity in gender-dysphoric adults; citation_author=Terada  S; citation_author=Matsumoto  Y; citation_author=Sato  T; citation_author=Okabe  N; citation_author=Kishimoto  Y; citation_author=Uchitomi  Y;  citation_journal_title=Psychiatry Res;  citation_year=2012;  citation_volume=200;  citation_issue=2-3;  citation_pages=469-474; \" /><meta name=\"citation_reference\" content=\"citation_title=Autism spectrum disorder risk factors and autistic traits in gender dysphoric children; citation_author=VanderLaan  DP; citation_author=Leef  JH; citation_author=Wood  H; citation_author=Hughes  SK; citation_author=Zucker  KJ;  citation_journal_title=J Autism Dev Disord;  citation_year=2015;  citation_volume=45;  citation_issue=6;  citation_pages=1742-1750; \" /><meta name=\"citation_reference\" content=\"citation_title=Psychiatric comorbidity in gender dysphoric adolescents; citation_author=de Vries  ALC; citation_author=Doreleijers  TAH; citation_author=Steensma  TD; citation_author=Cohen-Kettenis  PT;  citation_journal_title=J Child Psychol Psychiatry;  citation_year=2011;  citation_volume=52;  citation_issue=11;  citation_pages=1195-1202; \" /><meta name=\"citation_reference\" content=\"citation_title=Autism spectrum disorders in gender dysphoric children and adolescents; citation_author=de Vries  ALC; citation_author=Noens  ILJ; citation_author=Cohen-Kettenis  PT; citation_author=van Berckelaer-Onnes  IA; citation_author=Doreleijers  TA;  citation_journal_title=J Autism Dev Disord;  citation_year=2010;  citation_volume=40;  citation_issue=8;  citation_pages=930-936; \" /><meta name=\"citation_reference\" content=\"citation_title=Psychiatric comorbidity among children with gender identity disorder; citation_author=Wallien  MSC; citation_author=Swaab  H; citation_author=Cohen-Kettenis  PT;  citation_journal_title=J Am Acad Child Adolesc Psychiatry;  citation_year=2007;  citation_volume=46;  citation_issue=10;  citation_pages=1307-1314; \" /><meta name=\"citation_reference\" content=\" Kuiper AJ, Cohen-Kettenis PT. Gender role reversal among postoperative transsexuals. Available at: https://www.atria.nl/ezines/web/IJT/97-03/numbers/symposion/ijtc0502.htm. Accessed 26 August 2016. \" /><meta name=\"citation_reference\" content=\"citation_title=Factors predictive of regret in sex reassignment; citation_author=Landén  M; citation_author=Wålinder  J; citation_author=Hambert  G; citation_author=Lundström  B;  citation_journal_title=Acta Psychiatr Scand;  citation_year=1998;  citation_volume=97;  citation_issue=4;  citation_pages=284-289; \" /><meta name=\"citation_reference\" content=\"citation_title=Regret after sex reassignment surgery in a male-to-female transsexual: a long-term follow-up; citation_author=Olsson  S-E; citation_author=Möller  A;  citation_journal_title=Arch Sex Behav;  citation_year=2006;  citation_volume=35;  citation_issue=4;  citation_pages=501-506; \" /><meta name=\"citation_reference\" content=\"citation_author=Pfäfflin  F; citation_author=Junge  A; citation_publisher=Schattauer, Stuttgart, Germany;  citation_title=Geschlechtsumwandlung: Abhandlungen zur Transsexualität;  citation_year=1992; \" /><meta name=\"citation_reference\" content=\"citation_title=Factors associated with satisfaction or regret following male-to-female sex reassignment surgery; citation_author=Lawrence  AA;  citation_journal_title=Arch Sex Behav;  citation_year=2003;  citation_volume=32;  citation_issue=4;  citation_pages=299-315; \" /><meta name=\"citation_reference\" content=\"citation_author=Cohen-Kettenis  PT; citation_author=Pfäfflin  F; citation_publisher=SAGE Publications, Thousand Oaks, CA;  citation_title=Transgenderism and Intersexuality in Childhood and Adolescence: Making Choices;  citation_year=2003; \" /><meta name=\"citation_reference\" content=\"Di Ceglie D, Freedman D, McPherson S, Richardson P. Children and adolescents referred to a specialist gender identity development service: clinical features and demographic characteristics. Available at: https://www.researchgate.net/publication/276061306_Children_and_Adolescents_Referred_to_a_Specialist_Gender_Identity_Development_Service_Clinical_Features_and_Demographic_Characteristics. Accessed 20 July 2017. \" /><meta name=\"citation_reference\" content=\"citation_title=Surgical treatment of gender dysphoria in adults and adolescents: recent developments, effectiveness, and challenges; citation_author=Gijs  L; citation_author=Brewaeys  A;  citation_journal_title=Annu Rev Sex Res;  citation_year=2007;  citation_volume=18;  citation_pages=178-224; \" /><meta name=\"citation_reference\" content=\"citation_title=Sex reassignment of adolescent transsexuals: a follow-up study; citation_author=Cohen-Kettenis  PT; citation_author=van Goozen  SHM;  citation_journal_title=J Am Acad Child Adolesc Psychiatry;  citation_year=1997;  citation_volume=36;  citation_issue=2;  citation_pages=263-271; \" /><meta name=\"citation_reference\" content=\"citation_title=Adolescents with gender identity disorder who were accepted or rejected for sex reassignment surgery: a prospective follow-up study; citation_author=Smith  YLS; citation_author=van Goozen  SHM; citation_author=Cohen-Kettenis  PT;  citation_journal_title=J Am Acad Child Adolesc Psychiatry;  citation_year=2001;  citation_volume=40;  citation_issue=4;  citation_pages=472-481; \" /><meta name=\"citation_reference\" content=\"citation_title=Sex reassignment: outcomes and predictors of treatment for adolescent and adult transsexuals; citation_author=Smith  YLS; citation_author=Van Goozen  SHM; citation_author=Kuiper  AJ; citation_author=Cohen-Kettenis  PT;  citation_journal_title=Psychol Med;  citation_year=2005;  citation_volume=35;  citation_issue=1;  citation_pages=89-99; \" /><meta name=\"citation_reference\" content=\"citation_title=Young adult psychological outcome after puberty suppression and gender reassignment; citation_author=de Vries  ALC; citation_author=McGuire  JK; citation_author=Steensma  TD; citation_author=Wagenaar  ECF; citation_author=Doreleijers  TAH; citation_author=Cohen-Kettenis  PT;  citation_journal_title=Pediatrics;  citation_year=2014;  citation_volume=134;  citation_issue=4;  citation_pages=696-704; \" /><meta name=\"citation_reference\" content=\"citation_title=Comorbidity of gender dysphoria and other major psychiatric diagnoses; citation_author=Cole  CM; citation_author=O’Boyle  M; citation_author=Emory  LE; citation_author=Meyer  WJ;  citation_journal_title=Arch Sex Behav;  citation_year=1997;  citation_volume=26;  citation_issue=1;  citation_pages=13-26; \" /><meta name=\"citation_reference\" content=\"citation_title=Puberty suppression in a gender-dysphoric adolescent: a 22-year follow-up; citation_author=Cohen-Kettenis  PT; citation_author=Schagen  SEE; citation_author=Steensma  TD; citation_author=de Vries  ALC; citation_author=Delemarre-van de Waal  HA;  citation_journal_title=Arch Sex Behav;  citation_year=2011;  citation_volume=40;  citation_issue=4;  citation_pages=843-847; \" /><meta name=\"citation_reference\" content=\"citation_title=Desire for amputation of a limb: paraphilia, psychosis, or a new type of identity disorder; citation_author=First  MB;  citation_journal_title=Psychol Med;  citation_year=2005;  citation_volume=35;  citation_issue=6;  citation_pages=919-928; \" /><meta name=\"citation_reference\" content=\"citation_title=Reproductive wish in transsexual men; citation_author=Wierckx  K; citation_author=Van Caenegem  E; citation_author=Pennings  G; citation_author=Elaut  E; citation_author=Dedecker  D; citation_author=Van de Peer  F; citation_author=Weyers  S; citation_author=De Sutter  P; citation_author=T’Sjoen  G;  citation_journal_title=Hum Reprod;  citation_year=2012;  citation_volume=27;  citation_issue=2;  citation_pages=483-487; \" /><meta name=\"citation_reference\" content=\"citation_title=Sperm freezing in transsexual women; citation_author=Wierckx  K; citation_author=Stuyver  I; citation_author=Weyers  S; citation_author=Hamada  A; citation_author=Agarwal  A; citation_author=De Sutter  P; citation_author=T’Sjoen  G;  citation_journal_title=Arch Sex Behav;  citation_year=2012;  citation_volume=41;  citation_issue=5;  citation_pages=1069-1071; \" /><meta name=\"citation_reference\" content=\"citation_title=Final height, gonadal function and bone mineral density of adolescent males with central precocious puberty after therapy with gonadotropin-releasing hormone analogues; citation_author=Bertelloni  S; citation_author=Baroncelli  GI; citation_author=Ferdeghini  M; citation_author=Menchini-Fabris  F; citation_author=Saggese  G;  citation_journal_title=Eur J Pediatr;  citation_year=2000;  citation_volume=159;  citation_issue=5;  citation_pages=369-374; \" /><meta name=\"citation_reference\" content=\"citation_title=Pulsatile GnRH or human chorionic gonadotropin/human menopausal gonadotropin as effective treatment for men with hypogonadotropic hypogonadism: a review of 42 cases; citation_author=Büchter  D; citation_author=Behre  HM; citation_author=Kliesch  S; citation_author=Nieschlag  E;  citation_journal_title=Eur J Endocrinol;  citation_year=1998;  citation_volume=139;  citation_issue=3;  citation_pages=298-303; \" /><meta name=\"citation_reference\" content=\"citation_title=Efficacy and safety of recombinant human follicle stimulating hormone (Gonal-F) with urinary human chorionic gonadotrophin for induction of spermatogenesis and fertility in gonadotrophin-deficient men; citation_author=Liu  PY; citation_author=Turner  L; citation_author=Rushford  D; citation_author=McDonald  J; citation_author=Baker  HW; citation_author=Conway  AJ; citation_author=Handelsman  DJ;  citation_journal_title=Hum Reprod;  citation_year=1999;  citation_volume=14;  citation_issue=6;  citation_pages=1540-1545; \" /><meta name=\"citation_reference\" content=\"citation_title=Long-term observation of 87 girls with idiopathic central precocious puberty treated with gonadotropin-releasing hormone analogs: impact on adult height, body mass index, bone mineral content, and reproductive function; citation_author=Pasquino  AM; citation_author=Pucarelli  I; citation_author=Accardo  F; citation_author=Demiraj  V; citation_author=Segni  M; citation_author=Di Nardo  R;  citation_journal_title=J Clin Endocrinol Metab;  citation_year=2008;  citation_volume=93;  citation_issue=1;  citation_pages=190-195; \" /><meta name=\"citation_reference\" content=\"citation_title=The efficacy and safety of gonadotropin-releasing hormone analog treatment in childhood and adolescence: a single center, long-term follow-up study; citation_author=Magiakou  MA; citation_author=Manousaki  D; citation_author=Papadaki  M; citation_author=Hadjidakis  D; citation_author=Levidou  G; citation_author=Vakaki  M; citation_author=Papaefstathiou  A; citation_author=Lalioti  N; citation_author=Kanaka-Gantenbein  C; citation_author=Piaditis  G; citation_author=Chrousos  GP; citation_author=Dacou-Voutetakis  C;  citation_journal_title=J Clin Endocrinol Metab;  citation_year=2010;  citation_volume=95;  citation_issue=1;  citation_pages=109-117; \" /><meta name=\"citation_reference\" content=\"citation_title=Association between polycystic ovary syndrome and female-to-male transsexuality; citation_author=Baba  T; citation_author=Endo  T; citation_author=Honnma  H; citation_author=Kitajima  Y; citation_author=Hayashi  T; citation_author=Ikeda  H; citation_author=Masumori  N; citation_author=Kamiya  H; citation_author=Moriwaka  O; citation_author=Saito  T;  citation_journal_title=Hum Reprod;  citation_year=2007;  citation_volume=22;  citation_issue=4;  citation_pages=1011-1016; \" /><meta name=\"citation_reference\" content=\"citation_title=The effects of long term testosterone administration on pulsatile luteinizing hormone secretion and on ovarian histology in eugonadal female to male transsexual subjects; citation_author=Spinder  T; citation_author=Spijkstra  JJ; citation_author=van den Tweel  JG; citation_author=Burger  CW; citation_author=van Kessel  H; citation_author=Hompes  PGA; citation_author=Gooren  LJG;  citation_journal_title=J Clin Endocrinol Metab;  citation_year=1989;  citation_volume=69;  citation_issue=1;  citation_pages=151-157; \" /><meta name=\"citation_reference\" content=\"citation_title=Distinctive features of female-to-male transsexualism and prevalence of gender identity disorder in Japan; citation_author=Baba  T; citation_author=Endo  T; citation_author=Ikeda  K; citation_author=Shimizu  A; citation_author=Honnma  H; citation_author=Ikeda  H; citation_author=Masumori  N; citation_author=Ohmura  T; citation_author=Kiya  T; citation_author=Fujimoto  T; citation_author=Koizumi  M; citation_author=Saito  T;  citation_journal_title=J Sex Med;  citation_year=2011;  citation_volume=8;  citation_issue=6;  citation_pages=1686-1693; \" /><meta name=\"citation_reference\" content=\"citation_title=Transsexualism in Serbia: a twenty-year follow-up study; citation_author=Vujovic  S; citation_author=Popovic  S; citation_author=Sbutega-Milosevic  G; citation_author=Djordjevic  M; citation_author=Gooren  L;  citation_journal_title=J Sex Med;  citation_year=2009;  citation_volume=6;  citation_issue=4;  citation_pages=1018-1023; \" /><meta name=\"citation_reference\" content=\"citation_title=Excessive androgen exposure in female-to-male transsexual persons of reproductive age induces hyperplasia of the ovarian cortex and stroma but not polycystic ovary morphology; citation_author=Ikeda  K; citation_author=Baba  T; citation_author=Noguchi  H; citation_author=Nagasawa  K; citation_author=Endo  T; citation_author=Kiya  T; citation_author=Saito  T;  citation_journal_title=Hum Reprod;  citation_year=2013;  citation_volume=28;  citation_issue=2;  citation_pages=453-461; \" /><meta name=\"citation_reference\" content=\" Trebay G. He’s pregnant. You’re speechles. New York Times. 22 June 2008. \" /><meta name=\"citation_reference\" content=\"citation_title=Transgender men who experienced pregnancy after female-to-male gender transitioning; citation_author=Light  AD; citation_author=Obedin-Maliver  J; citation_author=Sevelius  JM; citation_author=Kerns  JL;  citation_journal_title=Obstet Gynecol;  citation_year=2014;  citation_volume=124;  citation_issue=6;  citation_pages=1120-1127; \" /><meta name=\"citation_reference\" content=\"citation_title=Donor inseminations in partners of female-to-male transsexuals: should the question be asked?; citation_author=De Sutter  P;  citation_journal_title=Reprod Biomed Online;  citation_year=2003;  citation_volume=6;  citation_issue=3;  citation_pages=382\" /><meta name=\"citation_reference\" content=\"citation_title=Fertility options in transgender people; citation_author=De Roo  C; citation_author=Tilleman  K; citation_author=T’Sjoen  G; citation_author=De Sutter  P;  citation_journal_title=Int Rev Psychiatry;  citation_year=2016;  citation_volume=28;  citation_issue=1;  citation_pages=112-119; \" /><meta name=\"citation_reference\" content=\"citation_title=Luteinizing hormone and follicle stimulating hormone secretion patterns in boys throughout puberty measured using highly sensitive immunoradiometric assays; citation_author=Wennink  JMB; citation_author=Delemarre-van de Waal  HA; citation_author=Schoemaker  R; citation_author=Schoemaker  H; citation_author=Schoemaker  J;  citation_journal_title=Clin Endocrinol (Oxf);  citation_year=1989;  citation_volume=31;  citation_issue=5;  citation_pages=551-564; \" /><meta name=\"citation_reference\" content=\"citation_title=The treatment of adolescent transsexuals: changing insights; citation_author=Cohen-Kettenis  PT; citation_author=Delemarre-van de Waal  HA; citation_author=Gooren  LJG;  citation_journal_title=J Sex Med;  citation_year=2008;  citation_volume=5;  citation_issue=8;  citation_pages=1892-1897; \" /><meta name=\"citation_reference\" content=\"citation_title=Clinical management of gender identity disorder in adolescents: a protocol on psychological and paediatric endocrinology aspects; citation_author=Delemarre-van de Waal  HA; citation_author=Cohen-Kettenis  PT;  citation_journal_title=Eur J Endocrinol;  citation_year=2006;  citation_volume=155;  citation_pages=S131-S137; \" /><meta name=\"citation_reference\" content=\"citation_title=Puberty suppression in adolescents with gender identity disorder: a prospective follow-up study; citation_author=de Vries  ALC; citation_author=Steensma  TD; citation_author=Doreleijers  TAH; citation_author=Cohen-Kettenis  PT;  citation_journal_title=J Sex Med;  citation_year=2011;  citation_volume=8;  citation_issue=8;  citation_pages=2276-2283; \" /><meta name=\"citation_reference\" content=\"citation_title=Intestinal vaginoplasty revisited: a review of surgical techniques, complications, and sexual function; citation_author=Bouman  MB; citation_author=van Zeijl  MCT; citation_author=Buncamper  ME; citation_author=Meijerink  WJHJ; citation_author=van Bodegraven  AA; citation_author=Mullender  MG;  citation_journal_title=J Sex Med;  citation_year=2014;  citation_volume=11;  citation_issue=7;  citation_pages=1835-1847; \" /><meta name=\"citation_reference\" content=\"citation_title=Consensus statement on the use of gonadotropin-releasing hormone analogs in children; citation_author=ESPE-LWPES GnRH Analogs Consensus Conference Group; citation_author=Carel  JC; citation_author=Eugster  EA; citation_author=Rogol  A; citation_author=Ghizzoni  L; citation_author=Palmert  MR; citation_author=Antoniazzi  F; citation_author=Berenbaum  S; citation_author=Bourguignon  JP; citation_author=Chrousos  GP; citation_author=Coste  J; citation_author=Deal  S; citation_author=de Vries  L; citation_author=Foster  C; citation_author=Heger  S; citation_author=Holland  J; citation_author=Jahnukainen  K; citation_author=Juul  A; citation_author=Kaplowitz  P; citation_author=Lahlou  N; citation_author=Lee  MM; citation_author=Lee  P; citation_author=Merke  DP; citation_author=Neely  EK; citation_author=Oostdijk  W; citation_author=Phillip  M; citation_author=Rosenfield  RL; citation_author=Shulman  D; citation_author=Styne  D; citation_author=Tauber  M; citation_author=Wit  JM;  citation_journal_title=Pediatrics;  citation_year=2009;  citation_volume=123;  citation_issue=4;  citation_pages=e752-e762; \" /><meta name=\"citation_reference\" content=\"citation_title=Antagonistic and agonistic GnRH analogue treatment of precocious puberty: tracking gonadotropin concentrations in urine; citation_author=Roth  CL; citation_author=Brendel  L; citation_author=Rückert  C; citation_author=Hartmann  K;  citation_journal_title=Horm Res;  citation_year=2005;  citation_volume=63;  citation_issue=5;  citation_pages=257-262; \" /><meta name=\"citation_reference\" content=\"citation_title=Therapeutic potential of GnRH antagonists in the treatment of precocious puberty; citation_author=Roth  C;  citation_journal_title=Expert Opin Investig Drugs;  citation_year=2002;  citation_volume=11;  citation_issue=9;  citation_pages=1253-1259; \" /><meta name=\"citation_reference\" content=\"citation_title=Treatment of central precocious puberty; citation_author=Tuvemo  T;  citation_journal_title=Expert Opin Investig Drugs;  citation_year=2006;  citation_volume=15;  citation_issue=5;  citation_pages=495-505; \" /><meta name=\"citation_reference\" content=\"citation_title=Efficacy and safety of gonadotropin-releasing hormone agonist treatment to suppress puberty in gender dysphoric adolescents; citation_author=Schagen  SE; citation_author=Cohen-Kettenis  PT; citation_author=Delemarre-van de Waal  HA; citation_author=Hannema  SE;  citation_journal_title=J Sex Med;  citation_year=2016;  citation_volume=13;  citation_issue=7;  citation_pages=1125-1132; \" /><meta name=\"citation_reference\" content=\"citation_title=Resumption of puberty after long term luteinizing hormone-releasing hormone agonist treatment of central precocious puberty; citation_author=Manasco  PK; citation_author=Pescovitz  OH; citation_author=Feuillan  PP; citation_author=Hench  KD; citation_author=Barnes  KM; citation_author=Jones  J; citation_author=Hill  SC; citation_author=Loriaux  DL; citation_author=Cutler  GB;  citation_journal_title=J Clin Endocrinol Metab;  citation_year=1988;  citation_volume=67;  citation_issue=2;  citation_pages=368-372; \" /><meta name=\"citation_reference\" content=\"citation_title=Bone mass in young adulthood following gonadotropin-releasing hormone analog treatment and cross-sex hormone treatment in adolescents with gender dysphoria; citation_author=Klink  D; citation_author=Caris  M; citation_author=Heijboer  A; citation_author=van Trotsenburg  M; citation_author=Rotteveel  J;  citation_journal_title=J Clin Endocrinol Metab;  citation_year=2015;  citation_volume=100;  citation_issue=2;  citation_pages=E270-E275; \" /><meta name=\"citation_reference\" content=\"citation_title=A longitudinal evaluation of bone mineral density in adult men with histories of delayed puberty; citation_author=Finkelstein  JS; citation_author=Klibanski  A; citation_author=Neer  RM;  citation_journal_title=J Clin Endocrinol Metab;  citation_year=1996;  citation_volume=81;  citation_issue=3;  citation_pages=1152-1155; \" /><meta name=\"citation_reference\" content=\"citation_title=Normal volumetric bone mineral density and bone turnover in young men with histories of constitutional delay of puberty; citation_author=Bertelloni  S; citation_author=Baroncelli  GI; citation_author=Ferdeghini  M; citation_author=Perri  G; citation_author=Saggese  G;  citation_journal_title=J Clin Endocrinol Metab;  citation_year=1998;  citation_volume=83;  citation_issue=12;  citation_pages=4280-4283; \" /><meta name=\"citation_reference\" content=\"citation_title=Catch up in bone acquisition in young adult men with late normal puberty; citation_author=Darelid  A; citation_author=Ohlsson  C; citation_author=Nilsson  M; citation_author=Kindblom  JM; citation_author=Mellström  D; citation_author=Lorentzon  M;  citation_journal_title=J Bone Miner Res;  citation_year=2012;  citation_volume=27;  citation_issue=10;  citation_pages=2198-2207; \" /><meta name=\"citation_reference\" content=\"citation_title=Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs; citation_author=Mittan  D; citation_author=Lee  S; citation_author=Miller  E; citation_author=Perez  RC; citation_author=Basler  JW; citation_author=Bruder  JM;  citation_journal_title=J Clin Endocrinol Metab;  citation_year=2002;  citation_volume=87;  citation_issue=8;  citation_pages=3656-3661; \" /><meta name=\"citation_reference\" content=\"citation_title=Reduction of bone density: an effect of gonadotropin releasing hormone analogue treatment in central precocious puberty; citation_author=Saggese  G; citation_author=Bertelloni  S; citation_author=Baroncelli  GI; citation_author=Battini  R; citation_author=Franchi  G;  citation_journal_title=Eur J Pediatr;  citation_year=1993;  citation_volume=152;  citation_issue=9;  citation_pages=717-720; \" /><meta name=\"citation_reference\" content=\"citation_title=Bone mineral density during treatment of central precocious puberty; citation_author=Neely  EK; citation_author=Bachrach  LK; citation_author=Hintz  RL; citation_author=Habiby  RL; citation_author=Slemenda  CW; citation_author=Feezle  L; citation_author=Pescovitz  OH;  citation_journal_title=J Pediatr;  citation_year=1995;  citation_volume=127;  citation_issue=5;  citation_pages=819-822; \" /><meta name=\"citation_reference\" content=\"citation_title=Effect of central precocious puberty and gonadotropin-releasing hormone analogue treatment on peak bone mass and final height in females; citation_author=Bertelloni  S; citation_author=Baroncelli  GI; citation_author=Sorrentino  MC; citation_author=Perri  G; citation_author=Saggese  G;  citation_journal_title=Eur J Pediatr;  citation_year=1998;  citation_volume=157;  citation_issue=5;  citation_pages=363-367; \" /><meta name=\"citation_reference\" content=\"citation_title=Review of outcomes after cessation of gonadotropin-releasing hormone agonist treatment of girls with precocious puberty; citation_author=Thornton  P; citation_author=Silverman  LA; citation_author=Geffner  ME; citation_author=Neely  EK; citation_author=Gould  E; citation_author=Danoff  TM;  citation_journal_title=Pediatr Endocrinol Rev;  citation_year=2014;  citation_volume=11;  citation_issue=3;  citation_pages=306-317; \" /><meta name=\"citation_reference\" content=\"citation_title=Bone mineral density and body composition in short children born SGA during growth hormone and gonadotropin releasing hormone analog treatment; citation_author=Lem  AJ; citation_author=van der Kaay  DC; citation_author=Hokken-Koelega  AC;  citation_journal_title=J Clin Endocrinol Metab;  citation_year=2013;  citation_volume=98;  citation_issue=1;  citation_pages=77-86; \" /><meta name=\"citation_reference\" content=\"citation_title=Bone mass at final height in precocious puberty after gonadotropin-releasing hormone agonist with and without calcium supplementation; citation_author=Antoniazzi  F; citation_author=Zamboni  G; citation_author=Bertoldo  F; citation_author=Lauriola  S; citation_author=Mengarda  F; citation_author=Pietrobelli  A; citation_author=Tatò  L;  citation_journal_title=J Clin Endocrinol Metab;  citation_year=2003;  citation_volume=88;  citation_issue=3;  citation_pages=1096-1101; \" /><meta name=\"citation_reference\" content=\"citation_title=Hypertension during therapy with triptorelin in a girl with precocious puberty; citation_author=Calcaterra  V; citation_author=Mannarino  S; citation_author=Corana  G; citation_author=Codazzi  AC; citation_author=Mazzola  A; citation_author=Brambilla  P; citation_author=Larizza  D;  citation_journal_title=Indian J Pediatr;  citation_year=2013;  citation_volume=80;  citation_issue=10;  citation_pages=884-885; \" /><meta name=\"citation_reference\" content=\"citation_title=Arterial hypertension during treatment with triptorelin in a child with Williams-Beuren syndrome; citation_author=Siomou  E; citation_author=Kosmeri  C; citation_author=Pavlou  M; citation_author=Vlahos  AP; citation_author=Argyropoulou  MI; citation_author=Siamopoulou  A;  citation_journal_title=Pediatr Nephrol;  citation_year=2014;  citation_volume=29;  citation_issue=9;  citation_pages=1633-1636; \" /><meta name=\"citation_reference\" content=\"citation_title=Puberty suppression and executive functioning: an fMRI-study in adolescents with gender dysphoria; citation_author=Staphorsius  AS; citation_author=Kreukels  BPC; citation_author=Cohen-Kettenis  PT; citation_author=Veltman  DJ; citation_author=Burke  SM; citation_author=Schagen  SEE; citation_author=Wouters  FM; citation_author=Delemarre-van de Waal  HA; citation_author=Bakker  J;  citation_journal_title=Psychoneuroendocrinology;  citation_year=2015;  citation_volume=56;  citation_pages=190-199; \" /><meta name=\"citation_reference\" content=\"citation_title=Spatial memory is impaired by peripubertal GnRH agonist treatment and testosterone replacement in sheep; citation_author=Hough  D; citation_author=Bellingham  M; citation_author=Haraldsen  IR; citation_author=McLaughlin  M; citation_author=Rennie  M; citation_author=Robinson  JE; citation_author=Solbakk  AK; citation_author=Evans  NP;  citation_journal_title=Psychoneuroendocrinology;  citation_year=2017;  citation_volume=75;  citation_pages=173-182; \" /><meta name=\"citation_reference\" content=\"citation_title=Constitutional Isosexual Precocious Puberty; citation_author=Collipp  PJ; citation_author=Kaplan  SA; citation_author=Boyle  DC; citation_author=Plachte  F; citation_author=Kogut  MD;  citation_journal_title=Am J Dis Child;  citation_year=1964;  citation_volume=108;  citation_pages=399-405; \" /><meta name=\"citation_reference\" content=\"citation_title=Medroxyprogesterone and constitutional precocious puberty.; citation_author=Hahn  HB; citation_author=Hayles  AB; citation_author=Albert  A;  citation_journal_title=Mayo Clin Proc;  citation_year=1964;  citation_volume=39;  citation_pages=182-190; \" /><meta name=\"citation_reference\" content=\"citation_title=Idiopathic isosexual precocity; citation_author=Kaplan  SA; citation_author=Ling  SM; citation_author=Irani  NG;  citation_journal_title=Am J Dis Child;  citation_year=1968;  citation_volume=116;  citation_issue=6;  citation_pages=591-598; \" /><meta name=\"citation_reference\" content=\"citation_title=Treatment of idiopathic precocious puberty in boys; citation_author=Schoen  EJ;  citation_journal_title=J Clin Endocrinol Metab;  citation_year=1966;  citation_volume=26;  citation_issue=4;  citation_pages=363-370; \" /><meta name=\"citation_reference\" content=\"citation_title=Hormone treatment of the adult transsexual patient; citation_author=Gooren  L;  citation_journal_title=Horm Res;  citation_year=2005;  citation_volume=64;  citation_pages=31-36; \" /><meta name=\"citation_reference\" content=\"citation_title=Endocrine treatment of transsexual people: a review of treatment regimens, outcomes, and adverse effects; citation_author=Moore  E; citation_author=Wisniewski  A; citation_author=Dobs  A;  citation_journal_title=J Clin Endocrinol Metab;  citation_year=2003;  citation_volume=88;  citation_issue=8;  citation_pages=3467-3473; \" /><meta name=\"citation_reference\" content=\"citation_title=Prescription of medroxyprogesterone acetate to a patient with pedophilia, resulting in Cushing’s syndrome and adrenal insufficiency; citation_author=Krueger  RB; citation_author=Hembree  W; citation_author=Hill  M;  citation_journal_title=Sex Abuse;  citation_year=2006;  citation_volume=18;  citation_issue=2;  citation_pages=227-228; \" /><meta name=\"citation_reference\" content=\"citation_title=Retrospective study of the management of childhood and adolescent gender identity disorder using medroxyprogesterone acetate; citation_author=Lynch  MM; citation_author=Khandheria  MM; citation_author=Meyer  WJ;  citation_journal_title=Int J Transgenderism;  citation_year=2015;  citation_volume=16;  citation_pages=201-208; \" /><meta name=\"citation_reference\" content=\"citation_title=Consecutive lynestrenol and cross-sex hormone treatment in biological female adolescents with gender dysphoria: a retrospective analysis; citation_author=Tack  LJW; citation_author=Craen  M; citation_author=Dhondt  K; citation_author=Vanden Bossche  H; citation_author=Laridaen  J; citation_author=Cools  M;  citation_journal_title=Biol Sex Differ;  citation_year=2016;  citation_volume=7;  citation_pages=14\" /><meta name=\"citation_reference\" content=\"citation_title=Endocrine treatment of transsexual persons: an Endocrine Society clinical practice guideline; citation_author=Endocrine Society; citation_author=Hembree  WC; citation_author=Cohen-Kettenis  P; citation_author=Delemarre-van de Waal  HA; citation_author=Gooren  LJ; citation_author=Meyer  WJ; citation_author=Spack  NP; citation_author=Tangpricha  V; citation_author=Montori  VM;  citation_journal_title=J Clin Endocrinol Metab;  citation_year=2009;  citation_volume=94;  citation_issue=9;  citation_pages=3132-3154; \" /><meta name=\"citation_reference\" content=\"citation_title=Adolescent decision-making: the development of competence; citation_author=Mann  L; citation_author=Harmoni  R; citation_author=Power  C;  citation_journal_title=J Adolesc;  citation_year=1989;  citation_volume=12;  citation_issue=3;  citation_pages=265-278; \" /><meta name=\"citation_reference\" content=\"citation_title=Minors and informed consent: a comparative approach; citation_author=Stultiëns  L; citation_author=Goffin  T; citation_author=Borry  P; citation_author=Dierickx  K; citation_author=Nys  H;  citation_journal_title=Eur J Health Law;  citation_year=2007;  citation_volume=14;  citation_issue=1;  citation_pages=21-46; \" /><meta name=\"citation_reference\" content=\"Arshagouni P. “But I’m an adult now … sort of”. Adolescent consent in health care decision-making and the adolescent brain. Available at: http://digitalcommons.law.umaryland.edu/cgi/viewcontent.cgi?article=1124&amp;context=jhclp. Accessed 25 June 2017. \" /><meta name=\"citation_reference\" content=\"NHS. Prescribing of cross-sex hormones as part of the gender identity development service for children and adolescents. Available at: https://www.england.nhs.uk/commissioning/wp-content/uploads/sites/12/2016/08/clinical-com-pol-16046p.pdf. Accessed 14 June 2017. \" /><meta name=\"citation_reference\" content=\"citation_title=Physiological estrogen replacement therapy for puberty induction in girls: a clinical observational study; citation_author=Ankarberg-Lindgren  C; citation_author=Kriström  B; citation_author=Norjavaara  E;  citation_journal_title=Horm Res Paediatr;  citation_year=2014;  citation_volume=81;  citation_issue=4;  citation_pages=239-244; \" /><meta name=\"citation_reference\" content=\"citation_title=Subcutaneous testosterone: an effective delivery mechanism for masculinizing young transgender men; citation_author=Olson  J; citation_author=Schrager  SM; citation_author=Clark  LF; citation_author=Dunlap  SL; citation_author=Belzer  M;  citation_journal_title=LGBT Health;  citation_year=2014;  citation_volume=1;  citation_issue=3;  citation_pages=165-167; \" /><meta name=\"citation_reference\" content=\" Spratt DI,Stewart I,Savage C,Craig W,Spack NP,Chandler DW,Spratt LV,Eimicke T,Olshan JS. Subcutaneous injection of testosterone is an effective and preferred alternative to intramuscular injection: demonstration in female-to-male transgender patients. J Clin Endocrinol Metab. 2017. doi:10.1210/jc.2017-00359 \" /><meta name=\"citation_reference\" content=\"citation_title=Pharmacokinetics of testosterone and estradiol gel preparations in healthy young men; citation_author=Eisenegger  C; citation_author=von Eckardstein  A; citation_author=Fehr  E; citation_author=von Eckardstein  S;  citation_journal_title=Psychoneuroendocrinology;  citation_year=2013;  citation_volume=38;  citation_issue=2;  citation_pages=171-178; \" /><meta name=\"citation_reference\" content=\"citation_title=Effects of oestradiol on gonadotrophin levels in normal and castrated men; citation_author=de Ronde  W; citation_author=ten Kulve  J; citation_author=Woerdeman  J; citation_author=Kaufman  J-M; citation_author=de Jong  FH;  citation_journal_title=Clin Endocrinol (Oxf);  citation_year=2009;  citation_volume=71;  citation_issue=6;  citation_pages=874-879; \" /><meta name=\"citation_reference\" content=\" Money J, Ehrhardt A. Man &amp; woman, boy &amp; girl: differentiation and dimorphism of gender identity from conception to maturity.  Baltimore, MD : Johns Hopkins University Press ; 1972 : 202 – 206. \" /><meta name=\"citation_reference\" content=\"citation_title=Effects of different steps in gender reassignment therapy on psychopathology: a prospective study of persons with a gender identity disorder; citation_author=Heylens  G; citation_author=Verroken  C; citation_author=De Cock  S; citation_author=T’Sjoen  G; citation_author=De Cuypere  G;  citation_journal_title=J Sex Med;  citation_year=2014;  citation_volume=11;  citation_issue=1;  citation_pages=119-126; \" /><meta name=\"citation_reference\" content=\"citation_title=The effect of cross-sex hormonal treatment on gender dysphoria individuals’ mental health: a systematic review; citation_author=Costa  R; citation_author=Colizzi  M;  citation_journal_title=Neuropsychiatr Dis Treat;  citation_year=2016;  citation_volume=12;  citation_pages=1953-1966; \" /><meta name=\"citation_reference\" content=\"citation_title=Review of studies of androgen treatment of female-to-male transsexuals: effects and risks of administration of androgens to females; citation_author=Gooren  LJG; citation_author=Giltay  EJ;  citation_journal_title=J Sex Med;  citation_year=2008;  citation_volume=5;  citation_issue=4;  citation_pages=765-776; \" /><meta name=\"citation_reference\" content=\"citation_title=Endocrine intervention for transsexuals; citation_author=Levy  A; citation_author=Crown  A; citation_author=Reid  R;  citation_journal_title=Clin Endocrinol (Oxf);  citation_year=2003;  citation_volume=59;  citation_issue=4;  citation_pages=409-418; \" /><meta name=\"citation_reference\" content=\"citation_title=Endocrinologic treatment of gender identity disorders; citation_author=Tangpricha  V; citation_author=Ducharme  SH; citation_author=Barber  TW; citation_author=Chipkin  SR;  citation_journal_title=Endocr Pract;  citation_year=2003;  citation_volume=9;  citation_issue=1;  citation_pages=12-21; \" /><meta name=\"citation_reference\" content=\"citation_title=Endocrine care of transpeople part I. A review of cross-sex hormonal treatments, outcomes and adverse effects in transmen; citation_author=Meriggiola  MC; citation_author=Gava  G;  citation_journal_title=Clin Endocrinol (Oxf);  citation_year=2015;  citation_volume=83;  citation_issue=5;  citation_pages=597-606; \" /><meta name=\"citation_reference\" content=\"citation_title=Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline; citation_author=Bhasin  S; citation_author=Cunningham  GR; citation_author=Hayes  FJ; citation_author=Matsumoto  AM; citation_author=Snyder  PJ; citation_author=Swerdloff  RS; citation_author=Montori  VM;  citation_journal_title=J Clin Endocrinol Metab;  citation_year=2006;  citation_volume=91;  citation_issue=6;  citation_pages=1995-2010; \" /><meta name=\"citation_reference\" content=\"citation_title=Effects of three different testosterone formulations in female-to-male transsexual persons; citation_author=Pelusi  C; citation_author=Costantino  A; citation_author=Martelli  V; citation_author=Lambertini  M; citation_author=Bazzocchi  A; citation_author=Ponti  F; citation_author=Battista  G; citation_author=Venturoli  S; citation_author=Meriggiola  MC;  citation_journal_title=J Sex Med;  citation_year=2014;  citation_volume=11;  citation_issue=12;  citation_pages=3002-3011; \" /><meta name=\"citation_reference\" content=\"citation_title=Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial; citation_author=Women’s Health Initiative Steering Committee; citation_author=Anderson  GL; citation_author=Limacher  M; citation_author=Assaf  AR; citation_author=Bassford  T; citation_author=Beresford  SA; citation_author=Black  H; citation_author=Bonds  D; citation_author=Brunner  R; citation_author=Brzyski  R; citation_author=Caan  B; citation_author=Chlebowski  R; citation_author=Curb  D; citation_author=Gass  M; citation_author=Hays  J; citation_author=Heiss  G; citation_author=Hendrix  S; citation_author=Howard  BV; citation_author=Hsia  J; citation_author=Hubbell  A; citation_author=Jackson  R; citation_author=Johnson  KC; citation_author=Judd  H; citation_author=Kotchen  JM; citation_author=Kuller  L; citation_author=LaCroix  AZ; citation_author=Lane  D; citation_author=Langer  RD; citation_author=Lasser  N; citation_author=Lewis  CE; citation_author=Manson  J; citation_author=Margolis  K; citation_author=Ockene  J; citation_author=O’Sullivan  MJ; citation_author=Phillips  L; citation_author=Prentice  RL; citation_author=Ritenbaugh  C; citation_author=Robbins  J; citation_author=Rossouw  JE; citation_author=Sarto  G; citation_author=Stefanick  ML; citation_author=Van Horn  L; citation_author=Wactawski-Wende  J; citation_author=Wallace  R; citation_author=Wassertheil-Smoller  S;  citation_journal_title=JAMA;  citation_year=2004;  citation_volume=291;  citation_issue=14;  citation_pages=1701-1712; \" /><meta name=\"citation_reference\" content=\"citation_title=Hysterectomy compared with endometrial ablation for dysfunctional uterine bleeding: a randomized controlled trial; citation_author=Surgical Treatments Outcomes Project for Dysfunctional Uterine Bleeding (STOP-DUB) Research Group; citation_author=Dickersin  K; citation_author=Munro  MG; citation_author=Clark  M; citation_author=Langenberg  P; citation_author=Scherer  R; citation_author=Frick  K; citation_author=Zhu  Q; citation_author=Hallock  L; citation_author=Nichols  J; citation_author=Yalcinkaya  TM;  citation_journal_title=Obstet Gynecol;  citation_year=2007;  citation_volume=110;  citation_issue=6;  citation_pages=1279-1289; \" /><meta name=\"citation_reference\" content=\"citation_title=Long-term treatment of transsexuals with cross-sex hormones: extensive personal experience; citation_author=Gooren  LJ; citation_author=Giltay  EJ; citation_author=Bunck  MC;  citation_journal_title=J Clin Endocrinol Metab;  citation_year=2008;  citation_volume=93;  citation_issue=1;  citation_pages=19-25; \" /><meta name=\"citation_reference\" content=\"citation_title=Spironolactone with physiological female steroids for presurgical therapy of male-to-female transsexualism; citation_author=Prior  JC; citation_author=Vigna  YM; citation_author=Watson  D;  citation_journal_title=Arch Sex Behav;  citation_year=1989;  citation_volume=18;  citation_issue=1;  citation_pages=49-57; \" /><meta name=\"citation_reference\" content=\"citation_title=Endocrine treatment of male-to-female transsexuals using gonadotropin-releasing hormone agonist; citation_author=Dittrich  R; citation_author=Binder  H; citation_author=Cupisti  S; citation_author=Hoffmann  I; citation_author=Beckmann  MW; citation_author=Mueller  A;  citation_journal_title=Exp Clin Endocrinol Diabetes;  citation_year=2005;  citation_volume=113;  citation_issue=10;  citation_pages=586-592; \" /><meta name=\"citation_reference\" content=\"citation_title=Effect of spironolactone on sex hormones in man; citation_author=Stripp  B; citation_author=Taylor  AA; citation_author=Bartter  FC; citation_author=Gillette  JR; citation_author=Loriaux  DL; citation_author=Easley  R; citation_author=Menard  RH;  citation_journal_title=J Clin Endocrinol Metab;  citation_year=1975;  citation_volume=41;  citation_issue=4;  citation_pages=777-781; \" /><meta name=\"citation_reference\" content=\"citation_title=Interaction of spironolactone with oestradiol receptors in cytosol; citation_author=Levy  J; citation_author=Burshell  A; citation_author=Marbach  M; citation_author=Afllalo  L; citation_author=Glick  SM;  citation_journal_title=J Endocrinol;  citation_year=1980;  citation_volume=84;  citation_issue=3;  citation_pages=371-379; \" /><meta name=\"citation_reference\" content=\"citation_title=Sexual desire in trans persons: associations with sex reassignment treatment; citation_author=Wierckx  K; citation_author=Elaut  E; citation_author=Van Hoorde  B; citation_author=Heylens  G; citation_author=De Cuypere  G; citation_author=Monstrey  S; citation_author=Weyers  S; citation_author=Hoebeke  P; citation_author=T’Sjoen  G;  citation_journal_title=J Sex Med;  citation_year=2014;  citation_volume=11;  citation_issue=1;  citation_pages=107-118; \" /><meta name=\"citation_reference\" content=\"citation_title=An observational retrospective evaluation of 79 young men with long-term adverse effects after use of finasteride against androgenetic alopecia; citation_author=Chiriacò  G; citation_author=Cauci  S; citation_author=Mazzon  G; citation_author=Trombetta  C;  citation_journal_title=Andrology;  citation_year=2016;  citation_volume=4;  citation_issue=2;  citation_pages=245-250; \" /><meta name=\"citation_reference\" content=\"citation_title=Cyproterone acetate vs leuprolide acetate in combination with transdermal oestradiol in transwomen: a comparison of safety and effectiveness; citation_author=Gava  G; citation_author=Cerpolini  S; citation_author=Martelli  V; citation_author=Battista  G; citation_author=Seracchioli  R; citation_author=Meriggiola  MC;  citation_journal_title=Clin Endocrinol (Oxf);  citation_year=2016;  citation_volume=85;  citation_issue=2;  citation_pages=239-246; \" /><meta name=\"citation_reference\" content=\"citation_title=Rapid absorption of micronized estradiol-17 beta following sublingual administration; citation_author=Casper  RF; citation_author=Yen  SS;  citation_journal_title=Obstet Gynecol;  citation_year=1981;  citation_volume=57;  citation_issue=1;  citation_pages=62-64; \" /><meta name=\"citation_reference\" content=\"citation_title=Single-dose pharmacokinetics of sublingual versus oral administration of micronized 17β-estradiol; citation_author=Price  TM; citation_author=Blauer  KL; citation_author=Hansen  M; citation_author=Stanczyk  F; citation_author=Lobo  R; citation_author=Bates  GW;  citation_journal_title=Obstet Gynecol;  citation_year=1997;  citation_volume=89;  citation_issue=3;  citation_pages=340-345; \" /><meta name=\"citation_reference\" content=\"citation_title=Venous thrombosis and changes of hemostatic variables during cross-sex hormone treatment in transsexual people; citation_author=Toorians  AWFT; citation_author=Thomassen  MCLGD; citation_author=Zweegman  S; citation_author=Magdeleyns  EJP; citation_author=Tans  G; citation_author=Gooren  LJG; citation_author=Rosing  J;  citation_journal_title=J Clin Endocrinol Metab;  citation_year=2003;  citation_volume=88;  citation_issue=12;  citation_pages=5723-5729; \" /><meta name=\"citation_reference\" content=\"citation_title=People with gender dysphoria who self-prescribe cross-sex hormones: prevalence, sources, and side effects knowledge; citation_author=Mepham  N; citation_author=Bouman  WP; citation_author=Arcelus  J; citation_author=Hayter  M; citation_author=Wylie  KR;  citation_journal_title=J Sex Med;  citation_year=2014;  citation_volume=11;  citation_issue=12;  citation_pages=2995-3001; \" /><meta name=\"citation_reference\" content=\"citation_title=Non-binary or genderqueer genders; citation_author=Richards  C; citation_author=Bouman  WP; citation_author=Seal  L; citation_author=Barker  MJ; citation_author=Nieder  TO; citation_author=T’Sjoen  G;  citation_journal_title=Int Rev Psychiatry;  citation_year=2016;  citation_volume=28;  citation_issue=1;  citation_pages=95-102; \" /><meta name=\"citation_reference\" content=\"citation_title=Voice in female-to-male transsexual persons after long-term androgen therapy; citation_author=Cosyns  M; citation_author=Van Borsel  J; citation_author=Wierckx  K; citation_author=Dedecker  D; citation_author=Van de Peer  F; citation_author=Daelman  T; citation_author=Laenen  S; citation_author=T’Sjoen  G;  citation_journal_title=Laryngoscope;  citation_year=2014;  citation_volume=124;  citation_issue=6;  citation_pages=1409-1414; \" /><meta name=\"citation_reference\" content=\"citation_title=Voice deepening under testosterone treatment in female-to-male gender dysphoric individuals; citation_author=Deuster  D; citation_author=Matulat  P; citation_author=Knief  A; citation_author=Zitzmann  M; citation_author=Rosslau  K; citation_author=Szukaj  M; citation_author=am Zehnhoff-Dinnesen  A; citation_author=Schmidt  CM;  citation_journal_title=Eur Arch Otorhinolaryngol;  citation_year=2016;  citation_volume=273;  citation_issue=4;  citation_pages=959-965; \" /><meta name=\"citation_reference\" content=\"citation_title=Body composition, volumetric and areal bone parameters in male-to-female transsexual persons; citation_author=Lapauw  B; citation_author=Taes  Y; citation_author=Simoens  S; citation_author=Van Caenegem  E; citation_author=Weyers  S; citation_author=Goemaere  S; citation_author=Toye  K; citation_author=Kaufman  J-M; citation_author=T’Sjoen  GG;  citation_journal_title=Bone;  citation_year=2008;  citation_volume=43;  citation_issue=6;  citation_pages=1016-1021; \" /><meta name=\"citation_reference\" content=\"citation_title=Physical and hormonal evaluation of transsexual patients: a longitudinal study; citation_author=Meyer  WJ; citation_author=Webb  A; citation_author=Stuart  CA; citation_author=Finkelstein  JW; citation_author=Lawrence  B; citation_author=Walker  PA;  citation_journal_title=Arch Sex Behav;  citation_year=1986;  citation_volume=15;  citation_issue=2;  citation_pages=121-138; \" /><meta name=\"citation_reference\" content=\"citation_title=Prolactin levels and pituitary enlargement in hormone-treated male-to-female transsexuals; citation_author=Asscheman  H; citation_author=Gooren  LJ; citation_author=Assies  J; citation_author=Smits  JP; citation_author=de Slegte  R;  citation_journal_title=Clin Endocrinol (Oxf);  citation_year=1988;  citation_volume=28;  citation_issue=6;  citation_pages=583-588; \" /><meta name=\"citation_reference\" content=\"citation_title=Follow-up of prolactin levels in long-term oestrogen-treated male-to-female transsexuals with regard to prolactinoma induction; citation_author=Gooren  LJ; citation_author=Harmsen-Louman  W; citation_author=van Kessel  H;  citation_journal_title=Clin Endocrinol (Oxf);  citation_year=1985;  citation_volume=22;  citation_issue=2;  citation_pages=201-207; \" /><meta name=\"citation_reference\" content=\"citation_title=Cross-sex hormone therapy in trans persons is safe and effective at short-time follow-up: results from the European network for the investigation of gender incongruence; citation_author=Wierckx  K; citation_author=Van Caenegem  E; citation_author=Schreiner  T; citation_author=Haraldsen  I; citation_author=Fisher  AD; citation_author=Toye  K; citation_author=Kaufman  JM; citation_author=T’Sjoen  G;  citation_journal_title=J Sex Med;  citation_year=2014;  citation_volume=11;  citation_issue=8;  citation_pages=1999-2011; \" /><meta name=\"citation_reference\" content=\"citation_title=Incidence of thrombophilia and venous thrombosis in transsexuals under cross-sex hormone therapy; citation_author=Ott  J; citation_author=Kaufmann  U; citation_author=Bentz  EK; citation_author=Huber  JC; citation_author=Tempfer  CB;  citation_journal_title=Fertil Steril;  citation_year=2010;  citation_volume=93;  citation_issue=4;  citation_pages=1267-1272; \" /><meta name=\"citation_reference\" content=\"citation_title=Effects of sex steroids on plasma total homocysteine levels: a study in transsexual males and females; citation_author=Giltay  EJ; citation_author=Hoogeveen  EK; citation_author=Elbers  JMH; citation_author=Gooren  LJG; citation_author=Asscheman  H; citation_author=Stehouwer  CDA;  citation_journal_title=J Clin Endocrinol Metab;  citation_year=1998;  citation_volume=83;  citation_issue=2;  citation_pages=550-553; \" /><meta name=\"citation_reference\" content=\"citation_title=Mortality and morbidity in transsexual subjects treated with cross-sex hormones; citation_author=van Kesteren  PJM; citation_author=Asscheman  H; citation_author=Megens  JAJ; citation_author=Gooren  LJG;  citation_journal_title=Clin Endocrinol (Oxf);  citation_year=1997;  citation_volume=47;  citation_issue=3;  citation_pages=337-343; \" /><meta name=\"citation_reference\" content=\"citation_title=Clinical review: breast development in trans women receiving cross-sex hormones; citation_author=Wierckx  K; citation_author=Gooren  L; citation_author=T’Sjoen  G;  citation_journal_title=J Sex Med;  citation_year=2014;  citation_volume=11;  citation_issue=5;  citation_pages=1240-1247; \" /><meta name=\"citation_reference\" content=\"citation_title=Spontaneous rupture of a liver cell adenoma after long term methyltestosterone: report of a case successfully treated by emergency right hepatic lobectomy; citation_author=Bird  D; citation_author=Vowles  K; citation_author=Anthony  PP;  citation_journal_title=Br J Surg;  citation_year=1979;  citation_volume=66;  citation_issue=3;  citation_pages=212-213; \" /><meta name=\"citation_reference\" content=\"citation_title=Liver damage from long-term methyltestosterone; citation_author=Westaby  D; citation_author=Ogle  SJ; citation_author=Paradinas  FJ; citation_author=Randell  JB; citation_author=Murray-Lyon  IM;  citation_journal_title=Lancet;  citation_year=1977;  citation_volume=2;  citation_issue=8032;  citation_pages=262-263; \" /><meta name=\"citation_reference\" content=\"citation_title=Hormone therapy in transgender adults is safe with provider supervision; a review of hormone therapy sequelae for transgender individuals; citation_author=Weinand  JD; citation_author=Safer  JD;  citation_journal_title=J Clin Transl Endocrinol;  citation_year=2015;  citation_volume=2;  citation_issue=2;  citation_pages=55-60; \" /><meta name=\"citation_reference\" content=\"citation_title=Interpreting laboratory results in transgender patients on hormone therapy; citation_author=Roberts  TK; citation_author=Kraft  CS; citation_author=French  D; citation_author=Ji  W; citation_author=Wu  AH; citation_author=Tangpricha  V; citation_author=Fantz  CR;  citation_journal_title=Am J Med;  citation_year=2014;  citation_volume=127;  citation_issue=2;  citation_pages=159-162; \" /><meta name=\"citation_reference\" content=\"citation_title=Challenges and improvements in testosterone and estradiol testing; citation_author=Vesper  HW; citation_author=Botelho  JC; citation_author=Wang  Y;  citation_journal_title=Asian J Androl;  citation_year=2014;  citation_volume=16;  citation_issue=2;  citation_pages=178-184; \" /><meta name=\"citation_reference\" content=\"citation_title=Venous thrombo-embolism as a complication of cross-sex hormone treatment of male-to-female transsexual subjects: a review; citation_author=Asscheman  H; citation_author=T’Sjoen  G; citation_author=Lemaire  A; citation_author=Mas  M; citation_author=Meriggiola  MC; citation_author=Mueller  A; citation_author=Kuhn  A; citation_author=Dhejne  C; citation_author=Morel-Journel  N; citation_author=Gooren  LJ;  citation_journal_title=Andrologia;  citation_year=2014;  citation_volume=46;  citation_issue=7;  citation_pages=791-795; \" /><meta name=\"citation_reference\" content=\"citation_title=D-dimer for venous thromboembolism diagnosis: 20 years later; citation_author=Righini  M; citation_author=Perrier  A; citation_author=De Moerloose  P; citation_author=Bounameaux  H;  citation_journal_title=J Thromb Haemost;  citation_year=2008;  citation_volume=6;  citation_issue=7;  citation_pages=1059-1071; \" /><meta name=\"citation_reference\" content=\"citation_title=Estrogen-induced prolactinoma in a man; citation_author=Gooren  LJ; citation_author=Assies  J; citation_author=Asscheman  H; citation_author=de Slegte  R; citation_author=van Kessel  H;  citation_journal_title=J Clin Endocrinol Metab;  citation_year=1988;  citation_volume=66;  citation_issue=2;  citation_pages=444-446; \" /><meta name=\"citation_reference\" content=\"citation_title=Prolactin-producing pituitary adenoma in a male-to-female transsexual patient with protracted estrogen administration. A morphologic study; citation_author=Kovacs  K; citation_author=Stefaneanu  L; citation_author=Ezzat  S; citation_author=Smyth  HS;  citation_journal_title=Arch Pathol Lab Med;  citation_year=1994;  citation_volume=118;  citation_issue=5;  citation_pages=562-565; \" /><meta name=\"citation_reference\" content=\"citation_title=Lactotroph hyperplasia in an estrogen treated male-to-female transsexual patient; citation_author=Serri  O; citation_author=Noiseux  D; citation_author=Robert  F; citation_author=Hardy  J;  citation_journal_title=J Clin Endocrinol Metab;  citation_year=1996;  citation_volume=81;  citation_issue=9;  citation_pages=3177-3179; \" /><meta name=\"citation_reference\" content=\"citation_title=Diagnosis of prolactinoma in two male-to-female transsexual subjects following high-dose cross-sex hormone therapy; citation_author=Cunha  FS; citation_author=Domenice  S; citation_author=Câmara  VL; citation_author=Sircili  MH; citation_author=Gooren  LJ; citation_author=Mendonça  BB; citation_author=Costa  EM;  citation_journal_title=Andrologia;  citation_year=2015;  citation_volume=47;  citation_issue=6;  citation_pages=680-684; \" /><meta name=\"citation_reference\" content=\" Nota NM,Dekker MJHJ,Klaver M,Wiepjes CM,van Trotsenburg MA,Heijboer AC,den Heijer M. Prolactin levels during short- and long-term cross-sex hormone treatment: an observational study in transgender persons. Andrologia. 2017 ; 49(6). \" /><meta name=\"citation_reference\" content=\"citation_title=Autonomous prolactin secretion in two male-to-female transgender patients using conventional oestrogen dosages; citation_author=Bunck  MC; citation_author=Debono  M; citation_author=Giltay  EJ; citation_author=Verheijen  AT; citation_author=Diamant  M; citation_author=Gooren  LJ;  citation_journal_title=BMJ Case Rep;  citation_year=2009;  citation_volume=2009;  citation_pages=bcr0220091589\" /><meta name=\"citation_reference\" content=\"citation_title=Effect of sex steroid use on cardiovascular risk in transsexual individuals: a systematic review and meta-analyses; citation_author=Elamin  MB; citation_author=Garcia  MZ; citation_author=Murad  MH; citation_author=Erwin  PJ; citation_author=Montori  VM;  citation_journal_title=Clin Endocrinol (Oxf);  citation_year=2010;  citation_volume=72;  citation_issue=1;  citation_pages=1-10; \" /><meta name=\"citation_reference\" content=\"citation_title=Testosterone decreases adiponectin levels in female to male transsexuals; citation_author=Berra  M; citation_author=Armillotta  F; citation_author=D’Emidio  L; citation_author=Costantino  A; citation_author=Martorana  G; citation_author=Pelusi  G; citation_author=Meriggiola  MC;  citation_journal_title=Asian J Androl;  citation_year=2006;  citation_volume=8;  citation_issue=6;  citation_pages=725-729; \" /><meta name=\"citation_reference\" content=\"citation_title=Effects of sex steroids on components of the insulin resistance syndrome in transsexual subjects; citation_author=Elbers  JMH; citation_author=Giltay  EJ; citation_author=Teerlink  T; citation_author=Scheffer  PG; citation_author=Asscheman  H; citation_author=Seidell  JC; citation_author=Gooren  LJG;  citation_journal_title=Clin Endocrinol (Oxf);  citation_year=2003;  citation_volume=58;  citation_issue=5;  citation_pages=562-571; \" /><meta name=\"citation_reference\" content=\"citation_title=Sex steroids, insulin, and arterial stiffness in women and men; citation_author=Giltay  EJ; citation_author=Lambert  J; citation_author=Gooren  LJG; citation_author=Elbers  JMH; citation_author=Steyn  M; citation_author=Stehouwer  CDA;  citation_journal_title=Hypertension;  citation_year=1999;  citation_volume=34;  citation_issue=4 Pt 1;  citation_pages=590-597; \" /><meta name=\"citation_reference\" content=\"citation_title=Induction of insulin resistance by androgens and estrogens; citation_author=Polderman  KH; citation_author=Gooren  LJ; citation_author=Asscheman  H; citation_author=Bakker  A; citation_author=Heine  RJ;  citation_journal_title=J Clin Endocrinol Metab;  citation_year=1994;  citation_volume=79;  citation_issue=1;  citation_pages=265-271; \" /><meta name=\"citation_reference\" content=\"Maraka S. Effect of sex steroids on lipids, venous thromboembolism, cardiovascular disease and mortality in transgender individuals: a systematic review and meta-analysis. Available at: http://press.endocrine.org/doi/abs/10.1210/endo-meetings.2016.RE.15.FRI-136. Accessed 3 July 2017. \" /><meta name=\"citation_reference\" content=\"citation_title=Effects of testosterone undecanoate administered alone or in combination with letrozole or dutasteride in female to male transsexuals; citation_author=Meriggiola  MC; citation_author=Armillotta  F; citation_author=Costantino  A; citation_author=Altieri  P; citation_author=Saad  F; citation_author=Kalhorn  T; citation_author=Perrone  AM; citation_author=Ghi  T; citation_author=Pelusi  C; citation_author=Pelusi  G;  citation_journal_title=J Sex Med;  citation_year=2008;  citation_volume=5;  citation_issue=10;  citation_pages=2442-2453; \" /><meta name=\"citation_reference\" content=\"citation_title=Established risk factors for coronary heart disease are unrelated to androgen-induced baldness in female-to-male transsexuals; citation_author=Giltay  EJ; citation_author=Toorians  AW; citation_author=Sarabdjitsingh  AR; citation_author=de Vries  NA; citation_author=Gooren  LJ;  citation_journal_title=J Endocrinol;  citation_year=2004;  citation_volume=180;  citation_issue=1;  citation_pages=107-112; \" /><meta name=\"citation_reference\" content=\"citation_title=Oral and transdermal estrogens both lower plasma total homocysteine in male-to-female transsexuals; citation_author=Giltay  EJ; citation_author=Verhoef  P; citation_author=Gooren  LJG; citation_author=Geleijnse  JM; citation_author=Schouten  EG; citation_author=Stehouwer  CDA;  citation_journal_title=Atherosclerosis;  citation_year=2003;  citation_volume=168;  citation_issue=1;  citation_pages=139-146; \" /><meta name=\"citation_reference\" content=\"citation_title=Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials; citation_author=Calof  OM; citation_author=Singh  AB; citation_author=Lee  ML; citation_author=Kenny  AM; citation_author=Urban  RJ; citation_author=Tenover  JL; citation_author=Bhasin  S;  citation_journal_title=J Gerontol A Biol Sci Med Sci;  citation_year=2005;  citation_volume=60;  citation_issue=11;  citation_pages=1451-1457; \" /><meta name=\"citation_reference\" content=\"citation_title=Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III); citation_author=Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults;  citation_journal_title=JAMA;  citation_year=2001;  citation_volume=285;  citation_issue=19;  citation_pages=2486-2497; \" /><meta name=\"citation_reference\" content=\"citation_title=Hormonal therapy and sex reassignment: a systematic review and meta-analysis of quality of life and psychosocial outcomes; citation_author=Murad  MH; citation_author=Elamin  MB; citation_author=Garcia  MZ; citation_author=Mullan  RJ; citation_author=Murad  A; citation_author=Erwin  PJ; citation_author=Montori  VM;  citation_journal_title=Clin Endocrinol (Oxf);  citation_year=2010;  citation_volume=72;  citation_issue=2;  citation_pages=214-231; \" /><meta name=\"citation_reference\" content=\"citation_title=Body composition, bone turnover, and bone mass in trans men during testosterone treatment: 1-year follow-up data from a prospective case-controlled study (ENIGI); citation_author=Van Caenegem  E; citation_author=Wierckx  K; citation_author=Taes  Y; citation_author=Schreiner  T; citation_author=Vandewalle  S; citation_author=Toye  K; citation_author=Lapauw  B; citation_author=Kaufman  JM; citation_author=T’Sjoen  G;  citation_journal_title=Eur J Endocrinol;  citation_year=2015;  citation_volume=172;  citation_issue=2;  citation_pages=163-171; \" /><meta name=\"citation_reference\" content=\"citation_title=Testosterone increases bone mineral density in female-to-male transsexuals: a case series of 15 subjects; citation_author=Turner  A; citation_author=Chen  TC; citation_author=Barber  TW; citation_author=Malabanan  AO; citation_author=Holick  MF; citation_author=Tangpricha  V;  citation_journal_title=Clin Endocrinol (Oxf);  citation_year=2004;  citation_volume=61;  citation_issue=5;  citation_pages=560-566; \" /><meta name=\"citation_reference\" content=\"citation_title=Long-term follow-up of bone mineral density and bone metabolism in transsexuals treated with cross-sex hormones; citation_author=van Kesteren  P; citation_author=Lips  P; citation_author=Gooren  LJG; citation_author=Asscheman  H; citation_author=Megens  J;  citation_journal_title=Clin Endocrinol (Oxf);  citation_year=1998;  citation_volume=48;  citation_issue=3;  citation_pages=347-354; \" /><meta name=\"citation_reference\" content=\"citation_title=Low bone mass is prevalent in male-to-female transsexual persons before the start of cross-sex hormonal therapy and gonadectomy; citation_author=Van Caenegem  E; citation_author=Taes  Y; citation_author=Wierckx  K; citation_author=Vandewalle  S; citation_author=Toye  K; citation_author=Kaufman  JM; citation_author=Schreiner  T; citation_author=Haraldsen  I; citation_author=T’Sjoen  G;  citation_journal_title=Bone;  citation_year=2013;  citation_volume=54;  citation_issue=1;  citation_pages=92-97; \" /><meta name=\"citation_reference\" content=\"citation_title=Association of hypogonadism and estradiol levels with bone mineral density in elderly men from the Framingham study; citation_author=Amin  S; citation_author=Zhang  Y; citation_author=Sawin  CT; citation_author=Evans  SR; citation_author=Hannan  MT; citation_author=Kiel  DP; citation_author=Wilson  PW; citation_author=Felson  DT;  citation_journal_title=Ann Intern Med;  citation_year=2000;  citation_volume=133;  citation_issue=12;  citation_pages=951-963; \" /><meta name=\"citation_reference\" content=\"citation_title=Estrogen and fracture risk in men; citation_author=Gennari  L; citation_author=Khosla  S; citation_author=Bilezikian  JP;  citation_journal_title=J Bone Miner Res;  citation_year=2008;  citation_volume=23;  citation_issue=10;  citation_pages=1548-1551; \" /><meta name=\"citation_reference\" content=\"citation_title=Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: a key role for bioavailable estrogen; citation_author=Khosla  S; citation_author=Melton  LJ; citation_author=Atkinson  EJ; citation_author=O’Fallon  WM; citation_author=Klee  GG; citation_author=Riggs  BL;  citation_journal_title=J Clin Endocrinol Metab;  citation_year=1998;  citation_volume=83;  citation_issue=7;  citation_pages=2266-2274; \" /><meta name=\"citation_reference\" content=\"citation_title=High dose estrogen treatment increases bone mineral density in male-to-female transsexuals receiving gonadotropin-releasing hormone agonist in the absence of testosterone; citation_author=Mueller  A; citation_author=Dittrich  R; citation_author=Binder  H; citation_author=Kuehnel  W; citation_author=Maltaris  T; citation_author=Hoffmann  I; citation_author=Beckmann  MW;  citation_journal_title=Eur J Endocrinol;  citation_year=2005;  citation_volume=153;  citation_issue=1;  citation_pages=107-113; \" /><meta name=\"citation_reference\" content=\"citation_title=Cortical and trabecular bone mineral density in transsexuals after long-term cross-sex hormonal treatment: a cross-sectional study; citation_author=Ruetsche  AG; citation_author=Kneubuehl  R; citation_author=Birkhaeuser  MH; citation_author=Lippuner  K;  citation_journal_title=Osteoporos Int;  citation_year=2005;  citation_volume=16;  citation_issue=7;  citation_pages=791-798; \" /><meta name=\"citation_reference\" content=\"citation_title=Breast cancer in a trans-sexual man receiving hormone replacement therapy; citation_author=Ganly  I; citation_author=Taylor  EW;  citation_journal_title=Br J Surg;  citation_year=1995;  citation_volume=82;  citation_issue=3;  citation_pages=341\" /><meta name=\"citation_reference\" content=\"citation_title=Breast cancer in a male-to-female transsexual. A case report; citation_author=Pritchard  TJ; citation_author=Pankowsky  DA; citation_author=Crowe  JP; citation_author=Abdul-Karim  FW;  citation_journal_title=JAMA;  citation_year=1988;  citation_volume=259;  citation_issue=15;  citation_pages=2278-2280; \" /><meta name=\"citation_reference\" content=\"citation_title=Carcinoma of breast in trans-sexual individuals after surgical and hormonal interference with the primary and secondary sex characteristics; citation_author=Symmers  WS;  citation_journal_title=BMJ;  citation_year=1968;  citation_volume=2;  citation_issue=5597;  citation_pages=83-85; \" /><meta name=\"citation_reference\" content=\"citation_title=Breast cancer in transgender veterans: a ten-case series; citation_author=Brown  GR;  citation_journal_title=LGBT Health;  citation_year=2015;  citation_volume=2;  citation_issue=1;  citation_pages=77-80; \" /><meta name=\"citation_reference\" content=\"citation_title=Breast cancer in female-to-male transsexuals: two cases with a review of physiology and management; citation_author=Shao  T; citation_author=Grossbard  ML; citation_author=Klein  P;  citation_journal_title=Clin Breast Cancer;  citation_year=2011;  citation_volume=11;  citation_issue=6;  citation_pages=417-419; \" /><meta name=\"citation_reference\" content=\"citation_title=Importance of revealing a rare case of breast cancer in a female to male transsexual after bilateral mastectomy; citation_author=Nikolic  DV; citation_author=Djordjevic  ML; citation_author=Granic  M; citation_author=Nikolic  AT; citation_author=Stanimirovic  VV; citation_author=Zdravkovic  D; citation_author=Jelic  S;  citation_journal_title=World J Surg Oncol;  citation_year=2012;  citation_volume=10;  citation_pages=280\" /><meta name=\"citation_reference\" content=\"citation_title=Hormone replacement and the risk of breast cancer in Turner’s syndrome; citation_author=Bösze  P; citation_author=Tóth  A; citation_author=Török  M;  citation_journal_title=N Engl J Med;  citation_year=2006;  citation_volume=355;  citation_issue=24;  citation_pages=2599-2600; \" /><meta name=\"citation_reference\" content=\"citation_title=Cancer incidence in women with Turner syndrome in Great Britain: a national cohort study; citation_author=UK Clinical Cytogenetics Group; citation_author=Schoemaker  MJ; citation_author=Swerdlow  AJ; citation_author=Higgins  CD; citation_author=Wright  AF; citation_author=Jacobs  PA;  citation_journal_title=Lancet Oncol;  citation_year=2008;  citation_volume=9;  citation_issue=3;  citation_pages=239-246; \" /><meta name=\"citation_reference\" content=\"citation_title=American Cancer Society guidelines for the early detection of cancer, 2006; citation_author=Smith  RA; citation_author=Cokkinides  V; citation_author=Eyre  HJ;  citation_journal_title=CA Cancer J Clin;  citation_year=2006;  citation_volume=56;  citation_issue=1;  citation_pages=11-25, quiz 49–50; \" /><meta name=\"citation_reference\" content=\"citation_title=Long-term consequences of castration in men: lessons from the Skoptzy and the eunuchs of the Chinese and Ottoman courts; citation_author=Wilson  JD; citation_author=Roehrborn  C;  citation_journal_title=J Clin Endocrinol Metab;  citation_year=1999;  citation_volume=84;  citation_issue=12;  citation_pages=4324-4331; \" /><meta name=\"citation_reference\" content=\"citation_title=Effects of estrogens only on the prostates of aging men; citation_author=van Kesteren  P; citation_author=Meinhardt  W; citation_author=van der Valk  P; citation_author=Geldof  A; citation_author=Megens  J; citation_author=Gooren  L;  citation_journal_title=J Urol;  citation_year=1996;  citation_volume=156;  citation_issue=4;  citation_pages=1349-1353; \" /><meta name=\"citation_reference\" content=\"citation_title=Benign prostatic hyperplasia requiring transurethral resection of the prostate in a 60-year-old male-to-female transsexual; citation_author=Brown  JA; citation_author=Wilson  TM;  citation_journal_title=Br J Urol;  citation_year=1997;  citation_volume=80;  citation_issue=6;  citation_pages=956-957; \" /><meta name=\"citation_reference\" content=\"citation_title=Does the prostate really need androgens to grow? Transurethral resection of the prostate in a male-to-female transsexual 25 years after sex-changing operation; citation_author=Casella  R; citation_author=Bubendorf  L; citation_author=Schaefer  DJ; citation_author=Bachmann  A; citation_author=Gasser  TC; citation_author=Sulser  T;  citation_journal_title=Urol Int;  citation_year=2005;  citation_volume=75;  citation_issue=3;  citation_pages=288-290; \" /><meta name=\"citation_reference\" content=\"citation_title=Successful treatment of metastatic androgen-independent prostate carcinoma in a transsexual patient; citation_author=Dorff  TB; citation_author=Shazer  RL; citation_author=Nepomuceno  EM; citation_author=Tucker  SJ;  citation_journal_title=Clin Genitourin Cancer;  citation_year=2007;  citation_volume=5;  citation_issue=5;  citation_pages=344-346; \" /><meta name=\"citation_reference\" content=\"citation_title=Carcinoma of the prostate in a transsexual; citation_author=Thurston  AV;  citation_journal_title=Br J Urol;  citation_year=1994;  citation_volume=73;  citation_issue=2;  citation_pages=217\" /><meta name=\"citation_reference\" content=\" van Harst EP, Newling DW, Gooren LJ, Asscheman H, Prenger DM.  Metastatic prostatic carcinoma in a male-to-female transsexual. BJU Int. 1998 ; 81 : 776. \" /><meta name=\"citation_reference\" content=\"citation_title=Metastatic prostate cancer in transsexual diagnosed after three decades of estrogen therapy; citation_author=Turo  R; citation_author=Jallad  S; citation_author=Prescott  S; citation_author=Cross  WR;  citation_journal_title=Can Urol Assoc J;  citation_year=2013;  citation_volume=7;  citation_issue=7–8;  citation_pages=E544-E546; \" /><meta name=\"citation_reference\" content=\"citation_title=Prostate cancer in a transgender woman 41 years after initiation of feminization; citation_author=Miksad  RA; citation_author=Bubley  G; citation_author=Church  P; citation_author=Sanda  M; citation_author=Rofsky  N; citation_author=Kaplan  I; citation_author=Cooper  A;  citation_journal_title=JAMA;  citation_year=2006;  citation_volume=296;  citation_issue=19;  citation_pages=2316-2317; \" /><meta name=\"citation_reference\" content=\"citation_title=Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement; citation_author=U.S. Preventive Services Task Force; citation_author=Moyer  VA;  citation_journal_title=Ann Intern Med;  citation_year=2012;  citation_volume=157;  citation_issue=2;  citation_pages=120-134; \" /><meta name=\"citation_reference\" content=\"citation_title=Endocrine therapy of transsexualism and potential complications of long-term treatment; citation_author=Futterweit  W;  citation_journal_title=Arch Sex Behav;  citation_year=1998;  citation_volume=27;  citation_issue=2;  citation_pages=209-226; \" /><meta name=\"citation_reference\" content=\"citation_title=Histological changes in the genital tract in transsexual women following androgen therapy; citation_author=Miller  N; citation_author=Bédard  YC; citation_author=Cooter  NB; citation_author=Shaul  DL;  citation_journal_title=Histopathology;  citation_year=1986;  citation_volume=10;  citation_issue=7;  citation_pages=661-669; \" /><meta name=\"citation_reference\" content=\"citation_title=Total laparoscopic hysterectomy for female-to-male transsexuals; citation_author=O’Hanlan  KA; citation_author=Dibble  SL; citation_author=Young-Spint  M;  citation_journal_title=Obstet Gynecol;  citation_year=2007;  citation_volume=110;  citation_issue=5;  citation_pages=1096-1101; \" /><meta name=\"citation_reference\" content=\"citation_title=Ovarian cancer associated with testosterone supplementation in a female-to-male transsexual patient; citation_author=Dizon  DS; citation_author=Tejada-Berges  T; citation_author=Koelliker  S; citation_author=Steinhoff  M; citation_author=Granai  CO;  citation_journal_title=Gynecol Obstet Invest;  citation_year=2006;  citation_volume=62;  citation_issue=4;  citation_pages=226-228; \" /><meta name=\"citation_reference\" content=\"citation_title=Ovarian cancer in female-to-male transsexuals: report of two cases; citation_author=Hage  JJ; citation_author=Dekker  JJML; citation_author=Karim  RB; citation_author=Verheijen  RHM; citation_author=Bloemena  E;  citation_journal_title=Gynecol Oncol;  citation_year=2000;  citation_volume=76;  citation_issue=3;  citation_pages=413-415; \" /><meta name=\"citation_reference\" content=\"citation_title=Hormone-related tumors in transsexuals receiving treatment with cross-sex hormones; citation_author=Mueller  A; citation_author=Gooren  L;  citation_journal_title=Eur J Endocrinol;  citation_year=2008;  citation_volume=159;  citation_issue=3;  citation_pages=197-202; \" /><meta name=\"citation_reference\" content=\"citation_title=Standards of care for the health of transsexual, transgender, and gender-nonconforming people, version 7; citation_author=Coleman  E; citation_author=Bockting  W; citation_author=Botzer  M; citation_author=Cohen-Kettenis  P; citation_author=DeCuypere  G; citation_author=Feldman  J; citation_author=Fraser  L; citation_author=Green  J; citation_author=Knudson  G; citation_author=Meyer  WJ; citation_author=Monstrey  S; citation_author=Adler  RK; citation_author=Brown  GR; citation_author=Devor  AH; citation_author=Ehrbar  R; citation_author=Ettner  R; citation_author=Eyler  E; citation_author=Garofalo  R; citation_author=Karasic  DH; citation_author=Lev  AI; citation_author=Mayer  G; citation_author=Meyer-Bahlburg  H; citation_author=Hall  BP; citation_author=Pfaefflin  F; citation_author=Rachlin  K; citation_author=Robinson  B; citation_author=Schechter  LS; citation_author=Tangpricha  V; citation_author=van Trotsenburg  M; citation_author=Vitale  A; citation_author=Winter  S; citation_author=Whittle  S; citation_author=Wylie  KR; citation_author=Zucker  K;  citation_journal_title=Int J Transgenderism;  citation_year=2012;  citation_volume=13;  citation_pages=165-232; \" /><meta name=\"citation_reference\" content=\" Colebunders B,D’Arpa S,Weijers S,Lumen N,Hoebeke P,Monstrey S. Female-to-male gender reassignment surgery. In: Ettner R, Monstrey S, Coleman E, eds. Principles of Transgender Medicine and Surgery. 2nd ed. New York, NY: Routledge Taylor &amp; Francis Group; 2016:279–317.  \" /><meta name=\"citation_reference\" content=\"citation_title=Surgical therapy in transsexual patients: a multi-disciplinary approach; citation_author=Monstrey  S; citation_author=Hoebeke  P; citation_author=Dhont  M; citation_author=De Cuypere  G; citation_author=Rubens  R; citation_author=Moerman  M; citation_author=Hamdi  M; citation_author=Van Landuyt  K; citation_author=Blondeel  P;  citation_journal_title=Acta Chir Belg;  citation_year=2001;  citation_volume=101;  citation_issue=5;  citation_pages=200-209; \" /><meta name=\"citation_reference\" content=\"citation_title=Gender identity disorder: general overview and surgical treatment for vaginoplasty in male-to-female transsexuals; citation_author=Selvaggi  G; citation_author=Ceulemans  P; citation_author=De Cuypere  G; citation_author=VanLanduyt  K; citation_author=Blondeel  P; citation_author=Hamdi  M; citation_author=Bowman  C; citation_author=Monstrey  S;  citation_journal_title=Plast Reconstr Surg;  citation_year=2005;  citation_volume=116;  citation_issue=6;  citation_pages=135e-145e; \" /><meta name=\"citation_reference\" content=\"citation_title=Current management of male-to-female gender identity disorder in the UK; citation_author=Tugnet  N; citation_author=Goddard  JC; citation_author=Vickery  RM; citation_author=Khoosal  D; citation_author=Terry  TR;  citation_journal_title=Postgrad Med J;  citation_year=2007;  citation_volume=83;  citation_issue=984;  citation_pages=638-642; \" /><meta name=\"citation_reference\" content=\"citation_title=Outcome of vaginoplasty in male-to-female transgenders: a systematic review of surgical techniques; citation_author=Horbach  SER; citation_author=Bouman  M-B; citation_author=Smit  JM; citation_author=Özer  M; citation_author=Buncamper  ME; citation_author=Mullender  MG;  citation_journal_title=J Sex Med;  citation_year=2015;  citation_volume=12;  citation_issue=6;  citation_pages=1499-1512; \" /><meta name=\"citation_reference\" content=\"citation_title=Sex reassignment surgery for transsexuals; citation_author=Wroblewski  P; citation_author=Gustafsson  J; citation_author=Selvaggi  G;  citation_journal_title=Curr Opin Endocrinol Diabetes Obes;  citation_year=2013;  citation_volume=20;  citation_issue=6;  citation_pages=570-574; \" /><meta name=\"citation_reference\" content=\"citation_title=Long-term outcomes of rectosigmoid neocolporrhaphy in male-to-female gender reassignment surgery; citation_author=Morrison  SD; citation_author=Satterwhite  T; citation_author=Grant  DW; citation_author=Kirby  J; citation_author=Laub  DR; citation_author=VanMaasdam  J;  citation_journal_title=Plast Reconstr Surg;  citation_year=2015;  citation_volume=136;  citation_issue=2;  citation_pages=386-394; \" /><meta name=\"citation_reference\" content=\"citation_title=The use of cultured autologous oral epithelial cells for vaginoplasty in male-to-female transsexuals: a feasibility, safety, and advantageousness clinical pilot study; citation_author=Dessy  LA; citation_author=Mazzocchi  M; citation_author=Corrias  F; citation_author=Ceccarelli  S; citation_author=Marchese  C; citation_author=Scuderi  N;  citation_journal_title=Plast Reconstr Surg;  citation_year=2014;  citation_volume=133;  citation_issue=1;  citation_pages=158-161; \" /><meta name=\"citation_reference\" content=\"citation_title=Long-term outcomes of vaginoplasty with autologous buccal micromucosa; citation_author=Li  FY; citation_author=Xu  YS; citation_author=Zhou  CD; citation_author=Zhou  Y; citation_author=Li  SK; citation_author=Li  Q;  citation_journal_title=Obstet Gynecol;  citation_year=2014;  citation_volume=123;  citation_issue=5;  citation_pages=951-956; \" /><meta name=\"citation_reference\" content=\"citation_title=Sensate vagina pedicled-spot for male-to-female transsexuals: the experience in the first 50 patients; citation_author=Kanhai  RC;  citation_journal_title=Aesthetic Plast Surg;  citation_year=2016;  citation_volume=40;  citation_issue=2;  citation_pages=284-287; \" /><meta name=\"citation_reference\" content=\"citation_author=Straayer  C; \" /><meta name=\"citation_reference\" content=\"citation_title=Neovaginal prolapse in male-to-female transsexuals: an 18-year-long experience; citation_author=Bucci  S; citation_author=Mazzon  G; citation_author=Liguori  G; citation_author=Napoli  R; citation_author=Pavan  N; citation_author=Bormioli  S; citation_author=Ollandini  G; citation_author=De Concilio  B; citation_author=Trombetta  C.;  citation_journal_title=Biomed Res Int;  citation_year=2014;  citation_volume=2014;  citation_pages=240761\" /><meta name=\"citation_reference\" content=\"citation_title=Male-to-female genital reassignment surgery: a retrospective review of surgical technique and complications in 60 patients; citation_author=Raigosa  M; citation_author=Avvedimento  S; citation_author=Yoon  TS; citation_author=Cruz-Gimeno  J; citation_author=Rodriguez  G; citation_author=Fontdevila  J;  citation_journal_title=J Sex Med;  citation_year=2015;  citation_volume=12;  citation_issue=8;  citation_pages=1837-1845; \" /><meta name=\"citation_reference\" content=\"citation_title=Sexual functioning in post-operative transsexuals: male-to-female and female-to-male; citation_author=Green  R;  citation_journal_title=Int J Impot Res;  citation_year=1998;  citation_volume=10;  citation_pages=S22-S24; \" /><meta name=\"citation_reference\" content=\"citation_title=Satisfaction with male-to-female gender reassignment surgery; citation_author=Hess  J; citation_author=Rossi Neto  R; citation_author=Panic  L; citation_author=Rübben  H; citation_author=Senf  W;  citation_journal_title=Dtsch Arztebl Int;  citation_year=2014;  citation_volume=111;  citation_issue=47;  citation_pages=795-801; \" /><meta name=\"citation_reference\" content=\" Nygren U,Nordenskjold A,Arver S,Sodersten M. Effects on voice fundamental frequency and satisfaction with voice in trans men during testosterone treatment—a longitudinal study. J Voice. 2016;30(6):766.e23-766.e34. \" /><meta name=\"citation_reference\" content=\"citation_title=Transgender feminization of the facial skeleton; citation_author=Becking  AG; citation_author=Tuinzing  DB; citation_author=Hage  JJ; citation_author=Gooren  LJG;  citation_journal_title=Clin Plast Surg;  citation_year=2007;  citation_volume=34;  citation_issue=3;  citation_pages=557-564; \" /><meta name=\"citation_reference\" content=\"citation_title=Corona glans clitoroplasty and urethropreputial vestibuloplasty in male-to-female transsexuals: the vulval aesthetic refinement by the Andalusia Gender Team; citation_author=Andalusia Gender Team; citation_author=Giraldo  F; citation_author=Esteva  I; citation_author=Bergero  T; citation_author=Cano  G; citation_author=González  C; citation_author=Salinas  P; citation_author=Rivada  E; citation_author=Lara  JS; citation_author=Soriguer  F;  citation_journal_title=Plast Reconstr Surg;  citation_year=2004;  citation_volume=114;  citation_issue=6;  citation_pages=1543-1550; \" /><meta name=\"citation_reference\" content=\"citation_title=Development of feminizing genitoplasty for gender dysphoria; citation_author=Goddard  JC; citation_author=Vickery  RM; citation_author=Terry  TR;  citation_journal_title=J Sex Med;  citation_year=2007;  citation_volume=4;  citation_issue=4 Pt 1;  citation_pages=981-989; \" /><meta name=\"citation_reference\" content=\"citation_title=Sculpturing the glans in phalloplasty; citation_author=Hage  JJ; citation_author=de Graaf  FH; citation_author=Bouman  FG; citation_author=Bloem  JJAM;  citation_journal_title=Plast Reconstr Surg;  citation_year=1993;  citation_volume=92;  citation_issue=1;  citation_pages=157-161, discussion 162; \" /><meta name=\"citation_reference\" content=\"citation_title=Histopathology of the testes from male transsexuals on oestrogen therapy; citation_author=Thiagaraj  D; citation_author=Gunasegaram  R; citation_author=Loganath  A; citation_author=Peh  KL; citation_author=Kottegoda  SR; citation_author=Ratnam  SS;  citation_journal_title=Ann Acad Med Singapore;  citation_year=1987;  citation_volume=16;  citation_issue=2;  citation_pages=347-348; \" /><meta name=\"citation_reference\" content=\"citation_title=Sex reassignment surgery in the female-to-male transsexual; citation_author=Monstrey  SJ; citation_author=Ceulemans  P; citation_author=Hoebeke  P;  citation_journal_title=Semin Plast Surg;  citation_year=2011;  citation_volume=25;  citation_issue=3;  citation_pages=229-244; \" /><meta name=\"citation_reference\" content=\"citation_title=Total phalloplasty using a musculocutaneous latissimus dorsi flap; citation_author=Perovic  SV; citation_author=Djinovic  R; citation_author=Bumbasirevic  M; citation_author=Djordjevic  M; citation_author=Vukovic  P;  citation_journal_title=BJU Int;  citation_year=2007;  citation_volume=100;  citation_issue=4;  citation_pages=899-905, discussion 905; \" /><meta name=\"citation_reference\" content=\"citation_title=New technique of total phalloplasty with reinnervated latissimus dorsi myocutaneous free flap in female-to-male transsexuals; citation_author=Vesely  J; citation_author=Hyza  P; citation_author=Ranno  R; citation_author=Cigna  E; citation_author=Monni  N; citation_author=Stupka  I; citation_author=Justan  I; citation_author=Dvorak  Z; citation_author=Novak  P; citation_author=Ranno  S;  citation_journal_title=Ann Plast Surg;  citation_year=2007;  citation_volume=58;  citation_issue=5;  citation_pages=544-550; \" /><meta name=\"citation_reference\" content=\"citation_title=Neo-phalloplasty with re-innervated latissimus dorsi free flap: a functional study of a novel technique; citation_author=Ranno  R; citation_author=Veselý  J; citation_author=Hýza  P; citation_author=Stupka  I; citation_author=Justan  I; citation_author=Dvorák  Z; citation_author=Monni  N; citation_author=Novák  P; citation_author=Ranno  S;  citation_journal_title=Acta Chir Plast;  citation_year=2007;  citation_volume=49;  citation_issue=1;  citation_pages=3-7; \" /><meta name=\"citation_reference\" content=\"citation_title=Overall satisfaction, sexual function, and the durability of neophallus dimensions following staged female to male genital gender confirming surgery: the Institute of Urology, London U.K. experience; citation_author=Garcia  MM; citation_author=Christopher  NA; citation_author=De Luca  F; citation_author=Spilotros  M; citation_author=Ralph  DJ;  citation_journal_title=Transl Androl Urol;  citation_year=2014;  citation_volume=3;  citation_issue=2;  citation_pages=156-162; \" /><meta name=\"citation_reference\" content=\"citation_title=Prefabrication of the free fibula osteocutaneous flap to create a functional human penis using a controlled fistula method; citation_author=Chen  H-C; citation_author=Gedebou  TM; citation_author=Yazar  S; citation_author=Tang  Y-B;  citation_journal_title=J Reconstr Microsurg;  citation_year=2007;  citation_volume=23;  citation_issue=3;  citation_pages=151-154; \" /><meta name=\"citation_reference\" content=\"citation_title=Erectile implants in female-to-male transsexuals: our experience in 129 patients; citation_author=Hoebeke  PB; citation_author=Decaestecker  K; citation_author=Beysens  M; citation_author=Opdenakker  Y; citation_author=Lumen  N; citation_author=Monstrey  SM;  citation_journal_title=Eur Urol;  citation_year=2010;  citation_volume=57;  citation_issue=2;  citation_pages=334-341; \" /><meta name=\"citation_reference\" content=\"citation_title=Metaidoioplasty: an alternative phalloplasty technique in transsexuals; citation_author=Hage  JJ;  citation_journal_title=Plast Reconstr Surg;  citation_year=1996;  citation_volume=97;  citation_issue=1;  citation_pages=161-167; \" /><meta name=\"citation_reference\" content=\"citation_title=Extensive metoidioplasty as a technique capable of creating a compatible analogue to a natural penis in female transsexuals; citation_author=Cohanzad  S;  citation_journal_title=Aesthetic Plast Surg;  citation_year=2016;  citation_volume=40;  citation_issue=1;  citation_pages=130-138; \" /><meta name=\"citation_reference\" content=\"citation_title=Scrotal reconstruction in female-to-male transsexuals: a novel scrotoplasty; citation_author=Selvaggi  G; citation_author=Hoebeke  P; citation_author=Ceulemans  P; citation_author=Hamdi  M; citation_author=Van Landuyt  K; citation_author=Blondeel  P; citation_author=De Cuypere  G; citation_author=Monstrey  S;  citation_journal_title=Plast Reconstr Surg;  citation_year=2009;  citation_volume=123;  citation_issue=6;  citation_pages=1710-1718; \" /><meta name=\"citation_reference\" content=\"citation_title=Improved results after implementation of the Ghent algorithm for subcutaneous mastectomy in female-to-male transsexuals; citation_author=Bjerrome Ahlin  H; citation_author=Kölby  L; citation_author=Elander  A; citation_author=Selvaggi  G;  citation_journal_title=J Plast Surg Hand Surg;  citation_year=2014;  citation_volume=48;  citation_issue=6;  citation_pages=362-367; \" /><meta name=\"citation_reference\" content=\"citation_title=Sexual reassignment surgery in female-to-male transsexuals: an algorithm for subcutaneous mastectomy; citation_author=Wolter  A; citation_author=Diedrichson  J; citation_author=Scholz  T; citation_author=Arens-Landwehr  A; citation_author=Liebau  J;  citation_journal_title=J Plast Reconstr Aesthet Surg;  citation_year=2015;  citation_volume=68;  citation_issue=2;  citation_pages=184-191; \" /><meta name=\"citation_reference\" content=\"citation_title=The case for bilateral mastectomy and male chest contouring for the female-to-male transsexual; citation_author=Richards  C; citation_author=Barrett  J;  citation_journal_title=Ann R Coll Surg Engl;  citation_year=2013;  citation_volume=95;  citation_issue=2;  citation_pages=93-95; \" /><meta name=\"citation_reference\" content=\"citation_title=Evaluation of surgical procedures for sex reassignment: a systematic review; citation_author=Sutcliffe  PA; citation_author=Dixon  S; citation_author=Akehurst  RL; citation_author=Wilkinson  A; citation_author=Shippam  A; citation_author=White  S; citation_author=Richards  R; citation_author=Caddy  CM;  citation_journal_title=J Plast Reconstr Aesthet Surg;  citation_year=2009;  citation_volume=62;  citation_issue=3;  citation_pages=294-306, discussion 306–308; \" /><meta name=\"citation_reference\" content=\"citation_title=Penile reconstruction/formation; citation_author=Selvaggi  G; citation_author=Elander  A;  citation_journal_title=Curr Opin Urol;  citation_year=2008;  citation_volume=18;  citation_issue=6;  citation_pages=589-597; \" /><meta name=\"citation_reference\" content=\"citation_title=Long-term follow-up of transsexual persons undergoing sex reassignment surgery: cohort study in Sweden; citation_author=Dhejne  C; citation_author=Lichtenstein  P; citation_author=Boman  M; citation_author=Johansson  ALV; citation_author=Långström  N; citation_author=Landén  M;  citation_journal_title=PLoS One;  citation_year=2011;  citation_volume=6;  citation_issue=2;  citation_pages=e16885\" /><meta name=\"citation_reference\" content=\"citation_title=Quality of life 15 years after sex reassignment surgery for transsexualism; citation_author=Kuhn  A; citation_author=Bodmer  C; citation_author=Stadlmayr  W; citation_author=Kuhn  P; citation_author=Mueller  MD; citation_author=Birkhäuser  M;  citation_journal_title=Fertil Steril;  citation_year=2009;  citation_volume=92;  citation_issue=5;  citation_pages=1685-1689.e3; \" /><meta name=\"citation_reference\" content=\"citation_title=Quality of life and patient satisfaction following male-to-female sex reassignment surgery; citation_author=Papadopulos  NA; citation_author=Lellé  JD; citation_author=Zavlin  D; citation_author=Herschbach  P; citation_author=Henrich  G; citation_author=Kovacs  L; citation_author=Ehrenberger  B; citation_author=Kluger  AK; citation_author=Machens  HG; citation_author=Schaff  J;  citation_journal_title=J Sex Med;  citation_year=2017;  citation_volume=14;  citation_issue=5;  citation_pages=721-730; \" /><meta name=\"citation_reference\" content=\"citation_title=Long-term follow-up of individuals undergoing sex-reassignment surgery: somatic morbidity and cause of death; citation_author=Simonsen  RK; citation_author=Hald  GM; citation_author=Kristensen  E; citation_author=Giraldi  A;  citation_journal_title=Sex Med;  citation_year=2016;  citation_volume=4;  citation_issue=1;  citation_pages=e60-e68; \" /><meta name=\"citation_reference\" content=\"citation_title=Reversal Surgery in regretful male-to-female transsexuals after sex reassignment surgery; citation_author=Djordjevic  ML; citation_author=Bizic  MR; citation_author=Duisin  D; citation_author=Bouman  MB; citation_author=Buncamper  M;  citation_journal_title=J Sex Med;  citation_year=2016;  citation_volume=13;  citation_issue=6;  citation_pages=1000-1007; \" /><meta name=\"citation_reference\" content=\"citation_title=Compliance with lipid-lowering therapy and its impact on cardiovascular morbidity and mortality; citation_author=Liberopoulos  EN; citation_author=Florentin  M; citation_author=Mikhailidis  DP; citation_author=Elisaf  MS;  citation_journal_title=Expert Opin Drug Saf;  citation_year=2008;  citation_volume=7;  citation_issue=6;  citation_pages=717-725; \" /><meta name=\"citation_reference\" content=\"citation_title=Implementation of evidence-based practices for surgical site infection prophylaxis: results of a pre- and postintervention study; citation_author=Forbes  SS; citation_author=Stephen  WJ; citation_author=Harper  WL; citation_author=Loeb  M; citation_author=Smith  R; citation_author=Christoffersen  EP; citation_author=McLean  RF;  citation_journal_title=J Am Coll Surg;  citation_year=2008;  citation_volume=207;  citation_issue=3;  citation_pages=336-341; \" /><meta name=\"citation_reference\" content=\"citation_title=Practices and attitudes of surgeons toward the prevention of surgical site infections: a provincial survey in Alberta, Canada; citation_author=Davis  PJ; citation_author=Spady  D; citation_author=de Gara  C; citation_author=Forgie  SE;  citation_journal_title=Infect Control Hosp Epidemiol;  citation_year=2008;  citation_volume=29;  citation_issue=12;  citation_pages=1164-1166; \" /><meta name=\"citation_fulltext_world_readable\" content=\"\" /><meta name=\"citation_pdf_url\" content=\"https://academic.oup.com/jcem/article-pdf/102/11/3869/21533864/jc.2017-01658.pdf\" /><meta name=\"description\" content=\"Gender affirmation is multidisciplinary treatment. Gender-dysphoric/gender-incongruent persons seek and/or are referred to endocrinologists to develop the physi\" /><meta name=\"citation_xml_url\" content=\"https://academic.oup.com/jcem/article-xml/102/11/3869/4157558\" />\n\r\n\r\n    <link rel=\"canonical\" href=\"https://academic.oup.com/jcem/article/102/11/3869/4157558\" />\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n    \r\n    \r\n\r\n\r\n<script async=\"async\" src=\"https://www.googletagservices.com/tag/js/gpt.js\"></script>\r\n<script>\r\n    var googletag = googletag || {};\r\n    googletag.cmd = googletag.cmd || [];\r\n</script>\r\n    \r\n        <script type='text/javascript'>\r\n            var gptAdSlots = [];\r\n            googletag.cmd.push(function() {\r\n                    \r\n                    var mapping_ad1 = googletag.sizeMapping()\r\n                        .addSize([1024, 0], [[970, 90], [728, 90]])\r\n                        .addSize([768, 0], [728, 90])\r\n                        .addSize([0, 0], [320, 50])\r\n                        .build();\r\n                    gptAdSlots[\"ad1\"] = googletag.defineSlot('/9309/jcem_Supplement_Ad1',\r\n                            [[970, 90], [728, 90], [320, 50]], 'adBlockHeader')\r\n                        .defineSizeMapping(mapping_ad1)\r\n                        .addService(googletag.pubads());\r\n                    \r\n\r\n                    \r\n                    var mapping_ad2 = googletag.sizeMapping()\r\n                        .addSize([768, 0], [[300, 250], [300, 600], [160, 600]])\r\n                        .build();\r\n                    gptAdSlots[\"ad2\"] = googletag.defineSlot('/9309/jcem_Supplement_Ad2',\r\n                            [[300, 250], [160, 600], [300, 600]], 'adBlockMainBodyTop')\r\n                        .defineSizeMapping(mapping_ad2)\r\n                        .addService(googletag.pubads());\r\n                    \r\n\r\n                    \r\n                    var mapping_ad3 = googletag.sizeMapping()\r\n                        .addSize([768, 0], [[300, 250], [300, 600], [160, 600]])\r\n                        .build();\r\n                    gptAdSlots[\"ad3\"] = googletag.defineSlot('/9309/jcem_Supplement_Ad3',\r\n                        [[300, 250], [160, 600], [300, 600]], 'adBlockMainBodyBottom')\r\n                        .defineSizeMapping(mapping_ad3)\r\n                        .addService(googletag.pubads());\r\n                    \r\n\r\n                    \r\n                var mapping_ad4 = googletag.sizeMapping()\r\n                        .addSize([0,0], [320, 50])\r\n                        .addSize([768, 0], [728, 90])\r\n                        .build();\r\n                    gptAdSlots[\"ad4\"] = googletag.defineSlot('/9309/jcem_Supplement_Ad4',\r\n                        [728, 90], 'adBlockFooter')\r\n                        .defineSizeMapping(mapping_ad4)\r\n                        .addService(googletag.pubads());\r\n                    \r\n\r\n                    \r\n                    gptAdSlots[\"adInterstital\"] = googletag.defineOutOfPageSlot('/9309/jcem_Interstitial_Ad',\r\n                        googletag.enums.OutOfPageFormat.INTERSTITIAL)\r\n                        .addService(googletag.pubads());\r\n                                        \r\n\r\n                googletag.pubads().addEventListener('slotRenderEnded', function (event) {\r\n                    if (!event.isEmpty) {\r\n                        $('.js-' + event.slot.getSlotElementId()).each(function () {\r\n                            if ($(this).find('iframe').length) {\r\n                                $(this).removeClass('hide');\r\n                            }\r\n                        });\r\n                    }\r\n                });\r\n\r\n                googletag.pubads().addEventListener('impressionViewable', function (event) {\r\n                    if (!event.isEmpty) {\r\n                        $('.js-' + event.slot.getSlotElementId()).each(function () {\r\n                            var $adblockDiv = $(this).find('.js-adblock');\r\n                            var $adText = $(this).find('.js-adblock-advertisement-text');\r\n                            if ($adblockDiv && $adblockDiv.is(':visible') && $adblockDiv.find('*').length > 1) {\r\n                                $adText.removeClass('hide');\r\n                            }\r\n                            else {\r\n                                $adText.addClass('hide');\r\n                            }\r\n                        });\r\n                    }\r\n                });\r\n\r\n                googletag.pubads().setTargeting(\"jnlspage\", \"article\");\r\n                googletag.pubads().setTargeting(\"jnlsurl\", \"jcem/article/102/11/3869/4157558\");\r\n                googletag.pubads().enableSingleRequest();\r\n                googletag.pubads().collapseEmptyDivs();\r\n            });\r\n        </script>\r\n    \r\n<input type=\"hidden\"\r\n       class=\"hfInterstitial\"\r\n       data-interstitiallinks=\"jcem/issue,jcem/advance-articles,jcem/advance-article,jcem/supplements,jcem/article,jcem/article-abstract,jcem/pages\"\r\n       data-subdomain=\"jcem\"/>\r\n\r\n\r\n    \r\n    \r\n    \r\n        <script type=\"text/javascript\">\r\n                googletag.cmd.push(function () {\r\n                    \r\n                    googletag.pubads().setTargeting(\"jnlsdoi\", \"10.1210/jc.2017-01658\");\r\n                    googletag.enableServices();\r\n                });\r\n        </script>\r\n\r\n\r\n\r\n\r\n    \r\n\r\n\r\n    <script>\r\n        var oupcookiepolicy_siteid = \"journals\";        // the website id\r\n        var oupcookiepolicy_messagetype = 'implied';                        // type of alert message e.g, implied / explicit\r\n        var oupcookiepolicy_preferredlanguage = \"en\";      // preferred language of the website\r\n        var oupcookiepolicy_impliedmessageclass = 'cookiepolicyimplied';    // the css class for implied alert message\r\n        var oupcookiepolicy_documentroot = '/';\t  \t\t\t                // the document root the cookie is set to\r\n    </script>\r\n    <noscript>We use cookies to enhance your experience on our website.By continuing to use our website, you are agreeing to our use of cookies. You can change your cookie settings at any time. <a href=\"https://global.oup.com/cookiepolicy/\"> Find out more</a></noscript>\r\n    <script type=\"text/javascript\">\r\n        var NTPT_PGEXTRA= 'event_type=full-text&supplier_tag=SC_Journals&object_type=Article&siteid=jcem&authzrequired=false&doi=10.1210/jc.2017-01658';\r\n    </script>\r\n\r\n\r\n\n\n    <script src=\"https://scholar.google.com/scholar_js/casa.js\" async></script>\n</head>\r\n\r\n<body data-sitename=\"thejournalofclinicalendocrinology&amp;metabolism\" class=\"off-canvas pg_Article pg_article   \" theme-jcem data-sitestyletemplate=\"Journal\" >\r\n            <noscript>\r\n                <iframe src=\"https://www.googletagmanager.com/ns.html?id=GTM-W6DD7HV\"\r\n                        height=\"0\" width=\"0\" style=\"display:none;visibility:hidden\"></iframe>\r\n            </noscript>\r\n            <a href=\"#skipNav\" class=\"skipnav\">Skip to Main Content</a>\r\n<input id=\"hdnSiteID\" name=\"hdnSiteID\" type=\"hidden\" value=\"5591\" /><input id=\"hdnAdDelaySeconds\" name=\"hdnAdDelaySeconds\" type=\"hidden\" value=\"7000\" /><input id=\"hdnAdConfigurationTop\" name=\"hdnAdConfigurationTop\" type=\"hidden\" value=\"scrolldelay\" /><input id=\"hdnAdConfigurationRightRail\" name=\"hdnAdConfigurationRightRail\" type=\"hidden\" value=\"sticky\" />\r\n    \r\n\r\n\r\n\r\n\r\n\r\n\r\n<div class=\"master-container js-master-container\">\r\n<section class=\"master-header row js-master-header vt-site-page-header\">\r\n    <div class=\"widget widget-SitePageHeader widget-instance-SitePageHeader\">\n        \r\n\r\n    <div class=\"ad-banner js-ad-banner-header\">\r\n    <div class=\"widget widget-AdBlock widget-instance-HeaderAd\">\n        <div class=\"adBlockHeader-wrap js-adBlockHeader hide\">\r\n    \r\n    <div id=\"adBlockHeader\" class=\"js-adblock at-adblock\">\r\n        <script>\r\n            \r\n            googletag.cmd.push(function () {\r\n                googletag.display('adBlockHeader');\r\n            });\r\n        </script>\r\n    </div>\r\n        <div class=\"advertisement-text js-adblock-advertisement-text hide\">Advertisement</div>\r\n</div> \n    </div>\n\r\n    </div>\r\n\r\n    <div class=\"oup-header sigma \">\r\n        <div class=\"center-inner-row\">\r\n\r\n<div class=\"oup-header-logo\">\r\n    <a href=\"/\">\r\n        <img src=\"//oup.silverchair-cdn.com/UI/app/svg/umbrella/oxford-academic-logo.svg\" alt=\"Oxford Academic\"\r\n             class=\"oup-header-image at-oup-header-image \" />\r\n    </a>\r\n</div>                <div class=\"widget widget-CustomNavLinks widget-instance-CustomNavLinksDeskTop\">\n            <div class=\"custom-nav-links-box\">\r\n            <div class=\"custom-nav-link\">\r\n                <a href=\"/journals\">Journals</a>\r\n            </div>\r\n            <div class=\"custom-nav-link\">\r\n                <a href=\"/books\">Books</a>\r\n            </div>\r\n\r\n    </div>\r\n \n    </div>\n            <ul class=\"oup-header-menu account-menu sigma-account-menu \">\r\n\r\n                \r\n                <li class=\"oup-header-menu-item mobile\">\r\n                    <a href=\"javascript:;\" class=\"mobile-dropdown-toggle mobile-search-toggle\">\r\n                        <i class=\"icon-menu_search\"><span class=\"screenreader-text\">Search Menu</span></i>\r\n                    </a>\r\n                </li>\r\n\r\n                \r\n                \r\n        <li class=\"oup-header-menu-item mobile info-icon-menu-item\">\r\n            <a href=\"/pages/information\" target=\"_blank\" class=\"at-info-button sigma-info-wrapper\" role=\"button\">\r\n            <img class=\"sigma-info-icon\" src=\"//oup.silverchair-cdn.com/UI/app/svg/i.svg\" alt=\"Information\" />\r\n            </a>\r\n        </li>\r\n    <li class=\"oup-header-menu-item mobile account-icon-menu-item\">\r\n        <a href=\"javascript:;\" class=\"account-button js-account-button at-account-button \"\r\n                role=\"button\" data-turnawayparams=\"\">\r\n            <img class=\"sigma-account-icon\" src=\"//oup.silverchair-cdn.com/UI/app/svg/account.svg\" alt=\"Account\" />\r\n        </a>\r\n    </li>\r\n\r\n                \r\n                <li class=\"oup-header-menu-item mobile\">\r\n                    <a href=\"javascript:;\" class=\"mobile-dropdown-toggle mobile-nav-toggle\">\r\n                        <i class=\"icon-menu_hamburger\"><span class=\"screenreader-text\">Menu</span></i>\r\n                    </a>\r\n                </li>\r\n\r\n                \r\n                \r\n        <li class=\"oup-header-menu-item desktop info-icon-menu-item\">\r\n            <a href=\"/pages/information\" target=\"_blank\" class=\"at-info-button sigma-info-wrapper\" role=\"button\">\r\n            <img class=\"sigma-info-icon\" src=\"//oup.silverchair-cdn.com/UI/app/svg/i.svg\" alt=\"Information\" />\r\n            </a>\r\n        </li>\r\n    <li class=\"oup-header-menu-item desktop account-icon-menu-item\">\r\n        <a href=\"javascript:;\" class=\"account-button js-account-button at-account-button sigma-logo-wrapper\"\r\n                role=\"button\" data-turnawayparams=\"\">\r\n            <img class=\"sigma-account-icon\" src=\"//oup.silverchair-cdn.com/UI/app/svg/account.svg\" alt=\"Account\" />\r\n        </a>\r\n    </li>\r\n\r\n                \r\n                \r\n            </ul>\r\n\r\n            <div class=\"login-box-placeholder js-login-box-placeholder hide\">\r\n                <div class=\"spinner\"></div>\r\n            </div>\r\n        </div>\r\n    </div>\r\n<div class=\"dropdown-panel-wrap\">\r\n\r\n    \r\n    <div class=\"dropdown-panel mobile-search-dropdown\">\r\n        <div class=\"mobile-search-inner-wrap\">\r\n\r\n\r\n<div class=\"navbar-search\">\r\n    <div class=\"mobile-microsite-search\">\r\n            <label for=\"SitePageHeader-mobile-navbar-search-filter\" class=\"screenreader-text js-mobile-navbar-search-filter-label\">\r\n                Navbar Search Filter\r\n            </label>\r\n            <select class=\"mobile-navbar-search-filter js-mobile-navbar-search-filter at-navbar-search-filter\" id=\"SitePageHeader-mobile-navbar-search-filter\">\r\n\r\n<option class=\"navbar-search-filter-option at-navbar-search-filter-option\" value=\"\">The Journal of Clinical Endocrinology & Metabolism</option><option class=\"navbar-search-filter-option at-navbar-search-filter-option\" value=\"Issue\">This issue</option><option class=\"navbar-search-filter-option at-navbar-search-filter-option\" value=\"Parent\">Endocrine Society Journals</option>\r\n                    <optgroup class=\"navbar-search-optgroup\" label=\"Search across Oxford Academic\">\r\n<option class=\"navbar-search-filter-option at-navbar-search-filter-option\" value=\"AcademicSubjects/MED00160\">Clinical Medicine</option><option class=\"navbar-search-filter-option at-navbar-search-filter-option\" value=\"AcademicSubjects/MED00250\">Endocrinology and Diabetes</option><option class=\"navbar-search-filter-option at-navbar-search-filter-option\" value=\"AcademicSubjects/MED00010\">Medicine and Health</option><option class=\"navbar-search-filter-option at-navbar-search-filter-option\" value=\"Books\">Books</option><option class=\"navbar-search-filter-option at-navbar-search-filter-option\" value=\"Journals\">Journals</option><option class=\"navbar-search-filter-option at-navbar-search-filter-option\" value=\"Umbrella\">Oxford Academic</option>                    </optgroup>\r\n            </select>\r\n\r\n        <label for=\"SitePageHeader-mobile-microsite-search-term\" class=\"screenreader-text js-mobile-microsite-search-term-label\">\r\n            Mobile Microsite Search Term\r\n        </label>\r\n        <input class=\"mobile-search-input mobile-microsite-search-term js-mobile-microsite-search-term at-microsite-search-term\" type=\"text\"\r\n               maxlength=\"255\" placeholder=\"Search\" id=\"SitePageHeader-mobile-microsite-search-term\">\r\n\r\n        <a href=\"javascript:;\" class=\"mobile-microsite-search-icon mobile-search-submit icon-menu_search\">\r\n            <span class=\"screenreader-text\">Search</span>\r\n        </a>\r\n\r\n    </div>\r\n</div>\r\n\r\n        </div>\r\n    </div>\r\n    \r\n    <div class=\"dropdown-panel mobile-account-dropdown\">\r\n        <ul class=\"site-menu site-menu-lvl-0\">\r\n            <li class=\"site-menu-item site-menu-lvl-0\">\r\n                <a href=\"\" class=\"nav-link mobile-account-signin js-nav-dropdown js-header-account-info-user-fullname\" id=\"header-account-info-user-fullname-mobile\">\r\n                    \r\nSign In                    <i class=\"mobile-nav-arrow icon-general_arrow-down\"></i>\r\n                </a>\r\n                <ul class=\"site-menu site-menu-lvl-1 individual-menu\">\r\n                    <li class=\"dropdown-signin-form\">\r\n                        <div class=\"spinner\"></div>\r\n                    </li>\r\n                </ul>\r\n            </li>\r\n                    </ul>\r\n    </div>\r\n    \r\n    <div class=\"dropdown-panel mobile-nav-dropdown\">\r\n\r\n\r\n    <ul class=\"site-menu site-menu-lvl-0 at-site-menu\">\r\n        <li class=\"site-menu-item site-menu-lvl-0 at-site-menu-item\" id=\"site-menu-item-1551165\">\r\n\r\n                <a href=\"/jcem/issue\" class=\"nav-link\">\r\n                    Issues\r\n                </a>\r\n            \r\n        </li>\r\n        <li class=\"site-menu-item site-menu-lvl-0 at-site-menu-item\" id=\"site-menu-item-1551160\">\r\n\r\n                <a href=\"javascript:;\" class=\"nav-link js-nav-dropdown at-nav-dropdown\" role=\"button\" aria-expanded=\"false\">\r\n                    More Content\r\n                    <i class=\"desktop-nav-arrow icon-general-arrow-filled-down arrow-icon\"></i>\r\n                </a>\r\n                <i class=\"mobile-nav-arrow icon-general_arrow-down\"></i>\r\n                <ul class=\"site-menu site-menu-lvl-1 at-site-menu\">\r\n        <li class=\"site-menu-item site-menu-lvl-1 at-site-menu-item\" id=\"site-menu-item-1551166\">\r\n\r\n                <a href=\"/jcem/advance-articles\" class=\"nav-link\">\r\n                    Advance Articles\r\n                </a>\r\n            \r\n        </li>\r\n        <li class=\"site-menu-item site-menu-lvl-1 at-site-menu-item\" id=\"site-menu-item-1551167\">\r\n\r\n                <a href=\"https://academic.oup.com/endocrinesociety/pages/thematic_issues\" class=\"nav-link\">\r\n                    Thematic Issues\r\n                </a>\r\n            \r\n        </li>\r\n        <li class=\"site-menu-item site-menu-lvl-1 at-site-menu-item\" id=\"site-menu-item-1551168\">\r\n\r\n                <a href=\"https://www.endocrine.org/clinical-practice-guidelines\" class=\"nav-link\">\r\n                    Clinical Practice Guidelines\r\n                </a>\r\n            \r\n        </li>\r\n            </ul>\r\n\r\n        </li>\r\n        <li class=\"site-menu-item site-menu-lvl-0 at-site-menu-item\" id=\"site-menu-item-1551161\">\r\n\r\n                <a href=\"javascript:;\" class=\"nav-link js-nav-dropdown at-nav-dropdown\" role=\"button\" aria-expanded=\"false\">\r\n                    ES Journals\r\n                    <i class=\"desktop-nav-arrow icon-general-arrow-filled-down arrow-icon\"></i>\r\n                </a>\r\n                <i class=\"mobile-nav-arrow icon-general_arrow-down\"></i>\r\n                <ul class=\"site-menu site-menu-lvl-1 at-site-menu\">\r\n        <li class=\"site-menu-item site-menu-lvl-1 at-site-menu-item\" id=\"site-menu-item-1551169\">\r\n\r\n                <a href=\"https://academic.oup.com/edrv\" class=\"nav-link\">\r\n                    Endocrine Reviews\r\n                </a>\r\n            \r\n        </li>\r\n        <li class=\"site-menu-item site-menu-lvl-1 at-site-menu-item\" id=\"site-menu-item-1551170\">\r\n\r\n                <a href=\"https://academic.oup.com/endo\" class=\"nav-link\">\r\n                    Endocrinology\r\n                </a>\r\n            \r\n        </li>\r\n        <li class=\"site-menu-item site-menu-lvl-1 at-site-menu-item\" id=\"site-menu-item-1551171\">\r\n\r\n                <a href=\"https://academic.oup.com/jes\" class=\"nav-link\">\r\n                    Journal of the Endocrine Society\r\n                </a>\r\n            \r\n        </li>\r\n        <li class=\"site-menu-item site-menu-lvl-1 at-site-menu-item\" id=\"site-menu-item-1551172\">\r\n\r\n                <a href=\"/jcem/advance-articles\" class=\"nav-link\">\r\n                    The Journal of Clinical Endocrinology & Metabolism\r\n                </a>\r\n            \r\n        </li>\r\n        <li class=\"site-menu-item site-menu-lvl-1 at-site-menu-item\" id=\"site-menu-item-1551173\">\r\n\r\n                <a href=\"https://academic.oup.com/mend\" class=\"nav-link\">\r\n                    Molecular Endocrinology\r\n                </a>\r\n            \r\n        </li>\r\n        <li class=\"site-menu-item site-menu-lvl-1 at-site-menu-item\" id=\"site-menu-item-1551174\">\r\n\r\n                <a href=\"https://academic.oup.com/endocrinesociety\" class=\"nav-link\">\r\n                    ES Journals Portal\r\n                </a>\r\n            \r\n        </li>\r\n            </ul>\r\n\r\n        </li>\r\n        <li class=\"site-menu-item site-menu-lvl-0 at-site-menu-item\" id=\"site-menu-item-1551162\">\r\n\r\n                <a href=\"javascript:;\" class=\"nav-link js-nav-dropdown at-nav-dropdown\" role=\"button\" aria-expanded=\"false\">\r\n                    Submit\r\n                    <i class=\"desktop-nav-arrow icon-general-arrow-filled-down arrow-icon\"></i>\r\n                </a>\r\n                <i class=\"mobile-nav-arrow icon-general_arrow-down\"></i>\r\n                <ul class=\"site-menu site-menu-lvl-1 at-site-menu\">\r\n        <li class=\"site-menu-item site-menu-lvl-1 at-site-menu-item\" id=\"site-menu-item-1551175\">\r\n\r\n                <a href=\"/jcem/pages/Author_Guidelines\" class=\"nav-link\">\r\n                    Author Guidelines\r\n                </a>\r\n            \r\n        </li>\r\n        <li class=\"site-menu-item site-menu-lvl-1 at-site-menu-item\" id=\"site-menu-item-1551176\">\r\n\r\n                <a href=\"https://www.editorialmanager.com/jclinendometab/default.aspx\" class=\"nav-link\">\r\n                    Submission Site\r\n                </a>\r\n            \r\n        </li>\r\n        <li class=\"site-menu-item site-menu-lvl-1 at-site-menu-item\" id=\"site-menu-item-1551177\">\r\n\r\n                <a href=\"/jcem/pages/Author_Guidelines#charges\" class=\"nav-link\">\r\n                    Open Access\r\n                </a>\r\n            \r\n        </li>\r\n        <li class=\"site-menu-item site-menu-lvl-1 at-site-menu-item\" id=\"site-menu-item-1551178\">\r\n\r\n                <a href=\"https://academic.oup.com/endocrinesociety/pages/why_publish? \" class=\"nav-link\">\r\n                    Why Publish with the Endocrine Society\r\n                </a>\r\n            \r\n        </li>\r\n            </ul>\r\n\r\n        </li>\r\n        <li class=\"site-menu-item site-menu-lvl-0 at-site-menu-item\" id=\"site-menu-item-1551179\">\r\n\r\n                <a href=\"/jcem/subscribe\" class=\"nav-link\">\r\n                    Purchase\r\n                </a>\r\n            \r\n        </li>\r\n        <li class=\"site-menu-item site-menu-lvl-0 at-site-menu-item\" id=\"site-menu-item-1551163\">\r\n\r\n                <a href=\"javascript:;\" class=\"nav-link js-nav-dropdown at-nav-dropdown\" role=\"button\" aria-expanded=\"false\">\r\n                    Advertise\r\n                    <i class=\"desktop-nav-arrow icon-general-arrow-filled-down arrow-icon\"></i>\r\n                </a>\r\n                <i class=\"mobile-nav-arrow icon-general_arrow-down\"></i>\r\n                <ul class=\"site-menu site-menu-lvl-1 at-site-menu\">\r\n        <li class=\"site-menu-item site-menu-lvl-1 at-site-menu-item\" id=\"site-menu-item-1551180\">\r\n\r\n                <a href=\"http://www.endocrine.org/corporate-relations/print-and-online-advertising\" class=\"nav-link\">\r\n                    Advertising & Corporate Services\r\n                </a>\r\n            \r\n        </li>\r\n        <li class=\"site-menu-item site-menu-lvl-1 at-site-menu-item\" id=\"site-menu-item-1551181\">\r\n\r\n                <a href=\"http://www.endocrine.org/corporate-relations/commercial-reprints\" class=\"nav-link\">\r\n                    Reprints, ePrints, Supplements\r\n                </a>\r\n            \r\n        </li>\r\n            </ul>\r\n\r\n        </li>\r\n        <li class=\"site-menu-item site-menu-lvl-0 at-site-menu-item\" id=\"site-menu-item-1551164\">\r\n\r\n                <a href=\"javascript:;\" class=\"nav-link js-nav-dropdown at-nav-dropdown\" role=\"button\" aria-expanded=\"false\">\r\n                    About\r\n                    <i class=\"desktop-nav-arrow icon-general-arrow-filled-down arrow-icon\"></i>\r\n                </a>\r\n                <i class=\"mobile-nav-arrow icon-general_arrow-down\"></i>\r\n                <ul class=\"site-menu site-menu-lvl-1 at-site-menu\">\r\n        <li class=\"site-menu-item site-menu-lvl-1 at-site-menu-item\" id=\"site-menu-item-1551182\">\r\n\r\n                <a href=\"/jcem/pages/About\" class=\"nav-link\">\r\n                    About The Journal of Clinical Endocrinology & Metabolism\r\n                </a>\r\n            \r\n        </li>\r\n        <li class=\"site-menu-item site-menu-lvl-1 at-site-menu-item\" id=\"site-menu-item-1551183\">\r\n\r\n                <a href=\"/jcem/pages/Editorial_Board\" class=\"nav-link\">\r\n                    Editorial Board\r\n                </a>\r\n            \r\n        </li>\r\n        <li class=\"site-menu-item site-menu-lvl-1 at-site-menu-item\" id=\"site-menu-item-1551184\">\r\n\r\n                <a href=\"https://academic.oup.com/endocrinesociety/pages/author_resource_center\" class=\"nav-link\">\r\n                    Author Resources\r\n                </a>\r\n            \r\n        </li>\r\n        <li class=\"site-menu-item site-menu-lvl-1 at-site-menu-item\" id=\"site-menu-item-1551185\">\r\n\r\n                <a href=\" https://academic.oup.com/endocrinesociety/pages/reviewer_resource_center\" class=\"nav-link\">\r\n                    Reviewer Resources\r\n                </a>\r\n            \r\n        </li>\r\n        <li class=\"site-menu-item site-menu-lvl-1 at-site-menu-item\" id=\"site-menu-item-1551186\">\r\n\r\n                <a href=\"https://academic.oup.com/journals/pages/access_purchase/rights_and_permissions\" class=\"nav-link\">\r\n                    Rights & Permissions\r\n                </a>\r\n            \r\n        </li>\r\n        <li class=\"site-menu-item site-menu-lvl-1 at-site-menu-item\" id=\"site-menu-item-1551187\">\r\n\r\n                <a href=\"http://www.endocrine.org/endocrine-press\" class=\"nav-link\">\r\n                    Other Society Publications\r\n                </a>\r\n            \r\n        </li>\r\n        <li class=\"site-menu-item site-menu-lvl-1 at-site-menu-item\" id=\"site-menu-item-1551188\">\r\n\r\n                <a href=\"https://academic.oup.com/journals/pages/help/journal_alerts\" class=\"nav-link\">\r\n                    Alerts\r\n                </a>\r\n            \r\n        </li>\r\n        <li class=\"site-menu-item site-menu-lvl-1 at-site-menu-item\" id=\"site-menu-item-1551189\">\r\n\r\n                <a href=\"https://academic.oup.com/endocrinesociety/pages/member_access\" class=\"nav-link\">\r\n                    Member Access\r\n                </a>\r\n            \r\n        </li>\r\n        <li class=\"site-menu-item site-menu-lvl-1 at-site-menu-item\" id=\"site-menu-item-1551190\">\r\n\r\n                <a href=\"http://www.endocrine.org/endocareers\" class=\"nav-link\">\r\n                    Journals Career Network\r\n                </a>\r\n            \r\n        </li>\r\n        <li class=\"site-menu-item site-menu-lvl-1 at-site-menu-item\" id=\"site-menu-item-1551191\">\r\n\r\n                <a href=\"https://academic.oup.com/endocrinesociety/pages/terms_and_conditions\" class=\"nav-link\">\r\n                    Terms and Conditions\r\n                </a>\r\n            \r\n        </li>\r\n            </ul>\r\n\r\n        </li>\r\n                <li class=\"site-menu-item site-menu-lvl-0 at-site-menu-item\" id=\"site-menu-item-custom\">\r\n            <a href=\"/journals\" class=\"nav-link\">Journals on Oxford Academic</a>\r\n        </li>\r\n        <li class=\"site-menu-item site-menu-lvl-0 at-site-menu-item\" id=\"site-menu-item-custom\">\r\n            <a href=\"/books\" class=\"nav-link\">Books on Oxford Academic</a>\r\n        </li>\r\n    </ul>\r\n    </div>\r\n\r\n</div>\r\n\r\n    <div class=\"journal-header journal-bg\">\r\n        <div class=\"center-inner-row\">\r\n                <div class=\"site-parent-link-wrap\">\r\n                    <a href=\"//academic.oup.com/endocrinesociety\" class=\"site-parent-link\">Endocrine Society Journals</a>\r\n                </div>\r\n                            <a href=\"/jcem\" class=\"journal-logo-container\">\r\n                    <img id=\"logo-TheJournalofClinicalEndocrinology&amp;Metabolism\" class=\"journal-logo\" src=\"//oup.silverchair-cdn.com/data/SiteBuilderAssets/Live/Images/jcem/jcem_title729907635.svg\" alt=\"The Journal of Clinical Endocrinology &amp; Metabolism\" />\r\n                </a>\r\n\r\n            <div class=\"society-logo-block\">\r\n                    <div class=\"society-block-inner-wrap\">\r\n                            <a href=\"https://www.endocrine.org/\" target=\"\" class=\"society-logo-container\">\r\n                                <img id=\"logo-EndocrineSociety\" class=\"society-logo\" src=\"//oup.silverchair-cdn.com/data/SiteBuilderAssets/Live/Images/jcem/jcem_h1-392644295.svg\" alt=\"Endocrine Society\" />\r\n                            </a>\r\n                                            </div>            </div> \r\n        </div>\r\n    </div>\r\n<div class=\"navbar\">\r\n    <div class=\"center-inner-row\">\r\n        <nav class=\"navbar-menu\">\r\n\r\n\r\n    <ul class=\"site-menu site-menu-lvl-0 at-site-menu\">\r\n        <li class=\"site-menu-item site-menu-lvl-0 at-site-menu-item\" id=\"site-menu-item-1551165\">\r\n\r\n                <a href=\"/jcem/issue\" class=\"nav-link\">\r\n                    Issues\r\n                </a>\r\n            \r\n        </li>\r\n        <li class=\"site-menu-item site-menu-lvl-0 at-site-menu-item\" id=\"site-menu-item-1551160\">\r\n\r\n                <a href=\"javascript:;\" class=\"nav-link js-nav-dropdown at-nav-dropdown\" role=\"button\" aria-expanded=\"false\">\r\n                    More Content\r\n                    <i class=\"desktop-nav-arrow icon-general-arrow-filled-down arrow-icon\"></i>\r\n                </a>\r\n                <i class=\"mobile-nav-arrow icon-general_arrow-down\"></i>\r\n                <ul class=\"site-menu site-menu-lvl-1 at-site-menu\">\r\n        <li class=\"site-menu-item site-menu-lvl-1 at-site-menu-item\" id=\"site-menu-item-1551166\">\r\n\r\n                <a href=\"/jcem/advance-articles\" class=\"nav-link\">\r\n                    Advance Articles\r\n                </a>\r\n            \r\n        </li>\r\n        <li class=\"site-menu-item site-menu-lvl-1 at-site-menu-item\" id=\"site-menu-item-1551167\">\r\n\r\n                <a href=\"https://academic.oup.com/endocrinesociety/pages/thematic_issues\" class=\"nav-link\">\r\n                    Thematic Issues\r\n                </a>\r\n            \r\n        </li>\r\n        <li class=\"site-menu-item site-menu-lvl-1 at-site-menu-item\" id=\"site-menu-item-1551168\">\r\n\r\n                <a href=\"https://www.endocrine.org/clinical-practice-guidelines\" class=\"nav-link\">\r\n                    Clinical Practice Guidelines\r\n                </a>\r\n            \r\n        </li>\r\n            </ul>\r\n\r\n        </li>\r\n        <li class=\"site-menu-item site-menu-lvl-0 at-site-menu-item\" id=\"site-menu-item-1551161\">\r\n\r\n                <a href=\"javascript:;\" class=\"nav-link js-nav-dropdown at-nav-dropdown\" role=\"button\" aria-expanded=\"false\">\r\n                    ES Journals\r\n                    <i class=\"desktop-nav-arrow icon-general-arrow-filled-down arrow-icon\"></i>\r\n                </a>\r\n                <i class=\"mobile-nav-arrow icon-general_arrow-down\"></i>\r\n                <ul class=\"site-menu site-menu-lvl-1 at-site-menu\">\r\n        <li class=\"site-menu-item site-menu-lvl-1 at-site-menu-item\" id=\"site-menu-item-1551169\">\r\n\r\n                <a href=\"https://academic.oup.com/edrv\" class=\"nav-link\">\r\n                    Endocrine Reviews\r\n                </a>\r\n            \r\n        </li>\r\n        <li class=\"site-menu-item site-menu-lvl-1 at-site-menu-item\" id=\"site-menu-item-1551170\">\r\n\r\n                <a href=\"https://academic.oup.com/endo\" class=\"nav-link\">\r\n                    Endocrinology\r\n                </a>\r\n            \r\n        </li>\r\n        <li class=\"site-menu-item site-menu-lvl-1 at-site-menu-item\" id=\"site-menu-item-1551171\">\r\n\r\n                <a href=\"https://academic.oup.com/jes\" class=\"nav-link\">\r\n                    Journal of the Endocrine Society\r\n                </a>\r\n            \r\n        </li>\r\n        <li class=\"site-menu-item site-menu-lvl-1 at-site-menu-item\" id=\"site-menu-item-1551172\">\r\n\r\n                <a href=\"/jcem/advance-articles\" class=\"nav-link\">\r\n                    The Journal of Clinical Endocrinology & Metabolism\r\n                </a>\r\n            \r\n        </li>\r\n        <li class=\"site-menu-item site-menu-lvl-1 at-site-menu-item\" id=\"site-menu-item-1551173\">\r\n\r\n                <a href=\"https://academic.oup.com/mend\" class=\"nav-link\">\r\n                    Molecular Endocrinology\r\n                </a>\r\n            \r\n        </li>\r\n        <li class=\"site-menu-item site-menu-lvl-1 at-site-menu-item\" id=\"site-menu-item-1551174\">\r\n\r\n                <a href=\"https://academic.oup.com/endocrinesociety\" class=\"nav-link\">\r\n                    ES Journals Portal\r\n                </a>\r\n            \r\n        </li>\r\n            </ul>\r\n\r\n        </li>\r\n        <li class=\"site-menu-item site-menu-lvl-0 at-site-menu-item\" id=\"site-menu-item-1551162\">\r\n\r\n                <a href=\"javascript:;\" class=\"nav-link js-nav-dropdown at-nav-dropdown\" role=\"button\" aria-expanded=\"false\">\r\n                    Submit\r\n                    <i class=\"desktop-nav-arrow icon-general-arrow-filled-down arrow-icon\"></i>\r\n                </a>\r\n                <i class=\"mobile-nav-arrow icon-general_arrow-down\"></i>\r\n                <ul class=\"site-menu site-menu-lvl-1 at-site-menu\">\r\n        <li class=\"site-menu-item site-menu-lvl-1 at-site-menu-item\" id=\"site-menu-item-1551175\">\r\n\r\n                <a href=\"/jcem/pages/Author_Guidelines\" class=\"nav-link\">\r\n                    Author Guidelines\r\n                </a>\r\n            \r\n        </li>\r\n        <li class=\"site-menu-item site-menu-lvl-1 at-site-menu-item\" id=\"site-menu-item-1551176\">\r\n\r\n                <a href=\"https://www.editorialmanager.com/jclinendometab/default.aspx\" class=\"nav-link\">\r\n                    Submission Site\r\n                </a>\r\n            \r\n        </li>\r\n        <li class=\"site-menu-item site-menu-lvl-1 at-site-menu-item\" id=\"site-menu-item-1551177\">\r\n\r\n                <a href=\"/jcem/pages/Author_Guidelines#charges\" class=\"nav-link\">\r\n                    Open Access\r\n                </a>\r\n            \r\n        </li>\r\n        <li class=\"site-menu-item site-menu-lvl-1 at-site-menu-item\" id=\"site-menu-item-1551178\">\r\n\r\n                <a href=\"https://academic.oup.com/endocrinesociety/pages/why_publish? \" class=\"nav-link\">\r\n                    Why Publish with the Endocrine Society\r\n                </a>\r\n            \r\n        </li>\r\n            </ul>\r\n\r\n        </li>\r\n        <li class=\"site-menu-item site-menu-lvl-0 at-site-menu-item\" id=\"site-menu-item-1551179\">\r\n\r\n                <a href=\"/jcem/subscribe\" class=\"nav-link\">\r\n                    Purchase\r\n                </a>\r\n            \r\n        </li>\r\n        <li class=\"site-menu-item site-menu-lvl-0 at-site-menu-item\" id=\"site-menu-item-1551163\">\r\n\r\n                <a href=\"javascript:;\" class=\"nav-link js-nav-dropdown at-nav-dropdown\" role=\"button\" aria-expanded=\"false\">\r\n                    Advertise\r\n                    <i class=\"desktop-nav-arrow icon-general-arrow-filled-down arrow-icon\"></i>\r\n                </a>\r\n                <i class=\"mobile-nav-arrow icon-general_arrow-down\"></i>\r\n                <ul class=\"site-menu site-menu-lvl-1 at-site-menu\">\r\n        <li class=\"site-menu-item site-menu-lvl-1 at-site-menu-item\" id=\"site-menu-item-1551180\">\r\n\r\n                <a href=\"http://www.endocrine.org/corporate-relations/print-and-online-advertising\" class=\"nav-link\">\r\n                    Advertising & Corporate Services\r\n                </a>\r\n            \r\n        </li>\r\n        <li class=\"site-menu-item site-menu-lvl-1 at-site-menu-item\" id=\"site-menu-item-1551181\">\r\n\r\n                <a href=\"http://www.endocrine.org/corporate-relations/commercial-reprints\" class=\"nav-link\">\r\n                    Reprints, ePrints, Supplements\r\n                </a>\r\n            \r\n        </li>\r\n            </ul>\r\n\r\n        </li>\r\n        <li class=\"site-menu-item site-menu-lvl-0 at-site-menu-item\" id=\"site-menu-item-1551164\">\r\n\r\n                <a href=\"javascript:;\" class=\"nav-link js-nav-dropdown at-nav-dropdown\" role=\"button\" aria-expanded=\"false\">\r\n                    About\r\n                    <i class=\"desktop-nav-arrow icon-general-arrow-filled-down arrow-icon\"></i>\r\n                </a>\r\n                <i class=\"mobile-nav-arrow icon-general_arrow-down\"></i>\r\n                <ul class=\"site-menu site-menu-lvl-1 at-site-menu\">\r\n        <li class=\"site-menu-item site-menu-lvl-1 at-site-menu-item\" id=\"site-menu-item-1551182\">\r\n\r\n                <a href=\"/jcem/pages/About\" class=\"nav-link\">\r\n                    About The Journal of Clinical Endocrinology & Metabolism\r\n                </a>\r\n            \r\n        </li>\r\n        <li class=\"site-menu-item site-menu-lvl-1 at-site-menu-item\" id=\"site-menu-item-1551183\">\r\n\r\n                <a href=\"/jcem/pages/Editorial_Board\" class=\"nav-link\">\r\n                    Editorial Board\r\n                </a>\r\n            \r\n        </li>\r\n        <li class=\"site-menu-item site-menu-lvl-1 at-site-menu-item\" id=\"site-menu-item-1551184\">\r\n\r\n                <a href=\"https://academic.oup.com/endocrinesociety/pages/author_resource_center\" class=\"nav-link\">\r\n                    Author Resources\r\n                </a>\r\n            \r\n        </li>\r\n        <li class=\"site-menu-item site-menu-lvl-1 at-site-menu-item\" id=\"site-menu-item-1551185\">\r\n\r\n                <a href=\" https://academic.oup.com/endocrinesociety/pages/reviewer_resource_center\" class=\"nav-link\">\r\n                    Reviewer Resources\r\n                </a>\r\n            \r\n        </li>\r\n        <li class=\"site-menu-item site-menu-lvl-1 at-site-menu-item\" id=\"site-menu-item-1551186\">\r\n\r\n                <a href=\"https://academic.oup.com/journals/pages/access_purchase/rights_and_permissions\" class=\"nav-link\">\r\n                    Rights & Permissions\r\n                </a>\r\n            \r\n        </li>\r\n        <li class=\"site-menu-item site-menu-lvl-1 at-site-menu-item\" id=\"site-menu-item-1551187\">\r\n\r\n                <a href=\"http://www.endocrine.org/endocrine-press\" class=\"nav-link\">\r\n                    Other Society Publications\r\n                </a>\r\n            \r\n        </li>\r\n        <li class=\"site-menu-item site-menu-lvl-1 at-site-menu-item\" id=\"site-menu-item-1551188\">\r\n\r\n                <a href=\"https://academic.oup.com/journals/pages/help/journal_alerts\" class=\"nav-link\">\r\n                    Alerts\r\n                </a>\r\n            \r\n        </li>\r\n        <li class=\"site-menu-item site-menu-lvl-1 at-site-menu-item\" id=\"site-menu-item-1551189\">\r\n\r\n                <a href=\"https://academic.oup.com/endocrinesociety/pages/member_access\" class=\"nav-link\">\r\n                    Member Access\r\n                </a>\r\n            \r\n        </li>\r\n        <li class=\"site-menu-item site-menu-lvl-1 at-site-menu-item\" id=\"site-menu-item-1551190\">\r\n\r\n                <a href=\"http://www.endocrine.org/endocareers\" class=\"nav-link\">\r\n                    Journals Career Network\r\n                </a>\r\n            \r\n        </li>\r\n        <li class=\"site-menu-item site-menu-lvl-1 at-site-menu-item\" id=\"site-menu-item-1551191\">\r\n\r\n                <a href=\"https://academic.oup.com/endocrinesociety/pages/terms_and_conditions\" class=\"nav-link\">\r\n                    Terms and Conditions\r\n                </a>\r\n            \r\n        </li>\r\n            </ul>\r\n\r\n        </li>\r\n            </ul>\r\n        </nav>\r\n            <div class=\"navbar-search-container js-navbar-search-container\">\r\n                <a href=\"javascript:;\" class=\"navbar-search-close js_close-navsearch\">Close</a>\r\n\r\n\r\n<div class=\"navbar-search\">\r\n    <div class=\"microsite-search\">\r\n            <label for=\"SitePageHeader-navbar-search-filter\" class=\"screenreader-text js-navbar-search-filter-label\">\r\n                Navbar Search Filter\r\n            </label>\r\n            <select class=\"navbar-search-filter js-navbar-search-filter at-navbar-search-filter\" id=\"SitePageHeader-navbar-search-filter\">\r\n\r\n<option class=\"navbar-search-filter-option at-navbar-search-filter-option\" value=\"\">The Journal of Clinical Endocrinology & Metabolism</option><option class=\"navbar-search-filter-option at-navbar-search-filter-option\" value=\"Issue\">This issue</option><option class=\"navbar-search-filter-option at-navbar-search-filter-option\" value=\"Parent\">Endocrine Society Journals</option>\r\n                    <optgroup class=\"navbar-search-optgroup\" label=\"Search across Oxford Academic\">\r\n<option class=\"navbar-search-filter-option at-navbar-search-filter-option\" value=\"AcademicSubjects/MED00160\">Clinical Medicine</option><option class=\"navbar-search-filter-option at-navbar-search-filter-option\" value=\"AcademicSubjects/MED00250\">Endocrinology and Diabetes</option><option class=\"navbar-search-filter-option at-navbar-search-filter-option\" value=\"AcademicSubjects/MED00010\">Medicine and Health</option><option class=\"navbar-search-filter-option at-navbar-search-filter-option\" value=\"Books\">Books</option><option class=\"navbar-search-filter-option at-navbar-search-filter-option\" value=\"Journals\">Journals</option><option class=\"navbar-search-filter-option at-navbar-search-filter-option\" value=\"Umbrella\">Oxford Academic</option>                    </optgroup>\r\n            </select>\r\n\r\n        <label for=\"SitePageHeader-microsite-search-term\" class=\"screenreader-text js-microsite-search-term-label\">\r\n            Microsite Search Term\r\n        </label>\r\n        <input class=\"navbar-search-input microsite-search-term js-microsite-search-term at-microsite-search-term\" type=\"text\"\r\n               maxlength=\"255\" placeholder=\"Search\" id=\"SitePageHeader-microsite-search-term\">\r\n\r\n        <a href=\"javascript:;\" class=\"microsite-search-icon navbar-search-submit icon-menu_search\">\r\n            <span class=\"screenreader-text\">Search</span>\r\n        </a>\r\n\r\n    </div>\r\n</div>\r\n\r\n<input id=\"hfCurrentBookSearch\" name=\"hfCurrentBookSearch\" type=\"hidden\" value=\"\" /><input id=\"hfCurrentBookScope\" name=\"hfCurrentBookScope\" type=\"hidden\" value=\"CurrentBook\" /><input id=\"hfBookSiteScope\" name=\"hfBookSiteScope\" type=\"hidden\" value=\"Books\" /><input id=\"hfSeriesScope\" name=\"hfSeriesScope\" type=\"hidden\" value=\"taxWithOr\" /><input id=\"hfParentSiteName\" name=\"hfParentSiteName\" type=\"hidden\" value=\"Endocrine Society Journals\" /><input id=\"hfParentSiteUrl\" name=\"hfParentSiteUrl\" type=\"hidden\" value=\"academic.oup.com/endocrinesociety\" /><input id=\"hfSiteID\" name=\"hfSiteID\" type=\"hidden\" value=\"5591\" /><input id=\"hfParentSiteID\" name=\"hfParentSiteID\" type=\"hidden\" value=\"5590\" /><input id=\"hfJournalSiteScope\" name=\"hfJournalSiteScope\" type=\"hidden\" value=\"Journals\" /><input id=\"hfParentSiteScope\" name=\"hfParentSiteScope\" type=\"hidden\" value=\"Parent\" /><input id=\"hfDefaultSearchURL\" name=\"hfDefaultSearchURL\" type=\"hidden\" value=\"search-results?page=1&amp;q=\" /><input id=\"hfIssueSearch\" name=\"hfIssueSearch\" type=\"hidden\" value=\"&amp;fl_IssueID=100904\" /><input id=\"hfIssueSiteScope\" name=\"hfIssueSiteScope\" type=\"hidden\" value=\"Issue\" /><input id=\"hfUmbrellaScope\" name=\"hfUmbrellaScope\" type=\"hidden\" value=\"Umbrella\" /><input id=\"hfUmbrellaSiteUrl\" name=\"hfUmbrellaSiteUrl\" type=\"hidden\" value=\"academic.oup.com\" /><input id=\"hfUmbrellaSiteId\" name=\"hfUmbrellaSiteId\" type=\"hidden\" value=\"191\" /><input id=\"hfDefaultAdvancedSearchUrl\" name=\"hfDefaultAdvancedSearchUrl\" type=\"hidden\" value=\"advanced-search?page=1&amp;q=\" />                <div class=\"navbar-search-advanced\"><a href=\"/jcem/advanced-search\" class=\"advanced-search js-advanced-search\">Advanced Search</a></div>\r\n            </div>            <div class=\"navbar-search-collapsed\"><a href=\"javascript:;\" class=\"icon-menu_search js_expand-navsearch\"><span class=\"screenreader-text\">Search Menu</span></a></div>\r\n    </div>\r\n</div>\r\n<input id=\"hfEnableOupOnlineProductsFeatures\" name=\"hfEnableOupOnlineProductsFeatures\" type=\"hidden\" value=\"True\" />\r\n\r\n    <input type=\"hidden\" name=\"searchScope\" id=\"hfSolrJournalID\" value=\"\" />\r\n    <input type=\"hidden\" id=\"hfSolrJournalName\" value=\"\" />\r\n    <input type=\"hidden\" id=\"hfSolrMaxAllowSearchChar\" value=\"100\" />\r\n    <input type=\"hidden\" id=\"hfJournalShortName\" value=\"\" />\r\n    <input type=\"hidden\" id=\"hfSearchPlaceholder\" value=\"\" />\r\n    <input type=\"hidden\" name=\"hfGlobalSearchSiteURL\" id=\"hfGlobalSearchSiteURL\" value=\"\" />\r\n    <input type=\"hidden\" name=\"hfSearchSiteURL\" id=\"hfSiteURL\" value=\"academic.oup.com/jcem\" />\r\n    <script type=\"text/javascript\">\r\n        (function () {\r\n            var hfSiteUrl = document.getElementById('hfSiteURL');\r\n            var siteUrl = hfSiteUrl.value;\r\n            var subdomainIndex = siteUrl.indexOf('/');\r\n\r\n            hfSiteUrl.value = location.host + (subdomainIndex >= 0 ? siteUrl.substring(subdomainIndex) : '');\r\n        })();\r\n    </script>\r\n<input id=\"routename\" name=\"RouteName\" type=\"hidden\" value=\"jcem\" /> \n    </div>\n\r\n</section>\r\n        <div class=\"widget widget-SitewideBanner widget-instance-\">\n        \r\n\r\n \n    </div>\n\r\n\r\n    <div id=\"main\" class=\"content-main js-main ui-base\">\r\n            <section class=\"master-main row\">\r\n                <div class=\"center-inner-row no-overflow\">\r\n                    <div id=\"skipNav\" tabindex=\"-1\"></div>\r\n                    \r\n\r\n\r\n<div class=\"page-column-wrap\">\r\n<div id=\"InfoColumn\" class=\"page-column page-column--left js-left-nav-col\">\r\n    <div class=\"mobile-content-topbar hide\">\r\n        <button class=\"toggle-left-col toggle-left-col__article\">Article Navigation</button>\r\n    </div>\r\n    <div class=\"info-inner-wrap js-left-nav\">\r\n        <button class=\"toggle-left-col__close btn-as-icon icon-general-close\">\r\n            <span class=\"screenreader-text\">Close mobile search navigation</span>\r\n        </button>\r\n        <div class=\"responsive-nav-title\">Article Navigation</div>\r\n        <div class=\"info-widget-wrap\">\r\n    <div class=\"widget widget-IssueInfo widget-instance-OUP_IssueInfo_Article\">\n        \r\n\r\n<div id=\"issueInfo-OUP_IssueInfo_Article\" class=\"article-info-wrap clearfix\">\r\n    <i class=\"icon-general-close mobile-nav-btn nav-open\"></i>\r\n    <div class=\"article-issue-img\">\r\n            <a href=\"/jcem/issue/102/11\"><img id=\"issueImage\" class=\"fb-featured-image\" src=\"https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/jcem/Issue/102/11/3/m_cover.jpeg?Expires=1662566727&amp;Signature=ggwoTZSXVakP8oE2lgx-2PeWzV1gbgg4Q~GfN2IbH8ZU4G~RJvqfSmd--6XtFBkEfVYq-veYc42fdmUr8ysYmmstpsc4obnCCb-wUk~xvDjEy4vV~nbwlHwr44tv-RGxgyZJOzgYWeVxgTLxLFStv3tD8~tA6Baea9HnPZpvzWctqgkC4kuCPzqGe~C-P52GTHzLKfzmIehkfXT0iZ1LU72vuLVdh-37sPrNyEZzYjMRr7w8aBKfCp8jn48TZDorofIOi~McleW4nKJpmIiIkunCQmQAwaCDwfI7v6tYMP1wEv0TRDWTeQs-2tCuf-BpZ843nTI9ioUeyP2fV9e0tw__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA\" alt=\"Issue Cover\" /></a>\r\n    </div>\r\n    <div class=\"article-issue-info\">\r\n        <div class=\"volume-issue__wrap\">\r\n\r\n            <a href=\"/jcem/issue/102/11\">\r\n                        <div class=\"volume trailing-comma\">Volume 102</div>\r\n                        <div class=\"issue\">Issue 11</div>\r\n\r\n            </a>\r\n\r\n        </div>\r\n        <div class=\"ii-pub-date\">\r\n1 November 2017        </div>\r\n        \r\n    </div>\r\n\r\n</div> \n    </div>\n\r\n            <div class=\"content-nav\">\r\n    <div class=\"widget widget-ArticleJumpLinks widget-instance-OUP_ArticleJumpLinks_Widget\">\n        \r\n\r\n<h3 class=\"contents-title\" >Article Contents</h3>\r\n<ul class=\"jumplink-list js-jumplink-list\">\r\n        <li class=\"section-jump-link head-1\" link-destination=\"99603237\">\r\n            <div class=\"section-jump-link__link-wrap\">\r\n\r\n                <a class=\"js-jumplink scrollTo\" href=\"#99603237\">Abstract</a>\r\n            </div>\r\n        </li>\r\n        <li class=\"section-jump-link head-1\" link-destination=\"99603239\">\r\n            <div class=\"section-jump-link__link-wrap\">\r\n\r\n                <a class=\"js-jumplink scrollTo\" href=\"#99603239\">Summary of Recommendations</a>\r\n            </div>\r\n        </li>\r\n        <li class=\"section-jump-link head-1\" link-destination=\"99603250\">\r\n            <div class=\"section-jump-link__link-wrap\">\r\n\r\n                <a class=\"js-jumplink scrollTo\" href=\"#99603250\">Changes Since the Previous Guideline</a>\r\n            </div>\r\n        </li>\r\n        <li class=\"section-jump-link head-1\" link-destination=\"99603252\">\r\n            <div class=\"section-jump-link__link-wrap\">\r\n\r\n                <a class=\"js-jumplink scrollTo\" href=\"#99603252\">Method of Development of Evidence-Based Clinical Practice Guidelines</a>\r\n            </div>\r\n        </li>\r\n        <li class=\"section-jump-link head-1\" link-destination=\"99603258\">\r\n            <div class=\"section-jump-link__link-wrap\">\r\n\r\n                <a class=\"js-jumplink scrollTo\" href=\"#99603258\">Commissioned Systematic Review</a>\r\n            </div>\r\n        </li>\r\n        <li class=\"section-jump-link head-1\" link-destination=\"99603260\">\r\n            <div class=\"section-jump-link__link-wrap\">\r\n\r\n                <a class=\"js-jumplink scrollTo\" href=\"#99603260\">Introduction</a>\r\n            </div>\r\n        </li>\r\n        <li class=\"section-jump-link head-1\" link-destination=\"99603270\">\r\n            <div class=\"section-jump-link__link-wrap\">\r\n\r\n                <a class=\"js-jumplink scrollTo\" href=\"#99603270\">Biological Determinants of Gender Identity Development</a>\r\n            </div>\r\n        </li>\r\n        <li class=\"section-jump-link head-1\" link-destination=\"99603277\">\r\n            <div class=\"section-jump-link__link-wrap\">\r\n\r\n                <a class=\"js-jumplink scrollTo\" href=\"#99603277\">Natural History of Children With GD/Gender Incongruence</a>\r\n            </div>\r\n        </li>\r\n        <li class=\"section-jump-link head-1\" link-destination=\"99603280\">\r\n            <div class=\"section-jump-link__link-wrap\">\r\n\r\n                <a class=\"js-jumplink scrollTo\" href=\"#99603280\">1.0 Evaluation of Youth and Adults</a>\r\n            </div>\r\n        </li>\r\n        <li class=\"section-jump-link head-1\" link-destination=\"99603296\">\r\n            <div class=\"section-jump-link__link-wrap\">\r\n\r\n                <a class=\"js-jumplink scrollTo\" href=\"#99603296\">Recommendations for Those Involved in the Gender-Affirming Hormone Treatment of Individuals With GD/Gender Incongruence</a>\r\n            </div>\r\n        </li>\r\n        <li class=\"section-jump-link head-1\" link-destination=\"99603316\">\r\n            <div class=\"section-jump-link__link-wrap\">\r\n\r\n                <a class=\"js-jumplink scrollTo\" href=\"#99603316\">2.0 Treatment of Adolescents</a>\r\n            </div>\r\n        </li>\r\n        <li class=\"section-jump-link head-1\" link-destination=\"99603362\">\r\n            <div class=\"section-jump-link__link-wrap\">\r\n\r\n                <a class=\"js-jumplink scrollTo\" href=\"#99603362\">3.0 Hormonal Therapy for Transgender Adults</a>\r\n            </div>\r\n        </li>\r\n        <li class=\"section-jump-link head-1\" link-destination=\"99603396\">\r\n            <div class=\"section-jump-link__link-wrap\">\r\n\r\n                <a class=\"js-jumplink scrollTo\" href=\"#99603396\">4.0 Adverse Outcome Prevention and Long-Term Care</a>\r\n            </div>\r\n        </li>\r\n        <li class=\"section-jump-link head-1\" link-destination=\"99603441\">\r\n            <div class=\"section-jump-link__link-wrap\">\r\n\r\n                <a class=\"js-jumplink scrollTo\" href=\"#99603441\">5.0 Surgery for Sex Reassignment and Gender Confirmation</a>\r\n            </div>\r\n        </li>\r\n        <li class=\"section-jump-link head-1\" link-destination=\"99603461\">\r\n            <div class=\"section-jump-link__link-wrap\">\r\n\r\n                <a class=\"js-jumplink scrollTo\" href=\"#99603461\">Financial Disclosures of the Task Force*</a>\r\n            </div>\r\n        </li>\r\n        <li class=\"section-jump-link head-1\" link-destination=\"99603463\">\r\n            <div class=\"section-jump-link__link-wrap\">\r\n\r\n                <a class=\"js-jumplink scrollTo\" href=\"#99603463\">Abbreviations</a>\r\n            </div>\r\n        </li>\r\n        <li class=\"section-jump-link head-1\" link-destination=\"99603465\">\r\n            <div class=\"section-jump-link__link-wrap\">\r\n\r\n                <a class=\"js-jumplink scrollTo\" href=\"#99603465\">Acknowledgments</a>\r\n            </div>\r\n        </li>\r\n        <li class=\"section-jump-link head-1 backReferenceLink\" link-destination=\"99603467\">\r\n            <div class=\"section-jump-link__link-wrap\">\r\n\r\n                <a class=\"js-jumplink scrollTo\" href=\"#99603467\">References</a>\r\n            </div>\r\n        </li>\r\n</ul>\r\n \n    </div>\n\r\n            </div>\r\n    <div class=\"widget widget-ArticleNavLinks widget-instance-OUP_ArticleNavLinks_Article\">\n        <ul class=\"inline-list\">\r\n        <li class=\"empty arrow\">&nbsp;</li>\r\n            <li class=\"next arrow\">\r\n            <a href=\"/jcem/article/102/11/3904/4157556\">Next &gt;</a>\r\n        </li>\r\n</ul> \n    </div>\n\r\n        </div>\r\n    </div>\r\n</div>\r\n<div class=\"sticky-toolbar js-sticky-toolbar\"></div>\r\n<div id=\"ContentColumn\" class=\"page-column page-column--center\">\r\n\r\n    <div class=\"article-browse-top article-browse-mobile-nav js-mobile-nav\">\r\n    <div class=\"article-browse-mobile-nav-inner js-mobile-nav-inner\">\r\n        <button class=\"toggle-left-col toggle-left-col__article btn-as-link\">\r\n            Article Navigation\r\n        </button>\r\n    </div>\r\n</div>\r\n<div class=\"article-browse-top article-browse-mobile-nav mobile-sticky-toolbar js-mobile-nav-sticky\">\r\n    <div class=\"article-browse-mobile-nav-inner\">\r\n        <button class=\"toggle-left-col toggle-left-col__article btn-as-link\">\r\n            Article Navigation\r\n        </button>\r\n    </div>\r\n</div>\r\n\r\n    <div class=\"content-inner-wrap\">\r\n    <div class=\"widget widget-ArticleTopInfo widget-instance-OUP_ArticleTop_Info_Widget\">\n        <div class=\"module-widget article-top-widget\">\r\n\r\n    \r\n\r\n    \r\n        <div class=\"access-state-logos all-viewports\">\r\n            <span class=\"journal-info__format-label\">Journal Article</span>\r\n        <span class=\"article-flag\"><a href=\"https://academic.oup.com/jcem/search-results?f_OUPSeries=Editor's+Choice\">Editor's Choice</a></span>            </div>\r\n\r\n\r\n    <div class=\"widget-items\">\r\n                <div class=\"title-wrap\">\r\n                    <h1 class=\"wi-article-title article-title-main accessible-content-title at-articleTitle\">\r\n                        Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society<span class=\"xrefLink\" id=\"jumplink-fn-0001\"></span><a href=\"javascript:;\" reveal-id=\"fn-0001\" data-open=\"fn-0001\" class=\"link link-ref link-reveal xref-fn js-xref-fn\">*</a> Clinical Practice Guideline\r\n<i class='icon-availability_free' title='Free' ></i>                    </h1>\r\n\r\n                </div>\r\n                <div class=\"wi-authors at-ArticleAuthors\">\r\n                    <div class=\"al-authors-list\">\r\n                                <span class=\"al-author-name-more js-flyout-wrap\">\r\n\r\n\r\n\r\n\r\n\r\n\r\n                                    <a class=\"linked-name js-linked-name-trigger\" href=\"javascript:;\">Wylie C Hembree</a><span class='delimiter'>, </span>\r\n\r\n                                    <span class=\"al-author-info-wrap arrow-up\">\r\n<div class=\"info-card-author authorInfo_OUP_ArticleTop_Info_Widget\">\r\n    <div class=\"name-role-wrap\">\r\n        <div class=\"info-card-name\">\r\n    Wylie C Hembree\r\n</div>\r\n\r\n    </div>\r\n\r\n    <div class=\"info-card-affilitation\">\r\n        <div class=\"aff\"><span class=\"label\">1</span>New York Presbyterian Hospital, Columbia University Medical Center, New York, New York 10032 (Retired)</div>\r\n    </div>\r\n\r\n    <div class=\"info-card-search-label\">\r\n        Search for other works by this author on:\r\n    </div>\r\n\r\n<div class=\"info-card-search info-card-search-internal\">\r\n    <a href=\"/jcem/search-results?f_Authors=Wylie+C+Hembree\">Oxford Academic</a>\r\n</div>\r\n\r\n    <div class=\"info-card-search info-card-search-google\">\r\n        <a href=\"http://scholar.google.com/scholar?q=author:%22Hembree Wylie C%22\">Google Scholar</a>\r\n    </div>\r\n</div>                                    </span>\r\n                                </span>\r\n                                <span class=\"al-author-name-more js-flyout-wrap\">\r\n\r\n\r\n\r\n\r\n\r\n\r\n                                    <a class=\"linked-name js-linked-name-trigger\" href=\"javascript:;\">Peggy T Cohen-Kettenis</a><span class='delimiter'>, </span>\r\n\r\n                                    <span class=\"al-author-info-wrap arrow-up\">\r\n<div class=\"info-card-author authorInfo_OUP_ArticleTop_Info_Widget\">\r\n    <div class=\"name-role-wrap\">\r\n        <div class=\"info-card-name\">\r\n    Peggy T Cohen-Kettenis\r\n</div>\r\n\r\n    </div>\r\n\r\n    <div class=\"info-card-affilitation\">\r\n        <div class=\"aff\"><span class=\"label\">2</span>VU University Medical Center, 1007 MB Amsterdam, Netherlands (Retired)</div>\r\n    </div>\r\n\r\n    <div class=\"info-card-search-label\">\r\n        Search for other works by this author on:\r\n    </div>\r\n\r\n<div class=\"info-card-search info-card-search-internal\">\r\n    <a href=\"/jcem/search-results?f_Authors=Peggy+T+Cohen-Kettenis\">Oxford Academic</a>\r\n</div>\r\n\r\n    <div class=\"info-card-search info-card-search-google\">\r\n        <a href=\"http://scholar.google.com/scholar?q=author:%22Cohen-Kettenis Peggy T%22\">Google Scholar</a>\r\n    </div>\r\n</div>                                    </span>\r\n                                </span>\r\n                                <span class=\"al-author-name-more js-flyout-wrap\">\r\n\r\n\r\n\r\n\r\n\r\n\r\n                                    <a class=\"linked-name js-linked-name-trigger\" href=\"javascript:;\">Louis Gooren</a><span class='delimiter'>, </span>\r\n\r\n                                    <span class=\"al-author-info-wrap arrow-up\">\r\n<div class=\"info-card-author authorInfo_OUP_ArticleTop_Info_Widget\">\r\n    <div class=\"name-role-wrap\">\r\n        <div class=\"info-card-name\">\r\n    Louis Gooren\r\n</div>\r\n\r\n    </div>\r\n\r\n    <div class=\"info-card-affilitation\">\r\n        <div class=\"aff\"><span class=\"label\">3</span>VU University Medical Center, 1007 MB Amsterdam, Netherlands (Retired)</div>\r\n    </div>\r\n\r\n    <div class=\"info-card-search-label\">\r\n        Search for other works by this author on:\r\n    </div>\r\n\r\n<div class=\"info-card-search info-card-search-internal\">\r\n    <a href=\"/jcem/search-results?f_Authors=Louis+Gooren\">Oxford Academic</a>\r\n</div>\r\n\r\n    <div class=\"info-card-search info-card-search-google\">\r\n        <a href=\"http://scholar.google.com/scholar?q=author:%22Gooren Louis%22\">Google Scholar</a>\r\n    </div>\r\n</div>                                    </span>\r\n                                </span>\r\n                                <span class=\"al-author-name-more js-flyout-wrap\">\r\n\r\n\r\n\r\n\r\n\r\n\r\n                                    <a class=\"linked-name js-linked-name-trigger\" href=\"javascript:;\">Sabine E Hannema</a><span class='delimiter'>, </span>\r\n\r\n                                    <span class=\"al-author-info-wrap arrow-up\">\r\n<div class=\"info-card-author authorInfo_OUP_ArticleTop_Info_Widget\">\r\n    <div class=\"name-role-wrap\">\r\n        <div class=\"info-card-name\">\r\n    Sabine E Hannema\r\n</div>\r\n\r\n    </div>\r\n\r\n    <div class=\"info-card-affilitation\">\r\n        <div class=\"aff\"><span class=\"label\">4</span>Leiden University Medical Center, 2300 RC Leiden, Netherlands</div>\r\n    </div>\r\n\r\n    <div class=\"info-card-search-label\">\r\n        Search for other works by this author on:\r\n    </div>\r\n\r\n<div class=\"info-card-search info-card-search-internal\">\r\n    <a href=\"/jcem/search-results?f_Authors=Sabine+E+Hannema\">Oxford Academic</a>\r\n</div>\r\n\r\n    <div class=\"info-card-search info-card-search-google\">\r\n        <a href=\"http://scholar.google.com/scholar?q=author:%22Hannema Sabine E%22\">Google Scholar</a>\r\n    </div>\r\n</div>                                    </span>\r\n                                </span>\r\n                                <span class=\"al-author-name-more js-flyout-wrap\">\r\n\r\n\r\n\r\n\r\n\r\n\r\n                                    <a class=\"linked-name js-linked-name-trigger\" href=\"javascript:;\">Walter J Meyer</a><span class='delimiter'>, </span>\r\n\r\n                                    <span class=\"al-author-info-wrap arrow-up\">\r\n<div class=\"info-card-author authorInfo_OUP_ArticleTop_Info_Widget\">\r\n    <div class=\"name-role-wrap\">\r\n        <div class=\"info-card-name\">\r\n    Walter J Meyer\r\n</div>\r\n\r\n    </div>\r\n\r\n    <div class=\"info-card-affilitation\">\r\n        <div class=\"aff\"><span class=\"label\">5</span>University of Texas Medical Branch, Galveston, Texas 77555</div>\r\n    </div>\r\n\r\n    <div class=\"info-card-search-label\">\r\n        Search for other works by this author on:\r\n    </div>\r\n\r\n<div class=\"info-card-search info-card-search-internal\">\r\n    <a href=\"/jcem/search-results?f_Authors=Walter+J+Meyer\">Oxford Academic</a>\r\n</div>\r\n\r\n    <div class=\"info-card-search info-card-search-google\">\r\n        <a href=\"http://scholar.google.com/scholar?q=author:%22Meyer Walter J%22\">Google Scholar</a>\r\n    </div>\r\n</div>                                    </span>\r\n                                </span>\r\n                                <span class=\"al-author-name-more js-flyout-wrap\">\r\n\r\n\r\n\r\n\r\n\r\n\r\n                                    <a class=\"linked-name js-linked-name-trigger\" href=\"javascript:;\">M Hassan Murad</a><span class='delimiter'>, </span>\r\n\r\n                                    <span class=\"al-author-info-wrap arrow-up\">\r\n<div class=\"info-card-author authorInfo_OUP_ArticleTop_Info_Widget\">\r\n    <div class=\"name-role-wrap\">\r\n        <div class=\"info-card-name\">\r\n    M Hassan Murad\r\n</div>\r\n\r\n    </div>\r\n\r\n    <div class=\"info-card-affilitation\">\r\n        <div class=\"aff\"><span class=\"label\">6</span>Mayo Clinic Evidence-Based Practice Center, Rochester, Minnesota 55905</div>\r\n    </div>\r\n\r\n    <div class=\"info-card-search-label\">\r\n        Search for other works by this author on:\r\n    </div>\r\n\r\n<div class=\"info-card-search info-card-search-internal\">\r\n    <a href=\"/jcem/search-results?f_Authors=M+Hassan+Murad\">Oxford Academic</a>\r\n</div>\r\n\r\n    <div class=\"info-card-search info-card-search-google\">\r\n        <a href=\"http://scholar.google.com/scholar?q=author:%22Murad M Hassan%22\">Google Scholar</a>\r\n    </div>\r\n</div>                                    </span>\r\n                                </span>\r\n                                <span class=\"al-author-name-more js-flyout-wrap\">\r\n\r\n\r\n\r\n\r\n\r\n\r\n                                    <a class=\"linked-name js-linked-name-trigger\" href=\"javascript:;\">Stephen M Rosenthal</a><span class='delimiter'>, </span>\r\n\r\n                                    <span class=\"al-author-info-wrap arrow-up\">\r\n<div class=\"info-card-author authorInfo_OUP_ArticleTop_Info_Widget\">\r\n    <div class=\"name-role-wrap\">\r\n        <div class=\"info-card-name\">\r\n    Stephen M Rosenthal\r\n</div>\r\n\r\n    </div>\r\n\r\n    <div class=\"info-card-affilitation\">\r\n        <div class=\"aff\"><span class=\"label\">7</span>University of California San Francisco, Benioff Children’s Hospital, San Francisco, California 94143</div>\r\n    </div>\r\n\r\n    <div class=\"info-card-search-label\">\r\n        Search for other works by this author on:\r\n    </div>\r\n\r\n<div class=\"info-card-search info-card-search-internal\">\r\n    <a href=\"/jcem/search-results?f_Authors=Stephen+M+Rosenthal\">Oxford Academic</a>\r\n</div>\r\n\r\n    <div class=\"info-card-search info-card-search-google\">\r\n        <a href=\"http://scholar.google.com/scholar?q=author:%22Rosenthal Stephen M%22\">Google Scholar</a>\r\n    </div>\r\n</div>                                    </span>\r\n                                </span>\r\n                                <span class=\"al-author-name-more js-flyout-wrap\">\r\n\r\n\r\n\r\n\r\n\r\n\r\n                                    <a class=\"linked-name js-linked-name-trigger\" href=\"javascript:;\">Joshua D Safer</a><span class='delimiter'>, </span>\r\n\r\n                                    <span class=\"al-author-info-wrap arrow-up\">\r\n<div class=\"info-card-author authorInfo_OUP_ArticleTop_Info_Widget\">\r\n    <div class=\"name-role-wrap\">\r\n        <div class=\"info-card-name\">\r\n    Joshua D Safer\r\n</div>\r\n\r\n    </div>\r\n\r\n    <div class=\"info-card-affilitation\">\r\n        <div class=\"aff\"><span class=\"label\">8</span>Boston University School of Medicine, Boston, Massachusetts 02118</div>\r\n    </div>\r\n\r\n    <div class=\"info-card-search-label\">\r\n        Search for other works by this author on:\r\n    </div>\r\n\r\n<div class=\"info-card-search info-card-search-internal\">\r\n    <a href=\"/jcem/search-results?f_Authors=Joshua+D+Safer\">Oxford Academic</a>\r\n</div>\r\n\r\n    <div class=\"info-card-search info-card-search-google\">\r\n        <a href=\"http://scholar.google.com/scholar?q=author:%22Safer Joshua D%22\">Google Scholar</a>\r\n    </div>\r\n</div>                                    </span>\r\n                                </span>\r\n                                <span class=\"al-author-name-more js-flyout-wrap\">\r\n\r\n\r\n\r\n\r\n\r\n\r\n                                    <a class=\"linked-name js-linked-name-trigger\" href=\"javascript:;\">Vin Tangpricha</a><span class='delimiter'>, </span>\r\n\r\n                                    <span class=\"al-author-info-wrap arrow-up\">\r\n<div class=\"info-card-author authorInfo_OUP_ArticleTop_Info_Widget\">\r\n    <div class=\"name-role-wrap\">\r\n        <div class=\"info-card-name\">\r\n    Vin Tangpricha\r\n</div>\r\n\r\n    </div>\r\n\r\n    <div class=\"info-card-affilitation\">\r\n        <div class=\"aff\"><span class=\"label\">9</span>Emory University School of Medicine and the Atlanta VA Medical Center, Atlanta, Georgia 30322</div>\r\n    </div>\r\n\r\n    <div class=\"info-card-search-label\">\r\n        Search for other works by this author on:\r\n    </div>\r\n\r\n<div class=\"info-card-search info-card-search-internal\">\r\n    <a href=\"/jcem/search-results?f_Authors=Vin+Tangpricha\">Oxford Academic</a>\r\n</div>\r\n\r\n    <div class=\"info-card-search info-card-search-google\">\r\n        <a href=\"http://scholar.google.com/scholar?q=author:%22Tangpricha Vin%22\">Google Scholar</a>\r\n    </div>\r\n</div>                                    </span>\r\n                                </span>\r\n                                <span class=\"al-author-name-more js-flyout-wrap\">\r\n\r\n\r\n\r\n\r\n\r\n\r\n                                    <a class=\"linked-name js-linked-name-trigger\" href=\"javascript:;\">Guy G T’Sjoen</a><span class='delimiter'></span>\r\n\r\n                                    <span class=\"al-author-info-wrap arrow-up\">\r\n<div class=\"info-card-author authorInfo_OUP_ArticleTop_Info_Widget\">\r\n    <div class=\"name-role-wrap\">\r\n        <div class=\"info-card-name\">\r\n    Guy G T’Sjoen\r\n</div>\r\n\r\n    </div>\r\n\r\n    <div class=\"info-card-affilitation\">\r\n        <div class=\"aff\"><span class=\"label\">10</span>Ghent University Hospital, 9000 Ghent, Belgium</div>\r\n    </div>\r\n\r\n    <div class=\"info-card-search-label\">\r\n        Search for other works by this author on:\r\n    </div>\r\n\r\n<div class=\"info-card-search info-card-search-internal\">\r\n    <a href=\"/jcem/search-results?f_Authors=Guy+G+T%e2%80%99Sjoen\">Oxford Academic</a>\r\n</div>\r\n\r\n    <div class=\"info-card-search info-card-search-google\">\r\n        <a href=\"http://scholar.google.com/scholar?q=author:%22T’Sjoen Guy G%22\">Google Scholar</a>\r\n    </div>\r\n</div>                                    </span>\r\n                                </span>\r\n\r\n                            <div class=\"al-author-name al-author-footnotes\">\r\n                                <div class=\"al-author-info-wrap arrow-up\">\r\n    <div class=\"widget widget-SingleSection widget-instance-OUP_FootnoteSection\">\n        <div content-id=\"fn-0001\" class=\"footnote\"><span class=\"fn\"><span class=\"label fn-label\"><a rel=\"nofollow\" href=\"javascript:;\" data-fn-id=\"fn-0001\" class=\"js-end-note-link end-note-link\">*</a></span><div class=\"footnote-content\"><p class=\"footnote-compatibility\">Cosponsoring Associations: American Association of Clinical Endocrinologists, American Society of Andrology, European Society for Pediatric Endocrinology, European Society of Endocrinology, Pediatric Endocrine Society, and World Professional Association for Transgender Health.</p></div></span></div> \n    </div>\n                                </div>\r\n                                <a class=\"js-linked-footnotes\" href=\"javascript:;\">Author Notes</a>\r\n                            </div>\r\n                    </div>\r\n                </div>\r\n<div class=\"pub-history-wrap clearfix js-history-dropdown-wrap\">\r\n\r\n        <div class=\"pub-history-row clearfix\">\r\n            <div class=\"ww-citation-primary\"><em>The Journal of Clinical Endocrinology & Metabolism</em>, Volume 102, Issue 11, 1 November 2017, Pages 3869–3903, <a href='https://doi.org/10.1210/jc.2017-01658'>https://doi.org/10.1210/jc.2017-01658</a></div>\r\n        </div>\r\n        <div class=\"pub-history-row clearfix\">\r\n            <div class=\"ww-citation-date-wrap\">\r\n                <div class=\"citation-label\">Published:</div>\r\n                <div class=\"citation-date\">13 September 2017</div>\r\n            </div>\r\n                <a href=\"javascript:;\" class=\"history-label js-history-dropdown-trigger st-article-history at-ArticleHistory\">\r\n                    <span>Article history</span><i class=\"icon-general-arrow-filled-down arrow-icon\"></i>\r\n                </a>\r\n        </div>\r\n            <div class=\"ww-history js-history-entries-wrap at-history-entries-wrap\">\r\n                <div class=\"history-entry at-history-entry\">\r\n                    <div class=\"wi-state\">Received:</div>\r\n                    <div class=\"wi-date\">24 July 2017</div>\r\n                </div>\r\n                <div class=\"history-entry at-history-entry\">\r\n                    <div class=\"wi-state\">Accepted:</div>\r\n                    <div class=\"wi-date\">24 August 2017</div>\r\n                </div>\r\n                <div class=\"history-entry at-history-entry\">\r\n                    <div class=\"wi-state\">Published:</div>\r\n                    <div class=\"wi-date\">13 September 2017</div>\r\n                </div>\r\n        </div>\r\n</div>\r\n    </div>\r\n</div>\r\n\r\n<script>\r\n    $(document).ready(function () {\r\n        $('.article-top-widget').on('click', '.ati-toggle-trigger', function () {\r\n            $(this).find('.icon-general-add, .icon-minus').toggleClass('icon-minus icon-general-add');\r\n            $(this).siblings('.ati-toggle-content').toggleClass('hide');\r\n        });\r\n\r\n        // In Chrome, an anchor tag with target=\"_blank\" and a \"mailto:\" href opens a new tab/window as well as the email client\r\n        // I suspect this behavior will be corrected in the future\r\n        // Remove the target=\"_blank\"\r\n        $('ul.wi-affiliationList').find('a[href^=\"mailto:\"]').each(function () {\r\n            $(this).removeAttr('target');\r\n        });\r\n    });\r\n</script>\r\n\r\n \n    </div>\n    <div class=\"widget widget-ArticleLinks widget-instance-OUP_Article_Links_Widget\">\n                <div class=\"articlelinks at-ArticleLinks\">\r\n                            <div class=\"cc-row\">\r\n                        <span>A correction has been published: </span>\r\n                                                                <span class=\"article-link-citation\">\r\n                            <em>The Journal of Clinical Endocrinology & Metabolism</em>, Volume 103, Issue 2, February 2018, Page 699, <a href='https://doi.org/10.1210/jc.2017-02548'>https://doi.org/10.1210/jc.2017-02548</a>\r\n                        </span>\r\n                </div>\r\n                <div class=\"cc-row\">\r\n                        <span>A correction has been published: </span>\r\n                                                                <span class=\"article-link-citation\">\r\n                            <em>The Journal of Clinical Endocrinology & Metabolism</em>, Volume 103, Issue 7, July 2018, Pages 2758–2759, <a href='https://doi.org/10.1210/jc.2018-01268'>https://doi.org/10.1210/jc.2018-01268</a>\r\n                        </span>\r\n                </div>\r\n        </div>\r\n \n    </div>\n\r\n\r\n        <div class=\"article-body js-content-body\">\r\n            <div class=\"toolbar-wrap js-toolbar-wrap\">\r\n                <div class=\"toolbar-inner-wrap\">\r\n                    <ul id=\"Toolbar\" role=\"navigation\">\r\n    <li class=\"toolbar-item item-pdf js-item-pdf\">\r\n        <a class=\"al-link pdf article-pdfLink\" data-article-id=\"4157558\" href=\"/jcem/article-pdf/102/11/3869/21533864/jc.2017-01658.pdf\">\r\n            <img src=//oup.silverchair-cdn.com/UI/app/svg/pdf.svg alt=\"pdf\" /><span class=\"pdf-link-text\">PDF</span>\r\n        </a>\r\n    </li>\r\n                                                    <li class=\"toolbar-item item-link item-split-view\">\r\n                                <a href=\"javascript:;\"\r\n                                   class=\"split-view js-split-view st-split-view at-split-view\"\r\n                                   target=\"\">\r\n                                    <i class=\"icon-menu-split\"></i>\r\n                                    Split View\r\n                                </a>\r\n                            </li>\r\n\r\n                        <li class=\"toolbar-item item-with-dropdown item-views\">\r\n                            <a class=\"at-views-dropdown drop-trigger\" href=\"javascript:;\" data-dropdown=\"FilterDrop\" aria-haspopup=\"true\">\r\n                                <i class=\"icon-menu_views\"></i>\r\n                                <div class=\"toolbar-label\">\r\n                                    <div class=\"toolbar-text\">Views</div>\r\n                                    <i class=\"icon-general-arrow-filled-down arrow-icon\"></i>\r\n                                </div>\r\n                            </a>\r\n                            <ul id=\"ViewsDrop\" class=\"f-dropdown\" data-dropdown-content aria-label=\"submenu\">\r\n                                <div class=\"arrow-up\"></div>\r\n                                <li class=\"article-content-filter js-article-content-filter\" data-content-filter=\"article-content\">\r\n                                    <a href=\"javascript:;\"><span>Article contents</span></a>\r\n                                </li>\r\n                                <li class=\"at-figures-tables article-content-filter js-article-content-filter\" data-content-filter=\"figures-tables\">\r\n                                    <a href=\"javascript:;\"><span>Figures &amp; tables</span></a>\r\n                                </li>\r\n                                <li class=\"article-content-filter js-article-content-filter\" data-content-filter=\"video\">\r\n                                    <a href=\"javascript:;\"><span>Video</span></a>\r\n                                </li>\r\n                                <li class=\"article-content-filter js-article-content-filter\" data-content-filter=\"audio\">\r\n                                    <a href=\"javascript:;\"><span>Audio</span></a>\r\n                                </li>\r\n                                <li class=\"article-content-filter js-article-content-filter\" data-content-filter=\"supplementary-data\">\r\n                                    <a href=\"javascript:;\"><span>Supplementary Data</span></a>\r\n                                </li>\r\n                            </ul>\r\n                        </li>\r\n\r\n\r\n                        <li class=\"toolbar-item item-cite js-item-cite\">\r\n    <div class=\"widget widget-ToolboxGetCitation widget-instance-OUP_Get_Citation\">\n        <a href=\"#\" class=\"js-cite-button at-CiteButton\" data-reveal-id=\"getCitation\" data-reveal>\r\n    <i class=\"icon-read-more\"></i>\r\n    <span>Cite</span>\r\n</a>\r\n\r\n<div id=\"getCitation\" class=\"reveal-modal js-citation-modal\" data-reveal>\r\n    <h3 class=\"modal-title\">Cite</h3>\r\n        <div class=\"oxford-citation-text\">\r\n            <p>Wylie C Hembree, Peggy T Cohen-Kettenis, Louis Gooren, Sabine E Hannema, Walter J Meyer, M Hassan Murad, Stephen M Rosenthal, Joshua D Safer, Vin Tangpricha, Guy G T’Sjoen,  Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society Clinical Practice Guideline, <em>The Journal of Clinical Endocrinology & Metabolism</em>, Volume 102, Issue 11, 1 November 2017, Pages 3869–3903, <a href=\"https://doi.org/10.1210/jc.2017-01658\">https://doi.org/10.1210/jc.2017-01658</a></p>\r\n        </div>\r\n\r\n    <div class=\"citation-download-wrap\">\r\n        <form action=\"/Citation/Download\" method=\"get\" id=\"citationModal\">\r\n            <input type=\"hidden\" name=\"resourceId\" value=\"4157558\" />\r\n            <input type=\"hidden\" name=\"resourceType\" value=\"3\" />\r\n            <label for=\"selectFormat\" class=\"hide js-citation-format-label\">Select Format</label>\r\n            <select required name=\"citationFormat\" class=\"citation-download-format js-citation-format\" id=\"selectFormat\">\r\n                <option selected disabled >Select format</option>\r\n                        <option value=\"0\" >.ris (Mendeley, Papers, Zotero)</option>\r\n                        <option value=\"1\" >.enw (EndNote)</option>\r\n                        <option value=\"2\" >.bibtex (BibTex)</option>\r\n                        <option value=\"3\" >.txt (Medlars, RefWorks)</option>\r\n\r\n            </select>\r\n            <button class=\"btn citation-download-link disabled\" type=\"submit\">Download citation</button>\r\n        </form>\r\n    </div>\r\n\r\n    <a class=\"close-reveal-modal\" href=\"javascript:;\"><i class=\"icon-general-close\"></i><span class=\"screenreader-text\">Close</span></a>\r\n</div>\r\n \n    </div>\n\r\n                        </li>\r\n                        <li class=\"toolbar-item item-tools\">\r\n    <div class=\"widget widget-ToolboxPermissions widget-instance-OUP_Get_Permissions\">\n            <div class=\"module-widget\">\r\n        <a href=\"https://s100.copyright.com/AppDispatchServlet?publisherName=OUP&amp;publication=1945-7197&amp;title=Endocrine%20Treatment%20of%20Gender-Dysphoric%2FGender-Incongruent%20Persons%3A%20An%20Endocrine%20Society%26lt%3Bspan%20class%3D%26quot%3BxrefLink%26quot%3B%20id%3D%26quot%3Bjumplink-fn-0001%26quot%3B%26gt%3B%26lt%3B%2Fspan%26gt%3B%26lt%3Ba%20href%3D%26quot%3Bjavascript%3A%3B%26quot%3B%20reveal-id%3D%26quot%3Bfn-0001%26quot%3B%20data-open%3D%26quot%3Bfn-0001%26quot%3B%20class%3D%26quot%3Blink%20link-ref%20link-reveal%20xref-fn%20js-xref-fn%26quot%3B%26gt%3B%2A%26lt%3B%2Fa%26gt%3B%20Clinical%20Practice%20Guideline&amp;publicationDate=2017-09-13&amp;volumeNum=102&amp;issueNum=11&amp;author=Hembree%2C%20Wylie%20C%3B%20Cohen-Kettenis%2C%20Peggy%20T&amp;startPage=3869&amp;endPage=3903&amp;contentId=10.1210%2Fjc.2017-01658&amp;oa=&amp;copyright=Oxford%20University%20Press&amp;orderBeanReset=True\" id=\"PermissionsLink\" class=\"\" target=\"_blank\">\r\n            <i class=\"icon-menu_permissions\">\r\n                <span class=\"screenreader-text\">Permissions Icon</span>\r\n            </i>\r\n            Permissions\r\n        </a>\r\n    </div>\r\n \n    </div>\n\r\n                        </li>\r\n                        <li class=\"toolbar-item item-with-dropdown item-share last\">\r\n                            <a class=\"drop-trigger at-ShareButton\" href=\"javascript:;\" data-dropdown=\"ShareDrop\" aria-haspopup=\"true\">\r\n                                <i class=\"icon-menu_share\"></i>\r\n                                <div class=\"toolbar-label\">\r\n                                    <div class=\"toolbar-text\">Share</div>\r\n                                    <i class=\"icon-general-arrow-filled-down arrow-icon\"></i>\r\n                                </div>\r\n                            </a>\r\n                            <ul id=\"ShareDrop\" class=\"addthis_toolbox addthis_default_style addthis_20x20_style f-dropdown\" data-dropdown-content aria-label=\"submenu\">\r\n                                <div class=\"arrow-up\"></div>\r\n                                <li><a class=\"addthis_button_email\"><span>Email</span></a></li>\r\n                                <li><a class=\"addthis_button_twitter\"><span>Twitter</span></a></li>\r\n                                <li><a class=\"addthis_button_facebook\"><span>Facebook</span></a></li>\r\n                                <li><a class=\"addthis_button_compact\"><span>More</span></a></li>\r\n                            </ul>\r\n                        </li>\r\n                    </ul>\r\n                    <div class=\"toolbar-search\">\r\n    <div class=\"widget widget-SitePageHeader widget-instance-OUP_ArticleToolbarSearchBox\">\n        \r\n\r\n\r\n\r\n<div class=\"dropdown-panel-wrap\">\r\n\r\n    \r\n    <div class=\"dropdown-panel mobile-search-dropdown\">\r\n        <div class=\"mobile-search-inner-wrap\">\r\n\r\n\r\n<div class=\"navbar-search\">\r\n    <div class=\"mobile-microsite-search\">\r\n            <label for=\"OUP_ArticleToolbarSearchBox-mobile-navbar-search-filter\" class=\"screenreader-text js-mobile-navbar-search-filter-label\">\r\n                Navbar Search Filter\r\n            </label>\r\n            <select class=\"mobile-navbar-search-filter js-mobile-navbar-search-filter at-navbar-search-filter\" id=\"OUP_ArticleToolbarSearchBox-mobile-navbar-search-filter\">\r\n\r\n<option class=\"navbar-search-filter-option at-navbar-search-filter-option\" value=\"\">The Journal of Clinical Endocrinology & Metabolism</option><option class=\"navbar-search-filter-option at-navbar-search-filter-option\" value=\"Issue\">This issue</option><option class=\"navbar-search-filter-option at-navbar-search-filter-option\" value=\"Parent\">Endocrine Society Journals</option>\r\n                    <optgroup class=\"navbar-search-optgroup\" label=\"Search across Oxford Academic\">\r\n<option class=\"navbar-search-filter-option at-navbar-search-filter-option\" value=\"AcademicSubjects/MED00160\">Clinical Medicine</option><option class=\"navbar-search-filter-option at-navbar-search-filter-option\" value=\"AcademicSubjects/MED00250\">Endocrinology and Diabetes</option><option class=\"navbar-search-filter-option at-navbar-search-filter-option\" value=\"AcademicSubjects/MED00010\">Medicine and Health</option><option class=\"navbar-search-filter-option at-navbar-search-filter-option\" value=\"Books\">Books</option><option class=\"navbar-search-filter-option at-navbar-search-filter-option\" value=\"Journals\">Journals</option><option class=\"navbar-search-filter-option at-navbar-search-filter-option\" value=\"Umbrella\">Oxford Academic</option>                    </optgroup>\r\n            </select>\r\n\r\n        <label for=\"OUP_ArticleToolbarSearchBox-mobile-microsite-search-term\" class=\"screenreader-text js-mobile-microsite-search-term-label\">\r\n            Mobile Microsite Search Term\r\n        </label>\r\n        <input class=\"mobile-search-input mobile-microsite-search-term js-mobile-microsite-search-term at-microsite-search-term\" type=\"text\"\r\n               maxlength=\"255\" placeholder=\"Search\" id=\"OUP_ArticleToolbarSearchBox-mobile-microsite-search-term\">\r\n\r\n        <a href=\"javascript:;\" class=\"mobile-microsite-search-icon mobile-search-submit icon-menu_search\">\r\n            <span class=\"screenreader-text\">Search</span>\r\n        </a>\r\n\r\n    </div>\r\n</div>\r\n\r\n        </div>\r\n    </div>\r\n    \r\n    <div class=\"dropdown-panel mobile-account-dropdown\">\r\n        <ul class=\"site-menu site-menu-lvl-0\">\r\n            <li class=\"site-menu-item site-menu-lvl-0\">\r\n                <a href=\"\" class=\"nav-link mobile-account-signin js-nav-dropdown js-header-account-info-user-fullname\" id=\"header-account-info-user-fullname-mobile\">\r\n                    \r\nSign In                    <i class=\"mobile-nav-arrow icon-general_arrow-down\"></i>\r\n                </a>\r\n                <ul class=\"site-menu site-menu-lvl-1 individual-menu\">\r\n                    <li class=\"dropdown-signin-form\">\r\n                        <div class=\"spinner\"></div>\r\n                    </li>\r\n                </ul>\r\n            </li>\r\n                    </ul>\r\n    </div>\r\n    \r\n    <div class=\"dropdown-panel mobile-nav-dropdown\">\r\n\r\n    </div>\r\n\r\n</div>\r\n\r\n\r\n<div class=\"navbar\">\r\n    <div class=\"center-inner-row\">\r\n        <nav class=\"navbar-menu\">\r\n\r\n        </nav>\r\n            <div class=\"navbar-search-container js-navbar-search-container\">\r\n                <a href=\"javascript:;\" class=\"navbar-search-close js_close-navsearch\">Close</a>\r\n\r\n\r\n<div class=\"navbar-search\">\r\n    <div class=\"microsite-search\">\r\n            <label for=\"OUP_ArticleToolbarSearchBox-navbar-search-filter\" class=\"screenreader-text js-navbar-search-filter-label\">\r\n                Navbar Search Filter\r\n            </label>\r\n            <select class=\"navbar-search-filter js-navbar-search-filter at-navbar-search-filter\" id=\"OUP_ArticleToolbarSearchBox-navbar-search-filter\">\r\n\r\n<option class=\"navbar-search-filter-option at-navbar-search-filter-option\" value=\"\">The Journal of Clinical Endocrinology & Metabolism</option><option class=\"navbar-search-filter-option at-navbar-search-filter-option\" value=\"Issue\">This issue</option><option class=\"navbar-search-filter-option at-navbar-search-filter-option\" value=\"Parent\">Endocrine Society Journals</option>\r\n                    <optgroup class=\"navbar-search-optgroup\" label=\"Search across Oxford Academic\">\r\n<option class=\"navbar-search-filter-option at-navbar-search-filter-option\" value=\"AcademicSubjects/MED00160\">Clinical Medicine</option><option class=\"navbar-search-filter-option at-navbar-search-filter-option\" value=\"AcademicSubjects/MED00250\">Endocrinology and Diabetes</option><option class=\"navbar-search-filter-option at-navbar-search-filter-option\" value=\"AcademicSubjects/MED00010\">Medicine and Health</option><option class=\"navbar-search-filter-option at-navbar-search-filter-option\" value=\"Books\">Books</option><option class=\"navbar-search-filter-option at-navbar-search-filter-option\" value=\"Journals\">Journals</option><option class=\"navbar-search-filter-option at-navbar-search-filter-option\" value=\"Umbrella\">Oxford Academic</option>                    </optgroup>\r\n            </select>\r\n\r\n        <label for=\"OUP_ArticleToolbarSearchBox-microsite-search-term\" class=\"screenreader-text js-microsite-search-term-label\">\r\n            Microsite Search Term\r\n        </label>\r\n        <input class=\"navbar-search-input microsite-search-term js-microsite-search-term at-microsite-search-term\" type=\"text\"\r\n               maxlength=\"255\" placeholder=\"Search\" id=\"OUP_ArticleToolbarSearchBox-microsite-search-term\">\r\n\r\n        <a href=\"javascript:;\" class=\"microsite-search-icon navbar-search-submit icon-menu_search\">\r\n            <span class=\"screenreader-text\">Search</span>\r\n        </a>\r\n\r\n    </div>\r\n</div>\r\n\r\n                <div class=\"navbar-search-advanced\"><a href=\"/jcem/advanced-search\" class=\"advanced-search js-advanced-search\">Advanced Search</a></div>\r\n            </div>            <div class=\"navbar-search-collapsed\"><a href=\"javascript:;\" class=\"icon-menu_search js_expand-navsearch\"><span class=\"screenreader-text\">Search Menu</span></a></div>\r\n    </div>\r\n</div>\r\n<input id=\"hfEnableOupOnlineProductsFeatures\" name=\"hfEnableOupOnlineProductsFeatures\" type=\"hidden\" value=\"True\" />\r\n\r\n<input id=\"routename\" name=\"RouteName\" type=\"hidden\" value=\"jcem\" /> \n    </div>\n\r\n                    </div>\r\n                </div>\r\n            </div>\r\n            <div id=\"ContentTab\" class=\"content active\">\r\n    <div class=\"widget widget-ArticleFulltext widget-instance-OUP_Article_FullText_Widget\">\n        <div class=\"module-widget\">\r\n    <div class=\"widget-items\" data-widgetname=\"ArticleFulltext\">\r\n\r\n\r\n\r\n\r\n\r\n                    <h2 scrollto-destination=99603237 id=\"99603237\" class=\"abstract-title js-splitscreen-abstract-title\" >Abstract</h2>\r\n<section class=\"abstract\"><div class=\" sec\"><div class=\"title\">Objective</div><p class=\"chapter-para\">To update the “Endocrine Treatment of Transsexual Persons: An Endocrine Society Clinical Practice Guideline,” published by the Endocrine Society in 2009.</p></div><div class=\" sec\"><div class=\"title\">Participants</div><p class=\"chapter-para\">The participants include an Endocrine Society–appointed task force of nine experts, a methodologist, and a medical writer.</p></div><div class=\" sec\"><div class=\"title\">Evidence</div><p class=\"chapter-para\">This evidence-based guideline was developed using the Grading of Recommendations, Assessment, Development, and Evaluation approach to describe the strength of recommendations and the quality of evidence. The task force commissioned two systematic reviews and used the best available evidence from other published systematic reviews and individual studies.</p></div><div class=\" sec\"><div class=\"title\">Consensus Process</div><p class=\"chapter-para\">Group meetings, conference calls, and e-mail communications enabled consensus. Endocrine Society committees, members and cosponsoring organizations reviewed and commented on preliminary drafts of the guidelines.</p></div><div class=\" sec\"><div class=\"title\">Conclusion</div><p class=\"chapter-para\">Gender affirmation is multidisciplinary treatment in which endocrinologists play an important role. Gender-dysphoric/gender-incongruent persons seek and/or are referred to endocrinologists to develop the physical characteristics of the affirmed gender. They require a safe and effective hormone regimen that will (1) suppress endogenous sex hormone secretion determined by the person’s genetic/gonadal sex and (2) maintain sex hormone levels within the normal range for the person’s affirmed gender. Hormone treatment is not recommended for prepubertal gender-dysphoric/gender-incongruent persons. Those clinicians who recommend gender-affirming endocrine treatments—appropriately trained diagnosing clinicians (required), a mental health provider for adolescents (required) and mental health professional for adults (recommended)—should be knowledgeable about the diagnostic criteria and criteria for gender-affirming treatment, have sufficient training and experience in assessing psychopathology, and be willing to participate in the ongoing care throughout the endocrine transition. We recommend treating gender-dysphoric/gender-incongruent adolescents who have entered puberty at Tanner Stage G2/B2 by suppression with gonadotropin-releasing hormone agonists. Clinicians may add gender-affirming hormones after a multidisciplinary team has confirmed the persistence of gender dysphoria/gender incongruence and sufficient mental capacity to give informed consent to this partially irreversible treatment. Most adolescents have this capacity by age 16 years old. We recognize that there may be compelling reasons to initiate sex hormone treatment prior to age 16 years, although there is minimal published experience treating prior to 13.5 to 14 years of age. For the care of peripubertal youths and older adolescents, we recommend that an expert multidisciplinary team comprised of medical professionals and mental health professionals manage this treatment. The treating physician must confirm the criteria for treatment used by the referring mental health practitioner and collaborate with them in decisions about gender-affirming surgery in older adolescents. For adult gender-dysphoric/gender-incongruent persons, the treating clinicians (collectively) should have expertise in transgender-specific diagnostic criteria, mental health, primary care, hormone treatment, and surgery, as needed by the patient. We suggest maintaining physiologic levels of gender-appropriate hormones and monitoring for known risks and complications. When high doses of sex steroids are required to suppress endogenous sex steroids and/or in advanced age, clinicians may consider surgically removing natal gonads along with reducing sex steroid treatment. Clinicians should monitor both transgender males (female to male) and transgender females (male to female) for reproductive organ cancer risk when surgical removal is incomplete. Additionally, clinicians should persistently monitor adverse effects of sex steroids. For gender-affirming surgeries in adults, the treating physician must collaborate with and confirm the criteria for treatment used by the referring physician. Clinicians should avoid harming individuals (via hormone treatment) who have conditions other than gender dysphoria/gender incongruence and who may not benefit from the physical changes associated with this treatment.</p></div></section>                    <div class=\"article-metadata-panel clearfix at-ArticleMetadata\"></div>\r\n                    <h2 scrollto-destination=99603239 id=\"99603239\" class=\"section-title js-splitscreen-section-title\" data-legacy-id=s6>Summary of Recommendations</h2>\r\n                    <h3 scrollto-destination=99603240 id=\"99603240\" class=\"section-title js-splitscreen-section-title\" data-legacy-id=s7>1.0 Evaluation of youth and adults</h3>\r\n<ul class=\"list-simple\"><li><p class=\"chapter-para\">1.1. We advise that only trained mental health professionals (MHPs) who meet the following criteria should diagnose gender dysphoria (GD)/gender incongruence in adults: (1) competence in using the Diagnostic and Statistical Manual of Mental Disorders (DSM) and/or the International Statistical Classification of Diseases and Related Health Problems (ICD) for diagnostic purposes, (2) the ability to diagnose GD/gender incongruence and make a distinction between GD/gender incongruence and conditions that have similar features (<em>e.g.</em>, body dysmorphic disorder), (3) training in diagnosing psychiatric conditions, (4) the ability to undertake or refer for appropriate treatment, (5) the ability to psychosocially assess the person’s understanding, mental health, and social conditions that can impact gender-affirming hormone therapy, and (6) a practice of regularly attending relevant professional meetings. (Ungraded Good Practice Statement)</p></li><li><p class=\"chapter-para\">1.2. We advise that only MHPs who meet the following criteria should diagnose GD/gender incongruence in children and adolescents: (1) training in child and adolescent developmental psychology and psychopathology, (2) competence in using the DSM and/or the ICD for diagnostic purposes, (3) the ability to make a distinction between GD/gender incongruence and conditions that have similar features (<em>e.g.</em>, body dysmorphic disorder), (4) training in diagnosing psychiatric conditions, (5) the ability to undertake or refer for appropriate treatment, (6) the ability to psychosocially assess the person’s understanding and social conditions that can impact gender-affirming hormone therapy, (7) a practice of regularly attending relevant professional meetings, and (8) knowledge of the criteria for puberty blocking and gender-affirming hormone treatment in adolescents. (Ungraded Good Practice Statement)</p></li><li><p class=\"chapter-para\">1.3. We advise that decisions regarding the social transition of prepubertal youths with GD/gender incongruence are made with the assistance of an MHP or another experienced professional. (Ungraded Good Practice Statement).</p></li><li><p class=\"chapter-para\">1.4. We recommend against puberty blocking and gender-affirming hormone treatment in prepubertal children with GD/gender incongruence. (1 |⊕⊕○○)</p></li><li><p class=\"chapter-para\">1.5. We recommend that clinicians inform and counsel all individuals seeking gender-affirming medical treatment regarding options for fertility preservation prior to initiating puberty suppression in adolescents and prior to treating with hormonal therapy of the affirmed gender in both adolescents and adults. (1 |⊕⊕⊕○)</p></li></ul>                    <h3 scrollto-destination=99603242 id=\"99603242\" class=\"section-title js-splitscreen-section-title\" data-legacy-id=s8>2.0 Treatment of adolescents</h3>\r\n<ul class=\"list-simple\"><li><p class=\"chapter-para\">2.1. We suggest that adolescents who meet diagnostic criteria for GD/gender incongruence, fulfill criteria for treatment, and are requesting treatment should initially undergo treatment to suppress pubertal development. (2 |⊕⊕○○)</p></li><li><p class=\"chapter-para\">2.2. We suggest that clinicians begin pubertal hormone suppression after girls and boys first exhibit physical changes of puberty. (2 |⊕⊕○○)</p></li><li><p class=\"chapter-para\">2.3. We recommend that, where indicated, GnRH analogues are used to suppress pubertal hormones. (1 |⊕⊕○○)</p></li><li><p class=\"chapter-para\">2.4. In adolescents who request sex hormone treatment (given this is a partly irreversible treatment), we recommend initiating treatment using a gradually increasing dose schedule after a multidisciplinary team of medical and MHPs has confirmed the persistence of GD/gender incongruence and sufficient mental capacity to give informed consent, which most adolescents have by age 16 years. (1 |⊕⊕○○).</p></li><li><p class=\"chapter-para\">2.5. We recognize that there may be compelling reasons to initiate sex hormone treatment prior to the age of 16 years in some adolescents with GD/gender incongruence, even though there are minimal published studies of gender-affirming hormone treatments administered before age 13.5 to 14 years. As with the care of adolescents ≥16 years of age, we recommend that an expert multidisciplinary team of medical and MHPs manage this treatment. (1 |⊕○○○)</p></li><li><p class=\"chapter-para\">2.6. We suggest monitoring clinical pubertal development every 3 to 6 months and laboratory parameters every 6 to 12 months during sex hormone treatment. (2 |⊕⊕○○)</p></li></ul>                    <h3 scrollto-destination=99603244 id=\"99603244\" class=\"section-title js-splitscreen-section-title\" data-legacy-id=s9>3.0 Hormonal therapy for transgender adults</h3>\r\n<ul class=\"list-simple\"><li><p class=\"chapter-para\">3.1. We recommend that clinicians confirm the diagnostic criteria of GD/gender incongruence and the criteria for the endocrine phase of gender transition before beginning treatment. (1 |⊕⊕⊕○)</p></li><li><p class=\"chapter-para\">3.2. We recommend that clinicians evaluate and address medical conditions that can be exacerbated by hormone depletion and treatment with sex hormones of the affirmed gender before beginning treatment. (1 |⊕⊕⊕○)</p></li><li><p class=\"chapter-para\">3.3. We suggest that clinicians measure hormone levels during treatment to ensure that endogenous sex steroids are suppressed and administered sex steroids are maintained in the normal physiologic range for the affirmed gender. (2 |⊕⊕○○)</p></li><li><p class=\"chapter-para\">3.4. We suggest that endocrinologists provide education to transgender individuals undergoing treatment about the onset and time course of physical changes induced by sex hormone treatment. (2 |⊕○○○)</p></li></ul>                    <h3 scrollto-destination=99603246 id=\"99603246\" class=\"section-title js-splitscreen-section-title\" data-legacy-id=s10>4.0 Adverse outcome prevention and long-term care</h3>\r\n<ul class=\"list-simple\"><li><p class=\"chapter-para\">4.1. We suggest regular clinical evaluation for physical changes and potential adverse changes in response to sex steroid hormones and laboratory monitoring of sex steroid hormone levels every 3 months during the first year of hormone therapy for transgender males and females and then once or twice yearly. (2 |⊕⊕○○)</p></li><li><p class=\"chapter-para\">4.2. We suggest periodically monitoring prolactin levels in transgender females treated with estrogens. (2 |⊕⊕○○)</p></li><li><p class=\"chapter-para\">4.3. We suggest that clinicians evaluate transgender persons treated with hormones for cardiovascular risk factors using fasting lipid profiles, diabetes screening, and/or other diagnostic tools. (2 |⊕⊕○○)</p></li><li><p class=\"chapter-para\">4.4. We recommend that clinicians obtain bone mineral density (BMD) measurements when risk factors for osteoporosis exist, specifically in those who stop sex hormone therapy after gonadectomy. (1 |⊕⊕○○)</p></li><li><p class=\"chapter-para\">4.5. We suggest that transgender females with no known increased risk of breast cancer follow breast-screening guidelines recommended for non-transgender females. (2 |⊕⊕○○)</p></li><li><p class=\"chapter-para\">4.6. We suggest that transgender females treated with estrogens follow individualized screening according to personal risk for prostatic disease and prostate cancer. (2 |⊕○○○)</p></li><li><p class=\"chapter-para\">4.7. We advise that clinicians determine the medical necessity of including a total hysterectomy and oophorectomy as part of gender-affirming surgery. (Ungraded Good Practice Statement)</p></li></ul>                    <h3 scrollto-destination=99603248 id=\"99603248\" class=\"section-title js-splitscreen-section-title\" data-legacy-id=s11>5.0 Surgery for sex reassignment and gender confirmation</h3>\r\n<ul class=\"list-simple\"><li><p class=\"chapter-para\">5.1. We recommend that a patient pursue genital gender-affirming surgery only after the MHP and the clinician responsible for endocrine transition therapy both agree that surgery is medically necessary and would benefit the patient’s overall health and/or well-being. (1 |⊕⊕○○)</p></li><li><p class=\"chapter-para\">5.2. We advise that clinicians approve genital gender-affirming surgery only after completion of at least 1 year of consistent and compliant hormone treatment, unless hormone therapy is not desired or medically contraindicated. (Ungraded Good Practice Statement)</p></li><li><p class=\"chapter-para\">5.3. We advise that the clinician responsible for endocrine treatment and the primary care provider ensure appropriate medical clearance of transgender individuals for genital gender-affirming surgery and collaborate with the surgeon regarding hormone use during and after surgery. (Ungraded Good Practice Statement)</p></li><li><p class=\"chapter-para\">5.4. We recommend that clinicians refer hormone-treated transgender individuals for genital surgery when: (1) the individual has had a satisfactory social role change, (2) the individual is satisfied about the hormonal effects, and (3) the individual desires definitive surgical changes. (1 |⊕○○○)</p></li><li><p class=\"chapter-para\">5.5. We suggest that clinicians delay gender-affirming genital surgery involving gonadectomy and/or hysterectomy until the patient is at least 18 years old or legal age of majority in his or her country. (2 |⊕⊕○○).</p></li><li><p class=\"chapter-para\">5.6. We suggest that clinicians determine the timing of breast surgery for transgender males based upon the physical and mental health status of the individual. There is insufficient evidence to recommend a specific age requirement. (2 |⊕○○○)</p></li></ul>                    <h2 scrollto-destination=99603250 id=\"99603250\" class=\"section-title js-splitscreen-section-title\" data-legacy-id=s12>Changes Since the Previous Guideline</h2>\r\n<p class=\"chapter-para\">Both the current guideline and the one published in 2009 contain similar sections. Listed here are the sections contained in the current guideline and the corresponding number of recommendations: Introduction, Evaluation of Youth and Adults (5), Treatment of Adolescents (6), Hormonal Therapy for Transgender Adults (4), Adverse Outcomes Prevention and Long-term Care (7), and Surgery for Sex Reassignment and Gender Confirmation (6). The current introduction updates the diagnostic classification of “gender dysphoria/gender incongruence.” It also reviews the development of “gender identity” and summarizes its natural development. The section on clinical evaluation of both youth and adults, defines in detail the professional qualifications required of those who diagnose and treat both adolescents and adults. We advise that decisions regarding the social transition of prepubertal youth are made with the assistance of a mental health professional or similarly experienced professional. We recommend against puberty blocking followed by gender-affirming hormone treatment of prepubertal children. Clinicians should inform pubertal children, adolescents, and adults seeking gender-confirming treatment of their options for fertility preservation. Prior to treatment, clinicians should evaluate the presence of medical conditions that may be worsened by hormone depletion and/or treatment. A multidisciplinary team, preferably composed of medical and mental health professionals, should monitor treatments. Clinicians evaluating transgender adults for endocrine treatment should confirm the diagnosis of persistent gender dysphoria/gender incongruence. Physicians should educate transgender persons regarding the time course of steroid-induced physical changes. Treatment should include periodic monitoring of hormone levels and metabolic parameters, as well as assessments of bone density and the impact upon prostate, gonads, and uterus. We also make recommendations for transgender persons who plan genital gender-affirming surgery.</p>                    <h2 scrollto-destination=99603252 id=\"99603252\" class=\"section-title js-splitscreen-section-title\" data-legacy-id=s13>Method of Development of Evidence-Based Clinical Practice Guidelines</h2>\r\n<p class=\"chapter-para\">The Clinical Guidelines Subcommittee (CGS) of the Endocrine Society deemed the diagnosis and treatment of individuals with GD/gender incongruence a priority area for revision and appointed a task force to formulate evidence-based recommendations. The task force followed the approach recommended by the Grading of Recommendations, Assessment, Development, and Evaluation group, an international group with expertise in the development and implementation of evidence-based guidelines (<span class=\"xrefLink\" id=\"jumplink-B1\"></span><a href=\"javascript:;\" reveal-id=\"B1\" data-open=\"B1\" class=\"link link-ref link-reveal xref-bibr\">1</a>). A detailed description of the grading scheme has been published elsewhere (<span class=\"xrefLink\" id=\"jumplink-B2\"></span><a href=\"javascript:;\" reveal-id=\"B2\" data-open=\"B2\" class=\"link link-ref link-reveal xref-bibr\">2</a>). The task force used the best available research evidence to develop the recommendations. The task force also used consistent language and graphical descriptions of both the strength of a recommendation and the quality of evidence. In terms of the strength of the recommendation, strong recommendations use the phrase “we recommend” and the number 1, and weak recommendations use the phrase “we suggest” and the number 2. Cross-filled circles indicate the quality of the evidence, such that ⊕○○○ denotes very low–quality evidence; ⊕⊕○○, low quality; ⊕⊕⊕○, moderate quality; and ⊕⊕⊕⊕, high quality. The task force has confidence that persons who receive care according to the strong recommendations will derive, on average, more benefit than harm. Weak recommendations require more careful consideration of the person’s circumstances, values, and preferences to determine the best course of action. Linked to each recommendation is a description of the evidence and the values that the task force considered in making the recommendation. In some instances, there are remarks in which the task force offers technical suggestions for testing conditions, dosing, and monitoring. These technical comments reflect the best available evidence applied to a typical person being treated. Often this evidence comes from the unsystematic observations of the task force and their preferences; therefore, one should consider these remarks as suggestions.</p><p class=\"chapter-para\">In this guideline, the task force made several statements to emphasize the importance of shared decision-making, general preventive care measures, and basic principles of the treatment of transgender persons. They labeled these “Ungraded Good Practice Statement.” Direct evidence for these statements was either unavailable or not systematically appraised and considered out of the scope of this guideline. The intention of these statements is to draw attention to these principles.</p><p class=\"chapter-para\">The Endocrine Society maintains a rigorous conflict-of-interest review process for developing clinical practice guidelines. All task force members must declare any potential conflicts of interest by completing a conflict-of-interest form. The CGS reviews all conflicts of interest before the Society’s Council approves the members to participate on the task force and periodically during the development of the guideline. All others participating in the guideline’s development must also disclose any conflicts of interest in the matter under study, and most of these participants must be without any conflicts of interest. The CGS and the task force have reviewed all disclosures for this guideline and resolved or managed all identified conflicts of interest.</p><p class=\"chapter-para\">Conflicts of interest are defined as remuneration in any amount from commercial interests; grants; research support; consulting fees; salary; ownership interests [<em>e.g.</em>, stocks and stock options (excluding diversified mutual funds)]; honoraria and other payments for participation in speakers’ bureaus, advisory boards, or boards of directors; and all other financial benefits. Completed forms are available through the Endocrine Society office.</p><p class=\"chapter-para\">The Endocrine Society provided the funding for this guideline; the task force received no funding or remuneration from commercial or other entities.</p>                    <h2 scrollto-destination=99603258 id=\"99603258\" class=\"section-title js-splitscreen-section-title\" data-legacy-id=s14>Commissioned Systematic Review</h2>\r\n<p class=\"chapter-para\">The task force commissioned two systematic reviews to support this guideline. The first one aimed to summarize the available evidence on the effect of sex steroid use in transgender individuals on lipids and cardiovascular outcomes. The review identified 29 eligible studies at moderate risk of bias. In transgender males (female to male), sex steroid therapy was associated with a statistically significant increase in serum triglycerides and low-density lipoprotein cholesterol levels. High-density lipoprotein cholesterol levels decreased significantly across all follow-up time periods. In transgender females (male to female), serum triglycerides were significantly higher without any changes in other parameters. Few myocardial infarction, stroke, venous thromboembolism (VTE), and death events were reported. These events were more frequent in transgender females. However, the quality of the evidence was low. The second review summarized the available evidence regarding the effect of sex steroids on bone health in transgender individuals and identified 13 studies. In transgender males, there was no statistically significant difference in the lumbar spine, femoral neck, or total hip BMD at 12 and 24 months compared with baseline values before initiating masculinizing hormone therapy. In transgender females, there was a statistically significant increase in lumbar spine BMD at 12 months and 24 months compared with baseline values before initiation of feminizing hormone therapy. There was minimal information on fracture rates. The quality of evidence was also low.</p>                    <h2 scrollto-destination=99603260 id=\"99603260\" class=\"section-title js-splitscreen-section-title\" data-legacy-id=s15>Introduction</h2>\r\n<p class=\"chapter-para\">Throughout recorded history (in the absence of an endocrine disorder) some men and women have experienced confusion and anguish resulting from rigid, forced conformity to sexual dimorphism. In modern history, there have been numerous ongoing biological, psychological, cultural, political, and sociological debates over various aspects of gender variance. The 20th century marked the emergence of a social awakening for men and women with the belief that they are “trapped” in the wrong body (<span class=\"xrefLink\" id=\"jumplink-B3\"></span><a href=\"javascript:;\" reveal-id=\"B3\" data-open=\"B3\" class=\"link link-ref link-reveal xref-bibr\">3</a>). Magnus Hirschfeld and Harry Benjamin, among others, pioneered the medical responses to those who sought relief from and a resolution to their profound discomfort. Although the term transsexual became widely known after Benjamin wrote “The Transsexual Phenomenon” (<span class=\"xrefLink\" id=\"jumplink-B4\"></span><a href=\"javascript:;\" reveal-id=\"B4\" data-open=\"B4\" class=\"link link-ref link-reveal xref-bibr\">4</a>), it was Hirschfeld who coined the term “transsexual” in 1923 to describe people who want to live a life that corresponds with their experienced gender vs their designated gender (<span class=\"xrefLink\" id=\"jumplink-B5\"></span><a href=\"javascript:;\" reveal-id=\"B5\" data-open=\"B5\" class=\"link link-ref link-reveal xref-bibr\">5</a>). Magnus Hirschfeld (<span class=\"xrefLink\" id=\"jumplink-B6\"></span><a href=\"javascript:;\" reveal-id=\"B6\" data-open=\"B6\" class=\"link link-ref link-reveal xref-bibr\">6</a>) and others (<span class=\"xrefLink\" id=\"jumplink-B4\"></span><a href=\"javascript:;\" reveal-id=\"B4\" data-open=\"B4\" class=\"link link-ref link-reveal xref-bibr\">4</a>, <span class=\"xrefLink\" id=\"jumplink-B7\"></span><a href=\"javascript:;\" reveal-id=\"B7\" data-open=\"B7\" class=\"link link-ref link-reveal xref-bibr\">7</a>) have described other types of trans phenomena besides transsexualism. These early researchers proposed that the gender identity of these people was located somewhere along a unidimensional continuum. This continuum ranged from all male through “something in between” to all female. Yet such a classification does not take into account that people may have gender identities outside this continuum. For instance, some experience themselves as having both a male and female gender identity, whereas others completely renounce any gender classification (<span class=\"xrefLink\" id=\"jumplink-B8\"></span><a href=\"javascript:;\" reveal-id=\"B8\" data-open=\"B8\" class=\"link link-ref link-reveal xref-bibr\">8</a>, <span class=\"xrefLink\" id=\"jumplink-B9\"></span><a href=\"javascript:;\" reveal-id=\"B9\" data-open=\"B9\" class=\"link link-ref link-reveal xref-bibr\">9</a>). There are also reports of individuals experiencing a continuous and rapid involuntary alternation between a male and female identity (<span class=\"xrefLink\" id=\"jumplink-B10\"></span><a href=\"javascript:;\" reveal-id=\"B10\" data-open=\"B10\" class=\"link link-ref link-reveal xref-bibr\">10</a>) or men who do not experience themselves as men but do not want to live as women (<span class=\"xrefLink\" id=\"jumplink-B11\"></span><a href=\"javascript:;\" reveal-id=\"B11\" data-open=\"B11\" class=\"link link-ref link-reveal xref-bibr\">11</a>, <span class=\"xrefLink\" id=\"jumplink-B12\"></span><a href=\"javascript:;\" reveal-id=\"B12\" data-open=\"B12\" class=\"link link-ref link-reveal xref-bibr\">12</a>). In some countries, (<em>e.g.</em>, Nepal, Bangladesh, and Australia), these nonmale or nonfemale genders are officially recognized (<span class=\"xrefLink\" id=\"jumplink-B13\"></span><a href=\"javascript:;\" reveal-id=\"B13\" data-open=\"B13\" class=\"link link-ref link-reveal xref-bibr\">13</a>). Specific treatment protocols, however, have not yet been developed for these groups.</p><p class=\"chapter-para\">Instead of the term transsexualism, the current classification system of the American Psychiatric Association uses the term gender dysphoria in its diagnosis of persons who are not satisfied with their designated gender (<span class=\"xrefLink\" id=\"jumplink-B14\"></span><a href=\"javascript:;\" reveal-id=\"B14\" data-open=\"B14\" class=\"link link-ref link-reveal xref-bibr\">14</a>). The current version of the World Health Organization’s ICD-10 still uses the term transsexualism when diagnosing adolescents and adults. However, for the ICD-11, the World Health Organization has proposed using the term “gender incongruence” (<span class=\"xrefLink\" id=\"jumplink-B15\"></span><a href=\"javascript:;\" reveal-id=\"B15\" data-open=\"B15\" class=\"link link-ref link-reveal xref-bibr\">15</a>).</p><p class=\"chapter-para\">Treating persons with GD/gender incongruence (<span class=\"xrefLink\" id=\"jumplink-B15\"></span><a href=\"javascript:;\" reveal-id=\"B15\" data-open=\"B15\" class=\"link link-ref link-reveal xref-bibr\">15</a>) was previously limited to relatively ineffective elixirs or creams. However, more effective endocrinology-based treatments became possible with the availability of testosterone in 1935 and diethylstilbestrol in 1938. Reports of individuals with GD/gender incongruence who were treated with hormones and gender-affirming surgery appeared in the press during the second half of the 20th century. The Harry Benjamin International Gender Dysphoria Association was founded in September 1979 and is now called the World Professional Association for Transgender Health (WPATH). WPATH published its first Standards of Care in 1979. These standards have since been regularly updated, providing guidance for treating persons with GD/gender incongruence (<span class=\"xrefLink\" id=\"jumplink-B16\"></span><a href=\"javascript:;\" reveal-id=\"B16\" data-open=\"B16\" class=\"link link-ref link-reveal xref-bibr\">16</a>).</p><p class=\"chapter-para\">Prior to 1975, few peer-reviewed articles were published concerning endocrine treatment of transgender persons. Since then, more than two thousand articles about various aspects of transgender care have appeared.</p><p class=\"chapter-para\">It is the purpose of this guideline to make detailed recommendations and suggestions, based on existing medical literature and clinical experience, that will enable treating physicians to maximize benefit and minimize risk when caring for individuals diagnosed with GD/gender incongruence.</p><p class=\"chapter-para\">In the future, we need more rigorous evaluations of the effectiveness and safety of endocrine and surgical protocols. Specifically, endocrine treatment protocols for GD/gender incongruence should include the careful assessment of the following: (1) the effects of prolonged delay of puberty in adolescents on bone health, gonadal function, and the brain (including effects on cognitive, emotional, social, and sexual development); (2) the effects of treatment in adults on sex hormone levels; (3) the requirement for and the effects of progestins and other agents used to suppress endogenous sex steroids during treatment; and (4) the risks and benefits of gender-affirming hormone treatment in older transgender people.</p><p class=\"chapter-para\">To successfully establish and enact these protocols, a commitment of mental health and endocrine investigators is required to collaborate in long-term, large-scale studies across countries that use the same diagnostic and inclusion criteria, medications, assay methods, and response assessment tools (<em>e.g.</em>, the European Network for the Investigation of Gender Incongruence) (<span class=\"xrefLink\" id=\"jumplink-B17\"></span><a href=\"javascript:;\" reveal-id=\"B17\" data-open=\"B17\" class=\"link link-ref link-reveal xref-bibr\">17</a>, <span class=\"xrefLink\" id=\"jumplink-B18\"></span><a href=\"javascript:;\" reveal-id=\"B18\" data-open=\"B18\" class=\"link link-ref link-reveal xref-bibr\">18</a>).</p><p class=\"chapter-para\">Terminology and its use vary and continue to evolve. <span class=\"xrefLink\" id=\"jumplink-T1\"></span><a href=\"javascript:;\" reveal-id=\"T1\" data-open=\"T1\" class=\"link link-reveal link-table xref-fig\">Table 1</a> contains the definitions of terms as they are used throughout this guideline.</p>                    <a id=\"99603269\" scrollto-destination=\"99603269\"></a>\r\n<div content-id=\"T1\" class=\"table-modal table-full-width-wrap\"><div class=\"table-wrap table-wide\"><div class=\"table-wrap-title\" id=\"T1\" data-id=\"T1\"><span class=\"label\">Table 1.</span><div class=\"caption\"><p class=\"chapter-para\">Definitions of Terms Used in This Guideline</p></div> </div><div class=\"table-overflow\"><table><tbody><tr><td><em>Biological sex, biological male or female:</em> These terms refer to physical aspects of maleness and femaleness. As these may not be in line with each other (<em>e.g.</em>, a person with XY chromosomes may have female-appearing genitalia), the terms biological sex and biological male or female are imprecise and should be avoided. </td></tr><tr><td><em>Cisgender:</em> This means not transgender. An alternative way to describe individuals who are not transgender is “non-transgender people.” </td></tr><tr><td><em>Gender-affirming (hormone) treatment:</em> See “gender reassignment” </td></tr><tr><td><em>Gender dysphoria:</em> This is the distress and unease experienced if gender identity and designated gender are not completely congruent (see Table 2). In 2013, the American Psychiatric Association released the fifth edition of the DSM-5, which replaced “gender identity disorder” with “gender dysphoria” and changed the criteria for diagnosis. </td></tr><tr><td><em>Gender expression:</em> This refers to external manifestations of gender, expressed through one’s name, pronouns, clothing, haircut, behavior, voice, or body characteristics. Typically, transgender people seek to make their gender expression align with their gender identity, rather than their designated gender. </td></tr><tr><td><em>Gender identity/experienced gender:</em> This refers to one’s internal, deeply held sense of gender. For transgender people, their gender identity does not match their sex designated at birth. Most people have a gender identity of man or woman (or boy or girl). For some people, their gender identity does not fit neatly into one of those two choices. Unlike gender expression (see below), gender identity is not visible to others. </td></tr><tr><td><em>Gender identity disorder:</em> This is the term used for GD/gender incongruence in previous versions of DSM (see “gender dysphoria”). The ICD-10 still uses the term for diagnosing child diagnoses, but the upcoming ICD-11 has proposed using “gender incongruence of childhood.” </td></tr><tr><td><em>Gender incongruence:</em> This is an umbrella term used when the gender identity and/or gender expression differs from what is typically associated with the designated gender. Gender incongruence is also the proposed name of the gender identity–related diagnoses in ICD-11. Not all individuals with gender incongruence have gender dysphoria or seek treatment. </td></tr><tr><td><em>Gender variance:</em> See “gender incongruence” </td></tr><tr><td><em>Gender reassignment:</em> This refers to the treatment procedure for those who want to adapt their bodies to the experienced gender by means of hormones and/or surgery. This is also called gender-confirming or gender-affirming treatment. </td></tr><tr><td><em>Gender-reassignment surgery (gender-confirming/gender-affirming surgery):</em> These terms refer only to the surgical part of gender-confirming/gender-affirming treatment. </td></tr><tr><td><em>Gender role:</em> This refers to behaviors, attitudes, and personality traits that a society (in a given culture and historical period) designates as masculine or feminine and/or that society associates with or considers typical of the social role of men or women. </td></tr><tr><td><em>Sex designated at birth:</em> This refers to sex assigned at birth, usually based on genital anatomy. </td></tr><tr><td><em>Sex:</em> This refers to attributes that characterize biological maleness or femaleness. The best known attributes include the sex-determining genes, the sex chromosomes, the H-Y antigen, the gonads, sex hormones, internal and external genitalia, and secondary sex characteristics. </td></tr><tr><td><em>Sexual orientation:</em> This term describes an individual’s enduring physical and emotional attraction to another person. Gender identity and sexual orientation are not the same. Irrespective of their gender identity, transgender people may be attracted to women (gynephilic), attracted to men (androphilic), bisexual, asexual, or queer. </td></tr><tr><td><em>Transgender:</em> This is an umbrella term for people whose gender identity and/or gender expression differs from what is typically associated with their sex designated at birth. Not all transgender individuals seek treatment. </td></tr><tr><td><em>Transgender male (also: trans man, female-to-male, transgender male):</em> This refers to individuals assigned female at birth but who identify and live as men. </td></tr><tr><td><em>Transgender woman (also: trans woman, male-to female, transgender female):</em> This refers to individuals assigned male at birth but who identify and live as women. </td></tr><tr><td><em>Transition:</em> This refers to the process during which transgender persons change their physical, social, and/or legal characteristics consistent with the affirmed gender identity. Prepubertal children may choose to transition socially. </td></tr><tr><td><em>Transsexual:</em> This is an older term that originated in the medical and psychological communities to refer to individuals who have permanently transitioned through medical interventions or desired to do so. </td></tr></tbody></table></div><div class=\"table-modal\"><table><tbody><tr><td><em>Biological sex, biological male or female:</em> These terms refer to physical aspects of maleness and femaleness. As these may not be in line with each other (<em>e.g.</em>, a person with XY chromosomes may have female-appearing genitalia), the terms biological sex and biological male or female are imprecise and should be avoided. </td></tr><tr><td><em>Cisgender:</em> This means not transgender. An alternative way to describe individuals who are not transgender is “non-transgender people.” </td></tr><tr><td><em>Gender-affirming (hormone) treatment:</em> See “gender reassignment” </td></tr><tr><td><em>Gender dysphoria:</em> This is the distress and unease experienced if gender identity and designated gender are not completely congruent (see Table 2). In 2013, the American Psychiatric Association released the fifth edition of the DSM-5, which replaced “gender identity disorder” with “gender dysphoria” and changed the criteria for diagnosis. </td></tr><tr><td><em>Gender expression:</em> This refers to external manifestations of gender, expressed through one’s name, pronouns, clothing, haircut, behavior, voice, or body characteristics. Typically, transgender people seek to make their gender expression align with their gender identity, rather than their designated gender. </td></tr><tr><td><em>Gender identity/experienced gender:</em> This refers to one’s internal, deeply held sense of gender. For transgender people, their gender identity does not match their sex designated at birth. Most people have a gender identity of man or woman (or boy or girl). For some people, their gender identity does not fit neatly into one of those two choices. Unlike gender expression (see below), gender identity is not visible to others. </td></tr><tr><td><em>Gender identity disorder:</em> This is the term used for GD/gender incongruence in previous versions of DSM (see “gender dysphoria”). The ICD-10 still uses the term for diagnosing child diagnoses, but the upcoming ICD-11 has proposed using “gender incongruence of childhood.” </td></tr><tr><td><em>Gender incongruence:</em> This is an umbrella term used when the gender identity and/or gender expression differs from what is typically associated with the designated gender. Gender incongruence is also the proposed name of the gender identity–related diagnoses in ICD-11. Not all individuals with gender incongruence have gender dysphoria or seek treatment. </td></tr><tr><td><em>Gender variance:</em> See “gender incongruence” </td></tr><tr><td><em>Gender reassignment:</em> This refers to the treatment procedure for those who want to adapt their bodies to the experienced gender by means of hormones and/or surgery. This is also called gender-confirming or gender-affirming treatment. </td></tr><tr><td><em>Gender-reassignment surgery (gender-confirming/gender-affirming surgery):</em> These terms refer only to the surgical part of gender-confirming/gender-affirming treatment. </td></tr><tr><td><em>Gender role:</em> This refers to behaviors, attitudes, and personality traits that a society (in a given culture and historical period) designates as masculine or feminine and/or that society associates with or considers typical of the social role of men or women. </td></tr><tr><td><em>Sex designated at birth:</em> This refers to sex assigned at birth, usually based on genital anatomy. </td></tr><tr><td><em>Sex:</em> This refers to attributes that characterize biological maleness or femaleness. The best known attributes include the sex-determining genes, the sex chromosomes, the H-Y antigen, the gonads, sex hormones, internal and external genitalia, and secondary sex characteristics. </td></tr><tr><td><em>Sexual orientation:</em> This term describes an individual’s enduring physical and emotional attraction to another person. Gender identity and sexual orientation are not the same. Irrespective of their gender identity, transgender people may be attracted to women (gynephilic), attracted to men (androphilic), bisexual, asexual, or queer. </td></tr><tr><td><em>Transgender:</em> This is an umbrella term for people whose gender identity and/or gender expression differs from what is typically associated with their sex designated at birth. Not all transgender individuals seek treatment. </td></tr><tr><td><em>Transgender male (also: trans man, female-to-male, transgender male):</em> This refers to individuals assigned female at birth but who identify and live as men. </td></tr><tr><td><em>Transgender woman (also: trans woman, male-to female, transgender female):</em> This refers to individuals assigned male at birth but who identify and live as women. </td></tr><tr><td><em>Transition:</em> This refers to the process during which transgender persons change their physical, social, and/or legal characteristics consistent with the affirmed gender identity. Prepubertal children may choose to transition socially. </td></tr><tr><td><em>Transsexual:</em> This is an older term that originated in the medical and psychological communities to refer to individuals who have permanently transitioned through medical interventions or desired to do so. </td></tr></tbody></table></div><div class=\"&#xA;          graphic-wrap&#xA;          \"><a class=\"fig-view-orig openInAnotherWindow btn js-view-large\" target=\"_blank\" href=\"/view-large/99603269\">\r\n          Open in new tab\r\n        </a></div></div></div><div class=\"table-full-width-wrap\"><div class=\"table-wrap table-wide\"><div class=\"table-wrap-title\" id=\"T1\" data-id=\"T1\"><span class=\"label\">Table 1.</span><div class=\"caption\"><p class=\"chapter-para\">Definitions of Terms Used in This Guideline</p></div> </div><div class=\"table-overflow\"><table><tbody><tr><td><em>Biological sex, biological male or female:</em> These terms refer to physical aspects of maleness and femaleness. As these may not be in line with each other (<em>e.g.</em>, a person with XY chromosomes may have female-appearing genitalia), the terms biological sex and biological male or female are imprecise and should be avoided. </td></tr><tr><td><em>Cisgender:</em> This means not transgender. An alternative way to describe individuals who are not transgender is “non-transgender people.” </td></tr><tr><td><em>Gender-affirming (hormone) treatment:</em> See “gender reassignment” </td></tr><tr><td><em>Gender dysphoria:</em> This is the distress and unease experienced if gender identity and designated gender are not completely congruent (see Table 2). In 2013, the American Psychiatric Association released the fifth edition of the DSM-5, which replaced “gender identity disorder” with “gender dysphoria” and changed the criteria for diagnosis. </td></tr><tr><td><em>Gender expression:</em> This refers to external manifestations of gender, expressed through one’s name, pronouns, clothing, haircut, behavior, voice, or body characteristics. Typically, transgender people seek to make their gender expression align with their gender identity, rather than their designated gender. </td></tr><tr><td><em>Gender identity/experienced gender:</em> This refers to one’s internal, deeply held sense of gender. For transgender people, their gender identity does not match their sex designated at birth. Most people have a gender identity of man or woman (or boy or girl). For some people, their gender identity does not fit neatly into one of those two choices. Unlike gender expression (see below), gender identity is not visible to others. </td></tr><tr><td><em>Gender identity disorder:</em> This is the term used for GD/gender incongruence in previous versions of DSM (see “gender dysphoria”). The ICD-10 still uses the term for diagnosing child diagnoses, but the upcoming ICD-11 has proposed using “gender incongruence of childhood.” </td></tr><tr><td><em>Gender incongruence:</em> This is an umbrella term used when the gender identity and/or gender expression differs from what is typically associated with the designated gender. Gender incongruence is also the proposed name of the gender identity–related diagnoses in ICD-11. Not all individuals with gender incongruence have gender dysphoria or seek treatment. </td></tr><tr><td><em>Gender variance:</em> See “gender incongruence” </td></tr><tr><td><em>Gender reassignment:</em> This refers to the treatment procedure for those who want to adapt their bodies to the experienced gender by means of hormones and/or surgery. This is also called gender-confirming or gender-affirming treatment. </td></tr><tr><td><em>Gender-reassignment surgery (gender-confirming/gender-affirming surgery):</em> These terms refer only to the surgical part of gender-confirming/gender-affirming treatment. </td></tr><tr><td><em>Gender role:</em> This refers to behaviors, attitudes, and personality traits that a society (in a given culture and historical period) designates as masculine or feminine and/or that society associates with or considers typical of the social role of men or women. </td></tr><tr><td><em>Sex designated at birth:</em> This refers to sex assigned at birth, usually based on genital anatomy. </td></tr><tr><td><em>Sex:</em> This refers to attributes that characterize biological maleness or femaleness. The best known attributes include the sex-determining genes, the sex chromosomes, the H-Y antigen, the gonads, sex hormones, internal and external genitalia, and secondary sex characteristics. </td></tr><tr><td><em>Sexual orientation:</em> This term describes an individual’s enduring physical and emotional attraction to another person. Gender identity and sexual orientation are not the same. Irrespective of their gender identity, transgender people may be attracted to women (gynephilic), attracted to men (androphilic), bisexual, asexual, or queer. </td></tr><tr><td><em>Transgender:</em> This is an umbrella term for people whose gender identity and/or gender expression differs from what is typically associated with their sex designated at birth. Not all transgender individuals seek treatment. </td></tr><tr><td><em>Transgender male (also: trans man, female-to-male, transgender male):</em> This refers to individuals assigned female at birth but who identify and live as men. </td></tr><tr><td><em>Transgender woman (also: trans woman, male-to female, transgender female):</em> This refers to individuals assigned male at birth but who identify and live as women. </td></tr><tr><td><em>Transition:</em> This refers to the process during which transgender persons change their physical, social, and/or legal characteristics consistent with the affirmed gender identity. Prepubertal children may choose to transition socially. </td></tr><tr><td><em>Transsexual:</em> This is an older term that originated in the medical and psychological communities to refer to individuals who have permanently transitioned through medical interventions or desired to do so. </td></tr></tbody></table></div><div class=\"table-modal\"><table><tbody><tr><td><em>Biological sex, biological male or female:</em> These terms refer to physical aspects of maleness and femaleness. As these may not be in line with each other (<em>e.g.</em>, a person with XY chromosomes may have female-appearing genitalia), the terms biological sex and biological male or female are imprecise and should be avoided. </td></tr><tr><td><em>Cisgender:</em> This means not transgender. An alternative way to describe individuals who are not transgender is “non-transgender people.” </td></tr><tr><td><em>Gender-affirming (hormone) treatment:</em> See “gender reassignment” </td></tr><tr><td><em>Gender dysphoria:</em> This is the distress and unease experienced if gender identity and designated gender are not completely congruent (see Table 2). In 2013, the American Psychiatric Association released the fifth edition of the DSM-5, which replaced “gender identity disorder” with “gender dysphoria” and changed the criteria for diagnosis. </td></tr><tr><td><em>Gender expression:</em> This refers to external manifestations of gender, expressed through one’s name, pronouns, clothing, haircut, behavior, voice, or body characteristics. Typically, transgender people seek to make their gender expression align with their gender identity, rather than their designated gender. </td></tr><tr><td><em>Gender identity/experienced gender:</em> This refers to one’s internal, deeply held sense of gender. For transgender people, their gender identity does not match their sex designated at birth. Most people have a gender identity of man or woman (or boy or girl). For some people, their gender identity does not fit neatly into one of those two choices. Unlike gender expression (see below), gender identity is not visible to others. </td></tr><tr><td><em>Gender identity disorder:</em> This is the term used for GD/gender incongruence in previous versions of DSM (see “gender dysphoria”). The ICD-10 still uses the term for diagnosing child diagnoses, but the upcoming ICD-11 has proposed using “gender incongruence of childhood.” </td></tr><tr><td><em>Gender incongruence:</em> This is an umbrella term used when the gender identity and/or gender expression differs from what is typically associated with the designated gender. Gender incongruence is also the proposed name of the gender identity–related diagnoses in ICD-11. Not all individuals with gender incongruence have gender dysphoria or seek treatment. </td></tr><tr><td><em>Gender variance:</em> See “gender incongruence” </td></tr><tr><td><em>Gender reassignment:</em> This refers to the treatment procedure for those who want to adapt their bodies to the experienced gender by means of hormones and/or surgery. This is also called gender-confirming or gender-affirming treatment. </td></tr><tr><td><em>Gender-reassignment surgery (gender-confirming/gender-affirming surgery):</em> These terms refer only to the surgical part of gender-confirming/gender-affirming treatment. </td></tr><tr><td><em>Gender role:</em> This refers to behaviors, attitudes, and personality traits that a society (in a given culture and historical period) designates as masculine or feminine and/or that society associates with or considers typical of the social role of men or women. </td></tr><tr><td><em>Sex designated at birth:</em> This refers to sex assigned at birth, usually based on genital anatomy. </td></tr><tr><td><em>Sex:</em> This refers to attributes that characterize biological maleness or femaleness. The best known attributes include the sex-determining genes, the sex chromosomes, the H-Y antigen, the gonads, sex hormones, internal and external genitalia, and secondary sex characteristics. </td></tr><tr><td><em>Sexual orientation:</em> This term describes an individual’s enduring physical and emotional attraction to another person. Gender identity and sexual orientation are not the same. Irrespective of their gender identity, transgender people may be attracted to women (gynephilic), attracted to men (androphilic), bisexual, asexual, or queer. </td></tr><tr><td><em>Transgender:</em> This is an umbrella term for people whose gender identity and/or gender expression differs from what is typically associated with their sex designated at birth. Not all transgender individuals seek treatment. </td></tr><tr><td><em>Transgender male (also: trans man, female-to-male, transgender male):</em> This refers to individuals assigned female at birth but who identify and live as men. </td></tr><tr><td><em>Transgender woman (also: trans woman, male-to female, transgender female):</em> This refers to individuals assigned male at birth but who identify and live as women. </td></tr><tr><td><em>Transition:</em> This refers to the process during which transgender persons change their physical, social, and/or legal characteristics consistent with the affirmed gender identity. Prepubertal children may choose to transition socially. </td></tr><tr><td><em>Transsexual:</em> This is an older term that originated in the medical and psychological communities to refer to individuals who have permanently transitioned through medical interventions or desired to do so. </td></tr></tbody></table></div><div class=\"&#xA;          graphic-wrap&#xA;          \"><a class=\"fig-view-orig openInAnotherWindow btn js-view-large\" target=\"_blank\" href=\"/view-large/99603269\">\r\n          Open in new tab\r\n        </a></div></div></div>                    <h2 scrollto-destination=99603270 id=\"99603270\" class=\"section-title js-splitscreen-section-title\" data-legacy-id=s16>Biological Determinants of Gender Identity Development</h2>\r\n<p class=\"chapter-para\">One’s self-awareness as male or female changes gradually during infant life and childhood. This process of cognitive and affective learning evolves with interactions with parents, peers, and environment. A fairly accurate timetable exists outlining the steps in this process (<span class=\"xrefLink\" id=\"jumplink-B19\"></span><a href=\"javascript:;\" reveal-id=\"B19\" data-open=\"B19\" class=\"link link-ref link-reveal xref-bibr\">19</a>). Normative psychological literature, however, does not address if and when gender identity becomes crystallized and what factors contribute to the development of a gender identity that is not congruent with the gender of rearing. Results of studies from a variety of biomedical disciplines—genetic, endocrine, and neuroanatomic—support the concept that gender identity and/or gender expression (<span class=\"xrefLink\" id=\"jumplink-B20\"></span><a href=\"javascript:;\" reveal-id=\"B20\" data-open=\"B20\" class=\"link link-ref link-reveal xref-bibr\">20</a>) likely reflect a complex interplay of biological, environmental, and cultural factors (<span class=\"xrefLink\" id=\"jumplink-B21\"></span><a href=\"javascript:;\" reveal-id=\"B21\" data-open=\"B21\" class=\"link link-ref link-reveal xref-bibr\">21</a>, <span class=\"xrefLink\" id=\"jumplink-B22\"></span><a href=\"javascript:;\" reveal-id=\"B22\" data-open=\"B22\" class=\"link link-ref link-reveal xref-bibr\">22</a>).</p><p class=\"chapter-para\">With respect to endocrine considerations, studies have failed to find differences in circulating levels of sex steroids between transgender and nontransgender individuals (<span class=\"xrefLink\" id=\"jumplink-B23\"></span><a href=\"javascript:;\" reveal-id=\"B23\" data-open=\"B23\" class=\"link link-ref link-reveal xref-bibr\">23</a>). However, studies in individuals with a disorder/difference of sex development (DSD) have informed our understanding of the role that hormones may play in gender identity outcome, even though most persons with GD/gender incongruence do not have a DSD. For example, although most 46,XX adult individuals with virilizing congenital adrenal hyperplasia caused by mutations in <em>CYP21A2</em> reported a female gender identity, the prevalence of GD/gender incongruence was much greater in this group than in the general population without a DSD. This supports the concept that there is a role for prenatal/postnatal androgens in gender development (<span class=\"xrefLink\" id=\"jumplink-B24\"></span><a href=\"javascript:;\" reveal-id=\"B24\" data-open=\"B24\" class=\"link link-ref link-reveal xref-bibr\">24</a>–<span class=\"xrefLink\" id=\"jumplink-B26\"></span><a href=\"javascript:;\" reveal-id=\"B26\" data-open=\"B26\" class=\"link link-ref link-reveal xref-bibr\">26</a>), although some studies indicate that prenatal androgens are more likely to affect gender behavior and sexual orientation rather than gender identity <em>per se</em> (<span class=\"xrefLink\" id=\"jumplink-B27\"></span><a href=\"javascript:;\" reveal-id=\"B27\" data-open=\"B27\" class=\"link link-ref link-reveal xref-bibr\">27</a>, <span class=\"xrefLink\" id=\"jumplink-B28\"></span><a href=\"javascript:;\" reveal-id=\"B28\" data-open=\"B28\" class=\"link link-ref link-reveal xref-bibr\">28</a>).</p><p class=\"chapter-para\">Researchers have made similar observations regarding the potential role of androgens in the development of gender identity in other individuals with DSD. For example, a review of two groups of 46,XY persons, each with androgen synthesis deficiencies and female raised, reported transgender male (female-to-male) gender role changes in 56% to 63% and 39% to 64% of patients, respectively (<span class=\"xrefLink\" id=\"jumplink-B29\"></span><a href=\"javascript:;\" reveal-id=\"B29\" data-open=\"B29\" class=\"link link-ref link-reveal xref-bibr\">29</a>). Also, in 46,XY female-raised individuals with cloacal exstrophy and penile agenesis, the occurrence of transgender male changes was significantly more prevalent than in the general population (<span class=\"xrefLink\" id=\"jumplink-B30\"></span><a href=\"javascript:;\" reveal-id=\"B30\" data-open=\"B30\" class=\"link link-ref link-reveal xref-bibr\">30</a>, <span class=\"xrefLink\" id=\"jumplink-B31\"></span><a href=\"javascript:;\" reveal-id=\"B31\" data-open=\"B31\" class=\"link link-ref link-reveal xref-bibr\">31</a>). However, the fact that a high percentage of individuals with the same conditions did not change gender suggests that cultural factors may play a role as well.</p><p class=\"chapter-para\">With respect to genetics and gender identity, several studies have suggested heritability of GD/gender incongruence (<span class=\"xrefLink\" id=\"jumplink-B32\"></span><a href=\"javascript:;\" reveal-id=\"B32\" data-open=\"B32\" class=\"link link-ref link-reveal xref-bibr\">32</a>, <span class=\"xrefLink\" id=\"jumplink-B33\"></span><a href=\"javascript:;\" reveal-id=\"B33\" data-open=\"B33\" class=\"link link-ref link-reveal xref-bibr\">33</a>). In particular, a study by Heylens <em>et al.</em> (<span class=\"xrefLink\" id=\"jumplink-B33\"></span><a href=\"javascript:;\" reveal-id=\"B33\" data-open=\"B33\" class=\"link link-ref link-reveal xref-bibr\">33</a>) demonstrated a 39.1% concordance rate for gender identity disorder (based on the DSM-IV criteria) in 23 monozygotic twin pairs but no concordance in 21 same-sex dizygotic or seven opposite-sex twin pairs. Although numerous investigators have sought to identify specific genes associated with GD/gender incongruence, such studies have been inconsistent and without strong statistical significance (<span class=\"xrefLink\" id=\"jumplink-B34\"></span><a href=\"javascript:;\" reveal-id=\"B34\" data-open=\"B34\" class=\"link link-ref link-reveal xref-bibr\">34</a>–<span class=\"xrefLink\" id=\"jumplink-B38\"></span><a href=\"javascript:;\" reveal-id=\"B38\" data-open=\"B38\" class=\"link link-ref link-reveal xref-bibr\">38</a>).</p><p class=\"chapter-para\">Studies focusing on brain structure suggest that the brain phenotypes of people with GD/gender incongruence differ in various ways from control males and females, but that there is not a complete sex reversal in brain structures (<span class=\"xrefLink\" id=\"jumplink-B39\"></span><a href=\"javascript:;\" reveal-id=\"B39\" data-open=\"B39\" class=\"link link-ref link-reveal xref-bibr\">39</a>).</p><p class=\"chapter-para\">In summary, although there is much that is still unknown with respect to gender identity and its expression, compelling studies support the concept that biologic factors, in addition to environmental factors, contribute to this fundamental aspect of human development.</p>                    <h2 scrollto-destination=99603277 id=\"99603277\" class=\"section-title js-splitscreen-section-title\" data-legacy-id=s17>Natural History of Children With GD/Gender Incongruence</h2>\r\n<p class=\"chapter-para\">With current knowledge, we cannot predict the psychosexual outcome for any specific child. Prospective follow-up studies show that childhood GD/gender incongruence does not invariably persist into adolescence and adulthood (so-called “desisters”). Combining all outcome studies to date, the GD/gender incongruence of a minority of prepubertal children appears to persist in adolescence (<span class=\"xrefLink\" id=\"jumplink-B20\"></span><a href=\"javascript:;\" reveal-id=\"B20\" data-open=\"B20\" class=\"link link-ref link-reveal xref-bibr\">20</a>, <span class=\"xrefLink\" id=\"jumplink-B40\"></span><a href=\"javascript:;\" reveal-id=\"B40\" data-open=\"B40\" class=\"link link-ref link-reveal xref-bibr\">40</a>). In adolescence, a significant number of these desisters identify as homosexual or bisexual. It may be that children who only showed some gender nonconforming characteristics have been included in the follow-up studies, because the DSM-IV text revision criteria for a diagnosis were rather broad. However, the persistence of GD/gender incongruence into adolescence is more likely if it had been extreme in childhood (<span class=\"xrefLink\" id=\"jumplink-B41\"></span><a href=\"javascript:;\" reveal-id=\"B41\" data-open=\"B41\" class=\"link link-ref link-reveal xref-bibr\">41</a>, <span class=\"xrefLink\" id=\"jumplink-B42\"></span><a href=\"javascript:;\" reveal-id=\"B42\" data-open=\"B42\" class=\"link link-ref link-reveal xref-bibr\">42</a>). With the newer, stricter criteria of the DSM-5 (<span class=\"xrefLink\" id=\"jumplink-T2\"></span><a href=\"javascript:;\" reveal-id=\"T2\" data-open=\"T2\" class=\"link link-reveal link-table xref-fig\">Table 2</a>), persistence rates may well be different in future studies.</p>                    <a id=\"99603279\" scrollto-destination=\"99603279\"></a>\r\n<div content-id=\"T2\" class=\"table-modal table-full-width-wrap\"><div class=\"table-wrap table-wide\"><div class=\"table-wrap-title\" id=\"T2\" data-id=\"T2\"><span class=\"label\">Table 2.</span><div class=\"caption\"><p class=\"chapter-para\">DSM-5 Criteria for Gender Dysphoria in Adolescents and Adults</p></div> </div><div class=\"table-overflow\"><table><tbody><tr><td>A. A marked incongruence between one’s experienced/expressed gender and natal gender of at least 6 mo in duration, as manifested by at least two of the following: </td></tr><tr><td> 1. A marked incongruence between one’s experienced/expressed gender and primary and/or secondary sex characteristics (or in young adolescents, the anticipated secondary sex characteristics) </td></tr><tr><td> 2. A strong desire to be rid of one’s primary and/or secondary sex characteristics because of a marked incongruence with one’s experienced/expressed gender (or in young adolescents, a desire to prevent the development of the anticipated secondary sex characteristics) </td></tr><tr><td> 3. A strong desire for the primary and/or secondary sex characteristics of the other gender </td></tr><tr><td> 4. A strong desire to be of the other gender (or some alternative gender different from one’s designated gender) </td></tr><tr><td> 5. A strong desire to be treated as the other gender (or some alternative gender different from one’s designated gender) </td></tr><tr><td> 6. A strong conviction that one has the typical feelings and reactions of the other gender (or some alternative gender different from one’s designated gender) </td></tr><tr><td>B. The condition is associated with clinically significant distress or impairment in social, occupational, or other important areas of functioning. </td></tr><tr><td>Specify if: </td></tr><tr><td> 1. The condition exists with a disorder of sex development. </td></tr><tr><td> 2. The condition is posttransitional, in that the individual has transitioned to full-time living in the desired gender (with or without legalization of gender change) and has undergone (or is preparing to have) at least one sex-related medical procedure or treatment regimen—namely, regular sex hormone treatment or gender reassignment surgery confirming the desired gender (<em>e.g.</em>, penectomy, vaginoplasty in natal males; mastectomy or phalloplasty in natal females). </td></tr></tbody></table></div><div class=\"table-modal\"><table><tbody><tr><td>A. A marked incongruence between one’s experienced/expressed gender and natal gender of at least 6 mo in duration, as manifested by at least two of the following: </td></tr><tr><td> 1. A marked incongruence between one’s experienced/expressed gender and primary and/or secondary sex characteristics (or in young adolescents, the anticipated secondary sex characteristics) </td></tr><tr><td> 2. A strong desire to be rid of one’s primary and/or secondary sex characteristics because of a marked incongruence with one’s experienced/expressed gender (or in young adolescents, a desire to prevent the development of the anticipated secondary sex characteristics) </td></tr><tr><td> 3. A strong desire for the primary and/or secondary sex characteristics of the other gender </td></tr><tr><td> 4. A strong desire to be of the other gender (or some alternative gender different from one’s designated gender) </td></tr><tr><td> 5. A strong desire to be treated as the other gender (or some alternative gender different from one’s designated gender) </td></tr><tr><td> 6. A strong conviction that one has the typical feelings and reactions of the other gender (or some alternative gender different from one’s designated gender) </td></tr><tr><td>B. The condition is associated with clinically significant distress or impairment in social, occupational, or other important areas of functioning. </td></tr><tr><td>Specify if: </td></tr><tr><td> 1. The condition exists with a disorder of sex development. </td></tr><tr><td> 2. The condition is posttransitional, in that the individual has transitioned to full-time living in the desired gender (with or without legalization of gender change) and has undergone (or is preparing to have) at least one sex-related medical procedure or treatment regimen—namely, regular sex hormone treatment or gender reassignment surgery confirming the desired gender (<em>e.g.</em>, penectomy, vaginoplasty in natal males; mastectomy or phalloplasty in natal females). </td></tr></tbody></table></div><div class=\"table-wrap-foot\"><span id=\"fn-fn-01\"></span><div content-id=\"fn-01\" class=\"footnote\"><span class=\"fn\"><p class=\"chapter-para\">Reference: American Psychiatric Association (<span class=\"xrefLink\" id=\"jumplink-B14\"></span><a href=\"javascript:;\" reveal-id=\"B14\" data-open=\"B14\" class=\"link link-ref link-reveal xref-bibr\">14</a>).</p></span></div></div><div class=\"&#xA;          graphic-wrap&#xA;          \"><a class=\"fig-view-orig openInAnotherWindow btn js-view-large\" target=\"_blank\" href=\"/view-large/99603279\">\r\n          Open in new tab\r\n        </a></div></div></div><div class=\"table-full-width-wrap\"><div class=\"table-wrap table-wide\"><div class=\"table-wrap-title\" id=\"T2\" data-id=\"T2\"><span class=\"label\">Table 2.</span><div class=\"caption\"><p class=\"chapter-para\">DSM-5 Criteria for Gender Dysphoria in Adolescents and Adults</p></div> </div><div class=\"table-overflow\"><table><tbody><tr><td>A. A marked incongruence between one’s experienced/expressed gender and natal gender of at least 6 mo in duration, as manifested by at least two of the following: </td></tr><tr><td> 1. A marked incongruence between one’s experienced/expressed gender and primary and/or secondary sex characteristics (or in young adolescents, the anticipated secondary sex characteristics) </td></tr><tr><td> 2. A strong desire to be rid of one’s primary and/or secondary sex characteristics because of a marked incongruence with one’s experienced/expressed gender (or in young adolescents, a desire to prevent the development of the anticipated secondary sex characteristics) </td></tr><tr><td> 3. A strong desire for the primary and/or secondary sex characteristics of the other gender </td></tr><tr><td> 4. A strong desire to be of the other gender (or some alternative gender different from one’s designated gender) </td></tr><tr><td> 5. A strong desire to be treated as the other gender (or some alternative gender different from one’s designated gender) </td></tr><tr><td> 6. A strong conviction that one has the typical feelings and reactions of the other gender (or some alternative gender different from one’s designated gender) </td></tr><tr><td>B. The condition is associated with clinically significant distress or impairment in social, occupational, or other important areas of functioning. </td></tr><tr><td>Specify if: </td></tr><tr><td> 1. The condition exists with a disorder of sex development. </td></tr><tr><td> 2. The condition is posttransitional, in that the individual has transitioned to full-time living in the desired gender (with or without legalization of gender change) and has undergone (or is preparing to have) at least one sex-related medical procedure or treatment regimen—namely, regular sex hormone treatment or gender reassignment surgery confirming the desired gender (<em>e.g.</em>, penectomy, vaginoplasty in natal males; mastectomy or phalloplasty in natal females). </td></tr></tbody></table></div><div class=\"table-modal\"><table><tbody><tr><td>A. A marked incongruence between one’s experienced/expressed gender and natal gender of at least 6 mo in duration, as manifested by at least two of the following: </td></tr><tr><td> 1. A marked incongruence between one’s experienced/expressed gender and primary and/or secondary sex characteristics (or in young adolescents, the anticipated secondary sex characteristics) </td></tr><tr><td> 2. A strong desire to be rid of one’s primary and/or secondary sex characteristics because of a marked incongruence with one’s experienced/expressed gender (or in young adolescents, a desire to prevent the development of the anticipated secondary sex characteristics) </td></tr><tr><td> 3. A strong desire for the primary and/or secondary sex characteristics of the other gender </td></tr><tr><td> 4. A strong desire to be of the other gender (or some alternative gender different from one’s designated gender) </td></tr><tr><td> 5. A strong desire to be treated as the other gender (or some alternative gender different from one’s designated gender) </td></tr><tr><td> 6. A strong conviction that one has the typical feelings and reactions of the other gender (or some alternative gender different from one’s designated gender) </td></tr><tr><td>B. The condition is associated with clinically significant distress or impairment in social, occupational, or other important areas of functioning. </td></tr><tr><td>Specify if: </td></tr><tr><td> 1. The condition exists with a disorder of sex development. </td></tr><tr><td> 2. The condition is posttransitional, in that the individual has transitioned to full-time living in the desired gender (with or without legalization of gender change) and has undergone (or is preparing to have) at least one sex-related medical procedure or treatment regimen—namely, regular sex hormone treatment or gender reassignment surgery confirming the desired gender (<em>e.g.</em>, penectomy, vaginoplasty in natal males; mastectomy or phalloplasty in natal females). </td></tr></tbody></table></div><div class=\"table-wrap-foot\"><span id=\"fn-fn-01\"></span><div content-id=\"fn-01\" class=\"footnote\"><span class=\"fn\"><p class=\"chapter-para\">Reference: American Psychiatric Association (<span class=\"xrefLink\" id=\"jumplink-B14\"></span><a href=\"javascript:;\" reveal-id=\"B14\" data-open=\"B14\" class=\"link link-ref link-reveal xref-bibr\">14</a>).</p></span></div></div><div class=\"&#xA;          graphic-wrap&#xA;          \"><a class=\"fig-view-orig openInAnotherWindow btn js-view-large\" target=\"_blank\" href=\"/view-large/99603279\">\r\n          Open in new tab\r\n        </a></div></div></div>                    <h2 scrollto-destination=99603280 id=\"99603280\" class=\"section-title js-splitscreen-section-title\" data-legacy-id=s18>1.0 Evaluation of Youth and Adults</h2>\r\n<p class=\"chapter-para\">Gender-affirming treatment is a multidisciplinary effort. After evaluation, education, and diagnosis, treatment may include mental health care, hormone therapy, and/or surgical therapy. Together with an MHP, hormone-prescribing clinicians should examine the psychosocial impact of the potential changes on people’s lives, including mental health, friends, family, jobs, and their role in society. Transgender individuals should be encouraged to experience living in the new gender role and assess whether this improves their quality of life. Although the focus of this guideline is gender-affirming hormone therapy, collaboration with appropriate professionals responsible for each aspect of treatment maximizes a successful outcome.</p>                    <h4 scrollto-destination=99603283 id=\"99603283\" class=\"section-title js-splitscreen-section-title\" data-legacy-id=s20>Diagnostic assessment and mental health care</h4>\r\n<p class=\"chapter-para\">GD/gender incongruence may be accompanied with psychological or psychiatric problems (<span class=\"xrefLink\" id=\"jumplink-B43\"></span><a href=\"javascript:;\" reveal-id=\"B43\" data-open=\"B43\" class=\"link link-ref link-reveal xref-bibr\">43</a>–<span class=\"xrefLink\" id=\"jumplink-B51\"></span><a href=\"javascript:;\" reveal-id=\"B51\" data-open=\"B51\" class=\"link link-ref link-reveal xref-bibr\">51</a>). It is therefore necessary that clinicians who prescribe hormones and are involved in diagnosis and psychosocial assessment meet the following criteria: (1) are competent in using the DSM and/or the ICD for diagnostic purposes, (2) are able to diagnose GD/gender incongruence and make a distinction between GD/gender incongruence and conditions that have similar features (<em>e.g.</em>, body dysmorphic disorder), (3) are trained in diagnosing psychiatric conditions, (4) undertake or refer for appropriate treatment, (5) are able to do a psychosocial assessment of the patient’s understanding, mental health, and social conditions that can impact gender-affirming hormone therapy, and (6) regularly attend relevant professional meetings.</p><p class=\"chapter-para\">Because of the psychological vulnerability of many individuals with GD/gender incongruence, it is important that mental health care is available before, during, and sometimes also after transitioning. For children and adolescents, an MHP who has training/experience in child and adolescent gender development (as well as child and adolescent psychopathology) should make the diagnosis, because assessing GD/gender incongruence in children and adolescents is often extremely complex.</p><p class=\"chapter-para\">During assessment, the clinician obtains information from the individual seeking gender-affirming treatment. In the case of adolescents, the clinician also obtains information from the parents or guardians regarding various aspects of the child’s general and psychosexual development and current functioning. On the basis of this information, the clinician:</p><ul class=\"bullet\"><li><p class=\"chapter-para\">decides whether the individual fulfills criteria for treatment (see <span class=\"xrefLink\" id=\"jumplink-T2\"></span><a href=\"javascript:;\" reveal-id=\"T2\" data-open=\"T2\" class=\"link link-reveal link-table xref-fig\">Tables 2</a> and <span class=\"xrefLink\" id=\"jumplink-T3\"></span><a href=\"javascript:;\" reveal-id=\"T3\" data-open=\"T3\" class=\"link link-reveal link-table xref-fig\">3</a>) for GD/gender incongruence (DSM-5) or transsexualism (DSM-5 and/or ICD-10);<span id=\"T3\"></span><div content-id=\"T3\" class=\"table-modal\"><div class=\"table-wrap table-wide\"><div class=\"table-wrap-title\" id=\"T3\" data-id=\"T3\"><span class=\"label\">Table 3.</span><div class=\"caption\"><p class=\"chapter-para\">ICD-10 Criteria for Transsexualism</p></div> </div><div class=\"table-overflow\"><table><thead><tr><th>Transsexualism (F64.0) has three criteria:<span aria-hidden=\"true\" style=\"display: none;\">\r\n            . </span></th></tr></thead><tbody><tr><td>1. The desire to live and be accepted as a member of the opposite sex, usually accompanied by the wish to make his or her body as congruent as possible with the preferred sex through surgery and hormone treatments. </td></tr><tr><td>2. The transsexual identity has been present persistently for at least 2 y. </td></tr><tr><td>3. The disorder is not a symptom of another mental disorder or a genetic, DSD, or chromosomal abnormality. </td></tr></tbody></table></div><div class=\"table-modal\"><table><thead><tr><th>Transsexualism (F64.0) has three criteria:<span aria-hidden=\"true\" style=\"display: none;\">\r\n            . </span></th></tr></thead><tbody><tr><td>1. The desire to live and be accepted as a member of the opposite sex, usually accompanied by the wish to make his or her body as congruent as possible with the preferred sex through surgery and hormone treatments. </td></tr><tr><td>2. The transsexual identity has been present persistently for at least 2 y. </td></tr><tr><td>3. The disorder is not a symptom of another mental disorder or a genetic, DSD, or chromosomal abnormality. </td></tr></tbody></table></div><div class=\"&#xA;          graphic-wrap&#xA;           hide\"><a class=\"fig-view-orig openInAnotherWindow btn js-view-large\" target=\"_blank\" href=\"/view-large/\">\r\n          Open in new tab\r\n        </a></div></div></div><div class=\"table-wrap table-wide\"><div class=\"table-wrap-title\" id=\"T3\" data-id=\"T3\"><span class=\"label\">Table 3.</span><div class=\"caption\"><p class=\"chapter-para\">ICD-10 Criteria for Transsexualism</p></div> </div><div class=\"table-overflow\"><table><thead><tr><th>Transsexualism (F64.0) has three criteria:<span aria-hidden=\"true\" style=\"display: none;\">\r\n            . </span></th></tr></thead><tbody><tr><td>1. The desire to live and be accepted as a member of the opposite sex, usually accompanied by the wish to make his or her body as congruent as possible with the preferred sex through surgery and hormone treatments. </td></tr><tr><td>2. The transsexual identity has been present persistently for at least 2 y. </td></tr><tr><td>3. The disorder is not a symptom of another mental disorder or a genetic, DSD, or chromosomal abnormality. </td></tr></tbody></table></div><div class=\"table-modal\"><table><thead><tr><th>Transsexualism (F64.0) has three criteria:<span aria-hidden=\"true\" style=\"display: none;\">\r\n            . </span></th></tr></thead><tbody><tr><td>1. The desire to live and be accepted as a member of the opposite sex, usually accompanied by the wish to make his or her body as congruent as possible with the preferred sex through surgery and hormone treatments. </td></tr><tr><td>2. The transsexual identity has been present persistently for at least 2 y. </td></tr><tr><td>3. The disorder is not a symptom of another mental disorder or a genetic, DSD, or chromosomal abnormality. </td></tr></tbody></table></div><div class=\"&#xA;          graphic-wrap&#xA;           hide\"><a class=\"fig-view-orig openInAnotherWindow btn js-view-large\" target=\"_blank\" href=\"/view-large/\">\r\n          Open in new tab\r\n        </a></div></div></p></li><li><p class=\"chapter-para\">informs the individual about the possibilities and limitations of various kinds of treatment (hormonal/surgical and nonhormonal), and if medical treatment is desired, provides correct information to prevent unrealistically high expectations;</p></li><li><p class=\"chapter-para\">assesses whether medical interventions may result in unfavorable psychological and social outcomes.</p></li></ul><p class=\"chapter-para\">In cases in which severe psychopathology, circumstances, or both seriously interfere with the diagnostic work or make satisfactory treatment unlikely, clinicians should assist the adolescent in managing these other issues. Literature on postoperative regret suggests that besides poor quality of surgery, severe psychiatric comorbidity and lack of support may interfere with positive outcomes (<span class=\"xrefLink\" id=\"jumplink-B52\"></span><a href=\"javascript:;\" reveal-id=\"B52\" data-open=\"B52\" class=\"link link-ref link-reveal xref-bibr\">52</a>–<span class=\"xrefLink\" id=\"jumplink-B56\"></span><a href=\"javascript:;\" reveal-id=\"B56\" data-open=\"B56\" class=\"link link-ref link-reveal xref-bibr\">56</a>).</p><p class=\"chapter-para\">For adolescents, the diagnostic procedure usually includes a complete psychodiagnostic assessment (<span class=\"xrefLink\" id=\"jumplink-B57\"></span><a href=\"javascript:;\" reveal-id=\"B57\" data-open=\"B57\" class=\"link link-ref link-reveal xref-bibr\">57</a>) and an assessment of the decision-making capability of the youth. An evaluation to assess the family’s ability to endure stress, give support, and deal with the complexities of the adolescent’s situation should be part of the diagnostic phase (<span class=\"xrefLink\" id=\"jumplink-B58\"></span><a href=\"javascript:;\" reveal-id=\"B58\" data-open=\"B58\" class=\"link link-ref link-reveal xref-bibr\">58</a>).</p>                    <h4 scrollto-destination=99603290 id=\"99603290\" class=\"section-title js-splitscreen-section-title\" data-legacy-id=s21>Social transitioning</h4>\r\n<p class=\"chapter-para\">A change in gender expression and role (which may involve living part time or full time in another gender role that is consistent with one’s gender identity) may test the person’s resolve, the capacity to function in the affirmed gender, and the adequacy of social, economic, and psychological supports. It assists both the individual and the clinician in their judgments about how to proceed (<span class=\"xrefLink\" id=\"jumplink-B16\"></span><a href=\"javascript:;\" reveal-id=\"B16\" data-open=\"B16\" class=\"link link-ref link-reveal xref-bibr\">16</a>). During social transitioning, the person’s feelings about the social transformation (including coping with the responses of others) is a major focus of the counseling. The optimal timing for social transitioning may differ between individuals. Sometimes people wait until they start gender-affirming hormone treatment to make social transitioning easier, but individuals increasingly start social transitioning long before they receive medically supervised, gender-affirming hormone treatment.</p>                    <h4 scrollto-destination=99603292 id=\"99603292\" class=\"section-title js-splitscreen-section-title\" data-legacy-id=s22>Criteria</h4>\r\n<p class=\"chapter-para\">Adolescents and adults seeking gender-affirming hormone treatment and surgery should satisfy certain criteria before proceeding (<span class=\"xrefLink\" id=\"jumplink-B16\"></span><a href=\"javascript:;\" reveal-id=\"B16\" data-open=\"B16\" class=\"link link-ref link-reveal xref-bibr\">16</a>). Criteria for gender-affirming hormone therapy for adults are in <span class=\"xrefLink\" id=\"jumplink-T4\"></span><a href=\"javascript:;\" reveal-id=\"T4\" data-open=\"T4\" class=\"link link-reveal link-table xref-fig\">Table 4</a>, and criteria for gender-affirming hormone therapy for adolescents are in <span class=\"xrefLink\" id=\"jumplink-T5\"></span><a href=\"javascript:;\" reveal-id=\"T5\" data-open=\"T5\" class=\"link link-reveal link-table xref-fig\">Table 5</a>. Follow-up studies in adults meeting these criteria indicate a high satisfaction rate with treatment (<span class=\"xrefLink\" id=\"jumplink-B59\"></span><a href=\"javascript:;\" reveal-id=\"B59\" data-open=\"B59\" class=\"link link-ref link-reveal xref-bibr\">59</a>). However, the quality of evidence is usually low. A few follow-up studies on adolescents who fulfilled these criteria also indicated good treatment results (<span class=\"xrefLink\" id=\"jumplink-B60\"></span><a href=\"javascript:;\" reveal-id=\"B60\" data-open=\"B60\" class=\"link link-ref link-reveal xref-bibr\">60</a>–<span class=\"xrefLink\" id=\"jumplink-B63\"></span><a href=\"javascript:;\" reveal-id=\"B63\" data-open=\"B63\" class=\"link link-ref link-reveal xref-bibr\">63</a>).</p>                    <a id=\"99603294\" scrollto-destination=\"99603294\"></a>\r\n<div content-id=\"T4\" class=\"table-modal table-full-width-wrap\"><div class=\"table-wrap table-wide\"><div class=\"table-wrap-title\" id=\"T4\" data-id=\"T4\"><span class=\"label\">Table 4.</span><div class=\"caption\"><p class=\"chapter-para\">Criteria for Gender-Affirming Hormone Therapy for Adults</p></div> </div><div class=\"table-overflow\"><table><tbody><tr><td>1. Persistent, well-documented gender dysphoria/gender incongruence </td></tr><tr><td>2. The capacity to make a fully informed decision and to consent for treatment </td></tr><tr><td>3. The age of majority in a given country (if younger, follow the criteria for adolescents) </td></tr><tr><td>4. Mental health concerns, if present, must be reasonably well controlled </td></tr></tbody></table></div><div class=\"table-modal\"><table><tbody><tr><td>1. Persistent, well-documented gender dysphoria/gender incongruence </td></tr><tr><td>2. The capacity to make a fully informed decision and to consent for treatment </td></tr><tr><td>3. The age of majority in a given country (if younger, follow the criteria for adolescents) </td></tr><tr><td>4. Mental health concerns, if present, must be reasonably well controlled </td></tr></tbody></table></div><div class=\"table-wrap-foot\"><span id=\"fn-fn-02\"></span><div content-id=\"fn-02\" class=\"footnote\"><span class=\"fn\"><p class=\"chapter-para\">Reproduced from World Professional Association for Transgender Health (<span class=\"xrefLink\" id=\"jumplink-B16\"></span><a href=\"javascript:;\" reveal-id=\"B16\" data-open=\"B16\" class=\"link link-ref link-reveal xref-bibr\">16</a>).</p></span></div></div><div class=\"&#xA;          graphic-wrap&#xA;          \"><a class=\"fig-view-orig openInAnotherWindow btn js-view-large\" target=\"_blank\" href=\"/view-large/99603294\">\r\n          Open in new tab\r\n        </a></div></div></div><div class=\"table-full-width-wrap\"><div class=\"table-wrap table-wide\"><div class=\"table-wrap-title\" id=\"T4\" data-id=\"T4\"><span class=\"label\">Table 4.</span><div class=\"caption\"><p class=\"chapter-para\">Criteria for Gender-Affirming Hormone Therapy for Adults</p></div> </div><div class=\"table-overflow\"><table><tbody><tr><td>1. Persistent, well-documented gender dysphoria/gender incongruence </td></tr><tr><td>2. The capacity to make a fully informed decision and to consent for treatment </td></tr><tr><td>3. The age of majority in a given country (if younger, follow the criteria for adolescents) </td></tr><tr><td>4. Mental health concerns, if present, must be reasonably well controlled </td></tr></tbody></table></div><div class=\"table-modal\"><table><tbody><tr><td>1. Persistent, well-documented gender dysphoria/gender incongruence </td></tr><tr><td>2. The capacity to make a fully informed decision and to consent for treatment </td></tr><tr><td>3. The age of majority in a given country (if younger, follow the criteria for adolescents) </td></tr><tr><td>4. Mental health concerns, if present, must be reasonably well controlled </td></tr></tbody></table></div><div class=\"table-wrap-foot\"><span id=\"fn-fn-02\"></span><div content-id=\"fn-02\" class=\"footnote\"><span class=\"fn\"><p class=\"chapter-para\">Reproduced from World Professional Association for Transgender Health (<span class=\"xrefLink\" id=\"jumplink-B16\"></span><a href=\"javascript:;\" reveal-id=\"B16\" data-open=\"B16\" class=\"link link-ref link-reveal xref-bibr\">16</a>).</p></span></div></div><div class=\"&#xA;          graphic-wrap&#xA;          \"><a class=\"fig-view-orig openInAnotherWindow btn js-view-large\" target=\"_blank\" href=\"/view-large/99603294\">\r\n          Open in new tab\r\n        </a></div></div></div>                    <a id=\"99603295\" scrollto-destination=\"99603295\"></a>\r\n<div content-id=\"T5\" class=\"table-modal table-full-width-wrap\"><div class=\"table-wrap table-wide\"><div class=\"table-wrap-title\" id=\"T5\" data-id=\"T5\"><span class=\"label\">Table 5.</span><div class=\"caption\"><p class=\"chapter-para\">Criteria for Gender-Affirming Hormone Therapy for Adolescents</p></div> </div><div class=\"table-overflow\"><table><tbody><tr><td><strong>Adolescents are eligible for GnRH agonist treatment if:</strong> </td></tr><tr><td> 1. A qualified MHP has confirmed that: </td></tr><tr><td> •the adolescent has demonstrated a long-lasting and intense pattern of gender nonconformity or gender dysphoria (whether suppressed or expressed), </td></tr><tr><td> •gender dysphoria worsened with the onset of puberty, </td></tr><tr><td> •any coexisting psychological, medical, or social problems that could interfere with treatment (<em>e.g.</em>, that may compromise treatment adherence) have been addressed, such that the adolescent’s situation and functioning are stable enough to start treatment, </td></tr><tr><td> •the adolescent has sufficient mental capacity to give informed consent to this (reversible) treatment, </td></tr><tr><td> 2. And the adolescent: </td></tr><tr><td> •has been informed of the effects and side effects of treatment (including potential loss of fertility if the individual subsequently continues with sex hormone treatment) and options to preserve fertility, </td></tr><tr><td> •has given informed consent and (particularly when the adolescent has not reached the age of legal medical consent, depending on applicable legislation) the parents or other caretakers or guardians have consented to the treatment and are involved in supporting the adolescent throughout the treatment process, </td></tr><tr><td> 3. And a pediatric endocrinologist or other clinician experienced in pubertal assessment </td></tr><tr><td> •agrees with the indication for GnRH agonist treatment, </td></tr><tr><td> •has confirmed that puberty has started in the adolescent (Tanner stage ≥G2/B2), </td></tr><tr><td> •has confirmed that there are no medical contraindications to GnRH agonist treatment. </td></tr><tr><td><strong>Adolescents are eligible for subsequent sex hormone treatment if:</strong> </td></tr><tr><td> 1. A qualified MHP has confirmed: </td></tr><tr><td> •the persistence of gender dysphoria, </td></tr><tr><td> •any coexisting psychological, medical, or social problems that could interfere with treatment (<em>e.g.</em>, that may compromise treatment adherence) have been addressed, such that the adolescent’s situation and functioning are stable enough to start sex hormone treatment, </td></tr><tr><td> •the adolescent has sufficient mental capacity (which most adolescents have by age 16 years) to estimate the consequences of this (partly) irreversible treatment, weigh the benefits and risks, and give informed consent to this (partly) irreversible treatment, </td></tr><tr><td> 2. And the adolescent: </td></tr><tr><td> •has been informed of the (irreversible) effects and side effects of treatment (including potential loss of fertility and options to preserve fertility), </td></tr><tr><td> •has given informed consent and (particularly when the adolescent has not reached the age of legal medical consent, depending on applicable legislation) the parents or other caretakers or guardians have consented to the treatment and are involved in supporting the adolescent throughout the treatment process, </td></tr><tr><td> 3. And a pediatric endocrinologist or other clinician experienced in pubertal induction: </td></tr><tr><td> •agrees with the indication for sex hormone treatment, </td></tr><tr><td> •has confirmed that there are no medical contraindications to sex hormone treatment. </td></tr></tbody></table></div><div class=\"table-modal\"><table><tbody><tr><td><strong>Adolescents are eligible for GnRH agonist treatment if:</strong> </td></tr><tr><td> 1. A qualified MHP has confirmed that: </td></tr><tr><td> •the adolescent has demonstrated a long-lasting and intense pattern of gender nonconformity or gender dysphoria (whether suppressed or expressed), </td></tr><tr><td> •gender dysphoria worsened with the onset of puberty, </td></tr><tr><td> •any coexisting psychological, medical, or social problems that could interfere with treatment (<em>e.g.</em>, that may compromise treatment adherence) have been addressed, such that the adolescent’s situation and functioning are stable enough to start treatment, </td></tr><tr><td> •the adolescent has sufficient mental capacity to give informed consent to this (reversible) treatment, </td></tr><tr><td> 2. And the adolescent: </td></tr><tr><td> •has been informed of the effects and side effects of treatment (including potential loss of fertility if the individual subsequently continues with sex hormone treatment) and options to preserve fertility, </td></tr><tr><td> •has given informed consent and (particularly when the adolescent has not reached the age of legal medical consent, depending on applicable legislation) the parents or other caretakers or guardians have consented to the treatment and are involved in supporting the adolescent throughout the treatment process, </td></tr><tr><td> 3. And a pediatric endocrinologist or other clinician experienced in pubertal assessment </td></tr><tr><td> •agrees with the indication for GnRH agonist treatment, </td></tr><tr><td> •has confirmed that puberty has started in the adolescent (Tanner stage ≥G2/B2), </td></tr><tr><td> •has confirmed that there are no medical contraindications to GnRH agonist treatment. </td></tr><tr><td><strong>Adolescents are eligible for subsequent sex hormone treatment if:</strong> </td></tr><tr><td> 1. A qualified MHP has confirmed: </td></tr><tr><td> •the persistence of gender dysphoria, </td></tr><tr><td> •any coexisting psychological, medical, or social problems that could interfere with treatment (<em>e.g.</em>, that may compromise treatment adherence) have been addressed, such that the adolescent’s situation and functioning are stable enough to start sex hormone treatment, </td></tr><tr><td> •the adolescent has sufficient mental capacity (which most adolescents have by age 16 years) to estimate the consequences of this (partly) irreversible treatment, weigh the benefits and risks, and give informed consent to this (partly) irreversible treatment, </td></tr><tr><td> 2. And the adolescent: </td></tr><tr><td> •has been informed of the (irreversible) effects and side effects of treatment (including potential loss of fertility and options to preserve fertility), </td></tr><tr><td> •has given informed consent and (particularly when the adolescent has not reached the age of legal medical consent, depending on applicable legislation) the parents or other caretakers or guardians have consented to the treatment and are involved in supporting the adolescent throughout the treatment process, </td></tr><tr><td> 3. And a pediatric endocrinologist or other clinician experienced in pubertal induction: </td></tr><tr><td> •agrees with the indication for sex hormone treatment, </td></tr><tr><td> •has confirmed that there are no medical contraindications to sex hormone treatment. </td></tr></tbody></table></div><div class=\"table-wrap-foot\"><span id=\"fn-fn-03\"></span><div content-id=\"fn-03\" class=\"footnote\"><span class=\"fn\"><p class=\"chapter-para\">Reproduced from World Professional Association for Transgender Health (<span class=\"xrefLink\" id=\"jumplink-B16\"></span><a href=\"javascript:;\" reveal-id=\"B16\" data-open=\"B16\" class=\"link link-ref link-reveal xref-bibr\">16</a>).</p></span></div></div><div class=\"&#xA;          graphic-wrap&#xA;          \"><a class=\"fig-view-orig openInAnotherWindow btn js-view-large\" target=\"_blank\" href=\"/view-large/99603295\">\r\n          Open in new tab\r\n        </a></div></div></div><div class=\"table-full-width-wrap\"><div class=\"table-wrap table-wide\"><div class=\"table-wrap-title\" id=\"T5\" data-id=\"T5\"><span class=\"label\">Table 5.</span><div class=\"caption\"><p class=\"chapter-para\">Criteria for Gender-Affirming Hormone Therapy for Adolescents</p></div> </div><div class=\"table-overflow\"><table><tbody><tr><td><strong>Adolescents are eligible for GnRH agonist treatment if:</strong> </td></tr><tr><td> 1. A qualified MHP has confirmed that: </td></tr><tr><td> •the adolescent has demonstrated a long-lasting and intense pattern of gender nonconformity or gender dysphoria (whether suppressed or expressed), </td></tr><tr><td> •gender dysphoria worsened with the onset of puberty, </td></tr><tr><td> •any coexisting psychological, medical, or social problems that could interfere with treatment (<em>e.g.</em>, that may compromise treatment adherence) have been addressed, such that the adolescent’s situation and functioning are stable enough to start treatment, </td></tr><tr><td> •the adolescent has sufficient mental capacity to give informed consent to this (reversible) treatment, </td></tr><tr><td> 2. And the adolescent: </td></tr><tr><td> •has been informed of the effects and side effects of treatment (including potential loss of fertility if the individual subsequently continues with sex hormone treatment) and options to preserve fertility, </td></tr><tr><td> •has given informed consent and (particularly when the adolescent has not reached the age of legal medical consent, depending on applicable legislation) the parents or other caretakers or guardians have consented to the treatment and are involved in supporting the adolescent throughout the treatment process, </td></tr><tr><td> 3. And a pediatric endocrinologist or other clinician experienced in pubertal assessment </td></tr><tr><td> •agrees with the indication for GnRH agonist treatment, </td></tr><tr><td> •has confirmed that puberty has started in the adolescent (Tanner stage ≥G2/B2), </td></tr><tr><td> •has confirmed that there are no medical contraindications to GnRH agonist treatment. </td></tr><tr><td><strong>Adolescents are eligible for subsequent sex hormone treatment if:</strong> </td></tr><tr><td> 1. A qualified MHP has confirmed: </td></tr><tr><td> •the persistence of gender dysphoria, </td></tr><tr><td> •any coexisting psychological, medical, or social problems that could interfere with treatment (<em>e.g.</em>, that may compromise treatment adherence) have been addressed, such that the adolescent’s situation and functioning are stable enough to start sex hormone treatment, </td></tr><tr><td> •the adolescent has sufficient mental capacity (which most adolescents have by age 16 years) to estimate the consequences of this (partly) irreversible treatment, weigh the benefits and risks, and give informed consent to this (partly) irreversible treatment, </td></tr><tr><td> 2. And the adolescent: </td></tr><tr><td> •has been informed of the (irreversible) effects and side effects of treatment (including potential loss of fertility and options to preserve fertility), </td></tr><tr><td> •has given informed consent and (particularly when the adolescent has not reached the age of legal medical consent, depending on applicable legislation) the parents or other caretakers or guardians have consented to the treatment and are involved in supporting the adolescent throughout the treatment process, </td></tr><tr><td> 3. And a pediatric endocrinologist or other clinician experienced in pubertal induction: </td></tr><tr><td> •agrees with the indication for sex hormone treatment, </td></tr><tr><td> •has confirmed that there are no medical contraindications to sex hormone treatment. </td></tr></tbody></table></div><div class=\"table-modal\"><table><tbody><tr><td><strong>Adolescents are eligible for GnRH agonist treatment if:</strong> </td></tr><tr><td> 1. A qualified MHP has confirmed that: </td></tr><tr><td> •the adolescent has demonstrated a long-lasting and intense pattern of gender nonconformity or gender dysphoria (whether suppressed or expressed), </td></tr><tr><td> •gender dysphoria worsened with the onset of puberty, </td></tr><tr><td> •any coexisting psychological, medical, or social problems that could interfere with treatment (<em>e.g.</em>, that may compromise treatment adherence) have been addressed, such that the adolescent’s situation and functioning are stable enough to start treatment, </td></tr><tr><td> •the adolescent has sufficient mental capacity to give informed consent to this (reversible) treatment, </td></tr><tr><td> 2. And the adolescent: </td></tr><tr><td> •has been informed of the effects and side effects of treatment (including potential loss of fertility if the individual subsequently continues with sex hormone treatment) and options to preserve fertility, </td></tr><tr><td> •has given informed consent and (particularly when the adolescent has not reached the age of legal medical consent, depending on applicable legislation) the parents or other caretakers or guardians have consented to the treatment and are involved in supporting the adolescent throughout the treatment process, </td></tr><tr><td> 3. And a pediatric endocrinologist or other clinician experienced in pubertal assessment </td></tr><tr><td> •agrees with the indication for GnRH agonist treatment, </td></tr><tr><td> •has confirmed that puberty has started in the adolescent (Tanner stage ≥G2/B2), </td></tr><tr><td> •has confirmed that there are no medical contraindications to GnRH agonist treatment. </td></tr><tr><td><strong>Adolescents are eligible for subsequent sex hormone treatment if:</strong> </td></tr><tr><td> 1. A qualified MHP has confirmed: </td></tr><tr><td> •the persistence of gender dysphoria, </td></tr><tr><td> •any coexisting psychological, medical, or social problems that could interfere with treatment (<em>e.g.</em>, that may compromise treatment adherence) have been addressed, such that the adolescent’s situation and functioning are stable enough to start sex hormone treatment, </td></tr><tr><td> •the adolescent has sufficient mental capacity (which most adolescents have by age 16 years) to estimate the consequences of this (partly) irreversible treatment, weigh the benefits and risks, and give informed consent to this (partly) irreversible treatment, </td></tr><tr><td> 2. And the adolescent: </td></tr><tr><td> •has been informed of the (irreversible) effects and side effects of treatment (including potential loss of fertility and options to preserve fertility), </td></tr><tr><td> •has given informed consent and (particularly when the adolescent has not reached the age of legal medical consent, depending on applicable legislation) the parents or other caretakers or guardians have consented to the treatment and are involved in supporting the adolescent throughout the treatment process, </td></tr><tr><td> 3. And a pediatric endocrinologist or other clinician experienced in pubertal induction: </td></tr><tr><td> •agrees with the indication for sex hormone treatment, </td></tr><tr><td> •has confirmed that there are no medical contraindications to sex hormone treatment. </td></tr></tbody></table></div><div class=\"table-wrap-foot\"><span id=\"fn-fn-03\"></span><div content-id=\"fn-03\" class=\"footnote\"><span class=\"fn\"><p class=\"chapter-para\">Reproduced from World Professional Association for Transgender Health (<span class=\"xrefLink\" id=\"jumplink-B16\"></span><a href=\"javascript:;\" reveal-id=\"B16\" data-open=\"B16\" class=\"link link-ref link-reveal xref-bibr\">16</a>).</p></span></div></div><div class=\"&#xA;          graphic-wrap&#xA;          \"><a class=\"fig-view-orig openInAnotherWindow btn js-view-large\" target=\"_blank\" href=\"/view-large/99603295\">\r\n          Open in new tab\r\n        </a></div></div></div>                    <h2 scrollto-destination=99603296 id=\"99603296\" class=\"section-title js-splitscreen-section-title\" data-legacy-id=s23>Recommendations for Those Involved in the Gender-Affirming Hormone Treatment of Individuals With GD/Gender Incongruence</h2>\r\n<ul class=\"list-simple\"><li><p class=\"chapter-para\">1.1. We advise that only trained MHPs who meet the following criteria should diagnose GD/gender incongruence in adults: (1) competence in using the DSM and/or the ICD for diagnostic purposes, (2) the ability to diagnose GD/gender incongruence and make a distinction between GD/gender incongruence and conditions that have similar features (<em>e.g.</em>, body dysmorphic disorder), (3) training in diagnosing psychiatric conditions, (4) the ability to undertake or refer for appropriate treatment, (5) the ability to psychosocially assess the person’s understanding, mental health, and social conditions that can impact gender-affirming hormone therapy, and (6) a practice of regularly attending relevant professional meetings. (Ungraded Good Practice Statement)</p></li><li><p class=\"chapter-para\">1.2. We advise that only MHPs who meet the following criteria should diagnose GD/gender incongruence in children and adolescents: (1) training in child and adolescent developmental psychology and psychopathology, (2) competence in using the DSM and/or ICD for diagnostic purposes, (3) the ability to make a distinction between GD/gender incongruence and conditions that have similar features (<em>e.g.</em>, body dysmorphic disorder), (4) training in diagnosing psychiatric conditions, (5) the ability to undertake or refer for appropriate treatment, (6) the ability to psychosocially assess the person’s understanding and social conditions that can impact gender-affirming hormone therapy, (7) a practice of regularly attending relevant professional meetings, and (8) knowledge of the criteria for puberty blocking and gender-affirming hormone treatment in adolescents. (Ungraded Good Practice Statement)</p></li></ul>                    <h3 scrollto-destination=99603298 id=\"99603298\" class=\"section-title js-splitscreen-section-title\" data-legacy-id=s24>Evidence</h3>\r\n<p class=\"chapter-para\">Individuals with gender identity issues may have psychological or psychiatric problems (<span class=\"xrefLink\" id=\"jumplink-B43\"></span><a href=\"javascript:;\" reveal-id=\"B43\" data-open=\"B43\" class=\"link link-ref link-reveal xref-bibr\">43</a>–<span class=\"xrefLink\" id=\"jumplink-B48\"></span><a href=\"javascript:;\" reveal-id=\"B48\" data-open=\"B48\" class=\"link link-ref link-reveal xref-bibr\">48</a>, <span class=\"xrefLink\" id=\"jumplink-B50\"></span><a href=\"javascript:;\" reveal-id=\"B50\" data-open=\"B50\" class=\"link link-ref link-reveal xref-bibr\">50</a>, <span class=\"xrefLink\" id=\"jumplink-B51\"></span><a href=\"javascript:;\" reveal-id=\"B51\" data-open=\"B51\" class=\"link link-ref link-reveal xref-bibr\">51</a>, <span class=\"xrefLink\" id=\"jumplink-B64\"></span><a href=\"javascript:;\" reveal-id=\"B64\" data-open=\"B64\" class=\"link link-ref link-reveal xref-bibr\">64</a>, <span class=\"xrefLink\" id=\"jumplink-B65\"></span><a href=\"javascript:;\" reveal-id=\"B65\" data-open=\"B65\" class=\"link link-ref link-reveal xref-bibr\">65</a>). It is therefore necessary that clinicians making the diagnosis are able to make a distinction between GD/gender incongruence and conditions that have similar features. Examples of conditions with similar features are body dysmorphic disorder, body identity integrity disorder (a condition in which individuals have a sense that their anatomical configuration as an able-bodied person is somehow wrong or inappropriate) (<span class=\"xrefLink\" id=\"jumplink-B66\"></span><a href=\"javascript:;\" reveal-id=\"B66\" data-open=\"B66\" class=\"link link-ref link-reveal xref-bibr\">66</a>), or certain forms of eunuchism (in which a person is preoccupied with or engages in castration and/or penectomy for reasons that are not gender identity related) (<span class=\"xrefLink\" id=\"jumplink-B11\"></span><a href=\"javascript:;\" reveal-id=\"B11\" data-open=\"B11\" class=\"link link-ref link-reveal xref-bibr\">11</a>). Clinicians should also be able to diagnose psychiatric conditions accurately and ensure that these conditions are treated appropriately, particularly when the conditions may complicate treatment, affect the outcome of gender-affirming treatment, or be affected by hormone use.</p>                    <h3 scrollto-destination=99603300 id=\"99603300\" class=\"section-title js-splitscreen-section-title\" data-legacy-id=s25>Values and preferences</h3>\r\n<p class=\"chapter-para\">The task force placed a very high value on avoiding harm from hormone treatment in individuals who have conditions other than GD/gender incongruence and who may not benefit from the physical changes associated with this treatment and placed a low value on any potential benefit these persons believe they may derive from hormone treatment. This justifies the good practice statement.</p><ul class=\"list-simple\"><li><p class=\"chapter-para\">1.3. We advise that decisions regarding the social transition of prepubertal youths with GD/gender incongruence are made with the assistance of an MHP or another experienced professional. (Ungraded Good Practice Statement).</p></li><li><p class=\"chapter-para\">1.4. We recommend against puberty blocking and gender-affirming hormone treatment in prepubertal children with GD/gender incongruence. (1 |⊕⊕○○)</p></li></ul>                    <h3 scrollto-destination=99603303 id=\"99603303\" class=\"section-title js-splitscreen-section-title\" data-legacy-id=s26>Evidence</h3>\r\n<p class=\"chapter-para\">In most children diagnosed with GD/gender incongruence, it did not persist into adolescence. The percentages differed among studies, probably dependent on which version of the DSM clinicians used, the patient’s age, the recruitment criteria, and perhaps cultural factors. However, the large majority (about 85%) of prepubertal children with a childhood diagnosis did not remain GD/gender incongruent in adolescence (<span class=\"xrefLink\" id=\"jumplink-B20\"></span><a href=\"javascript:;\" reveal-id=\"B20\" data-open=\"B20\" class=\"link link-ref link-reveal xref-bibr\">20</a>). If children have completely socially transitioned, they may have great difficulty in returning to the original gender role upon entering puberty (<span class=\"xrefLink\" id=\"jumplink-B40\"></span><a href=\"javascript:;\" reveal-id=\"B40\" data-open=\"B40\" class=\"link link-ref link-reveal xref-bibr\">40</a>). Social transition is associated with the persistence of GD/gender incongruence as a child progresses into adolescence. It may be that the presence of GD/gender incongruence in prepubertal children is the earliest sign that a child is destined to be transgender as an adolescent/adult (<span class=\"xrefLink\" id=\"jumplink-B20\"></span><a href=\"javascript:;\" reveal-id=\"B20\" data-open=\"B20\" class=\"link link-ref link-reveal xref-bibr\">20</a>). However, social transition (in addition to GD/gender incongruence) has been found to contribute to the likelihood of persistence.</p><p class=\"chapter-para\">This recommendation, however, does not imply that children should be discouraged from showing gender-variant behaviors or should be punished for exhibiting such behaviors. In individual cases, an early complete social transition may result in a more favorable outcome, but there are currently no criteria to identify the GD/gender-incongruent children to whom this applies. At the present time, clinical experience suggests that persistence of GD/gender incongruence can only be reliably assessed after the first signs of puberty.</p>                    <h3 scrollto-destination=99603306 id=\"99603306\" class=\"section-title js-splitscreen-section-title\" data-legacy-id=s27>Values and preferences</h3>\r\n<p class=\"chapter-para\">The task force placed a high value on avoiding harm with gender-affirming hormone therapy in prepubertal children with GD/gender incongruence. This justifies the strong recommendation in the face of low-quality evidence.</p><ul class=\"list-simple\"><li><p class=\"chapter-para\">1.5. We recommend that clinicians inform and counsel all individuals seeking gender-affirming medical treatment regarding options for fertility preservation prior to initiating puberty suppression in adolescents and prior to treating with hormonal therapy of the affirmed gender in both adolescents and adults. (1 |⊕⊕⊕○)</p></li></ul>                    <h3 scrollto-destination=99603309 id=\"99603309\" class=\"section-title js-splitscreen-section-title\" data-legacy-id=s28>Remarks</h3>\r\n<p class=\"chapter-para\">Persons considering hormone use for gender affirmation need adequate information about this treatment in general and about fertility effects of hormone treatment in particular to make an informed and balanced decision (<span class=\"xrefLink\" id=\"jumplink-B67\"></span><a href=\"javascript:;\" reveal-id=\"B67\" data-open=\"B67\" class=\"link link-ref link-reveal xref-bibr\">67</a>, <span class=\"xrefLink\" id=\"jumplink-B68\"></span><a href=\"javascript:;\" reveal-id=\"B68\" data-open=\"B68\" class=\"link link-ref link-reveal xref-bibr\">68</a>). Because young adolescents may not feel qualified to make decisions about fertility and may not fully understand the potential effects of hormonal interventions, consent and protocol education should include parents, the referring MHP(s), and other members of the adolescent’s support group. To our knowledge, there are no formally evaluated decision aids available to assist in the discussion and decision regarding the future fertility of adolescents or adults beginning gender-affirming treatment.</p><p class=\"chapter-para\">Treating early pubertal youth with GnRH analogs will temporarily impair spermatogenesis and oocyte maturation. Given that an increasing number of transgender youth want to preserve fertility potential, delaying or temporarily discontinuing GnRH analogs to promote gamete maturation is an option. This option is often not preferred, because mature sperm production is associated with later stages of puberty and with the significant development of secondary sex characteristics.</p><p class=\"chapter-para\">For those designated male at birth with GD/gender incongruence and who are in early puberty, sperm production and the development of the reproductive tract are insufficient for the cryopreservation of sperm. However, prolonged pubertal suppression using GnRH analogs is reversible and clinicians should inform these individuals that sperm production can be initiated following prolonged gonadotropin suppression. This can be accomplished by spontaneous gonadotropin recovery after cessation of GnRH analogs or by gonadotropin treatment and will probably be associated with physical manifestations of testosterone production, as stated above. Note that there are no data in this population concerning the time required for sufficient spermatogenesis to collect enough sperm for later fertility. In males treated for precocious puberty, spermarche was reported 0.7 to 3 years after cessation of GnRH analogs (<span class=\"xrefLink\" id=\"jumplink-B69\"></span><a href=\"javascript:;\" reveal-id=\"B69\" data-open=\"B69\" class=\"link link-ref link-reveal xref-bibr\">69</a>). In adult men with gonadotropin deficiency, sperm are noted in seminal fluid by 6 to 12 months of gonadotropin treatment. However, sperm numbers when partners of these patients conceive are far below the “normal range” (<span class=\"xrefLink\" id=\"jumplink-B70\"></span><a href=\"javascript:;\" reveal-id=\"B70\" data-open=\"B70\" class=\"link link-ref link-reveal xref-bibr\">70</a>, <span class=\"xrefLink\" id=\"jumplink-B71\"></span><a href=\"javascript:;\" reveal-id=\"B71\" data-open=\"B71\" class=\"link link-ref link-reveal xref-bibr\">71</a>).</p><p class=\"chapter-para\">In girls, no studies have reported long-term, adverse effects of pubertal suppression on ovarian function after treatment cessation (<span class=\"xrefLink\" id=\"jumplink-B72\"></span><a href=\"javascript:;\" reveal-id=\"B72\" data-open=\"B72\" class=\"link link-ref link-reveal xref-bibr\">72</a>, <span class=\"xrefLink\" id=\"jumplink-B73\"></span><a href=\"javascript:;\" reveal-id=\"B73\" data-open=\"B73\" class=\"link link-ref link-reveal xref-bibr\">73</a>). Clinicians should inform adolescents that no data are available regarding either time to spontaneous ovulation after cessation of GnRH analogs or the response to ovulation induction following prolonged gonadotropin suppression.</p><p class=\"chapter-para\">In males with GD/gender incongruence, when medical treatment is started in a later phase of puberty or in adulthood, spermatogenesis is sufficient for cryopreservation and storage of sperm. <em>In vitro</em> spermatogenesis is currently under investigation. Restoration of spermatogenesis after prolonged estrogen treatment has not been studied.</p><p class=\"chapter-para\">In females with GD/gender incongruence, the effect of prolonged treatment with exogenous testosterone on ovarian function is uncertain. There have been reports of an increased incidence of polycystic ovaries in transgender males, both prior to and as a result of androgen treatment (<span class=\"xrefLink\" id=\"jumplink-B74\"></span><a href=\"javascript:;\" reveal-id=\"B74\" data-open=\"B74\" class=\"link link-ref link-reveal xref-bibr\">74</a>–<span class=\"xrefLink\" id=\"jumplink-B77\"></span><a href=\"javascript:;\" reveal-id=\"B77\" data-open=\"B77\" class=\"link link-ref link-reveal xref-bibr\">77</a>), although these reports were not confirmed by others (<span class=\"xrefLink\" id=\"jumplink-B78\"></span><a href=\"javascript:;\" reveal-id=\"B78\" data-open=\"B78\" class=\"link link-ref link-reveal xref-bibr\">78</a>). Pregnancy has been reported in transgender males who have had prolonged androgen treatment and have discontinued testosterone but have not had genital surgery (<span class=\"xrefLink\" id=\"jumplink-B79\"></span><a href=\"javascript:;\" reveal-id=\"B79\" data-open=\"B79\" class=\"link link-ref link-reveal xref-bibr\">79</a>, <span class=\"xrefLink\" id=\"jumplink-B80\"></span><a href=\"javascript:;\" reveal-id=\"B80\" data-open=\"B80\" class=\"link link-ref link-reveal xref-bibr\">80</a>). A reproductive endocrine gynecologist can counsel patients before gender-affirming hormone treatment or surgery regarding potential fertility options (<span class=\"xrefLink\" id=\"jumplink-B81\"></span><a href=\"javascript:;\" reveal-id=\"B81\" data-open=\"B81\" class=\"link link-ref link-reveal xref-bibr\">81</a>). Techniques for cryopreservation of oocytes, embryos, and ovarian tissue continue to improve, and oocyte maturation of immature tissue is being studied (<span class=\"xrefLink\" id=\"jumplink-B82\"></span><a href=\"javascript:;\" reveal-id=\"B82\" data-open=\"B82\" class=\"link link-ref link-reveal xref-bibr\">82</a>).</p>                    <h2 scrollto-destination=99603316 id=\"99603316\" class=\"section-title js-splitscreen-section-title\" data-legacy-id=s29>2.0 Treatment of Adolescents</h2>\r\n<p class=\"chapter-para\">During the past decade, clinicians have progressively acknowledged the suffering of young adolescents with GD/gender incongruence. In some forms of GD/gender incongruence, psychological interventions may be useful and sufficient. However, for many adolescents with GD/gender incongruence, the pubertal physical changes are unbearable. As early medical intervention may prevent psychological harm, various clinics have decided to start treating young adolescents with GD/gender incongruence with puberty-suppressing medication (a GnRH analog). As compared with starting gender-affirming treatment long after the first phases of puberty, a benefit of pubertal suppression at early puberty may be a better psychological and physical outcome.</p><p class=\"chapter-para\">In girls, the first physical sign of puberty is the budding of the breasts followed by an increase in breast and fat tissue. Breast development is also associated with the pubertal growth spurt, and menarche occurs ∼2 years later. In boys, the first physical change is testicular growth. A testicular volume ≥4 mL is seen as consistent with the initiation of physical puberty. At the beginning of puberty, estradiol and testosterone levels are still low and are best measured in the early morning with an ultrasensitive assay. From a testicular volume of 10 mL, daytime testosterone levels increase, leading to virilization (<span class=\"xrefLink\" id=\"jumplink-B83\"></span><a href=\"javascript:;\" reveal-id=\"B83\" data-open=\"B83\" class=\"link link-ref link-reveal xref-bibr\">83</a>). Note that pubic hair and/or axillary hair/odor may not reflect the onset of gonadarche; instead, it may reflect adrenarche alone.</p><ul class=\"list-simple\"><li><p class=\"chapter-para\">2.1. We suggest that adolescents who meet diagnostic criteria for GD/gender incongruence, fulfill criteria for treatment (<span class=\"xrefLink\" id=\"jumplink-T5\"></span><a href=\"javascript:;\" reveal-id=\"T5\" data-open=\"T5\" class=\"link link-reveal link-table xref-fig\">Table 5</a>), and are requesting treatment should initially undergo treatment to suppress pubertal development. (2 |⊕⊕○○)</p></li><li><p class=\"chapter-para\">2.2. We suggest that clinicians begin pubertal hormone suppression after girls and boys first exhibit physical changes of puberty (Tanner stages G2/B2). (2 |⊕⊕○○)</p></li></ul>                    <h3 scrollto-destination=99603320 id=\"99603320\" class=\"section-title js-splitscreen-section-title\" data-legacy-id=s30>Evidence</h3>\r\n<p class=\"chapter-para\">Pubertal suppression can expand the diagnostic phase by a long period, giving the subject more time to explore options and to live in the experienced gender before making a decision to proceed with gender-affirming sex hormone treatments and/or surgery, some of which is irreversible (<span class=\"xrefLink\" id=\"jumplink-B84\"></span><a href=\"javascript:;\" reveal-id=\"B84\" data-open=\"B84\" class=\"link link-ref link-reveal xref-bibr\">84</a>, <span class=\"xrefLink\" id=\"jumplink-B85\"></span><a href=\"javascript:;\" reveal-id=\"B85\" data-open=\"B85\" class=\"link link-ref link-reveal xref-bibr\">85</a>). Pubertal suppression is fully reversible, enabling full pubertal development in the natal gender, after cessation of treatment, if appropriate. The experience of full endogenous puberty is an undesirable condition for the GD/gender-incongruent individual and may seriously interfere with healthy psychological functioning and well-being. Treating GD/gender-incongruent adolescents entering puberty with GnRH analogs has been shown to improve psychological functioning in several domains (<span class=\"xrefLink\" id=\"jumplink-B86\"></span><a href=\"javascript:;\" reveal-id=\"B86\" data-open=\"B86\" class=\"link link-ref link-reveal xref-bibr\">86</a>).</p><p class=\"chapter-para\">Another reason to start blocking pubertal hormones early in puberty is that the physical outcome is improved compared with initiating physical transition after puberty has been completed (<span class=\"xrefLink\" id=\"jumplink-B60\"></span><a href=\"javascript:;\" reveal-id=\"B60\" data-open=\"B60\" class=\"link link-ref link-reveal xref-bibr\">60</a>, <span class=\"xrefLink\" id=\"jumplink-B62\"></span><a href=\"javascript:;\" reveal-id=\"B62\" data-open=\"B62\" class=\"link link-ref link-reveal xref-bibr\">62</a>). Looking like a man or woman when living as the opposite sex creates difficult barriers with enormous life-long disadvantages. We therefore advise starting suppression in early puberty to prevent the irreversible development of undesirable secondary sex characteristics. However, adolescents with GD/gender incongruence should experience the first changes of their endogenous spontaneous puberty, because their emotional reaction to these first physical changes has diagnostic value in establishing the persistence of GD/gender incongruence (<span class=\"xrefLink\" id=\"jumplink-B85\"></span><a href=\"javascript:;\" reveal-id=\"B85\" data-open=\"B85\" class=\"link link-ref link-reveal xref-bibr\">85</a>). Thus, Tanner stage 2 is the optimal time to start pubertal suppression. However, pubertal suppression treatment in early puberty will limit the growth of the penis and scrotum, which will have a potential effect on future surgical treatments (<span class=\"xrefLink\" id=\"jumplink-B87\"></span><a href=\"javascript:;\" reveal-id=\"B87\" data-open=\"B87\" class=\"link link-ref link-reveal xref-bibr\">87</a>).</p><p class=\"chapter-para\">Clinicians can also use pubertal suppression in adolescents in later pubertal stages to stop menses in transgender males and prevent facial hair growth in transgender females. However, in contrast to the effects in early pubertal adolescents, physical sex characteristics (such as more advanced breast development in transgender boys and lowering of the voice and outgrowth of the jaw and brow in transgender girls) are not reversible.</p>                    <h3 scrollto-destination=99603324 id=\"99603324\" class=\"section-title js-splitscreen-section-title\" data-legacy-id=s31>Values and preferences</h3>\r\n<p class=\"chapter-para\">These recommendations place a high value on avoiding an unsatisfactory physical outcome when secondary sex characteristics have become manifest and irreversible, a higher value on psychological well-being, and a lower value on avoiding potential harm from early pubertal suppression.</p>                    <h3 scrollto-destination=99603326 id=\"99603326\" class=\"section-title js-splitscreen-section-title\" data-legacy-id=s32>Remarks</h3>\r\n<p class=\"chapter-para\"><span class=\"xrefLink\" id=\"jumplink-T6\"></span><a href=\"javascript:;\" reveal-id=\"T6\" data-open=\"T6\" class=\"link link-reveal link-table xref-fig\">Table 6</a> lists the Tanner stages of breast and male genital development. Careful documentation of hallmarks of pubertal development will ensure precise timing when initiating pubertal suppression once puberty has started. Clinicians can use pubertal LH and sex steroid levels to confirm that puberty has progressed sufficiently before starting pubertal suppression (<span class=\"xrefLink\" id=\"jumplink-B88\"></span><a href=\"javascript:;\" reveal-id=\"B88\" data-open=\"B88\" class=\"link link-ref link-reveal xref-bibr\">88</a>). Reference ranges for sex steroids by Tanner stage may vary depending on the assay used. Ultrasensitive sex steroid and gonadotropin assays will help clinicians document early pubertal changes.</p>                    <a id=\"99603328\" scrollto-destination=\"99603328\"></a>\r\n<div content-id=\"T6\" class=\"table-modal table-full-width-wrap\"><div class=\"table-wrap table-wide\"><div class=\"table-wrap-title\" id=\"T6\" data-id=\"T6\"><span class=\"label\">Table 6.</span><div class=\"caption\"><p class=\"chapter-para\">Tanner Stages of Breast Development and Male External Genitalia</p></div> </div><div class=\"table-overflow\"><table><tbody><tr><td>The description of Tanner stages for breast development: </td></tr><tr><td> 1. Prepubertal </td></tr><tr><td> 2. Breast and papilla elevated as small mound; areolar diameter increased </td></tr><tr><td> 3. Breast and areola enlarged, no contour separation </td></tr><tr><td> 4. Areola and papilla form secondary mound </td></tr><tr><td> 5. Mature; nipple projects, areola part of general breast contour </td></tr><tr><td>For penis and testes: </td></tr><tr><td> 1. Prepubertal, testicular volume &lt;4 mL </td></tr><tr><td> 2. Slight enlargement of penis; enlarged scrotum, pink, texture altered, testes 4–6 mL </td></tr><tr><td> 3. Penis longer, testes larger (8–12 mL) </td></tr><tr><td> 4. Penis and glans larger, including increase in breadth; testes larger (12–15 mL), scrotum dark </td></tr><tr><td> 5. Penis adult size; testicular volume &gt; 15 ml </td></tr></tbody></table></div><div class=\"table-modal\"><table><tbody><tr><td>The description of Tanner stages for breast development: </td></tr><tr><td> 1. Prepubertal </td></tr><tr><td> 2. Breast and papilla elevated as small mound; areolar diameter increased </td></tr><tr><td> 3. Breast and areola enlarged, no contour separation </td></tr><tr><td> 4. Areola and papilla form secondary mound </td></tr><tr><td> 5. Mature; nipple projects, areola part of general breast contour </td></tr><tr><td>For penis and testes: </td></tr><tr><td> 1. Prepubertal, testicular volume &lt;4 mL </td></tr><tr><td> 2. Slight enlargement of penis; enlarged scrotum, pink, texture altered, testes 4–6 mL </td></tr><tr><td> 3. Penis longer, testes larger (8–12 mL) </td></tr><tr><td> 4. Penis and glans larger, including increase in breadth; testes larger (12–15 mL), scrotum dark </td></tr><tr><td> 5. Penis adult size; testicular volume &gt; 15 ml </td></tr></tbody></table></div><div class=\"table-wrap-foot\"><span id=\"fn-fn-04\"></span><div content-id=\"fn-04\" class=\"footnote\"><span class=\"fn\"><p class=\"chapter-para\">Adapted from Lawrence (<span class=\"xrefLink\" id=\"jumplink-B56\"></span><a href=\"javascript:;\" reveal-id=\"B56\" data-open=\"B56\" class=\"link link-ref link-reveal xref-bibr\">56</a>).</p></span></div></div><div class=\"&#xA;          graphic-wrap&#xA;          \"><a class=\"fig-view-orig openInAnotherWindow btn js-view-large\" target=\"_blank\" href=\"/view-large/99603328\">\r\n          Open in new tab\r\n        </a></div></div></div><div class=\"table-full-width-wrap\"><div class=\"table-wrap table-wide\"><div class=\"table-wrap-title\" id=\"T6\" data-id=\"T6\"><span class=\"label\">Table 6.</span><div class=\"caption\"><p class=\"chapter-para\">Tanner Stages of Breast Development and Male External Genitalia</p></div> </div><div class=\"table-overflow\"><table><tbody><tr><td>The description of Tanner stages for breast development: </td></tr><tr><td> 1. Prepubertal </td></tr><tr><td> 2. Breast and papilla elevated as small mound; areolar diameter increased </td></tr><tr><td> 3. Breast and areola enlarged, no contour separation </td></tr><tr><td> 4. Areola and papilla form secondary mound </td></tr><tr><td> 5. Mature; nipple projects, areola part of general breast contour </td></tr><tr><td>For penis and testes: </td></tr><tr><td> 1. Prepubertal, testicular volume &lt;4 mL </td></tr><tr><td> 2. Slight enlargement of penis; enlarged scrotum, pink, texture altered, testes 4–6 mL </td></tr><tr><td> 3. Penis longer, testes larger (8–12 mL) </td></tr><tr><td> 4. Penis and glans larger, including increase in breadth; testes larger (12–15 mL), scrotum dark </td></tr><tr><td> 5. Penis adult size; testicular volume &gt; 15 ml </td></tr></tbody></table></div><div class=\"table-modal\"><table><tbody><tr><td>The description of Tanner stages for breast development: </td></tr><tr><td> 1. Prepubertal </td></tr><tr><td> 2. Breast and papilla elevated as small mound; areolar diameter increased </td></tr><tr><td> 3. Breast and areola enlarged, no contour separation </td></tr><tr><td> 4. Areola and papilla form secondary mound </td></tr><tr><td> 5. Mature; nipple projects, areola part of general breast contour </td></tr><tr><td>For penis and testes: </td></tr><tr><td> 1. Prepubertal, testicular volume &lt;4 mL </td></tr><tr><td> 2. Slight enlargement of penis; enlarged scrotum, pink, texture altered, testes 4–6 mL </td></tr><tr><td> 3. Penis longer, testes larger (8–12 mL) </td></tr><tr><td> 4. Penis and glans larger, including increase in breadth; testes larger (12–15 mL), scrotum dark </td></tr><tr><td> 5. Penis adult size; testicular volume &gt; 15 ml </td></tr></tbody></table></div><div class=\"table-wrap-foot\"><span id=\"fn-fn-04\"></span><div content-id=\"fn-04\" class=\"footnote\"><span class=\"fn\"><p class=\"chapter-para\">Adapted from Lawrence (<span class=\"xrefLink\" id=\"jumplink-B56\"></span><a href=\"javascript:;\" reveal-id=\"B56\" data-open=\"B56\" class=\"link link-ref link-reveal xref-bibr\">56</a>).</p></span></div></div><div class=\"&#xA;          graphic-wrap&#xA;          \"><a class=\"fig-view-orig openInAnotherWindow btn js-view-large\" target=\"_blank\" href=\"/view-large/99603328\">\r\n          Open in new tab\r\n        </a></div></div></div><p class=\"chapter-para\">Irreversible and, for GD/gender-incongruent adolescents, undesirable sex characteristics in female puberty are breasts, female body habitus, and, in some cases, relative short stature. In male puberty, they are a prominent Adam’s apple; low voice; male bone configuration, such as a large jaw, big feet and hands, and tall stature; and male hair pattern on the face and extremities.</p><ul class=\"list-simple\"><li><p class=\"chapter-para\">2.3. We recommend that, where indicated, GnRH analogues are used to suppress pubertal hormones. (1 |⊕⊕○○)</p></li></ul>                    <h3 scrollto-destination=99603331 id=\"99603331\" class=\"section-title js-splitscreen-section-title\" data-legacy-id=s33>Evidence</h3>\r\n<p class=\"chapter-para\">Clinicians can suppress pubertal development and gonadal function most effectively via gonadotropin suppression using GnRH analogs. GnRH analogs are long-acting agonists that suppress gonadotropins by GnRH receptor desensitization after an initial increase of gonadotropins during ∼10 days after the first and (to a lesser degree) the second injection (<span class=\"xrefLink\" id=\"jumplink-B89\"></span><a href=\"javascript:;\" reveal-id=\"B89\" data-open=\"B89\" class=\"link link-ref link-reveal xref-bibr\">89</a>). Antagonists immediately suppress pituitary gonadotropin secretion (<span class=\"xrefLink\" id=\"jumplink-B90\"></span><a href=\"javascript:;\" reveal-id=\"B90\" data-open=\"B90\" class=\"link link-ref link-reveal xref-bibr\">90</a>, <span class=\"xrefLink\" id=\"jumplink-B91\"></span><a href=\"javascript:;\" reveal-id=\"B91\" data-open=\"B91\" class=\"link link-ref link-reveal xref-bibr\">91</a>). Long-acting GnRH analogs are the currently preferred treatment option. Clinicians may consider long-acting GnRH antagonists when evidence on their safety and efficacy in adolescents becomes available.</p><p class=\"chapter-para\">During GnRH analog treatment, slight development of secondary sex characteristics may regress, and in a later phase of pubertal development, it will stop. In girls, breast tissue will become atrophic, and menses will stop. In boys, virilization will stop, and testicular volume may decrease (<span class=\"xrefLink\" id=\"jumplink-B92\"></span><a href=\"javascript:;\" reveal-id=\"B92\" data-open=\"B92\" class=\"link link-ref link-reveal xref-bibr\">92</a>).</p><p class=\"chapter-para\">An advantage of using GnRH analogs is the reversibility of the intervention. If, after extensive exploration of his/her transition wish, the individual no longer desires transition, they can discontinue pubertal suppression. In subjects with precocious puberty, spontaneous pubertal development has been shown to resume after patients discontinue taking GnRH analogs (<span class=\"xrefLink\" id=\"jumplink-B93\"></span><a href=\"javascript:;\" reveal-id=\"B93\" data-open=\"B93\" class=\"link link-ref link-reveal xref-bibr\">93</a>).</p><p class=\"chapter-para\">Recommendations 2.1 to 2.3 are supported by a prospective follow-up study from The Netherlands. This report assessed mental health outcomes in 55 transgender adolescents/young adults (22 transgender females and 33 transgender males) at three time points: (1) before the start of GnRH agonist (average age of 14.8 years at start of treatment), (2) at initiation of gender-affirming hormones (average age of 16.7 years at start of treatment), and (3) 1 year after “gender-reassignment surgery” (average age of 20.7 years) (<span class=\"xrefLink\" id=\"jumplink-B63\"></span><a href=\"javascript:;\" reveal-id=\"B63\" data-open=\"B63\" class=\"link link-ref link-reveal xref-bibr\">63</a>). Despite a decrease in depression and an improvement in general mental health functioning, GD/gender incongruence persisted through pubertal suppression, as previously reported (<span class=\"xrefLink\" id=\"jumplink-B86\"></span><a href=\"javascript:;\" reveal-id=\"B86\" data-open=\"B86\" class=\"link link-ref link-reveal xref-bibr\">86</a>). However, following sex hormone treatment and gender-reassignment surgery, GD/gender incongruence was resolved and psychological functioning steadily improved (<span class=\"xrefLink\" id=\"jumplink-B63\"></span><a href=\"javascript:;\" reveal-id=\"B63\" data-open=\"B63\" class=\"link link-ref link-reveal xref-bibr\">63</a>). Furthermore, well-being was similar to or better than that reported by age-matched young adults from the general population, and none of the study participants regretted treatment. This study represents the first long-term follow-up of individuals managed according to currently existing clinical practice guidelines for transgender youth, and it underscores the benefit of the multidisciplinary approach pioneered in The Netherlands; however, further studies are needed.</p>                    <h3 scrollto-destination=99603336 id=\"99603336\" class=\"section-title js-splitscreen-section-title\" data-legacy-id=s34>Side effects</h3>\r\n<p class=\"chapter-para\">The primary risks of pubertal suppression in GD/gender-incongruent adolescents may include adverse effects on bone mineralization (which can theoretically be reversed with sex hormone treatment), compromised fertility if the person subsequently is treated with sex hormones, and unknown effects on brain development. Few data are available on the effect of GnRH analogs on BMD in adolescents with GD/gender incongruence. Initial data in GD/gender-incongruent subjects demonstrated no change of absolute areal BMD during 2 years of GnRH analog therapy but a decrease in BMD <em>z</em> scores (<span class=\"xrefLink\" id=\"jumplink-B85\"></span><a href=\"javascript:;\" reveal-id=\"B85\" data-open=\"B85\" class=\"link link-ref link-reveal xref-bibr\">85</a>). A recent study also suggested suboptimal bone mineral accrual during GnRH analog treatment. The study reported a decrease in areal BMD <em>z</em> scores and of bone mineral apparent density <em>z</em> scores (which takes the size of the bone into account) in 19 transgender males treated with GnRH analogs from a mean age of 15.0 years (standard deviation = 2.0 years) for a median duration of 1.5 years (0.3 to 5.2 years) and in 15 transgender females treated from 14.9 (±1.9) years for 1.3 years (0.5 to 3.8 years), although not all changes were statistically significant (<span class=\"xrefLink\" id=\"jumplink-B94\"></span><a href=\"javascript:;\" reveal-id=\"B94\" data-open=\"B94\" class=\"link link-ref link-reveal xref-bibr\">94</a>). There was incomplete catch-up at age 22 years after sex hormone treatment from age 16.6 (±1.4) years for a median duration of 5.8 years (3.0 to 8.0 years) in transgender females and from age 16.4 (±2.3) years for 5.4 years (2.8 to 7.8 years) in transgender males. Little is known about more prolonged use of GnRH analogs. Researchers reported normal BMD <em>z</em> scores at age 35 years in one individual who used GnRH analogs from age 13.7 years until age 18.6 years before initiating sex hormone treatment (<span class=\"xrefLink\" id=\"jumplink-B65\"></span><a href=\"javascript:;\" reveal-id=\"B65\" data-open=\"B65\" class=\"link link-ref link-reveal xref-bibr\">65</a>).</p><p class=\"chapter-para\">Additional data are available from individuals with late puberty or GnRH analog treatment of other indications. Some studies reported that men with constitutionally delayed puberty have decreased BMD in adulthood (<span class=\"xrefLink\" id=\"jumplink-B95\"></span><a href=\"javascript:;\" reveal-id=\"B95\" data-open=\"B95\" class=\"link link-ref link-reveal xref-bibr\">95</a>). However, other studies reported that these men have normal BMD (<span class=\"xrefLink\" id=\"jumplink-B96\"></span><a href=\"javascript:;\" reveal-id=\"B96\" data-open=\"B96\" class=\"link link-ref link-reveal xref-bibr\">96</a>, <span class=\"xrefLink\" id=\"jumplink-B97\"></span><a href=\"javascript:;\" reveal-id=\"B97\" data-open=\"B97\" class=\"link link-ref link-reveal xref-bibr\">97</a>). Treating adults with GnRH analogs results in a decrease of BMD (<span class=\"xrefLink\" id=\"jumplink-B98\"></span><a href=\"javascript:;\" reveal-id=\"B98\" data-open=\"B98\" class=\"link link-ref link-reveal xref-bibr\">98</a>). In children with central precocious puberty, treatment with GnRH analogs has been found to result in a decrease of BMD during treatment by some (<span class=\"xrefLink\" id=\"jumplink-B99\"></span><a href=\"javascript:;\" reveal-id=\"B99\" data-open=\"B99\" class=\"link link-ref link-reveal xref-bibr\">99</a>) but not others (<span class=\"xrefLink\" id=\"jumplink-B100\"></span><a href=\"javascript:;\" reveal-id=\"B100\" data-open=\"B100\" class=\"link link-ref link-reveal xref-bibr\">100</a>). Studies have reported normal BMD after discontinuing therapy (<span class=\"xrefLink\" id=\"jumplink-B69\"></span><a href=\"javascript:;\" reveal-id=\"B69\" data-open=\"B69\" class=\"link link-ref link-reveal xref-bibr\">69</a>, <span class=\"xrefLink\" id=\"jumplink-B72\"></span><a href=\"javascript:;\" reveal-id=\"B72\" data-open=\"B72\" class=\"link link-ref link-reveal xref-bibr\">72</a>, <span class=\"xrefLink\" id=\"jumplink-B73\"></span><a href=\"javascript:;\" reveal-id=\"B73\" data-open=\"B73\" class=\"link link-ref link-reveal xref-bibr\">73</a>, <span class=\"xrefLink\" id=\"jumplink-B101\"></span><a href=\"javascript:;\" reveal-id=\"B101\" data-open=\"B101\" class=\"link link-ref link-reveal xref-bibr\">101</a>, <span class=\"xrefLink\" id=\"jumplink-B102\"></span><a href=\"javascript:;\" reveal-id=\"B102\" data-open=\"B102\" class=\"link link-ref link-reveal xref-bibr\">102</a>). In adolescents treated with growth hormone who are small for gestational age and have normal pubertal timing, 2-year GnRH analog treatments did not adversely affect BMD (<span class=\"xrefLink\" id=\"jumplink-B103\"></span><a href=\"javascript:;\" reveal-id=\"B103\" data-open=\"B103\" class=\"link link-ref link-reveal xref-bibr\">103</a>). Calcium supplementation may be beneficial in optimizing bone health in GnRH analog–treated individuals (<span class=\"xrefLink\" id=\"jumplink-B104\"></span><a href=\"javascript:;\" reveal-id=\"B104\" data-open=\"B104\" class=\"link link-ref link-reveal xref-bibr\">104</a>). There are no studies of vitamin D supplementation in this context, but clinicians should offer supplements to vitamin D–deficient adolescents. Physical activity, especially during growth, is important for bone mass in healthy individuals (<span class=\"xrefLink\" id=\"jumplink-B103\"></span><a href=\"javascript:;\" reveal-id=\"B103\" data-open=\"B103\" class=\"link link-ref link-reveal xref-bibr\">103</a>) and is therefore likely to be beneficial for bone health in GnRH analog–treated subjects.</p><p class=\"chapter-para\">GnRH analogs did not induce a change in body mass index standard deviation score in GD/gender-incongruent adolescents (<span class=\"xrefLink\" id=\"jumplink-B94\"></span><a href=\"javascript:;\" reveal-id=\"B94\" data-open=\"B94\" class=\"link link-ref link-reveal xref-bibr\">94</a>) but caused an increase in fat mass and decrease in lean body mass percentage (<span class=\"xrefLink\" id=\"jumplink-B92\"></span><a href=\"javascript:;\" reveal-id=\"B92\" data-open=\"B92\" class=\"link link-ref link-reveal xref-bibr\">92</a>). Studies in girls treated for precocious puberty also reported a stable body mass index standard deviation score during treatment (<span class=\"xrefLink\" id=\"jumplink-B72\"></span><a href=\"javascript:;\" reveal-id=\"B72\" data-open=\"B72\" class=\"link link-ref link-reveal xref-bibr\">72</a>) and body mass index and body composition comparable to controls after treatment (<span class=\"xrefLink\" id=\"jumplink-B73\"></span><a href=\"javascript:;\" reveal-id=\"B73\" data-open=\"B73\" class=\"link link-ref link-reveal xref-bibr\">73</a>).</p><p class=\"chapter-para\">Arterial hypertension has been reported as an adverse effect in a few girls treated with GnRH analogs for precocious/early puberty (<span class=\"xrefLink\" id=\"jumplink-B105\"></span><a href=\"javascript:;\" reveal-id=\"B105\" data-open=\"B105\" class=\"link link-ref link-reveal xref-bibr\">105</a>, <span class=\"xrefLink\" id=\"jumplink-B106\"></span><a href=\"javascript:;\" reveal-id=\"B106\" data-open=\"B106\" class=\"link link-ref link-reveal xref-bibr\">106</a>). Blood pressure monitoring before and during treatment is recommended.</p><p class=\"chapter-para\">Individuals may also experience hot flashes, fatigue, and mood alterations as a consequence of pubertal suppression. There is no consensus on treatment of these side effects in this context.</p><p class=\"chapter-para\">It is recommended that any use of pubertal blockers (and subsequent use of sex hormones, as detailed below) include a discussion about implications for fertility (see recommendation 1.3). Transgender adolescents may want to preserve fertility, which may be otherwise compromised if puberty is suppressed at an early stage and the individual completes phenotypic transition with the use of sex hormones.</p><p class=\"chapter-para\">Limited data are available regarding the effects of GnRH analogs on brain development. A single cross-sectional study demonstrated no compromise of executive function (<span class=\"xrefLink\" id=\"jumplink-B107\"></span><a href=\"javascript:;\" reveal-id=\"B107\" data-open=\"B107\" class=\"link link-ref link-reveal xref-bibr\">107</a>), but animal data suggest there may be an effect of GnRH analogs on cognitive function (<span class=\"xrefLink\" id=\"jumplink-B108\"></span><a href=\"javascript:;\" reveal-id=\"B108\" data-open=\"B108\" class=\"link link-ref link-reveal xref-bibr\">108</a>).</p>                    <h3 scrollto-destination=99603344 id=\"99603344\" class=\"section-title js-splitscreen-section-title\" data-legacy-id=s35>Values and preferences</h3>\r\n<p class=\"chapter-para\">Our recommendation of GnRH analogs places a higher value on the superior efficacy, safety, and reversibility of the pubertal hormone suppression achieved (as compared with the alternatives) and a relatively lower value on limiting the cost of therapy. Of the available alternatives, depot and oral progestin preparations are effective. Experience with this treatment dates back prior to the emergence of GnRH analogs for treating precocious puberty in papers from the 1960s and early 1970s (<span class=\"xrefLink\" id=\"jumplink-B109\"></span><a href=\"javascript:;\" reveal-id=\"B109\" data-open=\"B109\" class=\"link link-ref link-reveal xref-bibr\">109</a>–<span class=\"xrefLink\" id=\"jumplink-B112\"></span><a href=\"javascript:;\" reveal-id=\"B112\" data-open=\"B112\" class=\"link link-ref link-reveal xref-bibr\">112</a>). These compounds are usually safe, but some side effects have been reported (<span class=\"xrefLink\" id=\"jumplink-B113\"></span><a href=\"javascript:;\" reveal-id=\"B113\" data-open=\"B113\" class=\"link link-ref link-reveal xref-bibr\">113</a>–<span class=\"xrefLink\" id=\"jumplink-B115\"></span><a href=\"javascript:;\" reveal-id=\"B115\" data-open=\"B115\" class=\"link link-ref link-reveal xref-bibr\">115</a>). Only two recent studies involved transgender youth (<span class=\"xrefLink\" id=\"jumplink-B116\"></span><a href=\"javascript:;\" reveal-id=\"B116\" data-open=\"B116\" class=\"link link-ref link-reveal xref-bibr\">116</a>, <span class=\"xrefLink\" id=\"jumplink-B117\"></span><a href=\"javascript:;\" reveal-id=\"B117\" data-open=\"B117\" class=\"link link-ref link-reveal xref-bibr\">117</a>). One of these studies described the use of oral lynestrenol monotherapy followed by the addition of testosterone treatment in transgender boys who were at Tanner stage B4 or further at the start of treatment (<span class=\"xrefLink\" id=\"jumplink-B117\"></span><a href=\"javascript:;\" reveal-id=\"B117\" data-open=\"B117\" class=\"link link-ref link-reveal xref-bibr\">117</a>). They found lynestrenol safe, but gonadotropins were not fully suppressed. The study reported metrorrhagia in approximately half of the individuals, mainly in the first 6 months. Acne, headache, hot flashes, and fatigue were other frequent side effects. Another progestin that has been studied in the United States is medroxyprogesterone. This agent is not as effective as GnRH analogs in lowering endogenous sex hormones either and may be associated with other side effects (<span class=\"xrefLink\" id=\"jumplink-B116\"></span><a href=\"javascript:;\" reveal-id=\"B116\" data-open=\"B116\" class=\"link link-ref link-reveal xref-bibr\">116</a>). Progestin preparations may be an acceptable treatment for persons without access to GnRH analogs or with a needle phobia. If GnRH analog treatment is not available (insurance denial, prohibitive cost, or other reasons), postpubertal, transgender female adolescents may be treated with an antiandrogen that directly suppresses androgen synthesis or action (see adult section).</p>                    <h3 scrollto-destination=99603346 id=\"99603346\" class=\"section-title js-splitscreen-section-title\" data-legacy-id=s36>Remarks</h3>\r\n<p class=\"chapter-para\">Measurements of gonadotropin and sex steroid levels give precise information about gonadal axis suppression, although there is insufficient evidence for any specific short-term monitoring scheme in children treated with GnRH analogs (<span class=\"xrefLink\" id=\"jumplink-B88\"></span><a href=\"javascript:;\" reveal-id=\"B88\" data-open=\"B88\" class=\"link link-ref link-reveal xref-bibr\">88</a>). If the gonadal axis is not completely suppressed—as evidenced by (for example) menses, erections, or progressive hair growth—the interval of GnRH analog treatment can be shortened or the dose increased. During treatment, adolescents should be monitored for negative effects of delaying puberty, including a halted growth spurt and impaired bone mineral accretion. <span class=\"xrefLink\" id=\"jumplink-T7\"></span><a href=\"javascript:;\" reveal-id=\"T7\" data-open=\"T7\" class=\"link link-reveal link-table xref-fig\">Table 7</a> illustrates a suggested clinical protocol.</p>                    <a id=\"99603348\" scrollto-destination=\"99603348\"></a>\r\n<div content-id=\"T7\" class=\"table-modal table-full-width-wrap\"><div class=\"table-wrap table-wide\"><div class=\"table-wrap-title\" id=\"T7\" data-id=\"T7\"><span class=\"label\">Table 7.</span><div class=\"caption\"><p class=\"chapter-para\">Baseline and Follow-Up Protocol During Suppression of Puberty</p></div> </div><div class=\"table-overflow\"><table><tbody><tr><td>Every 3–6 mo </td></tr><tr><td> Anthropometry: height, weight, sitting height, blood pressure, Tanner stages </td></tr><tr><td>Every 6–12 mo </td></tr><tr><td> Laboratory: LH, FSH, E2/T, 25OH vitamin D </td></tr><tr><td>Every 1–2 y </td></tr><tr><td> Bone density using DXA </td></tr><tr><td> Bone age on X-ray of the left hand (if clinically indicated) </td></tr></tbody></table></div><div class=\"table-modal\"><table><tbody><tr><td>Every 3–6 mo </td></tr><tr><td> Anthropometry: height, weight, sitting height, blood pressure, Tanner stages </td></tr><tr><td>Every 6–12 mo </td></tr><tr><td> Laboratory: LH, FSH, E2/T, 25OH vitamin D </td></tr><tr><td>Every 1–2 y </td></tr><tr><td> Bone density using DXA </td></tr><tr><td> Bone age on X-ray of the left hand (if clinically indicated) </td></tr></tbody></table></div><div class=\"table-wrap-foot\"><span id=\"fn-fn-05\"></span><div content-id=\"fn-05\" class=\"footnote\"><span class=\"fn\"><p class=\"chapter-para\">Adapted from Hembree <em>et al.</em> (<span class=\"xrefLink\" id=\"jumplink-B118\"></span><a href=\"javascript:;\" reveal-id=\"B118\" data-open=\"B118\" class=\"link link-ref link-reveal xref-bibr\">118</a>).</p><p class=\"chapter-para\">Abbreviations: DXA, dual-energy X-ray absorptiometry; E2, estradiol; FSH, follicle stimulating hormone; LH, luteinizing hormone; T, testosterone; </p></span></div></div><div class=\"&#xA;          graphic-wrap&#xA;          \"><a class=\"fig-view-orig openInAnotherWindow btn js-view-large\" target=\"_blank\" href=\"/view-large/99603348\">\r\n          Open in new tab\r\n        </a></div></div></div><div class=\"table-full-width-wrap\"><div class=\"table-wrap table-wide\"><div class=\"table-wrap-title\" id=\"T7\" data-id=\"T7\"><span class=\"label\">Table 7.</span><div class=\"caption\"><p class=\"chapter-para\">Baseline and Follow-Up Protocol During Suppression of Puberty</p></div> </div><div class=\"table-overflow\"><table><tbody><tr><td>Every 3–6 mo </td></tr><tr><td> Anthropometry: height, weight, sitting height, blood pressure, Tanner stages </td></tr><tr><td>Every 6–12 mo </td></tr><tr><td> Laboratory: LH, FSH, E2/T, 25OH vitamin D </td></tr><tr><td>Every 1–2 y </td></tr><tr><td> Bone density using DXA </td></tr><tr><td> Bone age on X-ray of the left hand (if clinically indicated) </td></tr></tbody></table></div><div class=\"table-modal\"><table><tbody><tr><td>Every 3–6 mo </td></tr><tr><td> Anthropometry: height, weight, sitting height, blood pressure, Tanner stages </td></tr><tr><td>Every 6–12 mo </td></tr><tr><td> Laboratory: LH, FSH, E2/T, 25OH vitamin D </td></tr><tr><td>Every 1–2 y </td></tr><tr><td> Bone density using DXA </td></tr><tr><td> Bone age on X-ray of the left hand (if clinically indicated) </td></tr></tbody></table></div><div class=\"table-wrap-foot\"><span id=\"fn-fn-05\"></span><div content-id=\"fn-05\" class=\"footnote\"><span class=\"fn\"><p class=\"chapter-para\">Adapted from Hembree <em>et al.</em> (<span class=\"xrefLink\" id=\"jumplink-B118\"></span><a href=\"javascript:;\" reveal-id=\"B118\" data-open=\"B118\" class=\"link link-ref link-reveal xref-bibr\">118</a>).</p><p class=\"chapter-para\">Abbreviations: DXA, dual-energy X-ray absorptiometry; E2, estradiol; FSH, follicle stimulating hormone; LH, luteinizing hormone; T, testosterone; </p></span></div></div><div class=\"&#xA;          graphic-wrap&#xA;          \"><a class=\"fig-view-orig openInAnotherWindow btn js-view-large\" target=\"_blank\" href=\"/view-large/99603348\">\r\n          Open in new tab\r\n        </a></div></div></div><p class=\"chapter-para\">Anthropometric measurements and X-rays of the left hand to monitor bone age are informative for evaluating growth. To assess BMD, clinicians can perform dual-energy X-ray absorptiometry scans.</p><ul class=\"list-simple\"><li><p class=\"chapter-para\">2.4. In adolescents who request sex hormone treatment (given this is a partly irreversible treatment), we recommend initiating treatment using a gradually increasing dose schedule (see <span class=\"xrefLink\" id=\"jumplink-T8\"></span><a href=\"javascript:;\" reveal-id=\"T8\" data-open=\"T8\" class=\"link link-reveal link-table xref-fig\">Table 8)</a>after a multidisciplinary team of medical and MHPs has confirmed the persistence of GD/gender incongruence and sufficient mental capacity to give informed consent, which most adolescents have by age 16 years (<span class=\"xrefLink\" id=\"jumplink-T5\"></span><a href=\"javascript:;\" reveal-id=\"T5\" data-open=\"T5\" class=\"link link-reveal link-table xref-fig\">Table 5</a>). (1 |⊕⊕○○)<span id=\"T8\"></span><div content-id=\"T8\" class=\"table-modal\"><div class=\"table-wrap table-wide\"><div class=\"table-wrap-title\" id=\"T8\" data-id=\"T8\"><span class=\"label\">Table 8.</span><div class=\"caption\"><p class=\"chapter-para\">Protocol Induction of Puberty</p></div> </div><div class=\"table-overflow\"><table><tbody><tr><td>Induction of female puberty with oral 17<em>β</em>-estradiol, increasing the dose every 6 mo: </td></tr><tr><td> 5 μg/kg/d </td></tr><tr><td> 10 μg/kg/d </td></tr><tr><td> 15 μg/kg/d </td></tr><tr><td> 20 μg/kg/d </td></tr><tr><td> Adult dose = 2–6 mg/d </td></tr><tr><td><em> In postpubertal transgender female adolescents, the dose of 17</em>β<em>-estradiol can be increased more rapidly:</em> </td></tr><tr><td>  1 mg/d for 6 mo </td></tr><tr><td>  2 mg/d </td></tr><tr><td>Induction of female puberty with transdermal 17<em>β</em>-estradiol, increasing the dose every 6 mo (new patch is placed every 3.5 d): </td></tr><tr><td> 6.25–12.5 μg/24 h (cut 25-μg patch into quarters, then halves) </td></tr><tr><td> 25 μg/24 h </td></tr><tr><td> 37.5 μg/24 h </td></tr><tr><td> Adult dose = 50–200 μg/24 h </td></tr><tr><td><em> For alternatives once at adult dose, see Table 11.</em> </td></tr><tr><td><em> Adjust maintenance dose to mimic physiological estradiol levels (see Table 15).</em> </td></tr><tr><td> </td></tr><tr><td>Induction of male puberty with testosterone esters increasing the dose every 6 mo (IM or SC): </td></tr><tr><td> 25 mg/m<sup>2</sup>/2 wk (or alternatively, half this dose weekly, or double the dose every 4 wk) </td></tr><tr><td> 50 mg/m<sup>2</sup>/2 wk </td></tr><tr><td> 75 mg/m<sup>2</sup>/2 wk </td></tr><tr><td> 100 mg/m<sup>2</sup>/2 wk </td></tr><tr><td> Adult dose = 100–200 mg every 2 wk </td></tr><tr><td><em> In postpubertal transgender male adolescents the dose of testosterone esters can be increased more rapidly:</em> </td></tr><tr><td>  75 mg/2 wk for 6 mo </td></tr><tr><td>  125 mg/2 wk </td></tr><tr><td><em> For alternatives once at adult dose, see Table 11.</em> </td></tr><tr><td><em> Adjust maintenance dose to mimic physiological testosterone levels (see Table 14).</em> </td></tr></tbody></table></div><div class=\"table-modal\"><table><tbody><tr><td>Induction of female puberty with oral 17<em>β</em>-estradiol, increasing the dose every 6 mo: </td></tr><tr><td> 5 μg/kg/d </td></tr><tr><td> 10 μg/kg/d </td></tr><tr><td> 15 μg/kg/d </td></tr><tr><td> 20 μg/kg/d </td></tr><tr><td> Adult dose = 2–6 mg/d </td></tr><tr><td><em> In postpubertal transgender female adolescents, the dose of 17</em>β<em>-estradiol can be increased more rapidly:</em> </td></tr><tr><td>  1 mg/d for 6 mo </td></tr><tr><td>  2 mg/d </td></tr><tr><td>Induction of female puberty with transdermal 17<em>β</em>-estradiol, increasing the dose every 6 mo (new patch is placed every 3.5 d): </td></tr><tr><td> 6.25–12.5 μg/24 h (cut 25-μg patch into quarters, then halves) </td></tr><tr><td> 25 μg/24 h </td></tr><tr><td> 37.5 μg/24 h </td></tr><tr><td> Adult dose = 50–200 μg/24 h </td></tr><tr><td><em> For alternatives once at adult dose, see Table 11.</em> </td></tr><tr><td><em> Adjust maintenance dose to mimic physiological estradiol levels (see Table 15).</em> </td></tr><tr><td> </td></tr><tr><td>Induction of male puberty with testosterone esters increasing the dose every 6 mo (IM or SC): </td></tr><tr><td> 25 mg/m<sup>2</sup>/2 wk (or alternatively, half this dose weekly, or double the dose every 4 wk) </td></tr><tr><td> 50 mg/m<sup>2</sup>/2 wk </td></tr><tr><td> 75 mg/m<sup>2</sup>/2 wk </td></tr><tr><td> 100 mg/m<sup>2</sup>/2 wk </td></tr><tr><td> Adult dose = 100–200 mg every 2 wk </td></tr><tr><td><em> In postpubertal transgender male adolescents the dose of testosterone esters can be increased more rapidly:</em> </td></tr><tr><td>  75 mg/2 wk for 6 mo </td></tr><tr><td>  125 mg/2 wk </td></tr><tr><td><em> For alternatives once at adult dose, see Table 11.</em> </td></tr><tr><td><em> Adjust maintenance dose to mimic physiological testosterone levels (see Table 14).</em> </td></tr></tbody></table></div><div class=\"table-wrap-foot\"><span id=\"fn-fn-06\"></span><div content-id=\"fn-06\" class=\"footnote\"><span class=\"fn\"><p class=\"chapter-para\">Adapted from Hembree <em>et al.</em> (<span class=\"xrefLink\" id=\"jumplink-B118\"></span><a href=\"javascript:;\" reveal-id=\"B118\" data-open=\"B118\" class=\"link link-ref link-reveal xref-bibr\">118</a>).</p><p class=\"chapter-para\">Abbreviations: IM, intramuscularly; SC, subcutaneously.</p></span></div></div><div class=\"&#xA;          graphic-wrap&#xA;           hide\"><a class=\"fig-view-orig openInAnotherWindow btn js-view-large\" target=\"_blank\" href=\"/view-large/\">\r\n          Open in new tab\r\n        </a></div></div></div><div class=\"table-wrap table-wide\"><div class=\"table-wrap-title\" id=\"T8\" data-id=\"T8\"><span class=\"label\">Table 8.</span><div class=\"caption\"><p class=\"chapter-para\">Protocol Induction of Puberty</p></div> </div><div class=\"table-overflow\"><table><tbody><tr><td>Induction of female puberty with oral 17<em>β</em>-estradiol, increasing the dose every 6 mo: </td></tr><tr><td> 5 μg/kg/d </td></tr><tr><td> 10 μg/kg/d </td></tr><tr><td> 15 μg/kg/d </td></tr><tr><td> 20 μg/kg/d </td></tr><tr><td> Adult dose = 2–6 mg/d </td></tr><tr><td><em> In postpubertal transgender female adolescents, the dose of 17</em>β<em>-estradiol can be increased more rapidly:</em> </td></tr><tr><td>  1 mg/d for 6 mo </td></tr><tr><td>  2 mg/d </td></tr><tr><td>Induction of female puberty with transdermal 17<em>β</em>-estradiol, increasing the dose every 6 mo (new patch is placed every 3.5 d): </td></tr><tr><td> 6.25–12.5 μg/24 h (cut 25-μg patch into quarters, then halves) </td></tr><tr><td> 25 μg/24 h </td></tr><tr><td> 37.5 μg/24 h </td></tr><tr><td> Adult dose = 50–200 μg/24 h </td></tr><tr><td><em> For alternatives once at adult dose, see Table 11.</em> </td></tr><tr><td><em> Adjust maintenance dose to mimic physiological estradiol levels (see Table 15).</em> </td></tr><tr><td> </td></tr><tr><td>Induction of male puberty with testosterone esters increasing the dose every 6 mo (IM or SC): </td></tr><tr><td> 25 mg/m<sup>2</sup>/2 wk (or alternatively, half this dose weekly, or double the dose every 4 wk) </td></tr><tr><td> 50 mg/m<sup>2</sup>/2 wk </td></tr><tr><td> 75 mg/m<sup>2</sup>/2 wk </td></tr><tr><td> 100 mg/m<sup>2</sup>/2 wk </td></tr><tr><td> Adult dose = 100–200 mg every 2 wk </td></tr><tr><td><em> In postpubertal transgender male adolescents the dose of testosterone esters can be increased more rapidly:</em> </td></tr><tr><td>  75 mg/2 wk for 6 mo </td></tr><tr><td>  125 mg/2 wk </td></tr><tr><td><em> For alternatives once at adult dose, see Table 11.</em> </td></tr><tr><td><em> Adjust maintenance dose to mimic physiological testosterone levels (see Table 14).</em> </td></tr></tbody></table></div><div class=\"table-modal\"><table><tbody><tr><td>Induction of female puberty with oral 17<em>β</em>-estradiol, increasing the dose every 6 mo: </td></tr><tr><td> 5 μg/kg/d </td></tr><tr><td> 10 μg/kg/d </td></tr><tr><td> 15 μg/kg/d </td></tr><tr><td> 20 μg/kg/d </td></tr><tr><td> Adult dose = 2–6 mg/d </td></tr><tr><td><em> In postpubertal transgender female adolescents, the dose of 17</em>β<em>-estradiol can be increased more rapidly:</em> </td></tr><tr><td>  1 mg/d for 6 mo </td></tr><tr><td>  2 mg/d </td></tr><tr><td>Induction of female puberty with transdermal 17<em>β</em>-estradiol, increasing the dose every 6 mo (new patch is placed every 3.5 d): </td></tr><tr><td> 6.25–12.5 μg/24 h (cut 25-μg patch into quarters, then halves) </td></tr><tr><td> 25 μg/24 h </td></tr><tr><td> 37.5 μg/24 h </td></tr><tr><td> Adult dose = 50–200 μg/24 h </td></tr><tr><td><em> For alternatives once at adult dose, see Table 11.</em> </td></tr><tr><td><em> Adjust maintenance dose to mimic physiological estradiol levels (see Table 15).</em> </td></tr><tr><td> </td></tr><tr><td>Induction of male puberty with testosterone esters increasing the dose every 6 mo (IM or SC): </td></tr><tr><td> 25 mg/m<sup>2</sup>/2 wk (or alternatively, half this dose weekly, or double the dose every 4 wk) </td></tr><tr><td> 50 mg/m<sup>2</sup>/2 wk </td></tr><tr><td> 75 mg/m<sup>2</sup>/2 wk </td></tr><tr><td> 100 mg/m<sup>2</sup>/2 wk </td></tr><tr><td> Adult dose = 100–200 mg every 2 wk </td></tr><tr><td><em> In postpubertal transgender male adolescents the dose of testosterone esters can be increased more rapidly:</em> </td></tr><tr><td>  75 mg/2 wk for 6 mo </td></tr><tr><td>  125 mg/2 wk </td></tr><tr><td><em> For alternatives once at adult dose, see Table 11.</em> </td></tr><tr><td><em> Adjust maintenance dose to mimic physiological testosterone levels (see Table 14).</em> </td></tr></tbody></table></div><div class=\"table-wrap-foot\"><span id=\"fn-fn-06\"></span><div content-id=\"fn-06\" class=\"footnote\"><span class=\"fn\"><p class=\"chapter-para\">Adapted from Hembree <em>et al.</em> (<span class=\"xrefLink\" id=\"jumplink-B118\"></span><a href=\"javascript:;\" reveal-id=\"B118\" data-open=\"B118\" class=\"link link-ref link-reveal xref-bibr\">118</a>).</p><p class=\"chapter-para\">Abbreviations: IM, intramuscularly; SC, subcutaneously.</p></span></div></div><div class=\"&#xA;          graphic-wrap&#xA;           hide\"><a class=\"fig-view-orig openInAnotherWindow btn js-view-large\" target=\"_blank\" href=\"/view-large/\">\r\n          Open in new tab\r\n        </a></div></div></p></li><li><p class=\"chapter-para\">2.5. We recognize that there may be compelling reasons to initiate sex hormone treatment prior to the age of 16 years in some adolescents with GD/gender incongruence, even though there are minimal published studies of gender-affirming hormone treatments administered before age 13.5 to 14 years. As with the care of adolescents ≥16 years of age, we recommend that an expert multidisciplinary team of medical and MHPs manage this treatment. (1 |⊕○○○)</p></li><li><p class=\"chapter-para\">2.6. We suggest monitoring clinical pubertal development every 3 to 6 months and laboratory parameters every 6 to 12 months during sex hormone treatment (<span class=\"xrefLink\" id=\"jumplink-T9\"></span><a href=\"javascript:;\" reveal-id=\"T9\" data-open=\"T9\" class=\"link link-reveal link-table xref-fig\">Table 9</a>). (2 |⊕⊕○○)<span id=\"T9\"></span><div content-id=\"T9\" class=\"table-modal\"><div class=\"table-wrap table-wide\"><div class=\"table-wrap-title\" id=\"T9\" data-id=\"T9\"><span class=\"label\">Table 9.</span><div class=\"caption\"><p class=\"chapter-para\">Baseline and Follow-up Protocol During Induction of Puberty</p></div> </div><div class=\"table-overflow\"><table><tbody><tr><td>Every 3–6 mo </td></tr><tr><td> •Anthropometry: height, weight, sitting height, blood pressure, Tanner stages </td></tr><tr><td>Every 6–12 mo </td></tr><tr><td> •In transgender males: hemoglobin/hematocrit, lipids, testosterone, 25OH vitamin D </td></tr><tr><td> •In transgender females: prolactin, estradiol, 25OH vitamin D </td></tr><tr><td>Every 1–2 y </td></tr><tr><td> •BMD using DXA </td></tr><tr><td> •Bone age on X-ray of the left hand (if clinically indicated) </td></tr><tr><td><em>BMD should be monitored into adulthood (until the age of 25–30 y or until peak bone mass has been reached).</em> </td></tr><tr><td><em>For recommendations on monitoring once pubertal induction has been completed, see Tables 14 and 15.</em> </td></tr></tbody></table></div><div class=\"table-modal\"><table><tbody><tr><td>Every 3–6 mo </td></tr><tr><td> •Anthropometry: height, weight, sitting height, blood pressure, Tanner stages </td></tr><tr><td>Every 6–12 mo </td></tr><tr><td> •In transgender males: hemoglobin/hematocrit, lipids, testosterone, 25OH vitamin D </td></tr><tr><td> •In transgender females: prolactin, estradiol, 25OH vitamin D </td></tr><tr><td>Every 1–2 y </td></tr><tr><td> •BMD using DXA </td></tr><tr><td> •Bone age on X-ray of the left hand (if clinically indicated) </td></tr><tr><td><em>BMD should be monitored into adulthood (until the age of 25–30 y or until peak bone mass has been reached).</em> </td></tr><tr><td><em>For recommendations on monitoring once pubertal induction has been completed, see Tables 14 and 15.</em> </td></tr></tbody></table></div><div class=\"table-wrap-foot\"><span id=\"fn-fn-07\"></span><div content-id=\"fn-07\" class=\"footnote\"><span class=\"fn\"><p class=\"chapter-para\">Adapted from Hembree <em>et al.</em> (<span class=\"xrefLink\" id=\"jumplink-B118\"></span><a href=\"javascript:;\" reveal-id=\"B118\" data-open=\"B118\" class=\"link link-ref link-reveal xref-bibr\">118</a>).</p><p class=\"chapter-para\">Abbreviation: DXA, dual-energy X-ray absorptiometry.</p></span></div></div><div class=\"&#xA;          graphic-wrap&#xA;           hide\"><a class=\"fig-view-orig openInAnotherWindow btn js-view-large\" target=\"_blank\" href=\"/view-large/\">\r\n          Open in new tab\r\n        </a></div></div></div><div class=\"table-wrap table-wide\"><div class=\"table-wrap-title\" id=\"T9\" data-id=\"T9\"><span class=\"label\">Table 9.</span><div class=\"caption\"><p class=\"chapter-para\">Baseline and Follow-up Protocol During Induction of Puberty</p></div> </div><div class=\"table-overflow\"><table><tbody><tr><td>Every 3–6 mo </td></tr><tr><td> •Anthropometry: height, weight, sitting height, blood pressure, Tanner stages </td></tr><tr><td>Every 6–12 mo </td></tr><tr><td> •In transgender males: hemoglobin/hematocrit, lipids, testosterone, 25OH vitamin D </td></tr><tr><td> •In transgender females: prolactin, estradiol, 25OH vitamin D </td></tr><tr><td>Every 1–2 y </td></tr><tr><td> •BMD using DXA </td></tr><tr><td> •Bone age on X-ray of the left hand (if clinically indicated) </td></tr><tr><td><em>BMD should be monitored into adulthood (until the age of 25–30 y or until peak bone mass has been reached).</em> </td></tr><tr><td><em>For recommendations on monitoring once pubertal induction has been completed, see Tables 14 and 15.</em> </td></tr></tbody></table></div><div class=\"table-modal\"><table><tbody><tr><td>Every 3–6 mo </td></tr><tr><td> •Anthropometry: height, weight, sitting height, blood pressure, Tanner stages </td></tr><tr><td>Every 6–12 mo </td></tr><tr><td> •In transgender males: hemoglobin/hematocrit, lipids, testosterone, 25OH vitamin D </td></tr><tr><td> •In transgender females: prolactin, estradiol, 25OH vitamin D </td></tr><tr><td>Every 1–2 y </td></tr><tr><td> •BMD using DXA </td></tr><tr><td> •Bone age on X-ray of the left hand (if clinically indicated) </td></tr><tr><td><em>BMD should be monitored into adulthood (until the age of 25–30 y or until peak bone mass has been reached).</em> </td></tr><tr><td><em>For recommendations on monitoring once pubertal induction has been completed, see Tables 14 and 15.</em> </td></tr></tbody></table></div><div class=\"table-wrap-foot\"><span id=\"fn-fn-07\"></span><div content-id=\"fn-07\" class=\"footnote\"><span class=\"fn\"><p class=\"chapter-para\">Adapted from Hembree <em>et al.</em> (<span class=\"xrefLink\" id=\"jumplink-B118\"></span><a href=\"javascript:;\" reveal-id=\"B118\" data-open=\"B118\" class=\"link link-ref link-reveal xref-bibr\">118</a>).</p><p class=\"chapter-para\">Abbreviation: DXA, dual-energy X-ray absorptiometry.</p></span></div></div><div class=\"&#xA;          graphic-wrap&#xA;           hide\"><a class=\"fig-view-orig openInAnotherWindow btn js-view-large\" target=\"_blank\" href=\"/view-large/\">\r\n          Open in new tab\r\n        </a></div></div></p></li></ul>                    <h3 scrollto-destination=99603351 id=\"99603351\" class=\"section-title js-splitscreen-section-title\" data-legacy-id=s37>Evidence</h3>\r\n<p class=\"chapter-para\">Adolescents develop competence in decision making at their own pace. Ideally, the supervising medical professionals should individually assess this competence, although no objective tools to make such an assessment are currently available.</p><p class=\"chapter-para\">Many adolescents have achieved a reasonable level of competence by age 15 to 16 years (<span class=\"xrefLink\" id=\"jumplink-B119\"></span><a href=\"javascript:;\" reveal-id=\"B119\" data-open=\"B119\" class=\"link link-ref link-reveal xref-bibr\">119</a>), and in many countries 16-year-olds are legally competent with regard to medical decision making (<span class=\"xrefLink\" id=\"jumplink-B120\"></span><a href=\"javascript:;\" reveal-id=\"B120\" data-open=\"B120\" class=\"link link-ref link-reveal xref-bibr\">120</a>). However, others believe that although some capacities are generally achieved before age 16 years, other abilities (such as good risk assessment) do not develop until well after 18 years (<span class=\"xrefLink\" id=\"jumplink-B121\"></span><a href=\"javascript:;\" reveal-id=\"B121\" data-open=\"B121\" class=\"link link-ref link-reveal xref-bibr\">121</a>). They suggest that health care procedures should be divided along a matrix of relative risk, so that younger adolescents can be allowed to decide about low-risk procedures, such as most diagnostic tests and common therapies, but not about high-risk procedures, such as most surgical procedures (<span class=\"xrefLink\" id=\"jumplink-B121\"></span><a href=\"javascript:;\" reveal-id=\"B121\" data-open=\"B121\" class=\"link link-ref link-reveal xref-bibr\">121</a>).</p><p class=\"chapter-para\">Currently available data from transgender adolescents support treatment with sex hormones starting at age 16 years (<span class=\"xrefLink\" id=\"jumplink-B63\"></span><a href=\"javascript:;\" reveal-id=\"B63\" data-open=\"B63\" class=\"link link-ref link-reveal xref-bibr\">63</a>, <span class=\"xrefLink\" id=\"jumplink-B122\"></span><a href=\"javascript:;\" reveal-id=\"B122\" data-open=\"B122\" class=\"link link-ref link-reveal xref-bibr\">122</a>). However, some patients may incur potential risks by waiting until age 16 years. These include the potential risk to bone health if puberty is suppressed for 6 to 7 years before initiating sex hormones (<em>e.g.</em>, if someone reached Tanner stage 2 at age 9-10 years old). Additionally, there may be concerns about inappropriate height and potential harm to mental health (emotional and social isolation) if initiation of secondary sex characteristics must wait until the person has reached 16 years of age. However, only minimal data supporting earlier use of gender-affirming hormones in transgender adolescents currently exist (<span class=\"xrefLink\" id=\"jumplink-B63\"></span><a href=\"javascript:;\" reveal-id=\"B63\" data-open=\"B63\" class=\"link link-ref link-reveal xref-bibr\">63</a>). Clearly, long-term studies are needed to determine the optimal age of sex hormone treatment in GD/gender-incongruent adolescents.</p><p class=\"chapter-para\">The MHP who has followed the adolescent during GnRH analog treatment plays an essential role in assessing whether the adolescent is eligible to start sex hormone therapy and capable of consenting to this treatment (<span class=\"xrefLink\" id=\"jumplink-T5\"></span><a href=\"javascript:;\" reveal-id=\"T5\" data-open=\"T5\" class=\"link link-reveal link-table xref-fig\">Table 5</a>). Support of the family/environment is essential. Prior to the start of sex hormones, clinicians should discuss the implications for fertility (see recommendation 1.5). Throughout pubertal induction, an MHP and a pediatric endocrinologist (or other clinician competent in the evaluation and induction of pubertal development) should monitor the adolescent. In addition to monitoring therapy, it is also important to pay attention to general adolescent health issues, including healthy life style choices, such as not smoking, contraception, and appropriate vaccinations (<em>e.g.</em>, human papillomavirus).</p><p class=\"chapter-para\">For the induction of puberty, clinicians can use a similar dose scheme for hypogonadal adolescents with GD/gender incongruence as they use in other individuals with hypogonadism, carefully monitoring for desired and undesired effects (<span class=\"xrefLink\" id=\"jumplink-T8\"></span><a href=\"javascript:;\" reveal-id=\"T8\" data-open=\"T8\" class=\"link link-reveal link-table xref-fig\">Table 8</a>). In transgender female adolescents, transdermal 17<em>β</em>-estradiol may be an alternative for oral 17<em>β</em>-estradiol. It is increasingly used for pubertal induction in hypogonadal females. However, the absence of low-dose estrogen patches may be a problem. As a result, individuals may need to cut patches to size themselves to achieve appropriate dosing (<span class=\"xrefLink\" id=\"jumplink-B123\"></span><a href=\"javascript:;\" reveal-id=\"B123\" data-open=\"B123\" class=\"link link-ref link-reveal xref-bibr\">123</a>). In transgender male adolescents, clinicians can give testosterone injections intramuscularly or subcutaneously (<span class=\"xrefLink\" id=\"jumplink-B124\"></span><a href=\"javascript:;\" reveal-id=\"B124\" data-open=\"B124\" class=\"link link-ref link-reveal xref-bibr\">124</a>, <span class=\"xrefLink\" id=\"jumplink-B125\"></span><a href=\"javascript:;\" reveal-id=\"B125\" data-open=\"B125\" class=\"link link-ref link-reveal xref-bibr\">125</a>).</p><p class=\"chapter-para\">When puberty is initiated with a gradually increasing schedule of sex steroid doses, the initial levels will not be high enough to suppress endogenous sex steroid secretion. Gonadotropin secretion and endogenous production of testosterone may resume and interfere with the effectiveness of estrogen treatment, in transgender female adolescents (<span class=\"xrefLink\" id=\"jumplink-B126\"></span><a href=\"javascript:;\" reveal-id=\"B126\" data-open=\"B126\" class=\"link link-ref link-reveal xref-bibr\">126</a>, <span class=\"xrefLink\" id=\"jumplink-B127\"></span><a href=\"javascript:;\" reveal-id=\"B127\" data-open=\"B127\" class=\"link link-ref link-reveal xref-bibr\">127</a>). Therefore, continuation of GnRH analog treatment is advised until gonadectomy. Given that GD/gender-incongruent adolescents may opt not to have gonadectomy, long-term studies are necessary to examine the potential risks of prolonged GnRH analog treatment. Alternatively, in transgender male adolescents, GnRH analog treatment can be discontinued once an adult dose of testosterone has been reached and the individual is well virilized. If uterine bleeding occurs, a progestin can be added. However, the combined use of a GnRH analog (for ovarian suppression) and testosterone may enable phenotypic transition with a lower dose of testosterone in comparison with testosterone alone. If there is a wish or need to discontinue GnRH analog treatment in transgender female adolescents, they may be treated with an antiandrogen that directly suppresses androgen synthesis or action (see section 3.0 “Hormonal Therapy for Transgender Adults”).</p>                    <h3 scrollto-destination=99603358 id=\"99603358\" class=\"section-title js-splitscreen-section-title\" data-legacy-id=s38>Values and preferences</h3>\r\n<p class=\"chapter-para\">The recommendation to initiate pubertal induction only when the individual has sufficient mental capacity (roughly age 16 years) to give informed consent for this partly irreversible treatment places a higher value on the ability of the adolescent to fully understand and oversee the partially irreversible consequences of sex hormone treatment and to give informed consent. It places a lower value on the possible negative effects of delayed puberty. We may not currently have the means to weigh adequately the potential benefits of waiting until around age 16 years to initiate sex hormones vs the potential risks/harm to BMD and the sense of social isolation from having the timing of puberty be so out of sync with peers (<span class=\"xrefLink\" id=\"jumplink-B128\"></span><a href=\"javascript:;\" reveal-id=\"B128\" data-open=\"B128\" class=\"link link-ref link-reveal xref-bibr\">128</a>).</p>                    <h3 scrollto-destination=99603360 id=\"99603360\" class=\"section-title js-splitscreen-section-title\" data-legacy-id=s39>Remarks</h3>\r\n<p class=\"chapter-para\">Before starting sex hormone treatment, effects on fertility and options for fertility preservation should be discussed. Adult height may be a concern in transgender adolescents. In a transgender female adolescent, clinicians may consider higher doses of estrogen or a more rapid tempo of dose escalation during pubertal induction. There are no established treatments yet to augment adult height in a transgender male adolescent with open epiphyses during pubertal induction. It is not uncommon for transgender adolescents to present for clinical services after having completed or nearly completed puberty. In such cases, induction of puberty with sex hormones can be done more rapidly (see <span class=\"xrefLink\" id=\"jumplink-T8\"></span><a href=\"javascript:;\" reveal-id=\"T8\" data-open=\"T8\" class=\"link link-reveal link-table xref-fig\">Table 8</a>). Additionally, an adult dose of testosterone in transgender male adolescents may suffice to suppress the gonadal axis without the need to use a separate agent. At the appropriate time, the multidisciplinary team should adequately prepare the adolescent for transition to adult care.</p>                    <h2 scrollto-destination=99603362 id=\"99603362\" class=\"section-title js-splitscreen-section-title\" data-legacy-id=s40>3.0 Hormonal Therapy for Transgender Adults</h2>\r\n<p class=\"chapter-para\">The two major goals of hormonal therapy are (1) to reduce endogenous sex hormone levels, and thus reduce the secondary sex characteristics of the individual’s designated gender, and (2) to replace endogenous sex hormone levels consistent with the individual’s gender identity by using the principles of hormone replacement treatment of hypogonadal patients. The timing of these two goals and the age at which to begin treatment with the sex hormones of the chosen gender is codetermined in collaboration with both the person pursuing transition and the health care providers. The treatment team should include a medical provider knowledgeable in transgender hormone therapy, an MHP knowledgeable in GD/gender incongruence and the mental health concerns of transition, and a primary care provider able to provide care appropriate for transgender individuals. The physical changes induced by this sex hormone transition are usually accompanied by an improvement in mental well-being (<span class=\"xrefLink\" id=\"jumplink-B129\"></span><a href=\"javascript:;\" reveal-id=\"B129\" data-open=\"B129\" class=\"link link-ref link-reveal xref-bibr\">129</a>, <span class=\"xrefLink\" id=\"jumplink-B130\"></span><a href=\"javascript:;\" reveal-id=\"B130\" data-open=\"B130\" class=\"link link-ref link-reveal xref-bibr\">130</a>).</p><ul class=\"list-simple\"><li><p class=\"chapter-para\">3.1. We recommend that clinicians confirm the diagnostic criteria of GD/gender incongruence and the criteria for the endocrine phase of gender transition before beginning treatment. (1 |⊕⊕⊕○)</p></li><li><p class=\"chapter-para\">3.2. We recommend that clinicians evaluate and address medical conditions that can be exacerbated by hormone depletion and treatment with sex hormones of the affirmed gender before beginning treatment (<span class=\"xrefLink\" id=\"jumplink-T10\"></span><a href=\"javascript:;\" reveal-id=\"T10\" data-open=\"T10\" class=\"link link-reveal link-table xref-fig\">Table 10</a>). (1 |⊕⊕⊕○)<span id=\"T10\"></span><div content-id=\"T10\" class=\"table-modal\"><div class=\"table-wrap table-wide\"><div class=\"table-wrap-title\" id=\"T10\" data-id=\"T10\"><span class=\"label\">Table 10.</span><div class=\"caption\"><p class=\"chapter-para\">Medical Risks Associated With Sex Hormone Therapy</p></div> </div><div class=\"table-overflow\"><table><tbody><tr><td>Transgender female: estrogen </td></tr><tr><td> Very high risk of adverse outcomes: </td></tr><tr><td>  •Thromboembolic disease </td></tr><tr><td> Moderate risk of adverse outcomes: </td></tr><tr><td>  •Macroprolactinoma </td></tr><tr><td>  •Breast cancer </td></tr><tr><td>  •Coronary artery disease </td></tr><tr><td>  •Cerebrovascular disease </td></tr><tr><td>  •Cholelithiasis </td></tr><tr><td>  •Hypertriglyceridemia </td></tr><tr><td> </td></tr><tr><td>Transgender male: testosterone </td></tr><tr><td> Very high risk of adverse outcomes: </td></tr><tr><td>  •Erythrocytosis (hematocrit &gt; 50%) </td></tr><tr><td> Moderate risk of adverse outcomes: </td></tr><tr><td>  •Severe liver dysfunction (transaminases &gt; threefold upper limit of normal) </td></tr><tr><td>  •Coronary artery disease </td></tr><tr><td>  •Cerebrovascular disease </td></tr><tr><td>  •Hypertension </td></tr><tr><td>  •Breast or uterine cancer </td></tr></tbody></table></div><div class=\"table-modal\"><table><tbody><tr><td>Transgender female: estrogen </td></tr><tr><td> Very high risk of adverse outcomes: </td></tr><tr><td>  •Thromboembolic disease </td></tr><tr><td> Moderate risk of adverse outcomes: </td></tr><tr><td>  •Macroprolactinoma </td></tr><tr><td>  •Breast cancer </td></tr><tr><td>  •Coronary artery disease </td></tr><tr><td>  •Cerebrovascular disease </td></tr><tr><td>  •Cholelithiasis </td></tr><tr><td>  •Hypertriglyceridemia </td></tr><tr><td> </td></tr><tr><td>Transgender male: testosterone </td></tr><tr><td> Very high risk of adverse outcomes: </td></tr><tr><td>  •Erythrocytosis (hematocrit &gt; 50%) </td></tr><tr><td> Moderate risk of adverse outcomes: </td></tr><tr><td>  •Severe liver dysfunction (transaminases &gt; threefold upper limit of normal) </td></tr><tr><td>  •Coronary artery disease </td></tr><tr><td>  •Cerebrovascular disease </td></tr><tr><td>  •Hypertension </td></tr><tr><td>  •Breast or uterine cancer </td></tr></tbody></table></div><div class=\"&#xA;          graphic-wrap&#xA;           hide\"><a class=\"fig-view-orig openInAnotherWindow btn js-view-large\" target=\"_blank\" href=\"/view-large/\">\r\n          Open in new tab\r\n        </a></div></div></div><div class=\"table-wrap table-wide\"><div class=\"table-wrap-title\" id=\"T10\" data-id=\"T10\"><span class=\"label\">Table 10.</span><div class=\"caption\"><p class=\"chapter-para\">Medical Risks Associated With Sex Hormone Therapy</p></div> </div><div class=\"table-overflow\"><table><tbody><tr><td>Transgender female: estrogen </td></tr><tr><td> Very high risk of adverse outcomes: </td></tr><tr><td>  •Thromboembolic disease </td></tr><tr><td> Moderate risk of adverse outcomes: </td></tr><tr><td>  •Macroprolactinoma </td></tr><tr><td>  •Breast cancer </td></tr><tr><td>  •Coronary artery disease </td></tr><tr><td>  •Cerebrovascular disease </td></tr><tr><td>  •Cholelithiasis </td></tr><tr><td>  •Hypertriglyceridemia </td></tr><tr><td> </td></tr><tr><td>Transgender male: testosterone </td></tr><tr><td> Very high risk of adverse outcomes: </td></tr><tr><td>  •Erythrocytosis (hematocrit &gt; 50%) </td></tr><tr><td> Moderate risk of adverse outcomes: </td></tr><tr><td>  •Severe liver dysfunction (transaminases &gt; threefold upper limit of normal) </td></tr><tr><td>  •Coronary artery disease </td></tr><tr><td>  •Cerebrovascular disease </td></tr><tr><td>  •Hypertension </td></tr><tr><td>  •Breast or uterine cancer </td></tr></tbody></table></div><div class=\"table-modal\"><table><tbody><tr><td>Transgender female: estrogen </td></tr><tr><td> Very high risk of adverse outcomes: </td></tr><tr><td>  •Thromboembolic disease </td></tr><tr><td> Moderate risk of adverse outcomes: </td></tr><tr><td>  •Macroprolactinoma </td></tr><tr><td>  •Breast cancer </td></tr><tr><td>  •Coronary artery disease </td></tr><tr><td>  •Cerebrovascular disease </td></tr><tr><td>  •Cholelithiasis </td></tr><tr><td>  •Hypertriglyceridemia </td></tr><tr><td> </td></tr><tr><td>Transgender male: testosterone </td></tr><tr><td> Very high risk of adverse outcomes: </td></tr><tr><td>  •Erythrocytosis (hematocrit &gt; 50%) </td></tr><tr><td> Moderate risk of adverse outcomes: </td></tr><tr><td>  •Severe liver dysfunction (transaminases &gt; threefold upper limit of normal) </td></tr><tr><td>  •Coronary artery disease </td></tr><tr><td>  •Cerebrovascular disease </td></tr><tr><td>  •Hypertension </td></tr><tr><td>  •Breast or uterine cancer </td></tr></tbody></table></div><div class=\"&#xA;          graphic-wrap&#xA;           hide\"><a class=\"fig-view-orig openInAnotherWindow btn js-view-large\" target=\"_blank\" href=\"/view-large/\">\r\n          Open in new tab\r\n        </a></div></div></p></li><li><p class=\"chapter-para\">3.3. We suggest that clinicians measure hormone levels during treatment to ensure that endogenous sex steroids are suppressed and administered sex steroids are maintained in the normal physiologic range for the affirmed gender. (2 |⊕⊕○○)</p></li></ul>                    <h3 scrollto-destination=99603365 id=\"99603365\" class=\"section-title js-splitscreen-section-title\" data-legacy-id=s41>Evidence</h3>\r\n<p class=\"chapter-para\">It is the responsibility of the treating clinician to confirm that the person fulfills criteria for treatment. The treating clinician should become familiar with the terms and criteria presented in <span class=\"xrefLink\" id=\"jumplink-T1 T2 T3 T4 T5\"></span><a href=\"javascript:;\" reveal-id=\"T1 T2 T3 T4 T5\" data-open=\"T1 T2 T3 T4 T5\" class=\"link link-reveal link-table xref-fig\">Tables 1–5</a> and take a thorough history from the patient in collaboration with the other members of the treatment team. The treating clinician must ensure that the desire for transition is appropriate; the consequences, risks, and benefits of treatment are well understood; and the desire for transition persists. They also need to discuss fertility preservation options (see recommendation 1.3) (<span class=\"xrefLink\" id=\"jumplink-B67\"></span><a href=\"javascript:;\" reveal-id=\"B67\" data-open=\"B67\" class=\"link link-ref link-reveal xref-bibr\">67</a>, <span class=\"xrefLink\" id=\"jumplink-B68\"></span><a href=\"javascript:;\" reveal-id=\"B68\" data-open=\"B68\" class=\"link link-ref link-reveal xref-bibr\">68</a>).</p>                    <h4 scrollto-destination=99603367 id=\"99603367\" class=\"section-title js-splitscreen-section-title\" data-legacy-id=s42>Transgender males</h4>\r\n<p class=\"chapter-para\">Clinical studies have demonstrated the efficacy of several different androgen preparations to induce masculinization in transgender males (Appendix A) (<span class=\"xrefLink\" id=\"jumplink-B113\"></span><a href=\"javascript:;\" reveal-id=\"B113\" data-open=\"B113\" class=\"link link-ref link-reveal xref-bibr\">113</a>, <span class=\"xrefLink\" id=\"jumplink-B114\"></span><a href=\"javascript:;\" reveal-id=\"B114\" data-open=\"B114\" class=\"link link-ref link-reveal xref-bibr\">114</a>, <span class=\"xrefLink\" id=\"jumplink-B131\"></span><a href=\"javascript:;\" reveal-id=\"B131\" data-open=\"B131\" class=\"link link-ref link-reveal xref-bibr\">131</a>–<span class=\"xrefLink\" id=\"jumplink-B134\"></span><a href=\"javascript:;\" reveal-id=\"B134\" data-open=\"B134\" class=\"link link-ref link-reveal xref-bibr\">134</a>). Regimens to change secondary sex characteristics follow the general principle of hormone replacement treatment of male hypogonadism (<span class=\"xrefLink\" id=\"jumplink-B135\"></span><a href=\"javascript:;\" reveal-id=\"B135\" data-open=\"B135\" class=\"link link-ref link-reveal xref-bibr\">135</a>). Clinicians can use either parenteral or transdermal preparations to achieve testosterone values in the normal male range (this is dependent on the specific assay, but is typically 320 to 1000 ng/dL) (<span class=\"xrefLink\" id=\"jumplink-T11\"></span><a href=\"javascript:;\" reveal-id=\"T11\" data-open=\"T11\" class=\"link link-reveal link-table xref-fig\">Table 11</a>) (<span class=\"xrefLink\" id=\"jumplink-B136\"></span><a href=\"javascript:;\" reveal-id=\"B136\" data-open=\"B136\" class=\"link link-ref link-reveal xref-bibr\">136</a>). Sustained supraphysiologic levels of testosterone increase the risk of adverse reactions (see section 4.0 “Adverse Outcome Prevention and Long-Term Care”) and should be avoided.</p>                    <a id=\"99603369\" scrollto-destination=\"99603369\"></a>\r\n<div content-id=\"T11\" class=\"table-modal table-full-width-wrap\"><div class=\"table-wrap table-wide\"><div class=\"table-wrap-title\" id=\"T11\" data-id=\"T11\"><span class=\"label\">Table 11.</span><div class=\"caption\"><p class=\"chapter-para\">Hormone Regimens in Transgender Persons</p></div> </div><div class=\"table-overflow\"><table><tbody><tr><td>Transgender females<span class=\"xrefLink\" id=\"jumplink-t11n1\"></span><a href=\"javascript:;\" reveal-id=\"t11n1\" data-open=\"t11n1\" class=\"link link-ref link-reveal xref-fn js-xref-fn\"><em><sup>a</sup></em></a> </td><td> </td></tr><tr><td> Estrogen </td><td> </td></tr><tr><td>  Oral </td><td> </td></tr><tr><td>   Estradiol </td><td>2.0–6.0 mg/d </td></tr><tr><td>  Transdermal </td><td> </td></tr><tr><td>   Estradiol transdermal patch </td><td>0.025–0.2 mg/d </td></tr><tr><td>   (New patch placed every 3–5 d) </td><td> </td></tr><tr><td>  Parenteral </td><td> </td></tr><tr><td>   Estradiol valerate or cypionate </td><td>5–30 mg IM every 2 wk </td></tr><tr><td> </td><td>2–10 mg IM every week </td></tr><tr><td> Anti-androgens </td><td> </td></tr><tr><td>  Spironolactone </td><td>100–300 mg/d </td></tr><tr><td>  Cyproterone acetate<span class=\"xrefLink\" id=\"jumplink-t11n2\"></span><a href=\"javascript:;\" reveal-id=\"t11n2\" data-open=\"t11n2\" class=\"link link-ref link-reveal xref-fn js-xref-fn\"><em><sup>b</sup></em></a> </td><td>25–50 mg/d </td></tr><tr><td rowspan=\"2\"> GnRH agonist </td><td>3.75 mg SQ (SC) monthly </td></tr><tr><td>11.25 mg SQ (SC) 3-monthly </td></tr><tr><td>Transgender males </td><td> </td></tr><tr><td> Testosterone </td><td> </td></tr><tr><td>  Parenteral testosterone </td><td> </td></tr><tr><td>   Testosterone enanthate or cypionate </td><td>100–200 mg SQ (IM) every 2 wk or SQ (SC) 50% per week </td></tr><tr><td>   Testosterone undecanoate<span class=\"xrefLink\" id=\"jumplink-t11n3\"></span><a href=\"javascript:;\" reveal-id=\"t11n3\" data-open=\"t11n3\" class=\"link link-ref link-reveal xref-fn js-xref-fn\"><em><sup>c</sup></em></a> </td><td>1000 mg every 12 wk </td></tr><tr><td>  Transdermal testosterone </td><td> </td></tr><tr><td>   Testosterone gel 1.6%<span class=\"xrefLink\" id=\"jumplink-t11n4\"></span><a href=\"javascript:;\" reveal-id=\"t11n4\" data-open=\"t11n4\" class=\"link link-ref link-reveal xref-fn js-xref-fn\"><em><sup>d</sup></em></a> </td><td>50–100 mg/d </td></tr><tr><td>   Testosterone transdermal patch </td><td>2.5–7.5 mg/d </td></tr></tbody></table></div><div class=\"table-modal\"><table><tbody><tr><td>Transgender females<span class=\"xrefLink\" id=\"jumplink-t11n1\"></span><a href=\"javascript:;\" reveal-id=\"t11n1\" data-open=\"t11n1\" class=\"link link-ref link-reveal xref-fn js-xref-fn\"><em><sup>a</sup></em></a> </td><td> </td></tr><tr><td> Estrogen </td><td> </td></tr><tr><td>  Oral </td><td> </td></tr><tr><td>   Estradiol </td><td>2.0–6.0 mg/d </td></tr><tr><td>  Transdermal </td><td> </td></tr><tr><td>   Estradiol transdermal patch </td><td>0.025–0.2 mg/d </td></tr><tr><td>   (New patch placed every 3–5 d) </td><td> </td></tr><tr><td>  Parenteral </td><td> </td></tr><tr><td>   Estradiol valerate or cypionate </td><td>5–30 mg IM every 2 wk </td></tr><tr><td> </td><td>2–10 mg IM every week </td></tr><tr><td> Anti-androgens </td><td> </td></tr><tr><td>  Spironolactone </td><td>100–300 mg/d </td></tr><tr><td>  Cyproterone acetate<span class=\"xrefLink\" id=\"jumplink-t11n2\"></span><a href=\"javascript:;\" reveal-id=\"t11n2\" data-open=\"t11n2\" class=\"link link-ref link-reveal xref-fn js-xref-fn\"><em><sup>b</sup></em></a> </td><td>25–50 mg/d </td></tr><tr><td rowspan=\"2\"> GnRH agonist </td><td>3.75 mg SQ (SC) monthly </td></tr><tr><td>11.25 mg SQ (SC) 3-monthly </td></tr><tr><td>Transgender males </td><td> </td></tr><tr><td> Testosterone </td><td> </td></tr><tr><td>  Parenteral testosterone </td><td> </td></tr><tr><td>   Testosterone enanthate or cypionate </td><td>100–200 mg SQ (IM) every 2 wk or SQ (SC) 50% per week </td></tr><tr><td>   Testosterone undecanoate<span class=\"xrefLink\" id=\"jumplink-t11n3\"></span><a href=\"javascript:;\" reveal-id=\"t11n3\" data-open=\"t11n3\" class=\"link link-ref link-reveal xref-fn js-xref-fn\"><em><sup>c</sup></em></a> </td><td>1000 mg every 12 wk </td></tr><tr><td>  Transdermal testosterone </td><td> </td></tr><tr><td>   Testosterone gel 1.6%<span class=\"xrefLink\" id=\"jumplink-t11n4\"></span><a href=\"javascript:;\" reveal-id=\"t11n4\" data-open=\"t11n4\" class=\"link link-ref link-reveal xref-fn js-xref-fn\"><em><sup>d</sup></em></a> </td><td>50–100 mg/d </td></tr><tr><td>   Testosterone transdermal patch </td><td>2.5–7.5 mg/d </td></tr></tbody></table></div><div class=\"table-wrap-foot\"><span id=\"fn-fn-08\"></span><div content-id=\"fn-08\" class=\"footnote\"><span class=\"fn\"><p class=\"chapter-para\">Abbreviations: IM, intramuscularly; SQ, sequentially; SC, subcutaneously.</p></span></div><span id=\"fn-t11n1\"></span><div content-id=\"t11n1\" class=\"footnote\"><span class=\"fn\"><span class=\"label fn-label\"><span rel=\"nofollow\" data-fn-id=\"t11n1\" class=\"end-note-link\"><sup>a</sup></span></span><p class=\"chapter-para\">Estrogens used with or without antiandrogens or GnRH agonist.</p></span></div><span id=\"fn-t11n2\"></span><div content-id=\"t11n2\" class=\"footnote\"><span class=\"fn\"><span class=\"label fn-label\"><span rel=\"nofollow\" data-fn-id=\"t11n2\" class=\"end-note-link\"><sup>b</sup></span></span><p class=\"chapter-para\">Not available in the United States.</p></span></div><span id=\"fn-t11n3\"></span><div content-id=\"t11n3\" class=\"footnote\"><span class=\"fn\"><span class=\"label fn-label\"><span rel=\"nofollow\" data-fn-id=\"t11n3\" class=\"end-note-link\"><sup>c</sup></span></span><p class=\"chapter-para\">One thousand milligrams initially followed by an injection at 6 wk then at 12-wk intervals.</p></span></div><span id=\"fn-t11n4\"></span><div content-id=\"t11n4\" class=\"footnote\"><span class=\"fn\"><span class=\"label fn-label\"><span rel=\"nofollow\" data-fn-id=\"t11n4\" class=\"end-note-link\"><sup>d</sup></span></span><p class=\"chapter-para\">Avoid cutaneous transfer to other individuals.</p></span></div></div><div class=\"&#xA;          graphic-wrap&#xA;          \"><a class=\"fig-view-orig openInAnotherWindow btn js-view-large\" target=\"_blank\" href=\"/view-large/99603369\">\r\n          Open in new tab\r\n        </a></div></div></div><div class=\"table-full-width-wrap\"><div class=\"table-wrap table-wide\"><div class=\"table-wrap-title\" id=\"T11\" data-id=\"T11\"><span class=\"label\">Table 11.</span><div class=\"caption\"><p class=\"chapter-para\">Hormone Regimens in Transgender Persons</p></div> </div><div class=\"table-overflow\"><table><tbody><tr><td>Transgender females<span class=\"xrefLink\" id=\"jumplink-t11n1\"></span><a href=\"javascript:;\" reveal-id=\"t11n1\" data-open=\"t11n1\" class=\"link link-ref link-reveal xref-fn js-xref-fn\"><em><sup>a</sup></em></a> </td><td> </td></tr><tr><td> Estrogen </td><td> </td></tr><tr><td>  Oral </td><td> </td></tr><tr><td>   Estradiol </td><td>2.0–6.0 mg/d </td></tr><tr><td>  Transdermal </td><td> </td></tr><tr><td>   Estradiol transdermal patch </td><td>0.025–0.2 mg/d </td></tr><tr><td>   (New patch placed every 3–5 d) </td><td> </td></tr><tr><td>  Parenteral </td><td> </td></tr><tr><td>   Estradiol valerate or cypionate </td><td>5–30 mg IM every 2 wk </td></tr><tr><td> </td><td>2–10 mg IM every week </td></tr><tr><td> Anti-androgens </td><td> </td></tr><tr><td>  Spironolactone </td><td>100–300 mg/d </td></tr><tr><td>  Cyproterone acetate<span class=\"xrefLink\" id=\"jumplink-t11n2\"></span><a href=\"javascript:;\" reveal-id=\"t11n2\" data-open=\"t11n2\" class=\"link link-ref link-reveal xref-fn js-xref-fn\"><em><sup>b</sup></em></a> </td><td>25–50 mg/d </td></tr><tr><td rowspan=\"2\"> GnRH agonist </td><td>3.75 mg SQ (SC) monthly </td></tr><tr><td>11.25 mg SQ (SC) 3-monthly </td></tr><tr><td>Transgender males </td><td> </td></tr><tr><td> Testosterone </td><td> </td></tr><tr><td>  Parenteral testosterone </td><td> </td></tr><tr><td>   Testosterone enanthate or cypionate </td><td>100–200 mg SQ (IM) every 2 wk or SQ (SC) 50% per week </td></tr><tr><td>   Testosterone undecanoate<span class=\"xrefLink\" id=\"jumplink-t11n3\"></span><a href=\"javascript:;\" reveal-id=\"t11n3\" data-open=\"t11n3\" class=\"link link-ref link-reveal xref-fn js-xref-fn\"><em><sup>c</sup></em></a> </td><td>1000 mg every 12 wk </td></tr><tr><td>  Transdermal testosterone </td><td> </td></tr><tr><td>   Testosterone gel 1.6%<span class=\"xrefLink\" id=\"jumplink-t11n4\"></span><a href=\"javascript:;\" reveal-id=\"t11n4\" data-open=\"t11n4\" class=\"link link-ref link-reveal xref-fn js-xref-fn\"><em><sup>d</sup></em></a> </td><td>50–100 mg/d </td></tr><tr><td>   Testosterone transdermal patch </td><td>2.5–7.5 mg/d </td></tr></tbody></table></div><div class=\"table-modal\"><table><tbody><tr><td>Transgender females<span class=\"xrefLink\" id=\"jumplink-t11n1\"></span><a href=\"javascript:;\" reveal-id=\"t11n1\" data-open=\"t11n1\" class=\"link link-ref link-reveal xref-fn js-xref-fn\"><em><sup>a</sup></em></a> </td><td> </td></tr><tr><td> Estrogen </td><td> </td></tr><tr><td>  Oral </td><td> </td></tr><tr><td>   Estradiol </td><td>2.0–6.0 mg/d </td></tr><tr><td>  Transdermal </td><td> </td></tr><tr><td>   Estradiol transdermal patch </td><td>0.025–0.2 mg/d </td></tr><tr><td>   (New patch placed every 3–5 d) </td><td> </td></tr><tr><td>  Parenteral </td><td> </td></tr><tr><td>   Estradiol valerate or cypionate </td><td>5–30 mg IM every 2 wk </td></tr><tr><td> </td><td>2–10 mg IM every week </td></tr><tr><td> Anti-androgens </td><td> </td></tr><tr><td>  Spironolactone </td><td>100–300 mg/d </td></tr><tr><td>  Cyproterone acetate<span class=\"xrefLink\" id=\"jumplink-t11n2\"></span><a href=\"javascript:;\" reveal-id=\"t11n2\" data-open=\"t11n2\" class=\"link link-ref link-reveal xref-fn js-xref-fn\"><em><sup>b</sup></em></a> </td><td>25–50 mg/d </td></tr><tr><td rowspan=\"2\"> GnRH agonist </td><td>3.75 mg SQ (SC) monthly </td></tr><tr><td>11.25 mg SQ (SC) 3-monthly </td></tr><tr><td>Transgender males </td><td> </td></tr><tr><td> Testosterone </td><td> </td></tr><tr><td>  Parenteral testosterone </td><td> </td></tr><tr><td>   Testosterone enanthate or cypionate </td><td>100–200 mg SQ (IM) every 2 wk or SQ (SC) 50% per week </td></tr><tr><td>   Testosterone undecanoate<span class=\"xrefLink\" id=\"jumplink-t11n3\"></span><a href=\"javascript:;\" reveal-id=\"t11n3\" data-open=\"t11n3\" class=\"link link-ref link-reveal xref-fn js-xref-fn\"><em><sup>c</sup></em></a> </td><td>1000 mg every 12 wk </td></tr><tr><td>  Transdermal testosterone </td><td> </td></tr><tr><td>   Testosterone gel 1.6%<span class=\"xrefLink\" id=\"jumplink-t11n4\"></span><a href=\"javascript:;\" reveal-id=\"t11n4\" data-open=\"t11n4\" class=\"link link-ref link-reveal xref-fn js-xref-fn\"><em><sup>d</sup></em></a> </td><td>50–100 mg/d </td></tr><tr><td>   Testosterone transdermal patch </td><td>2.5–7.5 mg/d </td></tr></tbody></table></div><div class=\"table-wrap-foot\"><span id=\"fn-fn-08\"></span><div content-id=\"fn-08\" class=\"footnote\"><span class=\"fn\"><p class=\"chapter-para\">Abbreviations: IM, intramuscularly; SQ, sequentially; SC, subcutaneously.</p></span></div><span id=\"fn-t11n1\"></span><div content-id=\"t11n1\" class=\"footnote\"><span class=\"fn\"><span class=\"label fn-label\"><span rel=\"nofollow\" data-fn-id=\"t11n1\" class=\"end-note-link\"><sup>a</sup></span></span><p class=\"chapter-para\">Estrogens used with or without antiandrogens or GnRH agonist.</p></span></div><span id=\"fn-t11n2\"></span><div content-id=\"t11n2\" class=\"footnote\"><span class=\"fn\"><span class=\"label fn-label\"><span rel=\"nofollow\" data-fn-id=\"t11n2\" class=\"end-note-link\"><sup>b</sup></span></span><p class=\"chapter-para\">Not available in the United States.</p></span></div><span id=\"fn-t11n3\"></span><div content-id=\"t11n3\" class=\"footnote\"><span class=\"fn\"><span class=\"label fn-label\"><span rel=\"nofollow\" data-fn-id=\"t11n3\" class=\"end-note-link\"><sup>c</sup></span></span><p class=\"chapter-para\">One thousand milligrams initially followed by an injection at 6 wk then at 12-wk intervals.</p></span></div><span id=\"fn-t11n4\"></span><div content-id=\"t11n4\" class=\"footnote\"><span class=\"fn\"><span class=\"label fn-label\"><span rel=\"nofollow\" data-fn-id=\"t11n4\" class=\"end-note-link\"><sup>d</sup></span></span><p class=\"chapter-para\">Avoid cutaneous transfer to other individuals.</p></span></div></div><div class=\"&#xA;          graphic-wrap&#xA;          \"><a class=\"fig-view-orig openInAnotherWindow btn js-view-large\" target=\"_blank\" href=\"/view-large/99603369\">\r\n          Open in new tab\r\n        </a></div></div></div><p class=\"chapter-para\">Similar to androgen therapy in hypogonadal men, testosterone treatment in transgender males results in increased muscle mass and decreased fat mass, increased facial hair and acne, male pattern baldness in those genetically predisposed, and increased sexual desire (<span class=\"xrefLink\" id=\"jumplink-B137\"></span><a href=\"javascript:;\" reveal-id=\"B137\" data-open=\"B137\" class=\"link link-ref link-reveal xref-bibr\">137</a>).</p><p class=\"chapter-para\">In transgender males, testosterone will result in clitoromegaly, temporary or permanent decreased fertility, deepening of the voice, cessation of menses (usually), and a significant increase in body hair, particularly on the face, chest, and abdomen. Cessation of menses may occur within a few months with testosterone treatment alone, although high doses of testosterone may be required. If uterine bleeding continues, clinicians may consider the addition of a progestational agent or endometrial ablation (<span class=\"xrefLink\" id=\"jumplink-B138\"></span><a href=\"javascript:;\" reveal-id=\"B138\" data-open=\"B138\" class=\"link link-ref link-reveal xref-bibr\">138</a>). Clinicians may also administer GnRH analogs or depot medroxyprogesterone to stop menses prior to testosterone treatment.</p>                    <h4 scrollto-destination=99603372 id=\"99603372\" class=\"section-title js-splitscreen-section-title\" data-legacy-id=s43>Transgender females</h4>\r\n<p class=\"chapter-para\">The hormone regimen for transgender females is more complex than the transgender male regimen (Appendix B). Treatment with physiologic doses of estrogen alone is insufficient to suppress testosterone levels into the normal range for females (<span class=\"xrefLink\" id=\"jumplink-B139\"></span><a href=\"javascript:;\" reveal-id=\"B139\" data-open=\"B139\" class=\"link link-ref link-reveal xref-bibr\">139</a>). Most published clinical studies report the need for adjunctive therapy to achieve testosterone levels in the female range (<span class=\"xrefLink\" id=\"jumplink-B21\"></span><a href=\"javascript:;\" reveal-id=\"B21\" data-open=\"B21\" class=\"link link-ref link-reveal xref-bibr\">21</a>, <span class=\"xrefLink\" id=\"jumplink-B113\"></span><a href=\"javascript:;\" reveal-id=\"B113\" data-open=\"B113\" class=\"link link-ref link-reveal xref-bibr\">113</a>, <span class=\"xrefLink\" id=\"jumplink-B114\"></span><a href=\"javascript:;\" reveal-id=\"B114\" data-open=\"B114\" class=\"link link-ref link-reveal xref-bibr\">114</a>, <span class=\"xrefLink\" id=\"jumplink-B132\"></span><a href=\"javascript:;\" reveal-id=\"B132\" data-open=\"B132\" class=\"link link-ref link-reveal xref-bibr\">132</a>–<span class=\"xrefLink\" id=\"jumplink-B134\"></span><a href=\"javascript:;\" reveal-id=\"B134\" data-open=\"B134\" class=\"link link-ref link-reveal xref-bibr\">134</a>, <span class=\"xrefLink\" id=\"jumplink-B139\"></span><a href=\"javascript:;\" reveal-id=\"B139\" data-open=\"B139\" class=\"link link-ref link-reveal xref-bibr\">139</a>, <span class=\"xrefLink\" id=\"jumplink-B140\"></span><a href=\"javascript:;\" reveal-id=\"B140\" data-open=\"B140\" class=\"link link-ref link-reveal xref-bibr\">140</a>).</p><p class=\"chapter-para\">Multiple adjunctive medications are available, such as progestins with antiandrogen activity and GnRH agonists (<span class=\"xrefLink\" id=\"jumplink-B141\"></span><a href=\"javascript:;\" reveal-id=\"B141\" data-open=\"B141\" class=\"link link-ref link-reveal xref-bibr\">141</a>). Spironolactone works by directly blocking androgens during their interaction with the androgen receptor (<span class=\"xrefLink\" id=\"jumplink-B114\"></span><a href=\"javascript:;\" reveal-id=\"B114\" data-open=\"B114\" class=\"link link-ref link-reveal xref-bibr\">114</a>, <span class=\"xrefLink\" id=\"jumplink-B133\"></span><a href=\"javascript:;\" reveal-id=\"B133\" data-open=\"B133\" class=\"link link-ref link-reveal xref-bibr\">133</a>, <span class=\"xrefLink\" id=\"jumplink-B142\"></span><a href=\"javascript:;\" reveal-id=\"B142\" data-open=\"B142\" class=\"link link-ref link-reveal xref-bibr\">142</a>). It may also have estrogenic activity (<span class=\"xrefLink\" id=\"jumplink-B143\"></span><a href=\"javascript:;\" reveal-id=\"B143\" data-open=\"B143\" class=\"link link-ref link-reveal xref-bibr\">143</a>). Cyproterone acetate, a progestational compound with antiandrogenic properties (<span class=\"xrefLink\" id=\"jumplink-B113\"></span><a href=\"javascript:;\" reveal-id=\"B113\" data-open=\"B113\" class=\"link link-ref link-reveal xref-bibr\">113</a>, <span class=\"xrefLink\" id=\"jumplink-B132\"></span><a href=\"javascript:;\" reveal-id=\"B132\" data-open=\"B132\" class=\"link link-ref link-reveal xref-bibr\">132</a>, <span class=\"xrefLink\" id=\"jumplink-B144\"></span><a href=\"javascript:;\" reveal-id=\"B144\" data-open=\"B144\" class=\"link link-ref link-reveal xref-bibr\">144</a>), is widely used in Europe. 5<em>α</em>-Reductase inhibitors do not reduce testosterone levels and have adverse effects (<span class=\"xrefLink\" id=\"jumplink-B145\"></span><a href=\"javascript:;\" reveal-id=\"B145\" data-open=\"B145\" class=\"link link-ref link-reveal xref-bibr\">145</a>).</p><p class=\"chapter-para\">Dittrich <em>et al.</em> (<span class=\"xrefLink\" id=\"jumplink-B141\"></span><a href=\"javascript:;\" reveal-id=\"B141\" data-open=\"B141\" class=\"link link-ref link-reveal xref-bibr\">141</a>) reported that monthly doses of the GnRH agonist goserelin acetate in combination with estrogen were effective in reducing testosterone levels with a low incidence of adverse reactions in 60 transgender females. Leuprolide and transdermal estrogen were as effective as cyproterone and transdermal estrogen in a comparative retrospective study (<span class=\"xrefLink\" id=\"jumplink-B146\"></span><a href=\"javascript:;\" reveal-id=\"B146\" data-open=\"B146\" class=\"link link-ref link-reveal xref-bibr\">146</a>).</p><p class=\"chapter-para\">Patients can take estrogen as oral conjugated estrogens, oral 17<em>β</em>-estradiol, or transdermal 17<em>β</em>-estradiol. Among estrogen options, the increased risk of thromboembolic events associated with estrogens in general seems most concerning with ethinyl estradiol specifically (<span class=\"xrefLink\" id=\"jumplink-B134\"></span><a href=\"javascript:;\" reveal-id=\"B134\" data-open=\"B134\" class=\"link link-ref link-reveal xref-bibr\">134</a>, <span class=\"xrefLink\" id=\"jumplink-B140\"></span><a href=\"javascript:;\" reveal-id=\"B140\" data-open=\"B140\" class=\"link link-ref link-reveal xref-bibr\">140</a>, <span class=\"xrefLink\" id=\"jumplink-B141\"></span><a href=\"javascript:;\" reveal-id=\"B141\" data-open=\"B141\" class=\"link link-ref link-reveal xref-bibr\">141</a>), which is why we specifically suggest that it not be used in any transgender treatment plan. Data distinguishing among other estrogen options are less well established although there is some thought that oral routes of administration are more thrombogenic due to the “first pass effect” than are transdermal and parenteral routes, and that the risk of thromboembolic events is dose-dependent. Injectable estrogen and sublingual estrogen may benefit from avoiding the first pass effect, but they can result in more rapid peaks with greater overall periodicity and thus are more difficult to monitor (<span class=\"xrefLink\" id=\"jumplink-B147\"></span><a href=\"javascript:;\" reveal-id=\"B147\" data-open=\"B147\" class=\"link link-ref link-reveal xref-bibr\">147</a>, <span class=\"xrefLink\" id=\"jumplink-B148\"></span><a href=\"javascript:;\" reveal-id=\"B148\" data-open=\"B148\" class=\"link link-ref link-reveal xref-bibr\">148</a>). However, there are no data demonstrating that increased periodicity is harmful otherwise.</p><p class=\"chapter-para\">Clinicians can use serum estradiol levels to monitor oral, transdermal, and intramuscular estradiol. Blood tests cannot monitor conjugated estrogens or synthetic estrogen use. Clinicians should measure serum estradiol and serum testosterone and maintain them at the level for premenopausal females (100 to 200 pg/mL and &lt;50 ng/dL, respectively). The transdermal preparations and injectable estradiol cypionate or valerate preparations may confer an advantage in older transgender females who may be at higher risk for thromboembolic disease (<span class=\"xrefLink\" id=\"jumplink-B149\"></span><a href=\"javascript:;\" reveal-id=\"B149\" data-open=\"B149\" class=\"link link-ref link-reveal xref-bibr\">149</a>).</p>                    <h3 scrollto-destination=99603378 id=\"99603378\" class=\"section-title js-splitscreen-section-title\" data-legacy-id=s44>Values</h3>\r\n<p class=\"chapter-para\">Our recommendation to maintain levels of gender-affirming hormones in the normal adult range places a high value on the avoidance of the long-term complications of pharmacologic doses. Those patients receiving endocrine treatment who have relative contraindications to hormones should have an in-depth discussion with their physician to balance the risks and benefits of therapy.</p>                    <h3 scrollto-destination=99603380 id=\"99603380\" class=\"section-title js-splitscreen-section-title\" data-legacy-id=s45>Remarks</h3>\r\n<p class=\"chapter-para\">Clinicians should inform all endocrine-treated individuals of all risks and benefits of gender-affirming hormones prior to initiating therapy. Clinicians should strongly encourage tobacco use cessation in transgender females to avoid increased risk of VTE and cardiovascular complications. We strongly discourage the unsupervised use of hormone therapy (<span class=\"xrefLink\" id=\"jumplink-B150\"></span><a href=\"javascript:;\" reveal-id=\"B150\" data-open=\"B150\" class=\"link link-ref link-reveal xref-bibr\">150</a>).</p><p class=\"chapter-para\">Not all individuals with GD/gender incongruence seek treatment as described (<em>e.g.</em>, male-to-eunuchs and individuals seeking partial transition). Tailoring current protocols to the individual may be done within the context of accepted safety guidelines using a multidisciplinary approach including mental health. No evidence-based protocols are available for these groups (<span class=\"xrefLink\" id=\"jumplink-B151\"></span><a href=\"javascript:;\" reveal-id=\"B151\" data-open=\"B151\" class=\"link link-ref link-reveal xref-bibr\">151</a>). We need prospective studies to better understand treatment options for these persons.</p><ul class=\"list-simple\"><li><p class=\"chapter-para\">3.4. We suggest that endocrinologists provide education to transgender individuals undergoing treatment about the onset and time course of physical changes induced by sex hormone treatment. (2 |⊕○○○)</p></li></ul>                    <h3 scrollto-destination=99603384 id=\"99603384\" class=\"section-title js-splitscreen-section-title\" data-legacy-id=s46>Evidence</h3>\r\n                    <h4 scrollto-destination=99603385 id=\"99603385\" class=\"section-title js-splitscreen-section-title\" data-legacy-id=s47>Transgender males</h4>\r\n<p class=\"chapter-para\">Physical changes that are expected to occur during the first 1 to 6 months of testosterone therapy include cessation of menses, increased sexual desire, increased facial and body hair, increased oiliness of skin, increased muscle, and redistribution of fat mass. Changes that occur within the first year of testosterone therapy include deepening of the voice (<span class=\"xrefLink\" id=\"jumplink-B152\"></span><a href=\"javascript:;\" reveal-id=\"B152\" data-open=\"B152\" class=\"link link-ref link-reveal xref-bibr\">152</a>, <span class=\"xrefLink\" id=\"jumplink-B153\"></span><a href=\"javascript:;\" reveal-id=\"B153\" data-open=\"B153\" class=\"link link-ref link-reveal xref-bibr\">153</a>), clitoromegaly, and male pattern hair loss (in some cases) (<span class=\"xrefLink\" id=\"jumplink-B114\"></span><a href=\"javascript:;\" reveal-id=\"B114\" data-open=\"B114\" class=\"link link-ref link-reveal xref-bibr\">114</a>, <span class=\"xrefLink\" id=\"jumplink-B144\"></span><a href=\"javascript:;\" reveal-id=\"B144\" data-open=\"B144\" class=\"link link-ref link-reveal xref-bibr\">144</a>, <span class=\"xrefLink\" id=\"jumplink-B154\"></span><a href=\"javascript:;\" reveal-id=\"B154\" data-open=\"B154\" class=\"link link-ref link-reveal xref-bibr\">154</a>, <span class=\"xrefLink\" id=\"jumplink-B155\"></span><a href=\"javascript:;\" reveal-id=\"B155\" data-open=\"B155\" class=\"link link-ref link-reveal xref-bibr\">155</a>) (<span class=\"xrefLink\" id=\"jumplink-T12\"></span><a href=\"javascript:;\" reveal-id=\"T12\" data-open=\"T12\" class=\"link link-reveal link-table xref-fig\">Table 12</a>).</p>                    <a id=\"99603387\" scrollto-destination=\"99603387\"></a>\r\n<div content-id=\"T12\" class=\"table-modal table-full-width-wrap\"><div class=\"table-wrap table-wide\"><div class=\"table-wrap-title\" id=\"T12\" data-id=\"T12\"><span class=\"label\">Table 12.</span><div class=\"caption\"><p class=\"chapter-para\">Masculinizing Effects in Transgender Males</p></div> </div><div class=\"table-overflow\"><table><thead><tr><th>Effect<span aria-hidden=\"true\" style=\"display: none;\">\r\n            . </span></th><th>Onset<span aria-hidden=\"true\" style=\"display: none;\">\r\n            . </span></th><th>Maximum<span aria-hidden=\"true\" style=\"display: none;\">\r\n            . </span></th></tr></thead><tbody><tr><td>Skin oiliness/acne </td><td>1–6 mo </td><td>1–2 y </td></tr><tr><td>Facial/body hair growth </td><td>6–12 mo </td><td>4–5 y </td></tr><tr><td>Scalp hair loss </td><td>6–12 mo </td><td>—<span class=\"xrefLink\" id=\"jumplink-t12n1\"></span><a href=\"javascript:;\" reveal-id=\"t12n1\" data-open=\"t12n1\" class=\"link link-ref link-reveal xref-fn js-xref-fn\"><em><sup>a</sup></em></a> </td></tr><tr><td>Increased muscle mass/strength </td><td>6–12 mo </td><td>2–5 y </td></tr><tr><td>Fat redistribution </td><td>1–6 mo </td><td>2–5 y </td></tr><tr><td>Cessation of menses </td><td>1–6 mo </td><td>—<span class=\"xrefLink\" id=\"jumplink-t12n2\"></span><a href=\"javascript:;\" reveal-id=\"t12n2\" data-open=\"t12n2\" class=\"link link-ref link-reveal xref-fn js-xref-fn\"><em><sup>b</sup></em></a> </td></tr><tr><td>Clitoral enlargement </td><td>1–6 mo </td><td>1–2 y </td></tr><tr><td>Vaginal atrophy </td><td>1–6 mo </td><td>1–2 y </td></tr><tr><td>Deepening of voice </td><td>6–12 mo </td><td>1–2 y </td></tr></tbody></table></div><div class=\"table-modal\"><table><thead><tr><th>Effect<span aria-hidden=\"true\" style=\"display: none;\">\r\n            . </span></th><th>Onset<span aria-hidden=\"true\" style=\"display: none;\">\r\n            . </span></th><th>Maximum<span aria-hidden=\"true\" style=\"display: none;\">\r\n            . </span></th></tr></thead><tbody><tr><td>Skin oiliness/acne </td><td>1–6 mo </td><td>1–2 y </td></tr><tr><td>Facial/body hair growth </td><td>6–12 mo </td><td>4–5 y </td></tr><tr><td>Scalp hair loss </td><td>6–12 mo </td><td>—<span class=\"xrefLink\" id=\"jumplink-t12n1\"></span><a href=\"javascript:;\" reveal-id=\"t12n1\" data-open=\"t12n1\" class=\"link link-ref link-reveal xref-fn js-xref-fn\"><em><sup>a</sup></em></a> </td></tr><tr><td>Increased muscle mass/strength </td><td>6–12 mo </td><td>2–5 y </td></tr><tr><td>Fat redistribution </td><td>1–6 mo </td><td>2–5 y </td></tr><tr><td>Cessation of menses </td><td>1–6 mo </td><td>—<span class=\"xrefLink\" id=\"jumplink-t12n2\"></span><a href=\"javascript:;\" reveal-id=\"t12n2\" data-open=\"t12n2\" class=\"link link-ref link-reveal xref-fn js-xref-fn\"><em><sup>b</sup></em></a> </td></tr><tr><td>Clitoral enlargement </td><td>1–6 mo </td><td>1–2 y </td></tr><tr><td>Vaginal atrophy </td><td>1–6 mo </td><td>1–2 y </td></tr><tr><td>Deepening of voice </td><td>6–12 mo </td><td>1–2 y </td></tr></tbody></table></div><div class=\"table-wrap-foot\"><span id=\"fn-fn-09\"></span><div content-id=\"fn-09\" class=\"footnote\"><span class=\"fn\"><p class=\"chapter-para\">Estimates represent clinical observations: Toorians <em>et al.</em> (<span class=\"xrefLink\" id=\"jumplink-B149\"></span><a href=\"javascript:;\" reveal-id=\"B149\" data-open=\"B149\" class=\"link link-ref link-reveal xref-bibr\">149</a>), Asscheman <em>et al.</em> (<span class=\"xrefLink\" id=\"jumplink-B156\"></span><a href=\"javascript:;\" reveal-id=\"B156\" data-open=\"B156\" class=\"link link-ref link-reveal xref-bibr\">156</a>), Gooren <em>et al.</em> (<span class=\"xrefLink\" id=\"jumplink-B157\"></span><a href=\"javascript:;\" reveal-id=\"B157\" data-open=\"B157\" class=\"link link-ref link-reveal xref-bibr\">157</a>), Wierckx <em>et al.</em> (<span class=\"xrefLink\" id=\"jumplink-B158\"></span><a href=\"javascript:;\" reveal-id=\"B158\" data-open=\"B158\" class=\"link link-ref link-reveal xref-bibr\">158</a>).</p></span></div><span id=\"fn-t12n1\"></span><div content-id=\"t12n1\" class=\"footnote\"><span class=\"fn\"><span class=\"label fn-label\"><span rel=\"nofollow\" data-fn-id=\"t12n1\" class=\"end-note-link\"><sup>a</sup></span></span><p class=\"chapter-para\">Prevention and treatment as recommended for biological men.</p></span></div><span id=\"fn-t12n2\"></span><div content-id=\"t12n2\" class=\"footnote\"><span class=\"fn\"><span class=\"label fn-label\"><span rel=\"nofollow\" data-fn-id=\"t12n2\" class=\"end-note-link\"><sup>b</sup></span></span><p class=\"chapter-para\">Menorrhagia requires diagnosis and treatment by a gynecologist.</p></span></div></div><div class=\"&#xA;          graphic-wrap&#xA;          \"><a class=\"fig-view-orig openInAnotherWindow btn js-view-large\" target=\"_blank\" href=\"/view-large/99603387\">\r\n          Open in new tab\r\n        </a></div></div></div><div class=\"table-full-width-wrap\"><div class=\"table-wrap table-wide\"><div class=\"table-wrap-title\" id=\"T12\" data-id=\"T12\"><span class=\"label\">Table 12.</span><div class=\"caption\"><p class=\"chapter-para\">Masculinizing Effects in Transgender Males</p></div> </div><div class=\"table-overflow\"><table><thead><tr><th>Effect<span aria-hidden=\"true\" style=\"display: none;\">\r\n            . </span></th><th>Onset<span aria-hidden=\"true\" style=\"display: none;\">\r\n            . </span></th><th>Maximum<span aria-hidden=\"true\" style=\"display: none;\">\r\n            . </span></th></tr></thead><tbody><tr><td>Skin oiliness/acne </td><td>1–6 mo </td><td>1–2 y </td></tr><tr><td>Facial/body hair growth </td><td>6–12 mo </td><td>4–5 y </td></tr><tr><td>Scalp hair loss </td><td>6–12 mo </td><td>—<span class=\"xrefLink\" id=\"jumplink-t12n1\"></span><a href=\"javascript:;\" reveal-id=\"t12n1\" data-open=\"t12n1\" class=\"link link-ref link-reveal xref-fn js-xref-fn\"><em><sup>a</sup></em></a> </td></tr><tr><td>Increased muscle mass/strength </td><td>6–12 mo </td><td>2–5 y </td></tr><tr><td>Fat redistribution </td><td>1–6 mo </td><td>2–5 y </td></tr><tr><td>Cessation of menses </td><td>1–6 mo </td><td>—<span class=\"xrefLink\" id=\"jumplink-t12n2\"></span><a href=\"javascript:;\" reveal-id=\"t12n2\" data-open=\"t12n2\" class=\"link link-ref link-reveal xref-fn js-xref-fn\"><em><sup>b</sup></em></a> </td></tr><tr><td>Clitoral enlargement </td><td>1–6 mo </td><td>1–2 y </td></tr><tr><td>Vaginal atrophy </td><td>1–6 mo </td><td>1–2 y </td></tr><tr><td>Deepening of voice </td><td>6–12 mo </td><td>1–2 y </td></tr></tbody></table></div><div class=\"table-modal\"><table><thead><tr><th>Effect<span aria-hidden=\"true\" style=\"display: none;\">\r\n            . </span></th><th>Onset<span aria-hidden=\"true\" style=\"display: none;\">\r\n            . </span></th><th>Maximum<span aria-hidden=\"true\" style=\"display: none;\">\r\n            . </span></th></tr></thead><tbody><tr><td>Skin oiliness/acne </td><td>1–6 mo </td><td>1–2 y </td></tr><tr><td>Facial/body hair growth </td><td>6–12 mo </td><td>4–5 y </td></tr><tr><td>Scalp hair loss </td><td>6–12 mo </td><td>—<span class=\"xrefLink\" id=\"jumplink-t12n1\"></span><a href=\"javascript:;\" reveal-id=\"t12n1\" data-open=\"t12n1\" class=\"link link-ref link-reveal xref-fn js-xref-fn\"><em><sup>a</sup></em></a> </td></tr><tr><td>Increased muscle mass/strength </td><td>6–12 mo </td><td>2–5 y </td></tr><tr><td>Fat redistribution </td><td>1–6 mo </td><td>2–5 y </td></tr><tr><td>Cessation of menses </td><td>1–6 mo </td><td>—<span class=\"xrefLink\" id=\"jumplink-t12n2\"></span><a href=\"javascript:;\" reveal-id=\"t12n2\" data-open=\"t12n2\" class=\"link link-ref link-reveal xref-fn js-xref-fn\"><em><sup>b</sup></em></a> </td></tr><tr><td>Clitoral enlargement </td><td>1–6 mo </td><td>1–2 y </td></tr><tr><td>Vaginal atrophy </td><td>1–6 mo </td><td>1–2 y </td></tr><tr><td>Deepening of voice </td><td>6–12 mo </td><td>1–2 y </td></tr></tbody></table></div><div class=\"table-wrap-foot\"><span id=\"fn-fn-09\"></span><div content-id=\"fn-09\" class=\"footnote\"><span class=\"fn\"><p class=\"chapter-para\">Estimates represent clinical observations: Toorians <em>et al.</em> (<span class=\"xrefLink\" id=\"jumplink-B149\"></span><a href=\"javascript:;\" reveal-id=\"B149\" data-open=\"B149\" class=\"link link-ref link-reveal xref-bibr\">149</a>), Asscheman <em>et al.</em> (<span class=\"xrefLink\" id=\"jumplink-B156\"></span><a href=\"javascript:;\" reveal-id=\"B156\" data-open=\"B156\" class=\"link link-ref link-reveal xref-bibr\">156</a>), Gooren <em>et al.</em> (<span class=\"xrefLink\" id=\"jumplink-B157\"></span><a href=\"javascript:;\" reveal-id=\"B157\" data-open=\"B157\" class=\"link link-ref link-reveal xref-bibr\">157</a>), Wierckx <em>et al.</em> (<span class=\"xrefLink\" id=\"jumplink-B158\"></span><a href=\"javascript:;\" reveal-id=\"B158\" data-open=\"B158\" class=\"link link-ref link-reveal xref-bibr\">158</a>).</p></span></div><span id=\"fn-t12n1\"></span><div content-id=\"t12n1\" class=\"footnote\"><span class=\"fn\"><span class=\"label fn-label\"><span rel=\"nofollow\" data-fn-id=\"t12n1\" class=\"end-note-link\"><sup>a</sup></span></span><p class=\"chapter-para\">Prevention and treatment as recommended for biological men.</p></span></div><span id=\"fn-t12n2\"></span><div content-id=\"t12n2\" class=\"footnote\"><span class=\"fn\"><span class=\"label fn-label\"><span rel=\"nofollow\" data-fn-id=\"t12n2\" class=\"end-note-link\"><sup>b</sup></span></span><p class=\"chapter-para\">Menorrhagia requires diagnosis and treatment by a gynecologist.</p></span></div></div><div class=\"&#xA;          graphic-wrap&#xA;          \"><a class=\"fig-view-orig openInAnotherWindow btn js-view-large\" target=\"_blank\" href=\"/view-large/99603387\">\r\n          Open in new tab\r\n        </a></div></div></div>                    <h4 scrollto-destination=99603388 id=\"99603388\" class=\"section-title js-splitscreen-section-title\" data-legacy-id=s48>Transgender females</h4>\r\n<p class=\"chapter-para\">Physical changes that may occur in transgender females in the first 3 to 12 months of estrogen and antiandrogen therapy include decreased sexual desire, decreased spontaneous erections, decreased facial and body hair (usually mild), decreased oiliness of skin, increased breast tissue growth, and redistribution of fat mass (<span class=\"xrefLink\" id=\"jumplink-B114\"></span><a href=\"javascript:;\" reveal-id=\"B114\" data-open=\"B114\" class=\"link link-ref link-reveal xref-bibr\">114</a>, <span class=\"xrefLink\" id=\"jumplink-B139\"></span><a href=\"javascript:;\" reveal-id=\"B139\" data-open=\"B139\" class=\"link link-ref link-reveal xref-bibr\">139</a>, <span class=\"xrefLink\" id=\"jumplink-B149\"></span><a href=\"javascript:;\" reveal-id=\"B149\" data-open=\"B149\" class=\"link link-ref link-reveal xref-bibr\">149</a>, <span class=\"xrefLink\" id=\"jumplink-B154\"></span><a href=\"javascript:;\" reveal-id=\"B154\" data-open=\"B154\" class=\"link link-ref link-reveal xref-bibr\">154</a>, <span class=\"xrefLink\" id=\"jumplink-B155\"></span><a href=\"javascript:;\" reveal-id=\"B155\" data-open=\"B155\" class=\"link link-ref link-reveal xref-bibr\">155</a>, <span class=\"xrefLink\" id=\"jumplink-B161\"></span><a href=\"javascript:;\" reveal-id=\"B161\" data-open=\"B161\" class=\"link link-ref link-reveal xref-bibr\">161</a>) (<span class=\"xrefLink\" id=\"jumplink-T13\"></span><a href=\"javascript:;\" reveal-id=\"T13\" data-open=\"T13\" class=\"link link-reveal link-table xref-fig\">Table 13</a>). Breast development is generally maximal at 2 years after initiating hormones (<span class=\"xrefLink\" id=\"jumplink-B114\"></span><a href=\"javascript:;\" reveal-id=\"B114\" data-open=\"B114\" class=\"link link-ref link-reveal xref-bibr\">114</a>, <span class=\"xrefLink\" id=\"jumplink-B139\"></span><a href=\"javascript:;\" reveal-id=\"B139\" data-open=\"B139\" class=\"link link-ref link-reveal xref-bibr\">139</a>, <span class=\"xrefLink\" id=\"jumplink-B149\"></span><a href=\"javascript:;\" reveal-id=\"B149\" data-open=\"B149\" class=\"link link-ref link-reveal xref-bibr\">149</a>, <span class=\"xrefLink\" id=\"jumplink-B155\"></span><a href=\"javascript:;\" reveal-id=\"B155\" data-open=\"B155\" class=\"link link-ref link-reveal xref-bibr\">155</a>). Over a long period of time, the prostate gland and testicles will undergo atrophy.</p>                    <a id=\"99603390\" scrollto-destination=\"99603390\"></a>\r\n<div content-id=\"T13\" class=\"table-modal table-full-width-wrap\"><div class=\"table-wrap table-wide\"><div class=\"table-wrap-title\" id=\"T13\" data-id=\"T13\"><span class=\"label\">Table 13.</span><div class=\"caption\"><p class=\"chapter-para\">Feminizing Effects in Transgender Females</p></div> </div><div class=\"table-overflow\"><table><thead><tr><th>Effect<span aria-hidden=\"true\" style=\"display: none;\">\r\n            . </span></th><th>Onset<span aria-hidden=\"true\" style=\"display: none;\">\r\n            . </span></th><th>Maximum<span aria-hidden=\"true\" style=\"display: none;\">\r\n            . </span></th></tr></thead><tbody><tr><td>Redistribution of body fat </td><td>3–6 mo </td><td>2–3 y </td></tr><tr><td>Decrease in muscle mass and strength </td><td>3–6 mo </td><td>1–2 y </td></tr><tr><td>Softening of skin/decreased oiliness </td><td>3–6 mo </td><td>Unknown </td></tr><tr><td>Decreased sexual desire </td><td>1–3 mo </td><td>3–6 mo </td></tr><tr><td>Decreased spontaneous erections </td><td>1–3 mo </td><td>3–6 mo </td></tr><tr><td>Male sexual dysfunction </td><td>Variable </td><td>Variable </td></tr><tr><td>Breast growth </td><td>3–6 mo </td><td>2–3 y </td></tr><tr><td>Decreased testicular volume </td><td>3–6 mo </td><td>2–3 y </td></tr><tr><td>Decreased sperm production </td><td>Unknown </td><td>&gt;3 y </td></tr><tr><td>Decreased terminal hair growth </td><td>6–12 mo </td><td>&gt;3 y<span class=\"xrefLink\" id=\"jumplink-t13n1\"></span><a href=\"javascript:;\" reveal-id=\"t13n1\" data-open=\"t13n1\" class=\"link link-ref link-reveal xref-fn js-xref-fn\"><em><sup>a</sup></em></a> </td></tr><tr><td>Scalp hair </td><td>Variable </td><td>—<span class=\"xrefLink\" id=\"jumplink-t13n2\"></span><a href=\"javascript:;\" reveal-id=\"t13n2\" data-open=\"t13n2\" class=\"link link-ref link-reveal xref-fn js-xref-fn\"><em><sup>b</sup></em></a> </td></tr><tr><td>Voice changes </td><td>None </td><td>—<em><sup>c</sup></em> </td></tr></tbody></table></div><div class=\"table-modal\"><table><thead><tr><th>Effect<span aria-hidden=\"true\" style=\"display: none;\">\r\n            . </span></th><th>Onset<span aria-hidden=\"true\" style=\"display: none;\">\r\n            . </span></th><th>Maximum<span aria-hidden=\"true\" style=\"display: none;\">\r\n            . </span></th></tr></thead><tbody><tr><td>Redistribution of body fat </td><td>3–6 mo </td><td>2–3 y </td></tr><tr><td>Decrease in muscle mass and strength </td><td>3–6 mo </td><td>1–2 y </td></tr><tr><td>Softening of skin/decreased oiliness </td><td>3–6 mo </td><td>Unknown </td></tr><tr><td>Decreased sexual desire </td><td>1–3 mo </td><td>3–6 mo </td></tr><tr><td>Decreased spontaneous erections </td><td>1–3 mo </td><td>3–6 mo </td></tr><tr><td>Male sexual dysfunction </td><td>Variable </td><td>Variable </td></tr><tr><td>Breast growth </td><td>3–6 mo </td><td>2–3 y </td></tr><tr><td>Decreased testicular volume </td><td>3–6 mo </td><td>2–3 y </td></tr><tr><td>Decreased sperm production </td><td>Unknown </td><td>&gt;3 y </td></tr><tr><td>Decreased terminal hair growth </td><td>6–12 mo </td><td>&gt;3 y<span class=\"xrefLink\" id=\"jumplink-t13n1\"></span><a href=\"javascript:;\" reveal-id=\"t13n1\" data-open=\"t13n1\" class=\"link link-ref link-reveal xref-fn js-xref-fn\"><em><sup>a</sup></em></a> </td></tr><tr><td>Scalp hair </td><td>Variable </td><td>—<span class=\"xrefLink\" id=\"jumplink-t13n2\"></span><a href=\"javascript:;\" reveal-id=\"t13n2\" data-open=\"t13n2\" class=\"link link-ref link-reveal xref-fn js-xref-fn\"><em><sup>b</sup></em></a> </td></tr><tr><td>Voice changes </td><td>None </td><td>—<em><sup>c</sup></em> </td></tr></tbody></table></div><div class=\"table-wrap-foot\"><span id=\"fn-fn-10\"></span><div content-id=\"fn-10\" class=\"footnote\"><span class=\"fn\"><p class=\"chapter-para\">Estimates represent clinical observations: Toorians <em>et al.</em> (<span class=\"xrefLink\" id=\"jumplink-B149\"></span><a href=\"javascript:;\" reveal-id=\"B149\" data-open=\"B149\" class=\"link link-ref link-reveal xref-bibr\">149</a>), Asscheman <em>et al.</em> (<span class=\"xrefLink\" id=\"jumplink-B156\"></span><a href=\"javascript:;\" reveal-id=\"B156\" data-open=\"B156\" class=\"link link-ref link-reveal xref-bibr\">156</a>), Gooren <em>et al.</em> (<span class=\"xrefLink\" id=\"jumplink-B157\"></span><a href=\"javascript:;\" reveal-id=\"B157\" data-open=\"B157\" class=\"link link-ref link-reveal xref-bibr\">157</a>).</p></span></div><span id=\"fn-t13n1\"></span><div content-id=\"t13n1\" class=\"footnote\"><span class=\"fn\"><span class=\"label fn-label\"><span rel=\"nofollow\" data-fn-id=\"t13n1\" class=\"end-note-link\"><sup>a</sup></span></span><p class=\"chapter-para\">Complete removal of male sexual hair requires electrolysis or laser treatment or both.</p></span></div><span id=\"fn-t13n2\"></span><div content-id=\"t13n2\" class=\"footnote\"><span class=\"fn\"><span class=\"label fn-label\"><span rel=\"nofollow\" data-fn-id=\"t13n2\" class=\"end-note-link\"><sup>b</sup></span></span><p class=\"chapter-para\">Familial scalp hair loss may occur if estrogens are stopped.</p></span></div><span id=\"fn-t13n3\"></span><div content-id=\"t13n3\" class=\"footnote\"><span class=\"fn\"><span class=\"label fn-label\"><span rel=\"nofollow\" data-fn-id=\"t13n3\" class=\"end-note-link\"><sup>c</sup></span></span><p class=\"chapter-para\">Treatment by speech pathologists for voice training is most effective.</p></span></div></div><div class=\"&#xA;          graphic-wrap&#xA;          \"><a class=\"fig-view-orig openInAnotherWindow btn js-view-large\" target=\"_blank\" href=\"/view-large/99603390\">\r\n          Open in new tab\r\n        </a></div></div></div><div class=\"table-full-width-wrap\"><div class=\"table-wrap table-wide\"><div class=\"table-wrap-title\" id=\"T13\" data-id=\"T13\"><span class=\"label\">Table 13.</span><div class=\"caption\"><p class=\"chapter-para\">Feminizing Effects in Transgender Females</p></div> </div><div class=\"table-overflow\"><table><thead><tr><th>Effect<span aria-hidden=\"true\" style=\"display: none;\">\r\n            . </span></th><th>Onset<span aria-hidden=\"true\" style=\"display: none;\">\r\n            . </span></th><th>Maximum<span aria-hidden=\"true\" style=\"display: none;\">\r\n            . </span></th></tr></thead><tbody><tr><td>Redistribution of body fat </td><td>3–6 mo </td><td>2–3 y </td></tr><tr><td>Decrease in muscle mass and strength </td><td>3–6 mo </td><td>1–2 y </td></tr><tr><td>Softening of skin/decreased oiliness </td><td>3–6 mo </td><td>Unknown </td></tr><tr><td>Decreased sexual desire </td><td>1–3 mo </td><td>3–6 mo </td></tr><tr><td>Decreased spontaneous erections </td><td>1–3 mo </td><td>3–6 mo </td></tr><tr><td>Male sexual dysfunction </td><td>Variable </td><td>Variable </td></tr><tr><td>Breast growth </td><td>3–6 mo </td><td>2–3 y </td></tr><tr><td>Decreased testicular volume </td><td>3–6 mo </td><td>2–3 y </td></tr><tr><td>Decreased sperm production </td><td>Unknown </td><td>&gt;3 y </td></tr><tr><td>Decreased terminal hair growth </td><td>6–12 mo </td><td>&gt;3 y<span class=\"xrefLink\" id=\"jumplink-t13n1\"></span><a href=\"javascript:;\" reveal-id=\"t13n1\" data-open=\"t13n1\" class=\"link link-ref link-reveal xref-fn js-xref-fn\"><em><sup>a</sup></em></a> </td></tr><tr><td>Scalp hair </td><td>Variable </td><td>—<span class=\"xrefLink\" id=\"jumplink-t13n2\"></span><a href=\"javascript:;\" reveal-id=\"t13n2\" data-open=\"t13n2\" class=\"link link-ref link-reveal xref-fn js-xref-fn\"><em><sup>b</sup></em></a> </td></tr><tr><td>Voice changes </td><td>None </td><td>—<em><sup>c</sup></em> </td></tr></tbody></table></div><div class=\"table-modal\"><table><thead><tr><th>Effect<span aria-hidden=\"true\" style=\"display: none;\">\r\n            . </span></th><th>Onset<span aria-hidden=\"true\" style=\"display: none;\">\r\n            . </span></th><th>Maximum<span aria-hidden=\"true\" style=\"display: none;\">\r\n            . </span></th></tr></thead><tbody><tr><td>Redistribution of body fat </td><td>3–6 mo </td><td>2–3 y </td></tr><tr><td>Decrease in muscle mass and strength </td><td>3–6 mo </td><td>1–2 y </td></tr><tr><td>Softening of skin/decreased oiliness </td><td>3–6 mo </td><td>Unknown </td></tr><tr><td>Decreased sexual desire </td><td>1–3 mo </td><td>3–6 mo </td></tr><tr><td>Decreased spontaneous erections </td><td>1–3 mo </td><td>3–6 mo </td></tr><tr><td>Male sexual dysfunction </td><td>Variable </td><td>Variable </td></tr><tr><td>Breast growth </td><td>3–6 mo </td><td>2–3 y </td></tr><tr><td>Decreased testicular volume </td><td>3–6 mo </td><td>2–3 y </td></tr><tr><td>Decreased sperm production </td><td>Unknown </td><td>&gt;3 y </td></tr><tr><td>Decreased terminal hair growth </td><td>6–12 mo </td><td>&gt;3 y<span class=\"xrefLink\" id=\"jumplink-t13n1\"></span><a href=\"javascript:;\" reveal-id=\"t13n1\" data-open=\"t13n1\" class=\"link link-ref link-reveal xref-fn js-xref-fn\"><em><sup>a</sup></em></a> </td></tr><tr><td>Scalp hair </td><td>Variable </td><td>—<span class=\"xrefLink\" id=\"jumplink-t13n2\"></span><a href=\"javascript:;\" reveal-id=\"t13n2\" data-open=\"t13n2\" class=\"link link-ref link-reveal xref-fn js-xref-fn\"><em><sup>b</sup></em></a> </td></tr><tr><td>Voice changes </td><td>None </td><td>—<em><sup>c</sup></em> </td></tr></tbody></table></div><div class=\"table-wrap-foot\"><span id=\"fn-fn-10\"></span><div content-id=\"fn-10\" class=\"footnote\"><span class=\"fn\"><p class=\"chapter-para\">Estimates represent clinical observations: Toorians <em>et al.</em> (<span class=\"xrefLink\" id=\"jumplink-B149\"></span><a href=\"javascript:;\" reveal-id=\"B149\" data-open=\"B149\" class=\"link link-ref link-reveal xref-bibr\">149</a>), Asscheman <em>et al.</em> (<span class=\"xrefLink\" id=\"jumplink-B156\"></span><a href=\"javascript:;\" reveal-id=\"B156\" data-open=\"B156\" class=\"link link-ref link-reveal xref-bibr\">156</a>), Gooren <em>et al.</em> (<span class=\"xrefLink\" id=\"jumplink-B157\"></span><a href=\"javascript:;\" reveal-id=\"B157\" data-open=\"B157\" class=\"link link-ref link-reveal xref-bibr\">157</a>).</p></span></div><span id=\"fn-t13n1\"></span><div content-id=\"t13n1\" class=\"footnote\"><span class=\"fn\"><span class=\"label fn-label\"><span rel=\"nofollow\" data-fn-id=\"t13n1\" class=\"end-note-link\"><sup>a</sup></span></span><p class=\"chapter-para\">Complete removal of male sexual hair requires electrolysis or laser treatment or both.</p></span></div><span id=\"fn-t13n2\"></span><div content-id=\"t13n2\" class=\"footnote\"><span class=\"fn\"><span class=\"label fn-label\"><span rel=\"nofollow\" data-fn-id=\"t13n2\" class=\"end-note-link\"><sup>b</sup></span></span><p class=\"chapter-para\">Familial scalp hair loss may occur if estrogens are stopped.</p></span></div><span id=\"fn-t13n3\"></span><div content-id=\"t13n3\" class=\"footnote\"><span class=\"fn\"><span class=\"label fn-label\"><span rel=\"nofollow\" data-fn-id=\"t13n3\" class=\"end-note-link\"><sup>c</sup></span></span><p class=\"chapter-para\">Treatment by speech pathologists for voice training is most effective.</p></span></div></div><div class=\"&#xA;          graphic-wrap&#xA;          \"><a class=\"fig-view-orig openInAnotherWindow btn js-view-large\" target=\"_blank\" href=\"/view-large/99603390\">\r\n          Open in new tab\r\n        </a></div></div></div><p class=\"chapter-para\">Although the time course of breast development in transgender females has been studied (<span class=\"xrefLink\" id=\"jumplink-B150\"></span><a href=\"javascript:;\" reveal-id=\"B150\" data-open=\"B150\" class=\"link link-ref link-reveal xref-bibr\">150</a>), precise information about other changes induced by sex hormones is lacking (<span class=\"xrefLink\" id=\"jumplink-B141\"></span><a href=\"javascript:;\" reveal-id=\"B141\" data-open=\"B141\" class=\"link link-ref link-reveal xref-bibr\">141</a>). There is a great deal of variability among individuals, as evidenced during pubertal development. We all know that a major concern for transgender females is breast development. If we work with estrogens, the result will be often not what the transgender female expects.</p><p class=\"chapter-para\">Alternatively, there are transgender females who report an anecdotal improved breast development, mood, or sexual desire with the use of progestogens. However, there have been no well-designed studies of the role of progestogens in feminizing hormone regimens, so the question is still open.</p><p class=\"chapter-para\">Our knowledge concerning the natural history and effects of different cross-sex hormone therapies on breast development in transgender females is extremely sparse and based on the low quality of evidence. Current evidence does not indicate that progestogens enhance breast development in transgender females, nor does evidence prove the absence of such an effect. This prevents us from drawing any firm conclusion at this moment and demonstrates the need for further research to clarify these important clinical questions (<span class=\"xrefLink\" id=\"jumplink-B162\"></span><a href=\"javascript:;\" reveal-id=\"B162\" data-open=\"B162\" class=\"link link-ref link-reveal xref-bibr\">162</a>).</p>                    <h3 scrollto-destination=99603394 id=\"99603394\" class=\"section-title js-splitscreen-section-title\" data-legacy-id=s49>Values and preferences</h3>\r\n<p class=\"chapter-para\">Transgender persons have very high expectations regarding the physical changes of hormone treatment and are aware that body changes can be enhanced by surgical procedures (<em>e.g.</em>, breast, face, and body habitus). Clear expectations for the extent and timing of sex hormone–induced changes may prevent the potential harm and expense of unnecessary procedures.</p>                    <h2 scrollto-destination=99603396 id=\"99603396\" class=\"section-title js-splitscreen-section-title\" data-legacy-id=s50>4.0 Adverse Outcome Prevention and Long-Term Care</h2>\r\n<p class=\"chapter-para\">Hormone therapy for transgender males and females confers many of the same risks associated with sex hormone replacement therapy in nontransgender persons. The risks arise from and are worsened by inadvertent or intentional use of supraphysiologic doses of sex hormones, as well as use of inadequate doses of sex hormones to maintain normal physiology (<span class=\"xrefLink\" id=\"jumplink-B131\"></span><a href=\"javascript:;\" reveal-id=\"B131\" data-open=\"B131\" class=\"link link-ref link-reveal xref-bibr\">131</a>, <span class=\"xrefLink\" id=\"jumplink-B139\"></span><a href=\"javascript:;\" reveal-id=\"B139\" data-open=\"B139\" class=\"link link-ref link-reveal xref-bibr\">139</a>).</p><ul class=\"list-simple\"><li><p class=\"chapter-para\">4.1. We suggest regular clinical evaluation for physical changes and potential adverse changes in response to sex steroid hormones and laboratory monitoring of sex steroid hormone levels every 3 months during the first year of hormone therapy for transgender males and females and then once or twice yearly. (2 |⊕⊕○○)</p></li></ul>                    <h3 scrollto-destination=99603399 id=\"99603399\" class=\"section-title js-splitscreen-section-title\" data-legacy-id=s51>Evidence</h3>\r\n<p class=\"chapter-para\">Pretreatment screening and appropriate regular medical monitoring are recommended for both transgender males and females during the endocrine transition and periodically thereafter (<span class=\"xrefLink\" id=\"jumplink-B26\"></span><a href=\"javascript:;\" reveal-id=\"B26\" data-open=\"B26\" class=\"link link-ref link-reveal xref-bibr\">26</a>, <span class=\"xrefLink\" id=\"jumplink-B155\"></span><a href=\"javascript:;\" reveal-id=\"B155\" data-open=\"B155\" class=\"link link-ref link-reveal xref-bibr\">155</a>). Clinicians should monitor weight and blood pressure, conduct physical exams, and assess routine health questions, such as tobacco use, symptoms of depression, and risk of adverse events such as deep vein thrombosis/pulmonary embolism and other adverse effects of sex steroids.</p>                    <h4 scrollto-destination=99603401 id=\"99603401\" class=\"section-title js-splitscreen-section-title\" data-legacy-id=s52>Transgender males</h4>\r\n<p class=\"chapter-para\"><span class=\"xrefLink\" id=\"jumplink-T14\"></span><a href=\"javascript:;\" reveal-id=\"T14\" data-open=\"T14\" class=\"link link-reveal link-table xref-fig\">Table 14</a> contains a standard monitoring plan for transgender males on testosterone therapy (<span class=\"xrefLink\" id=\"jumplink-B154\"></span><a href=\"javascript:;\" reveal-id=\"B154\" data-open=\"B154\" class=\"link link-ref link-reveal xref-bibr\">154</a>, <span class=\"xrefLink\" id=\"jumplink-B159\"></span><a href=\"javascript:;\" reveal-id=\"B159\" data-open=\"B159\" class=\"link link-ref link-reveal xref-bibr\">159</a>). Key issues include maintaining testosterone levels in the physiologic normal male range and avoiding adverse events resulting from excess testosterone therapy, particularly erythrocytosis, sleep apnea, hypertension, excessive weight gain, salt retention, lipid changes, and excessive or cystic acne (<span class=\"xrefLink\" id=\"jumplink-B135\"></span><a href=\"javascript:;\" reveal-id=\"B135\" data-open=\"B135\" class=\"link link-ref link-reveal xref-bibr\">135</a>).</p>                    <a id=\"99603403\" scrollto-destination=\"99603403\"></a>\r\n<div content-id=\"T14\" class=\"table-modal table-full-width-wrap\"><div class=\"table-wrap table-wide\"><div class=\"table-wrap-title\" id=\"T14\" data-id=\"T14\"><span class=\"label\">Table 14.</span><div class=\"caption\"><p class=\"chapter-para\">Monitoring of Transgender Persons on Gender-Affirming Hormone Therapy: Transgender Male</p></div> </div><div class=\"table-overflow\"><table><tbody><tr><td>1. Evaluate patient every 3 mo in the first year and then one to two times per year to monitor for appropriate signs of virilization and for development of adverse reactions. </td></tr><tr><td>2. Measure serum testosterone every 3 mo until levels are in the normal physiologic male range:<span class=\"xrefLink\" id=\"jumplink-t14n1\"></span><a href=\"javascript:;\" reveal-id=\"t14n1\" data-open=\"t14n1\" class=\"link link-ref link-reveal xref-fn js-xref-fn\"><em><sup>a</sup></em></a> </td></tr><tr><td> a. For testosterone enanthate/cypionate injections, the testosterone level should be measured midway between injections. The target level is 400–700 ng/dL to 400 ng/dL. Alternatively, measure peak and trough levels to ensure levels remain in the normal male range. </td></tr><tr><td> b. For parenteral testosterone undecanoate, testosterone should be measured just before the following injection. If the level is &lt;400 ng/dL, adjust dosing interval. </td></tr><tr><td> c. For transdermal testosterone, the testosterone level can be measured no sooner than after 1 wk of daily application (at least 2 h after application). </td></tr><tr><td>3. Measure hematocrit or hemoglobin at baseline and every 3 mo for the first year and then one to two times a year. Monitor weight, blood pressure, and lipids at regular intervals. </td></tr><tr><td>4. Screening for osteoporosis should be conducted in those who stop testosterone treatment, are not compliant with hormone therapy, or who develop risks for bone loss. </td></tr><tr><td>5. If cervical tissue is present, monitoring as recommended by the American College of Obstetricians and Gynecologists. </td></tr><tr><td>6. Ovariectomy can be considered after completion of hormone transition. </td></tr><tr><td>7. Conduct sub- and periareolar annual breast examinations if mastectomy performed. If mastectomy is not performed, then consider mammograms as recommended by the American Cancer Society. </td></tr></tbody></table></div><div class=\"table-modal\"><table><tbody><tr><td>1. Evaluate patient every 3 mo in the first year and then one to two times per year to monitor for appropriate signs of virilization and for development of adverse reactions. </td></tr><tr><td>2. Measure serum testosterone every 3 mo until levels are in the normal physiologic male range:<span class=\"xrefLink\" id=\"jumplink-t14n1\"></span><a href=\"javascript:;\" reveal-id=\"t14n1\" data-open=\"t14n1\" class=\"link link-ref link-reveal xref-fn js-xref-fn\"><em><sup>a</sup></em></a> </td></tr><tr><td> a. For testosterone enanthate/cypionate injections, the testosterone level should be measured midway between injections. The target level is 400–700 ng/dL to 400 ng/dL. Alternatively, measure peak and trough levels to ensure levels remain in the normal male range. </td></tr><tr><td> b. For parenteral testosterone undecanoate, testosterone should be measured just before the following injection. If the level is &lt;400 ng/dL, adjust dosing interval. </td></tr><tr><td> c. For transdermal testosterone, the testosterone level can be measured no sooner than after 1 wk of daily application (at least 2 h after application). </td></tr><tr><td>3. Measure hematocrit or hemoglobin at baseline and every 3 mo for the first year and then one to two times a year. Monitor weight, blood pressure, and lipids at regular intervals. </td></tr><tr><td>4. Screening for osteoporosis should be conducted in those who stop testosterone treatment, are not compliant with hormone therapy, or who develop risks for bone loss. </td></tr><tr><td>5. If cervical tissue is present, monitoring as recommended by the American College of Obstetricians and Gynecologists. </td></tr><tr><td>6. Ovariectomy can be considered after completion of hormone transition. </td></tr><tr><td>7. Conduct sub- and periareolar annual breast examinations if mastectomy performed. If mastectomy is not performed, then consider mammograms as recommended by the American Cancer Society. </td></tr></tbody></table></div><div class=\"table-wrap-foot\"><span id=\"fn-t14n1\"></span><div content-id=\"t14n1\" class=\"footnote\"><span class=\"fn\"><span class=\"label fn-label\"><span rel=\"nofollow\" data-fn-id=\"t14n1\" class=\"end-note-link\"><sup>a</sup></span></span><p class=\"chapter-para\">Adapted from Lapauw <em>et al.</em> (<span class=\"xrefLink\" id=\"jumplink-B154\"></span><a href=\"javascript:;\" reveal-id=\"B154\" data-open=\"B154\" class=\"link link-ref link-reveal xref-bibr\">154</a>) and Ott <em>et al.</em> (<span class=\"xrefLink\" id=\"jumplink-B159\"></span><a href=\"javascript:;\" reveal-id=\"B159\" data-open=\"B159\" class=\"link link-ref link-reveal xref-bibr\">159</a>).</p></span></div></div><div class=\"&#xA;          graphic-wrap&#xA;          \"><a class=\"fig-view-orig openInAnotherWindow btn js-view-large\" target=\"_blank\" href=\"/view-large/99603403\">\r\n          Open in new tab\r\n        </a></div></div></div><div class=\"table-full-width-wrap\"><div class=\"table-wrap table-wide\"><div class=\"table-wrap-title\" id=\"T14\" data-id=\"T14\"><span class=\"label\">Table 14.</span><div class=\"caption\"><p class=\"chapter-para\">Monitoring of Transgender Persons on Gender-Affirming Hormone Therapy: Transgender Male</p></div> </div><div class=\"table-overflow\"><table><tbody><tr><td>1. Evaluate patient every 3 mo in the first year and then one to two times per year to monitor for appropriate signs of virilization and for development of adverse reactions. </td></tr><tr><td>2. Measure serum testosterone every 3 mo until levels are in the normal physiologic male range:<span class=\"xrefLink\" id=\"jumplink-t14n1\"></span><a href=\"javascript:;\" reveal-id=\"t14n1\" data-open=\"t14n1\" class=\"link link-ref link-reveal xref-fn js-xref-fn\"><em><sup>a</sup></em></a> </td></tr><tr><td> a. For testosterone enanthate/cypionate injections, the testosterone level should be measured midway between injections. The target level is 400–700 ng/dL to 400 ng/dL. Alternatively, measure peak and trough levels to ensure levels remain in the normal male range. </td></tr><tr><td> b. For parenteral testosterone undecanoate, testosterone should be measured just before the following injection. If the level is &lt;400 ng/dL, adjust dosing interval. </td></tr><tr><td> c. For transdermal testosterone, the testosterone level can be measured no sooner than after 1 wk of daily application (at least 2 h after application). </td></tr><tr><td>3. Measure hematocrit or hemoglobin at baseline and every 3 mo for the first year and then one to two times a year. Monitor weight, blood pressure, and lipids at regular intervals. </td></tr><tr><td>4. Screening for osteoporosis should be conducted in those who stop testosterone treatment, are not compliant with hormone therapy, or who develop risks for bone loss. </td></tr><tr><td>5. If cervical tissue is present, monitoring as recommended by the American College of Obstetricians and Gynecologists. </td></tr><tr><td>6. Ovariectomy can be considered after completion of hormone transition. </td></tr><tr><td>7. Conduct sub- and periareolar annual breast examinations if mastectomy performed. If mastectomy is not performed, then consider mammograms as recommended by the American Cancer Society. </td></tr></tbody></table></div><div class=\"table-modal\"><table><tbody><tr><td>1. Evaluate patient every 3 mo in the first year and then one to two times per year to monitor for appropriate signs of virilization and for development of adverse reactions. </td></tr><tr><td>2. Measure serum testosterone every 3 mo until levels are in the normal physiologic male range:<span class=\"xrefLink\" id=\"jumplink-t14n1\"></span><a href=\"javascript:;\" reveal-id=\"t14n1\" data-open=\"t14n1\" class=\"link link-ref link-reveal xref-fn js-xref-fn\"><em><sup>a</sup></em></a> </td></tr><tr><td> a. For testosterone enanthate/cypionate injections, the testosterone level should be measured midway between injections. The target level is 400–700 ng/dL to 400 ng/dL. Alternatively, measure peak and trough levels to ensure levels remain in the normal male range. </td></tr><tr><td> b. For parenteral testosterone undecanoate, testosterone should be measured just before the following injection. If the level is &lt;400 ng/dL, adjust dosing interval. </td></tr><tr><td> c. For transdermal testosterone, the testosterone level can be measured no sooner than after 1 wk of daily application (at least 2 h after application). </td></tr><tr><td>3. Measure hematocrit or hemoglobin at baseline and every 3 mo for the first year and then one to two times a year. Monitor weight, blood pressure, and lipids at regular intervals. </td></tr><tr><td>4. Screening for osteoporosis should be conducted in those who stop testosterone treatment, are not compliant with hormone therapy, or who develop risks for bone loss. </td></tr><tr><td>5. If cervical tissue is present, monitoring as recommended by the American College of Obstetricians and Gynecologists. </td></tr><tr><td>6. Ovariectomy can be considered after completion of hormone transition. </td></tr><tr><td>7. Conduct sub- and periareolar annual breast examinations if mastectomy performed. If mastectomy is not performed, then consider mammograms as recommended by the American Cancer Society. </td></tr></tbody></table></div><div class=\"table-wrap-foot\"><span id=\"fn-t14n1\"></span><div content-id=\"t14n1\" class=\"footnote\"><span class=\"fn\"><span class=\"label fn-label\"><span rel=\"nofollow\" data-fn-id=\"t14n1\" class=\"end-note-link\"><sup>a</sup></span></span><p class=\"chapter-para\">Adapted from Lapauw <em>et al.</em> (<span class=\"xrefLink\" id=\"jumplink-B154\"></span><a href=\"javascript:;\" reveal-id=\"B154\" data-open=\"B154\" class=\"link link-ref link-reveal xref-bibr\">154</a>) and Ott <em>et al.</em> (<span class=\"xrefLink\" id=\"jumplink-B159\"></span><a href=\"javascript:;\" reveal-id=\"B159\" data-open=\"B159\" class=\"link link-ref link-reveal xref-bibr\">159</a>).</p></span></div></div><div class=\"&#xA;          graphic-wrap&#xA;          \"><a class=\"fig-view-orig openInAnotherWindow btn js-view-large\" target=\"_blank\" href=\"/view-large/99603403\">\r\n          Open in new tab\r\n        </a></div></div></div><p class=\"chapter-para\">Because oral 17-alkylated testosterone is not recommended, serious hepatic toxicity is not anticipated with parenteral or transdermal testosterone use (<span class=\"xrefLink\" id=\"jumplink-B163\"></span><a href=\"javascript:;\" reveal-id=\"B163\" data-open=\"B163\" class=\"link link-ref link-reveal xref-bibr\">163</a>, <span class=\"xrefLink\" id=\"jumplink-B164\"></span><a href=\"javascript:;\" reveal-id=\"B164\" data-open=\"B164\" class=\"link link-ref link-reveal xref-bibr\">164</a>). Past concerns regarding liver toxicity with testosterone have been alleviated with subsequent reports that indicate the risk of serious liver disease is minimal (<span class=\"xrefLink\" id=\"jumplink-B144\"></span><a href=\"javascript:;\" reveal-id=\"B144\" data-open=\"B144\" class=\"link link-ref link-reveal xref-bibr\">144</a>, <span class=\"xrefLink\" id=\"jumplink-B165\"></span><a href=\"javascript:;\" reveal-id=\"B165\" data-open=\"B165\" class=\"link link-ref link-reveal xref-bibr\">165</a>, <span class=\"xrefLink\" id=\"jumplink-B166\"></span><a href=\"javascript:;\" reveal-id=\"B166\" data-open=\"B166\" class=\"link link-ref link-reveal xref-bibr\">166</a>).</p>                    <h4 scrollto-destination=99603405 id=\"99603405\" class=\"section-title js-splitscreen-section-title\" data-legacy-id=s53>Transgender females</h4>\r\n<p class=\"chapter-para\"><span class=\"xrefLink\" id=\"jumplink-T15\"></span><a href=\"javascript:;\" reveal-id=\"T15\" data-open=\"T15\" class=\"link link-reveal link-table xref-fig\">Table 15</a> contains a standard monitoring plan for transgender females on estrogens, gonadotropin suppression, or antiandrogens (<span class=\"xrefLink\" id=\"jumplink-B160\"></span><a href=\"javascript:;\" reveal-id=\"B160\" data-open=\"B160\" class=\"link link-ref link-reveal xref-bibr\">160</a>). Key issues include avoiding supraphysiologic doses or blood levels of estrogen that may lead to increased risk for thromboembolic disease, liver dysfunction, and hypertension. Clinicians should monitor serum estradiol levels using laboratories participating in external quality control, as measurements of estradiol in blood can be very challenging (<span class=\"xrefLink\" id=\"jumplink-B167\"></span><a href=\"javascript:;\" reveal-id=\"B167\" data-open=\"B167\" class=\"link link-ref link-reveal xref-bibr\">167</a>).</p>                    <a id=\"99603407\" scrollto-destination=\"99603407\"></a>\r\n<div content-id=\"T15\" class=\"table-modal table-full-width-wrap\"><div class=\"table-wrap table-wide\"><div class=\"table-wrap-title\" id=\"T15\" data-id=\"T15\"><span class=\"label\">Table 15.</span><div class=\"caption\"><p class=\"chapter-para\">Monitoring of Transgender Persons on Gender-Affirming Hormone Therapy: Transgender Female</p></div> </div><div class=\"table-overflow\"><table><tbody><tr><td>1. Evaluate patient every 3 mo in the first year and then one to two times per year to monitor for appropriate signs of feminization and for development of adverse reactions. </td></tr><tr><td>2. Measure serum testosterone and estradiol every 3 mo. </td></tr><tr><td> a. Serum testosterone levels should be &lt;50 ng/dL. </td></tr><tr><td> b. Serum estradiol should not exceed the peak physiologic range: 100–200 pg/mL. </td></tr><tr><td>3. For individuals on spironolactone, serum electrolytes, particularly potassium, should be monitored every 3 mo in the first year and annually thereafter. </td></tr><tr><td>4. Routine cancer screening is recommended, as in nontransgender individuals (all tissues present). </td></tr><tr><td>5. Consider BMD testing at baseline (<span class=\"xrefLink\" id=\"jumplink-B160\"></span><a href=\"javascript:;\" reveal-id=\"B160\" data-open=\"B160\" class=\"link link-ref link-reveal xref-bibr\">160</a>). In individuals at low risk, screening for osteoporosis should be conducted at age 60 years or in those who are not compliant with hormone therapy. </td></tr></tbody></table></div><div class=\"table-modal\"><table><tbody><tr><td>1. Evaluate patient every 3 mo in the first year and then one to two times per year to monitor for appropriate signs of feminization and for development of adverse reactions. </td></tr><tr><td>2. Measure serum testosterone and estradiol every 3 mo. </td></tr><tr><td> a. Serum testosterone levels should be &lt;50 ng/dL. </td></tr><tr><td> b. Serum estradiol should not exceed the peak physiologic range: 100–200 pg/mL. </td></tr><tr><td>3. For individuals on spironolactone, serum electrolytes, particularly potassium, should be monitored every 3 mo in the first year and annually thereafter. </td></tr><tr><td>4. Routine cancer screening is recommended, as in nontransgender individuals (all tissues present). </td></tr><tr><td>5. Consider BMD testing at baseline (<span class=\"xrefLink\" id=\"jumplink-B160\"></span><a href=\"javascript:;\" reveal-id=\"B160\" data-open=\"B160\" class=\"link link-ref link-reveal xref-bibr\">160</a>). In individuals at low risk, screening for osteoporosis should be conducted at age 60 years or in those who are not compliant with hormone therapy. </td></tr></tbody></table></div><div class=\"table-wrap-foot\"><span id=\"fn-fn-11\"></span><div content-id=\"fn-11\" class=\"footnote\"><span class=\"fn\"><p class=\"chapter-para\">This table presents strong recommendations and does not include lower level recommendations.</p></span></div></div><div class=\"&#xA;          graphic-wrap&#xA;          \"><a class=\"fig-view-orig openInAnotherWindow btn js-view-large\" target=\"_blank\" href=\"/view-large/99603407\">\r\n          Open in new tab\r\n        </a></div></div></div><div class=\"table-full-width-wrap\"><div class=\"table-wrap table-wide\"><div class=\"table-wrap-title\" id=\"T15\" data-id=\"T15\"><span class=\"label\">Table 15.</span><div class=\"caption\"><p class=\"chapter-para\">Monitoring of Transgender Persons on Gender-Affirming Hormone Therapy: Transgender Female</p></div> </div><div class=\"table-overflow\"><table><tbody><tr><td>1. Evaluate patient every 3 mo in the first year and then one to two times per year to monitor for appropriate signs of feminization and for development of adverse reactions. </td></tr><tr><td>2. Measure serum testosterone and estradiol every 3 mo. </td></tr><tr><td> a. Serum testosterone levels should be &lt;50 ng/dL. </td></tr><tr><td> b. Serum estradiol should not exceed the peak physiologic range: 100–200 pg/mL. </td></tr><tr><td>3. For individuals on spironolactone, serum electrolytes, particularly potassium, should be monitored every 3 mo in the first year and annually thereafter. </td></tr><tr><td>4. Routine cancer screening is recommended, as in nontransgender individuals (all tissues present). </td></tr><tr><td>5. Consider BMD testing at baseline (<span class=\"xrefLink\" id=\"jumplink-B160\"></span><a href=\"javascript:;\" reveal-id=\"B160\" data-open=\"B160\" class=\"link link-ref link-reveal xref-bibr\">160</a>). In individuals at low risk, screening for osteoporosis should be conducted at age 60 years or in those who are not compliant with hormone therapy. </td></tr></tbody></table></div><div class=\"table-modal\"><table><tbody><tr><td>1. Evaluate patient every 3 mo in the first year and then one to two times per year to monitor for appropriate signs of feminization and for development of adverse reactions. </td></tr><tr><td>2. Measure serum testosterone and estradiol every 3 mo. </td></tr><tr><td> a. Serum testosterone levels should be &lt;50 ng/dL. </td></tr><tr><td> b. Serum estradiol should not exceed the peak physiologic range: 100–200 pg/mL. </td></tr><tr><td>3. For individuals on spironolactone, serum electrolytes, particularly potassium, should be monitored every 3 mo in the first year and annually thereafter. </td></tr><tr><td>4. Routine cancer screening is recommended, as in nontransgender individuals (all tissues present). </td></tr><tr><td>5. Consider BMD testing at baseline (<span class=\"xrefLink\" id=\"jumplink-B160\"></span><a href=\"javascript:;\" reveal-id=\"B160\" data-open=\"B160\" class=\"link link-ref link-reveal xref-bibr\">160</a>). In individuals at low risk, screening for osteoporosis should be conducted at age 60 years or in those who are not compliant with hormone therapy. </td></tr></tbody></table></div><div class=\"table-wrap-foot\"><span id=\"fn-fn-11\"></span><div content-id=\"fn-11\" class=\"footnote\"><span class=\"fn\"><p class=\"chapter-para\">This table presents strong recommendations and does not include lower level recommendations.</p></span></div></div><div class=\"&#xA;          graphic-wrap&#xA;          \"><a class=\"fig-view-orig openInAnotherWindow btn js-view-large\" target=\"_blank\" href=\"/view-large/99603407\">\r\n          Open in new tab\r\n        </a></div></div></div><p class=\"chapter-para\">VTE may be a serious complication. A study reported a 20-fold increase in venous thromboembolic disease in a large cohort of Dutch transgender subjects (<span class=\"xrefLink\" id=\"jumplink-B161\"></span><a href=\"javascript:;\" reveal-id=\"B161\" data-open=\"B161\" class=\"link link-ref link-reveal xref-bibr\">161</a>). This increase may have been associated with the use of the synthetic estrogen, ethinyl estradiol (<span class=\"xrefLink\" id=\"jumplink-B149\"></span><a href=\"javascript:;\" reveal-id=\"B149\" data-open=\"B149\" class=\"link link-ref link-reveal xref-bibr\">149</a>). The incidence decreased when clinicians stopped administering ethinyl estradiol (<span class=\"xrefLink\" id=\"jumplink-B161\"></span><a href=\"javascript:;\" reveal-id=\"B161\" data-open=\"B161\" class=\"link link-ref link-reveal xref-bibr\">161</a>). Thus, the use of synthetic estrogens and conjugated estrogens is undesirable because of the inability to regulate doses by measuring serum levels and the risk of thromboembolic disease. In a German gender clinic, deep vein thrombosis occurred in 1 of 60 of transgender females treated with a GnRH analog and oral estradiol (<span class=\"xrefLink\" id=\"jumplink-B141\"></span><a href=\"javascript:;\" reveal-id=\"B141\" data-open=\"B141\" class=\"link link-ref link-reveal xref-bibr\">141</a>). The patient who developed a deep vein thrombosis was found to have a homozygous C677 T mutation in the methylenetetrahydrofolate reductase gene. In an Austrian gender clinic, administering gender-affirming hormones to 162 transgender females and 89 transgender males was not associated with VTE, despite an 8.0% and 5.6% incidence of thrombophilia (<span class=\"xrefLink\" id=\"jumplink-B159\"></span><a href=\"javascript:;\" reveal-id=\"B159\" data-open=\"B159\" class=\"link link-ref link-reveal xref-bibr\">159</a>). A more recent multinational study reported only 10 cases of VTE from a cohort of 1073 subjects (<span class=\"xrefLink\" id=\"jumplink-B168\"></span><a href=\"javascript:;\" reveal-id=\"B168\" data-open=\"B168\" class=\"link link-ref link-reveal xref-bibr\">168</a>). Thrombophilia screening of transgender persons initiating hormone treatment should be restricted to those with a personal or family history of VTE (<span class=\"xrefLink\" id=\"jumplink-B159\"></span><a href=\"javascript:;\" reveal-id=\"B159\" data-open=\"B159\" class=\"link link-ref link-reveal xref-bibr\">159</a>). Monitoring <span class=\"small-caps\">D</span>-dimer levels during treatment is not recommended (<span class=\"xrefLink\" id=\"jumplink-B169\"></span><a href=\"javascript:;\" reveal-id=\"B169\" data-open=\"B169\" class=\"link link-ref link-reveal xref-bibr\">169</a>).</p><ul class=\"list-simple\"><li><p class=\"chapter-para\">4.2. We suggest periodically monitoring prolactin levels in transgender females treated with estrogens. (2 |⊕⊕○○)</p></li></ul>                    <h3 scrollto-destination=99603410 id=\"99603410\" class=\"section-title js-splitscreen-section-title\" data-legacy-id=s54>Evidence</h3>\r\n<p class=\"chapter-para\">Estrogen therapy can increase the growth of pituitary lactrotroph cells. There have been several reports of prolactinomas occurring after long-term, high-dose estrogen therapy (<span class=\"xrefLink\" id=\"jumplink-B170\"></span><a href=\"javascript:;\" reveal-id=\"B170\" data-open=\"B170\" class=\"link link-ref link-reveal xref-bibr\">170</a>–<span class=\"xrefLink\" id=\"jumplink-B173\"></span><a href=\"javascript:;\" reveal-id=\"B173\" data-open=\"B173\" class=\"link link-ref link-reveal xref-bibr\">173</a>). Up to 20% of transgender females treated with estrogens may have elevations in prolactin levels associated with enlargement of the pituitary gland (<span class=\"xrefLink\" id=\"jumplink-B156\"></span><a href=\"javascript:;\" reveal-id=\"B156\" data-open=\"B156\" class=\"link link-ref link-reveal xref-bibr\">156</a>). In most cases, the serum prolactin levels will return to the normal range with a reduction or discontinuation of the estrogen therapy or discontinuation of cyproterone acetate (<span class=\"xrefLink\" id=\"jumplink-B157\"></span><a href=\"javascript:;\" reveal-id=\"B157\" data-open=\"B157\" class=\"link link-ref link-reveal xref-bibr\">157</a>, <span class=\"xrefLink\" id=\"jumplink-B174\"></span><a href=\"javascript:;\" reveal-id=\"B174\" data-open=\"B174\" class=\"link link-ref link-reveal xref-bibr\">174</a>, <span class=\"xrefLink\" id=\"jumplink-B175\"></span><a href=\"javascript:;\" reveal-id=\"B175\" data-open=\"B175\" class=\"link link-ref link-reveal xref-bibr\">175</a>).</p><p class=\"chapter-para\">The onset and time course of hyperprolactinemia during estrogen treatment are not known. Clinicians should measure prolactin levels at baseline and then at least annually during the transition period and every 2 years thereafter. Given that only a few case studies reported prolactinomas, and prolactinomas were not reported in large cohorts of estrogen-treated persons, the risk is likely to be very low. Because the major presenting findings of microprolactinomas (hypogonadism and sometimes gynecomastia) are not apparent in transgender females, clinicians may perform radiologic examinations of the pituitary in those patients whose prolactin levels persistently increase despite stable or reduced estrogen levels. Some transgender individuals receive psychotropic medications that can increase prolactin levels (<span class=\"xrefLink\" id=\"jumplink-B174\"></span><a href=\"javascript:;\" reveal-id=\"B174\" data-open=\"B174\" class=\"link link-ref link-reveal xref-bibr\">174</a>).</p><ul class=\"list-simple\"><li><p class=\"chapter-para\">4.3. We suggest that clinicians evaluate transgender persons treated with hormones for cardiovascular risk factors using fasting lipid profiles, diabetes screening, and/or other diagnostic tools. (2 |⊕⊕○○)</p></li></ul>                    <h3 scrollto-destination=99603414 id=\"99603414\" class=\"section-title js-splitscreen-section-title\" data-legacy-id=s55>Evidence</h3>\r\n                    <h4 scrollto-destination=99603415 id=\"99603415\" class=\"section-title js-splitscreen-section-title\" data-legacy-id=s56>Transgender males</h4>\r\n<p class=\"chapter-para\">Administering testosterone to transgender males results in a more atherogenic lipid profile with lowered high-density lipoprotein cholesterol and higher triglyceride and low-density lipoprotein cholesterol values (<span class=\"xrefLink\" id=\"jumplink-B176\"></span><a href=\"javascript:;\" reveal-id=\"B176\" data-open=\"B176\" class=\"link link-ref link-reveal xref-bibr\">176</a>–<span class=\"xrefLink\" id=\"jumplink-B179\"></span><a href=\"javascript:;\" reveal-id=\"B179\" data-open=\"B179\" class=\"link link-ref link-reveal xref-bibr\">179</a>). Studies of the effect of testosterone on insulin sensitivity have mixed results (<span class=\"xrefLink\" id=\"jumplink-B178\"></span><a href=\"javascript:;\" reveal-id=\"B178\" data-open=\"B178\" class=\"link link-ref link-reveal xref-bibr\">178</a>, <span class=\"xrefLink\" id=\"jumplink-B180\"></span><a href=\"javascript:;\" reveal-id=\"B180\" data-open=\"B180\" class=\"link link-ref link-reveal xref-bibr\">180</a>). A randomized, open-label uncontrolled safety study of transgender males treated with testosterone undecanoate demonstrated no insulin resistance after 1 year (<span class=\"xrefLink\" id=\"jumplink-B181\"></span><a href=\"javascript:;\" reveal-id=\"B181\" data-open=\"B181\" class=\"link link-ref link-reveal xref-bibr\">181</a>, <span class=\"xrefLink\" id=\"jumplink-B182\"></span><a href=\"javascript:;\" reveal-id=\"B182\" data-open=\"B182\" class=\"link link-ref link-reveal xref-bibr\">182</a>). Numerous studies have demonstrated the effects of sex hormone treatment on the cardiovascular system (<span class=\"xrefLink\" id=\"jumplink-B160\"></span><a href=\"javascript:;\" reveal-id=\"B160\" data-open=\"B160\" class=\"link link-ref link-reveal xref-bibr\">160</a>, <span class=\"xrefLink\" id=\"jumplink-B179\"></span><a href=\"javascript:;\" reveal-id=\"B179\" data-open=\"B179\" class=\"link link-ref link-reveal xref-bibr\">179</a>, <span class=\"xrefLink\" id=\"jumplink-B183\"></span><a href=\"javascript:;\" reveal-id=\"B183\" data-open=\"B183\" class=\"link link-ref link-reveal xref-bibr\">183</a>, <span class=\"xrefLink\" id=\"jumplink-B184\"></span><a href=\"javascript:;\" reveal-id=\"B184\" data-open=\"B184\" class=\"link link-ref link-reveal xref-bibr\">184</a>). Long-term studies from The Netherlands found no increased risk for cardiovascular mortality (<span class=\"xrefLink\" id=\"jumplink-B161\"></span><a href=\"javascript:;\" reveal-id=\"B161\" data-open=\"B161\" class=\"link link-ref link-reveal xref-bibr\">161</a>). Likewise, a meta-analysis of 19 randomized trials in nontransgender males on testosterone replacement showed no increased incidence of cardiovascular events (<span class=\"xrefLink\" id=\"jumplink-B185\"></span><a href=\"javascript:;\" reveal-id=\"B185\" data-open=\"B185\" class=\"link link-ref link-reveal xref-bibr\">185</a>). A systematic review of the literature found that data were insufficient (due to very low–quality evidence) to allow a meaningful assessment of patient-important outcomes, such as death, stroke, myocardial infarction, or VTE in transgender males (<span class=\"xrefLink\" id=\"jumplink-B176\"></span><a href=\"javascript:;\" reveal-id=\"B176\" data-open=\"B176\" class=\"link link-ref link-reveal xref-bibr\">176</a>). Future research is needed to ascertain the potential harm of hormonal therapies (<span class=\"xrefLink\" id=\"jumplink-B176\"></span><a href=\"javascript:;\" reveal-id=\"B176\" data-open=\"B176\" class=\"link link-ref link-reveal xref-bibr\">176</a>). Clinicians should manage cardiovascular risk factors as they emerge according to established guidelines (<span class=\"xrefLink\" id=\"jumplink-B186\"></span><a href=\"javascript:;\" reveal-id=\"B186\" data-open=\"B186\" class=\"link link-ref link-reveal xref-bibr\">186</a>).</p>                    <h4 scrollto-destination=99603417 id=\"99603417\" class=\"section-title js-splitscreen-section-title\" data-legacy-id=s57>Transgender females</h4>\r\n<p class=\"chapter-para\">A prospective study of transgender females found favorable changes in lipid parameters with increased high-density lipoprotein and decreased low-density lipoprotein concentrations (<span class=\"xrefLink\" id=\"jumplink-B178\"></span><a href=\"javascript:;\" reveal-id=\"B178\" data-open=\"B178\" class=\"link link-ref link-reveal xref-bibr\">178</a>). However, increased weight, blood pressure, and markers of insulin resistance attenuated these favorable lipid changes. In a meta-analysis, only serum triglycerides were higher at ≥24 months without changes in other parameters (<span class=\"xrefLink\" id=\"jumplink-B187\"></span><a href=\"javascript:;\" reveal-id=\"B187\" data-open=\"B187\" class=\"link link-ref link-reveal xref-bibr\">187</a>). The largest cohort of transgender females (mean age 41 years, followed for a mean of 10 years) showed no increase in cardiovascular mortality despite a 32% rate of tobacco use (<span class=\"xrefLink\" id=\"jumplink-B161\"></span><a href=\"javascript:;\" reveal-id=\"B161\" data-open=\"B161\" class=\"link link-ref link-reveal xref-bibr\">161</a>).</p><p class=\"chapter-para\">Thus, there is limited evidence to determine whether estrogen is protective or detrimental on lipid and glucose metabolism in transgender females (<span class=\"xrefLink\" id=\"jumplink-B176\"></span><a href=\"javascript:;\" reveal-id=\"B176\" data-open=\"B176\" class=\"link link-ref link-reveal xref-bibr\">176</a>). With aging, there is usually an increase of body weight. Therefore, as with nontransgender individuals, clinicians should monitor and manage glucose and lipid metabolism and blood pressure regularly according to established guidelines (<span class=\"xrefLink\" id=\"jumplink-B186\"></span><a href=\"javascript:;\" reveal-id=\"B186\" data-open=\"B186\" class=\"link link-ref link-reveal xref-bibr\">186</a>).</p><ul class=\"list-simple\"><li><p class=\"chapter-para\">4.4. We recommend that clinicians obtain BMD measurements when risk factors for osteoporosis exist, specifically in those who stop sex hormone therapy after gonadectomy. (1 |⊕⊕○○)</p></li></ul>                    <h3 scrollto-destination=99603421 id=\"99603421\" class=\"section-title js-splitscreen-section-title\" data-legacy-id=s58>Evidence</h3>\r\n                    <h4 scrollto-destination=99603422 id=\"99603422\" class=\"section-title js-splitscreen-section-title\" data-legacy-id=s59>Transgender males</h4>\r\n<p class=\"chapter-para\">Baseline bone mineral measurements in transgender males are generally in the expected range for their pretreatment gender (<span class=\"xrefLink\" id=\"jumplink-B188\"></span><a href=\"javascript:;\" reveal-id=\"B188\" data-open=\"B188\" class=\"link link-ref link-reveal xref-bibr\">188</a>). However, adequate dosing of testosterone is important to maintain bone mass in transgender males (<span class=\"xrefLink\" id=\"jumplink-B189\"></span><a href=\"javascript:;\" reveal-id=\"B189\" data-open=\"B189\" class=\"link link-ref link-reveal xref-bibr\">189</a>, <span class=\"xrefLink\" id=\"jumplink-B190\"></span><a href=\"javascript:;\" reveal-id=\"B190\" data-open=\"B190\" class=\"link link-ref link-reveal xref-bibr\">190</a>). In one study (<span class=\"xrefLink\" id=\"jumplink-B190\"></span><a href=\"javascript:;\" reveal-id=\"B190\" data-open=\"B190\" class=\"link link-ref link-reveal xref-bibr\">190</a>), serum LH levels were inversely related to BMD, suggesting that low levels of sex hormones were associated with bone loss. Thus, LH levels in the normal range may serve as an indicator of the adequacy of sex steroid administration to preserve bone mass. The protective effect of testosterone may be mediated by peripheral conversion to estradiol, both systemically and locally in the bone.</p>                    <h4 scrollto-destination=99603424 id=\"99603424\" class=\"section-title js-splitscreen-section-title\" data-legacy-id=s60>Transgender females</h4>\r\n<p class=\"chapter-para\">A baseline study of BMD reported T scores less than −2.5 in 16% of transgender females (<span class=\"xrefLink\" id=\"jumplink-B191\"></span><a href=\"javascript:;\" reveal-id=\"B191\" data-open=\"B191\" class=\"link link-ref link-reveal xref-bibr\">191</a>). In aging males, studies suggest that serum estradiol more positively correlates with BMD than does testosterone (<span class=\"xrefLink\" id=\"jumplink-B192\"></span><a href=\"javascript:;\" reveal-id=\"B192\" data-open=\"B192\" class=\"link link-ref link-reveal xref-bibr\">192</a>, <span class=\"xrefLink\" id=\"jumplink-B193\"></span><a href=\"javascript:;\" reveal-id=\"B193\" data-open=\"B193\" class=\"link link-ref link-reveal xref-bibr\">193</a>) and is more important for peak bone mass (<span class=\"xrefLink\" id=\"jumplink-B194\"></span><a href=\"javascript:;\" reveal-id=\"B194\" data-open=\"B194\" class=\"link link-ref link-reveal xref-bibr\">194</a>). Estrogen preserves BMD in transgender females who continue on estrogen and antiandrogen therapies (<span class=\"xrefLink\" id=\"jumplink-B188\"></span><a href=\"javascript:;\" reveal-id=\"B188\" data-open=\"B188\" class=\"link link-ref link-reveal xref-bibr\">188</a>, <span class=\"xrefLink\" id=\"jumplink-B190\"></span><a href=\"javascript:;\" reveal-id=\"B190\" data-open=\"B190\" class=\"link link-ref link-reveal xref-bibr\">190</a>, <span class=\"xrefLink\" id=\"jumplink-B191\"></span><a href=\"javascript:;\" reveal-id=\"B191\" data-open=\"B191\" class=\"link link-ref link-reveal xref-bibr\">191</a>, <span class=\"xrefLink\" id=\"jumplink-B195\"></span><a href=\"javascript:;\" reveal-id=\"B195\" data-open=\"B195\" class=\"link link-ref link-reveal xref-bibr\">195</a>, <span class=\"xrefLink\" id=\"jumplink-B196\"></span><a href=\"javascript:;\" reveal-id=\"B196\" data-open=\"B196\" class=\"link link-ref link-reveal xref-bibr\">196</a>).</p><p class=\"chapter-para\">Fracture data in transgender males and females are not available. Transgender persons who have undergone gonadectomy may choose not to continue consistent sex steroid treatment after hormonal and surgical sex reassignment, thereby becoming at risk for bone loss. There have been no studies to determine whether clinicians should use the sex assigned at birth or affirmed gender for assessing osteoporosis (<em>e.g.</em>, when using the FRAX tool). Although some researchers use the sex assigned at birth (with the assumption that bone mass has usually peaked for transgender people who initiate hormones in early adulthood), this should be assessed on a case-by-case basis until there are more data available. This assumption will be further complicated by the increasing prevalence of transgender people who undergo hormonal transition at a pubertal age or soon after puberty. Sex for comparison within risk assessment tools may be based on the age at which hormones were initiated and the length of exposure to hormones. In some cases, it may be reasonable to assess risk using both the male and female calculators and using an intermediate value. Because all subjects underwent normal pubertal development, with known effects on bone size, reference values for birth sex were used for all participants (<span class=\"xrefLink\" id=\"jumplink-B154\"></span><a href=\"javascript:;\" reveal-id=\"B154\" data-open=\"B154\" class=\"link link-ref link-reveal xref-bibr\">154</a>).</p><ul class=\"list-simple\"><li><p class=\"chapter-para\">4.5. We suggest that transgender females with no known increased risk of breast cancer follow breast-screening guidelines recommended for those designated female at birth. (2 |⊕⊕○○)</p></li><li><p class=\"chapter-para\">4.6. We suggest that transgender females treated with estrogens follow individualized screening according to personal risk for prostatic disease and prostate cancer. (2 |⊕○○○)</p></li></ul>                    <h3 scrollto-destination=99603428 id=\"99603428\" class=\"section-title js-splitscreen-section-title\" data-legacy-id=s61>Evidence</h3>\r\n<p class=\"chapter-para\">Studies have reported a few cases of breast cancer in transgender females (<span class=\"xrefLink\" id=\"jumplink-B197\"></span><a href=\"javascript:;\" reveal-id=\"B197\" data-open=\"B197\" class=\"link link-ref link-reveal xref-bibr\">197</a>–<span class=\"xrefLink\" id=\"jumplink-B200\"></span><a href=\"javascript:;\" reveal-id=\"B200\" data-open=\"B200\" class=\"link link-ref link-reveal xref-bibr\">200</a>). A Dutch study of 1800 transgender females followed for a mean of 15 years (range of 1 30 years) found one case of breast cancer. The Women’s Health Initiative study reported that females taking conjugated equine estrogen without progesterone for 7 years did not have an increased risk of breast cancer as compared with females taking placebo (<span class=\"xrefLink\" id=\"jumplink-B137\"></span><a href=\"javascript:;\" reveal-id=\"B137\" data-open=\"B137\" class=\"link link-ref link-reveal xref-bibr\">137</a>).</p><p class=\"chapter-para\">In transgender males, a large retrospective study conducted at the U.S. Veterans Affairs medical health system identified seven breast cancers (<span class=\"xrefLink\" id=\"jumplink-B194\"></span><a href=\"javascript:;\" reveal-id=\"B194\" data-open=\"B194\" class=\"link link-ref link-reveal xref-bibr\">194</a>). The authors reported that this was not above the expected rate of breast cancers in cisgender females in this cohort. Furthermore, they did report one breast cancer that developed in a transgender male patient after mastectomy, supporting the fact that breast cancer can occur even after mastectomy. Indeed, there have been case reports of breast cancer developing in subareolar tissue in transgender males, which occurred after mastectomy (<span class=\"xrefLink\" id=\"jumplink-B201\"></span><a href=\"javascript:;\" reveal-id=\"B201\" data-open=\"B201\" class=\"link link-ref link-reveal xref-bibr\">201</a>, <span class=\"xrefLink\" id=\"jumplink-B202\"></span><a href=\"javascript:;\" reveal-id=\"B202\" data-open=\"B202\" class=\"link link-ref link-reveal xref-bibr\">202</a>).</p><p class=\"chapter-para\">Women with primary hypogonadism (Turner syndrome) treated with estrogen replacement exhibited a significantly decreased incidence of breast cancer as compared with national standardized incidence ratios (<span class=\"xrefLink\" id=\"jumplink-B203\"></span><a href=\"javascript:;\" reveal-id=\"B203\" data-open=\"B203\" class=\"link link-ref link-reveal xref-bibr\">203</a>, <span class=\"xrefLink\" id=\"jumplink-B204\"></span><a href=\"javascript:;\" reveal-id=\"B204\" data-open=\"B204\" class=\"link link-ref link-reveal xref-bibr\">204</a>). These studies suggest that estrogen therapy does not increase the risk of breast cancer in the short term (&lt;20 to 30 years). We need long-term studies to determine the actual risk, as well as the role of screening mammograms. Regular examinations and gynecologic advice should determine monitoring for breast cancer.</p><p class=\"chapter-para\">Prostate cancer is very rare before the age of 40, especially with androgen deprivation therapy (<span class=\"xrefLink\" id=\"jumplink-B205\"></span><a href=\"javascript:;\" reveal-id=\"B205\" data-open=\"B205\" class=\"link link-ref link-reveal xref-bibr\">205</a>). Childhood or pubertal castration results in regression of the prostate and adult castration reverses benign prostate hypertrophy (<span class=\"xrefLink\" id=\"jumplink-B206\"></span><a href=\"javascript:;\" reveal-id=\"B206\" data-open=\"B206\" class=\"link link-ref link-reveal xref-bibr\">206</a>). Although van Kesteren <em>et al.</em> (<span class=\"xrefLink\" id=\"jumplink-B207\"></span><a href=\"javascript:;\" reveal-id=\"B207\" data-open=\"B207\" class=\"link link-ref link-reveal xref-bibr\">207</a>) reported that estrogen therapy does not induce hypertrophy or premalignant changes in the prostates of transgender females, studies have reported cases of benign prostatic hyperplasia in transgender females treated with estrogens for 20 to 25 years (<span class=\"xrefLink\" id=\"jumplink-B208\"></span><a href=\"javascript:;\" reveal-id=\"B208\" data-open=\"B208\" class=\"link link-ref link-reveal xref-bibr\">208</a>, <span class=\"xrefLink\" id=\"jumplink-B209\"></span><a href=\"javascript:;\" reveal-id=\"B209\" data-open=\"B209\" class=\"link link-ref link-reveal xref-bibr\">209</a>). Studies have also reported a few cases of prostate carcinoma in transgender females (<span class=\"xrefLink\" id=\"jumplink-B210\"></span><a href=\"javascript:;\" reveal-id=\"B210\" data-open=\"B210\" class=\"link link-ref link-reveal xref-bibr\">210</a>–<span class=\"xrefLink\" id=\"jumplink-B214\"></span><a href=\"javascript:;\" reveal-id=\"B214\" data-open=\"B214\" class=\"link link-ref link-reveal xref-bibr\">214</a>).</p><p class=\"chapter-para\">Transgender females may feel uncomfortable scheduling regular prostate examinations. Gynecologists are not trained to screen for prostate cancer or to monitor prostate growth. Thus, it may be reasonable for transgender females who transitioned after age 20 years to have annual screening digital rectal examinations after age 50 years and prostate-specific antigen tests consistent with U.S. Preventive Services Task Force Guidelines (<span class=\"xrefLink\" id=\"jumplink-B215\"></span><a href=\"javascript:;\" reveal-id=\"B215\" data-open=\"B215\" class=\"link link-ref link-reveal xref-bibr\">215</a>).</p><ul class=\"list-simple\"><li><p class=\"chapter-para\">4.7. We advise that clinicians determine the medical necessity of including a total hysterectomy and oophorectomy as part of gender-affirming surgery. (Ungraded Good Practice Statement)</p></li></ul>                    <h3 scrollto-destination=99603435 id=\"99603435\" class=\"section-title js-splitscreen-section-title\" data-legacy-id=s62>Evidence</h3>\r\n<p class=\"chapter-para\">Although aromatization of testosterone to estradiol in transgender males has been suggested as a risk factor for endometrial cancer (<span class=\"xrefLink\" id=\"jumplink-B216\"></span><a href=\"javascript:;\" reveal-id=\"B216\" data-open=\"B216\" class=\"link link-ref link-reveal xref-bibr\">216</a>), no cases have been reported. When transgender males undergo hysterectomy, the uterus is small and there is endometrial atrophy (<span class=\"xrefLink\" id=\"jumplink-B217\"></span><a href=\"javascript:;\" reveal-id=\"B217\" data-open=\"B217\" class=\"link link-ref link-reveal xref-bibr\">217</a>, <span class=\"xrefLink\" id=\"jumplink-B218\"></span><a href=\"javascript:;\" reveal-id=\"B218\" data-open=\"B218\" class=\"link link-ref link-reveal xref-bibr\">218</a>). Studies have reported cases of ovarian cancer (<span class=\"xrefLink\" id=\"jumplink-B219\"></span><a href=\"javascript:;\" reveal-id=\"B219\" data-open=\"B219\" class=\"link link-ref link-reveal xref-bibr\">219</a>, <span class=\"xrefLink\" id=\"jumplink-B220\"></span><a href=\"javascript:;\" reveal-id=\"B220\" data-open=\"B220\" class=\"link link-ref link-reveal xref-bibr\">220</a>). Although there is limited evidence for increased risk of reproductive tract cancers in transgender males, health care providers should determine the medical necessity of a laparoscopic total hysterectomy as part of a gender-affirming surgery to prevent reproductive tract cancer (<span class=\"xrefLink\" id=\"jumplink-B221\"></span><a href=\"javascript:;\" reveal-id=\"B221\" data-open=\"B221\" class=\"link link-ref link-reveal xref-bibr\">221</a>).</p>                    <h3 scrollto-destination=99603437 id=\"99603437\" class=\"section-title js-splitscreen-section-title\" data-legacy-id=s63>Values</h3>\r\n<p class=\"chapter-para\">Given the discomfort that transgender males experience accessing gynecologic care, our recommendation for the medical necessity of total hysterectomy and oophorectomy places a high value on eliminating the risks of female reproductive tract disease and cancer and a lower value on avoiding the risks of these surgical procedures (related to the surgery and to the potential undesirable health consequences of oophorectomy) and their associated costs.</p>                    <h3 scrollto-destination=99603439 id=\"99603439\" class=\"section-title js-splitscreen-section-title\" data-legacy-id=s64>Remarks</h3>\r\n<p class=\"chapter-para\">The sexual orientation and type of sexual practices will determine the need and types of gynecologic care required following transition. Additionally, in certain countries, the approval required to change the sex in a birth certificate for transgender males may be dependent on having a complete hysterectomy. Clinicians should help patients research nonmedical administrative criteria and provide counseling. If individuals decide not to undergo hysterectomy, screening for cervical cancer is the same as all other females.</p>                    <h2 scrollto-destination=99603441 id=\"99603441\" class=\"section-title js-splitscreen-section-title\" data-legacy-id=s65>5.0 Surgery for Sex Reassignment and Gender Confirmation</h2>\r\n<p class=\"chapter-para\">For many transgender adults, genital gender-affirming surgery may be the necessary step toward achieving their ultimate goal of living successfully in their desired gender role. The type of surgery falls into two main categories: (1) those that directly affect fertility and (2) those that do not. Those that change fertility (previously called sex reassignment surgery) include genital surgery to remove the penis and gonads in the male and removal of the uterus and gonads in the female. The surgeries that effect fertility are often governed by the legal system of the state or country in which they are performed. Other gender-conforming surgeries that do not directly affect fertility are not so tightly governed.</p><p class=\"chapter-para\">Gender-affirming surgical techniques have improved markedly during the past 10 years. Reconstructive genital surgery that preserves neurologic sensation is now the standard. The satisfaction rate with surgical reassignment of sex is now very high (<span class=\"xrefLink\" id=\"jumplink-B187\"></span><a href=\"javascript:;\" reveal-id=\"B187\" data-open=\"B187\" class=\"link link-ref link-reveal xref-bibr\">187</a>). Additionally, the mental health of the individual seems to be improved by participating in a treatment program that defines a pathway of gender-affirming treatment that includes hormones and surgery (<span class=\"xrefLink\" id=\"jumplink-B130\"></span><a href=\"javascript:;\" reveal-id=\"B130\" data-open=\"B130\" class=\"link link-ref link-reveal xref-bibr\">130</a>, <span class=\"xrefLink\" id=\"jumplink-B144\"></span><a href=\"javascript:;\" reveal-id=\"B144\" data-open=\"B144\" class=\"link link-ref link-reveal xref-bibr\">144</a>) (<span class=\"xrefLink\" id=\"jumplink-T16\"></span><a href=\"javascript:;\" reveal-id=\"T16\" data-open=\"T16\" class=\"link link-reveal link-table xref-fig\">Table 16</a>).</p>                    <a id=\"99603444\" scrollto-destination=\"99603444\"></a>\r\n<div content-id=\"T16\" class=\"table-modal table-full-width-wrap\"><div class=\"table-wrap table-wide\"><div class=\"table-wrap-title\" id=\"T16\" data-id=\"T16\"><span class=\"label\">Table 16.</span><div class=\"caption\"><p class=\"chapter-para\">Criteria for Gender-Affirming Surgery, Which Affects Fertility</p></div> </div><div class=\"table-overflow\"><table><tbody><tr><td>1. Persistent, well-documented gender dysphoria </td></tr><tr><td>2. Legal age of majority in the given country </td></tr><tr><td>3. Having continuously and responsibly used gender-affirming hormones for 12 mo (if there is no medical contraindication to receiving such therapy) </td></tr><tr><td>4. Successful continuous full-time living in the new gender role for 12 mo </td></tr><tr><td>5. If significant medical or mental health concerns are present, they must be well controlled </td></tr><tr><td>6. Demonstrable knowledge of all practical aspects of surgery (<em>e.g.</em>, cost, required lengths of hospitalizations, likely complications, postsurgical rehabilitation) </td></tr></tbody></table></div><div class=\"table-modal\"><table><tbody><tr><td>1. Persistent, well-documented gender dysphoria </td></tr><tr><td>2. Legal age of majority in the given country </td></tr><tr><td>3. Having continuously and responsibly used gender-affirming hormones for 12 mo (if there is no medical contraindication to receiving such therapy) </td></tr><tr><td>4. Successful continuous full-time living in the new gender role for 12 mo </td></tr><tr><td>5. If significant medical or mental health concerns are present, they must be well controlled </td></tr><tr><td>6. Demonstrable knowledge of all practical aspects of surgery (<em>e.g.</em>, cost, required lengths of hospitalizations, likely complications, postsurgical rehabilitation) </td></tr></tbody></table></div><div class=\"&#xA;          graphic-wrap&#xA;          \"><a class=\"fig-view-orig openInAnotherWindow btn js-view-large\" target=\"_blank\" href=\"/view-large/99603444\">\r\n          Open in new tab\r\n        </a></div></div></div><div class=\"table-full-width-wrap\"><div class=\"table-wrap table-wide\"><div class=\"table-wrap-title\" id=\"T16\" data-id=\"T16\"><span class=\"label\">Table 16.</span><div class=\"caption\"><p class=\"chapter-para\">Criteria for Gender-Affirming Surgery, Which Affects Fertility</p></div> </div><div class=\"table-overflow\"><table><tbody><tr><td>1. Persistent, well-documented gender dysphoria </td></tr><tr><td>2. Legal age of majority in the given country </td></tr><tr><td>3. Having continuously and responsibly used gender-affirming hormones for 12 mo (if there is no medical contraindication to receiving such therapy) </td></tr><tr><td>4. Successful continuous full-time living in the new gender role for 12 mo </td></tr><tr><td>5. If significant medical or mental health concerns are present, they must be well controlled </td></tr><tr><td>6. Demonstrable knowledge of all practical aspects of surgery (<em>e.g.</em>, cost, required lengths of hospitalizations, likely complications, postsurgical rehabilitation) </td></tr></tbody></table></div><div class=\"table-modal\"><table><tbody><tr><td>1. Persistent, well-documented gender dysphoria </td></tr><tr><td>2. Legal age of majority in the given country </td></tr><tr><td>3. Having continuously and responsibly used gender-affirming hormones for 12 mo (if there is no medical contraindication to receiving such therapy) </td></tr><tr><td>4. Successful continuous full-time living in the new gender role for 12 mo </td></tr><tr><td>5. If significant medical or mental health concerns are present, they must be well controlled </td></tr><tr><td>6. Demonstrable knowledge of all practical aspects of surgery (<em>e.g.</em>, cost, required lengths of hospitalizations, likely complications, postsurgical rehabilitation) </td></tr></tbody></table></div><div class=\"&#xA;          graphic-wrap&#xA;          \"><a class=\"fig-view-orig openInAnotherWindow btn js-view-large\" target=\"_blank\" href=\"/view-large/99603444\">\r\n          Open in new tab\r\n        </a></div></div></div><p class=\"chapter-para\">Surgery that affects fertility is irreversible. The World Professional Association for Transgender Health Standards of Care (<span class=\"xrefLink\" id=\"jumplink-B222\"></span><a href=\"javascript:;\" reveal-id=\"B222\" data-open=\"B222\" class=\"link link-ref link-reveal xref-bibr\">222</a>) emphasizes that the “threshold of 18 should not be seen as an indication in itself for active intervention.” If the social transition has not been satisfactory, if the person is not satisfied with or is ambivalent about the effects of sex hormone treatment, or if the person is ambivalent about surgery then the individual should not be referred for surgery (<span class=\"xrefLink\" id=\"jumplink-B223\"></span><a href=\"javascript:;\" reveal-id=\"B223\" data-open=\"B223\" class=\"link link-ref link-reveal xref-bibr\">223</a>, <span class=\"xrefLink\" id=\"jumplink-B224\"></span><a href=\"javascript:;\" reveal-id=\"B224\" data-open=\"B224\" class=\"link link-ref link-reveal xref-bibr\">224</a>).</p><p class=\"chapter-para\">Gender-affirming genital surgeries for transgender females that affect fertility include gonadectomy, penectomy, and creation of a neovagina (<span class=\"xrefLink\" id=\"jumplink-B225\"></span><a href=\"javascript:;\" reveal-id=\"B225\" data-open=\"B225\" class=\"link link-ref link-reveal xref-bibr\">225</a>, <span class=\"xrefLink\" id=\"jumplink-B226\"></span><a href=\"javascript:;\" reveal-id=\"B226\" data-open=\"B226\" class=\"link link-ref link-reveal xref-bibr\">226</a>). Surgeons often invert the skin of the penis to form the wall of the vagina, and several literatures reviews have reported on outcomes (<span class=\"xrefLink\" id=\"jumplink-B227\"></span><a href=\"javascript:;\" reveal-id=\"B227\" data-open=\"B227\" class=\"link link-ref link-reveal xref-bibr\">227</a>). Sometimes there is inadequate tissue to form a full neovagina, so clinicians have revisited using intestine and found it to be successful (<span class=\"xrefLink\" id=\"jumplink-B87\"></span><a href=\"javascript:;\" reveal-id=\"B87\" data-open=\"B87\" class=\"link link-ref link-reveal xref-bibr\">87</a>, <span class=\"xrefLink\" id=\"jumplink-B228\"></span><a href=\"javascript:;\" reveal-id=\"B228\" data-open=\"B228\" class=\"link link-ref link-reveal xref-bibr\">228</a>, <span class=\"xrefLink\" id=\"jumplink-B229\"></span><a href=\"javascript:;\" reveal-id=\"B229\" data-open=\"B229\" class=\"link link-ref link-reveal xref-bibr\">229</a>). Some newer vaginoplasty techniques may involve autologuous oral epithelial cells (<span class=\"xrefLink\" id=\"jumplink-B230\"></span><a href=\"javascript:;\" reveal-id=\"B230\" data-open=\"B230\" class=\"link link-ref link-reveal xref-bibr\">230</a>, <span class=\"xrefLink\" id=\"jumplink-B231\"></span><a href=\"javascript:;\" reveal-id=\"B231\" data-open=\"B231\" class=\"link link-ref link-reveal xref-bibr\">231</a>).</p><p class=\"chapter-para\">The scrotum becomes the labia majora. Surgeons use reconstructive surgery to fashion the clitoris and its hood, preserving the neurovascular bundle at the tip of the penis as the neurosensory supply to the clitoris. Some surgeons are also creating a sensate pedicled-spot adding a G spot to the neovagina to increase sensation (<span class=\"xrefLink\" id=\"jumplink-B232\"></span><a href=\"javascript:;\" reveal-id=\"B232\" data-open=\"B232\" class=\"link link-ref link-reveal xref-bibr\">232</a>). Most recently, plastic surgeons have developed techniques to fashion labia minora. To further complete the feminization, uterine transplants have been proposed and even attempted (<span class=\"xrefLink\" id=\"jumplink-B233\"></span><a href=\"javascript:;\" reveal-id=\"B233\" data-open=\"B233\" class=\"link link-ref link-reveal xref-bibr\">233</a>).</p><p class=\"chapter-para\">Neovaginal prolapse, rectovaginal fistula, delayed healing, vaginal stenosis, and other complications do sometimes occur (<span class=\"xrefLink\" id=\"jumplink-B234\"></span><a href=\"javascript:;\" reveal-id=\"B234\" data-open=\"B234\" class=\"link link-ref link-reveal xref-bibr\">234</a>, <span class=\"xrefLink\" id=\"jumplink-B235\"></span><a href=\"javascript:;\" reveal-id=\"B235\" data-open=\"B235\" class=\"link link-ref link-reveal xref-bibr\">235</a>). Clinicians should strongly remind the transgender person to use their dilators to maintain the depth and width of the vagina throughout the postoperative period. Genital sexual responsivity and other aspects of sexual function are usually preserved following genital gender-affirming surgery (<span class=\"xrefLink\" id=\"jumplink-B236\"></span><a href=\"javascript:;\" reveal-id=\"B236\" data-open=\"B236\" class=\"link link-ref link-reveal xref-bibr\">236</a>, <span class=\"xrefLink\" id=\"jumplink-B237\"></span><a href=\"javascript:;\" reveal-id=\"B237\" data-open=\"B237\" class=\"link link-ref link-reveal xref-bibr\">237</a>).</p><p class=\"chapter-para\">Ancillary surgeries for more feminine or masculine appearance are not within the scope of this guideline. Voice therapy by a speech language pathologist is available to transform speech patterns to the affirmed gender (<span class=\"xrefLink\" id=\"jumplink-B148\"></span><a href=\"javascript:;\" reveal-id=\"B148\" data-open=\"B148\" class=\"link link-ref link-reveal xref-bibr\">148</a>). Spontaneous voice deepening occurs during testosterone treatment of transgender males (<span class=\"xrefLink\" id=\"jumplink-B152\"></span><a href=\"javascript:;\" reveal-id=\"B152\" data-open=\"B152\" class=\"link link-ref link-reveal xref-bibr\">152</a>, <span class=\"xrefLink\" id=\"jumplink-B238\"></span><a href=\"javascript:;\" reveal-id=\"B238\" data-open=\"B238\" class=\"link link-ref link-reveal xref-bibr\">238</a>). No studies have compared the effectiveness of speech therapy, laryngeal surgery, or combined treatment.</p><p class=\"chapter-para\">Breast surgery is a good example of gender-confirming surgery that does not affect fertility. In all females, breast size exhibits a very broad spectrum. For transgender females to make the best informed decision, clinicians should delay breast augmentation surgery until the patient has completed at least 2 years of estrogen therapy, because the breasts continue to grow during that time (<span class=\"xrefLink\" id=\"jumplink-B141\"></span><a href=\"javascript:;\" reveal-id=\"B141\" data-open=\"B141\" class=\"link link-ref link-reveal xref-bibr\">141</a>, <span class=\"xrefLink\" id=\"jumplink-B155\"></span><a href=\"javascript:;\" reveal-id=\"B155\" data-open=\"B155\" class=\"link link-ref link-reveal xref-bibr\">155</a>).</p><p class=\"chapter-para\">Another major procedure is the removal of facial and masculine-appearing body hair using either electrolysis or laser treatments. Other feminizing surgeries, such as that to feminize the face, are now becoming more popular (<span class=\"xrefLink\" id=\"jumplink-B239\"></span><a href=\"javascript:;\" reveal-id=\"B239\" data-open=\"B239\" class=\"link link-ref link-reveal xref-bibr\">239</a>–<span class=\"xrefLink\" id=\"jumplink-B241\"></span><a href=\"javascript:;\" reveal-id=\"B241\" data-open=\"B241\" class=\"link link-ref link-reveal xref-bibr\">241</a>).</p><p class=\"chapter-para\">In transgender males, clinicians usually delay gender-affirming genital surgeries until after a few years of androgen therapy. Those surgeries that affect fertility in this group include oophorectomy, vaginectomy, and complete hysterectomy. Surgeons can safely perform them vaginally with laparoscopy. These are sometimes done in conjunction with the creation of a neopenis. The cosmetic appearance of a neopenis is now very good, but the surgery is multistage and very expensive (<span class=\"xrefLink\" id=\"jumplink-B242\"></span><a href=\"javascript:;\" reveal-id=\"B242\" data-open=\"B242\" class=\"link link-ref link-reveal xref-bibr\">242</a>, <span class=\"xrefLink\" id=\"jumplink-B243\"></span><a href=\"javascript:;\" reveal-id=\"B243\" data-open=\"B243\" class=\"link link-ref link-reveal xref-bibr\">243</a>). Radial forearm flap seems to be the most satisfactory procedure (<span class=\"xrefLink\" id=\"jumplink-B228\"></span><a href=\"javascript:;\" reveal-id=\"B228\" data-open=\"B228\" class=\"link link-ref link-reveal xref-bibr\">228</a>, <span class=\"xrefLink\" id=\"jumplink-B244\"></span><a href=\"javascript:;\" reveal-id=\"B244\" data-open=\"B244\" class=\"link link-ref link-reveal xref-bibr\">244</a>). Other flaps also exist (<span class=\"xrefLink\" id=\"jumplink-B245\"></span><a href=\"javascript:;\" reveal-id=\"B245\" data-open=\"B245\" class=\"link link-ref link-reveal xref-bibr\">245</a>). Surgeons can make neopenile erections possible by reinervation of the flap and subsequent contraction of the muscle, leading to stiffening of the neopenis (<span class=\"xrefLink\" id=\"jumplink-B246\"></span><a href=\"javascript:;\" reveal-id=\"B246\" data-open=\"B246\" class=\"link link-ref link-reveal xref-bibr\">246</a>, <span class=\"xrefLink\" id=\"jumplink-B247\"></span><a href=\"javascript:;\" reveal-id=\"B247\" data-open=\"B247\" class=\"link link-ref link-reveal xref-bibr\">247</a>), but results are inconsistent (<span class=\"xrefLink\" id=\"jumplink-B248\"></span><a href=\"javascript:;\" reveal-id=\"B248\" data-open=\"B248\" class=\"link link-ref link-reveal xref-bibr\">248</a>). Surgeons can also stiffen the penis by imbedding some mechanical device (<em>e.g.</em>, a rod or some inflatable apparatus) (<span class=\"xrefLink\" id=\"jumplink-B249\"></span><a href=\"javascript:;\" reveal-id=\"B249\" data-open=\"B249\" class=\"link link-ref link-reveal xref-bibr\">249</a>, <span class=\"xrefLink\" id=\"jumplink-B250\"></span><a href=\"javascript:;\" reveal-id=\"B250\" data-open=\"B250\" class=\"link link-ref link-reveal xref-bibr\">250</a>). Because of these limitations, the creation of a neopenis has often been less than satisfactory. Recently, penis transplants are being proposed (<span class=\"xrefLink\" id=\"jumplink-B233\"></span><a href=\"javascript:;\" reveal-id=\"B233\" data-open=\"B233\" class=\"link link-ref link-reveal xref-bibr\">233</a>).</p><p class=\"chapter-para\">In fact, most transgender males do not have any external genital surgery because of the lack of access, high cost, and significant potential complications. Some choose a metaoidioplasty that brings forward the clitoris, thereby allowing them to void in a standing position without wetting themselves (<span class=\"xrefLink\" id=\"jumplink-B251\"></span><a href=\"javascript:;\" reveal-id=\"B251\" data-open=\"B251\" class=\"link link-ref link-reveal xref-bibr\">251</a>, <span class=\"xrefLink\" id=\"jumplink-B252\"></span><a href=\"javascript:;\" reveal-id=\"B252\" data-open=\"B252\" class=\"link link-ref link-reveal xref-bibr\">252</a>). Surgeons can create the scrotum from the labia majora with good cosmetic effect and can implant testicular prostheses (<span class=\"xrefLink\" id=\"jumplink-B253\"></span><a href=\"javascript:;\" reveal-id=\"B253\" data-open=\"B253\" class=\"link link-ref link-reveal xref-bibr\">253</a>).</p><p class=\"chapter-para\">The most important masculinizing surgery for the transgender male is mastectomy, and it does not affect fertility. Breast size only partially regresses with androgen therapy (<span class=\"xrefLink\" id=\"jumplink-B155\"></span><a href=\"javascript:;\" reveal-id=\"B155\" data-open=\"B155\" class=\"link link-ref link-reveal xref-bibr\">155</a>). In adults, discussions about mastectomy usually take place after androgen therapy has started. Because some transgender male adolescents present after significant breast development has occurred, they may also consider mastectomy 2 years after they begin androgen therapy and before age 18 years. Clinicians should individualize treatment based on the physical and mental health status of the individual. There are now newer approaches to mastectomy with better outcomes (<span class=\"xrefLink\" id=\"jumplink-B254\"></span><a href=\"javascript:;\" reveal-id=\"B254\" data-open=\"B254\" class=\"link link-ref link-reveal xref-bibr\">254</a>, <span class=\"xrefLink\" id=\"jumplink-B255\"></span><a href=\"javascript:;\" reveal-id=\"B255\" data-open=\"B255\" class=\"link link-ref link-reveal xref-bibr\">255</a>). These often involve chest contouring (<span class=\"xrefLink\" id=\"jumplink-B256\"></span><a href=\"javascript:;\" reveal-id=\"B256\" data-open=\"B256\" class=\"link link-ref link-reveal xref-bibr\">256</a>). Mastectomy is often necessary for living comfortably in the new gender (<span class=\"xrefLink\" id=\"jumplink-B256\"></span><a href=\"javascript:;\" reveal-id=\"B256\" data-open=\"B256\" class=\"link link-ref link-reveal xref-bibr\">256</a>).</p><ul class=\"list-simple\"><li><p class=\"chapter-para\">5.1. We recommend that a patient pursue genital gender-affirming surgery only after the MHP and the clinician responsible for endocrine transition therapy both agree that surgery is medically necessary and would benefit the patient’s overall health and/or well-being. (1 |⊕⊕○○)</p></li><li><p class=\"chapter-para\">5.2. We advise that clinicians approve genital gender-affirming surgery only after completion of at least 1 year of consistent and compliant hormone treatment, unless hormone therapy is not desired or medically contraindicated. (Ungraded Good Practice Statement)</p></li><li><p class=\"chapter-para\">5.3. We advise that the clinician responsible for endocrine treatment and the primary care provider ensure appropriate medical clearance of transgender individuals for genital gender-affirming surgery and collaborate with the surgeon regarding hormone use during and after surgery. (Ungraded Good Practice Statement)</p></li><li><p class=\"chapter-para\">5.4. We recommend that clinicians refer hormone-treated transgender individuals for genital surgery when: (1) the individual has had a satisfactory social role change, (2) the individual is satisfied about the hormonal effects, and (3) the individual desires definitive surgical changes. (1 |⊕○○○)</p></li><li><p class=\"chapter-para\">5.5. We suggest that clinicians delay gender-affirming genital surgery involving gonadectomy and/or hysterectomy until the patient is at least 18 years old or legal age of majority in his or her country. (2 |⊕⊕○○).</p></li><li><p class=\"chapter-para\">5.6. We suggest that clinicians determine the timing of breast surgery for transgender males based upon the physical and mental health status of the individual. There is insufficient evidence to recommend a specific age requirement. (2 |⊕○○○)</p></li></ul>                    <h3 scrollto-destination=99603456 id=\"99603456\" class=\"section-title js-splitscreen-section-title\" data-legacy-id=s66>Evidence</h3>\r\n<p class=\"chapter-para\">Owing to the lack of controlled studies, incomplete follow-up, and lack of valid assessment measures, evaluating various surgical approaches and techniques is difficult. However, one systematic review including a large numbers of studies reported satisfactory cosmetic and functional results for vaginoplasty/neovagina construction (<span class=\"xrefLink\" id=\"jumplink-B257\"></span><a href=\"javascript:;\" reveal-id=\"B257\" data-open=\"B257\" class=\"link link-ref link-reveal xref-bibr\">257</a>). For transgender males, the outcomes are less certain. However, the problems are now better understood (<span class=\"xrefLink\" id=\"jumplink-B258\"></span><a href=\"javascript:;\" reveal-id=\"B258\" data-open=\"B258\" class=\"link link-ref link-reveal xref-bibr\">258</a>). Several postoperative studies report significant long-term psychological and psychiatric pathology (<span class=\"xrefLink\" id=\"jumplink-B259\"></span><a href=\"javascript:;\" reveal-id=\"B259\" data-open=\"B259\" class=\"link link-ref link-reveal xref-bibr\">259</a>–<span class=\"xrefLink\" id=\"jumplink-B261\"></span><a href=\"javascript:;\" reveal-id=\"B261\" data-open=\"B261\" class=\"link link-ref link-reveal xref-bibr\">261</a>). One study showed satisfaction with breasts, genitals, and femininity increased significantly and showed the importance of surgical treatment as a key therapeutic option for transgender females (<span class=\"xrefLink\" id=\"jumplink-B262\"></span><a href=\"javascript:;\" reveal-id=\"B262\" data-open=\"B262\" class=\"link link-ref link-reveal xref-bibr\">262</a>). Another analysis demonstrated that, despite the young average age at death following surgery and the relatively larger number of individuals with somatic morbidity, the study does not allow for determination of causal relationships between, for example, specific types of hormonal or surgical treatment received and somatic morbidity and mortality (<span class=\"xrefLink\" id=\"jumplink-B263\"></span><a href=\"javascript:;\" reveal-id=\"B263\" data-open=\"B263\" class=\"link link-ref link-reveal xref-bibr\">263</a>). Reversal surgery in regretful male-to-female transsexuals after sexual reassignment surgery represents a complex, multistage procedure with satisfactory outcomes. Further insight into the characteristics of persons who regret their decision postoperatively would facilitate better future selection of applicants eligible for sexual reassignment surgery. We need more studies with appropriate controls that examine long-term quality of life, psychosocial outcomes, and psychiatric outcomes to determine the long-term benefits of surgical treatment.</p><p class=\"chapter-para\">When a transgender individual decides to have gender-affirming surgery, both the hormone prescribing clinician and the MHP must certify that the patient satisfies criteria for gender-affirming surgery (<span class=\"xrefLink\" id=\"jumplink-T16\"></span><a href=\"javascript:;\" reveal-id=\"T16\" data-open=\"T16\" class=\"link link-reveal link-table xref-fig\">Table 16</a>).</p><p class=\"chapter-para\">There is some concern that estrogen therapy may cause an increased risk for venous thrombosis during or following surgery (<span class=\"xrefLink\" id=\"jumplink-B176\"></span><a href=\"javascript:;\" reveal-id=\"B176\" data-open=\"B176\" class=\"link link-ref link-reveal xref-bibr\">176</a>). For this reason, the surgeon and the hormone-prescribing clinician should collaborate in making a decision about the use of hormones before and following surgery. One study suggests that preoperative factors (such as compliance) are less important for patient satisfaction than are the physical postoperative results (<span class=\"xrefLink\" id=\"jumplink-B56\"></span><a href=\"javascript:;\" reveal-id=\"B56\" data-open=\"B56\" class=\"link link-ref link-reveal xref-bibr\">56</a>). However, other studies and clinical experience dictate that individuals who do not follow medical instructions and do not work with their physicians toward a common goal do not achieve treatment goals (<span class=\"xrefLink\" id=\"jumplink-B264\"></span><a href=\"javascript:;\" reveal-id=\"B264\" data-open=\"B264\" class=\"link link-ref link-reveal xref-bibr\">264</a>) and experience higher rates of postoperative infections and other complications (<span class=\"xrefLink\" id=\"jumplink-B265\"></span><a href=\"javascript:;\" reveal-id=\"B265\" data-open=\"B265\" class=\"link link-ref link-reveal xref-bibr\">265</a>, <span class=\"xrefLink\" id=\"jumplink-B266\"></span><a href=\"javascript:;\" reveal-id=\"B266\" data-open=\"B266\" class=\"link link-ref link-reveal xref-bibr\">266</a>). It is also important that the person requesting surgery feels comfortable with the anatomical changes that have occurred during hormone therapy. Dissatisfaction with social and physical outcomes during the hormone transition may be a contraindication to surgery (<span class=\"xrefLink\" id=\"jumplink-B223\"></span><a href=\"javascript:;\" reveal-id=\"B223\" data-open=\"B223\" class=\"link link-ref link-reveal xref-bibr\">223</a>).</p><p class=\"chapter-para\">An endocrinologist or experienced medical provider should monitor transgender individuals after surgery. Those who undergo gonadectomy will require hormone replacement therapy, surveillance, or both to prevent adverse effects of chronic hormone deficiency.</p>                    <h2 scrollto-destination=99603461 id=\"99603461\" class=\"section-title js-splitscreen-section-title\" data-legacy-id=s67>Financial Disclosures of the Task Force*</h2>\r\n<p class=\"chapter-para\"><strong>Wylie C. Hembree (chair)</strong>—financial or business/organizational interests: none declared, significant financial interest or leadership position: none declared. <strong>Peggy T. Cohen-Kettenis</strong>—financial or business/organizational interests: none declared, significant financial interest or leadership position: none declared. <strong>Louis Gooren</strong>—financial or business/organizational interests: none declared, significant financial interest or leadership position: none declared. <strong>Sabine E. Hannema</strong>—financial or business/organizational interests: none declared, significant financial interest or leadership position: Ferring Pharmaceuticals Inc. (lecture/conference), Pfizer (lecture). <strong>Walter J. Meyer</strong>—financial or business/organizational interests: none declared, significant financial interest or leadership position: none declared. <strong>M. Hassan Murad**</strong>—financial or business/organizational interests: Mayo Clinic, Evidence-based Practice Center, significant financial interest or leadership position: none declared. <strong>Stephen M.</strong><strong>Rosenthal</strong>—financial or business/organizational interests: AbbVie (consultant), National Institutes of Health (grantee), significant financial interest or leadership position: Pediatric Endocrine Society (immediate past president). <strong>Joshua D. Safer, FACP</strong>—financial or business/organizational interests: none declared, significant financial interest or leadership position: none declared. <strong>Vin Tangpricha</strong>—financial or business/organizational interests: Cystic Fibrosis Foundation (grantee), National Institutes of Health (grantee), significant financial interest or leadership position, Elsevier <em>Journal of Clinical and Translational Endocrinology</em> (editor). <strong>Guy G. T’Sjoen</strong>—financial or business/organizational interests: none declared, significant financial interest or leadership position: none declared.* Financial, business, and organizational disclosures of the task force cover the year prior to publication. Disclosures prior to this time period are archived.**Evidence-based reviews for this guideline were prepared under contract with the Endocrine Society.</p>                    <h2 scrollto-destination=99603463 id=\"99603463\" class=\"backglossary-title js-splitscreen-backglossary-title\" >Abbreviations</h2>\r\n<ul class=\"def-list\"><a id=\"\" class=\"jumplink-placeholder\"> </a><li class=\"def-item\"><div class=\"term\">BMD</div><div class=\"def-wrap\"><div class=\"def\"><p class=\"chapter-para\">bone mineral density</p></div></div></li><a id=\"\" class=\"jumplink-placeholder\"> </a><li class=\"def-item\"><div class=\"term\">DSD</div><div class=\"def-wrap\"><div class=\"def\"><p class=\"chapter-para\">disorder/difference of sex development</p></div></div></li><a id=\"\" class=\"jumplink-placeholder\"> </a><li class=\"def-item\"><div class=\"term\">DSM</div><div class=\"def-wrap\"><div class=\"def\"><p class=\"chapter-para\">Diagnostic and Statistical Manual of Mental Disorders</p></div></div></li><a id=\"\" class=\"jumplink-placeholder\"> </a><li class=\"def-item\"><div class=\"term\">GD</div><div class=\"def-wrap\"><div class=\"def\"><p class=\"chapter-para\">gender dysphoria</p></div></div></li><a id=\"\" class=\"jumplink-placeholder\"> </a><li class=\"def-item\"><div class=\"term\">GnRH</div><div class=\"def-wrap\"><div class=\"def\"><p class=\"chapter-para\">gonadotropin-releasing hormone</p></div></div></li><a id=\"\" class=\"jumplink-placeholder\"> </a><li class=\"def-item\"><div class=\"term\">ICD</div><div class=\"def-wrap\"><div class=\"def\"><p class=\"chapter-para\">International Statistical Classification of Diseases and Related Health Problems</p></div></div></li><a id=\"\" class=\"jumplink-placeholder\"> </a><li class=\"def-item\"><div class=\"term\">MHP</div><div class=\"def-wrap\"><div class=\"def\"><p class=\"chapter-para\">mental health professional</p></div></div></li><a id=\"\" class=\"jumplink-placeholder\"> </a><li class=\"def-item\"><div class=\"term\">VTE</div><div class=\"def-wrap\"><div class=\"def\"><p class=\"chapter-para\">venous thromboembolism.</p></div></div></li></ul>                    <h2 scrollto-destination=99603465 id=\"99603465\" class=\"backacknowledgements-title js-splitscreen-backacknowledgements-title\" >Acknowledgments</h2>\r\n<p class=\"chapter-para\"><strong><em>Disclosure Summary:</em></strong> See Financial Disclosures.</p>                    <h2 scrollto-destination=99603467 id=\"99603467\" class=\"backreferences-title js-splitscreen-backreferences-title\" >References</h2>\r\n<div class=\"ref-list js-splitview-ref-list\"><div content-id=\"B1\" class=\"js-splitview-ref-item\" data-legacy-id=\"B1\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B1\" href=\"javascript:;\" aria-label=\"jumplink-B1\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B1\" class=\"ref-content \" data-id=\"B1\"><span class=\"label\">1.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Atkins</div>  <div class=\"given-names\">D</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Best</div>  <div class=\"given-names\">D</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Briss</div>  <div class=\"given-names\">PA</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Eccles</div>  <div class=\"given-names\">M</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Falck-Ytter</div>  <div class=\"given-names\">Y</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Flottorp</div>  <div class=\"given-names\">S</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Guyatt</div>  <div class=\"given-names\">GH</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Harbour</div>  <div class=\"given-names\">RT</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Haugh</div>  <div class=\"given-names\">MC</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Henry</div>  <div class=\"given-names\">D</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Hill</div>  <div class=\"given-names\">S</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Jaeschke</div>  <div class=\"given-names\">R</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Leng</div>  <div class=\"given-names\">G</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Liberati</div>  <div class=\"given-names\">A</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Magrini</div>  <div class=\"given-names\">N</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Mason</div>  <div class=\"given-names\">J</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Middleton</div>  <div class=\"given-names\">P</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Mrukowicz</div>  <div class=\"given-names\">J</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">O’Connell</div>  <div class=\"given-names\">D</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Oxman</div>  <div class=\"given-names\">AD</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Phillips</div>  <div class=\"given-names\">B</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Schünemann</div>  <div class=\"given-names\">HJ</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Edejer</div>  <div class=\"given-names\">T</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Varonen</div>  <div class=\"given-names\">H</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Vist</div>  <div class=\"given-names\">GE</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Williams</div>  <div class=\"given-names\">JW</div>, Jr\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Zaza</div>  <div class=\"given-names\">S</div>\r\n</span>; <div class=\"collab\">GRADE Working Group</div>\r\n</span>. <div class=\"article-title\">Grading quality of evidence and strength of recommendations</div>. <div class=\"source \">BMJ</div>. <div class=\"year\">2004</div>;<div class=\"volume\">328</div>(<div class=\"issue\">7454</div>):<div class=\"fpage\">1490</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Grading%20quality%20of%20evidence%20and%20strength%20of%20recommendations&amp;author=D%20Atkins&amp;author=D%20Best&amp;author=PA%20Briss&amp;author=M%20Eccles&amp;author=Y%20Falck-Ytter&amp;author=S%20Flottorp&amp;author=GH%20Guyatt&amp;author=RT%20Harbour&amp;author=MC%20Haugh&amp;author=D%20Henry&amp;author=S%20Hill&amp;author=R%20Jaeschke&amp;author=G%20Leng&amp;author=A%20Liberati&amp;author=N%20Magrini&amp;author=J%20Mason&amp;author=P%20Middleton&amp;author=J%20Mrukowicz&amp;author=D%20O%E2%80%99Connell&amp;author=AD%20Oxman&amp;author=B%20Phillips&amp;author=HJ%20Sch%C3%BCnemann&amp;author=T%20Edejer&amp;author=H%20Varonen&amp;author=GE%20Vist&amp;author=JW%20Williams&amp;author=S%20Zaza&amp;publication_year=2004&amp;journal=BMJ&amp;volume=328&amp;pages=1490\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1136/bmj.328.7454.1490\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1136%2Fbmj.328.7454.1490\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1136%2Fbmj.328.7454.1490\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/15205295\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Grading%20quality%20of%20evidence%20and%20strength%20of%20recommendations&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B2\" class=\"js-splitview-ref-item\" data-legacy-id=\"B2\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B2\" href=\"javascript:;\" aria-label=\"jumplink-B2\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B2\" class=\"ref-content \" data-id=\"B2\"><span class=\"label\">2.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Swiglo</div>  <div class=\"given-names\">BA</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Murad</div>  <div class=\"given-names\">MH</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Schünemann</div>  <div class=\"given-names\">HJ</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Kunz</div>  <div class=\"given-names\">R</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Vigersky</div>  <div class=\"given-names\">RA</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Guyatt</div>  <div class=\"given-names\">GH</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Montori</div>  <div class=\"given-names\">VM</div>\r\n</span>\r\n</span>. <div class=\"article-title\">A case for clarity, consistency, and helpfulness: state-of-the-art clinical practice guidelines in endocrinology using the grading of recommendations, assessment, development, and evaluation system</div>. <div class=\"source \">J Clin Endocrinol Metab</div>. <div class=\"year\">2008</div>;<div class=\"volume\">93</div>(<div class=\"issue\">3</div>):<div class=\"fpage\">666</div>–<div class=\"lpage\">673</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=A%20case%20for%20clarity%2C%20consistency%2C%20and%20helpfulness%3A%20state-of-the-art%20clinical%20practice%20guidelines%20in%20endocrinology%20using%20the%20grading%20of%20recommendations%2C%20assessment%2C%20development%2C%20and%20evaluation%20system&amp;author=BA%20Swiglo&amp;author=MH%20Murad&amp;author=HJ%20Sch%C3%BCnemann&amp;author=R%20Kunz&amp;author=RA%20Vigersky&amp;author=GH%20Guyatt&amp;author=VM%20Montori&amp;publication_year=2008&amp;journal=J%20Clin%20Endocrinol%20Metab&amp;volume=93&amp;pages=666-673\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1210/jc.2007-1907\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1210%2Fjc.2007-1907\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1210%2Fjc.2007-1907\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/18171699\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:A%20case%20for%20clarity%2C%20consistency%2C%20and%20helpfulness%3A%20state-of-the-art%20clinical%20practice%20guidelines%20in%20endocrinology%20using%20the%20grading%20of%20recommendations%2C%20assessment%2C%20development%2C%20and%20evaluation%20system&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B3\" class=\"js-splitview-ref-item\" data-legacy-id=\"B3\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B3\" href=\"javascript:;\" aria-label=\"jumplink-B3\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B3\" class=\"ref-content \" data-id=\"B3\"><span class=\"label\">3.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Bullough</div>  <div class=\"given-names\">VL</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Transsexualism in history</div>. <div class=\"source \">Arch Sex Behav</div>. <div class=\"year\">1975</div>;<div class=\"volume\">4</div>(<div class=\"issue\">5</div>):<div class=\"fpage\">561</div>–<div class=\"lpage\">571</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Transsexualism%20in%20history&amp;author=VL%20Bullough&amp;publication_year=1975&amp;journal=Arch%20Sex%20Behav&amp;volume=4&amp;pages=561-571\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1007/BF01542134\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1007%2FBF01542134\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1007%2FBF01542134\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/1103789\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Transsexualism%20in%20history&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B4\" class=\"js-splitview-ref-item\" data-legacy-id=\"B4\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B4\" href=\"javascript:;\" aria-label=\"jumplink-B4\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B4\" class=\"ref-content \" data-id=\"B4\"><span class=\"label\">4.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Benjamin</div>  <div class=\"given-names\">H</div>\r\n</span>\r\n</span>. <div class=\"article-title\">The transsexual phenomenon</div>. <div class=\"source \">Trans N Y Acad Sci</div>. <div class=\"year\">1967</div>;<div class=\"volume\">29</div>(<div class=\"issue\">4</div>):<div class=\"fpage\">428</div>–<div class=\"lpage\">430</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=The%20transsexual%20phenomenon&amp;author=H%20Benjamin&amp;publication_year=1967&amp;journal=Trans%20N%20Y%20Acad%20Sci&amp;volume=29&amp;pages=428-430\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1111/j.2164-0947.1967.tb02273.x\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1111%2Fj.2164-0947.1967.tb02273.x\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1111%2Fj.2164-0947.1967.tb02273.x\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/5233741\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:The%20transsexual%20phenomenon&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B5\" class=\"js-splitview-ref-item\" data-legacy-id=\"B5\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B5\" href=\"javascript:;\" aria-label=\"jumplink-B5\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B5\" class=\"ref-content \" data-id=\"B5\"><span class=\"label\">5.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Meyerowitz</div>  <div class=\"given-names\">J</div>\r\n</span>\r\n</span>. <div class=\"comment\"><em>How Sex Changed: A History of Transsexuality in the United States.</em> Cambridge, MA: Harvard University Press</div>; <div class=\"year\">2002</div>.</p></div></div></div></div><div content-id=\"B6\" class=\"js-splitview-ref-item\" data-legacy-id=\"B6\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B6\" href=\"javascript:;\" aria-label=\"jumplink-B6\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B6\" class=\"ref-content \" data-id=\"B6\"><span class=\"label\">6.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Hirschfeld</div>  <div class=\"given-names\">M.</div>\r\n</span>\r\n</span> <div class=\"comment\"><em>Was muss das Volk vom Dritten Geschlecht wissen</em>. Verlag Max Spohr, Leipzig; 1901.</div>\r\n</p></div></div></div></div><div content-id=\"B7\" class=\"js-splitview-ref-item\" data-legacy-id=\"B7\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B7\" href=\"javascript:;\" aria-label=\"jumplink-B7\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B7\" class=\"ref-content \" data-id=\"B7\"><span class=\"label\">7.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Fisk</div>  <div class=\"given-names\">NM</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Editorial: Gender dysphoria syndrome—the conceptualization that liberalizes indications for total gender reorientation and implies a broadly based multi-dimensional rehabilitative regimen</div>. <div class=\"source \">West J Med</div>. <div class=\"year\">1974</div>;<div class=\"volume\">120</div>(<div class=\"issue\">5</div>):<div class=\"fpage\">386</div>–<div class=\"lpage\">391</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Editorial%3A%20Gender%20dysphoria%20syndrome%E2%80%94the%20conceptualization%20that%20liberalizes%20indications%20for%20total%20gender%20reorientation%20and%20implies%20a%20broadly%20based%20multi-dimensional%20rehabilitative%20regimen&amp;author=NM%20Fisk&amp;publication_year=1974&amp;journal=West%20J%20Med&amp;volume=120&amp;pages=386-391\" target=\"_blank\">Google Scholar</a></span></p><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/4839483\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><div class=\"xslopenurl empty-target\"><span class=\"js-inst-open-url-holders-nodoi\"><a class=\"js-open-url-link\" data-href-template=\"{targetURL}?sid=oup:orr&amp;genre=article&amp;atitle=Editorial%3a+Gender+dysphoria+syndrome%e2%80%94the+conceptualization+that+liberalizes+indications+for+total+gender+reorientation+and+implies+a+broadly+based+multi-dimensional+rehabilitative+regimen&amp;aulast=Fisk&amp;title=West+J+Med&amp;date=1974&amp;spage=386&amp;epage=391&amp;volume=120&amp;issue=5\" href=\"javascript:;\"><span class=\"screenreader-text\">OpenURL Placeholder Text</span></a></span></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Editorial%3A%20Gender%20dysphoria%20syndrome%E2%80%94the%20conceptualization%20that%20liberalizes%20indications%20for%20total%20gender%20reorientation%20and%20implies%20a%20broadly%20based%20multi-dimensional%20rehabilitative%20regimen&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B8\" class=\"js-splitview-ref-item\" data-legacy-id=\"B8\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B8\" href=\"javascript:;\" aria-label=\"jumplink-B8\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B8\" class=\"ref-content \" data-id=\"B8\"><span class=\"label\">8.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Diamond</div>  <div class=\"given-names\">L</div>\r\n</span>\r\n</span>. <div class=\"comment\">Transgender experience and identity. In: Schwartz SJ, Luyckx K, Vignoles VL, eds. <em>Handbook of Identity Theory and Research</em>. New York, NY: Springer;</div> <div class=\"year\">2011</div>:<div class=\"fpage\">629</div>–<div class=\"lpage\">647</div>.</p></div></div></div></div><div content-id=\"B9\" class=\"js-splitview-ref-item\" data-legacy-id=\"B9\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B9\" href=\"javascript:;\" aria-label=\"jumplink-B9\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B9\" class=\"ref-content \" data-id=\"B9\"><span class=\"label\">9.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Queen</div>  <div class=\"given-names\">C</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Schimel</div>  <div class=\"given-names\">L</div>\r\n</span>\r\n</span>, eds. <div class=\"comment\"><em>PoMoSexuals: Challenging Assumptions About Gender and Sexuality</em>. San Francisco, CA: Cleis Press; 1997</div>.</p></div></div></div></div><div content-id=\"B10\" class=\"js-splitview-ref-item\" data-legacy-id=\"B10\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B10\" href=\"javascript:;\" aria-label=\"jumplink-B10\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B10\" class=\"ref-content \" data-id=\"B10\"><span class=\"label\">10.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Case</div>  <div class=\"given-names\">LK</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Ramachandran</div>  <div class=\"given-names\">VS</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Alternating gender incongruity: a new neuropsychiatric syndrome providing insight into the dynamic plasticity of brain-sex</div>. <div class=\"source \">Med Hypotheses</div>. <div class=\"year\">2012</div>;<div class=\"volume\">78</div>(<div class=\"issue\">5</div>):<div class=\"fpage\">626</div>–<div class=\"lpage\">631</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Alternating%20gender%20incongruity%3A%20a%20new%20neuropsychiatric%20syndrome%20providing%20insight%20into%20the%20dynamic%20plasticity%20of%20brain-sex&amp;author=LK%20Case&amp;author=VS%20Ramachandran&amp;publication_year=2012&amp;journal=Med%20Hypotheses&amp;volume=78&amp;pages=626-631\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1016/j.mehy.2012.01.041\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1016%2Fj.mehy.2012.01.041\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1016%2Fj.mehy.2012.01.041\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22364652\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Alternating%20gender%20incongruity%3A%20a%20new%20neuropsychiatric%20syndrome%20providing%20insight%20into%20the%20dynamic%20plasticity%20of%20brain-sex&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B11\" class=\"js-splitview-ref-item\" data-legacy-id=\"B11\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B11\" href=\"javascript:;\" aria-label=\"jumplink-B11\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B11\" class=\"ref-content \" data-id=\"B11\"><span class=\"label\">11.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Johnson</div>  <div class=\"given-names\">TW</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Wassersug</div>  <div class=\"given-names\">RJ</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Gender identity disorder outside the binary: when gender identity disorder-not otherwise specified is not good enough</div>. <div class=\"source \">Arch Sex Behav</div>. <div class=\"year\">2010</div>;<div class=\"volume\">39</div>(<div class=\"issue\">3</div>):<div class=\"fpage\">597</div>–<div class=\"lpage\">598</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Gender%20identity%20disorder%20outside%20the%20binary%3A%20when%20gender%20identity%20disorder-not%20otherwise%20specified%20is%20not%20good%20enough&amp;author=TW%20Johnson&amp;author=RJ%20Wassersug&amp;publication_year=2010&amp;journal=Arch%20Sex%20Behav&amp;volume=39&amp;pages=597-598\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1007/s10508-010-9608-1\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1007%2Fs10508-010-9608-1\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1007%2Fs10508-010-9608-1\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/20182785\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Gender%20identity%20disorder%20outside%20the%20binary%3A%20when%20gender%20identity%20disorder-not%20otherwise%20specified%20is%20not%20good%20enough&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B12\" class=\"js-splitview-ref-item\" data-legacy-id=\"B12\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B12\" href=\"javascript:;\" aria-label=\"jumplink-B12\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B12\" class=\"ref-content \" data-id=\"B12\"><span class=\"label\">12.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Wibowo</div>  <div class=\"given-names\">E</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Wassersug</div>  <div class=\"given-names\">R</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Warkentin</div>  <div class=\"given-names\">K</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Walker</div>  <div class=\"given-names\">L</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Robinson</div>  <div class=\"given-names\">J</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Brotto</div>  <div class=\"given-names\">L</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Johnson</div>  <div class=\"given-names\">T</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Impact of androgen deprivation therapy on sexual function: a response</div>. <div class=\"source \">Asian J Androl</div>. <div class=\"year\">2012</div>;<div class=\"volume\">14</div>(<div class=\"issue\">5</div>):<div class=\"fpage\">793</div>–<div class=\"lpage\">794</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Impact%20of%20androgen%20deprivation%20therapy%20on%20sexual%20function%3A%20a%20response&amp;author=E%20Wibowo&amp;author=R%20Wassersug&amp;author=K%20Warkentin&amp;author=L%20Walker&amp;author=J%20Robinson&amp;author=L%20Brotto&amp;author=T%20Johnson&amp;publication_year=2012&amp;journal=Asian%20J%20Androl&amp;volume=14&amp;pages=793-794\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1038/aja.2012.60\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1038%2Faja.2012.60\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1038%2Faja.2012.60\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22796736\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Impact%20of%20androgen%20deprivation%20therapy%20on%20sexual%20function%3A%20a%20response&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B13\" class=\"js-splitview-ref-item\" data-legacy-id=\"B13\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B13\" href=\"javascript:;\" aria-label=\"jumplink-B13\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B13\" class=\"ref-content \" data-id=\"B13\"><span class=\"label\">13.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">Pasquesoone V. 7 countries giving transgender people fundamental rights the U.S. still won’t. 2014. Available at: <a class=\"link link-uri openInAnotherWindow\" href=\"https://mic.com/articles/87149/7-countries-giving-transgender-people-fundamental-rights-the-u-s-still-won-t\" target=\"_blank\">https://mic.com/articles/87149/7-countries-giving-transgender-people-fundamental-rights-the-u-s-still-won-t</a>. Accessed 26 August 2016.</p></div></div></div></div><div content-id=\"B14\" class=\"js-splitview-ref-item\" data-legacy-id=\"B14\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B14\" href=\"javascript:;\" aria-label=\"jumplink-B14\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B14\" class=\"ref-content \" data-id=\"B14\"><span class=\"label\">14.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<div class=\"collab\">American Psychiatric Association</div>\r\n</span>. <div class=\"source \">Diagnostic and Statistical Manual of Mental Disorders</div>. <div class=\"comment\">5th ed. Arlington, VA: American Psychiatric Association Publishing</div>.</p></div></div></div></div><div content-id=\"B15\" class=\"js-splitview-ref-item\" data-legacy-id=\"B15\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B15\" href=\"javascript:;\" aria-label=\"jumplink-B15\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B15\" class=\"ref-content \" data-id=\"B15\"><span class=\"label\">15.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Drescher</div>  <div class=\"given-names\">J</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Cohen-Kettenis</div>  <div class=\"given-names\">P</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Winter</div>  <div class=\"given-names\">S</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Minding the body: situating gender identity diagnoses in the ICD-11</div>. <div class=\"source \">Int Rev Psychiatry</div>. <div class=\"year\">2012</div>;<div class=\"volume\">24</div>(<div class=\"issue\">6</div>):<div class=\"fpage\">568</div>–<div class=\"lpage\">577</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Minding%20the%20body%3A%20situating%20gender%20identity%20diagnoses%20in%20the%20ICD-11&amp;author=J%20Drescher&amp;author=P%20Cohen-Kettenis&amp;author=S%20Winter&amp;publication_year=2012&amp;journal=Int%20Rev%20Psychiatry&amp;volume=24&amp;pages=568-577\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.3109/09540261.2012.741575\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.3109%2F09540261.2012.741575\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.3109%2F09540261.2012.741575\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23244612\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Minding%20the%20body%3A%20situating%20gender%20identity%20diagnoses%20in%20the%20ICD-11&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B16\" class=\"js-splitview-ref-item\" data-legacy-id=\"B16\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B16\" href=\"javascript:;\" aria-label=\"jumplink-B16\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B16\" class=\"ref-content \" data-id=\"B16\"><span class=\"label\">16.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<div class=\"comment\">World Professional Association for Transgender Health. Standards of care for the health of transsexual, transgender, and gender nonconforming people. Available at: <a class=\"link link-uri openInAnotherWindow\" href=\"http://www.wpath.org/site_page.cfm?pk_association_webpage_menu=1351&amp;pk_association_webpage=3926\" target=\"_blank\">http://www.wpath.org/site_page.cfm?pk_association_webpage_menu=1351&amp;pk_association_webpage=3926</a>. Accessed 1 September 2017</div>.</p></div></div></div></div><div content-id=\"B17\" class=\"js-splitview-ref-item\" data-legacy-id=\"B17\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B17\" href=\"javascript:;\" aria-label=\"jumplink-B17\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B17\" class=\"ref-content \" data-id=\"B17\"><span class=\"label\">17.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Kreukels</div>  <div class=\"given-names\">BP</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Haraldsen</div>  <div class=\"given-names\">IR</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">De Cuypere</div>  <div class=\"given-names\">G</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Richter-Appelt</div>  <div class=\"given-names\">H</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Gijs</div>  <div class=\"given-names\">L</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Cohen-Kettenis</div>  <div class=\"given-names\">PT</div>\r\n</span>\r\n</span>. <div class=\"article-title\">A European network for the investigation of gender incongruence: the ENIGI initiative</div>. <div class=\"source \">Eur Psychiatry</div>. <div class=\"year\">2012</div>;<div class=\"volume\">27</div>(<div class=\"issue\">6</div>):<div class=\"fpage\">445</div>–<div class=\"lpage\">450</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=A%20European%20network%20for%20the%20investigation%20of%20gender%20incongruence%3A%20the%20ENIGI%20initiative&amp;author=BP%20Kreukels&amp;author=IR%20Haraldsen&amp;author=G%20De%20Cuypere&amp;author=H%20Richter-Appelt&amp;author=L%20Gijs&amp;author=PT%20Cohen-Kettenis&amp;publication_year=2012&amp;journal=Eur%20Psychiatry&amp;volume=27&amp;pages=445-450\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1016/j.eurpsy.2010.04.009\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1016%2Fj.eurpsy.2010.04.009\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1016%2Fj.eurpsy.2010.04.009\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/20620022\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:A%20European%20network%20for%20the%20investigation%20of%20gender%20incongruence%3A%20the%20ENIGI%20initiative&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B18\" class=\"js-splitview-ref-item\" data-legacy-id=\"B18\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B18\" href=\"javascript:;\" aria-label=\"jumplink-B18\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B18\" class=\"ref-content \" data-id=\"B18\"><span class=\"label\">18.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Dekker</div>  <div class=\"given-names\">MJ</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Wierckx</div>  <div class=\"given-names\">K</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Van Caenegem</div>  <div class=\"given-names\">E</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Klaver</div>  <div class=\"given-names\">M</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Kreukels</div>  <div class=\"given-names\">BP</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Elaut</div>  <div class=\"given-names\">E</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Fisher</div>  <div class=\"given-names\">AD</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">van Trotsenburg</div>  <div class=\"given-names\">MA</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Schreiner</div>  <div class=\"given-names\">T</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">den Heijer</div>  <div class=\"given-names\">M</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">T’Sjoen</div>  <div class=\"given-names\">G</div>\r\n</span>\r\n</span>. <div class=\"article-title\">A European network for the investigation of gender incongruence: endocrine part</div>. <div class=\"source \">J Sex Med</div>. <div class=\"year\">2016</div>;<div class=\"volume\">13</div>(<div class=\"issue\">6</div>):<div class=\"fpage\">994</div>–<div class=\"lpage\">999</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=A%20European%20network%20for%20the%20investigation%20of%20gender%20incongruence%3A%20endocrine%20part&amp;author=MJ%20Dekker&amp;author=K%20Wierckx&amp;author=E%20Van%20Caenegem&amp;author=M%20Klaver&amp;author=BP%20Kreukels&amp;author=E%20Elaut&amp;author=AD%20Fisher&amp;author=MA%20van%20Trotsenburg&amp;author=T%20Schreiner&amp;author=M%20den%20Heijer&amp;author=G%20T%E2%80%99Sjoen&amp;publication_year=2016&amp;journal=J%20Sex%20Med&amp;volume=13&amp;pages=994-999\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1016/j.jsxm.2016.03.371\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1016%2Fj.jsxm.2016.03.371\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1016%2Fj.jsxm.2016.03.371\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/27162190\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:A%20European%20network%20for%20the%20investigation%20of%20gender%20incongruence%3A%20endocrine%20part&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B19\" class=\"js-splitview-ref-item\" data-legacy-id=\"B19\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B19\" href=\"javascript:;\" aria-label=\"jumplink-B19\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B19\" class=\"ref-content \" data-id=\"B19\"><span class=\"label\">19.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Ruble</div>  <div class=\"given-names\">DN</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Martin</div>  <div class=\"given-names\">CL</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Berenbaum</div>  <div class=\"given-names\">SA</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Gender development</div>. In: <span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Damon</div>  <div class=\"given-names\">WL</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Lerner</div>  <div class=\"given-names\">RM</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Eisenberg</div>  <div class=\"given-names\">N</div>\r\n</span>\r\n</span>, eds. <div class=\"source \">Handbook of Child Psychology: Social, Emotional, and Personality Development</div>. <div class=\"volume\">Vol. 3</div>. 6th ed. <div class=\"publisher-loc\">New York, NY</div>: <div class=\"publisher-name\">Wiley</div>; <div class=\"year\">2006</div>;<div class=\"fpage\">858</div>–<div class=\"lpage\">931</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Handbook%20of%20Child%20Psychology%3A%20Social%2C%20Emotional%2C%20and%20Personality%20Development&amp;author=DN%20Ruble&amp;author=CL%20Martin&amp;author=SA%20Berenbaum&amp;author=WL%20Damon&amp;author=RM%20Lerner&amp;author=N%20Eisenberg&amp;publication_year=2006&amp;book=Handbook%20of%20Child%20Psychology%3A%20Social%2C%20Emotional%2C%20and%20Personality%20Development\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1002/9780470147658\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1002%2F9780470147658\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1002%2F9780470147658\"> </span></div><p class=\"citation-links-compatibility\"><span class=\"google-preview-ref-link js-google-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.google.com/search?q=Handbook%20of%20Child%20Psychology%3A%20Social%2C%20Emotional%2C%20and%20Personality%20Development&amp;btnG=Search+Books&amp;tbm=bks&amp;tbo=1\" target=\"_blank\">Google Preview</a></span></p><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Handbook%20of%20Child%20Psychology%3A%20Social%2C%20Emotional%2C%20and%20Personality%20Development&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p><div class=\"copac-reference-ref-link js-copac-preview-ref-link\" style=\"display:none\" data-pubtype=\"book\"><span class=\"inst-copac\"><a class=\"openInAnotherWindow\" target=\"_blank\" href=\"http://copac.ac.uk/search?ti=Handbook%20of%20Child%20Psychology%3A%20Social%2C%20Emotional%2C%20and%20Personality%20Development\">COPAC</a></span></div> </div></div></div></div></div><div content-id=\"B20\" class=\"js-splitview-ref-item\" data-legacy-id=\"B20\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B20\" href=\"javascript:;\" aria-label=\"jumplink-B20\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B20\" class=\"ref-content \" data-id=\"B20\"><span class=\"label\">20.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Steensma</div>  <div class=\"given-names\">TD</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Kreukels</div>  <div class=\"given-names\">BP</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">de Vries</div>  <div class=\"given-names\">AL</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Cohen-Kettenis</div>  <div class=\"given-names\">PT</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Gender identity development in adolescence</div>. <div class=\"source \">Horm Behav</div>. <div class=\"year\">2013</div>;<div class=\"volume\">64</div>(<div class=\"issue\">2</div>):<div class=\"fpage\">288</div>–<div class=\"lpage\">297</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Gender%20identity%20development%20in%20adolescence&amp;author=TD%20Steensma&amp;author=BP%20Kreukels&amp;author=AL%20de%20Vries&amp;author=PT%20Cohen-Kettenis&amp;publication_year=2013&amp;journal=Horm%20Behav&amp;volume=64&amp;pages=288-297\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1016/j.yhbeh.2013.02.020\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1016%2Fj.yhbeh.2013.02.020\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1016%2Fj.yhbeh.2013.02.020\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23998673\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Gender%20identity%20development%20in%20adolescence&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B21\" class=\"js-splitview-ref-item\" data-legacy-id=\"B21\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B21\" href=\"javascript:;\" aria-label=\"jumplink-B21\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B21\" class=\"ref-content \" data-id=\"B21\"><span class=\"label\">21.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Rosenthal</div>  <div class=\"given-names\">SM</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Approach to the patient: transgender youth: endocrine considerations</div>. <div class=\"source \">J Clin Endocrinol Metab</div>. <div class=\"year\">2014</div>;<div class=\"volume\">99</div>(<div class=\"issue\">12</div>):<div class=\"fpage\">4379</div>–<div class=\"lpage\">4389</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Approach%20to%20the%20patient%3A%20transgender%20youth%3A%20endocrine%20considerations&amp;author=SM%20Rosenthal&amp;publication_year=2014&amp;journal=J%20Clin%20Endocrinol%20Metab&amp;volume=99&amp;pages=4379-4389\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1210/jc.2014-1919\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1210%2Fjc.2014-1919\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1210%2Fjc.2014-1919\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/25140398\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Approach%20to%20the%20patient%3A%20transgender%20youth%3A%20endocrine%20considerations&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B22\" class=\"js-splitview-ref-item\" data-legacy-id=\"B22\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B22\" href=\"javascript:;\" aria-label=\"jumplink-B22\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B22\" class=\"ref-content \" data-id=\"B22\"><span class=\"label\">22.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Saraswat</div>  <div class=\"given-names\">A</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Weinand</div>  <div class=\"given-names\">JD</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Safer</div>  <div class=\"given-names\">JD</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Evidence supporting the biologic nature of gender identity</div>. <div class=\"source \">Endocr Pract</div>. <div class=\"year\">2015</div>;<div class=\"volume\">21</div>(<div class=\"issue\">2</div>):<div class=\"fpage\">199</div>–<div class=\"lpage\">204</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Evidence%20supporting%20the%20biologic%20nature%20of%20gender%20identity&amp;author=A%20Saraswat&amp;author=JD%20Weinand&amp;author=JD%20Safer&amp;publication_year=2015&amp;journal=Endocr%20Pract&amp;volume=21&amp;pages=199-204\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.4158/EP14351.RA\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.4158%2FEP14351.RA\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.4158%2FEP14351.RA\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/25667367\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Evidence%20supporting%20the%20biologic%20nature%20of%20gender%20identity&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B23\" class=\"js-splitview-ref-item\" data-legacy-id=\"B23\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B23\" href=\"javascript:;\" aria-label=\"jumplink-B23\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B23\" class=\"ref-content \" data-id=\"B23\"><span class=\"label\">23.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Gooren</div>  <div class=\"given-names\">L</div>\r\n</span>\r\n</span>. <div class=\"article-title\">The biology of human psychosexual differentiation</div>. <div class=\"source \">Horm Behav</div>. <div class=\"year\">2006</div>;<div class=\"volume\">50</div>(<div class=\"issue\">4</div>):<div class=\"fpage\">589</div>–<div class=\"lpage\">601</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=The%20biology%20of%20human%20psychosexual%20differentiation&amp;author=L%20Gooren&amp;publication_year=2006&amp;journal=Horm%20Behav&amp;volume=50&amp;pages=589-601\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1016/j.yhbeh.2006.06.011\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1016%2Fj.yhbeh.2006.06.011\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1016%2Fj.yhbeh.2006.06.011\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/16870186\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:The%20biology%20of%20human%20psychosexual%20differentiation&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B24\" class=\"js-splitview-ref-item\" data-legacy-id=\"B24\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B24\" href=\"javascript:;\" aria-label=\"jumplink-B24\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B24\" class=\"ref-content \" data-id=\"B24\"><span class=\"label\">24.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Berenbaum</div>  <div class=\"given-names\">SA</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Meyer-Bahlburg</div>  <div class=\"given-names\">HF</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Gender development and sexuality in disorders of sex development</div>. <div class=\"source \">Horm Metab Res</div>. <div class=\"year\">2015</div>;<div class=\"volume\">47</div>(<div class=\"issue\">5</div>):<div class=\"fpage\">361</div>–<div class=\"lpage\">366</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Gender%20development%20and%20sexuality%20in%20disorders%20of%20sex%20development&amp;author=SA%20Berenbaum&amp;author=HF%20Meyer-Bahlburg&amp;publication_year=2015&amp;journal=Horm%20Metab%20Res&amp;volume=47&amp;pages=361-366\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1055/s-00000025\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1055%2Fs-00000025\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1055%2Fs-00000025\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/25853895\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Gender%20development%20and%20sexuality%20in%20disorders%20of%20sex%20development&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B25\" class=\"js-splitview-ref-item\" data-legacy-id=\"B25\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B25\" href=\"javascript:;\" aria-label=\"jumplink-B25\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B25\" class=\"ref-content \" data-id=\"B25\"><span class=\"label\">25.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Dessens</div>  <div class=\"given-names\">AB</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Slijper</div>  <div class=\"given-names\">FME</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Drop</div>  <div class=\"given-names\">SLS</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Gender dysphoria and gender change in chromosomal females with congenital adrenal hyperplasia</div>. <div class=\"source \">Arch Sex Behav</div>. <div class=\"year\">2005</div>;<div class=\"volume\">34</div>(<div class=\"issue\">4</div>):<div class=\"fpage\">389</div>–<div class=\"lpage\">397</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Gender%20dysphoria%20and%20gender%20change%20in%20chromosomal%20females%20with%20congenital%20adrenal%20hyperplasia&amp;author=AB%20Dessens&amp;author=FME%20Slijper&amp;author=SLS%20Drop&amp;publication_year=2005&amp;journal=Arch%20Sex%20Behav&amp;volume=34&amp;pages=389-397\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1007/s10508-005-4338-5\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1007%2Fs10508-005-4338-5\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1007%2Fs10508-005-4338-5\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/16010462\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Gender%20dysphoria%20and%20gender%20change%20in%20chromosomal%20females%20with%20congenital%20adrenal%20hyperplasia&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B26\" class=\"js-splitview-ref-item\" data-legacy-id=\"B26\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B26\" href=\"javascript:;\" aria-label=\"jumplink-B26\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B26\" class=\"ref-content \" data-id=\"B26\"><span class=\"label\">26.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Meyer-Bahlburg</div>  <div class=\"given-names\">HFL</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Dolezal</div>  <div class=\"given-names\">C</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Baker</div>  <div class=\"given-names\">SW</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Ehrhardt</div>  <div class=\"given-names\">AA</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">New</div>  <div class=\"given-names\">MI</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Gender development in women with congenital adrenal hyperplasia as a function of disorder severity</div>. <div class=\"source \">Arch Sex Behav</div>. <div class=\"year\">2006</div>;<div class=\"volume\">35</div>(<div class=\"issue\">6</div>):<div class=\"fpage\">667</div>–<div class=\"lpage\">684</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Gender%20development%20in%20women%20with%20congenital%20adrenal%20hyperplasia%20as%20a%20function%20of%20disorder%20severity&amp;author=HFL%20Meyer-Bahlburg&amp;author=C%20Dolezal&amp;author=SW%20Baker&amp;author=AA%20Ehrhardt&amp;author=MI%20New&amp;publication_year=2006&amp;journal=Arch%20Sex%20Behav&amp;volume=35&amp;pages=667-684\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1007/s10508-006-9068-9\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1007%2Fs10508-006-9068-9\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1007%2Fs10508-006-9068-9\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/16902816\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Gender%20development%20in%20women%20with%20congenital%20adrenal%20hyperplasia%20as%20a%20function%20of%20disorder%20severity&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B27\" class=\"js-splitview-ref-item\" data-legacy-id=\"B27\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B27\" href=\"javascript:;\" aria-label=\"jumplink-B27\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B27\" class=\"ref-content \" data-id=\"B27\"><span class=\"label\">27.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Frisén</div>  <div class=\"given-names\">L</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Nordenström</div>  <div class=\"given-names\">A</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Falhammar</div>  <div class=\"given-names\">H</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Filipsson</div>  <div class=\"given-names\">H</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Holmdahl</div>  <div class=\"given-names\">G</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Janson</div>  <div class=\"given-names\">PO</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Thorén</div>  <div class=\"given-names\">M</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Hagenfeldt</div>  <div class=\"given-names\">K</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Möller</div>  <div class=\"given-names\">A</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Nordenskjöld</div>  <div class=\"given-names\">A</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Gender role behavior, sexuality, and psychosocial adaptation in women with congenital adrenal hyperplasia due to CYP21A2 deficiency</div>. <div class=\"source \">J Clin Endocrinol Metab</div>. <div class=\"year\">2009</div>;<div class=\"volume\">94</div>(<div class=\"issue\">9</div>):<div class=\"fpage\">3432</div>–<div class=\"lpage\">3439</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Gender%20role%20behavior%2C%20sexuality%2C%20and%20psychosocial%20adaptation%20in%20women%20with%20congenital%20adrenal%20hyperplasia%20due%20to%20CYP21A2%20deficiency&amp;author=L%20Fris%C3%A9n&amp;author=A%20Nordenstr%C3%B6m&amp;author=H%20Falhammar&amp;author=H%20Filipsson&amp;author=G%20Holmdahl&amp;author=PO%20Janson&amp;author=M%20Thor%C3%A9n&amp;author=K%20Hagenfeldt&amp;author=A%20M%C3%B6ller&amp;author=A%20Nordenskj%C3%B6ld&amp;publication_year=2009&amp;journal=J%20Clin%20Endocrinol%20Metab&amp;volume=94&amp;pages=3432-3439\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1210/jc.2009-0636\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1210%2Fjc.2009-0636\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1210%2Fjc.2009-0636\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/19567521\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Gender%20role%20behavior%2C%20sexuality%2C%20and%20psychosocial%20adaptation%20in%20women%20with%20congenital%20adrenal%20hyperplasia%20due%20to%20CYP21A2%20deficiency&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B28\" class=\"js-splitview-ref-item\" data-legacy-id=\"B28\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B28\" href=\"javascript:;\" aria-label=\"jumplink-B28\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B28\" class=\"ref-content \" data-id=\"B28\"><span class=\"label\">28.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Meyer-Bahlburg</div>  <div class=\"given-names\">HFL</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Dolezal</div>  <div class=\"given-names\">C</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Baker</div>  <div class=\"given-names\">SW</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Carlson</div>  <div class=\"given-names\">AD</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Obeid</div>  <div class=\"given-names\">JS</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">New</div>  <div class=\"given-names\">MI</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Prenatal androgenization affects gender-related behavior but not gender identity in 5–12-year-old girls with congenital adrenal hyperplasia</div>. <div class=\"source \">Arch Sex Behav</div>. <div class=\"year\">2004</div>;<div class=\"volume\">33</div>(<div class=\"issue\">2</div>):<div class=\"fpage\">97</div>–<div class=\"lpage\">104</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Prenatal%20androgenization%20affects%20gender-related%20behavior%20but%20not%20gender%20identity%20in%205%E2%80%9312-year-old%20girls%20with%20congenital%20adrenal%20hyperplasia&amp;author=HFL%20Meyer-Bahlburg&amp;author=C%20Dolezal&amp;author=SW%20Baker&amp;author=AD%20Carlson&amp;author=JS%20Obeid&amp;author=MI%20New&amp;publication_year=2004&amp;journal=Arch%20Sex%20Behav&amp;volume=33&amp;pages=97-104\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1023/B:ASEB.0000014324.25718.51\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1023%2FB:ASEB.0000014324.25718.51\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1023%2FB:ASEB.0000014324.25718.51\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/15146142\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Prenatal%20androgenization%20affects%20gender-related%20behavior%20but%20not%20gender%20identity%20in%205%E2%80%9312-year-old%20girls%20with%20congenital%20adrenal%20hyperplasia&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B29\" class=\"js-splitview-ref-item\" data-legacy-id=\"B29\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B29\" href=\"javascript:;\" aria-label=\"jumplink-B29\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B29\" class=\"ref-content \" data-id=\"B29\"><span class=\"label\">29.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Cohen-Kettenis</div>  <div class=\"given-names\">PT</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Gender change in 46,XY persons with 5α-reductase-2 deficiency and 17β-hydroxysteroid dehydrogenase-3 deficiency</div>. <div class=\"source \">Arch Sex Behav</div>. <div class=\"year\">2005</div>;<div class=\"volume\">34</div>(<div class=\"issue\">4</div>):<div class=\"fpage\">399</div>–<div class=\"lpage\">410</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Gender%20change%20in%2046%2CXY%20persons%20with%205%CE%B1-reductase-2%20deficiency%20and%2017%CE%B2-hydroxysteroid%20dehydrogenase-3%20deficiency&amp;author=PT%20Cohen-Kettenis&amp;publication_year=2005&amp;journal=Arch%20Sex%20Behav&amp;volume=34&amp;pages=399-410\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1007/s10508-005-4339-4\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1007%2Fs10508-005-4339-4\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1007%2Fs10508-005-4339-4\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/16010463\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Gender%20change%20in%2046%2CXY%20persons%20with%205%CE%B1-reductase-2%20deficiency%20and%2017%CE%B2-hydroxysteroid%20dehydrogenase-3%20deficiency&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B30\" class=\"js-splitview-ref-item\" data-legacy-id=\"B30\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B30\" href=\"javascript:;\" aria-label=\"jumplink-B30\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B30\" class=\"ref-content \" data-id=\"B30\"><span class=\"label\">30.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Reiner</div>  <div class=\"given-names\">WG</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Gearhart</div>  <div class=\"given-names\">JP</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Discordant sexual identity in some genetic males with cloacal exstrophy assigned to female sex at birth</div>. <div class=\"source \">N Engl J Med</div>. <div class=\"year\">2004</div>;<div class=\"volume\">350</div>(<div class=\"issue\">4</div>):<div class=\"fpage\">333</div>–<div class=\"lpage\">341</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Discordant%20sexual%20identity%20in%20some%20genetic%20males%20with%20cloacal%20exstrophy%20assigned%20to%20female%20sex%20at%20birth&amp;author=WG%20Reiner&amp;author=JP%20Gearhart&amp;publication_year=2004&amp;journal=N%20Engl%20J%20Med&amp;volume=350&amp;pages=333-341\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1056/NEJMoa022236\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1056%2FNEJMoa022236\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1056%2FNEJMoa022236\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/14736925\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Discordant%20sexual%20identity%20in%20some%20genetic%20males%20with%20cloacal%20exstrophy%20assigned%20to%20female%20sex%20at%20birth&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B31\" class=\"js-splitview-ref-item\" data-legacy-id=\"B31\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B31\" href=\"javascript:;\" aria-label=\"jumplink-B31\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B31\" class=\"ref-content \" data-id=\"B31\"><span class=\"label\">31.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Meyer-Bahlburg</div>  <div class=\"given-names\">HFL</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Gender identity outcome in female-raised 46,XY persons with penile agenesis, cloacal exstrophy of the bladder, or penile ablation</div>. <div class=\"source \">Arch Sex Behav</div>. <div class=\"year\">2005</div>;<div class=\"volume\">34</div>(<div class=\"issue\">4</div>):<div class=\"fpage\">423</div>–<div class=\"lpage\">438</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Gender%20identity%20outcome%20in%20female-raised%2046%2CXY%20persons%20with%20penile%20agenesis%2C%20cloacal%20exstrophy%20of%20the%20bladder%2C%20or%20penile%20ablation&amp;author=HFL%20Meyer-Bahlburg&amp;publication_year=2005&amp;journal=Arch%20Sex%20Behav&amp;volume=34&amp;pages=423-438\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1007/s10508-005-4342-9\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1007%2Fs10508-005-4342-9\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1007%2Fs10508-005-4342-9\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/16010465\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Gender%20identity%20outcome%20in%20female-raised%2046%2CXY%20persons%20with%20penile%20agenesis%2C%20cloacal%20exstrophy%20of%20the%20bladder%2C%20or%20penile%20ablation&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B32\" class=\"js-splitview-ref-item\" data-legacy-id=\"B32\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B32\" href=\"javascript:;\" aria-label=\"jumplink-B32\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B32\" class=\"ref-content \" data-id=\"B32\"><span class=\"label\">32.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Coolidge</div>  <div class=\"given-names\">FL</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Thede</div>  <div class=\"given-names\">LL</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Young</div>  <div class=\"given-names\">SE</div>\r\n</span>\r\n</span>. <div class=\"article-title\">The heritability of gender identity disorder in a child and adolescent twin sample</div>. <div class=\"source \">Behav Genet</div>. <div class=\"year\">2002</div>;<div class=\"volume\">32</div>(<div class=\"issue\">4</div>):<div class=\"fpage\">251</div>–<div class=\"lpage\">257</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=The%20heritability%20of%20gender%20identity%20disorder%20in%20a%20child%20and%20adolescent%20twin%20sample&amp;author=FL%20Coolidge&amp;author=LL%20Thede&amp;author=SE%20Young&amp;publication_year=2002&amp;journal=Behav%20Genet&amp;volume=32&amp;pages=251-257\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1023/A:1019724712983\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1023%2FA:1019724712983\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1023%2FA:1019724712983\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/12211624\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:The%20heritability%20of%20gender%20identity%20disorder%20in%20a%20child%20and%20adolescent%20twin%20sample&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B33\" class=\"js-splitview-ref-item\" data-legacy-id=\"B33\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B33\" href=\"javascript:;\" aria-label=\"jumplink-B33\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B33\" class=\"ref-content \" data-id=\"B33\"><span class=\"label\">33.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Heylens</div>  <div class=\"given-names\">G</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">De Cuypere</div>  <div class=\"given-names\">G</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Zucker</div>  <div class=\"given-names\">KJ</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Schelfaut</div>  <div class=\"given-names\">C</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Elaut</div>  <div class=\"given-names\">E</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Vanden Bossche</div>  <div class=\"given-names\">H</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">De Baere</div>  <div class=\"given-names\">E</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">T’Sjoen</div>  <div class=\"given-names\">G</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Gender identity disorder in twins: a review of the case report literature</div>. <div class=\"source \">J Sex Med</div>. <div class=\"year\">2012</div>;<div class=\"volume\">9</div>(<div class=\"issue\">3</div>):<div class=\"fpage\">751</div>–<div class=\"lpage\">757</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Gender%20identity%20disorder%20in%20twins%3A%20a%20review%20of%20the%20case%20report%20literature&amp;author=G%20Heylens&amp;author=G%20De%20Cuypere&amp;author=KJ%20Zucker&amp;author=C%20Schelfaut&amp;author=E%20Elaut&amp;author=H%20Vanden%20Bossche&amp;author=E%20De%20Baere&amp;author=G%20T%E2%80%99Sjoen&amp;publication_year=2012&amp;journal=J%20Sex%20Med&amp;volume=9&amp;pages=751-757\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1111/j.1743-6109.2011.02567.x\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1111%2Fj.1743-6109.2011.02567.x\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1111%2Fj.1743-6109.2011.02567.x\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22146048\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Gender%20identity%20disorder%20in%20twins%3A%20a%20review%20of%20the%20case%20report%20literature&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B34\" class=\"js-splitview-ref-item\" data-legacy-id=\"B34\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B34\" href=\"javascript:;\" aria-label=\"jumplink-B34\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B34\" class=\"ref-content \" data-id=\"B34\"><span class=\"label\">34.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Fernández</div>  <div class=\"given-names\">R</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Esteva</div>  <div class=\"given-names\">I</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Gómez-Gil</div>  <div class=\"given-names\">E</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Rumbo</div>  <div class=\"given-names\">T</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Almaraz</div>  <div class=\"given-names\">MC</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Roda</div>  <div class=\"given-names\">E</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Haro-Mora</div>  <div class=\"given-names\">J-J</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Guillamón</div>  <div class=\"given-names\">A</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Pásaro</div>  <div class=\"given-names\">E</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Association study of ERβ, AR, and CYP19A1 genes and MtF transsexualism</div>. <div class=\"source \">J Sex Med</div>. <div class=\"year\">2014</div>;<div class=\"volume\">11</div>(<div class=\"issue\">12</div>):<div class=\"fpage\">2986</div>–<div class=\"lpage\">2994</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Association%20study%20of%20ER%CE%B2%2C%20AR%2C%20and%20CYP19A1%20genes%20and%20MtF%20transsexualism&amp;author=R%20Fern%C3%A1ndez&amp;author=I%20Esteva&amp;author=E%20G%C3%B3mez-Gil&amp;author=T%20Rumbo&amp;author=MC%20Almaraz&amp;author=E%20Roda&amp;author=J-J%20Haro-Mora&amp;author=A%20Guillam%C3%B3n&amp;author=E%20P%C3%A1saro&amp;publication_year=2014&amp;journal=J%20Sex%20Med&amp;volume=11&amp;pages=2986-2994\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1111/jsm.12673\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1111%2Fjsm.12673\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1111%2Fjsm.12673\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/25124466\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Association%20study%20of%20ER%CE%B2%2C%20AR%2C%20and%20CYP19A1%20genes%20and%20MtF%20transsexualism&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B35\" class=\"js-splitview-ref-item\" data-legacy-id=\"B35\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B35\" href=\"javascript:;\" aria-label=\"jumplink-B35\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B35\" class=\"ref-content \" data-id=\"B35\"><span class=\"label\">35.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Henningsson</div>  <div class=\"given-names\">S</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Westberg</div>  <div class=\"given-names\">L</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Nilsson</div>  <div class=\"given-names\">S</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Lundström</div>  <div class=\"given-names\">B</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Ekselius</div>  <div class=\"given-names\">L</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Bodlund</div>  <div class=\"given-names\">O</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Lindström</div>  <div class=\"given-names\">E</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Hellstrand</div>  <div class=\"given-names\">M</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Rosmond</div>  <div class=\"given-names\">R</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Eriksson</div>  <div class=\"given-names\">E</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Landén</div>  <div class=\"given-names\">M</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Sex steroid-related genes and male-to-female transsexualism</div>. <div class=\"source \">Psychoneuroendocrinology</div>. <div class=\"year\">2005</div>;<div class=\"volume\">30</div>(<div class=\"issue\">7</div>):<div class=\"fpage\">657</div>–<div class=\"lpage\">664</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Sex%20steroid-related%20genes%20and%20male-to-female%20transsexualism&amp;author=S%20Henningsson&amp;author=L%20Westberg&amp;author=S%20Nilsson&amp;author=B%20Lundstr%C3%B6m&amp;author=L%20Ekselius&amp;author=O%20Bodlund&amp;author=E%20Lindstr%C3%B6m&amp;author=M%20Hellstrand&amp;author=R%20Rosmond&amp;author=E%20Eriksson&amp;author=M%20Land%C3%A9n&amp;publication_year=2005&amp;journal=Psychoneuroendocrinology&amp;volume=30&amp;pages=657-664\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1016/j.psyneuen.2005.02.006\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1016%2Fj.psyneuen.2005.02.006\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1016%2Fj.psyneuen.2005.02.006\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/15854782\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Sex%20steroid-related%20genes%20and%20male-to-female%20transsexualism&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B36\" class=\"js-splitview-ref-item\" data-legacy-id=\"B36\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B36\" href=\"javascript:;\" aria-label=\"jumplink-B36\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B36\" class=\"ref-content \" data-id=\"B36\"><span class=\"label\">36.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Hare</div>  <div class=\"given-names\">L</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Bernard</div>  <div class=\"given-names\">P</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Sánchez</div>  <div class=\"given-names\">FJ</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Baird</div>  <div class=\"given-names\">PN</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Vilain</div>  <div class=\"given-names\">E</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Kennedy</div>  <div class=\"given-names\">T</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Harley</div>  <div class=\"given-names\">VR</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Androgen receptor repeat length polymorphism associated with male-to-female transsexualism</div>. <div class=\"source \">Biol Psychiatry</div>. <div class=\"year\">2009</div>;<div class=\"volume\">65</div>(<div class=\"issue\">1</div>):<div class=\"fpage\">93</div>–<div class=\"lpage\">96</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Androgen%20receptor%20repeat%20length%20polymorphism%20associated%20with%20male-to-female%20transsexualism&amp;author=L%20Hare&amp;author=P%20Bernard&amp;author=FJ%20S%C3%A1nchez&amp;author=PN%20Baird&amp;author=E%20Vilain&amp;author=T%20Kennedy&amp;author=VR%20Harley&amp;publication_year=2009&amp;journal=Biol%20Psychiatry&amp;volume=65&amp;pages=93-96\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1016/j.biopsych.2008.08.033\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1016%2Fj.biopsych.2008.08.033\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1016%2Fj.biopsych.2008.08.033\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/18962445\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Androgen%20receptor%20repeat%20length%20polymorphism%20associated%20with%20male-to-female%20transsexualism&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B37\" class=\"js-splitview-ref-item\" data-legacy-id=\"B37\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B37\" href=\"javascript:;\" aria-label=\"jumplink-B37\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B37\" class=\"ref-content \" data-id=\"B37\"><span class=\"label\">37.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Lombardo</div>  <div class=\"given-names\">F</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Toselli</div>  <div class=\"given-names\">L</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Grassetti</div>  <div class=\"given-names\">D</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Paoli</div>  <div class=\"given-names\">D</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Masciandaro</div>  <div class=\"given-names\">P</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Valentini</div>  <div class=\"given-names\">F</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Lenzi</div>  <div class=\"given-names\">A</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Gandini</div>  <div class=\"given-names\">L</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Hormone and genetic study in male to female transsexual patients</div>. <div class=\"source \">J Endocrinol Invest</div>. <div class=\"year\">2013</div>;<div class=\"volume\">36</div>(<div class=\"issue\">8</div>):<div class=\"fpage\">550</div>–<div class=\"lpage\">557</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Hormone%20and%20genetic%20study%20in%20male%20to%20female%20transsexual%20patients&amp;author=F%20Lombardo&amp;author=L%20Toselli&amp;author=D%20Grassetti&amp;author=D%20Paoli&amp;author=P%20Masciandaro&amp;author=F%20Valentini&amp;author=A%20Lenzi&amp;author=L%20Gandini&amp;publication_year=2013&amp;journal=J%20Endocrinol%20Invest&amp;volume=36&amp;pages=550-557\" target=\"_blank\">Google Scholar</a></span></p><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23324476\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><div class=\"xslopenurl empty-target\"><span class=\"js-inst-open-url-holders-nodoi\"><a class=\"js-open-url-link\" data-href-template=\"{targetURL}?sid=oup:orr&amp;genre=article&amp;atitle=Hormone+and+genetic+study+in+male+to+female+transsexual+patients&amp;aulast=Lombardo&amp;title=J+Endocrinol+Invest&amp;date=2013&amp;spage=550&amp;epage=557&amp;volume=36&amp;issue=8\" href=\"javascript:;\"><span class=\"screenreader-text\">OpenURL Placeholder Text</span></a></span></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Hormone%20and%20genetic%20study%20in%20male%20to%20female%20transsexual%20patients&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B38\" class=\"js-splitview-ref-item\" data-legacy-id=\"B38\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B38\" href=\"javascript:;\" aria-label=\"jumplink-B38\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B38\" class=\"ref-content \" data-id=\"B38\"><span class=\"label\">38.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Ujike</div>  <div class=\"given-names\">H</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Otani</div>  <div class=\"given-names\">K</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Nakatsuka</div>  <div class=\"given-names\">M</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Ishii</div>  <div class=\"given-names\">K</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Sasaki</div>  <div class=\"given-names\">A</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Oishi</div>  <div class=\"given-names\">T</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Sato</div>  <div class=\"given-names\">T</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Okahisa</div>  <div class=\"given-names\">Y</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Matsumoto</div>  <div class=\"given-names\">Y</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Namba</div>  <div class=\"given-names\">Y</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Kimata</div>  <div class=\"given-names\">Y</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Kuroda</div>  <div class=\"given-names\">S</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Association study of gender identity disorder and sex hormone-related genes</div>. <div class=\"source \">Prog Neuropsychopharmacol Biol Psychiatry</div>. <div class=\"year\">2009</div>;<div class=\"volume\">33</div>(<div class=\"issue\">7</div>):<div class=\"fpage\">1241</div>–<div class=\"lpage\">1244</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Association%20study%20of%20gender%20identity%20disorder%20and%20sex%20hormone-related%20genes&amp;author=H%20Ujike&amp;author=K%20Otani&amp;author=M%20Nakatsuka&amp;author=K%20Ishii&amp;author=A%20Sasaki&amp;author=T%20Oishi&amp;author=T%20Sato&amp;author=Y%20Okahisa&amp;author=Y%20Matsumoto&amp;author=Y%20Namba&amp;author=Y%20Kimata&amp;author=S%20Kuroda&amp;publication_year=2009&amp;journal=Prog%20Neuropsychopharmacol%20Biol%20Psychiatry&amp;volume=33&amp;pages=1241-1244\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1016/j.pnpbp.2009.07.008\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1016%2Fj.pnpbp.2009.07.008\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1016%2Fj.pnpbp.2009.07.008\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/19604497\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Association%20study%20of%20gender%20identity%20disorder%20and%20sex%20hormone-related%20genes&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B39\" class=\"js-splitview-ref-item\" data-legacy-id=\"B39\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B39\" href=\"javascript:;\" aria-label=\"jumplink-B39\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B39\" class=\"ref-content \" data-id=\"B39\"><span class=\"label\">39.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Kreukels</div>  <div class=\"given-names\">BP</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Guillamon</div>  <div class=\"given-names\">A</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Neuroimaging studies in people with gender incongruence</div>. <div class=\"source \">Int Rev Psychiatry</div>. <div class=\"year\">2016</div>;<div class=\"volume\">28</div>(<div class=\"issue\">1</div>):<div class=\"fpage\">120</div>–<div class=\"lpage\">128</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Neuroimaging%20studies%20in%20people%20with%20gender%20incongruence&amp;author=BP%20Kreukels&amp;author=A%20Guillamon&amp;publication_year=2016&amp;journal=Int%20Rev%20Psychiatry&amp;volume=28&amp;pages=120-128\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.3109/09540261.2015.1113163\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.3109%2F09540261.2015.1113163\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.3109%2F09540261.2015.1113163\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/26766406\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Neuroimaging%20studies%20in%20people%20with%20gender%20incongruence&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B40\" class=\"js-splitview-ref-item\" data-legacy-id=\"B40\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B40\" href=\"javascript:;\" aria-label=\"jumplink-B40\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B40\" class=\"ref-content \" data-id=\"B40\"><span class=\"label\">40.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Steensma</div>  <div class=\"given-names\">TD</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Biemond</div>  <div class=\"given-names\">R</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">de Boer</div>  <div class=\"given-names\">F</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Cohen-Kettenis</div>  <div class=\"given-names\">PT</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Desisting and persisting gender dysphoria after childhood: a qualitative follow-up study</div>. <div class=\"source \">Clin Child Psychol Psychiatry</div>. <div class=\"year\">2011</div>;<div class=\"volume\">16</div>(<div class=\"issue\">4</div>):<div class=\"fpage\">499</div>–<div class=\"lpage\">516</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Desisting%20and%20persisting%20gender%20dysphoria%20after%20childhood%3A%20a%20qualitative%20follow-up%20study&amp;author=TD%20Steensma&amp;author=R%20Biemond&amp;author=F%20de%20Boer&amp;author=PT%20Cohen-Kettenis&amp;publication_year=2011&amp;journal=Clin%20Child%20Psychol%20Psychiatry&amp;volume=16&amp;pages=499-516\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1177/1359104510378303\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1177%2F1359104510378303\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1177%2F1359104510378303\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/21216800\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Desisting%20and%20persisting%20gender%20dysphoria%20after%20childhood%3A%20a%20qualitative%20follow-up%20study&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B41\" class=\"js-splitview-ref-item\" data-legacy-id=\"B41\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B41\" href=\"javascript:;\" aria-label=\"jumplink-B41\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B41\" class=\"ref-content \" data-id=\"B41\"><span class=\"label\">41.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Wallien</div>  <div class=\"given-names\">MSC</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Cohen-Kettenis</div>  <div class=\"given-names\">PT</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Psychosexual outcome of gender-dysphoric children</div>. <div class=\"source \">J Am Acad Child Adolesc Psychiatry</div>. <div class=\"year\">2008</div>;<div class=\"volume\">47</div>(<div class=\"issue\">12</div>):<div class=\"fpage\">1413</div>–<div class=\"lpage\">1423</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Psychosexual%20outcome%20of%20gender-dysphoric%20children&amp;author=MSC%20Wallien&amp;author=PT%20Cohen-Kettenis&amp;publication_year=2008&amp;journal=J%20Am%20Acad%20Child%20Adolesc%20Psychiatry&amp;volume=47&amp;pages=1413-1423\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1097/CHI.0b013e31818956b9\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1097%2FCHI.0b013e31818956b9\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1097%2FCHI.0b013e31818956b9\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/18981931\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Psychosexual%20outcome%20of%20gender-dysphoric%20children&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B42\" class=\"js-splitview-ref-item\" data-legacy-id=\"B42\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B42\" href=\"javascript:;\" aria-label=\"jumplink-B42\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B42\" class=\"ref-content \" data-id=\"B42\"><span class=\"label\">42.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Steensma</div>  <div class=\"given-names\">TD</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">McGuire</div>  <div class=\"given-names\">JK</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Kreukels</div>  <div class=\"given-names\">BPC</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Beekman</div>  <div class=\"given-names\">AJ</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Cohen-Kettenis</div>  <div class=\"given-names\">PT</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Factors associated with desistence and persistence of childhood gender dysphoria: a quantitative follow-up study</div>. <div class=\"source \">J Am Acad Child Adolesc Psychiatry</div>. <div class=\"year\">2013</div>;<div class=\"volume\">52</div>(<div class=\"issue\">6</div>):<div class=\"fpage\">582</div>–<div class=\"lpage\">590</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Factors%20associated%20with%20desistence%20and%20persistence%20of%20childhood%20gender%20dysphoria%3A%20a%20quantitative%20follow-up%20study&amp;author=TD%20Steensma&amp;author=JK%20McGuire&amp;author=BPC%20Kreukels&amp;author=AJ%20Beekman&amp;author=PT%20Cohen-Kettenis&amp;publication_year=2013&amp;journal=J%20Am%20Acad%20Child%20Adolesc%20Psychiatry&amp;volume=52&amp;pages=582-590\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1016/j.jaac.2013.03.016\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1016%2Fj.jaac.2013.03.016\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1016%2Fj.jaac.2013.03.016\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23702447\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Factors%20associated%20with%20desistence%20and%20persistence%20of%20childhood%20gender%20dysphoria%3A%20a%20quantitative%20follow-up%20study&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B43\" class=\"js-splitview-ref-item\" data-legacy-id=\"B43\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B43\" href=\"javascript:;\" aria-label=\"jumplink-B43\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B43\" class=\"ref-content \" data-id=\"B43\"><span class=\"label\">43.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Cohen-Kettenis</div>  <div class=\"given-names\">PT</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Owen</div>  <div class=\"given-names\">A</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Kaijser</div>  <div class=\"given-names\">VG</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Bradley</div>  <div class=\"given-names\">SJ</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Zucker</div>  <div class=\"given-names\">KJ</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Demographic characteristics, social competence, and behavior problems in children with gender identity disorder: a cross-national, cross-clinic comparative analysis</div>. <div class=\"source \">J Abnorm Child Psychol</div>. <div class=\"year\">2003</div>;<div class=\"volume\">31</div>(<div class=\"issue\">1</div>):<div class=\"fpage\">41</div>–<div class=\"lpage\">53</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Demographic%20characteristics%2C%20social%20competence%2C%20and%20behavior%20problems%20in%20children%20with%20gender%20identity%20disorder%3A%20a%20cross-national%2C%20cross-clinic%20comparative%20analysis&amp;author=PT%20Cohen-Kettenis&amp;author=A%20Owen&amp;author=VG%20Kaijser&amp;author=SJ%20Bradley&amp;author=KJ%20Zucker&amp;publication_year=2003&amp;journal=J%20Abnorm%20Child%20Psychol&amp;volume=31&amp;pages=41-53\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1023/A:1021769215342\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1023%2FA:1021769215342\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1023%2FA:1021769215342\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/12597698\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Demographic%20characteristics%2C%20social%20competence%2C%20and%20behavior%20problems%20in%20children%20with%20gender%20identity%20disorder%3A%20a%20cross-national%2C%20cross-clinic%20comparative%20analysis&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B44\" class=\"js-splitview-ref-item\" data-legacy-id=\"B44\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B44\" href=\"javascript:;\" aria-label=\"jumplink-B44\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B44\" class=\"ref-content \" data-id=\"B44\"><span class=\"label\">44.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Dhejne</div>  <div class=\"given-names\">C</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Van Vlerken</div>  <div class=\"given-names\">R</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Heylens</div>  <div class=\"given-names\">G</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Arcelus</div>  <div class=\"given-names\">J</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Mental health and gender dysphoria: a review of the literature</div>. <div class=\"source \">Int Rev Psychiatry</div>. <div class=\"year\">2016</div>;<div class=\"volume\">28</div>(<div class=\"issue\">1</div>):<div class=\"fpage\">44</div>–<div class=\"lpage\">57</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Mental%20health%20and%20gender%20dysphoria%3A%20a%20review%20of%20the%20literature&amp;author=C%20Dhejne&amp;author=R%20Van%20Vlerken&amp;author=G%20Heylens&amp;author=J%20Arcelus&amp;publication_year=2016&amp;journal=Int%20Rev%20Psychiatry&amp;volume=28&amp;pages=44-57\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.3109/09540261.2015.1115753\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.3109%2F09540261.2015.1115753\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.3109%2F09540261.2015.1115753\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/26835611\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Mental%20health%20and%20gender%20dysphoria%3A%20a%20review%20of%20the%20literature&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B45\" class=\"js-splitview-ref-item\" data-legacy-id=\"B45\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B45\" href=\"javascript:;\" aria-label=\"jumplink-B45\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B45\" class=\"ref-content \" data-id=\"B45\"><span class=\"label\">45.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Pasterski</div>  <div class=\"given-names\">V</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Gilligan</div>  <div class=\"given-names\">L</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Curtis</div>  <div class=\"given-names\">R</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Traits of autism spectrum disorders in adults with gender dysphoria</div>. <div class=\"source \">Arch Sex Behav</div>. <div class=\"year\">2014</div>;<div class=\"volume\">43</div>(<div class=\"issue\">2</div>):<div class=\"fpage\">387</div>–<div class=\"lpage\">393</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Traits%20of%20autism%20spectrum%20disorders%20in%20adults%20with%20gender%20dysphoria&amp;author=V%20Pasterski&amp;author=L%20Gilligan&amp;author=R%20Curtis&amp;publication_year=2014&amp;journal=Arch%20Sex%20Behav&amp;volume=43&amp;pages=387-393\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1007/s10508-013-0154-5\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1007%2Fs10508-013-0154-5\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1007%2Fs10508-013-0154-5\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23864402\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Traits%20of%20autism%20spectrum%20disorders%20in%20adults%20with%20gender%20dysphoria&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B46\" class=\"js-splitview-ref-item\" data-legacy-id=\"B46\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B46\" href=\"javascript:;\" aria-label=\"jumplink-B46\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B46\" class=\"ref-content \" data-id=\"B46\"><span class=\"label\">46.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Spack</div>  <div class=\"given-names\">NP</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Edwards-Leeper</div>  <div class=\"given-names\">L</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Feldman</div>  <div class=\"given-names\">HA</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Leibowitz</div>  <div class=\"given-names\">S</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Mandel</div>  <div class=\"given-names\">F</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Diamond</div>  <div class=\"given-names\">DA</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Vance</div>  <div class=\"given-names\">SR</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Children and adolescents with gender identity disorder referred to a pediatric medical center</div>. <div class=\"source \">Pediatrics</div>. <div class=\"year\">2012</div>;<div class=\"volume\">129</div>(<div class=\"issue\">3</div>):<div class=\"fpage\">418</div>–<div class=\"lpage\">425</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Children%20and%20adolescents%20with%20gender%20identity%20disorder%20referred%20to%20a%20pediatric%20medical%20center&amp;author=NP%20Spack&amp;author=L%20Edwards-Leeper&amp;author=HA%20Feldman&amp;author=S%20Leibowitz&amp;author=F%20Mandel&amp;author=DA%20Diamond&amp;author=SR%20Vance&amp;publication_year=2012&amp;journal=Pediatrics&amp;volume=129&amp;pages=418-425\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1542/peds.2011-0907\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1542%2Fpeds.2011-0907\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1542%2Fpeds.2011-0907\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22351896\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Children%20and%20adolescents%20with%20gender%20identity%20disorder%20referred%20to%20a%20pediatric%20medical%20center&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B47\" class=\"js-splitview-ref-item\" data-legacy-id=\"B47\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B47\" href=\"javascript:;\" aria-label=\"jumplink-B47\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B47\" class=\"ref-content \" data-id=\"B47\"><span class=\"label\">47.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Terada</div>  <div class=\"given-names\">S</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Matsumoto</div>  <div class=\"given-names\">Y</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Sato</div>  <div class=\"given-names\">T</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Okabe</div>  <div class=\"given-names\">N</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Kishimoto</div>  <div class=\"given-names\">Y</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Uchitomi</div>  <div class=\"given-names\">Y</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Factors predicting psychiatric co-morbidity in gender-dysphoric adults</div>. <div class=\"source \">Psychiatry Res</div>. <div class=\"year\">2012</div>;<div class=\"volume\">200</div>(<div class=\"issue\">2-3</div>):<div class=\"fpage\">469</div>–<div class=\"lpage\">474</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Factors%20predicting%20psychiatric%20co-morbidity%20in%20gender-dysphoric%20adults&amp;author=S%20Terada&amp;author=Y%20Matsumoto&amp;author=T%20Sato&amp;author=N%20Okabe&amp;author=Y%20Kishimoto&amp;author=Y%20Uchitomi&amp;publication_year=2012&amp;journal=Psychiatry%20Res&amp;volume=200&amp;pages=469-474\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1016/j.psychres.2012.07.018\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1016%2Fj.psychres.2012.07.018\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1016%2Fj.psychres.2012.07.018\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22884214\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Factors%20predicting%20psychiatric%20co-morbidity%20in%20gender-dysphoric%20adults&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B48\" class=\"js-splitview-ref-item\" data-legacy-id=\"B48\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B48\" href=\"javascript:;\" aria-label=\"jumplink-B48\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B48\" class=\"ref-content \" data-id=\"B48\"><span class=\"label\">48.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">VanderLaan</div>  <div class=\"given-names\">DP</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Leef</div>  <div class=\"given-names\">JH</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Wood</div>  <div class=\"given-names\">H</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Hughes</div>  <div class=\"given-names\">SK</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Zucker</div>  <div class=\"given-names\">KJ</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Autism spectrum disorder risk factors and autistic traits in gender dysphoric children</div>. <div class=\"source \">J Autism Dev Disord</div>. <div class=\"year\">2015</div>;<div class=\"volume\">45</div>(<div class=\"issue\">6</div>):<div class=\"fpage\">1742</div>–<div class=\"lpage\">1750</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Autism%20spectrum%20disorder%20risk%20factors%20and%20autistic%20traits%20in%20gender%20dysphoric%20children&amp;author=DP%20VanderLaan&amp;author=JH%20Leef&amp;author=H%20Wood&amp;author=SK%20Hughes&amp;author=KJ%20Zucker&amp;publication_year=2015&amp;journal=J%20Autism%20Dev%20Disord&amp;volume=45&amp;pages=1742-1750\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1007/s10803-014-2331-3\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1007%2Fs10803-014-2331-3\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1007%2Fs10803-014-2331-3\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/25503304\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Autism%20spectrum%20disorder%20risk%20factors%20and%20autistic%20traits%20in%20gender%20dysphoric%20children&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B49\" class=\"js-splitview-ref-item\" data-legacy-id=\"B49\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B49\" href=\"javascript:;\" aria-label=\"jumplink-B49\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B49\" class=\"ref-content \" data-id=\"B49\"><span class=\"label\">49.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">de Vries</div>  <div class=\"given-names\">ALC</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Doreleijers</div>  <div class=\"given-names\">TAH</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Steensma</div>  <div class=\"given-names\">TD</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Cohen-Kettenis</div>  <div class=\"given-names\">PT</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Psychiatric comorbidity in gender dysphoric adolescents</div>. <div class=\"source \">J Child Psychol Psychiatry</div>. <div class=\"year\">2011</div>;<div class=\"volume\">52</div>(<div class=\"issue\">11</div>):<div class=\"fpage\">1195</div>–<div class=\"lpage\">1202</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Psychiatric%20comorbidity%20in%20gender%20dysphoric%20adolescents&amp;author=ALC%20de%20Vries&amp;author=TAH%20Doreleijers&amp;author=TD%20Steensma&amp;author=PT%20Cohen-Kettenis&amp;publication_year=2011&amp;journal=J%20Child%20Psychol%20Psychiatry&amp;volume=52&amp;pages=1195-1202\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1111/jcpp.2011.52.issue-11\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1111%2Fjcpp.2011.52.issue-11\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1111%2Fjcpp.2011.52.issue-11\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/21671938\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Psychiatric%20comorbidity%20in%20gender%20dysphoric%20adolescents&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B50\" class=\"js-splitview-ref-item\" data-legacy-id=\"B50\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B50\" href=\"javascript:;\" aria-label=\"jumplink-B50\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B50\" class=\"ref-content \" data-id=\"B50\"><span class=\"label\">50.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">de Vries</div>  <div class=\"given-names\">ALC</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Noens</div>  <div class=\"given-names\">ILJ</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Cohen-Kettenis</div>  <div class=\"given-names\">PT</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">van Berckelaer-Onnes</div>  <div class=\"given-names\">IA</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Doreleijers</div>  <div class=\"given-names\">TA</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Autism spectrum disorders in gender dysphoric children and adolescents</div>. <div class=\"source \">J Autism Dev Disord</div>. <div class=\"year\">2010</div>;<div class=\"volume\">40</div>(<div class=\"issue\">8</div>):<div class=\"fpage\">930</div>–<div class=\"lpage\">936</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Autism%20spectrum%20disorders%20in%20gender%20dysphoric%20children%20and%20adolescents&amp;author=ALC%20de%20Vries&amp;author=ILJ%20Noens&amp;author=PT%20Cohen-Kettenis&amp;author=IA%20van%20Berckelaer-Onnes&amp;author=TA%20Doreleijers&amp;publication_year=2010&amp;journal=J%20Autism%20Dev%20Disord&amp;volume=40&amp;pages=930-936\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1007/s10803-010-0935-9\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1007%2Fs10803-010-0935-9\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1007%2Fs10803-010-0935-9\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/20094764\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Autism%20spectrum%20disorders%20in%20gender%20dysphoric%20children%20and%20adolescents&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B51\" class=\"js-splitview-ref-item\" data-legacy-id=\"B51\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B51\" href=\"javascript:;\" aria-label=\"jumplink-B51\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B51\" class=\"ref-content \" data-id=\"B51\"><span class=\"label\">51.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Wallien</div>  <div class=\"given-names\">MSC</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Swaab</div>  <div class=\"given-names\">H</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Cohen-Kettenis</div>  <div class=\"given-names\">PT</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Psychiatric comorbidity among children with gender identity disorder</div>. <div class=\"source \">J Am Acad Child Adolesc Psychiatry</div>. <div class=\"year\">2007</div>;<div class=\"volume\">46</div>(<div class=\"issue\">10</div>):<div class=\"fpage\">1307</div>–<div class=\"lpage\">1314</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Psychiatric%20comorbidity%20among%20children%20with%20gender%20identity%20disorder&amp;author=MSC%20Wallien&amp;author=H%20Swaab&amp;author=PT%20Cohen-Kettenis&amp;publication_year=2007&amp;journal=J%20Am%20Acad%20Child%20Adolesc%20Psychiatry&amp;volume=46&amp;pages=1307-1314\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1097/chi.0b013e3181373848\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1097%2Fchi.0b013e3181373848\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1097%2Fchi.0b013e3181373848\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/17885572\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Psychiatric%20comorbidity%20among%20children%20with%20gender%20identity%20disorder&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B52\" class=\"js-splitview-ref-item\" data-legacy-id=\"B52\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B52\" href=\"javascript:;\" aria-label=\"jumplink-B52\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B52\" class=\"ref-content \" data-id=\"B52\"><span class=\"label\">52.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<div class=\"comment\">Kuiper AJ, Cohen-Kettenis PT. Gender role reversal among postoperative transsexuals. Available at: https://www.atria.nl/ezines/web/IJT/97-03/numbers/symposion/ijtc0502.htm. Accessed 26 August 2016</div>.</p></div></div></div></div><div content-id=\"B53\" class=\"js-splitview-ref-item\" data-legacy-id=\"B53\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B53\" href=\"javascript:;\" aria-label=\"jumplink-B53\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B53\" class=\"ref-content \" data-id=\"B53\"><span class=\"label\">53.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Landén</div>  <div class=\"given-names\">M</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Wålinder</div>  <div class=\"given-names\">J</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Hambert</div>  <div class=\"given-names\">G</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Lundström</div>  <div class=\"given-names\">B</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Factors predictive of regret in sex reassignment</div>. <div class=\"source \">Acta Psychiatr Scand</div>. <div class=\"year\">1998</div>;<div class=\"volume\">97</div>(<div class=\"issue\">4</div>):<div class=\"fpage\">284</div>–<div class=\"lpage\">289</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Factors%20predictive%20of%20regret%20in%20sex%20reassignment&amp;author=M%20Land%C3%A9n&amp;author=J%20W%C3%A5linder&amp;author=G%20Hambert&amp;author=B%20Lundstr%C3%B6m&amp;publication_year=1998&amp;journal=Acta%20Psychiatr%20Scand&amp;volume=97&amp;pages=284-289\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1111/acp.1998.97.issue-4\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1111%2Facp.1998.97.issue-4\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1111%2Facp.1998.97.issue-4\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/9570489\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Factors%20predictive%20of%20regret%20in%20sex%20reassignment&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B54\" class=\"js-splitview-ref-item\" data-legacy-id=\"B54\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B54\" href=\"javascript:;\" aria-label=\"jumplink-B54\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B54\" class=\"ref-content \" data-id=\"B54\"><span class=\"label\">54.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Olsson</div>  <div class=\"given-names\">S-E</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Möller</div>  <div class=\"given-names\">A</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Regret after sex reassignment surgery in a male-to-female transsexual: a long-term follow-up</div>. <div class=\"source \">Arch Sex Behav</div>. <div class=\"year\">2006</div>;<div class=\"volume\">35</div>(<div class=\"issue\">4</div>):<div class=\"fpage\">501</div>–<div class=\"lpage\">506</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Regret%20after%20sex%20reassignment%20surgery%20in%20a%20male-to-female%20transsexual%3A%20a%20long-term%20follow-up&amp;author=S-E%20Olsson&amp;author=A%20M%C3%B6ller&amp;publication_year=2006&amp;journal=Arch%20Sex%20Behav&amp;volume=35&amp;pages=501-506\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1007/s10508-006-9040-8\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1007%2Fs10508-006-9040-8\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1007%2Fs10508-006-9040-8\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/16900416\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Regret%20after%20sex%20reassignment%20surgery%20in%20a%20male-to-female%20transsexual%3A%20a%20long-term%20follow-up&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B55\" class=\"js-splitview-ref-item\" data-legacy-id=\"B55\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B55\" href=\"javascript:;\" aria-label=\"jumplink-B55\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B55\" class=\"ref-content \" data-id=\"B55\"><span class=\"label\">55.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Pfäfflin</div>  <div class=\"given-names\">F</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Junge</div>  <div class=\"given-names\">A</div>\r\n</span>\r\n</span>, eds. <div class=\"source \">Geschlechtsumwandlung: Abhandlungen zur Transsexualität</div>. <div class=\"publisher-loc\">Stuttgart, Germany</div>: <div class=\"publisher-name\">Schattauer</div>; <div class=\"year\">1992</div>.</p><!--citationLinks: case 2--><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Geschlechtsumwandlung%3A%20Abhandlungen%20zur%20Transsexualit%C3%A4t&amp;author=F%20Pf%C3%A4fflin&amp;author=A%20Junge&amp;publication_year=1992&amp;book=Geschlechtsumwandlung%3A%20Abhandlungen%20zur%20Transsexualit%C3%A4t\" target=\"_blank\">Google Scholar</a></span></p><p class=\"citation-links-compatibility\"><span class=\"google-preview-ref-link js-google-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.google.com/search?q=Geschlechtsumwandlung%3A%20Abhandlungen%20zur%20Transsexualit%C3%A4t&amp;btnG=Search+Books&amp;tbm=bks&amp;tbo=1\" target=\"_blank\">Google Preview</a></span></p><div class=\"xslopenurl empty-target\"><span class=\"js-inst-open-url-holders-nodoi\"><a class=\"js-open-url-link\" data-href-template=\"{targetURL}?sid=oup:orr&amp;genre=book&amp;title=Geschlechtsumwandlung%3a+Abhandlungen+zur+Transsexualit%c3%a4t&amp;aulast=Pf%c3%a4fflin&amp;date=1992\" href=\"javascript:;\"><span class=\"screenreader-text\">OpenURL Placeholder Text</span></a></span></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Geschlechtsumwandlung%3A%20Abhandlungen%20zur%20Transsexualit%C3%A4t&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p><div class=\"copac-reference-ref-link js-copac-preview-ref-link\" style=\"display:none\" data-pubtype=\"book\"><span class=\"inst-copac\"><a class=\"openInAnotherWindow\" target=\"_blank\" href=\"http://copac.ac.uk/search?ti=Geschlechtsumwandlung%3A%20Abhandlungen%20zur%20Transsexualit%C3%A4t\">COPAC</a></span></div> </div></div></div></div></div><div content-id=\"B56\" class=\"js-splitview-ref-item\" data-legacy-id=\"B56\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B56\" href=\"javascript:;\" aria-label=\"jumplink-B56\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B56\" class=\"ref-content \" data-id=\"B56\"><span class=\"label\">56.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Lawrence</div>  <div class=\"given-names\">AA</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Factors associated with satisfaction or regret following male-to-female sex reassignment surgery</div>. <div class=\"source \">Arch Sex Behav</div>. <div class=\"year\">2003</div>;<div class=\"volume\">32</div>(<div class=\"issue\">4</div>):<div class=\"fpage\">299</div>–<div class=\"lpage\">315</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Factors%20associated%20with%20satisfaction%20or%20regret%20following%20male-to-female%20sex%20reassignment%20surgery&amp;author=AA%20Lawrence&amp;publication_year=2003&amp;journal=Arch%20Sex%20Behav&amp;volume=32&amp;pages=299-315\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1023/A:1024086814364\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1023%2FA:1024086814364\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1023%2FA:1024086814364\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/12856892\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Factors%20associated%20with%20satisfaction%20or%20regret%20following%20male-to-female%20sex%20reassignment%20surgery&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B57\" class=\"js-splitview-ref-item\" data-legacy-id=\"B57\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B57\" href=\"javascript:;\" aria-label=\"jumplink-B57\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B57\" class=\"ref-content \" data-id=\"B57\"><span class=\"label\">57.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Cohen-Kettenis</div>  <div class=\"given-names\">PT</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Pfäfflin</div>  <div class=\"given-names\">F</div>\r\n</span>\r\n</span>. <div class=\"source \">Transgenderism and Intersexuality in Childhood and Adolescence: Making Choices</div>. <div class=\"publisher-loc\">Thousand Oaks, CA</div>: <div class=\"publisher-name\">SAGE Publications</div>; <div class=\"year\">2003</div>.</p><!--citationLinks: case 2--><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Transgenderism%20and%20Intersexuality%20in%20Childhood%20and%20Adolescence%3A%20Making%20Choices&amp;author=PT%20Cohen-Kettenis&amp;author=F%20Pf%C3%A4fflin&amp;publication_year=2003&amp;book=Transgenderism%20and%20Intersexuality%20in%20Childhood%20and%20Adolescence%3A%20Making%20Choices\" target=\"_blank\">Google Scholar</a></span></p><p class=\"citation-links-compatibility\"><span class=\"google-preview-ref-link js-google-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.google.com/search?q=Transgenderism%20and%20Intersexuality%20in%20Childhood%20and%20Adolescence%3A%20Making%20Choices&amp;btnG=Search+Books&amp;tbm=bks&amp;tbo=1\" target=\"_blank\">Google Preview</a></span></p><div class=\"xslopenurl empty-target\"><span class=\"js-inst-open-url-holders-nodoi\"><a class=\"js-open-url-link\" data-href-template=\"{targetURL}?sid=oup:orr&amp;genre=book&amp;title=Transgenderism+and+Intersexuality+in+Childhood+and+Adolescence%3a+Making+Choices&amp;aulast=Cohen-Kettenis&amp;date=2003\" href=\"javascript:;\"><span class=\"screenreader-text\">OpenURL Placeholder Text</span></a></span></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Transgenderism%20and%20Intersexuality%20in%20Childhood%20and%20Adolescence%3A%20Making%20Choices&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p><div class=\"copac-reference-ref-link js-copac-preview-ref-link\" style=\"display:none\" data-pubtype=\"book\"><span class=\"inst-copac\"><a class=\"openInAnotherWindow\" target=\"_blank\" href=\"http://copac.ac.uk/search?ti=Transgenderism%20and%20Intersexuality%20in%20Childhood%20and%20Adolescence%3A%20Making%20Choices\">COPAC</a></span></div> </div></div></div></div></div><div content-id=\"B58\" class=\"js-splitview-ref-item\" data-legacy-id=\"B58\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B58\" href=\"javascript:;\" aria-label=\"jumplink-B58\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B58\" class=\"ref-content \" data-id=\"B58\"><span class=\"label\">58.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">Di Ceglie D, Freedman D, McPherson S, Richardson P. Children and adolescents referred to a specialist gender identity development service: clinical features and demographic characteristics. Available at: <a class=\"link link-uri openInAnotherWindow\" href=\"https://www.researchgate.net/publication/276061306_Children_and_Adolescents_Referred_to_a_Specialist_Gender_Identity_Development_Service_Clinical_Features_and_Demographic_Characteristics\" target=\"_blank\">https://www.researchgate.net/publication/276061306_Children_and_Adolescents_Referred_to_a_Specialist_Gender_Identity_Development_Service_Clinical_Features_and_Demographic_Characteristics</a>. Accessed 20 July 2017.</p></div></div></div></div><div content-id=\"B59\" class=\"js-splitview-ref-item\" data-legacy-id=\"B59\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B59\" href=\"javascript:;\" aria-label=\"jumplink-B59\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B59\" class=\"ref-content \" data-id=\"B59\"><span class=\"label\">59.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Gijs</div>  <div class=\"given-names\">L</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Brewaeys</div>  <div class=\"given-names\">A</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Surgical treatment of gender dysphoria in adults and adolescents: recent developments, effectiveness, and challenges</div>. <div class=\"source \">Annu Rev Sex Res</div>. <div class=\"year\">2007</div>;<div class=\"volume\">18</div>:<div class=\"fpage\">178</div>–<div class=\"lpage\">224</div>.</p><!--citationLinks: case 2--><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Surgical%20treatment%20of%20gender%20dysphoria%20in%20adults%20and%20adolescents%3A%20recent%20developments%2C%20effectiveness%2C%20and%20challenges&amp;author=L%20Gijs&amp;author=A%20Brewaeys&amp;publication_year=2007&amp;journal=Annu%20Rev%20Sex%20Res&amp;volume=18&amp;pages=178-224\" target=\"_blank\">Google Scholar</a></span></p><div class=\"xslopenurl empty-target\"><span class=\"js-inst-open-url-holders-nodoi\"><a class=\"js-open-url-link\" data-href-template=\"{targetURL}?sid=oup:orr&amp;genre=article&amp;atitle=Surgical+treatment+of+gender+dysphoria+in+adults+and+adolescents%3a+recent+developments%2c+effectiveness%2c+and+challenges&amp;aulast=Gijs&amp;title=Annu+Rev+Sex+Res&amp;date=2007&amp;spage=178&amp;epage=224&amp;volume=18\" href=\"javascript:;\"><span class=\"screenreader-text\">OpenURL Placeholder Text</span></a></span></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Surgical%20treatment%20of%20gender%20dysphoria%20in%20adults%20and%20adolescents%3A%20recent%20developments%2C%20effectiveness%2C%20and%20challenges&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B60\" class=\"js-splitview-ref-item\" data-legacy-id=\"B60\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B60\" href=\"javascript:;\" aria-label=\"jumplink-B60\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B60\" class=\"ref-content \" data-id=\"B60\"><span class=\"label\">60.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Cohen-Kettenis</div>  <div class=\"given-names\">PT</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">van Goozen</div>  <div class=\"given-names\">SHM</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Sex reassignment of adolescent transsexuals: a follow-up study</div>. <div class=\"source \">J Am Acad Child Adolesc Psychiatry</div>. <div class=\"year\">1997</div>;<div class=\"volume\">36</div>(<div class=\"issue\">2</div>):<div class=\"fpage\">263</div>–<div class=\"lpage\">271</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Sex%20reassignment%20of%20adolescent%20transsexuals%3A%20a%20follow-up%20study&amp;author=PT%20Cohen-Kettenis&amp;author=SHM%20van%20Goozen&amp;publication_year=1997&amp;journal=J%20Am%20Acad%20Child%20Adolesc%20Psychiatry&amp;volume=36&amp;pages=263-271\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1097/00004583-199702000-00017\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1097%2F00004583-199702000-00017\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1097%2F00004583-199702000-00017\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/9031580\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Sex%20reassignment%20of%20adolescent%20transsexuals%3A%20a%20follow-up%20study&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B61\" class=\"js-splitview-ref-item\" data-legacy-id=\"B61\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B61\" href=\"javascript:;\" aria-label=\"jumplink-B61\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B61\" class=\"ref-content \" data-id=\"B61\"><span class=\"label\">61.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Smith</div>  <div class=\"given-names\">YLS</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">van Goozen</div>  <div class=\"given-names\">SHM</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Cohen-Kettenis</div>  <div class=\"given-names\">PT</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Adolescents with gender identity disorder who were accepted or rejected for sex reassignment surgery: a prospective follow-up study</div>. <div class=\"source \">J Am Acad Child Adolesc Psychiatry</div>. <div class=\"year\">2001</div>;<div class=\"volume\">40</div>(<div class=\"issue\">4</div>):<div class=\"fpage\">472</div>–<div class=\"lpage\">481</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Adolescents%20with%20gender%20identity%20disorder%20who%20were%20accepted%20or%20rejected%20for%20sex%20reassignment%20surgery%3A%20a%20prospective%20follow-up%20study&amp;author=YLS%20Smith&amp;author=SHM%20van%20Goozen&amp;author=PT%20Cohen-Kettenis&amp;publication_year=2001&amp;journal=J%20Am%20Acad%20Child%20Adolesc%20Psychiatry&amp;volume=40&amp;pages=472-481\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1097/00004583-200104000-00017\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1097%2F00004583-200104000-00017\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1097%2F00004583-200104000-00017\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/11314574\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Adolescents%20with%20gender%20identity%20disorder%20who%20were%20accepted%20or%20rejected%20for%20sex%20reassignment%20surgery%3A%20a%20prospective%20follow-up%20study&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B62\" class=\"js-splitview-ref-item\" data-legacy-id=\"B62\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B62\" href=\"javascript:;\" aria-label=\"jumplink-B62\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B62\" class=\"ref-content \" data-id=\"B62\"><span class=\"label\">62.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Smith</div>  <div class=\"given-names\">YLS</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Van Goozen</div>  <div class=\"given-names\">SHM</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Kuiper</div>  <div class=\"given-names\">AJ</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Cohen-Kettenis</div>  <div class=\"given-names\">PT</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Sex reassignment: outcomes and predictors of treatment for adolescent and adult transsexuals</div>. <div class=\"source \">Psychol Med</div>. <div class=\"year\">2005</div>;<div class=\"volume\">35</div>(<div class=\"issue\">1</div>):<div class=\"fpage\">89</div>–<div class=\"lpage\">99</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Sex%20reassignment%3A%20outcomes%20and%20predictors%20of%20treatment%20for%20adolescent%20and%20adult%20transsexuals&amp;author=YLS%20Smith&amp;author=SHM%20Van%20Goozen&amp;author=AJ%20Kuiper&amp;author=PT%20Cohen-Kettenis&amp;publication_year=2005&amp;journal=Psychol%20Med&amp;volume=35&amp;pages=89-99\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1017/S0033291704002776\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1017%2FS0033291704002776\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1017%2FS0033291704002776\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/15842032\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Sex%20reassignment%3A%20outcomes%20and%20predictors%20of%20treatment%20for%20adolescent%20and%20adult%20transsexuals&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B63\" class=\"js-splitview-ref-item\" data-legacy-id=\"B63\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B63\" href=\"javascript:;\" aria-label=\"jumplink-B63\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B63\" class=\"ref-content \" data-id=\"B63\"><span class=\"label\">63.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">de Vries</div>  <div class=\"given-names\">ALC</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">McGuire</div>  <div class=\"given-names\">JK</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Steensma</div>  <div class=\"given-names\">TD</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Wagenaar</div>  <div class=\"given-names\">ECF</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Doreleijers</div>  <div class=\"given-names\">TAH</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Cohen-Kettenis</div>  <div class=\"given-names\">PT</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Young adult psychological outcome after puberty suppression and gender reassignment</div>. <div class=\"source \">Pediatrics</div>. <div class=\"year\">2014</div>;<div class=\"volume\">134</div>(<div class=\"issue\">4</div>):<div class=\"fpage\">696</div>–<div class=\"lpage\">704</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Young%20adult%20psychological%20outcome%20after%20puberty%20suppression%20and%20gender%20reassignment&amp;author=ALC%20de%20Vries&amp;author=JK%20McGuire&amp;author=TD%20Steensma&amp;author=ECF%20Wagenaar&amp;author=TAH%20Doreleijers&amp;author=PT%20Cohen-Kettenis&amp;publication_year=2014&amp;journal=Pediatrics&amp;volume=134&amp;pages=696-704\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1542/peds.2013-2958\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1542%2Fpeds.2013-2958\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1542%2Fpeds.2013-2958\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/25201798\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Young%20adult%20psychological%20outcome%20after%20puberty%20suppression%20and%20gender%20reassignment&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B64\" class=\"js-splitview-ref-item\" data-legacy-id=\"B64\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B64\" href=\"javascript:;\" aria-label=\"jumplink-B64\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B64\" class=\"ref-content \" data-id=\"B64\"><span class=\"label\">64.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Cole</div>  <div class=\"given-names\">CM</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">O’Boyle</div>  <div class=\"given-names\">M</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Emory</div>  <div class=\"given-names\">LE</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Meyer</div>  <div class=\"given-names\">WJ</div> III\r\n</span>\r\n</span>. <div class=\"article-title\">Comorbidity of gender dysphoria and other major psychiatric diagnoses</div>. <div class=\"source \">Arch Sex Behav</div>. <div class=\"year\">1997</div>;<div class=\"volume\">26</div>(<div class=\"issue\">1</div>):<div class=\"fpage\">13</div>–<div class=\"lpage\">26</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Comorbidity%20of%20gender%20dysphoria%20and%20other%20major%20psychiatric%20diagnoses&amp;author=CM%20Cole&amp;author=M%20O%E2%80%99Boyle&amp;author=LE%20Emory&amp;author=WJ%20Meyer&amp;publication_year=1997&amp;journal=Arch%20Sex%20Behav&amp;volume=26&amp;pages=13-26\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1023/A:1024517302481\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1023%2FA:1024517302481\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1023%2FA:1024517302481\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/9015577\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Comorbidity%20of%20gender%20dysphoria%20and%20other%20major%20psychiatric%20diagnoses&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B65\" class=\"js-splitview-ref-item\" data-legacy-id=\"B65\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B65\" href=\"javascript:;\" aria-label=\"jumplink-B65\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B65\" class=\"ref-content \" data-id=\"B65\"><span class=\"label\">65.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Cohen-Kettenis</div>  <div class=\"given-names\">PT</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Schagen</div>  <div class=\"given-names\">SEE</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Steensma</div>  <div class=\"given-names\">TD</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">de Vries</div>  <div class=\"given-names\">ALC</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Delemarre-van de Waal</div>  <div class=\"given-names\">HA</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Puberty suppression in a gender-dysphoric adolescent: a 22-year follow-up</div>. <div class=\"source \">Arch Sex Behav</div>. <div class=\"year\">2011</div>;<div class=\"volume\">40</div>(<div class=\"issue\">4</div>):<div class=\"fpage\">843</div>–<div class=\"lpage\">847</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Puberty%20suppression%20in%20a%20gender-dysphoric%20adolescent%3A%20a%2022-year%20follow-up&amp;author=PT%20Cohen-Kettenis&amp;author=SEE%20Schagen&amp;author=TD%20Steensma&amp;author=ALC%20de%20Vries&amp;author=HA%20Delemarre-van%20de%20Waal&amp;publication_year=2011&amp;journal=Arch%20Sex%20Behav&amp;volume=40&amp;pages=843-847\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1007/s10508-011-9758-9\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1007%2Fs10508-011-9758-9\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1007%2Fs10508-011-9758-9\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/21503817\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Puberty%20suppression%20in%20a%20gender-dysphoric%20adolescent%3A%20a%2022-year%20follow-up&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B66\" class=\"js-splitview-ref-item\" data-legacy-id=\"B66\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B66\" href=\"javascript:;\" aria-label=\"jumplink-B66\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B66\" class=\"ref-content \" data-id=\"B66\"><span class=\"label\">66.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">First</div>  <div class=\"given-names\">MB</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Desire for amputation of a limb: paraphilia, psychosis, or a new type of identity disorder</div>. <div class=\"source \">Psychol Med</div>. <div class=\"year\">2005</div>;<div class=\"volume\">35</div>(<div class=\"issue\">6</div>):<div class=\"fpage\">919</div>–<div class=\"lpage\">928</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Desire%20for%20amputation%20of%20a%20limb%3A%20paraphilia%2C%20psychosis%2C%20or%20a%20new%20type%20of%20identity%20disorder&amp;author=MB%20First&amp;publication_year=2005&amp;journal=Psychol%20Med&amp;volume=35&amp;pages=919-928\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1017/S0033291704003320\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1017%2FS0033291704003320\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1017%2FS0033291704003320\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/15997612\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Desire%20for%20amputation%20of%20a%20limb%3A%20paraphilia%2C%20psychosis%2C%20or%20a%20new%20type%20of%20identity%20disorder&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B67\" class=\"js-splitview-ref-item\" data-legacy-id=\"B67\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B67\" href=\"javascript:;\" aria-label=\"jumplink-B67\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B67\" class=\"ref-content \" data-id=\"B67\"><span class=\"label\">67.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Wierckx</div>  <div class=\"given-names\">K</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Van Caenegem</div>  <div class=\"given-names\">E</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Pennings</div>  <div class=\"given-names\">G</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Elaut</div>  <div class=\"given-names\">E</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Dedecker</div>  <div class=\"given-names\">D</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Van de Peer</div>  <div class=\"given-names\">F</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Weyers</div>  <div class=\"given-names\">S</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">De Sutter</div>  <div class=\"given-names\">P</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">T’Sjoen</div>  <div class=\"given-names\">G</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Reproductive wish in transsexual men</div>. <div class=\"source \">Hum Reprod</div>. <div class=\"year\">2012</div>;<div class=\"volume\">27</div>(<div class=\"issue\">2</div>):<div class=\"fpage\">483</div>–<div class=\"lpage\">487</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Reproductive%20wish%20in%20transsexual%20men&amp;author=K%20Wierckx&amp;author=E%20Van%20Caenegem&amp;author=G%20Pennings&amp;author=E%20Elaut&amp;author=D%20Dedecker&amp;author=F%20Van%20de%20Peer&amp;author=S%20Weyers&amp;author=P%20De%20Sutter&amp;author=G%20T%E2%80%99Sjoen&amp;publication_year=2012&amp;journal=Hum%20Reprod&amp;volume=27&amp;pages=483-487\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1093/humrep/der406\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1093%2Fhumrep%2Fder406\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1093%2Fhumrep%2Fder406\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22128292\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Reproductive%20wish%20in%20transsexual%20men&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B68\" class=\"js-splitview-ref-item\" data-legacy-id=\"B68\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B68\" href=\"javascript:;\" aria-label=\"jumplink-B68\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B68\" class=\"ref-content \" data-id=\"B68\"><span class=\"label\">68.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Wierckx</div>  <div class=\"given-names\">K</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Stuyver</div>  <div class=\"given-names\">I</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Weyers</div>  <div class=\"given-names\">S</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Hamada</div>  <div class=\"given-names\">A</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Agarwal</div>  <div class=\"given-names\">A</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">De Sutter</div>  <div class=\"given-names\">P</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">T’Sjoen</div>  <div class=\"given-names\">G</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Sperm freezing in transsexual women</div>. <div class=\"source \">Arch Sex Behav</div>. <div class=\"year\">2012</div>;<div class=\"volume\">41</div>(<div class=\"issue\">5</div>):<div class=\"fpage\">1069</div>–<div class=\"lpage\">1071</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Sperm%20freezing%20in%20transsexual%20women&amp;author=K%20Wierckx&amp;author=I%20Stuyver&amp;author=S%20Weyers&amp;author=A%20Hamada&amp;author=A%20Agarwal&amp;author=P%20De%20Sutter&amp;author=G%20T%E2%80%99Sjoen&amp;publication_year=2012&amp;journal=Arch%20Sex%20Behav&amp;volume=41&amp;pages=1069-1071\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1007/s10508-012-0012-x\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1007%2Fs10508-012-0012-x\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1007%2Fs10508-012-0012-x\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22968492\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Sperm%20freezing%20in%20transsexual%20women&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B69\" class=\"js-splitview-ref-item\" data-legacy-id=\"B69\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B69\" href=\"javascript:;\" aria-label=\"jumplink-B69\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B69\" class=\"ref-content \" data-id=\"B69\"><span class=\"label\">69.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Bertelloni</div>  <div class=\"given-names\">S</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Baroncelli</div>  <div class=\"given-names\">GI</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Ferdeghini</div>  <div class=\"given-names\">M</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Menchini-Fabris</div>  <div class=\"given-names\">F</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Saggese</div>  <div class=\"given-names\">G</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Final height, gonadal function and bone mineral density of adolescent males with central precocious puberty after therapy with gonadotropin-releasing hormone analogues</div>. <div class=\"source \">Eur J Pediatr</div>. <div class=\"year\">2000</div>;<div class=\"volume\">159</div>(<div class=\"issue\">5</div>):<div class=\"fpage\">369</div>–<div class=\"lpage\">374</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Final%20height%2C%20gonadal%20function%20and%20bone%20mineral%20density%20of%20adolescent%20males%20with%20central%20precocious%20puberty%20after%20therapy%20with%20gonadotropin-releasing%20hormone%20analogues&amp;author=S%20Bertelloni&amp;author=GI%20Baroncelli&amp;author=M%20Ferdeghini&amp;author=F%20Menchini-Fabris&amp;author=G%20Saggese&amp;publication_year=2000&amp;journal=Eur%20J%20Pediatr&amp;volume=159&amp;pages=369-374\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1007/s004310051289\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1007%2Fs004310051289\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1007%2Fs004310051289\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/10834524\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Final%20height%2C%20gonadal%20function%20and%20bone%20mineral%20density%20of%20adolescent%20males%20with%20central%20precocious%20puberty%20after%20therapy%20with%20gonadotropin-releasing%20hormone%20analogues&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B70\" class=\"js-splitview-ref-item\" data-legacy-id=\"B70\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B70\" href=\"javascript:;\" aria-label=\"jumplink-B70\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B70\" class=\"ref-content \" data-id=\"B70\"><span class=\"label\">70.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Büchter</div>  <div class=\"given-names\">D</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Behre</div>  <div class=\"given-names\">HM</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Kliesch</div>  <div class=\"given-names\">S</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Nieschlag</div>  <div class=\"given-names\">E</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Pulsatile GnRH or human chorionic gonadotropin/human menopausal gonadotropin as effective treatment for men with hypogonadotropic hypogonadism: a review of 42 cases</div>. <div class=\"source \">Eur J Endocrinol</div>. <div class=\"year\">1998</div>;<div class=\"volume\">139</div>(<div class=\"issue\">3</div>):<div class=\"fpage\">298</div>–<div class=\"lpage\">303</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Pulsatile%20GnRH%20or%20human%20chorionic%20gonadotropin%2Fhuman%20menopausal%20gonadotropin%20as%20effective%20treatment%20for%20men%20with%20hypogonadotropic%20hypogonadism%3A%20a%20review%20of%2042%20cases&amp;author=D%20B%C3%BCchter&amp;author=HM%20Behre&amp;author=S%20Kliesch&amp;author=E%20Nieschlag&amp;publication_year=1998&amp;journal=Eur%20J%20Endocrinol&amp;volume=139&amp;pages=298-303\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1530/eje.0.1390298\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1530%2Feje.0.1390298\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1530%2Feje.0.1390298\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/9758439\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Pulsatile%20GnRH%20or%20human%20chorionic%20gonadotropin%2Fhuman%20menopausal%20gonadotropin%20as%20effective%20treatment%20for%20men%20with%20hypogonadotropic%20hypogonadism%3A%20a%20review%20of%2042%20cases&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B71\" class=\"js-splitview-ref-item\" data-legacy-id=\"B71\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B71\" href=\"javascript:;\" aria-label=\"jumplink-B71\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B71\" class=\"ref-content \" data-id=\"B71\"><span class=\"label\">71.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Liu</div>  <div class=\"given-names\">PY</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Turner</div>  <div class=\"given-names\">L</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Rushford</div>  <div class=\"given-names\">D</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">McDonald</div>  <div class=\"given-names\">J</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Baker</div>  <div class=\"given-names\">HW</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Conway</div>  <div class=\"given-names\">AJ</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Handelsman</div>  <div class=\"given-names\">DJ</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Efficacy and safety of recombinant human follicle stimulating hormone (Gonal-F) with urinary human chorionic gonadotrophin for induction of spermatogenesis and fertility in gonadotrophin-deficient men</div>. <div class=\"source \">Hum Reprod</div>. <div class=\"year\">1999</div>;<div class=\"volume\">14</div>(<div class=\"issue\">6</div>):<div class=\"fpage\">1540</div>–<div class=\"lpage\">1545</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Efficacy%20and%20safety%20of%20recombinant%20human%20follicle%20stimulating%20hormone%20%28Gonal-F%29%20with%20urinary%20human%20chorionic%20gonadotrophin%20for%20induction%20of%20spermatogenesis%20and%20fertility%20in%20gonadotrophin-deficient%20men&amp;author=PY%20Liu&amp;author=L%20Turner&amp;author=D%20Rushford&amp;author=J%20McDonald&amp;author=HW%20Baker&amp;author=AJ%20Conway&amp;author=DJ%20Handelsman&amp;publication_year=1999&amp;journal=Hum%20Reprod&amp;volume=14&amp;pages=1540-1545\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1093/humrep/14.6.1540\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1093%2Fhumrep%2F14.6.1540\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1093%2Fhumrep%2F14.6.1540\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/10357972\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Efficacy%20and%20safety%20of%20recombinant%20human%20follicle%20stimulating%20hormone%20%28Gonal-F%29%20with%20urinary%20human%20chorionic%20gonadotrophin%20for%20induction%20of%20spermatogenesis%20and%20fertility%20in%20gonadotrophin-deficient%20men&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B72\" class=\"js-splitview-ref-item\" data-legacy-id=\"B72\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B72\" href=\"javascript:;\" aria-label=\"jumplink-B72\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B72\" class=\"ref-content \" data-id=\"B72\"><span class=\"label\">72.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Pasquino</div>  <div class=\"given-names\">AM</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Pucarelli</div>  <div class=\"given-names\">I</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Accardo</div>  <div class=\"given-names\">F</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Demiraj</div>  <div class=\"given-names\">V</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Segni</div>  <div class=\"given-names\">M</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Di Nardo</div>  <div class=\"given-names\">R</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Long-term observation of 87 girls with idiopathic central precocious puberty treated with gonadotropin-releasing hormone analogs: impact on adult height, body mass index, bone mineral content, and reproductive function</div>. <div class=\"source \">J Clin Endocrinol Metab</div>. <div class=\"year\">2008</div>;<div class=\"volume\">93</div>(<div class=\"issue\">1</div>):<div class=\"fpage\">190</div>–<div class=\"lpage\">195</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Long-term%20observation%20of%2087%20girls%20with%20idiopathic%20central%20precocious%20puberty%20treated%20with%20gonadotropin-releasing%20hormone%20analogs%3A%20impact%20on%20adult%20height%2C%20body%20mass%20index%2C%20bone%20mineral%20content%2C%20and%20reproductive%20function&amp;author=AM%20Pasquino&amp;author=I%20Pucarelli&amp;author=F%20Accardo&amp;author=V%20Demiraj&amp;author=M%20Segni&amp;author=R%20Di%20Nardo&amp;publication_year=2008&amp;journal=J%20Clin%20Endocrinol%20Metab&amp;volume=93&amp;pages=190-195\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1210/jc.2007-1216\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1210%2Fjc.2007-1216\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1210%2Fjc.2007-1216\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/17940112\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Long-term%20observation%20of%2087%20girls%20with%20idiopathic%20central%20precocious%20puberty%20treated%20with%20gonadotropin-releasing%20hormone%20analogs%3A%20impact%20on%20adult%20height%2C%20body%20mass%20index%2C%20bone%20mineral%20content%2C%20and%20reproductive%20function&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B73\" class=\"js-splitview-ref-item\" data-legacy-id=\"B73\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B73\" href=\"javascript:;\" aria-label=\"jumplink-B73\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B73\" class=\"ref-content \" data-id=\"B73\"><span class=\"label\">73.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Magiakou</div>  <div class=\"given-names\">MA</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Manousaki</div>  <div class=\"given-names\">D</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Papadaki</div>  <div class=\"given-names\">M</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Hadjidakis</div>  <div class=\"given-names\">D</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Levidou</div>  <div class=\"given-names\">G</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Vakaki</div>  <div class=\"given-names\">M</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Papaefstathiou</div>  <div class=\"given-names\">A</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Lalioti</div>  <div class=\"given-names\">N</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Kanaka-Gantenbein</div>  <div class=\"given-names\">C</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Piaditis</div>  <div class=\"given-names\">G</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Chrousos</div>  <div class=\"given-names\">GP</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Dacou-Voutetakis</div>  <div class=\"given-names\">C</div>\r\n</span>\r\n</span>. <div class=\"article-title\">The efficacy and safety of gonadotropin-releasing hormone analog treatment in childhood and adolescence: a single center, long-term follow-up study</div>. <div class=\"source \">J Clin Endocrinol Metab</div>. <div class=\"year\">2010</div>;<div class=\"volume\">95</div>(<div class=\"issue\">1</div>):<div class=\"fpage\">109</div>–<div class=\"lpage\">117</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=The%20efficacy%20and%20safety%20of%20gonadotropin-releasing%20hormone%20analog%20treatment%20in%20childhood%20and%20adolescence%3A%20a%20single%20center%2C%20long-term%20follow-up%20study&amp;author=MA%20Magiakou&amp;author=D%20Manousaki&amp;author=M%20Papadaki&amp;author=D%20Hadjidakis&amp;author=G%20Levidou&amp;author=M%20Vakaki&amp;author=A%20Papaefstathiou&amp;author=N%20Lalioti&amp;author=C%20Kanaka-Gantenbein&amp;author=G%20Piaditis&amp;author=GP%20Chrousos&amp;author=C%20Dacou-Voutetakis&amp;publication_year=2010&amp;journal=J%20Clin%20Endocrinol%20Metab&amp;volume=95&amp;pages=109-117\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1210/jc.2009-0793\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1210%2Fjc.2009-0793\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1210%2Fjc.2009-0793\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/19897682\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:The%20efficacy%20and%20safety%20of%20gonadotropin-releasing%20hormone%20analog%20treatment%20in%20childhood%20and%20adolescence%3A%20a%20single%20center%2C%20long-term%20follow-up%20study&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B74\" class=\"js-splitview-ref-item\" data-legacy-id=\"B74\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B74\" href=\"javascript:;\" aria-label=\"jumplink-B74\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B74\" class=\"ref-content \" data-id=\"B74\"><span class=\"label\">74.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Baba</div>  <div class=\"given-names\">T</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Endo</div>  <div class=\"given-names\">T</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Honnma</div>  <div class=\"given-names\">H</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Kitajima</div>  <div class=\"given-names\">Y</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Hayashi</div>  <div class=\"given-names\">T</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Ikeda</div>  <div class=\"given-names\">H</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Masumori</div>  <div class=\"given-names\">N</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Kamiya</div>  <div class=\"given-names\">H</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Moriwaka</div>  <div class=\"given-names\">O</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Saito</div>  <div class=\"given-names\">T</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Association between polycystic ovary syndrome and female-to-male transsexuality</div>. <div class=\"source \">Hum Reprod</div>. <div class=\"year\">2007</div>;<div class=\"volume\">22</div>(<div class=\"issue\">4</div>):<div class=\"fpage\">1011</div>–<div class=\"lpage\">1016</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Association%20between%20polycystic%20ovary%20syndrome%20and%20female-to-male%20transsexuality&amp;author=T%20Baba&amp;author=T%20Endo&amp;author=H%20Honnma&amp;author=Y%20Kitajima&amp;author=T%20Hayashi&amp;author=H%20Ikeda&amp;author=N%20Masumori&amp;author=H%20Kamiya&amp;author=O%20Moriwaka&amp;author=T%20Saito&amp;publication_year=2007&amp;journal=Hum%20Reprod&amp;volume=22&amp;pages=1011-1016\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1093/humrep/del474\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1093%2Fhumrep%2Fdel474\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1093%2Fhumrep%2Fdel474\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/17166864\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Association%20between%20polycystic%20ovary%20syndrome%20and%20female-to-male%20transsexuality&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B75\" class=\"js-splitview-ref-item\" data-legacy-id=\"B75\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B75\" href=\"javascript:;\" aria-label=\"jumplink-B75\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B75\" class=\"ref-content \" data-id=\"B75\"><span class=\"label\">75.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Spinder</div>  <div class=\"given-names\">T</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Spijkstra</div>  <div class=\"given-names\">JJ</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">van den Tweel</div>  <div class=\"given-names\">JG</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Burger</div>  <div class=\"given-names\">CW</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">van Kessel</div>  <div class=\"given-names\">H</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Hompes</div>  <div class=\"given-names\">PGA</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Gooren</div>  <div class=\"given-names\">LJG</div>\r\n</span>\r\n</span>. <div class=\"article-title\">The effects of long term testosterone administration on pulsatile luteinizing hormone secretion and on ovarian histology in eugonadal female to male transsexual subjects</div>. <div class=\"source \">J Clin Endocrinol Metab</div>. <div class=\"year\">1989</div>;<div class=\"volume\">69</div>(<div class=\"issue\">1</div>):<div class=\"fpage\">151</div>–<div class=\"lpage\">157</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=The%20effects%20of%20long%20term%20testosterone%20administration%20on%20pulsatile%20luteinizing%20hormone%20secretion%20and%20on%20ovarian%20histology%20in%20eugonadal%20female%20to%20male%20transsexual%20subjects&amp;author=T%20Spinder&amp;author=JJ%20Spijkstra&amp;author=JG%20van%20den%20Tweel&amp;author=CW%20Burger&amp;author=H%20van%20Kessel&amp;author=PGA%20Hompes&amp;author=LJG%20Gooren&amp;publication_year=1989&amp;journal=J%20Clin%20Endocrinol%20Metab&amp;volume=69&amp;pages=151-157\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1210/jcem-69-1-151\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1210%2Fjcem-69-1-151\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1210%2Fjcem-69-1-151\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/2471710\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:The%20effects%20of%20long%20term%20testosterone%20administration%20on%20pulsatile%20luteinizing%20hormone%20secretion%20and%20on%20ovarian%20histology%20in%20eugonadal%20female%20to%20male%20transsexual%20subjects&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B76\" class=\"js-splitview-ref-item\" data-legacy-id=\"B76\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B76\" href=\"javascript:;\" aria-label=\"jumplink-B76\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B76\" class=\"ref-content \" data-id=\"B76\"><span class=\"label\">76.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Baba</div>  <div class=\"given-names\">T</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Endo</div>  <div class=\"given-names\">T</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Ikeda</div>  <div class=\"given-names\">K</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Shimizu</div>  <div class=\"given-names\">A</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Honnma</div>  <div class=\"given-names\">H</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Ikeda</div>  <div class=\"given-names\">H</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Masumori</div>  <div class=\"given-names\">N</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Ohmura</div>  <div class=\"given-names\">T</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Kiya</div>  <div class=\"given-names\">T</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Fujimoto</div>  <div class=\"given-names\">T</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Koizumi</div>  <div class=\"given-names\">M</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Saito</div>  <div class=\"given-names\">T</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Distinctive features of female-to-male transsexualism and prevalence of gender identity disorder in Japan</div>. <div class=\"source \">J Sex Med</div>. <div class=\"year\">2011</div>;<div class=\"volume\">8</div>(<div class=\"issue\">6</div>):<div class=\"fpage\">1686</div>–<div class=\"lpage\">1693</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Distinctive%20features%20of%20female-to-male%20transsexualism%20and%20prevalence%20of%20gender%20identity%20disorder%20in%20Japan&amp;author=T%20Baba&amp;author=T%20Endo&amp;author=K%20Ikeda&amp;author=A%20Shimizu&amp;author=H%20Honnma&amp;author=H%20Ikeda&amp;author=N%20Masumori&amp;author=T%20Ohmura&amp;author=T%20Kiya&amp;author=T%20Fujimoto&amp;author=M%20Koizumi&amp;author=T%20Saito&amp;publication_year=2011&amp;journal=J%20Sex%20Med&amp;volume=8&amp;pages=1686-1693\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1111/j.1743-6109.2011.02252.x\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1111%2Fj.1743-6109.2011.02252.x\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1111%2Fj.1743-6109.2011.02252.x\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/21477021\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Distinctive%20features%20of%20female-to-male%20transsexualism%20and%20prevalence%20of%20gender%20identity%20disorder%20in%20Japan&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B77\" class=\"js-splitview-ref-item\" data-legacy-id=\"B77\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B77\" href=\"javascript:;\" aria-label=\"jumplink-B77\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B77\" class=\"ref-content \" data-id=\"B77\"><span class=\"label\">77.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Vujovic</div>  <div class=\"given-names\">S</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Popovic</div>  <div class=\"given-names\">S</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Sbutega-Milosevic</div>  <div class=\"given-names\">G</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Djordjevic</div>  <div class=\"given-names\">M</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Gooren</div>  <div class=\"given-names\">L</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Transsexualism in Serbia: a twenty-year follow-up study</div>. <div class=\"source \">J Sex Med</div>. <div class=\"year\">2009</div>;<div class=\"volume\">6</div>(<div class=\"issue\">4</div>):<div class=\"fpage\">1018</div>–<div class=\"lpage\">1023</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Transsexualism%20in%20Serbia%3A%20a%20twenty-year%20follow-up%20study&amp;author=S%20Vujovic&amp;author=S%20Popovic&amp;author=G%20Sbutega-Milosevic&amp;author=M%20Djordjevic&amp;author=L%20Gooren&amp;publication_year=2009&amp;journal=J%20Sex%20Med&amp;volume=6&amp;pages=1018-1023\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1111/j.1743-6109.2008.00799.x\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1111%2Fj.1743-6109.2008.00799.x\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1111%2Fj.1743-6109.2008.00799.x\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/18331254\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Transsexualism%20in%20Serbia%3A%20a%20twenty-year%20follow-up%20study&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B78\" class=\"js-splitview-ref-item\" data-legacy-id=\"B78\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B78\" href=\"javascript:;\" aria-label=\"jumplink-B78\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B78\" class=\"ref-content \" data-id=\"B78\"><span class=\"label\">78.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Ikeda</div>  <div class=\"given-names\">K</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Baba</div>  <div class=\"given-names\">T</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Noguchi</div>  <div class=\"given-names\">H</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Nagasawa</div>  <div class=\"given-names\">K</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Endo</div>  <div class=\"given-names\">T</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Kiya</div>  <div class=\"given-names\">T</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Saito</div>  <div class=\"given-names\">T</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Excessive androgen exposure in female-to-male transsexual persons of reproductive age induces hyperplasia of the ovarian cortex and stroma but not polycystic ovary morphology</div>. <div class=\"source \">Hum Reprod</div>. <div class=\"year\">2013</div>;<div class=\"volume\">28</div>(<div class=\"issue\">2</div>):<div class=\"fpage\">453</div>–<div class=\"lpage\">461</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Excessive%20androgen%20exposure%20in%20female-to-male%20transsexual%20persons%20of%20reproductive%20age%20induces%20hyperplasia%20of%20the%20ovarian%20cortex%20and%20stroma%20but%20not%20polycystic%20ovary%20morphology&amp;author=K%20Ikeda&amp;author=T%20Baba&amp;author=H%20Noguchi&amp;author=K%20Nagasawa&amp;author=T%20Endo&amp;author=T%20Kiya&amp;author=T%20Saito&amp;publication_year=2013&amp;journal=Hum%20Reprod&amp;volume=28&amp;pages=453-461\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1093/humrep/des385\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1093%2Fhumrep%2Fdes385\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1093%2Fhumrep%2Fdes385\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23188113\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Excessive%20androgen%20exposure%20in%20female-to-male%20transsexual%20persons%20of%20reproductive%20age%20induces%20hyperplasia%20of%20the%20ovarian%20cortex%20and%20stroma%20but%20not%20polycystic%20ovary%20morphology&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B79\" class=\"js-splitview-ref-item\" data-legacy-id=\"B79\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B79\" href=\"javascript:;\" aria-label=\"jumplink-B79\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B79\" class=\"ref-content \" data-id=\"B79\"><span class=\"label\">79.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Trebay</div>  <div class=\"given-names\">G</div>\r\n</span>\r\n</span>. <div class=\"comment\">He’s pregnant. You’re speechles. New York Times. 22 June 2008</div>.</p></div></div></div></div><div content-id=\"B80\" class=\"js-splitview-ref-item\" data-legacy-id=\"B80\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B80\" href=\"javascript:;\" aria-label=\"jumplink-B80\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B80\" class=\"ref-content \" data-id=\"B80\"><span class=\"label\">80.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Light</div>  <div class=\"given-names\">AD</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Obedin-Maliver</div>  <div class=\"given-names\">J</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Sevelius</div>  <div class=\"given-names\">JM</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Kerns</div>  <div class=\"given-names\">JL</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Transgender men who experienced pregnancy after female-to-male gender transitioning</div>. <div class=\"source \">Obstet Gynecol</div>. <div class=\"year\">2014</div>;<div class=\"volume\">124</div>(<div class=\"issue\">6</div>):<div class=\"fpage\">1120</div>–<div class=\"lpage\">1127</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Transgender%20men%20who%20experienced%20pregnancy%20after%20female-to-male%20gender%20transitioning&amp;author=AD%20Light&amp;author=J%20Obedin-Maliver&amp;author=JM%20Sevelius&amp;author=JL%20Kerns&amp;publication_year=2014&amp;journal=Obstet%20Gynecol&amp;volume=124&amp;pages=1120-1127\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1097/AOG.0000000000000540\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1097%2FAOG.0000000000000540\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1097%2FAOG.0000000000000540\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/25415163\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Transgender%20men%20who%20experienced%20pregnancy%20after%20female-to-male%20gender%20transitioning&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B81\" class=\"js-splitview-ref-item\" data-legacy-id=\"B81\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B81\" href=\"javascript:;\" aria-label=\"jumplink-B81\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B81\" class=\"ref-content \" data-id=\"B81\"><span class=\"label\">81.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">De Sutter</div>  <div class=\"given-names\">P</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Donor inseminations in partners of female-to-male transsexuals: should the question be asked?</div> <div class=\"source \">Reprod Biomed Online</div>. <div class=\"year\">2003</div>;<div class=\"volume\">6</div>(<div class=\"issue\">3</div>):<div class=\"fpage\">382</div>, author reply 282–283.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Donor%20inseminations%20in%20partners%20of%20female-to-male%20transsexuals%3A%20should%20the%20question%20be%20asked%3F&amp;author=P%20De%20Sutter&amp;publication_year=2003&amp;journal=Reprod%20Biomed%20Online&amp;volume=6&amp;pages=382\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1016/S1472-6483(10)61861-5\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1016%2FS1472-6483(10)61861-5\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1016%2FS1472-6483(10)61861-5\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/12735880\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Donor%20inseminations%20in%20partners%20of%20female-to-male%20transsexuals%3A%20should%20the%20question%20be%20asked%3F&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B82\" class=\"js-splitview-ref-item\" data-legacy-id=\"B82\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B82\" href=\"javascript:;\" aria-label=\"jumplink-B82\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B82\" class=\"ref-content \" data-id=\"B82\"><span class=\"label\">82.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">De Roo</div>  <div class=\"given-names\">C</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Tilleman</div>  <div class=\"given-names\">K</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">T’Sjoen</div>  <div class=\"given-names\">G</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">De Sutter</div>  <div class=\"given-names\">P</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Fertility options in transgender people</div>. <div class=\"source \">Int Rev Psychiatry</div>. <div class=\"year\">2016</div>;<div class=\"volume\">28</div>(<div class=\"issue\">1</div>):<div class=\"fpage\">112</div>–<div class=\"lpage\">119</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Fertility%20options%20in%20transgender%20people&amp;author=C%20De%20Roo&amp;author=K%20Tilleman&amp;author=G%20T%E2%80%99Sjoen&amp;author=P%20De%20Sutter&amp;publication_year=2016&amp;journal=Int%20Rev%20Psychiatry&amp;volume=28&amp;pages=112-119\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.3109/09540261.2015.1084275\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.3109%2F09540261.2015.1084275\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.3109%2F09540261.2015.1084275\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/26835612\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Fertility%20options%20in%20transgender%20people&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B83\" class=\"js-splitview-ref-item\" data-legacy-id=\"B83\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B83\" href=\"javascript:;\" aria-label=\"jumplink-B83\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B83\" class=\"ref-content \" data-id=\"B83\"><span class=\"label\">83.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Wennink</div>  <div class=\"given-names\">JMB</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Delemarre-van de Waal</div>  <div class=\"given-names\">HA</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Schoemaker</div>  <div class=\"given-names\">R</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Schoemaker</div>  <div class=\"given-names\">H</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Schoemaker</div>  <div class=\"given-names\">J</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Luteinizing hormone and follicle stimulating hormone secretion patterns in boys throughout puberty measured using highly sensitive immunoradiometric assays</div>. <div class=\"source \">Clin Endocrinol (Oxf)</div>. <div class=\"year\">1989</div>;<div class=\"volume\">31</div>(<div class=\"issue\">5</div>):<div class=\"fpage\">551</div>–<div class=\"lpage\">564</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Luteinizing%20hormone%20and%20follicle%20stimulating%20hormone%20secretion%20patterns%20in%20boys%20throughout%20puberty%20measured%20using%20highly%20sensitive%20immunoradiometric%20assays&amp;author=JMB%20Wennink&amp;author=HA%20Delemarre-van%20de%20Waal&amp;author=R%20Schoemaker&amp;author=H%20Schoemaker&amp;author=J%20Schoemaker&amp;publication_year=1989&amp;journal=Clin%20Endocrinol%20%28Oxf%29&amp;volume=31&amp;pages=551-564\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1111/j.1365-2265.1989.tb01279.x\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1111%2Fj.1365-2265.1989.tb01279.x\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1111%2Fj.1365-2265.1989.tb01279.x\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/2516786\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Luteinizing%20hormone%20and%20follicle%20stimulating%20hormone%20secretion%20patterns%20in%20boys%20throughout%20puberty%20measured%20using%20highly%20sensitive%20immunoradiometric%20assays&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B84\" class=\"js-splitview-ref-item\" data-legacy-id=\"B84\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B84\" href=\"javascript:;\" aria-label=\"jumplink-B84\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B84\" class=\"ref-content \" data-id=\"B84\"><span class=\"label\">84.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Cohen-Kettenis</div>  <div class=\"given-names\">PT</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Delemarre-van de Waal</div>  <div class=\"given-names\">HA</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Gooren</div>  <div class=\"given-names\">LJG</div>\r\n</span>\r\n</span>. <div class=\"article-title\">The treatment of adolescent transsexuals: changing insights</div>. <div class=\"source \">J Sex Med</div>. <div class=\"year\">2008</div>;<div class=\"volume\">5</div>(<div class=\"issue\">8</div>):<div class=\"fpage\">1892</div>–<div class=\"lpage\">1897</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=The%20treatment%20of%20adolescent%20transsexuals%3A%20changing%20insights&amp;author=PT%20Cohen-Kettenis&amp;author=HA%20Delemarre-van%20de%20Waal&amp;author=LJG%20Gooren&amp;publication_year=2008&amp;journal=J%20Sex%20Med&amp;volume=5&amp;pages=1892-1897\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1111/j.1743-6109.2008.00870.x\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1111%2Fj.1743-6109.2008.00870.x\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1111%2Fj.1743-6109.2008.00870.x\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/18564158\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:The%20treatment%20of%20adolescent%20transsexuals%3A%20changing%20insights&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B85\" class=\"js-splitview-ref-item\" data-legacy-id=\"B85\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B85\" href=\"javascript:;\" aria-label=\"jumplink-B85\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B85\" class=\"ref-content \" data-id=\"B85\"><span class=\"label\">85.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Delemarre-van de Waal</div>  <div class=\"given-names\">HA</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Cohen-Kettenis</div>  <div class=\"given-names\">PT</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Clinical management of gender identity disorder in adolescents: a protocol on psychological and paediatric endocrinology aspects</div>. <div class=\"source \">Eur J Endocrinol</div>. <div class=\"year\">2006</div>;<div class=\"volume\">155</div>:<div class=\"fpage\">S131</div>–<div class=\"lpage\">S137</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Clinical%20management%20of%20gender%20identity%20disorder%20in%20adolescents%3A%20a%20protocol%20on%20psychological%20and%20paediatric%20endocrinology%20aspects&amp;author=HA%20Delemarre-van%20de%20Waal&amp;author=PT%20Cohen-Kettenis&amp;publication_year=2006&amp;journal=Eur%20J%20Endocrinol&amp;volume=155&amp;pages=S131-S137\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1530/eje.1.02231\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1530%2Feje.1.02231\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1530%2Feje.1.02231\"> </span></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Clinical%20management%20of%20gender%20identity%20disorder%20in%20adolescents%3A%20a%20protocol%20on%20psychological%20and%20paediatric%20endocrinology%20aspects&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B86\" class=\"js-splitview-ref-item\" data-legacy-id=\"B86\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B86\" href=\"javascript:;\" aria-label=\"jumplink-B86\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B86\" class=\"ref-content \" data-id=\"B86\"><span class=\"label\">86.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">de Vries</div>  <div class=\"given-names\">ALC</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Steensma</div>  <div class=\"given-names\">TD</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Doreleijers</div>  <div class=\"given-names\">TAH</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Cohen-Kettenis</div>  <div class=\"given-names\">PT</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Puberty suppression in adolescents with gender identity disorder: a prospective follow-up study</div>. <div class=\"source \">J Sex Med</div>. <div class=\"year\">2011</div>;<div class=\"volume\">8</div>(<div class=\"issue\">8</div>):<div class=\"fpage\">2276</div>–<div class=\"lpage\">2283</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Puberty%20suppression%20in%20adolescents%20with%20gender%20identity%20disorder%3A%20a%20prospective%20follow-up%20study&amp;author=ALC%20de%20Vries&amp;author=TD%20Steensma&amp;author=TAH%20Doreleijers&amp;author=PT%20Cohen-Kettenis&amp;publication_year=2011&amp;journal=J%20Sex%20Med&amp;volume=8&amp;pages=2276-2283\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1111/j.1743-6109.2010.01943.x\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1111%2Fj.1743-6109.2010.01943.x\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1111%2Fj.1743-6109.2010.01943.x\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/20646177\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Puberty%20suppression%20in%20adolescents%20with%20gender%20identity%20disorder%3A%20a%20prospective%20follow-up%20study&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B87\" class=\"js-splitview-ref-item\" data-legacy-id=\"B87\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B87\" href=\"javascript:;\" aria-label=\"jumplink-B87\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B87\" class=\"ref-content \" data-id=\"B87\"><span class=\"label\">87.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Bouman</div>  <div class=\"given-names\">MB</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">van Zeijl</div>  <div class=\"given-names\">MCT</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Buncamper</div>  <div class=\"given-names\">ME</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Meijerink</div>  <div class=\"given-names\">WJHJ</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">van Bodegraven</div>  <div class=\"given-names\">AA</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Mullender</div>  <div class=\"given-names\">MG</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Intestinal vaginoplasty revisited: a review of surgical techniques, complications, and sexual function</div>. <div class=\"source \">J Sex Med</div>. <div class=\"year\">2014</div>;<div class=\"volume\">11</div>(<div class=\"issue\">7</div>):<div class=\"fpage\">1835</div>–<div class=\"lpage\">1847</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Intestinal%20vaginoplasty%20revisited%3A%20a%20review%20of%20surgical%20techniques%2C%20complications%2C%20and%20sexual%20function&amp;author=MB%20Bouman&amp;author=MCT%20van%20Zeijl&amp;author=ME%20Buncamper&amp;author=WJHJ%20Meijerink&amp;author=AA%20van%20Bodegraven&amp;author=MG%20Mullender&amp;publication_year=2014&amp;journal=J%20Sex%20Med&amp;volume=11&amp;pages=1835-1847\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1111/jsm.12538\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1111%2Fjsm.12538\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1111%2Fjsm.12538\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/24697986\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Intestinal%20vaginoplasty%20revisited%3A%20a%20review%20of%20surgical%20techniques%2C%20complications%2C%20and%20sexual%20function&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B88\" class=\"js-splitview-ref-item\" data-legacy-id=\"B88\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B88\" href=\"javascript:;\" aria-label=\"jumplink-B88\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B88\" class=\"ref-content \" data-id=\"B88\"><span class=\"label\">88.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Carel</div>  <div class=\"given-names\">JC</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Eugster</div>  <div class=\"given-names\">EA</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Rogol</div>  <div class=\"given-names\">A</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Ghizzoni</div>  <div class=\"given-names\">L</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Palmert</div>  <div class=\"given-names\">MR</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Antoniazzi</div>  <div class=\"given-names\">F</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Berenbaum</div>  <div class=\"given-names\">S</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Bourguignon</div>  <div class=\"given-names\">JP</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Chrousos</div>  <div class=\"given-names\">GP</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Coste</div>  <div class=\"given-names\">J</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Deal</div>  <div class=\"given-names\">S</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">de Vries</div>  <div class=\"given-names\">L</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Foster</div>  <div class=\"given-names\">C</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Heger</div>  <div class=\"given-names\">S</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Holland</div>  <div class=\"given-names\">J</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Jahnukainen</div>  <div class=\"given-names\">K</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Juul</div>  <div class=\"given-names\">A</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Kaplowitz</div>  <div class=\"given-names\">P</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Lahlou</div>  <div class=\"given-names\">N</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Lee</div>  <div class=\"given-names\">MM</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Lee</div>  <div class=\"given-names\">P</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Merke</div>  <div class=\"given-names\">DP</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Neely</div>  <div class=\"given-names\">EK</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Oostdijk</div>  <div class=\"given-names\">W</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Phillip</div>  <div class=\"given-names\">M</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Rosenfield</div>  <div class=\"given-names\">RL</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Shulman</div>  <div class=\"given-names\">D</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Styne</div>  <div class=\"given-names\">D</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Tauber</div>  <div class=\"given-names\">M</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Wit</div>  <div class=\"given-names\">JM</div>\r\n</span>; <div class=\"collab\">ESPE-LWPES GnRH Analogs Consensus Conference Group</div>\r\n</span>. <div class=\"article-title\">Consensus statement on the use of gonadotropin-releasing hormone analogs in children</div>. <div class=\"source \">Pediatrics</div>. <div class=\"year\">2009</div>;<div class=\"volume\">123</div>(<div class=\"issue\">4</div>):<div class=\"fpage\">e752</div>–<div class=\"lpage\">e762</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Consensus%20statement%20on%20the%20use%20of%20gonadotropin-releasing%20hormone%20analogs%20in%20children&amp;author=JC%20Carel&amp;author=EA%20Eugster&amp;author=A%20Rogol&amp;author=L%20Ghizzoni&amp;author=MR%20Palmert&amp;author=F%20Antoniazzi&amp;author=S%20Berenbaum&amp;author=JP%20Bourguignon&amp;author=GP%20Chrousos&amp;author=J%20Coste&amp;author=S%20Deal&amp;author=L%20de%20Vries&amp;author=C%20Foster&amp;author=S%20Heger&amp;author=J%20Holland&amp;author=K%20Jahnukainen&amp;author=A%20Juul&amp;author=P%20Kaplowitz&amp;author=N%20Lahlou&amp;author=MM%20Lee&amp;author=P%20Lee&amp;author=DP%20Merke&amp;author=EK%20Neely&amp;author=W%20Oostdijk&amp;author=M%20Phillip&amp;author=RL%20Rosenfield&amp;author=D%20Shulman&amp;author=D%20Styne&amp;author=M%20Tauber&amp;author=JM%20Wit&amp;publication_year=2009&amp;journal=Pediatrics&amp;volume=123&amp;pages=e752-e762\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1542/peds.2008-1783\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1542%2Fpeds.2008-1783\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1542%2Fpeds.2008-1783\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/19332438\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Consensus%20statement%20on%20the%20use%20of%20gonadotropin-releasing%20hormone%20analogs%20in%20children&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B89\" class=\"js-splitview-ref-item\" data-legacy-id=\"B89\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B89\" href=\"javascript:;\" aria-label=\"jumplink-B89\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B89\" class=\"ref-content \" data-id=\"B89\"><span class=\"label\">89.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Roth</div>  <div class=\"given-names\">CL</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Brendel</div>  <div class=\"given-names\">L</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Rückert</div>  <div class=\"given-names\">C</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Hartmann</div>  <div class=\"given-names\">K</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Antagonistic and agonistic GnRH analogue treatment of precocious puberty: tracking gonadotropin concentrations in urine</div>. <div class=\"source \">Horm Res</div>. <div class=\"year\">2005</div>;<div class=\"volume\">63</div>(<div class=\"issue\">5</div>):<div class=\"fpage\">257</div>–<div class=\"lpage\">262</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Antagonistic%20and%20agonistic%20GnRH%20analogue%20treatment%20of%20precocious%20puberty%3A%20tracking%20gonadotropin%20concentrations%20in%20urine&amp;author=CL%20Roth&amp;author=L%20Brendel&amp;author=C%20R%C3%BCckert&amp;author=K%20Hartmann&amp;publication_year=2005&amp;journal=Horm%20Res&amp;volume=63&amp;pages=257-262\" target=\"_blank\">Google Scholar</a></span></p><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/15995342\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><div class=\"xslopenurl empty-target\"><span class=\"js-inst-open-url-holders-nodoi\"><a class=\"js-open-url-link\" data-href-template=\"{targetURL}?sid=oup:orr&amp;genre=article&amp;atitle=Antagonistic+and+agonistic+GnRH+analogue+treatment+of+precocious+puberty%3a+tracking+gonadotropin+concentrations+in+urine&amp;aulast=Roth&amp;title=Horm+Res&amp;date=2005&amp;spage=257&amp;epage=262&amp;volume=63&amp;issue=5\" href=\"javascript:;\"><span class=\"screenreader-text\">OpenURL Placeholder Text</span></a></span></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Antagonistic%20and%20agonistic%20GnRH%20analogue%20treatment%20of%20precocious%20puberty%3A%20tracking%20gonadotropin%20concentrations%20in%20urine&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B90\" class=\"js-splitview-ref-item\" data-legacy-id=\"B90\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B90\" href=\"javascript:;\" aria-label=\"jumplink-B90\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B90\" class=\"ref-content \" data-id=\"B90\"><span class=\"label\">90.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Roth</div>  <div class=\"given-names\">C</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Therapeutic potential of GnRH antagonists in the treatment of precocious puberty</div>. <div class=\"source \">Expert Opin Investig Drugs</div>. <div class=\"year\">2002</div>;<div class=\"volume\">11</div>(<div class=\"issue\">9</div>):<div class=\"fpage\">1253</div>–<div class=\"lpage\">1259</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Therapeutic%20potential%20of%20GnRH%20antagonists%20in%20the%20treatment%20of%20precocious%20puberty&amp;author=C%20Roth&amp;publication_year=2002&amp;journal=Expert%20Opin%20Investig%20Drugs&amp;volume=11&amp;pages=1253-1259\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1517/13543784.11.9.1253\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1517%2F13543784.11.9.1253\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1517%2F13543784.11.9.1253\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/12225246\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Therapeutic%20potential%20of%20GnRH%20antagonists%20in%20the%20treatment%20of%20precocious%20puberty&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B91\" class=\"js-splitview-ref-item\" data-legacy-id=\"B91\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B91\" href=\"javascript:;\" aria-label=\"jumplink-B91\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B91\" class=\"ref-content \" data-id=\"B91\"><span class=\"label\">91.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Tuvemo</div>  <div class=\"given-names\">T</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Treatment of central precocious puberty</div>. <div class=\"source \">Expert Opin Investig Drugs</div>. <div class=\"year\">2006</div>;<div class=\"volume\">15</div>(<div class=\"issue\">5</div>):<div class=\"fpage\">495</div>–<div class=\"lpage\">505</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Treatment%20of%20central%20precocious%20puberty&amp;author=T%20Tuvemo&amp;publication_year=2006&amp;journal=Expert%20Opin%20Investig%20Drugs&amp;volume=15&amp;pages=495-505\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1517/13543784.15.5.495\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1517%2F13543784.15.5.495\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1517%2F13543784.15.5.495\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/16634688\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Treatment%20of%20central%20precocious%20puberty&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B92\" class=\"js-splitview-ref-item\" data-legacy-id=\"B92\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B92\" href=\"javascript:;\" aria-label=\"jumplink-B92\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B92\" class=\"ref-content \" data-id=\"B92\"><span class=\"label\">92.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Schagen</div>  <div class=\"given-names\">SE</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Cohen-Kettenis</div>  <div class=\"given-names\">PT</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Delemarre-van de Waal</div>  <div class=\"given-names\">HA</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Hannema</div>  <div class=\"given-names\">SE</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Efficacy and safety of gonadotropin-releasing hormone agonist treatment to suppress puberty in gender dysphoric adolescents</div>. <div class=\"source \">J Sex Med</div>. <div class=\"year\">2016</div>;<div class=\"volume\">13</div>(<div class=\"issue\">7</div>):<div class=\"fpage\">1125</div>–<div class=\"lpage\">1132</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Efficacy%20and%20safety%20of%20gonadotropin-releasing%20hormone%20agonist%20treatment%20to%20suppress%20puberty%20in%20gender%20dysphoric%20adolescents&amp;author=SE%20Schagen&amp;author=PT%20Cohen-Kettenis&amp;author=HA%20Delemarre-van%20de%20Waal&amp;author=SE%20Hannema&amp;publication_year=2016&amp;journal=J%20Sex%20Med&amp;volume=13&amp;pages=1125-1132\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1016/j.jsxm.2016.05.004\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1016%2Fj.jsxm.2016.05.004\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1016%2Fj.jsxm.2016.05.004\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/27318023\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Efficacy%20and%20safety%20of%20gonadotropin-releasing%20hormone%20agonist%20treatment%20to%20suppress%20puberty%20in%20gender%20dysphoric%20adolescents&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B93\" class=\"js-splitview-ref-item\" data-legacy-id=\"B93\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B93\" href=\"javascript:;\" aria-label=\"jumplink-B93\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B93\" class=\"ref-content \" data-id=\"B93\"><span class=\"label\">93.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Manasco</div>  <div class=\"given-names\">PK</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Pescovitz</div>  <div class=\"given-names\">OH</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Feuillan</div>  <div class=\"given-names\">PP</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Hench</div>  <div class=\"given-names\">KD</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Barnes</div>  <div class=\"given-names\">KM</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Jones</div>  <div class=\"given-names\">J</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Hill</div>  <div class=\"given-names\">SC</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Loriaux</div>  <div class=\"given-names\">DL</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Cutler</div>  <div class=\"given-names\">GB</div>, Jr\r\n</span>\r\n</span>. <div class=\"article-title\">Resumption of puberty after long term luteinizing hormone-releasing hormone agonist treatment of central precocious puberty</div>. <div class=\"source \">J Clin Endocrinol Metab</div>. <div class=\"year\">1988</div>;<div class=\"volume\">67</div>(<div class=\"issue\">2</div>):<div class=\"fpage\">368</div>–<div class=\"lpage\">372</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Resumption%20of%20puberty%20after%20long%20term%20luteinizing%20hormone-releasing%20hormone%20agonist%20treatment%20of%20central%20precocious%20puberty&amp;author=PK%20Manasco&amp;author=OH%20Pescovitz&amp;author=PP%20Feuillan&amp;author=KD%20Hench&amp;author=KM%20Barnes&amp;author=J%20Jones&amp;author=SC%20Hill&amp;author=DL%20Loriaux&amp;author=GB%20Cutler&amp;publication_year=1988&amp;journal=J%20Clin%20Endocrinol%20Metab&amp;volume=67&amp;pages=368-372\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1210/jcem-67-2-368\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1210%2Fjcem-67-2-368\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1210%2Fjcem-67-2-368\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/3292562\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Resumption%20of%20puberty%20after%20long%20term%20luteinizing%20hormone-releasing%20hormone%20agonist%20treatment%20of%20central%20precocious%20puberty&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B94\" class=\"js-splitview-ref-item\" data-legacy-id=\"B94\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B94\" href=\"javascript:;\" aria-label=\"jumplink-B94\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B94\" class=\"ref-content \" data-id=\"B94\"><span class=\"label\">94.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Klink</div>  <div class=\"given-names\">D</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Caris</div>  <div class=\"given-names\">M</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Heijboer</div>  <div class=\"given-names\">A</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">van Trotsenburg</div>  <div class=\"given-names\">M</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Rotteveel</div>  <div class=\"given-names\">J</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Bone mass in young adulthood following gonadotropin-releasing hormone analog treatment and cross-sex hormone treatment in adolescents with gender dysphoria</div>. <div class=\"source \">J Clin Endocrinol Metab</div>. <div class=\"year\">2015</div>;<div class=\"volume\">100</div>(<div class=\"issue\">2</div>):<div class=\"fpage\">E270</div>–<div class=\"lpage\">E275</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Bone%20mass%20in%20young%20adulthood%20following%20gonadotropin-releasing%20hormone%20analog%20treatment%20and%20cross-sex%20hormone%20treatment%20in%20adolescents%20with%20gender%20dysphoria&amp;author=D%20Klink&amp;author=M%20Caris&amp;author=A%20Heijboer&amp;author=M%20van%20Trotsenburg&amp;author=J%20Rotteveel&amp;publication_year=2015&amp;journal=J%20Clin%20Endocrinol%20Metab&amp;volume=100&amp;pages=E270-E275\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1210/jc.2014-2439\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1210%2Fjc.2014-2439\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1210%2Fjc.2014-2439\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/25427144\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Bone%20mass%20in%20young%20adulthood%20following%20gonadotropin-releasing%20hormone%20analog%20treatment%20and%20cross-sex%20hormone%20treatment%20in%20adolescents%20with%20gender%20dysphoria&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B95\" class=\"js-splitview-ref-item\" data-legacy-id=\"B95\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B95\" href=\"javascript:;\" aria-label=\"jumplink-B95\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B95\" class=\"ref-content \" data-id=\"B95\"><span class=\"label\">95.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Finkelstein</div>  <div class=\"given-names\">JS</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Klibanski</div>  <div class=\"given-names\">A</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Neer</div>  <div class=\"given-names\">RM</div>\r\n</span>\r\n</span>. <div class=\"article-title\">A longitudinal evaluation of bone mineral density in adult men with histories of delayed puberty</div>. <div class=\"source \">J Clin Endocrinol Metab</div>. <div class=\"year\">1996</div>;<div class=\"volume\">81</div>(<div class=\"issue\">3</div>):<div class=\"fpage\">1152</div>–<div class=\"lpage\">1155</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=A%20longitudinal%20evaluation%20of%20bone%20mineral%20density%20in%20adult%20men%20with%20histories%20of%20delayed%20puberty&amp;author=JS%20Finkelstein&amp;author=A%20Klibanski&amp;author=RM%20Neer&amp;publication_year=1996&amp;journal=J%20Clin%20Endocrinol%20Metab&amp;volume=81&amp;pages=1152-1155\" target=\"_blank\">Google Scholar</a></span></p><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/8772591\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><div class=\"xslopenurl empty-target\"><span class=\"js-inst-open-url-holders-nodoi\"><a class=\"js-open-url-link\" data-href-template=\"{targetURL}?sid=oup:orr&amp;genre=article&amp;atitle=A+longitudinal+evaluation+of+bone+mineral+density+in+adult+men+with+histories+of+delayed+puberty&amp;aulast=Finkelstein&amp;title=J+Clin+Endocrinol+Metab&amp;date=1996&amp;spage=1152&amp;epage=1155&amp;volume=81&amp;issue=3\" href=\"javascript:;\"><span class=\"screenreader-text\">OpenURL Placeholder Text</span></a></span></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:A%20longitudinal%20evaluation%20of%20bone%20mineral%20density%20in%20adult%20men%20with%20histories%20of%20delayed%20puberty&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B96\" class=\"js-splitview-ref-item\" data-legacy-id=\"B96\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B96\" href=\"javascript:;\" aria-label=\"jumplink-B96\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B96\" class=\"ref-content \" data-id=\"B96\"><span class=\"label\">96.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Bertelloni</div>  <div class=\"given-names\">S</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Baroncelli</div>  <div class=\"given-names\">GI</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Ferdeghini</div>  <div class=\"given-names\">M</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Perri</div>  <div class=\"given-names\">G</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Saggese</div>  <div class=\"given-names\">G</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Normal volumetric bone mineral density and bone turnover in young men with histories of constitutional delay of puberty</div>. <div class=\"source \">J Clin Endocrinol Metab</div>. <div class=\"year\">1998</div>;<div class=\"volume\">83</div>(<div class=\"issue\">12</div>):<div class=\"fpage\">4280</div>–<div class=\"lpage\">4283</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Normal%20volumetric%20bone%20mineral%20density%20and%20bone%20turnover%20in%20young%20men%20with%20histories%20of%20constitutional%20delay%20of%20puberty&amp;author=S%20Bertelloni&amp;author=GI%20Baroncelli&amp;author=M%20Ferdeghini&amp;author=G%20Perri&amp;author=G%20Saggese&amp;publication_year=1998&amp;journal=J%20Clin%20Endocrinol%20Metab&amp;volume=83&amp;pages=4280-4283\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1210/jcem.83.12.5348\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1210%2Fjcem.83.12.5348\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1210%2Fjcem.83.12.5348\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/9851764\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Normal%20volumetric%20bone%20mineral%20density%20and%20bone%20turnover%20in%20young%20men%20with%20histories%20of%20constitutional%20delay%20of%20puberty&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B97\" class=\"js-splitview-ref-item\" data-legacy-id=\"B97\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B97\" href=\"javascript:;\" aria-label=\"jumplink-B97\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B97\" class=\"ref-content \" data-id=\"B97\"><span class=\"label\">97.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Darelid</div>  <div class=\"given-names\">A</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Ohlsson</div>  <div class=\"given-names\">C</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Nilsson</div>  <div class=\"given-names\">M</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Kindblom</div>  <div class=\"given-names\">JM</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Mellström</div>  <div class=\"given-names\">D</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Lorentzon</div>  <div class=\"given-names\">M</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Catch up in bone acquisition in young adult men with late normal puberty</div>. <div class=\"source \">J Bone Miner Res</div>. <div class=\"year\">2012</div>;<div class=\"volume\">27</div>(<div class=\"issue\">10</div>):<div class=\"fpage\">2198</div>–<div class=\"lpage\">2207</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Catch%20up%20in%20bone%20acquisition%20in%20young%20adult%20men%20with%20late%20normal%20puberty&amp;author=A%20Darelid&amp;author=C%20Ohlsson&amp;author=M%20Nilsson&amp;author=JM%20Kindblom&amp;author=D%20Mellstr%C3%B6m&amp;author=M%20Lorentzon&amp;publication_year=2012&amp;journal=J%20Bone%20Miner%20Res&amp;volume=27&amp;pages=2198-2207\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1002/jbmr.1675\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1002%2Fjbmr.1675\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1002%2Fjbmr.1675\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22653693\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Catch%20up%20in%20bone%20acquisition%20in%20young%20adult%20men%20with%20late%20normal%20puberty&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B98\" class=\"js-splitview-ref-item\" data-legacy-id=\"B98\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B98\" href=\"javascript:;\" aria-label=\"jumplink-B98\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B98\" class=\"ref-content \" data-id=\"B98\"><span class=\"label\">98.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Mittan</div>  <div class=\"given-names\">D</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Lee</div>  <div class=\"given-names\">S</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Miller</div>  <div class=\"given-names\">E</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Perez</div>  <div class=\"given-names\">RC</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Basler</div>  <div class=\"given-names\">JW</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Bruder</div>  <div class=\"given-names\">JM</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs</div>. <div class=\"source \">J Clin Endocrinol Metab</div>. <div class=\"year\">2002</div>;<div class=\"volume\">87</div>(<div class=\"issue\">8</div>):<div class=\"fpage\">3656</div>–<div class=\"lpage\">3661</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Bone%20loss%20following%20hypogonadism%20in%20men%20with%20prostate%20cancer%20treated%20with%20GnRH%20analogs&amp;author=D%20Mittan&amp;author=S%20Lee&amp;author=E%20Miller&amp;author=RC%20Perez&amp;author=JW%20Basler&amp;author=JM%20Bruder&amp;publication_year=2002&amp;journal=J%20Clin%20Endocrinol%20Metab&amp;volume=87&amp;pages=3656-3661\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1210/jcem.87.8.8782\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1210%2Fjcem.87.8.8782\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1210%2Fjcem.87.8.8782\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/12161491\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Bone%20loss%20following%20hypogonadism%20in%20men%20with%20prostate%20cancer%20treated%20with%20GnRH%20analogs&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B99\" class=\"js-splitview-ref-item\" data-legacy-id=\"B99\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B99\" href=\"javascript:;\" aria-label=\"jumplink-B99\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B99\" class=\"ref-content \" data-id=\"B99\"><span class=\"label\">99.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Saggese</div>  <div class=\"given-names\">G</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Bertelloni</div>  <div class=\"given-names\">S</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Baroncelli</div>  <div class=\"given-names\">GI</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Battini</div>  <div class=\"given-names\">R</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Franchi</div>  <div class=\"given-names\">G</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Reduction of bone density: an effect of gonadotropin releasing hormone analogue treatment in central precocious puberty</div>. <div class=\"source \">Eur J Pediatr</div>. <div class=\"year\">1993</div>;<div class=\"volume\">152</div>(<div class=\"issue\">9</div>):<div class=\"fpage\">717</div>–<div class=\"lpage\">720</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Reduction%20of%20bone%20density%3A%20an%20effect%20of%20gonadotropin%20releasing%20hormone%20analogue%20treatment%20in%20central%20precocious%20puberty&amp;author=G%20Saggese&amp;author=S%20Bertelloni&amp;author=GI%20Baroncelli&amp;author=R%20Battini&amp;author=G%20Franchi&amp;publication_year=1993&amp;journal=Eur%20J%20Pediatr&amp;volume=152&amp;pages=717-720\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1007/BF01953983\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1007%2FBF01953983\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1007%2FBF01953983\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/8223799\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Reduction%20of%20bone%20density%3A%20an%20effect%20of%20gonadotropin%20releasing%20hormone%20analogue%20treatment%20in%20central%20precocious%20puberty&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B100\" class=\"js-splitview-ref-item\" data-legacy-id=\"B100\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B100\" href=\"javascript:;\" aria-label=\"jumplink-B100\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B100\" class=\"ref-content \" data-id=\"B100\"><span class=\"label\">100.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Neely</div>  <div class=\"given-names\">EK</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Bachrach</div>  <div class=\"given-names\">LK</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Hintz</div>  <div class=\"given-names\">RL</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Habiby</div>  <div class=\"given-names\">RL</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Slemenda</div>  <div class=\"given-names\">CW</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Feezle</div>  <div class=\"given-names\">L</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Pescovitz</div>  <div class=\"given-names\">OH</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Bone mineral density during treatment of central precocious puberty</div>. <div class=\"source \">J Pediatr</div>. <div class=\"year\">1995</div>;<div class=\"volume\">127</div>(<div class=\"issue\">5</div>):<div class=\"fpage\">819</div>–<div class=\"lpage\">822</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Bone%20mineral%20density%20during%20treatment%20of%20central%20precocious%20puberty&amp;author=EK%20Neely&amp;author=LK%20Bachrach&amp;author=RL%20Hintz&amp;author=RL%20Habiby&amp;author=CW%20Slemenda&amp;author=L%20Feezle&amp;author=OH%20Pescovitz&amp;publication_year=1995&amp;journal=J%20Pediatr&amp;volume=127&amp;pages=819-822\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1016/S0022-3476(95)70182-6\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1016%2FS0022-3476(95)70182-6\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1016%2FS0022-3476(95)70182-6\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/7472845\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Bone%20mineral%20density%20during%20treatment%20of%20central%20precocious%20puberty&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B101\" class=\"js-splitview-ref-item\" data-legacy-id=\"B101\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B101\" href=\"javascript:;\" aria-label=\"jumplink-B101\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B101\" class=\"ref-content \" data-id=\"B101\"><span class=\"label\">101.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Bertelloni</div>  <div class=\"given-names\">S</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Baroncelli</div>  <div class=\"given-names\">GI</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Sorrentino</div>  <div class=\"given-names\">MC</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Perri</div>  <div class=\"given-names\">G</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Saggese</div>  <div class=\"given-names\">G</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Effect of central precocious puberty and gonadotropin-releasing hormone analogue treatment on peak bone mass and final height in females</div>. <div class=\"source \">Eur J Pediatr</div>. <div class=\"year\">1998</div>;<div class=\"volume\">157</div>(<div class=\"issue\">5</div>):<div class=\"fpage\">363</div>–<div class=\"lpage\">367</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Effect%20of%20central%20precocious%20puberty%20and%20gonadotropin-releasing%20hormone%20analogue%20treatment%20on%20peak%20bone%20mass%20and%20final%20height%20in%20females&amp;author=S%20Bertelloni&amp;author=GI%20Baroncelli&amp;author=MC%20Sorrentino&amp;author=G%20Perri&amp;author=G%20Saggese&amp;publication_year=1998&amp;journal=Eur%20J%20Pediatr&amp;volume=157&amp;pages=363-367\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1007/s004310050831\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1007%2Fs004310050831\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1007%2Fs004310050831\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/9625331\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Effect%20of%20central%20precocious%20puberty%20and%20gonadotropin-releasing%20hormone%20analogue%20treatment%20on%20peak%20bone%20mass%20and%20final%20height%20in%20females&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B102\" class=\"js-splitview-ref-item\" data-legacy-id=\"B102\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B102\" href=\"javascript:;\" aria-label=\"jumplink-B102\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B102\" class=\"ref-content \" data-id=\"B102\"><span class=\"label\">102.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Thornton</div>  <div class=\"given-names\">P</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Silverman</div>  <div class=\"given-names\">LA</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Geffner</div>  <div class=\"given-names\">ME</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Neely</div>  <div class=\"given-names\">EK</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Gould</div>  <div class=\"given-names\">E</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Danoff</div>  <div class=\"given-names\">TM</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Review of outcomes after cessation of gonadotropin-releasing hormone agonist treatment of girls with precocious puberty</div>. <div class=\"source \">Pediatr Endocrinol Rev</div>. <div class=\"year\">2014</div>;<div class=\"volume\">11</div>(<div class=\"issue\">3</div>):<div class=\"fpage\">306</div>–<div class=\"lpage\">317</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Review%20of%20outcomes%20after%20cessation%20of%20gonadotropin-releasing%20hormone%20agonist%20treatment%20of%20girls%20with%20precocious%20puberty&amp;author=P%20Thornton&amp;author=LA%20Silverman&amp;author=ME%20Geffner&amp;author=EK%20Neely&amp;author=E%20Gould&amp;author=TM%20Danoff&amp;publication_year=2014&amp;journal=Pediatr%20Endocrinol%20Rev&amp;volume=11&amp;pages=306-317\" target=\"_blank\">Google Scholar</a></span></p><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/24719967\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><div class=\"xslopenurl empty-target\"><span class=\"js-inst-open-url-holders-nodoi\"><a class=\"js-open-url-link\" data-href-template=\"{targetURL}?sid=oup:orr&amp;genre=article&amp;atitle=Review+of+outcomes+after+cessation+of+gonadotropin-releasing+hormone+agonist+treatment+of+girls+with+precocious+puberty&amp;aulast=Thornton&amp;title=Pediatr+Endocrinol+Rev&amp;date=2014&amp;spage=306&amp;epage=317&amp;volume=11&amp;issue=3\" href=\"javascript:;\"><span class=\"screenreader-text\">OpenURL Placeholder Text</span></a></span></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Review%20of%20outcomes%20after%20cessation%20of%20gonadotropin-releasing%20hormone%20agonist%20treatment%20of%20girls%20with%20precocious%20puberty&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B103\" class=\"js-splitview-ref-item\" data-legacy-id=\"B103\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B103\" href=\"javascript:;\" aria-label=\"jumplink-B103\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B103\" class=\"ref-content \" data-id=\"B103\"><span class=\"label\">103.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Lem</div>  <div class=\"given-names\">AJ</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">van der Kaay</div>  <div class=\"given-names\">DC</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Hokken-Koelega</div>  <div class=\"given-names\">AC</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Bone mineral density and body composition in short children born SGA during growth hormone and gonadotropin releasing hormone analog treatment</div>. <div class=\"source \">J Clin Endocrinol Metab</div>. <div class=\"year\">2013</div>;<div class=\"volume\">98</div>(<div class=\"issue\">1</div>):<div class=\"fpage\">77</div>–<div class=\"lpage\">86</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Bone%20mineral%20density%20and%20body%20composition%20in%20short%20children%20born%20SGA%20during%20growth%20hormone%20and%20gonadotropin%20releasing%20hormone%20analog%20treatment&amp;author=AJ%20Lem&amp;author=DC%20van%20der%20Kaay&amp;author=AC%20Hokken-Koelega&amp;publication_year=2013&amp;journal=J%20Clin%20Endocrinol%20Metab&amp;volume=98&amp;pages=77-86\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1210/jc.2012-2492\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1210%2Fjc.2012-2492\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1210%2Fjc.2012-2492\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23125290\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Bone%20mineral%20density%20and%20body%20composition%20in%20short%20children%20born%20SGA%20during%20growth%20hormone%20and%20gonadotropin%20releasing%20hormone%20analog%20treatment&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B104\" class=\"js-splitview-ref-item\" data-legacy-id=\"B104\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B104\" href=\"javascript:;\" aria-label=\"jumplink-B104\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B104\" class=\"ref-content \" data-id=\"B104\"><span class=\"label\">104.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Antoniazzi</div>  <div class=\"given-names\">F</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Zamboni</div>  <div class=\"given-names\">G</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Bertoldo</div>  <div class=\"given-names\">F</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Lauriola</div>  <div class=\"given-names\">S</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Mengarda</div>  <div class=\"given-names\">F</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Pietrobelli</div>  <div class=\"given-names\">A</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Tatò</div>  <div class=\"given-names\">L</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Bone mass at final height in precocious puberty after gonadotropin-releasing hormone agonist with and without calcium supplementation</div>. <div class=\"source \">J Clin Endocrinol Metab</div>. <div class=\"year\">2003</div>;<div class=\"volume\">88</div>(<div class=\"issue\">3</div>):<div class=\"fpage\">1096</div>–<div class=\"lpage\">1101</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Bone%20mass%20at%20final%20height%20in%20precocious%20puberty%20after%20gonadotropin-releasing%20hormone%20agonist%20with%20and%20without%20calcium%20supplementation&amp;author=F%20Antoniazzi&amp;author=G%20Zamboni&amp;author=F%20Bertoldo&amp;author=S%20Lauriola&amp;author=F%20Mengarda&amp;author=A%20Pietrobelli&amp;author=L%20Tat%C3%B2&amp;publication_year=2003&amp;journal=J%20Clin%20Endocrinol%20Metab&amp;volume=88&amp;pages=1096-1101\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1210/jc.2002-021154\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1210%2Fjc.2002-021154\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1210%2Fjc.2002-021154\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/12629090\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Bone%20mass%20at%20final%20height%20in%20precocious%20puberty%20after%20gonadotropin-releasing%20hormone%20agonist%20with%20and%20without%20calcium%20supplementation&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B105\" class=\"js-splitview-ref-item\" data-legacy-id=\"B105\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B105\" href=\"javascript:;\" aria-label=\"jumplink-B105\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B105\" class=\"ref-content \" data-id=\"B105\"><span class=\"label\">105.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Calcaterra</div>  <div class=\"given-names\">V</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Mannarino</div>  <div class=\"given-names\">S</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Corana</div>  <div class=\"given-names\">G</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Codazzi</div>  <div class=\"given-names\">AC</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Mazzola</div>  <div class=\"given-names\">A</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Brambilla</div>  <div class=\"given-names\">P</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Larizza</div>  <div class=\"given-names\">D</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Hypertension during therapy with triptorelin in a girl with precocious puberty</div>. <div class=\"source \">Indian J Pediatr</div>. <div class=\"year\">2013</div>;<div class=\"volume\">80</div>(<div class=\"issue\">10</div>):<div class=\"fpage\">884</div>–<div class=\"lpage\">885</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Hypertension%20during%20therapy%20with%20triptorelin%20in%20a%20girl%20with%20precocious%20puberty&amp;author=V%20Calcaterra&amp;author=S%20Mannarino&amp;author=G%20Corana&amp;author=AC%20Codazzi&amp;author=A%20Mazzola&amp;author=P%20Brambilla&amp;author=D%20Larizza&amp;publication_year=2013&amp;journal=Indian%20J%20Pediatr&amp;volume=80&amp;pages=884-885\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1007/s12098-012-0898-2\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1007%2Fs12098-012-0898-2\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1007%2Fs12098-012-0898-2\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23180401\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Hypertension%20during%20therapy%20with%20triptorelin%20in%20a%20girl%20with%20precocious%20puberty&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B106\" class=\"js-splitview-ref-item\" data-legacy-id=\"B106\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B106\" href=\"javascript:;\" aria-label=\"jumplink-B106\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B106\" class=\"ref-content \" data-id=\"B106\"><span class=\"label\">106.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Siomou</div>  <div class=\"given-names\">E</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Kosmeri</div>  <div class=\"given-names\">C</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Pavlou</div>  <div class=\"given-names\">M</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Vlahos</div>  <div class=\"given-names\">AP</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Argyropoulou</div>  <div class=\"given-names\">MI</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Siamopoulou</div>  <div class=\"given-names\">A</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Arterial hypertension during treatment with triptorelin in a child with Williams-Beuren syndrome</div>. <div class=\"source \">Pediatr Nephrol</div>. <div class=\"year\">2014</div>;<div class=\"volume\">29</div>(<div class=\"issue\">9</div>):<div class=\"fpage\">1633</div>–<div class=\"lpage\">1636</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Arterial%20hypertension%20during%20treatment%20with%20triptorelin%20in%20a%20child%20with%20Williams-Beuren%20syndrome&amp;author=E%20Siomou&amp;author=C%20Kosmeri&amp;author=M%20Pavlou&amp;author=AP%20Vlahos&amp;author=MI%20Argyropoulou&amp;author=A%20Siamopoulou&amp;publication_year=2014&amp;journal=Pediatr%20Nephrol&amp;volume=29&amp;pages=1633-1636\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1007/s00467-014-2795-6\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1007%2Fs00467-014-2795-6\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1007%2Fs00467-014-2795-6\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/24604705\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Arterial%20hypertension%20during%20treatment%20with%20triptorelin%20in%20a%20child%20with%20Williams-Beuren%20syndrome&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B107\" class=\"js-splitview-ref-item\" data-legacy-id=\"B107\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B107\" href=\"javascript:;\" aria-label=\"jumplink-B107\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B107\" class=\"ref-content \" data-id=\"B107\"><span class=\"label\">107.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Staphorsius</div>  <div class=\"given-names\">AS</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Kreukels</div>  <div class=\"given-names\">BPC</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Cohen-Kettenis</div>  <div class=\"given-names\">PT</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Veltman</div>  <div class=\"given-names\">DJ</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Burke</div>  <div class=\"given-names\">SM</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Schagen</div>  <div class=\"given-names\">SEE</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Wouters</div>  <div class=\"given-names\">FM</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Delemarre-van de Waal</div>  <div class=\"given-names\">HA</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Bakker</div>  <div class=\"given-names\">J</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Puberty suppression and executive functioning: an fMRI-study in adolescents with gender dysphoria</div>. <div class=\"source \">Psychoneuroendocrinology</div>. <div class=\"year\">2015</div>;<div class=\"volume\">56</div>:<div class=\"fpage\">190</div>–<div class=\"lpage\">199</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Puberty%20suppression%20and%20executive%20functioning%3A%20an%20fMRI-study%20in%20adolescents%20with%20gender%20dysphoria&amp;author=AS%20Staphorsius&amp;author=BPC%20Kreukels&amp;author=PT%20Cohen-Kettenis&amp;author=DJ%20Veltman&amp;author=SM%20Burke&amp;author=SEE%20Schagen&amp;author=FM%20Wouters&amp;author=HA%20Delemarre-van%20de%20Waal&amp;author=J%20Bakker&amp;publication_year=2015&amp;journal=Psychoneuroendocrinology&amp;volume=56&amp;pages=190-199\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1016/j.psyneuen.2015.03.007\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1016%2Fj.psyneuen.2015.03.007\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1016%2Fj.psyneuen.2015.03.007\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/25837854\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Puberty%20suppression%20and%20executive%20functioning%3A%20an%20fMRI-study%20in%20adolescents%20with%20gender%20dysphoria&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B108\" class=\"js-splitview-ref-item\" data-legacy-id=\"B108\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B108\" href=\"javascript:;\" aria-label=\"jumplink-B108\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B108\" class=\"ref-content \" data-id=\"B108\"><span class=\"label\">108.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Hough</div>  <div class=\"given-names\">D</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Bellingham</div>  <div class=\"given-names\">M</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Haraldsen</div>  <div class=\"given-names\">IR</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">McLaughlin</div>  <div class=\"given-names\">M</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Rennie</div>  <div class=\"given-names\">M</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Robinson</div>  <div class=\"given-names\">JE</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Solbakk</div>  <div class=\"given-names\">AK</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Evans</div>  <div class=\"given-names\">NP</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Spatial memory is impaired by peripubertal GnRH agonist treatment and testosterone replacement in sheep</div>. <div class=\"source \">Psychoneuroendocrinology</div>. <div class=\"year\">2017</div>;<div class=\"volume\">75</div>:<div class=\"fpage\">173</div>–<div class=\"lpage\">182</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Spatial%20memory%20is%20impaired%20by%20peripubertal%20GnRH%20agonist%20treatment%20and%20testosterone%20replacement%20in%20sheep&amp;author=D%20Hough&amp;author=M%20Bellingham&amp;author=IR%20Haraldsen&amp;author=M%20McLaughlin&amp;author=M%20Rennie&amp;author=JE%20Robinson&amp;author=AK%20Solbakk&amp;author=NP%20Evans&amp;publication_year=2017&amp;journal=Psychoneuroendocrinology&amp;volume=75&amp;pages=173-182\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1016/j.psyneuen.2016.10.016\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1016%2Fj.psyneuen.2016.10.016\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1016%2Fj.psyneuen.2016.10.016\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/27837697\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Spatial%20memory%20is%20impaired%20by%20peripubertal%20GnRH%20agonist%20treatment%20and%20testosterone%20replacement%20in%20sheep&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B109\" class=\"js-splitview-ref-item\" data-legacy-id=\"B109\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B109\" href=\"javascript:;\" aria-label=\"jumplink-B109\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B109\" class=\"ref-content \" data-id=\"B109\"><span class=\"label\">109.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Collipp</div>  <div class=\"given-names\">PJ</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Kaplan</div>  <div class=\"given-names\">SA</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Boyle</div>  <div class=\"given-names\">DC</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Plachte</div>  <div class=\"given-names\">F</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Kogut</div>  <div class=\"given-names\">MD</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Constitutional Isosexual Precocious Puberty</div>. <div class=\"source \">Am J Dis Child</div>. <div class=\"year\">1964</div>;<div class=\"volume\">108</div>:<div class=\"fpage\">399</div>–<div class=\"lpage\">405</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Constitutional%20Isosexual%20Precocious%20Puberty&amp;author=PJ%20Collipp&amp;author=SA%20Kaplan&amp;author=DC%20Boyle&amp;author=F%20Plachte&amp;author=MD%20Kogut&amp;publication_year=1964&amp;journal=Am%20J%20Dis%20Child&amp;volume=108&amp;pages=399-405\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1001/archpedi.1964.02090010401010\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1001%2Farchpedi.1964.02090010401010\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1001%2Farchpedi.1964.02090010401010\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/14186660\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Constitutional%20Isosexual%20Precocious%20Puberty&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B110\" class=\"js-splitview-ref-item\" data-legacy-id=\"B110\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B110\" href=\"javascript:;\" aria-label=\"jumplink-B110\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B110\" class=\"ref-content \" data-id=\"B110\"><span class=\"label\">110.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Hahn</div>  <div class=\"given-names\">HB</div>, Jr\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Hayles</div>  <div class=\"given-names\">AB</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Albert</div>  <div class=\"given-names\">A</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Medroxyprogesterone and constitutional precocious puberty.</div> <div class=\"source \">Mayo Clin Proc</div>. <div class=\"year\">1964</div>;<div class=\"volume\">39</div>:<div class=\"fpage\">182</div>–<div class=\"lpage\">190</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Medroxyprogesterone%20and%20constitutional%20precocious%20puberty.&amp;author=HB%20Hahn&amp;author=AB%20Hayles&amp;author=A%20Albert&amp;publication_year=1964&amp;journal=Mayo%20Clin%20Proc&amp;volume=39&amp;pages=182-190\" target=\"_blank\">Google Scholar</a></span></p><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/14127737\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><div class=\"xslopenurl empty-target\"><span class=\"js-inst-open-url-holders-nodoi\"><a class=\"js-open-url-link\" data-href-template=\"{targetURL}?sid=oup:orr&amp;genre=article&amp;atitle=Medroxyprogesterone+and+constitutional+precocious+puberty.&amp;aulast=Hahn&amp;title=Mayo+Clin+Proc&amp;date=1964&amp;spage=182&amp;epage=190&amp;volume=39\" href=\"javascript:;\"><span class=\"screenreader-text\">OpenURL Placeholder Text</span></a></span></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Medroxyprogesterone%20and%20constitutional%20precocious%20puberty.&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B111\" class=\"js-splitview-ref-item\" data-legacy-id=\"B111\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B111\" href=\"javascript:;\" aria-label=\"jumplink-B111\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B111\" class=\"ref-content \" data-id=\"B111\"><span class=\"label\">111.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Kaplan</div>  <div class=\"given-names\">SA</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Ling</div>  <div class=\"given-names\">SM</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Irani</div>  <div class=\"given-names\">NG</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Idiopathic isosexual precocity</div>. <div class=\"source \">Am J Dis Child</div>. <div class=\"year\">1968</div>;<div class=\"volume\">116</div>(<div class=\"issue\">6</div>):<div class=\"fpage\">591</div>–<div class=\"lpage\">598</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Idiopathic%20isosexual%20precocity&amp;author=SA%20Kaplan&amp;author=SM%20Ling&amp;author=NG%20Irani&amp;publication_year=1968&amp;journal=Am%20J%20Dis%20Child&amp;volume=116&amp;pages=591-598\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1001/archpedi.1968.02100020595004\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1001%2Farchpedi.1968.02100020595004\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1001%2Farchpedi.1968.02100020595004\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/5697190\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Idiopathic%20isosexual%20precocity&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B112\" class=\"js-splitview-ref-item\" data-legacy-id=\"B112\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B112\" href=\"javascript:;\" aria-label=\"jumplink-B112\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B112\" class=\"ref-content \" data-id=\"B112\"><span class=\"label\">112.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Schoen</div>  <div class=\"given-names\">EJ</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Treatment of idiopathic precocious puberty in boys</div>. <div class=\"source \">J Clin Endocrinol Metab</div>. <div class=\"year\">1966</div>;<div class=\"volume\">26</div>(<div class=\"issue\">4</div>):<div class=\"fpage\">363</div>–<div class=\"lpage\">370</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Treatment%20of%20idiopathic%20precocious%20puberty%20in%20boys&amp;author=EJ%20Schoen&amp;publication_year=1966&amp;journal=J%20Clin%20Endocrinol%20Metab&amp;volume=26&amp;pages=363-370\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1210/jcem-26-4-363\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1210%2Fjcem-26-4-363\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1210%2Fjcem-26-4-363\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/5929626\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Treatment%20of%20idiopathic%20precocious%20puberty%20in%20boys&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B113\" class=\"js-splitview-ref-item\" data-legacy-id=\"B113\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B113\" href=\"javascript:;\" aria-label=\"jumplink-B113\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B113\" class=\"ref-content \" data-id=\"B113\"><span class=\"label\">113.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Gooren</div>  <div class=\"given-names\">L</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Hormone treatment of the adult transsexual patient</div>. <div class=\"source \">Horm Res</div>. <div class=\"year\">2005</div>;<div class=\"volume\">64</div>(<div class=\"supplement\">Suppl 2</div>):<div class=\"fpage\">31</div>–<div class=\"lpage\">36</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Hormone%20treatment%20of%20the%20adult%20transsexual%20patient&amp;author=L%20Gooren&amp;publication_year=2005&amp;journal=Horm%20Res&amp;volume=64&amp;pages=31-36\" target=\"_blank\">Google Scholar</a></span></p><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/16286768\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><div class=\"xslopenurl empty-target\"><span class=\"js-inst-open-url-holders-nodoi\"><a class=\"js-open-url-link\" data-href-template=\"{targetURL}?sid=oup:orr&amp;genre=article&amp;atitle=Hormone+treatment+of+the+adult+transsexual+patient&amp;aulast=Gooren&amp;title=Horm+Res&amp;date=2005&amp;spage=31&amp;epage=36&amp;volume=64\" href=\"javascript:;\"><span class=\"screenreader-text\">OpenURL Placeholder Text</span></a></span></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Hormone%20treatment%20of%20the%20adult%20transsexual%20patient&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B114\" class=\"js-splitview-ref-item\" data-legacy-id=\"B114\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B114\" href=\"javascript:;\" aria-label=\"jumplink-B114\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B114\" class=\"ref-content \" data-id=\"B114\"><span class=\"label\">114.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Moore</div>  <div class=\"given-names\">E</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Wisniewski</div>  <div class=\"given-names\">A</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Dobs</div>  <div class=\"given-names\">A</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Endocrine treatment of transsexual people: a review of treatment regimens, outcomes, and adverse effects</div>. <div class=\"source \">J Clin Endocrinol Metab</div>. <div class=\"year\">2003</div>;<div class=\"volume\">88</div>(<div class=\"issue\">8</div>):<div class=\"fpage\">3467</div>–<div class=\"lpage\">3473</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Endocrine%20treatment%20of%20transsexual%20people%3A%20a%20review%20of%20treatment%20regimens%2C%20outcomes%2C%20and%20adverse%20effects&amp;author=E%20Moore&amp;author=A%20Wisniewski&amp;author=A%20Dobs&amp;publication_year=2003&amp;journal=J%20Clin%20Endocrinol%20Metab&amp;volume=88&amp;pages=3467-3473\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1210/jc.2002-021967\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1210%2Fjc.2002-021967\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1210%2Fjc.2002-021967\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/12915619\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Endocrine%20treatment%20of%20transsexual%20people%3A%20a%20review%20of%20treatment%20regimens%2C%20outcomes%2C%20and%20adverse%20effects&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B115\" class=\"js-splitview-ref-item\" data-legacy-id=\"B115\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B115\" href=\"javascript:;\" aria-label=\"jumplink-B115\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B115\" class=\"ref-content \" data-id=\"B115\"><span class=\"label\">115.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Krueger</div>  <div class=\"given-names\">RB</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Hembree</div>  <div class=\"given-names\">W</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Hill</div>  <div class=\"given-names\">M</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Prescription of medroxyprogesterone acetate to a patient with pedophilia, resulting in Cushing’s syndrome and adrenal insufficiency</div>. <div class=\"source \">Sex Abuse</div>. <div class=\"year\">2006</div>;<div class=\"volume\">18</div>(<div class=\"issue\">2</div>):<div class=\"fpage\">227</div>–<div class=\"lpage\">228</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Prescription%20of%20medroxyprogesterone%20acetate%20to%20a%20patient%20with%20pedophilia%2C%20resulting%20in%20Cushing%E2%80%99s%20syndrome%20and%20adrenal%20insufficiency&amp;author=RB%20Krueger&amp;author=W%20Hembree&amp;author=M%20Hill&amp;publication_year=2006&amp;journal=Sex%20Abuse&amp;volume=18&amp;pages=227-228\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1177/107906320601800208\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1177%2F107906320601800208\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1177%2F107906320601800208\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/16868842\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Prescription%20of%20medroxyprogesterone%20acetate%20to%20a%20patient%20with%20pedophilia%2C%20resulting%20in%20Cushing%E2%80%99s%20syndrome%20and%20adrenal%20insufficiency&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B116\" class=\"js-splitview-ref-item\" data-legacy-id=\"B116\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B116\" href=\"javascript:;\" aria-label=\"jumplink-B116\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B116\" class=\"ref-content \" data-id=\"B116\"><span class=\"label\">116.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Lynch</div>  <div class=\"given-names\">MM</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Khandheria</div>  <div class=\"given-names\">MM</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Meyer</div>  <div class=\"given-names\">WJ</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Retrospective study of the management of childhood and adolescent gender identity disorder using medroxyprogesterone acetate</div>. <div class=\"source \">Int J Transgenderism</div>. <div class=\"year\">2015</div>;<div class=\"volume\">16</div>:<div class=\"fpage\">201</div>–<div class=\"lpage\">208</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Retrospective%20study%20of%20the%20management%20of%20childhood%20and%20adolescent%20gender%20identity%20disorder%20using%20medroxyprogesterone%20acetate&amp;author=MM%20Lynch&amp;author=MM%20Khandheria&amp;author=WJ%20Meyer&amp;publication_year=2015&amp;journal=Int%20J%20Transgenderism&amp;volume=16&amp;pages=201-208\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1080/15532739.2015.1080649\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1080%2F15532739.2015.1080649\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1080%2F15532739.2015.1080649\"> </span></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Retrospective%20study%20of%20the%20management%20of%20childhood%20and%20adolescent%20gender%20identity%20disorder%20using%20medroxyprogesterone%20acetate&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B117\" class=\"js-splitview-ref-item\" data-legacy-id=\"B117\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B117\" href=\"javascript:;\" aria-label=\"jumplink-B117\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B117\" class=\"ref-content \" data-id=\"B117\"><span class=\"label\">117.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Tack</div>  <div class=\"given-names\">LJW</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Craen</div>  <div class=\"given-names\">M</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Dhondt</div>  <div class=\"given-names\">K</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Vanden Bossche</div>  <div class=\"given-names\">H</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Laridaen</div>  <div class=\"given-names\">J</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Cools</div>  <div class=\"given-names\">M</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Consecutive lynestrenol and cross-sex hormone treatment in biological female adolescents with gender dysphoria: a retrospective analysis</div>. <div class=\"source \">Biol Sex Differ</div>. <div class=\"year\">2016</div>;<div class=\"volume\">7</div>:<div class=\"fpage\">14</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Consecutive%20lynestrenol%20and%20cross-sex%20hormone%20treatment%20in%20biological%20female%20adolescents%20with%20gender%20dysphoria%3A%20a%20retrospective%20analysis&amp;author=LJW%20Tack&amp;author=M%20Craen&amp;author=K%20Dhondt&amp;author=H%20Vanden%20Bossche&amp;author=J%20Laridaen&amp;author=M%20Cools&amp;publication_year=2016&amp;journal=Biol%20Sex%20Differ&amp;volume=7&amp;pages=14\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1186/s13293-016-0067-9\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1186%2Fs13293-016-0067-9\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1186%2Fs13293-016-0067-9\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/26885361\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Consecutive%20lynestrenol%20and%20cross-sex%20hormone%20treatment%20in%20biological%20female%20adolescents%20with%20gender%20dysphoria%3A%20a%20retrospective%20analysis&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B118\" class=\"js-splitview-ref-item\" data-legacy-id=\"B118\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B118\" href=\"javascript:;\" aria-label=\"jumplink-B118\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B118\" class=\"ref-content \" data-id=\"B118\"><span class=\"label\">118.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Hembree</div>  <div class=\"given-names\">WC</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Cohen-Kettenis</div>  <div class=\"given-names\">P</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Delemarre-van de Waal</div>  <div class=\"given-names\">HA</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Gooren</div>  <div class=\"given-names\">LJ</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Meyer</div>  <div class=\"given-names\">WJ</div> 3rd\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Spack</div>  <div class=\"given-names\">NP</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Tangpricha</div>  <div class=\"given-names\">V</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Montori</div>  <div class=\"given-names\">VM</div>\r\n</span>; <div class=\"collab\">Endocrine Society</div>\r\n</span>. <div class=\"article-title\">Endocrine treatment of transsexual persons: an Endocrine Society clinical practice guideline</div>. <div class=\"source \">J Clin Endocrinol Metab</div>. <div class=\"year\">2009</div>;<div class=\"volume\">94</div>(<div class=\"issue\">9</div>):<div class=\"fpage\">3132</div>–<div class=\"lpage\">3154</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Endocrine%20treatment%20of%20transsexual%20persons%3A%20an%20Endocrine%20Society%20clinical%20practice%20guideline&amp;author=WC%20Hembree&amp;author=P%20Cohen-Kettenis&amp;author=HA%20Delemarre-van%20de%20Waal&amp;author=LJ%20Gooren&amp;author=WJ%20Meyer&amp;author=NP%20Spack&amp;author=V%20Tangpricha&amp;author=VM%20Montori&amp;publication_year=2009&amp;journal=J%20Clin%20Endocrinol%20Metab&amp;volume=94&amp;pages=3132-3154\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1210/jc.2009-0345\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1210%2Fjc.2009-0345\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1210%2Fjc.2009-0345\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/19509099\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Endocrine%20treatment%20of%20transsexual%20persons%3A%20an%20Endocrine%20Society%20clinical%20practice%20guideline&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B119\" class=\"js-splitview-ref-item\" data-legacy-id=\"B119\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B119\" href=\"javascript:;\" aria-label=\"jumplink-B119\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B119\" class=\"ref-content \" data-id=\"B119\"><span class=\"label\">119.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Mann</div>  <div class=\"given-names\">L</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Harmoni</div>  <div class=\"given-names\">R</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Power</div>  <div class=\"given-names\">C</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Adolescent decision-making: the development of competence</div>. <div class=\"source \">J Adolesc</div>. <div class=\"year\">1989</div>;<div class=\"volume\">12</div>(<div class=\"issue\">3</div>):<div class=\"fpage\">265</div>–<div class=\"lpage\">278</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Adolescent%20decision-making%3A%20the%20development%20of%20competence&amp;author=L%20Mann&amp;author=R%20Harmoni&amp;author=C%20Power&amp;publication_year=1989&amp;journal=J%20Adolesc&amp;volume=12&amp;pages=265-278\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1016/0140-1971(89)90077-8\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1016%2F0140-1971(89)90077-8\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1016%2F0140-1971(89)90077-8\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/2687339\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Adolescent%20decision-making%3A%20the%20development%20of%20competence&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B120\" class=\"js-splitview-ref-item\" data-legacy-id=\"B120\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B120\" href=\"javascript:;\" aria-label=\"jumplink-B120\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B120\" class=\"ref-content \" data-id=\"B120\"><span class=\"label\">120.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Stultiëns</div>  <div class=\"given-names\">L</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Goffin</div>  <div class=\"given-names\">T</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Borry</div>  <div class=\"given-names\">P</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Dierickx</div>  <div class=\"given-names\">K</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Nys</div>  <div class=\"given-names\">H</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Minors and informed consent: a comparative approach</div>. <div class=\"source \">Eur J Health Law</div>. <div class=\"year\">2007</div>;<div class=\"volume\">14</div>(<div class=\"issue\">1</div>):<div class=\"fpage\">21</div>–<div class=\"lpage\">46</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Minors%20and%20informed%20consent%3A%20a%20comparative%20approach&amp;author=L%20Stulti%C3%ABns&amp;author=T%20Goffin&amp;author=P%20Borry&amp;author=K%20Dierickx&amp;author=H%20Nys&amp;publication_year=2007&amp;journal=Eur%20J%20Health%20Law&amp;volume=14&amp;pages=21-46\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1163/092902707X182788\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1163%2F092902707X182788\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1163%2F092902707X182788\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/17566319\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Minors%20and%20informed%20consent%3A%20a%20comparative%20approach&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B121\" class=\"js-splitview-ref-item\" data-legacy-id=\"B121\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B121\" href=\"javascript:;\" aria-label=\"jumplink-B121\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B121\" class=\"ref-content \" data-id=\"B121\"><span class=\"label\">121.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">Arshagouni P. “But I’m an adult now … sort of”. Adolescent consent in health care decision-making and the adolescent brain. Available at: <a class=\"link link-uri openInAnotherWindow\" href=\"http://digitalcommons.law.umaryland.edu/cgi/viewcontent.cgi?article=1124&amp;context=jhclp\" target=\"_blank\">http://digitalcommons.law.umaryland.edu/cgi/viewcontent.cgi?article=1124&amp;context=jhclp</a>. Accessed 25 June 2017.</p></div></div></div></div><div content-id=\"B122\" class=\"js-splitview-ref-item\" data-legacy-id=\"B122\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B122\" href=\"javascript:;\" aria-label=\"jumplink-B122\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B122\" class=\"ref-content \" data-id=\"B122\"><span class=\"label\">122.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">NHS. Prescribing of cross-sex hormones as part of the gender identity development service for children and adolescents. Available at: <a class=\"link link-uri openInAnotherWindow\" href=\"https://www.england.nhs.uk/commissioning/wp-content/uploads/sites/12/2016/08/clinical-com-pol-16046p.pdf\" target=\"_blank\">https://www.england.nhs.uk/commissioning/wp-content/uploads/sites/12/2016/08/clinical-com-pol-16046p.pdf</a>. Accessed 14 June 2017.</p></div></div></div></div><div content-id=\"B123\" class=\"js-splitview-ref-item\" data-legacy-id=\"B123\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B123\" href=\"javascript:;\" aria-label=\"jumplink-B123\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B123\" class=\"ref-content \" data-id=\"B123\"><span class=\"label\">123.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Ankarberg-Lindgren</div>  <div class=\"given-names\">C</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Kriström</div>  <div class=\"given-names\">B</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Norjavaara</div>  <div class=\"given-names\">E</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Physiological estrogen replacement therapy for puberty induction in girls: a clinical observational study</div>. <div class=\"source \">Horm Res Paediatr</div>. <div class=\"year\">2014</div>;<div class=\"volume\">81</div>(<div class=\"issue\">4</div>):<div class=\"fpage\">239</div>–<div class=\"lpage\">244</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Physiological%20estrogen%20replacement%20therapy%20for%20puberty%20induction%20in%20girls%3A%20a%20clinical%20observational%20study&amp;author=C%20Ankarberg-Lindgren&amp;author=B%20Kristr%C3%B6m&amp;author=E%20Norjavaara&amp;publication_year=2014&amp;journal=Horm%20Res%20Paediatr&amp;volume=81&amp;pages=239-244\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1159/000356922\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1159%2F000356922\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1159%2F000356922\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/24503929\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Physiological%20estrogen%20replacement%20therapy%20for%20puberty%20induction%20in%20girls%3A%20a%20clinical%20observational%20study&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B124\" class=\"js-splitview-ref-item\" data-legacy-id=\"B124\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B124\" href=\"javascript:;\" aria-label=\"jumplink-B124\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B124\" class=\"ref-content \" data-id=\"B124\"><span class=\"label\">124.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Olson</div>  <div class=\"given-names\">J</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Schrager</div>  <div class=\"given-names\">SM</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Clark</div>  <div class=\"given-names\">LF</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Dunlap</div>  <div class=\"given-names\">SL</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Belzer</div>  <div class=\"given-names\">M</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Subcutaneous testosterone: an effective delivery mechanism for masculinizing young transgender men</div>. <div class=\"source \">LGBT Health</div>. <div class=\"year\">2014</div>;<div class=\"volume\">1</div>(<div class=\"issue\">3</div>):<div class=\"fpage\">165</div>–<div class=\"lpage\">167</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Subcutaneous%20testosterone%3A%20an%20effective%20delivery%20mechanism%20for%20masculinizing%20young%20transgender%20men&amp;author=J%20Olson&amp;author=SM%20Schrager&amp;author=LF%20Clark&amp;author=SL%20Dunlap&amp;author=M%20Belzer&amp;publication_year=2014&amp;journal=LGBT%20Health&amp;volume=1&amp;pages=165-167\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1089/lgbt.2014.0018\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1089%2Flgbt.2014.0018\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1089%2Flgbt.2014.0018\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/26789709\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Subcutaneous%20testosterone%3A%20an%20effective%20delivery%20mechanism%20for%20masculinizing%20young%20transgender%20men&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B125\" class=\"js-splitview-ref-item\" data-legacy-id=\"B125\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B125\" href=\"javascript:;\" aria-label=\"jumplink-B125\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B125\" class=\"ref-content \" data-id=\"B125\"><span class=\"label\">125.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Spratt</div>  <div class=\"given-names\">DI</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Stewart</div>  <div class=\"given-names\">I</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Savage</div>  <div class=\"given-names\">C</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Craig</div>  <div class=\"given-names\">W</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Spack</div>  <div class=\"given-names\">NP</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Chandler</div>  <div class=\"given-names\">DW</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Spratt</div>  <div class=\"given-names\">LV</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Eimicke</div>  <div class=\"given-names\">T</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Olshan</div>  <div class=\"given-names\">JS</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Subcutaneous injection of testosterone is an effective and preferred alternative to intramuscular injection: demonstration in female-to-male transgender patients</div>. <div class=\"source \">J Clin Endocrinol Metab</div>. <div class=\"year\">2017</div>. doi:10.1210/jc.2017-00359</p></div></div></div></div><div content-id=\"B126\" class=\"js-splitview-ref-item\" data-legacy-id=\"B126\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B126\" href=\"javascript:;\" aria-label=\"jumplink-B126\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B126\" class=\"ref-content \" data-id=\"B126\"><span class=\"label\">126.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Eisenegger</div>  <div class=\"given-names\">C</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">von Eckardstein</div>  <div class=\"given-names\">A</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Fehr</div>  <div class=\"given-names\">E</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">von Eckardstein</div>  <div class=\"given-names\">S</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Pharmacokinetics of testosterone and estradiol gel preparations in healthy young men</div>. <div class=\"source \">Psychoneuroendocrinology</div>. <div class=\"year\">2013</div>;<div class=\"volume\">38</div>(<div class=\"issue\">2</div>):<div class=\"fpage\">171</div>–<div class=\"lpage\">178</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Pharmacokinetics%20of%20testosterone%20and%20estradiol%20gel%20preparations%20in%20healthy%20young%20men&amp;author=C%20Eisenegger&amp;author=A%20von%20Eckardstein&amp;author=E%20Fehr&amp;author=S%20von%20Eckardstein&amp;publication_year=2013&amp;journal=Psychoneuroendocrinology&amp;volume=38&amp;pages=171-178\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1016/j.psyneuen.2012.05.018\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1016%2Fj.psyneuen.2012.05.018\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1016%2Fj.psyneuen.2012.05.018\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22721608\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Pharmacokinetics%20of%20testosterone%20and%20estradiol%20gel%20preparations%20in%20healthy%20young%20men&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B127\" class=\"js-splitview-ref-item\" data-legacy-id=\"B127\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B127\" href=\"javascript:;\" aria-label=\"jumplink-B127\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B127\" class=\"ref-content \" data-id=\"B127\"><span class=\"label\">127.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">de Ronde</div>  <div class=\"given-names\">W</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">ten Kulve</div>  <div class=\"given-names\">J</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Woerdeman</div>  <div class=\"given-names\">J</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Kaufman</div>  <div class=\"given-names\">J-M</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">de Jong</div>  <div class=\"given-names\">FH</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Effects of oestradiol on gonadotrophin levels in normal and castrated men</div>. <div class=\"source \">Clin Endocrinol (Oxf)</div>. <div class=\"year\">2009</div>;<div class=\"volume\">71</div>(<div class=\"issue\">6</div>):<div class=\"fpage\">874</div>–<div class=\"lpage\">879</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Effects%20of%20oestradiol%20on%20gonadotrophin%20levels%20in%20normal%20and%20castrated%20men&amp;author=W%20de%20Ronde&amp;author=J%20ten%20Kulve&amp;author=J%20Woerdeman&amp;author=J-M%20Kaufman&amp;author=FH%20de%20Jong&amp;publication_year=2009&amp;journal=Clin%20Endocrinol%20%28Oxf%29&amp;volume=71&amp;pages=874-879\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1111/cen.2009.71.issue-6\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1111%2Fcen.2009.71.issue-6\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1111%2Fcen.2009.71.issue-6\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/19320652\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Effects%20of%20oestradiol%20on%20gonadotrophin%20levels%20in%20normal%20and%20castrated%20men&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B128\" class=\"js-splitview-ref-item\" data-legacy-id=\"B128\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B128\" href=\"javascript:;\" aria-label=\"jumplink-B128\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B128\" class=\"ref-content \" data-id=\"B128\"><span class=\"label\">128.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<div class=\"comment\">Money J, Ehrhardt A. Man &amp; woman, boy &amp; girl: differentiation and dimorphism of gender identity from conception to maturity.</div> <div class=\"publisher-loc\">Baltimore, MD</div>: <div class=\"publisher-name\">Johns Hopkins University Press</div>; <div class=\"year\">1972</div>:<div class=\"fpage\">202</div>–<div class=\"lpage\">206</div>.</p></div></div></div></div><div content-id=\"B129\" class=\"js-splitview-ref-item\" data-legacy-id=\"B129\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B129\" href=\"javascript:;\" aria-label=\"jumplink-B129\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B129\" class=\"ref-content \" data-id=\"B129\"><span class=\"label\">129.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Heylens</div>  <div class=\"given-names\">G</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Verroken</div>  <div class=\"given-names\">C</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">De Cock</div>  <div class=\"given-names\">S</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">T’Sjoen</div>  <div class=\"given-names\">G</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">De Cuypere</div>  <div class=\"given-names\">G</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Effects of different steps in gender reassignment therapy on psychopathology: a prospective study of persons with a gender identity disorder</div>. <div class=\"source \">J Sex Med</div>. <div class=\"year\">2014</div>;<div class=\"volume\">11</div>(<div class=\"issue\">1</div>):<div class=\"fpage\">119</div>–<div class=\"lpage\">126</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Effects%20of%20different%20steps%20in%20gender%20reassignment%20therapy%20on%20psychopathology%3A%20a%20prospective%20study%20of%20persons%20with%20a%20gender%20identity%20disorder&amp;author=G%20Heylens&amp;author=C%20Verroken&amp;author=S%20De%20Cock&amp;author=G%20T%E2%80%99Sjoen&amp;author=G%20De%20Cuypere&amp;publication_year=2014&amp;journal=J%20Sex%20Med&amp;volume=11&amp;pages=119-126\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1111/jsm.12363\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1111%2Fjsm.12363\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1111%2Fjsm.12363\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/24344788\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Effects%20of%20different%20steps%20in%20gender%20reassignment%20therapy%20on%20psychopathology%3A%20a%20prospective%20study%20of%20persons%20with%20a%20gender%20identity%20disorder&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B130\" class=\"js-splitview-ref-item\" data-legacy-id=\"B130\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B130\" href=\"javascript:;\" aria-label=\"jumplink-B130\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B130\" class=\"ref-content \" data-id=\"B130\"><span class=\"label\">130.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Costa</div>  <div class=\"given-names\">R</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Colizzi</div>  <div class=\"given-names\">M</div>\r\n</span>\r\n</span>. <div class=\"article-title\">The effect of cross-sex hormonal treatment on gender dysphoria individuals’ mental health: a systematic review</div>. <div class=\"source \">Neuropsychiatr Dis Treat</div>. <div class=\"year\">2016</div>;<div class=\"volume\">12</div>:<div class=\"fpage\">1953</div>–<div class=\"lpage\">1966</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=The%20effect%20of%20cross-sex%20hormonal%20treatment%20on%20gender%20dysphoria%20individuals%E2%80%99%20mental%20health%3A%20a%20systematic%20review&amp;author=R%20Costa&amp;author=M%20Colizzi&amp;publication_year=2016&amp;journal=Neuropsychiatr%20Dis%20Treat&amp;volume=12&amp;pages=1953-1966\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.2147/NDT\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.2147%2FNDT\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.2147%2FNDT\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/27536118\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:The%20effect%20of%20cross-sex%20hormonal%20treatment%20on%20gender%20dysphoria%20individuals%E2%80%99%20mental%20health%3A%20a%20systematic%20review&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B131\" class=\"js-splitview-ref-item\" data-legacy-id=\"B131\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B131\" href=\"javascript:;\" aria-label=\"jumplink-B131\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B131\" class=\"ref-content \" data-id=\"B131\"><span class=\"label\">131.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Gooren</div>  <div class=\"given-names\">LJG</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Giltay</div>  <div class=\"given-names\">EJ</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Review of studies of androgen treatment of female-to-male transsexuals: effects and risks of administration of androgens to females</div>. <div class=\"source \">J Sex Med</div>. <div class=\"year\">2008</div>;<div class=\"volume\">5</div>(<div class=\"issue\">4</div>):<div class=\"fpage\">765</div>–<div class=\"lpage\">776</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Review%20of%20studies%20of%20androgen%20treatment%20of%20female-to-male%20transsexuals%3A%20effects%20and%20risks%20of%20administration%20of%20androgens%20to%20females&amp;author=LJG%20Gooren&amp;author=EJ%20Giltay&amp;publication_year=2008&amp;journal=J%20Sex%20Med&amp;volume=5&amp;pages=765-776\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1111/j.1743-6109.2007.00646.x\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1111%2Fj.1743-6109.2007.00646.x\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1111%2Fj.1743-6109.2007.00646.x\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/17971101\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Review%20of%20studies%20of%20androgen%20treatment%20of%20female-to-male%20transsexuals%3A%20effects%20and%20risks%20of%20administration%20of%20androgens%20to%20females&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B132\" class=\"js-splitview-ref-item\" data-legacy-id=\"B132\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B132\" href=\"javascript:;\" aria-label=\"jumplink-B132\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B132\" class=\"ref-content \" data-id=\"B132\"><span class=\"label\">132.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Levy</div>  <div class=\"given-names\">A</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Crown</div>  <div class=\"given-names\">A</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Reid</div>  <div class=\"given-names\">R</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Endocrine intervention for transsexuals</div>. <div class=\"source \">Clin Endocrinol (Oxf)</div>. <div class=\"year\">2003</div>;<div class=\"volume\">59</div>(<div class=\"issue\">4</div>):<div class=\"fpage\">409</div>–<div class=\"lpage\">418</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Endocrine%20intervention%20for%20transsexuals&amp;author=A%20Levy&amp;author=A%20Crown&amp;author=R%20Reid&amp;publication_year=2003&amp;journal=Clin%20Endocrinol%20%28Oxf%29&amp;volume=59&amp;pages=409-418\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1046/j.1365-2265.2003.01821.x\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1046%2Fj.1365-2265.2003.01821.x\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1046%2Fj.1365-2265.2003.01821.x\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/14510900\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Endocrine%20intervention%20for%20transsexuals&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B133\" class=\"js-splitview-ref-item\" data-legacy-id=\"B133\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B133\" href=\"javascript:;\" aria-label=\"jumplink-B133\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B133\" class=\"ref-content \" data-id=\"B133\"><span class=\"label\">133.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Tangpricha</div>  <div class=\"given-names\">V</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Ducharme</div>  <div class=\"given-names\">SH</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Barber</div>  <div class=\"given-names\">TW</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Chipkin</div>  <div class=\"given-names\">SR</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Endocrinologic treatment of gender identity disorders</div>. <div class=\"source \">Endocr Pract</div>. <div class=\"year\">2003</div>;<div class=\"volume\">9</div>(<div class=\"issue\">1</div>):<div class=\"fpage\">12</div>–<div class=\"lpage\">21</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Endocrinologic%20treatment%20of%20gender%20identity%20disorders&amp;author=V%20Tangpricha&amp;author=SH%20Ducharme&amp;author=TW%20Barber&amp;author=SR%20Chipkin&amp;publication_year=2003&amp;journal=Endocr%20Pract&amp;volume=9&amp;pages=12-21\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.4158/EP.9.1.12\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.4158%2FEP.9.1.12\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.4158%2FEP.9.1.12\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/12917087\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Endocrinologic%20treatment%20of%20gender%20identity%20disorders&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B134\" class=\"js-splitview-ref-item\" data-legacy-id=\"B134\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B134\" href=\"javascript:;\" aria-label=\"jumplink-B134\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B134\" class=\"ref-content \" data-id=\"B134\"><span class=\"label\">134.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Meriggiola</div>  <div class=\"given-names\">MC</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Gava</div>  <div class=\"given-names\">G</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Endocrine care of transpeople part I. A review of cross-sex hormonal treatments, outcomes and adverse effects in transmen</div>. <div class=\"source \">Clin Endocrinol (Oxf)</div>. <div class=\"year\">2015</div>;<div class=\"volume\">83</div>(<div class=\"issue\">5</div>):<div class=\"fpage\">597</div>–<div class=\"lpage\">606</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Endocrine%20care%20of%20transpeople%20part%20I.%20A%20review%20of%20cross-sex%20hormonal%20treatments%2C%20outcomes%20and%20adverse%20effects%20in%20transmen&amp;author=MC%20Meriggiola&amp;author=G%20Gava&amp;publication_year=2015&amp;journal=Clin%20Endocrinol%20%28Oxf%29&amp;volume=83&amp;pages=597-606\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1111/cen.2015.83.issue-5\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1111%2Fcen.2015.83.issue-5\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1111%2Fcen.2015.83.issue-5\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/25692791\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Endocrine%20care%20of%20transpeople%20part%20I.%20A%20review%20of%20cross-sex%20hormonal%20treatments%2C%20outcomes%20and%20adverse%20effects%20in%20transmen&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B135\" class=\"js-splitview-ref-item\" data-legacy-id=\"B135\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B135\" href=\"javascript:;\" aria-label=\"jumplink-B135\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B135\" class=\"ref-content \" data-id=\"B135\"><span class=\"label\">135.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Bhasin</div>  <div class=\"given-names\">S</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Cunningham</div>  <div class=\"given-names\">GR</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Hayes</div>  <div class=\"given-names\">FJ</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Matsumoto</div>  <div class=\"given-names\">AM</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Snyder</div>  <div class=\"given-names\">PJ</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Swerdloff</div>  <div class=\"given-names\">RS</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Montori</div>  <div class=\"given-names\">VM</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline</div>. <div class=\"source \">J Clin Endocrinol Metab</div>. <div class=\"year\">2006</div>;<div class=\"volume\">91</div>(<div class=\"issue\">6</div>):<div class=\"fpage\">1995</div>–<div class=\"lpage\">2010</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Testosterone%20therapy%20in%20adult%20men%20with%20androgen%20deficiency%20syndromes%3A%20an%20endocrine%20society%20clinical%20practice%20guideline&amp;author=S%20Bhasin&amp;author=GR%20Cunningham&amp;author=FJ%20Hayes&amp;author=AM%20Matsumoto&amp;author=PJ%20Snyder&amp;author=RS%20Swerdloff&amp;author=VM%20Montori&amp;publication_year=2006&amp;journal=J%20Clin%20Endocrinol%20Metab&amp;volume=91&amp;pages=1995-2010\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1210/jc.2005-2847\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1210%2Fjc.2005-2847\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1210%2Fjc.2005-2847\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/16720669\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Testosterone%20therapy%20in%20adult%20men%20with%20androgen%20deficiency%20syndromes%3A%20an%20endocrine%20society%20clinical%20practice%20guideline&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B136\" class=\"js-splitview-ref-item\" data-legacy-id=\"B136\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B136\" href=\"javascript:;\" aria-label=\"jumplink-B136\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B136\" class=\"ref-content \" data-id=\"B136\"><span class=\"label\">136.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Pelusi</div>  <div class=\"given-names\">C</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Costantino</div>  <div class=\"given-names\">A</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Martelli</div>  <div class=\"given-names\">V</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Lambertini</div>  <div class=\"given-names\">M</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Bazzocchi</div>  <div class=\"given-names\">A</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Ponti</div>  <div class=\"given-names\">F</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Battista</div>  <div class=\"given-names\">G</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Venturoli</div>  <div class=\"given-names\">S</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Meriggiola</div>  <div class=\"given-names\">MC</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Effects of three different testosterone formulations in female-to-male transsexual persons</div>. <div class=\"source \">J Sex Med</div>. <div class=\"year\">2014</div>;<div class=\"volume\">11</div>(<div class=\"issue\">12</div>):<div class=\"fpage\">3002</div>–<div class=\"lpage\">3011</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Effects%20of%20three%20different%20testosterone%20formulations%20in%20female-to-male%20transsexual%20persons&amp;author=C%20Pelusi&amp;author=A%20Costantino&amp;author=V%20Martelli&amp;author=M%20Lambertini&amp;author=A%20Bazzocchi&amp;author=F%20Ponti&amp;author=G%20Battista&amp;author=S%20Venturoli&amp;author=MC%20Meriggiola&amp;publication_year=2014&amp;journal=J%20Sex%20Med&amp;volume=11&amp;pages=3002-3011\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1111/jsm.12698\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1111%2Fjsm.12698\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1111%2Fjsm.12698\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/25250780\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Effects%20of%20three%20different%20testosterone%20formulations%20in%20female-to-male%20transsexual%20persons&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B137\" class=\"js-splitview-ref-item\" data-legacy-id=\"B137\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B137\" href=\"javascript:;\" aria-label=\"jumplink-B137\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B137\" class=\"ref-content \" data-id=\"B137\"><span class=\"label\">137.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Anderson</div>  <div class=\"given-names\">GL</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Limacher</div>  <div class=\"given-names\">M</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Assaf</div>  <div class=\"given-names\">AR</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Bassford</div>  <div class=\"given-names\">T</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Beresford</div>  <div class=\"given-names\">SA</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Black</div>  <div class=\"given-names\">H</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Bonds</div>  <div class=\"given-names\">D</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Brunner</div>  <div class=\"given-names\">R</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Brzyski</div>  <div class=\"given-names\">R</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Caan</div>  <div class=\"given-names\">B</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Chlebowski</div>  <div class=\"given-names\">R</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Curb</div>  <div class=\"given-names\">D</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Gass</div>  <div class=\"given-names\">M</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Hays</div>  <div class=\"given-names\">J</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Heiss</div>  <div class=\"given-names\">G</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Hendrix</div>  <div class=\"given-names\">S</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Howard</div>  <div class=\"given-names\">BV</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Hsia</div>  <div class=\"given-names\">J</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Hubbell</div>  <div class=\"given-names\">A</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Jackson</div>  <div class=\"given-names\">R</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Johnson</div>  <div class=\"given-names\">KC</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Judd</div>  <div class=\"given-names\">H</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Kotchen</div>  <div class=\"given-names\">JM</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Kuller</div>  <div class=\"given-names\">L</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">LaCroix</div>  <div class=\"given-names\">AZ</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Lane</div>  <div class=\"given-names\">D</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Langer</div>  <div class=\"given-names\">RD</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Lasser</div>  <div class=\"given-names\">N</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Lewis</div>  <div class=\"given-names\">CE</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Manson</div>  <div class=\"given-names\">J</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Margolis</div>  <div class=\"given-names\">K</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Ockene</div>  <div class=\"given-names\">J</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">O’Sullivan</div>  <div class=\"given-names\">MJ</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Phillips</div>  <div class=\"given-names\">L</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Prentice</div>  <div class=\"given-names\">RL</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Ritenbaugh</div>  <div class=\"given-names\">C</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Robbins</div>  <div class=\"given-names\">J</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Rossouw</div>  <div class=\"given-names\">JE</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Sarto</div>  <div class=\"given-names\">G</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Stefanick</div>  <div class=\"given-names\">ML</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Van Horn</div>  <div class=\"given-names\">L</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Wactawski-Wende</div>  <div class=\"given-names\">J</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Wallace</div>  <div class=\"given-names\">R</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Wassertheil-Smoller</div>  <div class=\"given-names\">S</div>\r\n</span>; <div class=\"collab\">Women’s Health Initiative Steering Committee</div>\r\n</span>. <div class=\"article-title\">Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial</div>. <div class=\"source \">JAMA</div>. <div class=\"year\">2004</div>;<div class=\"volume\">291</div>(<div class=\"issue\">14</div>):<div class=\"fpage\">1701</div>–<div class=\"lpage\">1712</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Effects%20of%20conjugated%20equine%20estrogen%20in%20postmenopausal%20women%20with%20hysterectomy%3A%20the%20Women%E2%80%99s%20Health%20Initiative%20randomized%20controlled%20trial&amp;author=GL%20Anderson&amp;author=M%20Limacher&amp;author=AR%20Assaf&amp;author=T%20Bassford&amp;author=SA%20Beresford&amp;author=H%20Black&amp;author=D%20Bonds&amp;author=R%20Brunner&amp;author=R%20Brzyski&amp;author=B%20Caan&amp;author=R%20Chlebowski&amp;author=D%20Curb&amp;author=M%20Gass&amp;author=J%20Hays&amp;author=G%20Heiss&amp;author=S%20Hendrix&amp;author=BV%20Howard&amp;author=J%20Hsia&amp;author=A%20Hubbell&amp;author=R%20Jackson&amp;author=KC%20Johnson&amp;author=H%20Judd&amp;author=JM%20Kotchen&amp;author=L%20Kuller&amp;author=AZ%20LaCroix&amp;author=D%20Lane&amp;author=RD%20Langer&amp;author=N%20Lasser&amp;author=CE%20Lewis&amp;author=J%20Manson&amp;author=K%20Margolis&amp;author=J%20Ockene&amp;author=MJ%20O%E2%80%99Sullivan&amp;author=L%20Phillips&amp;author=RL%20Prentice&amp;author=C%20Ritenbaugh&amp;author=J%20Robbins&amp;author=JE%20Rossouw&amp;author=G%20Sarto&amp;author=ML%20Stefanick&amp;author=L%20Van%20Horn&amp;author=J%20Wactawski-Wende&amp;author=R%20Wallace&amp;author=S%20Wassertheil-Smoller&amp;publication_year=2004&amp;journal=JAMA&amp;volume=291&amp;pages=1701-1712\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1001/jama.291.14.1775\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1001%2Fjama.291.14.1775\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1001%2Fjama.291.14.1775\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/15082697\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Effects%20of%20conjugated%20equine%20estrogen%20in%20postmenopausal%20women%20with%20hysterectomy%3A%20the%20Women%E2%80%99s%20Health%20Initiative%20randomized%20controlled%20trial&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B138\" class=\"js-splitview-ref-item\" data-legacy-id=\"B138\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B138\" href=\"javascript:;\" aria-label=\"jumplink-B138\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B138\" class=\"ref-content \" data-id=\"B138\"><span class=\"label\">138.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Dickersin</div>  <div class=\"given-names\">K</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Munro</div>  <div class=\"given-names\">MG</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Clark</div>  <div class=\"given-names\">M</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Langenberg</div>  <div class=\"given-names\">P</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Scherer</div>  <div class=\"given-names\">R</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Frick</div>  <div class=\"given-names\">K</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Zhu</div>  <div class=\"given-names\">Q</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Hallock</div>  <div class=\"given-names\">L</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Nichols</div>  <div class=\"given-names\">J</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Yalcinkaya</div>  <div class=\"given-names\">TM</div>\r\n</span>; <div class=\"collab\">Surgical Treatments Outcomes Project for Dysfunctional Uterine Bleeding (STOP-DUB) Research Group</div>\r\n</span>. <div class=\"article-title\">Hysterectomy compared with endometrial ablation for dysfunctional uterine bleeding: a randomized controlled trial</div>. <div class=\"source \">Obstet Gynecol</div>. <div class=\"year\">2007</div>;<div class=\"volume\">110</div>(<div class=\"issue\">6</div>):<div class=\"fpage\">1279</div>–<div class=\"lpage\">1289</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Hysterectomy%20compared%20with%20endometrial%20ablation%20for%20dysfunctional%20uterine%20bleeding%3A%20a%20randomized%20controlled%20trial&amp;author=K%20Dickersin&amp;author=MG%20Munro&amp;author=M%20Clark&amp;author=P%20Langenberg&amp;author=R%20Scherer&amp;author=K%20Frick&amp;author=Q%20Zhu&amp;author=L%20Hallock&amp;author=J%20Nichols&amp;author=TM%20Yalcinkaya&amp;publication_year=2007&amp;journal=Obstet%20Gynecol&amp;volume=110&amp;pages=1279-1289\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1097/01.AOG.0000292083.97478.38\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1097%2F01.AOG.0000292083.97478.38\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1097%2F01.AOG.0000292083.97478.38\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/18055721\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Hysterectomy%20compared%20with%20endometrial%20ablation%20for%20dysfunctional%20uterine%20bleeding%3A%20a%20randomized%20controlled%20trial&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B139\" class=\"js-splitview-ref-item\" data-legacy-id=\"B139\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B139\" href=\"javascript:;\" aria-label=\"jumplink-B139\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B139\" class=\"ref-content \" data-id=\"B139\"><span class=\"label\">139.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Gooren</div>  <div class=\"given-names\">LJ</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Giltay</div>  <div class=\"given-names\">EJ</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Bunck</div>  <div class=\"given-names\">MC</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Long-term treatment of transsexuals with cross-sex hormones: extensive personal experience</div>. <div class=\"source \">J Clin Endocrinol Metab</div>. <div class=\"year\">2008</div>;<div class=\"volume\">93</div>(<div class=\"issue\">1</div>):<div class=\"fpage\">19</div>–<div class=\"lpage\">25</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Long-term%20treatment%20of%20transsexuals%20with%20cross-sex%20hormones%3A%20extensive%20personal%20experience&amp;author=LJ%20Gooren&amp;author=EJ%20Giltay&amp;author=MC%20Bunck&amp;publication_year=2008&amp;journal=J%20Clin%20Endocrinol%20Metab&amp;volume=93&amp;pages=19-25\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1210/jc.2007-1809\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1210%2Fjc.2007-1809\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1210%2Fjc.2007-1809\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/17986639\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Long-term%20treatment%20of%20transsexuals%20with%20cross-sex%20hormones%3A%20extensive%20personal%20experience&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B140\" class=\"js-splitview-ref-item\" data-legacy-id=\"B140\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B140\" href=\"javascript:;\" aria-label=\"jumplink-B140\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B140\" class=\"ref-content \" data-id=\"B140\"><span class=\"label\">140.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Prior</div>  <div class=\"given-names\">JC</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Vigna</div>  <div class=\"given-names\">YM</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Watson</div>  <div class=\"given-names\">D</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Spironolactone with physiological female steroids for presurgical therapy of male-to-female transsexualism</div>. <div class=\"source \">Arch Sex Behav</div>. <div class=\"year\">1989</div>;<div class=\"volume\">18</div>(<div class=\"issue\">1</div>):<div class=\"fpage\">49</div>–<div class=\"lpage\">57</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Spironolactone%20with%20physiological%20female%20steroids%20for%20presurgical%20therapy%20of%20male-to-female%20transsexualism&amp;author=JC%20Prior&amp;author=YM%20Vigna&amp;author=D%20Watson&amp;publication_year=1989&amp;journal=Arch%20Sex%20Behav&amp;volume=18&amp;pages=49-57\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1007/BF01579291\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1007%2FBF01579291\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1007%2FBF01579291\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/2540730\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Spironolactone%20with%20physiological%20female%20steroids%20for%20presurgical%20therapy%20of%20male-to-female%20transsexualism&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B141\" class=\"js-splitview-ref-item\" data-legacy-id=\"B141\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B141\" href=\"javascript:;\" aria-label=\"jumplink-B141\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B141\" class=\"ref-content \" data-id=\"B141\"><span class=\"label\">141.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Dittrich</div>  <div class=\"given-names\">R</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Binder</div>  <div class=\"given-names\">H</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Cupisti</div>  <div class=\"given-names\">S</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Hoffmann</div>  <div class=\"given-names\">I</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Beckmann</div>  <div class=\"given-names\">MW</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Mueller</div>  <div class=\"given-names\">A</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Endocrine treatment of male-to-female transsexuals using gonadotropin-releasing hormone agonist</div>. <div class=\"source \">Exp Clin Endocrinol Diabetes</div>. <div class=\"year\">2005</div>;<div class=\"volume\">113</div>(<div class=\"issue\">10</div>):<div class=\"fpage\">586</div>–<div class=\"lpage\">592</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Endocrine%20treatment%20of%20male-to-female%20transsexuals%20using%20gonadotropin-releasing%20hormone%20agonist&amp;author=R%20Dittrich&amp;author=H%20Binder&amp;author=S%20Cupisti&amp;author=I%20Hoffmann&amp;author=MW%20Beckmann&amp;author=A%20Mueller&amp;publication_year=2005&amp;journal=Exp%20Clin%20Endocrinol%20Diabetes&amp;volume=113&amp;pages=586-592\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1055/s-2005-865900\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1055%2Fs-2005-865900\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1055%2Fs-2005-865900\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/16320157\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Endocrine%20treatment%20of%20male-to-female%20transsexuals%20using%20gonadotropin-releasing%20hormone%20agonist&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B142\" class=\"js-splitview-ref-item\" data-legacy-id=\"B142\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B142\" href=\"javascript:;\" aria-label=\"jumplink-B142\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B142\" class=\"ref-content \" data-id=\"B142\"><span class=\"label\">142.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Stripp</div>  <div class=\"given-names\">B</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Taylor</div>  <div class=\"given-names\">AA</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Bartter</div>  <div class=\"given-names\">FC</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Gillette</div>  <div class=\"given-names\">JR</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Loriaux</div>  <div class=\"given-names\">DL</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Easley</div>  <div class=\"given-names\">R</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Menard</div>  <div class=\"given-names\">RH</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Effect of spironolactone on sex hormones in man</div>. <div class=\"source \">J Clin Endocrinol Metab</div>. <div class=\"year\">1975</div>;<div class=\"volume\">41</div>(<div class=\"issue\">4</div>):<div class=\"fpage\">777</div>–<div class=\"lpage\">781</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Effect%20of%20spironolactone%20on%20sex%20hormones%20in%20man&amp;author=B%20Stripp&amp;author=AA%20Taylor&amp;author=FC%20Bartter&amp;author=JR%20Gillette&amp;author=DL%20Loriaux&amp;author=R%20Easley&amp;author=RH%20Menard&amp;publication_year=1975&amp;journal=J%20Clin%20Endocrinol%20Metab&amp;volume=41&amp;pages=777-781\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1210/jcem-41-4-777\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1210%2Fjcem-41-4-777\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1210%2Fjcem-41-4-777\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/1176584\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Effect%20of%20spironolactone%20on%20sex%20hormones%20in%20man&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B143\" class=\"js-splitview-ref-item\" data-legacy-id=\"B143\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B143\" href=\"javascript:;\" aria-label=\"jumplink-B143\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B143\" class=\"ref-content \" data-id=\"B143\"><span class=\"label\">143.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Levy</div>  <div class=\"given-names\">J</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Burshell</div>  <div class=\"given-names\">A</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Marbach</div>  <div class=\"given-names\">M</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Afllalo</div>  <div class=\"given-names\">L</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Glick</div>  <div class=\"given-names\">SM</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Interaction of spironolactone with oestradiol receptors in cytosol</div>. <div class=\"source \">J Endocrinol</div>. <div class=\"year\">1980</div>;<div class=\"volume\">84</div>(<div class=\"issue\">3</div>):<div class=\"fpage\">371</div>–<div class=\"lpage\">379</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Interaction%20of%20spironolactone%20with%20oestradiol%20receptors%20in%20cytosol&amp;author=J%20Levy&amp;author=A%20Burshell&amp;author=M%20Marbach&amp;author=L%20Afllalo&amp;author=SM%20Glick&amp;publication_year=1980&amp;journal=J%20Endocrinol&amp;volume=84&amp;pages=371-379\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1677/joe.0.0840371\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1677%2Fjoe.0.0840371\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1677%2Fjoe.0.0840371\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/7391714\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Interaction%20of%20spironolactone%20with%20oestradiol%20receptors%20in%20cytosol&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B144\" class=\"js-splitview-ref-item\" data-legacy-id=\"B144\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B144\" href=\"javascript:;\" aria-label=\"jumplink-B144\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B144\" class=\"ref-content \" data-id=\"B144\"><span class=\"label\">144.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Wierckx</div>  <div class=\"given-names\">K</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Elaut</div>  <div class=\"given-names\">E</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Van Hoorde</div>  <div class=\"given-names\">B</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Heylens</div>  <div class=\"given-names\">G</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">De Cuypere</div>  <div class=\"given-names\">G</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Monstrey</div>  <div class=\"given-names\">S</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Weyers</div>  <div class=\"given-names\">S</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Hoebeke</div>  <div class=\"given-names\">P</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">T’Sjoen</div>  <div class=\"given-names\">G</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Sexual desire in trans persons: associations with sex reassignment treatment</div>. <div class=\"source \">J Sex Med</div>. <div class=\"year\">2014</div>;<div class=\"volume\">11</div>(<div class=\"issue\">1</div>):<div class=\"fpage\">107</div>–<div class=\"lpage\">118</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Sexual%20desire%20in%20trans%20persons%3A%20associations%20with%20sex%20reassignment%20treatment&amp;author=K%20Wierckx&amp;author=E%20Elaut&amp;author=B%20Van%20Hoorde&amp;author=G%20Heylens&amp;author=G%20De%20Cuypere&amp;author=S%20Monstrey&amp;author=S%20Weyers&amp;author=P%20Hoebeke&amp;author=G%20T%E2%80%99Sjoen&amp;publication_year=2014&amp;journal=J%20Sex%20Med&amp;volume=11&amp;pages=107-118\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1111/jsm.12365\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1111%2Fjsm.12365\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1111%2Fjsm.12365\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/24165564\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Sexual%20desire%20in%20trans%20persons%3A%20associations%20with%20sex%20reassignment%20treatment&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B145\" class=\"js-splitview-ref-item\" data-legacy-id=\"B145\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B145\" href=\"javascript:;\" aria-label=\"jumplink-B145\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B145\" class=\"ref-content \" data-id=\"B145\"><span class=\"label\">145.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Chiriacò</div>  <div class=\"given-names\">G</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Cauci</div>  <div class=\"given-names\">S</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Mazzon</div>  <div class=\"given-names\">G</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Trombetta</div>  <div class=\"given-names\">C</div>\r\n</span>\r\n</span>. <div class=\"article-title\">An observational retrospective evaluation of 79 young men with long-term adverse effects after use of finasteride against androgenetic alopecia</div>. <div class=\"source \">Andrology</div>. <div class=\"year\">2016</div>;<div class=\"volume\">4</div>(<div class=\"issue\">2</div>):<div class=\"fpage\">245</div>–<div class=\"lpage\">250</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=An%20observational%20retrospective%20evaluation%20of%2079%20young%20men%20with%20long-term%20adverse%20effects%20after%20use%20of%20finasteride%20against%20androgenetic%20alopecia&amp;author=G%20Chiriac%C3%B2&amp;author=S%20Cauci&amp;author=G%20Mazzon&amp;author=C%20Trombetta&amp;publication_year=2016&amp;journal=Andrology&amp;volume=4&amp;pages=245-250\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1111/andr.2016.4.issue-2\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1111%2Fandr.2016.4.issue-2\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1111%2Fandr.2016.4.issue-2\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/26763726\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:An%20observational%20retrospective%20evaluation%20of%2079%20young%20men%20with%20long-term%20adverse%20effects%20after%20use%20of%20finasteride%20against%20androgenetic%20alopecia&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B146\" class=\"js-splitview-ref-item\" data-legacy-id=\"B146\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B146\" href=\"javascript:;\" aria-label=\"jumplink-B146\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B146\" class=\"ref-content \" data-id=\"B146\"><span class=\"label\">146.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Gava</div>  <div class=\"given-names\">G</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Cerpolini</div>  <div class=\"given-names\">S</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Martelli</div>  <div class=\"given-names\">V</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Battista</div>  <div class=\"given-names\">G</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Seracchioli</div>  <div class=\"given-names\">R</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Meriggiola</div>  <div class=\"given-names\">MC</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Cyproterone acetate vs leuprolide acetate in combination with transdermal oestradiol in transwomen: a comparison of safety and effectiveness</div>. <div class=\"source \">Clin Endocrinol (Oxf)</div>. <div class=\"year\">2016</div>;<div class=\"volume\">85</div>(<div class=\"issue\">2</div>):<div class=\"fpage\">239</div>–<div class=\"lpage\">246</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Cyproterone%20acetate%20vs%20leuprolide%20acetate%20in%20combination%20with%20transdermal%20oestradiol%20in%20transwomen%3A%20a%20comparison%20of%20safety%20and%20effectiveness&amp;author=G%20Gava&amp;author=S%20Cerpolini&amp;author=V%20Martelli&amp;author=G%20Battista&amp;author=R%20Seracchioli&amp;author=MC%20Meriggiola&amp;publication_year=2016&amp;journal=Clin%20Endocrinol%20%28Oxf%29&amp;volume=85&amp;pages=239-246\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1111/cen.13050\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1111%2Fcen.13050\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1111%2Fcen.13050\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/26932202\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Cyproterone%20acetate%20vs%20leuprolide%20acetate%20in%20combination%20with%20transdermal%20oestradiol%20in%20transwomen%3A%20a%20comparison%20of%20safety%20and%20effectiveness&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B147\" class=\"js-splitview-ref-item\" data-legacy-id=\"B147\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B147\" href=\"javascript:;\" aria-label=\"jumplink-B147\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B147\" class=\"ref-content \" data-id=\"B147\"><span class=\"label\">147.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Casper</div>  <div class=\"given-names\">RF</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Yen</div>  <div class=\"given-names\">SS</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Rapid absorption of micronized estradiol-17 beta following sublingual administration</div>. <div class=\"source \">Obstet Gynecol</div>. <div class=\"year\">1981</div>;<div class=\"volume\">57</div>(<div class=\"issue\">1</div>):<div class=\"fpage\">62</div>–<div class=\"lpage\">64</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Rapid%20absorption%20of%20micronized%20estradiol-17%20beta%20following%20sublingual%20administration&amp;author=RF%20Casper&amp;author=SS%20Yen&amp;publication_year=1981&amp;journal=Obstet%20Gynecol&amp;volume=57&amp;pages=62-64\" target=\"_blank\">Google Scholar</a></span></p><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/7454177\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><div class=\"xslopenurl empty-target\"><span class=\"js-inst-open-url-holders-nodoi\"><a class=\"js-open-url-link\" data-href-template=\"{targetURL}?sid=oup:orr&amp;genre=article&amp;atitle=Rapid+absorption+of+micronized+estradiol-17+beta+following+sublingual+administration&amp;aulast=Casper&amp;title=Obstet+Gynecol&amp;date=1981&amp;spage=62&amp;epage=64&amp;volume=57&amp;issue=1\" href=\"javascript:;\"><span class=\"screenreader-text\">OpenURL Placeholder Text</span></a></span></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Rapid%20absorption%20of%20micronized%20estradiol-17%20beta%20following%20sublingual%20administration&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B148\" class=\"js-splitview-ref-item\" data-legacy-id=\"B148\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B148\" href=\"javascript:;\" aria-label=\"jumplink-B148\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B148\" class=\"ref-content \" data-id=\"B148\"><span class=\"label\">148.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Price</div>  <div class=\"given-names\">TM</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Blauer</div>  <div class=\"given-names\">KL</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Hansen</div>  <div class=\"given-names\">M</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Stanczyk</div>  <div class=\"given-names\">F</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Lobo</div>  <div class=\"given-names\">R</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Bates</div>  <div class=\"given-names\">GW</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Single-dose pharmacokinetics of sublingual versus oral administration of micronized 17β-estradiol</div>. <div class=\"source \">Obstet Gynecol</div>. <div class=\"year\">1997</div>;<div class=\"volume\">89</div>(<div class=\"issue\">3</div>):<div class=\"fpage\">340</div>–<div class=\"lpage\">345</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Single-dose%20pharmacokinetics%20of%20sublingual%20versus%20oral%20administration%20of%20micronized%2017%CE%B2-estradiol&amp;author=TM%20Price&amp;author=KL%20Blauer&amp;author=M%20Hansen&amp;author=F%20Stanczyk&amp;author=R%20Lobo&amp;author=GW%20Bates&amp;publication_year=1997&amp;journal=Obstet%20Gynecol&amp;volume=89&amp;pages=340-345\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1016/S0029-7844(96)00513-3\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1016%2FS0029-7844(96)00513-3\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1016%2FS0029-7844(96)00513-3\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/9052581\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Single-dose%20pharmacokinetics%20of%20sublingual%20versus%20oral%20administration%20of%20micronized%2017%CE%B2-estradiol&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B149\" class=\"js-splitview-ref-item\" data-legacy-id=\"B149\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B149\" href=\"javascript:;\" aria-label=\"jumplink-B149\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B149\" class=\"ref-content \" data-id=\"B149\"><span class=\"label\">149.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Toorians</div>  <div class=\"given-names\">AWFT</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Thomassen</div>  <div class=\"given-names\">MCLGD</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Zweegman</div>  <div class=\"given-names\">S</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Magdeleyns</div>  <div class=\"given-names\">EJP</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Tans</div>  <div class=\"given-names\">G</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Gooren</div>  <div class=\"given-names\">LJG</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Rosing</div>  <div class=\"given-names\">J</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Venous thrombosis and changes of hemostatic variables during cross-sex hormone treatment in transsexual people</div>. <div class=\"source \">J Clin Endocrinol Metab</div>. <div class=\"year\">2003</div>;<div class=\"volume\">88</div>(<div class=\"issue\">12</div>):<div class=\"fpage\">5723</div>–<div class=\"lpage\">5729</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Venous%20thrombosis%20and%20changes%20of%20hemostatic%20variables%20during%20cross-sex%20hormone%20treatment%20in%20transsexual%20people&amp;author=AWFT%20Toorians&amp;author=MCLGD%20Thomassen&amp;author=S%20Zweegman&amp;author=EJP%20Magdeleyns&amp;author=G%20Tans&amp;author=LJG%20Gooren&amp;author=J%20Rosing&amp;publication_year=2003&amp;journal=J%20Clin%20Endocrinol%20Metab&amp;volume=88&amp;pages=5723-5729\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1210/jc.2003-030520\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1210%2Fjc.2003-030520\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1210%2Fjc.2003-030520\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/14671159\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Venous%20thrombosis%20and%20changes%20of%20hemostatic%20variables%20during%20cross-sex%20hormone%20treatment%20in%20transsexual%20people&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B150\" class=\"js-splitview-ref-item\" data-legacy-id=\"B150\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B150\" href=\"javascript:;\" aria-label=\"jumplink-B150\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B150\" class=\"ref-content \" data-id=\"B150\"><span class=\"label\">150.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Mepham</div>  <div class=\"given-names\">N</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Bouman</div>  <div class=\"given-names\">WP</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Arcelus</div>  <div class=\"given-names\">J</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Hayter</div>  <div class=\"given-names\">M</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Wylie</div>  <div class=\"given-names\">KR</div>\r\n</span>\r\n</span>. <div class=\"article-title\">People with gender dysphoria who self-prescribe cross-sex hormones: prevalence, sources, and side effects knowledge</div>. <div class=\"source \">J Sex Med</div>. <div class=\"year\">2014</div>;<div class=\"volume\">11</div>(<div class=\"issue\">12</div>):<div class=\"fpage\">2995</div>–<div class=\"lpage\">3001</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=People%20with%20gender%20dysphoria%20who%20self-prescribe%20cross-sex%20hormones%3A%20prevalence%2C%20sources%2C%20and%20side%20effects%20knowledge&amp;author=N%20Mepham&amp;author=WP%20Bouman&amp;author=J%20Arcelus&amp;author=M%20Hayter&amp;author=KR%20Wylie&amp;publication_year=2014&amp;journal=J%20Sex%20Med&amp;volume=11&amp;pages=2995-3001\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1111/jsm.12691\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1111%2Fjsm.12691\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1111%2Fjsm.12691\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/25213018\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:People%20with%20gender%20dysphoria%20who%20self-prescribe%20cross-sex%20hormones%3A%20prevalence%2C%20sources%2C%20and%20side%20effects%20knowledge&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B151\" class=\"js-splitview-ref-item\" data-legacy-id=\"B151\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B151\" href=\"javascript:;\" aria-label=\"jumplink-B151\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B151\" class=\"ref-content \" data-id=\"B151\"><span class=\"label\">151.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Richards</div>  <div class=\"given-names\">C</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Bouman</div>  <div class=\"given-names\">WP</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Seal</div>  <div class=\"given-names\">L</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Barker</div>  <div class=\"given-names\">MJ</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Nieder</div>  <div class=\"given-names\">TO</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">T’Sjoen</div>  <div class=\"given-names\">G</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Non-binary or genderqueer genders</div>. <div class=\"source \">Int Rev Psychiatry</div>. <div class=\"year\">2016</div>;<div class=\"volume\">28</div>(<div class=\"issue\">1</div>):<div class=\"fpage\">95</div>–<div class=\"lpage\">102</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Non-binary%20or%20genderqueer%20genders&amp;author=C%20Richards&amp;author=WP%20Bouman&amp;author=L%20Seal&amp;author=MJ%20Barker&amp;author=TO%20Nieder&amp;author=G%20T%E2%80%99Sjoen&amp;publication_year=2016&amp;journal=Int%20Rev%20Psychiatry&amp;volume=28&amp;pages=95-102\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.3109/09540261.2015.1106446\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.3109%2F09540261.2015.1106446\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.3109%2F09540261.2015.1106446\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/26753630\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Non-binary%20or%20genderqueer%20genders&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B152\" class=\"js-splitview-ref-item\" data-legacy-id=\"B152\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B152\" href=\"javascript:;\" aria-label=\"jumplink-B152\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B152\" class=\"ref-content \" data-id=\"B152\"><span class=\"label\">152.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Cosyns</div>  <div class=\"given-names\">M</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Van Borsel</div>  <div class=\"given-names\">J</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Wierckx</div>  <div class=\"given-names\">K</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Dedecker</div>  <div class=\"given-names\">D</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Van de Peer</div>  <div class=\"given-names\">F</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Daelman</div>  <div class=\"given-names\">T</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Laenen</div>  <div class=\"given-names\">S</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">T’Sjoen</div>  <div class=\"given-names\">G</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Voice in female-to-male transsexual persons after long-term androgen therapy</div>. <div class=\"source \">Laryngoscope</div>. <div class=\"year\">2014</div>;<div class=\"volume\">124</div>(<div class=\"issue\">6</div>):<div class=\"fpage\">1409</div>–<div class=\"lpage\">1414</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Voice%20in%20female-to-male%20transsexual%20persons%20after%20long-term%20androgen%20therapy&amp;author=M%20Cosyns&amp;author=J%20Van%20Borsel&amp;author=K%20Wierckx&amp;author=D%20Dedecker&amp;author=F%20Van%20de%20Peer&amp;author=T%20Daelman&amp;author=S%20Laenen&amp;author=G%20T%E2%80%99Sjoen&amp;publication_year=2014&amp;journal=Laryngoscope&amp;volume=124&amp;pages=1409-1414\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1002/lary.v124.6\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1002%2Flary.v124.6\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1002%2Flary.v124.6\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/24155064\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Voice%20in%20female-to-male%20transsexual%20persons%20after%20long-term%20androgen%20therapy&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B153\" class=\"js-splitview-ref-item\" data-legacy-id=\"B153\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B153\" href=\"javascript:;\" aria-label=\"jumplink-B153\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B153\" class=\"ref-content \" data-id=\"B153\"><span class=\"label\">153.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Deuster</div>  <div class=\"given-names\">D</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Matulat</div>  <div class=\"given-names\">P</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Knief</div>  <div class=\"given-names\">A</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Zitzmann</div>  <div class=\"given-names\">M</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Rosslau</div>  <div class=\"given-names\">K</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Szukaj</div>  <div class=\"given-names\">M</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">am Zehnhoff-Dinnesen</div>  <div class=\"given-names\">A</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Schmidt</div>  <div class=\"given-names\">CM</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Voice deepening under testosterone treatment in female-to-male gender dysphoric individuals</div>. <div class=\"source \">Eur Arch Otorhinolaryngol</div>. <div class=\"year\">2016</div>;<div class=\"volume\">273</div>(<div class=\"issue\">4</div>):<div class=\"fpage\">959</div>–<div class=\"lpage\">965</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Voice%20deepening%20under%20testosterone%20treatment%20in%20female-to-male%20gender%20dysphoric%20individuals&amp;author=D%20Deuster&amp;author=P%20Matulat&amp;author=A%20Knief&amp;author=M%20Zitzmann&amp;author=K%20Rosslau&amp;author=M%20Szukaj&amp;author=A%20am%20Zehnhoff-Dinnesen&amp;author=CM%20Schmidt&amp;publication_year=2016&amp;journal=Eur%20Arch%20Otorhinolaryngol&amp;volume=273&amp;pages=959-965\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1007/s00405-015-3846-8\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1007%2Fs00405-015-3846-8\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1007%2Fs00405-015-3846-8\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/26650551\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Voice%20deepening%20under%20testosterone%20treatment%20in%20female-to-male%20gender%20dysphoric%20individuals&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B154\" class=\"js-splitview-ref-item\" data-legacy-id=\"B154\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B154\" href=\"javascript:;\" aria-label=\"jumplink-B154\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B154\" class=\"ref-content \" data-id=\"B154\"><span class=\"label\">154.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Lapauw</div>  <div class=\"given-names\">B</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Taes</div>  <div class=\"given-names\">Y</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Simoens</div>  <div class=\"given-names\">S</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Van Caenegem</div>  <div class=\"given-names\">E</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Weyers</div>  <div class=\"given-names\">S</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Goemaere</div>  <div class=\"given-names\">S</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Toye</div>  <div class=\"given-names\">K</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Kaufman</div>  <div class=\"given-names\">J-M</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">T’Sjoen</div>  <div class=\"given-names\">GG</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Body composition, volumetric and areal bone parameters in male-to-female transsexual persons</div>. <div class=\"source \">Bone</div>. <div class=\"year\">2008</div>;<div class=\"volume\">43</div>(<div class=\"issue\">6</div>):<div class=\"fpage\">1016</div>–<div class=\"lpage\">1021</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Body%20composition%2C%20volumetric%20and%20areal%20bone%20parameters%20in%20male-to-female%20transsexual%20persons&amp;author=B%20Lapauw&amp;author=Y%20Taes&amp;author=S%20Simoens&amp;author=E%20Van%20Caenegem&amp;author=S%20Weyers&amp;author=S%20Goemaere&amp;author=K%20Toye&amp;author=J-M%20Kaufman&amp;author=GG%20T%E2%80%99Sjoen&amp;publication_year=2008&amp;journal=Bone&amp;volume=43&amp;pages=1016-1021\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1016/j.bone.2008.09.001\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1016%2Fj.bone.2008.09.001\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1016%2Fj.bone.2008.09.001\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/18835591\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Body%20composition%2C%20volumetric%20and%20areal%20bone%20parameters%20in%20male-to-female%20transsexual%20persons&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B155\" class=\"js-splitview-ref-item\" data-legacy-id=\"B155\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B155\" href=\"javascript:;\" aria-label=\"jumplink-B155\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B155\" class=\"ref-content \" data-id=\"B155\"><span class=\"label\">155.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Meyer</div> III <div class=\"given-names\">WJ</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Webb</div>  <div class=\"given-names\">A</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Stuart</div>  <div class=\"given-names\">CA</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Finkelstein</div>  <div class=\"given-names\">JW</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Lawrence</div>  <div class=\"given-names\">B</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Walker</div>  <div class=\"given-names\">PA</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Physical and hormonal evaluation of transsexual patients: a longitudinal study</div>. <div class=\"source \">Arch Sex Behav</div>. <div class=\"year\">1986</div>;<div class=\"volume\">15</div>(<div class=\"issue\">2</div>):<div class=\"fpage\">121</div>–<div class=\"lpage\">138</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Physical%20and%20hormonal%20evaluation%20of%20transsexual%20patients%3A%20a%20longitudinal%20study&amp;author=WJ%20Meyer&amp;author=A%20Webb&amp;author=CA%20Stuart&amp;author=JW%20Finkelstein&amp;author=B%20Lawrence&amp;author=PA%20Walker&amp;publication_year=1986&amp;journal=Arch%20Sex%20Behav&amp;volume=15&amp;pages=121-138\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1007/BF01542220\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1007%2FBF01542220\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1007%2FBF01542220\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/3013122\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Physical%20and%20hormonal%20evaluation%20of%20transsexual%20patients%3A%20a%20longitudinal%20study&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B156\" class=\"js-splitview-ref-item\" data-legacy-id=\"B156\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B156\" href=\"javascript:;\" aria-label=\"jumplink-B156\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B156\" class=\"ref-content \" data-id=\"B156\"><span class=\"label\">156.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Asscheman</div>  <div class=\"given-names\">H</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Gooren</div>  <div class=\"given-names\">LJ</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Assies</div>  <div class=\"given-names\">J</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Smits</div>  <div class=\"given-names\">JP</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">de Slegte</div>  <div class=\"given-names\">R</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Prolactin levels and pituitary enlargement in hormone-treated male-to-female transsexuals</div>. <div class=\"source \">Clin Endocrinol (Oxf)</div>. <div class=\"year\">1988</div>;<div class=\"volume\">28</div>(<div class=\"issue\">6</div>):<div class=\"fpage\">583</div>–<div class=\"lpage\">588</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Prolactin%20levels%20and%20pituitary%20enlargement%20in%20hormone-treated%20male-to-female%20transsexuals&amp;author=H%20Asscheman&amp;author=LJ%20Gooren&amp;author=J%20Assies&amp;author=JP%20Smits&amp;author=R%20de%20Slegte&amp;publication_year=1988&amp;journal=Clin%20Endocrinol%20%28Oxf%29&amp;volume=28&amp;pages=583-588\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1111/j.1365-2265.1988.tb03849.x\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1111%2Fj.1365-2265.1988.tb03849.x\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1111%2Fj.1365-2265.1988.tb03849.x\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/2978262\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Prolactin%20levels%20and%20pituitary%20enlargement%20in%20hormone-treated%20male-to-female%20transsexuals&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B157\" class=\"js-splitview-ref-item\" data-legacy-id=\"B157\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B157\" href=\"javascript:;\" aria-label=\"jumplink-B157\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B157\" class=\"ref-content \" data-id=\"B157\"><span class=\"label\">157.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Gooren</div>  <div class=\"given-names\">LJ</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Harmsen-Louman</div>  <div class=\"given-names\">W</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">van Kessel</div>  <div class=\"given-names\">H</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Follow-up of prolactin levels in long-term oestrogen-treated male-to-female transsexuals with regard to prolactinoma induction</div>. <div class=\"source \">Clin Endocrinol (Oxf)</div>. <div class=\"year\">1985</div>;<div class=\"volume\">22</div>(<div class=\"issue\">2</div>):<div class=\"fpage\">201</div>–<div class=\"lpage\">207</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Follow-up%20of%20prolactin%20levels%20in%20long-term%20oestrogen-treated%20male-to-female%20transsexuals%20with%20regard%20to%20prolactinoma%20induction&amp;author=LJ%20Gooren&amp;author=W%20Harmsen-Louman&amp;author=H%20van%20Kessel&amp;publication_year=1985&amp;journal=Clin%20Endocrinol%20%28Oxf%29&amp;volume=22&amp;pages=201-207\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1111/j.1365-2265.1985.tb01081.x\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1111%2Fj.1365-2265.1985.tb01081.x\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1111%2Fj.1365-2265.1985.tb01081.x\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/3157511\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Follow-up%20of%20prolactin%20levels%20in%20long-term%20oestrogen-treated%20male-to-female%20transsexuals%20with%20regard%20to%20prolactinoma%20induction&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B158\" class=\"js-splitview-ref-item\" data-legacy-id=\"B158\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B158\" href=\"javascript:;\" aria-label=\"jumplink-B158\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B158\" class=\"ref-content \" data-id=\"B158\"><span class=\"label\">158.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Wierckx</div>  <div class=\"given-names\">K</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Van Caenegem</div>  <div class=\"given-names\">E</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Schreiner</div>  <div class=\"given-names\">T</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Haraldsen</div>  <div class=\"given-names\">I</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Fisher</div>  <div class=\"given-names\">AD</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Toye</div>  <div class=\"given-names\">K</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Kaufman</div>  <div class=\"given-names\">JM</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">T’Sjoen</div>  <div class=\"given-names\">G</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Cross-sex hormone therapy in trans persons is safe and effective at short-time follow-up: results from the European network for the investigation of gender incongruence</div>. <div class=\"source \">J Sex Med</div>. <div class=\"year\">2014</div>;<div class=\"volume\">11</div>(<div class=\"issue\">8</div>):<div class=\"fpage\">1999</div>–<div class=\"lpage\">2011</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Cross-sex%20hormone%20therapy%20in%20trans%20persons%20is%20safe%20and%20effective%20at%20short-time%20follow-up%3A%20results%20from%20the%20European%20network%20for%20the%20investigation%20of%20gender%20incongruence&amp;author=K%20Wierckx&amp;author=E%20Van%20Caenegem&amp;author=T%20Schreiner&amp;author=I%20Haraldsen&amp;author=AD%20Fisher&amp;author=K%20Toye&amp;author=JM%20Kaufman&amp;author=G%20T%E2%80%99Sjoen&amp;publication_year=2014&amp;journal=J%20Sex%20Med&amp;volume=11&amp;pages=1999-2011\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1111/jsm.12571\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1111%2Fjsm.12571\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1111%2Fjsm.12571\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/24828032\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Cross-sex%20hormone%20therapy%20in%20trans%20persons%20is%20safe%20and%20effective%20at%20short-time%20follow-up%3A%20results%20from%20the%20European%20network%20for%20the%20investigation%20of%20gender%20incongruence&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B159\" class=\"js-splitview-ref-item\" data-legacy-id=\"B159\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B159\" href=\"javascript:;\" aria-label=\"jumplink-B159\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B159\" class=\"ref-content \" data-id=\"B159\"><span class=\"label\">159.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Ott</div>  <div class=\"given-names\">J</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Kaufmann</div>  <div class=\"given-names\">U</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Bentz</div>  <div class=\"given-names\">EK</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Huber</div>  <div class=\"given-names\">JC</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Tempfer</div>  <div class=\"given-names\">CB</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Incidence of thrombophilia and venous thrombosis in transsexuals under cross-sex hormone therapy</div>. <div class=\"source \">Fertil Steril</div>. <div class=\"year\">2010</div>;<div class=\"volume\">93</div>(<div class=\"issue\">4</div>):<div class=\"fpage\">1267</div>–<div class=\"lpage\">1272</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Incidence%20of%20thrombophilia%20and%20venous%20thrombosis%20in%20transsexuals%20under%20cross-sex%20hormone%20therapy&amp;author=J%20Ott&amp;author=U%20Kaufmann&amp;author=EK%20Bentz&amp;author=JC%20Huber&amp;author=CB%20Tempfer&amp;publication_year=2010&amp;journal=Fertil%20Steril&amp;volume=93&amp;pages=1267-1272\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1016/j.fertnstert.2008.12.017\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1016%2Fj.fertnstert.2008.12.017\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1016%2Fj.fertnstert.2008.12.017\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/19200981\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Incidence%20of%20thrombophilia%20and%20venous%20thrombosis%20in%20transsexuals%20under%20cross-sex%20hormone%20therapy&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B160\" class=\"js-splitview-ref-item\" data-legacy-id=\"B160\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B160\" href=\"javascript:;\" aria-label=\"jumplink-B160\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B160\" class=\"ref-content \" data-id=\"B160\"><span class=\"label\">160.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Giltay</div>  <div class=\"given-names\">EJ</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Hoogeveen</div>  <div class=\"given-names\">EK</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Elbers</div>  <div class=\"given-names\">JMH</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Gooren</div>  <div class=\"given-names\">LJG</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Asscheman</div>  <div class=\"given-names\">H</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Stehouwer</div>  <div class=\"given-names\">CDA</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Effects of sex steroids on plasma total homocysteine levels: a study in transsexual males and females</div>. <div class=\"source \">J Clin Endocrinol Metab</div>. <div class=\"year\">1998</div>;<div class=\"volume\">83</div>(<div class=\"issue\">2</div>):<div class=\"fpage\">550</div>–<div class=\"lpage\">553</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Effects%20of%20sex%20steroids%20on%20plasma%20total%20homocysteine%20levels%3A%20a%20study%20in%20transsexual%20males%20and%20females&amp;author=EJ%20Giltay&amp;author=EK%20Hoogeveen&amp;author=JMH%20Elbers&amp;author=LJG%20Gooren&amp;author=H%20Asscheman&amp;author=CDA%20Stehouwer&amp;publication_year=1998&amp;journal=J%20Clin%20Endocrinol%20Metab&amp;volume=83&amp;pages=550-553\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1210/jcem.83.2.4574\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1210%2Fjcem.83.2.4574\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1210%2Fjcem.83.2.4574\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/9467573\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Effects%20of%20sex%20steroids%20on%20plasma%20total%20homocysteine%20levels%3A%20a%20study%20in%20transsexual%20males%20and%20females&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B161\" class=\"js-splitview-ref-item\" data-legacy-id=\"B161\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B161\" href=\"javascript:;\" aria-label=\"jumplink-B161\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B161\" class=\"ref-content \" data-id=\"B161\"><span class=\"label\">161.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">van Kesteren</div>  <div class=\"given-names\">PJM</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Asscheman</div>  <div class=\"given-names\">H</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Megens</div>  <div class=\"given-names\">JAJ</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Gooren</div>  <div class=\"given-names\">LJG</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Mortality and morbidity in transsexual subjects treated with cross-sex hormones</div>. <div class=\"source \">Clin Endocrinol (Oxf)</div>. <div class=\"year\">1997</div>;<div class=\"volume\">47</div>(<div class=\"issue\">3</div>):<div class=\"fpage\">337</div>–<div class=\"lpage\">343</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Mortality%20and%20morbidity%20in%20transsexual%20subjects%20treated%20with%20cross-sex%20hormones&amp;author=PJM%20van%20Kesteren&amp;author=H%20Asscheman&amp;author=JAJ%20Megens&amp;author=LJG%20Gooren&amp;publication_year=1997&amp;journal=Clin%20Endocrinol%20%28Oxf%29&amp;volume=47&amp;pages=337-343\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1046/j.1365-2265.1997.2601068.x\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1046%2Fj.1365-2265.1997.2601068.x\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1046%2Fj.1365-2265.1997.2601068.x\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/9373456\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Mortality%20and%20morbidity%20in%20transsexual%20subjects%20treated%20with%20cross-sex%20hormones&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B162\" class=\"js-splitview-ref-item\" data-legacy-id=\"B162\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B162\" href=\"javascript:;\" aria-label=\"jumplink-B162\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B162\" class=\"ref-content \" data-id=\"B162\"><span class=\"label\">162.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Wierckx</div>  <div class=\"given-names\">K</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Gooren</div>  <div class=\"given-names\">L</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">T’Sjoen</div>  <div class=\"given-names\">G</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Clinical review: breast development in trans women receiving cross-sex hormones</div>. <div class=\"source \">J Sex Med</div>. <div class=\"year\">2014</div>;<div class=\"volume\">11</div>(<div class=\"issue\">5</div>):<div class=\"fpage\">1240</div>–<div class=\"lpage\">1247</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Clinical%20review%3A%20breast%20development%20in%20trans%20women%20receiving%20cross-sex%20hormones&amp;author=K%20Wierckx&amp;author=L%20Gooren&amp;author=G%20T%E2%80%99Sjoen&amp;publication_year=2014&amp;journal=J%20Sex%20Med&amp;volume=11&amp;pages=1240-1247\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1111/jsm.12487\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1111%2Fjsm.12487\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1111%2Fjsm.12487\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/24618412\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Clinical%20review%3A%20breast%20development%20in%20trans%20women%20receiving%20cross-sex%20hormones&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B163\" class=\"js-splitview-ref-item\" data-legacy-id=\"B163\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B163\" href=\"javascript:;\" aria-label=\"jumplink-B163\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B163\" class=\"ref-content \" data-id=\"B163\"><span class=\"label\">163.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Bird</div>  <div class=\"given-names\">D</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Vowles</div>  <div class=\"given-names\">K</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Anthony</div>  <div class=\"given-names\">PP</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Spontaneous rupture of a liver cell adenoma after long term methyltestosterone: report of a case successfully treated by emergency right hepatic lobectomy</div>. <div class=\"source \">Br J Surg</div>. <div class=\"year\">1979</div>;<div class=\"volume\">66</div>(<div class=\"issue\">3</div>):<div class=\"fpage\">212</div>–<div class=\"lpage\">213</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Spontaneous%20rupture%20of%20a%20liver%20cell%20adenoma%20after%20long%20term%20methyltestosterone%3A%20report%20of%20a%20case%20successfully%20treated%20by%20emergency%20right%20hepatic%20lobectomy&amp;author=D%20Bird&amp;author=K%20Vowles&amp;author=PP%20Anthony&amp;publication_year=1979&amp;journal=Br%20J%20Surg&amp;volume=66&amp;pages=212-213\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1002/(ISSN)1365-2168\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1002%2F(ISSN)1365-2168\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1002%2F(ISSN)1365-2168\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/218669\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Spontaneous%20rupture%20of%20a%20liver%20cell%20adenoma%20after%20long%20term%20methyltestosterone%3A%20report%20of%20a%20case%20successfully%20treated%20by%20emergency%20right%20hepatic%20lobectomy&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B164\" class=\"js-splitview-ref-item\" data-legacy-id=\"B164\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B164\" href=\"javascript:;\" aria-label=\"jumplink-B164\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B164\" class=\"ref-content \" data-id=\"B164\"><span class=\"label\">164.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Westaby</div>  <div class=\"given-names\">D</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Ogle</div>  <div class=\"given-names\">SJ</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Paradinas</div>  <div class=\"given-names\">FJ</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Randell</div>  <div class=\"given-names\">JB</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Murray-Lyon</div>  <div class=\"given-names\">IM</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Liver damage from long-term methyltestosterone</div>. <div class=\"source \">Lancet</div>. <div class=\"year\">1977</div>;<div class=\"volume\">2</div>(<div class=\"issue\">8032</div>):<div class=\"fpage\">262</div>–<div class=\"lpage\">263</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Liver%20damage%20from%20long-term%20methyltestosterone&amp;author=D%20Westaby&amp;author=SJ%20Ogle&amp;author=FJ%20Paradinas&amp;author=JB%20Randell&amp;author=IM%20Murray-Lyon&amp;publication_year=1977&amp;journal=Lancet&amp;volume=2&amp;pages=262-263\" target=\"_blank\">Google Scholar</a></span></p><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/69876\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><div class=\"xslopenurl empty-target\"><span class=\"js-inst-open-url-holders-nodoi\"><a class=\"js-open-url-link\" data-href-template=\"{targetURL}?sid=oup:orr&amp;genre=article&amp;atitle=Liver+damage+from+long-term+methyltestosterone&amp;aulast=Westaby&amp;title=Lancet&amp;date=1977&amp;spage=262&amp;epage=263&amp;volume=2&amp;issue=8032\" href=\"javascript:;\"><span class=\"screenreader-text\">OpenURL Placeholder Text</span></a></span></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Liver%20damage%20from%20long-term%20methyltestosterone&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B165\" class=\"js-splitview-ref-item\" data-legacy-id=\"B165\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B165\" href=\"javascript:;\" aria-label=\"jumplink-B165\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B165\" class=\"ref-content \" data-id=\"B165\"><span class=\"label\">165.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Weinand</div>  <div class=\"given-names\">JD</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Safer</div>  <div class=\"given-names\">JD</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Hormone therapy in transgender adults is safe with provider supervision; a review of hormone therapy sequelae for transgender individuals</div>. <div class=\"source \">J Clin Transl Endocrinol</div>. <div class=\"year\">2015</div>;<div class=\"volume\">2</div>(<div class=\"issue\">2</div>):<div class=\"fpage\">55</div>–<div class=\"lpage\">60</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Hormone%20therapy%20in%20transgender%20adults%20is%20safe%20with%20provider%20supervision%3B%20a%20review%20of%20hormone%20therapy%20sequelae%20for%20transgender%20individuals&amp;author=JD%20Weinand&amp;author=JD%20Safer&amp;publication_year=2015&amp;journal=J%20Clin%20Transl%20Endocrinol&amp;volume=2&amp;pages=55-60\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1016/j.jcte.2015.02.003\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1016%2Fj.jcte.2015.02.003\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1016%2Fj.jcte.2015.02.003\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/28090436\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Hormone%20therapy%20in%20transgender%20adults%20is%20safe%20with%20provider%20supervision%3B%20a%20review%20of%20hormone%20therapy%20sequelae%20for%20transgender%20individuals&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B166\" class=\"js-splitview-ref-item\" data-legacy-id=\"B166\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B166\" href=\"javascript:;\" aria-label=\"jumplink-B166\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B166\" class=\"ref-content \" data-id=\"B166\"><span class=\"label\">166.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Roberts</div>  <div class=\"given-names\">TK</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Kraft</div>  <div class=\"given-names\">CS</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">French</div>  <div class=\"given-names\">D</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Ji</div>  <div class=\"given-names\">W</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Wu</div>  <div class=\"given-names\">AH</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Tangpricha</div>  <div class=\"given-names\">V</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Fantz</div>  <div class=\"given-names\">CR</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Interpreting laboratory results in transgender patients on hormone therapy</div>. <div class=\"source \">Am J Med</div>. <div class=\"year\">2014</div>;<div class=\"volume\">127</div>(<div class=\"issue\">2</div>):<div class=\"fpage\">159</div>–<div class=\"lpage\">162</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Interpreting%20laboratory%20results%20in%20transgender%20patients%20on%20hormone%20therapy&amp;author=TK%20Roberts&amp;author=CS%20Kraft&amp;author=D%20French&amp;author=W%20Ji&amp;author=AH%20Wu&amp;author=V%20Tangpricha&amp;author=CR%20Fantz&amp;publication_year=2014&amp;journal=Am%20J%20Med&amp;volume=127&amp;pages=159-162\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1016/j.amjmed.2013.10.009\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1016%2Fj.amjmed.2013.10.009\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1016%2Fj.amjmed.2013.10.009\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/24332725\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Interpreting%20laboratory%20results%20in%20transgender%20patients%20on%20hormone%20therapy&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B167\" class=\"js-splitview-ref-item\" data-legacy-id=\"B167\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B167\" href=\"javascript:;\" aria-label=\"jumplink-B167\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B167\" class=\"ref-content \" data-id=\"B167\"><span class=\"label\">167.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Vesper</div>  <div class=\"given-names\">HW</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Botelho</div>  <div class=\"given-names\">JC</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Wang</div>  <div class=\"given-names\">Y</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Challenges and improvements in testosterone and estradiol testing</div>. <div class=\"source \">Asian J Androl</div>. <div class=\"year\">2014</div>;<div class=\"volume\">16</div>(<div class=\"issue\">2</div>):<div class=\"fpage\">178</div>–<div class=\"lpage\">184</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Challenges%20and%20improvements%20in%20testosterone%20and%20estradiol%20testing&amp;author=HW%20Vesper&amp;author=JC%20Botelho&amp;author=Y%20Wang&amp;publication_year=2014&amp;journal=Asian%20J%20Androl&amp;volume=16&amp;pages=178-184\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.4103/1008-682X.122338\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.4103%2F1008-682X.122338\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.4103%2F1008-682X.122338\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/24407184\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Challenges%20and%20improvements%20in%20testosterone%20and%20estradiol%20testing&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B168\" class=\"js-splitview-ref-item\" data-legacy-id=\"B168\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B168\" href=\"javascript:;\" aria-label=\"jumplink-B168\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B168\" class=\"ref-content \" data-id=\"B168\"><span class=\"label\">168.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Asscheman</div>  <div class=\"given-names\">H</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">T’Sjoen</div>  <div class=\"given-names\">G</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Lemaire</div>  <div class=\"given-names\">A</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Mas</div>  <div class=\"given-names\">M</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Meriggiola</div>  <div class=\"given-names\">MC</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Mueller</div>  <div class=\"given-names\">A</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Kuhn</div>  <div class=\"given-names\">A</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Dhejne</div>  <div class=\"given-names\">C</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Morel-Journel</div>  <div class=\"given-names\">N</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Gooren</div>  <div class=\"given-names\">LJ</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Venous thrombo-embolism as a complication of cross-sex hormone treatment of male-to-female transsexual subjects: a review</div>. <div class=\"source \">Andrologia</div>. <div class=\"year\">2014</div>;<div class=\"volume\">46</div>(<div class=\"issue\">7</div>):<div class=\"fpage\">791</div>–<div class=\"lpage\">795</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Venous%20thrombo-embolism%20as%20a%20complication%20of%20cross-sex%20hormone%20treatment%20of%20male-to-female%20transsexual%20subjects%3A%20a%20review&amp;author=H%20Asscheman&amp;author=G%20T%E2%80%99Sjoen&amp;author=A%20Lemaire&amp;author=M%20Mas&amp;author=MC%20Meriggiola&amp;author=A%20Mueller&amp;author=A%20Kuhn&amp;author=C%20Dhejne&amp;author=N%20Morel-Journel&amp;author=LJ%20Gooren&amp;publication_year=2014&amp;journal=Andrologia&amp;volume=46&amp;pages=791-795\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1111/and.2014.46.issue-7\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1111%2Fand.2014.46.issue-7\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1111%2Fand.2014.46.issue-7\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23944849\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Venous%20thrombo-embolism%20as%20a%20complication%20of%20cross-sex%20hormone%20treatment%20of%20male-to-female%20transsexual%20subjects%3A%20a%20review&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B169\" class=\"js-splitview-ref-item\" data-legacy-id=\"B169\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B169\" href=\"javascript:;\" aria-label=\"jumplink-B169\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B169\" class=\"ref-content \" data-id=\"B169\"><span class=\"label\">169.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Righini</div>  <div class=\"given-names\">M</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Perrier</div>  <div class=\"given-names\">A</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">De Moerloose</div>  <div class=\"given-names\">P</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Bounameaux</div>  <div class=\"given-names\">H</div>\r\n</span>\r\n</span>. <div class=\"article-title\">D-dimer for venous thromboembolism diagnosis: 20 years later</div>. <div class=\"source \">J Thromb Haemost</div>. <div class=\"year\">2008</div>;<div class=\"volume\">6</div>(<div class=\"issue\">7</div>):<div class=\"fpage\">1059</div>–<div class=\"lpage\">1071</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=D-dimer%20for%20venous%20thromboembolism%20diagnosis%3A%2020%20years%20later&amp;author=M%20Righini&amp;author=A%20Perrier&amp;author=P%20De%20Moerloose&amp;author=H%20Bounameaux&amp;publication_year=2008&amp;journal=J%20Thromb%20Haemost&amp;volume=6&amp;pages=1059-1071\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1111/j.1538-7836.2008.02981.x\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1111%2Fj.1538-7836.2008.02981.x\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1111%2Fj.1538-7836.2008.02981.x\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/18419743\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:D-dimer%20for%20venous%20thromboembolism%20diagnosis%3A%2020%20years%20later&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B170\" class=\"js-splitview-ref-item\" data-legacy-id=\"B170\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B170\" href=\"javascript:;\" aria-label=\"jumplink-B170\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B170\" class=\"ref-content \" data-id=\"B170\"><span class=\"label\">170.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Gooren</div>  <div class=\"given-names\">LJ</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Assies</div>  <div class=\"given-names\">J</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Asscheman</div>  <div class=\"given-names\">H</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">de Slegte</div>  <div class=\"given-names\">R</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">van Kessel</div>  <div class=\"given-names\">H</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Estrogen-induced prolactinoma in a man</div>. <div class=\"source \">J Clin Endocrinol Metab</div>. <div class=\"year\">1988</div>;<div class=\"volume\">66</div>(<div class=\"issue\">2</div>):<div class=\"fpage\">444</div>–<div class=\"lpage\">446</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Estrogen-induced%20prolactinoma%20in%20a%20man&amp;author=LJ%20Gooren&amp;author=J%20Assies&amp;author=H%20Asscheman&amp;author=R%20de%20Slegte&amp;author=H%20van%20Kessel&amp;publication_year=1988&amp;journal=J%20Clin%20Endocrinol%20Metab&amp;volume=66&amp;pages=444-446\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1210/jcem-66-2-444\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1210%2Fjcem-66-2-444\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1210%2Fjcem-66-2-444\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/3339116\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Estrogen-induced%20prolactinoma%20in%20a%20man&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B171\" class=\"js-splitview-ref-item\" data-legacy-id=\"B171\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B171\" href=\"javascript:;\" aria-label=\"jumplink-B171\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B171\" class=\"ref-content \" data-id=\"B171\"><span class=\"label\">171.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Kovacs</div>  <div class=\"given-names\">K</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Stefaneanu</div>  <div class=\"given-names\">L</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Ezzat</div>  <div class=\"given-names\">S</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Smyth</div>  <div class=\"given-names\">HS</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Prolactin-producing pituitary adenoma in a male-to-female transsexual patient with protracted estrogen administration. A morphologic study</div>. <div class=\"source \">Arch Pathol Lab Med</div>. <div class=\"year\">1994</div>;<div class=\"volume\">118</div>(<div class=\"issue\">5</div>):<div class=\"fpage\">562</div>–<div class=\"lpage\">565</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Prolactin-producing%20pituitary%20adenoma%20in%20a%20male-to-female%20transsexual%20patient%20with%20protracted%20estrogen%20administration.%20A%20morphologic%20study&amp;author=K%20Kovacs&amp;author=L%20Stefaneanu&amp;author=S%20Ezzat&amp;author=HS%20Smyth&amp;publication_year=1994&amp;journal=Arch%20Pathol%20Lab%20Med&amp;volume=118&amp;pages=562-565\" target=\"_blank\">Google Scholar</a></span></p><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/8192565\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><div class=\"xslopenurl empty-target\"><span class=\"js-inst-open-url-holders-nodoi\"><a class=\"js-open-url-link\" data-href-template=\"{targetURL}?sid=oup:orr&amp;genre=article&amp;atitle=Prolactin-producing+pituitary+adenoma+in+a+male-to-female+transsexual+patient+with+protracted+estrogen+administration.+A+morphologic+study&amp;aulast=Kovacs&amp;title=Arch+Pathol+Lab+Med&amp;date=1994&amp;spage=562&amp;epage=565&amp;volume=118&amp;issue=5\" href=\"javascript:;\"><span class=\"screenreader-text\">OpenURL Placeholder Text</span></a></span></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Prolactin-producing%20pituitary%20adenoma%20in%20a%20male-to-female%20transsexual%20patient%20with%20protracted%20estrogen%20administration.%20A%20morphologic%20study&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B172\" class=\"js-splitview-ref-item\" data-legacy-id=\"B172\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B172\" href=\"javascript:;\" aria-label=\"jumplink-B172\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B172\" class=\"ref-content \" data-id=\"B172\"><span class=\"label\">172.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Serri</div>  <div class=\"given-names\">O</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Noiseux</div>  <div class=\"given-names\">D</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Robert</div>  <div class=\"given-names\">F</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Hardy</div>  <div class=\"given-names\">J</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Lactotroph hyperplasia in an estrogen treated male-to-female transsexual patient</div>. <div class=\"source \">J Clin Endocrinol Metab</div>. <div class=\"year\">1996</div>;<div class=\"volume\">81</div>(<div class=\"issue\">9</div>):<div class=\"fpage\">3177</div>–<div class=\"lpage\">3179</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Lactotroph%20hyperplasia%20in%20an%20estrogen%20treated%20male-to-female%20transsexual%20patient&amp;author=O%20Serri&amp;author=D%20Noiseux&amp;author=F%20Robert&amp;author=J%20Hardy&amp;publication_year=1996&amp;journal=J%20Clin%20Endocrinol%20Metab&amp;volume=81&amp;pages=3177-3179\" target=\"_blank\">Google Scholar</a></span></p><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/8784065\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><div class=\"xslopenurl empty-target\"><span class=\"js-inst-open-url-holders-nodoi\"><a class=\"js-open-url-link\" data-href-template=\"{targetURL}?sid=oup:orr&amp;genre=article&amp;atitle=Lactotroph+hyperplasia+in+an+estrogen+treated+male-to-female+transsexual+patient&amp;aulast=Serri&amp;title=J+Clin+Endocrinol+Metab&amp;date=1996&amp;spage=3177&amp;epage=3179&amp;volume=81&amp;issue=9\" href=\"javascript:;\"><span class=\"screenreader-text\">OpenURL Placeholder Text</span></a></span></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Lactotroph%20hyperplasia%20in%20an%20estrogen%20treated%20male-to-female%20transsexual%20patient&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B173\" class=\"js-splitview-ref-item\" data-legacy-id=\"B173\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B173\" href=\"javascript:;\" aria-label=\"jumplink-B173\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B173\" class=\"ref-content \" data-id=\"B173\"><span class=\"label\">173.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Cunha</div>  <div class=\"given-names\">FS</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Domenice</div>  <div class=\"given-names\">S</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Câmara</div>  <div class=\"given-names\">VL</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Sircili</div>  <div class=\"given-names\">MH</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Gooren</div>  <div class=\"given-names\">LJ</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Mendonça</div>  <div class=\"given-names\">BB</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Costa</div>  <div class=\"given-names\">EM</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Diagnosis of prolactinoma in two male-to-female transsexual subjects following high-dose cross-sex hormone therapy</div>. <div class=\"source \">Andrologia</div>. <div class=\"year\">2015</div>;<div class=\"volume\">47</div>(<div class=\"issue\">6</div>):<div class=\"fpage\">680</div>–<div class=\"lpage\">684</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Diagnosis%20of%20prolactinoma%20in%20two%20male-to-female%20transsexual%20subjects%20following%20high-dose%20cross-sex%20hormone%20therapy&amp;author=FS%20Cunha&amp;author=S%20Domenice&amp;author=VL%20C%C3%A2mara&amp;author=MH%20Sircili&amp;author=LJ%20Gooren&amp;author=BB%20Mendon%C3%A7a&amp;author=EM%20Costa&amp;publication_year=2015&amp;journal=Andrologia&amp;volume=47&amp;pages=680-684\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1111/and.2015.47.issue-6\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1111%2Fand.2015.47.issue-6\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1111%2Fand.2015.47.issue-6\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/25059808\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Diagnosis%20of%20prolactinoma%20in%20two%20male-to-female%20transsexual%20subjects%20following%20high-dose%20cross-sex%20hormone%20therapy&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B174\" class=\"js-splitview-ref-item\" data-legacy-id=\"B174\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B174\" href=\"javascript:;\" aria-label=\"jumplink-B174\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B174\" class=\"ref-content \" data-id=\"B174\"><span class=\"label\">174.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Nota</div>  <div class=\"given-names\">NM</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Dekker</div>  <div class=\"given-names\">MJHJ</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Klaver</div>  <div class=\"given-names\">M</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Wiepjes</div>  <div class=\"given-names\">CM</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">van Trotsenburg</div>  <div class=\"given-names\">MA</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Heijboer</div>  <div class=\"given-names\">AC</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">den Heijer</div>  <div class=\"given-names\">M</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Prolactin levels during short- and long-term cross-sex hormone treatment: an observational study in transgender persons</div>. <div class=\"source \">Andrologia</div>. <div class=\"year\">2017</div>;<div class=\"comment\"><strong>49</strong>(6)</div>.</p></div></div></div></div><div content-id=\"B175\" class=\"js-splitview-ref-item\" data-legacy-id=\"B175\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B175\" href=\"javascript:;\" aria-label=\"jumplink-B175\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B175\" class=\"ref-content \" data-id=\"B175\"><span class=\"label\">175.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Bunck</div>  <div class=\"given-names\">MC</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Debono</div>  <div class=\"given-names\">M</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Giltay</div>  <div class=\"given-names\">EJ</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Verheijen</div>  <div class=\"given-names\">AT</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Diamant</div>  <div class=\"given-names\">M</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Gooren</div>  <div class=\"given-names\">LJ</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Autonomous prolactin secretion in two male-to-female transgender patients using conventional oestrogen dosages</div>. <div class=\"source \">BMJ Case Rep</div>. <div class=\"year\">2009</div>;<div class=\"volume\">2009</div>:<div class=\"fpage\">bcr0220091589</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Autonomous%20prolactin%20secretion%20in%20two%20male-to-female%20transgender%20patients%20using%20conventional%20oestrogen%20dosages&amp;author=MC%20Bunck&amp;author=M%20Debono&amp;author=EJ%20Giltay&amp;author=AT%20Verheijen&amp;author=M%20Diamant&amp;author=LJ%20Gooren&amp;publication_year=2009&amp;journal=BMJ%20Case%20Rep&amp;volume=2009&amp;pages=bcr0220091589\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1136/bcr.02.2009.1589\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1136%2Fbcr.02.2009.1589\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1136%2Fbcr.02.2009.1589\"> </span></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Autonomous%20prolactin%20secretion%20in%20two%20male-to-female%20transgender%20patients%20using%20conventional%20oestrogen%20dosages&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B176\" class=\"js-splitview-ref-item\" data-legacy-id=\"B176\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B176\" href=\"javascript:;\" aria-label=\"jumplink-B176\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B176\" class=\"ref-content \" data-id=\"B176\"><span class=\"label\">176.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Elamin</div>  <div class=\"given-names\">MB</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Garcia</div>  <div class=\"given-names\">MZ</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Murad</div>  <div class=\"given-names\">MH</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Erwin</div>  <div class=\"given-names\">PJ</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Montori</div>  <div class=\"given-names\">VM</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Effect of sex steroid use on cardiovascular risk in transsexual individuals: a systematic review and meta-analyses</div>. <div class=\"source \">Clin Endocrinol (Oxf)</div>. <div class=\"year\">2010</div>;<div class=\"volume\">72</div>(<div class=\"issue\">1</div>):<div class=\"fpage\">1</div>–<div class=\"lpage\">10</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Effect%20of%20sex%20steroid%20use%20on%20cardiovascular%20risk%20in%20transsexual%20individuals%3A%20a%20systematic%20review%20and%20meta-analyses&amp;author=MB%20Elamin&amp;author=MZ%20Garcia&amp;author=MH%20Murad&amp;author=PJ%20Erwin&amp;author=VM%20Montori&amp;publication_year=2010&amp;journal=Clin%20Endocrinol%20%28Oxf%29&amp;volume=72&amp;pages=1-10\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1111/(ISSN)1365-2265\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1111%2F(ISSN)1365-2265\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1111%2F(ISSN)1365-2265\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/19473174\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Effect%20of%20sex%20steroid%20use%20on%20cardiovascular%20risk%20in%20transsexual%20individuals%3A%20a%20systematic%20review%20and%20meta-analyses&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B177\" class=\"js-splitview-ref-item\" data-legacy-id=\"B177\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B177\" href=\"javascript:;\" aria-label=\"jumplink-B177\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B177\" class=\"ref-content \" data-id=\"B177\"><span class=\"label\">177.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Berra</div>  <div class=\"given-names\">M</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Armillotta</div>  <div class=\"given-names\">F</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">D’Emidio</div>  <div class=\"given-names\">L</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Costantino</div>  <div class=\"given-names\">A</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Martorana</div>  <div class=\"given-names\">G</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Pelusi</div>  <div class=\"given-names\">G</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Meriggiola</div>  <div class=\"given-names\">MC</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Testosterone decreases adiponectin levels in female to male transsexuals</div>. <div class=\"source \">Asian J Androl</div>. <div class=\"year\">2006</div>;<div class=\"volume\">8</div>(<div class=\"issue\">6</div>):<div class=\"fpage\">725</div>–<div class=\"lpage\">729</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Testosterone%20decreases%20adiponectin%20levels%20in%20female%20to%20male%20transsexuals&amp;author=M%20Berra&amp;author=F%20Armillotta&amp;author=L%20D%E2%80%99Emidio&amp;author=A%20Costantino&amp;author=G%20Martorana&amp;author=G%20Pelusi&amp;author=MC%20Meriggiola&amp;publication_year=2006&amp;journal=Asian%20J%20Androl&amp;volume=8&amp;pages=725-729\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1111/ajan.2006.8.issue-6\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1111%2Fajan.2006.8.issue-6\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1111%2Fajan.2006.8.issue-6\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/16855767\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Testosterone%20decreases%20adiponectin%20levels%20in%20female%20to%20male%20transsexuals&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B178\" class=\"js-splitview-ref-item\" data-legacy-id=\"B178\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B178\" href=\"javascript:;\" aria-label=\"jumplink-B178\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B178\" class=\"ref-content \" data-id=\"B178\"><span class=\"label\">178.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Elbers</div>  <div class=\"given-names\">JMH</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Giltay</div>  <div class=\"given-names\">EJ</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Teerlink</div>  <div class=\"given-names\">T</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Scheffer</div>  <div class=\"given-names\">PG</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Asscheman</div>  <div class=\"given-names\">H</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Seidell</div>  <div class=\"given-names\">JC</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Gooren</div>  <div class=\"given-names\">LJG</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Effects of sex steroids on components of the insulin resistance syndrome in transsexual subjects</div>. <div class=\"source \">Clin Endocrinol (Oxf)</div>. <div class=\"year\">2003</div>;<div class=\"volume\">58</div>(<div class=\"issue\">5</div>):<div class=\"fpage\">562</div>–<div class=\"lpage\">571</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Effects%20of%20sex%20steroids%20on%20components%20of%20the%20insulin%20resistance%20syndrome%20in%20transsexual%20subjects&amp;author=JMH%20Elbers&amp;author=EJ%20Giltay&amp;author=T%20Teerlink&amp;author=PG%20Scheffer&amp;author=H%20Asscheman&amp;author=JC%20Seidell&amp;author=LJG%20Gooren&amp;publication_year=2003&amp;journal=Clin%20Endocrinol%20%28Oxf%29&amp;volume=58&amp;pages=562-571\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1046/j.1365-2265.2003.01753.x\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1046%2Fj.1365-2265.2003.01753.x\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1046%2Fj.1365-2265.2003.01753.x\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/12699437\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Effects%20of%20sex%20steroids%20on%20components%20of%20the%20insulin%20resistance%20syndrome%20in%20transsexual%20subjects&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B179\" class=\"js-splitview-ref-item\" data-legacy-id=\"B179\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B179\" href=\"javascript:;\" aria-label=\"jumplink-B179\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B179\" class=\"ref-content \" data-id=\"B179\"><span class=\"label\">179.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Giltay</div>  <div class=\"given-names\">EJ</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Lambert</div>  <div class=\"given-names\">J</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Gooren</div>  <div class=\"given-names\">LJG</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Elbers</div>  <div class=\"given-names\">JMH</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Steyn</div>  <div class=\"given-names\">M</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Stehouwer</div>  <div class=\"given-names\">CDA</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Sex steroids, insulin, and arterial stiffness in women and men</div>. <div class=\"source \">Hypertension</div>. <div class=\"year\">1999</div>;<div class=\"volume\">34</div>(<div class=\"issue\">4 Pt 1</div>):<div class=\"fpage\">590</div>–<div class=\"lpage\">597</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Sex%20steroids%2C%20insulin%2C%20and%20arterial%20stiffness%20in%20women%20and%20men&amp;author=EJ%20Giltay&amp;author=J%20Lambert&amp;author=LJG%20Gooren&amp;author=JMH%20Elbers&amp;author=M%20Steyn&amp;author=CDA%20Stehouwer&amp;publication_year=1999&amp;journal=Hypertension&amp;volume=34&amp;pages=590-597\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1161/01.HYP.34.4.590\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1161%2F01.HYP.34.4.590\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1161%2F01.HYP.34.4.590\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/10523332\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Sex%20steroids%2C%20insulin%2C%20and%20arterial%20stiffness%20in%20women%20and%20men&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B180\" class=\"js-splitview-ref-item\" data-legacy-id=\"B180\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B180\" href=\"javascript:;\" aria-label=\"jumplink-B180\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B180\" class=\"ref-content \" data-id=\"B180\"><span class=\"label\">180.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Polderman</div>  <div class=\"given-names\">KH</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Gooren</div>  <div class=\"given-names\">LJ</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Asscheman</div>  <div class=\"given-names\">H</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Bakker</div>  <div class=\"given-names\">A</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Heine</div>  <div class=\"given-names\">RJ</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Induction of insulin resistance by androgens and estrogens</div>. <div class=\"source \">J Clin Endocrinol Metab</div>. <div class=\"year\">1994</div>;<div class=\"volume\">79</div>(<div class=\"issue\">1</div>):<div class=\"fpage\">265</div>–<div class=\"lpage\">271</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Induction%20of%20insulin%20resistance%20by%20androgens%20and%20estrogens&amp;author=KH%20Polderman&amp;author=LJ%20Gooren&amp;author=H%20Asscheman&amp;author=A%20Bakker&amp;author=RJ%20Heine&amp;publication_year=1994&amp;journal=J%20Clin%20Endocrinol%20Metab&amp;volume=79&amp;pages=265-271\" target=\"_blank\">Google Scholar</a></span></p><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/8027240\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><div class=\"xslopenurl empty-target\"><span class=\"js-inst-open-url-holders-nodoi\"><a class=\"js-open-url-link\" data-href-template=\"{targetURL}?sid=oup:orr&amp;genre=article&amp;atitle=Induction+of+insulin+resistance+by+androgens+and+estrogens&amp;aulast=Polderman&amp;title=J+Clin+Endocrinol+Metab&amp;date=1994&amp;spage=265&amp;epage=271&amp;volume=79&amp;issue=1\" href=\"javascript:;\"><span class=\"screenreader-text\">OpenURL Placeholder Text</span></a></span></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Induction%20of%20insulin%20resistance%20by%20androgens%20and%20estrogens&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B181\" class=\"js-splitview-ref-item\" data-legacy-id=\"B181\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B181\" href=\"javascript:;\" aria-label=\"jumplink-B181\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B181\" class=\"ref-content \" data-id=\"B181\"><span class=\"label\">181.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">Maraka S. Effect of sex steroids on lipids, venous thromboembolism, cardiovascular disease and mortality in transgender individuals: a systematic review and meta-analysis. Available at: <a class=\"link link-uri openInAnotherWindow\" href=\"http://press.endocrine.org/doi/abs/10.1210/endo-meetings.2016.RE.15.FRI-136\" target=\"_blank\">http://press.endocrine.org/doi/abs/10.1210/endo-meetings.2016.RE.15.FRI-136</a>. Accessed 3 July 2017.</p></div></div></div></div><div content-id=\"B182\" class=\"js-splitview-ref-item\" data-legacy-id=\"B182\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B182\" href=\"javascript:;\" aria-label=\"jumplink-B182\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B182\" class=\"ref-content \" data-id=\"B182\"><span class=\"label\">182.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Meriggiola</div>  <div class=\"given-names\">MC</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Armillotta</div>  <div class=\"given-names\">F</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Costantino</div>  <div class=\"given-names\">A</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Altieri</div>  <div class=\"given-names\">P</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Saad</div>  <div class=\"given-names\">F</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Kalhorn</div>  <div class=\"given-names\">T</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Perrone</div>  <div class=\"given-names\">AM</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Ghi</div>  <div class=\"given-names\">T</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Pelusi</div>  <div class=\"given-names\">C</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Pelusi</div>  <div class=\"given-names\">G</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Effects of testosterone undecanoate administered alone or in combination with letrozole or dutasteride in female to male transsexuals</div>. <div class=\"source \">J Sex Med</div>. <div class=\"year\">2008</div>;<div class=\"volume\">5</div>(<div class=\"issue\">10</div>):<div class=\"fpage\">2442</div>–<div class=\"lpage\">2453</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Effects%20of%20testosterone%20undecanoate%20administered%20alone%20or%20in%20combination%20with%20letrozole%20or%20dutasteride%20in%20female%20to%20male%20transsexuals&amp;author=MC%20Meriggiola&amp;author=F%20Armillotta&amp;author=A%20Costantino&amp;author=P%20Altieri&amp;author=F%20Saad&amp;author=T%20Kalhorn&amp;author=AM%20Perrone&amp;author=T%20Ghi&amp;author=C%20Pelusi&amp;author=G%20Pelusi&amp;publication_year=2008&amp;journal=J%20Sex%20Med&amp;volume=5&amp;pages=2442-2453\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1111/j.1743-6109.2008.00909.x\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1111%2Fj.1743-6109.2008.00909.x\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1111%2Fj.1743-6109.2008.00909.x\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/18624972\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Effects%20of%20testosterone%20undecanoate%20administered%20alone%20or%20in%20combination%20with%20letrozole%20or%20dutasteride%20in%20female%20to%20male%20transsexuals&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B183\" class=\"js-splitview-ref-item\" data-legacy-id=\"B183\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B183\" href=\"javascript:;\" aria-label=\"jumplink-B183\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B183\" class=\"ref-content \" data-id=\"B183\"><span class=\"label\">183.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Giltay</div>  <div class=\"given-names\">EJ</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Toorians</div>  <div class=\"given-names\">AW</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Sarabdjitsingh</div>  <div class=\"given-names\">AR</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">de Vries</div>  <div class=\"given-names\">NA</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Gooren</div>  <div class=\"given-names\">LJ</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Established risk factors for coronary heart disease are unrelated to androgen-induced baldness in female-to-male transsexuals</div>. <div class=\"source \">J Endocrinol</div>. <div class=\"year\">2004</div>;<div class=\"volume\">180</div>(<div class=\"issue\">1</div>):<div class=\"fpage\">107</div>–<div class=\"lpage\">112</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Established%20risk%20factors%20for%20coronary%20heart%20disease%20are%20unrelated%20to%20androgen-induced%20baldness%20in%20female-to-male%20transsexuals&amp;author=EJ%20Giltay&amp;author=AW%20Toorians&amp;author=AR%20Sarabdjitsingh&amp;author=NA%20de%20Vries&amp;author=LJ%20Gooren&amp;publication_year=2004&amp;journal=J%20Endocrinol&amp;volume=180&amp;pages=107-112\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1677/joe.0.1800107\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1677%2Fjoe.0.1800107\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1677%2Fjoe.0.1800107\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/14709149\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Established%20risk%20factors%20for%20coronary%20heart%20disease%20are%20unrelated%20to%20androgen-induced%20baldness%20in%20female-to-male%20transsexuals&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B184\" class=\"js-splitview-ref-item\" data-legacy-id=\"B184\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B184\" href=\"javascript:;\" aria-label=\"jumplink-B184\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B184\" class=\"ref-content \" data-id=\"B184\"><span class=\"label\">184.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Giltay</div>  <div class=\"given-names\">EJ</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Verhoef</div>  <div class=\"given-names\">P</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Gooren</div>  <div class=\"given-names\">LJG</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Geleijnse</div>  <div class=\"given-names\">JM</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Schouten</div>  <div class=\"given-names\">EG</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Stehouwer</div>  <div class=\"given-names\">CDA</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Oral and transdermal estrogens both lower plasma total homocysteine in male-to-female transsexuals</div>. <div class=\"source \">Atherosclerosis</div>. <div class=\"year\">2003</div>;<div class=\"volume\">168</div>(<div class=\"issue\">1</div>):<div class=\"fpage\">139</div>–<div class=\"lpage\">146</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Oral%20and%20transdermal%20estrogens%20both%20lower%20plasma%20total%20homocysteine%20in%20male-to-female%20transsexuals&amp;author=EJ%20Giltay&amp;author=P%20Verhoef&amp;author=LJG%20Gooren&amp;author=JM%20Geleijnse&amp;author=EG%20Schouten&amp;author=CDA%20Stehouwer&amp;publication_year=2003&amp;journal=Atherosclerosis&amp;volume=168&amp;pages=139-146\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1016/S0021-9150(03)00090-X\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1016%2FS0021-9150(03)00090-X\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1016%2FS0021-9150(03)00090-X\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/12732397\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Oral%20and%20transdermal%20estrogens%20both%20lower%20plasma%20total%20homocysteine%20in%20male-to-female%20transsexuals&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B185\" class=\"js-splitview-ref-item\" data-legacy-id=\"B185\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B185\" href=\"javascript:;\" aria-label=\"jumplink-B185\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B185\" class=\"ref-content \" data-id=\"B185\"><span class=\"label\">185.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Calof</div>  <div class=\"given-names\">OM</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Singh</div>  <div class=\"given-names\">AB</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Lee</div>  <div class=\"given-names\">ML</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Kenny</div>  <div class=\"given-names\">AM</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Urban</div>  <div class=\"given-names\">RJ</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Tenover</div>  <div class=\"given-names\">JL</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Bhasin</div>  <div class=\"given-names\">S</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials</div>. <div class=\"source \">J Gerontol A Biol Sci Med Sci</div>. <div class=\"year\">2005</div>;<div class=\"volume\">60</div>(<div class=\"issue\">11</div>):<div class=\"fpage\">1451</div>–<div class=\"lpage\">1457</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Adverse%20events%20associated%20with%20testosterone%20replacement%20in%20middle-aged%20and%20older%20men%3A%20a%20meta-analysis%20of%20randomized%2C%20placebo-controlled%20trials&amp;author=OM%20Calof&amp;author=AB%20Singh&amp;author=ML%20Lee&amp;author=AM%20Kenny&amp;author=RJ%20Urban&amp;author=JL%20Tenover&amp;author=S%20Bhasin&amp;publication_year=2005&amp;journal=J%20Gerontol%20A%20Biol%20Sci%20Med%20Sci&amp;volume=60&amp;pages=1451-1457\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1093/gerona/60.11.1451\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1093%2Fgerona%2F60.11.1451\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1093%2Fgerona%2F60.11.1451\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/16339333\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Adverse%20events%20associated%20with%20testosterone%20replacement%20in%20middle-aged%20and%20older%20men%3A%20a%20meta-analysis%20of%20randomized%2C%20placebo-controlled%20trials&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B186\" class=\"js-splitview-ref-item\" data-legacy-id=\"B186\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B186\" href=\"javascript:;\" aria-label=\"jumplink-B186\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B186\" class=\"ref-content \" data-id=\"B186\"><span class=\"label\">186.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<div class=\"collab\">Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults</div>\r\n</span>. <div class=\"article-title\">Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)</div>. <div class=\"source \">JAMA</div>. <div class=\"year\">2001</div>;<div class=\"volume\">285</div>(<div class=\"issue\">19</div>):<div class=\"fpage\">2486</div>–<div class=\"lpage\">2497</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1001/jama.285.19.2486\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1001%2Fjama.285.19.2486\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1001%2Fjama.285.19.2486\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/11368702\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Executive%20summary%20of%20the%20Third%20Report%20of%20the%20National%20Cholesterol%20Education%20Program%20%28NCEP%29%20Expert%20Panel%20on%20Detection%2C%20Evaluation%2C%20and%20Treatment%20of%20High%20Blood%20Cholesterol%20in%20Adults%20%28Adult%20Treatment%20Panel%20III%29&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B187\" class=\"js-splitview-ref-item\" data-legacy-id=\"B187\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B187\" href=\"javascript:;\" aria-label=\"jumplink-B187\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B187\" class=\"ref-content \" data-id=\"B187\"><span class=\"label\">187.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Murad</div>  <div class=\"given-names\">MH</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Elamin</div>  <div class=\"given-names\">MB</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Garcia</div>  <div class=\"given-names\">MZ</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Mullan</div>  <div class=\"given-names\">RJ</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Murad</div>  <div class=\"given-names\">A</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Erwin</div>  <div class=\"given-names\">PJ</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Montori</div>  <div class=\"given-names\">VM</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Hormonal therapy and sex reassignment: a systematic review and meta-analysis of quality of life and psychosocial outcomes</div>. <div class=\"source \">Clin Endocrinol (Oxf)</div>. <div class=\"year\">2010</div>;<div class=\"volume\">72</div>(<div class=\"issue\">2</div>):<div class=\"fpage\">214</div>–<div class=\"lpage\">231</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Hormonal%20therapy%20and%20sex%20reassignment%3A%20a%20systematic%20review%20and%20meta-analysis%20of%20quality%20of%20life%20and%20psychosocial%20outcomes&amp;author=MH%20Murad&amp;author=MB%20Elamin&amp;author=MZ%20Garcia&amp;author=RJ%20Mullan&amp;author=A%20Murad&amp;author=PJ%20Erwin&amp;author=VM%20Montori&amp;publication_year=2010&amp;journal=Clin%20Endocrinol%20%28Oxf%29&amp;volume=72&amp;pages=214-231\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1111/cen.2010.72.issue-2\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1111%2Fcen.2010.72.issue-2\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1111%2Fcen.2010.72.issue-2\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/19473181\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Hormonal%20therapy%20and%20sex%20reassignment%3A%20a%20systematic%20review%20and%20meta-analysis%20of%20quality%20of%20life%20and%20psychosocial%20outcomes&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B188\" class=\"js-splitview-ref-item\" data-legacy-id=\"B188\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B188\" href=\"javascript:;\" aria-label=\"jumplink-B188\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B188\" class=\"ref-content \" data-id=\"B188\"><span class=\"label\">188.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Van Caenegem</div>  <div class=\"given-names\">E</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Wierckx</div>  <div class=\"given-names\">K</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Taes</div>  <div class=\"given-names\">Y</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Schreiner</div>  <div class=\"given-names\">T</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Vandewalle</div>  <div class=\"given-names\">S</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Toye</div>  <div class=\"given-names\">K</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Lapauw</div>  <div class=\"given-names\">B</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Kaufman</div>  <div class=\"given-names\">JM</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">T’Sjoen</div>  <div class=\"given-names\">G</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Body composition, bone turnover, and bone mass in trans men during testosterone treatment: 1-year follow-up data from a prospective case-controlled study (ENIGI)</div>. <div class=\"source \">Eur J Endocrinol</div>. <div class=\"year\">2015</div>;<div class=\"volume\">172</div>(<div class=\"issue\">2</div>):<div class=\"fpage\">163</div>–<div class=\"lpage\">171</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Body%20composition%2C%20bone%20turnover%2C%20and%20bone%20mass%20in%20trans%20men%20during%20testosterone%20treatment%3A%201-year%20follow-up%20data%20from%20a%20prospective%20case-controlled%20study%20%28ENIGI%29&amp;author=E%20Van%20Caenegem&amp;author=K%20Wierckx&amp;author=Y%20Taes&amp;author=T%20Schreiner&amp;author=S%20Vandewalle&amp;author=K%20Toye&amp;author=B%20Lapauw&amp;author=JM%20Kaufman&amp;author=G%20T%E2%80%99Sjoen&amp;publication_year=2015&amp;journal=Eur%20J%20Endocrinol&amp;volume=172&amp;pages=163-171\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1530/EJE-14-0586\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1530%2FEJE-14-0586\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1530%2FEJE-14-0586\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/25550352\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Body%20composition%2C%20bone%20turnover%2C%20and%20bone%20mass%20in%20trans%20men%20during%20testosterone%20treatment%3A%201-year%20follow-up%20data%20from%20a%20prospective%20case-controlled%20study%20%28ENIGI%29&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B189\" class=\"js-splitview-ref-item\" data-legacy-id=\"B189\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B189\" href=\"javascript:;\" aria-label=\"jumplink-B189\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B189\" class=\"ref-content \" data-id=\"B189\"><span class=\"label\">189.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Turner</div>  <div class=\"given-names\">A</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Chen</div>  <div class=\"given-names\">TC</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Barber</div>  <div class=\"given-names\">TW</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Malabanan</div>  <div class=\"given-names\">AO</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Holick</div>  <div class=\"given-names\">MF</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Tangpricha</div>  <div class=\"given-names\">V</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Testosterone increases bone mineral density in female-to-male transsexuals: a case series of 15 subjects</div>. <div class=\"source \">Clin Endocrinol (Oxf)</div>. <div class=\"year\">2004</div>;<div class=\"volume\">61</div>(<div class=\"issue\">5</div>):<div class=\"fpage\">560</div>–<div class=\"lpage\">566</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Testosterone%20increases%20bone%20mineral%20density%20in%20female-to-male%20transsexuals%3A%20a%20case%20series%20of%2015%20subjects&amp;author=A%20Turner&amp;author=TC%20Chen&amp;author=TW%20Barber&amp;author=AO%20Malabanan&amp;author=MF%20Holick&amp;author=V%20Tangpricha&amp;publication_year=2004&amp;journal=Clin%20Endocrinol%20%28Oxf%29&amp;volume=61&amp;pages=560-566\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1111/cen.2004.61.issue-5\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1111%2Fcen.2004.61.issue-5\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1111%2Fcen.2004.61.issue-5\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/15521957\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Testosterone%20increases%20bone%20mineral%20density%20in%20female-to-male%20transsexuals%3A%20a%20case%20series%20of%2015%20subjects&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B190\" class=\"js-splitview-ref-item\" data-legacy-id=\"B190\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B190\" href=\"javascript:;\" aria-label=\"jumplink-B190\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B190\" class=\"ref-content \" data-id=\"B190\"><span class=\"label\">190.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">van Kesteren</div>  <div class=\"given-names\">P</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Lips</div>  <div class=\"given-names\">P</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Gooren</div>  <div class=\"given-names\">LJG</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Asscheman</div>  <div class=\"given-names\">H</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Megens</div>  <div class=\"given-names\">J</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Long-term follow-up of bone mineral density and bone metabolism in transsexuals treated with cross-sex hormones</div>. <div class=\"source \">Clin Endocrinol (Oxf)</div>. <div class=\"year\">1998</div>;<div class=\"volume\">48</div>(<div class=\"issue\">3</div>):<div class=\"fpage\">347</div>–<div class=\"lpage\">354</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Long-term%20follow-up%20of%20bone%20mineral%20density%20and%20bone%20metabolism%20in%20transsexuals%20treated%20with%20cross-sex%20hormones&amp;author=P%20van%20Kesteren&amp;author=P%20Lips&amp;author=LJG%20Gooren&amp;author=H%20Asscheman&amp;author=J%20Megens&amp;publication_year=1998&amp;journal=Clin%20Endocrinol%20%28Oxf%29&amp;volume=48&amp;pages=347-354\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1046/j.1365-2265.1998.00396.x\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1046%2Fj.1365-2265.1998.00396.x\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1046%2Fj.1365-2265.1998.00396.x\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/9578826\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Long-term%20follow-up%20of%20bone%20mineral%20density%20and%20bone%20metabolism%20in%20transsexuals%20treated%20with%20cross-sex%20hormones&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B191\" class=\"js-splitview-ref-item\" data-legacy-id=\"B191\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B191\" href=\"javascript:;\" aria-label=\"jumplink-B191\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B191\" class=\"ref-content \" data-id=\"B191\"><span class=\"label\">191.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Van Caenegem</div>  <div class=\"given-names\">E</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Taes</div>  <div class=\"given-names\">Y</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Wierckx</div>  <div class=\"given-names\">K</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Vandewalle</div>  <div class=\"given-names\">S</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Toye</div>  <div class=\"given-names\">K</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Kaufman</div>  <div class=\"given-names\">JM</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Schreiner</div>  <div class=\"given-names\">T</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Haraldsen</div>  <div class=\"given-names\">I</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">T’Sjoen</div>  <div class=\"given-names\">G</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Low bone mass is prevalent in male-to-female transsexual persons before the start of cross-sex hormonal therapy and gonadectomy</div>. <div class=\"source \">Bone</div>. <div class=\"year\">2013</div>;<div class=\"volume\">54</div>(<div class=\"issue\">1</div>):<div class=\"fpage\">92</div>–<div class=\"lpage\">97</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Low%20bone%20mass%20is%20prevalent%20in%20male-to-female%20transsexual%20persons%20before%20the%20start%20of%20cross-sex%20hormonal%20therapy%20and%20gonadectomy&amp;author=E%20Van%20Caenegem&amp;author=Y%20Taes&amp;author=K%20Wierckx&amp;author=S%20Vandewalle&amp;author=K%20Toye&amp;author=JM%20Kaufman&amp;author=T%20Schreiner&amp;author=I%20Haraldsen&amp;author=G%20T%E2%80%99Sjoen&amp;publication_year=2013&amp;journal=Bone&amp;volume=54&amp;pages=92-97\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1016/j.bone.2013.01.039\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1016%2Fj.bone.2013.01.039\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1016%2Fj.bone.2013.01.039\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23369987\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Low%20bone%20mass%20is%20prevalent%20in%20male-to-female%20transsexual%20persons%20before%20the%20start%20of%20cross-sex%20hormonal%20therapy%20and%20gonadectomy&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B192\" class=\"js-splitview-ref-item\" data-legacy-id=\"B192\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B192\" href=\"javascript:;\" aria-label=\"jumplink-B192\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B192\" class=\"ref-content \" data-id=\"B192\"><span class=\"label\">192.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Amin</div>  <div class=\"given-names\">S</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Zhang</div>  <div class=\"given-names\">Y</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Sawin</div>  <div class=\"given-names\">CT</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Evans</div>  <div class=\"given-names\">SR</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Hannan</div>  <div class=\"given-names\">MT</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Kiel</div>  <div class=\"given-names\">DP</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Wilson</div>  <div class=\"given-names\">PW</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Felson</div>  <div class=\"given-names\">DT</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Association of hypogonadism and estradiol levels with bone mineral density in elderly men from the Framingham study</div>. <div class=\"source \">Ann Intern Med</div>. <div class=\"year\">2000</div>;<div class=\"volume\">133</div>(<div class=\"issue\">12</div>):<div class=\"fpage\">951</div>–<div class=\"lpage\">963</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Association%20of%20hypogonadism%20and%20estradiol%20levels%20with%20bone%20mineral%20density%20in%20elderly%20men%20from%20the%20Framingham%20study&amp;author=S%20Amin&amp;author=Y%20Zhang&amp;author=CT%20Sawin&amp;author=SR%20Evans&amp;author=MT%20Hannan&amp;author=DP%20Kiel&amp;author=PW%20Wilson&amp;author=DT%20Felson&amp;publication_year=2000&amp;journal=Ann%20Intern%20Med&amp;volume=133&amp;pages=951-963\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.7326/0003-4819-133-12-200012190-00010\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.7326%2F0003-4819-133-12-200012190-00010\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.7326%2F0003-4819-133-12-200012190-00010\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/11119396\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Association%20of%20hypogonadism%20and%20estradiol%20levels%20with%20bone%20mineral%20density%20in%20elderly%20men%20from%20the%20Framingham%20study&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B193\" class=\"js-splitview-ref-item\" data-legacy-id=\"B193\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B193\" href=\"javascript:;\" aria-label=\"jumplink-B193\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B193\" class=\"ref-content \" data-id=\"B193\"><span class=\"label\">193.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Gennari</div>  <div class=\"given-names\">L</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Khosla</div>  <div class=\"given-names\">S</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Bilezikian</div>  <div class=\"given-names\">JP</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Estrogen and fracture risk in men</div>. <div class=\"source \">J Bone Miner Res</div>. <div class=\"year\">2008</div>;<div class=\"volume\">23</div>(<div class=\"issue\">10</div>):<div class=\"fpage\">1548</div>–<div class=\"lpage\">1551</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Estrogen%20and%20fracture%20risk%20in%20men&amp;author=L%20Gennari&amp;author=S%20Khosla&amp;author=JP%20Bilezikian&amp;publication_year=2008&amp;journal=J%20Bone%20Miner%20Res&amp;volume=23&amp;pages=1548-1551\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1359/jbmr.0810c\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1359%2Fjbmr.0810c\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1359%2Fjbmr.0810c\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/18800918\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Estrogen%20and%20fracture%20risk%20in%20men&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B194\" class=\"js-splitview-ref-item\" data-legacy-id=\"B194\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B194\" href=\"javascript:;\" aria-label=\"jumplink-B194\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B194\" class=\"ref-content \" data-id=\"B194\"><span class=\"label\">194.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Khosla</div>  <div class=\"given-names\">S</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Melton</div>  <div class=\"given-names\">LJ</div> III\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Atkinson</div>  <div class=\"given-names\">EJ</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">O’Fallon</div>  <div class=\"given-names\">WM</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Klee</div>  <div class=\"given-names\">GG</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Riggs</div>  <div class=\"given-names\">BL</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: a key role for bioavailable estrogen</div>. <div class=\"source \">J Clin Endocrinol Metab</div>. <div class=\"year\">1998</div>;<div class=\"volume\">83</div>(<div class=\"issue\">7</div>):<div class=\"fpage\">2266</div>–<div class=\"lpage\">2274</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Relationship%20of%20serum%20sex%20steroid%20levels%20and%20bone%20turnover%20markers%20with%20bone%20mineral%20density%20in%20men%20and%20women%3A%20a%20key%20role%20for%20bioavailable%20estrogen&amp;author=S%20Khosla&amp;author=LJ%20Melton&amp;author=EJ%20Atkinson&amp;author=WM%20O%E2%80%99Fallon&amp;author=GG%20Klee&amp;author=BL%20Riggs&amp;publication_year=1998&amp;journal=J%20Clin%20Endocrinol%20Metab&amp;volume=83&amp;pages=2266-2274\" target=\"_blank\">Google Scholar</a></span></p><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/9661593\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><div class=\"xslopenurl empty-target\"><span class=\"js-inst-open-url-holders-nodoi\"><a class=\"js-open-url-link\" data-href-template=\"{targetURL}?sid=oup:orr&amp;genre=article&amp;atitle=Relationship+of+serum+sex+steroid+levels+and+bone+turnover+markers+with+bone+mineral+density+in+men+and+women%3a+a+key+role+for+bioavailable+estrogen&amp;aulast=Khosla&amp;title=J+Clin+Endocrinol+Metab&amp;date=1998&amp;spage=2266&amp;epage=2274&amp;volume=83&amp;issue=7\" href=\"javascript:;\"><span class=\"screenreader-text\">OpenURL Placeholder Text</span></a></span></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Relationship%20of%20serum%20sex%20steroid%20levels%20and%20bone%20turnover%20markers%20with%20bone%20mineral%20density%20in%20men%20and%20women%3A%20a%20key%20role%20for%20bioavailable%20estrogen&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B195\" class=\"js-splitview-ref-item\" data-legacy-id=\"B195\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B195\" href=\"javascript:;\" aria-label=\"jumplink-B195\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B195\" class=\"ref-content \" data-id=\"B195\"><span class=\"label\">195.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Mueller</div>  <div class=\"given-names\">A</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Dittrich</div>  <div class=\"given-names\">R</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Binder</div>  <div class=\"given-names\">H</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Kuehnel</div>  <div class=\"given-names\">W</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Maltaris</div>  <div class=\"given-names\">T</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Hoffmann</div>  <div class=\"given-names\">I</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Beckmann</div>  <div class=\"given-names\">MW</div>\r\n</span>\r\n</span>. <div class=\"article-title\">High dose estrogen treatment increases bone mineral density in male-to-female transsexuals receiving gonadotropin-releasing hormone agonist in the absence of testosterone</div>. <div class=\"source \">Eur J Endocrinol</div>. <div class=\"year\">2005</div>;<div class=\"volume\">153</div>(<div class=\"issue\">1</div>):<div class=\"fpage\">107</div>–<div class=\"lpage\">113</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=High%20dose%20estrogen%20treatment%20increases%20bone%20mineral%20density%20in%20male-to-female%20transsexuals%20receiving%20gonadotropin-releasing%20hormone%20agonist%20in%20the%20absence%20of%20testosterone&amp;author=A%20Mueller&amp;author=R%20Dittrich&amp;author=H%20Binder&amp;author=W%20Kuehnel&amp;author=T%20Maltaris&amp;author=I%20Hoffmann&amp;author=MW%20Beckmann&amp;publication_year=2005&amp;journal=Eur%20J%20Endocrinol&amp;volume=153&amp;pages=107-113\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1530/eje.1.01943\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1530%2Feje.1.01943\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1530%2Feje.1.01943\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/15994752\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:High%20dose%20estrogen%20treatment%20increases%20bone%20mineral%20density%20in%20male-to-female%20transsexuals%20receiving%20gonadotropin-releasing%20hormone%20agonist%20in%20the%20absence%20of%20testosterone&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B196\" class=\"js-splitview-ref-item\" data-legacy-id=\"B196\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B196\" href=\"javascript:;\" aria-label=\"jumplink-B196\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B196\" class=\"ref-content \" data-id=\"B196\"><span class=\"label\">196.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Ruetsche</div>  <div class=\"given-names\">AG</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Kneubuehl</div>  <div class=\"given-names\">R</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Birkhaeuser</div>  <div class=\"given-names\">MH</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Lippuner</div>  <div class=\"given-names\">K</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Cortical and trabecular bone mineral density in transsexuals after long-term cross-sex hormonal treatment: a cross-sectional study</div>. <div class=\"source \">Osteoporos Int</div>. <div class=\"year\">2005</div>;<div class=\"volume\">16</div>(<div class=\"issue\">7</div>):<div class=\"fpage\">791</div>–<div class=\"lpage\">798</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Cortical%20and%20trabecular%20bone%20mineral%20density%20in%20transsexuals%20after%20long-term%20cross-sex%20hormonal%20treatment%3A%20a%20cross-sectional%20study&amp;author=AG%20Ruetsche&amp;author=R%20Kneubuehl&amp;author=MH%20Birkhaeuser&amp;author=K%20Lippuner&amp;publication_year=2005&amp;journal=Osteoporos%20Int&amp;volume=16&amp;pages=791-798\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1007/s00198-004-1754-7\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1007%2Fs00198-004-1754-7\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1007%2Fs00198-004-1754-7\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/15502960\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Cortical%20and%20trabecular%20bone%20mineral%20density%20in%20transsexuals%20after%20long-term%20cross-sex%20hormonal%20treatment%3A%20a%20cross-sectional%20study&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B197\" class=\"js-splitview-ref-item\" data-legacy-id=\"B197\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B197\" href=\"javascript:;\" aria-label=\"jumplink-B197\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B197\" class=\"ref-content \" data-id=\"B197\"><span class=\"label\">197.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Ganly</div>  <div class=\"given-names\">I</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Taylor</div>  <div class=\"given-names\">EW</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Breast cancer in a trans-sexual man receiving hormone replacement therapy</div>. <div class=\"source \">Br J Surg</div>. <div class=\"year\">1995</div>;<div class=\"volume\">82</div>(<div class=\"issue\">3</div>):<div class=\"fpage\">341</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Breast%20cancer%20in%20a%20trans-sexual%20man%20receiving%20hormone%20replacement%20therapy&amp;author=I%20Ganly&amp;author=EW%20Taylor&amp;publication_year=1995&amp;journal=Br%20J%20Surg&amp;volume=82&amp;pages=341\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1002/(ISSN)1365-2168\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1002%2F(ISSN)1365-2168\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1002%2F(ISSN)1365-2168\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/7796003\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Breast%20cancer%20in%20a%20trans-sexual%20man%20receiving%20hormone%20replacement%20therapy&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B198\" class=\"js-splitview-ref-item\" data-legacy-id=\"B198\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B198\" href=\"javascript:;\" aria-label=\"jumplink-B198\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B198\" class=\"ref-content \" data-id=\"B198\"><span class=\"label\">198.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Pritchard</div>  <div class=\"given-names\">TJ</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Pankowsky</div>  <div class=\"given-names\">DA</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Crowe</div>  <div class=\"given-names\">JP</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Abdul-Karim</div>  <div class=\"given-names\">FW</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Breast cancer in a male-to-female transsexual. A case report</div>. <div class=\"source \">JAMA</div>. <div class=\"year\">1988</div>;<div class=\"volume\">259</div>(<div class=\"issue\">15</div>):<div class=\"fpage\">2278</div>–<div class=\"lpage\">2280</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Breast%20cancer%20in%20a%20male-to-female%20transsexual.%20A%20case%20report&amp;author=TJ%20Pritchard&amp;author=DA%20Pankowsky&amp;author=JP%20Crowe&amp;author=FW%20Abdul-Karim&amp;publication_year=1988&amp;journal=JAMA&amp;volume=259&amp;pages=2278-2280\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1001/jama.1988.03720150054036\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1001%2Fjama.1988.03720150054036\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1001%2Fjama.1988.03720150054036\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/2832627\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Breast%20cancer%20in%20a%20male-to-female%20transsexual.%20A%20case%20report&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B199\" class=\"js-splitview-ref-item\" data-legacy-id=\"B199\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B199\" href=\"javascript:;\" aria-label=\"jumplink-B199\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B199\" class=\"ref-content \" data-id=\"B199\"><span class=\"label\">199.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Symmers</div>  <div class=\"given-names\">WS</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Carcinoma of breast in trans-sexual individuals after surgical and hormonal interference with the primary and secondary sex characteristics</div>. <div class=\"source \">BMJ</div>. <div class=\"year\">1968</div>;<div class=\"volume\">2</div>(<div class=\"issue\">5597</div>):<div class=\"fpage\">83</div>–<div class=\"lpage\">85</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Carcinoma%20of%20breast%20in%20trans-sexual%20individuals%20after%20surgical%20and%20hormonal%20interference%20with%20the%20primary%20and%20secondary%20sex%20characteristics&amp;author=WS%20Symmers&amp;publication_year=1968&amp;journal=BMJ&amp;volume=2&amp;pages=83-85\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1136/bmj.2.5597.83\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1136%2Fbmj.2.5597.83\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1136%2Fbmj.2.5597.83\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/5689553\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Carcinoma%20of%20breast%20in%20trans-sexual%20individuals%20after%20surgical%20and%20hormonal%20interference%20with%20the%20primary%20and%20secondary%20sex%20characteristics&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B200\" class=\"js-splitview-ref-item\" data-legacy-id=\"B200\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B200\" href=\"javascript:;\" aria-label=\"jumplink-B200\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B200\" class=\"ref-content \" data-id=\"B200\"><span class=\"label\">200.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Brown</div>  <div class=\"given-names\">GR</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Breast cancer in transgender veterans: a ten-case series</div>. <div class=\"source \">LGBT Health</div>. <div class=\"year\">2015</div>;<div class=\"volume\">2</div>(<div class=\"issue\">1</div>):<div class=\"fpage\">77</div>–<div class=\"lpage\">80</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Breast%20cancer%20in%20transgender%20veterans%3A%20a%20ten-case%20series&amp;author=GR%20Brown&amp;publication_year=2015&amp;journal=LGBT%20Health&amp;volume=2&amp;pages=77-80\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1089/lgbt.2014.0123\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1089%2Flgbt.2014.0123\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1089%2Flgbt.2014.0123\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/26790021\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Breast%20cancer%20in%20transgender%20veterans%3A%20a%20ten-case%20series&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B201\" class=\"js-splitview-ref-item\" data-legacy-id=\"B201\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B201\" href=\"javascript:;\" aria-label=\"jumplink-B201\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B201\" class=\"ref-content \" data-id=\"B201\"><span class=\"label\">201.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Shao</div>  <div class=\"given-names\">T</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Grossbard</div>  <div class=\"given-names\">ML</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Klein</div>  <div class=\"given-names\">P</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Breast cancer in female-to-male transsexuals: two cases with a review of physiology and management</div>. <div class=\"source \">Clin Breast Cancer</div>. <div class=\"year\">2011</div>;<div class=\"volume\">11</div>(<div class=\"issue\">6</div>):<div class=\"fpage\">417</div>–<div class=\"lpage\">419</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Breast%20cancer%20in%20female-to-male%20transsexuals%3A%20two%20cases%20with%20a%20review%20of%20physiology%20and%20management&amp;author=T%20Shao&amp;author=ML%20Grossbard&amp;author=P%20Klein&amp;publication_year=2011&amp;journal=Clin%20Breast%20Cancer&amp;volume=11&amp;pages=417-419\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1016/j.clbc.2011.06.006\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1016%2Fj.clbc.2011.06.006\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1016%2Fj.clbc.2011.06.006\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/21831723\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Breast%20cancer%20in%20female-to-male%20transsexuals%3A%20two%20cases%20with%20a%20review%20of%20physiology%20and%20management&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B202\" class=\"js-splitview-ref-item\" data-legacy-id=\"B202\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B202\" href=\"javascript:;\" aria-label=\"jumplink-B202\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B202\" class=\"ref-content \" data-id=\"B202\"><span class=\"label\">202.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Nikolic</div>  <div class=\"given-names\">DV</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Djordjevic</div>  <div class=\"given-names\">ML</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Granic</div>  <div class=\"given-names\">M</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Nikolic</div>  <div class=\"given-names\">AT</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Stanimirovic</div>  <div class=\"given-names\">VV</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Zdravkovic</div>  <div class=\"given-names\">D</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Jelic</div>  <div class=\"given-names\">S</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Importance of revealing a rare case of breast cancer in a female to male transsexual after bilateral mastectomy</div>. <div class=\"source \">World J Surg Oncol</div>. <div class=\"year\">2012</div>;<div class=\"volume\">10</div>:<div class=\"fpage\">280</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Importance%20of%20revealing%20a%20rare%20case%20of%20breast%20cancer%20in%20a%20female%20to%20male%20transsexual%20after%20bilateral%20mastectomy&amp;author=DV%20Nikolic&amp;author=ML%20Djordjevic&amp;author=M%20Granic&amp;author=AT%20Nikolic&amp;author=VV%20Stanimirovic&amp;author=D%20Zdravkovic&amp;author=S%20Jelic&amp;publication_year=2012&amp;journal=World%20J%20Surg%20Oncol&amp;volume=10&amp;pages=280\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1186/1477-7819-10-280\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1186%2F1477-7819-10-280\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1186%2F1477-7819-10-280\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23273269\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Importance%20of%20revealing%20a%20rare%20case%20of%20breast%20cancer%20in%20a%20female%20to%20male%20transsexual%20after%20bilateral%20mastectomy&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B203\" class=\"js-splitview-ref-item\" data-legacy-id=\"B203\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B203\" href=\"javascript:;\" aria-label=\"jumplink-B203\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B203\" class=\"ref-content \" data-id=\"B203\"><span class=\"label\">203.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Bösze</div>  <div class=\"given-names\">P</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Tóth</div>  <div class=\"given-names\">A</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Török</div>  <div class=\"given-names\">M</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Hormone replacement and the risk of breast cancer in Turner’s syndrome</div>. <div class=\"source \">N Engl J Med</div>. <div class=\"year\">2006</div>;<div class=\"volume\">355</div>(<div class=\"issue\">24</div>):<div class=\"fpage\">2599</div>–<div class=\"lpage\">2600</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Hormone%20replacement%20and%20the%20risk%20of%20breast%20cancer%20in%20Turner%E2%80%99s%20syndrome&amp;author=P%20B%C3%B6sze&amp;author=A%20T%C3%B3th&amp;author=M%20T%C3%B6r%C3%B6k&amp;publication_year=2006&amp;journal=N%20Engl%20J%20Med&amp;volume=355&amp;pages=2599-2600\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1056/NEJMc062795\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1056%2FNEJMc062795\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1056%2FNEJMc062795\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/17167149\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Hormone%20replacement%20and%20the%20risk%20of%20breast%20cancer%20in%20Turner%E2%80%99s%20syndrome&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B204\" class=\"js-splitview-ref-item\" data-legacy-id=\"B204\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B204\" href=\"javascript:;\" aria-label=\"jumplink-B204\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B204\" class=\"ref-content \" data-id=\"B204\"><span class=\"label\">204.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Schoemaker</div>  <div class=\"given-names\">MJ</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Swerdlow</div>  <div class=\"given-names\">AJ</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Higgins</div>  <div class=\"given-names\">CD</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Wright</div>  <div class=\"given-names\">AF</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Jacobs</div>  <div class=\"given-names\">PA</div>\r\n</span>; <div class=\"collab\">UK Clinical Cytogenetics Group</div>\r\n</span>. <div class=\"article-title\">Cancer incidence in women with Turner syndrome in Great Britain: a national cohort study</div>. <div class=\"source \">Lancet Oncol</div>. <div class=\"year\">2008</div>;<div class=\"volume\">9</div>(<div class=\"issue\">3</div>):<div class=\"fpage\">239</div>–<div class=\"lpage\">246</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Cancer%20incidence%20in%20women%20with%20Turner%20syndrome%20in%20Great%20Britain%3A%20a%20national%20cohort%20study&amp;author=MJ%20Schoemaker&amp;author=AJ%20Swerdlow&amp;author=CD%20Higgins&amp;author=AF%20Wright&amp;author=PA%20Jacobs&amp;publication_year=2008&amp;journal=Lancet%20Oncol&amp;volume=9&amp;pages=239-246\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1016/S1470-2045(08)70033-0\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1016%2FS1470-2045(08)70033-0\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1016%2FS1470-2045(08)70033-0\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/18282803\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Cancer%20incidence%20in%20women%20with%20Turner%20syndrome%20in%20Great%20Britain%3A%20a%20national%20cohort%20study&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B205\" class=\"js-splitview-ref-item\" data-legacy-id=\"B205\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B205\" href=\"javascript:;\" aria-label=\"jumplink-B205\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B205\" class=\"ref-content \" data-id=\"B205\"><span class=\"label\">205.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Smith</div>  <div class=\"given-names\">RA</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Cokkinides</div>  <div class=\"given-names\">V</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Eyre</div>  <div class=\"given-names\">HJ</div>\r\n</span>\r\n</span>. <div class=\"article-title\">American Cancer Society guidelines for the early detection of cancer, 2006</div>. <div class=\"source \">CA Cancer J Clin</div>. <div class=\"year\">2006</div>;<div class=\"volume\">56</div>(<div class=\"issue\">1</div>):<div class=\"fpage\">11</div>–<div class=\"lpage\">25, quiz 49–50</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=American%20Cancer%20Society%20guidelines%20for%20the%20early%20detection%20of%20cancer%2C%202006&amp;author=RA%20Smith&amp;author=V%20Cokkinides&amp;author=HJ%20Eyre&amp;publication_year=2006&amp;journal=CA%20Cancer%20J%20Clin&amp;volume=56&amp;pages=11-25, quiz 49–50\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.3322/canjclin.56.1.11\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.3322%2Fcanjclin.56.1.11\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.3322%2Fcanjclin.56.1.11\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/16449183\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:American%20Cancer%20Society%20guidelines%20for%20the%20early%20detection%20of%20cancer%2C%202006&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B206\" class=\"js-splitview-ref-item\" data-legacy-id=\"B206\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B206\" href=\"javascript:;\" aria-label=\"jumplink-B206\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B206\" class=\"ref-content \" data-id=\"B206\"><span class=\"label\">206.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Wilson</div>  <div class=\"given-names\">JD</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Roehrborn</div>  <div class=\"given-names\">C</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Long-term consequences of castration in men: lessons from the Skoptzy and the eunuchs of the Chinese and Ottoman courts</div>. <div class=\"source \">J Clin Endocrinol Metab</div>. <div class=\"year\">1999</div>;<div class=\"volume\">84</div>(<div class=\"issue\">12</div>):<div class=\"fpage\">4324</div>–<div class=\"lpage\">4331</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Long-term%20consequences%20of%20castration%20in%20men%3A%20lessons%20from%20the%20Skoptzy%20and%20the%20eunuchs%20of%20the%20Chinese%20and%20Ottoman%20courts&amp;author=JD%20Wilson&amp;author=C%20Roehrborn&amp;publication_year=1999&amp;journal=J%20Clin%20Endocrinol%20Metab&amp;volume=84&amp;pages=4324-4331\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1210/jcem.84.12.6206\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1210%2Fjcem.84.12.6206\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1210%2Fjcem.84.12.6206\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/10599682\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Long-term%20consequences%20of%20castration%20in%20men%3A%20lessons%20from%20the%20Skoptzy%20and%20the%20eunuchs%20of%20the%20Chinese%20and%20Ottoman%20courts&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B207\" class=\"js-splitview-ref-item\" data-legacy-id=\"B207\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B207\" href=\"javascript:;\" aria-label=\"jumplink-B207\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B207\" class=\"ref-content \" data-id=\"B207\"><span class=\"label\">207.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">van Kesteren</div>  <div class=\"given-names\">P</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Meinhardt</div>  <div class=\"given-names\">W</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">van der Valk</div>  <div class=\"given-names\">P</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Geldof</div>  <div class=\"given-names\">A</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Megens</div>  <div class=\"given-names\">J</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Gooren</div>  <div class=\"given-names\">L</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Effects of estrogens only on the prostates of aging men</div>. <div class=\"source \">J Urol</div>. <div class=\"year\">1996</div>;<div class=\"volume\">156</div>(<div class=\"issue\">4</div>):<div class=\"fpage\">1349</div>–<div class=\"lpage\">1353</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Effects%20of%20estrogens%20only%20on%20the%20prostates%20of%20aging%20men&amp;author=P%20van%20Kesteren&amp;author=W%20Meinhardt&amp;author=P%20van%20der%20Valk&amp;author=A%20Geldof&amp;author=J%20Megens&amp;author=L%20Gooren&amp;publication_year=1996&amp;journal=J%20Urol&amp;volume=156&amp;pages=1349-1353\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1016/S0022-5347(01)65584-8\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1016%2FS0022-5347(01)65584-8\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1016%2FS0022-5347(01)65584-8\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/8808869\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Effects%20of%20estrogens%20only%20on%20the%20prostates%20of%20aging%20men&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B208\" class=\"js-splitview-ref-item\" data-legacy-id=\"B208\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B208\" href=\"javascript:;\" aria-label=\"jumplink-B208\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B208\" class=\"ref-content \" data-id=\"B208\"><span class=\"label\">208.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Brown</div>  <div class=\"given-names\">JA</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Wilson</div>  <div class=\"given-names\">TM</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Benign prostatic hyperplasia requiring transurethral resection of the prostate in a 60-year-old male-to-female transsexual</div>. <div class=\"source \">Br J Urol</div>. <div class=\"year\">1997</div>;<div class=\"volume\">80</div>(<div class=\"issue\">6</div>):<div class=\"fpage\">956</div>–<div class=\"lpage\">957</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Benign%20prostatic%20hyperplasia%20requiring%20transurethral%20resection%20of%20the%20prostate%20in%20a%2060-year-old%20male-to-female%20transsexual&amp;author=JA%20Brown&amp;author=TM%20Wilson&amp;publication_year=1997&amp;journal=Br%20J%20Urol&amp;volume=80&amp;pages=956-957\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1046/j.1464-410X.1997.00342.x\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1046%2Fj.1464-410X.1997.00342.x\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1046%2Fj.1464-410X.1997.00342.x\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/9439420\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Benign%20prostatic%20hyperplasia%20requiring%20transurethral%20resection%20of%20the%20prostate%20in%20a%2060-year-old%20male-to-female%20transsexual&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B209\" class=\"js-splitview-ref-item\" data-legacy-id=\"B209\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B209\" href=\"javascript:;\" aria-label=\"jumplink-B209\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B209\" class=\"ref-content \" data-id=\"B209\"><span class=\"label\">209.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Casella</div>  <div class=\"given-names\">R</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Bubendorf</div>  <div class=\"given-names\">L</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Schaefer</div>  <div class=\"given-names\">DJ</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Bachmann</div>  <div class=\"given-names\">A</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Gasser</div>  <div class=\"given-names\">TC</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Sulser</div>  <div class=\"given-names\">T</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Does the prostate really need androgens to grow? Transurethral resection of the prostate in a male-to-female transsexual 25 years after sex-changing operation</div>. <div class=\"source \">Urol Int</div>. <div class=\"year\">2005</div>;<div class=\"volume\">75</div>(<div class=\"issue\">3</div>):<div class=\"fpage\">288</div>–<div class=\"lpage\">290</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Does%20the%20prostate%20really%20need%20androgens%20to%20grow%3F%20Transurethral%20resection%20of%20the%20prostate%20in%20a%20male-to-female%20transsexual%2025%20years%20after%20sex-changing%20operation&amp;author=R%20Casella&amp;author=L%20Bubendorf&amp;author=DJ%20Schaefer&amp;author=A%20Bachmann&amp;author=TC%20Gasser&amp;author=T%20Sulser&amp;publication_year=2005&amp;journal=Urol%20Int&amp;volume=75&amp;pages=288-290\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1159/000087811\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1159%2F000087811\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1159%2F000087811\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/16215322\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Does%20the%20prostate%20really%20need%20androgens%20to%20grow%3F%20Transurethral%20resection%20of%20the%20prostate%20in%20a%20male-to-female%20transsexual%2025%20years%20after%20sex-changing%20operation&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B210\" class=\"js-splitview-ref-item\" data-legacy-id=\"B210\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B210\" href=\"javascript:;\" aria-label=\"jumplink-B210\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B210\" class=\"ref-content \" data-id=\"B210\"><span class=\"label\">210.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Dorff</div>  <div class=\"given-names\">TB</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Shazer</div>  <div class=\"given-names\">RL</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Nepomuceno</div>  <div class=\"given-names\">EM</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Tucker</div>  <div class=\"given-names\">SJ</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Successful treatment of metastatic androgen-independent prostate carcinoma in a transsexual patient</div>. <div class=\"source \">Clin Genitourin Cancer</div>. <div class=\"year\">2007</div>;<div class=\"volume\">5</div>(<div class=\"issue\">5</div>):<div class=\"fpage\">344</div>–<div class=\"lpage\">346</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Successful%20treatment%20of%20metastatic%20androgen-independent%20prostate%20carcinoma%20in%20a%20transsexual%20patient&amp;author=TB%20Dorff&amp;author=RL%20Shazer&amp;author=EM%20Nepomuceno&amp;author=SJ%20Tucker&amp;publication_year=2007&amp;journal=Clin%20Genitourin%20Cancer&amp;volume=5&amp;pages=344-346\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.3816/CGC.2007.n.016\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.3816%2FCGC.2007.n.016\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.3816%2FCGC.2007.n.016\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/17645834\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Successful%20treatment%20of%20metastatic%20androgen-independent%20prostate%20carcinoma%20in%20a%20transsexual%20patient&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B211\" class=\"js-splitview-ref-item\" data-legacy-id=\"B211\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B211\" href=\"javascript:;\" aria-label=\"jumplink-B211\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B211\" class=\"ref-content \" data-id=\"B211\"><span class=\"label\">211.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Thurston</div>  <div class=\"given-names\">AV</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Carcinoma of the prostate in a transsexual</div>. <div class=\"source \">Br J Urol</div>. <div class=\"year\">1994</div>;<div class=\"volume\">73</div>(<div class=\"issue\">2</div>):<div class=\"fpage\">217</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Carcinoma%20of%20the%20prostate%20in%20a%20transsexual&amp;author=AV%20Thurston&amp;publication_year=1994&amp;journal=Br%20J%20Urol&amp;volume=73&amp;pages=217\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1111/bju.1994.73.issue-2\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1111%2Fbju.1994.73.issue-2\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1111%2Fbju.1994.73.issue-2\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/8131033\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Carcinoma%20of%20the%20prostate%20in%20a%20transsexual&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B212\" class=\"js-splitview-ref-item\" data-legacy-id=\"B212\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B212\" href=\"javascript:;\" aria-label=\"jumplink-B212\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B212\" class=\"ref-content \" data-id=\"B212\"><span class=\"label\">212.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<div class=\"comment\">van Harst EP, Newling DW, Gooren LJ, Asscheman H, Prenger DM.</div>\r\n<div class=\"article-title\"> Metastatic prostatic carcinoma in a male-to-female transsexual</div>. <div class=\"source \">BJU Int</div>. <div class=\"year\">1998</div>;<div class=\"volume\">81</div>:<div class=\"fpage\">776</div>.</p></div></div></div></div><div content-id=\"B213\" class=\"js-splitview-ref-item\" data-legacy-id=\"B213\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B213\" href=\"javascript:;\" aria-label=\"jumplink-B213\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B213\" class=\"ref-content \" data-id=\"B213\"><span class=\"label\">213.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Turo</div>  <div class=\"given-names\">R</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Jallad</div>  <div class=\"given-names\">S</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Prescott</div>  <div class=\"given-names\">S</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Cross</div>  <div class=\"given-names\">WR</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Metastatic prostate cancer in transsexual diagnosed after three decades of estrogen therapy</div>. <div class=\"source \">Can Urol Assoc J</div>. <div class=\"year\">2013</div>;<div class=\"volume\">7</div>(<div class=\"issue\">7–8</div>):<div class=\"fpage\">E544</div>–<div class=\"lpage\">E546</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Metastatic%20prostate%20cancer%20in%20transsexual%20diagnosed%20after%20three%20decades%20of%20estrogen%20therapy&amp;author=R%20Turo&amp;author=S%20Jallad&amp;author=S%20Prescott&amp;author=WR%20Cross&amp;publication_year=2013&amp;journal=Can%20Urol%20Assoc%20J&amp;volume=7&amp;pages=E544-E546\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.5489/cuaj.175\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.5489%2Fcuaj.175\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.5489%2Fcuaj.175\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/24032068\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Metastatic%20prostate%20cancer%20in%20transsexual%20diagnosed%20after%20three%20decades%20of%20estrogen%20therapy&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B214\" class=\"js-splitview-ref-item\" data-legacy-id=\"B214\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B214\" href=\"javascript:;\" aria-label=\"jumplink-B214\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B214\" class=\"ref-content \" data-id=\"B214\"><span class=\"label\">214.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Miksad</div>  <div class=\"given-names\">RA</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Bubley</div>  <div class=\"given-names\">G</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Church</div>  <div class=\"given-names\">P</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Sanda</div>  <div class=\"given-names\">M</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Rofsky</div>  <div class=\"given-names\">N</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Kaplan</div>  <div class=\"given-names\">I</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Cooper</div>  <div class=\"given-names\">A</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Prostate cancer in a transgender woman 41 years after initiation of feminization</div>. <div class=\"source \">JAMA</div>. <div class=\"year\">2006</div>;<div class=\"volume\">296</div>(<div class=\"issue\">19</div>):<div class=\"fpage\">2316</div>–<div class=\"lpage\">2317</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Prostate%20cancer%20in%20a%20transgender%20woman%2041%20years%20after%20initiation%20of%20feminization&amp;author=RA%20Miksad&amp;author=G%20Bubley&amp;author=P%20Church&amp;author=M%20Sanda&amp;author=N%20Rofsky&amp;author=I%20Kaplan&amp;author=A%20Cooper&amp;publication_year=2006&amp;journal=JAMA&amp;volume=296&amp;pages=2316-2317\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1001/jama.296.19.2316\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1001%2Fjama.296.19.2316\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1001%2Fjama.296.19.2316\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/17105793\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Prostate%20cancer%20in%20a%20transgender%20woman%2041%20years%20after%20initiation%20of%20feminization&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B215\" class=\"js-splitview-ref-item\" data-legacy-id=\"B215\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B215\" href=\"javascript:;\" aria-label=\"jumplink-B215\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B215\" class=\"ref-content \" data-id=\"B215\"><span class=\"label\">215.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Moyer</div>  <div class=\"given-names\">VA</div>\r\n</span>; <div class=\"collab\">U.S. Preventive Services Task Force</div>\r\n</span>. <div class=\"article-title\">Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement</div>. <div class=\"source \">Ann Intern Med</div>. <div class=\"year\">2012</div>;<div class=\"volume\">157</div>(<div class=\"issue\">2</div>):<div class=\"fpage\">120</div>–<div class=\"lpage\">134</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Screening%20for%20prostate%20cancer%3A%20U.S.%20Preventive%20Services%20Task%20Force%20recommendation%20statement&amp;author=VA%20Moyer&amp;publication_year=2012&amp;journal=Ann%20Intern%20Med&amp;volume=157&amp;pages=120-134\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.7326/0003-4819-157-2-201207170-00459\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.7326%2F0003-4819-157-2-201207170-00459\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.7326%2F0003-4819-157-2-201207170-00459\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22801674\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Screening%20for%20prostate%20cancer%3A%20U.S.%20Preventive%20Services%20Task%20Force%20recommendation%20statement&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B216\" class=\"js-splitview-ref-item\" data-legacy-id=\"B216\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B216\" href=\"javascript:;\" aria-label=\"jumplink-B216\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B216\" class=\"ref-content \" data-id=\"B216\"><span class=\"label\">216.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Futterweit</div>  <div class=\"given-names\">W</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Endocrine therapy of transsexualism and potential complications of long-term treatment</div>. <div class=\"source \">Arch Sex Behav</div>. <div class=\"year\">1998</div>;<div class=\"volume\">27</div>(<div class=\"issue\">2</div>):<div class=\"fpage\">209</div>–<div class=\"lpage\">226</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Endocrine%20therapy%20of%20transsexualism%20and%20potential%20complications%20of%20long-term%20treatment&amp;author=W%20Futterweit&amp;publication_year=1998&amp;journal=Arch%20Sex%20Behav&amp;volume=27&amp;pages=209-226\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1023/A:1018638715498\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1023%2FA:1018638715498\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1023%2FA:1018638715498\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/9562902\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Endocrine%20therapy%20of%20transsexualism%20and%20potential%20complications%20of%20long-term%20treatment&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B217\" class=\"js-splitview-ref-item\" data-legacy-id=\"B217\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B217\" href=\"javascript:;\" aria-label=\"jumplink-B217\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B217\" class=\"ref-content \" data-id=\"B217\"><span class=\"label\">217.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Miller</div>  <div class=\"given-names\">N</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Bédard</div>  <div class=\"given-names\">YC</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Cooter</div>  <div class=\"given-names\">NB</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Shaul</div>  <div class=\"given-names\">DL</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Histological changes in the genital tract in transsexual women following androgen therapy</div>. <div class=\"source \">Histopathology</div>. <div class=\"year\">1986</div>;<div class=\"volume\">10</div>(<div class=\"issue\">7</div>):<div class=\"fpage\">661</div>–<div class=\"lpage\">669</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Histological%20changes%20in%20the%20genital%20tract%20in%20transsexual%20women%20following%20androgen%20therapy&amp;author=N%20Miller&amp;author=YC%20B%C3%A9dard&amp;author=NB%20Cooter&amp;author=DL%20Shaul&amp;publication_year=1986&amp;journal=Histopathology&amp;volume=10&amp;pages=661-669\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1111/his.1986.10.issue-7\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1111%2Fhis.1986.10.issue-7\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1111%2Fhis.1986.10.issue-7\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/2427430\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Histological%20changes%20in%20the%20genital%20tract%20in%20transsexual%20women%20following%20androgen%20therapy&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B218\" class=\"js-splitview-ref-item\" data-legacy-id=\"B218\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B218\" href=\"javascript:;\" aria-label=\"jumplink-B218\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B218\" class=\"ref-content \" data-id=\"B218\"><span class=\"label\">218.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">O’Hanlan</div>  <div class=\"given-names\">KA</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Dibble</div>  <div class=\"given-names\">SL</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Young-Spint</div>  <div class=\"given-names\">M</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Total laparoscopic hysterectomy for female-to-male transsexuals</div>. <div class=\"source \">Obstet Gynecol</div>. <div class=\"year\">2007</div>;<div class=\"volume\">110</div>(<div class=\"issue\">5</div>):<div class=\"fpage\">1096</div>–<div class=\"lpage\">1101</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Total%20laparoscopic%20hysterectomy%20for%20female-to-male%20transsexuals&amp;author=KA%20O%E2%80%99Hanlan&amp;author=SL%20Dibble&amp;author=M%20Young-Spint&amp;publication_year=2007&amp;journal=Obstet%20Gynecol&amp;volume=110&amp;pages=1096-1101\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1097/01.AOG.0000286778.44943.5a\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1097%2F01.AOG.0000286778.44943.5a\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1097%2F01.AOG.0000286778.44943.5a\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/17978125\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Total%20laparoscopic%20hysterectomy%20for%20female-to-male%20transsexuals&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B219\" class=\"js-splitview-ref-item\" data-legacy-id=\"B219\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B219\" href=\"javascript:;\" aria-label=\"jumplink-B219\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B219\" class=\"ref-content \" data-id=\"B219\"><span class=\"label\">219.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Dizon</div>  <div class=\"given-names\">DS</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Tejada-Berges</div>  <div class=\"given-names\">T</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Koelliker</div>  <div class=\"given-names\">S</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Steinhoff</div>  <div class=\"given-names\">M</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Granai</div>  <div class=\"given-names\">CO</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Ovarian cancer associated with testosterone supplementation in a female-to-male transsexual patient</div>. <div class=\"source \">Gynecol Obstet Invest</div>. <div class=\"year\">2006</div>;<div class=\"volume\">62</div>(<div class=\"issue\">4</div>):<div class=\"fpage\">226</div>–<div class=\"lpage\">228</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Ovarian%20cancer%20associated%20with%20testosterone%20supplementation%20in%20a%20female-to-male%20transsexual%20patient&amp;author=DS%20Dizon&amp;author=T%20Tejada-Berges&amp;author=S%20Koelliker&amp;author=M%20Steinhoff&amp;author=CO%20Granai&amp;publication_year=2006&amp;journal=Gynecol%20Obstet%20Invest&amp;volume=62&amp;pages=226-228\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1159/000094097\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1159%2F000094097\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1159%2F000094097\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/16804313\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Ovarian%20cancer%20associated%20with%20testosterone%20supplementation%20in%20a%20female-to-male%20transsexual%20patient&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B220\" class=\"js-splitview-ref-item\" data-legacy-id=\"B220\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B220\" href=\"javascript:;\" aria-label=\"jumplink-B220\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B220\" class=\"ref-content \" data-id=\"B220\"><span class=\"label\">220.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Hage</div>  <div class=\"given-names\">JJ</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Dekker</div>  <div class=\"given-names\">JJML</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Karim</div>  <div class=\"given-names\">RB</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Verheijen</div>  <div class=\"given-names\">RHM</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Bloemena</div>  <div class=\"given-names\">E</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Ovarian cancer in female-to-male transsexuals: report of two cases</div>. <div class=\"source \">Gynecol Oncol</div>. <div class=\"year\">2000</div>;<div class=\"volume\">76</div>(<div class=\"issue\">3</div>):<div class=\"fpage\">413</div>–<div class=\"lpage\">415</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Ovarian%20cancer%20in%20female-to-male%20transsexuals%3A%20report%20of%20two%20cases&amp;author=JJ%20Hage&amp;author=JJML%20Dekker&amp;author=RB%20Karim&amp;author=RHM%20Verheijen&amp;author=E%20Bloemena&amp;publication_year=2000&amp;journal=Gynecol%20Oncol&amp;volume=76&amp;pages=413-415\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1006/gyno.1999.5720\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1006%2Fgyno.1999.5720\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1006%2Fgyno.1999.5720\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/10684720\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Ovarian%20cancer%20in%20female-to-male%20transsexuals%3A%20report%20of%20two%20cases&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B221\" class=\"js-splitview-ref-item\" data-legacy-id=\"B221\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B221\" href=\"javascript:;\" aria-label=\"jumplink-B221\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B221\" class=\"ref-content \" data-id=\"B221\"><span class=\"label\">221.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Mueller</div>  <div class=\"given-names\">A</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Gooren</div>  <div class=\"given-names\">L</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Hormone-related tumors in transsexuals receiving treatment with cross-sex hormones</div>. <div class=\"source \">Eur J Endocrinol</div>. <div class=\"year\">2008</div>;<div class=\"volume\">159</div>(<div class=\"issue\">3</div>):<div class=\"fpage\">197</div>–<div class=\"lpage\">202</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Hormone-related%20tumors%20in%20transsexuals%20receiving%20treatment%20with%20cross-sex%20hormones&amp;author=A%20Mueller&amp;author=L%20Gooren&amp;publication_year=2008&amp;journal=Eur%20J%20Endocrinol&amp;volume=159&amp;pages=197-202\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1530/EJE-08-0289\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1530%2FEJE-08-0289\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1530%2FEJE-08-0289\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/18567667\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Hormone-related%20tumors%20in%20transsexuals%20receiving%20treatment%20with%20cross-sex%20hormones&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B222\" class=\"js-splitview-ref-item\" data-legacy-id=\"B222\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B222\" href=\"javascript:;\" aria-label=\"jumplink-B222\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B222\" class=\"ref-content \" data-id=\"B222\"><span class=\"label\">222.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Coleman</div>  <div class=\"given-names\">E</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Bockting</div>  <div class=\"given-names\">W</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Botzer</div>  <div class=\"given-names\">M</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Cohen-Kettenis</div>  <div class=\"given-names\">P</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">DeCuypere</div>  <div class=\"given-names\">G</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Feldman</div>  <div class=\"given-names\">J</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Fraser</div>  <div class=\"given-names\">L</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Green</div>  <div class=\"given-names\">J</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Knudson</div>  <div class=\"given-names\">G</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Meyer</div>  <div class=\"given-names\">WJ</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Monstrey</div>  <div class=\"given-names\">S</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Adler</div>  <div class=\"given-names\">RK</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Brown</div>  <div class=\"given-names\">GR</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Devor</div>  <div class=\"given-names\">AH</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Ehrbar</div>  <div class=\"given-names\">R</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Ettner</div>  <div class=\"given-names\">R</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Eyler</div>  <div class=\"given-names\">E</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Garofalo</div>  <div class=\"given-names\">R</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Karasic</div>  <div class=\"given-names\">DH</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Lev</div>  <div class=\"given-names\">AI</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Mayer</div>  <div class=\"given-names\">G</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Meyer-Bahlburg</div>  <div class=\"given-names\">H</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Hall</div>  <div class=\"given-names\">BP</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Pfaefflin</div>  <div class=\"given-names\">F</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Rachlin</div>  <div class=\"given-names\">K</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Robinson</div>  <div class=\"given-names\">B</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Schechter</div>  <div class=\"given-names\">LS</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Tangpricha</div>  <div class=\"given-names\">V</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">van Trotsenburg</div>  <div class=\"given-names\">M</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Vitale</div>  <div class=\"given-names\">A</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Winter</div>  <div class=\"given-names\">S</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Whittle</div>  <div class=\"given-names\">S</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Wylie</div>  <div class=\"given-names\">KR</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Zucker</div>  <div class=\"given-names\">K</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Standards of care for the health of transsexual, transgender, and gender-nonconforming people, version 7</div>. <div class=\"source \">Int J Transgenderism</div>. <div class=\"year\">2012</div>;<div class=\"volume\">13</div>:<div class=\"fpage\">165</div>–<div class=\"lpage\">232</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Standards%20of%20care%20for%20the%20health%20of%20transsexual%2C%20transgender%2C%20and%20gender-nonconforming%20people%2C%20version%207&amp;author=E%20Coleman&amp;author=W%20Bockting&amp;author=M%20Botzer&amp;author=P%20Cohen-Kettenis&amp;author=G%20DeCuypere&amp;author=J%20Feldman&amp;author=L%20Fraser&amp;author=J%20Green&amp;author=G%20Knudson&amp;author=WJ%20Meyer&amp;author=S%20Monstrey&amp;author=RK%20Adler&amp;author=GR%20Brown&amp;author=AH%20Devor&amp;author=R%20Ehrbar&amp;author=R%20Ettner&amp;author=E%20Eyler&amp;author=R%20Garofalo&amp;author=DH%20Karasic&amp;author=AI%20Lev&amp;author=G%20Mayer&amp;author=H%20Meyer-Bahlburg&amp;author=BP%20Hall&amp;author=F%20Pfaefflin&amp;author=K%20Rachlin&amp;author=B%20Robinson&amp;author=LS%20Schechter&amp;author=V%20Tangpricha&amp;author=M%20van%20Trotsenburg&amp;author=A%20Vitale&amp;author=S%20Winter&amp;author=S%20Whittle&amp;author=KR%20Wylie&amp;author=K%20Zucker&amp;publication_year=2012&amp;journal=Int%20J%20Transgenderism&amp;volume=13&amp;pages=165-232\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1080/15532739.2011.700873\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1080%2F15532739.2011.700873\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1080%2F15532739.2011.700873\"> </span></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Standards%20of%20care%20for%20the%20health%20of%20transsexual%2C%20transgender%2C%20and%20gender-nonconforming%20people%2C%20version%207&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B223\" class=\"js-splitview-ref-item\" data-legacy-id=\"B223\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B223\" href=\"javascript:;\" aria-label=\"jumplink-B223\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B223\" class=\"ref-content \" data-id=\"B223\"><span class=\"label\">223.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Colebunders</div>  <div class=\"given-names\">B</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">D’Arpa</div>  <div class=\"given-names\">S</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Weijers</div>  <div class=\"given-names\">S</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Lumen</div>  <div class=\"given-names\">N</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Hoebeke</div>  <div class=\"given-names\">P</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Monstrey</div>  <div class=\"given-names\">S</div>\r\n</span>\r\n</span>. <div class=\"comment\">Female-to-male gender reassignment surgery. In: Ettner R, Monstrey S, Coleman E, eds. <em>Principles of Transgender Medicine and Surgery</em>. 2nd ed. New York, NY: Routledge Taylor &amp; Francis Group; 2016:279–317.</div>\r\n</p></div></div></div></div><div content-id=\"B224\" class=\"js-splitview-ref-item\" data-legacy-id=\"B224\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B224\" href=\"javascript:;\" aria-label=\"jumplink-B224\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B224\" class=\"ref-content \" data-id=\"B224\"><span class=\"label\">224.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Monstrey</div>  <div class=\"given-names\">S</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Hoebeke</div>  <div class=\"given-names\">P</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Dhont</div>  <div class=\"given-names\">M</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">De Cuypere</div>  <div class=\"given-names\">G</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Rubens</div>  <div class=\"given-names\">R</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Moerman</div>  <div class=\"given-names\">M</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Hamdi</div>  <div class=\"given-names\">M</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Van Landuyt</div>  <div class=\"given-names\">K</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Blondeel</div>  <div class=\"given-names\">P</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Surgical therapy in transsexual patients: a multi-disciplinary approach</div>. <div class=\"source \">Acta Chir Belg</div>. <div class=\"year\">2001</div>;<div class=\"volume\">101</div>(<div class=\"issue\">5</div>):<div class=\"fpage\">200</div>–<div class=\"lpage\">209</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Surgical%20therapy%20in%20transsexual%20patients%3A%20a%20multi-disciplinary%20approach&amp;author=S%20Monstrey&amp;author=P%20Hoebeke&amp;author=M%20Dhont&amp;author=G%20De%20Cuypere&amp;author=R%20Rubens&amp;author=M%20Moerman&amp;author=M%20Hamdi&amp;author=K%20Van%20Landuyt&amp;author=P%20Blondeel&amp;publication_year=2001&amp;journal=Acta%20Chir%20Belg&amp;volume=101&amp;pages=200-209\" target=\"_blank\">Google Scholar</a></span></p><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/11758101\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><div class=\"xslopenurl empty-target\"><span class=\"js-inst-open-url-holders-nodoi\"><a class=\"js-open-url-link\" data-href-template=\"{targetURL}?sid=oup:orr&amp;genre=article&amp;atitle=Surgical+therapy+in+transsexual+patients%3a+a+multi-disciplinary+approach&amp;aulast=Monstrey&amp;title=Acta+Chir+Belg&amp;date=2001&amp;spage=200&amp;epage=209&amp;volume=101&amp;issue=5\" href=\"javascript:;\"><span class=\"screenreader-text\">OpenURL Placeholder Text</span></a></span></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Surgical%20therapy%20in%20transsexual%20patients%3A%20a%20multi-disciplinary%20approach&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B225\" class=\"js-splitview-ref-item\" data-legacy-id=\"B225\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B225\" href=\"javascript:;\" aria-label=\"jumplink-B225\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B225\" class=\"ref-content \" data-id=\"B225\"><span class=\"label\">225.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Selvaggi</div>  <div class=\"given-names\">G</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Ceulemans</div>  <div class=\"given-names\">P</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">De Cuypere</div>  <div class=\"given-names\">G</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">VanLanduyt</div>  <div class=\"given-names\">K</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Blondeel</div>  <div class=\"given-names\">P</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Hamdi</div>  <div class=\"given-names\">M</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Bowman</div>  <div class=\"given-names\">C</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Monstrey</div>  <div class=\"given-names\">S</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Gender identity disorder: general overview and surgical treatment for vaginoplasty in male-to-female transsexuals</div>. <div class=\"source \">Plast Reconstr Surg</div>. <div class=\"year\">2005</div>;<div class=\"volume\">116</div>(<div class=\"issue\">6</div>):<div class=\"fpage\">135e</div>–<div class=\"lpage\">145e</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Gender%20identity%20disorder%3A%20general%20overview%20and%20surgical%20treatment%20for%20vaginoplasty%20in%20male-to-female%20transsexuals&amp;author=G%20Selvaggi&amp;author=P%20Ceulemans&amp;author=G%20De%20Cuypere&amp;author=K%20VanLanduyt&amp;author=P%20Blondeel&amp;author=M%20Hamdi&amp;author=C%20Bowman&amp;author=S%20Monstrey&amp;publication_year=2005&amp;journal=Plast%20Reconstr%20Surg&amp;volume=116&amp;pages=135e-145e\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1097/01.prs.0000185999.71439.06\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1097%2F01.prs.0000185999.71439.06\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1097%2F01.prs.0000185999.71439.06\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/16267416\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Gender%20identity%20disorder%3A%20general%20overview%20and%20surgical%20treatment%20for%20vaginoplasty%20in%20male-to-female%20transsexuals&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B226\" class=\"js-splitview-ref-item\" data-legacy-id=\"B226\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B226\" href=\"javascript:;\" aria-label=\"jumplink-B226\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B226\" class=\"ref-content \" data-id=\"B226\"><span class=\"label\">226.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Tugnet</div>  <div class=\"given-names\">N</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Goddard</div>  <div class=\"given-names\">JC</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Vickery</div>  <div class=\"given-names\">RM</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Khoosal</div>  <div class=\"given-names\">D</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Terry</div>  <div class=\"given-names\">TR</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Current management of male-to-female gender identity disorder in the UK</div>. <div class=\"source \">Postgrad Med J</div>. <div class=\"year\">2007</div>;<div class=\"volume\">83</div>(<div class=\"issue\">984</div>):<div class=\"fpage\">638</div>–<div class=\"lpage\">642</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Current%20management%20of%20male-to-female%20gender%20identity%20disorder%20in%20the%20UK&amp;author=N%20Tugnet&amp;author=JC%20Goddard&amp;author=RM%20Vickery&amp;author=D%20Khoosal&amp;author=TR%20Terry&amp;publication_year=2007&amp;journal=Postgrad%20Med%20J&amp;volume=83&amp;pages=638-642\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1136/pgmj.2007.060533\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1136%2Fpgmj.2007.060533\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1136%2Fpgmj.2007.060533\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/17916872\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Current%20management%20of%20male-to-female%20gender%20identity%20disorder%20in%20the%20UK&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B227\" class=\"js-splitview-ref-item\" data-legacy-id=\"B227\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B227\" href=\"javascript:;\" aria-label=\"jumplink-B227\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B227\" class=\"ref-content \" data-id=\"B227\"><span class=\"label\">227.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Horbach</div>  <div class=\"given-names\">SER</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Bouman</div>  <div class=\"given-names\">M-B</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Smit</div>  <div class=\"given-names\">JM</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Özer</div>  <div class=\"given-names\">M</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Buncamper</div>  <div class=\"given-names\">ME</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Mullender</div>  <div class=\"given-names\">MG</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Outcome of vaginoplasty in male-to-female transgenders: a systematic review of surgical techniques</div>. <div class=\"source \">J Sex Med</div>. <div class=\"year\">2015</div>;<div class=\"volume\">12</div>(<div class=\"issue\">6</div>):<div class=\"fpage\">1499</div>–<div class=\"lpage\">1512</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Outcome%20of%20vaginoplasty%20in%20male-to-female%20transgenders%3A%20a%20systematic%20review%20of%20surgical%20techniques&amp;author=SER%20Horbach&amp;author=M-B%20Bouman&amp;author=JM%20Smit&amp;author=M%20%C3%96zer&amp;author=ME%20Buncamper&amp;author=MG%20Mullender&amp;publication_year=2015&amp;journal=J%20Sex%20Med&amp;volume=12&amp;pages=1499-1512\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1111/jsm.12868\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1111%2Fjsm.12868\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1111%2Fjsm.12868\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/25817066\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Outcome%20of%20vaginoplasty%20in%20male-to-female%20transgenders%3A%20a%20systematic%20review%20of%20surgical%20techniques&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B228\" class=\"js-splitview-ref-item\" data-legacy-id=\"B228\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B228\" href=\"javascript:;\" aria-label=\"jumplink-B228\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B228\" class=\"ref-content \" data-id=\"B228\"><span class=\"label\">228.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Wroblewski</div>  <div class=\"given-names\">P</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Gustafsson</div>  <div class=\"given-names\">J</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Selvaggi</div>  <div class=\"given-names\">G</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Sex reassignment surgery for transsexuals</div>. <div class=\"source \">Curr Opin Endocrinol Diabetes Obes</div>. <div class=\"year\">2013</div>;<div class=\"volume\">20</div>(<div class=\"issue\">6</div>):<div class=\"fpage\">570</div>–<div class=\"lpage\">574</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Sex%20reassignment%20surgery%20for%20transsexuals&amp;author=P%20Wroblewski&amp;author=J%20Gustafsson&amp;author=G%20Selvaggi&amp;publication_year=2013&amp;journal=Curr%20Opin%20Endocrinol%20Diabetes%20Obes&amp;volume=20&amp;pages=570-574\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1097/01.med.0000436190.80104.56\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1097%2F01.med.0000436190.80104.56\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1097%2F01.med.0000436190.80104.56\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/24468760\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Sex%20reassignment%20surgery%20for%20transsexuals&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B229\" class=\"js-splitview-ref-item\" data-legacy-id=\"B229\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B229\" href=\"javascript:;\" aria-label=\"jumplink-B229\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B229\" class=\"ref-content \" data-id=\"B229\"><span class=\"label\">229.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Morrison</div>  <div class=\"given-names\">SD</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Satterwhite</div>  <div class=\"given-names\">T</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Grant</div>  <div class=\"given-names\">DW</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Kirby</div>  <div class=\"given-names\">J</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Laub</div>  <div class=\"given-names\">DR</div>, Sr\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">VanMaasdam</div>  <div class=\"given-names\">J</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Long-term outcomes of rectosigmoid neocolporrhaphy in male-to-female gender reassignment surgery</div>. <div class=\"source \">Plast Reconstr Surg</div>. <div class=\"year\">2015</div>;<div class=\"volume\">136</div>(<div class=\"issue\">2</div>):<div class=\"fpage\">386</div>–<div class=\"lpage\">394</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Long-term%20outcomes%20of%20rectosigmoid%20neocolporrhaphy%20in%20male-to-female%20gender%20reassignment%20surgery&amp;author=SD%20Morrison&amp;author=T%20Satterwhite&amp;author=DW%20Grant&amp;author=J%20Kirby&amp;author=DR%20Laub&amp;author=J%20VanMaasdam&amp;publication_year=2015&amp;journal=Plast%20Reconstr%20Surg&amp;volume=136&amp;pages=386-394\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1097/PRS.0000000000001459\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1097%2FPRS.0000000000001459\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1097%2FPRS.0000000000001459\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/26218383\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Long-term%20outcomes%20of%20rectosigmoid%20neocolporrhaphy%20in%20male-to-female%20gender%20reassignment%20surgery&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B230\" class=\"js-splitview-ref-item\" data-legacy-id=\"B230\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B230\" href=\"javascript:;\" aria-label=\"jumplink-B230\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B230\" class=\"ref-content \" data-id=\"B230\"><span class=\"label\">230.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Dessy</div>  <div class=\"given-names\">LA</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Mazzocchi</div>  <div class=\"given-names\">M</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Corrias</div>  <div class=\"given-names\">F</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Ceccarelli</div>  <div class=\"given-names\">S</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Marchese</div>  <div class=\"given-names\">C</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Scuderi</div>  <div class=\"given-names\">N</div>\r\n</span>\r\n</span>. <div class=\"article-title\">The use of cultured autologous oral epithelial cells for vaginoplasty in male-to-female transsexuals: a feasibility, safety, and advantageousness clinical pilot study</div>. <div class=\"source \">Plast Reconstr Surg</div>. <div class=\"year\">2014</div>;<div class=\"volume\">133</div>(<div class=\"issue\">1</div>):<div class=\"fpage\">158</div>–<div class=\"lpage\">161</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=The%20use%20of%20cultured%20autologous%20oral%20epithelial%20cells%20for%20vaginoplasty%20in%20male-to-female%20transsexuals%3A%20a%20feasibility%2C%20safety%2C%20and%20advantageousness%20clinical%20pilot%20study&amp;author=LA%20Dessy&amp;author=M%20Mazzocchi&amp;author=F%20Corrias&amp;author=S%20Ceccarelli&amp;author=C%20Marchese&amp;author=N%20Scuderi&amp;publication_year=2014&amp;journal=Plast%20Reconstr%20Surg&amp;volume=133&amp;pages=158-161\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1097/01.prs.0000435844.95551.35\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1097%2F01.prs.0000435844.95551.35\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1097%2F01.prs.0000435844.95551.35\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/24374675\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:The%20use%20of%20cultured%20autologous%20oral%20epithelial%20cells%20for%20vaginoplasty%20in%20male-to-female%20transsexuals%3A%20a%20feasibility%2C%20safety%2C%20and%20advantageousness%20clinical%20pilot%20study&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B231\" class=\"js-splitview-ref-item\" data-legacy-id=\"B231\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B231\" href=\"javascript:;\" aria-label=\"jumplink-B231\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B231\" class=\"ref-content \" data-id=\"B231\"><span class=\"label\">231.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Li</div>  <div class=\"given-names\">FY</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Xu</div>  <div class=\"given-names\">YS</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Zhou</div>  <div class=\"given-names\">CD</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Zhou</div>  <div class=\"given-names\">Y</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Li</div>  <div class=\"given-names\">SK</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Li</div>  <div class=\"given-names\">Q</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Long-term outcomes of vaginoplasty with autologous buccal micromucosa</div>. <div class=\"source \">Obstet Gynecol</div>. <div class=\"year\">2014</div>;<div class=\"volume\">123</div>(<div class=\"issue\">5</div>):<div class=\"fpage\">951</div>–<div class=\"lpage\">956</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Long-term%20outcomes%20of%20vaginoplasty%20with%20autologous%20buccal%20micromucosa&amp;author=FY%20Li&amp;author=YS%20Xu&amp;author=CD%20Zhou&amp;author=Y%20Zhou&amp;author=SK%20Li&amp;author=Q%20Li&amp;publication_year=2014&amp;journal=Obstet%20Gynecol&amp;volume=123&amp;pages=951-956\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1097/AOG.0000000000000161\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1097%2FAOG.0000000000000161\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1097%2FAOG.0000000000000161\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/24785845\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Long-term%20outcomes%20of%20vaginoplasty%20with%20autologous%20buccal%20micromucosa&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B232\" class=\"js-splitview-ref-item\" data-legacy-id=\"B232\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B232\" href=\"javascript:;\" aria-label=\"jumplink-B232\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B232\" class=\"ref-content \" data-id=\"B232\"><span class=\"label\">232.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Kanhai</div>  <div class=\"given-names\">RC</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Sensate vagina pedicled-spot for male-to-female transsexuals: the experience in the first 50 patients</div>. <div class=\"source \">Aesthetic Plast Surg</div>. <div class=\"year\">2016</div>;<div class=\"volume\">40</div>(<div class=\"issue\">2</div>):<div class=\"fpage\">284</div>–<div class=\"lpage\">287</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Sensate%20vagina%20pedicled-spot%20for%20male-to-female%20transsexuals%3A%20the%20experience%20in%20the%20first%2050%20patients&amp;author=RC%20Kanhai&amp;publication_year=2016&amp;journal=Aesthetic%20Plast%20Surg&amp;volume=40&amp;pages=284-287\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1007/s00266-016-0620-2\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1007%2Fs00266-016-0620-2\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1007%2Fs00266-016-0620-2\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/26893274\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Sensate%20vagina%20pedicled-spot%20for%20male-to-female%20transsexuals%3A%20the%20experience%20in%20the%20first%2050%20patients&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B233\" class=\"js-splitview-ref-item\" data-legacy-id=\"B233\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B233\" href=\"javascript:;\" aria-label=\"jumplink-B233\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B233\" class=\"ref-content \" data-id=\"B233\"><span class=\"label\">233.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Straayer</div>  <div class=\"given-names\">C</div>\r\n</span>\r\n</span>. <div class=\"comment\">Transplants for transsexuals? Ambitions, concerns, ideology. Paper presented at: Trans*Studies: An International Transdisciplinary Conference on Gender, Embodiment, and Sexuality; 7–10 September 2016; University of Arizona, Tucson, AZ.</div>\r\n</p></div></div></div></div><div content-id=\"B234\" class=\"js-splitview-ref-item\" data-legacy-id=\"B234\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B234\" href=\"javascript:;\" aria-label=\"jumplink-B234\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B234\" class=\"ref-content \" data-id=\"B234\"><span class=\"label\">234.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Bucci</div>  <div class=\"given-names\">S</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Mazzon</div>  <div class=\"given-names\">G</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Liguori</div>  <div class=\"given-names\">G</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Napoli</div>  <div class=\"given-names\">R</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Pavan</div>  <div class=\"given-names\">N</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Bormioli</div>  <div class=\"given-names\">S</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Ollandini</div>  <div class=\"given-names\">G</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">De Concilio</div>  <div class=\"given-names\">B</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Trombetta</div>  <div class=\"given-names\">C.</div>\r\n</span>\r\n</span> <div class=\"article-title\">Neovaginal prolapse in male-to-female transsexuals: an 18-year-long experience</div>. <div class=\"source \">Biomed Res Int</div>. <div class=\"year\">2014</div>;<div class=\"volume\">2014</div>:<div class=\"fpage\">240761</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Neovaginal%20prolapse%20in%20male-to-female%20transsexuals%3A%20an%2018-year-long%20experience&amp;author=S%20Bucci&amp;author=G%20Mazzon&amp;author=G%20Liguori&amp;author=R%20Napoli&amp;author=N%20Pavan&amp;author=S%20Bormioli&amp;author=G%20Ollandini&amp;author=B%20De%20Concilio&amp;author=C.%20Trombetta&amp;publication_year=2014&amp;journal=Biomed%20Res%20Int&amp;volume=2014&amp;pages=240761\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1155/2014/240761\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1155%2F2014%2F240761\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1155%2F2014%2F240761\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/24895556\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Neovaginal%20prolapse%20in%20male-to-female%20transsexuals%3A%20an%2018-year-long%20experience&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B235\" class=\"js-splitview-ref-item\" data-legacy-id=\"B235\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B235\" href=\"javascript:;\" aria-label=\"jumplink-B235\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B235\" class=\"ref-content \" data-id=\"B235\"><span class=\"label\">235.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Raigosa</div>  <div class=\"given-names\">M</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Avvedimento</div>  <div class=\"given-names\">S</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Yoon</div>  <div class=\"given-names\">TS</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Cruz-Gimeno</div>  <div class=\"given-names\">J</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Rodriguez</div>  <div class=\"given-names\">G</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Fontdevila</div>  <div class=\"given-names\">J</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Male-to-female genital reassignment surgery: a retrospective review of surgical technique and complications in 60 patients</div>. <div class=\"source \">J Sex Med</div>. <div class=\"year\">2015</div>;<div class=\"volume\">12</div>(<div class=\"issue\">8</div>):<div class=\"fpage\">1837</div>–<div class=\"lpage\">1845</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Male-to-female%20genital%20reassignment%20surgery%3A%20a%20retrospective%20review%20of%20surgical%20technique%20and%20complications%20in%2060%20patients&amp;author=M%20Raigosa&amp;author=S%20Avvedimento&amp;author=TS%20Yoon&amp;author=J%20Cruz-Gimeno&amp;author=G%20Rodriguez&amp;author=J%20Fontdevila&amp;publication_year=2015&amp;journal=J%20Sex%20Med&amp;volume=12&amp;pages=1837-1845\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1111/jsm.12936\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1111%2Fjsm.12936\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1111%2Fjsm.12936\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/26139337\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Male-to-female%20genital%20reassignment%20surgery%3A%20a%20retrospective%20review%20of%20surgical%20technique%20and%20complications%20in%2060%20patients&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B236\" class=\"js-splitview-ref-item\" data-legacy-id=\"B236\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B236\" href=\"javascript:;\" aria-label=\"jumplink-B236\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B236\" class=\"ref-content \" data-id=\"B236\"><span class=\"label\">236.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Green</div>  <div class=\"given-names\">R</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Sexual functioning in post-operative transsexuals: male-to-female and female-to-male</div>. <div class=\"source \">Int J Impot Res</div>. <div class=\"year\">1998</div>;<div class=\"volume\">10</div>(<div class=\"supplement\">Suppl 1</div>):<div class=\"fpage\">S22</div>–<div class=\"lpage\">S24</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Sexual%20functioning%20in%20post-operative%20transsexuals%3A%20male-to-female%20and%20female-to-male&amp;author=R%20Green&amp;publication_year=1998&amp;journal=Int%20J%20Impot%20Res&amp;volume=10&amp;pages=S22-S24\" target=\"_blank\">Google Scholar</a></span></p><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/9669217\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><div class=\"xslopenurl empty-target\"><span class=\"js-inst-open-url-holders-nodoi\"><a class=\"js-open-url-link\" data-href-template=\"{targetURL}?sid=oup:orr&amp;genre=article&amp;atitle=Sexual+functioning+in+post-operative+transsexuals%3a+male-to-female+and+female-to-male&amp;aulast=Green&amp;title=Int+J+Impot+Res&amp;date=1998&amp;spage=S22&amp;epage=S24&amp;volume=10\" href=\"javascript:;\"><span class=\"screenreader-text\">OpenURL Placeholder Text</span></a></span></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Sexual%20functioning%20in%20post-operative%20transsexuals%3A%20male-to-female%20and%20female-to-male&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B237\" class=\"js-splitview-ref-item\" data-legacy-id=\"B237\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B237\" href=\"javascript:;\" aria-label=\"jumplink-B237\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B237\" class=\"ref-content \" data-id=\"B237\"><span class=\"label\">237.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Hess</div>  <div class=\"given-names\">J</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Rossi Neto</div>  <div class=\"given-names\">R</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Panic</div>  <div class=\"given-names\">L</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Rübben</div>  <div class=\"given-names\">H</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Senf</div>  <div class=\"given-names\">W</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Satisfaction with male-to-female gender reassignment surgery</div>. <div class=\"source \">Dtsch Arztebl Int</div>. <div class=\"year\">2014</div>;<div class=\"volume\">111</div>(<div class=\"issue\">47</div>):<div class=\"fpage\">795</div>–<div class=\"lpage\">801</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Satisfaction%20with%20male-to-female%20gender%20reassignment%20surgery&amp;author=J%20Hess&amp;author=R%20Rossi%20Neto&amp;author=L%20Panic&amp;author=H%20R%C3%BCbben&amp;author=W%20Senf&amp;publication_year=2014&amp;journal=Dtsch%20Arztebl%20Int&amp;volume=111&amp;pages=795-801\" target=\"_blank\">Google Scholar</a></span></p><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/25487762\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><div class=\"xslopenurl empty-target\"><span class=\"js-inst-open-url-holders-nodoi\"><a class=\"js-open-url-link\" data-href-template=\"{targetURL}?sid=oup:orr&amp;genre=article&amp;atitle=Satisfaction+with+male-to-female+gender+reassignment+surgery&amp;aulast=Hess&amp;title=Dtsch+Arztebl+Int&amp;date=2014&amp;spage=795&amp;epage=801&amp;volume=111&amp;issue=47\" href=\"javascript:;\"><span class=\"screenreader-text\">OpenURL Placeholder Text</span></a></span></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Satisfaction%20with%20male-to-female%20gender%20reassignment%20surgery&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B238\" class=\"js-splitview-ref-item\" data-legacy-id=\"B238\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B238\" href=\"javascript:;\" aria-label=\"jumplink-B238\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B238\" class=\"ref-content \" data-id=\"B238\"><span class=\"label\">238.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Nygren</div>  <div class=\"given-names\">U</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Nordenskjold</div>  <div class=\"given-names\">A</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Arver</div>  <div class=\"given-names\">S</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Sodersten</div>  <div class=\"given-names\">M</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Effects on voice fundamental frequency and satisfaction with voice in trans men during testosterone treatment—a longitudinal study</div>. <div class=\"source \">J Voice</div>. <div class=\"comment\">2016;<strong>30</strong>(6):766.e23-766.e34</div>.</p></div></div></div></div><div content-id=\"B239\" class=\"js-splitview-ref-item\" data-legacy-id=\"B239\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B239\" href=\"javascript:;\" aria-label=\"jumplink-B239\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B239\" class=\"ref-content \" data-id=\"B239\"><span class=\"label\">239.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Becking</div>  <div class=\"given-names\">AG</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Tuinzing</div>  <div class=\"given-names\">DB</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Hage</div>  <div class=\"given-names\">JJ</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Gooren</div>  <div class=\"given-names\">LJG</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Transgender feminization of the facial skeleton</div>. <div class=\"source \">Clin Plast Surg</div>. <div class=\"year\">2007</div>;<div class=\"volume\">34</div>(<div class=\"issue\">3</div>):<div class=\"fpage\">557</div>–<div class=\"lpage\">564</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Transgender%20feminization%20of%20the%20facial%20skeleton&amp;author=AG%20Becking&amp;author=DB%20Tuinzing&amp;author=JJ%20Hage&amp;author=LJG%20Gooren&amp;publication_year=2007&amp;journal=Clin%20Plast%20Surg&amp;volume=34&amp;pages=557-564\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1016/j.cps.2007.04.009\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1016%2Fj.cps.2007.04.009\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1016%2Fj.cps.2007.04.009\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/17692711\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Transgender%20feminization%20of%20the%20facial%20skeleton&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B240\" class=\"js-splitview-ref-item\" data-legacy-id=\"B240\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B240\" href=\"javascript:;\" aria-label=\"jumplink-B240\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B240\" class=\"ref-content \" data-id=\"B240\"><span class=\"label\">240.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Giraldo</div>  <div class=\"given-names\">F</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Esteva</div>  <div class=\"given-names\">I</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Bergero</div>  <div class=\"given-names\">T</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Cano</div>  <div class=\"given-names\">G</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">González</div>  <div class=\"given-names\">C</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Salinas</div>  <div class=\"given-names\">P</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Rivada</div>  <div class=\"given-names\">E</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Lara</div>  <div class=\"given-names\">JS</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Soriguer</div>  <div class=\"given-names\">F</div>\r\n</span>; <div class=\"collab\">Andalusia Gender Team</div>\r\n</span>. <div class=\"article-title\">Corona glans clitoroplasty and urethropreputial vestibuloplasty in male-to-female transsexuals: the vulval aesthetic refinement by the Andalusia Gender Team</div>. <div class=\"source \">Plast Reconstr Surg</div>. <div class=\"year\">2004</div>;<div class=\"volume\">114</div>(<div class=\"issue\">6</div>):<div class=\"fpage\">1543</div>–<div class=\"lpage\">1550</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Corona%20glans%20clitoroplasty%20and%20urethropreputial%20vestibuloplasty%20in%20male-to-female%20transsexuals%3A%20the%20vulval%20aesthetic%20refinement%20by%20the%20Andalusia%20Gender%20Team&amp;author=F%20Giraldo&amp;author=I%20Esteva&amp;author=T%20Bergero&amp;author=G%20Cano&amp;author=C%20Gonz%C3%A1lez&amp;author=P%20Salinas&amp;author=E%20Rivada&amp;author=JS%20Lara&amp;author=F%20Soriguer&amp;publication_year=2004&amp;journal=Plast%20Reconstr%20Surg&amp;volume=114&amp;pages=1543-1550\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1097/01.PRS.0000138240.85825.2E\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1097%2F01.PRS.0000138240.85825.2E\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1097%2F01.PRS.0000138240.85825.2E\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/15509947\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Corona%20glans%20clitoroplasty%20and%20urethropreputial%20vestibuloplasty%20in%20male-to-female%20transsexuals%3A%20the%20vulval%20aesthetic%20refinement%20by%20the%20Andalusia%20Gender%20Team&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B241\" class=\"js-splitview-ref-item\" data-legacy-id=\"B241\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B241\" href=\"javascript:;\" aria-label=\"jumplink-B241\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B241\" class=\"ref-content \" data-id=\"B241\"><span class=\"label\">241.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Goddard</div>  <div class=\"given-names\">JC</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Vickery</div>  <div class=\"given-names\">RM</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Terry</div>  <div class=\"given-names\">TR</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Development of feminizing genitoplasty for gender dysphoria</div>. <div class=\"source \">J Sex Med</div>. <div class=\"year\">2007</div>;<div class=\"volume\">4</div>(<div class=\"issue\">4 Pt 1</div>):<div class=\"fpage\">981</div>–<div class=\"lpage\">989</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Development%20of%20feminizing%20genitoplasty%20for%20gender%20dysphoria&amp;author=JC%20Goddard&amp;author=RM%20Vickery&amp;author=TR%20Terry&amp;publication_year=2007&amp;journal=J%20Sex%20Med&amp;volume=4&amp;pages=981-989\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1111/j.1743-6109.2007.00480.x\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1111%2Fj.1743-6109.2007.00480.x\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1111%2Fj.1743-6109.2007.00480.x\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/17451484\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Development%20of%20feminizing%20genitoplasty%20for%20gender%20dysphoria&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B242\" class=\"js-splitview-ref-item\" data-legacy-id=\"B242\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B242\" href=\"javascript:;\" aria-label=\"jumplink-B242\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B242\" class=\"ref-content \" data-id=\"B242\"><span class=\"label\">242.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Hage</div>  <div class=\"given-names\">JJ</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">de Graaf</div>  <div class=\"given-names\">FH</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Bouman</div>  <div class=\"given-names\">FG</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Bloem</div>  <div class=\"given-names\">JJAM</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Sculpturing the glans in phalloplasty</div>. <div class=\"source \">Plast Reconstr Surg</div>. <div class=\"year\">1993</div>;<div class=\"volume\">92</div>(<div class=\"issue\">1</div>):<div class=\"fpage\">157</div>–<div class=\"lpage\">161, discussion 162</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Sculpturing%20the%20glans%20in%20phalloplasty&amp;author=JJ%20Hage&amp;author=FH%20de%20Graaf&amp;author=FG%20Bouman&amp;author=JJAM%20Bloem&amp;publication_year=1993&amp;journal=Plast%20Reconstr%20Surg&amp;volume=92&amp;pages=157-161, discussion 162\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1097/00006534-199307000-00026\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1097%2F00006534-199307000-00026\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1097%2F00006534-199307000-00026\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/8516394\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Sculpturing%20the%20glans%20in%20phalloplasty&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B243\" class=\"js-splitview-ref-item\" data-legacy-id=\"B243\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B243\" href=\"javascript:;\" aria-label=\"jumplink-B243\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B243\" class=\"ref-content \" data-id=\"B243\"><span class=\"label\">243.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Thiagaraj</div>  <div class=\"given-names\">D</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Gunasegaram</div>  <div class=\"given-names\">R</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Loganath</div>  <div class=\"given-names\">A</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Peh</div>  <div class=\"given-names\">KL</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Kottegoda</div>  <div class=\"given-names\">SR</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Ratnam</div>  <div class=\"given-names\">SS</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Histopathology of the testes from male transsexuals on oestrogen therapy</div>. <div class=\"source \">Ann Acad Med Singapore</div>. <div class=\"year\">1987</div>;<div class=\"volume\">16</div>(<div class=\"issue\">2</div>):<div class=\"fpage\">347</div>–<div class=\"lpage\">348</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Histopathology%20of%20the%20testes%20from%20male%20transsexuals%20on%20oestrogen%20therapy&amp;author=D%20Thiagaraj&amp;author=R%20Gunasegaram&amp;author=A%20Loganath&amp;author=KL%20Peh&amp;author=SR%20Kottegoda&amp;author=SS%20Ratnam&amp;publication_year=1987&amp;journal=Ann%20Acad%20Med%20Singapore&amp;volume=16&amp;pages=347-348\" target=\"_blank\">Google Scholar</a></span></p><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/3688813\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><div class=\"xslopenurl empty-target\"><span class=\"js-inst-open-url-holders-nodoi\"><a class=\"js-open-url-link\" data-href-template=\"{targetURL}?sid=oup:orr&amp;genre=article&amp;atitle=Histopathology+of+the+testes+from+male+transsexuals+on+oestrogen+therapy&amp;aulast=Thiagaraj&amp;title=Ann+Acad+Med+Singapore&amp;date=1987&amp;spage=347&amp;epage=348&amp;volume=16&amp;issue=2\" href=\"javascript:;\"><span class=\"screenreader-text\">OpenURL Placeholder Text</span></a></span></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Histopathology%20of%20the%20testes%20from%20male%20transsexuals%20on%20oestrogen%20therapy&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B244\" class=\"js-splitview-ref-item\" data-legacy-id=\"B244\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B244\" href=\"javascript:;\" aria-label=\"jumplink-B244\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B244\" class=\"ref-content \" data-id=\"B244\"><span class=\"label\">244.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Monstrey</div>  <div class=\"given-names\">SJ</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Ceulemans</div>  <div class=\"given-names\">P</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Hoebeke</div>  <div class=\"given-names\">P</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Sex reassignment surgery in the female-to-male transsexual</div>. <div class=\"source \">Semin Plast Surg</div>. <div class=\"year\">2011</div>;<div class=\"volume\">25</div>(<div class=\"issue\">3</div>):<div class=\"fpage\">229</div>–<div class=\"lpage\">244</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Sex%20reassignment%20surgery%20in%20the%20female-to-male%20transsexual&amp;author=SJ%20Monstrey&amp;author=P%20Ceulemans&amp;author=P%20Hoebeke&amp;publication_year=2011&amp;journal=Semin%20Plast%20Surg&amp;volume=25&amp;pages=229-244\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1055/s-0031-1281493\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1055%2Fs-0031-1281493\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1055%2Fs-0031-1281493\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22851915\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Sex%20reassignment%20surgery%20in%20the%20female-to-male%20transsexual&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B245\" class=\"js-splitview-ref-item\" data-legacy-id=\"B245\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B245\" href=\"javascript:;\" aria-label=\"jumplink-B245\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B245\" class=\"ref-content \" data-id=\"B245\"><span class=\"label\">245.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Perovic</div>  <div class=\"given-names\">SV</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Djinovic</div>  <div class=\"given-names\">R</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Bumbasirevic</div>  <div class=\"given-names\">M</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Djordjevic</div>  <div class=\"given-names\">M</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Vukovic</div>  <div class=\"given-names\">P</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Total phalloplasty using a musculocutaneous latissimus dorsi flap</div>. <div class=\"source \">BJU Int</div>. <div class=\"year\">2007</div>;<div class=\"volume\">100</div>(<div class=\"issue\">4</div>):<div class=\"fpage\">899</div>–<div class=\"lpage\">905, discussion 905</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Total%20phalloplasty%20using%20a%20musculocutaneous%20latissimus%20dorsi%20flap&amp;author=SV%20Perovic&amp;author=R%20Djinovic&amp;author=M%20Bumbasirevic&amp;author=M%20Djordjevic&amp;author=P%20Vukovic&amp;publication_year=2007&amp;journal=BJU%20Int&amp;volume=100&amp;pages=899-905, discussion 905\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1111/bju.2007.100.issue-4\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1111%2Fbju.2007.100.issue-4\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1111%2Fbju.2007.100.issue-4\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/17822468\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Total%20phalloplasty%20using%20a%20musculocutaneous%20latissimus%20dorsi%20flap&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B246\" class=\"js-splitview-ref-item\" data-legacy-id=\"B246\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B246\" href=\"javascript:;\" aria-label=\"jumplink-B246\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B246\" class=\"ref-content \" data-id=\"B246\"><span class=\"label\">246.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Vesely</div>  <div class=\"given-names\">J</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Hyza</div>  <div class=\"given-names\">P</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Ranno</div>  <div class=\"given-names\">R</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Cigna</div>  <div class=\"given-names\">E</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Monni</div>  <div class=\"given-names\">N</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Stupka</div>  <div class=\"given-names\">I</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Justan</div>  <div class=\"given-names\">I</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Dvorak</div>  <div class=\"given-names\">Z</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Novak</div>  <div class=\"given-names\">P</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Ranno</div>  <div class=\"given-names\">S</div>\r\n</span>\r\n</span>. <div class=\"article-title\">New technique of total phalloplasty with reinnervated latissimus dorsi myocutaneous free flap in female-to-male transsexuals</div>. <div class=\"source \">Ann Plast Surg</div>. <div class=\"year\">2007</div>;<div class=\"volume\">58</div>(<div class=\"issue\">5</div>):<div class=\"fpage\">544</div>–<div class=\"lpage\">550</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=New%20technique%20of%20total%20phalloplasty%20with%20reinnervated%20latissimus%20dorsi%20myocutaneous%20free%20flap%20in%20female-to-male%20transsexuals&amp;author=J%20Vesely&amp;author=P%20Hyza&amp;author=R%20Ranno&amp;author=E%20Cigna&amp;author=N%20Monni&amp;author=I%20Stupka&amp;author=I%20Justan&amp;author=Z%20Dvorak&amp;author=P%20Novak&amp;author=S%20Ranno&amp;publication_year=2007&amp;journal=Ann%20Plast%20Surg&amp;volume=58&amp;pages=544-550\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1097/01.sap.0000245123.16757.15\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1097%2F01.sap.0000245123.16757.15\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1097%2F01.sap.0000245123.16757.15\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/17452841\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:New%20technique%20of%20total%20phalloplasty%20with%20reinnervated%20latissimus%20dorsi%20myocutaneous%20free%20flap%20in%20female-to-male%20transsexuals&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B247\" class=\"js-splitview-ref-item\" data-legacy-id=\"B247\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B247\" href=\"javascript:;\" aria-label=\"jumplink-B247\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B247\" class=\"ref-content \" data-id=\"B247\"><span class=\"label\">247.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Ranno</div>  <div class=\"given-names\">R</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Veselý</div>  <div class=\"given-names\">J</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Hýza</div>  <div class=\"given-names\">P</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Stupka</div>  <div class=\"given-names\">I</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Justan</div>  <div class=\"given-names\">I</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Dvorák</div>  <div class=\"given-names\">Z</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Monni</div>  <div class=\"given-names\">N</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Novák</div>  <div class=\"given-names\">P</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Ranno</div>  <div class=\"given-names\">S</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Neo-phalloplasty with re-innervated latissimus dorsi free flap: a functional study of a novel technique</div>. <div class=\"source \">Acta Chir Plast</div>. <div class=\"year\">2007</div>;<div class=\"volume\">49</div>(<div class=\"issue\">1</div>):<div class=\"fpage\">3</div>–<div class=\"lpage\">7</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Neo-phalloplasty%20with%20re-innervated%20latissimus%20dorsi%20free%20flap%3A%20a%20functional%20study%20of%20a%20novel%20technique&amp;author=R%20Ranno&amp;author=J%20Vesel%C3%BD&amp;author=P%20H%C3%BDza&amp;author=I%20Stupka&amp;author=I%20Justan&amp;author=Z%20Dvor%C3%A1k&amp;author=N%20Monni&amp;author=P%20Nov%C3%A1k&amp;author=S%20Ranno&amp;publication_year=2007&amp;journal=Acta%20Chir%20Plast&amp;volume=49&amp;pages=3-7\" target=\"_blank\">Google Scholar</a></span></p><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/17469438\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><div class=\"xslopenurl empty-target\"><span class=\"js-inst-open-url-holders-nodoi\"><a class=\"js-open-url-link\" data-href-template=\"{targetURL}?sid=oup:orr&amp;genre=article&amp;atitle=Neo-phalloplasty+with+re-innervated+latissimus+dorsi+free+flap%3a+a+functional+study+of+a+novel+technique&amp;aulast=Ranno&amp;title=Acta+Chir+Plast&amp;date=2007&amp;spage=3&amp;epage=7&amp;volume=49&amp;issue=1\" href=\"javascript:;\"><span class=\"screenreader-text\">OpenURL Placeholder Text</span></a></span></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Neo-phalloplasty%20with%20re-innervated%20latissimus%20dorsi%20free%20flap%3A%20a%20functional%20study%20of%20a%20novel%20technique&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B248\" class=\"js-splitview-ref-item\" data-legacy-id=\"B248\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B248\" href=\"javascript:;\" aria-label=\"jumplink-B248\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B248\" class=\"ref-content \" data-id=\"B248\"><span class=\"label\">248.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Garcia</div>  <div class=\"given-names\">MM</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Christopher</div>  <div class=\"given-names\">NA</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">De Luca</div>  <div class=\"given-names\">F</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Spilotros</div>  <div class=\"given-names\">M</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Ralph</div>  <div class=\"given-names\">DJ</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Overall satisfaction, sexual function, and the durability of neophallus dimensions following staged female to male genital gender confirming surgery: the Institute of Urology, London U.K. experience</div>. <div class=\"source \">Transl Androl Urol</div>. <div class=\"year\">2014</div>;<div class=\"volume\">3</div>(<div class=\"issue\">2</div>):<div class=\"fpage\">156</div>–<div class=\"lpage\">162</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Overall%20satisfaction%2C%20sexual%20function%2C%20and%20the%20durability%20of%20neophallus%20dimensions%20following%20staged%20female%20to%20male%20genital%20gender%20confirming%20surgery%3A%20the%20Institute%20of%20Urology%2C%20London%20U.K.%20experience&amp;author=MM%20Garcia&amp;author=NA%20Christopher&amp;author=F%20De%20Luca&amp;author=M%20Spilotros&amp;author=DJ%20Ralph&amp;publication_year=2014&amp;journal=Transl%20Androl%20Urol&amp;volume=3&amp;pages=156-162\" target=\"_blank\">Google Scholar</a></span></p><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/26816764\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><div class=\"xslopenurl empty-target\"><span class=\"js-inst-open-url-holders-nodoi\"><a class=\"js-open-url-link\" data-href-template=\"{targetURL}?sid=oup:orr&amp;genre=article&amp;atitle=Overall+satisfaction%2c+sexual+function%2c+and+the+durability+of+neophallus+dimensions+following+staged+female+to+male+genital+gender+confirming+surgery%3a+the+Institute+of+Urology%2c+London+U.K.+experience&amp;aulast=Garcia&amp;title=Transl+Androl+Urol&amp;date=2014&amp;spage=156&amp;epage=162&amp;volume=3&amp;issue=2\" href=\"javascript:;\"><span class=\"screenreader-text\">OpenURL Placeholder Text</span></a></span></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Overall%20satisfaction%2C%20sexual%20function%2C%20and%20the%20durability%20of%20neophallus%20dimensions%20following%20staged%20female%20to%20male%20genital%20gender%20confirming%20surgery%3A%20the%20Institute%20of%20Urology%2C%20London%20U.K.%20experience&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B249\" class=\"js-splitview-ref-item\" data-legacy-id=\"B249\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B249\" href=\"javascript:;\" aria-label=\"jumplink-B249\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B249\" class=\"ref-content \" data-id=\"B249\"><span class=\"label\">249.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Chen</div>  <div class=\"given-names\">H-C</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Gedebou</div>  <div class=\"given-names\">TM</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Yazar</div>  <div class=\"given-names\">S</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Tang</div>  <div class=\"given-names\">Y-B</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Prefabrication of the free fibula osteocutaneous flap to create a functional human penis using a controlled fistula method</div>. <div class=\"source \">J Reconstr Microsurg</div>. <div class=\"year\">2007</div>;<div class=\"volume\">23</div>(<div class=\"issue\">3</div>):<div class=\"fpage\">151</div>–<div class=\"lpage\">154</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Prefabrication%20of%20the%20free%20fibula%20osteocutaneous%20flap%20to%20create%20a%20functional%20human%20penis%20using%20a%20controlled%20fistula%20method&amp;author=H-C%20Chen&amp;author=TM%20Gedebou&amp;author=S%20Yazar&amp;author=Y-B%20Tang&amp;publication_year=2007&amp;journal=J%20Reconstr%20Microsurg&amp;volume=23&amp;pages=151-154\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1055/s-2007-974650\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1055%2Fs-2007-974650\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1055%2Fs-2007-974650\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/17479453\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Prefabrication%20of%20the%20free%20fibula%20osteocutaneous%20flap%20to%20create%20a%20functional%20human%20penis%20using%20a%20controlled%20fistula%20method&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B250\" class=\"js-splitview-ref-item\" data-legacy-id=\"B250\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B250\" href=\"javascript:;\" aria-label=\"jumplink-B250\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B250\" class=\"ref-content \" data-id=\"B250\"><span class=\"label\">250.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Hoebeke</div>  <div class=\"given-names\">PB</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Decaestecker</div>  <div class=\"given-names\">K</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Beysens</div>  <div class=\"given-names\">M</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Opdenakker</div>  <div class=\"given-names\">Y</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Lumen</div>  <div class=\"given-names\">N</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Monstrey</div>  <div class=\"given-names\">SM</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Erectile implants in female-to-male transsexuals: our experience in 129 patients</div>. <div class=\"source \">Eur Urol</div>. <div class=\"year\">2010</div>;<div class=\"volume\">57</div>(<div class=\"issue\">2</div>):<div class=\"fpage\">334</div>–<div class=\"lpage\">341</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Erectile%20implants%20in%20female-to-male%20transsexuals%3A%20our%20experience%20in%20129%20patients&amp;author=PB%20Hoebeke&amp;author=K%20Decaestecker&amp;author=M%20Beysens&amp;author=Y%20Opdenakker&amp;author=N%20Lumen&amp;author=SM%20Monstrey&amp;publication_year=2010&amp;journal=Eur%20Urol&amp;volume=57&amp;pages=334-341\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1016/j.eururo.2009.03.013\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1016%2Fj.eururo.2009.03.013\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1016%2Fj.eururo.2009.03.013\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/19303200\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Erectile%20implants%20in%20female-to-male%20transsexuals%3A%20our%20experience%20in%20129%20patients&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B251\" class=\"js-splitview-ref-item\" data-legacy-id=\"B251\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B251\" href=\"javascript:;\" aria-label=\"jumplink-B251\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B251\" class=\"ref-content \" data-id=\"B251\"><span class=\"label\">251.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Hage</div>  <div class=\"given-names\">JJ</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Metaidoioplasty: an alternative phalloplasty technique in transsexuals</div>. <div class=\"source \">Plast Reconstr Surg</div>. <div class=\"year\">1996</div>;<div class=\"volume\">97</div>(<div class=\"issue\">1</div>):<div class=\"fpage\">161</div>–<div class=\"lpage\">167</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Metaidoioplasty%3A%20an%20alternative%20phalloplasty%20technique%20in%20transsexuals&amp;author=JJ%20Hage&amp;publication_year=1996&amp;journal=Plast%20Reconstr%20Surg&amp;volume=97&amp;pages=161-167\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1097/00006534-199601000-00026\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1097%2F00006534-199601000-00026\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1097%2F00006534-199601000-00026\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/8532774\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Metaidoioplasty%3A%20an%20alternative%20phalloplasty%20technique%20in%20transsexuals&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B252\" class=\"js-splitview-ref-item\" data-legacy-id=\"B252\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B252\" href=\"javascript:;\" aria-label=\"jumplink-B252\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B252\" class=\"ref-content \" data-id=\"B252\"><span class=\"label\">252.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Cohanzad</div>  <div class=\"given-names\">S</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Extensive metoidioplasty as a technique capable of creating a compatible analogue to a natural penis in female transsexuals</div>. <div class=\"source \">Aesthetic Plast Surg</div>. <div class=\"year\">2016</div>;<div class=\"volume\">40</div>(<div class=\"issue\">1</div>):<div class=\"fpage\">130</div>–<div class=\"lpage\">138</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Extensive%20metoidioplasty%20as%20a%20technique%20capable%20of%20creating%20a%20compatible%20analogue%20to%20a%20natural%20penis%20in%20female%20transsexuals&amp;author=S%20Cohanzad&amp;publication_year=2016&amp;journal=Aesthetic%20Plast%20Surg&amp;volume=40&amp;pages=130-138\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1007/s00266-015-0607-4\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1007%2Fs00266-015-0607-4\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1007%2Fs00266-015-0607-4\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/26744289\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Extensive%20metoidioplasty%20as%20a%20technique%20capable%20of%20creating%20a%20compatible%20analogue%20to%20a%20natural%20penis%20in%20female%20transsexuals&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B253\" class=\"js-splitview-ref-item\" data-legacy-id=\"B253\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B253\" href=\"javascript:;\" aria-label=\"jumplink-B253\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B253\" class=\"ref-content \" data-id=\"B253\"><span class=\"label\">253.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Selvaggi</div>  <div class=\"given-names\">G</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Hoebeke</div>  <div class=\"given-names\">P</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Ceulemans</div>  <div class=\"given-names\">P</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Hamdi</div>  <div class=\"given-names\">M</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Van Landuyt</div>  <div class=\"given-names\">K</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Blondeel</div>  <div class=\"given-names\">P</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">De Cuypere</div>  <div class=\"given-names\">G</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Monstrey</div>  <div class=\"given-names\">S</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Scrotal reconstruction in female-to-male transsexuals: a novel scrotoplasty</div>. <div class=\"source \">Plast Reconstr Surg</div>. <div class=\"year\">2009</div>;<div class=\"volume\">123</div>(<div class=\"issue\">6</div>):<div class=\"fpage\">1710</div>–<div class=\"lpage\">1718</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Scrotal%20reconstruction%20in%20female-to-male%20transsexuals%3A%20a%20novel%20scrotoplasty&amp;author=G%20Selvaggi&amp;author=P%20Hoebeke&amp;author=P%20Ceulemans&amp;author=M%20Hamdi&amp;author=K%20Van%20Landuyt&amp;author=P%20Blondeel&amp;author=G%20De%20Cuypere&amp;author=S%20Monstrey&amp;publication_year=2009&amp;journal=Plast%20Reconstr%20Surg&amp;volume=123&amp;pages=1710-1718\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1097/PRS.0b013e3181a659fe\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1097%2FPRS.0b013e3181a659fe\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1097%2FPRS.0b013e3181a659fe\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/19483569\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Scrotal%20reconstruction%20in%20female-to-male%20transsexuals%3A%20a%20novel%20scrotoplasty&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B254\" class=\"js-splitview-ref-item\" data-legacy-id=\"B254\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B254\" href=\"javascript:;\" aria-label=\"jumplink-B254\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B254\" class=\"ref-content \" data-id=\"B254\"><span class=\"label\">254.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Bjerrome Ahlin</div>  <div class=\"given-names\">H</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Kölby</div>  <div class=\"given-names\">L</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Elander</div>  <div class=\"given-names\">A</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Selvaggi</div>  <div class=\"given-names\">G</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Improved results after implementation of the Ghent algorithm for subcutaneous mastectomy in female-to-male transsexuals</div>. <div class=\"source \">J Plast Surg Hand Surg</div>. <div class=\"year\">2014</div>;<div class=\"volume\">48</div>(<div class=\"issue\">6</div>):<div class=\"fpage\">362</div>–<div class=\"lpage\">367</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Improved%20results%20after%20implementation%20of%20the%20Ghent%20algorithm%20for%20subcutaneous%20mastectomy%20in%20female-to-male%20transsexuals&amp;author=H%20Bjerrome%20Ahlin&amp;author=L%20K%C3%B6lby&amp;author=A%20Elander&amp;author=G%20Selvaggi&amp;publication_year=2014&amp;journal=J%20Plast%20Surg%20Hand%20Surg&amp;volume=48&amp;pages=362-367\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.3109/2000656X.2014.893887\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.3109%2F2000656X.2014.893887\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.3109%2F2000656X.2014.893887\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/24611803\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Improved%20results%20after%20implementation%20of%20the%20Ghent%20algorithm%20for%20subcutaneous%20mastectomy%20in%20female-to-male%20transsexuals&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B255\" class=\"js-splitview-ref-item\" data-legacy-id=\"B255\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B255\" href=\"javascript:;\" aria-label=\"jumplink-B255\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B255\" class=\"ref-content \" data-id=\"B255\"><span class=\"label\">255.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Wolter</div>  <div class=\"given-names\">A</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Diedrichson</div>  <div class=\"given-names\">J</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Scholz</div>  <div class=\"given-names\">T</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Arens-Landwehr</div>  <div class=\"given-names\">A</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Liebau</div>  <div class=\"given-names\">J</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Sexual reassignment surgery in female-to-male transsexuals: an algorithm for subcutaneous mastectomy</div>. <div class=\"source \">J Plast Reconstr Aesthet Surg</div>. <div class=\"year\">2015</div>;<div class=\"volume\">68</div>(<div class=\"issue\">2</div>):<div class=\"fpage\">184</div>–<div class=\"lpage\">191</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Sexual%20reassignment%20surgery%20in%20female-to-male%20transsexuals%3A%20an%20algorithm%20for%20subcutaneous%20mastectomy&amp;author=A%20Wolter&amp;author=J%20Diedrichson&amp;author=T%20Scholz&amp;author=A%20Arens-Landwehr&amp;author=J%20Liebau&amp;publication_year=2015&amp;journal=J%20Plast%20Reconstr%20Aesthet%20Surg&amp;volume=68&amp;pages=184-191\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1016/j.bjps.2014.10.016\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1016%2Fj.bjps.2014.10.016\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1016%2Fj.bjps.2014.10.016\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/25455292\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Sexual%20reassignment%20surgery%20in%20female-to-male%20transsexuals%3A%20an%20algorithm%20for%20subcutaneous%20mastectomy&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B256\" class=\"js-splitview-ref-item\" data-legacy-id=\"B256\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B256\" href=\"javascript:;\" aria-label=\"jumplink-B256\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B256\" class=\"ref-content \" data-id=\"B256\"><span class=\"label\">256.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Richards</div>  <div class=\"given-names\">C</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Barrett</div>  <div class=\"given-names\">J</div>\r\n</span>\r\n</span>. <div class=\"article-title\">The case for bilateral mastectomy and male chest contouring for the female-to-male transsexual</div>. <div class=\"source \">Ann R Coll Surg Engl</div>. <div class=\"year\">2013</div>;<div class=\"volume\">95</div>(<div class=\"issue\">2</div>):<div class=\"fpage\">93</div>–<div class=\"lpage\">95</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=The%20case%20for%20bilateral%20mastectomy%20and%20male%20chest%20contouring%20for%20the%20female-to-male%20transsexual&amp;author=C%20Richards&amp;author=J%20Barrett&amp;publication_year=2013&amp;journal=Ann%20R%20Coll%20Surg%20Engl&amp;volume=95&amp;pages=93-95\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1308/003588413X13511609957290\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1308%2F003588413X13511609957290\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1308%2F003588413X13511609957290\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23484987\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:The%20case%20for%20bilateral%20mastectomy%20and%20male%20chest%20contouring%20for%20the%20female-to-male%20transsexual&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B257\" class=\"js-splitview-ref-item\" data-legacy-id=\"B257\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B257\" href=\"javascript:;\" aria-label=\"jumplink-B257\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B257\" class=\"ref-content \" data-id=\"B257\"><span class=\"label\">257.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Sutcliffe</div>  <div class=\"given-names\">PA</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Dixon</div>  <div class=\"given-names\">S</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Akehurst</div>  <div class=\"given-names\">RL</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Wilkinson</div>  <div class=\"given-names\">A</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Shippam</div>  <div class=\"given-names\">A</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">White</div>  <div class=\"given-names\">S</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Richards</div>  <div class=\"given-names\">R</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Caddy</div>  <div class=\"given-names\">CM</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Evaluation of surgical procedures for sex reassignment: a systematic review</div>. <div class=\"source \">J Plast Reconstr Aesthet Surg</div>. <div class=\"year\">2009</div>;<div class=\"volume\">62</div>(<div class=\"issue\">3</div>):<div class=\"fpage\">294</div>–<div class=\"lpage\">306, discussion 306–308</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Evaluation%20of%20surgical%20procedures%20for%20sex%20reassignment%3A%20a%20systematic%20review&amp;author=PA%20Sutcliffe&amp;author=S%20Dixon&amp;author=RL%20Akehurst&amp;author=A%20Wilkinson&amp;author=A%20Shippam&amp;author=S%20White&amp;author=R%20Richards&amp;author=CM%20Caddy&amp;publication_year=2009&amp;journal=J%20Plast%20Reconstr%20Aesthet%20Surg&amp;volume=62&amp;pages=294-306, discussion 306–308\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1016/j.bjps.2007.12.009\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1016%2Fj.bjps.2007.12.009\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1016%2Fj.bjps.2007.12.009\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/18222742\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Evaluation%20of%20surgical%20procedures%20for%20sex%20reassignment%3A%20a%20systematic%20review&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B258\" class=\"js-splitview-ref-item\" data-legacy-id=\"B258\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B258\" href=\"javascript:;\" aria-label=\"jumplink-B258\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B258\" class=\"ref-content \" data-id=\"B258\"><span class=\"label\">258.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Selvaggi</div>  <div class=\"given-names\">G</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Elander</div>  <div class=\"given-names\">A</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Penile reconstruction/formation</div>. <div class=\"source \">Curr Opin Urol</div>. <div class=\"year\">2008</div>;<div class=\"volume\">18</div>(<div class=\"issue\">6</div>):<div class=\"fpage\">589</div>–<div class=\"lpage\">597</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Penile%20reconstruction%2Fformation&amp;author=G%20Selvaggi&amp;author=A%20Elander&amp;publication_year=2008&amp;journal=Curr%20Opin%20Urol&amp;volume=18&amp;pages=589-597\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1097/MOU.0b013e328313679c\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1097%2FMOU.0b013e328313679c\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1097%2FMOU.0b013e328313679c\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/18832944\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Penile%20reconstruction%2Fformation&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B259\" class=\"js-splitview-ref-item\" data-legacy-id=\"B259\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B259\" href=\"javascript:;\" aria-label=\"jumplink-B259\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B259\" class=\"ref-content \" data-id=\"B259\"><span class=\"label\">259.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Dhejne</div>  <div class=\"given-names\">C</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Lichtenstein</div>  <div class=\"given-names\">P</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Boman</div>  <div class=\"given-names\">M</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Johansson</div>  <div class=\"given-names\">ALV</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Långström</div>  <div class=\"given-names\">N</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Landén</div>  <div class=\"given-names\">M</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Long-term follow-up of transsexual persons undergoing sex reassignment surgery: cohort study in Sweden</div>. <div class=\"source \">PLoS One</div>. <div class=\"year\">2011</div>;<div class=\"volume\">6</div>(<div class=\"issue\">2</div>):<div class=\"fpage\">e16885</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Long-term%20follow-up%20of%20transsexual%20persons%20undergoing%20sex%20reassignment%20surgery%3A%20cohort%20study%20in%20Sweden&amp;author=C%20Dhejne&amp;author=P%20Lichtenstein&amp;author=M%20Boman&amp;author=ALV%20Johansson&amp;author=N%20L%C3%A5ngstr%C3%B6m&amp;author=M%20Land%C3%A9n&amp;publication_year=2011&amp;journal=PLoS%20One&amp;volume=6&amp;pages=e16885\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1371/journal.pone.0016885\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1371%2Fjournal.pone.0016885\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1371%2Fjournal.pone.0016885\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/21364939\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Long-term%20follow-up%20of%20transsexual%20persons%20undergoing%20sex%20reassignment%20surgery%3A%20cohort%20study%20in%20Sweden&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B260\" class=\"js-splitview-ref-item\" data-legacy-id=\"B260\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B260\" href=\"javascript:;\" aria-label=\"jumplink-B260\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B260\" class=\"ref-content \" data-id=\"B260\"><span class=\"label\">260.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Kuhn</div>  <div class=\"given-names\">A</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Bodmer</div>  <div class=\"given-names\">C</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Stadlmayr</div>  <div class=\"given-names\">W</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Kuhn</div>  <div class=\"given-names\">P</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Mueller</div>  <div class=\"given-names\">MD</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Birkhäuser</div>  <div class=\"given-names\">M</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Quality of life 15 years after sex reassignment surgery for transsexualism</div>. <div class=\"source \">Fertil Steril</div>. <div class=\"year\">2009</div>;<div class=\"volume\">92</div>(<div class=\"issue\">5</div>):<div class=\"fpage\">1685</div>–<div class=\"lpage\">1689.e3</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Quality%20of%20life%2015%20years%20after%20sex%20reassignment%20surgery%20for%20transsexualism&amp;author=A%20Kuhn&amp;author=C%20Bodmer&amp;author=W%20Stadlmayr&amp;author=P%20Kuhn&amp;author=MD%20Mueller&amp;author=M%20Birkh%C3%A4user&amp;publication_year=2009&amp;journal=Fertil%20Steril&amp;volume=92&amp;pages=1685-1689.e3\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1016/j.fertnstert.2008.08.126\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1016%2Fj.fertnstert.2008.08.126\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1016%2Fj.fertnstert.2008.08.126\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/18990387\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Quality%20of%20life%2015%20years%20after%20sex%20reassignment%20surgery%20for%20transsexualism&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B261\" class=\"js-splitview-ref-item\" data-legacy-id=\"B261\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B261\" href=\"javascript:;\" aria-label=\"jumplink-B261\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B261\" class=\"ref-content \" data-id=\"B261\"><span class=\"label\">261.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Papadopulos</div>  <div class=\"given-names\">NA</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Lellé</div>  <div class=\"given-names\">JD</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Zavlin</div>  <div class=\"given-names\">D</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Herschbach</div>  <div class=\"given-names\">P</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Henrich</div>  <div class=\"given-names\">G</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Kovacs</div>  <div class=\"given-names\">L</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Ehrenberger</div>  <div class=\"given-names\">B</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Kluger</div>  <div class=\"given-names\">AK</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Machens</div>  <div class=\"given-names\">HG</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Schaff</div>  <div class=\"given-names\">J</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Quality of life and patient satisfaction following male-to-female sex reassignment surgery</div>. <div class=\"source \">J Sex Med</div>. <div class=\"year\">2017</div>;<div class=\"volume\">14</div>(<div class=\"issue\">5</div>):<div class=\"fpage\">721</div>–<div class=\"lpage\">730</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Quality%20of%20life%20and%20patient%20satisfaction%20following%20male-to-female%20sex%20reassignment%20surgery&amp;author=NA%20Papadopulos&amp;author=JD%20Lell%C3%A9&amp;author=D%20Zavlin&amp;author=P%20Herschbach&amp;author=G%20Henrich&amp;author=L%20Kovacs&amp;author=B%20Ehrenberger&amp;author=AK%20Kluger&amp;author=HG%20Machens&amp;author=J%20Schaff&amp;publication_year=2017&amp;journal=J%20Sex%20Med&amp;volume=14&amp;pages=721-730\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1016/j.jsxm.2017.01.022\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1016%2Fj.jsxm.2017.01.022\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1016%2Fj.jsxm.2017.01.022\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/28366591\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Quality%20of%20life%20and%20patient%20satisfaction%20following%20male-to-female%20sex%20reassignment%20surgery&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B262\" class=\"js-splitview-ref-item\" data-legacy-id=\"B262\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B262\" href=\"javascript:;\" aria-label=\"jumplink-B262\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B262\" class=\"ref-content \" data-id=\"B262\"><span class=\"label\">262.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Simonsen</div>  <div class=\"given-names\">RK</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Hald</div>  <div class=\"given-names\">GM</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Kristensen</div>  <div class=\"given-names\">E</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Giraldi</div>  <div class=\"given-names\">A</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Long-term follow-up of individuals undergoing sex-reassignment surgery: somatic morbidity and cause of death</div>. <div class=\"source \">Sex Med</div>. <div class=\"year\">2016</div>;<div class=\"volume\">4</div>(<div class=\"issue\">1</div>):<div class=\"fpage\">e60</div>–<div class=\"lpage\">e68</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Long-term%20follow-up%20of%20individuals%20undergoing%20sex-reassignment%20surgery%3A%20somatic%20morbidity%20and%20cause%20of%20death&amp;author=RK%20Simonsen&amp;author=GM%20Hald&amp;author=E%20Kristensen&amp;author=A%20Giraldi&amp;publication_year=2016&amp;journal=Sex%20Med&amp;volume=4&amp;pages=e60-e68\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1016/j.esxm.2016.01.001\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1016%2Fj.esxm.2016.01.001\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1016%2Fj.esxm.2016.01.001\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/26944779\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Long-term%20follow-up%20of%20individuals%20undergoing%20sex-reassignment%20surgery%3A%20somatic%20morbidity%20and%20cause%20of%20death&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B263\" class=\"js-splitview-ref-item\" data-legacy-id=\"B263\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B263\" href=\"javascript:;\" aria-label=\"jumplink-B263\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B263\" class=\"ref-content \" data-id=\"B263\"><span class=\"label\">263.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Djordjevic</div>  <div class=\"given-names\">ML</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Bizic</div>  <div class=\"given-names\">MR</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Duisin</div>  <div class=\"given-names\">D</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Bouman</div>  <div class=\"given-names\">MB</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Buncamper</div>  <div class=\"given-names\">M</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Reversal Surgery in regretful male-to-female transsexuals after sex reassignment surgery</div>. <div class=\"source \">J Sex Med</div>. <div class=\"year\">2016</div>;<div class=\"volume\">13</div>(<div class=\"issue\">6</div>):<div class=\"fpage\">1000</div>–<div class=\"lpage\">1007</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Reversal%20Surgery%20in%20regretful%20male-to-female%20transsexuals%20after%20sex%20reassignment%20surgery&amp;author=ML%20Djordjevic&amp;author=MR%20Bizic&amp;author=D%20Duisin&amp;author=MB%20Bouman&amp;author=M%20Buncamper&amp;publication_year=2016&amp;journal=J%20Sex%20Med&amp;volume=13&amp;pages=1000-1007\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1016/j.jsxm.2016.02.173\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1016%2Fj.jsxm.2016.02.173\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1016%2Fj.jsxm.2016.02.173\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/27156012\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Reversal%20Surgery%20in%20regretful%20male-to-female%20transsexuals%20after%20sex%20reassignment%20surgery&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B264\" class=\"js-splitview-ref-item\" data-legacy-id=\"B264\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B264\" href=\"javascript:;\" aria-label=\"jumplink-B264\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B264\" class=\"ref-content \" data-id=\"B264\"><span class=\"label\">264.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Liberopoulos</div>  <div class=\"given-names\">EN</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Florentin</div>  <div class=\"given-names\">M</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Mikhailidis</div>  <div class=\"given-names\">DP</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Elisaf</div>  <div class=\"given-names\">MS</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Compliance with lipid-lowering therapy and its impact on cardiovascular morbidity and mortality</div>. <div class=\"source \">Expert Opin Drug Saf</div>. <div class=\"year\">2008</div>;<div class=\"volume\">7</div>(<div class=\"issue\">6</div>):<div class=\"fpage\">717</div>–<div class=\"lpage\">725</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Compliance%20with%20lipid-lowering%20therapy%20and%20its%20impact%20on%20cardiovascular%20morbidity%20and%20mortality&amp;author=EN%20Liberopoulos&amp;author=M%20Florentin&amp;author=DP%20Mikhailidis&amp;author=MS%20Elisaf&amp;publication_year=2008&amp;journal=Expert%20Opin%20Drug%20Saf&amp;volume=7&amp;pages=717-725\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1517/14740330802396984\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1517%2F14740330802396984\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1517%2F14740330802396984\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/18983218\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Compliance%20with%20lipid-lowering%20therapy%20and%20its%20impact%20on%20cardiovascular%20morbidity%20and%20mortality&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B265\" class=\"js-splitview-ref-item\" data-legacy-id=\"B265\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B265\" href=\"javascript:;\" aria-label=\"jumplink-B265\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B265\" class=\"ref-content \" data-id=\"B265\"><span class=\"label\">265.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Forbes</div>  <div class=\"given-names\">SS</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Stephen</div>  <div class=\"given-names\">WJ</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Harper</div>  <div class=\"given-names\">WL</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Loeb</div>  <div class=\"given-names\">M</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Smith</div>  <div class=\"given-names\">R</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Christoffersen</div>  <div class=\"given-names\">EP</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">McLean</div>  <div class=\"given-names\">RF</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Implementation of evidence-based practices for surgical site infection prophylaxis: results of a pre- and postintervention study</div>. <div class=\"source \">J Am Coll Surg</div>. <div class=\"year\">2008</div>;<div class=\"volume\">207</div>(<div class=\"issue\">3</div>):<div class=\"fpage\">336</div>–<div class=\"lpage\">341</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Implementation%20of%20evidence-based%20practices%20for%20surgical%20site%20infection%20prophylaxis%3A%20results%20of%20a%20pre-%20and%20postintervention%20study&amp;author=SS%20Forbes&amp;author=WJ%20Stephen&amp;author=WL%20Harper&amp;author=M%20Loeb&amp;author=R%20Smith&amp;author=EP%20Christoffersen&amp;author=RF%20McLean&amp;publication_year=2008&amp;journal=J%20Am%20Coll%20Surg&amp;volume=207&amp;pages=336-341\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1016/j.jamcollsurg.2008.03.014\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1016%2Fj.jamcollsurg.2008.03.014\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1016%2Fj.jamcollsurg.2008.03.014\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/18722937\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Implementation%20of%20evidence-based%20practices%20for%20surgical%20site%20infection%20prophylaxis%3A%20results%20of%20a%20pre-%20and%20postintervention%20study&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div><div content-id=\"B266\" class=\"js-splitview-ref-item\" data-legacy-id=\"B266\"><div class=\"refLink-parent\"><span class=\"refLink\"><a name=\"jumplink-B266\" href=\"javascript:;\" aria-label=\"jumplink-B266\" data-id=\"\"></a></span></div><div class=\"ref false\"><div id=\"ref-auto-B266\" class=\"ref-content \" data-id=\"B266\"><span class=\"label\">266.</span><div class=\"mixed-citation citation\"><p class=\"mixed-citation-compatibility\">\r\n<span class=\"person-group\">\r\n<span class=\"name string-name\">\r\n<div class=\"surname\">Davis</div>  <div class=\"given-names\">PJ</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Spady</div>  <div class=\"given-names\">D</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">de Gara</div>  <div class=\"given-names\">C</div>\r\n</span>, <span class=\"name string-name\">\r\n<div class=\"surname\">Forgie</div>  <div class=\"given-names\">SE</div>\r\n</span>\r\n</span>. <div class=\"article-title\">Practices and attitudes of surgeons toward the prevention of surgical site infections: a provincial survey in Alberta, Canada</div>. <div class=\"source \">Infect Control Hosp Epidemiol</div>. <div class=\"year\">2008</div>;<div class=\"volume\">29</div>(<div class=\"issue\">12</div>):<div class=\"fpage\">1164</div>–<div class=\"lpage\">1166</div>.</p><!--citationLinks: case 1--><div class=\"citation-links\"></div><div class=\"citation-links\"><p class=\"citation-links-compatibility\"><span class=\"google-scholar-ref-link\"><a class=\"openInAnotherWindow\" href=\"https://scholar.google.com/scholar_lookup?title=Practices%20and%20attitudes%20of%20surgeons%20toward%20the%20prevention%20of%20surgical%20site%20infections%3A%20a%20provincial%20survey%20in%20Alberta%2C%20Canada&amp;author=PJ%20Davis&amp;author=D%20Spady&amp;author=C%20de%20Gara&amp;author=SE%20Forgie&amp;publication_year=2008&amp;journal=Infect%20Control%20Hosp%20Epidemiol&amp;volume=29&amp;pages=1164-1166\" target=\"_blank\">Google Scholar</a></span></p><div class=\"crossref-doi js-ref-link\"><a class=\"openInAnotherWindow\" href=\"http://dx.doi.org/10.1086/592699\" target=\"_blank\">Crossref</a></div><div class=\"adsDoiReference hide\"><a class=\"openInAnotherWindow\" href=\"http://adsabs.harvard.edu/cgi-bin/basic_connect?qsearch=10.1086%2F592699\" target=\"_blank\">Search ADS</a></div><div class=\"xslopenurl empty-target\"><span class=\"inst-open-url-holders\" data-targetId=\"10.1086%2F592699\"> </span></div><div class=\"pub-id\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/18991507\" class=\"link link-pub-id openInAnotherWindow\" target=\"_blank\">PubMed</a></div><p class=\"citation-links-compatibility\"><span class=\"worldcat-reference-ref-link js-worldcat-preview-ref-link\" style=\"display:none\"><a class=\"openInAnotherWindow\" href=\"https://www.worldcat.org/search?q=ti:Practices%20and%20attitudes%20of%20surgeons%20toward%20the%20prevention%20of%20surgical%20site%20infections%3A%20a%20provincial%20survey%20in%20Alberta%2C%20Canada&amp;qt=advanced&amp;dblist=638\" target=\"_blank\">WorldCat</a></span></p> </div></div></div></div></div></div>    <!-- /foreach in Model.Sections -->\r\n    <div class=\"widget widget-ArticlePubStateInfo widget-instance-OUP_ArticlePubStateInfo\">\n         \n    </div>\n\r\n\r\n\r\n        <div class=\"article-metadata-standalone-panel clearfix\"></div>\r\n\r\n        \r\n                    <h2 class=\"authorNotes-section-title\" id=\"authorNotesSectionTitle\" scrollto-destination=\"authorNotesSectionTitle\">Author notes</h2>\r\n<div content-id=\"fn-0001\" class=\"footnote\"><span class=\"fn\"><span class=\"label fn-label\"><span rel=\"nofollow\" data-fn-id=\"fn-0001\" class=\"end-note-link\">*</span></span><div class=\"footnote-content\"><p class=\"footnote-compatibility\">Cosponsoring Associations: American Association of Clinical Endocrinologists, American Society of Andrology, European Society for Pediatric Endocrinology, European Society of Endocrinology, Pediatric Endocrine Society, and World Professional Association for Transgender Health.</p></div></span></div><div class=\"copyright copyright-statement\">Copyright © 2017 Endocrine Society</div><div class=\"copyright-custom-symbol\"><div class=\"copyright copyright-statement\">Copyright © 2017 Endocrine Society</div></div><!-- /foreach -->\r\n\r\n        <span id=\"UserHasAccess\" data-userHasAccess=\"True\"></span>\r\n\r\n    </div><!-- /.widget-items -->\r\n</div><!-- /.module-widget -->\r\n\r\n\r\n\r\n\r\n\r\n \n    </div>\n    <div class=\"widget widget-SolrResourceMetadata widget-instance-OUP_Article_ResourceMetadata_Widget\">\n        \r\n    <div class=\"article-metadata-panel solr-resource-metadata js-metadata-panel at-ContentMetadata\">\r\n                <div class=\"article-metadata-tocSections\">\r\n                    <div class=\"article-metadata-tocSections-title\">Issue Section:</div>\r\n                        <a href=\"/jcem/search-results?f_TocHeadingTitle=Reproductive+Biology+and+Sex-Based+Medicine\">Reproductive Biology and Sex-Based Medicine</a>\r\n                </div>\r\n\r\n    </div>\r\n\r\n\r\n \n    </div>\n    <div class=\"widget widget-EditorInformation widget-instance-OUP_Article_EditorInformation_Widget\">\n        \n \n    </div>\n    <div class=\"widget widget-ArticleOpenScienceBadges widget-instance-OUP_Article_OpenScienceBadge_Widget\">\n        \r\n \n    </div>\n\r\n                <div id=\"ContentTabFilteredView\"></div>\r\n                <div class=\"downloadImagesppt js-download-images-ppt st-download-images-ppt\">\r\n                    <a id=\"lnkDownloadAllImages\"\r\n                       class=\"js-download-all-images-link btn\"\r\n                       href=\"/DownloadFile/DownloadImage.aspx?image=&amp;PPTtype=SlideSet&amp;ar=4157558&amp;xsltPath=~/UI/app/XSLT&amp;siteId=5591\">Download all slides</a>\r\n                </div>\r\n    <div class=\"widget widget-ArticleDataSupplements widget-instance-OUP_Data_Supplements_Tab\">\n            <a name=\"SupplementalTab\" id=\"SupplementalTab\"></a>\r\n        <li class=\"section-jump-link head-1 dataSupplements-jumplink\">\r\n            <div class=\"section-jump-link__link-wrap\">\r\n                <a class=\"jumplink js-jumplink scrollTo\" href=\"#supplementary-data\">Supplementary data</a>\r\n            </div>\r\n        </li>\r\n        <h2 scrollto-destination=\"supplementary-data\"  id=\"supplementary-data\" class=\"section-title\">Supplementary data</h2>\r\n        <div class=\"dataSuppLink\"><a href=\"https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/jcem/102/11/10.1210_jc.2017-01658/2/jc.2017-01658_supplemental_materials_1.docx?Expires=1662567008&amp;Signature=kSNmh9z5chQVVnc8Y3-4cbfc3yz~hNtjegLdOvXnMkpxIXs7eyym51t8KOIHlkn2w9yr-epvpFgZAkZAIhgvuzyds2CtMWTIaHa4a1CODdwTgmY1ODnku0gXQKJ~V4raOs~0waCejP~e-c0O67LbCONoTgCxKqJP0dFteLSXef7Ruz31s32m5L8nttaSmUlg7ITVdeL32qJcyiNHgLdt-scAyD1nBf3o8s3mfRW8jR3R3L~QjIdFE82n0L5LV8nhBWUYZc0kHfwFGxUz8Dkm0ZzhemKNCIq3B1xUbX9e92~BoCT1NgQ2OlVY4MYmeNrPhu7zzwLFZUQGFWxAp6a8mQ__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA\"><span class=\"label\">Supplemental Materials</span></a> - docx file</div>\r\n \n    </div>\n                    <div class=\"widget widget-ArticleDataRepositories widget-instance-Article_DryadLink\">\n         \n    </div>\n\r\n                <div class=\"comments\">\r\n    <div class=\"widget widget-UserCommentBody widget-instance-UserCommentBody_Article\">\n        \r\n\r\n \n    </div>\n    <div class=\"widget widget-UserComment widget-instance-OUP_UserComment_Article\">\n         \n    </div>\n\r\n                </div>\r\n            </div>\r\n        </div>\r\n\r\n    </div>\r\n</div>\r\n<div id=\"Sidebar\" class=\"page-column page-column--right\">\r\n    <div class=\"widget widget-AdBlock widget-instance-ArticlePageTopSidebar\">\n        <div class=\"adBlockMainBodyTop-wrap js-adBlockMainBodyTop hide\">\r\n    \r\n    <div id=\"adBlockMainBodyTop\" class=\"js-adblock at-adblock\">\r\n        <script>\r\n            \r\n            googletag.cmd.push(function () {\r\n                googletag.display('adBlockMainBodyTop');\r\n            });\r\n        </script>\r\n    </div>\r\n        <div class=\"advertisement-text js-adblock-advertisement-text hide\">Advertisement</div>\r\n</div> \n    </div>\n<div class=\"widget widget-dynamic \" data-count=\"1\"> \r\n\r\n    <div class=\"widget-dynamic-inner-wrap\">\r\n\r\n<div class=\"widget widget-dynamic \" data-count=\"11\"> \r\n\r\n    <div class=\"widget-dynamic-inner-wrap\">\r\n\r\n    <div class=\"widget widget-ArticleLevelMetrics widget-instance-Article_RightRailB0Article_RightRail_ArticleLevelMetrics\">\n        \r\n\r\n\r\n\r\n        <div class=\"artmet-wrapper horizontal-artmet\">\r\n\r\n<div class=\"contentmet-border\">\r\n    <div class=\"contentmet-wrapper horizontal-contentmet\">\r\n            <div class=\"contentmet-citations contentmet-badges-wrap js-contentmet-citations hide\">\r\n                <h3 class=\"contentmet-text\">Citations</h3>\r\n                    <div class=\"contentmet-item contentmet-dimensions\">\r\n    <div class=\"widget widget-DimensionsBadge widget-instance-ArticleLevelMetrics_DimensionsBadge\">\n        <span class=\"__dimensions_badge_embed__\" \n      data-doi=\"10.1210/jc.2017-01658\" \n      data-legend=\"never\" \n      data-style=\"small_circle\" \n      data-hide-zero-citations=\"true\"></span>\n<script async src=\"https://badge.dimensions.ai/badge.js\" charset=\"utf-8\"></script>\n \n    </div>\n\r\n                    </div>\r\n                            </div>\r\n                    <div class=\"contentmet-views contentmet-badges-wrap js-contentmet-views\">\r\n                <h3 class=\"contentmet-text\">Views</h3>\r\n                <div class=\"contentmet-item circle-text circle-text-views\">\r\n                    <div class=\"contentmet-number\">398,213</div>\r\n                </div>\r\n            </div>\r\n                    <div class=\"contentmet-item contentmet-badges-wrap\">\r\n                    <h3 class=\"contentmet-text\">Altmetric</h3>\r\n                    <div class=\"contentmet-item contentmet-altmetric\">\r\n    <div class=\"widget widget-AltmetricLink widget-instance-ArticleLevelMetrics_AltmetricLinkSummary\">\n            <!-- Altmetrics -->\r\n    <div id=\"altmetricEmbedId\"\r\n         runat=\"server\"\r\n         class='altmetric-embed'\r\n         data-badge-type=\"donut\"\r\n         data-hide-no-mentions=\"false\"\r\n         data-doi=\"10.1210/jc.2017-01658\"\r\n\r\n        \r\n\r\n        ></div>\r\n         <script type='text/javascript' src='https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js'></script>\r\n \n    </div>\n\r\n                    </div>\r\n\r\n\r\n            </div>\r\n                    <div class=\"contentmet-modal-trigger-wrap clearfix\">\r\n                <a class=\"artmet-modal-trigger js-artmet-modal-trigger at-alm-metrics-modal-trigger\" data-resource-id=\"4157558\" data-resource-type=\"3\">\r\n                    <img class=\"contentmet-info-icon\" src=\"/UI/app/svg/i.svg\" alt=\"Information\">\r\n                    <span class=\"contentmet-more-info\">More metrics information</span>\r\n                </a>\r\n            </div>\r\n    </div>\r\n</div>\r\n\r\n                <div class=\"artmet-modal js-artmet-modal\" id=\"MetricsModal\">\r\n                    <div class=\"artmet-modal-contents js-metric-modal-contents at-alm-modal-contents\">\r\n                        <a class=\"artmet-close-modal js-artmet-close-modal\">&#215;</a>\r\n                    </div>\r\n                </div>\r\n        </div>\r\n \n    </div>\n    <div class=\"widget widget-Alerts widget-instance-Article_RightRailB0Article_RightRail_Alerts\">\n        \r\n    <div class=\"alertsWidget\">\r\n        <h3>Email alerts</h3>\r\n                <div class=\"userAlert alertType-1\">\r\n                    <a href=\"javascript:;\" class=\"js-user-alert\" role=\"button\"\r\n                       data-userLoggedIn=\"False\"\r\n                       data-alertType=\"1\" href=\"javascript:;\">Article activity alert</a>\r\n                </div>\r\n                <div class=\"userAlert alertType-3\">\r\n                    <a href=\"javascript:;\" class=\"js-user-alert\" role=\"button\"\r\n                       data-userLoggedIn=\"False\"\r\n                       data-alertType=\"3\" href=\"javascript:;\">Advance article alerts</a>\r\n                </div>\r\n                <div class=\"userAlert alertType-5\">\r\n                    <a href=\"javascript:;\" class=\"js-user-alert\" role=\"button\"\r\n                       data-userLoggedIn=\"False\"\r\n                       data-alertType=\"5\" href=\"javascript:;\">New issue alert</a>\r\n                </div>\r\n                    <div class=\"userAlert alertType-MarketingLink\">\r\n                <a href=\"javascript:;\" class=\"js-user-alert\" role=\"button\"\r\n                   data-userLoggedIn=\"False\"\r\n                   data-additionalUrl=\"/my-account/communication-preferences\" href=\"javascript:;\">Receive exclusive offers and updates from Oxford Academic</a>\r\n            </div>\r\n        <div class=\"userAlertSignUpModal reveal-modal small\" data-reveal>\r\n            <div class=\"userAlertSignUp at-userAlertSignUp\"></div>\r\n            <a href=\"javascript:;\" role=\"button\" aria-label=\"Close\" class=\"close-reveal-modal\" href=\"javascript:;\">\r\n                <i class=\"icon-general-close\"></i>\r\n            </a>\r\n        </div>\r\n    </div>\r\n \n    </div>\n    <div class=\"widget widget-TrendMD widget-instance-Article_RightRailB0trendmd\">\n        <script defer async src='//js.trendmd.com/trendmd.min.js'  data-trendmdconfig='{\"journal_id\":\"62418\",\"element\":\"#trendmd-suggestions\"}'></script>\r\n\r\n<div id=\"trendmd-suggestions\"></div> \n    </div>\n    <div class=\"widget widget-SeeAlso widget-instance-Article_RightRailB0Article_RightRail_SeeAlso\">\n            <div class=\"vt-see-also rail-widget_wrap\">\r\n        <h3 class=\"seeAlso-title\">See also</h3>\r\n                    <div class=\"widget-links_wrap\">\r\n                <ul class=\"seeAlso-articleLinks\">\r\n                        <li>\r\n                                <h4 class=\"seeAlso-group-header\">Companion Articles</h4>\r\n                            <ul>\r\n                                    <li class=\"js-seeAlso-link\">\r\n                                        <a href=\"/jcem/article/102/11/3904/4157556\">Effect of Sex Steroids on the Bone Health of Transgender Individuals: A Systematic Review and Meta-Analysis</a>\r\n                                    </li>\r\n                                    <li class=\"js-seeAlso-link\">\r\n                                        <a href=\"/jcem/article/102/11/3914/4157557\">Sex Steroids and Cardiovascular Outcomes in Transgender Individuals: A Systematic Review and Meta-Analysis</a>\r\n                                    </li>\r\n                                    <li class=\"js-seeAlso-link\">\r\n                                        <a href=\"/jcem/article/104/3/686/5198654\">Letter to the Editor: “Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society Clinical Practice Guideline” </a>\r\n                                    </li>\r\n                            </ul>\r\n                        </li>\r\n                </ul>\r\n            </div>\r\n    </div>\r\n \n    </div>\n    <div class=\"widget widget-RelatedContent widget-instance-Article_RightRailB0Article_RightRail_RelatedContent\">\n         \n    </div>\n    <div class=\"widget widget-RelatedArticleIn widget-instance-Article_RightRailB0Article_RightRail_RelatedArticleIn\">\n            <h3 class=\"relatedArticleIn-title\">Related articles in</h3>\r\n    <div class=\"relatedArticleIn-content\">\r\n        <ul>\r\n                <li>\r\n                    <a href=\"http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;SrcApp=PARTNER_APP&amp;SrcAuth=LinksAMR&amp;KeyUT=WOS:000414558500001&amp;DestLinkType=RelatedRecords&amp;DestApp=ALL_WOS&amp;UsrCustomerID=61f30d8ae69c46f86624c5f98a3bc13a\">Web of Science</a>\r\n                </li>\r\n                <li>\r\n                    <a href=\"https://scholar.google.com/scholar?q=related:https%3a%2f%2facademic.oup.com%2fjcem%2farticle%2f102%2f11%2f3869%2f4157558\">Google Scholar</a>\r\n                </li>\r\n        </ul>\r\n    </div>\r\n \n    </div>\n    <div class=\"widget widget-ArticleCitedBy widget-instance-Article_RightRailB0Article_RightRail_ArticleCitedBy\">\n        <div class=\"rail-widget_wrap vt-articles-cited-by\">\r\n    <h3 class=\"article-cited-title\">Citing articles via</h3>\r\n    <div class=\"widget-links_wrap\">\r\n            <div class=\"article-cited-link-wrap web-of-science\">\r\n                <a href=\"http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000414558500001&DestLinkType=CitingArticles&DestApp=ALL_WOS&UsrCustomerID=61f30d8ae69c46f86624c5f98a3bc13a\" target=\"_blank\">Web of Science (14)</a>\r\n            </div>\r\n                    <div class=\"article-cited-link-wrap google-scholar-url\">\r\n                <a href=\"http://scholar.google.com/scholar?q=link:https%3A%2F%2Facademic.oup.com%2Fjcem%2Farticle%2F102%2F11%2F3869%2F4157558\" target=\"_blank\">Google Scholar</a>\r\n            </div>\r\n                    <div class=\"article-cited-link-wrap crossref-citedby\">\r\n                <a href='https://academic.oup.com/jcem/crossref-citedby/4157558'>Crossref</a>\r\n            </div>\r\n    </div>\r\n</div> \n    </div>\n    <div class=\"widget widget-ArticleListNewAndPopular widget-instance-Article_RightRailB0Article_RightRail_ArticleNewPopularCombined\">\n            <ul class=\"articleListNewAndPopularCombinedView\">\r\n            <li>\r\n                <h3>\r\n                    <a href=\"javascript:;\" class=\"articleListNewAndPopular-mode active\" data-mode=\"MostRecent\">Latest</a>\r\n                </h3>\r\n            </li>\r\n            <li>\r\n                <h3>\r\n                    <a href=\"javascript:;\" class=\"articleListNewAndPopular-mode \" data-mode=\"MostRead\">Most Read</a>\r\n                </h3>\r\n            </li>\r\n            <li>\r\n                <h3>\r\n                    <a href=\"javascript:;\" class=\"articleListNewAndPopular-mode \" data-mode=\"MostCited\">Most Cited</a>\r\n                </h3>\r\n            </li>\r\n    </ul>\r\n        <section class=\"articleListNewPopContent articleListNewAndPopular-ContentView-MostRecent hasContent\">\r\n\r\n\r\n\r\n\r\n<div id=\"newPopularList-Article_RightRailB0Article_RightRail_ArticleNewPopularCombined\" class=\"fb\">\r\n\r\n    \r\n\r\n\r\n\r\n<div class=\"widget-layout widget-layout--vert \">\r\n            <div class=\"widget-columns widget-col-1\">\r\n                    <div class=\"col\">\r\n\r\n<div class=\"widget-dynamic-entry journalArticleItem at-widget-entry-SCL\">\r\n    <span class=\"hfDoi\" data-attribute=\"10.1210/clinem/dgac467\" aria-hidden=\"true\"></span>\r\n\r\n\r\n    \r\n\r\n\r\n<a class=\"journal-link\" href=\"/jcem/advance-article/doi/10.1210/clinem/dgac467/6653516?searchresult=1\">\r\n        <div class=\"widget-dynamic-journal-title\">\r\nElevated TSH level, TgAb and prior use of ramucirumab or TKIs as risk factors for thyroid dysfunction in PD-L1 blockade    </div>\r\n</a>\r\n\r\n\r\n \r\n\r\n\r\n\r\n\r\n\r\n<div class=\"widget-dynamic-journal-image-synopsis\">\r\n        <div class=\"widget-dynamic-journal-synopsis\">\r\n            \r\n        </div>\r\n</div>\r\n</div>\r\n<div class=\"widget-dynamic-entry journalArticleItem at-widget-entry-SCL\">\r\n    <span class=\"hfDoi\" data-attribute=\"10.1210/clinem/dgac466\" aria-hidden=\"true\"></span>\r\n\r\n\r\n    \r\n\r\n\r\n<a class=\"journal-link\" href=\"/jcem/advance-article/doi/10.1210/clinem/dgac466/6653515?searchresult=1\">\r\n        <div class=\"widget-dynamic-journal-title\">\r\nVariation in the diagnosis of noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP)    </div>\r\n</a>\r\n\r\n\r\n \r\n\r\n\r\n\r\n\r\n\r\n<div class=\"widget-dynamic-journal-image-synopsis\">\r\n        <div class=\"widget-dynamic-journal-synopsis\">\r\n            \r\n        </div>\r\n</div>\r\n</div>\r\n<div class=\"widget-dynamic-entry journalArticleItem at-widget-entry-SCL\">\r\n    <span class=\"hfDoi\" data-attribute=\"10.1210/clinem/dgac464\" aria-hidden=\"true\"></span>\r\n\r\n\r\n    \r\n\r\n\r\n<a class=\"journal-link\" href=\"/jcem/advance-article/doi/10.1210/clinem/dgac464/6653511?searchresult=1\">\r\n        <div class=\"widget-dynamic-journal-title\">\r\nDiabetic Ketoacidosis in Pregnancy: Clinical Risk factors, Presentation, and Outcomes    </div>\r\n</a>\r\n\r\n\r\n \r\n\r\n\r\n\r\n\r\n\r\n<div class=\"widget-dynamic-journal-image-synopsis\">\r\n        <div class=\"widget-dynamic-journal-synopsis\">\r\n            \r\n        </div>\r\n</div>\r\n</div>\r\n<div class=\"widget-dynamic-entry journalArticleItem at-widget-entry-SCL\">\r\n    <span class=\"hfDoi\" data-attribute=\"10.1210/clinem/dgac463\" aria-hidden=\"true\"></span>\r\n\r\n\r\n    \r\n\r\n\r\n<a class=\"journal-link\" href=\"/jcem/advance-article/doi/10.1210/clinem/dgac463/6653510?searchresult=1\">\r\n        <div class=\"widget-dynamic-journal-title\">\r\nLongitudinal branched-chain amino acids, lifestyle intervention and type 2 diabetes in Finnish Diabetes Prevention Study    </div>\r\n</a>\r\n\r\n\r\n \r\n\r\n\r\n\r\n\r\n\r\n<div class=\"widget-dynamic-journal-image-synopsis\">\r\n        <div class=\"widget-dynamic-journal-synopsis\">\r\n            \r\n        </div>\r\n</div>\r\n</div>\r\n<div class=\"widget-dynamic-entry journalArticleItem at-widget-entry-SCL\">\r\n    <span class=\"hfDoi\" data-attribute=\"10.1210/clinem/dgac436\" aria-hidden=\"true\"></span>\r\n\r\n\r\n    \r\n\r\n\r\n<a class=\"journal-link\" href=\"/jcem/advance-article/doi/10.1210/clinem/dgac436/6653488?searchresult=1\">\r\n        <div class=\"widget-dynamic-journal-title\">\r\nA randomized controlled trial of R-form verapamil added to ongoing metformin therapy in patients with type 2 diabetes    </div>\r\n</a>\r\n\r\n\r\n \r\n\r\n\r\n\r\n\r\n\r\n<div class=\"widget-dynamic-journal-image-synopsis\">\r\n        <div class=\"widget-dynamic-journal-synopsis\">\r\n            \r\n        </div>\r\n</div>\r\n</div>\r\n                    </div>\r\n            </div>\r\n\r\n</div></div>\r\n        </section>\r\n        <section class=\"articleListNewPopContent articleListNewAndPopular-ContentView-MostRead hide\">\r\n        </section>\r\n        <section class=\"articleListNewPopContent articleListNewAndPopular-ContentView-MostCited hide\">\r\n        </section>\r\n \n    </div>\n    <div class=\"widget widget-RelatedTaxonomies widget-instance-Article_RightRailB0Article_RightRail_RelatedTaxonomies\">\n            <div class=\"widget-related-taxonomies-wrap vt-related-taxonomies\">\r\n        <div class=\"widget-related-taxonomies_title\">More from Oxford Academic</div>\r\n            <div class=\"widget-related-taxonomies\">\r\n                <a id=\"more-from-oa-AcademicSubjects_MED00160\" class=\"related-taxonomies-link\" href=\"/search-results?tax=AcademicSubjects/MED00160\">Clinical Medicine</a>\r\n            </div>\r\n            <div class=\"widget-related-taxonomies\">\r\n                <a id=\"more-from-oa-AcademicSubjects_MED00250\" class=\"related-taxonomies-link\" href=\"/search-results?tax=AcademicSubjects/MED00250\">Endocrinology and Diabetes</a>\r\n            </div>\r\n            <div class=\"widget-related-taxonomies\">\r\n                <a id=\"more-from-oa-AcademicSubjects_MED00010\" class=\"related-taxonomies-link\" href=\"/search-results?tax=AcademicSubjects/MED00010\">Medicine and Health</a>\r\n            </div>\r\n\r\n            <div class=\"widget-related-taxonomies\">\r\n                <a id=\"more-from-oa-format-Books\" class=\"related-taxonomies-link\" href=\"/books\">Books</a>\r\n            </div>\r\n            <div class=\"widget-related-taxonomies\">\r\n                <a id=\"more-from-oa-format-Journals\" class=\"related-taxonomies-link\" href=\"/journals\">Journals</a>\r\n            </div>\r\n    </div>\r\n \n    </div>\n\r\n    </div>\r\n\r\n</div>\r\n    </div>\r\n\r\n</div>    <div class=\"widget widget-AdBlock widget-instance-ArticlePageTopMainBodyBottom\">\n        <div class=\"adBlockMainBodyBottom-wrap js-adBlockMainBodyBottom hide\">\r\n    \r\n    <div id=\"adBlockMainBodyBottom\" class=\"js-adblock at-adblock\">\r\n        <script>\r\n            \r\n            googletag.cmd.push(function () {\r\n                googletag.display('adBlockMainBodyBottom');\r\n            });\r\n        </script>\r\n    </div>\r\n        <div class=\"advertisement-text js-adblock-advertisement-text hide\">Advertisement</div>\r\n</div> \n    </div>\n\r\n</div>\r\n\r\n</div>\r\n<input id=\"hfArticleTitle\" name=\"hfArticleTitle\" type=\"hidden\" value=\"\" />\r\n<input id=\"hfLeftNavStickyOffset\" name=\"hfLeftNavStickyOffset\" type=\"hidden\" value=\"29\" />\r\n<input id=\"hfAreOpFeaturesEnabled\" name=\"hfAreOpFeaturesEnabled\" type=\"hidden\" value=\"True\" />\r\n\r\n\r\n\r\n                </div><!-- /.center-inner-row no-overflow -->\r\n            </section>\r\n    </div>\r\n\r\n        <div class=\"mobile-mask\">\r\n        </div>\r\n\r\n        <section class=\"footer_wrap vt-site-footer\">\r\n            \r\n\r\n\r\n    <div class=\"widget widget-SitePageFooter widget-instance-SitePageFooter\">\n            <div class=\"ad-banner ad-banner-footer\">\n    <div class=\"widget widget-AdBlock widget-instance-FooterAd\">\n        <div class=\"adBlockFooter-wrap js-adBlockFooter hide\">\r\n    \r\n    <div id=\"adBlockFooter\" class=\"js-adblock at-adblock\">\r\n        <script>\r\n            \r\n            googletag.cmd.push(function () {\r\n                googletag.display('adBlockFooter');\r\n            });\r\n        </script>\r\n    </div>\r\n        <div class=\"advertisement-text js-adblock-advertisement-text hide\">Advertisement</div>\r\n</div> \n    </div>\n\n    </div>\n\n<div class=\"journal-footer journal-bg\">\n    <div class=\"center-inner-row\">\n\n<div class=\"journal-footer-menu\">\n\n    <ul>\n<li class=\"link-1\">\n    <a href=\"/jcem/pages/About\">About The Journal of Clinical Endocrinology &amp; Metabolism</a>\n</li> <li class=\"link-2\">\n    <a href=\"https://www.endocrine.org/about-us\">About the Endocrine Society</a>\n</li> <li class=\"link-3\">\n    <a href=\"/jcem/pages/Editorial_Board\">Editorial Board</a>\n</li> <li class=\"link-4\">\n    <a href=\"/jcem/pages/Author_Guidelines\">Author Guidelines</a>\n</li> <li class=\"link-5\">\n    <a href=\"http://www.endocrine.org/about-us/contacts-and-directions\">Contact Us</a>\n</li> </ul><ul><li class=\"link-1\">\n    <a href=\"https://www.facebook.com/EndocrineSociety\">Facebook</a>\n</li> <li class=\"link-2\">\n    <a href=\"https://twitter.com/TheEndoSociety\">Twitter</a>\n</li> <li class=\"link-3\">\n    <a href=\"http://www.linkedin.com/groups/Endocrine-Society-2486814/about\">LinkedIn</a>\n</li> <li class=\"link-4\">\n    <a href=\"/jcem/subscribe\">Purchase</a>\n</li> <li class=\"link-5\">\n    <a href=\"http://www.oxfordjournals.org/en/library-recommendation-form.html\">Recommend to Your Librarian</a>\n</li> </ul><ul><li class=\"link-1\">\n    <a href=\"http://www.endocrine.org/corporate-relations/print-and-online-advertising\">Advertising and Corporate Services</a>\n</li> <li class=\"link-2\">\n    <a href=\"http://www.endocrine.org/endocareers\">Journals Career Network</a>\n</li> \n    </ul>\n\n\n</div><!-- /.journal-footer-menu -->\n        <div class=\"journal-footer-affiliations\">\n            <!-- <h3>Affiliations</h3> -->\n<a href=\"http://academic.oup.com/jcem\" target=\"\">\n    <img id=\"footer-logo-TheJournalofClinicalEndocrinology&amp;Metabolism\" class=\"journal-footer-affiliations-logo\" src=\"//oup.silverchair-cdn.com/data/SiteBuilderAssets/Live/Images/jcem/jcem_f1729907635.svg\" alt=\"The Journal of Clinical Endocrinology &amp; Metabolism\" />\n</a>                        </div><!-- /.journal-footer-affiliations -->\n\n        <div class=\"journal-footer-colophon\">\n            <ul>\n<li>Online ISSN 1945-7197</li>                <li>Print ISSN 0021-972X</li>                <li>Copyright &#169; 2022 Oxford University Press</li>\n            </ul>\n        </div><!-- /.journal-footer-colophon -->\n\n\n    </div><!-- /.center-inner-row -->\n</div><!-- /.journal-footer --> \n    </div>\n\r\n    <div class=\"oup-footer\">\r\n        <div class=\"center-inner-row\">\r\n    <div class=\"widget widget-SelfServeContent widget-instance-OupUmbrellaFooterSelfServe\">\n        \r\n<div class=\"oup-footer-row journal-links\">\n<div class=\"global-footer selfservelinks\">\n<ul>\n    <li><a href=\"/pages/about-oxford-academic\">About Oxford Academic</a></li>\n    <li><a href=\"/pages/about-oxford-academic/publish-journals-with-us\">Publish journals with us</a></li>\n    <li><a href=\"/pages/about-oxford-academic/our-university-press-partners\">University press partners</a></li>\n    <li><a href=\"/pages/what-we-publish\">What we publish</a></li>\n    <li><a href=\"/pages/new-features\">New features</a>&nbsp;</li>\n</ul>\n</div>\n<div class=\"global-footer selfservelinks\">\n<ul>\n    <li><a href=\"/pages/authoring\">Authoring</a></li>\n    <li><a href=\"/pages/open-research/open-access\">Open access</a></li>\n    <li><a href=\"/pages/purchasing\">Purchasing</a></li>\n    <li><a href=\"/pages/get-help-with-access\">Get help with access</a></li>\n    <li><a href=\"/pages/institutional-account-management\">Institutional account management</a></li>\n</ul>\n</div>\n<div class=\"global-footer selfservelinks\">\n<ul>\n    <li><a href=\"/pages/about-oxford-academic/accessibility\">Accessibility</a></li>\n    <li><a href=\"/pages/contact-us\">Contact us</a></li>\n    <li><a href=\"/pages/advertising\">Advertising</a></li>\n    <li><a href=\"/pages/media-enquiries\">Media enquiries</a></li>\n    <li><a href=\"/pages/legal-and-policy\">Legal and policy</a></li>\n</ul>\n</div>\n<div class=\"global-footer selfservelinks global-footer-external\">\n<ul>\n    <li><a href=\"https://global.oup.com/\">Oxford University Press</a></li>\n    <li><a href=\"https://www.mynewsdesk.com/uk/oxford-university-press\">News</a></li>\n    <li><a href=\"https://languages.oup.com/\">Oxford Languages</a></li>\n    <li><a href=\"https://www.epigeum.com/\">Epigeum</a></li>\n    <li><a href=\"https://www.ox.ac.uk/\">University of Oxford</a></li>\n</ul>\n</div>\n<div class=\"OUP-mission\">\n<p>Oxford University Press is a department of the University of Oxford. It furthers the University's objective of excellence in research, scholarship, and education by publishing worldwide</p>\n<img class=\"journal-footer-logo\" src=\"//oup.silverchair-cdn.com/UI/app/svg/umbrella/oup-logo.svg\" alt=\"Oxford University Press\" width=\"150\" height=\"42\" />\n</div>\n</div>\n<div class=\"oup-footer-row\">\n<div class=\"oup-footer-row-links\">\n<ul>\n    <li>Copyright © 2022 Oxford University Press</li>\n    <li><a href=\"https://global.oup.com/cookiepolicy\">Cookie policy</a></li>\n    <li><a href=\"https://global.oup.com/privacy\">Privacy policy</a></li>\n    <li><a href=\"/pages/legal-and-policy/legal-notice\">Legal notice</a></li>\n</ul>\n</div>\n</div>\n<style type=\"text/css\">\n    /* Issue right column fix for tablet/mobile */\n    @media (max-width: 1200px) {\n    .pg_issue .widget-instance-OUP_Issue {\n    width: 100%;\n    }\n    }\n    .sf-facet-list .sf-facet label,\n    .sf-facet-list .taxonomy-label-wrap label {\n    font-size: 0.9375rem;\n    }\n    .issue-pagination-wrap .pagination-container {\n    float: right;\n    }\n</style>\r\n\r\n\r\n     \n    </div>\n\r\n        </div>\r\n    </div>\r\n    <div class=\"ss-ui-only\">\r\n\r\n    </div>\r\n\r\n        </section>\r\n</div>\r\n\r\n\r\n\r\n\r\n\r\n\r\n    \r\n\r\n\r\n\r\n    <div class=\"widget widget-SiteWideModals widget-instance-SiteWideModals\">\n        <div id=\"revealModal\" class=\"reveal-modal\" data-reveal>\r\n    <div id=\"revealContent\"></div>\r\n    <a class=\"close-reveal-modal\" href=\"javascript:;\"><i class=\"icon-general-close\"></i><span class=\"screenreader-text\">Close</span></a>\r\n</div>\r\n\r\n<div id=\"globalModalContainer\" class=\"modal-global-container\">\r\n    <div id=\"globalModalContent\">\r\n        <div class=\"js-globalModalPlaceholder\"></div>\r\n    </div>\r\n    <a class=\"close-modal js-close-modal\" href=\"javascript:;\"><i class=\"icon-general-close\"><span class=\"screenreader-text\">Close</span></i></a>\r\n</div>\r\n<div id=\"globalModalOverlay\" class=\"modal-overlay js-modal-overlay\"></div>\r\n\r\n<div id=\"NeedSubscription\" class=\"reveal-modal small\" data-reveal>\r\n    <div class=\"subscription-needed\">\r\n        <h5>This Feature Is Available To Subscribers Only</h5>\r\n        <p><a href=\"/sign-in\">Sign In</a> or <a href=\"/my-account/register?siteId=5591&amp;returnUrl=%2fjcem%2farticle%2f102%2f11%2f3869%2f4157558%3flogin%3dfalse\">Create an Account</a></p>\r\n    </div>\r\n    <a class=\"close-reveal-modal\" href=\"javascript:;\"><i class=\"icon-general-close\"></i><span class=\"screenreader-text\">Close</span></a>\r\n</div>\r\n\r\n<div id=\"noAccessReveal\" class=\"reveal-modal tiny\" data-reveal>\r\n    <p>This PDF is available to Subscribers Only</p>\r\n    <a class=\"hide-for-article-page\" id=\"articleLinkToPurchase\" data-reveal><span>View Article Abstract & Purchase Options</span></a>\r\n    <div class=\"issue-purchase-modal\">\r\n        <p>For full access to this pdf, sign in to an existing account, or purchase an annual subscription.</p>\r\n    </div>\r\n    <a class=\"close-reveal-modal\" href=\"javascript:;\"><i class=\"icon-general-close\"></i><span class=\"screenreader-text\">Close</span></a>\r\n</div>\r\n \n    </div>\n\r\n    \r\n\r\n\r\n<script src=\"//cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-AMS-MML_HTMLorMML\"></script>\r\n\r\n\r\n<script src=\"//cdn.jsdelivr.net/npm/promise-polyfill@8/dist/polyfill.min.js\"></script>\r\n\r\n    <script type=\"text/javascript\" src=\"//oup.silverchair-cdn.com/Themes/Client/app/jsdist/v-637941262761996892/site.min.js\"></script>\r\n    <script async src=\"//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-5265518246c10183&domready=1\"></script>\r\n\r\n\r\n    \r\n    \r\n    <script type=\"text/javascript\" src=\"https://www.google.com/recaptcha/api.js?onload=onloadCallback&render=explicit\"></script>\r\n\r\n    \r\n    <script type=\"text/javascript\" src=\"https://cdn.jsdelivr.net/chartist.js/latest/chartist.min.js\"></script>\r\n\r\n    <script type=\"text/javascript\" src=\"//oup.silverchair-cdn.com/Themes/Client/app/jsdist/v-637941262642847682/article-page.min.js\"></script>\r\n\r\n\r\n\r\n    \r\n\r\n    \r\n    \r\n\r\n\r\n\r\n\r\n    \r\n\r\n\r\n    <script>\r\n        var NTPT_PGEXTRA = 'event_type=full-text\\u0026supplier_tag=SC_Journals\\u0026object_type=Article\\u0026siteid=jcem\\u0026authzrequired=false\\u0026doi=10.1210/jc.2017-01658';\r\n    </script>\r\n    <!-- Copyright 2001-2010, IBM Corporation All rights reserved. -->\r\n    <script src=\"//ouptag.scholarlyiq.com/ntpagetag.js\"></script>    \r\n        <noscript>\r\n            <img src=\"//ouptag.scholarlyiq.com/ntpagetag.gif?js=0\" height=\"1\" width=\"1\" border=\"0\" hspace=\"0\" vspace=\"0\" alt=\"Scholarly IQ\" />\r\n        </noscript>\r\n\r\n\r\n    <div class=\"ad-banner js-ad-riser ad-banner-riser\">\r\n\r\n    <div class=\"widget widget-AdBlock widget-instance-RiserAd\">\n            \r\n\r\n \n    </div>\n\r\n    </div>\r\n\r\n\r\n\r\n</body>\r\n</html>\r\n\r\n","oembed":false,"readabilityObject":{"title":"Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society* Clinical Practice Guideline","content":"<div id=\"readability-page-1\" class=\"page\"><div id=\"main\">\n\n\n<div id=\"ContentColumn\">\n    <div>\n                \n                <div>\n                                <p><span>\n\n\n\n\n\n\n                                    Wylie C Hembree<span>, </span>\n\n                                    <span>\n<div>\n    \n\n    <div>\n        <p><span>1</span>New York Presbyterian Hospital, Columbia University Medical Center, New York, New York 10032 (Retired)</p>\n    </div>\n\n    <p>\n        Search for other works by this author on:\n    </p>\n\n\n\n    \n</div>                                    </span>\n                                </span>\n                                <span>\n\n\n\n\n\n\n                                    Peggy T Cohen-Kettenis<span>, </span>\n\n                                    <span>\n<div>\n    \n\n    <div>\n        <p><span>2</span>VU University Medical Center, 1007 MB Amsterdam, Netherlands (Retired)</p>\n    </div>\n\n    <p>\n        Search for other works by this author on:\n    </p>\n\n\n\n    \n</div>                                    </span>\n                                </span>\n                                <span>\n\n\n\n\n\n\n                                    Louis Gooren<span>, </span>\n\n                                    <span>\n<div>\n    \n\n    <div>\n        <p><span>3</span>VU University Medical Center, 1007 MB Amsterdam, Netherlands (Retired)</p>\n    </div>\n\n    <p>\n        Search for other works by this author on:\n    </p>\n\n\n\n    \n</div>                                    </span>\n                                </span>\n                                <span>\n\n\n\n\n\n\n                                    Sabine E Hannema<span>, </span>\n\n                                    <span>\n<div>\n    \n\n    <div>\n        <p><span>4</span>Leiden University Medical Center, 2300 RC Leiden, Netherlands</p>\n    </div>\n\n    <p>\n        Search for other works by this author on:\n    </p>\n\n\n\n    \n</div>                                    </span>\n                                </span>\n                                <span>\n\n\n\n\n\n\n                                    Walter J Meyer<span>, </span>\n\n                                    <span>\n<div>\n    \n\n    <div>\n        <p><span>5</span>University of Texas Medical Branch, Galveston, Texas 77555</p>\n    </div>\n\n    <p>\n        Search for other works by this author on:\n    </p>\n\n\n\n    \n</div>                                    </span>\n                                </span>\n                                <span>\n\n\n\n\n\n\n                                    M Hassan Murad<span>, </span>\n\n                                    <span>\n<div>\n    \n\n    <div>\n        <p><span>6</span>Mayo Clinic Evidence-Based Practice Center, Rochester, Minnesota 55905</p>\n    </div>\n\n    <p>\n        Search for other works by this author on:\n    </p>\n\n\n\n    \n</div>                                    </span>\n                                </span>\n                                <span>\n\n\n\n\n\n\n                                    Stephen M Rosenthal<span>, </span>\n\n                                    <span>\n<div>\n    \n\n    <div>\n        <p><span>7</span>University of California San Francisco, Benioff Children’s Hospital, San Francisco, California 94143</p>\n    </div>\n\n    <p>\n        Search for other works by this author on:\n    </p>\n\n\n\n    \n</div>                                    </span>\n                                </span>\n                                <span>\n\n\n\n\n\n\n                                    Joshua D Safer<span>, </span>\n\n                                    <span>\n<div>\n    \n\n    <div>\n        <p><span>8</span>Boston University School of Medicine, Boston, Massachusetts 02118</p>\n    </div>\n\n    <p>\n        Search for other works by this author on:\n    </p>\n\n\n\n    \n</div>                                    </span>\n                                </span>\n                                <span>\n\n\n\n\n\n\n                                    Vin Tangpricha<span>, </span>\n\n                                    <span>\n<div>\n    \n\n    <div>\n        <p><span>9</span>Emory University School of Medicine and the Atlanta VA Medical Center, Atlanta, Georgia 30322</p>\n    </div>\n\n    <p>\n        Search for other works by this author on:\n    </p>\n\n\n\n    \n</div>                                    </span>\n                                </span>\n                                <span>\n\n\n\n\n\n\n                                    Guy G T’Sjoen<span></span>\n\n                                    <span>\n<div>\n    \n\n    <div>\n        <p><span>10</span>Ghent University Hospital, 9000 Ghent, Belgium</p>\n    </div>\n\n    <p>\n        Search for other works by this author on:\n    </p>\n\n\n\n    \n</div>                                    </span>\n                                </span></p><div>\n                                <div>\n        <p><span><span>*</span><p>Cosponsoring Associations: American Association of Clinical Endocrinologists, American Society of Andrology, European Society for Pediatric Endocrinology, European Society of Endocrinology, Pediatric Endocrine Society, and World Professional Association for Transgender Health.</p></span></p> \n    </div>\n                                <p>Author Notes\n                            </p></div>\n                    </div>\n<div>\n                    <p>Published:</p>\n                    <p>13 September 2017</p>\n                </div>\n    </div>\n    <div>\n                            <p><span>A correction has been published: </span>\n                                                                <span>\n                            <em>The Journal of Clinical Endocrinology &amp; Metabolism</em>, Volume 103, Issue 2, February 2018, Page 699, <a href=\"https://doi.org/10.1210/jc.2017-02548\">https://doi.org/10.1210/jc.2017-02548</a>\n                        </span>\n                </p>\n                <p><span>A correction has been published: </span>\n                                                                <span>\n                            <em>The Journal of Clinical Endocrinology &amp; Metabolism</em>, Volume 103, Issue 7, July 2018, Pages 2758–2759, <a href=\"https://doi.org/10.1210/jc.2018-01268\">https://doi.org/10.1210/jc.2018-01268</a>\n                        </span>\n                </p>\n        </div>\n\n\n        <div>\n            <div>\n                    <ul id=\"Toolbar\" role=\"navigation\">\n    <li>\n        <a data-article-id=\"4157558\" href=\"/jcem/article-pdf/102/11/3869/21533864/jc.2017-01658.pdf\">\n            <img src=\"//oup.silverchair-cdn.com/UI/app/svg/pdf.svg\" alt=\"pdf\"><span>PDF</span>\n        </a>\n    </li>\n                                                    <li>\n                                <span>\n                                    <i></i>\n                                    Split View\n                                </span>\n                            </li>\n\n                        <li>\n                            <span>\n                                <i></i>\n                                \n                            </span>\n                            <ul id=\"ViewsDrop\" data-dropdown-content=\"\" aria-label=\"submenu\">\n                                \n                                <li data-content-filter=\"article-content\">\n                                    <span><span>Article contents</span></span>\n                                </li>\n                                <li data-content-filter=\"figures-tables\">\n                                    <span><span>Figures &amp; tables</span></span>\n                                </li>\n                                <li data-content-filter=\"video\">\n                                    <span><span>Video</span></span>\n                                </li>\n                                <li data-content-filter=\"audio\">\n                                    <span><span>Audio</span></span>\n                                </li>\n                                <li data-content-filter=\"supplementary-data\">\n                                    <span><span>Supplementary Data</span></span>\n                                </li>\n                            </ul>\n                        </li>\n\n\n                        <li>\n    <div>\n        <p><a href=\"#\" data-reveal-id=\"getCitation\" data-reveal=\"\">\n    <i></i>\n    <span>Cite</span>\n</a></p><div id=\"getCitation\" data-reveal=\"\">\n    <h3>Cite</h3>\n        <p>Wylie C Hembree, Peggy T Cohen-Kettenis, Louis Gooren, Sabine E Hannema, Walter J Meyer, M Hassan Murad, Stephen M Rosenthal, Joshua D Safer, Vin Tangpricha, Guy G T’Sjoen,  Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society Clinical Practice Guideline, <em>The Journal of Clinical Endocrinology &amp; Metabolism</em>, Volume 102, Issue 11, 1 November 2017, Pages 3869–3903, <a href=\"https://doi.org/10.1210/jc.2017-01658\">https://doi.org/10.1210/jc.2017-01658</a></p>\n\n    \n\n    <p><span><i></i><span>Close</span></span>\n</p></div>\n \n    </div>\n\n                        </li>\n                        <li>\n    \n\n                        </li>\n                        <li>\n                            <span>\n                                \n                                \n                            </span>\n                            <ul id=\"ShareDrop\" data-dropdown-content=\"\" aria-label=\"submenu\">\n                                \n                                <li><a><span>Email</span></a></li>\n                                <li><a><span>Twitter</span></a></li>\n                                <li><a><span>Facebook</span></a></li>\n                                <li><a><span>More</span></a></li>\n                            </ul>\n                        </li>\n                    </ul>\n                    <div>\n        <nav>\n\n        </nav>\n            <div>\n                <p>Close</p><div>\n    <p><label for=\"OUP_ArticleToolbarSearchBox-navbar-search-filter\">\n                Navbar Search Filter\n            </label>\n            \n\n        <label for=\"OUP_ArticleToolbarSearchBox-microsite-search-term\">\n            Microsite Search Term\n        </label>\n        \n\n        <span>\n            <span>Search</span>\n        </span>\n\n    </p>\n</div>\n\n                \n            </div>            \n    </div>\n                </div>\n            <div id=\"ContentTab\">\n    <div data-widgetname=\"ArticleFulltext\">\n\n\n\n\n\n                    <h2 scrollto-destination=\"99603237\" id=\"99603237\">Abstract</h2>\n<section><div><p>Objective</p><p>To update the “Endocrine Treatment of Transsexual Persons: An Endocrine Society Clinical Practice Guideline,” published by the Endocrine Society in 2009.</p></div><div><p>Participants</p><p>The participants include an Endocrine Society–appointed task force of nine experts, a methodologist, and a medical writer.</p></div><div><p>Evidence</p><p>This evidence-based guideline was developed using the Grading of Recommendations, Assessment, Development, and Evaluation approach to describe the strength of recommendations and the quality of evidence. The task force commissioned two systematic reviews and used the best available evidence from other published systematic reviews and individual studies.</p></div><div><p>Consensus Process</p><p>Group meetings, conference calls, and e-mail communications enabled consensus. Endocrine Society committees, members and cosponsoring organizations reviewed and commented on preliminary drafts of the guidelines.</p></div><div><p>Conclusion</p><p>Gender affirmation is multidisciplinary treatment in which endocrinologists play an important role. Gender-dysphoric/gender-incongruent persons seek and/or are referred to endocrinologists to develop the physical characteristics of the affirmed gender. They require a safe and effective hormone regimen that will (1) suppress endogenous sex hormone secretion determined by the person’s genetic/gonadal sex and (2) maintain sex hormone levels within the normal range for the person’s affirmed gender. Hormone treatment is not recommended for prepubertal gender-dysphoric/gender-incongruent persons. Those clinicians who recommend gender-affirming endocrine treatments—appropriately trained diagnosing clinicians (required), a mental health provider for adolescents (required) and mental health professional for adults (recommended)—should be knowledgeable about the diagnostic criteria and criteria for gender-affirming treatment, have sufficient training and experience in assessing psychopathology, and be willing to participate in the ongoing care throughout the endocrine transition. We recommend treating gender-dysphoric/gender-incongruent adolescents who have entered puberty at Tanner Stage G2/B2 by suppression with gonadotropin-releasing hormone agonists. Clinicians may add gender-affirming hormones after a multidisciplinary team has confirmed the persistence of gender dysphoria/gender incongruence and sufficient mental capacity to give informed consent to this partially irreversible treatment. Most adolescents have this capacity by age 16 years old. We recognize that there may be compelling reasons to initiate sex hormone treatment prior to age 16 years, although there is minimal published experience treating prior to 13.5 to 14 years of age. For the care of peripubertal youths and older adolescents, we recommend that an expert multidisciplinary team comprised of medical professionals and mental health professionals manage this treatment. The treating physician must confirm the criteria for treatment used by the referring mental health practitioner and collaborate with them in decisions about gender-affirming surgery in older adolescents. For adult gender-dysphoric/gender-incongruent persons, the treating clinicians (collectively) should have expertise in transgender-specific diagnostic criteria, mental health, primary care, hormone treatment, and surgery, as needed by the patient. We suggest maintaining physiologic levels of gender-appropriate hormones and monitoring for known risks and complications. When high doses of sex steroids are required to suppress endogenous sex steroids and/or in advanced age, clinicians may consider surgically removing natal gonads along with reducing sex steroid treatment. Clinicians should monitor both transgender males (female to male) and transgender females (male to female) for reproductive organ cancer risk when surgical removal is incomplete. Additionally, clinicians should persistently monitor adverse effects of sex steroids. For gender-affirming surgeries in adults, the treating physician must collaborate with and confirm the criteria for treatment used by the referring physician. Clinicians should avoid harming individuals (via hormone treatment) who have conditions other than gender dysphoria/gender incongruence and who may not benefit from the physical changes associated with this treatment.</p></div></section>                    \n                    <h2 scrollto-destination=\"99603239\" id=\"99603239\" data-legacy-id=\"s6\">Summary of Recommendations</h2>\n                    <h3 scrollto-destination=\"99603240\" id=\"99603240\" data-legacy-id=\"s7\">1.0 Evaluation of youth and adults</h3>\n<ul><li><p>1.1. We advise that only trained mental health professionals (MHPs) who meet the following criteria should diagnose gender dysphoria (GD)/gender incongruence in adults: (1) competence in using the Diagnostic and Statistical Manual of Mental Disorders (DSM) and/or the International Statistical Classification of Diseases and Related Health Problems (ICD) for diagnostic purposes, (2) the ability to diagnose GD/gender incongruence and make a distinction between GD/gender incongruence and conditions that have similar features (<em>e.g.</em>, body dysmorphic disorder), (3) training in diagnosing psychiatric conditions, (4) the ability to undertake or refer for appropriate treatment, (5) the ability to psychosocially assess the person’s understanding, mental health, and social conditions that can impact gender-affirming hormone therapy, and (6) a practice of regularly attending relevant professional meetings. (Ungraded Good Practice Statement)</p></li><li><p>1.2. We advise that only MHPs who meet the following criteria should diagnose GD/gender incongruence in children and adolescents: (1) training in child and adolescent developmental psychology and psychopathology, (2) competence in using the DSM and/or the ICD for diagnostic purposes, (3) the ability to make a distinction between GD/gender incongruence and conditions that have similar features (<em>e.g.</em>, body dysmorphic disorder), (4) training in diagnosing psychiatric conditions, (5) the ability to undertake or refer for appropriate treatment, (6) the ability to psychosocially assess the person’s understanding and social conditions that can impact gender-affirming hormone therapy, (7) a practice of regularly attending relevant professional meetings, and (8) knowledge of the criteria for puberty blocking and gender-affirming hormone treatment in adolescents. (Ungraded Good Practice Statement)</p></li><li><p>1.3. We advise that decisions regarding the social transition of prepubertal youths with GD/gender incongruence are made with the assistance of an MHP or another experienced professional. (Ungraded Good Practice Statement).</p></li><li><p>1.4. We recommend against puberty blocking and gender-affirming hormone treatment in prepubertal children with GD/gender incongruence. (1 |⊕⊕○○)</p></li><li><p>1.5. We recommend that clinicians inform and counsel all individuals seeking gender-affirming medical treatment regarding options for fertility preservation prior to initiating puberty suppression in adolescents and prior to treating with hormonal therapy of the affirmed gender in both adolescents and adults. (1 |⊕⊕⊕○)</p></li></ul>                    <h3 scrollto-destination=\"99603242\" id=\"99603242\" data-legacy-id=\"s8\">2.0 Treatment of adolescents</h3>\n<ul><li><p>2.1. We suggest that adolescents who meet diagnostic criteria for GD/gender incongruence, fulfill criteria for treatment, and are requesting treatment should initially undergo treatment to suppress pubertal development. (2 |⊕⊕○○)</p></li><li><p>2.2. We suggest that clinicians begin pubertal hormone suppression after girls and boys first exhibit physical changes of puberty. (2 |⊕⊕○○)</p></li><li><p>2.3. We recommend that, where indicated, GnRH analogues are used to suppress pubertal hormones. (1 |⊕⊕○○)</p></li><li><p>2.4. In adolescents who request sex hormone treatment (given this is a partly irreversible treatment), we recommend initiating treatment using a gradually increasing dose schedule after a multidisciplinary team of medical and MHPs has confirmed the persistence of GD/gender incongruence and sufficient mental capacity to give informed consent, which most adolescents have by age 16 years. (1 |⊕⊕○○).</p></li><li><p>2.5. We recognize that there may be compelling reasons to initiate sex hormone treatment prior to the age of 16 years in some adolescents with GD/gender incongruence, even though there are minimal published studies of gender-affirming hormone treatments administered before age 13.5 to 14 years. As with the care of adolescents ≥16 years of age, we recommend that an expert multidisciplinary team of medical and MHPs manage this treatment. (1 |⊕○○○)</p></li><li><p>2.6. We suggest monitoring clinical pubertal development every 3 to 6 months and laboratory parameters every 6 to 12 months during sex hormone treatment. (2 |⊕⊕○○)</p></li></ul>                    <h3 scrollto-destination=\"99603244\" id=\"99603244\" data-legacy-id=\"s9\">3.0 Hormonal therapy for transgender adults</h3>\n<ul><li><p>3.1. We recommend that clinicians confirm the diagnostic criteria of GD/gender incongruence and the criteria for the endocrine phase of gender transition before beginning treatment. (1 |⊕⊕⊕○)</p></li><li><p>3.2. We recommend that clinicians evaluate and address medical conditions that can be exacerbated by hormone depletion and treatment with sex hormones of the affirmed gender before beginning treatment. (1 |⊕⊕⊕○)</p></li><li><p>3.3. We suggest that clinicians measure hormone levels during treatment to ensure that endogenous sex steroids are suppressed and administered sex steroids are maintained in the normal physiologic range for the affirmed gender. (2 |⊕⊕○○)</p></li><li><p>3.4. We suggest that endocrinologists provide education to transgender individuals undergoing treatment about the onset and time course of physical changes induced by sex hormone treatment. (2 |⊕○○○)</p></li></ul>                    <h3 scrollto-destination=\"99603246\" id=\"99603246\" data-legacy-id=\"s10\">4.0 Adverse outcome prevention and long-term care</h3>\n<ul><li><p>4.1. We suggest regular clinical evaluation for physical changes and potential adverse changes in response to sex steroid hormones and laboratory monitoring of sex steroid hormone levels every 3 months during the first year of hormone therapy for transgender males and females and then once or twice yearly. (2 |⊕⊕○○)</p></li><li><p>4.2. We suggest periodically monitoring prolactin levels in transgender females treated with estrogens. (2 |⊕⊕○○)</p></li><li><p>4.3. We suggest that clinicians evaluate transgender persons treated with hormones for cardiovascular risk factors using fasting lipid profiles, diabetes screening, and/or other diagnostic tools. (2 |⊕⊕○○)</p></li><li><p>4.4. We recommend that clinicians obtain bone mineral density (BMD) measurements when risk factors for osteoporosis exist, specifically in those who stop sex hormone therapy after gonadectomy. (1 |⊕⊕○○)</p></li><li><p>4.5. We suggest that transgender females with no known increased risk of breast cancer follow breast-screening guidelines recommended for non-transgender females. (2 |⊕⊕○○)</p></li><li><p>4.6. We suggest that transgender females treated with estrogens follow individualized screening according to personal risk for prostatic disease and prostate cancer. (2 |⊕○○○)</p></li><li><p>4.7. We advise that clinicians determine the medical necessity of including a total hysterectomy and oophorectomy as part of gender-affirming surgery. (Ungraded Good Practice Statement)</p></li></ul>                    <h3 scrollto-destination=\"99603248\" id=\"99603248\" data-legacy-id=\"s11\">5.0 Surgery for sex reassignment and gender confirmation</h3>\n<ul><li><p>5.1. We recommend that a patient pursue genital gender-affirming surgery only after the MHP and the clinician responsible for endocrine transition therapy both agree that surgery is medically necessary and would benefit the patient’s overall health and/or well-being. (1 |⊕⊕○○)</p></li><li><p>5.2. We advise that clinicians approve genital gender-affirming surgery only after completion of at least 1 year of consistent and compliant hormone treatment, unless hormone therapy is not desired or medically contraindicated. (Ungraded Good Practice Statement)</p></li><li><p>5.3. We advise that the clinician responsible for endocrine treatment and the primary care provider ensure appropriate medical clearance of transgender individuals for genital gender-affirming surgery and collaborate with the surgeon regarding hormone use during and after surgery. (Ungraded Good Practice Statement)</p></li><li><p>5.4. We recommend that clinicians refer hormone-treated transgender individuals for genital surgery when: (1) the individual has had a satisfactory social role change, (2) the individual is satisfied about the hormonal effects, and (3) the individual desires definitive surgical changes. (1 |⊕○○○)</p></li><li><p>5.5. We suggest that clinicians delay gender-affirming genital surgery involving gonadectomy and/or hysterectomy until the patient is at least 18 years old or legal age of majority in his or her country. (2 |⊕⊕○○).</p></li><li><p>5.6. We suggest that clinicians determine the timing of breast surgery for transgender males based upon the physical and mental health status of the individual. There is insufficient evidence to recommend a specific age requirement. (2 |⊕○○○)</p></li></ul>                    <h2 scrollto-destination=\"99603250\" id=\"99603250\" data-legacy-id=\"s12\">Changes Since the Previous Guideline</h2>\n<p>Both the current guideline and the one published in 2009 contain similar sections. Listed here are the sections contained in the current guideline and the corresponding number of recommendations: Introduction, Evaluation of Youth and Adults (5), Treatment of Adolescents (6), Hormonal Therapy for Transgender Adults (4), Adverse Outcomes Prevention and Long-term Care (7), and Surgery for Sex Reassignment and Gender Confirmation (6). The current introduction updates the diagnostic classification of “gender dysphoria/gender incongruence.” It also reviews the development of “gender identity” and summarizes its natural development. The section on clinical evaluation of both youth and adults, defines in detail the professional qualifications required of those who diagnose and treat both adolescents and adults. We advise that decisions regarding the social transition of prepubertal youth are made with the assistance of a mental health professional or similarly experienced professional. We recommend against puberty blocking followed by gender-affirming hormone treatment of prepubertal children. Clinicians should inform pubertal children, adolescents, and adults seeking gender-confirming treatment of their options for fertility preservation. Prior to treatment, clinicians should evaluate the presence of medical conditions that may be worsened by hormone depletion and/or treatment. A multidisciplinary team, preferably composed of medical and mental health professionals, should monitor treatments. Clinicians evaluating transgender adults for endocrine treatment should confirm the diagnosis of persistent gender dysphoria/gender incongruence. Physicians should educate transgender persons regarding the time course of steroid-induced physical changes. Treatment should include periodic monitoring of hormone levels and metabolic parameters, as well as assessments of bone density and the impact upon prostate, gonads, and uterus. We also make recommendations for transgender persons who plan genital gender-affirming surgery.</p>                    <h2 scrollto-destination=\"99603252\" id=\"99603252\" data-legacy-id=\"s13\">Method of Development of Evidence-Based Clinical Practice Guidelines</h2>\n<p>The Clinical Guidelines Subcommittee (CGS) of the Endocrine Society deemed the diagnosis and treatment of individuals with GD/gender incongruence a priority area for revision and appointed a task force to formulate evidence-based recommendations. The task force followed the approach recommended by the Grading of Recommendations, Assessment, Development, and Evaluation group, an international group with expertise in the development and implementation of evidence-based guidelines (<span id=\"jumplink-B1\"></span>1). A detailed description of the grading scheme has been published elsewhere (<span id=\"jumplink-B2\"></span>2). The task force used the best available research evidence to develop the recommendations. The task force also used consistent language and graphical descriptions of both the strength of a recommendation and the quality of evidence. In terms of the strength of the recommendation, strong recommendations use the phrase “we recommend” and the number 1, and weak recommendations use the phrase “we suggest” and the number 2. Cross-filled circles indicate the quality of the evidence, such that ⊕○○○ denotes very low–quality evidence; ⊕⊕○○, low quality; ⊕⊕⊕○, moderate quality; and ⊕⊕⊕⊕, high quality. The task force has confidence that persons who receive care according to the strong recommendations will derive, on average, more benefit than harm. Weak recommendations require more careful consideration of the person’s circumstances, values, and preferences to determine the best course of action. Linked to each recommendation is a description of the evidence and the values that the task force considered in making the recommendation. In some instances, there are remarks in which the task force offers technical suggestions for testing conditions, dosing, and monitoring. These technical comments reflect the best available evidence applied to a typical person being treated. Often this evidence comes from the unsystematic observations of the task force and their preferences; therefore, one should consider these remarks as suggestions.</p><p>In this guideline, the task force made several statements to emphasize the importance of shared decision-making, general preventive care measures, and basic principles of the treatment of transgender persons. They labeled these “Ungraded Good Practice Statement.” Direct evidence for these statements was either unavailable or not systematically appraised and considered out of the scope of this guideline. The intention of these statements is to draw attention to these principles.</p><p>The Endocrine Society maintains a rigorous conflict-of-interest review process for developing clinical practice guidelines. All task force members must declare any potential conflicts of interest by completing a conflict-of-interest form. The CGS reviews all conflicts of interest before the Society’s Council approves the members to participate on the task force and periodically during the development of the guideline. All others participating in the guideline’s development must also disclose any conflicts of interest in the matter under study, and most of these participants must be without any conflicts of interest. The CGS and the task force have reviewed all disclosures for this guideline and resolved or managed all identified conflicts of interest.</p><p>Conflicts of interest are defined as remuneration in any amount from commercial interests; grants; research support; consulting fees; salary; ownership interests [<em>e.g.</em>, stocks and stock options (excluding diversified mutual funds)]; honoraria and other payments for participation in speakers’ bureaus, advisory boards, or boards of directors; and all other financial benefits. Completed forms are available through the Endocrine Society office.</p><p>The Endocrine Society provided the funding for this guideline; the task force received no funding or remuneration from commercial or other entities.</p>                    <h2 scrollto-destination=\"99603258\" id=\"99603258\" data-legacy-id=\"s14\">Commissioned Systematic Review</h2>\n<p>The task force commissioned two systematic reviews to support this guideline. The first one aimed to summarize the available evidence on the effect of sex steroid use in transgender individuals on lipids and cardiovascular outcomes. The review identified 29 eligible studies at moderate risk of bias. In transgender males (female to male), sex steroid therapy was associated with a statistically significant increase in serum triglycerides and low-density lipoprotein cholesterol levels. High-density lipoprotein cholesterol levels decreased significantly across all follow-up time periods. In transgender females (male to female), serum triglycerides were significantly higher without any changes in other parameters. Few myocardial infarction, stroke, venous thromboembolism (VTE), and death events were reported. These events were more frequent in transgender females. However, the quality of the evidence was low. The second review summarized the available evidence regarding the effect of sex steroids on bone health in transgender individuals and identified 13 studies. In transgender males, there was no statistically significant difference in the lumbar spine, femoral neck, or total hip BMD at 12 and 24 months compared with baseline values before initiating masculinizing hormone therapy. In transgender females, there was a statistically significant increase in lumbar spine BMD at 12 months and 24 months compared with baseline values before initiation of feminizing hormone therapy. There was minimal information on fracture rates. The quality of evidence was also low.</p>                    <h2 scrollto-destination=\"99603260\" id=\"99603260\" data-legacy-id=\"s15\">Introduction</h2>\n<p>Throughout recorded history (in the absence of an endocrine disorder) some men and women have experienced confusion and anguish resulting from rigid, forced conformity to sexual dimorphism. In modern history, there have been numerous ongoing biological, psychological, cultural, political, and sociological debates over various aspects of gender variance. The 20th century marked the emergence of a social awakening for men and women with the belief that they are “trapped” in the wrong body (<span id=\"jumplink-B3\"></span>3). Magnus Hirschfeld and Harry Benjamin, among others, pioneered the medical responses to those who sought relief from and a resolution to their profound discomfort. Although the term transsexual became widely known after Benjamin wrote “The Transsexual Phenomenon” (<span id=\"jumplink-B4\"></span>4), it was Hirschfeld who coined the term “transsexual” in 1923 to describe people who want to live a life that corresponds with their experienced gender vs their designated gender (<span id=\"jumplink-B5\"></span>5). Magnus Hirschfeld (<span id=\"jumplink-B6\"></span>6) and others (<span id=\"jumplink-B4\"></span>4, <span id=\"jumplink-B7\"></span>7) have described other types of trans phenomena besides transsexualism. These early researchers proposed that the gender identity of these people was located somewhere along a unidimensional continuum. This continuum ranged from all male through “something in between” to all female. Yet such a classification does not take into account that people may have gender identities outside this continuum. For instance, some experience themselves as having both a male and female gender identity, whereas others completely renounce any gender classification (<span id=\"jumplink-B8\"></span>8, <span id=\"jumplink-B9\"></span>9). There are also reports of individuals experiencing a continuous and rapid involuntary alternation between a male and female identity (<span id=\"jumplink-B10\"></span>10) or men who do not experience themselves as men but do not want to live as women (<span id=\"jumplink-B11\"></span>11, <span id=\"jumplink-B12\"></span>12). In some countries, (<em>e.g.</em>, Nepal, Bangladesh, and Australia), these nonmale or nonfemale genders are officially recognized (<span id=\"jumplink-B13\"></span>13). Specific treatment protocols, however, have not yet been developed for these groups.</p><p>Instead of the term transsexualism, the current classification system of the American Psychiatric Association uses the term gender dysphoria in its diagnosis of persons who are not satisfied with their designated gender (<span id=\"jumplink-B14\"></span>14). The current version of the World Health Organization’s ICD-10 still uses the term transsexualism when diagnosing adolescents and adults. However, for the ICD-11, the World Health Organization has proposed using the term “gender incongruence” (<span id=\"jumplink-B15\"></span>15).</p><p>Treating persons with GD/gender incongruence (<span id=\"jumplink-B15\"></span>15) was previously limited to relatively ineffective elixirs or creams. However, more effective endocrinology-based treatments became possible with the availability of testosterone in 1935 and diethylstilbestrol in 1938. Reports of individuals with GD/gender incongruence who were treated with hormones and gender-affirming surgery appeared in the press during the second half of the 20th century. The Harry Benjamin International Gender Dysphoria Association was founded in September 1979 and is now called the World Professional Association for Transgender Health (WPATH). WPATH published its first Standards of Care in 1979. These standards have since been regularly updated, providing guidance for treating persons with GD/gender incongruence (<span id=\"jumplink-B16\"></span>16).</p><p>Prior to 1975, few peer-reviewed articles were published concerning endocrine treatment of transgender persons. Since then, more than two thousand articles about various aspects of transgender care have appeared.</p><p>It is the purpose of this guideline to make detailed recommendations and suggestions, based on existing medical literature and clinical experience, that will enable treating physicians to maximize benefit and minimize risk when caring for individuals diagnosed with GD/gender incongruence.</p><p>In the future, we need more rigorous evaluations of the effectiveness and safety of endocrine and surgical protocols. Specifically, endocrine treatment protocols for GD/gender incongruence should include the careful assessment of the following: (1) the effects of prolonged delay of puberty in adolescents on bone health, gonadal function, and the brain (including effects on cognitive, emotional, social, and sexual development); (2) the effects of treatment in adults on sex hormone levels; (3) the requirement for and the effects of progestins and other agents used to suppress endogenous sex steroids during treatment; and (4) the risks and benefits of gender-affirming hormone treatment in older transgender people.</p><p>To successfully establish and enact these protocols, a commitment of mental health and endocrine investigators is required to collaborate in long-term, large-scale studies across countries that use the same diagnostic and inclusion criteria, medications, assay methods, and response assessment tools (<em>e.g.</em>, the European Network for the Investigation of Gender Incongruence) (<span id=\"jumplink-B17\"></span>17, <span id=\"jumplink-B18\"></span>18).</p><p>Terminology and its use vary and continue to evolve. <span id=\"jumplink-T1\"></span>Table 1 contains the definitions of terms as they are used throughout this guideline.</p>                    <div content-id=\"T1\"><div id=\"T1\" data-id=\"T1\"><p><span>Table 1.</span></p><p>Definitions of Terms Used in This Guideline</p> </div><div><table><tbody><tr><td><em>Biological sex, biological male or female:</em> These terms refer to physical aspects of maleness and femaleness. As these may not be in line with each other (<em>e.g.</em>, a person with XY chromosomes may have female-appearing genitalia), the terms biological sex and biological male or female are imprecise and should be avoided.&nbsp;</td></tr><tr><td><em>Cisgender:</em> This means not transgender. An alternative way to describe individuals who are not transgender is “non-transgender people.”&nbsp;</td></tr><tr><td><em>Gender-affirming (hormone) treatment:</em> See “gender reassignment”&nbsp;</td></tr><tr><td><em>Gender dysphoria:</em> This is the distress and unease experienced if gender identity and designated gender are not completely congruent (see Table 2). In 2013, the American Psychiatric Association released the fifth edition of the DSM-5, which replaced “gender identity disorder” with “gender dysphoria” and changed the criteria for diagnosis.&nbsp;</td></tr><tr><td><em>Gender expression:</em> This refers to external manifestations of gender, expressed through one’s name, pronouns, clothing, haircut, behavior, voice, or body characteristics. Typically, transgender people seek to make their gender expression align with their gender identity, rather than their designated gender.&nbsp;</td></tr><tr><td><em>Gender identity/experienced gender:</em> This refers to one’s internal, deeply held sense of gender. For transgender people, their gender identity does not match their sex designated at birth. Most people have a gender identity of man or woman (or boy or girl). For some people, their gender identity does not fit neatly into one of those two choices. Unlike gender expression (see below), gender identity is not visible to others.&nbsp;</td></tr><tr><td><em>Gender identity disorder:</em> This is the term used for GD/gender incongruence in previous versions of DSM (see “gender dysphoria”). The ICD-10 still uses the term for diagnosing child diagnoses, but the upcoming ICD-11 has proposed using “gender incongruence of childhood.”&nbsp;</td></tr><tr><td><em>Gender incongruence:</em> This is an umbrella term used when the gender identity and/or gender expression differs from what is typically associated with the designated gender. Gender incongruence is also the proposed name of the gender identity–related diagnoses in ICD-11. Not all individuals with gender incongruence have gender dysphoria or seek treatment.&nbsp;</td></tr><tr><td><em>Gender variance:</em> See “gender incongruence”&nbsp;</td></tr><tr><td><em>Gender reassignment:</em> This refers to the treatment procedure for those who want to adapt their bodies to the experienced gender by means of hormones and/or surgery. This is also called gender-confirming or gender-affirming treatment.&nbsp;</td></tr><tr><td><em>Gender-reassignment surgery (gender-confirming/gender-affirming surgery):</em> These terms refer only to the surgical part of gender-confirming/gender-affirming treatment.&nbsp;</td></tr><tr><td><em>Gender role:</em> This refers to behaviors, attitudes, and personality traits that a society (in a given culture and historical period) designates as masculine or feminine and/or that society associates with or considers typical of the social role of men or women.&nbsp;</td></tr><tr><td><em>Sex designated at birth:</em> This refers to sex assigned at birth, usually based on genital anatomy.&nbsp;</td></tr><tr><td><em>Sex:</em> This refers to attributes that characterize biological maleness or femaleness. The best known attributes include the sex-determining genes, the sex chromosomes, the H-Y antigen, the gonads, sex hormones, internal and external genitalia, and secondary sex characteristics.&nbsp;</td></tr><tr><td><em>Sexual orientation:</em> This term describes an individual’s enduring physical and emotional attraction to another person. Gender identity and sexual orientation are not the same. Irrespective of their gender identity, transgender people may be attracted to women (gynephilic), attracted to men (androphilic), bisexual, asexual, or queer.&nbsp;</td></tr><tr><td><em>Transgender:</em> This is an umbrella term for people whose gender identity and/or gender expression differs from what is typically associated with their sex designated at birth. Not all transgender individuals seek treatment.&nbsp;</td></tr><tr><td><em>Transgender male (also: trans man, female-to-male, transgender male):</em> This refers to individuals assigned female at birth but who identify and live as men.&nbsp;</td></tr><tr><td><em>Transgender woman (also: trans woman, male-to female, transgender female):</em> This refers to individuals assigned male at birth but who identify and live as women.&nbsp;</td></tr><tr><td><em>Transition:</em> This refers to the process during which transgender persons change their physical, social, and/or legal characteristics consistent with the affirmed gender identity. Prepubertal children may choose to transition socially.&nbsp;</td></tr><tr><td><em>Transsexual:</em> This is an older term that originated in the medical and psychological communities to refer to individuals who have permanently transitioned through medical interventions or desired to do so.&nbsp;</td></tr></tbody></table></div><div><table><tbody><tr><td><em>Biological sex, biological male or female:</em> These terms refer to physical aspects of maleness and femaleness. As these may not be in line with each other (<em>e.g.</em>, a person with XY chromosomes may have female-appearing genitalia), the terms biological sex and biological male or female are imprecise and should be avoided.&nbsp;</td></tr><tr><td><em>Cisgender:</em> This means not transgender. An alternative way to describe individuals who are not transgender is “non-transgender people.”&nbsp;</td></tr><tr><td><em>Gender-affirming (hormone) treatment:</em> See “gender reassignment”&nbsp;</td></tr><tr><td><em>Gender dysphoria:</em> This is the distress and unease experienced if gender identity and designated gender are not completely congruent (see Table 2). In 2013, the American Psychiatric Association released the fifth edition of the DSM-5, which replaced “gender identity disorder” with “gender dysphoria” and changed the criteria for diagnosis.&nbsp;</td></tr><tr><td><em>Gender expression:</em> This refers to external manifestations of gender, expressed through one’s name, pronouns, clothing, haircut, behavior, voice, or body characteristics. Typically, transgender people seek to make their gender expression align with their gender identity, rather than their designated gender.&nbsp;</td></tr><tr><td><em>Gender identity/experienced gender:</em> This refers to one’s internal, deeply held sense of gender. For transgender people, their gender identity does not match their sex designated at birth. Most people have a gender identity of man or woman (or boy or girl). For some people, their gender identity does not fit neatly into one of those two choices. Unlike gender expression (see below), gender identity is not visible to others.&nbsp;</td></tr><tr><td><em>Gender identity disorder:</em> This is the term used for GD/gender incongruence in previous versions of DSM (see “gender dysphoria”). The ICD-10 still uses the term for diagnosing child diagnoses, but the upcoming ICD-11 has proposed using “gender incongruence of childhood.”&nbsp;</td></tr><tr><td><em>Gender incongruence:</em> This is an umbrella term used when the gender identity and/or gender expression differs from what is typically associated with the designated gender. Gender incongruence is also the proposed name of the gender identity–related diagnoses in ICD-11. Not all individuals with gender incongruence have gender dysphoria or seek treatment.&nbsp;</td></tr><tr><td><em>Gender variance:</em> See “gender incongruence”&nbsp;</td></tr><tr><td><em>Gender reassignment:</em> This refers to the treatment procedure for those who want to adapt their bodies to the experienced gender by means of hormones and/or surgery. This is also called gender-confirming or gender-affirming treatment.&nbsp;</td></tr><tr><td><em>Gender-reassignment surgery (gender-confirming/gender-affirming surgery):</em> These terms refer only to the surgical part of gender-confirming/gender-affirming treatment.&nbsp;</td></tr><tr><td><em>Gender role:</em> This refers to behaviors, attitudes, and personality traits that a society (in a given culture and historical period) designates as masculine or feminine and/or that society associates with or considers typical of the social role of men or women.&nbsp;</td></tr><tr><td><em>Sex designated at birth:</em> This refers to sex assigned at birth, usually based on genital anatomy.&nbsp;</td></tr><tr><td><em>Sex:</em> This refers to attributes that characterize biological maleness or femaleness. The best known attributes include the sex-determining genes, the sex chromosomes, the H-Y antigen, the gonads, sex hormones, internal and external genitalia, and secondary sex characteristics.&nbsp;</td></tr><tr><td><em>Sexual orientation:</em> This term describes an individual’s enduring physical and emotional attraction to another person. Gender identity and sexual orientation are not the same. Irrespective of their gender identity, transgender people may be attracted to women (gynephilic), attracted to men (androphilic), bisexual, asexual, or queer.&nbsp;</td></tr><tr><td><em>Transgender:</em> This is an umbrella term for people whose gender identity and/or gender expression differs from what is typically associated with their sex designated at birth. Not all transgender individuals seek treatment.&nbsp;</td></tr><tr><td><em>Transgender male (also: trans man, female-to-male, transgender male):</em> This refers to individuals assigned female at birth but who identify and live as men.&nbsp;</td></tr><tr><td><em>Transgender woman (also: trans woman, male-to female, transgender female):</em> This refers to individuals assigned male at birth but who identify and live as women.&nbsp;</td></tr><tr><td><em>Transition:</em> This refers to the process during which transgender persons change their physical, social, and/or legal characteristics consistent with the affirmed gender identity. Prepubertal children may choose to transition socially.&nbsp;</td></tr><tr><td><em>Transsexual:</em> This is an older term that originated in the medical and psychological communities to refer to individuals who have permanently transitioned through medical interventions or desired to do so.&nbsp;</td></tr></tbody></table></div></div><div><div id=\"T1\" data-id=\"T1\"><p><span>Table 1.</span></p><p>Definitions of Terms Used in This Guideline</p> </div><div><table><tbody><tr><td><em>Biological sex, biological male or female:</em> These terms refer to physical aspects of maleness and femaleness. As these may not be in line with each other (<em>e.g.</em>, a person with XY chromosomes may have female-appearing genitalia), the terms biological sex and biological male or female are imprecise and should be avoided.&nbsp;</td></tr><tr><td><em>Cisgender:</em> This means not transgender. An alternative way to describe individuals who are not transgender is “non-transgender people.”&nbsp;</td></tr><tr><td><em>Gender-affirming (hormone) treatment:</em> See “gender reassignment”&nbsp;</td></tr><tr><td><em>Gender dysphoria:</em> This is the distress and unease experienced if gender identity and designated gender are not completely congruent (see Table 2). In 2013, the American Psychiatric Association released the fifth edition of the DSM-5, which replaced “gender identity disorder” with “gender dysphoria” and changed the criteria for diagnosis.&nbsp;</td></tr><tr><td><em>Gender expression:</em> This refers to external manifestations of gender, expressed through one’s name, pronouns, clothing, haircut, behavior, voice, or body characteristics. Typically, transgender people seek to make their gender expression align with their gender identity, rather than their designated gender.&nbsp;</td></tr><tr><td><em>Gender identity/experienced gender:</em> This refers to one’s internal, deeply held sense of gender. For transgender people, their gender identity does not match their sex designated at birth. Most people have a gender identity of man or woman (or boy or girl). For some people, their gender identity does not fit neatly into one of those two choices. Unlike gender expression (see below), gender identity is not visible to others.&nbsp;</td></tr><tr><td><em>Gender identity disorder:</em> This is the term used for GD/gender incongruence in previous versions of DSM (see “gender dysphoria”). The ICD-10 still uses the term for diagnosing child diagnoses, but the upcoming ICD-11 has proposed using “gender incongruence of childhood.”&nbsp;</td></tr><tr><td><em>Gender incongruence:</em> This is an umbrella term used when the gender identity and/or gender expression differs from what is typically associated with the designated gender. Gender incongruence is also the proposed name of the gender identity–related diagnoses in ICD-11. Not all individuals with gender incongruence have gender dysphoria or seek treatment.&nbsp;</td></tr><tr><td><em>Gender variance:</em> See “gender incongruence”&nbsp;</td></tr><tr><td><em>Gender reassignment:</em> This refers to the treatment procedure for those who want to adapt their bodies to the experienced gender by means of hormones and/or surgery. This is also called gender-confirming or gender-affirming treatment.&nbsp;</td></tr><tr><td><em>Gender-reassignment surgery (gender-confirming/gender-affirming surgery):</em> These terms refer only to the surgical part of gender-confirming/gender-affirming treatment.&nbsp;</td></tr><tr><td><em>Gender role:</em> This refers to behaviors, attitudes, and personality traits that a society (in a given culture and historical period) designates as masculine or feminine and/or that society associates with or considers typical of the social role of men or women.&nbsp;</td></tr><tr><td><em>Sex designated at birth:</em> This refers to sex assigned at birth, usually based on genital anatomy.&nbsp;</td></tr><tr><td><em>Sex:</em> This refers to attributes that characterize biological maleness or femaleness. The best known attributes include the sex-determining genes, the sex chromosomes, the H-Y antigen, the gonads, sex hormones, internal and external genitalia, and secondary sex characteristics.&nbsp;</td></tr><tr><td><em>Sexual orientation:</em> This term describes an individual’s enduring physical and emotional attraction to another person. Gender identity and sexual orientation are not the same. Irrespective of their gender identity, transgender people may be attracted to women (gynephilic), attracted to men (androphilic), bisexual, asexual, or queer.&nbsp;</td></tr><tr><td><em>Transgender:</em> This is an umbrella term for people whose gender identity and/or gender expression differs from what is typically associated with their sex designated at birth. Not all transgender individuals seek treatment.&nbsp;</td></tr><tr><td><em>Transgender male (also: trans man, female-to-male, transgender male):</em> This refers to individuals assigned female at birth but who identify and live as men.&nbsp;</td></tr><tr><td><em>Transgender woman (also: trans woman, male-to female, transgender female):</em> This refers to individuals assigned male at birth but who identify and live as women.&nbsp;</td></tr><tr><td><em>Transition:</em> This refers to the process during which transgender persons change their physical, social, and/or legal characteristics consistent with the affirmed gender identity. Prepubertal children may choose to transition socially.&nbsp;</td></tr><tr><td><em>Transsexual:</em> This is an older term that originated in the medical and psychological communities to refer to individuals who have permanently transitioned through medical interventions or desired to do so.&nbsp;</td></tr></tbody></table></div><div><table><tbody><tr><td><em>Biological sex, biological male or female:</em> These terms refer to physical aspects of maleness and femaleness. As these may not be in line with each other (<em>e.g.</em>, a person with XY chromosomes may have female-appearing genitalia), the terms biological sex and biological male or female are imprecise and should be avoided.&nbsp;</td></tr><tr><td><em>Cisgender:</em> This means not transgender. An alternative way to describe individuals who are not transgender is “non-transgender people.”&nbsp;</td></tr><tr><td><em>Gender-affirming (hormone) treatment:</em> See “gender reassignment”&nbsp;</td></tr><tr><td><em>Gender dysphoria:</em> This is the distress and unease experienced if gender identity and designated gender are not completely congruent (see Table 2). In 2013, the American Psychiatric Association released the fifth edition of the DSM-5, which replaced “gender identity disorder” with “gender dysphoria” and changed the criteria for diagnosis.&nbsp;</td></tr><tr><td><em>Gender expression:</em> This refers to external manifestations of gender, expressed through one’s name, pronouns, clothing, haircut, behavior, voice, or body characteristics. Typically, transgender people seek to make their gender expression align with their gender identity, rather than their designated gender.&nbsp;</td></tr><tr><td><em>Gender identity/experienced gender:</em> This refers to one’s internal, deeply held sense of gender. For transgender people, their gender identity does not match their sex designated at birth. Most people have a gender identity of man or woman (or boy or girl). For some people, their gender identity does not fit neatly into one of those two choices. Unlike gender expression (see below), gender identity is not visible to others.&nbsp;</td></tr><tr><td><em>Gender identity disorder:</em> This is the term used for GD/gender incongruence in previous versions of DSM (see “gender dysphoria”). The ICD-10 still uses the term for diagnosing child diagnoses, but the upcoming ICD-11 has proposed using “gender incongruence of childhood.”&nbsp;</td></tr><tr><td><em>Gender incongruence:</em> This is an umbrella term used when the gender identity and/or gender expression differs from what is typically associated with the designated gender. Gender incongruence is also the proposed name of the gender identity–related diagnoses in ICD-11. Not all individuals with gender incongruence have gender dysphoria or seek treatment.&nbsp;</td></tr><tr><td><em>Gender variance:</em> See “gender incongruence”&nbsp;</td></tr><tr><td><em>Gender reassignment:</em> This refers to the treatment procedure for those who want to adapt their bodies to the experienced gender by means of hormones and/or surgery. This is also called gender-confirming or gender-affirming treatment.&nbsp;</td></tr><tr><td><em>Gender-reassignment surgery (gender-confirming/gender-affirming surgery):</em> These terms refer only to the surgical part of gender-confirming/gender-affirming treatment.&nbsp;</td></tr><tr><td><em>Gender role:</em> This refers to behaviors, attitudes, and personality traits that a society (in a given culture and historical period) designates as masculine or feminine and/or that society associates with or considers typical of the social role of men or women.&nbsp;</td></tr><tr><td><em>Sex designated at birth:</em> This refers to sex assigned at birth, usually based on genital anatomy.&nbsp;</td></tr><tr><td><em>Sex:</em> This refers to attributes that characterize biological maleness or femaleness. The best known attributes include the sex-determining genes, the sex chromosomes, the H-Y antigen, the gonads, sex hormones, internal and external genitalia, and secondary sex characteristics.&nbsp;</td></tr><tr><td><em>Sexual orientation:</em> This term describes an individual’s enduring physical and emotional attraction to another person. Gender identity and sexual orientation are not the same. Irrespective of their gender identity, transgender people may be attracted to women (gynephilic), attracted to men (androphilic), bisexual, asexual, or queer.&nbsp;</td></tr><tr><td><em>Transgender:</em> This is an umbrella term for people whose gender identity and/or gender expression differs from what is typically associated with their sex designated at birth. Not all transgender individuals seek treatment.&nbsp;</td></tr><tr><td><em>Transgender male (also: trans man, female-to-male, transgender male):</em> This refers to individuals assigned female at birth but who identify and live as men.&nbsp;</td></tr><tr><td><em>Transgender woman (also: trans woman, male-to female, transgender female):</em> This refers to individuals assigned male at birth but who identify and live as women.&nbsp;</td></tr><tr><td><em>Transition:</em> This refers to the process during which transgender persons change their physical, social, and/or legal characteristics consistent with the affirmed gender identity. Prepubertal children may choose to transition socially.&nbsp;</td></tr><tr><td><em>Transsexual:</em> This is an older term that originated in the medical and psychological communities to refer to individuals who have permanently transitioned through medical interventions or desired to do so.&nbsp;</td></tr></tbody></table></div></div>                    <h2 scrollto-destination=\"99603270\" id=\"99603270\" data-legacy-id=\"s16\">Biological Determinants of Gender Identity Development</h2>\n<p>One’s self-awareness as male or female changes gradually during infant life and childhood. This process of cognitive and affective learning evolves with interactions with parents, peers, and environment. A fairly accurate timetable exists outlining the steps in this process (<span id=\"jumplink-B19\"></span>19). Normative psychological literature, however, does not address if and when gender identity becomes crystallized and what factors contribute to the development of a gender identity that is not congruent with the gender of rearing. Results of studies from a variety of biomedical disciplines—genetic, endocrine, and neuroanatomic—support the concept that gender identity and/or gender expression (<span id=\"jumplink-B20\"></span>20) likely reflect a complex interplay of biological, environmental, and cultural factors (<span id=\"jumplink-B21\"></span>21, <span id=\"jumplink-B22\"></span>22).</p><p>With respect to endocrine considerations, studies have failed to find differences in circulating levels of sex steroids between transgender and nontransgender individuals (<span id=\"jumplink-B23\"></span>23). However, studies in individuals with a disorder/difference of sex development (DSD) have informed our understanding of the role that hormones may play in gender identity outcome, even though most persons with GD/gender incongruence do not have a DSD. For example, although most 46,XX adult individuals with virilizing congenital adrenal hyperplasia caused by mutations in <em>CYP21A2</em> reported a female gender identity, the prevalence of GD/gender incongruence was much greater in this group than in the general population without a DSD. This supports the concept that there is a role for prenatal/postnatal androgens in gender development (<span id=\"jumplink-B24\"></span>24–<span id=\"jumplink-B26\"></span>26), although some studies indicate that prenatal androgens are more likely to affect gender behavior and sexual orientation rather than gender identity <em>per se</em> (<span id=\"jumplink-B27\"></span>27, <span id=\"jumplink-B28\"></span>28).</p><p>Researchers have made similar observations regarding the potential role of androgens in the development of gender identity in other individuals with DSD. For example, a review of two groups of 46,XY persons, each with androgen synthesis deficiencies and female raised, reported transgender male (female-to-male) gender role changes in 56% to 63% and 39% to 64% of patients, respectively (<span id=\"jumplink-B29\"></span>29). Also, in 46,XY female-raised individuals with cloacal exstrophy and penile agenesis, the occurrence of transgender male changes was significantly more prevalent than in the general population (<span id=\"jumplink-B30\"></span>30, <span id=\"jumplink-B31\"></span>31). However, the fact that a high percentage of individuals with the same conditions did not change gender suggests that cultural factors may play a role as well.</p><p>With respect to genetics and gender identity, several studies have suggested heritability of GD/gender incongruence (<span id=\"jumplink-B32\"></span>32, <span id=\"jumplink-B33\"></span>33). In particular, a study by Heylens <em>et al.</em> (<span id=\"jumplink-B33\"></span>33) demonstrated a 39.1% concordance rate for gender identity disorder (based on the DSM-IV criteria) in 23 monozygotic twin pairs but no concordance in 21 same-sex dizygotic or seven opposite-sex twin pairs. Although numerous investigators have sought to identify specific genes associated with GD/gender incongruence, such studies have been inconsistent and without strong statistical significance (<span id=\"jumplink-B34\"></span>34–<span id=\"jumplink-B38\"></span>38).</p><p>Studies focusing on brain structure suggest that the brain phenotypes of people with GD/gender incongruence differ in various ways from control males and females, but that there is not a complete sex reversal in brain structures (<span id=\"jumplink-B39\"></span>39).</p><p>In summary, although there is much that is still unknown with respect to gender identity and its expression, compelling studies support the concept that biologic factors, in addition to environmental factors, contribute to this fundamental aspect of human development.</p>                    <h2 scrollto-destination=\"99603277\" id=\"99603277\" data-legacy-id=\"s17\">Natural History of Children With GD/Gender Incongruence</h2>\n<p>With current knowledge, we cannot predict the psychosexual outcome for any specific child. Prospective follow-up studies show that childhood GD/gender incongruence does not invariably persist into adolescence and adulthood (so-called “desisters”). Combining all outcome studies to date, the GD/gender incongruence of a minority of prepubertal children appears to persist in adolescence (<span id=\"jumplink-B20\"></span>20, <span id=\"jumplink-B40\"></span>40). In adolescence, a significant number of these desisters identify as homosexual or bisexual. It may be that children who only showed some gender nonconforming characteristics have been included in the follow-up studies, because the DSM-IV text revision criteria for a diagnosis were rather broad. However, the persistence of GD/gender incongruence into adolescence is more likely if it had been extreme in childhood (<span id=\"jumplink-B41\"></span>41, <span id=\"jumplink-B42\"></span>42). With the newer, stricter criteria of the DSM-5 (<span id=\"jumplink-T2\"></span>Table 2), persistence rates may well be different in future studies.</p>                    <div content-id=\"T2\"><div id=\"T2\" data-id=\"T2\"><p><span>Table 2.</span></p><p>DSM-5 Criteria for Gender Dysphoria in Adolescents and Adults</p> </div><div><table><tbody><tr><td>A. A marked incongruence between one’s experienced/expressed gender and natal gender of at least 6 mo in duration, as manifested by at least two of the following:&nbsp;</td></tr><tr><td> 1. A marked incongruence between one’s experienced/expressed gender and primary and/or secondary sex characteristics (or in young adolescents, the anticipated secondary sex characteristics)&nbsp;</td></tr><tr><td> 2. A strong desire to be rid of one’s primary and/or secondary sex characteristics because of a marked incongruence with one’s experienced/expressed gender (or in young adolescents, a desire to prevent the development of the anticipated secondary sex characteristics)&nbsp;</td></tr><tr><td> 3. A strong desire for the primary and/or secondary sex characteristics of the other gender&nbsp;</td></tr><tr><td> 4. A strong desire to be of the other gender (or some alternative gender different from one’s designated gender)&nbsp;</td></tr><tr><td> 5. A strong desire to be treated as the other gender (or some alternative gender different from one’s designated gender)&nbsp;</td></tr><tr><td> 6. A strong conviction that one has the typical feelings and reactions of the other gender (or some alternative gender different from one’s designated gender)&nbsp;</td></tr><tr><td>B. The condition is associated with clinically significant distress or impairment in social, occupational, or other important areas of functioning.&nbsp;</td></tr><tr><td>Specify if:&nbsp;</td></tr><tr><td> 1. The condition exists with a disorder of sex development.&nbsp;</td></tr><tr><td> 2. The condition is posttransitional, in that the individual has transitioned to full-time living in the desired gender (with or without legalization of gender change) and has undergone (or is preparing to have) at least one sex-related medical procedure or treatment regimen—namely, regular sex hormone treatment or gender reassignment surgery confirming the desired gender (<em>e.g.</em>, penectomy, vaginoplasty in natal males; mastectomy or phalloplasty in natal females).&nbsp;</td></tr></tbody></table></div><div><table><tbody><tr><td>A. A marked incongruence between one’s experienced/expressed gender and natal gender of at least 6 mo in duration, as manifested by at least two of the following:&nbsp;</td></tr><tr><td> 1. A marked incongruence between one’s experienced/expressed gender and primary and/or secondary sex characteristics (or in young adolescents, the anticipated secondary sex characteristics)&nbsp;</td></tr><tr><td> 2. A strong desire to be rid of one’s primary and/or secondary sex characteristics because of a marked incongruence with one’s experienced/expressed gender (or in young adolescents, a desire to prevent the development of the anticipated secondary sex characteristics)&nbsp;</td></tr><tr><td> 3. A strong desire for the primary and/or secondary sex characteristics of the other gender&nbsp;</td></tr><tr><td> 4. A strong desire to be of the other gender (or some alternative gender different from one’s designated gender)&nbsp;</td></tr><tr><td> 5. A strong desire to be treated as the other gender (or some alternative gender different from one’s designated gender)&nbsp;</td></tr><tr><td> 6. A strong conviction that one has the typical feelings and reactions of the other gender (or some alternative gender different from one’s designated gender)&nbsp;</td></tr><tr><td>B. The condition is associated with clinically significant distress or impairment in social, occupational, or other important areas of functioning.&nbsp;</td></tr><tr><td>Specify if:&nbsp;</td></tr><tr><td> 1. The condition exists with a disorder of sex development.&nbsp;</td></tr><tr><td> 2. The condition is posttransitional, in that the individual has transitioned to full-time living in the desired gender (with or without legalization of gender change) and has undergone (or is preparing to have) at least one sex-related medical procedure or treatment regimen—namely, regular sex hormone treatment or gender reassignment surgery confirming the desired gender (<em>e.g.</em>, penectomy, vaginoplasty in natal males; mastectomy or phalloplasty in natal females).&nbsp;</td></tr></tbody></table></div><div><p><span><p>Reference: American Psychiatric Association (<span id=\"jumplink-B14\"></span>14).</p></span></p></div></div><div><div id=\"T2\" data-id=\"T2\"><p><span>Table 2.</span></p><p>DSM-5 Criteria for Gender Dysphoria in Adolescents and Adults</p> </div><div><table><tbody><tr><td>A. A marked incongruence between one’s experienced/expressed gender and natal gender of at least 6 mo in duration, as manifested by at least two of the following:&nbsp;</td></tr><tr><td> 1. A marked incongruence between one’s experienced/expressed gender and primary and/or secondary sex characteristics (or in young adolescents, the anticipated secondary sex characteristics)&nbsp;</td></tr><tr><td> 2. A strong desire to be rid of one’s primary and/or secondary sex characteristics because of a marked incongruence with one’s experienced/expressed gender (or in young adolescents, a desire to prevent the development of the anticipated secondary sex characteristics)&nbsp;</td></tr><tr><td> 3. A strong desire for the primary and/or secondary sex characteristics of the other gender&nbsp;</td></tr><tr><td> 4. A strong desire to be of the other gender (or some alternative gender different from one’s designated gender)&nbsp;</td></tr><tr><td> 5. A strong desire to be treated as the other gender (or some alternative gender different from one’s designated gender)&nbsp;</td></tr><tr><td> 6. A strong conviction that one has the typical feelings and reactions of the other gender (or some alternative gender different from one’s designated gender)&nbsp;</td></tr><tr><td>B. The condition is associated with clinically significant distress or impairment in social, occupational, or other important areas of functioning.&nbsp;</td></tr><tr><td>Specify if:&nbsp;</td></tr><tr><td> 1. The condition exists with a disorder of sex development.&nbsp;</td></tr><tr><td> 2. The condition is posttransitional, in that the individual has transitioned to full-time living in the desired gender (with or without legalization of gender change) and has undergone (or is preparing to have) at least one sex-related medical procedure or treatment regimen—namely, regular sex hormone treatment or gender reassignment surgery confirming the desired gender (<em>e.g.</em>, penectomy, vaginoplasty in natal males; mastectomy or phalloplasty in natal females).&nbsp;</td></tr></tbody></table></div><div><table><tbody><tr><td>A. A marked incongruence between one’s experienced/expressed gender and natal gender of at least 6 mo in duration, as manifested by at least two of the following:&nbsp;</td></tr><tr><td> 1. A marked incongruence between one’s experienced/expressed gender and primary and/or secondary sex characteristics (or in young adolescents, the anticipated secondary sex characteristics)&nbsp;</td></tr><tr><td> 2. A strong desire to be rid of one’s primary and/or secondary sex characteristics because of a marked incongruence with one’s experienced/expressed gender (or in young adolescents, a desire to prevent the development of the anticipated secondary sex characteristics)&nbsp;</td></tr><tr><td> 3. A strong desire for the primary and/or secondary sex characteristics of the other gender&nbsp;</td></tr><tr><td> 4. A strong desire to be of the other gender (or some alternative gender different from one’s designated gender)&nbsp;</td></tr><tr><td> 5. A strong desire to be treated as the other gender (or some alternative gender different from one’s designated gender)&nbsp;</td></tr><tr><td> 6. A strong conviction that one has the typical feelings and reactions of the other gender (or some alternative gender different from one’s designated gender)&nbsp;</td></tr><tr><td>B. The condition is associated with clinically significant distress or impairment in social, occupational, or other important areas of functioning.&nbsp;</td></tr><tr><td>Specify if:&nbsp;</td></tr><tr><td> 1. The condition exists with a disorder of sex development.&nbsp;</td></tr><tr><td> 2. The condition is posttransitional, in that the individual has transitioned to full-time living in the desired gender (with or without legalization of gender change) and has undergone (or is preparing to have) at least one sex-related medical procedure or treatment regimen—namely, regular sex hormone treatment or gender reassignment surgery confirming the desired gender (<em>e.g.</em>, penectomy, vaginoplasty in natal males; mastectomy or phalloplasty in natal females).&nbsp;</td></tr></tbody></table></div><div><p><span><p>Reference: American Psychiatric Association (<span id=\"jumplink-B14\"></span>14).</p></span></p></div></div>                    <h2 scrollto-destination=\"99603280\" id=\"99603280\" data-legacy-id=\"s18\">1.0 Evaluation of Youth and Adults</h2>\n<p>Gender-affirming treatment is a multidisciplinary effort. After evaluation, education, and diagnosis, treatment may include mental health care, hormone therapy, and/or surgical therapy. Together with an MHP, hormone-prescribing clinicians should examine the psychosocial impact of the potential changes on people’s lives, including mental health, friends, family, jobs, and their role in society. Transgender individuals should be encouraged to experience living in the new gender role and assess whether this improves their quality of life. Although the focus of this guideline is gender-affirming hormone therapy, collaboration with appropriate professionals responsible for each aspect of treatment maximizes a successful outcome.</p>                    <h4 scrollto-destination=\"99603283\" id=\"99603283\" data-legacy-id=\"s20\">Diagnostic assessment and mental health care</h4>\n<p>GD/gender incongruence may be accompanied with psychological or psychiatric problems (<span id=\"jumplink-B43\"></span>43–<span id=\"jumplink-B51\"></span>51). It is therefore necessary that clinicians who prescribe hormones and are involved in diagnosis and psychosocial assessment meet the following criteria: (1) are competent in using the DSM and/or the ICD for diagnostic purposes, (2) are able to diagnose GD/gender incongruence and make a distinction between GD/gender incongruence and conditions that have similar features (<em>e.g.</em>, body dysmorphic disorder), (3) are trained in diagnosing psychiatric conditions, (4) undertake or refer for appropriate treatment, (5) are able to do a psychosocial assessment of the patient’s understanding, mental health, and social conditions that can impact gender-affirming hormone therapy, and (6) regularly attend relevant professional meetings.</p><p>Because of the psychological vulnerability of many individuals with GD/gender incongruence, it is important that mental health care is available before, during, and sometimes also after transitioning. For children and adolescents, an MHP who has training/experience in child and adolescent gender development (as well as child and adolescent psychopathology) should make the diagnosis, because assessing GD/gender incongruence in children and adolescents is often extremely complex.</p><p>During assessment, the clinician obtains information from the individual seeking gender-affirming treatment. In the case of adolescents, the clinician also obtains information from the parents or guardians regarding various aspects of the child’s general and psychosexual development and current functioning. On the basis of this information, the clinician:</p><ul><li><p>decides whether the individual fulfills criteria for treatment (see <span id=\"jumplink-T2\"></span>Tables 2 and <span id=\"jumplink-T3\"></span>3) for GD/gender incongruence (DSM-5) or transsexualism (DSM-5 and/or ICD-10);<span id=\"T3\"></span></p><div content-id=\"T3\"><div id=\"T3\" data-id=\"T3\"><p><span>Table 3.</span></p><p>ICD-10 Criteria for Transsexualism</p> </div><div><table><thead><tr><th>Transsexualism (F64.0) has three criteria:</th></tr></thead><tbody><tr><td>1. The desire to live and be accepted as a member of the opposite sex, usually accompanied by the wish to make his or her body as congruent as possible with the preferred sex through surgery and hormone treatments.&nbsp;</td></tr><tr><td>2. The transsexual identity has been present persistently for at least 2 y.&nbsp;</td></tr><tr><td>3. The disorder is not a symptom of another mental disorder or a genetic, DSD, or chromosomal abnormality.&nbsp;</td></tr></tbody></table></div><div><table><thead><tr><th>Transsexualism (F64.0) has three criteria:</th></tr></thead><tbody><tr><td>1. The desire to live and be accepted as a member of the opposite sex, usually accompanied by the wish to make his or her body as congruent as possible with the preferred sex through surgery and hormone treatments.&nbsp;</td></tr><tr><td>2. The transsexual identity has been present persistently for at least 2 y.&nbsp;</td></tr><tr><td>3. The disorder is not a symptom of another mental disorder or a genetic, DSD, or chromosomal abnormality.&nbsp;</td></tr></tbody></table></div></div><div><div id=\"T3\" data-id=\"T3\"><p><span>Table 3.</span></p><p>ICD-10 Criteria for Transsexualism</p> </div><div><table><thead><tr><th>Transsexualism (F64.0) has three criteria:</th></tr></thead><tbody><tr><td>1. The desire to live and be accepted as a member of the opposite sex, usually accompanied by the wish to make his or her body as congruent as possible with the preferred sex through surgery and hormone treatments.&nbsp;</td></tr><tr><td>2. The transsexual identity has been present persistently for at least 2 y.&nbsp;</td></tr><tr><td>3. The disorder is not a symptom of another mental disorder or a genetic, DSD, or chromosomal abnormality.&nbsp;</td></tr></tbody></table></div><div><table><thead><tr><th>Transsexualism (F64.0) has three criteria:</th></tr></thead><tbody><tr><td>1. The desire to live and be accepted as a member of the opposite sex, usually accompanied by the wish to make his or her body as congruent as possible with the preferred sex through surgery and hormone treatments.&nbsp;</td></tr><tr><td>2. The transsexual identity has been present persistently for at least 2 y.&nbsp;</td></tr><tr><td>3. The disorder is not a symptom of another mental disorder or a genetic, DSD, or chromosomal abnormality.&nbsp;</td></tr></tbody></table></div></div></li><li><p>informs the individual about the possibilities and limitations of various kinds of treatment (hormonal/surgical and nonhormonal), and if medical treatment is desired, provides correct information to prevent unrealistically high expectations;</p></li><li><p>assesses whether medical interventions may result in unfavorable psychological and social outcomes.</p></li></ul><p>In cases in which severe psychopathology, circumstances, or both seriously interfere with the diagnostic work or make satisfactory treatment unlikely, clinicians should assist the adolescent in managing these other issues. Literature on postoperative regret suggests that besides poor quality of surgery, severe psychiatric comorbidity and lack of support may interfere with positive outcomes (<span id=\"jumplink-B52\"></span>52–<span id=\"jumplink-B56\"></span>56).</p><p>For adolescents, the diagnostic procedure usually includes a complete psychodiagnostic assessment (<span id=\"jumplink-B57\"></span>57) and an assessment of the decision-making capability of the youth. An evaluation to assess the family’s ability to endure stress, give support, and deal with the complexities of the adolescent’s situation should be part of the diagnostic phase (<span id=\"jumplink-B58\"></span>58).</p>                    <h4 scrollto-destination=\"99603290\" id=\"99603290\" data-legacy-id=\"s21\">Social transitioning</h4>\n<p>A change in gender expression and role (which may involve living part time or full time in another gender role that is consistent with one’s gender identity) may test the person’s resolve, the capacity to function in the affirmed gender, and the adequacy of social, economic, and psychological supports. It assists both the individual and the clinician in their judgments about how to proceed (<span id=\"jumplink-B16\"></span>16). During social transitioning, the person’s feelings about the social transformation (including coping with the responses of others) is a major focus of the counseling. The optimal timing for social transitioning may differ between individuals. Sometimes people wait until they start gender-affirming hormone treatment to make social transitioning easier, but individuals increasingly start social transitioning long before they receive medically supervised, gender-affirming hormone treatment.</p>                    <h4 scrollto-destination=\"99603292\" id=\"99603292\" data-legacy-id=\"s22\">Criteria</h4>\n<p>Adolescents and adults seeking gender-affirming hormone treatment and surgery should satisfy certain criteria before proceeding (<span id=\"jumplink-B16\"></span>16). Criteria for gender-affirming hormone therapy for adults are in <span id=\"jumplink-T4\"></span>Table 4, and criteria for gender-affirming hormone therapy for adolescents are in <span id=\"jumplink-T5\"></span>Table 5. Follow-up studies in adults meeting these criteria indicate a high satisfaction rate with treatment (<span id=\"jumplink-B59\"></span>59). However, the quality of evidence is usually low. A few follow-up studies on adolescents who fulfilled these criteria also indicated good treatment results (<span id=\"jumplink-B60\"></span>60–<span id=\"jumplink-B63\"></span>63).</p>                    <div content-id=\"T4\"><div id=\"T4\" data-id=\"T4\"><p><span>Table 4.</span></p><p>Criteria for Gender-Affirming Hormone Therapy for Adults</p> </div><div><table><tbody><tr><td>1. Persistent, well-documented gender dysphoria/gender incongruence&nbsp;</td></tr><tr><td>2. The capacity to make a fully informed decision and to consent for treatment&nbsp;</td></tr><tr><td>3. The age of majority in a given country (if younger, follow the criteria for adolescents)&nbsp;</td></tr><tr><td>4. Mental health concerns, if present, must be reasonably well controlled&nbsp;</td></tr></tbody></table></div><div><table><tbody><tr><td>1. Persistent, well-documented gender dysphoria/gender incongruence&nbsp;</td></tr><tr><td>2. The capacity to make a fully informed decision and to consent for treatment&nbsp;</td></tr><tr><td>3. The age of majority in a given country (if younger, follow the criteria for adolescents)&nbsp;</td></tr><tr><td>4. Mental health concerns, if present, must be reasonably well controlled&nbsp;</td></tr></tbody></table></div><div><p><span><p>Reproduced from World Professional Association for Transgender Health (<span id=\"jumplink-B16\"></span>16).</p></span></p></div></div><div><div id=\"T4\" data-id=\"T4\"><p><span>Table 4.</span></p><p>Criteria for Gender-Affirming Hormone Therapy for Adults</p> </div><div><table><tbody><tr><td>1. Persistent, well-documented gender dysphoria/gender incongruence&nbsp;</td></tr><tr><td>2. The capacity to make a fully informed decision and to consent for treatment&nbsp;</td></tr><tr><td>3. The age of majority in a given country (if younger, follow the criteria for adolescents)&nbsp;</td></tr><tr><td>4. Mental health concerns, if present, must be reasonably well controlled&nbsp;</td></tr></tbody></table></div><div><table><tbody><tr><td>1. Persistent, well-documented gender dysphoria/gender incongruence&nbsp;</td></tr><tr><td>2. The capacity to make a fully informed decision and to consent for treatment&nbsp;</td></tr><tr><td>3. The age of majority in a given country (if younger, follow the criteria for adolescents)&nbsp;</td></tr><tr><td>4. Mental health concerns, if present, must be reasonably well controlled&nbsp;</td></tr></tbody></table></div><div><p><span><p>Reproduced from World Professional Association for Transgender Health (<span id=\"jumplink-B16\"></span>16).</p></span></p></div></div>                    <div content-id=\"T5\"><div id=\"T5\" data-id=\"T5\"><p><span>Table 5.</span></p><p>Criteria for Gender-Affirming Hormone Therapy for Adolescents</p> </div><div><table><tbody><tr><td><strong>Adolescents are eligible for GnRH agonist treatment if:</strong>&nbsp;</td></tr><tr><td> 1. A qualified MHP has confirmed that:&nbsp;</td></tr><tr><td> •the adolescent has demonstrated a long-lasting and intense pattern of gender nonconformity or gender dysphoria (whether suppressed or expressed),&nbsp;</td></tr><tr><td> •gender dysphoria worsened with the onset of puberty,&nbsp;</td></tr><tr><td> •any coexisting psychological, medical, or social problems that could interfere with treatment (<em>e.g.</em>, that may compromise treatment adherence) have been addressed, such that the adolescent’s situation and functioning are stable enough to start treatment,&nbsp;</td></tr><tr><td> •the adolescent has sufficient mental capacity to give informed consent to this (reversible) treatment,&nbsp;</td></tr><tr><td> 2. And the adolescent:&nbsp;</td></tr><tr><td> •has been informed of the effects and side effects of treatment (including potential loss of fertility if the individual subsequently continues with sex hormone treatment) and options to preserve fertility,&nbsp;</td></tr><tr><td> •has given informed consent and (particularly when the adolescent has not reached the age of legal medical consent, depending on applicable legislation) the parents or other caretakers or guardians have consented to the treatment and are involved in supporting the adolescent throughout the treatment process,&nbsp;</td></tr><tr><td> 3. And a pediatric endocrinologist or other clinician experienced in pubertal assessment&nbsp;</td></tr><tr><td> •agrees with the indication for GnRH agonist treatment,&nbsp;</td></tr><tr><td> •has confirmed that puberty has started in the adolescent (Tanner stage ≥G2/B2),&nbsp;</td></tr><tr><td> •has confirmed that there are no medical contraindications to GnRH agonist treatment.&nbsp;</td></tr><tr><td><strong>Adolescents are eligible for subsequent sex hormone treatment if:</strong>&nbsp;</td></tr><tr><td> 1. A qualified MHP has confirmed:&nbsp;</td></tr><tr><td> •the persistence of gender dysphoria,&nbsp;</td></tr><tr><td> •any coexisting psychological, medical, or social problems that could interfere with treatment (<em>e.g.</em>, that may compromise treatment adherence) have been addressed, such that the adolescent’s situation and functioning are stable enough to start sex hormone treatment,&nbsp;</td></tr><tr><td> •the adolescent has sufficient mental capacity (which most adolescents have by age 16 years) to estimate the consequences of this (partly) irreversible treatment, weigh the benefits and risks, and give informed consent to this (partly) irreversible treatment,&nbsp;</td></tr><tr><td> 2. And the adolescent:&nbsp;</td></tr><tr><td> •has been informed of the (irreversible) effects and side effects of treatment (including potential loss of fertility and options to preserve fertility),&nbsp;</td></tr><tr><td> •has given informed consent and (particularly when the adolescent has not reached the age of legal medical consent, depending on applicable legislation) the parents or other caretakers or guardians have consented to the treatment and are involved in supporting the adolescent throughout the treatment process,&nbsp;</td></tr><tr><td> 3. And a pediatric endocrinologist or other clinician experienced in pubertal induction:&nbsp;</td></tr><tr><td> •agrees with the indication for sex hormone treatment,&nbsp;</td></tr><tr><td> •has confirmed that there are no medical contraindications to sex hormone treatment.&nbsp;</td></tr></tbody></table></div><div><table><tbody><tr><td><strong>Adolescents are eligible for GnRH agonist treatment if:</strong>&nbsp;</td></tr><tr><td> 1. A qualified MHP has confirmed that:&nbsp;</td></tr><tr><td> •the adolescent has demonstrated a long-lasting and intense pattern of gender nonconformity or gender dysphoria (whether suppressed or expressed),&nbsp;</td></tr><tr><td> •gender dysphoria worsened with the onset of puberty,&nbsp;</td></tr><tr><td> •any coexisting psychological, medical, or social problems that could interfere with treatment (<em>e.g.</em>, that may compromise treatment adherence) have been addressed, such that the adolescent’s situation and functioning are stable enough to start treatment,&nbsp;</td></tr><tr><td> •the adolescent has sufficient mental capacity to give informed consent to this (reversible) treatment,&nbsp;</td></tr><tr><td> 2. And the adolescent:&nbsp;</td></tr><tr><td> •has been informed of the effects and side effects of treatment (including potential loss of fertility if the individual subsequently continues with sex hormone treatment) and options to preserve fertility,&nbsp;</td></tr><tr><td> •has given informed consent and (particularly when the adolescent has not reached the age of legal medical consent, depending on applicable legislation) the parents or other caretakers or guardians have consented to the treatment and are involved in supporting the adolescent throughout the treatment process,&nbsp;</td></tr><tr><td> 3. And a pediatric endocrinologist or other clinician experienced in pubertal assessment&nbsp;</td></tr><tr><td> •agrees with the indication for GnRH agonist treatment,&nbsp;</td></tr><tr><td> •has confirmed that puberty has started in the adolescent (Tanner stage ≥G2/B2),&nbsp;</td></tr><tr><td> •has confirmed that there are no medical contraindications to GnRH agonist treatment.&nbsp;</td></tr><tr><td><strong>Adolescents are eligible for subsequent sex hormone treatment if:</strong>&nbsp;</td></tr><tr><td> 1. A qualified MHP has confirmed:&nbsp;</td></tr><tr><td> •the persistence of gender dysphoria,&nbsp;</td></tr><tr><td> •any coexisting psychological, medical, or social problems that could interfere with treatment (<em>e.g.</em>, that may compromise treatment adherence) have been addressed, such that the adolescent’s situation and functioning are stable enough to start sex hormone treatment,&nbsp;</td></tr><tr><td> •the adolescent has sufficient mental capacity (which most adolescents have by age 16 years) to estimate the consequences of this (partly) irreversible treatment, weigh the benefits and risks, and give informed consent to this (partly) irreversible treatment,&nbsp;</td></tr><tr><td> 2. And the adolescent:&nbsp;</td></tr><tr><td> •has been informed of the (irreversible) effects and side effects of treatment (including potential loss of fertility and options to preserve fertility),&nbsp;</td></tr><tr><td> •has given informed consent and (particularly when the adolescent has not reached the age of legal medical consent, depending on applicable legislation) the parents or other caretakers or guardians have consented to the treatment and are involved in supporting the adolescent throughout the treatment process,&nbsp;</td></tr><tr><td> 3. And a pediatric endocrinologist or other clinician experienced in pubertal induction:&nbsp;</td></tr><tr><td> •agrees with the indication for sex hormone treatment,&nbsp;</td></tr><tr><td> •has confirmed that there are no medical contraindications to sex hormone treatment.&nbsp;</td></tr></tbody></table></div><div><p><span><p>Reproduced from World Professional Association for Transgender Health (<span id=\"jumplink-B16\"></span>16).</p></span></p></div></div><div><div id=\"T5\" data-id=\"T5\"><p><span>Table 5.</span></p><p>Criteria for Gender-Affirming Hormone Therapy for Adolescents</p> </div><div><table><tbody><tr><td><strong>Adolescents are eligible for GnRH agonist treatment if:</strong>&nbsp;</td></tr><tr><td> 1. A qualified MHP has confirmed that:&nbsp;</td></tr><tr><td> •the adolescent has demonstrated a long-lasting and intense pattern of gender nonconformity or gender dysphoria (whether suppressed or expressed),&nbsp;</td></tr><tr><td> •gender dysphoria worsened with the onset of puberty,&nbsp;</td></tr><tr><td> •any coexisting psychological, medical, or social problems that could interfere with treatment (<em>e.g.</em>, that may compromise treatment adherence) have been addressed, such that the adolescent’s situation and functioning are stable enough to start treatment,&nbsp;</td></tr><tr><td> •the adolescent has sufficient mental capacity to give informed consent to this (reversible) treatment,&nbsp;</td></tr><tr><td> 2. And the adolescent:&nbsp;</td></tr><tr><td> •has been informed of the effects and side effects of treatment (including potential loss of fertility if the individual subsequently continues with sex hormone treatment) and options to preserve fertility,&nbsp;</td></tr><tr><td> •has given informed consent and (particularly when the adolescent has not reached the age of legal medical consent, depending on applicable legislation) the parents or other caretakers or guardians have consented to the treatment and are involved in supporting the adolescent throughout the treatment process,&nbsp;</td></tr><tr><td> 3. And a pediatric endocrinologist or other clinician experienced in pubertal assessment&nbsp;</td></tr><tr><td> •agrees with the indication for GnRH agonist treatment,&nbsp;</td></tr><tr><td> •has confirmed that puberty has started in the adolescent (Tanner stage ≥G2/B2),&nbsp;</td></tr><tr><td> •has confirmed that there are no medical contraindications to GnRH agonist treatment.&nbsp;</td></tr><tr><td><strong>Adolescents are eligible for subsequent sex hormone treatment if:</strong>&nbsp;</td></tr><tr><td> 1. A qualified MHP has confirmed:&nbsp;</td></tr><tr><td> •the persistence of gender dysphoria,&nbsp;</td></tr><tr><td> •any coexisting psychological, medical, or social problems that could interfere with treatment (<em>e.g.</em>, that may compromise treatment adherence) have been addressed, such that the adolescent’s situation and functioning are stable enough to start sex hormone treatment,&nbsp;</td></tr><tr><td> •the adolescent has sufficient mental capacity (which most adolescents have by age 16 years) to estimate the consequences of this (partly) irreversible treatment, weigh the benefits and risks, and give informed consent to this (partly) irreversible treatment,&nbsp;</td></tr><tr><td> 2. And the adolescent:&nbsp;</td></tr><tr><td> •has been informed of the (irreversible) effects and side effects of treatment (including potential loss of fertility and options to preserve fertility),&nbsp;</td></tr><tr><td> •has given informed consent and (particularly when the adolescent has not reached the age of legal medical consent, depending on applicable legislation) the parents or other caretakers or guardians have consented to the treatment and are involved in supporting the adolescent throughout the treatment process,&nbsp;</td></tr><tr><td> 3. And a pediatric endocrinologist or other clinician experienced in pubertal induction:&nbsp;</td></tr><tr><td> •agrees with the indication for sex hormone treatment,&nbsp;</td></tr><tr><td> •has confirmed that there are no medical contraindications to sex hormone treatment.&nbsp;</td></tr></tbody></table></div><div><table><tbody><tr><td><strong>Adolescents are eligible for GnRH agonist treatment if:</strong>&nbsp;</td></tr><tr><td> 1. A qualified MHP has confirmed that:&nbsp;</td></tr><tr><td> •the adolescent has demonstrated a long-lasting and intense pattern of gender nonconformity or gender dysphoria (whether suppressed or expressed),&nbsp;</td></tr><tr><td> •gender dysphoria worsened with the onset of puberty,&nbsp;</td></tr><tr><td> •any coexisting psychological, medical, or social problems that could interfere with treatment (<em>e.g.</em>, that may compromise treatment adherence) have been addressed, such that the adolescent’s situation and functioning are stable enough to start treatment,&nbsp;</td></tr><tr><td> •the adolescent has sufficient mental capacity to give informed consent to this (reversible) treatment,&nbsp;</td></tr><tr><td> 2. And the adolescent:&nbsp;</td></tr><tr><td> •has been informed of the effects and side effects of treatment (including potential loss of fertility if the individual subsequently continues with sex hormone treatment) and options to preserve fertility,&nbsp;</td></tr><tr><td> •has given informed consent and (particularly when the adolescent has not reached the age of legal medical consent, depending on applicable legislation) the parents or other caretakers or guardians have consented to the treatment and are involved in supporting the adolescent throughout the treatment process,&nbsp;</td></tr><tr><td> 3. And a pediatric endocrinologist or other clinician experienced in pubertal assessment&nbsp;</td></tr><tr><td> •agrees with the indication for GnRH agonist treatment,&nbsp;</td></tr><tr><td> •has confirmed that puberty has started in the adolescent (Tanner stage ≥G2/B2),&nbsp;</td></tr><tr><td> •has confirmed that there are no medical contraindications to GnRH agonist treatment.&nbsp;</td></tr><tr><td><strong>Adolescents are eligible for subsequent sex hormone treatment if:</strong>&nbsp;</td></tr><tr><td> 1. A qualified MHP has confirmed:&nbsp;</td></tr><tr><td> •the persistence of gender dysphoria,&nbsp;</td></tr><tr><td> •any coexisting psychological, medical, or social problems that could interfere with treatment (<em>e.g.</em>, that may compromise treatment adherence) have been addressed, such that the adolescent’s situation and functioning are stable enough to start sex hormone treatment,&nbsp;</td></tr><tr><td> •the adolescent has sufficient mental capacity (which most adolescents have by age 16 years) to estimate the consequences of this (partly) irreversible treatment, weigh the benefits and risks, and give informed consent to this (partly) irreversible treatment,&nbsp;</td></tr><tr><td> 2. And the adolescent:&nbsp;</td></tr><tr><td> •has been informed of the (irreversible) effects and side effects of treatment (including potential loss of fertility and options to preserve fertility),&nbsp;</td></tr><tr><td> •has given informed consent and (particularly when the adolescent has not reached the age of legal medical consent, depending on applicable legislation) the parents or other caretakers or guardians have consented to the treatment and are involved in supporting the adolescent throughout the treatment process,&nbsp;</td></tr><tr><td> 3. And a pediatric endocrinologist or other clinician experienced in pubertal induction:&nbsp;</td></tr><tr><td> •agrees with the indication for sex hormone treatment,&nbsp;</td></tr><tr><td> •has confirmed that there are no medical contraindications to sex hormone treatment.&nbsp;</td></tr></tbody></table></div><div><p><span><p>Reproduced from World Professional Association for Transgender Health (<span id=\"jumplink-B16\"></span>16).</p></span></p></div></div>                    <h2 scrollto-destination=\"99603296\" id=\"99603296\" data-legacy-id=\"s23\">Recommendations for Those Involved in the Gender-Affirming Hormone Treatment of Individuals With GD/Gender Incongruence</h2>\n<ul><li><p>1.1. We advise that only trained MHPs who meet the following criteria should diagnose GD/gender incongruence in adults: (1) competence in using the DSM and/or the ICD for diagnostic purposes, (2) the ability to diagnose GD/gender incongruence and make a distinction between GD/gender incongruence and conditions that have similar features (<em>e.g.</em>, body dysmorphic disorder), (3) training in diagnosing psychiatric conditions, (4) the ability to undertake or refer for appropriate treatment, (5) the ability to psychosocially assess the person’s understanding, mental health, and social conditions that can impact gender-affirming hormone therapy, and (6) a practice of regularly attending relevant professional meetings. (Ungraded Good Practice Statement)</p></li><li><p>1.2. We advise that only MHPs who meet the following criteria should diagnose GD/gender incongruence in children and adolescents: (1) training in child and adolescent developmental psychology and psychopathology, (2) competence in using the DSM and/or ICD for diagnostic purposes, (3) the ability to make a distinction between GD/gender incongruence and conditions that have similar features (<em>e.g.</em>, body dysmorphic disorder), (4) training in diagnosing psychiatric conditions, (5) the ability to undertake or refer for appropriate treatment, (6) the ability to psychosocially assess the person’s understanding and social conditions that can impact gender-affirming hormone therapy, (7) a practice of regularly attending relevant professional meetings, and (8) knowledge of the criteria for puberty blocking and gender-affirming hormone treatment in adolescents. (Ungraded Good Practice Statement)</p></li></ul>                    <h3 scrollto-destination=\"99603298\" id=\"99603298\" data-legacy-id=\"s24\">Evidence</h3>\n<p>Individuals with gender identity issues may have psychological or psychiatric problems (<span id=\"jumplink-B43\"></span>43–<span id=\"jumplink-B48\"></span>48, <span id=\"jumplink-B50\"></span>50, <span id=\"jumplink-B51\"></span>51, <span id=\"jumplink-B64\"></span>64, <span id=\"jumplink-B65\"></span>65). It is therefore necessary that clinicians making the diagnosis are able to make a distinction between GD/gender incongruence and conditions that have similar features. Examples of conditions with similar features are body dysmorphic disorder, body identity integrity disorder (a condition in which individuals have a sense that their anatomical configuration as an able-bodied person is somehow wrong or inappropriate) (<span id=\"jumplink-B66\"></span>66), or certain forms of eunuchism (in which a person is preoccupied with or engages in castration and/or penectomy for reasons that are not gender identity related) (<span id=\"jumplink-B11\"></span>11). Clinicians should also be able to diagnose psychiatric conditions accurately and ensure that these conditions are treated appropriately, particularly when the conditions may complicate treatment, affect the outcome of gender-affirming treatment, or be affected by hormone use.</p>                    <h3 scrollto-destination=\"99603300\" id=\"99603300\" data-legacy-id=\"s25\">Values and preferences</h3>\n<p>The task force placed a very high value on avoiding harm from hormone treatment in individuals who have conditions other than GD/gender incongruence and who may not benefit from the physical changes associated with this treatment and placed a low value on any potential benefit these persons believe they may derive from hormone treatment. This justifies the good practice statement.</p><ul><li><p>1.3. We advise that decisions regarding the social transition of prepubertal youths with GD/gender incongruence are made with the assistance of an MHP or another experienced professional. (Ungraded Good Practice Statement).</p></li><li><p>1.4. We recommend against puberty blocking and gender-affirming hormone treatment in prepubertal children with GD/gender incongruence. (1 |⊕⊕○○)</p></li></ul>                    <h3 scrollto-destination=\"99603303\" id=\"99603303\" data-legacy-id=\"s26\">Evidence</h3>\n<p>In most children diagnosed with GD/gender incongruence, it did not persist into adolescence. The percentages differed among studies, probably dependent on which version of the DSM clinicians used, the patient’s age, the recruitment criteria, and perhaps cultural factors. However, the large majority (about 85%) of prepubertal children with a childhood diagnosis did not remain GD/gender incongruent in adolescence (<span id=\"jumplink-B20\"></span>20). If children have completely socially transitioned, they may have great difficulty in returning to the original gender role upon entering puberty (<span id=\"jumplink-B40\"></span>40). Social transition is associated with the persistence of GD/gender incongruence as a child progresses into adolescence. It may be that the presence of GD/gender incongruence in prepubertal children is the earliest sign that a child is destined to be transgender as an adolescent/adult (<span id=\"jumplink-B20\"></span>20). However, social transition (in addition to GD/gender incongruence) has been found to contribute to the likelihood of persistence.</p><p>This recommendation, however, does not imply that children should be discouraged from showing gender-variant behaviors or should be punished for exhibiting such behaviors. In individual cases, an early complete social transition may result in a more favorable outcome, but there are currently no criteria to identify the GD/gender-incongruent children to whom this applies. At the present time, clinical experience suggests that persistence of GD/gender incongruence can only be reliably assessed after the first signs of puberty.</p>                    <h3 scrollto-destination=\"99603306\" id=\"99603306\" data-legacy-id=\"s27\">Values and preferences</h3>\n<p>The task force placed a high value on avoiding harm with gender-affirming hormone therapy in prepubertal children with GD/gender incongruence. This justifies the strong recommendation in the face of low-quality evidence.</p><ul><li><p>1.5. We recommend that clinicians inform and counsel all individuals seeking gender-affirming medical treatment regarding options for fertility preservation prior to initiating puberty suppression in adolescents and prior to treating with hormonal therapy of the affirmed gender in both adolescents and adults. (1 |⊕⊕⊕○)</p></li></ul>                    <h3 scrollto-destination=\"99603309\" id=\"99603309\" data-legacy-id=\"s28\">Remarks</h3>\n<p>Persons considering hormone use for gender affirmation need adequate information about this treatment in general and about fertility effects of hormone treatment in particular to make an informed and balanced decision (<span id=\"jumplink-B67\"></span>67, <span id=\"jumplink-B68\"></span>68). Because young adolescents may not feel qualified to make decisions about fertility and may not fully understand the potential effects of hormonal interventions, consent and protocol education should include parents, the referring MHP(s), and other members of the adolescent’s support group. To our knowledge, there are no formally evaluated decision aids available to assist in the discussion and decision regarding the future fertility of adolescents or adults beginning gender-affirming treatment.</p><p>Treating early pubertal youth with GnRH analogs will temporarily impair spermatogenesis and oocyte maturation. Given that an increasing number of transgender youth want to preserve fertility potential, delaying or temporarily discontinuing GnRH analogs to promote gamete maturation is an option. This option is often not preferred, because mature sperm production is associated with later stages of puberty and with the significant development of secondary sex characteristics.</p><p>For those designated male at birth with GD/gender incongruence and who are in early puberty, sperm production and the development of the reproductive tract are insufficient for the cryopreservation of sperm. However, prolonged pubertal suppression using GnRH analogs is reversible and clinicians should inform these individuals that sperm production can be initiated following prolonged gonadotropin suppression. This can be accomplished by spontaneous gonadotropin recovery after cessation of GnRH analogs or by gonadotropin treatment and will probably be associated with physical manifestations of testosterone production, as stated above. Note that there are no data in this population concerning the time required for sufficient spermatogenesis to collect enough sperm for later fertility. In males treated for precocious puberty, spermarche was reported 0.7 to 3 years after cessation of GnRH analogs (<span id=\"jumplink-B69\"></span>69). In adult men with gonadotropin deficiency, sperm are noted in seminal fluid by 6 to 12 months of gonadotropin treatment. However, sperm numbers when partners of these patients conceive are far below the “normal range” (<span id=\"jumplink-B70\"></span>70, <span id=\"jumplink-B71\"></span>71).</p><p>In girls, no studies have reported long-term, adverse effects of pubertal suppression on ovarian function after treatment cessation (<span id=\"jumplink-B72\"></span>72, <span id=\"jumplink-B73\"></span>73). Clinicians should inform adolescents that no data are available regarding either time to spontaneous ovulation after cessation of GnRH analogs or the response to ovulation induction following prolonged gonadotropin suppression.</p><p>In males with GD/gender incongruence, when medical treatment is started in a later phase of puberty or in adulthood, spermatogenesis is sufficient for cryopreservation and storage of sperm. <em>In vitro</em> spermatogenesis is currently under investigation. Restoration of spermatogenesis after prolonged estrogen treatment has not been studied.</p><p>In females with GD/gender incongruence, the effect of prolonged treatment with exogenous testosterone on ovarian function is uncertain. There have been reports of an increased incidence of polycystic ovaries in transgender males, both prior to and as a result of androgen treatment (<span id=\"jumplink-B74\"></span>74–<span id=\"jumplink-B77\"></span>77), although these reports were not confirmed by others (<span id=\"jumplink-B78\"></span>78). Pregnancy has been reported in transgender males who have had prolonged androgen treatment and have discontinued testosterone but have not had genital surgery (<span id=\"jumplink-B79\"></span>79, <span id=\"jumplink-B80\"></span>80). A reproductive endocrine gynecologist can counsel patients before gender-affirming hormone treatment or surgery regarding potential fertility options (<span id=\"jumplink-B81\"></span>81). Techniques for cryopreservation of oocytes, embryos, and ovarian tissue continue to improve, and oocyte maturation of immature tissue is being studied (<span id=\"jumplink-B82\"></span>82).</p>                    <h2 scrollto-destination=\"99603316\" id=\"99603316\" data-legacy-id=\"s29\">2.0 Treatment of Adolescents</h2>\n<p>During the past decade, clinicians have progressively acknowledged the suffering of young adolescents with GD/gender incongruence. In some forms of GD/gender incongruence, psychological interventions may be useful and sufficient. However, for many adolescents with GD/gender incongruence, the pubertal physical changes are unbearable. As early medical intervention may prevent psychological harm, various clinics have decided to start treating young adolescents with GD/gender incongruence with puberty-suppressing medication (a GnRH analog). As compared with starting gender-affirming treatment long after the first phases of puberty, a benefit of pubertal suppression at early puberty may be a better psychological and physical outcome.</p><p>In girls, the first physical sign of puberty is the budding of the breasts followed by an increase in breast and fat tissue. Breast development is also associated with the pubertal growth spurt, and menarche occurs ∼2 years later. In boys, the first physical change is testicular growth. A testicular volume ≥4 mL is seen as consistent with the initiation of physical puberty. At the beginning of puberty, estradiol and testosterone levels are still low and are best measured in the early morning with an ultrasensitive assay. From a testicular volume of 10 mL, daytime testosterone levels increase, leading to virilization (<span id=\"jumplink-B83\"></span>83). Note that pubic hair and/or axillary hair/odor may not reflect the onset of gonadarche; instead, it may reflect adrenarche alone.</p><ul><li><p>2.1. We suggest that adolescents who meet diagnostic criteria for GD/gender incongruence, fulfill criteria for treatment (<span id=\"jumplink-T5\"></span>Table 5), and are requesting treatment should initially undergo treatment to suppress pubertal development. (2 |⊕⊕○○)</p></li><li><p>2.2. We suggest that clinicians begin pubertal hormone suppression after girls and boys first exhibit physical changes of puberty (Tanner stages G2/B2). (2 |⊕⊕○○)</p></li></ul>                    <h3 scrollto-destination=\"99603320\" id=\"99603320\" data-legacy-id=\"s30\">Evidence</h3>\n<p>Pubertal suppression can expand the diagnostic phase by a long period, giving the subject more time to explore options and to live in the experienced gender before making a decision to proceed with gender-affirming sex hormone treatments and/or surgery, some of which is irreversible (<span id=\"jumplink-B84\"></span>84, <span id=\"jumplink-B85\"></span>85). Pubertal suppression is fully reversible, enabling full pubertal development in the natal gender, after cessation of treatment, if appropriate. The experience of full endogenous puberty is an undesirable condition for the GD/gender-incongruent individual and may seriously interfere with healthy psychological functioning and well-being. Treating GD/gender-incongruent adolescents entering puberty with GnRH analogs has been shown to improve psychological functioning in several domains (<span id=\"jumplink-B86\"></span>86).</p><p>Another reason to start blocking pubertal hormones early in puberty is that the physical outcome is improved compared with initiating physical transition after puberty has been completed (<span id=\"jumplink-B60\"></span>60, <span id=\"jumplink-B62\"></span>62). Looking like a man or woman when living as the opposite sex creates difficult barriers with enormous life-long disadvantages. We therefore advise starting suppression in early puberty to prevent the irreversible development of undesirable secondary sex characteristics. However, adolescents with GD/gender incongruence should experience the first changes of their endogenous spontaneous puberty, because their emotional reaction to these first physical changes has diagnostic value in establishing the persistence of GD/gender incongruence (<span id=\"jumplink-B85\"></span>85). Thus, Tanner stage 2 is the optimal time to start pubertal suppression. However, pubertal suppression treatment in early puberty will limit the growth of the penis and scrotum, which will have a potential effect on future surgical treatments (<span id=\"jumplink-B87\"></span>87).</p><p>Clinicians can also use pubertal suppression in adolescents in later pubertal stages to stop menses in transgender males and prevent facial hair growth in transgender females. However, in contrast to the effects in early pubertal adolescents, physical sex characteristics (such as more advanced breast development in transgender boys and lowering of the voice and outgrowth of the jaw and brow in transgender girls) are not reversible.</p>                    <h3 scrollto-destination=\"99603324\" id=\"99603324\" data-legacy-id=\"s31\">Values and preferences</h3>\n<p>These recommendations place a high value on avoiding an unsatisfactory physical outcome when secondary sex characteristics have become manifest and irreversible, a higher value on psychological well-being, and a lower value on avoiding potential harm from early pubertal suppression.</p>                    <h3 scrollto-destination=\"99603326\" id=\"99603326\" data-legacy-id=\"s32\">Remarks</h3>\n<p><span id=\"jumplink-T6\"></span>Table 6 lists the Tanner stages of breast and male genital development. Careful documentation of hallmarks of pubertal development will ensure precise timing when initiating pubertal suppression once puberty has started. Clinicians can use pubertal LH and sex steroid levels to confirm that puberty has progressed sufficiently before starting pubertal suppression (<span id=\"jumplink-B88\"></span>88). Reference ranges for sex steroids by Tanner stage may vary depending on the assay used. Ultrasensitive sex steroid and gonadotropin assays will help clinicians document early pubertal changes.</p>                    <div content-id=\"T6\"><div id=\"T6\" data-id=\"T6\"><p><span>Table 6.</span></p><p>Tanner Stages of Breast Development and Male External Genitalia</p> </div><div><table><tbody><tr><td>The description of Tanner stages for breast development:&nbsp;</td></tr><tr><td> 1. Prepubertal&nbsp;</td></tr><tr><td> 2. Breast and papilla elevated as small mound; areolar diameter increased&nbsp;</td></tr><tr><td> 3. Breast and areola enlarged, no contour separation&nbsp;</td></tr><tr><td> 4. Areola and papilla form secondary mound&nbsp;</td></tr><tr><td> 5. Mature; nipple projects, areola part of general breast contour&nbsp;</td></tr><tr><td>For penis and testes:&nbsp;</td></tr><tr><td> 1. Prepubertal, testicular volume &lt;4 mL&nbsp;</td></tr><tr><td> 2. Slight enlargement of penis; enlarged scrotum, pink, texture altered, testes 4–6 mL&nbsp;</td></tr><tr><td> 3. Penis longer, testes larger (8–12 mL)&nbsp;</td></tr><tr><td> 4. Penis and glans larger, including increase in breadth; testes larger (12–15 mL), scrotum dark&nbsp;</td></tr><tr><td> 5. Penis adult size; testicular volume &gt; 15 ml&nbsp;</td></tr></tbody></table></div><div><table><tbody><tr><td>The description of Tanner stages for breast development:&nbsp;</td></tr><tr><td> 1. Prepubertal&nbsp;</td></tr><tr><td> 2. Breast and papilla elevated as small mound; areolar diameter increased&nbsp;</td></tr><tr><td> 3. Breast and areola enlarged, no contour separation&nbsp;</td></tr><tr><td> 4. Areola and papilla form secondary mound&nbsp;</td></tr><tr><td> 5. Mature; nipple projects, areola part of general breast contour&nbsp;</td></tr><tr><td>For penis and testes:&nbsp;</td></tr><tr><td> 1. Prepubertal, testicular volume &lt;4 mL&nbsp;</td></tr><tr><td> 2. Slight enlargement of penis; enlarged scrotum, pink, texture altered, testes 4–6 mL&nbsp;</td></tr><tr><td> 3. Penis longer, testes larger (8–12 mL)&nbsp;</td></tr><tr><td> 4. Penis and glans larger, including increase in breadth; testes larger (12–15 mL), scrotum dark&nbsp;</td></tr><tr><td> 5. Penis adult size; testicular volume &gt; 15 ml&nbsp;</td></tr></tbody></table></div><div><p><span><p>Adapted from Lawrence (<span id=\"jumplink-B56\"></span>56).</p></span></p></div></div><div><div id=\"T6\" data-id=\"T6\"><p><span>Table 6.</span></p><p>Tanner Stages of Breast Development and Male External Genitalia</p> </div><div><table><tbody><tr><td>The description of Tanner stages for breast development:&nbsp;</td></tr><tr><td> 1. Prepubertal&nbsp;</td></tr><tr><td> 2. Breast and papilla elevated as small mound; areolar diameter increased&nbsp;</td></tr><tr><td> 3. Breast and areola enlarged, no contour separation&nbsp;</td></tr><tr><td> 4. Areola and papilla form secondary mound&nbsp;</td></tr><tr><td> 5. Mature; nipple projects, areola part of general breast contour&nbsp;</td></tr><tr><td>For penis and testes:&nbsp;</td></tr><tr><td> 1. Prepubertal, testicular volume &lt;4 mL&nbsp;</td></tr><tr><td> 2. Slight enlargement of penis; enlarged scrotum, pink, texture altered, testes 4–6 mL&nbsp;</td></tr><tr><td> 3. Penis longer, testes larger (8–12 mL)&nbsp;</td></tr><tr><td> 4. Penis and glans larger, including increase in breadth; testes larger (12–15 mL), scrotum dark&nbsp;</td></tr><tr><td> 5. Penis adult size; testicular volume &gt; 15 ml&nbsp;</td></tr></tbody></table></div><div><table><tbody><tr><td>The description of Tanner stages for breast development:&nbsp;</td></tr><tr><td> 1. Prepubertal&nbsp;</td></tr><tr><td> 2. Breast and papilla elevated as small mound; areolar diameter increased&nbsp;</td></tr><tr><td> 3. Breast and areola enlarged, no contour separation&nbsp;</td></tr><tr><td> 4. Areola and papilla form secondary mound&nbsp;</td></tr><tr><td> 5. Mature; nipple projects, areola part of general breast contour&nbsp;</td></tr><tr><td>For penis and testes:&nbsp;</td></tr><tr><td> 1. Prepubertal, testicular volume &lt;4 mL&nbsp;</td></tr><tr><td> 2. Slight enlargement of penis; enlarged scrotum, pink, texture altered, testes 4–6 mL&nbsp;</td></tr><tr><td> 3. Penis longer, testes larger (8–12 mL)&nbsp;</td></tr><tr><td> 4. Penis and glans larger, including increase in breadth; testes larger (12–15 mL), scrotum dark&nbsp;</td></tr><tr><td> 5. Penis adult size; testicular volume &gt; 15 ml&nbsp;</td></tr></tbody></table></div><div><p><span><p>Adapted from Lawrence (<span id=\"jumplink-B56\"></span>56).</p></span></p></div></div><p>Irreversible and, for GD/gender-incongruent adolescents, undesirable sex characteristics in female puberty are breasts, female body habitus, and, in some cases, relative short stature. In male puberty, they are a prominent Adam’s apple; low voice; male bone configuration, such as a large jaw, big feet and hands, and tall stature; and male hair pattern on the face and extremities.</p><ul><li><p>2.3. We recommend that, where indicated, GnRH analogues are used to suppress pubertal hormones. (1 |⊕⊕○○)</p></li></ul>                    <h3 scrollto-destination=\"99603331\" id=\"99603331\" data-legacy-id=\"s33\">Evidence</h3>\n<p>Clinicians can suppress pubertal development and gonadal function most effectively via gonadotropin suppression using GnRH analogs. GnRH analogs are long-acting agonists that suppress gonadotropins by GnRH receptor desensitization after an initial increase of gonadotropins during ∼10 days after the first and (to a lesser degree) the second injection (<span id=\"jumplink-B89\"></span>89). Antagonists immediately suppress pituitary gonadotropin secretion (<span id=\"jumplink-B90\"></span>90, <span id=\"jumplink-B91\"></span>91). Long-acting GnRH analogs are the currently preferred treatment option. Clinicians may consider long-acting GnRH antagonists when evidence on their safety and efficacy in adolescents becomes available.</p><p>During GnRH analog treatment, slight development of secondary sex characteristics may regress, and in a later phase of pubertal development, it will stop. In girls, breast tissue will become atrophic, and menses will stop. In boys, virilization will stop, and testicular volume may decrease (<span id=\"jumplink-B92\"></span>92).</p><p>An advantage of using GnRH analogs is the reversibility of the intervention. If, after extensive exploration of his/her transition wish, the individual no longer desires transition, they can discontinue pubertal suppression. In subjects with precocious puberty, spontaneous pubertal development has been shown to resume after patients discontinue taking GnRH analogs (<span id=\"jumplink-B93\"></span>93).</p><p>Recommendations 2.1 to 2.3 are supported by a prospective follow-up study from The Netherlands. This report assessed mental health outcomes in 55 transgender adolescents/young adults (22 transgender females and 33 transgender males) at three time points: (1) before the start of GnRH agonist (average age of 14.8 years at start of treatment), (2) at initiation of gender-affirming hormones (average age of 16.7 years at start of treatment), and (3) 1 year after “gender-reassignment surgery” (average age of 20.7 years) (<span id=\"jumplink-B63\"></span>63). Despite a decrease in depression and an improvement in general mental health functioning, GD/gender incongruence persisted through pubertal suppression, as previously reported (<span id=\"jumplink-B86\"></span>86). However, following sex hormone treatment and gender-reassignment surgery, GD/gender incongruence was resolved and psychological functioning steadily improved (<span id=\"jumplink-B63\"></span>63). Furthermore, well-being was similar to or better than that reported by age-matched young adults from the general population, and none of the study participants regretted treatment. This study represents the first long-term follow-up of individuals managed according to currently existing clinical practice guidelines for transgender youth, and it underscores the benefit of the multidisciplinary approach pioneered in The Netherlands; however, further studies are needed.</p>                    <h3 scrollto-destination=\"99603336\" id=\"99603336\" data-legacy-id=\"s34\">Side effects</h3>\n<p>The primary risks of pubertal suppression in GD/gender-incongruent adolescents may include adverse effects on bone mineralization (which can theoretically be reversed with sex hormone treatment), compromised fertility if the person subsequently is treated with sex hormones, and unknown effects on brain development. Few data are available on the effect of GnRH analogs on BMD in adolescents with GD/gender incongruence. Initial data in GD/gender-incongruent subjects demonstrated no change of absolute areal BMD during 2 years of GnRH analog therapy but a decrease in BMD <em>z</em> scores (<span id=\"jumplink-B85\"></span>85). A recent study also suggested suboptimal bone mineral accrual during GnRH analog treatment. The study reported a decrease in areal BMD <em>z</em> scores and of bone mineral apparent density <em>z</em> scores (which takes the size of the bone into account) in 19 transgender males treated with GnRH analogs from a mean age of 15.0 years (standard deviation = 2.0 years) for a median duration of 1.5 years (0.3 to 5.2 years) and in 15 transgender females treated from 14.9 (±1.9) years for 1.3 years (0.5 to 3.8 years), although not all changes were statistically significant (<span id=\"jumplink-B94\"></span>94). There was incomplete catch-up at age 22 years after sex hormone treatment from age 16.6 (±1.4) years for a median duration of 5.8 years (3.0 to 8.0 years) in transgender females and from age 16.4 (±2.3) years for 5.4 years (2.8 to 7.8 years) in transgender males. Little is known about more prolonged use of GnRH analogs. Researchers reported normal BMD <em>z</em> scores at age 35 years in one individual who used GnRH analogs from age 13.7 years until age 18.6 years before initiating sex hormone treatment (<span id=\"jumplink-B65\"></span>65).</p><p>Additional data are available from individuals with late puberty or GnRH analog treatment of other indications. Some studies reported that men with constitutionally delayed puberty have decreased BMD in adulthood (<span id=\"jumplink-B95\"></span>95). However, other studies reported that these men have normal BMD (<span id=\"jumplink-B96\"></span>96, <span id=\"jumplink-B97\"></span>97). Treating adults with GnRH analogs results in a decrease of BMD (<span id=\"jumplink-B98\"></span>98). In children with central precocious puberty, treatment with GnRH analogs has been found to result in a decrease of BMD during treatment by some (<span id=\"jumplink-B99\"></span>99) but not others (<span id=\"jumplink-B100\"></span>100). Studies have reported normal BMD after discontinuing therapy (<span id=\"jumplink-B69\"></span>69, <span id=\"jumplink-B72\"></span>72, <span id=\"jumplink-B73\"></span>73, <span id=\"jumplink-B101\"></span>101, <span id=\"jumplink-B102\"></span>102). In adolescents treated with growth hormone who are small for gestational age and have normal pubertal timing, 2-year GnRH analog treatments did not adversely affect BMD (<span id=\"jumplink-B103\"></span>103). Calcium supplementation may be beneficial in optimizing bone health in GnRH analog–treated individuals (<span id=\"jumplink-B104\"></span>104). There are no studies of vitamin D supplementation in this context, but clinicians should offer supplements to vitamin D–deficient adolescents. Physical activity, especially during growth, is important for bone mass in healthy individuals (<span id=\"jumplink-B103\"></span>103) and is therefore likely to be beneficial for bone health in GnRH analog–treated subjects.</p><p>GnRH analogs did not induce a change in body mass index standard deviation score in GD/gender-incongruent adolescents (<span id=\"jumplink-B94\"></span>94) but caused an increase in fat mass and decrease in lean body mass percentage (<span id=\"jumplink-B92\"></span>92). Studies in girls treated for precocious puberty also reported a stable body mass index standard deviation score during treatment (<span id=\"jumplink-B72\"></span>72) and body mass index and body composition comparable to controls after treatment (<span id=\"jumplink-B73\"></span>73).</p><p>Arterial hypertension has been reported as an adverse effect in a few girls treated with GnRH analogs for precocious/early puberty (<span id=\"jumplink-B105\"></span>105, <span id=\"jumplink-B106\"></span>106). Blood pressure monitoring before and during treatment is recommended.</p><p>Individuals may also experience hot flashes, fatigue, and mood alterations as a consequence of pubertal suppression. There is no consensus on treatment of these side effects in this context.</p><p>It is recommended that any use of pubertal blockers (and subsequent use of sex hormones, as detailed below) include a discussion about implications for fertility (see recommendation 1.3). Transgender adolescents may want to preserve fertility, which may be otherwise compromised if puberty is suppressed at an early stage and the individual completes phenotypic transition with the use of sex hormones.</p><p>Limited data are available regarding the effects of GnRH analogs on brain development. A single cross-sectional study demonstrated no compromise of executive function (<span id=\"jumplink-B107\"></span>107), but animal data suggest there may be an effect of GnRH analogs on cognitive function (<span id=\"jumplink-B108\"></span>108).</p>                    <h3 scrollto-destination=\"99603344\" id=\"99603344\" data-legacy-id=\"s35\">Values and preferences</h3>\n<p>Our recommendation of GnRH analogs places a higher value on the superior efficacy, safety, and reversibility of the pubertal hormone suppression achieved (as compared with the alternatives) and a relatively lower value on limiting the cost of therapy. Of the available alternatives, depot and oral progestin preparations are effective. Experience with this treatment dates back prior to the emergence of GnRH analogs for treating precocious puberty in papers from the 1960s and early 1970s (<span id=\"jumplink-B109\"></span>109–<span id=\"jumplink-B112\"></span>112). These compounds are usually safe, but some side effects have been reported (<span id=\"jumplink-B113\"></span>113–<span id=\"jumplink-B115\"></span>115). Only two recent studies involved transgender youth (<span id=\"jumplink-B116\"></span>116, <span id=\"jumplink-B117\"></span>117). One of these studies described the use of oral lynestrenol monotherapy followed by the addition of testosterone treatment in transgender boys who were at Tanner stage B4 or further at the start of treatment (<span id=\"jumplink-B117\"></span>117). They found lynestrenol safe, but gonadotropins were not fully suppressed. The study reported metrorrhagia in approximately half of the individuals, mainly in the first 6 months. Acne, headache, hot flashes, and fatigue were other frequent side effects. Another progestin that has been studied in the United States is medroxyprogesterone. This agent is not as effective as GnRH analogs in lowering endogenous sex hormones either and may be associated with other side effects (<span id=\"jumplink-B116\"></span>116). Progestin preparations may be an acceptable treatment for persons without access to GnRH analogs or with a needle phobia. If GnRH analog treatment is not available (insurance denial, prohibitive cost, or other reasons), postpubertal, transgender female adolescents may be treated with an antiandrogen that directly suppresses androgen synthesis or action (see adult section).</p>                    <h3 scrollto-destination=\"99603346\" id=\"99603346\" data-legacy-id=\"s36\">Remarks</h3>\n<p>Measurements of gonadotropin and sex steroid levels give precise information about gonadal axis suppression, although there is insufficient evidence for any specific short-term monitoring scheme in children treated with GnRH analogs (<span id=\"jumplink-B88\"></span>88). If the gonadal axis is not completely suppressed—as evidenced by (for example) menses, erections, or progressive hair growth—the interval of GnRH analog treatment can be shortened or the dose increased. During treatment, adolescents should be monitored for negative effects of delaying puberty, including a halted growth spurt and impaired bone mineral accretion. <span id=\"jumplink-T7\"></span>Table 7 illustrates a suggested clinical protocol.</p>                    <div content-id=\"T7\"><div id=\"T7\" data-id=\"T7\"><p><span>Table 7.</span></p><p>Baseline and Follow-Up Protocol During Suppression of Puberty</p> </div><div><table><tbody><tr><td>Every 3–6 mo&nbsp;</td></tr><tr><td> Anthropometry: height, weight, sitting height, blood pressure, Tanner stages&nbsp;</td></tr><tr><td>Every 6–12 mo&nbsp;</td></tr><tr><td> Laboratory: LH, FSH, E2/T, 25OH vitamin D&nbsp;</td></tr><tr><td>Every 1–2 y&nbsp;</td></tr><tr><td> Bone density using DXA&nbsp;</td></tr><tr><td> Bone age on X-ray of the left hand (if clinically indicated)&nbsp;</td></tr></tbody></table></div><div><table><tbody><tr><td>Every 3–6 mo&nbsp;</td></tr><tr><td> Anthropometry: height, weight, sitting height, blood pressure, Tanner stages&nbsp;</td></tr><tr><td>Every 6–12 mo&nbsp;</td></tr><tr><td> Laboratory: LH, FSH, E2/T, 25OH vitamin D&nbsp;</td></tr><tr><td>Every 1–2 y&nbsp;</td></tr><tr><td> Bone density using DXA&nbsp;</td></tr><tr><td> Bone age on X-ray of the left hand (if clinically indicated)&nbsp;</td></tr></tbody></table></div><div><p><span><p>Adapted from Hembree <em>et al.</em> (<span id=\"jumplink-B118\"></span>118).</p><p>Abbreviations: DXA, dual-energy X-ray absorptiometry; E2, estradiol; FSH, follicle stimulating hormone; LH, luteinizing hormone; T, testosterone; </p></span></p></div></div><div><div id=\"T7\" data-id=\"T7\"><p><span>Table 7.</span></p><p>Baseline and Follow-Up Protocol During Suppression of Puberty</p> </div><div><table><tbody><tr><td>Every 3–6 mo&nbsp;</td></tr><tr><td> Anthropometry: height, weight, sitting height, blood pressure, Tanner stages&nbsp;</td></tr><tr><td>Every 6–12 mo&nbsp;</td></tr><tr><td> Laboratory: LH, FSH, E2/T, 25OH vitamin D&nbsp;</td></tr><tr><td>Every 1–2 y&nbsp;</td></tr><tr><td> Bone density using DXA&nbsp;</td></tr><tr><td> Bone age on X-ray of the left hand (if clinically indicated)&nbsp;</td></tr></tbody></table></div><div><table><tbody><tr><td>Every 3–6 mo&nbsp;</td></tr><tr><td> Anthropometry: height, weight, sitting height, blood pressure, Tanner stages&nbsp;</td></tr><tr><td>Every 6–12 mo&nbsp;</td></tr><tr><td> Laboratory: LH, FSH, E2/T, 25OH vitamin D&nbsp;</td></tr><tr><td>Every 1–2 y&nbsp;</td></tr><tr><td> Bone density using DXA&nbsp;</td></tr><tr><td> Bone age on X-ray of the left hand (if clinically indicated)&nbsp;</td></tr></tbody></table></div><div><p><span><p>Adapted from Hembree <em>et al.</em> (<span id=\"jumplink-B118\"></span>118).</p><p>Abbreviations: DXA, dual-energy X-ray absorptiometry; E2, estradiol; FSH, follicle stimulating hormone; LH, luteinizing hormone; T, testosterone; </p></span></p></div></div><p>Anthropometric measurements and X-rays of the left hand to monitor bone age are informative for evaluating growth. To assess BMD, clinicians can perform dual-energy X-ray absorptiometry scans.</p><ul><li><p>2.4. In adolescents who request sex hormone treatment (given this is a partly irreversible treatment), we recommend initiating treatment using a gradually increasing dose schedule (see <span id=\"jumplink-T8\"></span>Table 8)after a multidisciplinary team of medical and MHPs has confirmed the persistence of GD/gender incongruence and sufficient mental capacity to give informed consent, which most adolescents have by age 16 years (<span id=\"jumplink-T5\"></span>Table 5). (1 |⊕⊕○○)<span id=\"T8\"></span></p><div content-id=\"T8\"><div id=\"T8\" data-id=\"T8\"><p><span>Table 8.</span></p><p>Protocol Induction of Puberty</p> </div><div><table><tbody><tr><td>Induction of female puberty with oral 17<em>β</em>-estradiol, increasing the dose every 6 mo:&nbsp;</td></tr><tr><td> 5 μg/kg/d&nbsp;</td></tr><tr><td> 10 μg/kg/d&nbsp;</td></tr><tr><td> 15 μg/kg/d&nbsp;</td></tr><tr><td> 20 μg/kg/d&nbsp;</td></tr><tr><td> Adult dose = 2–6 mg/d&nbsp;</td></tr><tr><td><em> In postpubertal transgender female adolescents, the dose of 17</em>β<em>-estradiol can be increased more rapidly:</em>&nbsp;</td></tr><tr><td>  1 mg/d for 6 mo&nbsp;</td></tr><tr><td>  2 mg/d&nbsp;</td></tr><tr><td>Induction of female puberty with transdermal 17<em>β</em>-estradiol, increasing the dose every 6 mo (new patch is placed every 3.5 d):&nbsp;</td></tr><tr><td> 6.25–12.5 μg/24 h (cut 25-μg patch into quarters, then halves)&nbsp;</td></tr><tr><td> 25 μg/24 h&nbsp;</td></tr><tr><td> 37.5 μg/24 h&nbsp;</td></tr><tr><td> Adult dose = 50–200 μg/24 h&nbsp;</td></tr><tr><td><em> For alternatives once at adult dose, see Table 11.</em>&nbsp;</td></tr><tr><td><em> Adjust maintenance dose to mimic physiological estradiol levels (see Table 15).</em>&nbsp;</td></tr><tr><td>&nbsp;</td></tr><tr><td>Induction of male puberty with testosterone esters increasing the dose every 6 mo (IM or SC):&nbsp;</td></tr><tr><td> 25 mg/m<sup>2</sup>/2 wk (or alternatively, half this dose weekly, or double the dose every 4 wk)&nbsp;</td></tr><tr><td> 50 mg/m<sup>2</sup>/2 wk&nbsp;</td></tr><tr><td> 75 mg/m<sup>2</sup>/2 wk&nbsp;</td></tr><tr><td> 100 mg/m<sup>2</sup>/2 wk&nbsp;</td></tr><tr><td> Adult dose = 100–200 mg every 2 wk&nbsp;</td></tr><tr><td><em> In postpubertal transgender male adolescents the dose of testosterone esters can be increased more rapidly:</em>&nbsp;</td></tr><tr><td>  75 mg/2 wk for 6 mo&nbsp;</td></tr><tr><td>  125 mg/2 wk&nbsp;</td></tr><tr><td><em> For alternatives once at adult dose, see Table 11.</em>&nbsp;</td></tr><tr><td><em> Adjust maintenance dose to mimic physiological testosterone levels (see Table 14).</em>&nbsp;</td></tr></tbody></table></div><div><table><tbody><tr><td>Induction of female puberty with oral 17<em>β</em>-estradiol, increasing the dose every 6 mo:&nbsp;</td></tr><tr><td> 5 μg/kg/d&nbsp;</td></tr><tr><td> 10 μg/kg/d&nbsp;</td></tr><tr><td> 15 μg/kg/d&nbsp;</td></tr><tr><td> 20 μg/kg/d&nbsp;</td></tr><tr><td> Adult dose = 2–6 mg/d&nbsp;</td></tr><tr><td><em> In postpubertal transgender female adolescents, the dose of 17</em>β<em>-estradiol can be increased more rapidly:</em>&nbsp;</td></tr><tr><td>  1 mg/d for 6 mo&nbsp;</td></tr><tr><td>  2 mg/d&nbsp;</td></tr><tr><td>Induction of female puberty with transdermal 17<em>β</em>-estradiol, increasing the dose every 6 mo (new patch is placed every 3.5 d):&nbsp;</td></tr><tr><td> 6.25–12.5 μg/24 h (cut 25-μg patch into quarters, then halves)&nbsp;</td></tr><tr><td> 25 μg/24 h&nbsp;</td></tr><tr><td> 37.5 μg/24 h&nbsp;</td></tr><tr><td> Adult dose = 50–200 μg/24 h&nbsp;</td></tr><tr><td><em> For alternatives once at adult dose, see Table 11.</em>&nbsp;</td></tr><tr><td><em> Adjust maintenance dose to mimic physiological estradiol levels (see Table 15).</em>&nbsp;</td></tr><tr><td>&nbsp;</td></tr><tr><td>Induction of male puberty with testosterone esters increasing the dose every 6 mo (IM or SC):&nbsp;</td></tr><tr><td> 25 mg/m<sup>2</sup>/2 wk (or alternatively, half this dose weekly, or double the dose every 4 wk)&nbsp;</td></tr><tr><td> 50 mg/m<sup>2</sup>/2 wk&nbsp;</td></tr><tr><td> 75 mg/m<sup>2</sup>/2 wk&nbsp;</td></tr><tr><td> 100 mg/m<sup>2</sup>/2 wk&nbsp;</td></tr><tr><td> Adult dose = 100–200 mg every 2 wk&nbsp;</td></tr><tr><td><em> In postpubertal transgender male adolescents the dose of testosterone esters can be increased more rapidly:</em>&nbsp;</td></tr><tr><td>  75 mg/2 wk for 6 mo&nbsp;</td></tr><tr><td>  125 mg/2 wk&nbsp;</td></tr><tr><td><em> For alternatives once at adult dose, see Table 11.</em>&nbsp;</td></tr><tr><td><em> Adjust maintenance dose to mimic physiological testosterone levels (see Table 14).</em>&nbsp;</td></tr></tbody></table></div><div><p><span><p>Adapted from Hembree <em>et al.</em> (<span id=\"jumplink-B118\"></span>118).</p><p>Abbreviations: IM, intramuscularly; SC, subcutaneously.</p></span></p></div></div><div><div id=\"T8\" data-id=\"T8\"><p><span>Table 8.</span></p><p>Protocol Induction of Puberty</p> </div><div><table><tbody><tr><td>Induction of female puberty with oral 17<em>β</em>-estradiol, increasing the dose every 6 mo:&nbsp;</td></tr><tr><td> 5 μg/kg/d&nbsp;</td></tr><tr><td> 10 μg/kg/d&nbsp;</td></tr><tr><td> 15 μg/kg/d&nbsp;</td></tr><tr><td> 20 μg/kg/d&nbsp;</td></tr><tr><td> Adult dose = 2–6 mg/d&nbsp;</td></tr><tr><td><em> In postpubertal transgender female adolescents, the dose of 17</em>β<em>-estradiol can be increased more rapidly:</em>&nbsp;</td></tr><tr><td>  1 mg/d for 6 mo&nbsp;</td></tr><tr><td>  2 mg/d&nbsp;</td></tr><tr><td>Induction of female puberty with transdermal 17<em>β</em>-estradiol, increasing the dose every 6 mo (new patch is placed every 3.5 d):&nbsp;</td></tr><tr><td> 6.25–12.5 μg/24 h (cut 25-μg patch into quarters, then halves)&nbsp;</td></tr><tr><td> 25 μg/24 h&nbsp;</td></tr><tr><td> 37.5 μg/24 h&nbsp;</td></tr><tr><td> Adult dose = 50–200 μg/24 h&nbsp;</td></tr><tr><td><em> For alternatives once at adult dose, see Table 11.</em>&nbsp;</td></tr><tr><td><em> Adjust maintenance dose to mimic physiological estradiol levels (see Table 15).</em>&nbsp;</td></tr><tr><td>&nbsp;</td></tr><tr><td>Induction of male puberty with testosterone esters increasing the dose every 6 mo (IM or SC):&nbsp;</td></tr><tr><td> 25 mg/m<sup>2</sup>/2 wk (or alternatively, half this dose weekly, or double the dose every 4 wk)&nbsp;</td></tr><tr><td> 50 mg/m<sup>2</sup>/2 wk&nbsp;</td></tr><tr><td> 75 mg/m<sup>2</sup>/2 wk&nbsp;</td></tr><tr><td> 100 mg/m<sup>2</sup>/2 wk&nbsp;</td></tr><tr><td> Adult dose = 100–200 mg every 2 wk&nbsp;</td></tr><tr><td><em> In postpubertal transgender male adolescents the dose of testosterone esters can be increased more rapidly:</em>&nbsp;</td></tr><tr><td>  75 mg/2 wk for 6 mo&nbsp;</td></tr><tr><td>  125 mg/2 wk&nbsp;</td></tr><tr><td><em> For alternatives once at adult dose, see Table 11.</em>&nbsp;</td></tr><tr><td><em> Adjust maintenance dose to mimic physiological testosterone levels (see Table 14).</em>&nbsp;</td></tr></tbody></table></div><div><table><tbody><tr><td>Induction of female puberty with oral 17<em>β</em>-estradiol, increasing the dose every 6 mo:&nbsp;</td></tr><tr><td> 5 μg/kg/d&nbsp;</td></tr><tr><td> 10 μg/kg/d&nbsp;</td></tr><tr><td> 15 μg/kg/d&nbsp;</td></tr><tr><td> 20 μg/kg/d&nbsp;</td></tr><tr><td> Adult dose = 2–6 mg/d&nbsp;</td></tr><tr><td><em> In postpubertal transgender female adolescents, the dose of 17</em>β<em>-estradiol can be increased more rapidly:</em>&nbsp;</td></tr><tr><td>  1 mg/d for 6 mo&nbsp;</td></tr><tr><td>  2 mg/d&nbsp;</td></tr><tr><td>Induction of female puberty with transdermal 17<em>β</em>-estradiol, increasing the dose every 6 mo (new patch is placed every 3.5 d):&nbsp;</td></tr><tr><td> 6.25–12.5 μg/24 h (cut 25-μg patch into quarters, then halves)&nbsp;</td></tr><tr><td> 25 μg/24 h&nbsp;</td></tr><tr><td> 37.5 μg/24 h&nbsp;</td></tr><tr><td> Adult dose = 50–200 μg/24 h&nbsp;</td></tr><tr><td><em> For alternatives once at adult dose, see Table 11.</em>&nbsp;</td></tr><tr><td><em> Adjust maintenance dose to mimic physiological estradiol levels (see Table 15).</em>&nbsp;</td></tr><tr><td>&nbsp;</td></tr><tr><td>Induction of male puberty with testosterone esters increasing the dose every 6 mo (IM or SC):&nbsp;</td></tr><tr><td> 25 mg/m<sup>2</sup>/2 wk (or alternatively, half this dose weekly, or double the dose every 4 wk)&nbsp;</td></tr><tr><td> 50 mg/m<sup>2</sup>/2 wk&nbsp;</td></tr><tr><td> 75 mg/m<sup>2</sup>/2 wk&nbsp;</td></tr><tr><td> 100 mg/m<sup>2</sup>/2 wk&nbsp;</td></tr><tr><td> Adult dose = 100–200 mg every 2 wk&nbsp;</td></tr><tr><td><em> In postpubertal transgender male adolescents the dose of testosterone esters can be increased more rapidly:</em>&nbsp;</td></tr><tr><td>  75 mg/2 wk for 6 mo&nbsp;</td></tr><tr><td>  125 mg/2 wk&nbsp;</td></tr><tr><td><em> For alternatives once at adult dose, see Table 11.</em>&nbsp;</td></tr><tr><td><em> Adjust maintenance dose to mimic physiological testosterone levels (see Table 14).</em>&nbsp;</td></tr></tbody></table></div><div><p><span><p>Adapted from Hembree <em>et al.</em> (<span id=\"jumplink-B118\"></span>118).</p><p>Abbreviations: IM, intramuscularly; SC, subcutaneously.</p></span></p></div></div></li><li><p>2.5. We recognize that there may be compelling reasons to initiate sex hormone treatment prior to the age of 16 years in some adolescents with GD/gender incongruence, even though there are minimal published studies of gender-affirming hormone treatments administered before age 13.5 to 14 years. As with the care of adolescents ≥16 years of age, we recommend that an expert multidisciplinary team of medical and MHPs manage this treatment. (1 |⊕○○○)</p></li><li><p>2.6. We suggest monitoring clinical pubertal development every 3 to 6 months and laboratory parameters every 6 to 12 months during sex hormone treatment (<span id=\"jumplink-T9\"></span>Table 9). (2 |⊕⊕○○)<span id=\"T9\"></span></p><div content-id=\"T9\"><div id=\"T9\" data-id=\"T9\"><p><span>Table 9.</span></p><p>Baseline and Follow-up Protocol During Induction of Puberty</p> </div><div><table><tbody><tr><td>Every 3–6 mo&nbsp;</td></tr><tr><td> •Anthropometry: height, weight, sitting height, blood pressure, Tanner stages&nbsp;</td></tr><tr><td>Every 6–12 mo&nbsp;</td></tr><tr><td> •In transgender males: hemoglobin/hematocrit, lipids, testosterone, 25OH vitamin D&nbsp;</td></tr><tr><td> •In transgender females: prolactin, estradiol, 25OH vitamin D&nbsp;</td></tr><tr><td>Every 1–2 y&nbsp;</td></tr><tr><td> •BMD using DXA&nbsp;</td></tr><tr><td> •Bone age on X-ray of the left hand (if clinically indicated)&nbsp;</td></tr><tr><td><em>BMD should be monitored into adulthood (until the age of 25–30 y or until peak bone mass has been reached).</em>&nbsp;</td></tr><tr><td><em>For recommendations on monitoring once pubertal induction has been completed, see Tables 14 and 15.</em>&nbsp;</td></tr></tbody></table></div><div><table><tbody><tr><td>Every 3–6 mo&nbsp;</td></tr><tr><td> •Anthropometry: height, weight, sitting height, blood pressure, Tanner stages&nbsp;</td></tr><tr><td>Every 6–12 mo&nbsp;</td></tr><tr><td> •In transgender males: hemoglobin/hematocrit, lipids, testosterone, 25OH vitamin D&nbsp;</td></tr><tr><td> •In transgender females: prolactin, estradiol, 25OH vitamin D&nbsp;</td></tr><tr><td>Every 1–2 y&nbsp;</td></tr><tr><td> •BMD using DXA&nbsp;</td></tr><tr><td> •Bone age on X-ray of the left hand (if clinically indicated)&nbsp;</td></tr><tr><td><em>BMD should be monitored into adulthood (until the age of 25–30 y or until peak bone mass has been reached).</em>&nbsp;</td></tr><tr><td><em>For recommendations on monitoring once pubertal induction has been completed, see Tables 14 and 15.</em>&nbsp;</td></tr></tbody></table></div><div><p><span><p>Adapted from Hembree <em>et al.</em> (<span id=\"jumplink-B118\"></span>118).</p><p>Abbreviation: DXA, dual-energy X-ray absorptiometry.</p></span></p></div></div><div><div id=\"T9\" data-id=\"T9\"><p><span>Table 9.</span></p><p>Baseline and Follow-up Protocol During Induction of Puberty</p> </div><div><table><tbody><tr><td>Every 3–6 mo&nbsp;</td></tr><tr><td> •Anthropometry: height, weight, sitting height, blood pressure, Tanner stages&nbsp;</td></tr><tr><td>Every 6–12 mo&nbsp;</td></tr><tr><td> •In transgender males: hemoglobin/hematocrit, lipids, testosterone, 25OH vitamin D&nbsp;</td></tr><tr><td> •In transgender females: prolactin, estradiol, 25OH vitamin D&nbsp;</td></tr><tr><td>Every 1–2 y&nbsp;</td></tr><tr><td> •BMD using DXA&nbsp;</td></tr><tr><td> •Bone age on X-ray of the left hand (if clinically indicated)&nbsp;</td></tr><tr><td><em>BMD should be monitored into adulthood (until the age of 25–30 y or until peak bone mass has been reached).</em>&nbsp;</td></tr><tr><td><em>For recommendations on monitoring once pubertal induction has been completed, see Tables 14 and 15.</em>&nbsp;</td></tr></tbody></table></div><div><table><tbody><tr><td>Every 3–6 mo&nbsp;</td></tr><tr><td> •Anthropometry: height, weight, sitting height, blood pressure, Tanner stages&nbsp;</td></tr><tr><td>Every 6–12 mo&nbsp;</td></tr><tr><td> •In transgender males: hemoglobin/hematocrit, lipids, testosterone, 25OH vitamin D&nbsp;</td></tr><tr><td> •In transgender females: prolactin, estradiol, 25OH vitamin D&nbsp;</td></tr><tr><td>Every 1–2 y&nbsp;</td></tr><tr><td> •BMD using DXA&nbsp;</td></tr><tr><td> •Bone age on X-ray of the left hand (if clinically indicated)&nbsp;</td></tr><tr><td><em>BMD should be monitored into adulthood (until the age of 25–30 y or until peak bone mass has been reached).</em>&nbsp;</td></tr><tr><td><em>For recommendations on monitoring once pubertal induction has been completed, see Tables 14 and 15.</em>&nbsp;</td></tr></tbody></table></div><div><p><span><p>Adapted from Hembree <em>et al.</em> (<span id=\"jumplink-B118\"></span>118).</p><p>Abbreviation: DXA, dual-energy X-ray absorptiometry.</p></span></p></div></div></li></ul>                    <h3 scrollto-destination=\"99603351\" id=\"99603351\" data-legacy-id=\"s37\">Evidence</h3>\n<p>Adolescents develop competence in decision making at their own pace. Ideally, the supervising medical professionals should individually assess this competence, although no objective tools to make such an assessment are currently available.</p><p>Many adolescents have achieved a reasonable level of competence by age 15 to 16 years (<span id=\"jumplink-B119\"></span>119), and in many countries 16-year-olds are legally competent with regard to medical decision making (<span id=\"jumplink-B120\"></span>120). However, others believe that although some capacities are generally achieved before age 16 years, other abilities (such as good risk assessment) do not develop until well after 18 years (<span id=\"jumplink-B121\"></span>121). They suggest that health care procedures should be divided along a matrix of relative risk, so that younger adolescents can be allowed to decide about low-risk procedures, such as most diagnostic tests and common therapies, but not about high-risk procedures, such as most surgical procedures (<span id=\"jumplink-B121\"></span>121).</p><p>Currently available data from transgender adolescents support treatment with sex hormones starting at age 16 years (<span id=\"jumplink-B63\"></span>63, <span id=\"jumplink-B122\"></span>122). However, some patients may incur potential risks by waiting until age 16 years. These include the potential risk to bone health if puberty is suppressed for 6 to 7 years before initiating sex hormones (<em>e.g.</em>, if someone reached Tanner stage 2 at age 9-10 years old). Additionally, there may be concerns about inappropriate height and potential harm to mental health (emotional and social isolation) if initiation of secondary sex characteristics must wait until the person has reached 16 years of age. However, only minimal data supporting earlier use of gender-affirming hormones in transgender adolescents currently exist (<span id=\"jumplink-B63\"></span>63). Clearly, long-term studies are needed to determine the optimal age of sex hormone treatment in GD/gender-incongruent adolescents.</p><p>The MHP who has followed the adolescent during GnRH analog treatment plays an essential role in assessing whether the adolescent is eligible to start sex hormone therapy and capable of consenting to this treatment (<span id=\"jumplink-T5\"></span>Table 5). Support of the family/environment is essential. Prior to the start of sex hormones, clinicians should discuss the implications for fertility (see recommendation 1.5). Throughout pubertal induction, an MHP and a pediatric endocrinologist (or other clinician competent in the evaluation and induction of pubertal development) should monitor the adolescent. In addition to monitoring therapy, it is also important to pay attention to general adolescent health issues, including healthy life style choices, such as not smoking, contraception, and appropriate vaccinations (<em>e.g.</em>, human papillomavirus).</p><p>For the induction of puberty, clinicians can use a similar dose scheme for hypogonadal adolescents with GD/gender incongruence as they use in other individuals with hypogonadism, carefully monitoring for desired and undesired effects (<span id=\"jumplink-T8\"></span>Table 8). In transgender female adolescents, transdermal 17<em>β</em>-estradiol may be an alternative for oral 17<em>β</em>-estradiol. It is increasingly used for pubertal induction in hypogonadal females. However, the absence of low-dose estrogen patches may be a problem. As a result, individuals may need to cut patches to size themselves to achieve appropriate dosing (<span id=\"jumplink-B123\"></span>123). In transgender male adolescents, clinicians can give testosterone injections intramuscularly or subcutaneously (<span id=\"jumplink-B124\"></span>124, <span id=\"jumplink-B125\"></span>125).</p><p>When puberty is initiated with a gradually increasing schedule of sex steroid doses, the initial levels will not be high enough to suppress endogenous sex steroid secretion. Gonadotropin secretion and endogenous production of testosterone may resume and interfere with the effectiveness of estrogen treatment, in transgender female adolescents (<span id=\"jumplink-B126\"></span>126, <span id=\"jumplink-B127\"></span>127). Therefore, continuation of GnRH analog treatment is advised until gonadectomy. Given that GD/gender-incongruent adolescents may opt not to have gonadectomy, long-term studies are necessary to examine the potential risks of prolonged GnRH analog treatment. Alternatively, in transgender male adolescents, GnRH analog treatment can be discontinued once an adult dose of testosterone has been reached and the individual is well virilized. If uterine bleeding occurs, a progestin can be added. However, the combined use of a GnRH analog (for ovarian suppression) and testosterone may enable phenotypic transition with a lower dose of testosterone in comparison with testosterone alone. If there is a wish or need to discontinue GnRH analog treatment in transgender female adolescents, they may be treated with an antiandrogen that directly suppresses androgen synthesis or action (see section 3.0 “Hormonal Therapy for Transgender Adults”).</p>                    <h3 scrollto-destination=\"99603358\" id=\"99603358\" data-legacy-id=\"s38\">Values and preferences</h3>\n<p>The recommendation to initiate pubertal induction only when the individual has sufficient mental capacity (roughly age 16 years) to give informed consent for this partly irreversible treatment places a higher value on the ability of the adolescent to fully understand and oversee the partially irreversible consequences of sex hormone treatment and to give informed consent. It places a lower value on the possible negative effects of delayed puberty. We may not currently have the means to weigh adequately the potential benefits of waiting until around age 16 years to initiate sex hormones vs the potential risks/harm to BMD and the sense of social isolation from having the timing of puberty be so out of sync with peers (<span id=\"jumplink-B128\"></span>128).</p>                    <h3 scrollto-destination=\"99603360\" id=\"99603360\" data-legacy-id=\"s39\">Remarks</h3>\n<p>Before starting sex hormone treatment, effects on fertility and options for fertility preservation should be discussed. Adult height may be a concern in transgender adolescents. In a transgender female adolescent, clinicians may consider higher doses of estrogen or a more rapid tempo of dose escalation during pubertal induction. There are no established treatments yet to augment adult height in a transgender male adolescent with open epiphyses during pubertal induction. It is not uncommon for transgender adolescents to present for clinical services after having completed or nearly completed puberty. In such cases, induction of puberty with sex hormones can be done more rapidly (see <span id=\"jumplink-T8\"></span>Table 8). Additionally, an adult dose of testosterone in transgender male adolescents may suffice to suppress the gonadal axis without the need to use a separate agent. At the appropriate time, the multidisciplinary team should adequately prepare the adolescent for transition to adult care.</p>                    <h2 scrollto-destination=\"99603362\" id=\"99603362\" data-legacy-id=\"s40\">3.0 Hormonal Therapy for Transgender Adults</h2>\n<p>The two major goals of hormonal therapy are (1) to reduce endogenous sex hormone levels, and thus reduce the secondary sex characteristics of the individual’s designated gender, and (2) to replace endogenous sex hormone levels consistent with the individual’s gender identity by using the principles of hormone replacement treatment of hypogonadal patients. The timing of these two goals and the age at which to begin treatment with the sex hormones of the chosen gender is codetermined in collaboration with both the person pursuing transition and the health care providers. The treatment team should include a medical provider knowledgeable in transgender hormone therapy, an MHP knowledgeable in GD/gender incongruence and the mental health concerns of transition, and a primary care provider able to provide care appropriate for transgender individuals. The physical changes induced by this sex hormone transition are usually accompanied by an improvement in mental well-being (<span id=\"jumplink-B129\"></span>129, <span id=\"jumplink-B130\"></span>130).</p><ul><li><p>3.1. We recommend that clinicians confirm the diagnostic criteria of GD/gender incongruence and the criteria for the endocrine phase of gender transition before beginning treatment. (1 |⊕⊕⊕○)</p></li><li><p>3.2. We recommend that clinicians evaluate and address medical conditions that can be exacerbated by hormone depletion and treatment with sex hormones of the affirmed gender before beginning treatment (<span id=\"jumplink-T10\"></span>Table 10). (1 |⊕⊕⊕○)<span id=\"T10\"></span></p><div content-id=\"T10\"><div id=\"T10\" data-id=\"T10\"><p><span>Table 10.</span></p><p>Medical Risks Associated With Sex Hormone Therapy</p> </div><div><table><tbody><tr><td>Transgender female: estrogen&nbsp;</td></tr><tr><td> Very high risk of adverse outcomes:&nbsp;</td></tr><tr><td>  •Thromboembolic disease&nbsp;</td></tr><tr><td> Moderate risk of adverse outcomes:&nbsp;</td></tr><tr><td>  •Macroprolactinoma&nbsp;</td></tr><tr><td>  •Breast cancer&nbsp;</td></tr><tr><td>  •Coronary artery disease&nbsp;</td></tr><tr><td>  •Cerebrovascular disease&nbsp;</td></tr><tr><td>  •Cholelithiasis&nbsp;</td></tr><tr><td>  •Hypertriglyceridemia&nbsp;</td></tr><tr><td>&nbsp;</td></tr><tr><td>Transgender male: testosterone&nbsp;</td></tr><tr><td> Very high risk of adverse outcomes:&nbsp;</td></tr><tr><td>  •Erythrocytosis (hematocrit &gt; 50%)&nbsp;</td></tr><tr><td> Moderate risk of adverse outcomes:&nbsp;</td></tr><tr><td>  •Severe liver dysfunction (transaminases &gt; threefold upper limit of normal)&nbsp;</td></tr><tr><td>  •Coronary artery disease&nbsp;</td></tr><tr><td>  •Cerebrovascular disease&nbsp;</td></tr><tr><td>  •Hypertension&nbsp;</td></tr><tr><td>  •Breast or uterine cancer&nbsp;</td></tr></tbody></table></div><div><table><tbody><tr><td>Transgender female: estrogen&nbsp;</td></tr><tr><td> Very high risk of adverse outcomes:&nbsp;</td></tr><tr><td>  •Thromboembolic disease&nbsp;</td></tr><tr><td> Moderate risk of adverse outcomes:&nbsp;</td></tr><tr><td>  •Macroprolactinoma&nbsp;</td></tr><tr><td>  •Breast cancer&nbsp;</td></tr><tr><td>  •Coronary artery disease&nbsp;</td></tr><tr><td>  •Cerebrovascular disease&nbsp;</td></tr><tr><td>  •Cholelithiasis&nbsp;</td></tr><tr><td>  •Hypertriglyceridemia&nbsp;</td></tr><tr><td>&nbsp;</td></tr><tr><td>Transgender male: testosterone&nbsp;</td></tr><tr><td> Very high risk of adverse outcomes:&nbsp;</td></tr><tr><td>  •Erythrocytosis (hematocrit &gt; 50%)&nbsp;</td></tr><tr><td> Moderate risk of adverse outcomes:&nbsp;</td></tr><tr><td>  •Severe liver dysfunction (transaminases &gt; threefold upper limit of normal)&nbsp;</td></tr><tr><td>  •Coronary artery disease&nbsp;</td></tr><tr><td>  •Cerebrovascular disease&nbsp;</td></tr><tr><td>  •Hypertension&nbsp;</td></tr><tr><td>  •Breast or uterine cancer&nbsp;</td></tr></tbody></table></div></div><div><div id=\"T10\" data-id=\"T10\"><p><span>Table 10.</span></p><p>Medical Risks Associated With Sex Hormone Therapy</p> </div><div><table><tbody><tr><td>Transgender female: estrogen&nbsp;</td></tr><tr><td> Very high risk of adverse outcomes:&nbsp;</td></tr><tr><td>  •Thromboembolic disease&nbsp;</td></tr><tr><td> Moderate risk of adverse outcomes:&nbsp;</td></tr><tr><td>  •Macroprolactinoma&nbsp;</td></tr><tr><td>  •Breast cancer&nbsp;</td></tr><tr><td>  •Coronary artery disease&nbsp;</td></tr><tr><td>  •Cerebrovascular disease&nbsp;</td></tr><tr><td>  •Cholelithiasis&nbsp;</td></tr><tr><td>  •Hypertriglyceridemia&nbsp;</td></tr><tr><td>&nbsp;</td></tr><tr><td>Transgender male: testosterone&nbsp;</td></tr><tr><td> Very high risk of adverse outcomes:&nbsp;</td></tr><tr><td>  •Erythrocytosis (hematocrit &gt; 50%)&nbsp;</td></tr><tr><td> Moderate risk of adverse outcomes:&nbsp;</td></tr><tr><td>  •Severe liver dysfunction (transaminases &gt; threefold upper limit of normal)&nbsp;</td></tr><tr><td>  •Coronary artery disease&nbsp;</td></tr><tr><td>  •Cerebrovascular disease&nbsp;</td></tr><tr><td>  •Hypertension&nbsp;</td></tr><tr><td>  •Breast or uterine cancer&nbsp;</td></tr></tbody></table></div><div><table><tbody><tr><td>Transgender female: estrogen&nbsp;</td></tr><tr><td> Very high risk of adverse outcomes:&nbsp;</td></tr><tr><td>  •Thromboembolic disease&nbsp;</td></tr><tr><td> Moderate risk of adverse outcomes:&nbsp;</td></tr><tr><td>  •Macroprolactinoma&nbsp;</td></tr><tr><td>  •Breast cancer&nbsp;</td></tr><tr><td>  •Coronary artery disease&nbsp;</td></tr><tr><td>  •Cerebrovascular disease&nbsp;</td></tr><tr><td>  •Cholelithiasis&nbsp;</td></tr><tr><td>  •Hypertriglyceridemia&nbsp;</td></tr><tr><td>&nbsp;</td></tr><tr><td>Transgender male: testosterone&nbsp;</td></tr><tr><td> Very high risk of adverse outcomes:&nbsp;</td></tr><tr><td>  •Erythrocytosis (hematocrit &gt; 50%)&nbsp;</td></tr><tr><td> Moderate risk of adverse outcomes:&nbsp;</td></tr><tr><td>  •Severe liver dysfunction (transaminases &gt; threefold upper limit of normal)&nbsp;</td></tr><tr><td>  •Coronary artery disease&nbsp;</td></tr><tr><td>  •Cerebrovascular disease&nbsp;</td></tr><tr><td>  •Hypertension&nbsp;</td></tr><tr><td>  •Breast or uterine cancer&nbsp;</td></tr></tbody></table></div></div></li><li><p>3.3. We suggest that clinicians measure hormone levels during treatment to ensure that endogenous sex steroids are suppressed and administered sex steroids are maintained in the normal physiologic range for the affirmed gender. (2 |⊕⊕○○)</p></li></ul>                    <h3 scrollto-destination=\"99603365\" id=\"99603365\" data-legacy-id=\"s41\">Evidence</h3>\n<p>It is the responsibility of the treating clinician to confirm that the person fulfills criteria for treatment. The treating clinician should become familiar with the terms and criteria presented in <span id=\"jumplink-T1 T2 T3 T4 T5\"></span>Tables 1–5 and take a thorough history from the patient in collaboration with the other members of the treatment team. The treating clinician must ensure that the desire for transition is appropriate; the consequences, risks, and benefits of treatment are well understood; and the desire for transition persists. They also need to discuss fertility preservation options (see recommendation 1.3) (<span id=\"jumplink-B67\"></span>67, <span id=\"jumplink-B68\"></span>68).</p>                    <h4 scrollto-destination=\"99603367\" id=\"99603367\" data-legacy-id=\"s42\">Transgender males</h4>\n<p>Clinical studies have demonstrated the efficacy of several different androgen preparations to induce masculinization in transgender males (Appendix A) (<span id=\"jumplink-B113\"></span>113, <span id=\"jumplink-B114\"></span>114, <span id=\"jumplink-B131\"></span>131–<span id=\"jumplink-B134\"></span>134). Regimens to change secondary sex characteristics follow the general principle of hormone replacement treatment of male hypogonadism (<span id=\"jumplink-B135\"></span>135). Clinicians can use either parenteral or transdermal preparations to achieve testosterone values in the normal male range (this is dependent on the specific assay, but is typically 320 to 1000 ng/dL) (<span id=\"jumplink-T11\"></span>Table 11) (<span id=\"jumplink-B136\"></span>136). Sustained supraphysiologic levels of testosterone increase the risk of adverse reactions (see section 4.0 “Adverse Outcome Prevention and Long-Term Care”) and should be avoided.</p>                    <div content-id=\"T11\"><div id=\"T11\" data-id=\"T11\"><p><span>Table 11.</span></p><p>Hormone Regimens in Transgender Persons</p> </div><div><table><tbody><tr><td>Transgender females<span id=\"jumplink-t11n1\"></span><span><em><sup>a</sup></em></span>&nbsp;</td><td>&nbsp;</td></tr><tr><td> Estrogen&nbsp;</td><td>&nbsp;</td></tr><tr><td>  Oral&nbsp;</td><td>&nbsp;</td></tr><tr><td>   Estradiol&nbsp;</td><td>2.0–6.0 mg/d&nbsp;</td></tr><tr><td>  Transdermal&nbsp;</td><td>&nbsp;</td></tr><tr><td>   Estradiol transdermal patch&nbsp;</td><td>0.025–0.2 mg/d&nbsp;</td></tr><tr><td>   (New patch placed every 3–5 d)&nbsp;</td><td>&nbsp;</td></tr><tr><td>  Parenteral&nbsp;</td><td>&nbsp;</td></tr><tr><td>   Estradiol valerate or cypionate&nbsp;</td><td>5–30 mg IM every 2 wk&nbsp;</td></tr><tr><td>&nbsp;</td><td>2–10 mg IM every week&nbsp;</td></tr><tr><td> Anti-androgens&nbsp;</td><td>&nbsp;</td></tr><tr><td>  Spironolactone&nbsp;</td><td>100–300 mg/d&nbsp;</td></tr><tr><td>  Cyproterone acetate<span id=\"jumplink-t11n2\"></span><span><em><sup>b</sup></em></span>&nbsp;</td><td>25–50 mg/d&nbsp;</td></tr><tr><td rowspan=\"2\"> GnRH agonist&nbsp;</td><td>3.75 mg SQ (SC) monthly&nbsp;</td></tr><tr><td>11.25 mg SQ (SC) 3-monthly&nbsp;</td></tr><tr><td>Transgender males&nbsp;</td><td>&nbsp;</td></tr><tr><td> Testosterone&nbsp;</td><td>&nbsp;</td></tr><tr><td>  Parenteral testosterone&nbsp;</td><td>&nbsp;</td></tr><tr><td>   Testosterone enanthate or cypionate&nbsp;</td><td>100–200 mg SQ (IM) every 2 wk or SQ (SC) 50% per week&nbsp;</td></tr><tr><td>   Testosterone undecanoate<span id=\"jumplink-t11n3\"></span><span><em><sup>c</sup></em></span>&nbsp;</td><td>1000 mg every 12 wk&nbsp;</td></tr><tr><td>  Transdermal testosterone&nbsp;</td><td>&nbsp;</td></tr><tr><td>   Testosterone gel 1.6%<span id=\"jumplink-t11n4\"></span><span><em><sup>d</sup></em></span>&nbsp;</td><td>50–100 mg/d&nbsp;</td></tr><tr><td>   Testosterone transdermal patch&nbsp;</td><td>2.5–7.5 mg/d&nbsp;</td></tr></tbody></table></div><div><table><tbody><tr><td>Transgender females<span id=\"jumplink-t11n1\"></span><span><em><sup>a</sup></em></span>&nbsp;</td><td>&nbsp;</td></tr><tr><td> Estrogen&nbsp;</td><td>&nbsp;</td></tr><tr><td>  Oral&nbsp;</td><td>&nbsp;</td></tr><tr><td>   Estradiol&nbsp;</td><td>2.0–6.0 mg/d&nbsp;</td></tr><tr><td>  Transdermal&nbsp;</td><td>&nbsp;</td></tr><tr><td>   Estradiol transdermal patch&nbsp;</td><td>0.025–0.2 mg/d&nbsp;</td></tr><tr><td>   (New patch placed every 3–5 d)&nbsp;</td><td>&nbsp;</td></tr><tr><td>  Parenteral&nbsp;</td><td>&nbsp;</td></tr><tr><td>   Estradiol valerate or cypionate&nbsp;</td><td>5–30 mg IM every 2 wk&nbsp;</td></tr><tr><td>&nbsp;</td><td>2–10 mg IM every week&nbsp;</td></tr><tr><td> Anti-androgens&nbsp;</td><td>&nbsp;</td></tr><tr><td>  Spironolactone&nbsp;</td><td>100–300 mg/d&nbsp;</td></tr><tr><td>  Cyproterone acetate<span id=\"jumplink-t11n2\"></span><span><em><sup>b</sup></em></span>&nbsp;</td><td>25–50 mg/d&nbsp;</td></tr><tr><td rowspan=\"2\"> GnRH agonist&nbsp;</td><td>3.75 mg SQ (SC) monthly&nbsp;</td></tr><tr><td>11.25 mg SQ (SC) 3-monthly&nbsp;</td></tr><tr><td>Transgender males&nbsp;</td><td>&nbsp;</td></tr><tr><td> Testosterone&nbsp;</td><td>&nbsp;</td></tr><tr><td>  Parenteral testosterone&nbsp;</td><td>&nbsp;</td></tr><tr><td>   Testosterone enanthate or cypionate&nbsp;</td><td>100–200 mg SQ (IM) every 2 wk or SQ (SC) 50% per week&nbsp;</td></tr><tr><td>   Testosterone undecanoate<span id=\"jumplink-t11n3\"></span><span><em><sup>c</sup></em></span>&nbsp;</td><td>1000 mg every 12 wk&nbsp;</td></tr><tr><td>  Transdermal testosterone&nbsp;</td><td>&nbsp;</td></tr><tr><td>   Testosterone gel 1.6%<span id=\"jumplink-t11n4\"></span><span><em><sup>d</sup></em></span>&nbsp;</td><td>50–100 mg/d&nbsp;</td></tr><tr><td>   Testosterone transdermal patch&nbsp;</td><td>2.5–7.5 mg/d&nbsp;</td></tr></tbody></table></div><div><p><span><p>Abbreviations: IM, intramuscularly; SQ, sequentially; SC, subcutaneously.</p></span></p><p><span><span><span rel=\"nofollow\" data-fn-id=\"t11n1\"><sup>a</sup></span></span><p>Estrogens used with or without antiandrogens or GnRH agonist.</p></span></p><p><span><span><span rel=\"nofollow\" data-fn-id=\"t11n2\"><sup>b</sup></span></span><p>Not available in the United States.</p></span></p><p><span><span><span rel=\"nofollow\" data-fn-id=\"t11n3\"><sup>c</sup></span></span><p>One thousand milligrams initially followed by an injection at 6 wk then at 12-wk intervals.</p></span></p><p><span><span><span rel=\"nofollow\" data-fn-id=\"t11n4\"><sup>d</sup></span></span><p>Avoid cutaneous transfer to other individuals.</p></span></p></div></div><div><div id=\"T11\" data-id=\"T11\"><p><span>Table 11.</span></p><p>Hormone Regimens in Transgender Persons</p> </div><div><table><tbody><tr><td>Transgender females<span id=\"jumplink-t11n1\"></span><span><em><sup>a</sup></em></span>&nbsp;</td><td>&nbsp;</td></tr><tr><td> Estrogen&nbsp;</td><td>&nbsp;</td></tr><tr><td>  Oral&nbsp;</td><td>&nbsp;</td></tr><tr><td>   Estradiol&nbsp;</td><td>2.0–6.0 mg/d&nbsp;</td></tr><tr><td>  Transdermal&nbsp;</td><td>&nbsp;</td></tr><tr><td>   Estradiol transdermal patch&nbsp;</td><td>0.025–0.2 mg/d&nbsp;</td></tr><tr><td>   (New patch placed every 3–5 d)&nbsp;</td><td>&nbsp;</td></tr><tr><td>  Parenteral&nbsp;</td><td>&nbsp;</td></tr><tr><td>   Estradiol valerate or cypionate&nbsp;</td><td>5–30 mg IM every 2 wk&nbsp;</td></tr><tr><td>&nbsp;</td><td>2–10 mg IM every week&nbsp;</td></tr><tr><td> Anti-androgens&nbsp;</td><td>&nbsp;</td></tr><tr><td>  Spironolactone&nbsp;</td><td>100–300 mg/d&nbsp;</td></tr><tr><td>  Cyproterone acetate<span id=\"jumplink-t11n2\"></span><span><em><sup>b</sup></em></span>&nbsp;</td><td>25–50 mg/d&nbsp;</td></tr><tr><td rowspan=\"2\"> GnRH agonist&nbsp;</td><td>3.75 mg SQ (SC) monthly&nbsp;</td></tr><tr><td>11.25 mg SQ (SC) 3-monthly&nbsp;</td></tr><tr><td>Transgender males&nbsp;</td><td>&nbsp;</td></tr><tr><td> Testosterone&nbsp;</td><td>&nbsp;</td></tr><tr><td>  Parenteral testosterone&nbsp;</td><td>&nbsp;</td></tr><tr><td>   Testosterone enanthate or cypionate&nbsp;</td><td>100–200 mg SQ (IM) every 2 wk or SQ (SC) 50% per week&nbsp;</td></tr><tr><td>   Testosterone undecanoate<span id=\"jumplink-t11n3\"></span><span><em><sup>c</sup></em></span>&nbsp;</td><td>1000 mg every 12 wk&nbsp;</td></tr><tr><td>  Transdermal testosterone&nbsp;</td><td>&nbsp;</td></tr><tr><td>   Testosterone gel 1.6%<span id=\"jumplink-t11n4\"></span><span><em><sup>d</sup></em></span>&nbsp;</td><td>50–100 mg/d&nbsp;</td></tr><tr><td>   Testosterone transdermal patch&nbsp;</td><td>2.5–7.5 mg/d&nbsp;</td></tr></tbody></table></div><div><table><tbody><tr><td>Transgender females<span id=\"jumplink-t11n1\"></span><span><em><sup>a</sup></em></span>&nbsp;</td><td>&nbsp;</td></tr><tr><td> Estrogen&nbsp;</td><td>&nbsp;</td></tr><tr><td>  Oral&nbsp;</td><td>&nbsp;</td></tr><tr><td>   Estradiol&nbsp;</td><td>2.0–6.0 mg/d&nbsp;</td></tr><tr><td>  Transdermal&nbsp;</td><td>&nbsp;</td></tr><tr><td>   Estradiol transdermal patch&nbsp;</td><td>0.025–0.2 mg/d&nbsp;</td></tr><tr><td>   (New patch placed every 3–5 d)&nbsp;</td><td>&nbsp;</td></tr><tr><td>  Parenteral&nbsp;</td><td>&nbsp;</td></tr><tr><td>   Estradiol valerate or cypionate&nbsp;</td><td>5–30 mg IM every 2 wk&nbsp;</td></tr><tr><td>&nbsp;</td><td>2–10 mg IM every week&nbsp;</td></tr><tr><td> Anti-androgens&nbsp;</td><td>&nbsp;</td></tr><tr><td>  Spironolactone&nbsp;</td><td>100–300 mg/d&nbsp;</td></tr><tr><td>  Cyproterone acetate<span id=\"jumplink-t11n2\"></span><span><em><sup>b</sup></em></span>&nbsp;</td><td>25–50 mg/d&nbsp;</td></tr><tr><td rowspan=\"2\"> GnRH agonist&nbsp;</td><td>3.75 mg SQ (SC) monthly&nbsp;</td></tr><tr><td>11.25 mg SQ (SC) 3-monthly&nbsp;</td></tr><tr><td>Transgender males&nbsp;</td><td>&nbsp;</td></tr><tr><td> Testosterone&nbsp;</td><td>&nbsp;</td></tr><tr><td>  Parenteral testosterone&nbsp;</td><td>&nbsp;</td></tr><tr><td>   Testosterone enanthate or cypionate&nbsp;</td><td>100–200 mg SQ (IM) every 2 wk or SQ (SC) 50% per week&nbsp;</td></tr><tr><td>   Testosterone undecanoate<span id=\"jumplink-t11n3\"></span><span><em><sup>c</sup></em></span>&nbsp;</td><td>1000 mg every 12 wk&nbsp;</td></tr><tr><td>  Transdermal testosterone&nbsp;</td><td>&nbsp;</td></tr><tr><td>   Testosterone gel 1.6%<span id=\"jumplink-t11n4\"></span><span><em><sup>d</sup></em></span>&nbsp;</td><td>50–100 mg/d&nbsp;</td></tr><tr><td>   Testosterone transdermal patch&nbsp;</td><td>2.5–7.5 mg/d&nbsp;</td></tr></tbody></table></div><div><p><span><p>Abbreviations: IM, intramuscularly; SQ, sequentially; SC, subcutaneously.</p></span></p><p><span><span><span rel=\"nofollow\" data-fn-id=\"t11n1\"><sup>a</sup></span></span><p>Estrogens used with or without antiandrogens or GnRH agonist.</p></span></p><p><span><span><span rel=\"nofollow\" data-fn-id=\"t11n2\"><sup>b</sup></span></span><p>Not available in the United States.</p></span></p><p><span><span><span rel=\"nofollow\" data-fn-id=\"t11n3\"><sup>c</sup></span></span><p>One thousand milligrams initially followed by an injection at 6 wk then at 12-wk intervals.</p></span></p><p><span><span><span rel=\"nofollow\" data-fn-id=\"t11n4\"><sup>d</sup></span></span><p>Avoid cutaneous transfer to other individuals.</p></span></p></div></div><p>Similar to androgen therapy in hypogonadal men, testosterone treatment in transgender males results in increased muscle mass and decreased fat mass, increased facial hair and acne, male pattern baldness in those genetically predisposed, and increased sexual desire (<span id=\"jumplink-B137\"></span>137).</p><p>In transgender males, testosterone will result in clitoromegaly, temporary or permanent decreased fertility, deepening of the voice, cessation of menses (usually), and a significant increase in body hair, particularly on the face, chest, and abdomen. Cessation of menses may occur within a few months with testosterone treatment alone, although high doses of testosterone may be required. If uterine bleeding continues, clinicians may consider the addition of a progestational agent or endometrial ablation (<span id=\"jumplink-B138\"></span>138). Clinicians may also administer GnRH analogs or depot medroxyprogesterone to stop menses prior to testosterone treatment.</p>                    <h4 scrollto-destination=\"99603372\" id=\"99603372\" data-legacy-id=\"s43\">Transgender females</h4>\n<p>The hormone regimen for transgender females is more complex than the transgender male regimen (Appendix B). Treatment with physiologic doses of estrogen alone is insufficient to suppress testosterone levels into the normal range for females (<span id=\"jumplink-B139\"></span>139). Most published clinical studies report the need for adjunctive therapy to achieve testosterone levels in the female range (<span id=\"jumplink-B21\"></span>21, <span id=\"jumplink-B113\"></span>113, <span id=\"jumplink-B114\"></span>114, <span id=\"jumplink-B132\"></span>132–<span id=\"jumplink-B134\"></span>134, <span id=\"jumplink-B139\"></span>139, <span id=\"jumplink-B140\"></span>140).</p><p>Multiple adjunctive medications are available, such as progestins with antiandrogen activity and GnRH agonists (<span id=\"jumplink-B141\"></span>141). Spironolactone works by directly blocking androgens during their interaction with the androgen receptor (<span id=\"jumplink-B114\"></span>114, <span id=\"jumplink-B133\"></span>133, <span id=\"jumplink-B142\"></span>142). It may also have estrogenic activity (<span id=\"jumplink-B143\"></span>143). Cyproterone acetate, a progestational compound with antiandrogenic properties (<span id=\"jumplink-B113\"></span>113, <span id=\"jumplink-B132\"></span>132, <span id=\"jumplink-B144\"></span>144), is widely used in Europe. 5<em>α</em>-Reductase inhibitors do not reduce testosterone levels and have adverse effects (<span id=\"jumplink-B145\"></span>145).</p><p>Dittrich <em>et al.</em> (<span id=\"jumplink-B141\"></span>141) reported that monthly doses of the GnRH agonist goserelin acetate in combination with estrogen were effective in reducing testosterone levels with a low incidence of adverse reactions in 60 transgender females. Leuprolide and transdermal estrogen were as effective as cyproterone and transdermal estrogen in a comparative retrospective study (<span id=\"jumplink-B146\"></span>146).</p><p>Patients can take estrogen as oral conjugated estrogens, oral 17<em>β</em>-estradiol, or transdermal 17<em>β</em>-estradiol. Among estrogen options, the increased risk of thromboembolic events associated with estrogens in general seems most concerning with ethinyl estradiol specifically (<span id=\"jumplink-B134\"></span>134, <span id=\"jumplink-B140\"></span>140, <span id=\"jumplink-B141\"></span>141), which is why we specifically suggest that it not be used in any transgender treatment plan. Data distinguishing among other estrogen options are less well established although there is some thought that oral routes of administration are more thrombogenic due to the “first pass effect” than are transdermal and parenteral routes, and that the risk of thromboembolic events is dose-dependent. Injectable estrogen and sublingual estrogen may benefit from avoiding the first pass effect, but they can result in more rapid peaks with greater overall periodicity and thus are more difficult to monitor (<span id=\"jumplink-B147\"></span>147, <span id=\"jumplink-B148\"></span>148). However, there are no data demonstrating that increased periodicity is harmful otherwise.</p><p>Clinicians can use serum estradiol levels to monitor oral, transdermal, and intramuscular estradiol. Blood tests cannot monitor conjugated estrogens or synthetic estrogen use. Clinicians should measure serum estradiol and serum testosterone and maintain them at the level for premenopausal females (100 to 200 pg/mL and &lt;50 ng/dL, respectively). The transdermal preparations and injectable estradiol cypionate or valerate preparations may confer an advantage in older transgender females who may be at higher risk for thromboembolic disease (<span id=\"jumplink-B149\"></span>149).</p>                    <h3 scrollto-destination=\"99603378\" id=\"99603378\" data-legacy-id=\"s44\">Values</h3>\n<p>Our recommendation to maintain levels of gender-affirming hormones in the normal adult range places a high value on the avoidance of the long-term complications of pharmacologic doses. Those patients receiving endocrine treatment who have relative contraindications to hormones should have an in-depth discussion with their physician to balance the risks and benefits of therapy.</p>                    <h3 scrollto-destination=\"99603380\" id=\"99603380\" data-legacy-id=\"s45\">Remarks</h3>\n<p>Clinicians should inform all endocrine-treated individuals of all risks and benefits of gender-affirming hormones prior to initiating therapy. Clinicians should strongly encourage tobacco use cessation in transgender females to avoid increased risk of VTE and cardiovascular complications. We strongly discourage the unsupervised use of hormone therapy (<span id=\"jumplink-B150\"></span>150).</p><p>Not all individuals with GD/gender incongruence seek treatment as described (<em>e.g.</em>, male-to-eunuchs and individuals seeking partial transition). Tailoring current protocols to the individual may be done within the context of accepted safety guidelines using a multidisciplinary approach including mental health. No evidence-based protocols are available for these groups (<span id=\"jumplink-B151\"></span>151). We need prospective studies to better understand treatment options for these persons.</p><ul><li><p>3.4. We suggest that endocrinologists provide education to transgender individuals undergoing treatment about the onset and time course of physical changes induced by sex hormone treatment. (2 |⊕○○○)</p></li></ul>                    <h3 scrollto-destination=\"99603384\" id=\"99603384\" data-legacy-id=\"s46\">Evidence</h3>\n                    <h4 scrollto-destination=\"99603385\" id=\"99603385\" data-legacy-id=\"s47\">Transgender males</h4>\n<p>Physical changes that are expected to occur during the first 1 to 6 months of testosterone therapy include cessation of menses, increased sexual desire, increased facial and body hair, increased oiliness of skin, increased muscle, and redistribution of fat mass. Changes that occur within the first year of testosterone therapy include deepening of the voice (<span id=\"jumplink-B152\"></span>152, <span id=\"jumplink-B153\"></span>153), clitoromegaly, and male pattern hair loss (in some cases) (<span id=\"jumplink-B114\"></span>114, <span id=\"jumplink-B144\"></span>144, <span id=\"jumplink-B154\"></span>154, <span id=\"jumplink-B155\"></span>155) (<span id=\"jumplink-T12\"></span>Table 12).</p>                    <div content-id=\"T12\"><div id=\"T12\" data-id=\"T12\"><p><span>Table 12.</span></p><p>Masculinizing Effects in Transgender Males</p> </div><div><table><thead><tr><th>Effect</th><th>Onset</th><th>Maximum</th></tr></thead><tbody><tr><td>Skin oiliness/acne&nbsp;</td><td>1–6 mo&nbsp;</td><td>1–2 y&nbsp;</td></tr><tr><td>Facial/body hair growth&nbsp;</td><td>6–12 mo&nbsp;</td><td>4–5 y&nbsp;</td></tr><tr><td>Scalp hair loss&nbsp;</td><td>6–12 mo&nbsp;</td><td>—<span id=\"jumplink-t12n1\"></span><span><em><sup>a</sup></em></span>&nbsp;</td></tr><tr><td>Increased muscle mass/strength&nbsp;</td><td>6–12 mo&nbsp;</td><td>2–5 y&nbsp;</td></tr><tr><td>Fat redistribution&nbsp;</td><td>1–6 mo&nbsp;</td><td>2–5 y&nbsp;</td></tr><tr><td>Cessation of menses&nbsp;</td><td>1–6 mo&nbsp;</td><td>—<span id=\"jumplink-t12n2\"></span><span><em><sup>b</sup></em></span>&nbsp;</td></tr><tr><td>Clitoral enlargement&nbsp;</td><td>1–6 mo&nbsp;</td><td>1–2 y&nbsp;</td></tr><tr><td>Vaginal atrophy&nbsp;</td><td>1–6 mo&nbsp;</td><td>1–2 y&nbsp;</td></tr><tr><td>Deepening of voice&nbsp;</td><td>6–12 mo&nbsp;</td><td>1–2 y&nbsp;</td></tr></tbody></table></div><div><table><thead><tr><th>Effect</th><th>Onset</th><th>Maximum</th></tr></thead><tbody><tr><td>Skin oiliness/acne&nbsp;</td><td>1–6 mo&nbsp;</td><td>1–2 y&nbsp;</td></tr><tr><td>Facial/body hair growth&nbsp;</td><td>6–12 mo&nbsp;</td><td>4–5 y&nbsp;</td></tr><tr><td>Scalp hair loss&nbsp;</td><td>6–12 mo&nbsp;</td><td>—<span id=\"jumplink-t12n1\"></span><span><em><sup>a</sup></em></span>&nbsp;</td></tr><tr><td>Increased muscle mass/strength&nbsp;</td><td>6–12 mo&nbsp;</td><td>2–5 y&nbsp;</td></tr><tr><td>Fat redistribution&nbsp;</td><td>1–6 mo&nbsp;</td><td>2–5 y&nbsp;</td></tr><tr><td>Cessation of menses&nbsp;</td><td>1–6 mo&nbsp;</td><td>—<span id=\"jumplink-t12n2\"></span><span><em><sup>b</sup></em></span>&nbsp;</td></tr><tr><td>Clitoral enlargement&nbsp;</td><td>1–6 mo&nbsp;</td><td>1–2 y&nbsp;</td></tr><tr><td>Vaginal atrophy&nbsp;</td><td>1–6 mo&nbsp;</td><td>1–2 y&nbsp;</td></tr><tr><td>Deepening of voice&nbsp;</td><td>6–12 mo&nbsp;</td><td>1–2 y&nbsp;</td></tr></tbody></table></div><div><p><span><p>Estimates represent clinical observations: Toorians <em>et al.</em> (<span id=\"jumplink-B149\"></span>149), Asscheman <em>et al.</em> (<span id=\"jumplink-B156\"></span>156), Gooren <em>et al.</em> (<span id=\"jumplink-B157\"></span>157), Wierckx <em>et al.</em> (<span id=\"jumplink-B158\"></span>158).</p></span></p><p><span><span><span rel=\"nofollow\" data-fn-id=\"t12n1\"><sup>a</sup></span></span><p>Prevention and treatment as recommended for biological men.</p></span></p><p><span><span><span rel=\"nofollow\" data-fn-id=\"t12n2\"><sup>b</sup></span></span><p>Menorrhagia requires diagnosis and treatment by a gynecologist.</p></span></p></div></div><div><div id=\"T12\" data-id=\"T12\"><p><span>Table 12.</span></p><p>Masculinizing Effects in Transgender Males</p> </div><div><table><thead><tr><th>Effect</th><th>Onset</th><th>Maximum</th></tr></thead><tbody><tr><td>Skin oiliness/acne&nbsp;</td><td>1–6 mo&nbsp;</td><td>1–2 y&nbsp;</td></tr><tr><td>Facial/body hair growth&nbsp;</td><td>6–12 mo&nbsp;</td><td>4–5 y&nbsp;</td></tr><tr><td>Scalp hair loss&nbsp;</td><td>6–12 mo&nbsp;</td><td>—<span id=\"jumplink-t12n1\"></span><span><em><sup>a</sup></em></span>&nbsp;</td></tr><tr><td>Increased muscle mass/strength&nbsp;</td><td>6–12 mo&nbsp;</td><td>2–5 y&nbsp;</td></tr><tr><td>Fat redistribution&nbsp;</td><td>1–6 mo&nbsp;</td><td>2–5 y&nbsp;</td></tr><tr><td>Cessation of menses&nbsp;</td><td>1–6 mo&nbsp;</td><td>—<span id=\"jumplink-t12n2\"></span><span><em><sup>b</sup></em></span>&nbsp;</td></tr><tr><td>Clitoral enlargement&nbsp;</td><td>1–6 mo&nbsp;</td><td>1–2 y&nbsp;</td></tr><tr><td>Vaginal atrophy&nbsp;</td><td>1–6 mo&nbsp;</td><td>1–2 y&nbsp;</td></tr><tr><td>Deepening of voice&nbsp;</td><td>6–12 mo&nbsp;</td><td>1–2 y&nbsp;</td></tr></tbody></table></div><div><table><thead><tr><th>Effect</th><th>Onset</th><th>Maximum</th></tr></thead><tbody><tr><td>Skin oiliness/acne&nbsp;</td><td>1–6 mo&nbsp;</td><td>1–2 y&nbsp;</td></tr><tr><td>Facial/body hair growth&nbsp;</td><td>6–12 mo&nbsp;</td><td>4–5 y&nbsp;</td></tr><tr><td>Scalp hair loss&nbsp;</td><td>6–12 mo&nbsp;</td><td>—<span id=\"jumplink-t12n1\"></span><span><em><sup>a</sup></em></span>&nbsp;</td></tr><tr><td>Increased muscle mass/strength&nbsp;</td><td>6–12 mo&nbsp;</td><td>2–5 y&nbsp;</td></tr><tr><td>Fat redistribution&nbsp;</td><td>1–6 mo&nbsp;</td><td>2–5 y&nbsp;</td></tr><tr><td>Cessation of menses&nbsp;</td><td>1–6 mo&nbsp;</td><td>—<span id=\"jumplink-t12n2\"></span><span><em><sup>b</sup></em></span>&nbsp;</td></tr><tr><td>Clitoral enlargement&nbsp;</td><td>1–6 mo&nbsp;</td><td>1–2 y&nbsp;</td></tr><tr><td>Vaginal atrophy&nbsp;</td><td>1–6 mo&nbsp;</td><td>1–2 y&nbsp;</td></tr><tr><td>Deepening of voice&nbsp;</td><td>6–12 mo&nbsp;</td><td>1–2 y&nbsp;</td></tr></tbody></table></div><div><p><span><p>Estimates represent clinical observations: Toorians <em>et al.</em> (<span id=\"jumplink-B149\"></span>149), Asscheman <em>et al.</em> (<span id=\"jumplink-B156\"></span>156), Gooren <em>et al.</em> (<span id=\"jumplink-B157\"></span>157), Wierckx <em>et al.</em> (<span id=\"jumplink-B158\"></span>158).</p></span></p><p><span><span><span rel=\"nofollow\" data-fn-id=\"t12n1\"><sup>a</sup></span></span><p>Prevention and treatment as recommended for biological men.</p></span></p><p><span><span><span rel=\"nofollow\" data-fn-id=\"t12n2\"><sup>b</sup></span></span><p>Menorrhagia requires diagnosis and treatment by a gynecologist.</p></span></p></div></div>                    <h4 scrollto-destination=\"99603388\" id=\"99603388\" data-legacy-id=\"s48\">Transgender females</h4>\n<p>Physical changes that may occur in transgender females in the first 3 to 12 months of estrogen and antiandrogen therapy include decreased sexual desire, decreased spontaneous erections, decreased facial and body hair (usually mild), decreased oiliness of skin, increased breast tissue growth, and redistribution of fat mass (<span id=\"jumplink-B114\"></span>114, <span id=\"jumplink-B139\"></span>139, <span id=\"jumplink-B149\"></span>149, <span id=\"jumplink-B154\"></span>154, <span id=\"jumplink-B155\"></span>155, <span id=\"jumplink-B161\"></span>161) (<span id=\"jumplink-T13\"></span>Table 13). Breast development is generally maximal at 2 years after initiating hormones (<span id=\"jumplink-B114\"></span>114, <span id=\"jumplink-B139\"></span>139, <span id=\"jumplink-B149\"></span>149, <span id=\"jumplink-B155\"></span>155). Over a long period of time, the prostate gland and testicles will undergo atrophy.</p>                    <div content-id=\"T13\"><div id=\"T13\" data-id=\"T13\"><p><span>Table 13.</span></p><p>Feminizing Effects in Transgender Females</p> </div><div><table><thead><tr><th>Effect</th><th>Onset</th><th>Maximum</th></tr></thead><tbody><tr><td>Redistribution of body fat&nbsp;</td><td>3–6 mo&nbsp;</td><td>2–3 y&nbsp;</td></tr><tr><td>Decrease in muscle mass and strength&nbsp;</td><td>3–6 mo&nbsp;</td><td>1–2 y&nbsp;</td></tr><tr><td>Softening of skin/decreased oiliness&nbsp;</td><td>3–6 mo&nbsp;</td><td>Unknown&nbsp;</td></tr><tr><td>Decreased sexual desire&nbsp;</td><td>1–3 mo&nbsp;</td><td>3–6 mo&nbsp;</td></tr><tr><td>Decreased spontaneous erections&nbsp;</td><td>1–3 mo&nbsp;</td><td>3–6 mo&nbsp;</td></tr><tr><td>Male sexual dysfunction&nbsp;</td><td>Variable&nbsp;</td><td>Variable&nbsp;</td></tr><tr><td>Breast growth&nbsp;</td><td>3–6 mo&nbsp;</td><td>2–3 y&nbsp;</td></tr><tr><td>Decreased testicular volume&nbsp;</td><td>3–6 mo&nbsp;</td><td>2–3 y&nbsp;</td></tr><tr><td>Decreased sperm production&nbsp;</td><td>Unknown&nbsp;</td><td>&gt;3 y&nbsp;</td></tr><tr><td>Decreased terminal hair growth&nbsp;</td><td>6–12 mo&nbsp;</td><td>&gt;3 y<span id=\"jumplink-t13n1\"></span><span><em><sup>a</sup></em></span>&nbsp;</td></tr><tr><td>Scalp hair&nbsp;</td><td>Variable&nbsp;</td><td>—<span id=\"jumplink-t13n2\"></span><span><em><sup>b</sup></em></span>&nbsp;</td></tr><tr><td>Voice changes&nbsp;</td><td>None&nbsp;</td><td>—<em><sup>c</sup></em>&nbsp;</td></tr></tbody></table></div><div><table><thead><tr><th>Effect</th><th>Onset</th><th>Maximum</th></tr></thead><tbody><tr><td>Redistribution of body fat&nbsp;</td><td>3–6 mo&nbsp;</td><td>2–3 y&nbsp;</td></tr><tr><td>Decrease in muscle mass and strength&nbsp;</td><td>3–6 mo&nbsp;</td><td>1–2 y&nbsp;</td></tr><tr><td>Softening of skin/decreased oiliness&nbsp;</td><td>3–6 mo&nbsp;</td><td>Unknown&nbsp;</td></tr><tr><td>Decreased sexual desire&nbsp;</td><td>1–3 mo&nbsp;</td><td>3–6 mo&nbsp;</td></tr><tr><td>Decreased spontaneous erections&nbsp;</td><td>1–3 mo&nbsp;</td><td>3–6 mo&nbsp;</td></tr><tr><td>Male sexual dysfunction&nbsp;</td><td>Variable&nbsp;</td><td>Variable&nbsp;</td></tr><tr><td>Breast growth&nbsp;</td><td>3–6 mo&nbsp;</td><td>2–3 y&nbsp;</td></tr><tr><td>Decreased testicular volume&nbsp;</td><td>3–6 mo&nbsp;</td><td>2–3 y&nbsp;</td></tr><tr><td>Decreased sperm production&nbsp;</td><td>Unknown&nbsp;</td><td>&gt;3 y&nbsp;</td></tr><tr><td>Decreased terminal hair growth&nbsp;</td><td>6–12 mo&nbsp;</td><td>&gt;3 y<span id=\"jumplink-t13n1\"></span><span><em><sup>a</sup></em></span>&nbsp;</td></tr><tr><td>Scalp hair&nbsp;</td><td>Variable&nbsp;</td><td>—<span id=\"jumplink-t13n2\"></span><span><em><sup>b</sup></em></span>&nbsp;</td></tr><tr><td>Voice changes&nbsp;</td><td>None&nbsp;</td><td>—<em><sup>c</sup></em>&nbsp;</td></tr></tbody></table></div><div><p><span><p>Estimates represent clinical observations: Toorians <em>et al.</em> (<span id=\"jumplink-B149\"></span>149), Asscheman <em>et al.</em> (<span id=\"jumplink-B156\"></span>156), Gooren <em>et al.</em> (<span id=\"jumplink-B157\"></span>157).</p></span></p><p><span><span><span rel=\"nofollow\" data-fn-id=\"t13n1\"><sup>a</sup></span></span><p>Complete removal of male sexual hair requires electrolysis or laser treatment or both.</p></span></p><p><span><span><span rel=\"nofollow\" data-fn-id=\"t13n2\"><sup>b</sup></span></span><p>Familial scalp hair loss may occur if estrogens are stopped.</p></span></p><p><span><span><span rel=\"nofollow\" data-fn-id=\"t13n3\"><sup>c</sup></span></span><p>Treatment by speech pathologists for voice training is most effective.</p></span></p></div></div><div><div id=\"T13\" data-id=\"T13\"><p><span>Table 13.</span></p><p>Feminizing Effects in Transgender Females</p> </div><div><table><thead><tr><th>Effect</th><th>Onset</th><th>Maximum</th></tr></thead><tbody><tr><td>Redistribution of body fat&nbsp;</td><td>3–6 mo&nbsp;</td><td>2–3 y&nbsp;</td></tr><tr><td>Decrease in muscle mass and strength&nbsp;</td><td>3–6 mo&nbsp;</td><td>1–2 y&nbsp;</td></tr><tr><td>Softening of skin/decreased oiliness&nbsp;</td><td>3–6 mo&nbsp;</td><td>Unknown&nbsp;</td></tr><tr><td>Decreased sexual desire&nbsp;</td><td>1–3 mo&nbsp;</td><td>3–6 mo&nbsp;</td></tr><tr><td>Decreased spontaneous erections&nbsp;</td><td>1–3 mo&nbsp;</td><td>3–6 mo&nbsp;</td></tr><tr><td>Male sexual dysfunction&nbsp;</td><td>Variable&nbsp;</td><td>Variable&nbsp;</td></tr><tr><td>Breast growth&nbsp;</td><td>3–6 mo&nbsp;</td><td>2–3 y&nbsp;</td></tr><tr><td>Decreased testicular volume&nbsp;</td><td>3–6 mo&nbsp;</td><td>2–3 y&nbsp;</td></tr><tr><td>Decreased sperm production&nbsp;</td><td>Unknown&nbsp;</td><td>&gt;3 y&nbsp;</td></tr><tr><td>Decreased terminal hair growth&nbsp;</td><td>6–12 mo&nbsp;</td><td>&gt;3 y<span id=\"jumplink-t13n1\"></span><span><em><sup>a</sup></em></span>&nbsp;</td></tr><tr><td>Scalp hair&nbsp;</td><td>Variable&nbsp;</td><td>—<span id=\"jumplink-t13n2\"></span><span><em><sup>b</sup></em></span>&nbsp;</td></tr><tr><td>Voice changes&nbsp;</td><td>None&nbsp;</td><td>—<em><sup>c</sup></em>&nbsp;</td></tr></tbody></table></div><div><table><thead><tr><th>Effect</th><th>Onset</th><th>Maximum</th></tr></thead><tbody><tr><td>Redistribution of body fat&nbsp;</td><td>3–6 mo&nbsp;</td><td>2–3 y&nbsp;</td></tr><tr><td>Decrease in muscle mass and strength&nbsp;</td><td>3–6 mo&nbsp;</td><td>1–2 y&nbsp;</td></tr><tr><td>Softening of skin/decreased oiliness&nbsp;</td><td>3–6 mo&nbsp;</td><td>Unknown&nbsp;</td></tr><tr><td>Decreased sexual desire&nbsp;</td><td>1–3 mo&nbsp;</td><td>3–6 mo&nbsp;</td></tr><tr><td>Decreased spontaneous erections&nbsp;</td><td>1–3 mo&nbsp;</td><td>3–6 mo&nbsp;</td></tr><tr><td>Male sexual dysfunction&nbsp;</td><td>Variable&nbsp;</td><td>Variable&nbsp;</td></tr><tr><td>Breast growth&nbsp;</td><td>3–6 mo&nbsp;</td><td>2–3 y&nbsp;</td></tr><tr><td>Decreased testicular volume&nbsp;</td><td>3–6 mo&nbsp;</td><td>2–3 y&nbsp;</td></tr><tr><td>Decreased sperm production&nbsp;</td><td>Unknown&nbsp;</td><td>&gt;3 y&nbsp;</td></tr><tr><td>Decreased terminal hair growth&nbsp;</td><td>6–12 mo&nbsp;</td><td>&gt;3 y<span id=\"jumplink-t13n1\"></span><span><em><sup>a</sup></em></span>&nbsp;</td></tr><tr><td>Scalp hair&nbsp;</td><td>Variable&nbsp;</td><td>—<span id=\"jumplink-t13n2\"></span><span><em><sup>b</sup></em></span>&nbsp;</td></tr><tr><td>Voice changes&nbsp;</td><td>None&nbsp;</td><td>—<em><sup>c</sup></em>&nbsp;</td></tr></tbody></table></div><div><p><span><p>Estimates represent clinical observations: Toorians <em>et al.</em> (<span id=\"jumplink-B149\"></span>149), Asscheman <em>et al.</em> (<span id=\"jumplink-B156\"></span>156), Gooren <em>et al.</em> (<span id=\"jumplink-B157\"></span>157).</p></span></p><p><span><span><span rel=\"nofollow\" data-fn-id=\"t13n1\"><sup>a</sup></span></span><p>Complete removal of male sexual hair requires electrolysis or laser treatment or both.</p></span></p><p><span><span><span rel=\"nofollow\" data-fn-id=\"t13n2\"><sup>b</sup></span></span><p>Familial scalp hair loss may occur if estrogens are stopped.</p></span></p><p><span><span><span rel=\"nofollow\" data-fn-id=\"t13n3\"><sup>c</sup></span></span><p>Treatment by speech pathologists for voice training is most effective.</p></span></p></div></div><p>Although the time course of breast development in transgender females has been studied (<span id=\"jumplink-B150\"></span>150), precise information about other changes induced by sex hormones is lacking (<span id=\"jumplink-B141\"></span>141). There is a great deal of variability among individuals, as evidenced during pubertal development. We all know that a major concern for transgender females is breast development. If we work with estrogens, the result will be often not what the transgender female expects.</p><p>Alternatively, there are transgender females who report an anecdotal improved breast development, mood, or sexual desire with the use of progestogens. However, there have been no well-designed studies of the role of progestogens in feminizing hormone regimens, so the question is still open.</p><p>Our knowledge concerning the natural history and effects of different cross-sex hormone therapies on breast development in transgender females is extremely sparse and based on the low quality of evidence. Current evidence does not indicate that progestogens enhance breast development in transgender females, nor does evidence prove the absence of such an effect. This prevents us from drawing any firm conclusion at this moment and demonstrates the need for further research to clarify these important clinical questions (<span id=\"jumplink-B162\"></span>162).</p>                    <h3 scrollto-destination=\"99603394\" id=\"99603394\" data-legacy-id=\"s49\">Values and preferences</h3>\n<p>Transgender persons have very high expectations regarding the physical changes of hormone treatment and are aware that body changes can be enhanced by surgical procedures (<em>e.g.</em>, breast, face, and body habitus). Clear expectations for the extent and timing of sex hormone–induced changes may prevent the potential harm and expense of unnecessary procedures.</p>                    <h2 scrollto-destination=\"99603396\" id=\"99603396\" data-legacy-id=\"s50\">4.0 Adverse Outcome Prevention and Long-Term Care</h2>\n<p>Hormone therapy for transgender males and females confers many of the same risks associated with sex hormone replacement therapy in nontransgender persons. The risks arise from and are worsened by inadvertent or intentional use of supraphysiologic doses of sex hormones, as well as use of inadequate doses of sex hormones to maintain normal physiology (<span id=\"jumplink-B131\"></span>131, <span id=\"jumplink-B139\"></span>139).</p><ul><li><p>4.1. We suggest regular clinical evaluation for physical changes and potential adverse changes in response to sex steroid hormones and laboratory monitoring of sex steroid hormone levels every 3 months during the first year of hormone therapy for transgender males and females and then once or twice yearly. (2 |⊕⊕○○)</p></li></ul>                    <h3 scrollto-destination=\"99603399\" id=\"99603399\" data-legacy-id=\"s51\">Evidence</h3>\n<p>Pretreatment screening and appropriate regular medical monitoring are recommended for both transgender males and females during the endocrine transition and periodically thereafter (<span id=\"jumplink-B26\"></span>26, <span id=\"jumplink-B155\"></span>155). Clinicians should monitor weight and blood pressure, conduct physical exams, and assess routine health questions, such as tobacco use, symptoms of depression, and risk of adverse events such as deep vein thrombosis/pulmonary embolism and other adverse effects of sex steroids.</p>                    <h4 scrollto-destination=\"99603401\" id=\"99603401\" data-legacy-id=\"s52\">Transgender males</h4>\n<p><span id=\"jumplink-T14\"></span>Table 14 contains a standard monitoring plan for transgender males on testosterone therapy (<span id=\"jumplink-B154\"></span>154, <span id=\"jumplink-B159\"></span>159). Key issues include maintaining testosterone levels in the physiologic normal male range and avoiding adverse events resulting from excess testosterone therapy, particularly erythrocytosis, sleep apnea, hypertension, excessive weight gain, salt retention, lipid changes, and excessive or cystic acne (<span id=\"jumplink-B135\"></span>135).</p>                    <div content-id=\"T14\"><div id=\"T14\" data-id=\"T14\"><p><span>Table 14.</span></p><p>Monitoring of Transgender Persons on Gender-Affirming Hormone Therapy: Transgender Male</p> </div><div><table><tbody><tr><td>1. Evaluate patient every 3 mo in the first year and then one to two times per year to monitor for appropriate signs of virilization and for development of adverse reactions.&nbsp;</td></tr><tr><td>2. Measure serum testosterone every 3 mo until levels are in the normal physiologic male range:<span id=\"jumplink-t14n1\"></span><span><em><sup>a</sup></em></span>&nbsp;</td></tr><tr><td> a. For testosterone enanthate/cypionate injections, the testosterone level should be measured midway between injections. The target level is 400–700 ng/dL to 400 ng/dL. Alternatively, measure peak and trough levels to ensure levels remain in the normal male range.&nbsp;</td></tr><tr><td> b. For parenteral testosterone undecanoate, testosterone should be measured just before the following injection. If the level is &lt;400 ng/dL, adjust dosing interval.&nbsp;</td></tr><tr><td> c. For transdermal testosterone, the testosterone level can be measured no sooner than after 1 wk of daily application (at least 2 h after application).&nbsp;</td></tr><tr><td>3. Measure hematocrit or hemoglobin at baseline and every 3 mo for the first year and then one to two times a year. Monitor weight, blood pressure, and lipids at regular intervals.&nbsp;</td></tr><tr><td>4. Screening for osteoporosis should be conducted in those who stop testosterone treatment, are not compliant with hormone therapy, or who develop risks for bone loss.&nbsp;</td></tr><tr><td>5. If cervical tissue is present, monitoring as recommended by the American College of Obstetricians and Gynecologists.&nbsp;</td></tr><tr><td>6. Ovariectomy can be considered after completion of hormone transition.&nbsp;</td></tr><tr><td>7. Conduct sub- and periareolar annual breast examinations if mastectomy performed. If mastectomy is not performed, then consider mammograms as recommended by the American Cancer Society.&nbsp;</td></tr></tbody></table></div><div><table><tbody><tr><td>1. Evaluate patient every 3 mo in the first year and then one to two times per year to monitor for appropriate signs of virilization and for development of adverse reactions.&nbsp;</td></tr><tr><td>2. Measure serum testosterone every 3 mo until levels are in the normal physiologic male range:<span id=\"jumplink-t14n1\"></span><span><em><sup>a</sup></em></span>&nbsp;</td></tr><tr><td> a. For testosterone enanthate/cypionate injections, the testosterone level should be measured midway between injections. The target level is 400–700 ng/dL to 400 ng/dL. Alternatively, measure peak and trough levels to ensure levels remain in the normal male range.&nbsp;</td></tr><tr><td> b. For parenteral testosterone undecanoate, testosterone should be measured just before the following injection. If the level is &lt;400 ng/dL, adjust dosing interval.&nbsp;</td></tr><tr><td> c. For transdermal testosterone, the testosterone level can be measured no sooner than after 1 wk of daily application (at least 2 h after application).&nbsp;</td></tr><tr><td>3. Measure hematocrit or hemoglobin at baseline and every 3 mo for the first year and then one to two times a year. Monitor weight, blood pressure, and lipids at regular intervals.&nbsp;</td></tr><tr><td>4. Screening for osteoporosis should be conducted in those who stop testosterone treatment, are not compliant with hormone therapy, or who develop risks for bone loss.&nbsp;</td></tr><tr><td>5. If cervical tissue is present, monitoring as recommended by the American College of Obstetricians and Gynecologists.&nbsp;</td></tr><tr><td>6. Ovariectomy can be considered after completion of hormone transition.&nbsp;</td></tr><tr><td>7. Conduct sub- and periareolar annual breast examinations if mastectomy performed. If mastectomy is not performed, then consider mammograms as recommended by the American Cancer Society.&nbsp;</td></tr></tbody></table></div><div><p><span><span><span rel=\"nofollow\" data-fn-id=\"t14n1\"><sup>a</sup></span></span><p>Adapted from Lapauw <em>et al.</em> (<span id=\"jumplink-B154\"></span>154) and Ott <em>et al.</em> (<span id=\"jumplink-B159\"></span>159).</p></span></p></div></div><div><div id=\"T14\" data-id=\"T14\"><p><span>Table 14.</span></p><p>Monitoring of Transgender Persons on Gender-Affirming Hormone Therapy: Transgender Male</p> </div><div><table><tbody><tr><td>1. Evaluate patient every 3 mo in the first year and then one to two times per year to monitor for appropriate signs of virilization and for development of adverse reactions.&nbsp;</td></tr><tr><td>2. Measure serum testosterone every 3 mo until levels are in the normal physiologic male range:<span id=\"jumplink-t14n1\"></span><span><em><sup>a</sup></em></span>&nbsp;</td></tr><tr><td> a. For testosterone enanthate/cypionate injections, the testosterone level should be measured midway between injections. The target level is 400–700 ng/dL to 400 ng/dL. Alternatively, measure peak and trough levels to ensure levels remain in the normal male range.&nbsp;</td></tr><tr><td> b. For parenteral testosterone undecanoate, testosterone should be measured just before the following injection. If the level is &lt;400 ng/dL, adjust dosing interval.&nbsp;</td></tr><tr><td> c. For transdermal testosterone, the testosterone level can be measured no sooner than after 1 wk of daily application (at least 2 h after application).&nbsp;</td></tr><tr><td>3. Measure hematocrit or hemoglobin at baseline and every 3 mo for the first year and then one to two times a year. Monitor weight, blood pressure, and lipids at regular intervals.&nbsp;</td></tr><tr><td>4. Screening for osteoporosis should be conducted in those who stop testosterone treatment, are not compliant with hormone therapy, or who develop risks for bone loss.&nbsp;</td></tr><tr><td>5. If cervical tissue is present, monitoring as recommended by the American College of Obstetricians and Gynecologists.&nbsp;</td></tr><tr><td>6. Ovariectomy can be considered after completion of hormone transition.&nbsp;</td></tr><tr><td>7. Conduct sub- and periareolar annual breast examinations if mastectomy performed. If mastectomy is not performed, then consider mammograms as recommended by the American Cancer Society.&nbsp;</td></tr></tbody></table></div><div><table><tbody><tr><td>1. Evaluate patient every 3 mo in the first year and then one to two times per year to monitor for appropriate signs of virilization and for development of adverse reactions.&nbsp;</td></tr><tr><td>2. Measure serum testosterone every 3 mo until levels are in the normal physiologic male range:<span id=\"jumplink-t14n1\"></span><span><em><sup>a</sup></em></span>&nbsp;</td></tr><tr><td> a. For testosterone enanthate/cypionate injections, the testosterone level should be measured midway between injections. The target level is 400–700 ng/dL to 400 ng/dL. Alternatively, measure peak and trough levels to ensure levels remain in the normal male range.&nbsp;</td></tr><tr><td> b. For parenteral testosterone undecanoate, testosterone should be measured just before the following injection. If the level is &lt;400 ng/dL, adjust dosing interval.&nbsp;</td></tr><tr><td> c. For transdermal testosterone, the testosterone level can be measured no sooner than after 1 wk of daily application (at least 2 h after application).&nbsp;</td></tr><tr><td>3. Measure hematocrit or hemoglobin at baseline and every 3 mo for the first year and then one to two times a year. Monitor weight, blood pressure, and lipids at regular intervals.&nbsp;</td></tr><tr><td>4. Screening for osteoporosis should be conducted in those who stop testosterone treatment, are not compliant with hormone therapy, or who develop risks for bone loss.&nbsp;</td></tr><tr><td>5. If cervical tissue is present, monitoring as recommended by the American College of Obstetricians and Gynecologists.&nbsp;</td></tr><tr><td>6. Ovariectomy can be considered after completion of hormone transition.&nbsp;</td></tr><tr><td>7. Conduct sub- and periareolar annual breast examinations if mastectomy performed. If mastectomy is not performed, then consider mammograms as recommended by the American Cancer Society.&nbsp;</td></tr></tbody></table></div><div><p><span><span><span rel=\"nofollow\" data-fn-id=\"t14n1\"><sup>a</sup></span></span><p>Adapted from Lapauw <em>et al.</em> (<span id=\"jumplink-B154\"></span>154) and Ott <em>et al.</em> (<span id=\"jumplink-B159\"></span>159).</p></span></p></div></div><p>Because oral 17-alkylated testosterone is not recommended, serious hepatic toxicity is not anticipated with parenteral or transdermal testosterone use (<span id=\"jumplink-B163\"></span>163, <span id=\"jumplink-B164\"></span>164). Past concerns regarding liver toxicity with testosterone have been alleviated with subsequent reports that indicate the risk of serious liver disease is minimal (<span id=\"jumplink-B144\"></span>144, <span id=\"jumplink-B165\"></span>165, <span id=\"jumplink-B166\"></span>166).</p>                    <h4 scrollto-destination=\"99603405\" id=\"99603405\" data-legacy-id=\"s53\">Transgender females</h4>\n<p><span id=\"jumplink-T15\"></span>Table 15 contains a standard monitoring plan for transgender females on estrogens, gonadotropin suppression, or antiandrogens (<span id=\"jumplink-B160\"></span>160). Key issues include avoiding supraphysiologic doses or blood levels of estrogen that may lead to increased risk for thromboembolic disease, liver dysfunction, and hypertension. Clinicians should monitor serum estradiol levels using laboratories participating in external quality control, as measurements of estradiol in blood can be very challenging (<span id=\"jumplink-B167\"></span>167).</p>                    <div content-id=\"T15\"><div id=\"T15\" data-id=\"T15\"><p><span>Table 15.</span></p><p>Monitoring of Transgender Persons on Gender-Affirming Hormone Therapy: Transgender Female</p> </div><div><table><tbody><tr><td>1. Evaluate patient every 3 mo in the first year and then one to two times per year to monitor for appropriate signs of feminization and for development of adverse reactions.&nbsp;</td></tr><tr><td>2. Measure serum testosterone and estradiol every 3 mo.&nbsp;</td></tr><tr><td> a. Serum testosterone levels should be &lt;50 ng/dL.&nbsp;</td></tr><tr><td> b. Serum estradiol should not exceed the peak physiologic range: 100–200 pg/mL.&nbsp;</td></tr><tr><td>3. For individuals on spironolactone, serum electrolytes, particularly potassium, should be monitored every 3 mo in the first year and annually thereafter.&nbsp;</td></tr><tr><td>4. Routine cancer screening is recommended, as in nontransgender individuals (all tissues present).&nbsp;</td></tr><tr><td>5. Consider BMD testing at baseline (<span id=\"jumplink-B160\"></span>160). In individuals at low risk, screening for osteoporosis should be conducted at age 60 years or in those who are not compliant with hormone therapy.&nbsp;</td></tr></tbody></table></div><div><table><tbody><tr><td>1. Evaluate patient every 3 mo in the first year and then one to two times per year to monitor for appropriate signs of feminization and for development of adverse reactions.&nbsp;</td></tr><tr><td>2. Measure serum testosterone and estradiol every 3 mo.&nbsp;</td></tr><tr><td> a. Serum testosterone levels should be &lt;50 ng/dL.&nbsp;</td></tr><tr><td> b. Serum estradiol should not exceed the peak physiologic range: 100–200 pg/mL.&nbsp;</td></tr><tr><td>3. For individuals on spironolactone, serum electrolytes, particularly potassium, should be monitored every 3 mo in the first year and annually thereafter.&nbsp;</td></tr><tr><td>4. Routine cancer screening is recommended, as in nontransgender individuals (all tissues present).&nbsp;</td></tr><tr><td>5. Consider BMD testing at baseline (<span id=\"jumplink-B160\"></span>160). In individuals at low risk, screening for osteoporosis should be conducted at age 60 years or in those who are not compliant with hormone therapy.&nbsp;</td></tr></tbody></table></div><div><p><span><p>This table presents strong recommendations and does not include lower level recommendations.</p></span></p></div></div><div><div id=\"T15\" data-id=\"T15\"><p><span>Table 15.</span></p><p>Monitoring of Transgender Persons on Gender-Affirming Hormone Therapy: Transgender Female</p> </div><div><table><tbody><tr><td>1. Evaluate patient every 3 mo in the first year and then one to two times per year to monitor for appropriate signs of feminization and for development of adverse reactions.&nbsp;</td></tr><tr><td>2. Measure serum testosterone and estradiol every 3 mo.&nbsp;</td></tr><tr><td> a. Serum testosterone levels should be &lt;50 ng/dL.&nbsp;</td></tr><tr><td> b. Serum estradiol should not exceed the peak physiologic range: 100–200 pg/mL.&nbsp;</td></tr><tr><td>3. For individuals on spironolactone, serum electrolytes, particularly potassium, should be monitored every 3 mo in the first year and annually thereafter.&nbsp;</td></tr><tr><td>4. Routine cancer screening is recommended, as in nontransgender individuals (all tissues present).&nbsp;</td></tr><tr><td>5. Consider BMD testing at baseline (<span id=\"jumplink-B160\"></span>160). In individuals at low risk, screening for osteoporosis should be conducted at age 60 years or in those who are not compliant with hormone therapy.&nbsp;</td></tr></tbody></table></div><div><table><tbody><tr><td>1. Evaluate patient every 3 mo in the first year and then one to two times per year to monitor for appropriate signs of feminization and for development of adverse reactions.&nbsp;</td></tr><tr><td>2. Measure serum testosterone and estradiol every 3 mo.&nbsp;</td></tr><tr><td> a. Serum testosterone levels should be &lt;50 ng/dL.&nbsp;</td></tr><tr><td> b. Serum estradiol should not exceed the peak physiologic range: 100–200 pg/mL.&nbsp;</td></tr><tr><td>3. For individuals on spironolactone, serum electrolytes, particularly potassium, should be monitored every 3 mo in the first year and annually thereafter.&nbsp;</td></tr><tr><td>4. Routine cancer screening is recommended, as in nontransgender individuals (all tissues present).&nbsp;</td></tr><tr><td>5. Consider BMD testing at baseline (<span id=\"jumplink-B160\"></span>160). In individuals at low risk, screening for osteoporosis should be conducted at age 60 years or in those who are not compliant with hormone therapy.&nbsp;</td></tr></tbody></table></div><div><p><span><p>This table presents strong recommendations and does not include lower level recommendations.</p></span></p></div></div><p>VTE may be a serious complication. A study reported a 20-fold increase in venous thromboembolic disease in a large cohort of Dutch transgender subjects (<span id=\"jumplink-B161\"></span>161). This increase may have been associated with the use of the synthetic estrogen, ethinyl estradiol (<span id=\"jumplink-B149\"></span>149). The incidence decreased when clinicians stopped administering ethinyl estradiol (<span id=\"jumplink-B161\"></span>161). Thus, the use of synthetic estrogens and conjugated estrogens is undesirable because of the inability to regulate doses by measuring serum levels and the risk of thromboembolic disease. In a German gender clinic, deep vein thrombosis occurred in 1 of 60 of transgender females treated with a GnRH analog and oral estradiol (<span id=\"jumplink-B141\"></span>141). The patient who developed a deep vein thrombosis was found to have a homozygous C677 T mutation in the methylenetetrahydrofolate reductase gene. In an Austrian gender clinic, administering gender-affirming hormones to 162 transgender females and 89 transgender males was not associated with VTE, despite an 8.0% and 5.6% incidence of thrombophilia (<span id=\"jumplink-B159\"></span>159). A more recent multinational study reported only 10 cases of VTE from a cohort of 1073 subjects (<span id=\"jumplink-B168\"></span>168). Thrombophilia screening of transgender persons initiating hormone treatment should be restricted to those with a personal or family history of VTE (<span id=\"jumplink-B159\"></span>159). Monitoring <span>D</span>-dimer levels during treatment is not recommended (<span id=\"jumplink-B169\"></span>169).</p><ul><li><p>4.2. We suggest periodically monitoring prolactin levels in transgender females treated with estrogens. (2 |⊕⊕○○)</p></li></ul>                    <h3 scrollto-destination=\"99603410\" id=\"99603410\" data-legacy-id=\"s54\">Evidence</h3>\n<p>Estrogen therapy can increase the growth of pituitary lactrotroph cells. There have been several reports of prolactinomas occurring after long-term, high-dose estrogen therapy (<span id=\"jumplink-B170\"></span>170–<span id=\"jumplink-B173\"></span>173). Up to 20% of transgender females treated with estrogens may have elevations in prolactin levels associated with enlargement of the pituitary gland (<span id=\"jumplink-B156\"></span>156). In most cases, the serum prolactin levels will return to the normal range with a reduction or discontinuation of the estrogen therapy or discontinuation of cyproterone acetate (<span id=\"jumplink-B157\"></span>157, <span id=\"jumplink-B174\"></span>174, <span id=\"jumplink-B175\"></span>175).</p><p>The onset and time course of hyperprolactinemia during estrogen treatment are not known. Clinicians should measure prolactin levels at baseline and then at least annually during the transition period and every 2 years thereafter. Given that only a few case studies reported prolactinomas, and prolactinomas were not reported in large cohorts of estrogen-treated persons, the risk is likely to be very low. Because the major presenting findings of microprolactinomas (hypogonadism and sometimes gynecomastia) are not apparent in transgender females, clinicians may perform radiologic examinations of the pituitary in those patients whose prolactin levels persistently increase despite stable or reduced estrogen levels. Some transgender individuals receive psychotropic medications that can increase prolactin levels (<span id=\"jumplink-B174\"></span>174).</p><ul><li><p>4.3. We suggest that clinicians evaluate transgender persons treated with hormones for cardiovascular risk factors using fasting lipid profiles, diabetes screening, and/or other diagnostic tools. (2 |⊕⊕○○)</p></li></ul>                    <h3 scrollto-destination=\"99603414\" id=\"99603414\" data-legacy-id=\"s55\">Evidence</h3>\n                    <h4 scrollto-destination=\"99603415\" id=\"99603415\" data-legacy-id=\"s56\">Transgender males</h4>\n<p>Administering testosterone to transgender males results in a more atherogenic lipid profile with lowered high-density lipoprotein cholesterol and higher triglyceride and low-density lipoprotein cholesterol values (<span id=\"jumplink-B176\"></span>176–<span id=\"jumplink-B179\"></span>179). Studies of the effect of testosterone on insulin sensitivity have mixed results (<span id=\"jumplink-B178\"></span>178, <span id=\"jumplink-B180\"></span>180). A randomized, open-label uncontrolled safety study of transgender males treated with testosterone undecanoate demonstrated no insulin resistance after 1 year (<span id=\"jumplink-B181\"></span>181, <span id=\"jumplink-B182\"></span>182). Numerous studies have demonstrated the effects of sex hormone treatment on the cardiovascular system (<span id=\"jumplink-B160\"></span>160, <span id=\"jumplink-B179\"></span>179, <span id=\"jumplink-B183\"></span>183, <span id=\"jumplink-B184\"></span>184). Long-term studies from The Netherlands found no increased risk for cardiovascular mortality (<span id=\"jumplink-B161\"></span>161). Likewise, a meta-analysis of 19 randomized trials in nontransgender males on testosterone replacement showed no increased incidence of cardiovascular events (<span id=\"jumplink-B185\"></span>185). A systematic review of the literature found that data were insufficient (due to very low–quality evidence) to allow a meaningful assessment of patient-important outcomes, such as death, stroke, myocardial infarction, or VTE in transgender males (<span id=\"jumplink-B176\"></span>176). Future research is needed to ascertain the potential harm of hormonal therapies (<span id=\"jumplink-B176\"></span>176). Clinicians should manage cardiovascular risk factors as they emerge according to established guidelines (<span id=\"jumplink-B186\"></span>186).</p>                    <h4 scrollto-destination=\"99603417\" id=\"99603417\" data-legacy-id=\"s57\">Transgender females</h4>\n<p>A prospective study of transgender females found favorable changes in lipid parameters with increased high-density lipoprotein and decreased low-density lipoprotein concentrations (<span id=\"jumplink-B178\"></span>178). However, increased weight, blood pressure, and markers of insulin resistance attenuated these favorable lipid changes. In a meta-analysis, only serum triglycerides were higher at ≥24 months without changes in other parameters (<span id=\"jumplink-B187\"></span>187). The largest cohort of transgender females (mean age 41 years, followed for a mean of 10 years) showed no increase in cardiovascular mortality despite a 32% rate of tobacco use (<span id=\"jumplink-B161\"></span>161).</p><p>Thus, there is limited evidence to determine whether estrogen is protective or detrimental on lipid and glucose metabolism in transgender females (<span id=\"jumplink-B176\"></span>176). With aging, there is usually an increase of body weight. Therefore, as with nontransgender individuals, clinicians should monitor and manage glucose and lipid metabolism and blood pressure regularly according to established guidelines (<span id=\"jumplink-B186\"></span>186).</p><ul><li><p>4.4. We recommend that clinicians obtain BMD measurements when risk factors for osteoporosis exist, specifically in those who stop sex hormone therapy after gonadectomy. (1 |⊕⊕○○)</p></li></ul>                    <h3 scrollto-destination=\"99603421\" id=\"99603421\" data-legacy-id=\"s58\">Evidence</h3>\n                    <h4 scrollto-destination=\"99603422\" id=\"99603422\" data-legacy-id=\"s59\">Transgender males</h4>\n<p>Baseline bone mineral measurements in transgender males are generally in the expected range for their pretreatment gender (<span id=\"jumplink-B188\"></span>188). However, adequate dosing of testosterone is important to maintain bone mass in transgender males (<span id=\"jumplink-B189\"></span>189, <span id=\"jumplink-B190\"></span>190). In one study (<span id=\"jumplink-B190\"></span>190), serum LH levels were inversely related to BMD, suggesting that low levels of sex hormones were associated with bone loss. Thus, LH levels in the normal range may serve as an indicator of the adequacy of sex steroid administration to preserve bone mass. The protective effect of testosterone may be mediated by peripheral conversion to estradiol, both systemically and locally in the bone.</p>                    <h4 scrollto-destination=\"99603424\" id=\"99603424\" data-legacy-id=\"s60\">Transgender females</h4>\n<p>A baseline study of BMD reported T scores less than −2.5 in 16% of transgender females (<span id=\"jumplink-B191\"></span>191). In aging males, studies suggest that serum estradiol more positively correlates with BMD than does testosterone (<span id=\"jumplink-B192\"></span>192, <span id=\"jumplink-B193\"></span>193) and is more important for peak bone mass (<span id=\"jumplink-B194\"></span>194). Estrogen preserves BMD in transgender females who continue on estrogen and antiandrogen therapies (<span id=\"jumplink-B188\"></span>188, <span id=\"jumplink-B190\"></span>190, <span id=\"jumplink-B191\"></span>191, <span id=\"jumplink-B195\"></span>195, <span id=\"jumplink-B196\"></span>196).</p><p>Fracture data in transgender males and females are not available. Transgender persons who have undergone gonadectomy may choose not to continue consistent sex steroid treatment after hormonal and surgical sex reassignment, thereby becoming at risk for bone loss. There have been no studies to determine whether clinicians should use the sex assigned at birth or affirmed gender for assessing osteoporosis (<em>e.g.</em>, when using the FRAX tool). Although some researchers use the sex assigned at birth (with the assumption that bone mass has usually peaked for transgender people who initiate hormones in early adulthood), this should be assessed on a case-by-case basis until there are more data available. This assumption will be further complicated by the increasing prevalence of transgender people who undergo hormonal transition at a pubertal age or soon after puberty. Sex for comparison within risk assessment tools may be based on the age at which hormones were initiated and the length of exposure to hormones. In some cases, it may be reasonable to assess risk using both the male and female calculators and using an intermediate value. Because all subjects underwent normal pubertal development, with known effects on bone size, reference values for birth sex were used for all participants (<span id=\"jumplink-B154\"></span>154).</p><ul><li><p>4.5. We suggest that transgender females with no known increased risk of breast cancer follow breast-screening guidelines recommended for those designated female at birth. (2 |⊕⊕○○)</p></li><li><p>4.6. We suggest that transgender females treated with estrogens follow individualized screening according to personal risk for prostatic disease and prostate cancer. (2 |⊕○○○)</p></li></ul>                    <h3 scrollto-destination=\"99603428\" id=\"99603428\" data-legacy-id=\"s61\">Evidence</h3>\n<p>Studies have reported a few cases of breast cancer in transgender females (<span id=\"jumplink-B197\"></span>197–<span id=\"jumplink-B200\"></span>200). A Dutch study of 1800 transgender females followed for a mean of 15 years (range of 1 30 years) found one case of breast cancer. The Women’s Health Initiative study reported that females taking conjugated equine estrogen without progesterone for 7 years did not have an increased risk of breast cancer as compared with females taking placebo (<span id=\"jumplink-B137\"></span>137).</p><p>In transgender males, a large retrospective study conducted at the U.S. Veterans Affairs medical health system identified seven breast cancers (<span id=\"jumplink-B194\"></span>194). The authors reported that this was not above the expected rate of breast cancers in cisgender females in this cohort. Furthermore, they did report one breast cancer that developed in a transgender male patient after mastectomy, supporting the fact that breast cancer can occur even after mastectomy. Indeed, there have been case reports of breast cancer developing in subareolar tissue in transgender males, which occurred after mastectomy (<span id=\"jumplink-B201\"></span>201, <span id=\"jumplink-B202\"></span>202).</p><p>Women with primary hypogonadism (Turner syndrome) treated with estrogen replacement exhibited a significantly decreased incidence of breast cancer as compared with national standardized incidence ratios (<span id=\"jumplink-B203\"></span>203, <span id=\"jumplink-B204\"></span>204). These studies suggest that estrogen therapy does not increase the risk of breast cancer in the short term (&lt;20 to 30 years). We need long-term studies to determine the actual risk, as well as the role of screening mammograms. Regular examinations and gynecologic advice should determine monitoring for breast cancer.</p><p>Prostate cancer is very rare before the age of 40, especially with androgen deprivation therapy (<span id=\"jumplink-B205\"></span>205). Childhood or pubertal castration results in regression of the prostate and adult castration reverses benign prostate hypertrophy (<span id=\"jumplink-B206\"></span>206). Although van Kesteren <em>et al.</em> (<span id=\"jumplink-B207\"></span>207) reported that estrogen therapy does not induce hypertrophy or premalignant changes in the prostates of transgender females, studies have reported cases of benign prostatic hyperplasia in transgender females treated with estrogens for 20 to 25 years (<span id=\"jumplink-B208\"></span>208, <span id=\"jumplink-B209\"></span>209). Studies have also reported a few cases of prostate carcinoma in transgender females (<span id=\"jumplink-B210\"></span>210–<span id=\"jumplink-B214\"></span>214).</p><p>Transgender females may feel uncomfortable scheduling regular prostate examinations. Gynecologists are not trained to screen for prostate cancer or to monitor prostate growth. Thus, it may be reasonable for transgender females who transitioned after age 20 years to have annual screening digital rectal examinations after age 50 years and prostate-specific antigen tests consistent with U.S. Preventive Services Task Force Guidelines (<span id=\"jumplink-B215\"></span>215).</p><ul><li><p>4.7. We advise that clinicians determine the medical necessity of including a total hysterectomy and oophorectomy as part of gender-affirming surgery. (Ungraded Good Practice Statement)</p></li></ul>                    <h3 scrollto-destination=\"99603435\" id=\"99603435\" data-legacy-id=\"s62\">Evidence</h3>\n<p>Although aromatization of testosterone to estradiol in transgender males has been suggested as a risk factor for endometrial cancer (<span id=\"jumplink-B216\"></span>216), no cases have been reported. When transgender males undergo hysterectomy, the uterus is small and there is endometrial atrophy (<span id=\"jumplink-B217\"></span>217, <span id=\"jumplink-B218\"></span>218). Studies have reported cases of ovarian cancer (<span id=\"jumplink-B219\"></span>219, <span id=\"jumplink-B220\"></span>220). Although there is limited evidence for increased risk of reproductive tract cancers in transgender males, health care providers should determine the medical necessity of a laparoscopic total hysterectomy as part of a gender-affirming surgery to prevent reproductive tract cancer (<span id=\"jumplink-B221\"></span>221).</p>                    <h3 scrollto-destination=\"99603437\" id=\"99603437\" data-legacy-id=\"s63\">Values</h3>\n<p>Given the discomfort that transgender males experience accessing gynecologic care, our recommendation for the medical necessity of total hysterectomy and oophorectomy places a high value on eliminating the risks of female reproductive tract disease and cancer and a lower value on avoiding the risks of these surgical procedures (related to the surgery and to the potential undesirable health consequences of oophorectomy) and their associated costs.</p>                    <h3 scrollto-destination=\"99603439\" id=\"99603439\" data-legacy-id=\"s64\">Remarks</h3>\n<p>The sexual orientation and type of sexual practices will determine the need and types of gynecologic care required following transition. Additionally, in certain countries, the approval required to change the sex in a birth certificate for transgender males may be dependent on having a complete hysterectomy. Clinicians should help patients research nonmedical administrative criteria and provide counseling. If individuals decide not to undergo hysterectomy, screening for cervical cancer is the same as all other females.</p>                    <h2 scrollto-destination=\"99603441\" id=\"99603441\" data-legacy-id=\"s65\">5.0 Surgery for Sex Reassignment and Gender Confirmation</h2>\n<p>For many transgender adults, genital gender-affirming surgery may be the necessary step toward achieving their ultimate goal of living successfully in their desired gender role. The type of surgery falls into two main categories: (1) those that directly affect fertility and (2) those that do not. Those that change fertility (previously called sex reassignment surgery) include genital surgery to remove the penis and gonads in the male and removal of the uterus and gonads in the female. The surgeries that effect fertility are often governed by the legal system of the state or country in which they are performed. Other gender-conforming surgeries that do not directly affect fertility are not so tightly governed.</p><p>Gender-affirming surgical techniques have improved markedly during the past 10 years. Reconstructive genital surgery that preserves neurologic sensation is now the standard. The satisfaction rate with surgical reassignment of sex is now very high (<span id=\"jumplink-B187\"></span>187). Additionally, the mental health of the individual seems to be improved by participating in a treatment program that defines a pathway of gender-affirming treatment that includes hormones and surgery (<span id=\"jumplink-B130\"></span>130, <span id=\"jumplink-B144\"></span>144) (<span id=\"jumplink-T16\"></span>Table 16).</p>                    <div content-id=\"T16\"><div id=\"T16\" data-id=\"T16\"><p><span>Table 16.</span></p><p>Criteria for Gender-Affirming Surgery, Which Affects Fertility</p> </div><div><table><tbody><tr><td>1. Persistent, well-documented gender dysphoria&nbsp;</td></tr><tr><td>2. Legal age of majority in the given country&nbsp;</td></tr><tr><td>3. Having continuously and responsibly used gender-affirming hormones for 12 mo (if there is no medical contraindication to receiving such therapy)&nbsp;</td></tr><tr><td>4. Successful continuous full-time living in the new gender role for 12 mo&nbsp;</td></tr><tr><td>5. If significant medical or mental health concerns are present, they must be well controlled&nbsp;</td></tr><tr><td>6. Demonstrable knowledge of all practical aspects of surgery (<em>e.g.</em>, cost, required lengths of hospitalizations, likely complications, postsurgical rehabilitation)&nbsp;</td></tr></tbody></table></div><div><table><tbody><tr><td>1. Persistent, well-documented gender dysphoria&nbsp;</td></tr><tr><td>2. Legal age of majority in the given country&nbsp;</td></tr><tr><td>3. Having continuously and responsibly used gender-affirming hormones for 12 mo (if there is no medical contraindication to receiving such therapy)&nbsp;</td></tr><tr><td>4. Successful continuous full-time living in the new gender role for 12 mo&nbsp;</td></tr><tr><td>5. If significant medical or mental health concerns are present, they must be well controlled&nbsp;</td></tr><tr><td>6. Demonstrable knowledge of all practical aspects of surgery (<em>e.g.</em>, cost, required lengths of hospitalizations, likely complications, postsurgical rehabilitation)&nbsp;</td></tr></tbody></table></div></div><div><div id=\"T16\" data-id=\"T16\"><p><span>Table 16.</span></p><p>Criteria for Gender-Affirming Surgery, Which Affects Fertility</p> </div><div><table><tbody><tr><td>1. Persistent, well-documented gender dysphoria&nbsp;</td></tr><tr><td>2. Legal age of majority in the given country&nbsp;</td></tr><tr><td>3. Having continuously and responsibly used gender-affirming hormones for 12 mo (if there is no medical contraindication to receiving such therapy)&nbsp;</td></tr><tr><td>4. Successful continuous full-time living in the new gender role for 12 mo&nbsp;</td></tr><tr><td>5. If significant medical or mental health concerns are present, they must be well controlled&nbsp;</td></tr><tr><td>6. Demonstrable knowledge of all practical aspects of surgery (<em>e.g.</em>, cost, required lengths of hospitalizations, likely complications, postsurgical rehabilitation)&nbsp;</td></tr></tbody></table></div><div><table><tbody><tr><td>1. Persistent, well-documented gender dysphoria&nbsp;</td></tr><tr><td>2. Legal age of majority in the given country&nbsp;</td></tr><tr><td>3. Having continuously and responsibly used gender-affirming hormones for 12 mo (if there is no medical contraindication to receiving such therapy)&nbsp;</td></tr><tr><td>4. Successful continuous full-time living in the new gender role for 12 mo&nbsp;</td></tr><tr><td>5. If significant medical or mental health concerns are present, they must be well controlled&nbsp;</td></tr><tr><td>6. Demonstrable knowledge of all practical aspects of surgery (<em>e.g.</em>, cost, required lengths of hospitalizations, likely complications, postsurgical rehabilitation)&nbsp;</td></tr></tbody></table></div></div><p>Surgery that affects fertility is irreversible. The World Professional Association for Transgender Health Standards of Care (<span id=\"jumplink-B222\"></span>222) emphasizes that the “threshold of 18 should not be seen as an indication in itself for active intervention.” If the social transition has not been satisfactory, if the person is not satisfied with or is ambivalent about the effects of sex hormone treatment, or if the person is ambivalent about surgery then the individual should not be referred for surgery (<span id=\"jumplink-B223\"></span>223, <span id=\"jumplink-B224\"></span>224).</p><p>Gender-affirming genital surgeries for transgender females that affect fertility include gonadectomy, penectomy, and creation of a neovagina (<span id=\"jumplink-B225\"></span>225, <span id=\"jumplink-B226\"></span>226). Surgeons often invert the skin of the penis to form the wall of the vagina, and several literatures reviews have reported on outcomes (<span id=\"jumplink-B227\"></span>227). Sometimes there is inadequate tissue to form a full neovagina, so clinicians have revisited using intestine and found it to be successful (<span id=\"jumplink-B87\"></span>87, <span id=\"jumplink-B228\"></span>228, <span id=\"jumplink-B229\"></span>229). Some newer vaginoplasty techniques may involve autologuous oral epithelial cells (<span id=\"jumplink-B230\"></span>230, <span id=\"jumplink-B231\"></span>231).</p><p>The scrotum becomes the labia majora. Surgeons use reconstructive surgery to fashion the clitoris and its hood, preserving the neurovascular bundle at the tip of the penis as the neurosensory supply to the clitoris. Some surgeons are also creating a sensate pedicled-spot adding a G spot to the neovagina to increase sensation (<span id=\"jumplink-B232\"></span>232). Most recently, plastic surgeons have developed techniques to fashion labia minora. To further complete the feminization, uterine transplants have been proposed and even attempted (<span id=\"jumplink-B233\"></span>233).</p><p>Neovaginal prolapse, rectovaginal fistula, delayed healing, vaginal stenosis, and other complications do sometimes occur (<span id=\"jumplink-B234\"></span>234, <span id=\"jumplink-B235\"></span>235). Clinicians should strongly remind the transgender person to use their dilators to maintain the depth and width of the vagina throughout the postoperative period. Genital sexual responsivity and other aspects of sexual function are usually preserved following genital gender-affirming surgery (<span id=\"jumplink-B236\"></span>236, <span id=\"jumplink-B237\"></span>237).</p><p>Ancillary surgeries for more feminine or masculine appearance are not within the scope of this guideline. Voice therapy by a speech language pathologist is available to transform speech patterns to the affirmed gender (<span id=\"jumplink-B148\"></span>148). Spontaneous voice deepening occurs during testosterone treatment of transgender males (<span id=\"jumplink-B152\"></span>152, <span id=\"jumplink-B238\"></span>238). No studies have compared the effectiveness of speech therapy, laryngeal surgery, or combined treatment.</p><p>Breast surgery is a good example of gender-confirming surgery that does not affect fertility. In all females, breast size exhibits a very broad spectrum. For transgender females to make the best informed decision, clinicians should delay breast augmentation surgery until the patient has completed at least 2 years of estrogen therapy, because the breasts continue to grow during that time (<span id=\"jumplink-B141\"></span>141, <span id=\"jumplink-B155\"></span>155).</p><p>Another major procedure is the removal of facial and masculine-appearing body hair using either electrolysis or laser treatments. Other feminizing surgeries, such as that to feminize the face, are now becoming more popular (<span id=\"jumplink-B239\"></span>239–<span id=\"jumplink-B241\"></span>241).</p><p>In transgender males, clinicians usually delay gender-affirming genital surgeries until after a few years of androgen therapy. Those surgeries that affect fertility in this group include oophorectomy, vaginectomy, and complete hysterectomy. Surgeons can safely perform them vaginally with laparoscopy. These are sometimes done in conjunction with the creation of a neopenis. The cosmetic appearance of a neopenis is now very good, but the surgery is multistage and very expensive (<span id=\"jumplink-B242\"></span>242, <span id=\"jumplink-B243\"></span>243). Radial forearm flap seems to be the most satisfactory procedure (<span id=\"jumplink-B228\"></span>228, <span id=\"jumplink-B244\"></span>244). Other flaps also exist (<span id=\"jumplink-B245\"></span>245). Surgeons can make neopenile erections possible by reinervation of the flap and subsequent contraction of the muscle, leading to stiffening of the neopenis (<span id=\"jumplink-B246\"></span>246, <span id=\"jumplink-B247\"></span>247), but results are inconsistent (<span id=\"jumplink-B248\"></span>248). Surgeons can also stiffen the penis by imbedding some mechanical device (<em>e.g.</em>, a rod or some inflatable apparatus) (<span id=\"jumplink-B249\"></span>249, <span id=\"jumplink-B250\"></span>250). Because of these limitations, the creation of a neopenis has often been less than satisfactory. Recently, penis transplants are being proposed (<span id=\"jumplink-B233\"></span>233).</p><p>In fact, most transgender males do not have any external genital surgery because of the lack of access, high cost, and significant potential complications. Some choose a metaoidioplasty that brings forward the clitoris, thereby allowing them to void in a standing position without wetting themselves (<span id=\"jumplink-B251\"></span>251, <span id=\"jumplink-B252\"></span>252). Surgeons can create the scrotum from the labia majora with good cosmetic effect and can implant testicular prostheses (<span id=\"jumplink-B253\"></span>253).</p><p>The most important masculinizing surgery for the transgender male is mastectomy, and it does not affect fertility. Breast size only partially regresses with androgen therapy (<span id=\"jumplink-B155\"></span>155). In adults, discussions about mastectomy usually take place after androgen therapy has started. Because some transgender male adolescents present after significant breast development has occurred, they may also consider mastectomy 2 years after they begin androgen therapy and before age 18 years. Clinicians should individualize treatment based on the physical and mental health status of the individual. There are now newer approaches to mastectomy with better outcomes (<span id=\"jumplink-B254\"></span>254, <span id=\"jumplink-B255\"></span>255). These often involve chest contouring (<span id=\"jumplink-B256\"></span>256). Mastectomy is often necessary for living comfortably in the new gender (<span id=\"jumplink-B256\"></span>256).</p><ul><li><p>5.1. We recommend that a patient pursue genital gender-affirming surgery only after the MHP and the clinician responsible for endocrine transition therapy both agree that surgery is medically necessary and would benefit the patient’s overall health and/or well-being. (1 |⊕⊕○○)</p></li><li><p>5.2. We advise that clinicians approve genital gender-affirming surgery only after completion of at least 1 year of consistent and compliant hormone treatment, unless hormone therapy is not desired or medically contraindicated. (Ungraded Good Practice Statement)</p></li><li><p>5.3. We advise that the clinician responsible for endocrine treatment and the primary care provider ensure appropriate medical clearance of transgender individuals for genital gender-affirming surgery and collaborate with the surgeon regarding hormone use during and after surgery. (Ungraded Good Practice Statement)</p></li><li><p>5.4. We recommend that clinicians refer hormone-treated transgender individuals for genital surgery when: (1) the individual has had a satisfactory social role change, (2) the individual is satisfied about the hormonal effects, and (3) the individual desires definitive surgical changes. (1 |⊕○○○)</p></li><li><p>5.5. We suggest that clinicians delay gender-affirming genital surgery involving gonadectomy and/or hysterectomy until the patient is at least 18 years old or legal age of majority in his or her country. (2 |⊕⊕○○).</p></li><li><p>5.6. We suggest that clinicians determine the timing of breast surgery for transgender males based upon the physical and mental health status of the individual. There is insufficient evidence to recommend a specific age requirement. (2 |⊕○○○)</p></li></ul>                    <h3 scrollto-destination=\"99603456\" id=\"99603456\" data-legacy-id=\"s66\">Evidence</h3>\n<p>Owing to the lack of controlled studies, incomplete follow-up, and lack of valid assessment measures, evaluating various surgical approaches and techniques is difficult. However, one systematic review including a large numbers of studies reported satisfactory cosmetic and functional results for vaginoplasty/neovagina construction (<span id=\"jumplink-B257\"></span>257). For transgender males, the outcomes are less certain. However, the problems are now better understood (<span id=\"jumplink-B258\"></span>258). Several postoperative studies report significant long-term psychological and psychiatric pathology (<span id=\"jumplink-B259\"></span>259–<span id=\"jumplink-B261\"></span>261). One study showed satisfaction with breasts, genitals, and femininity increased significantly and showed the importance of surgical treatment as a key therapeutic option for transgender females (<span id=\"jumplink-B262\"></span>262). Another analysis demonstrated that, despite the young average age at death following surgery and the relatively larger number of individuals with somatic morbidity, the study does not allow for determination of causal relationships between, for example, specific types of hormonal or surgical treatment received and somatic morbidity and mortality (<span id=\"jumplink-B263\"></span>263). Reversal surgery in regretful male-to-female transsexuals after sexual reassignment surgery represents a complex, multistage procedure with satisfactory outcomes. Further insight into the characteristics of persons who regret their decision postoperatively would facilitate better future selection of applicants eligible for sexual reassignment surgery. We need more studies with appropriate controls that examine long-term quality of life, psychosocial outcomes, and psychiatric outcomes to determine the long-term benefits of surgical treatment.</p><p>When a transgender individual decides to have gender-affirming surgery, both the hormone prescribing clinician and the MHP must certify that the patient satisfies criteria for gender-affirming surgery (<span id=\"jumplink-T16\"></span>Table 16).</p><p>There is some concern that estrogen therapy may cause an increased risk for venous thrombosis during or following surgery (<span id=\"jumplink-B176\"></span>176). For this reason, the surgeon and the hormone-prescribing clinician should collaborate in making a decision about the use of hormones before and following surgery. One study suggests that preoperative factors (such as compliance) are less important for patient satisfaction than are the physical postoperative results (<span id=\"jumplink-B56\"></span>56). However, other studies and clinical experience dictate that individuals who do not follow medical instructions and do not work with their physicians toward a common goal do not achieve treatment goals (<span id=\"jumplink-B264\"></span>264) and experience higher rates of postoperative infections and other complications (<span id=\"jumplink-B265\"></span>265, <span id=\"jumplink-B266\"></span>266). It is also important that the person requesting surgery feels comfortable with the anatomical changes that have occurred during hormone therapy. Dissatisfaction with social and physical outcomes during the hormone transition may be a contraindication to surgery (<span id=\"jumplink-B223\"></span>223).</p><p>An endocrinologist or experienced medical provider should monitor transgender individuals after surgery. Those who undergo gonadectomy will require hormone replacement therapy, surveillance, or both to prevent adverse effects of chronic hormone deficiency.</p>                    <h2 scrollto-destination=\"99603461\" id=\"99603461\" data-legacy-id=\"s67\">Financial Disclosures of the Task Force*</h2>\n<p><strong>Wylie C. Hembree (chair)</strong>—financial or business/organizational interests: none declared, significant financial interest or leadership position: none declared. <strong>Peggy T. Cohen-Kettenis</strong>—financial or business/organizational interests: none declared, significant financial interest or leadership position: none declared. <strong>Louis Gooren</strong>—financial or business/organizational interests: none declared, significant financial interest or leadership position: none declared. <strong>Sabine E. Hannema</strong>—financial or business/organizational interests: none declared, significant financial interest or leadership position: Ferring Pharmaceuticals Inc. (lecture/conference), Pfizer (lecture). <strong>Walter J. Meyer</strong>—financial or business/organizational interests: none declared, significant financial interest or leadership position: none declared. <strong>M. Hassan Murad**</strong>—financial or business/organizational interests: Mayo Clinic, Evidence-based Practice Center, significant financial interest or leadership position: none declared. <strong>Stephen M.</strong><strong>Rosenthal</strong>—financial or business/organizational interests: AbbVie (consultant), National Institutes of Health (grantee), significant financial interest or leadership position: Pediatric Endocrine Society (immediate past president). <strong>Joshua D. Safer, FACP</strong>—financial or business/organizational interests: none declared, significant financial interest or leadership position: none declared. <strong>Vin Tangpricha</strong>—financial or business/organizational interests: Cystic Fibrosis Foundation (grantee), National Institutes of Health (grantee), significant financial interest or leadership position, Elsevier <em>Journal of Clinical and Translational Endocrinology</em> (editor). <strong>Guy G. T’Sjoen</strong>—financial or business/organizational interests: none declared, significant financial interest or leadership position: none declared.* Financial, business, and organizational disclosures of the task force cover the year prior to publication. Disclosures prior to this time period are archived.**Evidence-based reviews for this guideline were prepared under contract with the Endocrine Society.</p>                    <h2 scrollto-destination=\"99603463\" id=\"99603463\">Abbreviations</h2>\n<ul><a id=\"\">&nbsp;</a><li><p>BMD</p></li><a id=\"\">&nbsp;</a><li><p>DSD</p><div><p>disorder/difference of sex development</p></div></li><a id=\"\">&nbsp;</a><li><p>DSM</p><div><p>Diagnostic and Statistical Manual of Mental Disorders</p></div></li><a id=\"\">&nbsp;</a><li><p>GD</p></li><a id=\"\">&nbsp;</a><li><p>GnRH</p><div><p>gonadotropin-releasing hormone</p></div></li><a id=\"\">&nbsp;</a><li><p>ICD</p><div><p>International Statistical Classification of Diseases and Related Health Problems</p></div></li><a id=\"\">&nbsp;</a><li><p>MHP</p><div><p>mental health professional</p></div></li><a id=\"\">&nbsp;</a><li><p>VTE</p></li></ul>                    <h2 scrollto-destination=\"99603465\" id=\"99603465\">Acknowledgments</h2>\n<p><strong><em>Disclosure Summary:</em></strong> See Financial Disclosures.</p>                    <h2 scrollto-destination=\"99603467\" id=\"99603467\">References</h2>\n<div><div id=\"ref-auto-B1\" data-id=\"B1\" content-id=\"B1\" data-legacy-id=\"B1\"><p><span>1.</span></p><div><p>Atkins</p>  <p>D</p><p>\n, <span>\n<p>Best</p>  <p>D</p>\n</span>, <span>\n<p>Briss</p>  <p>PA</p>\n</span>, <span>\n<p>Eccles</p>  <p>M</p>\n</span>, <span>\n<p>Falck-Ytter</p>  <p>Y</p>\n</span>, <span>\n<p>Flottorp</p>  <p>S</p>\n</span>, <span>\n<p>Guyatt</p>  <p>GH</p>\n</span>, <span>\n<p>Harbour</p>  <p>RT</p>\n</span>, <span>\n<p>Haugh</p>  <p>MC</p>\n</span>, <span>\n<p>Henry</p>  <p>D</p>\n</span>, <span>\n<p>Hill</p>  <p>S</p>\n</span>, <span>\n<p>Jaeschke</p>  <p>R</p>\n</span>, <span>\n<p>Leng</p>  <p>G</p>\n</span>, <span>\n<p>Liberati</p>  <p>A</p>\n</span>, <span>\n<p>Magrini</p>  <p>N</p>\n</span>, <span>\n<p>Mason</p>  <p>J</p>\n</span>, <span>\n<p>Middleton</p>  <p>P</p>\n</span>, <span>\n<p>Mrukowicz</p>  <p>J</p>\n</span>, <span>\n<p>O’Connell</p>  <p>D</p>\n</span>, <span>\n<p>Oxman</p>  <p>AD</p>\n</span>, <span>\n<p>Phillips</p>  <p>B</p>\n</span>, <span>\n<p>Schünemann</p>  <p>HJ</p>\n</span>, <span>\n<p>Edejer</p>  <p>T</p>\n</span>, <span>\n<p>Varonen</p>  <p>H</p>\n</span>, <span>\n<p>Vist</p>  <p>GE</p>\n</span>, <span>\n<p>Williams</p>  <p>JW</p>, Jr\n</span>, <span>\n<p>Zaza</p>  <p>S</p>\n</span>; </p><p>GRADE Working Group</p><p>\n. </p><p>Grading quality of evidence and strength of recommendations</p><p>. </p><p>BMJ</p><p>. </p><p>2004</p><p>;</p><p>328</p><p>(</p><p>7454</p><p>):</p><p>1490</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B2\" data-id=\"B2\" content-id=\"B2\" data-legacy-id=\"B2\"><p><span>2.</span></p><div><p>Swiglo</p>  <p>BA</p><p>\n, <span>\n<p>Murad</p>  <p>MH</p>\n</span>, <span>\n<p>Schünemann</p>  <p>HJ</p>\n</span>, <span>\n<p>Kunz</p>  <p>R</p>\n</span>, <span>\n<p>Vigersky</p>  <p>RA</p>\n</span>, <span>\n<p>Guyatt</p>  <p>GH</p>\n</span>, <span>\n<p>Montori</p>  <p>VM</p>\n</span>\n. </p><p>A case for clarity, consistency, and helpfulness: state-of-the-art clinical practice guidelines in endocrinology using the grading of recommendations, assessment, development, and evaluation system</p><p>. </p><p>J Clin Endocrinol Metab</p><p>. </p><p>2008</p><p>;</p><p>93</p><p>(</p><p>3</p><p>):</p><p>666</p><p>–</p><p>673</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B3\" data-id=\"B3\" content-id=\"B3\" data-legacy-id=\"B3\"><p><span>3.</span></p><div><p>Bullough</p>  <p>VL</p><p>\n\n. </p><p>Transsexualism in history</p><p>. </p><p>Arch Sex Behav</p><p>. </p><p>1975</p><p>;</p><p>4</p><p>(</p><p>5</p><p>):</p><p>561</p><p>–</p><p>571</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B4\" data-id=\"B4\" content-id=\"B4\" data-legacy-id=\"B4\"><p><span>4.</span></p><div><p>Benjamin</p>  <p>H</p><p>\n\n. </p><p>The transsexual phenomenon</p><p>. </p><p>Trans N Y Acad Sci</p><p>. </p><p>1967</p><p>;</p><p>29</p><p>(</p><p>4</p><p>):</p><p>428</p><p>–</p><p>430</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B5\" data-id=\"B5\" content-id=\"B5\" data-legacy-id=\"B5\"><p><span>5.</span></p><div><p>Meyerowitz</p>  <p>J</p><p>\n\n. </p><p><em>How Sex Changed: A History of Transsexuality in the United States.</em> Cambridge, MA: Harvard University Press</p><p>; </p><p>2002</p><p>.</p></div></div><div id=\"ref-auto-B6\" data-id=\"B6\" content-id=\"B6\" data-legacy-id=\"B6\"><p><span>6.</span></p><div><p>Hirschfeld</p>  <p>M.</p>\n\n <p><em>Was muss das Volk vom Dritten Geschlecht wissen</em>. Verlag Max Spohr, Leipzig; 1901.</p>\n</div></div><div id=\"ref-auto-B7\" data-id=\"B7\" content-id=\"B7\" data-legacy-id=\"B7\"><p><span>7.</span></p><div><p>Fisk</p>  <p>NM</p><p>\n\n. </p><p>Editorial: Gender dysphoria syndrome—the conceptualization that liberalizes indications for total gender reorientation and implies a broadly based multi-dimensional rehabilitative regimen</p><p>. </p><p>West J Med</p><p>. </p><p>1974</p><p>;</p><p>120</p><p>(</p><p>5</p><p>):</p><p>386</p><p>–</p><p>391</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B8\" data-id=\"B8\" content-id=\"B8\" data-legacy-id=\"B8\"><p><span>8.</span></p><div><p>Diamond</p>  <p>L</p><p>\n\n. </p><p>Transgender experience and identity. In: Schwartz SJ, Luyckx K, Vignoles VL, eds. <em>Handbook of Identity Theory and Research</em>. New York, NY: Springer;</p> <p>2011</p><p>:</p><p>629</p><p>–</p><p>647</p><p>.</p></div></div><div id=\"ref-auto-B9\" data-id=\"B9\" content-id=\"B9\" data-legacy-id=\"B9\"><p><span>9.</span></p><div><p>Queen</p>  <p>C</p><p>\n, <span>\n<p>Schimel</p>  <p>L</p>\n</span>\n, eds. </p><p><em>PoMoSexuals: Challenging Assumptions About Gender and Sexuality</em>. San Francisco, CA: Cleis Press; 1997</p><p>.</p></div></div><div id=\"ref-auto-B10\" data-id=\"B10\" content-id=\"B10\" data-legacy-id=\"B10\"><p><span>10.</span></p><div><p>Case</p>  <p>LK</p><p>\n, <span>\n<p>Ramachandran</p>  <p>VS</p>\n</span>\n. </p><p>Alternating gender incongruity: a new neuropsychiatric syndrome providing insight into the dynamic plasticity of brain-sex</p><p>. </p><p>Med Hypotheses</p><p>. </p><p>2012</p><p>;</p><p>78</p><p>(</p><p>5</p><p>):</p><p>626</p><p>–</p><p>631</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B11\" data-id=\"B11\" content-id=\"B11\" data-legacy-id=\"B11\"><p><span>11.</span></p><div><p>Johnson</p>  <p>TW</p><p>\n, <span>\n<p>Wassersug</p>  <p>RJ</p>\n</span>\n. </p><p>Gender identity disorder outside the binary: when gender identity disorder-not otherwise specified is not good enough</p><p>. </p><p>Arch Sex Behav</p><p>. </p><p>2010</p><p>;</p><p>39</p><p>(</p><p>3</p><p>):</p><p>597</p><p>–</p><p>598</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B12\" data-id=\"B12\" content-id=\"B12\" data-legacy-id=\"B12\"><p><span>12.</span></p><div><p>Wibowo</p>  <p>E</p><p>\n, <span>\n<p>Wassersug</p>  <p>R</p>\n</span>, <span>\n<p>Warkentin</p>  <p>K</p>\n</span>, <span>\n<p>Walker</p>  <p>L</p>\n</span>, <span>\n<p>Robinson</p>  <p>J</p>\n</span>, <span>\n<p>Brotto</p>  <p>L</p>\n</span>, <span>\n<p>Johnson</p>  <p>T</p>\n</span>\n. </p><p>Impact of androgen deprivation therapy on sexual function: a response</p><p>. </p><p>Asian J Androl</p><p>. </p><p>2012</p><p>;</p><p>14</p><p>(</p><p>5</p><p>):</p><p>793</p><p>–</p><p>794</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B14\" data-id=\"B14\" content-id=\"B14\" data-legacy-id=\"B14\"><p><span>14.</span></p><div><p>American Psychiatric Association</p><p>\n. </p><p>Diagnostic and Statistical Manual of Mental Disorders</p><p>. </p><p>5th ed. Arlington, VA: American Psychiatric Association Publishing</p><p>.</p></div></div><div id=\"ref-auto-B15\" data-id=\"B15\" content-id=\"B15\" data-legacy-id=\"B15\"><p><span>15.</span></p><div><p>Drescher</p>  <p>J</p><p>\n, <span>\n<p>Cohen-Kettenis</p>  <p>P</p>\n</span>, <span>\n<p>Winter</p>  <p>S</p>\n</span>\n. </p><p>Minding the body: situating gender identity diagnoses in the ICD-11</p><p>. </p><p>Int Rev Psychiatry</p><p>. </p><p>2012</p><p>;</p><p>24</p><p>(</p><p>6</p><p>):</p><p>568</p><p>–</p><p>577</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B17\" data-id=\"B17\" content-id=\"B17\" data-legacy-id=\"B17\"><p><span>17.</span></p><div><p>Kreukels</p>  <p>BP</p><p>\n, <span>\n<p>Haraldsen</p>  <p>IR</p>\n</span>, <span>\n<p>De Cuypere</p>  <p>G</p>\n</span>, <span>\n<p>Richter-Appelt</p>  <p>H</p>\n</span>, <span>\n<p>Gijs</p>  <p>L</p>\n</span>, <span>\n<p>Cohen-Kettenis</p>  <p>PT</p>\n</span>\n. </p><p>A European network for the investigation of gender incongruence: the ENIGI initiative</p><p>. </p><p>Eur Psychiatry</p><p>. </p><p>2012</p><p>;</p><p>27</p><p>(</p><p>6</p><p>):</p><p>445</p><p>–</p><p>450</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B18\" data-id=\"B18\" content-id=\"B18\" data-legacy-id=\"B18\"><p><span>18.</span></p><div><p>Dekker</p>  <p>MJ</p><p>\n, <span>\n<p>Wierckx</p>  <p>K</p>\n</span>, <span>\n<p>Van Caenegem</p>  <p>E</p>\n</span>, <span>\n<p>Klaver</p>  <p>M</p>\n</span>, <span>\n<p>Kreukels</p>  <p>BP</p>\n</span>, <span>\n<p>Elaut</p>  <p>E</p>\n</span>, <span>\n<p>Fisher</p>  <p>AD</p>\n</span>, <span>\n<p>van Trotsenburg</p>  <p>MA</p>\n</span>, <span>\n<p>Schreiner</p>  <p>T</p>\n</span>, <span>\n<p>den Heijer</p>  <p>M</p>\n</span>, <span>\n<p>T’Sjoen</p>  <p>G</p>\n</span>\n. </p><p>A European network for the investigation of gender incongruence: endocrine part</p><p>. </p><p>J Sex Med</p><p>. </p><p>2016</p><p>;</p><p>13</p><p>(</p><p>6</p><p>):</p><p>994</p><p>–</p><p>999</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B19\" data-id=\"B19\" content-id=\"B19\" data-legacy-id=\"B19\"><p><span>19.</span></p><div><p>Ruble</p>  <p>DN</p><p>\n, <span>\n<p>Martin</p>  <p>CL</p>\n</span>, <span>\n<p>Berenbaum</p>  <p>SA</p>\n</span>\n. </p><p>Gender development</p><p>. In: <span>\n<span>\n<p>Damon</p>  <p>WL</p>\n</span>, <span>\n<p>Lerner</p>  <p>RM</p>\n</span>, <span>\n<p>Eisenberg</p>  <p>N</p>\n</span>\n</span>, eds. </p><p>Handbook of Child Psychology: Social, Emotional, and Personality Development</p><p>. </p><p>Vol. 3</p><p>. 6th ed. </p><p>New York, NY</p><p>: </p><p>Wiley</p><p>; </p><p>2006</p><p>;</p><p>858</p><p>–</p><p>931</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B20\" data-id=\"B20\" content-id=\"B20\" data-legacy-id=\"B20\"><p><span>20.</span></p><div><p>Steensma</p>  <p>TD</p><p>\n, <span>\n<p>Kreukels</p>  <p>BP</p>\n</span>, <span>\n<p>de Vries</p>  <p>AL</p>\n</span>, <span>\n<p>Cohen-Kettenis</p>  <p>PT</p>\n</span>\n. </p><p>Gender identity development in adolescence</p><p>. </p><p>Horm Behav</p><p>. </p><p>2013</p><p>;</p><p>64</p><p>(</p><p>2</p><p>):</p><p>288</p><p>–</p><p>297</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B21\" data-id=\"B21\" content-id=\"B21\" data-legacy-id=\"B21\"><p><span>21.</span></p><div><p>Rosenthal</p>  <p>SM</p><p>\n\n. </p><p>Approach to the patient: transgender youth: endocrine considerations</p><p>. </p><p>J Clin Endocrinol Metab</p><p>. </p><p>2014</p><p>;</p><p>99</p><p>(</p><p>12</p><p>):</p><p>4379</p><p>–</p><p>4389</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B22\" data-id=\"B22\" content-id=\"B22\" data-legacy-id=\"B22\"><p><span>22.</span></p><div><p>Saraswat</p>  <p>A</p><p>\n, <span>\n<p>Weinand</p>  <p>JD</p>\n</span>, <span>\n<p>Safer</p>  <p>JD</p>\n</span>\n. </p><p>Evidence supporting the biologic nature of gender identity</p><p>. </p><p>Endocr Pract</p><p>. </p><p>2015</p><p>;</p><p>21</p><p>(</p><p>2</p><p>):</p><p>199</p><p>–</p><p>204</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B23\" data-id=\"B23\" content-id=\"B23\" data-legacy-id=\"B23\"><p><span>23.</span></p><div><p>Gooren</p>  <p>L</p><p>\n\n. </p><p>The biology of human psychosexual differentiation</p><p>. </p><p>Horm Behav</p><p>. </p><p>2006</p><p>;</p><p>50</p><p>(</p><p>4</p><p>):</p><p>589</p><p>–</p><p>601</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B24\" data-id=\"B24\" content-id=\"B24\" data-legacy-id=\"B24\"><p><span>24.</span></p><div><p>Berenbaum</p>  <p>SA</p><p>\n, <span>\n<p>Meyer-Bahlburg</p>  <p>HF</p>\n</span>\n. </p><p>Gender development and sexuality in disorders of sex development</p><p>. </p><p>Horm Metab Res</p><p>. </p><p>2015</p><p>;</p><p>47</p><p>(</p><p>5</p><p>):</p><p>361</p><p>–</p><p>366</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B25\" data-id=\"B25\" content-id=\"B25\" data-legacy-id=\"B25\"><p><span>25.</span></p><div><p>Dessens</p>  <p>AB</p><p>\n, <span>\n<p>Slijper</p>  <p>FME</p>\n</span>, <span>\n<p>Drop</p>  <p>SLS</p>\n</span>\n. </p><p>Gender dysphoria and gender change in chromosomal females with congenital adrenal hyperplasia</p><p>. </p><p>Arch Sex Behav</p><p>. </p><p>2005</p><p>;</p><p>34</p><p>(</p><p>4</p><p>):</p><p>389</p><p>–</p><p>397</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B26\" data-id=\"B26\" content-id=\"B26\" data-legacy-id=\"B26\"><p><span>26.</span></p><div><p>Meyer-Bahlburg</p>  <p>HFL</p><p>\n, <span>\n<p>Dolezal</p>  <p>C</p>\n</span>, <span>\n<p>Baker</p>  <p>SW</p>\n</span>, <span>\n<p>Ehrhardt</p>  <p>AA</p>\n</span>, <span>\n<p>New</p>  <p>MI</p>\n</span>\n. </p><p>Gender development in women with congenital adrenal hyperplasia as a function of disorder severity</p><p>. </p><p>Arch Sex Behav</p><p>. </p><p>2006</p><p>;</p><p>35</p><p>(</p><p>6</p><p>):</p><p>667</p><p>–</p><p>684</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B27\" data-id=\"B27\" content-id=\"B27\" data-legacy-id=\"B27\"><p><span>27.</span></p><div><p>Frisén</p>  <p>L</p><p>\n, <span>\n<p>Nordenström</p>  <p>A</p>\n</span>, <span>\n<p>Falhammar</p>  <p>H</p>\n</span>, <span>\n<p>Filipsson</p>  <p>H</p>\n</span>, <span>\n<p>Holmdahl</p>  <p>G</p>\n</span>, <span>\n<p>Janson</p>  <p>PO</p>\n</span>, <span>\n<p>Thorén</p>  <p>M</p>\n</span>, <span>\n<p>Hagenfeldt</p>  <p>K</p>\n</span>, <span>\n<p>Möller</p>  <p>A</p>\n</span>, <span>\n<p>Nordenskjöld</p>  <p>A</p>\n</span>\n. </p><p>Gender role behavior, sexuality, and psychosocial adaptation in women with congenital adrenal hyperplasia due to CYP21A2 deficiency</p><p>. </p><p>J Clin Endocrinol Metab</p><p>. </p><p>2009</p><p>;</p><p>94</p><p>(</p><p>9</p><p>):</p><p>3432</p><p>–</p><p>3439</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B28\" data-id=\"B28\" content-id=\"B28\" data-legacy-id=\"B28\"><p><span>28.</span></p><div><p>Meyer-Bahlburg</p>  <p>HFL</p><p>\n, <span>\n<p>Dolezal</p>  <p>C</p>\n</span>, <span>\n<p>Baker</p>  <p>SW</p>\n</span>, <span>\n<p>Carlson</p>  <p>AD</p>\n</span>, <span>\n<p>Obeid</p>  <p>JS</p>\n</span>, <span>\n<p>New</p>  <p>MI</p>\n</span>\n. </p><p>Prenatal androgenization affects gender-related behavior but not gender identity in 5–12-year-old girls with congenital adrenal hyperplasia</p><p>. </p><p>Arch Sex Behav</p><p>. </p><p>2004</p><p>;</p><p>33</p><p>(</p><p>2</p><p>):</p><p>97</p><p>–</p><p>104</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B29\" data-id=\"B29\" content-id=\"B29\" data-legacy-id=\"B29\"><p><span>29.</span></p><div><p>Cohen-Kettenis</p>  <p>PT</p><p>\n\n. </p><p>Gender change in 46,XY persons with 5α-reductase-2 deficiency and 17β-hydroxysteroid dehydrogenase-3 deficiency</p><p>. </p><p>Arch Sex Behav</p><p>. </p><p>2005</p><p>;</p><p>34</p><p>(</p><p>4</p><p>):</p><p>399</p><p>–</p><p>410</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B30\" data-id=\"B30\" content-id=\"B30\" data-legacy-id=\"B30\"><p><span>30.</span></p><div><p>Reiner</p>  <p>WG</p><p>\n, <span>\n<p>Gearhart</p>  <p>JP</p>\n</span>\n. </p><p>Discordant sexual identity in some genetic males with cloacal exstrophy assigned to female sex at birth</p><p>. </p><p>N Engl J Med</p><p>. </p><p>2004</p><p>;</p><p>350</p><p>(</p><p>4</p><p>):</p><p>333</p><p>–</p><p>341</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B31\" data-id=\"B31\" content-id=\"B31\" data-legacy-id=\"B31\"><p><span>31.</span></p><div><p>Meyer-Bahlburg</p>  <p>HFL</p><p>\n\n. </p><p>Gender identity outcome in female-raised 46,XY persons with penile agenesis, cloacal exstrophy of the bladder, or penile ablation</p><p>. </p><p>Arch Sex Behav</p><p>. </p><p>2005</p><p>;</p><p>34</p><p>(</p><p>4</p><p>):</p><p>423</p><p>–</p><p>438</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B32\" data-id=\"B32\" content-id=\"B32\" data-legacy-id=\"B32\"><p><span>32.</span></p><div><p>Coolidge</p>  <p>FL</p><p>\n, <span>\n<p>Thede</p>  <p>LL</p>\n</span>, <span>\n<p>Young</p>  <p>SE</p>\n</span>\n. </p><p>The heritability of gender identity disorder in a child and adolescent twin sample</p><p>. </p><p>Behav Genet</p><p>. </p><p>2002</p><p>;</p><p>32</p><p>(</p><p>4</p><p>):</p><p>251</p><p>–</p><p>257</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B33\" data-id=\"B33\" content-id=\"B33\" data-legacy-id=\"B33\"><p><span>33.</span></p><div><p>Heylens</p>  <p>G</p><p>\n, <span>\n<p>De Cuypere</p>  <p>G</p>\n</span>, <span>\n<p>Zucker</p>  <p>KJ</p>\n</span>, <span>\n<p>Schelfaut</p>  <p>C</p>\n</span>, <span>\n<p>Elaut</p>  <p>E</p>\n</span>, <span>\n<p>Vanden Bossche</p>  <p>H</p>\n</span>, <span>\n<p>De Baere</p>  <p>E</p>\n</span>, <span>\n<p>T’Sjoen</p>  <p>G</p>\n</span>\n. </p><p>Gender identity disorder in twins: a review of the case report literature</p><p>. </p><p>J Sex Med</p><p>. </p><p>2012</p><p>;</p><p>9</p><p>(</p><p>3</p><p>):</p><p>751</p><p>–</p><p>757</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B34\" data-id=\"B34\" content-id=\"B34\" data-legacy-id=\"B34\"><p><span>34.</span></p><div><p>Fernández</p>  <p>R</p><p>\n, <span>\n<p>Esteva</p>  <p>I</p>\n</span>, <span>\n<p>Gómez-Gil</p>  <p>E</p>\n</span>, <span>\n<p>Rumbo</p>  <p>T</p>\n</span>, <span>\n<p>Almaraz</p>  <p>MC</p>\n</span>, <span>\n<p>Roda</p>  <p>E</p>\n</span>, <span>\n<p>Haro-Mora</p>  <p>J-J</p>\n</span>, <span>\n<p>Guillamón</p>  <p>A</p>\n</span>, <span>\n<p>Pásaro</p>  <p>E</p>\n</span>\n. </p><p>Association study of ERβ, AR, and CYP19A1 genes and MtF transsexualism</p><p>. </p><p>J Sex Med</p><p>. </p><p>2014</p><p>;</p><p>11</p><p>(</p><p>12</p><p>):</p><p>2986</p><p>–</p><p>2994</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B35\" data-id=\"B35\" content-id=\"B35\" data-legacy-id=\"B35\"><p><span>35.</span></p><div><p>Henningsson</p>  <p>S</p><p>\n, <span>\n<p>Westberg</p>  <p>L</p>\n</span>, <span>\n<p>Nilsson</p>  <p>S</p>\n</span>, <span>\n<p>Lundström</p>  <p>B</p>\n</span>, <span>\n<p>Ekselius</p>  <p>L</p>\n</span>, <span>\n<p>Bodlund</p>  <p>O</p>\n</span>, <span>\n<p>Lindström</p>  <p>E</p>\n</span>, <span>\n<p>Hellstrand</p>  <p>M</p>\n</span>, <span>\n<p>Rosmond</p>  <p>R</p>\n</span>, <span>\n<p>Eriksson</p>  <p>E</p>\n</span>, <span>\n<p>Landén</p>  <p>M</p>\n</span>\n. </p><p>Sex steroid-related genes and male-to-female transsexualism</p><p>. </p><p>Psychoneuroendocrinology</p><p>. </p><p>2005</p><p>;</p><p>30</p><p>(</p><p>7</p><p>):</p><p>657</p><p>–</p><p>664</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B36\" data-id=\"B36\" content-id=\"B36\" data-legacy-id=\"B36\"><p><span>36.</span></p><div><p>Hare</p>  <p>L</p><p>\n, <span>\n<p>Bernard</p>  <p>P</p>\n</span>, <span>\n<p>Sánchez</p>  <p>FJ</p>\n</span>, <span>\n<p>Baird</p>  <p>PN</p>\n</span>, <span>\n<p>Vilain</p>  <p>E</p>\n</span>, <span>\n<p>Kennedy</p>  <p>T</p>\n</span>, <span>\n<p>Harley</p>  <p>VR</p>\n</span>\n. </p><p>Androgen receptor repeat length polymorphism associated with male-to-female transsexualism</p><p>. </p><p>Biol Psychiatry</p><p>. </p><p>2009</p><p>;</p><p>65</p><p>(</p><p>1</p><p>):</p><p>93</p><p>–</p><p>96</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B37\" data-id=\"B37\" content-id=\"B37\" data-legacy-id=\"B37\"><p><span>37.</span></p><div><p>Lombardo</p>  <p>F</p><p>\n, <span>\n<p>Toselli</p>  <p>L</p>\n</span>, <span>\n<p>Grassetti</p>  <p>D</p>\n</span>, <span>\n<p>Paoli</p>  <p>D</p>\n</span>, <span>\n<p>Masciandaro</p>  <p>P</p>\n</span>, <span>\n<p>Valentini</p>  <p>F</p>\n</span>, <span>\n<p>Lenzi</p>  <p>A</p>\n</span>, <span>\n<p>Gandini</p>  <p>L</p>\n</span>\n. </p><p>Hormone and genetic study in male to female transsexual patients</p><p>. </p><p>J Endocrinol Invest</p><p>. </p><p>2013</p><p>;</p><p>36</p><p>(</p><p>8</p><p>):</p><p>550</p><p>–</p><p>557</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B38\" data-id=\"B38\" content-id=\"B38\" data-legacy-id=\"B38\"><p><span>38.</span></p><div><p>Ujike</p>  <p>H</p><p>\n, <span>\n<p>Otani</p>  <p>K</p>\n</span>, <span>\n<p>Nakatsuka</p>  <p>M</p>\n</span>, <span>\n<p>Ishii</p>  <p>K</p>\n</span>, <span>\n<p>Sasaki</p>  <p>A</p>\n</span>, <span>\n<p>Oishi</p>  <p>T</p>\n</span>, <span>\n<p>Sato</p>  <p>T</p>\n</span>, <span>\n<p>Okahisa</p>  <p>Y</p>\n</span>, <span>\n<p>Matsumoto</p>  <p>Y</p>\n</span>, <span>\n<p>Namba</p>  <p>Y</p>\n</span>, <span>\n<p>Kimata</p>  <p>Y</p>\n</span>, <span>\n<p>Kuroda</p>  <p>S</p>\n</span>\n. </p><p>Association study of gender identity disorder and sex hormone-related genes</p><p>. </p><p>Prog Neuropsychopharmacol Biol Psychiatry</p><p>. </p><p>2009</p><p>;</p><p>33</p><p>(</p><p>7</p><p>):</p><p>1241</p><p>–</p><p>1244</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B39\" data-id=\"B39\" content-id=\"B39\" data-legacy-id=\"B39\"><p><span>39.</span></p><div><p>Kreukels</p>  <p>BP</p><p>\n, <span>\n<p>Guillamon</p>  <p>A</p>\n</span>\n. </p><p>Neuroimaging studies in people with gender incongruence</p><p>. </p><p>Int Rev Psychiatry</p><p>. </p><p>2016</p><p>;</p><p>28</p><p>(</p><p>1</p><p>):</p><p>120</p><p>–</p><p>128</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B40\" data-id=\"B40\" content-id=\"B40\" data-legacy-id=\"B40\"><p><span>40.</span></p><div><p>Steensma</p>  <p>TD</p><p>\n, <span>\n<p>Biemond</p>  <p>R</p>\n</span>, <span>\n<p>de Boer</p>  <p>F</p>\n</span>, <span>\n<p>Cohen-Kettenis</p>  <p>PT</p>\n</span>\n. </p><p>Desisting and persisting gender dysphoria after childhood: a qualitative follow-up study</p><p>. </p><p>Clin Child Psychol Psychiatry</p><p>. </p><p>2011</p><p>;</p><p>16</p><p>(</p><p>4</p><p>):</p><p>499</p><p>–</p><p>516</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B41\" data-id=\"B41\" content-id=\"B41\" data-legacy-id=\"B41\"><p><span>41.</span></p><div><p>Wallien</p>  <p>MSC</p><p>\n, <span>\n<p>Cohen-Kettenis</p>  <p>PT</p>\n</span>\n. </p><p>Psychosexual outcome of gender-dysphoric children</p><p>. </p><p>J Am Acad Child Adolesc Psychiatry</p><p>. </p><p>2008</p><p>;</p><p>47</p><p>(</p><p>12</p><p>):</p><p>1413</p><p>–</p><p>1423</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B42\" data-id=\"B42\" content-id=\"B42\" data-legacy-id=\"B42\"><p><span>42.</span></p><div><p>Steensma</p>  <p>TD</p><p>\n, <span>\n<p>McGuire</p>  <p>JK</p>\n</span>, <span>\n<p>Kreukels</p>  <p>BPC</p>\n</span>, <span>\n<p>Beekman</p>  <p>AJ</p>\n</span>, <span>\n<p>Cohen-Kettenis</p>  <p>PT</p>\n</span>\n. </p><p>Factors associated with desistence and persistence of childhood gender dysphoria: a quantitative follow-up study</p><p>. </p><p>J Am Acad Child Adolesc Psychiatry</p><p>. </p><p>2013</p><p>;</p><p>52</p><p>(</p><p>6</p><p>):</p><p>582</p><p>–</p><p>590</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B43\" data-id=\"B43\" content-id=\"B43\" data-legacy-id=\"B43\"><p><span>43.</span></p><div><p>Cohen-Kettenis</p>  <p>PT</p><p>\n, <span>\n<p>Owen</p>  <p>A</p>\n</span>, <span>\n<p>Kaijser</p>  <p>VG</p>\n</span>, <span>\n<p>Bradley</p>  <p>SJ</p>\n</span>, <span>\n<p>Zucker</p>  <p>KJ</p>\n</span>\n. </p><p>Demographic characteristics, social competence, and behavior problems in children with gender identity disorder: a cross-national, cross-clinic comparative analysis</p><p>. </p><p>J Abnorm Child Psychol</p><p>. </p><p>2003</p><p>;</p><p>31</p><p>(</p><p>1</p><p>):</p><p>41</p><p>–</p><p>53</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B44\" data-id=\"B44\" content-id=\"B44\" data-legacy-id=\"B44\"><p><span>44.</span></p><div><p>Dhejne</p>  <p>C</p><p>\n, <span>\n<p>Van Vlerken</p>  <p>R</p>\n</span>, <span>\n<p>Heylens</p>  <p>G</p>\n</span>, <span>\n<p>Arcelus</p>  <p>J</p>\n</span>\n. </p><p>Mental health and gender dysphoria: a review of the literature</p><p>. </p><p>Int Rev Psychiatry</p><p>. </p><p>2016</p><p>;</p><p>28</p><p>(</p><p>1</p><p>):</p><p>44</p><p>–</p><p>57</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B45\" data-id=\"B45\" content-id=\"B45\" data-legacy-id=\"B45\"><p><span>45.</span></p><div><p>Pasterski</p>  <p>V</p><p>\n, <span>\n<p>Gilligan</p>  <p>L</p>\n</span>, <span>\n<p>Curtis</p>  <p>R</p>\n</span>\n. </p><p>Traits of autism spectrum disorders in adults with gender dysphoria</p><p>. </p><p>Arch Sex Behav</p><p>. </p><p>2014</p><p>;</p><p>43</p><p>(</p><p>2</p><p>):</p><p>387</p><p>–</p><p>393</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B46\" data-id=\"B46\" content-id=\"B46\" data-legacy-id=\"B46\"><p><span>46.</span></p><div><p>Spack</p>  <p>NP</p><p>\n, <span>\n<p>Edwards-Leeper</p>  <p>L</p>\n</span>, <span>\n<p>Feldman</p>  <p>HA</p>\n</span>, <span>\n<p>Leibowitz</p>  <p>S</p>\n</span>, <span>\n<p>Mandel</p>  <p>F</p>\n</span>, <span>\n<p>Diamond</p>  <p>DA</p>\n</span>, <span>\n<p>Vance</p>  <p>SR</p>\n</span>\n. </p><p>Children and adolescents with gender identity disorder referred to a pediatric medical center</p><p>. </p><p>Pediatrics</p><p>. </p><p>2012</p><p>;</p><p>129</p><p>(</p><p>3</p><p>):</p><p>418</p><p>–</p><p>425</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B47\" data-id=\"B47\" content-id=\"B47\" data-legacy-id=\"B47\"><p><span>47.</span></p><div><p>Terada</p>  <p>S</p><p>\n, <span>\n<p>Matsumoto</p>  <p>Y</p>\n</span>, <span>\n<p>Sato</p>  <p>T</p>\n</span>, <span>\n<p>Okabe</p>  <p>N</p>\n</span>, <span>\n<p>Kishimoto</p>  <p>Y</p>\n</span>, <span>\n<p>Uchitomi</p>  <p>Y</p>\n</span>\n. </p><p>Factors predicting psychiatric co-morbidity in gender-dysphoric adults</p><p>. </p><p>Psychiatry Res</p><p>. </p><p>2012</p><p>;</p><p>200</p><p>(</p><p>2-3</p><p>):</p><p>469</p><p>–</p><p>474</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B48\" data-id=\"B48\" content-id=\"B48\" data-legacy-id=\"B48\"><p><span>48.</span></p><div><p>VanderLaan</p>  <p>DP</p><p>\n, <span>\n<p>Leef</p>  <p>JH</p>\n</span>, <span>\n<p>Wood</p>  <p>H</p>\n</span>, <span>\n<p>Hughes</p>  <p>SK</p>\n</span>, <span>\n<p>Zucker</p>  <p>KJ</p>\n</span>\n. </p><p>Autism spectrum disorder risk factors and autistic traits in gender dysphoric children</p><p>. </p><p>J Autism Dev Disord</p><p>. </p><p>2015</p><p>;</p><p>45</p><p>(</p><p>6</p><p>):</p><p>1742</p><p>–</p><p>1750</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B49\" data-id=\"B49\" content-id=\"B49\" data-legacy-id=\"B49\"><p><span>49.</span></p><div><p>de Vries</p>  <p>ALC</p><p>\n, <span>\n<p>Doreleijers</p>  <p>TAH</p>\n</span>, <span>\n<p>Steensma</p>  <p>TD</p>\n</span>, <span>\n<p>Cohen-Kettenis</p>  <p>PT</p>\n</span>\n. </p><p>Psychiatric comorbidity in gender dysphoric adolescents</p><p>. </p><p>J Child Psychol Psychiatry</p><p>. </p><p>2011</p><p>;</p><p>52</p><p>(</p><p>11</p><p>):</p><p>1195</p><p>–</p><p>1202</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B50\" data-id=\"B50\" content-id=\"B50\" data-legacy-id=\"B50\"><p><span>50.</span></p><div><p>de Vries</p>  <p>ALC</p><p>\n, <span>\n<p>Noens</p>  <p>ILJ</p>\n</span>, <span>\n<p>Cohen-Kettenis</p>  <p>PT</p>\n</span>, <span>\n<p>van Berckelaer-Onnes</p>  <p>IA</p>\n</span>, <span>\n<p>Doreleijers</p>  <p>TA</p>\n</span>\n. </p><p>Autism spectrum disorders in gender dysphoric children and adolescents</p><p>. </p><p>J Autism Dev Disord</p><p>. </p><p>2010</p><p>;</p><p>40</p><p>(</p><p>8</p><p>):</p><p>930</p><p>–</p><p>936</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B51\" data-id=\"B51\" content-id=\"B51\" data-legacy-id=\"B51\"><p><span>51.</span></p><div><p>Wallien</p>  <p>MSC</p><p>\n, <span>\n<p>Swaab</p>  <p>H</p>\n</span>, <span>\n<p>Cohen-Kettenis</p>  <p>PT</p>\n</span>\n. </p><p>Psychiatric comorbidity among children with gender identity disorder</p><p>. </p><p>J Am Acad Child Adolesc Psychiatry</p><p>. </p><p>2007</p><p>;</p><p>46</p><p>(</p><p>10</p><p>):</p><p>1307</p><p>–</p><p>1314</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B52\" data-id=\"B52\" content-id=\"B52\" data-legacy-id=\"B52\"><p><span>52.</span></p><div><p>Kuiper AJ, Cohen-Kettenis PT. Gender role reversal among postoperative transsexuals. Available at: https://www.atria.nl/ezines/web/IJT/97-03/numbers/symposion/ijtc0502.htm. Accessed 26 August 2016</p><p>.</p></div></div><div id=\"ref-auto-B53\" data-id=\"B53\" content-id=\"B53\" data-legacy-id=\"B53\"><p><span>53.</span></p><div><p>Landén</p>  <p>M</p><p>\n, <span>\n<p>Wålinder</p>  <p>J</p>\n</span>, <span>\n<p>Hambert</p>  <p>G</p>\n</span>, <span>\n<p>Lundström</p>  <p>B</p>\n</span>\n. </p><p>Factors predictive of regret in sex reassignment</p><p>. </p><p>Acta Psychiatr Scand</p><p>. </p><p>1998</p><p>;</p><p>97</p><p>(</p><p>4</p><p>):</p><p>284</p><p>–</p><p>289</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B54\" data-id=\"B54\" content-id=\"B54\" data-legacy-id=\"B54\"><p><span>54.</span></p><div><p>Olsson</p>  <p>S-E</p><p>\n, <span>\n<p>Möller</p>  <p>A</p>\n</span>\n. </p><p>Regret after sex reassignment surgery in a male-to-female transsexual: a long-term follow-up</p><p>. </p><p>Arch Sex Behav</p><p>. </p><p>2006</p><p>;</p><p>35</p><p>(</p><p>4</p><p>):</p><p>501</p><p>–</p><p>506</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B55\" data-id=\"B55\" content-id=\"B55\" data-legacy-id=\"B55\"><p><span>55.</span></p><div><p>Pfäfflin</p>  <p>F</p><p>\n, <span>\n<p>Junge</p>  <p>A</p>\n</span>\n, eds. </p><p>Geschlechtsumwandlung: Abhandlungen zur Transsexualität</p><p>. </p><p>Stuttgart, Germany</p><p>: </p><p>Schattauer</p><p>; </p><p>1992</p><p>.</p><!--citationLinks: case 2--></div></div><div id=\"ref-auto-B56\" data-id=\"B56\" content-id=\"B56\" data-legacy-id=\"B56\"><p><span>56.</span></p><div><p>Lawrence</p>  <p>AA</p><p>\n\n. </p><p>Factors associated with satisfaction or regret following male-to-female sex reassignment surgery</p><p>. </p><p>Arch Sex Behav</p><p>. </p><p>2003</p><p>;</p><p>32</p><p>(</p><p>4</p><p>):</p><p>299</p><p>–</p><p>315</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B57\" data-id=\"B57\" content-id=\"B57\" data-legacy-id=\"B57\"><p><span>57.</span></p><div><p>Cohen-Kettenis</p>  <p>PT</p><p>\n, <span>\n<p>Pfäfflin</p>  <p>F</p>\n</span>\n. </p><p>Transgenderism and Intersexuality in Childhood and Adolescence: Making Choices</p><p>. </p><p>Thousand Oaks, CA</p><p>: </p><p>SAGE Publications</p><p>; </p><p>2003</p><p>.</p><!--citationLinks: case 2--></div></div><div id=\"ref-auto-B59\" data-id=\"B59\" content-id=\"B59\" data-legacy-id=\"B59\"><p><span>59.</span></p><div><p>Gijs</p>  <p>L</p><p>\n, <span>\n<p>Brewaeys</p>  <p>A</p>\n</span>\n. </p><p>Surgical treatment of gender dysphoria in adults and adolescents: recent developments, effectiveness, and challenges</p><p>. </p><p>Annu Rev Sex Res</p><p>. </p><p>2007</p><p>;</p><p>18</p><p>:</p><p>178</p><p>–</p><p>224</p><p>.</p><!--citationLinks: case 2--></div></div><div id=\"ref-auto-B60\" data-id=\"B60\" content-id=\"B60\" data-legacy-id=\"B60\"><p><span>60.</span></p><div><p>Cohen-Kettenis</p>  <p>PT</p><p>\n, <span>\n<p>van Goozen</p>  <p>SHM</p>\n</span>\n. </p><p>Sex reassignment of adolescent transsexuals: a follow-up study</p><p>. </p><p>J Am Acad Child Adolesc Psychiatry</p><p>. </p><p>1997</p><p>;</p><p>36</p><p>(</p><p>2</p><p>):</p><p>263</p><p>–</p><p>271</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B61\" data-id=\"B61\" content-id=\"B61\" data-legacy-id=\"B61\"><p><span>61.</span></p><div><p>Smith</p>  <p>YLS</p><p>\n, <span>\n<p>van Goozen</p>  <p>SHM</p>\n</span>, <span>\n<p>Cohen-Kettenis</p>  <p>PT</p>\n</span>\n. </p><p>Adolescents with gender identity disorder who were accepted or rejected for sex reassignment surgery: a prospective follow-up study</p><p>. </p><p>J Am Acad Child Adolesc Psychiatry</p><p>. </p><p>2001</p><p>;</p><p>40</p><p>(</p><p>4</p><p>):</p><p>472</p><p>–</p><p>481</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B62\" data-id=\"B62\" content-id=\"B62\" data-legacy-id=\"B62\"><p><span>62.</span></p><div><p>Smith</p>  <p>YLS</p><p>\n, <span>\n<p>Van Goozen</p>  <p>SHM</p>\n</span>, <span>\n<p>Kuiper</p>  <p>AJ</p>\n</span>, <span>\n<p>Cohen-Kettenis</p>  <p>PT</p>\n</span>\n. </p><p>Sex reassignment: outcomes and predictors of treatment for adolescent and adult transsexuals</p><p>. </p><p>Psychol Med</p><p>. </p><p>2005</p><p>;</p><p>35</p><p>(</p><p>1</p><p>):</p><p>89</p><p>–</p><p>99</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B63\" data-id=\"B63\" content-id=\"B63\" data-legacy-id=\"B63\"><p><span>63.</span></p><div><p>de Vries</p>  <p>ALC</p><p>\n, <span>\n<p>McGuire</p>  <p>JK</p>\n</span>, <span>\n<p>Steensma</p>  <p>TD</p>\n</span>, <span>\n<p>Wagenaar</p>  <p>ECF</p>\n</span>, <span>\n<p>Doreleijers</p>  <p>TAH</p>\n</span>, <span>\n<p>Cohen-Kettenis</p>  <p>PT</p>\n</span>\n. </p><p>Young adult psychological outcome after puberty suppression and gender reassignment</p><p>. </p><p>Pediatrics</p><p>. </p><p>2014</p><p>;</p><p>134</p><p>(</p><p>4</p><p>):</p><p>696</p><p>–</p><p>704</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B64\" data-id=\"B64\" content-id=\"B64\" data-legacy-id=\"B64\"><p><span>64.</span></p><div><p>Cole</p>  <p>CM</p><p>\n, <span>\n<p>O’Boyle</p>  <p>M</p>\n</span>, <span>\n<p>Emory</p>  <p>LE</p>\n</span>, <span>\n<p>Meyer</p>  <p>WJ</p> III\n</span>\n. </p><p>Comorbidity of gender dysphoria and other major psychiatric diagnoses</p><p>. </p><p>Arch Sex Behav</p><p>. </p><p>1997</p><p>;</p><p>26</p><p>(</p><p>1</p><p>):</p><p>13</p><p>–</p><p>26</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B65\" data-id=\"B65\" content-id=\"B65\" data-legacy-id=\"B65\"><p><span>65.</span></p><div><p>Cohen-Kettenis</p>  <p>PT</p><p>\n, <span>\n<p>Schagen</p>  <p>SEE</p>\n</span>, <span>\n<p>Steensma</p>  <p>TD</p>\n</span>, <span>\n<p>de Vries</p>  <p>ALC</p>\n</span>, <span>\n<p>Delemarre-van de Waal</p>  <p>HA</p>\n</span>\n. </p><p>Puberty suppression in a gender-dysphoric adolescent: a 22-year follow-up</p><p>. </p><p>Arch Sex Behav</p><p>. </p><p>2011</p><p>;</p><p>40</p><p>(</p><p>4</p><p>):</p><p>843</p><p>–</p><p>847</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B66\" data-id=\"B66\" content-id=\"B66\" data-legacy-id=\"B66\"><p><span>66.</span></p><div><p>First</p>  <p>MB</p><p>\n\n. </p><p>Desire for amputation of a limb: paraphilia, psychosis, or a new type of identity disorder</p><p>. </p><p>Psychol Med</p><p>. </p><p>2005</p><p>;</p><p>35</p><p>(</p><p>6</p><p>):</p><p>919</p><p>–</p><p>928</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B67\" data-id=\"B67\" content-id=\"B67\" data-legacy-id=\"B67\"><p><span>67.</span></p><div><p>Wierckx</p>  <p>K</p><p>\n, <span>\n<p>Van Caenegem</p>  <p>E</p>\n</span>, <span>\n<p>Pennings</p>  <p>G</p>\n</span>, <span>\n<p>Elaut</p>  <p>E</p>\n</span>, <span>\n<p>Dedecker</p>  <p>D</p>\n</span>, <span>\n<p>Van de Peer</p>  <p>F</p>\n</span>, <span>\n<p>Weyers</p>  <p>S</p>\n</span>, <span>\n<p>De Sutter</p>  <p>P</p>\n</span>, <span>\n<p>T’Sjoen</p>  <p>G</p>\n</span>\n. </p><p>Reproductive wish in transsexual men</p><p>. </p><p>Hum Reprod</p><p>. </p><p>2012</p><p>;</p><p>27</p><p>(</p><p>2</p><p>):</p><p>483</p><p>–</p><p>487</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B68\" data-id=\"B68\" content-id=\"B68\" data-legacy-id=\"B68\"><p><span>68.</span></p><div><p>Wierckx</p>  <p>K</p><p>\n, <span>\n<p>Stuyver</p>  <p>I</p>\n</span>, <span>\n<p>Weyers</p>  <p>S</p>\n</span>, <span>\n<p>Hamada</p>  <p>A</p>\n</span>, <span>\n<p>Agarwal</p>  <p>A</p>\n</span>, <span>\n<p>De Sutter</p>  <p>P</p>\n</span>, <span>\n<p>T’Sjoen</p>  <p>G</p>\n</span>\n. </p><p>Sperm freezing in transsexual women</p><p>. </p><p>Arch Sex Behav</p><p>. </p><p>2012</p><p>;</p><p>41</p><p>(</p><p>5</p><p>):</p><p>1069</p><p>–</p><p>1071</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B69\" data-id=\"B69\" content-id=\"B69\" data-legacy-id=\"B69\"><p><span>69.</span></p><div><p>Bertelloni</p>  <p>S</p><p>\n, <span>\n<p>Baroncelli</p>  <p>GI</p>\n</span>, <span>\n<p>Ferdeghini</p>  <p>M</p>\n</span>, <span>\n<p>Menchini-Fabris</p>  <p>F</p>\n</span>, <span>\n<p>Saggese</p>  <p>G</p>\n</span>\n. </p><p>Final height, gonadal function and bone mineral density of adolescent males with central precocious puberty after therapy with gonadotropin-releasing hormone analogues</p><p>. </p><p>Eur J Pediatr</p><p>. </p><p>2000</p><p>;</p><p>159</p><p>(</p><p>5</p><p>):</p><p>369</p><p>–</p><p>374</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B70\" data-id=\"B70\" content-id=\"B70\" data-legacy-id=\"B70\"><p><span>70.</span></p><div><p>Büchter</p>  <p>D</p><p>\n, <span>\n<p>Behre</p>  <p>HM</p>\n</span>, <span>\n<p>Kliesch</p>  <p>S</p>\n</span>, <span>\n<p>Nieschlag</p>  <p>E</p>\n</span>\n. </p><p>Pulsatile GnRH or human chorionic gonadotropin/human menopausal gonadotropin as effective treatment for men with hypogonadotropic hypogonadism: a review of 42 cases</p><p>. </p><p>Eur J Endocrinol</p><p>. </p><p>1998</p><p>;</p><p>139</p><p>(</p><p>3</p><p>):</p><p>298</p><p>–</p><p>303</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B71\" data-id=\"B71\" content-id=\"B71\" data-legacy-id=\"B71\"><p><span>71.</span></p><div><p>Liu</p>  <p>PY</p><p>\n, <span>\n<p>Turner</p>  <p>L</p>\n</span>, <span>\n<p>Rushford</p>  <p>D</p>\n</span>, <span>\n<p>McDonald</p>  <p>J</p>\n</span>, <span>\n<p>Baker</p>  <p>HW</p>\n</span>, <span>\n<p>Conway</p>  <p>AJ</p>\n</span>, <span>\n<p>Handelsman</p>  <p>DJ</p>\n</span>\n. </p><p>Efficacy and safety of recombinant human follicle stimulating hormone (Gonal-F) with urinary human chorionic gonadotrophin for induction of spermatogenesis and fertility in gonadotrophin-deficient men</p><p>. </p><p>Hum Reprod</p><p>. </p><p>1999</p><p>;</p><p>14</p><p>(</p><p>6</p><p>):</p><p>1540</p><p>–</p><p>1545</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B72\" data-id=\"B72\" content-id=\"B72\" data-legacy-id=\"B72\"><p><span>72.</span></p><div><p>Pasquino</p>  <p>AM</p><p>\n, <span>\n<p>Pucarelli</p>  <p>I</p>\n</span>, <span>\n<p>Accardo</p>  <p>F</p>\n</span>, <span>\n<p>Demiraj</p>  <p>V</p>\n</span>, <span>\n<p>Segni</p>  <p>M</p>\n</span>, <span>\n<p>Di Nardo</p>  <p>R</p>\n</span>\n. </p><p>Long-term observation of 87 girls with idiopathic central precocious puberty treated with gonadotropin-releasing hormone analogs: impact on adult height, body mass index, bone mineral content, and reproductive function</p><p>. </p><p>J Clin Endocrinol Metab</p><p>. </p><p>2008</p><p>;</p><p>93</p><p>(</p><p>1</p><p>):</p><p>190</p><p>–</p><p>195</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B73\" data-id=\"B73\" content-id=\"B73\" data-legacy-id=\"B73\"><p><span>73.</span></p><div><p>Magiakou</p>  <p>MA</p><p>\n, <span>\n<p>Manousaki</p>  <p>D</p>\n</span>, <span>\n<p>Papadaki</p>  <p>M</p>\n</span>, <span>\n<p>Hadjidakis</p>  <p>D</p>\n</span>, <span>\n<p>Levidou</p>  <p>G</p>\n</span>, <span>\n<p>Vakaki</p>  <p>M</p>\n</span>, <span>\n<p>Papaefstathiou</p>  <p>A</p>\n</span>, <span>\n<p>Lalioti</p>  <p>N</p>\n</span>, <span>\n<p>Kanaka-Gantenbein</p>  <p>C</p>\n</span>, <span>\n<p>Piaditis</p>  <p>G</p>\n</span>, <span>\n<p>Chrousos</p>  <p>GP</p>\n</span>, <span>\n<p>Dacou-Voutetakis</p>  <p>C</p>\n</span>\n. </p><p>The efficacy and safety of gonadotropin-releasing hormone analog treatment in childhood and adolescence: a single center, long-term follow-up study</p><p>. </p><p>J Clin Endocrinol Metab</p><p>. </p><p>2010</p><p>;</p><p>95</p><p>(</p><p>1</p><p>):</p><p>109</p><p>–</p><p>117</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B74\" data-id=\"B74\" content-id=\"B74\" data-legacy-id=\"B74\"><p><span>74.</span></p><div><p>Baba</p>  <p>T</p><p>\n, <span>\n<p>Endo</p>  <p>T</p>\n</span>, <span>\n<p>Honnma</p>  <p>H</p>\n</span>, <span>\n<p>Kitajima</p>  <p>Y</p>\n</span>, <span>\n<p>Hayashi</p>  <p>T</p>\n</span>, <span>\n<p>Ikeda</p>  <p>H</p>\n</span>, <span>\n<p>Masumori</p>  <p>N</p>\n</span>, <span>\n<p>Kamiya</p>  <p>H</p>\n</span>, <span>\n<p>Moriwaka</p>  <p>O</p>\n</span>, <span>\n<p>Saito</p>  <p>T</p>\n</span>\n. </p><p>Association between polycystic ovary syndrome and female-to-male transsexuality</p><p>. </p><p>Hum Reprod</p><p>. </p><p>2007</p><p>;</p><p>22</p><p>(</p><p>4</p><p>):</p><p>1011</p><p>–</p><p>1016</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B75\" data-id=\"B75\" content-id=\"B75\" data-legacy-id=\"B75\"><p><span>75.</span></p><div><p>Spinder</p>  <p>T</p><p>\n, <span>\n<p>Spijkstra</p>  <p>JJ</p>\n</span>, <span>\n<p>van den Tweel</p>  <p>JG</p>\n</span>, <span>\n<p>Burger</p>  <p>CW</p>\n</span>, <span>\n<p>van Kessel</p>  <p>H</p>\n</span>, <span>\n<p>Hompes</p>  <p>PGA</p>\n</span>, <span>\n<p>Gooren</p>  <p>LJG</p>\n</span>\n. </p><p>The effects of long term testosterone administration on pulsatile luteinizing hormone secretion and on ovarian histology in eugonadal female to male transsexual subjects</p><p>. </p><p>J Clin Endocrinol Metab</p><p>. </p><p>1989</p><p>;</p><p>69</p><p>(</p><p>1</p><p>):</p><p>151</p><p>–</p><p>157</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B76\" data-id=\"B76\" content-id=\"B76\" data-legacy-id=\"B76\"><p><span>76.</span></p><div><p>Baba</p>  <p>T</p><p>\n, <span>\n<p>Endo</p>  <p>T</p>\n</span>, <span>\n<p>Ikeda</p>  <p>K</p>\n</span>, <span>\n<p>Shimizu</p>  <p>A</p>\n</span>, <span>\n<p>Honnma</p>  <p>H</p>\n</span>, <span>\n<p>Ikeda</p>  <p>H</p>\n</span>, <span>\n<p>Masumori</p>  <p>N</p>\n</span>, <span>\n<p>Ohmura</p>  <p>T</p>\n</span>, <span>\n<p>Kiya</p>  <p>T</p>\n</span>, <span>\n<p>Fujimoto</p>  <p>T</p>\n</span>, <span>\n<p>Koizumi</p>  <p>M</p>\n</span>, <span>\n<p>Saito</p>  <p>T</p>\n</span>\n. </p><p>Distinctive features of female-to-male transsexualism and prevalence of gender identity disorder in Japan</p><p>. </p><p>J Sex Med</p><p>. </p><p>2011</p><p>;</p><p>8</p><p>(</p><p>6</p><p>):</p><p>1686</p><p>–</p><p>1693</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B77\" data-id=\"B77\" content-id=\"B77\" data-legacy-id=\"B77\"><p><span>77.</span></p><div><p>Vujovic</p>  <p>S</p><p>\n, <span>\n<p>Popovic</p>  <p>S</p>\n</span>, <span>\n<p>Sbutega-Milosevic</p>  <p>G</p>\n</span>, <span>\n<p>Djordjevic</p>  <p>M</p>\n</span>, <span>\n<p>Gooren</p>  <p>L</p>\n</span>\n. </p><p>Transsexualism in Serbia: a twenty-year follow-up study</p><p>. </p><p>J Sex Med</p><p>. </p><p>2009</p><p>;</p><p>6</p><p>(</p><p>4</p><p>):</p><p>1018</p><p>–</p><p>1023</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B78\" data-id=\"B78\" content-id=\"B78\" data-legacy-id=\"B78\"><p><span>78.</span></p><div><p>Ikeda</p>  <p>K</p><p>\n, <span>\n<p>Baba</p>  <p>T</p>\n</span>, <span>\n<p>Noguchi</p>  <p>H</p>\n</span>, <span>\n<p>Nagasawa</p>  <p>K</p>\n</span>, <span>\n<p>Endo</p>  <p>T</p>\n</span>, <span>\n<p>Kiya</p>  <p>T</p>\n</span>, <span>\n<p>Saito</p>  <p>T</p>\n</span>\n. </p><p>Excessive androgen exposure in female-to-male transsexual persons of reproductive age induces hyperplasia of the ovarian cortex and stroma but not polycystic ovary morphology</p><p>. </p><p>Hum Reprod</p><p>. </p><p>2013</p><p>;</p><p>28</p><p>(</p><p>2</p><p>):</p><p>453</p><p>–</p><p>461</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B79\" data-id=\"B79\" content-id=\"B79\" data-legacy-id=\"B79\"><p><span>79.</span></p><div><p>Trebay</p>  <p>G</p><p>\n\n. </p><p>He’s pregnant. You’re speechles. New York Times. 22 June 2008</p><p>.</p></div></div><div id=\"ref-auto-B80\" data-id=\"B80\" content-id=\"B80\" data-legacy-id=\"B80\"><p><span>80.</span></p><div><p>Light</p>  <p>AD</p><p>\n, <span>\n<p>Obedin-Maliver</p>  <p>J</p>\n</span>, <span>\n<p>Sevelius</p>  <p>JM</p>\n</span>, <span>\n<p>Kerns</p>  <p>JL</p>\n</span>\n. </p><p>Transgender men who experienced pregnancy after female-to-male gender transitioning</p><p>. </p><p>Obstet Gynecol</p><p>. </p><p>2014</p><p>;</p><p>124</p><p>(</p><p>6</p><p>):</p><p>1120</p><p>–</p><p>1127</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B81\" data-id=\"B81\" content-id=\"B81\" data-legacy-id=\"B81\"><p><span>81.</span></p><div><p>De Sutter</p>  <p>P</p><p>\n\n. </p><p>Donor inseminations in partners of female-to-male transsexuals: should the question be asked?</p> <p>Reprod Biomed Online</p><p>. </p><p>2003</p><p>;</p><p>6</p><p>(</p><p>3</p><p>):</p><p>382</p><p>, author reply 282–283.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B82\" data-id=\"B82\" content-id=\"B82\" data-legacy-id=\"B82\"><p><span>82.</span></p><div><p>De Roo</p>  <p>C</p><p>\n, <span>\n<p>Tilleman</p>  <p>K</p>\n</span>, <span>\n<p>T’Sjoen</p>  <p>G</p>\n</span>, <span>\n<p>De Sutter</p>  <p>P</p>\n</span>\n. </p><p>Fertility options in transgender people</p><p>. </p><p>Int Rev Psychiatry</p><p>. </p><p>2016</p><p>;</p><p>28</p><p>(</p><p>1</p><p>):</p><p>112</p><p>–</p><p>119</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B83\" data-id=\"B83\" content-id=\"B83\" data-legacy-id=\"B83\"><p><span>83.</span></p><div><p>Wennink</p>  <p>JMB</p><p>\n, <span>\n<p>Delemarre-van de Waal</p>  <p>HA</p>\n</span>, <span>\n<p>Schoemaker</p>  <p>R</p>\n</span>, <span>\n<p>Schoemaker</p>  <p>H</p>\n</span>, <span>\n<p>Schoemaker</p>  <p>J</p>\n</span>\n. </p><p>Luteinizing hormone and follicle stimulating hormone secretion patterns in boys throughout puberty measured using highly sensitive immunoradiometric assays</p><p>. </p><p>Clin Endocrinol (Oxf)</p><p>. </p><p>1989</p><p>;</p><p>31</p><p>(</p><p>5</p><p>):</p><p>551</p><p>–</p><p>564</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B84\" data-id=\"B84\" content-id=\"B84\" data-legacy-id=\"B84\"><p><span>84.</span></p><div><p>Cohen-Kettenis</p>  <p>PT</p><p>\n, <span>\n<p>Delemarre-van de Waal</p>  <p>HA</p>\n</span>, <span>\n<p>Gooren</p>  <p>LJG</p>\n</span>\n. </p><p>The treatment of adolescent transsexuals: changing insights</p><p>. </p><p>J Sex Med</p><p>. </p><p>2008</p><p>;</p><p>5</p><p>(</p><p>8</p><p>):</p><p>1892</p><p>–</p><p>1897</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B85\" data-id=\"B85\" content-id=\"B85\" data-legacy-id=\"B85\"><p><span>85.</span></p><div><p>Delemarre-van de Waal</p>  <p>HA</p><p>\n, <span>\n<p>Cohen-Kettenis</p>  <p>PT</p>\n</span>\n. </p><p>Clinical management of gender identity disorder in adolescents: a protocol on psychological and paediatric endocrinology aspects</p><p>. </p><p>Eur J Endocrinol</p><p>. </p><p>2006</p><p>;</p><p>155</p><p>:</p><p>S131</p><p>–</p><p>S137</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B86\" data-id=\"B86\" content-id=\"B86\" data-legacy-id=\"B86\"><p><span>86.</span></p><div><p>de Vries</p>  <p>ALC</p><p>\n, <span>\n<p>Steensma</p>  <p>TD</p>\n</span>, <span>\n<p>Doreleijers</p>  <p>TAH</p>\n</span>, <span>\n<p>Cohen-Kettenis</p>  <p>PT</p>\n</span>\n. </p><p>Puberty suppression in adolescents with gender identity disorder: a prospective follow-up study</p><p>. </p><p>J Sex Med</p><p>. </p><p>2011</p><p>;</p><p>8</p><p>(</p><p>8</p><p>):</p><p>2276</p><p>–</p><p>2283</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B87\" data-id=\"B87\" content-id=\"B87\" data-legacy-id=\"B87\"><p><span>87.</span></p><div><p>Bouman</p>  <p>MB</p><p>\n, <span>\n<p>van Zeijl</p>  <p>MCT</p>\n</span>, <span>\n<p>Buncamper</p>  <p>ME</p>\n</span>, <span>\n<p>Meijerink</p>  <p>WJHJ</p>\n</span>, <span>\n<p>van Bodegraven</p>  <p>AA</p>\n</span>, <span>\n<p>Mullender</p>  <p>MG</p>\n</span>\n. </p><p>Intestinal vaginoplasty revisited: a review of surgical techniques, complications, and sexual function</p><p>. </p><p>J Sex Med</p><p>. </p><p>2014</p><p>;</p><p>11</p><p>(</p><p>7</p><p>):</p><p>1835</p><p>–</p><p>1847</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B88\" data-id=\"B88\" content-id=\"B88\" data-legacy-id=\"B88\"><p><span>88.</span></p><div><p>Carel</p>  <p>JC</p><p>\n, <span>\n<p>Eugster</p>  <p>EA</p>\n</span>, <span>\n<p>Rogol</p>  <p>A</p>\n</span>, <span>\n<p>Ghizzoni</p>  <p>L</p>\n</span>, <span>\n<p>Palmert</p>  <p>MR</p>\n</span>, <span>\n<p>Antoniazzi</p>  <p>F</p>\n</span>, <span>\n<p>Berenbaum</p>  <p>S</p>\n</span>, <span>\n<p>Bourguignon</p>  <p>JP</p>\n</span>, <span>\n<p>Chrousos</p>  <p>GP</p>\n</span>, <span>\n<p>Coste</p>  <p>J</p>\n</span>, <span>\n<p>Deal</p>  <p>S</p>\n</span>, <span>\n<p>de Vries</p>  <p>L</p>\n</span>, <span>\n<p>Foster</p>  <p>C</p>\n</span>, <span>\n<p>Heger</p>  <p>S</p>\n</span>, <span>\n<p>Holland</p>  <p>J</p>\n</span>, <span>\n<p>Jahnukainen</p>  <p>K</p>\n</span>, <span>\n<p>Juul</p>  <p>A</p>\n</span>, <span>\n<p>Kaplowitz</p>  <p>P</p>\n</span>, <span>\n<p>Lahlou</p>  <p>N</p>\n</span>, <span>\n<p>Lee</p>  <p>MM</p>\n</span>, <span>\n<p>Lee</p>  <p>P</p>\n</span>, <span>\n<p>Merke</p>  <p>DP</p>\n</span>, <span>\n<p>Neely</p>  <p>EK</p>\n</span>, <span>\n<p>Oostdijk</p>  <p>W</p>\n</span>, <span>\n<p>Phillip</p>  <p>M</p>\n</span>, <span>\n<p>Rosenfield</p>  <p>RL</p>\n</span>, <span>\n<p>Shulman</p>  <p>D</p>\n</span>, <span>\n<p>Styne</p>  <p>D</p>\n</span>, <span>\n<p>Tauber</p>  <p>M</p>\n</span>, <span>\n<p>Wit</p>  <p>JM</p>\n</span>; </p><p>ESPE-LWPES GnRH Analogs Consensus Conference Group</p><p>\n. </p><p>Consensus statement on the use of gonadotropin-releasing hormone analogs in children</p><p>. </p><p>Pediatrics</p><p>. </p><p>2009</p><p>;</p><p>123</p><p>(</p><p>4</p><p>):</p><p>e752</p><p>–</p><p>e762</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B89\" data-id=\"B89\" content-id=\"B89\" data-legacy-id=\"B89\"><p><span>89.</span></p><div><p>Roth</p>  <p>CL</p><p>\n, <span>\n<p>Brendel</p>  <p>L</p>\n</span>, <span>\n<p>Rückert</p>  <p>C</p>\n</span>, <span>\n<p>Hartmann</p>  <p>K</p>\n</span>\n. </p><p>Antagonistic and agonistic GnRH analogue treatment of precocious puberty: tracking gonadotropin concentrations in urine</p><p>. </p><p>Horm Res</p><p>. </p><p>2005</p><p>;</p><p>63</p><p>(</p><p>5</p><p>):</p><p>257</p><p>–</p><p>262</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B90\" data-id=\"B90\" content-id=\"B90\" data-legacy-id=\"B90\"><p><span>90.</span></p><div><p>Roth</p>  <p>C</p><p>\n\n. </p><p>Therapeutic potential of GnRH antagonists in the treatment of precocious puberty</p><p>. </p><p>Expert Opin Investig Drugs</p><p>. </p><p>2002</p><p>;</p><p>11</p><p>(</p><p>9</p><p>):</p><p>1253</p><p>–</p><p>1259</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B91\" data-id=\"B91\" content-id=\"B91\" data-legacy-id=\"B91\"><p><span>91.</span></p><div><p>Tuvemo</p>  <p>T</p><p>\n\n. </p><p>Treatment of central precocious puberty</p><p>. </p><p>Expert Opin Investig Drugs</p><p>. </p><p>2006</p><p>;</p><p>15</p><p>(</p><p>5</p><p>):</p><p>495</p><p>–</p><p>505</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B92\" data-id=\"B92\" content-id=\"B92\" data-legacy-id=\"B92\"><p><span>92.</span></p><div><p>Schagen</p>  <p>SE</p><p>\n, <span>\n<p>Cohen-Kettenis</p>  <p>PT</p>\n</span>, <span>\n<p>Delemarre-van de Waal</p>  <p>HA</p>\n</span>, <span>\n<p>Hannema</p>  <p>SE</p>\n</span>\n. </p><p>Efficacy and safety of gonadotropin-releasing hormone agonist treatment to suppress puberty in gender dysphoric adolescents</p><p>. </p><p>J Sex Med</p><p>. </p><p>2016</p><p>;</p><p>13</p><p>(</p><p>7</p><p>):</p><p>1125</p><p>–</p><p>1132</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B93\" data-id=\"B93\" content-id=\"B93\" data-legacy-id=\"B93\"><p><span>93.</span></p><div><p>Manasco</p>  <p>PK</p><p>\n, <span>\n<p>Pescovitz</p>  <p>OH</p>\n</span>, <span>\n<p>Feuillan</p>  <p>PP</p>\n</span>, <span>\n<p>Hench</p>  <p>KD</p>\n</span>, <span>\n<p>Barnes</p>  <p>KM</p>\n</span>, <span>\n<p>Jones</p>  <p>J</p>\n</span>, <span>\n<p>Hill</p>  <p>SC</p>\n</span>, <span>\n<p>Loriaux</p>  <p>DL</p>\n</span>, <span>\n<p>Cutler</p>  <p>GB</p>, Jr\n</span>\n. </p><p>Resumption of puberty after long term luteinizing hormone-releasing hormone agonist treatment of central precocious puberty</p><p>. </p><p>J Clin Endocrinol Metab</p><p>. </p><p>1988</p><p>;</p><p>67</p><p>(</p><p>2</p><p>):</p><p>368</p><p>–</p><p>372</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B94\" data-id=\"B94\" content-id=\"B94\" data-legacy-id=\"B94\"><p><span>94.</span></p><div><p>Klink</p>  <p>D</p><p>\n, <span>\n<p>Caris</p>  <p>M</p>\n</span>, <span>\n<p>Heijboer</p>  <p>A</p>\n</span>, <span>\n<p>van Trotsenburg</p>  <p>M</p>\n</span>, <span>\n<p>Rotteveel</p>  <p>J</p>\n</span>\n. </p><p>Bone mass in young adulthood following gonadotropin-releasing hormone analog treatment and cross-sex hormone treatment in adolescents with gender dysphoria</p><p>. </p><p>J Clin Endocrinol Metab</p><p>. </p><p>2015</p><p>;</p><p>100</p><p>(</p><p>2</p><p>):</p><p>E270</p><p>–</p><p>E275</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B95\" data-id=\"B95\" content-id=\"B95\" data-legacy-id=\"B95\"><p><span>95.</span></p><div><p>Finkelstein</p>  <p>JS</p><p>\n, <span>\n<p>Klibanski</p>  <p>A</p>\n</span>, <span>\n<p>Neer</p>  <p>RM</p>\n</span>\n. </p><p>A longitudinal evaluation of bone mineral density in adult men with histories of delayed puberty</p><p>. </p><p>J Clin Endocrinol Metab</p><p>. </p><p>1996</p><p>;</p><p>81</p><p>(</p><p>3</p><p>):</p><p>1152</p><p>–</p><p>1155</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B96\" data-id=\"B96\" content-id=\"B96\" data-legacy-id=\"B96\"><p><span>96.</span></p><div><p>Bertelloni</p>  <p>S</p><p>\n, <span>\n<p>Baroncelli</p>  <p>GI</p>\n</span>, <span>\n<p>Ferdeghini</p>  <p>M</p>\n</span>, <span>\n<p>Perri</p>  <p>G</p>\n</span>, <span>\n<p>Saggese</p>  <p>G</p>\n</span>\n. </p><p>Normal volumetric bone mineral density and bone turnover in young men with histories of constitutional delay of puberty</p><p>. </p><p>J Clin Endocrinol Metab</p><p>. </p><p>1998</p><p>;</p><p>83</p><p>(</p><p>12</p><p>):</p><p>4280</p><p>–</p><p>4283</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B97\" data-id=\"B97\" content-id=\"B97\" data-legacy-id=\"B97\"><p><span>97.</span></p><div><p>Darelid</p>  <p>A</p><p>\n, <span>\n<p>Ohlsson</p>  <p>C</p>\n</span>, <span>\n<p>Nilsson</p>  <p>M</p>\n</span>, <span>\n<p>Kindblom</p>  <p>JM</p>\n</span>, <span>\n<p>Mellström</p>  <p>D</p>\n</span>, <span>\n<p>Lorentzon</p>  <p>M</p>\n</span>\n. </p><p>Catch up in bone acquisition in young adult men with late normal puberty</p><p>. </p><p>J Bone Miner Res</p><p>. </p><p>2012</p><p>;</p><p>27</p><p>(</p><p>10</p><p>):</p><p>2198</p><p>–</p><p>2207</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B98\" data-id=\"B98\" content-id=\"B98\" data-legacy-id=\"B98\"><p><span>98.</span></p><div><p>Mittan</p>  <p>D</p><p>\n, <span>\n<p>Lee</p>  <p>S</p>\n</span>, <span>\n<p>Miller</p>  <p>E</p>\n</span>, <span>\n<p>Perez</p>  <p>RC</p>\n</span>, <span>\n<p>Basler</p>  <p>JW</p>\n</span>, <span>\n<p>Bruder</p>  <p>JM</p>\n</span>\n. </p><p>Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs</p><p>. </p><p>J Clin Endocrinol Metab</p><p>. </p><p>2002</p><p>;</p><p>87</p><p>(</p><p>8</p><p>):</p><p>3656</p><p>–</p><p>3661</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B99\" data-id=\"B99\" content-id=\"B99\" data-legacy-id=\"B99\"><p><span>99.</span></p><div><p>Saggese</p>  <p>G</p><p>\n, <span>\n<p>Bertelloni</p>  <p>S</p>\n</span>, <span>\n<p>Baroncelli</p>  <p>GI</p>\n</span>, <span>\n<p>Battini</p>  <p>R</p>\n</span>, <span>\n<p>Franchi</p>  <p>G</p>\n</span>\n. </p><p>Reduction of bone density: an effect of gonadotropin releasing hormone analogue treatment in central precocious puberty</p><p>. </p><p>Eur J Pediatr</p><p>. </p><p>1993</p><p>;</p><p>152</p><p>(</p><p>9</p><p>):</p><p>717</p><p>–</p><p>720</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B100\" data-id=\"B100\" content-id=\"B100\" data-legacy-id=\"B100\"><p><span>100.</span></p><div><p>Neely</p>  <p>EK</p><p>\n, <span>\n<p>Bachrach</p>  <p>LK</p>\n</span>, <span>\n<p>Hintz</p>  <p>RL</p>\n</span>, <span>\n<p>Habiby</p>  <p>RL</p>\n</span>, <span>\n<p>Slemenda</p>  <p>CW</p>\n</span>, <span>\n<p>Feezle</p>  <p>L</p>\n</span>, <span>\n<p>Pescovitz</p>  <p>OH</p>\n</span>\n. </p><p>Bone mineral density during treatment of central precocious puberty</p><p>. </p><p>J Pediatr</p><p>. </p><p>1995</p><p>;</p><p>127</p><p>(</p><p>5</p><p>):</p><p>819</p><p>–</p><p>822</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B101\" data-id=\"B101\" content-id=\"B101\" data-legacy-id=\"B101\"><p><span>101.</span></p><div><p>Bertelloni</p>  <p>S</p><p>\n, <span>\n<p>Baroncelli</p>  <p>GI</p>\n</span>, <span>\n<p>Sorrentino</p>  <p>MC</p>\n</span>, <span>\n<p>Perri</p>  <p>G</p>\n</span>, <span>\n<p>Saggese</p>  <p>G</p>\n</span>\n. </p><p>Effect of central precocious puberty and gonadotropin-releasing hormone analogue treatment on peak bone mass and final height in females</p><p>. </p><p>Eur J Pediatr</p><p>. </p><p>1998</p><p>;</p><p>157</p><p>(</p><p>5</p><p>):</p><p>363</p><p>–</p><p>367</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B102\" data-id=\"B102\" content-id=\"B102\" data-legacy-id=\"B102\"><p><span>102.</span></p><div><p>Thornton</p>  <p>P</p><p>\n, <span>\n<p>Silverman</p>  <p>LA</p>\n</span>, <span>\n<p>Geffner</p>  <p>ME</p>\n</span>, <span>\n<p>Neely</p>  <p>EK</p>\n</span>, <span>\n<p>Gould</p>  <p>E</p>\n</span>, <span>\n<p>Danoff</p>  <p>TM</p>\n</span>\n. </p><p>Review of outcomes after cessation of gonadotropin-releasing hormone agonist treatment of girls with precocious puberty</p><p>. </p><p>Pediatr Endocrinol Rev</p><p>. </p><p>2014</p><p>;</p><p>11</p><p>(</p><p>3</p><p>):</p><p>306</p><p>–</p><p>317</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B103\" data-id=\"B103\" content-id=\"B103\" data-legacy-id=\"B103\"><p><span>103.</span></p><div><p>Lem</p>  <p>AJ</p><p>\n, <span>\n<p>van der Kaay</p>  <p>DC</p>\n</span>, <span>\n<p>Hokken-Koelega</p>  <p>AC</p>\n</span>\n. </p><p>Bone mineral density and body composition in short children born SGA during growth hormone and gonadotropin releasing hormone analog treatment</p><p>. </p><p>J Clin Endocrinol Metab</p><p>. </p><p>2013</p><p>;</p><p>98</p><p>(</p><p>1</p><p>):</p><p>77</p><p>–</p><p>86</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B104\" data-id=\"B104\" content-id=\"B104\" data-legacy-id=\"B104\"><p><span>104.</span></p><div><p>Antoniazzi</p>  <p>F</p><p>\n, <span>\n<p>Zamboni</p>  <p>G</p>\n</span>, <span>\n<p>Bertoldo</p>  <p>F</p>\n</span>, <span>\n<p>Lauriola</p>  <p>S</p>\n</span>, <span>\n<p>Mengarda</p>  <p>F</p>\n</span>, <span>\n<p>Pietrobelli</p>  <p>A</p>\n</span>, <span>\n<p>Tatò</p>  <p>L</p>\n</span>\n. </p><p>Bone mass at final height in precocious puberty after gonadotropin-releasing hormone agonist with and without calcium supplementation</p><p>. </p><p>J Clin Endocrinol Metab</p><p>. </p><p>2003</p><p>;</p><p>88</p><p>(</p><p>3</p><p>):</p><p>1096</p><p>–</p><p>1101</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B105\" data-id=\"B105\" content-id=\"B105\" data-legacy-id=\"B105\"><p><span>105.</span></p><div><p>Calcaterra</p>  <p>V</p><p>\n, <span>\n<p>Mannarino</p>  <p>S</p>\n</span>, <span>\n<p>Corana</p>  <p>G</p>\n</span>, <span>\n<p>Codazzi</p>  <p>AC</p>\n</span>, <span>\n<p>Mazzola</p>  <p>A</p>\n</span>, <span>\n<p>Brambilla</p>  <p>P</p>\n</span>, <span>\n<p>Larizza</p>  <p>D</p>\n</span>\n. </p><p>Hypertension during therapy with triptorelin in a girl with precocious puberty</p><p>. </p><p>Indian J Pediatr</p><p>. </p><p>2013</p><p>;</p><p>80</p><p>(</p><p>10</p><p>):</p><p>884</p><p>–</p><p>885</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B106\" data-id=\"B106\" content-id=\"B106\" data-legacy-id=\"B106\"><p><span>106.</span></p><div><p>Siomou</p>  <p>E</p><p>\n, <span>\n<p>Kosmeri</p>  <p>C</p>\n</span>, <span>\n<p>Pavlou</p>  <p>M</p>\n</span>, <span>\n<p>Vlahos</p>  <p>AP</p>\n</span>, <span>\n<p>Argyropoulou</p>  <p>MI</p>\n</span>, <span>\n<p>Siamopoulou</p>  <p>A</p>\n</span>\n. </p><p>Arterial hypertension during treatment with triptorelin in a child with Williams-Beuren syndrome</p><p>. </p><p>Pediatr Nephrol</p><p>. </p><p>2014</p><p>;</p><p>29</p><p>(</p><p>9</p><p>):</p><p>1633</p><p>–</p><p>1636</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B107\" data-id=\"B107\" content-id=\"B107\" data-legacy-id=\"B107\"><p><span>107.</span></p><div><p>Staphorsius</p>  <p>AS</p><p>\n, <span>\n<p>Kreukels</p>  <p>BPC</p>\n</span>, <span>\n<p>Cohen-Kettenis</p>  <p>PT</p>\n</span>, <span>\n<p>Veltman</p>  <p>DJ</p>\n</span>, <span>\n<p>Burke</p>  <p>SM</p>\n</span>, <span>\n<p>Schagen</p>  <p>SEE</p>\n</span>, <span>\n<p>Wouters</p>  <p>FM</p>\n</span>, <span>\n<p>Delemarre-van de Waal</p>  <p>HA</p>\n</span>, <span>\n<p>Bakker</p>  <p>J</p>\n</span>\n. </p><p>Puberty suppression and executive functioning: an fMRI-study in adolescents with gender dysphoria</p><p>. </p><p>Psychoneuroendocrinology</p><p>. </p><p>2015</p><p>;</p><p>56</p><p>:</p><p>190</p><p>–</p><p>199</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B108\" data-id=\"B108\" content-id=\"B108\" data-legacy-id=\"B108\"><p><span>108.</span></p><div><p>Hough</p>  <p>D</p><p>\n, <span>\n<p>Bellingham</p>  <p>M</p>\n</span>, <span>\n<p>Haraldsen</p>  <p>IR</p>\n</span>, <span>\n<p>McLaughlin</p>  <p>M</p>\n</span>, <span>\n<p>Rennie</p>  <p>M</p>\n</span>, <span>\n<p>Robinson</p>  <p>JE</p>\n</span>, <span>\n<p>Solbakk</p>  <p>AK</p>\n</span>, <span>\n<p>Evans</p>  <p>NP</p>\n</span>\n. </p><p>Spatial memory is impaired by peripubertal GnRH agonist treatment and testosterone replacement in sheep</p><p>. </p><p>Psychoneuroendocrinology</p><p>. </p><p>2017</p><p>;</p><p>75</p><p>:</p><p>173</p><p>–</p><p>182</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B109\" data-id=\"B109\" content-id=\"B109\" data-legacy-id=\"B109\"><p><span>109.</span></p><div><p>Collipp</p>  <p>PJ</p><p>\n, <span>\n<p>Kaplan</p>  <p>SA</p>\n</span>, <span>\n<p>Boyle</p>  <p>DC</p>\n</span>, <span>\n<p>Plachte</p>  <p>F</p>\n</span>, <span>\n<p>Kogut</p>  <p>MD</p>\n</span>\n. </p><p>Constitutional Isosexual Precocious Puberty</p><p>. </p><p>Am J Dis Child</p><p>. </p><p>1964</p><p>;</p><p>108</p><p>:</p><p>399</p><p>–</p><p>405</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B110\" data-id=\"B110\" content-id=\"B110\" data-legacy-id=\"B110\"><p><span>110.</span></p><div><p>Hahn</p>  <p>HB</p><p>, Jr\n, <span>\n<p>Hayles</p>  <p>AB</p>\n</span>, <span>\n<p>Albert</p>  <p>A</p>\n</span>\n. </p><p>Medroxyprogesterone and constitutional precocious puberty.</p> <p>Mayo Clin Proc</p><p>. </p><p>1964</p><p>;</p><p>39</p><p>:</p><p>182</p><p>–</p><p>190</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B111\" data-id=\"B111\" content-id=\"B111\" data-legacy-id=\"B111\"><p><span>111.</span></p><div><p>Kaplan</p>  <p>SA</p><p>\n, <span>\n<p>Ling</p>  <p>SM</p>\n</span>, <span>\n<p>Irani</p>  <p>NG</p>\n</span>\n. </p><p>Idiopathic isosexual precocity</p><p>. </p><p>Am J Dis Child</p><p>. </p><p>1968</p><p>;</p><p>116</p><p>(</p><p>6</p><p>):</p><p>591</p><p>–</p><p>598</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B112\" data-id=\"B112\" content-id=\"B112\" data-legacy-id=\"B112\"><p><span>112.</span></p><div><p>Schoen</p>  <p>EJ</p><p>\n\n. </p><p>Treatment of idiopathic precocious puberty in boys</p><p>. </p><p>J Clin Endocrinol Metab</p><p>. </p><p>1966</p><p>;</p><p>26</p><p>(</p><p>4</p><p>):</p><p>363</p><p>–</p><p>370</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B113\" data-id=\"B113\" content-id=\"B113\" data-legacy-id=\"B113\"><p><span>113.</span></p><div><p>Gooren</p>  <p>L</p><p>\n\n. </p><p>Hormone treatment of the adult transsexual patient</p><p>. </p><p>Horm Res</p><p>. </p><p>2005</p><p>;</p><p>64</p><p>(</p><p>Suppl 2</p><p>):</p><p>31</p><p>–</p><p>36</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B114\" data-id=\"B114\" content-id=\"B114\" data-legacy-id=\"B114\"><p><span>114.</span></p><div><p>Moore</p>  <p>E</p><p>\n, <span>\n<p>Wisniewski</p>  <p>A</p>\n</span>, <span>\n<p>Dobs</p>  <p>A</p>\n</span>\n. </p><p>Endocrine treatment of transsexual people: a review of treatment regimens, outcomes, and adverse effects</p><p>. </p><p>J Clin Endocrinol Metab</p><p>. </p><p>2003</p><p>;</p><p>88</p><p>(</p><p>8</p><p>):</p><p>3467</p><p>–</p><p>3473</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B115\" data-id=\"B115\" content-id=\"B115\" data-legacy-id=\"B115\"><p><span>115.</span></p><div><p>Krueger</p>  <p>RB</p><p>\n, <span>\n<p>Hembree</p>  <p>W</p>\n</span>, <span>\n<p>Hill</p>  <p>M</p>\n</span>\n. </p><p>Prescription of medroxyprogesterone acetate to a patient with pedophilia, resulting in Cushing’s syndrome and adrenal insufficiency</p><p>. </p><p>Sex Abuse</p><p>. </p><p>2006</p><p>;</p><p>18</p><p>(</p><p>2</p><p>):</p><p>227</p><p>–</p><p>228</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B116\" data-id=\"B116\" content-id=\"B116\" data-legacy-id=\"B116\"><p><span>116.</span></p><div><p>Lynch</p>  <p>MM</p><p>\n, <span>\n<p>Khandheria</p>  <p>MM</p>\n</span>, <span>\n<p>Meyer</p>  <p>WJ</p>\n</span>\n. </p><p>Retrospective study of the management of childhood and adolescent gender identity disorder using medroxyprogesterone acetate</p><p>. </p><p>Int J Transgenderism</p><p>. </p><p>2015</p><p>;</p><p>16</p><p>:</p><p>201</p><p>–</p><p>208</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B117\" data-id=\"B117\" content-id=\"B117\" data-legacy-id=\"B117\"><p><span>117.</span></p><div><p>Tack</p>  <p>LJW</p><p>\n, <span>\n<p>Craen</p>  <p>M</p>\n</span>, <span>\n<p>Dhondt</p>  <p>K</p>\n</span>, <span>\n<p>Vanden Bossche</p>  <p>H</p>\n</span>, <span>\n<p>Laridaen</p>  <p>J</p>\n</span>, <span>\n<p>Cools</p>  <p>M</p>\n</span>\n. </p><p>Consecutive lynestrenol and cross-sex hormone treatment in biological female adolescents with gender dysphoria: a retrospective analysis</p><p>. </p><p>Biol Sex Differ</p><p>. </p><p>2016</p><p>;</p><p>7</p><p>:</p><p>14</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B118\" data-id=\"B118\" content-id=\"B118\" data-legacy-id=\"B118\"><p><span>118.</span></p><div><p>Hembree</p>  <p>WC</p><p>\n, <span>\n<p>Cohen-Kettenis</p>  <p>P</p>\n</span>, <span>\n<p>Delemarre-van de Waal</p>  <p>HA</p>\n</span>, <span>\n<p>Gooren</p>  <p>LJ</p>\n</span>, <span>\n<p>Meyer</p>  <p>WJ</p> 3rd\n</span>, <span>\n<p>Spack</p>  <p>NP</p>\n</span>, <span>\n<p>Tangpricha</p>  <p>V</p>\n</span>, <span>\n<p>Montori</p>  <p>VM</p>\n</span>; </p><p>Endocrine Society</p><p>\n. </p><p>Endocrine treatment of transsexual persons: an Endocrine Society clinical practice guideline</p><p>. </p><p>J Clin Endocrinol Metab</p><p>. </p><p>2009</p><p>;</p><p>94</p><p>(</p><p>9</p><p>):</p><p>3132</p><p>–</p><p>3154</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B119\" data-id=\"B119\" content-id=\"B119\" data-legacy-id=\"B119\"><p><span>119.</span></p><div><p>Mann</p>  <p>L</p><p>\n, <span>\n<p>Harmoni</p>  <p>R</p>\n</span>, <span>\n<p>Power</p>  <p>C</p>\n</span>\n. </p><p>Adolescent decision-making: the development of competence</p><p>. </p><p>J Adolesc</p><p>. </p><p>1989</p><p>;</p><p>12</p><p>(</p><p>3</p><p>):</p><p>265</p><p>–</p><p>278</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B120\" data-id=\"B120\" content-id=\"B120\" data-legacy-id=\"B120\"><p><span>120.</span></p><div><p>Stultiëns</p>  <p>L</p><p>\n, <span>\n<p>Goffin</p>  <p>T</p>\n</span>, <span>\n<p>Borry</p>  <p>P</p>\n</span>, <span>\n<p>Dierickx</p>  <p>K</p>\n</span>, <span>\n<p>Nys</p>  <p>H</p>\n</span>\n. </p><p>Minors and informed consent: a comparative approach</p><p>. </p><p>Eur J Health Law</p><p>. </p><p>2007</p><p>;</p><p>14</p><p>(</p><p>1</p><p>):</p><p>21</p><p>–</p><p>46</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B123\" data-id=\"B123\" content-id=\"B123\" data-legacy-id=\"B123\"><p><span>123.</span></p><div><p>Ankarberg-Lindgren</p>  <p>C</p><p>\n, <span>\n<p>Kriström</p>  <p>B</p>\n</span>, <span>\n<p>Norjavaara</p>  <p>E</p>\n</span>\n. </p><p>Physiological estrogen replacement therapy for puberty induction in girls: a clinical observational study</p><p>. </p><p>Horm Res Paediatr</p><p>. </p><p>2014</p><p>;</p><p>81</p><p>(</p><p>4</p><p>):</p><p>239</p><p>–</p><p>244</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B124\" data-id=\"B124\" content-id=\"B124\" data-legacy-id=\"B124\"><p><span>124.</span></p><div><p>Olson</p>  <p>J</p><p>\n, <span>\n<p>Schrager</p>  <p>SM</p>\n</span>, <span>\n<p>Clark</p>  <p>LF</p>\n</span>, <span>\n<p>Dunlap</p>  <p>SL</p>\n</span>, <span>\n<p>Belzer</p>  <p>M</p>\n</span>\n. </p><p>Subcutaneous testosterone: an effective delivery mechanism for masculinizing young transgender men</p><p>. </p><p>LGBT Health</p><p>. </p><p>2014</p><p>;</p><p>1</p><p>(</p><p>3</p><p>):</p><p>165</p><p>–</p><p>167</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B125\" data-id=\"B125\" content-id=\"B125\" data-legacy-id=\"B125\"><p><span>125.</span></p><div><p>Spratt</p>  <p>DI</p><p>\n, <span>\n<p>Stewart</p>  <p>I</p>\n</span>, <span>\n<p>Savage</p>  <p>C</p>\n</span>, <span>\n<p>Craig</p>  <p>W</p>\n</span>, <span>\n<p>Spack</p>  <p>NP</p>\n</span>, <span>\n<p>Chandler</p>  <p>DW</p>\n</span>, <span>\n<p>Spratt</p>  <p>LV</p>\n</span>, <span>\n<p>Eimicke</p>  <p>T</p>\n</span>, <span>\n<p>Olshan</p>  <p>JS</p>\n</span>\n. </p><p>Subcutaneous injection of testosterone is an effective and preferred alternative to intramuscular injection: demonstration in female-to-male transgender patients</p><p>. </p><p>J Clin Endocrinol Metab</p><p>. </p><p>2017</p><p>. doi:10.1210/jc.2017-00359</p></div></div><div id=\"ref-auto-B126\" data-id=\"B126\" content-id=\"B126\" data-legacy-id=\"B126\"><p><span>126.</span></p><div><p>Eisenegger</p>  <p>C</p><p>\n, <span>\n<p>von Eckardstein</p>  <p>A</p>\n</span>, <span>\n<p>Fehr</p>  <p>E</p>\n</span>, <span>\n<p>von Eckardstein</p>  <p>S</p>\n</span>\n. </p><p>Pharmacokinetics of testosterone and estradiol gel preparations in healthy young men</p><p>. </p><p>Psychoneuroendocrinology</p><p>. </p><p>2013</p><p>;</p><p>38</p><p>(</p><p>2</p><p>):</p><p>171</p><p>–</p><p>178</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B127\" data-id=\"B127\" content-id=\"B127\" data-legacy-id=\"B127\"><p><span>127.</span></p><div><p>de Ronde</p>  <p>W</p><p>\n, <span>\n<p>ten Kulve</p>  <p>J</p>\n</span>, <span>\n<p>Woerdeman</p>  <p>J</p>\n</span>, <span>\n<p>Kaufman</p>  <p>J-M</p>\n</span>, <span>\n<p>de Jong</p>  <p>FH</p>\n</span>\n. </p><p>Effects of oestradiol on gonadotrophin levels in normal and castrated men</p><p>. </p><p>Clin Endocrinol (Oxf)</p><p>. </p><p>2009</p><p>;</p><p>71</p><p>(</p><p>6</p><p>):</p><p>874</p><p>–</p><p>879</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B128\" data-id=\"B128\" content-id=\"B128\" data-legacy-id=\"B128\"><p><span>128.</span></p><div><p>Money J, Ehrhardt A. Man &amp; woman, boy &amp; girl: differentiation and dimorphism of gender identity from conception to maturity.</p> <p>Baltimore, MD</p><p>: </p><p>Johns Hopkins University Press</p><p>; </p><p>1972</p><p>:</p><p>202</p><p>–</p><p>206</p><p>.</p></div></div><div id=\"ref-auto-B129\" data-id=\"B129\" content-id=\"B129\" data-legacy-id=\"B129\"><p><span>129.</span></p><div><p>Heylens</p>  <p>G</p><p>\n, <span>\n<p>Verroken</p>  <p>C</p>\n</span>, <span>\n<p>De Cock</p>  <p>S</p>\n</span>, <span>\n<p>T’Sjoen</p>  <p>G</p>\n</span>, <span>\n<p>De Cuypere</p>  <p>G</p>\n</span>\n. </p><p>Effects of different steps in gender reassignment therapy on psychopathology: a prospective study of persons with a gender identity disorder</p><p>. </p><p>J Sex Med</p><p>. </p><p>2014</p><p>;</p><p>11</p><p>(</p><p>1</p><p>):</p><p>119</p><p>–</p><p>126</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B130\" data-id=\"B130\" content-id=\"B130\" data-legacy-id=\"B130\"><p><span>130.</span></p><div><p>Costa</p>  <p>R</p><p>\n, <span>\n<p>Colizzi</p>  <p>M</p>\n</span>\n. </p><p>The effect of cross-sex hormonal treatment on gender dysphoria individuals’ mental health: a systematic review</p><p>. </p><p>Neuropsychiatr Dis Treat</p><p>. </p><p>2016</p><p>;</p><p>12</p><p>:</p><p>1953</p><p>–</p><p>1966</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B131\" data-id=\"B131\" content-id=\"B131\" data-legacy-id=\"B131\"><p><span>131.</span></p><div><p>Gooren</p>  <p>LJG</p><p>\n, <span>\n<p>Giltay</p>  <p>EJ</p>\n</span>\n. </p><p>Review of studies of androgen treatment of female-to-male transsexuals: effects and risks of administration of androgens to females</p><p>. </p><p>J Sex Med</p><p>. </p><p>2008</p><p>;</p><p>5</p><p>(</p><p>4</p><p>):</p><p>765</p><p>–</p><p>776</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B132\" data-id=\"B132\" content-id=\"B132\" data-legacy-id=\"B132\"><p><span>132.</span></p><div><p>Levy</p>  <p>A</p><p>\n, <span>\n<p>Crown</p>  <p>A</p>\n</span>, <span>\n<p>Reid</p>  <p>R</p>\n</span>\n. </p><p>Endocrine intervention for transsexuals</p><p>. </p><p>Clin Endocrinol (Oxf)</p><p>. </p><p>2003</p><p>;</p><p>59</p><p>(</p><p>4</p><p>):</p><p>409</p><p>–</p><p>418</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B133\" data-id=\"B133\" content-id=\"B133\" data-legacy-id=\"B133\"><p><span>133.</span></p><div><p>Tangpricha</p>  <p>V</p><p>\n, <span>\n<p>Ducharme</p>  <p>SH</p>\n</span>, <span>\n<p>Barber</p>  <p>TW</p>\n</span>, <span>\n<p>Chipkin</p>  <p>SR</p>\n</span>\n. </p><p>Endocrinologic treatment of gender identity disorders</p><p>. </p><p>Endocr Pract</p><p>. </p><p>2003</p><p>;</p><p>9</p><p>(</p><p>1</p><p>):</p><p>12</p><p>–</p><p>21</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B134\" data-id=\"B134\" content-id=\"B134\" data-legacy-id=\"B134\"><p><span>134.</span></p><div><p>Meriggiola</p>  <p>MC</p><p>\n, <span>\n<p>Gava</p>  <p>G</p>\n</span>\n. </p><p>Endocrine care of transpeople part I. A review of cross-sex hormonal treatments, outcomes and adverse effects in transmen</p><p>. </p><p>Clin Endocrinol (Oxf)</p><p>. </p><p>2015</p><p>;</p><p>83</p><p>(</p><p>5</p><p>):</p><p>597</p><p>–</p><p>606</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B135\" data-id=\"B135\" content-id=\"B135\" data-legacy-id=\"B135\"><p><span>135.</span></p><div><p>Bhasin</p>  <p>S</p><p>\n, <span>\n<p>Cunningham</p>  <p>GR</p>\n</span>, <span>\n<p>Hayes</p>  <p>FJ</p>\n</span>, <span>\n<p>Matsumoto</p>  <p>AM</p>\n</span>, <span>\n<p>Snyder</p>  <p>PJ</p>\n</span>, <span>\n<p>Swerdloff</p>  <p>RS</p>\n</span>, <span>\n<p>Montori</p>  <p>VM</p>\n</span>\n. </p><p>Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline</p><p>. </p><p>J Clin Endocrinol Metab</p><p>. </p><p>2006</p><p>;</p><p>91</p><p>(</p><p>6</p><p>):</p><p>1995</p><p>–</p><p>2010</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B136\" data-id=\"B136\" content-id=\"B136\" data-legacy-id=\"B136\"><p><span>136.</span></p><div><p>Pelusi</p>  <p>C</p><p>\n, <span>\n<p>Costantino</p>  <p>A</p>\n</span>, <span>\n<p>Martelli</p>  <p>V</p>\n</span>, <span>\n<p>Lambertini</p>  <p>M</p>\n</span>, <span>\n<p>Bazzocchi</p>  <p>A</p>\n</span>, <span>\n<p>Ponti</p>  <p>F</p>\n</span>, <span>\n<p>Battista</p>  <p>G</p>\n</span>, <span>\n<p>Venturoli</p>  <p>S</p>\n</span>, <span>\n<p>Meriggiola</p>  <p>MC</p>\n</span>\n. </p><p>Effects of three different testosterone formulations in female-to-male transsexual persons</p><p>. </p><p>J Sex Med</p><p>. </p><p>2014</p><p>;</p><p>11</p><p>(</p><p>12</p><p>):</p><p>3002</p><p>–</p><p>3011</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B137\" data-id=\"B137\" content-id=\"B137\" data-legacy-id=\"B137\"><p><span>137.</span></p><div><p>Anderson</p>  <p>GL</p><p>\n, <span>\n<p>Limacher</p>  <p>M</p>\n</span>, <span>\n<p>Assaf</p>  <p>AR</p>\n</span>, <span>\n<p>Bassford</p>  <p>T</p>\n</span>, <span>\n<p>Beresford</p>  <p>SA</p>\n</span>, <span>\n<p>Black</p>  <p>H</p>\n</span>, <span>\n<p>Bonds</p>  <p>D</p>\n</span>, <span>\n<p>Brunner</p>  <p>R</p>\n</span>, <span>\n<p>Brzyski</p>  <p>R</p>\n</span>, <span>\n<p>Caan</p>  <p>B</p>\n</span>, <span>\n<p>Chlebowski</p>  <p>R</p>\n</span>, <span>\n<p>Curb</p>  <p>D</p>\n</span>, <span>\n<p>Gass</p>  <p>M</p>\n</span>, <span>\n<p>Hays</p>  <p>J</p>\n</span>, <span>\n<p>Heiss</p>  <p>G</p>\n</span>, <span>\n<p>Hendrix</p>  <p>S</p>\n</span>, <span>\n<p>Howard</p>  <p>BV</p>\n</span>, <span>\n<p>Hsia</p>  <p>J</p>\n</span>, <span>\n<p>Hubbell</p>  <p>A</p>\n</span>, <span>\n<p>Jackson</p>  <p>R</p>\n</span>, <span>\n<p>Johnson</p>  <p>KC</p>\n</span>, <span>\n<p>Judd</p>  <p>H</p>\n</span>, <span>\n<p>Kotchen</p>  <p>JM</p>\n</span>, <span>\n<p>Kuller</p>  <p>L</p>\n</span>, <span>\n<p>LaCroix</p>  <p>AZ</p>\n</span>, <span>\n<p>Lane</p>  <p>D</p>\n</span>, <span>\n<p>Langer</p>  <p>RD</p>\n</span>, <span>\n<p>Lasser</p>  <p>N</p>\n</span>, <span>\n<p>Lewis</p>  <p>CE</p>\n</span>, <span>\n<p>Manson</p>  <p>J</p>\n</span>, <span>\n<p>Margolis</p>  <p>K</p>\n</span>, <span>\n<p>Ockene</p>  <p>J</p>\n</span>, <span>\n<p>O’Sullivan</p>  <p>MJ</p>\n</span>, <span>\n<p>Phillips</p>  <p>L</p>\n</span>, <span>\n<p>Prentice</p>  <p>RL</p>\n</span>, <span>\n<p>Ritenbaugh</p>  <p>C</p>\n</span>, <span>\n<p>Robbins</p>  <p>J</p>\n</span>, <span>\n<p>Rossouw</p>  <p>JE</p>\n</span>, <span>\n<p>Sarto</p>  <p>G</p>\n</span>, <span>\n<p>Stefanick</p>  <p>ML</p>\n</span>, <span>\n<p>Van Horn</p>  <p>L</p>\n</span>, <span>\n<p>Wactawski-Wende</p>  <p>J</p>\n</span>, <span>\n<p>Wallace</p>  <p>R</p>\n</span>, <span>\n<p>Wassertheil-Smoller</p>  <p>S</p>\n</span>; </p><p>Women’s Health Initiative Steering Committee</p><p>\n. </p><p>Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial</p><p>. </p><p>JAMA</p><p>. </p><p>2004</p><p>;</p><p>291</p><p>(</p><p>14</p><p>):</p><p>1701</p><p>–</p><p>1712</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B138\" data-id=\"B138\" content-id=\"B138\" data-legacy-id=\"B138\"><p><span>138.</span></p><div><p>Dickersin</p>  <p>K</p><p>\n, <span>\n<p>Munro</p>  <p>MG</p>\n</span>, <span>\n<p>Clark</p>  <p>M</p>\n</span>, <span>\n<p>Langenberg</p>  <p>P</p>\n</span>, <span>\n<p>Scherer</p>  <p>R</p>\n</span>, <span>\n<p>Frick</p>  <p>K</p>\n</span>, <span>\n<p>Zhu</p>  <p>Q</p>\n</span>, <span>\n<p>Hallock</p>  <p>L</p>\n</span>, <span>\n<p>Nichols</p>  <p>J</p>\n</span>, <span>\n<p>Yalcinkaya</p>  <p>TM</p>\n</span>; </p><p>Surgical Treatments Outcomes Project for Dysfunctional Uterine Bleeding (STOP-DUB) Research Group</p><p>\n. </p><p>Hysterectomy compared with endometrial ablation for dysfunctional uterine bleeding: a randomized controlled trial</p><p>. </p><p>Obstet Gynecol</p><p>. </p><p>2007</p><p>;</p><p>110</p><p>(</p><p>6</p><p>):</p><p>1279</p><p>–</p><p>1289</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B139\" data-id=\"B139\" content-id=\"B139\" data-legacy-id=\"B139\"><p><span>139.</span></p><div><p>Gooren</p>  <p>LJ</p><p>\n, <span>\n<p>Giltay</p>  <p>EJ</p>\n</span>, <span>\n<p>Bunck</p>  <p>MC</p>\n</span>\n. </p><p>Long-term treatment of transsexuals with cross-sex hormones: extensive personal experience</p><p>. </p><p>J Clin Endocrinol Metab</p><p>. </p><p>2008</p><p>;</p><p>93</p><p>(</p><p>1</p><p>):</p><p>19</p><p>–</p><p>25</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B140\" data-id=\"B140\" content-id=\"B140\" data-legacy-id=\"B140\"><p><span>140.</span></p><div><p>Prior</p>  <p>JC</p><p>\n, <span>\n<p>Vigna</p>  <p>YM</p>\n</span>, <span>\n<p>Watson</p>  <p>D</p>\n</span>\n. </p><p>Spironolactone with physiological female steroids for presurgical therapy of male-to-female transsexualism</p><p>. </p><p>Arch Sex Behav</p><p>. </p><p>1989</p><p>;</p><p>18</p><p>(</p><p>1</p><p>):</p><p>49</p><p>–</p><p>57</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B141\" data-id=\"B141\" content-id=\"B141\" data-legacy-id=\"B141\"><p><span>141.</span></p><div><p>Dittrich</p>  <p>R</p><p>\n, <span>\n<p>Binder</p>  <p>H</p>\n</span>, <span>\n<p>Cupisti</p>  <p>S</p>\n</span>, <span>\n<p>Hoffmann</p>  <p>I</p>\n</span>, <span>\n<p>Beckmann</p>  <p>MW</p>\n</span>, <span>\n<p>Mueller</p>  <p>A</p>\n</span>\n. </p><p>Endocrine treatment of male-to-female transsexuals using gonadotropin-releasing hormone agonist</p><p>. </p><p>Exp Clin Endocrinol Diabetes</p><p>. </p><p>2005</p><p>;</p><p>113</p><p>(</p><p>10</p><p>):</p><p>586</p><p>–</p><p>592</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B142\" data-id=\"B142\" content-id=\"B142\" data-legacy-id=\"B142\"><p><span>142.</span></p><div><p>Stripp</p>  <p>B</p><p>\n, <span>\n<p>Taylor</p>  <p>AA</p>\n</span>, <span>\n<p>Bartter</p>  <p>FC</p>\n</span>, <span>\n<p>Gillette</p>  <p>JR</p>\n</span>, <span>\n<p>Loriaux</p>  <p>DL</p>\n</span>, <span>\n<p>Easley</p>  <p>R</p>\n</span>, <span>\n<p>Menard</p>  <p>RH</p>\n</span>\n. </p><p>Effect of spironolactone on sex hormones in man</p><p>. </p><p>J Clin Endocrinol Metab</p><p>. </p><p>1975</p><p>;</p><p>41</p><p>(</p><p>4</p><p>):</p><p>777</p><p>–</p><p>781</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B143\" data-id=\"B143\" content-id=\"B143\" data-legacy-id=\"B143\"><p><span>143.</span></p><div><p>Levy</p>  <p>J</p><p>\n, <span>\n<p>Burshell</p>  <p>A</p>\n</span>, <span>\n<p>Marbach</p>  <p>M</p>\n</span>, <span>\n<p>Afllalo</p>  <p>L</p>\n</span>, <span>\n<p>Glick</p>  <p>SM</p>\n</span>\n. </p><p>Interaction of spironolactone with oestradiol receptors in cytosol</p><p>. </p><p>J Endocrinol</p><p>. </p><p>1980</p><p>;</p><p>84</p><p>(</p><p>3</p><p>):</p><p>371</p><p>–</p><p>379</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B144\" data-id=\"B144\" content-id=\"B144\" data-legacy-id=\"B144\"><p><span>144.</span></p><div><p>Wierckx</p>  <p>K</p><p>\n, <span>\n<p>Elaut</p>  <p>E</p>\n</span>, <span>\n<p>Van Hoorde</p>  <p>B</p>\n</span>, <span>\n<p>Heylens</p>  <p>G</p>\n</span>, <span>\n<p>De Cuypere</p>  <p>G</p>\n</span>, <span>\n<p>Monstrey</p>  <p>S</p>\n</span>, <span>\n<p>Weyers</p>  <p>S</p>\n</span>, <span>\n<p>Hoebeke</p>  <p>P</p>\n</span>, <span>\n<p>T’Sjoen</p>  <p>G</p>\n</span>\n. </p><p>Sexual desire in trans persons: associations with sex reassignment treatment</p><p>. </p><p>J Sex Med</p><p>. </p><p>2014</p><p>;</p><p>11</p><p>(</p><p>1</p><p>):</p><p>107</p><p>–</p><p>118</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B145\" data-id=\"B145\" content-id=\"B145\" data-legacy-id=\"B145\"><p><span>145.</span></p><div><p>Chiriacò</p>  <p>G</p><p>\n, <span>\n<p>Cauci</p>  <p>S</p>\n</span>, <span>\n<p>Mazzon</p>  <p>G</p>\n</span>, <span>\n<p>Trombetta</p>  <p>C</p>\n</span>\n. </p><p>An observational retrospective evaluation of 79 young men with long-term adverse effects after use of finasteride against androgenetic alopecia</p><p>. </p><p>Andrology</p><p>. </p><p>2016</p><p>;</p><p>4</p><p>(</p><p>2</p><p>):</p><p>245</p><p>–</p><p>250</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B146\" data-id=\"B146\" content-id=\"B146\" data-legacy-id=\"B146\"><p><span>146.</span></p><div><p>Gava</p>  <p>G</p><p>\n, <span>\n<p>Cerpolini</p>  <p>S</p>\n</span>, <span>\n<p>Martelli</p>  <p>V</p>\n</span>, <span>\n<p>Battista</p>  <p>G</p>\n</span>, <span>\n<p>Seracchioli</p>  <p>R</p>\n</span>, <span>\n<p>Meriggiola</p>  <p>MC</p>\n</span>\n. </p><p>Cyproterone acetate vs leuprolide acetate in combination with transdermal oestradiol in transwomen: a comparison of safety and effectiveness</p><p>. </p><p>Clin Endocrinol (Oxf)</p><p>. </p><p>2016</p><p>;</p><p>85</p><p>(</p><p>2</p><p>):</p><p>239</p><p>–</p><p>246</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B147\" data-id=\"B147\" content-id=\"B147\" data-legacy-id=\"B147\"><p><span>147.</span></p><div><p>Casper</p>  <p>RF</p><p>\n, <span>\n<p>Yen</p>  <p>SS</p>\n</span>\n. </p><p>Rapid absorption of micronized estradiol-17 beta following sublingual administration</p><p>. </p><p>Obstet Gynecol</p><p>. </p><p>1981</p><p>;</p><p>57</p><p>(</p><p>1</p><p>):</p><p>62</p><p>–</p><p>64</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B148\" data-id=\"B148\" content-id=\"B148\" data-legacy-id=\"B148\"><p><span>148.</span></p><div><p>Price</p>  <p>TM</p><p>\n, <span>\n<p>Blauer</p>  <p>KL</p>\n</span>, <span>\n<p>Hansen</p>  <p>M</p>\n</span>, <span>\n<p>Stanczyk</p>  <p>F</p>\n</span>, <span>\n<p>Lobo</p>  <p>R</p>\n</span>, <span>\n<p>Bates</p>  <p>GW</p>\n</span>\n. </p><p>Single-dose pharmacokinetics of sublingual versus oral administration of micronized 17β-estradiol</p><p>. </p><p>Obstet Gynecol</p><p>. </p><p>1997</p><p>;</p><p>89</p><p>(</p><p>3</p><p>):</p><p>340</p><p>–</p><p>345</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B149\" data-id=\"B149\" content-id=\"B149\" data-legacy-id=\"B149\"><p><span>149.</span></p><div><p>Toorians</p>  <p>AWFT</p><p>\n, <span>\n<p>Thomassen</p>  <p>MCLGD</p>\n</span>, <span>\n<p>Zweegman</p>  <p>S</p>\n</span>, <span>\n<p>Magdeleyns</p>  <p>EJP</p>\n</span>, <span>\n<p>Tans</p>  <p>G</p>\n</span>, <span>\n<p>Gooren</p>  <p>LJG</p>\n</span>, <span>\n<p>Rosing</p>  <p>J</p>\n</span>\n. </p><p>Venous thrombosis and changes of hemostatic variables during cross-sex hormone treatment in transsexual people</p><p>. </p><p>J Clin Endocrinol Metab</p><p>. </p><p>2003</p><p>;</p><p>88</p><p>(</p><p>12</p><p>):</p><p>5723</p><p>–</p><p>5729</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B150\" data-id=\"B150\" content-id=\"B150\" data-legacy-id=\"B150\"><p><span>150.</span></p><div><p>Mepham</p>  <p>N</p><p>\n, <span>\n<p>Bouman</p>  <p>WP</p>\n</span>, <span>\n<p>Arcelus</p>  <p>J</p>\n</span>, <span>\n<p>Hayter</p>  <p>M</p>\n</span>, <span>\n<p>Wylie</p>  <p>KR</p>\n</span>\n. </p><p>People with gender dysphoria who self-prescribe cross-sex hormones: prevalence, sources, and side effects knowledge</p><p>. </p><p>J Sex Med</p><p>. </p><p>2014</p><p>;</p><p>11</p><p>(</p><p>12</p><p>):</p><p>2995</p><p>–</p><p>3001</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B151\" data-id=\"B151\" content-id=\"B151\" data-legacy-id=\"B151\"><p><span>151.</span></p><div><p>Richards</p>  <p>C</p><p>\n, <span>\n<p>Bouman</p>  <p>WP</p>\n</span>, <span>\n<p>Seal</p>  <p>L</p>\n</span>, <span>\n<p>Barker</p>  <p>MJ</p>\n</span>, <span>\n<p>Nieder</p>  <p>TO</p>\n</span>, <span>\n<p>T’Sjoen</p>  <p>G</p>\n</span>\n. </p><p>Non-binary or genderqueer genders</p><p>. </p><p>Int Rev Psychiatry</p><p>. </p><p>2016</p><p>;</p><p>28</p><p>(</p><p>1</p><p>):</p><p>95</p><p>–</p><p>102</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B152\" data-id=\"B152\" content-id=\"B152\" data-legacy-id=\"B152\"><p><span>152.</span></p><div><p>Cosyns</p>  <p>M</p><p>\n, <span>\n<p>Van Borsel</p>  <p>J</p>\n</span>, <span>\n<p>Wierckx</p>  <p>K</p>\n</span>, <span>\n<p>Dedecker</p>  <p>D</p>\n</span>, <span>\n<p>Van de Peer</p>  <p>F</p>\n</span>, <span>\n<p>Daelman</p>  <p>T</p>\n</span>, <span>\n<p>Laenen</p>  <p>S</p>\n</span>, <span>\n<p>T’Sjoen</p>  <p>G</p>\n</span>\n. </p><p>Voice in female-to-male transsexual persons after long-term androgen therapy</p><p>. </p><p>Laryngoscope</p><p>. </p><p>2014</p><p>;</p><p>124</p><p>(</p><p>6</p><p>):</p><p>1409</p><p>–</p><p>1414</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B153\" data-id=\"B153\" content-id=\"B153\" data-legacy-id=\"B153\"><p><span>153.</span></p><div><p>Deuster</p>  <p>D</p><p>\n, <span>\n<p>Matulat</p>  <p>P</p>\n</span>, <span>\n<p>Knief</p>  <p>A</p>\n</span>, <span>\n<p>Zitzmann</p>  <p>M</p>\n</span>, <span>\n<p>Rosslau</p>  <p>K</p>\n</span>, <span>\n<p>Szukaj</p>  <p>M</p>\n</span>, <span>\n<p>am Zehnhoff-Dinnesen</p>  <p>A</p>\n</span>, <span>\n<p>Schmidt</p>  <p>CM</p>\n</span>\n. </p><p>Voice deepening under testosterone treatment in female-to-male gender dysphoric individuals</p><p>. </p><p>Eur Arch Otorhinolaryngol</p><p>. </p><p>2016</p><p>;</p><p>273</p><p>(</p><p>4</p><p>):</p><p>959</p><p>–</p><p>965</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B154\" data-id=\"B154\" content-id=\"B154\" data-legacy-id=\"B154\"><p><span>154.</span></p><div><p>Lapauw</p>  <p>B</p><p>\n, <span>\n<p>Taes</p>  <p>Y</p>\n</span>, <span>\n<p>Simoens</p>  <p>S</p>\n</span>, <span>\n<p>Van Caenegem</p>  <p>E</p>\n</span>, <span>\n<p>Weyers</p>  <p>S</p>\n</span>, <span>\n<p>Goemaere</p>  <p>S</p>\n</span>, <span>\n<p>Toye</p>  <p>K</p>\n</span>, <span>\n<p>Kaufman</p>  <p>J-M</p>\n</span>, <span>\n<p>T’Sjoen</p>  <p>GG</p>\n</span>\n. </p><p>Body composition, volumetric and areal bone parameters in male-to-female transsexual persons</p><p>. </p><p>Bone</p><p>. </p><p>2008</p><p>;</p><p>43</p><p>(</p><p>6</p><p>):</p><p>1016</p><p>–</p><p>1021</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B155\" data-id=\"B155\" content-id=\"B155\" data-legacy-id=\"B155\"><p><span>155.</span></p><div><p>Meyer</p><p> III </p><p>WJ</p><p>\n, <span>\n<p>Webb</p>  <p>A</p>\n</span>, <span>\n<p>Stuart</p>  <p>CA</p>\n</span>, <span>\n<p>Finkelstein</p>  <p>JW</p>\n</span>, <span>\n<p>Lawrence</p>  <p>B</p>\n</span>, <span>\n<p>Walker</p>  <p>PA</p>\n</span>\n. </p><p>Physical and hormonal evaluation of transsexual patients: a longitudinal study</p><p>. </p><p>Arch Sex Behav</p><p>. </p><p>1986</p><p>;</p><p>15</p><p>(</p><p>2</p><p>):</p><p>121</p><p>–</p><p>138</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B156\" data-id=\"B156\" content-id=\"B156\" data-legacy-id=\"B156\"><p><span>156.</span></p><div><p>Asscheman</p>  <p>H</p><p>\n, <span>\n<p>Gooren</p>  <p>LJ</p>\n</span>, <span>\n<p>Assies</p>  <p>J</p>\n</span>, <span>\n<p>Smits</p>  <p>JP</p>\n</span>, <span>\n<p>de Slegte</p>  <p>R</p>\n</span>\n. </p><p>Prolactin levels and pituitary enlargement in hormone-treated male-to-female transsexuals</p><p>. </p><p>Clin Endocrinol (Oxf)</p><p>. </p><p>1988</p><p>;</p><p>28</p><p>(</p><p>6</p><p>):</p><p>583</p><p>–</p><p>588</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B157\" data-id=\"B157\" content-id=\"B157\" data-legacy-id=\"B157\"><p><span>157.</span></p><div><p>Gooren</p>  <p>LJ</p><p>\n, <span>\n<p>Harmsen-Louman</p>  <p>W</p>\n</span>, <span>\n<p>van Kessel</p>  <p>H</p>\n</span>\n. </p><p>Follow-up of prolactin levels in long-term oestrogen-treated male-to-female transsexuals with regard to prolactinoma induction</p><p>. </p><p>Clin Endocrinol (Oxf)</p><p>. </p><p>1985</p><p>;</p><p>22</p><p>(</p><p>2</p><p>):</p><p>201</p><p>–</p><p>207</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B158\" data-id=\"B158\" content-id=\"B158\" data-legacy-id=\"B158\"><p><span>158.</span></p><div><p>Wierckx</p>  <p>K</p><p>\n, <span>\n<p>Van Caenegem</p>  <p>E</p>\n</span>, <span>\n<p>Schreiner</p>  <p>T</p>\n</span>, <span>\n<p>Haraldsen</p>  <p>I</p>\n</span>, <span>\n<p>Fisher</p>  <p>AD</p>\n</span>, <span>\n<p>Toye</p>  <p>K</p>\n</span>, <span>\n<p>Kaufman</p>  <p>JM</p>\n</span>, <span>\n<p>T’Sjoen</p>  <p>G</p>\n</span>\n. </p><p>Cross-sex hormone therapy in trans persons is safe and effective at short-time follow-up: results from the European network for the investigation of gender incongruence</p><p>. </p><p>J Sex Med</p><p>. </p><p>2014</p><p>;</p><p>11</p><p>(</p><p>8</p><p>):</p><p>1999</p><p>–</p><p>2011</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B159\" data-id=\"B159\" content-id=\"B159\" data-legacy-id=\"B159\"><p><span>159.</span></p><div><p>Ott</p>  <p>J</p><p>\n, <span>\n<p>Kaufmann</p>  <p>U</p>\n</span>, <span>\n<p>Bentz</p>  <p>EK</p>\n</span>, <span>\n<p>Huber</p>  <p>JC</p>\n</span>, <span>\n<p>Tempfer</p>  <p>CB</p>\n</span>\n. </p><p>Incidence of thrombophilia and venous thrombosis in transsexuals under cross-sex hormone therapy</p><p>. </p><p>Fertil Steril</p><p>. </p><p>2010</p><p>;</p><p>93</p><p>(</p><p>4</p><p>):</p><p>1267</p><p>–</p><p>1272</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B160\" data-id=\"B160\" content-id=\"B160\" data-legacy-id=\"B160\"><p><span>160.</span></p><div><p>Giltay</p>  <p>EJ</p><p>\n, <span>\n<p>Hoogeveen</p>  <p>EK</p>\n</span>, <span>\n<p>Elbers</p>  <p>JMH</p>\n</span>, <span>\n<p>Gooren</p>  <p>LJG</p>\n</span>, <span>\n<p>Asscheman</p>  <p>H</p>\n</span>, <span>\n<p>Stehouwer</p>  <p>CDA</p>\n</span>\n. </p><p>Effects of sex steroids on plasma total homocysteine levels: a study in transsexual males and females</p><p>. </p><p>J Clin Endocrinol Metab</p><p>. </p><p>1998</p><p>;</p><p>83</p><p>(</p><p>2</p><p>):</p><p>550</p><p>–</p><p>553</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B161\" data-id=\"B161\" content-id=\"B161\" data-legacy-id=\"B161\"><p><span>161.</span></p><div><p>van Kesteren</p>  <p>PJM</p><p>\n, <span>\n<p>Asscheman</p>  <p>H</p>\n</span>, <span>\n<p>Megens</p>  <p>JAJ</p>\n</span>, <span>\n<p>Gooren</p>  <p>LJG</p>\n</span>\n. </p><p>Mortality and morbidity in transsexual subjects treated with cross-sex hormones</p><p>. </p><p>Clin Endocrinol (Oxf)</p><p>. </p><p>1997</p><p>;</p><p>47</p><p>(</p><p>3</p><p>):</p><p>337</p><p>–</p><p>343</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B162\" data-id=\"B162\" content-id=\"B162\" data-legacy-id=\"B162\"><p><span>162.</span></p><div><p>Wierckx</p>  <p>K</p><p>\n, <span>\n<p>Gooren</p>  <p>L</p>\n</span>, <span>\n<p>T’Sjoen</p>  <p>G</p>\n</span>\n. </p><p>Clinical review: breast development in trans women receiving cross-sex hormones</p><p>. </p><p>J Sex Med</p><p>. </p><p>2014</p><p>;</p><p>11</p><p>(</p><p>5</p><p>):</p><p>1240</p><p>–</p><p>1247</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B163\" data-id=\"B163\" content-id=\"B163\" data-legacy-id=\"B163\"><p><span>163.</span></p><div><p>Bird</p>  <p>D</p><p>\n, <span>\n<p>Vowles</p>  <p>K</p>\n</span>, <span>\n<p>Anthony</p>  <p>PP</p>\n</span>\n. </p><p>Spontaneous rupture of a liver cell adenoma after long term methyltestosterone: report of a case successfully treated by emergency right hepatic lobectomy</p><p>. </p><p>Br J Surg</p><p>. </p><p>1979</p><p>;</p><p>66</p><p>(</p><p>3</p><p>):</p><p>212</p><p>–</p><p>213</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B164\" data-id=\"B164\" content-id=\"B164\" data-legacy-id=\"B164\"><p><span>164.</span></p><div><p>Westaby</p>  <p>D</p><p>\n, <span>\n<p>Ogle</p>  <p>SJ</p>\n</span>, <span>\n<p>Paradinas</p>  <p>FJ</p>\n</span>, <span>\n<p>Randell</p>  <p>JB</p>\n</span>, <span>\n<p>Murray-Lyon</p>  <p>IM</p>\n</span>\n. </p><p>Liver damage from long-term methyltestosterone</p><p>. </p><p>Lancet</p><p>. </p><p>1977</p><p>;</p><p>2</p><p>(</p><p>8032</p><p>):</p><p>262</p><p>–</p><p>263</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B165\" data-id=\"B165\" content-id=\"B165\" data-legacy-id=\"B165\"><p><span>165.</span></p><div><p>Weinand</p>  <p>JD</p><p>\n, <span>\n<p>Safer</p>  <p>JD</p>\n</span>\n. </p><p>Hormone therapy in transgender adults is safe with provider supervision; a review of hormone therapy sequelae for transgender individuals</p><p>. </p><p>J Clin Transl Endocrinol</p><p>. </p><p>2015</p><p>;</p><p>2</p><p>(</p><p>2</p><p>):</p><p>55</p><p>–</p><p>60</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B166\" data-id=\"B166\" content-id=\"B166\" data-legacy-id=\"B166\"><p><span>166.</span></p><div><p>Roberts</p>  <p>TK</p><p>\n, <span>\n<p>Kraft</p>  <p>CS</p>\n</span>, <span>\n<p>French</p>  <p>D</p>\n</span>, <span>\n<p>Ji</p>  <p>W</p>\n</span>, <span>\n<p>Wu</p>  <p>AH</p>\n</span>, <span>\n<p>Tangpricha</p>  <p>V</p>\n</span>, <span>\n<p>Fantz</p>  <p>CR</p>\n</span>\n. </p><p>Interpreting laboratory results in transgender patients on hormone therapy</p><p>. </p><p>Am J Med</p><p>. </p><p>2014</p><p>;</p><p>127</p><p>(</p><p>2</p><p>):</p><p>159</p><p>–</p><p>162</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B167\" data-id=\"B167\" content-id=\"B167\" data-legacy-id=\"B167\"><p><span>167.</span></p><div><p>Vesper</p>  <p>HW</p><p>\n, <span>\n<p>Botelho</p>  <p>JC</p>\n</span>, <span>\n<p>Wang</p>  <p>Y</p>\n</span>\n. </p><p>Challenges and improvements in testosterone and estradiol testing</p><p>. </p><p>Asian J Androl</p><p>. </p><p>2014</p><p>;</p><p>16</p><p>(</p><p>2</p><p>):</p><p>178</p><p>–</p><p>184</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B168\" data-id=\"B168\" content-id=\"B168\" data-legacy-id=\"B168\"><p><span>168.</span></p><div><p>Asscheman</p>  <p>H</p><p>\n, <span>\n<p>T’Sjoen</p>  <p>G</p>\n</span>, <span>\n<p>Lemaire</p>  <p>A</p>\n</span>, <span>\n<p>Mas</p>  <p>M</p>\n</span>, <span>\n<p>Meriggiola</p>  <p>MC</p>\n</span>, <span>\n<p>Mueller</p>  <p>A</p>\n</span>, <span>\n<p>Kuhn</p>  <p>A</p>\n</span>, <span>\n<p>Dhejne</p>  <p>C</p>\n</span>, <span>\n<p>Morel-Journel</p>  <p>N</p>\n</span>, <span>\n<p>Gooren</p>  <p>LJ</p>\n</span>\n. </p><p>Venous thrombo-embolism as a complication of cross-sex hormone treatment of male-to-female transsexual subjects: a review</p><p>. </p><p>Andrologia</p><p>. </p><p>2014</p><p>;</p><p>46</p><p>(</p><p>7</p><p>):</p><p>791</p><p>–</p><p>795</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B169\" data-id=\"B169\" content-id=\"B169\" data-legacy-id=\"B169\"><p><span>169.</span></p><div><p>Righini</p>  <p>M</p><p>\n, <span>\n<p>Perrier</p>  <p>A</p>\n</span>, <span>\n<p>De Moerloose</p>  <p>P</p>\n</span>, <span>\n<p>Bounameaux</p>  <p>H</p>\n</span>\n. </p><p>D-dimer for venous thromboembolism diagnosis: 20 years later</p><p>. </p><p>J Thromb Haemost</p><p>. </p><p>2008</p><p>;</p><p>6</p><p>(</p><p>7</p><p>):</p><p>1059</p><p>–</p><p>1071</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B170\" data-id=\"B170\" content-id=\"B170\" data-legacy-id=\"B170\"><p><span>170.</span></p><div><p>Gooren</p>  <p>LJ</p><p>\n, <span>\n<p>Assies</p>  <p>J</p>\n</span>, <span>\n<p>Asscheman</p>  <p>H</p>\n</span>, <span>\n<p>de Slegte</p>  <p>R</p>\n</span>, <span>\n<p>van Kessel</p>  <p>H</p>\n</span>\n. </p><p>Estrogen-induced prolactinoma in a man</p><p>. </p><p>J Clin Endocrinol Metab</p><p>. </p><p>1988</p><p>;</p><p>66</p><p>(</p><p>2</p><p>):</p><p>444</p><p>–</p><p>446</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B171\" data-id=\"B171\" content-id=\"B171\" data-legacy-id=\"B171\"><p><span>171.</span></p><div><p>Kovacs</p>  <p>K</p><p>\n, <span>\n<p>Stefaneanu</p>  <p>L</p>\n</span>, <span>\n<p>Ezzat</p>  <p>S</p>\n</span>, <span>\n<p>Smyth</p>  <p>HS</p>\n</span>\n. </p><p>Prolactin-producing pituitary adenoma in a male-to-female transsexual patient with protracted estrogen administration. A morphologic study</p><p>. </p><p>Arch Pathol Lab Med</p><p>. </p><p>1994</p><p>;</p><p>118</p><p>(</p><p>5</p><p>):</p><p>562</p><p>–</p><p>565</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B172\" data-id=\"B172\" content-id=\"B172\" data-legacy-id=\"B172\"><p><span>172.</span></p><div><p>Serri</p>  <p>O</p><p>\n, <span>\n<p>Noiseux</p>  <p>D</p>\n</span>, <span>\n<p>Robert</p>  <p>F</p>\n</span>, <span>\n<p>Hardy</p>  <p>J</p>\n</span>\n. </p><p>Lactotroph hyperplasia in an estrogen treated male-to-female transsexual patient</p><p>. </p><p>J Clin Endocrinol Metab</p><p>. </p><p>1996</p><p>;</p><p>81</p><p>(</p><p>9</p><p>):</p><p>3177</p><p>–</p><p>3179</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B173\" data-id=\"B173\" content-id=\"B173\" data-legacy-id=\"B173\"><p><span>173.</span></p><div><p>Cunha</p>  <p>FS</p><p>\n, <span>\n<p>Domenice</p>  <p>S</p>\n</span>, <span>\n<p>Câmara</p>  <p>VL</p>\n</span>, <span>\n<p>Sircili</p>  <p>MH</p>\n</span>, <span>\n<p>Gooren</p>  <p>LJ</p>\n</span>, <span>\n<p>Mendonça</p>  <p>BB</p>\n</span>, <span>\n<p>Costa</p>  <p>EM</p>\n</span>\n. </p><p>Diagnosis of prolactinoma in two male-to-female transsexual subjects following high-dose cross-sex hormone therapy</p><p>. </p><p>Andrologia</p><p>. </p><p>2015</p><p>;</p><p>47</p><p>(</p><p>6</p><p>):</p><p>680</p><p>–</p><p>684</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B174\" data-id=\"B174\" content-id=\"B174\" data-legacy-id=\"B174\"><p><span>174.</span></p><div><p>Nota</p>  <p>NM</p><p>\n, <span>\n<p>Dekker</p>  <p>MJHJ</p>\n</span>, <span>\n<p>Klaver</p>  <p>M</p>\n</span>, <span>\n<p>Wiepjes</p>  <p>CM</p>\n</span>, <span>\n<p>van Trotsenburg</p>  <p>MA</p>\n</span>, <span>\n<p>Heijboer</p>  <p>AC</p>\n</span>, <span>\n<p>den Heijer</p>  <p>M</p>\n</span>\n. </p><p>Prolactin levels during short- and long-term cross-sex hormone treatment: an observational study in transgender persons</p><p>. </p><p>Andrologia</p><p>. </p><p>2017</p><p>;</p><p><strong>49</strong>(6)</p><p>.</p></div></div><div id=\"ref-auto-B175\" data-id=\"B175\" content-id=\"B175\" data-legacy-id=\"B175\"><p><span>175.</span></p><div><p>Bunck</p>  <p>MC</p><p>\n, <span>\n<p>Debono</p>  <p>M</p>\n</span>, <span>\n<p>Giltay</p>  <p>EJ</p>\n</span>, <span>\n<p>Verheijen</p>  <p>AT</p>\n</span>, <span>\n<p>Diamant</p>  <p>M</p>\n</span>, <span>\n<p>Gooren</p>  <p>LJ</p>\n</span>\n. </p><p>Autonomous prolactin secretion in two male-to-female transgender patients using conventional oestrogen dosages</p><p>. </p><p>BMJ Case Rep</p><p>. </p><p>2009</p><p>;</p><p>2009</p><p>:</p><p>bcr0220091589</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B176\" data-id=\"B176\" content-id=\"B176\" data-legacy-id=\"B176\"><p><span>176.</span></p><div><p>Elamin</p>  <p>MB</p><p>\n, <span>\n<p>Garcia</p>  <p>MZ</p>\n</span>, <span>\n<p>Murad</p>  <p>MH</p>\n</span>, <span>\n<p>Erwin</p>  <p>PJ</p>\n</span>, <span>\n<p>Montori</p>  <p>VM</p>\n</span>\n. </p><p>Effect of sex steroid use on cardiovascular risk in transsexual individuals: a systematic review and meta-analyses</p><p>. </p><p>Clin Endocrinol (Oxf)</p><p>. </p><p>2010</p><p>;</p><p>72</p><p>(</p><p>1</p><p>):</p><p>1</p><p>–</p><p>10</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B177\" data-id=\"B177\" content-id=\"B177\" data-legacy-id=\"B177\"><p><span>177.</span></p><div><p>Berra</p>  <p>M</p><p>\n, <span>\n<p>Armillotta</p>  <p>F</p>\n</span>, <span>\n<p>D’Emidio</p>  <p>L</p>\n</span>, <span>\n<p>Costantino</p>  <p>A</p>\n</span>, <span>\n<p>Martorana</p>  <p>G</p>\n</span>, <span>\n<p>Pelusi</p>  <p>G</p>\n</span>, <span>\n<p>Meriggiola</p>  <p>MC</p>\n</span>\n. </p><p>Testosterone decreases adiponectin levels in female to male transsexuals</p><p>. </p><p>Asian J Androl</p><p>. </p><p>2006</p><p>;</p><p>8</p><p>(</p><p>6</p><p>):</p><p>725</p><p>–</p><p>729</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B178\" data-id=\"B178\" content-id=\"B178\" data-legacy-id=\"B178\"><p><span>178.</span></p><div><p>Elbers</p>  <p>JMH</p><p>\n, <span>\n<p>Giltay</p>  <p>EJ</p>\n</span>, <span>\n<p>Teerlink</p>  <p>T</p>\n</span>, <span>\n<p>Scheffer</p>  <p>PG</p>\n</span>, <span>\n<p>Asscheman</p>  <p>H</p>\n</span>, <span>\n<p>Seidell</p>  <p>JC</p>\n</span>, <span>\n<p>Gooren</p>  <p>LJG</p>\n</span>\n. </p><p>Effects of sex steroids on components of the insulin resistance syndrome in transsexual subjects</p><p>. </p><p>Clin Endocrinol (Oxf)</p><p>. </p><p>2003</p><p>;</p><p>58</p><p>(</p><p>5</p><p>):</p><p>562</p><p>–</p><p>571</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B179\" data-id=\"B179\" content-id=\"B179\" data-legacy-id=\"B179\"><p><span>179.</span></p><div><p>Giltay</p>  <p>EJ</p><p>\n, <span>\n<p>Lambert</p>  <p>J</p>\n</span>, <span>\n<p>Gooren</p>  <p>LJG</p>\n</span>, <span>\n<p>Elbers</p>  <p>JMH</p>\n</span>, <span>\n<p>Steyn</p>  <p>M</p>\n</span>, <span>\n<p>Stehouwer</p>  <p>CDA</p>\n</span>\n. </p><p>Sex steroids, insulin, and arterial stiffness in women and men</p><p>. </p><p>Hypertension</p><p>. </p><p>1999</p><p>;</p><p>34</p><p>(</p><p>4 Pt 1</p><p>):</p><p>590</p><p>–</p><p>597</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B180\" data-id=\"B180\" content-id=\"B180\" data-legacy-id=\"B180\"><p><span>180.</span></p><div><p>Polderman</p>  <p>KH</p><p>\n, <span>\n<p>Gooren</p>  <p>LJ</p>\n</span>, <span>\n<p>Asscheman</p>  <p>H</p>\n</span>, <span>\n<p>Bakker</p>  <p>A</p>\n</span>, <span>\n<p>Heine</p>  <p>RJ</p>\n</span>\n. </p><p>Induction of insulin resistance by androgens and estrogens</p><p>. </p><p>J Clin Endocrinol Metab</p><p>. </p><p>1994</p><p>;</p><p>79</p><p>(</p><p>1</p><p>):</p><p>265</p><p>–</p><p>271</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B182\" data-id=\"B182\" content-id=\"B182\" data-legacy-id=\"B182\"><p><span>182.</span></p><div><p>Meriggiola</p>  <p>MC</p><p>\n, <span>\n<p>Armillotta</p>  <p>F</p>\n</span>, <span>\n<p>Costantino</p>  <p>A</p>\n</span>, <span>\n<p>Altieri</p>  <p>P</p>\n</span>, <span>\n<p>Saad</p>  <p>F</p>\n</span>, <span>\n<p>Kalhorn</p>  <p>T</p>\n</span>, <span>\n<p>Perrone</p>  <p>AM</p>\n</span>, <span>\n<p>Ghi</p>  <p>T</p>\n</span>, <span>\n<p>Pelusi</p>  <p>C</p>\n</span>, <span>\n<p>Pelusi</p>  <p>G</p>\n</span>\n. </p><p>Effects of testosterone undecanoate administered alone or in combination with letrozole or dutasteride in female to male transsexuals</p><p>. </p><p>J Sex Med</p><p>. </p><p>2008</p><p>;</p><p>5</p><p>(</p><p>10</p><p>):</p><p>2442</p><p>–</p><p>2453</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B183\" data-id=\"B183\" content-id=\"B183\" data-legacy-id=\"B183\"><p><span>183.</span></p><div><p>Giltay</p>  <p>EJ</p><p>\n, <span>\n<p>Toorians</p>  <p>AW</p>\n</span>, <span>\n<p>Sarabdjitsingh</p>  <p>AR</p>\n</span>, <span>\n<p>de Vries</p>  <p>NA</p>\n</span>, <span>\n<p>Gooren</p>  <p>LJ</p>\n</span>\n. </p><p>Established risk factors for coronary heart disease are unrelated to androgen-induced baldness in female-to-male transsexuals</p><p>. </p><p>J Endocrinol</p><p>. </p><p>2004</p><p>;</p><p>180</p><p>(</p><p>1</p><p>):</p><p>107</p><p>–</p><p>112</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B184\" data-id=\"B184\" content-id=\"B184\" data-legacy-id=\"B184\"><p><span>184.</span></p><div><p>Giltay</p>  <p>EJ</p><p>\n, <span>\n<p>Verhoef</p>  <p>P</p>\n</span>, <span>\n<p>Gooren</p>  <p>LJG</p>\n</span>, <span>\n<p>Geleijnse</p>  <p>JM</p>\n</span>, <span>\n<p>Schouten</p>  <p>EG</p>\n</span>, <span>\n<p>Stehouwer</p>  <p>CDA</p>\n</span>\n. </p><p>Oral and transdermal estrogens both lower plasma total homocysteine in male-to-female transsexuals</p><p>. </p><p>Atherosclerosis</p><p>. </p><p>2003</p><p>;</p><p>168</p><p>(</p><p>1</p><p>):</p><p>139</p><p>–</p><p>146</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B185\" data-id=\"B185\" content-id=\"B185\" data-legacy-id=\"B185\"><p><span>185.</span></p><div><p>Calof</p>  <p>OM</p><p>\n, <span>\n<p>Singh</p>  <p>AB</p>\n</span>, <span>\n<p>Lee</p>  <p>ML</p>\n</span>, <span>\n<p>Kenny</p>  <p>AM</p>\n</span>, <span>\n<p>Urban</p>  <p>RJ</p>\n</span>, <span>\n<p>Tenover</p>  <p>JL</p>\n</span>, <span>\n<p>Bhasin</p>  <p>S</p>\n</span>\n. </p><p>Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials</p><p>. </p><p>J Gerontol A Biol Sci Med Sci</p><p>. </p><p>2005</p><p>;</p><p>60</p><p>(</p><p>11</p><p>):</p><p>1451</p><p>–</p><p>1457</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B186\" data-id=\"B186\" content-id=\"B186\" data-legacy-id=\"B186\"><p><span>186.</span></p><div><p>Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults</p><p>\n. </p><p>Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)</p><p>. </p><p>JAMA</p><p>. </p><p>2001</p><p>;</p><p>285</p><p>(</p><p>19</p><p>):</p><p>2486</p><p>–</p><p>2497</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B187\" data-id=\"B187\" content-id=\"B187\" data-legacy-id=\"B187\"><p><span>187.</span></p><div><p>Murad</p>  <p>MH</p><p>\n, <span>\n<p>Elamin</p>  <p>MB</p>\n</span>, <span>\n<p>Garcia</p>  <p>MZ</p>\n</span>, <span>\n<p>Mullan</p>  <p>RJ</p>\n</span>, <span>\n<p>Murad</p>  <p>A</p>\n</span>, <span>\n<p>Erwin</p>  <p>PJ</p>\n</span>, <span>\n<p>Montori</p>  <p>VM</p>\n</span>\n. </p><p>Hormonal therapy and sex reassignment: a systematic review and meta-analysis of quality of life and psychosocial outcomes</p><p>. </p><p>Clin Endocrinol (Oxf)</p><p>. </p><p>2010</p><p>;</p><p>72</p><p>(</p><p>2</p><p>):</p><p>214</p><p>–</p><p>231</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B188\" data-id=\"B188\" content-id=\"B188\" data-legacy-id=\"B188\"><p><span>188.</span></p><div><p>Van Caenegem</p>  <p>E</p><p>\n, <span>\n<p>Wierckx</p>  <p>K</p>\n</span>, <span>\n<p>Taes</p>  <p>Y</p>\n</span>, <span>\n<p>Schreiner</p>  <p>T</p>\n</span>, <span>\n<p>Vandewalle</p>  <p>S</p>\n</span>, <span>\n<p>Toye</p>  <p>K</p>\n</span>, <span>\n<p>Lapauw</p>  <p>B</p>\n</span>, <span>\n<p>Kaufman</p>  <p>JM</p>\n</span>, <span>\n<p>T’Sjoen</p>  <p>G</p>\n</span>\n. </p><p>Body composition, bone turnover, and bone mass in trans men during testosterone treatment: 1-year follow-up data from a prospective case-controlled study (ENIGI)</p><p>. </p><p>Eur J Endocrinol</p><p>. </p><p>2015</p><p>;</p><p>172</p><p>(</p><p>2</p><p>):</p><p>163</p><p>–</p><p>171</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B189\" data-id=\"B189\" content-id=\"B189\" data-legacy-id=\"B189\"><p><span>189.</span></p><div><p>Turner</p>  <p>A</p><p>\n, <span>\n<p>Chen</p>  <p>TC</p>\n</span>, <span>\n<p>Barber</p>  <p>TW</p>\n</span>, <span>\n<p>Malabanan</p>  <p>AO</p>\n</span>, <span>\n<p>Holick</p>  <p>MF</p>\n</span>, <span>\n<p>Tangpricha</p>  <p>V</p>\n</span>\n. </p><p>Testosterone increases bone mineral density in female-to-male transsexuals: a case series of 15 subjects</p><p>. </p><p>Clin Endocrinol (Oxf)</p><p>. </p><p>2004</p><p>;</p><p>61</p><p>(</p><p>5</p><p>):</p><p>560</p><p>–</p><p>566</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B190\" data-id=\"B190\" content-id=\"B190\" data-legacy-id=\"B190\"><p><span>190.</span></p><div><p>van Kesteren</p>  <p>P</p><p>\n, <span>\n<p>Lips</p>  <p>P</p>\n</span>, <span>\n<p>Gooren</p>  <p>LJG</p>\n</span>, <span>\n<p>Asscheman</p>  <p>H</p>\n</span>, <span>\n<p>Megens</p>  <p>J</p>\n</span>\n. </p><p>Long-term follow-up of bone mineral density and bone metabolism in transsexuals treated with cross-sex hormones</p><p>. </p><p>Clin Endocrinol (Oxf)</p><p>. </p><p>1998</p><p>;</p><p>48</p><p>(</p><p>3</p><p>):</p><p>347</p><p>–</p><p>354</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B191\" data-id=\"B191\" content-id=\"B191\" data-legacy-id=\"B191\"><p><span>191.</span></p><div><p>Van Caenegem</p>  <p>E</p><p>\n, <span>\n<p>Taes</p>  <p>Y</p>\n</span>, <span>\n<p>Wierckx</p>  <p>K</p>\n</span>, <span>\n<p>Vandewalle</p>  <p>S</p>\n</span>, <span>\n<p>Toye</p>  <p>K</p>\n</span>, <span>\n<p>Kaufman</p>  <p>JM</p>\n</span>, <span>\n<p>Schreiner</p>  <p>T</p>\n</span>, <span>\n<p>Haraldsen</p>  <p>I</p>\n</span>, <span>\n<p>T’Sjoen</p>  <p>G</p>\n</span>\n. </p><p>Low bone mass is prevalent in male-to-female transsexual persons before the start of cross-sex hormonal therapy and gonadectomy</p><p>. </p><p>Bone</p><p>. </p><p>2013</p><p>;</p><p>54</p><p>(</p><p>1</p><p>):</p><p>92</p><p>–</p><p>97</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B192\" data-id=\"B192\" content-id=\"B192\" data-legacy-id=\"B192\"><p><span>192.</span></p><div><p>Amin</p>  <p>S</p><p>\n, <span>\n<p>Zhang</p>  <p>Y</p>\n</span>, <span>\n<p>Sawin</p>  <p>CT</p>\n</span>, <span>\n<p>Evans</p>  <p>SR</p>\n</span>, <span>\n<p>Hannan</p>  <p>MT</p>\n</span>, <span>\n<p>Kiel</p>  <p>DP</p>\n</span>, <span>\n<p>Wilson</p>  <p>PW</p>\n</span>, <span>\n<p>Felson</p>  <p>DT</p>\n</span>\n. </p><p>Association of hypogonadism and estradiol levels with bone mineral density in elderly men from the Framingham study</p><p>. </p><p>Ann Intern Med</p><p>. </p><p>2000</p><p>;</p><p>133</p><p>(</p><p>12</p><p>):</p><p>951</p><p>–</p><p>963</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B193\" data-id=\"B193\" content-id=\"B193\" data-legacy-id=\"B193\"><p><span>193.</span></p><div><p>Gennari</p>  <p>L</p><p>\n, <span>\n<p>Khosla</p>  <p>S</p>\n</span>, <span>\n<p>Bilezikian</p>  <p>JP</p>\n</span>\n. </p><p>Estrogen and fracture risk in men</p><p>. </p><p>J Bone Miner Res</p><p>. </p><p>2008</p><p>;</p><p>23</p><p>(</p><p>10</p><p>):</p><p>1548</p><p>–</p><p>1551</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B194\" data-id=\"B194\" content-id=\"B194\" data-legacy-id=\"B194\"><p><span>194.</span></p><div><p>Khosla</p>  <p>S</p><p>\n, <span>\n<p>Melton</p>  <p>LJ</p> III\n</span>, <span>\n<p>Atkinson</p>  <p>EJ</p>\n</span>, <span>\n<p>O’Fallon</p>  <p>WM</p>\n</span>, <span>\n<p>Klee</p>  <p>GG</p>\n</span>, <span>\n<p>Riggs</p>  <p>BL</p>\n</span>\n. </p><p>Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: a key role for bioavailable estrogen</p><p>. </p><p>J Clin Endocrinol Metab</p><p>. </p><p>1998</p><p>;</p><p>83</p><p>(</p><p>7</p><p>):</p><p>2266</p><p>–</p><p>2274</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B195\" data-id=\"B195\" content-id=\"B195\" data-legacy-id=\"B195\"><p><span>195.</span></p><div><p>Mueller</p>  <p>A</p><p>\n, <span>\n<p>Dittrich</p>  <p>R</p>\n</span>, <span>\n<p>Binder</p>  <p>H</p>\n</span>, <span>\n<p>Kuehnel</p>  <p>W</p>\n</span>, <span>\n<p>Maltaris</p>  <p>T</p>\n</span>, <span>\n<p>Hoffmann</p>  <p>I</p>\n</span>, <span>\n<p>Beckmann</p>  <p>MW</p>\n</span>\n. </p><p>High dose estrogen treatment increases bone mineral density in male-to-female transsexuals receiving gonadotropin-releasing hormone agonist in the absence of testosterone</p><p>. </p><p>Eur J Endocrinol</p><p>. </p><p>2005</p><p>;</p><p>153</p><p>(</p><p>1</p><p>):</p><p>107</p><p>–</p><p>113</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B196\" data-id=\"B196\" content-id=\"B196\" data-legacy-id=\"B196\"><p><span>196.</span></p><div><p>Ruetsche</p>  <p>AG</p><p>\n, <span>\n<p>Kneubuehl</p>  <p>R</p>\n</span>, <span>\n<p>Birkhaeuser</p>  <p>MH</p>\n</span>, <span>\n<p>Lippuner</p>  <p>K</p>\n</span>\n. </p><p>Cortical and trabecular bone mineral density in transsexuals after long-term cross-sex hormonal treatment: a cross-sectional study</p><p>. </p><p>Osteoporos Int</p><p>. </p><p>2005</p><p>;</p><p>16</p><p>(</p><p>7</p><p>):</p><p>791</p><p>–</p><p>798</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B197\" data-id=\"B197\" content-id=\"B197\" data-legacy-id=\"B197\"><p><span>197.</span></p><div><p>Ganly</p>  <p>I</p><p>\n, <span>\n<p>Taylor</p>  <p>EW</p>\n</span>\n. </p><p>Breast cancer in a trans-sexual man receiving hormone replacement therapy</p><p>. </p><p>Br J Surg</p><p>. </p><p>1995</p><p>;</p><p>82</p><p>(</p><p>3</p><p>):</p><p>341</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B198\" data-id=\"B198\" content-id=\"B198\" data-legacy-id=\"B198\"><p><span>198.</span></p><div><p>Pritchard</p>  <p>TJ</p><p>\n, <span>\n<p>Pankowsky</p>  <p>DA</p>\n</span>, <span>\n<p>Crowe</p>  <p>JP</p>\n</span>, <span>\n<p>Abdul-Karim</p>  <p>FW</p>\n</span>\n. </p><p>Breast cancer in a male-to-female transsexual. A case report</p><p>. </p><p>JAMA</p><p>. </p><p>1988</p><p>;</p><p>259</p><p>(</p><p>15</p><p>):</p><p>2278</p><p>–</p><p>2280</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B199\" data-id=\"B199\" content-id=\"B199\" data-legacy-id=\"B199\"><p><span>199.</span></p><div><p>Symmers</p>  <p>WS</p><p>\n\n. </p><p>Carcinoma of breast in trans-sexual individuals after surgical and hormonal interference with the primary and secondary sex characteristics</p><p>. </p><p>BMJ</p><p>. </p><p>1968</p><p>;</p><p>2</p><p>(</p><p>5597</p><p>):</p><p>83</p><p>–</p><p>85</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B200\" data-id=\"B200\" content-id=\"B200\" data-legacy-id=\"B200\"><p><span>200.</span></p><div><p>Brown</p>  <p>GR</p><p>\n\n. </p><p>Breast cancer in transgender veterans: a ten-case series</p><p>. </p><p>LGBT Health</p><p>. </p><p>2015</p><p>;</p><p>2</p><p>(</p><p>1</p><p>):</p><p>77</p><p>–</p><p>80</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B201\" data-id=\"B201\" content-id=\"B201\" data-legacy-id=\"B201\"><p><span>201.</span></p><div><p>Shao</p>  <p>T</p><p>\n, <span>\n<p>Grossbard</p>  <p>ML</p>\n</span>, <span>\n<p>Klein</p>  <p>P</p>\n</span>\n. </p><p>Breast cancer in female-to-male transsexuals: two cases with a review of physiology and management</p><p>. </p><p>Clin Breast Cancer</p><p>. </p><p>2011</p><p>;</p><p>11</p><p>(</p><p>6</p><p>):</p><p>417</p><p>–</p><p>419</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B202\" data-id=\"B202\" content-id=\"B202\" data-legacy-id=\"B202\"><p><span>202.</span></p><div><p>Nikolic</p>  <p>DV</p><p>\n, <span>\n<p>Djordjevic</p>  <p>ML</p>\n</span>, <span>\n<p>Granic</p>  <p>M</p>\n</span>, <span>\n<p>Nikolic</p>  <p>AT</p>\n</span>, <span>\n<p>Stanimirovic</p>  <p>VV</p>\n</span>, <span>\n<p>Zdravkovic</p>  <p>D</p>\n</span>, <span>\n<p>Jelic</p>  <p>S</p>\n</span>\n. </p><p>Importance of revealing a rare case of breast cancer in a female to male transsexual after bilateral mastectomy</p><p>. </p><p>World J Surg Oncol</p><p>. </p><p>2012</p><p>;</p><p>10</p><p>:</p><p>280</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B203\" data-id=\"B203\" content-id=\"B203\" data-legacy-id=\"B203\"><p><span>203.</span></p><div><p>Bösze</p>  <p>P</p><p>\n, <span>\n<p>Tóth</p>  <p>A</p>\n</span>, <span>\n<p>Török</p>  <p>M</p>\n</span>\n. </p><p>Hormone replacement and the risk of breast cancer in Turner’s syndrome</p><p>. </p><p>N Engl J Med</p><p>. </p><p>2006</p><p>;</p><p>355</p><p>(</p><p>24</p><p>):</p><p>2599</p><p>–</p><p>2600</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B204\" data-id=\"B204\" content-id=\"B204\" data-legacy-id=\"B204\"><p><span>204.</span></p><div><p>Schoemaker</p>  <p>MJ</p><p>\n, <span>\n<p>Swerdlow</p>  <p>AJ</p>\n</span>, <span>\n<p>Higgins</p>  <p>CD</p>\n</span>, <span>\n<p>Wright</p>  <p>AF</p>\n</span>, <span>\n<p>Jacobs</p>  <p>PA</p>\n</span>; </p><p>UK Clinical Cytogenetics Group</p><p>\n. </p><p>Cancer incidence in women with Turner syndrome in Great Britain: a national cohort study</p><p>. </p><p>Lancet Oncol</p><p>. </p><p>2008</p><p>;</p><p>9</p><p>(</p><p>3</p><p>):</p><p>239</p><p>–</p><p>246</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B205\" data-id=\"B205\" content-id=\"B205\" data-legacy-id=\"B205\"><p><span>205.</span></p><div><p>Smith</p>  <p>RA</p><p>\n, <span>\n<p>Cokkinides</p>  <p>V</p>\n</span>, <span>\n<p>Eyre</p>  <p>HJ</p>\n</span>\n. </p><p>American Cancer Society guidelines for the early detection of cancer, 2006</p><p>. </p><p>CA Cancer J Clin</p><p>. </p><p>2006</p><p>;</p><p>56</p><p>(</p><p>1</p><p>):</p><p>11</p><p>–</p><p>25, quiz 49–50</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B206\" data-id=\"B206\" content-id=\"B206\" data-legacy-id=\"B206\"><p><span>206.</span></p><div><p>Wilson</p>  <p>JD</p><p>\n, <span>\n<p>Roehrborn</p>  <p>C</p>\n</span>\n. </p><p>Long-term consequences of castration in men: lessons from the Skoptzy and the eunuchs of the Chinese and Ottoman courts</p><p>. </p><p>J Clin Endocrinol Metab</p><p>. </p><p>1999</p><p>;</p><p>84</p><p>(</p><p>12</p><p>):</p><p>4324</p><p>–</p><p>4331</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B207\" data-id=\"B207\" content-id=\"B207\" data-legacy-id=\"B207\"><p><span>207.</span></p><div><p>van Kesteren</p>  <p>P</p><p>\n, <span>\n<p>Meinhardt</p>  <p>W</p>\n</span>, <span>\n<p>van der Valk</p>  <p>P</p>\n</span>, <span>\n<p>Geldof</p>  <p>A</p>\n</span>, <span>\n<p>Megens</p>  <p>J</p>\n</span>, <span>\n<p>Gooren</p>  <p>L</p>\n</span>\n. </p><p>Effects of estrogens only on the prostates of aging men</p><p>. </p><p>J Urol</p><p>. </p><p>1996</p><p>;</p><p>156</p><p>(</p><p>4</p><p>):</p><p>1349</p><p>–</p><p>1353</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B208\" data-id=\"B208\" content-id=\"B208\" data-legacy-id=\"B208\"><p><span>208.</span></p><div><p>Brown</p>  <p>JA</p><p>\n, <span>\n<p>Wilson</p>  <p>TM</p>\n</span>\n. </p><p>Benign prostatic hyperplasia requiring transurethral resection of the prostate in a 60-year-old male-to-female transsexual</p><p>. </p><p>Br J Urol</p><p>. </p><p>1997</p><p>;</p><p>80</p><p>(</p><p>6</p><p>):</p><p>956</p><p>–</p><p>957</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B209\" data-id=\"B209\" content-id=\"B209\" data-legacy-id=\"B209\"><p><span>209.</span></p><div><p>Casella</p>  <p>R</p><p>\n, <span>\n<p>Bubendorf</p>  <p>L</p>\n</span>, <span>\n<p>Schaefer</p>  <p>DJ</p>\n</span>, <span>\n<p>Bachmann</p>  <p>A</p>\n</span>, <span>\n<p>Gasser</p>  <p>TC</p>\n</span>, <span>\n<p>Sulser</p>  <p>T</p>\n</span>\n. </p><p>Does the prostate really need androgens to grow? Transurethral resection of the prostate in a male-to-female transsexual 25 years after sex-changing operation</p><p>. </p><p>Urol Int</p><p>. </p><p>2005</p><p>;</p><p>75</p><p>(</p><p>3</p><p>):</p><p>288</p><p>–</p><p>290</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B210\" data-id=\"B210\" content-id=\"B210\" data-legacy-id=\"B210\"><p><span>210.</span></p><div><p>Dorff</p>  <p>TB</p><p>\n, <span>\n<p>Shazer</p>  <p>RL</p>\n</span>, <span>\n<p>Nepomuceno</p>  <p>EM</p>\n</span>, <span>\n<p>Tucker</p>  <p>SJ</p>\n</span>\n. </p><p>Successful treatment of metastatic androgen-independent prostate carcinoma in a transsexual patient</p><p>. </p><p>Clin Genitourin Cancer</p><p>. </p><p>2007</p><p>;</p><p>5</p><p>(</p><p>5</p><p>):</p><p>344</p><p>–</p><p>346</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B211\" data-id=\"B211\" content-id=\"B211\" data-legacy-id=\"B211\"><p><span>211.</span></p><div><p>Thurston</p>  <p>AV</p><p>\n\n. </p><p>Carcinoma of the prostate in a transsexual</p><p>. </p><p>Br J Urol</p><p>. </p><p>1994</p><p>;</p><p>73</p><p>(</p><p>2</p><p>):</p><p>217</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B212\" data-id=\"B212\" content-id=\"B212\" data-legacy-id=\"B212\"><p><span>212.</span></p><div><p>van Harst EP, Newling DW, Gooren LJ, Asscheman H, Prenger DM.</p>\n<p> Metastatic prostatic carcinoma in a male-to-female transsexual</p><p>. </p><p>BJU Int</p><p>. </p><p>1998</p><p>;</p><p>81</p><p>:</p><p>776</p><p>.</p></div></div><div id=\"ref-auto-B213\" data-id=\"B213\" content-id=\"B213\" data-legacy-id=\"B213\"><p><span>213.</span></p><div><p>Turo</p>  <p>R</p><p>\n, <span>\n<p>Jallad</p>  <p>S</p>\n</span>, <span>\n<p>Prescott</p>  <p>S</p>\n</span>, <span>\n<p>Cross</p>  <p>WR</p>\n</span>\n. </p><p>Metastatic prostate cancer in transsexual diagnosed after three decades of estrogen therapy</p><p>. </p><p>Can Urol Assoc J</p><p>. </p><p>2013</p><p>;</p><p>7</p><p>(</p><p>7–8</p><p>):</p><p>E544</p><p>–</p><p>E546</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B214\" data-id=\"B214\" content-id=\"B214\" data-legacy-id=\"B214\"><p><span>214.</span></p><div><p>Miksad</p>  <p>RA</p><p>\n, <span>\n<p>Bubley</p>  <p>G</p>\n</span>, <span>\n<p>Church</p>  <p>P</p>\n</span>, <span>\n<p>Sanda</p>  <p>M</p>\n</span>, <span>\n<p>Rofsky</p>  <p>N</p>\n</span>, <span>\n<p>Kaplan</p>  <p>I</p>\n</span>, <span>\n<p>Cooper</p>  <p>A</p>\n</span>\n. </p><p>Prostate cancer in a transgender woman 41 years after initiation of feminization</p><p>. </p><p>JAMA</p><p>. </p><p>2006</p><p>;</p><p>296</p><p>(</p><p>19</p><p>):</p><p>2316</p><p>–</p><p>2317</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B215\" data-id=\"B215\" content-id=\"B215\" data-legacy-id=\"B215\"><p><span>215.</span></p><div><p>Moyer</p>  <p>VA</p><p>\n; </p><p>U.S. Preventive Services Task Force</p><p>\n. </p><p>Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement</p><p>. </p><p>Ann Intern Med</p><p>. </p><p>2012</p><p>;</p><p>157</p><p>(</p><p>2</p><p>):</p><p>120</p><p>–</p><p>134</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B216\" data-id=\"B216\" content-id=\"B216\" data-legacy-id=\"B216\"><p><span>216.</span></p><div><p>Futterweit</p>  <p>W</p><p>\n\n. </p><p>Endocrine therapy of transsexualism and potential complications of long-term treatment</p><p>. </p><p>Arch Sex Behav</p><p>. </p><p>1998</p><p>;</p><p>27</p><p>(</p><p>2</p><p>):</p><p>209</p><p>–</p><p>226</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B217\" data-id=\"B217\" content-id=\"B217\" data-legacy-id=\"B217\"><p><span>217.</span></p><div><p>Miller</p>  <p>N</p><p>\n, <span>\n<p>Bédard</p>  <p>YC</p>\n</span>, <span>\n<p>Cooter</p>  <p>NB</p>\n</span>, <span>\n<p>Shaul</p>  <p>DL</p>\n</span>\n. </p><p>Histological changes in the genital tract in transsexual women following androgen therapy</p><p>. </p><p>Histopathology</p><p>. </p><p>1986</p><p>;</p><p>10</p><p>(</p><p>7</p><p>):</p><p>661</p><p>–</p><p>669</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B218\" data-id=\"B218\" content-id=\"B218\" data-legacy-id=\"B218\"><p><span>218.</span></p><div><p>O’Hanlan</p>  <p>KA</p><p>\n, <span>\n<p>Dibble</p>  <p>SL</p>\n</span>, <span>\n<p>Young-Spint</p>  <p>M</p>\n</span>\n. </p><p>Total laparoscopic hysterectomy for female-to-male transsexuals</p><p>. </p><p>Obstet Gynecol</p><p>. </p><p>2007</p><p>;</p><p>110</p><p>(</p><p>5</p><p>):</p><p>1096</p><p>–</p><p>1101</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B219\" data-id=\"B219\" content-id=\"B219\" data-legacy-id=\"B219\"><p><span>219.</span></p><div><p>Dizon</p>  <p>DS</p><p>\n, <span>\n<p>Tejada-Berges</p>  <p>T</p>\n</span>, <span>\n<p>Koelliker</p>  <p>S</p>\n</span>, <span>\n<p>Steinhoff</p>  <p>M</p>\n</span>, <span>\n<p>Granai</p>  <p>CO</p>\n</span>\n. </p><p>Ovarian cancer associated with testosterone supplementation in a female-to-male transsexual patient</p><p>. </p><p>Gynecol Obstet Invest</p><p>. </p><p>2006</p><p>;</p><p>62</p><p>(</p><p>4</p><p>):</p><p>226</p><p>–</p><p>228</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B220\" data-id=\"B220\" content-id=\"B220\" data-legacy-id=\"B220\"><p><span>220.</span></p><div><p>Hage</p>  <p>JJ</p><p>\n, <span>\n<p>Dekker</p>  <p>JJML</p>\n</span>, <span>\n<p>Karim</p>  <p>RB</p>\n</span>, <span>\n<p>Verheijen</p>  <p>RHM</p>\n</span>, <span>\n<p>Bloemena</p>  <p>E</p>\n</span>\n. </p><p>Ovarian cancer in female-to-male transsexuals: report of two cases</p><p>. </p><p>Gynecol Oncol</p><p>. </p><p>2000</p><p>;</p><p>76</p><p>(</p><p>3</p><p>):</p><p>413</p><p>–</p><p>415</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B221\" data-id=\"B221\" content-id=\"B221\" data-legacy-id=\"B221\"><p><span>221.</span></p><div><p>Mueller</p>  <p>A</p><p>\n, <span>\n<p>Gooren</p>  <p>L</p>\n</span>\n. </p><p>Hormone-related tumors in transsexuals receiving treatment with cross-sex hormones</p><p>. </p><p>Eur J Endocrinol</p><p>. </p><p>2008</p><p>;</p><p>159</p><p>(</p><p>3</p><p>):</p><p>197</p><p>–</p><p>202</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B222\" data-id=\"B222\" content-id=\"B222\" data-legacy-id=\"B222\"><p><span>222.</span></p><div><p>Coleman</p>  <p>E</p><p>\n, <span>\n<p>Bockting</p>  <p>W</p>\n</span>, <span>\n<p>Botzer</p>  <p>M</p>\n</span>, <span>\n<p>Cohen-Kettenis</p>  <p>P</p>\n</span>, <span>\n<p>DeCuypere</p>  <p>G</p>\n</span>, <span>\n<p>Feldman</p>  <p>J</p>\n</span>, <span>\n<p>Fraser</p>  <p>L</p>\n</span>, <span>\n<p>Green</p>  <p>J</p>\n</span>, <span>\n<p>Knudson</p>  <p>G</p>\n</span>, <span>\n<p>Meyer</p>  <p>WJ</p>\n</span>, <span>\n<p>Monstrey</p>  <p>S</p>\n</span>, <span>\n<p>Adler</p>  <p>RK</p>\n</span>, <span>\n<p>Brown</p>  <p>GR</p>\n</span>, <span>\n<p>Devor</p>  <p>AH</p>\n</span>, <span>\n<p>Ehrbar</p>  <p>R</p>\n</span>, <span>\n<p>Ettner</p>  <p>R</p>\n</span>, <span>\n<p>Eyler</p>  <p>E</p>\n</span>, <span>\n<p>Garofalo</p>  <p>R</p>\n</span>, <span>\n<p>Karasic</p>  <p>DH</p>\n</span>, <span>\n<p>Lev</p>  <p>AI</p>\n</span>, <span>\n<p>Mayer</p>  <p>G</p>\n</span>, <span>\n<p>Meyer-Bahlburg</p>  <p>H</p>\n</span>, <span>\n<p>Hall</p>  <p>BP</p>\n</span>, <span>\n<p>Pfaefflin</p>  <p>F</p>\n</span>, <span>\n<p>Rachlin</p>  <p>K</p>\n</span>, <span>\n<p>Robinson</p>  <p>B</p>\n</span>, <span>\n<p>Schechter</p>  <p>LS</p>\n</span>, <span>\n<p>Tangpricha</p>  <p>V</p>\n</span>, <span>\n<p>van Trotsenburg</p>  <p>M</p>\n</span>, <span>\n<p>Vitale</p>  <p>A</p>\n</span>, <span>\n<p>Winter</p>  <p>S</p>\n</span>, <span>\n<p>Whittle</p>  <p>S</p>\n</span>, <span>\n<p>Wylie</p>  <p>KR</p>\n</span>, <span>\n<p>Zucker</p>  <p>K</p>\n</span>\n. </p><p>Standards of care for the health of transsexual, transgender, and gender-nonconforming people, version 7</p><p>. </p><p>Int J Transgenderism</p><p>. </p><p>2012</p><p>;</p><p>13</p><p>:</p><p>165</p><p>–</p><p>232</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B223\" data-id=\"B223\" content-id=\"B223\" data-legacy-id=\"B223\"><p><span>223.</span></p><div><p>Colebunders</p>  <p>B</p><p>\n, <span>\n<p>D’Arpa</p>  <p>S</p>\n</span>, <span>\n<p>Weijers</p>  <p>S</p>\n</span>, <span>\n<p>Lumen</p>  <p>N</p>\n</span>, <span>\n<p>Hoebeke</p>  <p>P</p>\n</span>, <span>\n<p>Monstrey</p>  <p>S</p>\n</span>\n. </p><p>Female-to-male gender reassignment surgery. In: Ettner R, Monstrey S, Coleman E, eds. <em>Principles of Transgender Medicine and Surgery</em>. 2nd ed. New York, NY: Routledge Taylor &amp; Francis Group; 2016:279–317.</p>\n</div></div><div id=\"ref-auto-B224\" data-id=\"B224\" content-id=\"B224\" data-legacy-id=\"B224\"><p><span>224.</span></p><div><p>Monstrey</p>  <p>S</p><p>\n, <span>\n<p>Hoebeke</p>  <p>P</p>\n</span>, <span>\n<p>Dhont</p>  <p>M</p>\n</span>, <span>\n<p>De Cuypere</p>  <p>G</p>\n</span>, <span>\n<p>Rubens</p>  <p>R</p>\n</span>, <span>\n<p>Moerman</p>  <p>M</p>\n</span>, <span>\n<p>Hamdi</p>  <p>M</p>\n</span>, <span>\n<p>Van Landuyt</p>  <p>K</p>\n</span>, <span>\n<p>Blondeel</p>  <p>P</p>\n</span>\n. </p><p>Surgical therapy in transsexual patients: a multi-disciplinary approach</p><p>. </p><p>Acta Chir Belg</p><p>. </p><p>2001</p><p>;</p><p>101</p><p>(</p><p>5</p><p>):</p><p>200</p><p>–</p><p>209</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B225\" data-id=\"B225\" content-id=\"B225\" data-legacy-id=\"B225\"><p><span>225.</span></p><div><p>Selvaggi</p>  <p>G</p><p>\n, <span>\n<p>Ceulemans</p>  <p>P</p>\n</span>, <span>\n<p>De Cuypere</p>  <p>G</p>\n</span>, <span>\n<p>VanLanduyt</p>  <p>K</p>\n</span>, <span>\n<p>Blondeel</p>  <p>P</p>\n</span>, <span>\n<p>Hamdi</p>  <p>M</p>\n</span>, <span>\n<p>Bowman</p>  <p>C</p>\n</span>, <span>\n<p>Monstrey</p>  <p>S</p>\n</span>\n. </p><p>Gender identity disorder: general overview and surgical treatment for vaginoplasty in male-to-female transsexuals</p><p>. </p><p>Plast Reconstr Surg</p><p>. </p><p>2005</p><p>;</p><p>116</p><p>(</p><p>6</p><p>):</p><p>135e</p><p>–</p><p>145e</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B226\" data-id=\"B226\" content-id=\"B226\" data-legacy-id=\"B226\"><p><span>226.</span></p><div><p>Tugnet</p>  <p>N</p><p>\n, <span>\n<p>Goddard</p>  <p>JC</p>\n</span>, <span>\n<p>Vickery</p>  <p>RM</p>\n</span>, <span>\n<p>Khoosal</p>  <p>D</p>\n</span>, <span>\n<p>Terry</p>  <p>TR</p>\n</span>\n. </p><p>Current management of male-to-female gender identity disorder in the UK</p><p>. </p><p>Postgrad Med J</p><p>. </p><p>2007</p><p>;</p><p>83</p><p>(</p><p>984</p><p>):</p><p>638</p><p>–</p><p>642</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B227\" data-id=\"B227\" content-id=\"B227\" data-legacy-id=\"B227\"><p><span>227.</span></p><div><p>Horbach</p>  <p>SER</p><p>\n, <span>\n<p>Bouman</p>  <p>M-B</p>\n</span>, <span>\n<p>Smit</p>  <p>JM</p>\n</span>, <span>\n<p>Özer</p>  <p>M</p>\n</span>, <span>\n<p>Buncamper</p>  <p>ME</p>\n</span>, <span>\n<p>Mullender</p>  <p>MG</p>\n</span>\n. </p><p>Outcome of vaginoplasty in male-to-female transgenders: a systematic review of surgical techniques</p><p>. </p><p>J Sex Med</p><p>. </p><p>2015</p><p>;</p><p>12</p><p>(</p><p>6</p><p>):</p><p>1499</p><p>–</p><p>1512</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B228\" data-id=\"B228\" content-id=\"B228\" data-legacy-id=\"B228\"><p><span>228.</span></p><div><p>Wroblewski</p>  <p>P</p><p>\n, <span>\n<p>Gustafsson</p>  <p>J</p>\n</span>, <span>\n<p>Selvaggi</p>  <p>G</p>\n</span>\n. </p><p>Sex reassignment surgery for transsexuals</p><p>. </p><p>Curr Opin Endocrinol Diabetes Obes</p><p>. </p><p>2013</p><p>;</p><p>20</p><p>(</p><p>6</p><p>):</p><p>570</p><p>–</p><p>574</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B229\" data-id=\"B229\" content-id=\"B229\" data-legacy-id=\"B229\"><p><span>229.</span></p><div><p>Morrison</p>  <p>SD</p><p>\n, <span>\n<p>Satterwhite</p>  <p>T</p>\n</span>, <span>\n<p>Grant</p>  <p>DW</p>\n</span>, <span>\n<p>Kirby</p>  <p>J</p>\n</span>, <span>\n<p>Laub</p>  <p>DR</p>, Sr\n</span>, <span>\n<p>VanMaasdam</p>  <p>J</p>\n</span>\n. </p><p>Long-term outcomes of rectosigmoid neocolporrhaphy in male-to-female gender reassignment surgery</p><p>. </p><p>Plast Reconstr Surg</p><p>. </p><p>2015</p><p>;</p><p>136</p><p>(</p><p>2</p><p>):</p><p>386</p><p>–</p><p>394</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B230\" data-id=\"B230\" content-id=\"B230\" data-legacy-id=\"B230\"><p><span>230.</span></p><div><p>Dessy</p>  <p>LA</p><p>\n, <span>\n<p>Mazzocchi</p>  <p>M</p>\n</span>, <span>\n<p>Corrias</p>  <p>F</p>\n</span>, <span>\n<p>Ceccarelli</p>  <p>S</p>\n</span>, <span>\n<p>Marchese</p>  <p>C</p>\n</span>, <span>\n<p>Scuderi</p>  <p>N</p>\n</span>\n. </p><p>The use of cultured autologous oral epithelial cells for vaginoplasty in male-to-female transsexuals: a feasibility, safety, and advantageousness clinical pilot study</p><p>. </p><p>Plast Reconstr Surg</p><p>. </p><p>2014</p><p>;</p><p>133</p><p>(</p><p>1</p><p>):</p><p>158</p><p>–</p><p>161</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B231\" data-id=\"B231\" content-id=\"B231\" data-legacy-id=\"B231\"><p><span>231.</span></p><div><p>Li</p>  <p>FY</p><p>\n, <span>\n<p>Xu</p>  <p>YS</p>\n</span>, <span>\n<p>Zhou</p>  <p>CD</p>\n</span>, <span>\n<p>Zhou</p>  <p>Y</p>\n</span>, <span>\n<p>Li</p>  <p>SK</p>\n</span>, <span>\n<p>Li</p>  <p>Q</p>\n</span>\n. </p><p>Long-term outcomes of vaginoplasty with autologous buccal micromucosa</p><p>. </p><p>Obstet Gynecol</p><p>. </p><p>2014</p><p>;</p><p>123</p><p>(</p><p>5</p><p>):</p><p>951</p><p>–</p><p>956</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B232\" data-id=\"B232\" content-id=\"B232\" data-legacy-id=\"B232\"><p><span>232.</span></p><div><p>Kanhai</p>  <p>RC</p><p>\n\n. </p><p>Sensate vagina pedicled-spot for male-to-female transsexuals: the experience in the first 50 patients</p><p>. </p><p>Aesthetic Plast Surg</p><p>. </p><p>2016</p><p>;</p><p>40</p><p>(</p><p>2</p><p>):</p><p>284</p><p>–</p><p>287</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B233\" data-id=\"B233\" content-id=\"B233\" data-legacy-id=\"B233\"><p><span>233.</span></p><div><p>Straayer</p>  <p>C</p><p>\n\n. </p><p>Transplants for transsexuals? Ambitions, concerns, ideology. Paper presented at: Trans*Studies: An International Transdisciplinary Conference on Gender, Embodiment, and Sexuality; 7–10 September 2016; University of Arizona, Tucson, AZ.</p>\n</div></div><div id=\"ref-auto-B234\" data-id=\"B234\" content-id=\"B234\" data-legacy-id=\"B234\"><p><span>234.</span></p><div><p>Bucci</p>  <p>S</p><p>\n, <span>\n<p>Mazzon</p>  <p>G</p>\n</span>, <span>\n<p>Liguori</p>  <p>G</p>\n</span>, <span>\n<p>Napoli</p>  <p>R</p>\n</span>, <span>\n<p>Pavan</p>  <p>N</p>\n</span>, <span>\n<p>Bormioli</p>  <p>S</p>\n</span>, <span>\n<p>Ollandini</p>  <p>G</p>\n</span>, <span>\n<p>De Concilio</p>  <p>B</p>\n</span>, <span>\n<p>Trombetta</p>  <p>C.</p>\n</span></p><p>Neovaginal prolapse in male-to-female transsexuals: an 18-year-long experience</p><p>. </p><p>Biomed Res Int</p><p>. </p><p>2014</p><p>;</p><p>2014</p><p>:</p><p>240761</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B235\" data-id=\"B235\" content-id=\"B235\" data-legacy-id=\"B235\"><p><span>235.</span></p><div><p>Raigosa</p>  <p>M</p><p>\n, <span>\n<p>Avvedimento</p>  <p>S</p>\n</span>, <span>\n<p>Yoon</p>  <p>TS</p>\n</span>, <span>\n<p>Cruz-Gimeno</p>  <p>J</p>\n</span>, <span>\n<p>Rodriguez</p>  <p>G</p>\n</span>, <span>\n<p>Fontdevila</p>  <p>J</p>\n</span>\n. </p><p>Male-to-female genital reassignment surgery: a retrospective review of surgical technique and complications in 60 patients</p><p>. </p><p>J Sex Med</p><p>. </p><p>2015</p><p>;</p><p>12</p><p>(</p><p>8</p><p>):</p><p>1837</p><p>–</p><p>1845</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B236\" data-id=\"B236\" content-id=\"B236\" data-legacy-id=\"B236\"><p><span>236.</span></p><div><p>Green</p>  <p>R</p><p>\n\n. </p><p>Sexual functioning in post-operative transsexuals: male-to-female and female-to-male</p><p>. </p><p>Int J Impot Res</p><p>. </p><p>1998</p><p>;</p><p>10</p><p>(</p><p>Suppl 1</p><p>):</p><p>S22</p><p>–</p><p>S24</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B237\" data-id=\"B237\" content-id=\"B237\" data-legacy-id=\"B237\"><p><span>237.</span></p><div><p>Hess</p>  <p>J</p><p>\n, <span>\n<p>Rossi Neto</p>  <p>R</p>\n</span>, <span>\n<p>Panic</p>  <p>L</p>\n</span>, <span>\n<p>Rübben</p>  <p>H</p>\n</span>, <span>\n<p>Senf</p>  <p>W</p>\n</span>\n. </p><p>Satisfaction with male-to-female gender reassignment surgery</p><p>. </p><p>Dtsch Arztebl Int</p><p>. </p><p>2014</p><p>;</p><p>111</p><p>(</p><p>47</p><p>):</p><p>795</p><p>–</p><p>801</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B238\" data-id=\"B238\" content-id=\"B238\" data-legacy-id=\"B238\"><p><span>238.</span></p><div><p>Nygren</p>  <p>U</p><p>\n, <span>\n<p>Nordenskjold</p>  <p>A</p>\n</span>, <span>\n<p>Arver</p>  <p>S</p>\n</span>, <span>\n<p>Sodersten</p>  <p>M</p>\n</span>\n. </p><p>Effects on voice fundamental frequency and satisfaction with voice in trans men during testosterone treatment—a longitudinal study</p><p>. </p><p>J Voice</p><p>. </p><p>2016;<strong>30</strong>(6):766.e23-766.e34</p><p>.</p></div></div><div id=\"ref-auto-B239\" data-id=\"B239\" content-id=\"B239\" data-legacy-id=\"B239\"><p><span>239.</span></p><div><p>Becking</p>  <p>AG</p><p>\n, <span>\n<p>Tuinzing</p>  <p>DB</p>\n</span>, <span>\n<p>Hage</p>  <p>JJ</p>\n</span>, <span>\n<p>Gooren</p>  <p>LJG</p>\n</span>\n. </p><p>Transgender feminization of the facial skeleton</p><p>. </p><p>Clin Plast Surg</p><p>. </p><p>2007</p><p>;</p><p>34</p><p>(</p><p>3</p><p>):</p><p>557</p><p>–</p><p>564</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B240\" data-id=\"B240\" content-id=\"B240\" data-legacy-id=\"B240\"><p><span>240.</span></p><div><p>Giraldo</p>  <p>F</p><p>\n, <span>\n<p>Esteva</p>  <p>I</p>\n</span>, <span>\n<p>Bergero</p>  <p>T</p>\n</span>, <span>\n<p>Cano</p>  <p>G</p>\n</span>, <span>\n<p>González</p>  <p>C</p>\n</span>, <span>\n<p>Salinas</p>  <p>P</p>\n</span>, <span>\n<p>Rivada</p>  <p>E</p>\n</span>, <span>\n<p>Lara</p>  <p>JS</p>\n</span>, <span>\n<p>Soriguer</p>  <p>F</p>\n</span>; </p><p>Andalusia Gender Team</p><p>\n. </p><p>Corona glans clitoroplasty and urethropreputial vestibuloplasty in male-to-female transsexuals: the vulval aesthetic refinement by the Andalusia Gender Team</p><p>. </p><p>Plast Reconstr Surg</p><p>. </p><p>2004</p><p>;</p><p>114</p><p>(</p><p>6</p><p>):</p><p>1543</p><p>–</p><p>1550</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B241\" data-id=\"B241\" content-id=\"B241\" data-legacy-id=\"B241\"><p><span>241.</span></p><div><p>Goddard</p>  <p>JC</p><p>\n, <span>\n<p>Vickery</p>  <p>RM</p>\n</span>, <span>\n<p>Terry</p>  <p>TR</p>\n</span>\n. </p><p>Development of feminizing genitoplasty for gender dysphoria</p><p>. </p><p>J Sex Med</p><p>. </p><p>2007</p><p>;</p><p>4</p><p>(</p><p>4 Pt 1</p><p>):</p><p>981</p><p>–</p><p>989</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B242\" data-id=\"B242\" content-id=\"B242\" data-legacy-id=\"B242\"><p><span>242.</span></p><div><p>Hage</p>  <p>JJ</p><p>\n, <span>\n<p>de Graaf</p>  <p>FH</p>\n</span>, <span>\n<p>Bouman</p>  <p>FG</p>\n</span>, <span>\n<p>Bloem</p>  <p>JJAM</p>\n</span>\n. </p><p>Sculpturing the glans in phalloplasty</p><p>. </p><p>Plast Reconstr Surg</p><p>. </p><p>1993</p><p>;</p><p>92</p><p>(</p><p>1</p><p>):</p><p>157</p><p>–</p><p>161, discussion 162</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B243\" data-id=\"B243\" content-id=\"B243\" data-legacy-id=\"B243\"><p><span>243.</span></p><div><p>Thiagaraj</p>  <p>D</p><p>\n, <span>\n<p>Gunasegaram</p>  <p>R</p>\n</span>, <span>\n<p>Loganath</p>  <p>A</p>\n</span>, <span>\n<p>Peh</p>  <p>KL</p>\n</span>, <span>\n<p>Kottegoda</p>  <p>SR</p>\n</span>, <span>\n<p>Ratnam</p>  <p>SS</p>\n</span>\n. </p><p>Histopathology of the testes from male transsexuals on oestrogen therapy</p><p>. </p><p>Ann Acad Med Singapore</p><p>. </p><p>1987</p><p>;</p><p>16</p><p>(</p><p>2</p><p>):</p><p>347</p><p>–</p><p>348</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B244\" data-id=\"B244\" content-id=\"B244\" data-legacy-id=\"B244\"><p><span>244.</span></p><div><p>Monstrey</p>  <p>SJ</p><p>\n, <span>\n<p>Ceulemans</p>  <p>P</p>\n</span>, <span>\n<p>Hoebeke</p>  <p>P</p>\n</span>\n. </p><p>Sex reassignment surgery in the female-to-male transsexual</p><p>. </p><p>Semin Plast Surg</p><p>. </p><p>2011</p><p>;</p><p>25</p><p>(</p><p>3</p><p>):</p><p>229</p><p>–</p><p>244</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B245\" data-id=\"B245\" content-id=\"B245\" data-legacy-id=\"B245\"><p><span>245.</span></p><div><p>Perovic</p>  <p>SV</p><p>\n, <span>\n<p>Djinovic</p>  <p>R</p>\n</span>, <span>\n<p>Bumbasirevic</p>  <p>M</p>\n</span>, <span>\n<p>Djordjevic</p>  <p>M</p>\n</span>, <span>\n<p>Vukovic</p>  <p>P</p>\n</span>\n. </p><p>Total phalloplasty using a musculocutaneous latissimus dorsi flap</p><p>. </p><p>BJU Int</p><p>. </p><p>2007</p><p>;</p><p>100</p><p>(</p><p>4</p><p>):</p><p>899</p><p>–</p><p>905, discussion 905</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B246\" data-id=\"B246\" content-id=\"B246\" data-legacy-id=\"B246\"><p><span>246.</span></p><div><p>Vesely</p>  <p>J</p><p>\n, <span>\n<p>Hyza</p>  <p>P</p>\n</span>, <span>\n<p>Ranno</p>  <p>R</p>\n</span>, <span>\n<p>Cigna</p>  <p>E</p>\n</span>, <span>\n<p>Monni</p>  <p>N</p>\n</span>, <span>\n<p>Stupka</p>  <p>I</p>\n</span>, <span>\n<p>Justan</p>  <p>I</p>\n</span>, <span>\n<p>Dvorak</p>  <p>Z</p>\n</span>, <span>\n<p>Novak</p>  <p>P</p>\n</span>, <span>\n<p>Ranno</p>  <p>S</p>\n</span>\n. </p><p>New technique of total phalloplasty with reinnervated latissimus dorsi myocutaneous free flap in female-to-male transsexuals</p><p>. </p><p>Ann Plast Surg</p><p>. </p><p>2007</p><p>;</p><p>58</p><p>(</p><p>5</p><p>):</p><p>544</p><p>–</p><p>550</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B247\" data-id=\"B247\" content-id=\"B247\" data-legacy-id=\"B247\"><p><span>247.</span></p><div><p>Ranno</p>  <p>R</p><p>\n, <span>\n<p>Veselý</p>  <p>J</p>\n</span>, <span>\n<p>Hýza</p>  <p>P</p>\n</span>, <span>\n<p>Stupka</p>  <p>I</p>\n</span>, <span>\n<p>Justan</p>  <p>I</p>\n</span>, <span>\n<p>Dvorák</p>  <p>Z</p>\n</span>, <span>\n<p>Monni</p>  <p>N</p>\n</span>, <span>\n<p>Novák</p>  <p>P</p>\n</span>, <span>\n<p>Ranno</p>  <p>S</p>\n</span>\n. </p><p>Neo-phalloplasty with re-innervated latissimus dorsi free flap: a functional study of a novel technique</p><p>. </p><p>Acta Chir Plast</p><p>. </p><p>2007</p><p>;</p><p>49</p><p>(</p><p>1</p><p>):</p><p>3</p><p>–</p><p>7</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B248\" data-id=\"B248\" content-id=\"B248\" data-legacy-id=\"B248\"><p><span>248.</span></p><div><p>Garcia</p>  <p>MM</p><p>\n, <span>\n<p>Christopher</p>  <p>NA</p>\n</span>, <span>\n<p>De Luca</p>  <p>F</p>\n</span>, <span>\n<p>Spilotros</p>  <p>M</p>\n</span>, <span>\n<p>Ralph</p>  <p>DJ</p>\n</span>\n. </p><p>Overall satisfaction, sexual function, and the durability of neophallus dimensions following staged female to male genital gender confirming surgery: the Institute of Urology, London U.K. experience</p><p>. </p><p>Transl Androl Urol</p><p>. </p><p>2014</p><p>;</p><p>3</p><p>(</p><p>2</p><p>):</p><p>156</p><p>–</p><p>162</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B249\" data-id=\"B249\" content-id=\"B249\" data-legacy-id=\"B249\"><p><span>249.</span></p><div><p>Chen</p>  <p>H-C</p><p>\n, <span>\n<p>Gedebou</p>  <p>TM</p>\n</span>, <span>\n<p>Yazar</p>  <p>S</p>\n</span>, <span>\n<p>Tang</p>  <p>Y-B</p>\n</span>\n. </p><p>Prefabrication of the free fibula osteocutaneous flap to create a functional human penis using a controlled fistula method</p><p>. </p><p>J Reconstr Microsurg</p><p>. </p><p>2007</p><p>;</p><p>23</p><p>(</p><p>3</p><p>):</p><p>151</p><p>–</p><p>154</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B250\" data-id=\"B250\" content-id=\"B250\" data-legacy-id=\"B250\"><p><span>250.</span></p><div><p>Hoebeke</p>  <p>PB</p><p>\n, <span>\n<p>Decaestecker</p>  <p>K</p>\n</span>, <span>\n<p>Beysens</p>  <p>M</p>\n</span>, <span>\n<p>Opdenakker</p>  <p>Y</p>\n</span>, <span>\n<p>Lumen</p>  <p>N</p>\n</span>, <span>\n<p>Monstrey</p>  <p>SM</p>\n</span>\n. </p><p>Erectile implants in female-to-male transsexuals: our experience in 129 patients</p><p>. </p><p>Eur Urol</p><p>. </p><p>2010</p><p>;</p><p>57</p><p>(</p><p>2</p><p>):</p><p>334</p><p>–</p><p>341</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B251\" data-id=\"B251\" content-id=\"B251\" data-legacy-id=\"B251\"><p><span>251.</span></p><div><p>Hage</p>  <p>JJ</p><p>\n\n. </p><p>Metaidoioplasty: an alternative phalloplasty technique in transsexuals</p><p>. </p><p>Plast Reconstr Surg</p><p>. </p><p>1996</p><p>;</p><p>97</p><p>(</p><p>1</p><p>):</p><p>161</p><p>–</p><p>167</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B252\" data-id=\"B252\" content-id=\"B252\" data-legacy-id=\"B252\"><p><span>252.</span></p><div><p>Cohanzad</p>  <p>S</p><p>\n\n. </p><p>Extensive metoidioplasty as a technique capable of creating a compatible analogue to a natural penis in female transsexuals</p><p>. </p><p>Aesthetic Plast Surg</p><p>. </p><p>2016</p><p>;</p><p>40</p><p>(</p><p>1</p><p>):</p><p>130</p><p>–</p><p>138</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B253\" data-id=\"B253\" content-id=\"B253\" data-legacy-id=\"B253\"><p><span>253.</span></p><div><p>Selvaggi</p>  <p>G</p><p>\n, <span>\n<p>Hoebeke</p>  <p>P</p>\n</span>, <span>\n<p>Ceulemans</p>  <p>P</p>\n</span>, <span>\n<p>Hamdi</p>  <p>M</p>\n</span>, <span>\n<p>Van Landuyt</p>  <p>K</p>\n</span>, <span>\n<p>Blondeel</p>  <p>P</p>\n</span>, <span>\n<p>De Cuypere</p>  <p>G</p>\n</span>, <span>\n<p>Monstrey</p>  <p>S</p>\n</span>\n. </p><p>Scrotal reconstruction in female-to-male transsexuals: a novel scrotoplasty</p><p>. </p><p>Plast Reconstr Surg</p><p>. </p><p>2009</p><p>;</p><p>123</p><p>(</p><p>6</p><p>):</p><p>1710</p><p>–</p><p>1718</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B254\" data-id=\"B254\" content-id=\"B254\" data-legacy-id=\"B254\"><p><span>254.</span></p><div><p>Bjerrome Ahlin</p>  <p>H</p><p>\n, <span>\n<p>Kölby</p>  <p>L</p>\n</span>, <span>\n<p>Elander</p>  <p>A</p>\n</span>, <span>\n<p>Selvaggi</p>  <p>G</p>\n</span>\n. </p><p>Improved results after implementation of the Ghent algorithm for subcutaneous mastectomy in female-to-male transsexuals</p><p>. </p><p>J Plast Surg Hand Surg</p><p>. </p><p>2014</p><p>;</p><p>48</p><p>(</p><p>6</p><p>):</p><p>362</p><p>–</p><p>367</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B255\" data-id=\"B255\" content-id=\"B255\" data-legacy-id=\"B255\"><p><span>255.</span></p><div><p>Wolter</p>  <p>A</p><p>\n, <span>\n<p>Diedrichson</p>  <p>J</p>\n</span>, <span>\n<p>Scholz</p>  <p>T</p>\n</span>, <span>\n<p>Arens-Landwehr</p>  <p>A</p>\n</span>, <span>\n<p>Liebau</p>  <p>J</p>\n</span>\n. </p><p>Sexual reassignment surgery in female-to-male transsexuals: an algorithm for subcutaneous mastectomy</p><p>. </p><p>J Plast Reconstr Aesthet Surg</p><p>. </p><p>2015</p><p>;</p><p>68</p><p>(</p><p>2</p><p>):</p><p>184</p><p>–</p><p>191</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B256\" data-id=\"B256\" content-id=\"B256\" data-legacy-id=\"B256\"><p><span>256.</span></p><div><p>Richards</p>  <p>C</p><p>\n, <span>\n<p>Barrett</p>  <p>J</p>\n</span>\n. </p><p>The case for bilateral mastectomy and male chest contouring for the female-to-male transsexual</p><p>. </p><p>Ann R Coll Surg Engl</p><p>. </p><p>2013</p><p>;</p><p>95</p><p>(</p><p>2</p><p>):</p><p>93</p><p>–</p><p>95</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B257\" data-id=\"B257\" content-id=\"B257\" data-legacy-id=\"B257\"><p><span>257.</span></p><div><p>Sutcliffe</p>  <p>PA</p><p>\n, <span>\n<p>Dixon</p>  <p>S</p>\n</span>, <span>\n<p>Akehurst</p>  <p>RL</p>\n</span>, <span>\n<p>Wilkinson</p>  <p>A</p>\n</span>, <span>\n<p>Shippam</p>  <p>A</p>\n</span>, <span>\n<p>White</p>  <p>S</p>\n</span>, <span>\n<p>Richards</p>  <p>R</p>\n</span>, <span>\n<p>Caddy</p>  <p>CM</p>\n</span>\n. </p><p>Evaluation of surgical procedures for sex reassignment: a systematic review</p><p>. </p><p>J Plast Reconstr Aesthet Surg</p><p>. </p><p>2009</p><p>;</p><p>62</p><p>(</p><p>3</p><p>):</p><p>294</p><p>–</p><p>306, discussion 306–308</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B258\" data-id=\"B258\" content-id=\"B258\" data-legacy-id=\"B258\"><p><span>258.</span></p><div><p>Selvaggi</p>  <p>G</p><p>\n, <span>\n<p>Elander</p>  <p>A</p>\n</span>\n. </p><p>Penile reconstruction/formation</p><p>. </p><p>Curr Opin Urol</p><p>. </p><p>2008</p><p>;</p><p>18</p><p>(</p><p>6</p><p>):</p><p>589</p><p>–</p><p>597</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B259\" data-id=\"B259\" content-id=\"B259\" data-legacy-id=\"B259\"><p><span>259.</span></p><div><p>Dhejne</p>  <p>C</p><p>\n, <span>\n<p>Lichtenstein</p>  <p>P</p>\n</span>, <span>\n<p>Boman</p>  <p>M</p>\n</span>, <span>\n<p>Johansson</p>  <p>ALV</p>\n</span>, <span>\n<p>Långström</p>  <p>N</p>\n</span>, <span>\n<p>Landén</p>  <p>M</p>\n</span>\n. </p><p>Long-term follow-up of transsexual persons undergoing sex reassignment surgery: cohort study in Sweden</p><p>. </p><p>PLoS One</p><p>. </p><p>2011</p><p>;</p><p>6</p><p>(</p><p>2</p><p>):</p><p>e16885</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B260\" data-id=\"B260\" content-id=\"B260\" data-legacy-id=\"B260\"><p><span>260.</span></p><div><p>Kuhn</p>  <p>A</p><p>\n, <span>\n<p>Bodmer</p>  <p>C</p>\n</span>, <span>\n<p>Stadlmayr</p>  <p>W</p>\n</span>, <span>\n<p>Kuhn</p>  <p>P</p>\n</span>, <span>\n<p>Mueller</p>  <p>MD</p>\n</span>, <span>\n<p>Birkhäuser</p>  <p>M</p>\n</span>\n. </p><p>Quality of life 15 years after sex reassignment surgery for transsexualism</p><p>. </p><p>Fertil Steril</p><p>. </p><p>2009</p><p>;</p><p>92</p><p>(</p><p>5</p><p>):</p><p>1685</p><p>–</p><p>1689.e3</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B261\" data-id=\"B261\" content-id=\"B261\" data-legacy-id=\"B261\"><p><span>261.</span></p><div><p>Papadopulos</p>  <p>NA</p><p>\n, <span>\n<p>Lellé</p>  <p>JD</p>\n</span>, <span>\n<p>Zavlin</p>  <p>D</p>\n</span>, <span>\n<p>Herschbach</p>  <p>P</p>\n</span>, <span>\n<p>Henrich</p>  <p>G</p>\n</span>, <span>\n<p>Kovacs</p>  <p>L</p>\n</span>, <span>\n<p>Ehrenberger</p>  <p>B</p>\n</span>, <span>\n<p>Kluger</p>  <p>AK</p>\n</span>, <span>\n<p>Machens</p>  <p>HG</p>\n</span>, <span>\n<p>Schaff</p>  <p>J</p>\n</span>\n. </p><p>Quality of life and patient satisfaction following male-to-female sex reassignment surgery</p><p>. </p><p>J Sex Med</p><p>. </p><p>2017</p><p>;</p><p>14</p><p>(</p><p>5</p><p>):</p><p>721</p><p>–</p><p>730</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B262\" data-id=\"B262\" content-id=\"B262\" data-legacy-id=\"B262\"><p><span>262.</span></p><div><p>Simonsen</p>  <p>RK</p><p>\n, <span>\n<p>Hald</p>  <p>GM</p>\n</span>, <span>\n<p>Kristensen</p>  <p>E</p>\n</span>, <span>\n<p>Giraldi</p>  <p>A</p>\n</span>\n. </p><p>Long-term follow-up of individuals undergoing sex-reassignment surgery: somatic morbidity and cause of death</p><p>. </p><p>Sex Med</p><p>. </p><p>2016</p><p>;</p><p>4</p><p>(</p><p>1</p><p>):</p><p>e60</p><p>–</p><p>e68</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B263\" data-id=\"B263\" content-id=\"B263\" data-legacy-id=\"B263\"><p><span>263.</span></p><div><p>Djordjevic</p>  <p>ML</p><p>\n, <span>\n<p>Bizic</p>  <p>MR</p>\n</span>, <span>\n<p>Duisin</p>  <p>D</p>\n</span>, <span>\n<p>Bouman</p>  <p>MB</p>\n</span>, <span>\n<p>Buncamper</p>  <p>M</p>\n</span>\n. </p><p>Reversal Surgery in regretful male-to-female transsexuals after sex reassignment surgery</p><p>. </p><p>J Sex Med</p><p>. </p><p>2016</p><p>;</p><p>13</p><p>(</p><p>6</p><p>):</p><p>1000</p><p>–</p><p>1007</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B264\" data-id=\"B264\" content-id=\"B264\" data-legacy-id=\"B264\"><p><span>264.</span></p><div><p>Liberopoulos</p>  <p>EN</p><p>\n, <span>\n<p>Florentin</p>  <p>M</p>\n</span>, <span>\n<p>Mikhailidis</p>  <p>DP</p>\n</span>, <span>\n<p>Elisaf</p>  <p>MS</p>\n</span>\n. </p><p>Compliance with lipid-lowering therapy and its impact on cardiovascular morbidity and mortality</p><p>. </p><p>Expert Opin Drug Saf</p><p>. </p><p>2008</p><p>;</p><p>7</p><p>(</p><p>6</p><p>):</p><p>717</p><p>–</p><p>725</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B265\" data-id=\"B265\" content-id=\"B265\" data-legacy-id=\"B265\"><p><span>265.</span></p><div><p>Forbes</p>  <p>SS</p><p>\n, <span>\n<p>Stephen</p>  <p>WJ</p>\n</span>, <span>\n<p>Harper</p>  <p>WL</p>\n</span>, <span>\n<p>Loeb</p>  <p>M</p>\n</span>, <span>\n<p>Smith</p>  <p>R</p>\n</span>, <span>\n<p>Christoffersen</p>  <p>EP</p>\n</span>, <span>\n<p>McLean</p>  <p>RF</p>\n</span>\n. </p><p>Implementation of evidence-based practices for surgical site infection prophylaxis: results of a pre- and postintervention study</p><p>. </p><p>J Am Coll Surg</p><p>. </p><p>2008</p><p>;</p><p>207</p><p>(</p><p>3</p><p>):</p><p>336</p><p>–</p><p>341</p><p>.</p><!--citationLinks: case 1--></div></div><div id=\"ref-auto-B266\" data-id=\"B266\" content-id=\"B266\" data-legacy-id=\"B266\"><p><span>266.</span></p><div><p>Davis</p>  <p>PJ</p><p>\n, <span>\n<p>Spady</p>  <p>D</p>\n</span>, <span>\n<p>de Gara</p>  <p>C</p>\n</span>, <span>\n<p>Forgie</p>  <p>SE</p>\n</span>\n. </p><p>Practices and attitudes of surgeons toward the prevention of surgical site infections: a provincial survey in Alberta, Canada</p><p>. </p><p>Infect Control Hosp Epidemiol</p><p>. </p><p>2008</p><p>;</p><p>29</p><p>(</p><p>12</p><p>):</p><p>1164</p><p>–</p><p>1166</p><p>.</p><!--citationLinks: case 1--></div></div></div>    <!-- /foreach in Model.Sections -->\n    \n\n\n\n        \n\n        \n                    <h2 id=\"authorNotesSectionTitle\" scrollto-destination=\"authorNotesSectionTitle\">Author notes</h2>\n<p><span><span><span rel=\"nofollow\" data-fn-id=\"fn-0001\">*</span></span><p>Cosponsoring Associations: American Association of Clinical Endocrinologists, American Society of Andrology, European Society for Pediatric Endocrinology, European Society of Endocrinology, Pediatric Endocrine Society, and World Professional Association for Transgender Health.</p></span></p><p>Copyright © 2017 Endocrine Society</p><div><p>Copyright © 2017 Endocrine Society</p></div><!-- /foreach -->\n\n        </div>\n    \n    \n    \n\n                \n                \n    <div>\n            <li>\n            \n        </li>\n        <h2 scrollto-destination=\"supplementary-data\" id=\"supplementary-data\">Supplementary data</h2>\n        \n \n    </div>\n                    \n\n                \n            </div>\n        </div>\n\n    </div>\n<div data-count=\"1\" id=\"Sidebar\">\n\n    <div>\n            <div>\n                <h3>Citations</h3>\n                    \n                            </div>\n                    <div>\n                <h3>Views</h3>\n                \n            </div>\n                    <div>\n                    <h3>Altmetric</h3>\n                    \n\n\n            </div>\n                    \n    </div>\n    <div>\n        <h3>Email alerts</h3>\n                \n                \n                \n                    \n        \n    </div>\n    \n    <div>\n        <h3>See also</h3>\n                    <div>\n                <ul>\n                        <li>\n                                <h4>Companion Articles</h4>\n                            <ul>\n                                    <li>\n                                        <a href=\"/jcem/article/102/11/3904/4157556\">Effect of Sex Steroids on the Bone Health of Transgender Individuals: A Systematic Review and Meta-Analysis</a>\n                                    </li>\n                                    <li>\n                                        <a href=\"/jcem/article/102/11/3914/4157557\">Sex Steroids and Cardiovascular Outcomes in Transgender Individuals: A Systematic Review and Meta-Analysis</a>\n                                    </li>\n                                    <li>\n                                        <a href=\"/jcem/article/104/3/686/5198654\">Letter to the Editor: “Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society Clinical Practice Guideline” </a>\n                                    </li>\n                            </ul>\n                        </li>\n                </ul>\n            </div>\n    </div>\n    \n    \n    <div>\n    <h3>Citing articles via</h3>\n    \n</div>\n    <div>\n            <ul>\n            <li>\n                <h3>\n                    Latest\n                </h3>\n            </li>\n            <li>\n                <h3>\n                    Most Read\n                </h3>\n            </li>\n            <li>\n                <h3>\n                    Most Cited\n                </h3>\n            </li>\n    </ul>\n        \n        \n        \n \n    </div>\n    <div>\n        <p>More from Oxford Academic</p>\n            \n            \n            \n\n            \n            \n    </div>\n\n    </div>\n\n</div></div>","textContent":"\n\n\n\n    \n                \n                \n                                \n\n\n\n\n\n\n                                    Wylie C Hembree, \n\n                                    \n\n    \n\n    \n        1New York Presbyterian Hospital, Columbia University Medical Center, New York, New York 10032 (Retired)\n    \n\n    \n        Search for other works by this author on:\n    \n\n\n\n    \n                                    \n                                \n                                \n\n\n\n\n\n\n                                    Peggy T Cohen-Kettenis, \n\n                                    \n\n    \n\n    \n        2VU University Medical Center, 1007 MB Amsterdam, Netherlands (Retired)\n    \n\n    \n        Search for other works by this author on:\n    \n\n\n\n    \n                                    \n                                \n                                \n\n\n\n\n\n\n                                    Louis Gooren, \n\n                                    \n\n    \n\n    \n        3VU University Medical Center, 1007 MB Amsterdam, Netherlands (Retired)\n    \n\n    \n        Search for other works by this author on:\n    \n\n\n\n    \n                                    \n                                \n                                \n\n\n\n\n\n\n                                    Sabine E Hannema, \n\n                                    \n\n    \n\n    \n        4Leiden University Medical Center, 2300 RC Leiden, Netherlands\n    \n\n    \n        Search for other works by this author on:\n    \n\n\n\n    \n                                    \n                                \n                                \n\n\n\n\n\n\n                                    Walter J Meyer, \n\n                                    \n\n    \n\n    \n        5University of Texas Medical Branch, Galveston, Texas 77555\n    \n\n    \n        Search for other works by this author on:\n    \n\n\n\n    \n                                    \n                                \n                                \n\n\n\n\n\n\n                                    M Hassan Murad, \n\n                                    \n\n    \n\n    \n        6Mayo Clinic Evidence-Based Practice Center, Rochester, Minnesota 55905\n    \n\n    \n        Search for other works by this author on:\n    \n\n\n\n    \n                                    \n                                \n                                \n\n\n\n\n\n\n                                    Stephen M Rosenthal, \n\n                                    \n\n    \n\n    \n        7University of California San Francisco, Benioff Children’s Hospital, San Francisco, California 94143\n    \n\n    \n        Search for other works by this author on:\n    \n\n\n\n    \n                                    \n                                \n                                \n\n\n\n\n\n\n                                    Joshua D Safer, \n\n                                    \n\n    \n\n    \n        8Boston University School of Medicine, Boston, Massachusetts 02118\n    \n\n    \n        Search for other works by this author on:\n    \n\n\n\n    \n                                    \n                                \n                                \n\n\n\n\n\n\n                                    Vin Tangpricha, \n\n                                    \n\n    \n\n    \n        9Emory University School of Medicine and the Atlanta VA Medical Center, Atlanta, Georgia 30322\n    \n\n    \n        Search for other works by this author on:\n    \n\n\n\n    \n                                    \n                                \n                                \n\n\n\n\n\n\n                                    Guy G T’Sjoen\n\n                                    \n\n    \n\n    \n        10Ghent University Hospital, 9000 Ghent, Belgium\n    \n\n    \n        Search for other works by this author on:\n    \n\n\n\n    \n                                    \n                                \n                                \n        *Cosponsoring Associations: American Association of Clinical Endocrinologists, American Society of Andrology, European Society for Pediatric Endocrinology, European Society of Endocrinology, Pediatric Endocrine Society, and World Professional Association for Transgender Health. \n    \n                                Author Notes\n                            \n                    \n\n                    Published:\n                    13 September 2017\n                \n    \n    \n                            A correction has been published: \n                                                                \n                            The Journal of Clinical Endocrinology & Metabolism, Volume 103, Issue 2, February 2018, Page 699, https://doi.org/10.1210/jc.2017-02548\n                        \n                \n                A correction has been published: \n                                                                \n                            The Journal of Clinical Endocrinology & Metabolism, Volume 103, Issue 7, July 2018, Pages 2758–2759, https://doi.org/10.1210/jc.2018-01268\n                        \n                \n        \n\n\n        \n            \n                    \n    \n        \n            PDF\n        \n    \n                                                    \n                                \n                                    \n                                    Split View\n                                \n                            \n\n                        \n                            \n                                \n                                \n                            \n                            \n                                \n                                \n                                    Article contents\n                                \n                                \n                                    Figures & tables\n                                \n                                \n                                    Video\n                                \n                                \n                                    Audio\n                                \n                                \n                                    Supplementary Data\n                                \n                            \n                        \n\n\n                        \n    \n        \n    \n    Cite\n\n    Cite\n        Wylie C Hembree, Peggy T Cohen-Kettenis, Louis Gooren, Sabine E Hannema, Walter J Meyer, M Hassan Murad, Stephen M Rosenthal, Joshua D Safer, Vin Tangpricha, Guy G T’Sjoen,  Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society Clinical Practice Guideline, The Journal of Clinical Endocrinology & Metabolism, Volume 102, Issue 11, 1 November 2017, Pages 3869–3903, https://doi.org/10.1210/jc.2017-01658\n\n    \n\n    Close\n\n \n    \n\n                        \n                        \n    \n\n                        \n                        \n                            \n                                \n                                \n                            \n                            \n                                \n                                Email\n                                Twitter\n                                Facebook\n                                More\n                            \n                        \n                    \n                    \n        \n\n        \n            \n                Close\n    \n                Navbar Search Filter\n            \n            \n\n        \n            Microsite Search Term\n        \n        \n\n        \n            Search\n        \n\n    \n\n\n                \n                        \n    \n                \n            \n    \n\n\n\n\n\n                    Abstract\nObjectiveTo update the “Endocrine Treatment of Transsexual Persons: An Endocrine Society Clinical Practice Guideline,” published by the Endocrine Society in 2009.ParticipantsThe participants include an Endocrine Society–appointed task force of nine experts, a methodologist, and a medical writer.EvidenceThis evidence-based guideline was developed using the Grading of Recommendations, Assessment, Development, and Evaluation approach to describe the strength of recommendations and the quality of evidence. The task force commissioned two systematic reviews and used the best available evidence from other published systematic reviews and individual studies.Consensus ProcessGroup meetings, conference calls, and e-mail communications enabled consensus. Endocrine Society committees, members and cosponsoring organizations reviewed and commented on preliminary drafts of the guidelines.ConclusionGender affirmation is multidisciplinary treatment in which endocrinologists play an important role. Gender-dysphoric/gender-incongruent persons seek and/or are referred to endocrinologists to develop the physical characteristics of the affirmed gender. They require a safe and effective hormone regimen that will (1) suppress endogenous sex hormone secretion determined by the person’s genetic/gonadal sex and (2) maintain sex hormone levels within the normal range for the person’s affirmed gender. Hormone treatment is not recommended for prepubertal gender-dysphoric/gender-incongruent persons. Those clinicians who recommend gender-affirming endocrine treatments—appropriately trained diagnosing clinicians (required), a mental health provider for adolescents (required) and mental health professional for adults (recommended)—should be knowledgeable about the diagnostic criteria and criteria for gender-affirming treatment, have sufficient training and experience in assessing psychopathology, and be willing to participate in the ongoing care throughout the endocrine transition. We recommend treating gender-dysphoric/gender-incongruent adolescents who have entered puberty at Tanner Stage G2/B2 by suppression with gonadotropin-releasing hormone agonists. Clinicians may add gender-affirming hormones after a multidisciplinary team has confirmed the persistence of gender dysphoria/gender incongruence and sufficient mental capacity to give informed consent to this partially irreversible treatment. Most adolescents have this capacity by age 16 years old. We recognize that there may be compelling reasons to initiate sex hormone treatment prior to age 16 years, although there is minimal published experience treating prior to 13.5 to 14 years of age. For the care of peripubertal youths and older adolescents, we recommend that an expert multidisciplinary team comprised of medical professionals and mental health professionals manage this treatment. The treating physician must confirm the criteria for treatment used by the referring mental health practitioner and collaborate with them in decisions about gender-affirming surgery in older adolescents. For adult gender-dysphoric/gender-incongruent persons, the treating clinicians (collectively) should have expertise in transgender-specific diagnostic criteria, mental health, primary care, hormone treatment, and surgery, as needed by the patient. We suggest maintaining physiologic levels of gender-appropriate hormones and monitoring for known risks and complications. When high doses of sex steroids are required to suppress endogenous sex steroids and/or in advanced age, clinicians may consider surgically removing natal gonads along with reducing sex steroid treatment. Clinicians should monitor both transgender males (female to male) and transgender females (male to female) for reproductive organ cancer risk when surgical removal is incomplete. Additionally, clinicians should persistently monitor adverse effects of sex steroids. For gender-affirming surgeries in adults, the treating physician must collaborate with and confirm the criteria for treatment used by the referring physician. Clinicians should avoid harming individuals (via hormone treatment) who have conditions other than gender dysphoria/gender incongruence and who may not benefit from the physical changes associated with this treatment.                    \n                    Summary of Recommendations\n                    1.0 Evaluation of youth and adults\n1.1. We advise that only trained mental health professionals (MHPs) who meet the following criteria should diagnose gender dysphoria (GD)/gender incongruence in adults: (1) competence in using the Diagnostic and Statistical Manual of Mental Disorders (DSM) and/or the International Statistical Classification of Diseases and Related Health Problems (ICD) for diagnostic purposes, (2) the ability to diagnose GD/gender incongruence and make a distinction between GD/gender incongruence and conditions that have similar features (e.g., body dysmorphic disorder), (3) training in diagnosing psychiatric conditions, (4) the ability to undertake or refer for appropriate treatment, (5) the ability to psychosocially assess the person’s understanding, mental health, and social conditions that can impact gender-affirming hormone therapy, and (6) a practice of regularly attending relevant professional meetings. (Ungraded Good Practice Statement)1.2. We advise that only MHPs who meet the following criteria should diagnose GD/gender incongruence in children and adolescents: (1) training in child and adolescent developmental psychology and psychopathology, (2) competence in using the DSM and/or the ICD for diagnostic purposes, (3) the ability to make a distinction between GD/gender incongruence and conditions that have similar features (e.g., body dysmorphic disorder), (4) training in diagnosing psychiatric conditions, (5) the ability to undertake or refer for appropriate treatment, (6) the ability to psychosocially assess the person’s understanding and social conditions that can impact gender-affirming hormone therapy, (7) a practice of regularly attending relevant professional meetings, and (8) knowledge of the criteria for puberty blocking and gender-affirming hormone treatment in adolescents. (Ungraded Good Practice Statement)1.3. We advise that decisions regarding the social transition of prepubertal youths with GD/gender incongruence are made with the assistance of an MHP or another experienced professional. (Ungraded Good Practice Statement).1.4. We recommend against puberty blocking and gender-affirming hormone treatment in prepubertal children with GD/gender incongruence. (1 |⊕⊕○○)1.5. We recommend that clinicians inform and counsel all individuals seeking gender-affirming medical treatment regarding options for fertility preservation prior to initiating puberty suppression in adolescents and prior to treating with hormonal therapy of the affirmed gender in both adolescents and adults. (1 |⊕⊕⊕○)                    2.0 Treatment of adolescents\n2.1. We suggest that adolescents who meet diagnostic criteria for GD/gender incongruence, fulfill criteria for treatment, and are requesting treatment should initially undergo treatment to suppress pubertal development. (2 |⊕⊕○○)2.2. We suggest that clinicians begin pubertal hormone suppression after girls and boys first exhibit physical changes of puberty. (2 |⊕⊕○○)2.3. We recommend that, where indicated, GnRH analogues are used to suppress pubertal hormones. (1 |⊕⊕○○)2.4. In adolescents who request sex hormone treatment (given this is a partly irreversible treatment), we recommend initiating treatment using a gradually increasing dose schedule after a multidisciplinary team of medical and MHPs has confirmed the persistence of GD/gender incongruence and sufficient mental capacity to give informed consent, which most adolescents have by age 16 years. (1 |⊕⊕○○).2.5. We recognize that there may be compelling reasons to initiate sex hormone treatment prior to the age of 16 years in some adolescents with GD/gender incongruence, even though there are minimal published studies of gender-affirming hormone treatments administered before age 13.5 to 14 years. As with the care of adolescents ≥16 years of age, we recommend that an expert multidisciplinary team of medical and MHPs manage this treatment. (1 |⊕○○○)2.6. We suggest monitoring clinical pubertal development every 3 to 6 months and laboratory parameters every 6 to 12 months during sex hormone treatment. (2 |⊕⊕○○)                    3.0 Hormonal therapy for transgender adults\n3.1. We recommend that clinicians confirm the diagnostic criteria of GD/gender incongruence and the criteria for the endocrine phase of gender transition before beginning treatment. (1 |⊕⊕⊕○)3.2. We recommend that clinicians evaluate and address medical conditions that can be exacerbated by hormone depletion and treatment with sex hormones of the affirmed gender before beginning treatment. (1 |⊕⊕⊕○)3.3. We suggest that clinicians measure hormone levels during treatment to ensure that endogenous sex steroids are suppressed and administered sex steroids are maintained in the normal physiologic range for the affirmed gender. (2 |⊕⊕○○)3.4. We suggest that endocrinologists provide education to transgender individuals undergoing treatment about the onset and time course of physical changes induced by sex hormone treatment. (2 |⊕○○○)                    4.0 Adverse outcome prevention and long-term care\n4.1. We suggest regular clinical evaluation for physical changes and potential adverse changes in response to sex steroid hormones and laboratory monitoring of sex steroid hormone levels every 3 months during the first year of hormone therapy for transgender males and females and then once or twice yearly. (2 |⊕⊕○○)4.2. We suggest periodically monitoring prolactin levels in transgender females treated with estrogens. (2 |⊕⊕○○)4.3. We suggest that clinicians evaluate transgender persons treated with hormones for cardiovascular risk factors using fasting lipid profiles, diabetes screening, and/or other diagnostic tools. (2 |⊕⊕○○)4.4. We recommend that clinicians obtain bone mineral density (BMD) measurements when risk factors for osteoporosis exist, specifically in those who stop sex hormone therapy after gonadectomy. (1 |⊕⊕○○)4.5. We suggest that transgender females with no known increased risk of breast cancer follow breast-screening guidelines recommended for non-transgender females. (2 |⊕⊕○○)4.6. We suggest that transgender females treated with estrogens follow individualized screening according to personal risk for prostatic disease and prostate cancer. (2 |⊕○○○)4.7. We advise that clinicians determine the medical necessity of including a total hysterectomy and oophorectomy as part of gender-affirming surgery. (Ungraded Good Practice Statement)                    5.0 Surgery for sex reassignment and gender confirmation\n5.1. We recommend that a patient pursue genital gender-affirming surgery only after the MHP and the clinician responsible for endocrine transition therapy both agree that surgery is medically necessary and would benefit the patient’s overall health and/or well-being. (1 |⊕⊕○○)5.2. We advise that clinicians approve genital gender-affirming surgery only after completion of at least 1 year of consistent and compliant hormone treatment, unless hormone therapy is not desired or medically contraindicated. (Ungraded Good Practice Statement)5.3. We advise that the clinician responsible for endocrine treatment and the primary care provider ensure appropriate medical clearance of transgender individuals for genital gender-affirming surgery and collaborate with the surgeon regarding hormone use during and after surgery. (Ungraded Good Practice Statement)5.4. We recommend that clinicians refer hormone-treated transgender individuals for genital surgery when: (1) the individual has had a satisfactory social role change, (2) the individual is satisfied about the hormonal effects, and (3) the individual desires definitive surgical changes. (1 |⊕○○○)5.5. We suggest that clinicians delay gender-affirming genital surgery involving gonadectomy and/or hysterectomy until the patient is at least 18 years old or legal age of majority in his or her country. (2 |⊕⊕○○).5.6. We suggest that clinicians determine the timing of breast surgery for transgender males based upon the physical and mental health status of the individual. There is insufficient evidence to recommend a specific age requirement. (2 |⊕○○○)                    Changes Since the Previous Guideline\nBoth the current guideline and the one published in 2009 contain similar sections. Listed here are the sections contained in the current guideline and the corresponding number of recommendations: Introduction, Evaluation of Youth and Adults (5), Treatment of Adolescents (6), Hormonal Therapy for Transgender Adults (4), Adverse Outcomes Prevention and Long-term Care (7), and Surgery for Sex Reassignment and Gender Confirmation (6). The current introduction updates the diagnostic classification of “gender dysphoria/gender incongruence.” It also reviews the development of “gender identity” and summarizes its natural development. The section on clinical evaluation of both youth and adults, defines in detail the professional qualifications required of those who diagnose and treat both adolescents and adults. We advise that decisions regarding the social transition of prepubertal youth are made with the assistance of a mental health professional or similarly experienced professional. We recommend against puberty blocking followed by gender-affirming hormone treatment of prepubertal children. Clinicians should inform pubertal children, adolescents, and adults seeking gender-confirming treatment of their options for fertility preservation. Prior to treatment, clinicians should evaluate the presence of medical conditions that may be worsened by hormone depletion and/or treatment. A multidisciplinary team, preferably composed of medical and mental health professionals, should monitor treatments. Clinicians evaluating transgender adults for endocrine treatment should confirm the diagnosis of persistent gender dysphoria/gender incongruence. Physicians should educate transgender persons regarding the time course of steroid-induced physical changes. Treatment should include periodic monitoring of hormone levels and metabolic parameters, as well as assessments of bone density and the impact upon prostate, gonads, and uterus. We also make recommendations for transgender persons who plan genital gender-affirming surgery.                    Method of Development of Evidence-Based Clinical Practice Guidelines\nThe Clinical Guidelines Subcommittee (CGS) of the Endocrine Society deemed the diagnosis and treatment of individuals with GD/gender incongruence a priority area for revision and appointed a task force to formulate evidence-based recommendations. The task force followed the approach recommended by the Grading of Recommendations, Assessment, Development, and Evaluation group, an international group with expertise in the development and implementation of evidence-based guidelines (1). A detailed description of the grading scheme has been published elsewhere (2). The task force used the best available research evidence to develop the recommendations. The task force also used consistent language and graphical descriptions of both the strength of a recommendation and the quality of evidence. In terms of the strength of the recommendation, strong recommendations use the phrase “we recommend” and the number 1, and weak recommendations use the phrase “we suggest” and the number 2. Cross-filled circles indicate the quality of the evidence, such that ⊕○○○ denotes very low–quality evidence; ⊕⊕○○, low quality; ⊕⊕⊕○, moderate quality; and ⊕⊕⊕⊕, high quality. The task force has confidence that persons who receive care according to the strong recommendations will derive, on average, more benefit than harm. Weak recommendations require more careful consideration of the person’s circumstances, values, and preferences to determine the best course of action. Linked to each recommendation is a description of the evidence and the values that the task force considered in making the recommendation. In some instances, there are remarks in which the task force offers technical suggestions for testing conditions, dosing, and monitoring. These technical comments reflect the best available evidence applied to a typical person being treated. Often this evidence comes from the unsystematic observations of the task force and their preferences; therefore, one should consider these remarks as suggestions.In this guideline, the task force made several statements to emphasize the importance of shared decision-making, general preventive care measures, and basic principles of the treatment of transgender persons. They labeled these “Ungraded Good Practice Statement.” Direct evidence for these statements was either unavailable or not systematically appraised and considered out of the scope of this guideline. The intention of these statements is to draw attention to these principles.The Endocrine Society maintains a rigorous conflict-of-interest review process for developing clinical practice guidelines. All task force members must declare any potential conflicts of interest by completing a conflict-of-interest form. The CGS reviews all conflicts of interest before the Society’s Council approves the members to participate on the task force and periodically during the development of the guideline. All others participating in the guideline’s development must also disclose any conflicts of interest in the matter under study, and most of these participants must be without any conflicts of interest. The CGS and the task force have reviewed all disclosures for this guideline and resolved or managed all identified conflicts of interest.Conflicts of interest are defined as remuneration in any amount from commercial interests; grants; research support; consulting fees; salary; ownership interests [e.g., stocks and stock options (excluding diversified mutual funds)]; honoraria and other payments for participation in speakers’ bureaus, advisory boards, or boards of directors; and all other financial benefits. Completed forms are available through the Endocrine Society office.The Endocrine Society provided the funding for this guideline; the task force received no funding or remuneration from commercial or other entities.                    Commissioned Systematic Review\nThe task force commissioned two systematic reviews to support this guideline. The first one aimed to summarize the available evidence on the effect of sex steroid use in transgender individuals on lipids and cardiovascular outcomes. The review identified 29 eligible studies at moderate risk of bias. In transgender males (female to male), sex steroid therapy was associated with a statistically significant increase in serum triglycerides and low-density lipoprotein cholesterol levels. High-density lipoprotein cholesterol levels decreased significantly across all follow-up time periods. In transgender females (male to female), serum triglycerides were significantly higher without any changes in other parameters. Few myocardial infarction, stroke, venous thromboembolism (VTE), and death events were reported. These events were more frequent in transgender females. However, the quality of the evidence was low. The second review summarized the available evidence regarding the effect of sex steroids on bone health in transgender individuals and identified 13 studies. In transgender males, there was no statistically significant difference in the lumbar spine, femoral neck, or total hip BMD at 12 and 24 months compared with baseline values before initiating masculinizing hormone therapy. In transgender females, there was a statistically significant increase in lumbar spine BMD at 12 months and 24 months compared with baseline values before initiation of feminizing hormone therapy. There was minimal information on fracture rates. The quality of evidence was also low.                    Introduction\nThroughout recorded history (in the absence of an endocrine disorder) some men and women have experienced confusion and anguish resulting from rigid, forced conformity to sexual dimorphism. In modern history, there have been numerous ongoing biological, psychological, cultural, political, and sociological debates over various aspects of gender variance. The 20th century marked the emergence of a social awakening for men and women with the belief that they are “trapped” in the wrong body (3). Magnus Hirschfeld and Harry Benjamin, among others, pioneered the medical responses to those who sought relief from and a resolution to their profound discomfort. Although the term transsexual became widely known after Benjamin wrote “The Transsexual Phenomenon” (4), it was Hirschfeld who coined the term “transsexual” in 1923 to describe people who want to live a life that corresponds with their experienced gender vs their designated gender (5). Magnus Hirschfeld (6) and others (4, 7) have described other types of trans phenomena besides transsexualism. These early researchers proposed that the gender identity of these people was located somewhere along a unidimensional continuum. This continuum ranged from all male through “something in between” to all female. Yet such a classification does not take into account that people may have gender identities outside this continuum. For instance, some experience themselves as having both a male and female gender identity, whereas others completely renounce any gender classification (8, 9). There are also reports of individuals experiencing a continuous and rapid involuntary alternation between a male and female identity (10) or men who do not experience themselves as men but do not want to live as women (11, 12). In some countries, (e.g., Nepal, Bangladesh, and Australia), these nonmale or nonfemale genders are officially recognized (13). Specific treatment protocols, however, have not yet been developed for these groups.Instead of the term transsexualism, the current classification system of the American Psychiatric Association uses the term gender dysphoria in its diagnosis of persons who are not satisfied with their designated gender (14). The current version of the World Health Organization’s ICD-10 still uses the term transsexualism when diagnosing adolescents and adults. However, for the ICD-11, the World Health Organization has proposed using the term “gender incongruence” (15).Treating persons with GD/gender incongruence (15) was previously limited to relatively ineffective elixirs or creams. However, more effective endocrinology-based treatments became possible with the availability of testosterone in 1935 and diethylstilbestrol in 1938. Reports of individuals with GD/gender incongruence who were treated with hormones and gender-affirming surgery appeared in the press during the second half of the 20th century. The Harry Benjamin International Gender Dysphoria Association was founded in September 1979 and is now called the World Professional Association for Transgender Health (WPATH). WPATH published its first Standards of Care in 1979. These standards have since been regularly updated, providing guidance for treating persons with GD/gender incongruence (16).Prior to 1975, few peer-reviewed articles were published concerning endocrine treatment of transgender persons. Since then, more than two thousand articles about various aspects of transgender care have appeared.It is the purpose of this guideline to make detailed recommendations and suggestions, based on existing medical literature and clinical experience, that will enable treating physicians to maximize benefit and minimize risk when caring for individuals diagnosed with GD/gender incongruence.In the future, we need more rigorous evaluations of the effectiveness and safety of endocrine and surgical protocols. Specifically, endocrine treatment protocols for GD/gender incongruence should include the careful assessment of the following: (1) the effects of prolonged delay of puberty in adolescents on bone health, gonadal function, and the brain (including effects on cognitive, emotional, social, and sexual development); (2) the effects of treatment in adults on sex hormone levels; (3) the requirement for and the effects of progestins and other agents used to suppress endogenous sex steroids during treatment; and (4) the risks and benefits of gender-affirming hormone treatment in older transgender people.To successfully establish and enact these protocols, a commitment of mental health and endocrine investigators is required to collaborate in long-term, large-scale studies across countries that use the same diagnostic and inclusion criteria, medications, assay methods, and response assessment tools (e.g., the European Network for the Investigation of Gender Incongruence) (17, 18).Terminology and its use vary and continue to evolve. Table 1 contains the definitions of terms as they are used throughout this guideline.                    Table 1.Definitions of Terms Used in This Guideline Biological sex, biological male or female: These terms refer to physical aspects of maleness and femaleness. As these may not be in line with each other (e.g., a person with XY chromosomes may have female-appearing genitalia), the terms biological sex and biological male or female are imprecise and should be avoided. Cisgender: This means not transgender. An alternative way to describe individuals who are not transgender is “non-transgender people.” Gender-affirming (hormone) treatment: See “gender reassignment” Gender dysphoria: This is the distress and unease experienced if gender identity and designated gender are not completely congruent (see Table 2). In 2013, the American Psychiatric Association released the fifth edition of the DSM-5, which replaced “gender identity disorder” with “gender dysphoria” and changed the criteria for diagnosis. Gender expression: This refers to external manifestations of gender, expressed through one’s name, pronouns, clothing, haircut, behavior, voice, or body characteristics. Typically, transgender people seek to make their gender expression align with their gender identity, rather than their designated gender. Gender identity/experienced gender: This refers to one’s internal, deeply held sense of gender. For transgender people, their gender identity does not match their sex designated at birth. Most people have a gender identity of man or woman (or boy or girl). For some people, their gender identity does not fit neatly into one of those two choices. Unlike gender expression (see below), gender identity is not visible to others. Gender identity disorder: This is the term used for GD/gender incongruence in previous versions of DSM (see “gender dysphoria”). The ICD-10 still uses the term for diagnosing child diagnoses, but the upcoming ICD-11 has proposed using “gender incongruence of childhood.” Gender incongruence: This is an umbrella term used when the gender identity and/or gender expression differs from what is typically associated with the designated gender. Gender incongruence is also the proposed name of the gender identity–related diagnoses in ICD-11. Not all individuals with gender incongruence have gender dysphoria or seek treatment. Gender variance: See “gender incongruence” Gender reassignment: This refers to the treatment procedure for those who want to adapt their bodies to the experienced gender by means of hormones and/or surgery. This is also called gender-confirming or gender-affirming treatment. Gender-reassignment surgery (gender-confirming/gender-affirming surgery): These terms refer only to the surgical part of gender-confirming/gender-affirming treatment. Gender role: This refers to behaviors, attitudes, and personality traits that a society (in a given culture and historical period) designates as masculine or feminine and/or that society associates with or considers typical of the social role of men or women. Sex designated at birth: This refers to sex assigned at birth, usually based on genital anatomy. Sex: This refers to attributes that characterize biological maleness or femaleness. The best known attributes include the sex-determining genes, the sex chromosomes, the H-Y antigen, the gonads, sex hormones, internal and external genitalia, and secondary sex characteristics. Sexual orientation: This term describes an individual’s enduring physical and emotional attraction to another person. Gender identity and sexual orientation are not the same. Irrespective of their gender identity, transgender people may be attracted to women (gynephilic), attracted to men (androphilic), bisexual, asexual, or queer. Transgender: This is an umbrella term for people whose gender identity and/or gender expression differs from what is typically associated with their sex designated at birth. Not all transgender individuals seek treatment. Transgender male (also: trans man, female-to-male, transgender male): This refers to individuals assigned female at birth but who identify and live as men. Transgender woman (also: trans woman, male-to female, transgender female): This refers to individuals assigned male at birth but who identify and live as women. Transition: This refers to the process during which transgender persons change their physical, social, and/or legal characteristics consistent with the affirmed gender identity. Prepubertal children may choose to transition socially. Transsexual: This is an older term that originated in the medical and psychological communities to refer to individuals who have permanently transitioned through medical interventions or desired to do so. Biological sex, biological male or female: These terms refer to physical aspects of maleness and femaleness. As these may not be in line with each other (e.g., a person with XY chromosomes may have female-appearing genitalia), the terms biological sex and biological male or female are imprecise and should be avoided. Cisgender: This means not transgender. An alternative way to describe individuals who are not transgender is “non-transgender people.” Gender-affirming (hormone) treatment: See “gender reassignment” Gender dysphoria: This is the distress and unease experienced if gender identity and designated gender are not completely congruent (see Table 2). In 2013, the American Psychiatric Association released the fifth edition of the DSM-5, which replaced “gender identity disorder” with “gender dysphoria” and changed the criteria for diagnosis. Gender expression: This refers to external manifestations of gender, expressed through one’s name, pronouns, clothing, haircut, behavior, voice, or body characteristics. Typically, transgender people seek to make their gender expression align with their gender identity, rather than their designated gender. Gender identity/experienced gender: This refers to one’s internal, deeply held sense of gender. For transgender people, their gender identity does not match their sex designated at birth. Most people have a gender identity of man or woman (or boy or girl). For some people, their gender identity does not fit neatly into one of those two choices. Unlike gender expression (see below), gender identity is not visible to others. Gender identity disorder: This is the term used for GD/gender incongruence in previous versions of DSM (see “gender dysphoria”). The ICD-10 still uses the term for diagnosing child diagnoses, but the upcoming ICD-11 has proposed using “gender incongruence of childhood.” Gender incongruence: This is an umbrella term used when the gender identity and/or gender expression differs from what is typically associated with the designated gender. Gender incongruence is also the proposed name of the gender identity–related diagnoses in ICD-11. Not all individuals with gender incongruence have gender dysphoria or seek treatment. Gender variance: See “gender incongruence” Gender reassignment: This refers to the treatment procedure for those who want to adapt their bodies to the experienced gender by means of hormones and/or surgery. This is also called gender-confirming or gender-affirming treatment. Gender-reassignment surgery (gender-confirming/gender-affirming surgery): These terms refer only to the surgical part of gender-confirming/gender-affirming treatment. Gender role: This refers to behaviors, attitudes, and personality traits that a society (in a given culture and historical period) designates as masculine or feminine and/or that society associates with or considers typical of the social role of men or women. Sex designated at birth: This refers to sex assigned at birth, usually based on genital anatomy. Sex: This refers to attributes that characterize biological maleness or femaleness. The best known attributes include the sex-determining genes, the sex chromosomes, the H-Y antigen, the gonads, sex hormones, internal and external genitalia, and secondary sex characteristics. Sexual orientation: This term describes an individual’s enduring physical and emotional attraction to another person. Gender identity and sexual orientation are not the same. Irrespective of their gender identity, transgender people may be attracted to women (gynephilic), attracted to men (androphilic), bisexual, asexual, or queer. Transgender: This is an umbrella term for people whose gender identity and/or gender expression differs from what is typically associated with their sex designated at birth. Not all transgender individuals seek treatment. Transgender male (also: trans man, female-to-male, transgender male): This refers to individuals assigned female at birth but who identify and live as men. Transgender woman (also: trans woman, male-to female, transgender female): This refers to individuals assigned male at birth but who identify and live as women. Transition: This refers to the process during which transgender persons change their physical, social, and/or legal characteristics consistent with the affirmed gender identity. Prepubertal children may choose to transition socially. Transsexual: This is an older term that originated in the medical and psychological communities to refer to individuals who have permanently transitioned through medical interventions or desired to do so. Table 1.Definitions of Terms Used in This Guideline Biological sex, biological male or female: These terms refer to physical aspects of maleness and femaleness. As these may not be in line with each other (e.g., a person with XY chromosomes may have female-appearing genitalia), the terms biological sex and biological male or female are imprecise and should be avoided. Cisgender: This means not transgender. An alternative way to describe individuals who are not transgender is “non-transgender people.” Gender-affirming (hormone) treatment: See “gender reassignment” Gender dysphoria: This is the distress and unease experienced if gender identity and designated gender are not completely congruent (see Table 2). In 2013, the American Psychiatric Association released the fifth edition of the DSM-5, which replaced “gender identity disorder” with “gender dysphoria” and changed the criteria for diagnosis. Gender expression: This refers to external manifestations of gender, expressed through one’s name, pronouns, clothing, haircut, behavior, voice, or body characteristics. Typically, transgender people seek to make their gender expression align with their gender identity, rather than their designated gender. Gender identity/experienced gender: This refers to one’s internal, deeply held sense of gender. For transgender people, their gender identity does not match their sex designated at birth. Most people have a gender identity of man or woman (or boy or girl). For some people, their gender identity does not fit neatly into one of those two choices. Unlike gender expression (see below), gender identity is not visible to others. Gender identity disorder: This is the term used for GD/gender incongruence in previous versions of DSM (see “gender dysphoria”). The ICD-10 still uses the term for diagnosing child diagnoses, but the upcoming ICD-11 has proposed using “gender incongruence of childhood.” Gender incongruence: This is an umbrella term used when the gender identity and/or gender expression differs from what is typically associated with the designated gender. Gender incongruence is also the proposed name of the gender identity–related diagnoses in ICD-11. Not all individuals with gender incongruence have gender dysphoria or seek treatment. Gender variance: See “gender incongruence” Gender reassignment: This refers to the treatment procedure for those who want to adapt their bodies to the experienced gender by means of hormones and/or surgery. This is also called gender-confirming or gender-affirming treatment. Gender-reassignment surgery (gender-confirming/gender-affirming surgery): These terms refer only to the surgical part of gender-confirming/gender-affirming treatment. Gender role: This refers to behaviors, attitudes, and personality traits that a society (in a given culture and historical period) designates as masculine or feminine and/or that society associates with or considers typical of the social role of men or women. Sex designated at birth: This refers to sex assigned at birth, usually based on genital anatomy. Sex: This refers to attributes that characterize biological maleness or femaleness. The best known attributes include the sex-determining genes, the sex chromosomes, the H-Y antigen, the gonads, sex hormones, internal and external genitalia, and secondary sex characteristics. Sexual orientation: This term describes an individual’s enduring physical and emotional attraction to another person. Gender identity and sexual orientation are not the same. Irrespective of their gender identity, transgender people may be attracted to women (gynephilic), attracted to men (androphilic), bisexual, asexual, or queer. Transgender: This is an umbrella term for people whose gender identity and/or gender expression differs from what is typically associated with their sex designated at birth. Not all transgender individuals seek treatment. Transgender male (also: trans man, female-to-male, transgender male): This refers to individuals assigned female at birth but who identify and live as men. Transgender woman (also: trans woman, male-to female, transgender female): This refers to individuals assigned male at birth but who identify and live as women. Transition: This refers to the process during which transgender persons change their physical, social, and/or legal characteristics consistent with the affirmed gender identity. Prepubertal children may choose to transition socially. Transsexual: This is an older term that originated in the medical and psychological communities to refer to individuals who have permanently transitioned through medical interventions or desired to do so. Biological sex, biological male or female: These terms refer to physical aspects of maleness and femaleness. As these may not be in line with each other (e.g., a person with XY chromosomes may have female-appearing genitalia), the terms biological sex and biological male or female are imprecise and should be avoided. Cisgender: This means not transgender. An alternative way to describe individuals who are not transgender is “non-transgender people.” Gender-affirming (hormone) treatment: See “gender reassignment” Gender dysphoria: This is the distress and unease experienced if gender identity and designated gender are not completely congruent (see Table 2). In 2013, the American Psychiatric Association released the fifth edition of the DSM-5, which replaced “gender identity disorder” with “gender dysphoria” and changed the criteria for diagnosis. Gender expression: This refers to external manifestations of gender, expressed through one’s name, pronouns, clothing, haircut, behavior, voice, or body characteristics. Typically, transgender people seek to make their gender expression align with their gender identity, rather than their designated gender. Gender identity/experienced gender: This refers to one’s internal, deeply held sense of gender. For transgender people, their gender identity does not match their sex designated at birth. Most people have a gender identity of man or woman (or boy or girl). For some people, their gender identity does not fit neatly into one of those two choices. Unlike gender expression (see below), gender identity is not visible to others. Gender identity disorder: This is the term used for GD/gender incongruence in previous versions of DSM (see “gender dysphoria”). The ICD-10 still uses the term for diagnosing child diagnoses, but the upcoming ICD-11 has proposed using “gender incongruence of childhood.” Gender incongruence: This is an umbrella term used when the gender identity and/or gender expression differs from what is typically associated with the designated gender. Gender incongruence is also the proposed name of the gender identity–related diagnoses in ICD-11. Not all individuals with gender incongruence have gender dysphoria or seek treatment. Gender variance: See “gender incongruence” Gender reassignment: This refers to the treatment procedure for those who want to adapt their bodies to the experienced gender by means of hormones and/or surgery. This is also called gender-confirming or gender-affirming treatment. Gender-reassignment surgery (gender-confirming/gender-affirming surgery): These terms refer only to the surgical part of gender-confirming/gender-affirming treatment. Gender role: This refers to behaviors, attitudes, and personality traits that a society (in a given culture and historical period) designates as masculine or feminine and/or that society associates with or considers typical of the social role of men or women. Sex designated at birth: This refers to sex assigned at birth, usually based on genital anatomy. Sex: This refers to attributes that characterize biological maleness or femaleness. The best known attributes include the sex-determining genes, the sex chromosomes, the H-Y antigen, the gonads, sex hormones, internal and external genitalia, and secondary sex characteristics. Sexual orientation: This term describes an individual’s enduring physical and emotional attraction to another person. Gender identity and sexual orientation are not the same. Irrespective of their gender identity, transgender people may be attracted to women (gynephilic), attracted to men (androphilic), bisexual, asexual, or queer. Transgender: This is an umbrella term for people whose gender identity and/or gender expression differs from what is typically associated with their sex designated at birth. Not all transgender individuals seek treatment. Transgender male (also: trans man, female-to-male, transgender male): This refers to individuals assigned female at birth but who identify and live as men. Transgender woman (also: trans woman, male-to female, transgender female): This refers to individuals assigned male at birth but who identify and live as women. Transition: This refers to the process during which transgender persons change their physical, social, and/or legal characteristics consistent with the affirmed gender identity. Prepubertal children may choose to transition socially. Transsexual: This is an older term that originated in the medical and psychological communities to refer to individuals who have permanently transitioned through medical interventions or desired to do so.                     Biological Determinants of Gender Identity Development\nOne’s self-awareness as male or female changes gradually during infant life and childhood. This process of cognitive and affective learning evolves with interactions with parents, peers, and environment. A fairly accurate timetable exists outlining the steps in this process (19). Normative psychological literature, however, does not address if and when gender identity becomes crystallized and what factors contribute to the development of a gender identity that is not congruent with the gender of rearing. Results of studies from a variety of biomedical disciplines—genetic, endocrine, and neuroanatomic—support the concept that gender identity and/or gender expression (20) likely reflect a complex interplay of biological, environmental, and cultural factors (21, 22).With respect to endocrine considerations, studies have failed to find differences in circulating levels of sex steroids between transgender and nontransgender individuals (23). However, studies in individuals with a disorder/difference of sex development (DSD) have informed our understanding of the role that hormones may play in gender identity outcome, even though most persons with GD/gender incongruence do not have a DSD. For example, although most 46,XX adult individuals with virilizing congenital adrenal hyperplasia caused by mutations in CYP21A2 reported a female gender identity, the prevalence of GD/gender incongruence was much greater in this group than in the general population without a DSD. This supports the concept that there is a role for prenatal/postnatal androgens in gender development (24–26), although some studies indicate that prenatal androgens are more likely to affect gender behavior and sexual orientation rather than gender identity per se (27, 28).Researchers have made similar observations regarding the potential role of androgens in the development of gender identity in other individuals with DSD. For example, a review of two groups of 46,XY persons, each with androgen synthesis deficiencies and female raised, reported transgender male (female-to-male) gender role changes in 56% to 63% and 39% to 64% of patients, respectively (29). Also, in 46,XY female-raised individuals with cloacal exstrophy and penile agenesis, the occurrence of transgender male changes was significantly more prevalent than in the general population (30, 31). However, the fact that a high percentage of individuals with the same conditions did not change gender suggests that cultural factors may play a role as well.With respect to genetics and gender identity, several studies have suggested heritability of GD/gender incongruence (32, 33). In particular, a study by Heylens et al. (33) demonstrated a 39.1% concordance rate for gender identity disorder (based on the DSM-IV criteria) in 23 monozygotic twin pairs but no concordance in 21 same-sex dizygotic or seven opposite-sex twin pairs. Although numerous investigators have sought to identify specific genes associated with GD/gender incongruence, such studies have been inconsistent and without strong statistical significance (34–38).Studies focusing on brain structure suggest that the brain phenotypes of people with GD/gender incongruence differ in various ways from control males and females, but that there is not a complete sex reversal in brain structures (39).In summary, although there is much that is still unknown with respect to gender identity and its expression, compelling studies support the concept that biologic factors, in addition to environmental factors, contribute to this fundamental aspect of human development.                    Natural History of Children With GD/Gender Incongruence\nWith current knowledge, we cannot predict the psychosexual outcome for any specific child. Prospective follow-up studies show that childhood GD/gender incongruence does not invariably persist into adolescence and adulthood (so-called “desisters”). Combining all outcome studies to date, the GD/gender incongruence of a minority of prepubertal children appears to persist in adolescence (20, 40). In adolescence, a significant number of these desisters identify as homosexual or bisexual. It may be that children who only showed some gender nonconforming characteristics have been included in the follow-up studies, because the DSM-IV text revision criteria for a diagnosis were rather broad. However, the persistence of GD/gender incongruence into adolescence is more likely if it had been extreme in childhood (41, 42). With the newer, stricter criteria of the DSM-5 (Table 2), persistence rates may well be different in future studies.                    Table 2.DSM-5 Criteria for Gender Dysphoria in Adolescents and Adults A. A marked incongruence between one’s experienced/expressed gender and natal gender of at least 6 mo in duration, as manifested by at least two of the following:  1. A marked incongruence between one’s experienced/expressed gender and primary and/or secondary sex characteristics (or in young adolescents, the anticipated secondary sex characteristics)  2. A strong desire to be rid of one’s primary and/or secondary sex characteristics because of a marked incongruence with one’s experienced/expressed gender (or in young adolescents, a desire to prevent the development of the anticipated secondary sex characteristics)  3. A strong desire for the primary and/or secondary sex characteristics of the other gender  4. A strong desire to be of the other gender (or some alternative gender different from one’s designated gender)  5. A strong desire to be treated as the other gender (or some alternative gender different from one’s designated gender)  6. A strong conviction that one has the typical feelings and reactions of the other gender (or some alternative gender different from one’s designated gender) B. The condition is associated with clinically significant distress or impairment in social, occupational, or other important areas of functioning. Specify if:  1. The condition exists with a disorder of sex development.  2. The condition is posttransitional, in that the individual has transitioned to full-time living in the desired gender (with or without legalization of gender change) and has undergone (or is preparing to have) at least one sex-related medical procedure or treatment regimen—namely, regular sex hormone treatment or gender reassignment surgery confirming the desired gender (e.g., penectomy, vaginoplasty in natal males; mastectomy or phalloplasty in natal females). A. A marked incongruence between one’s experienced/expressed gender and natal gender of at least 6 mo in duration, as manifested by at least two of the following:  1. A marked incongruence between one’s experienced/expressed gender and primary and/or secondary sex characteristics (or in young adolescents, the anticipated secondary sex characteristics)  2. A strong desire to be rid of one’s primary and/or secondary sex characteristics because of a marked incongruence with one’s experienced/expressed gender (or in young adolescents, a desire to prevent the development of the anticipated secondary sex characteristics)  3. A strong desire for the primary and/or secondary sex characteristics of the other gender  4. A strong desire to be of the other gender (or some alternative gender different from one’s designated gender)  5. A strong desire to be treated as the other gender (or some alternative gender different from one’s designated gender)  6. A strong conviction that one has the typical feelings and reactions of the other gender (or some alternative gender different from one’s designated gender) B. The condition is associated with clinically significant distress or impairment in social, occupational, or other important areas of functioning. Specify if:  1. The condition exists with a disorder of sex development.  2. The condition is posttransitional, in that the individual has transitioned to full-time living in the desired gender (with or without legalization of gender change) and has undergone (or is preparing to have) at least one sex-related medical procedure or treatment regimen—namely, regular sex hormone treatment or gender reassignment surgery confirming the desired gender (e.g., penectomy, vaginoplasty in natal males; mastectomy or phalloplasty in natal females). Reference: American Psychiatric Association (14).Table 2.DSM-5 Criteria for Gender Dysphoria in Adolescents and Adults A. A marked incongruence between one’s experienced/expressed gender and natal gender of at least 6 mo in duration, as manifested by at least two of the following:  1. A marked incongruence between one’s experienced/expressed gender and primary and/or secondary sex characteristics (or in young adolescents, the anticipated secondary sex characteristics)  2. A strong desire to be rid of one’s primary and/or secondary sex characteristics because of a marked incongruence with one’s experienced/expressed gender (or in young adolescents, a desire to prevent the development of the anticipated secondary sex characteristics)  3. A strong desire for the primary and/or secondary sex characteristics of the other gender  4. A strong desire to be of the other gender (or some alternative gender different from one’s designated gender)  5. A strong desire to be treated as the other gender (or some alternative gender different from one’s designated gender)  6. A strong conviction that one has the typical feelings and reactions of the other gender (or some alternative gender different from one’s designated gender) B. The condition is associated with clinically significant distress or impairment in social, occupational, or other important areas of functioning. Specify if:  1. The condition exists with a disorder of sex development.  2. The condition is posttransitional, in that the individual has transitioned to full-time living in the desired gender (with or without legalization of gender change) and has undergone (or is preparing to have) at least one sex-related medical procedure or treatment regimen—namely, regular sex hormone treatment or gender reassignment surgery confirming the desired gender (e.g., penectomy, vaginoplasty in natal males; mastectomy or phalloplasty in natal females). A. A marked incongruence between one’s experienced/expressed gender and natal gender of at least 6 mo in duration, as manifested by at least two of the following:  1. A marked incongruence between one’s experienced/expressed gender and primary and/or secondary sex characteristics (or in young adolescents, the anticipated secondary sex characteristics)  2. A strong desire to be rid of one’s primary and/or secondary sex characteristics because of a marked incongruence with one’s experienced/expressed gender (or in young adolescents, a desire to prevent the development of the anticipated secondary sex characteristics)  3. A strong desire for the primary and/or secondary sex characteristics of the other gender  4. A strong desire to be of the other gender (or some alternative gender different from one’s designated gender)  5. A strong desire to be treated as the other gender (or some alternative gender different from one’s designated gender)  6. A strong conviction that one has the typical feelings and reactions of the other gender (or some alternative gender different from one’s designated gender) B. The condition is associated with clinically significant distress or impairment in social, occupational, or other important areas of functioning. Specify if:  1. The condition exists with a disorder of sex development.  2. The condition is posttransitional, in that the individual has transitioned to full-time living in the desired gender (with or without legalization of gender change) and has undergone (or is preparing to have) at least one sex-related medical procedure or treatment regimen—namely, regular sex hormone treatment or gender reassignment surgery confirming the desired gender (e.g., penectomy, vaginoplasty in natal males; mastectomy or phalloplasty in natal females). Reference: American Psychiatric Association (14).                    1.0 Evaluation of Youth and Adults\nGender-affirming treatment is a multidisciplinary effort. After evaluation, education, and diagnosis, treatment may include mental health care, hormone therapy, and/or surgical therapy. Together with an MHP, hormone-prescribing clinicians should examine the psychosocial impact of the potential changes on people’s lives, including mental health, friends, family, jobs, and their role in society. Transgender individuals should be encouraged to experience living in the new gender role and assess whether this improves their quality of life. Although the focus of this guideline is gender-affirming hormone therapy, collaboration with appropriate professionals responsible for each aspect of treatment maximizes a successful outcome.                    Diagnostic assessment and mental health care\nGD/gender incongruence may be accompanied with psychological or psychiatric problems (43–51). It is therefore necessary that clinicians who prescribe hormones and are involved in diagnosis and psychosocial assessment meet the following criteria: (1) are competent in using the DSM and/or the ICD for diagnostic purposes, (2) are able to diagnose GD/gender incongruence and make a distinction between GD/gender incongruence and conditions that have similar features (e.g., body dysmorphic disorder), (3) are trained in diagnosing psychiatric conditions, (4) undertake or refer for appropriate treatment, (5) are able to do a psychosocial assessment of the patient’s understanding, mental health, and social conditions that can impact gender-affirming hormone therapy, and (6) regularly attend relevant professional meetings.Because of the psychological vulnerability of many individuals with GD/gender incongruence, it is important that mental health care is available before, during, and sometimes also after transitioning. For children and adolescents, an MHP who has training/experience in child and adolescent gender development (as well as child and adolescent psychopathology) should make the diagnosis, because assessing GD/gender incongruence in children and adolescents is often extremely complex.During assessment, the clinician obtains information from the individual seeking gender-affirming treatment. In the case of adolescents, the clinician also obtains information from the parents or guardians regarding various aspects of the child’s general and psychosexual development and current functioning. On the basis of this information, the clinician:decides whether the individual fulfills criteria for treatment (see Tables 2 and 3) for GD/gender incongruence (DSM-5) or transsexualism (DSM-5 and/or ICD-10);Table 3.ICD-10 Criteria for Transsexualism Transsexualism (F64.0) has three criteria:1. The desire to live and be accepted as a member of the opposite sex, usually accompanied by the wish to make his or her body as congruent as possible with the preferred sex through surgery and hormone treatments. 2. The transsexual identity has been present persistently for at least 2 y. 3. The disorder is not a symptom of another mental disorder or a genetic, DSD, or chromosomal abnormality. Transsexualism (F64.0) has three criteria:1. The desire to live and be accepted as a member of the opposite sex, usually accompanied by the wish to make his or her body as congruent as possible with the preferred sex through surgery and hormone treatments. 2. The transsexual identity has been present persistently for at least 2 y. 3. The disorder is not a symptom of another mental disorder or a genetic, DSD, or chromosomal abnormality. Table 3.ICD-10 Criteria for Transsexualism Transsexualism (F64.0) has three criteria:1. The desire to live and be accepted as a member of the opposite sex, usually accompanied by the wish to make his or her body as congruent as possible with the preferred sex through surgery and hormone treatments. 2. The transsexual identity has been present persistently for at least 2 y. 3. The disorder is not a symptom of another mental disorder or a genetic, DSD, or chromosomal abnormality. Transsexualism (F64.0) has three criteria:1. The desire to live and be accepted as a member of the opposite sex, usually accompanied by the wish to make his or her body as congruent as possible with the preferred sex through surgery and hormone treatments. 2. The transsexual identity has been present persistently for at least 2 y. 3. The disorder is not a symptom of another mental disorder or a genetic, DSD, or chromosomal abnormality. informs the individual about the possibilities and limitations of various kinds of treatment (hormonal/surgical and nonhormonal), and if medical treatment is desired, provides correct information to prevent unrealistically high expectations;assesses whether medical interventions may result in unfavorable psychological and social outcomes.In cases in which severe psychopathology, circumstances, or both seriously interfere with the diagnostic work or make satisfactory treatment unlikely, clinicians should assist the adolescent in managing these other issues. Literature on postoperative regret suggests that besides poor quality of surgery, severe psychiatric comorbidity and lack of support may interfere with positive outcomes (52–56).For adolescents, the diagnostic procedure usually includes a complete psychodiagnostic assessment (57) and an assessment of the decision-making capability of the youth. An evaluation to assess the family’s ability to endure stress, give support, and deal with the complexities of the adolescent’s situation should be part of the diagnostic phase (58).                    Social transitioning\nA change in gender expression and role (which may involve living part time or full time in another gender role that is consistent with one’s gender identity) may test the person’s resolve, the capacity to function in the affirmed gender, and the adequacy of social, economic, and psychological supports. It assists both the individual and the clinician in their judgments about how to proceed (16). During social transitioning, the person’s feelings about the social transformation (including coping with the responses of others) is a major focus of the counseling. The optimal timing for social transitioning may differ between individuals. Sometimes people wait until they start gender-affirming hormone treatment to make social transitioning easier, but individuals increasingly start social transitioning long before they receive medically supervised, gender-affirming hormone treatment.                    Criteria\nAdolescents and adults seeking gender-affirming hormone treatment and surgery should satisfy certain criteria before proceeding (16). Criteria for gender-affirming hormone therapy for adults are in Table 4, and criteria for gender-affirming hormone therapy for adolescents are in Table 5. Follow-up studies in adults meeting these criteria indicate a high satisfaction rate with treatment (59). However, the quality of evidence is usually low. A few follow-up studies on adolescents who fulfilled these criteria also indicated good treatment results (60–63).                    Table 4.Criteria for Gender-Affirming Hormone Therapy for Adults 1. Persistent, well-documented gender dysphoria/gender incongruence 2. The capacity to make a fully informed decision and to consent for treatment 3. The age of majority in a given country (if younger, follow the criteria for adolescents) 4. Mental health concerns, if present, must be reasonably well controlled 1. Persistent, well-documented gender dysphoria/gender incongruence 2. The capacity to make a fully informed decision and to consent for treatment 3. The age of majority in a given country (if younger, follow the criteria for adolescents) 4. Mental health concerns, if present, must be reasonably well controlled Reproduced from World Professional Association for Transgender Health (16).Table 4.Criteria for Gender-Affirming Hormone Therapy for Adults 1. Persistent, well-documented gender dysphoria/gender incongruence 2. The capacity to make a fully informed decision and to consent for treatment 3. The age of majority in a given country (if younger, follow the criteria for adolescents) 4. Mental health concerns, if present, must be reasonably well controlled 1. Persistent, well-documented gender dysphoria/gender incongruence 2. The capacity to make a fully informed decision and to consent for treatment 3. The age of majority in a given country (if younger, follow the criteria for adolescents) 4. Mental health concerns, if present, must be reasonably well controlled Reproduced from World Professional Association for Transgender Health (16).                    Table 5.Criteria for Gender-Affirming Hormone Therapy for Adolescents Adolescents are eligible for GnRH agonist treatment if:  1. A qualified MHP has confirmed that:  •the adolescent has demonstrated a long-lasting and intense pattern of gender nonconformity or gender dysphoria (whether suppressed or expressed),  •gender dysphoria worsened with the onset of puberty,  •any coexisting psychological, medical, or social problems that could interfere with treatment (e.g., that may compromise treatment adherence) have been addressed, such that the adolescent’s situation and functioning are stable enough to start treatment,  •the adolescent has sufficient mental capacity to give informed consent to this (reversible) treatment,  2. And the adolescent:  •has been informed of the effects and side effects of treatment (including potential loss of fertility if the individual subsequently continues with sex hormone treatment) and options to preserve fertility,  •has given informed consent and (particularly when the adolescent has not reached the age of legal medical consent, depending on applicable legislation) the parents or other caretakers or guardians have consented to the treatment and are involved in supporting the adolescent throughout the treatment process,  3. And a pediatric endocrinologist or other clinician experienced in pubertal assessment  •agrees with the indication for GnRH agonist treatment,  •has confirmed that puberty has started in the adolescent (Tanner stage ≥G2/B2),  •has confirmed that there are no medical contraindications to GnRH agonist treatment. Adolescents are eligible for subsequent sex hormone treatment if:  1. A qualified MHP has confirmed:  •the persistence of gender dysphoria,  •any coexisting psychological, medical, or social problems that could interfere with treatment (e.g., that may compromise treatment adherence) have been addressed, such that the adolescent’s situation and functioning are stable enough to start sex hormone treatment,  •the adolescent has sufficient mental capacity (which most adolescents have by age 16 years) to estimate the consequences of this (partly) irreversible treatment, weigh the benefits and risks, and give informed consent to this (partly) irreversible treatment,  2. And the adolescent:  •has been informed of the (irreversible) effects and side effects of treatment (including potential loss of fertility and options to preserve fertility),  •has given informed consent and (particularly when the adolescent has not reached the age of legal medical consent, depending on applicable legislation) the parents or other caretakers or guardians have consented to the treatment and are involved in supporting the adolescent throughout the treatment process,  3. And a pediatric endocrinologist or other clinician experienced in pubertal induction:  •agrees with the indication for sex hormone treatment,  •has confirmed that there are no medical contraindications to sex hormone treatment. Adolescents are eligible for GnRH agonist treatment if:  1. A qualified MHP has confirmed that:  •the adolescent has demonstrated a long-lasting and intense pattern of gender nonconformity or gender dysphoria (whether suppressed or expressed),  •gender dysphoria worsened with the onset of puberty,  •any coexisting psychological, medical, or social problems that could interfere with treatment (e.g., that may compromise treatment adherence) have been addressed, such that the adolescent’s situation and functioning are stable enough to start treatment,  •the adolescent has sufficient mental capacity to give informed consent to this (reversible) treatment,  2. And the adolescent:  •has been informed of the effects and side effects of treatment (including potential loss of fertility if the individual subsequently continues with sex hormone treatment) and options to preserve fertility,  •has given informed consent and (particularly when the adolescent has not reached the age of legal medical consent, depending on applicable legislation) the parents or other caretakers or guardians have consented to the treatment and are involved in supporting the adolescent throughout the treatment process,  3. And a pediatric endocrinologist or other clinician experienced in pubertal assessment  •agrees with the indication for GnRH agonist treatment,  •has confirmed that puberty has started in the adolescent (Tanner stage ≥G2/B2),  •has confirmed that there are no medical contraindications to GnRH agonist treatment. Adolescents are eligible for subsequent sex hormone treatment if:  1. A qualified MHP has confirmed:  •the persistence of gender dysphoria,  •any coexisting psychological, medical, or social problems that could interfere with treatment (e.g., that may compromise treatment adherence) have been addressed, such that the adolescent’s situation and functioning are stable enough to start sex hormone treatment,  •the adolescent has sufficient mental capacity (which most adolescents have by age 16 years) to estimate the consequences of this (partly) irreversible treatment, weigh the benefits and risks, and give informed consent to this (partly) irreversible treatment,  2. And the adolescent:  •has been informed of the (irreversible) effects and side effects of treatment (including potential loss of fertility and options to preserve fertility),  •has given informed consent and (particularly when the adolescent has not reached the age of legal medical consent, depending on applicable legislation) the parents or other caretakers or guardians have consented to the treatment and are involved in supporting the adolescent throughout the treatment process,  3. And a pediatric endocrinologist or other clinician experienced in pubertal induction:  •agrees with the indication for sex hormone treatment,  •has confirmed that there are no medical contraindications to sex hormone treatment. Reproduced from World Professional Association for Transgender Health (16).Table 5.Criteria for Gender-Affirming Hormone Therapy for Adolescents Adolescents are eligible for GnRH agonist treatment if:  1. A qualified MHP has confirmed that:  •the adolescent has demonstrated a long-lasting and intense pattern of gender nonconformity or gender dysphoria (whether suppressed or expressed),  •gender dysphoria worsened with the onset of puberty,  •any coexisting psychological, medical, or social problems that could interfere with treatment (e.g., that may compromise treatment adherence) have been addressed, such that the adolescent’s situation and functioning are stable enough to start treatment,  •the adolescent has sufficient mental capacity to give informed consent to this (reversible) treatment,  2. And the adolescent:  •has been informed of the effects and side effects of treatment (including potential loss of fertility if the individual subsequently continues with sex hormone treatment) and options to preserve fertility,  •has given informed consent and (particularly when the adolescent has not reached the age of legal medical consent, depending on applicable legislation) the parents or other caretakers or guardians have consented to the treatment and are involved in supporting the adolescent throughout the treatment process,  3. And a pediatric endocrinologist or other clinician experienced in pubertal assessment  •agrees with the indication for GnRH agonist treatment,  •has confirmed that puberty has started in the adolescent (Tanner stage ≥G2/B2),  •has confirmed that there are no medical contraindications to GnRH agonist treatment. Adolescents are eligible for subsequent sex hormone treatment if:  1. A qualified MHP has confirmed:  •the persistence of gender dysphoria,  •any coexisting psychological, medical, or social problems that could interfere with treatment (e.g., that may compromise treatment adherence) have been addressed, such that the adolescent’s situation and functioning are stable enough to start sex hormone treatment,  •the adolescent has sufficient mental capacity (which most adolescents have by age 16 years) to estimate the consequences of this (partly) irreversible treatment, weigh the benefits and risks, and give informed consent to this (partly) irreversible treatment,  2. And the adolescent:  •has been informed of the (irreversible) effects and side effects of treatment (including potential loss of fertility and options to preserve fertility),  •has given informed consent and (particularly when the adolescent has not reached the age of legal medical consent, depending on applicable legislation) the parents or other caretakers or guardians have consented to the treatment and are involved in supporting the adolescent throughout the treatment process,  3. And a pediatric endocrinologist or other clinician experienced in pubertal induction:  •agrees with the indication for sex hormone treatment,  •has confirmed that there are no medical contraindications to sex hormone treatment. Adolescents are eligible for GnRH agonist treatment if:  1. A qualified MHP has confirmed that:  •the adolescent has demonstrated a long-lasting and intense pattern of gender nonconformity or gender dysphoria (whether suppressed or expressed),  •gender dysphoria worsened with the onset of puberty,  •any coexisting psychological, medical, or social problems that could interfere with treatment (e.g., that may compromise treatment adherence) have been addressed, such that the adolescent’s situation and functioning are stable enough to start treatment,  •the adolescent has sufficient mental capacity to give informed consent to this (reversible) treatment,  2. And the adolescent:  •has been informed of the effects and side effects of treatment (including potential loss of fertility if the individual subsequently continues with sex hormone treatment) and options to preserve fertility,  •has given informed consent and (particularly when the adolescent has not reached the age of legal medical consent, depending on applicable legislation) the parents or other caretakers or guardians have consented to the treatment and are involved in supporting the adolescent throughout the treatment process,  3. And a pediatric endocrinologist or other clinician experienced in pubertal assessment  •agrees with the indication for GnRH agonist treatment,  •has confirmed that puberty has started in the adolescent (Tanner stage ≥G2/B2),  •has confirmed that there are no medical contraindications to GnRH agonist treatment. Adolescents are eligible for subsequent sex hormone treatment if:  1. A qualified MHP has confirmed:  •the persistence of gender dysphoria,  •any coexisting psychological, medical, or social problems that could interfere with treatment (e.g., that may compromise treatment adherence) have been addressed, such that the adolescent’s situation and functioning are stable enough to start sex hormone treatment,  •the adolescent has sufficient mental capacity (which most adolescents have by age 16 years) to estimate the consequences of this (partly) irreversible treatment, weigh the benefits and risks, and give informed consent to this (partly) irreversible treatment,  2. And the adolescent:  •has been informed of the (irreversible) effects and side effects of treatment (including potential loss of fertility and options to preserve fertility),  •has given informed consent and (particularly when the adolescent has not reached the age of legal medical consent, depending on applicable legislation) the parents or other caretakers or guardians have consented to the treatment and are involved in supporting the adolescent throughout the treatment process,  3. And a pediatric endocrinologist or other clinician experienced in pubertal induction:  •agrees with the indication for sex hormone treatment,  •has confirmed that there are no medical contraindications to sex hormone treatment. Reproduced from World Professional Association for Transgender Health (16).                    Recommendations for Those Involved in the Gender-Affirming Hormone Treatment of Individuals With GD/Gender Incongruence\n1.1. We advise that only trained MHPs who meet the following criteria should diagnose GD/gender incongruence in adults: (1) competence in using the DSM and/or the ICD for diagnostic purposes, (2) the ability to diagnose GD/gender incongruence and make a distinction between GD/gender incongruence and conditions that have similar features (e.g., body dysmorphic disorder), (3) training in diagnosing psychiatric conditions, (4) the ability to undertake or refer for appropriate treatment, (5) the ability to psychosocially assess the person’s understanding, mental health, and social conditions that can impact gender-affirming hormone therapy, and (6) a practice of regularly attending relevant professional meetings. (Ungraded Good Practice Statement)1.2. We advise that only MHPs who meet the following criteria should diagnose GD/gender incongruence in children and adolescents: (1) training in child and adolescent developmental psychology and psychopathology, (2) competence in using the DSM and/or ICD for diagnostic purposes, (3) the ability to make a distinction between GD/gender incongruence and conditions that have similar features (e.g., body dysmorphic disorder), (4) training in diagnosing psychiatric conditions, (5) the ability to undertake or refer for appropriate treatment, (6) the ability to psychosocially assess the person’s understanding and social conditions that can impact gender-affirming hormone therapy, (7) a practice of regularly attending relevant professional meetings, and (8) knowledge of the criteria for puberty blocking and gender-affirming hormone treatment in adolescents. (Ungraded Good Practice Statement)                    Evidence\nIndividuals with gender identity issues may have psychological or psychiatric problems (43–48, 50, 51, 64, 65). It is therefore necessary that clinicians making the diagnosis are able to make a distinction between GD/gender incongruence and conditions that have similar features. Examples of conditions with similar features are body dysmorphic disorder, body identity integrity disorder (a condition in which individuals have a sense that their anatomical configuration as an able-bodied person is somehow wrong or inappropriate) (66), or certain forms of eunuchism (in which a person is preoccupied with or engages in castration and/or penectomy for reasons that are not gender identity related) (11). Clinicians should also be able to diagnose psychiatric conditions accurately and ensure that these conditions are treated appropriately, particularly when the conditions may complicate treatment, affect the outcome of gender-affirming treatment, or be affected by hormone use.                    Values and preferences\nThe task force placed a very high value on avoiding harm from hormone treatment in individuals who have conditions other than GD/gender incongruence and who may not benefit from the physical changes associated with this treatment and placed a low value on any potential benefit these persons believe they may derive from hormone treatment. This justifies the good practice statement.1.3. We advise that decisions regarding the social transition of prepubertal youths with GD/gender incongruence are made with the assistance of an MHP or another experienced professional. (Ungraded Good Practice Statement).1.4. We recommend against puberty blocking and gender-affirming hormone treatment in prepubertal children with GD/gender incongruence. (1 |⊕⊕○○)                    Evidence\nIn most children diagnosed with GD/gender incongruence, it did not persist into adolescence. The percentages differed among studies, probably dependent on which version of the DSM clinicians used, the patient’s age, the recruitment criteria, and perhaps cultural factors. However, the large majority (about 85%) of prepubertal children with a childhood diagnosis did not remain GD/gender incongruent in adolescence (20). If children have completely socially transitioned, they may have great difficulty in returning to the original gender role upon entering puberty (40). Social transition is associated with the persistence of GD/gender incongruence as a child progresses into adolescence. It may be that the presence of GD/gender incongruence in prepubertal children is the earliest sign that a child is destined to be transgender as an adolescent/adult (20). However, social transition (in addition to GD/gender incongruence) has been found to contribute to the likelihood of persistence.This recommendation, however, does not imply that children should be discouraged from showing gender-variant behaviors or should be punished for exhibiting such behaviors. In individual cases, an early complete social transition may result in a more favorable outcome, but there are currently no criteria to identify the GD/gender-incongruent children to whom this applies. At the present time, clinical experience suggests that persistence of GD/gender incongruence can only be reliably assessed after the first signs of puberty.                    Values and preferences\nThe task force placed a high value on avoiding harm with gender-affirming hormone therapy in prepubertal children with GD/gender incongruence. This justifies the strong recommendation in the face of low-quality evidence.1.5. We recommend that clinicians inform and counsel all individuals seeking gender-affirming medical treatment regarding options for fertility preservation prior to initiating puberty suppression in adolescents and prior to treating with hormonal therapy of the affirmed gender in both adolescents and adults. (1 |⊕⊕⊕○)                    Remarks\nPersons considering hormone use for gender affirmation need adequate information about this treatment in general and about fertility effects of hormone treatment in particular to make an informed and balanced decision (67, 68). Because young adolescents may not feel qualified to make decisions about fertility and may not fully understand the potential effects of hormonal interventions, consent and protocol education should include parents, the referring MHP(s), and other members of the adolescent’s support group. To our knowledge, there are no formally evaluated decision aids available to assist in the discussion and decision regarding the future fertility of adolescents or adults beginning gender-affirming treatment.Treating early pubertal youth with GnRH analogs will temporarily impair spermatogenesis and oocyte maturation. Given that an increasing number of transgender youth want to preserve fertility potential, delaying or temporarily discontinuing GnRH analogs to promote gamete maturation is an option. This option is often not preferred, because mature sperm production is associated with later stages of puberty and with the significant development of secondary sex characteristics.For those designated male at birth with GD/gender incongruence and who are in early puberty, sperm production and the development of the reproductive tract are insufficient for the cryopreservation of sperm. However, prolonged pubertal suppression using GnRH analogs is reversible and clinicians should inform these individuals that sperm production can be initiated following prolonged gonadotropin suppression. This can be accomplished by spontaneous gonadotropin recovery after cessation of GnRH analogs or by gonadotropin treatment and will probably be associated with physical manifestations of testosterone production, as stated above. Note that there are no data in this population concerning the time required for sufficient spermatogenesis to collect enough sperm for later fertility. In males treated for precocious puberty, spermarche was reported 0.7 to 3 years after cessation of GnRH analogs (69). In adult men with gonadotropin deficiency, sperm are noted in seminal fluid by 6 to 12 months of gonadotropin treatment. However, sperm numbers when partners of these patients conceive are far below the “normal range” (70, 71).In girls, no studies have reported long-term, adverse effects of pubertal suppression on ovarian function after treatment cessation (72, 73). Clinicians should inform adolescents that no data are available regarding either time to spontaneous ovulation after cessation of GnRH analogs or the response to ovulation induction following prolonged gonadotropin suppression.In males with GD/gender incongruence, when medical treatment is started in a later phase of puberty or in adulthood, spermatogenesis is sufficient for cryopreservation and storage of sperm. In vitro spermatogenesis is currently under investigation. Restoration of spermatogenesis after prolonged estrogen treatment has not been studied.In females with GD/gender incongruence, the effect of prolonged treatment with exogenous testosterone on ovarian function is uncertain. There have been reports of an increased incidence of polycystic ovaries in transgender males, both prior to and as a result of androgen treatment (74–77), although these reports were not confirmed by others (78). Pregnancy has been reported in transgender males who have had prolonged androgen treatment and have discontinued testosterone but have not had genital surgery (79, 80). A reproductive endocrine gynecologist can counsel patients before gender-affirming hormone treatment or surgery regarding potential fertility options (81). Techniques for cryopreservation of oocytes, embryos, and ovarian tissue continue to improve, and oocyte maturation of immature tissue is being studied (82).                    2.0 Treatment of Adolescents\nDuring the past decade, clinicians have progressively acknowledged the suffering of young adolescents with GD/gender incongruence. In some forms of GD/gender incongruence, psychological interventions may be useful and sufficient. However, for many adolescents with GD/gender incongruence, the pubertal physical changes are unbearable. As early medical intervention may prevent psychological harm, various clinics have decided to start treating young adolescents with GD/gender incongruence with puberty-suppressing medication (a GnRH analog). As compared with starting gender-affirming treatment long after the first phases of puberty, a benefit of pubertal suppression at early puberty may be a better psychological and physical outcome.In girls, the first physical sign of puberty is the budding of the breasts followed by an increase in breast and fat tissue. Breast development is also associated with the pubertal growth spurt, and menarche occurs ∼2 years later. In boys, the first physical change is testicular growth. A testicular volume ≥4 mL is seen as consistent with the initiation of physical puberty. At the beginning of puberty, estradiol and testosterone levels are still low and are best measured in the early morning with an ultrasensitive assay. From a testicular volume of 10 mL, daytime testosterone levels increase, leading to virilization (83). Note that pubic hair and/or axillary hair/odor may not reflect the onset of gonadarche; instead, it may reflect adrenarche alone.2.1. We suggest that adolescents who meet diagnostic criteria for GD/gender incongruence, fulfill criteria for treatment (Table 5), and are requesting treatment should initially undergo treatment to suppress pubertal development. (2 |⊕⊕○○)2.2. We suggest that clinicians begin pubertal hormone suppression after girls and boys first exhibit physical changes of puberty (Tanner stages G2/B2). (2 |⊕⊕○○)                    Evidence\nPubertal suppression can expand the diagnostic phase by a long period, giving the subject more time to explore options and to live in the experienced gender before making a decision to proceed with gender-affirming sex hormone treatments and/or surgery, some of which is irreversible (84, 85). Pubertal suppression is fully reversible, enabling full pubertal development in the natal gender, after cessation of treatment, if appropriate. The experience of full endogenous puberty is an undesirable condition for the GD/gender-incongruent individual and may seriously interfere with healthy psychological functioning and well-being. Treating GD/gender-incongruent adolescents entering puberty with GnRH analogs has been shown to improve psychological functioning in several domains (86).Another reason to start blocking pubertal hormones early in puberty is that the physical outcome is improved compared with initiating physical transition after puberty has been completed (60, 62). Looking like a man or woman when living as the opposite sex creates difficult barriers with enormous life-long disadvantages. We therefore advise starting suppression in early puberty to prevent the irreversible development of undesirable secondary sex characteristics. However, adolescents with GD/gender incongruence should experience the first changes of their endogenous spontaneous puberty, because their emotional reaction to these first physical changes has diagnostic value in establishing the persistence of GD/gender incongruence (85). Thus, Tanner stage 2 is the optimal time to start pubertal suppression. However, pubertal suppression treatment in early puberty will limit the growth of the penis and scrotum, which will have a potential effect on future surgical treatments (87).Clinicians can also use pubertal suppression in adolescents in later pubertal stages to stop menses in transgender males and prevent facial hair growth in transgender females. However, in contrast to the effects in early pubertal adolescents, physical sex characteristics (such as more advanced breast development in transgender boys and lowering of the voice and outgrowth of the jaw and brow in transgender girls) are not reversible.                    Values and preferences\nThese recommendations place a high value on avoiding an unsatisfactory physical outcome when secondary sex characteristics have become manifest and irreversible, a higher value on psychological well-being, and a lower value on avoiding potential harm from early pubertal suppression.                    Remarks\nTable 6 lists the Tanner stages of breast and male genital development. Careful documentation of hallmarks of pubertal development will ensure precise timing when initiating pubertal suppression once puberty has started. Clinicians can use pubertal LH and sex steroid levels to confirm that puberty has progressed sufficiently before starting pubertal suppression (88). Reference ranges for sex steroids by Tanner stage may vary depending on the assay used. Ultrasensitive sex steroid and gonadotropin assays will help clinicians document early pubertal changes.                    Table 6.Tanner Stages of Breast Development and Male External Genitalia The description of Tanner stages for breast development:  1. Prepubertal  2. Breast and papilla elevated as small mound; areolar diameter increased  3. Breast and areola enlarged, no contour separation  4. Areola and papilla form secondary mound  5. Mature; nipple projects, areola part of general breast contour For penis and testes:  1. Prepubertal, testicular volume <4 mL  2. Slight enlargement of penis; enlarged scrotum, pink, texture altered, testes 4–6 mL  3. Penis longer, testes larger (8–12 mL)  4. Penis and glans larger, including increase in breadth; testes larger (12–15 mL), scrotum dark  5. Penis adult size; testicular volume > 15 ml The description of Tanner stages for breast development:  1. Prepubertal  2. Breast and papilla elevated as small mound; areolar diameter increased  3. Breast and areola enlarged, no contour separation  4. Areola and papilla form secondary mound  5. Mature; nipple projects, areola part of general breast contour For penis and testes:  1. Prepubertal, testicular volume <4 mL  2. Slight enlargement of penis; enlarged scrotum, pink, texture altered, testes 4–6 mL  3. Penis longer, testes larger (8–12 mL)  4. Penis and glans larger, including increase in breadth; testes larger (12–15 mL), scrotum dark  5. Penis adult size; testicular volume > 15 ml Adapted from Lawrence (56).Table 6.Tanner Stages of Breast Development and Male External Genitalia The description of Tanner stages for breast development:  1. Prepubertal  2. Breast and papilla elevated as small mound; areolar diameter increased  3. Breast and areola enlarged, no contour separation  4. Areola and papilla form secondary mound  5. Mature; nipple projects, areola part of general breast contour For penis and testes:  1. Prepubertal, testicular volume <4 mL  2. Slight enlargement of penis; enlarged scrotum, pink, texture altered, testes 4–6 mL  3. Penis longer, testes larger (8–12 mL)  4. Penis and glans larger, including increase in breadth; testes larger (12–15 mL), scrotum dark  5. Penis adult size; testicular volume > 15 ml The description of Tanner stages for breast development:  1. Prepubertal  2. Breast and papilla elevated as small mound; areolar diameter increased  3. Breast and areola enlarged, no contour separation  4. Areola and papilla form secondary mound  5. Mature; nipple projects, areola part of general breast contour For penis and testes:  1. Prepubertal, testicular volume <4 mL  2. Slight enlargement of penis; enlarged scrotum, pink, texture altered, testes 4–6 mL  3. Penis longer, testes larger (8–12 mL)  4. Penis and glans larger, including increase in breadth; testes larger (12–15 mL), scrotum dark  5. Penis adult size; testicular volume > 15 ml Adapted from Lawrence (56).Irreversible and, for GD/gender-incongruent adolescents, undesirable sex characteristics in female puberty are breasts, female body habitus, and, in some cases, relative short stature. In male puberty, they are a prominent Adam’s apple; low voice; male bone configuration, such as a large jaw, big feet and hands, and tall stature; and male hair pattern on the face and extremities.2.3. We recommend that, where indicated, GnRH analogues are used to suppress pubertal hormones. (1 |⊕⊕○○)                    Evidence\nClinicians can suppress pubertal development and gonadal function most effectively via gonadotropin suppression using GnRH analogs. GnRH analogs are long-acting agonists that suppress gonadotropins by GnRH receptor desensitization after an initial increase of gonadotropins during ∼10 days after the first and (to a lesser degree) the second injection (89). Antagonists immediately suppress pituitary gonadotropin secretion (90, 91). Long-acting GnRH analogs are the currently preferred treatment option. Clinicians may consider long-acting GnRH antagonists when evidence on their safety and efficacy in adolescents becomes available.During GnRH analog treatment, slight development of secondary sex characteristics may regress, and in a later phase of pubertal development, it will stop. In girls, breast tissue will become atrophic, and menses will stop. In boys, virilization will stop, and testicular volume may decrease (92).An advantage of using GnRH analogs is the reversibility of the intervention. If, after extensive exploration of his/her transition wish, the individual no longer desires transition, they can discontinue pubertal suppression. In subjects with precocious puberty, spontaneous pubertal development has been shown to resume after patients discontinue taking GnRH analogs (93).Recommendations 2.1 to 2.3 are supported by a prospective follow-up study from The Netherlands. This report assessed mental health outcomes in 55 transgender adolescents/young adults (22 transgender females and 33 transgender males) at three time points: (1) before the start of GnRH agonist (average age of 14.8 years at start of treatment), (2) at initiation of gender-affirming hormones (average age of 16.7 years at start of treatment), and (3) 1 year after “gender-reassignment surgery” (average age of 20.7 years) (63). Despite a decrease in depression and an improvement in general mental health functioning, GD/gender incongruence persisted through pubertal suppression, as previously reported (86). However, following sex hormone treatment and gender-reassignment surgery, GD/gender incongruence was resolved and psychological functioning steadily improved (63). Furthermore, well-being was similar to or better than that reported by age-matched young adults from the general population, and none of the study participants regretted treatment. This study represents the first long-term follow-up of individuals managed according to currently existing clinical practice guidelines for transgender youth, and it underscores the benefit of the multidisciplinary approach pioneered in The Netherlands; however, further studies are needed.                    Side effects\nThe primary risks of pubertal suppression in GD/gender-incongruent adolescents may include adverse effects on bone mineralization (which can theoretically be reversed with sex hormone treatment), compromised fertility if the person subsequently is treated with sex hormones, and unknown effects on brain development. Few data are available on the effect of GnRH analogs on BMD in adolescents with GD/gender incongruence. Initial data in GD/gender-incongruent subjects demonstrated no change of absolute areal BMD during 2 years of GnRH analog therapy but a decrease in BMD z scores (85). A recent study also suggested suboptimal bone mineral accrual during GnRH analog treatment. The study reported a decrease in areal BMD z scores and of bone mineral apparent density z scores (which takes the size of the bone into account) in 19 transgender males treated with GnRH analogs from a mean age of 15.0 years (standard deviation = 2.0 years) for a median duration of 1.5 years (0.3 to 5.2 years) and in 15 transgender females treated from 14.9 (±1.9) years for 1.3 years (0.5 to 3.8 years), although not all changes were statistically significant (94). There was incomplete catch-up at age 22 years after sex hormone treatment from age 16.6 (±1.4) years for a median duration of 5.8 years (3.0 to 8.0 years) in transgender females and from age 16.4 (±2.3) years for 5.4 years (2.8 to 7.8 years) in transgender males. Little is known about more prolonged use of GnRH analogs. Researchers reported normal BMD z scores at age 35 years in one individual who used GnRH analogs from age 13.7 years until age 18.6 years before initiating sex hormone treatment (65).Additional data are available from individuals with late puberty or GnRH analog treatment of other indications. Some studies reported that men with constitutionally delayed puberty have decreased BMD in adulthood (95). However, other studies reported that these men have normal BMD (96, 97). Treating adults with GnRH analogs results in a decrease of BMD (98). In children with central precocious puberty, treatment with GnRH analogs has been found to result in a decrease of BMD during treatment by some (99) but not others (100). Studies have reported normal BMD after discontinuing therapy (69, 72, 73, 101, 102). In adolescents treated with growth hormone who are small for gestational age and have normal pubertal timing, 2-year GnRH analog treatments did not adversely affect BMD (103). Calcium supplementation may be beneficial in optimizing bone health in GnRH analog–treated individuals (104). There are no studies of vitamin D supplementation in this context, but clinicians should offer supplements to vitamin D–deficient adolescents. Physical activity, especially during growth, is important for bone mass in healthy individuals (103) and is therefore likely to be beneficial for bone health in GnRH analog–treated subjects.GnRH analogs did not induce a change in body mass index standard deviation score in GD/gender-incongruent adolescents (94) but caused an increase in fat mass and decrease in lean body mass percentage (92). Studies in girls treated for precocious puberty also reported a stable body mass index standard deviation score during treatment (72) and body mass index and body composition comparable to controls after treatment (73).Arterial hypertension has been reported as an adverse effect in a few girls treated with GnRH analogs for precocious/early puberty (105, 106). Blood pressure monitoring before and during treatment is recommended.Individuals may also experience hot flashes, fatigue, and mood alterations as a consequence of pubertal suppression. There is no consensus on treatment of these side effects in this context.It is recommended that any use of pubertal blockers (and subsequent use of sex hormones, as detailed below) include a discussion about implications for fertility (see recommendation 1.3). Transgender adolescents may want to preserve fertility, which may be otherwise compromised if puberty is suppressed at an early stage and the individual completes phenotypic transition with the use of sex hormones.Limited data are available regarding the effects of GnRH analogs on brain development. A single cross-sectional study demonstrated no compromise of executive function (107), but animal data suggest there may be an effect of GnRH analogs on cognitive function (108).                    Values and preferences\nOur recommendation of GnRH analogs places a higher value on the superior efficacy, safety, and reversibility of the pubertal hormone suppression achieved (as compared with the alternatives) and a relatively lower value on limiting the cost of therapy. Of the available alternatives, depot and oral progestin preparations are effective. Experience with this treatment dates back prior to the emergence of GnRH analogs for treating precocious puberty in papers from the 1960s and early 1970s (109–112). These compounds are usually safe, but some side effects have been reported (113–115). Only two recent studies involved transgender youth (116, 117). One of these studies described the use of oral lynestrenol monotherapy followed by the addition of testosterone treatment in transgender boys who were at Tanner stage B4 or further at the start of treatment (117). They found lynestrenol safe, but gonadotropins were not fully suppressed. The study reported metrorrhagia in approximately half of the individuals, mainly in the first 6 months. Acne, headache, hot flashes, and fatigue were other frequent side effects. Another progestin that has been studied in the United States is medroxyprogesterone. This agent is not as effective as GnRH analogs in lowering endogenous sex hormones either and may be associated with other side effects (116). Progestin preparations may be an acceptable treatment for persons without access to GnRH analogs or with a needle phobia. If GnRH analog treatment is not available (insurance denial, prohibitive cost, or other reasons), postpubertal, transgender female adolescents may be treated with an antiandrogen that directly suppresses androgen synthesis or action (see adult section).                    Remarks\nMeasurements of gonadotropin and sex steroid levels give precise information about gonadal axis suppression, although there is insufficient evidence for any specific short-term monitoring scheme in children treated with GnRH analogs (88). If the gonadal axis is not completely suppressed—as evidenced by (for example) menses, erections, or progressive hair growth—the interval of GnRH analog treatment can be shortened or the dose increased. During treatment, adolescents should be monitored for negative effects of delaying puberty, including a halted growth spurt and impaired bone mineral accretion. Table 7 illustrates a suggested clinical protocol.                    Table 7.Baseline and Follow-Up Protocol During Suppression of Puberty Every 3–6 mo  Anthropometry: height, weight, sitting height, blood pressure, Tanner stages Every 6–12 mo  Laboratory: LH, FSH, E2/T, 25OH vitamin D Every 1–2 y  Bone density using DXA  Bone age on X-ray of the left hand (if clinically indicated) Every 3–6 mo  Anthropometry: height, weight, sitting height, blood pressure, Tanner stages Every 6–12 mo  Laboratory: LH, FSH, E2/T, 25OH vitamin D Every 1–2 y  Bone density using DXA  Bone age on X-ray of the left hand (if clinically indicated) Adapted from Hembree et al. (118).Abbreviations: DXA, dual-energy X-ray absorptiometry; E2, estradiol; FSH, follicle stimulating hormone; LH, luteinizing hormone; T, testosterone; Table 7.Baseline and Follow-Up Protocol During Suppression of Puberty Every 3–6 mo  Anthropometry: height, weight, sitting height, blood pressure, Tanner stages Every 6–12 mo  Laboratory: LH, FSH, E2/T, 25OH vitamin D Every 1–2 y  Bone density using DXA  Bone age on X-ray of the left hand (if clinically indicated) Every 3–6 mo  Anthropometry: height, weight, sitting height, blood pressure, Tanner stages Every 6–12 mo  Laboratory: LH, FSH, E2/T, 25OH vitamin D Every 1–2 y  Bone density using DXA  Bone age on X-ray of the left hand (if clinically indicated) Adapted from Hembree et al. (118).Abbreviations: DXA, dual-energy X-ray absorptiometry; E2, estradiol; FSH, follicle stimulating hormone; LH, luteinizing hormone; T, testosterone; Anthropometric measurements and X-rays of the left hand to monitor bone age are informative for evaluating growth. To assess BMD, clinicians can perform dual-energy X-ray absorptiometry scans.2.4. In adolescents who request sex hormone treatment (given this is a partly irreversible treatment), we recommend initiating treatment using a gradually increasing dose schedule (see Table 8)after a multidisciplinary team of medical and MHPs has confirmed the persistence of GD/gender incongruence and sufficient mental capacity to give informed consent, which most adolescents have by age 16 years (Table 5). (1 |⊕⊕○○)Table 8.Protocol Induction of Puberty Induction of female puberty with oral 17β-estradiol, increasing the dose every 6 mo:  5 μg/kg/d  10 μg/kg/d  15 μg/kg/d  20 μg/kg/d  Adult dose = 2–6 mg/d  In postpubertal transgender female adolescents, the dose of 17β-estradiol can be increased more rapidly:   1 mg/d for 6 mo   2 mg/d Induction of female puberty with transdermal 17β-estradiol, increasing the dose every 6 mo (new patch is placed every 3.5 d):  6.25–12.5 μg/24 h (cut 25-μg patch into quarters, then halves)  25 μg/24 h  37.5 μg/24 h  Adult dose = 50–200 μg/24 h  For alternatives once at adult dose, see Table 11.  Adjust maintenance dose to mimic physiological estradiol levels (see Table 15).  Induction of male puberty with testosterone esters increasing the dose every 6 mo (IM or SC):  25 mg/m2/2 wk (or alternatively, half this dose weekly, or double the dose every 4 wk)  50 mg/m2/2 wk  75 mg/m2/2 wk  100 mg/m2/2 wk  Adult dose = 100–200 mg every 2 wk  In postpubertal transgender male adolescents the dose of testosterone esters can be increased more rapidly:   75 mg/2 wk for 6 mo   125 mg/2 wk  For alternatives once at adult dose, see Table 11.  Adjust maintenance dose to mimic physiological testosterone levels (see Table 14). Induction of female puberty with oral 17β-estradiol, increasing the dose every 6 mo:  5 μg/kg/d  10 μg/kg/d  15 μg/kg/d  20 μg/kg/d  Adult dose = 2–6 mg/d  In postpubertal transgender female adolescents, the dose of 17β-estradiol can be increased more rapidly:   1 mg/d for 6 mo   2 mg/d Induction of female puberty with transdermal 17β-estradiol, increasing the dose every 6 mo (new patch is placed every 3.5 d):  6.25–12.5 μg/24 h (cut 25-μg patch into quarters, then halves)  25 μg/24 h  37.5 μg/24 h  Adult dose = 50–200 μg/24 h  For alternatives once at adult dose, see Table 11.  Adjust maintenance dose to mimic physiological estradiol levels (see Table 15).  Induction of male puberty with testosterone esters increasing the dose every 6 mo (IM or SC):  25 mg/m2/2 wk (or alternatively, half this dose weekly, or double the dose every 4 wk)  50 mg/m2/2 wk  75 mg/m2/2 wk  100 mg/m2/2 wk  Adult dose = 100–200 mg every 2 wk  In postpubertal transgender male adolescents the dose of testosterone esters can be increased more rapidly:   75 mg/2 wk for 6 mo   125 mg/2 wk  For alternatives once at adult dose, see Table 11.  Adjust maintenance dose to mimic physiological testosterone levels (see Table 14). Adapted from Hembree et al. (118).Abbreviations: IM, intramuscularly; SC, subcutaneously.Table 8.Protocol Induction of Puberty Induction of female puberty with oral 17β-estradiol, increasing the dose every 6 mo:  5 μg/kg/d  10 μg/kg/d  15 μg/kg/d  20 μg/kg/d  Adult dose = 2–6 mg/d  In postpubertal transgender female adolescents, the dose of 17β-estradiol can be increased more rapidly:   1 mg/d for 6 mo   2 mg/d Induction of female puberty with transdermal 17β-estradiol, increasing the dose every 6 mo (new patch is placed every 3.5 d):  6.25–12.5 μg/24 h (cut 25-μg patch into quarters, then halves)  25 μg/24 h  37.5 μg/24 h  Adult dose = 50–200 μg/24 h  For alternatives once at adult dose, see Table 11.  Adjust maintenance dose to mimic physiological estradiol levels (see Table 15).  Induction of male puberty with testosterone esters increasing the dose every 6 mo (IM or SC):  25 mg/m2/2 wk (or alternatively, half this dose weekly, or double the dose every 4 wk)  50 mg/m2/2 wk  75 mg/m2/2 wk  100 mg/m2/2 wk  Adult dose = 100–200 mg every 2 wk  In postpubertal transgender male adolescents the dose of testosterone esters can be increased more rapidly:   75 mg/2 wk for 6 mo   125 mg/2 wk  For alternatives once at adult dose, see Table 11.  Adjust maintenance dose to mimic physiological testosterone levels (see Table 14). Induction of female puberty with oral 17β-estradiol, increasing the dose every 6 mo:  5 μg/kg/d  10 μg/kg/d  15 μg/kg/d  20 μg/kg/d  Adult dose = 2–6 mg/d  In postpubertal transgender female adolescents, the dose of 17β-estradiol can be increased more rapidly:   1 mg/d for 6 mo   2 mg/d Induction of female puberty with transdermal 17β-estradiol, increasing the dose every 6 mo (new patch is placed every 3.5 d):  6.25–12.5 μg/24 h (cut 25-μg patch into quarters, then halves)  25 μg/24 h  37.5 μg/24 h  Adult dose = 50–200 μg/24 h  For alternatives once at adult dose, see Table 11.  Adjust maintenance dose to mimic physiological estradiol levels (see Table 15).  Induction of male puberty with testosterone esters increasing the dose every 6 mo (IM or SC):  25 mg/m2/2 wk (or alternatively, half this dose weekly, or double the dose every 4 wk)  50 mg/m2/2 wk  75 mg/m2/2 wk  100 mg/m2/2 wk  Adult dose = 100–200 mg every 2 wk  In postpubertal transgender male adolescents the dose of testosterone esters can be increased more rapidly:   75 mg/2 wk for 6 mo   125 mg/2 wk  For alternatives once at adult dose, see Table 11.  Adjust maintenance dose to mimic physiological testosterone levels (see Table 14). Adapted from Hembree et al. (118).Abbreviations: IM, intramuscularly; SC, subcutaneously.2.5. We recognize that there may be compelling reasons to initiate sex hormone treatment prior to the age of 16 years in some adolescents with GD/gender incongruence, even though there are minimal published studies of gender-affirming hormone treatments administered before age 13.5 to 14 years. As with the care of adolescents ≥16 years of age, we recommend that an expert multidisciplinary team of medical and MHPs manage this treatment. (1 |⊕○○○)2.6. We suggest monitoring clinical pubertal development every 3 to 6 months and laboratory parameters every 6 to 12 months during sex hormone treatment (Table 9). (2 |⊕⊕○○)Table 9.Baseline and Follow-up Protocol During Induction of Puberty Every 3–6 mo  •Anthropometry: height, weight, sitting height, blood pressure, Tanner stages Every 6–12 mo  •In transgender males: hemoglobin/hematocrit, lipids, testosterone, 25OH vitamin D  •In transgender females: prolactin, estradiol, 25OH vitamin D Every 1–2 y  •BMD using DXA  •Bone age on X-ray of the left hand (if clinically indicated) BMD should be monitored into adulthood (until the age of 25–30 y or until peak bone mass has been reached). For recommendations on monitoring once pubertal induction has been completed, see Tables 14 and 15. Every 3–6 mo  •Anthropometry: height, weight, sitting height, blood pressure, Tanner stages Every 6–12 mo  •In transgender males: hemoglobin/hematocrit, lipids, testosterone, 25OH vitamin D  •In transgender females: prolactin, estradiol, 25OH vitamin D Every 1–2 y  •BMD using DXA  •Bone age on X-ray of the left hand (if clinically indicated) BMD should be monitored into adulthood (until the age of 25–30 y or until peak bone mass has been reached). For recommendations on monitoring once pubertal induction has been completed, see Tables 14 and 15. Adapted from Hembree et al. (118).Abbreviation: DXA, dual-energy X-ray absorptiometry.Table 9.Baseline and Follow-up Protocol During Induction of Puberty Every 3–6 mo  •Anthropometry: height, weight, sitting height, blood pressure, Tanner stages Every 6–12 mo  •In transgender males: hemoglobin/hematocrit, lipids, testosterone, 25OH vitamin D  •In transgender females: prolactin, estradiol, 25OH vitamin D Every 1–2 y  •BMD using DXA  •Bone age on X-ray of the left hand (if clinically indicated) BMD should be monitored into adulthood (until the age of 25–30 y or until peak bone mass has been reached). For recommendations on monitoring once pubertal induction has been completed, see Tables 14 and 15. Every 3–6 mo  •Anthropometry: height, weight, sitting height, blood pressure, Tanner stages Every 6–12 mo  •In transgender males: hemoglobin/hematocrit, lipids, testosterone, 25OH vitamin D  •In transgender females: prolactin, estradiol, 25OH vitamin D Every 1–2 y  •BMD using DXA  •Bone age on X-ray of the left hand (if clinically indicated) BMD should be monitored into adulthood (until the age of 25–30 y or until peak bone mass has been reached). For recommendations on monitoring once pubertal induction has been completed, see Tables 14 and 15. Adapted from Hembree et al. (118).Abbreviation: DXA, dual-energy X-ray absorptiometry.                    Evidence\nAdolescents develop competence in decision making at their own pace. Ideally, the supervising medical professionals should individually assess this competence, although no objective tools to make such an assessment are currently available.Many adolescents have achieved a reasonable level of competence by age 15 to 16 years (119), and in many countries 16-year-olds are legally competent with regard to medical decision making (120). However, others believe that although some capacities are generally achieved before age 16 years, other abilities (such as good risk assessment) do not develop until well after 18 years (121). They suggest that health care procedures should be divided along a matrix of relative risk, so that younger adolescents can be allowed to decide about low-risk procedures, such as most diagnostic tests and common therapies, but not about high-risk procedures, such as most surgical procedures (121).Currently available data from transgender adolescents support treatment with sex hormones starting at age 16 years (63, 122). However, some patients may incur potential risks by waiting until age 16 years. These include the potential risk to bone health if puberty is suppressed for 6 to 7 years before initiating sex hormones (e.g., if someone reached Tanner stage 2 at age 9-10 years old). Additionally, there may be concerns about inappropriate height and potential harm to mental health (emotional and social isolation) if initiation of secondary sex characteristics must wait until the person has reached 16 years of age. However, only minimal data supporting earlier use of gender-affirming hormones in transgender adolescents currently exist (63). Clearly, long-term studies are needed to determine the optimal age of sex hormone treatment in GD/gender-incongruent adolescents.The MHP who has followed the adolescent during GnRH analog treatment plays an essential role in assessing whether the adolescent is eligible to start sex hormone therapy and capable of consenting to this treatment (Table 5). Support of the family/environment is essential. Prior to the start of sex hormones, clinicians should discuss the implications for fertility (see recommendation 1.5). Throughout pubertal induction, an MHP and a pediatric endocrinologist (or other clinician competent in the evaluation and induction of pubertal development) should monitor the adolescent. In addition to monitoring therapy, it is also important to pay attention to general adolescent health issues, including healthy life style choices, such as not smoking, contraception, and appropriate vaccinations (e.g., human papillomavirus).For the induction of puberty, clinicians can use a similar dose scheme for hypogonadal adolescents with GD/gender incongruence as they use in other individuals with hypogonadism, carefully monitoring for desired and undesired effects (Table 8). In transgender female adolescents, transdermal 17β-estradiol may be an alternative for oral 17β-estradiol. It is increasingly used for pubertal induction in hypogonadal females. However, the absence of low-dose estrogen patches may be a problem. As a result, individuals may need to cut patches to size themselves to achieve appropriate dosing (123). In transgender male adolescents, clinicians can give testosterone injections intramuscularly or subcutaneously (124, 125).When puberty is initiated with a gradually increasing schedule of sex steroid doses, the initial levels will not be high enough to suppress endogenous sex steroid secretion. Gonadotropin secretion and endogenous production of testosterone may resume and interfere with the effectiveness of estrogen treatment, in transgender female adolescents (126, 127). Therefore, continuation of GnRH analog treatment is advised until gonadectomy. Given that GD/gender-incongruent adolescents may opt not to have gonadectomy, long-term studies are necessary to examine the potential risks of prolonged GnRH analog treatment. Alternatively, in transgender male adolescents, GnRH analog treatment can be discontinued once an adult dose of testosterone has been reached and the individual is well virilized. If uterine bleeding occurs, a progestin can be added. However, the combined use of a GnRH analog (for ovarian suppression) and testosterone may enable phenotypic transition with a lower dose of testosterone in comparison with testosterone alone. If there is a wish or need to discontinue GnRH analog treatment in transgender female adolescents, they may be treated with an antiandrogen that directly suppresses androgen synthesis or action (see section 3.0 “Hormonal Therapy for Transgender Adults”).                    Values and preferences\nThe recommendation to initiate pubertal induction only when the individual has sufficient mental capacity (roughly age 16 years) to give informed consent for this partly irreversible treatment places a higher value on the ability of the adolescent to fully understand and oversee the partially irreversible consequences of sex hormone treatment and to give informed consent. It places a lower value on the possible negative effects of delayed puberty. We may not currently have the means to weigh adequately the potential benefits of waiting until around age 16 years to initiate sex hormones vs the potential risks/harm to BMD and the sense of social isolation from having the timing of puberty be so out of sync with peers (128).                    Remarks\nBefore starting sex hormone treatment, effects on fertility and options for fertility preservation should be discussed. Adult height may be a concern in transgender adolescents. In a transgender female adolescent, clinicians may consider higher doses of estrogen or a more rapid tempo of dose escalation during pubertal induction. There are no established treatments yet to augment adult height in a transgender male adolescent with open epiphyses during pubertal induction. It is not uncommon for transgender adolescents to present for clinical services after having completed or nearly completed puberty. In such cases, induction of puberty with sex hormones can be done more rapidly (see Table 8). Additionally, an adult dose of testosterone in transgender male adolescents may suffice to suppress the gonadal axis without the need to use a separate agent. At the appropriate time, the multidisciplinary team should adequately prepare the adolescent for transition to adult care.                    3.0 Hormonal Therapy for Transgender Adults\nThe two major goals of hormonal therapy are (1) to reduce endogenous sex hormone levels, and thus reduce the secondary sex characteristics of the individual’s designated gender, and (2) to replace endogenous sex hormone levels consistent with the individual’s gender identity by using the principles of hormone replacement treatment of hypogonadal patients. The timing of these two goals and the age at which to begin treatment with the sex hormones of the chosen gender is codetermined in collaboration with both the person pursuing transition and the health care providers. The treatment team should include a medical provider knowledgeable in transgender hormone therapy, an MHP knowledgeable in GD/gender incongruence and the mental health concerns of transition, and a primary care provider able to provide care appropriate for transgender individuals. The physical changes induced by this sex hormone transition are usually accompanied by an improvement in mental well-being (129, 130).3.1. We recommend that clinicians confirm the diagnostic criteria of GD/gender incongruence and the criteria for the endocrine phase of gender transition before beginning treatment. (1 |⊕⊕⊕○)3.2. We recommend that clinicians evaluate and address medical conditions that can be exacerbated by hormone depletion and treatment with sex hormones of the affirmed gender before beginning treatment (Table 10). (1 |⊕⊕⊕○)Table 10.Medical Risks Associated With Sex Hormone Therapy Transgender female: estrogen  Very high risk of adverse outcomes:   •Thromboembolic disease  Moderate risk of adverse outcomes:   •Macroprolactinoma   •Breast cancer   •Coronary artery disease   •Cerebrovascular disease   •Cholelithiasis   •Hypertriglyceridemia  Transgender male: testosterone  Very high risk of adverse outcomes:   •Erythrocytosis (hematocrit > 50%)  Moderate risk of adverse outcomes:   •Severe liver dysfunction (transaminases > threefold upper limit of normal)   •Coronary artery disease   •Cerebrovascular disease   •Hypertension   •Breast or uterine cancer Transgender female: estrogen  Very high risk of adverse outcomes:   •Thromboembolic disease  Moderate risk of adverse outcomes:   •Macroprolactinoma   •Breast cancer   •Coronary artery disease   •Cerebrovascular disease   •Cholelithiasis   •Hypertriglyceridemia  Transgender male: testosterone  Very high risk of adverse outcomes:   •Erythrocytosis (hematocrit > 50%)  Moderate risk of adverse outcomes:   •Severe liver dysfunction (transaminases > threefold upper limit of normal)   •Coronary artery disease   •Cerebrovascular disease   •Hypertension   •Breast or uterine cancer Table 10.Medical Risks Associated With Sex Hormone Therapy Transgender female: estrogen  Very high risk of adverse outcomes:   •Thromboembolic disease  Moderate risk of adverse outcomes:   •Macroprolactinoma   •Breast cancer   •Coronary artery disease   •Cerebrovascular disease   •Cholelithiasis   •Hypertriglyceridemia  Transgender male: testosterone  Very high risk of adverse outcomes:   •Erythrocytosis (hematocrit > 50%)  Moderate risk of adverse outcomes:   •Severe liver dysfunction (transaminases > threefold upper limit of normal)   •Coronary artery disease   •Cerebrovascular disease   •Hypertension   •Breast or uterine cancer Transgender female: estrogen  Very high risk of adverse outcomes:   •Thromboembolic disease  Moderate risk of adverse outcomes:   •Macroprolactinoma   •Breast cancer   •Coronary artery disease   •Cerebrovascular disease   •Cholelithiasis   •Hypertriglyceridemia  Transgender male: testosterone  Very high risk of adverse outcomes:   •Erythrocytosis (hematocrit > 50%)  Moderate risk of adverse outcomes:   •Severe liver dysfunction (transaminases > threefold upper limit of normal)   •Coronary artery disease   •Cerebrovascular disease   •Hypertension   •Breast or uterine cancer 3.3. We suggest that clinicians measure hormone levels during treatment to ensure that endogenous sex steroids are suppressed and administered sex steroids are maintained in the normal physiologic range for the affirmed gender. (2 |⊕⊕○○)                    Evidence\nIt is the responsibility of the treating clinician to confirm that the person fulfills criteria for treatment. The treating clinician should become familiar with the terms and criteria presented in Tables 1–5 and take a thorough history from the patient in collaboration with the other members of the treatment team. The treating clinician must ensure that the desire for transition is appropriate; the consequences, risks, and benefits of treatment are well understood; and the desire for transition persists. They also need to discuss fertility preservation options (see recommendation 1.3) (67, 68).                    Transgender males\nClinical studies have demonstrated the efficacy of several different androgen preparations to induce masculinization in transgender males (Appendix A) (113, 114, 131–134). Regimens to change secondary sex characteristics follow the general principle of hormone replacement treatment of male hypogonadism (135). Clinicians can use either parenteral or transdermal preparations to achieve testosterone values in the normal male range (this is dependent on the specific assay, but is typically 320 to 1000 ng/dL) (Table 11) (136). Sustained supraphysiologic levels of testosterone increase the risk of adverse reactions (see section 4.0 “Adverse Outcome Prevention and Long-Term Care”) and should be avoided.                    Table 11.Hormone Regimens in Transgender Persons Transgender femalesa   Estrogen    Oral     Estradiol 2.0–6.0 mg/d   Transdermal     Estradiol transdermal patch 0.025–0.2 mg/d    (New patch placed every 3–5 d)    Parenteral     Estradiol valerate or cypionate 5–30 mg IM every 2 wk  2–10 mg IM every week  Anti-androgens    Spironolactone 100–300 mg/d   Cyproterone acetateb 25–50 mg/d  GnRH agonist 3.75 mg SQ (SC) monthly 11.25 mg SQ (SC) 3-monthly Transgender males   Testosterone    Parenteral testosterone     Testosterone enanthate or cypionate 100–200 mg SQ (IM) every 2 wk or SQ (SC) 50% per week    Testosterone undecanoatec 1000 mg every 12 wk   Transdermal testosterone     Testosterone gel 1.6%d 50–100 mg/d    Testosterone transdermal patch 2.5–7.5 mg/d Transgender femalesa   Estrogen    Oral     Estradiol 2.0–6.0 mg/d   Transdermal     Estradiol transdermal patch 0.025–0.2 mg/d    (New patch placed every 3–5 d)    Parenteral     Estradiol valerate or cypionate 5–30 mg IM every 2 wk  2–10 mg IM every week  Anti-androgens    Spironolactone 100–300 mg/d   Cyproterone acetateb 25–50 mg/d  GnRH agonist 3.75 mg SQ (SC) monthly 11.25 mg SQ (SC) 3-monthly Transgender males   Testosterone    Parenteral testosterone     Testosterone enanthate or cypionate 100–200 mg SQ (IM) every 2 wk or SQ (SC) 50% per week    Testosterone undecanoatec 1000 mg every 12 wk   Transdermal testosterone     Testosterone gel 1.6%d 50–100 mg/d    Testosterone transdermal patch 2.5–7.5 mg/d Abbreviations: IM, intramuscularly; SQ, sequentially; SC, subcutaneously.aEstrogens used with or without antiandrogens or GnRH agonist.bNot available in the United States.cOne thousand milligrams initially followed by an injection at 6 wk then at 12-wk intervals.dAvoid cutaneous transfer to other individuals.Table 11.Hormone Regimens in Transgender Persons Transgender femalesa   Estrogen    Oral     Estradiol 2.0–6.0 mg/d   Transdermal     Estradiol transdermal patch 0.025–0.2 mg/d    (New patch placed every 3–5 d)    Parenteral     Estradiol valerate or cypionate 5–30 mg IM every 2 wk  2–10 mg IM every week  Anti-androgens    Spironolactone 100–300 mg/d   Cyproterone acetateb 25–50 mg/d  GnRH agonist 3.75 mg SQ (SC) monthly 11.25 mg SQ (SC) 3-monthly Transgender males   Testosterone    Parenteral testosterone     Testosterone enanthate or cypionate 100–200 mg SQ (IM) every 2 wk or SQ (SC) 50% per week    Testosterone undecanoatec 1000 mg every 12 wk   Transdermal testosterone     Testosterone gel 1.6%d 50–100 mg/d    Testosterone transdermal patch 2.5–7.5 mg/d Transgender femalesa   Estrogen    Oral     Estradiol 2.0–6.0 mg/d   Transdermal     Estradiol transdermal patch 0.025–0.2 mg/d    (New patch placed every 3–5 d)    Parenteral     Estradiol valerate or cypionate 5–30 mg IM every 2 wk  2–10 mg IM every week  Anti-androgens    Spironolactone 100–300 mg/d   Cyproterone acetateb 25–50 mg/d  GnRH agonist 3.75 mg SQ (SC) monthly 11.25 mg SQ (SC) 3-monthly Transgender males   Testosterone    Parenteral testosterone     Testosterone enanthate or cypionate 100–200 mg SQ (IM) every 2 wk or SQ (SC) 50% per week    Testosterone undecanoatec 1000 mg every 12 wk   Transdermal testosterone     Testosterone gel 1.6%d 50–100 mg/d    Testosterone transdermal patch 2.5–7.5 mg/d Abbreviations: IM, intramuscularly; SQ, sequentially; SC, subcutaneously.aEstrogens used with or without antiandrogens or GnRH agonist.bNot available in the United States.cOne thousand milligrams initially followed by an injection at 6 wk then at 12-wk intervals.dAvoid cutaneous transfer to other individuals.Similar to androgen therapy in hypogonadal men, testosterone treatment in transgender males results in increased muscle mass and decreased fat mass, increased facial hair and acne, male pattern baldness in those genetically predisposed, and increased sexual desire (137).In transgender males, testosterone will result in clitoromegaly, temporary or permanent decreased fertility, deepening of the voice, cessation of menses (usually), and a significant increase in body hair, particularly on the face, chest, and abdomen. Cessation of menses may occur within a few months with testosterone treatment alone, although high doses of testosterone may be required. If uterine bleeding continues, clinicians may consider the addition of a progestational agent or endometrial ablation (138). Clinicians may also administer GnRH analogs or depot medroxyprogesterone to stop menses prior to testosterone treatment.                    Transgender females\nThe hormone regimen for transgender females is more complex than the transgender male regimen (Appendix B). Treatment with physiologic doses of estrogen alone is insufficient to suppress testosterone levels into the normal range for females (139). Most published clinical studies report the need for adjunctive therapy to achieve testosterone levels in the female range (21, 113, 114, 132–134, 139, 140).Multiple adjunctive medications are available, such as progestins with antiandrogen activity and GnRH agonists (141). Spironolactone works by directly blocking androgens during their interaction with the androgen receptor (114, 133, 142). It may also have estrogenic activity (143). Cyproterone acetate, a progestational compound with antiandrogenic properties (113, 132, 144), is widely used in Europe. 5α-Reductase inhibitors do not reduce testosterone levels and have adverse effects (145).Dittrich et al. (141) reported that monthly doses of the GnRH agonist goserelin acetate in combination with estrogen were effective in reducing testosterone levels with a low incidence of adverse reactions in 60 transgender females. Leuprolide and transdermal estrogen were as effective as cyproterone and transdermal estrogen in a comparative retrospective study (146).Patients can take estrogen as oral conjugated estrogens, oral 17β-estradiol, or transdermal 17β-estradiol. Among estrogen options, the increased risk of thromboembolic events associated with estrogens in general seems most concerning with ethinyl estradiol specifically (134, 140, 141), which is why we specifically suggest that it not be used in any transgender treatment plan. Data distinguishing among other estrogen options are less well established although there is some thought that oral routes of administration are more thrombogenic due to the “first pass effect” than are transdermal and parenteral routes, and that the risk of thromboembolic events is dose-dependent. Injectable estrogen and sublingual estrogen may benefit from avoiding the first pass effect, but they can result in more rapid peaks with greater overall periodicity and thus are more difficult to monitor (147, 148). However, there are no data demonstrating that increased periodicity is harmful otherwise.Clinicians can use serum estradiol levels to monitor oral, transdermal, and intramuscular estradiol. Blood tests cannot monitor conjugated estrogens or synthetic estrogen use. Clinicians should measure serum estradiol and serum testosterone and maintain them at the level for premenopausal females (100 to 200 pg/mL and <50 ng/dL, respectively). The transdermal preparations and injectable estradiol cypionate or valerate preparations may confer an advantage in older transgender females who may be at higher risk for thromboembolic disease (149).                    Values\nOur recommendation to maintain levels of gender-affirming hormones in the normal adult range places a high value on the avoidance of the long-term complications of pharmacologic doses. Those patients receiving endocrine treatment who have relative contraindications to hormones should have an in-depth discussion with their physician to balance the risks and benefits of therapy.                    Remarks\nClinicians should inform all endocrine-treated individuals of all risks and benefits of gender-affirming hormones prior to initiating therapy. Clinicians should strongly encourage tobacco use cessation in transgender females to avoid increased risk of VTE and cardiovascular complications. We strongly discourage the unsupervised use of hormone therapy (150).Not all individuals with GD/gender incongruence seek treatment as described (e.g., male-to-eunuchs and individuals seeking partial transition). Tailoring current protocols to the individual may be done within the context of accepted safety guidelines using a multidisciplinary approach including mental health. No evidence-based protocols are available for these groups (151). We need prospective studies to better understand treatment options for these persons.3.4. We suggest that endocrinologists provide education to transgender individuals undergoing treatment about the onset and time course of physical changes induced by sex hormone treatment. (2 |⊕○○○)                    Evidence\n                    Transgender males\nPhysical changes that are expected to occur during the first 1 to 6 months of testosterone therapy include cessation of menses, increased sexual desire, increased facial and body hair, increased oiliness of skin, increased muscle, and redistribution of fat mass. Changes that occur within the first year of testosterone therapy include deepening of the voice (152, 153), clitoromegaly, and male pattern hair loss (in some cases) (114, 144, 154, 155) (Table 12).                    Table 12.Masculinizing Effects in Transgender Males EffectOnsetMaximumSkin oiliness/acne 1–6 mo 1–2 y Facial/body hair growth 6–12 mo 4–5 y Scalp hair loss 6–12 mo —a Increased muscle mass/strength 6–12 mo 2–5 y Fat redistribution 1–6 mo 2–5 y Cessation of menses 1–6 mo —b Clitoral enlargement 1–6 mo 1–2 y Vaginal atrophy 1–6 mo 1–2 y Deepening of voice 6–12 mo 1–2 y EffectOnsetMaximumSkin oiliness/acne 1–6 mo 1–2 y Facial/body hair growth 6–12 mo 4–5 y Scalp hair loss 6–12 mo —a Increased muscle mass/strength 6–12 mo 2–5 y Fat redistribution 1–6 mo 2–5 y Cessation of menses 1–6 mo —b Clitoral enlargement 1–6 mo 1–2 y Vaginal atrophy 1–6 mo 1–2 y Deepening of voice 6–12 mo 1–2 y Estimates represent clinical observations: Toorians et al. (149), Asscheman et al. (156), Gooren et al. (157), Wierckx et al. (158).aPrevention and treatment as recommended for biological men.bMenorrhagia requires diagnosis and treatment by a gynecologist.Table 12.Masculinizing Effects in Transgender Males EffectOnsetMaximumSkin oiliness/acne 1–6 mo 1–2 y Facial/body hair growth 6–12 mo 4–5 y Scalp hair loss 6–12 mo —a Increased muscle mass/strength 6–12 mo 2–5 y Fat redistribution 1–6 mo 2–5 y Cessation of menses 1–6 mo —b Clitoral enlargement 1–6 mo 1–2 y Vaginal atrophy 1–6 mo 1–2 y Deepening of voice 6–12 mo 1–2 y EffectOnsetMaximumSkin oiliness/acne 1–6 mo 1–2 y Facial/body hair growth 6–12 mo 4–5 y Scalp hair loss 6–12 mo —a Increased muscle mass/strength 6–12 mo 2–5 y Fat redistribution 1–6 mo 2–5 y Cessation of menses 1–6 mo —b Clitoral enlargement 1–6 mo 1–2 y Vaginal atrophy 1–6 mo 1–2 y Deepening of voice 6–12 mo 1–2 y Estimates represent clinical observations: Toorians et al. (149), Asscheman et al. (156), Gooren et al. (157), Wierckx et al. (158).aPrevention and treatment as recommended for biological men.bMenorrhagia requires diagnosis and treatment by a gynecologist.                    Transgender females\nPhysical changes that may occur in transgender females in the first 3 to 12 months of estrogen and antiandrogen therapy include decreased sexual desire, decreased spontaneous erections, decreased facial and body hair (usually mild), decreased oiliness of skin, increased breast tissue growth, and redistribution of fat mass (114, 139, 149, 154, 155, 161) (Table 13). Breast development is generally maximal at 2 years after initiating hormones (114, 139, 149, 155). Over a long period of time, the prostate gland and testicles will undergo atrophy.                    Table 13.Feminizing Effects in Transgender Females EffectOnsetMaximumRedistribution of body fat 3–6 mo 2–3 y Decrease in muscle mass and strength 3–6 mo 1–2 y Softening of skin/decreased oiliness 3–6 mo Unknown Decreased sexual desire 1–3 mo 3–6 mo Decreased spontaneous erections 1–3 mo 3–6 mo Male sexual dysfunction Variable Variable Breast growth 3–6 mo 2–3 y Decreased testicular volume 3–6 mo 2–3 y Decreased sperm production Unknown >3 y Decreased terminal hair growth 6–12 mo >3 ya Scalp hair Variable —b Voice changes None —c EffectOnsetMaximumRedistribution of body fat 3–6 mo 2–3 y Decrease in muscle mass and strength 3–6 mo 1–2 y Softening of skin/decreased oiliness 3–6 mo Unknown Decreased sexual desire 1–3 mo 3–6 mo Decreased spontaneous erections 1–3 mo 3–6 mo Male sexual dysfunction Variable Variable Breast growth 3–6 mo 2–3 y Decreased testicular volume 3–6 mo 2–3 y Decreased sperm production Unknown >3 y Decreased terminal hair growth 6–12 mo >3 ya Scalp hair Variable —b Voice changes None —c Estimates represent clinical observations: Toorians et al. (149), Asscheman et al. (156), Gooren et al. (157).aComplete removal of male sexual hair requires electrolysis or laser treatment or both.bFamilial scalp hair loss may occur if estrogens are stopped.cTreatment by speech pathologists for voice training is most effective.Table 13.Feminizing Effects in Transgender Females EffectOnsetMaximumRedistribution of body fat 3–6 mo 2–3 y Decrease in muscle mass and strength 3–6 mo 1–2 y Softening of skin/decreased oiliness 3–6 mo Unknown Decreased sexual desire 1–3 mo 3–6 mo Decreased spontaneous erections 1–3 mo 3–6 mo Male sexual dysfunction Variable Variable Breast growth 3–6 mo 2–3 y Decreased testicular volume 3–6 mo 2–3 y Decreased sperm production Unknown >3 y Decreased terminal hair growth 6–12 mo >3 ya Scalp hair Variable —b Voice changes None —c EffectOnsetMaximumRedistribution of body fat 3–6 mo 2–3 y Decrease in muscle mass and strength 3–6 mo 1–2 y Softening of skin/decreased oiliness 3–6 mo Unknown Decreased sexual desire 1–3 mo 3–6 mo Decreased spontaneous erections 1–3 mo 3–6 mo Male sexual dysfunction Variable Variable Breast growth 3–6 mo 2–3 y Decreased testicular volume 3–6 mo 2–3 y Decreased sperm production Unknown >3 y Decreased terminal hair growth 6–12 mo >3 ya Scalp hair Variable —b Voice changes None —c Estimates represent clinical observations: Toorians et al. (149), Asscheman et al. (156), Gooren et al. (157).aComplete removal of male sexual hair requires electrolysis or laser treatment or both.bFamilial scalp hair loss may occur if estrogens are stopped.cTreatment by speech pathologists for voice training is most effective.Although the time course of breast development in transgender females has been studied (150), precise information about other changes induced by sex hormones is lacking (141). There is a great deal of variability among individuals, as evidenced during pubertal development. We all know that a major concern for transgender females is breast development. If we work with estrogens, the result will be often not what the transgender female expects.Alternatively, there are transgender females who report an anecdotal improved breast development, mood, or sexual desire with the use of progestogens. However, there have been no well-designed studies of the role of progestogens in feminizing hormone regimens, so the question is still open.Our knowledge concerning the natural history and effects of different cross-sex hormone therapies on breast development in transgender females is extremely sparse and based on the low quality of evidence. Current evidence does not indicate that progestogens enhance breast development in transgender females, nor does evidence prove the absence of such an effect. This prevents us from drawing any firm conclusion at this moment and demonstrates the need for further research to clarify these important clinical questions (162).                    Values and preferences\nTransgender persons have very high expectations regarding the physical changes of hormone treatment and are aware that body changes can be enhanced by surgical procedures (e.g., breast, face, and body habitus). Clear expectations for the extent and timing of sex hormone–induced changes may prevent the potential harm and expense of unnecessary procedures.                    4.0 Adverse Outcome Prevention and Long-Term Care\nHormone therapy for transgender males and females confers many of the same risks associated with sex hormone replacement therapy in nontransgender persons. The risks arise from and are worsened by inadvertent or intentional use of supraphysiologic doses of sex hormones, as well as use of inadequate doses of sex hormones to maintain normal physiology (131, 139).4.1. We suggest regular clinical evaluation for physical changes and potential adverse changes in response to sex steroid hormones and laboratory monitoring of sex steroid hormone levels every 3 months during the first year of hormone therapy for transgender males and females and then once or twice yearly. (2 |⊕⊕○○)                    Evidence\nPretreatment screening and appropriate regular medical monitoring are recommended for both transgender males and females during the endocrine transition and periodically thereafter (26, 155). Clinicians should monitor weight and blood pressure, conduct physical exams, and assess routine health questions, such as tobacco use, symptoms of depression, and risk of adverse events such as deep vein thrombosis/pulmonary embolism and other adverse effects of sex steroids.                    Transgender males\nTable 14 contains a standard monitoring plan for transgender males on testosterone therapy (154, 159). Key issues include maintaining testosterone levels in the physiologic normal male range and avoiding adverse events resulting from excess testosterone therapy, particularly erythrocytosis, sleep apnea, hypertension, excessive weight gain, salt retention, lipid changes, and excessive or cystic acne (135).                    Table 14.Monitoring of Transgender Persons on Gender-Affirming Hormone Therapy: Transgender Male 1. Evaluate patient every 3 mo in the first year and then one to two times per year to monitor for appropriate signs of virilization and for development of adverse reactions. 2. Measure serum testosterone every 3 mo until levels are in the normal physiologic male range:a  a. For testosterone enanthate/cypionate injections, the testosterone level should be measured midway between injections. The target level is 400–700 ng/dL to 400 ng/dL. Alternatively, measure peak and trough levels to ensure levels remain in the normal male range.  b. For parenteral testosterone undecanoate, testosterone should be measured just before the following injection. If the level is <400 ng/dL, adjust dosing interval.  c. For transdermal testosterone, the testosterone level can be measured no sooner than after 1 wk of daily application (at least 2 h after application). 3. Measure hematocrit or hemoglobin at baseline and every 3 mo for the first year and then one to two times a year. Monitor weight, blood pressure, and lipids at regular intervals. 4. Screening for osteoporosis should be conducted in those who stop testosterone treatment, are not compliant with hormone therapy, or who develop risks for bone loss. 5. If cervical tissue is present, monitoring as recommended by the American College of Obstetricians and Gynecologists. 6. Ovariectomy can be considered after completion of hormone transition. 7. Conduct sub- and periareolar annual breast examinations if mastectomy performed. If mastectomy is not performed, then consider mammograms as recommended by the American Cancer Society. 1. Evaluate patient every 3 mo in the first year and then one to two times per year to monitor for appropriate signs of virilization and for development of adverse reactions. 2. Measure serum testosterone every 3 mo until levels are in the normal physiologic male range:a  a. For testosterone enanthate/cypionate injections, the testosterone level should be measured midway between injections. The target level is 400–700 ng/dL to 400 ng/dL. Alternatively, measure peak and trough levels to ensure levels remain in the normal male range.  b. For parenteral testosterone undecanoate, testosterone should be measured just before the following injection. If the level is <400 ng/dL, adjust dosing interval.  c. For transdermal testosterone, the testosterone level can be measured no sooner than after 1 wk of daily application (at least 2 h after application). 3. Measure hematocrit or hemoglobin at baseline and every 3 mo for the first year and then one to two times a year. Monitor weight, blood pressure, and lipids at regular intervals. 4. Screening for osteoporosis should be conducted in those who stop testosterone treatment, are not compliant with hormone therapy, or who develop risks for bone loss. 5. If cervical tissue is present, monitoring as recommended by the American College of Obstetricians and Gynecologists. 6. Ovariectomy can be considered after completion of hormone transition. 7. Conduct sub- and periareolar annual breast examinations if mastectomy performed. If mastectomy is not performed, then consider mammograms as recommended by the American Cancer Society. aAdapted from Lapauw et al. (154) and Ott et al. (159).Table 14.Monitoring of Transgender Persons on Gender-Affirming Hormone Therapy: Transgender Male 1. Evaluate patient every 3 mo in the first year and then one to two times per year to monitor for appropriate signs of virilization and for development of adverse reactions. 2. Measure serum testosterone every 3 mo until levels are in the normal physiologic male range:a  a. For testosterone enanthate/cypionate injections, the testosterone level should be measured midway between injections. The target level is 400–700 ng/dL to 400 ng/dL. Alternatively, measure peak and trough levels to ensure levels remain in the normal male range.  b. For parenteral testosterone undecanoate, testosterone should be measured just before the following injection. If the level is <400 ng/dL, adjust dosing interval.  c. For transdermal testosterone, the testosterone level can be measured no sooner than after 1 wk of daily application (at least 2 h after application). 3. Measure hematocrit or hemoglobin at baseline and every 3 mo for the first year and then one to two times a year. Monitor weight, blood pressure, and lipids at regular intervals. 4. Screening for osteoporosis should be conducted in those who stop testosterone treatment, are not compliant with hormone therapy, or who develop risks for bone loss. 5. If cervical tissue is present, monitoring as recommended by the American College of Obstetricians and Gynecologists. 6. Ovariectomy can be considered after completion of hormone transition. 7. Conduct sub- and periareolar annual breast examinations if mastectomy performed. If mastectomy is not performed, then consider mammograms as recommended by the American Cancer Society. 1. Evaluate patient every 3 mo in the first year and then one to two times per year to monitor for appropriate signs of virilization and for development of adverse reactions. 2. Measure serum testosterone every 3 mo until levels are in the normal physiologic male range:a  a. For testosterone enanthate/cypionate injections, the testosterone level should be measured midway between injections. The target level is 400–700 ng/dL to 400 ng/dL. Alternatively, measure peak and trough levels to ensure levels remain in the normal male range.  b. For parenteral testosterone undecanoate, testosterone should be measured just before the following injection. If the level is <400 ng/dL, adjust dosing interval.  c. For transdermal testosterone, the testosterone level can be measured no sooner than after 1 wk of daily application (at least 2 h after application). 3. Measure hematocrit or hemoglobin at baseline and every 3 mo for the first year and then one to two times a year. Monitor weight, blood pressure, and lipids at regular intervals. 4. Screening for osteoporosis should be conducted in those who stop testosterone treatment, are not compliant with hormone therapy, or who develop risks for bone loss. 5. If cervical tissue is present, monitoring as recommended by the American College of Obstetricians and Gynecologists. 6. Ovariectomy can be considered after completion of hormone transition. 7. Conduct sub- and periareolar annual breast examinations if mastectomy performed. If mastectomy is not performed, then consider mammograms as recommended by the American Cancer Society. aAdapted from Lapauw et al. (154) and Ott et al. (159).Because oral 17-alkylated testosterone is not recommended, serious hepatic toxicity is not anticipated with parenteral or transdermal testosterone use (163, 164). Past concerns regarding liver toxicity with testosterone have been alleviated with subsequent reports that indicate the risk of serious liver disease is minimal (144, 165, 166).                    Transgender females\nTable 15 contains a standard monitoring plan for transgender females on estrogens, gonadotropin suppression, or antiandrogens (160). Key issues include avoiding supraphysiologic doses or blood levels of estrogen that may lead to increased risk for thromboembolic disease, liver dysfunction, and hypertension. Clinicians should monitor serum estradiol levels using laboratories participating in external quality control, as measurements of estradiol in blood can be very challenging (167).                    Table 15.Monitoring of Transgender Persons on Gender-Affirming Hormone Therapy: Transgender Female 1. Evaluate patient every 3 mo in the first year and then one to two times per year to monitor for appropriate signs of feminization and for development of adverse reactions. 2. Measure serum testosterone and estradiol every 3 mo.  a. Serum testosterone levels should be <50 ng/dL.  b. Serum estradiol should not exceed the peak physiologic range: 100–200 pg/mL. 3. For individuals on spironolactone, serum electrolytes, particularly potassium, should be monitored every 3 mo in the first year and annually thereafter. 4. Routine cancer screening is recommended, as in nontransgender individuals (all tissues present). 5. Consider BMD testing at baseline (160). In individuals at low risk, screening for osteoporosis should be conducted at age 60 years or in those who are not compliant with hormone therapy. 1. Evaluate patient every 3 mo in the first year and then one to two times per year to monitor for appropriate signs of feminization and for development of adverse reactions. 2. Measure serum testosterone and estradiol every 3 mo.  a. Serum testosterone levels should be <50 ng/dL.  b. Serum estradiol should not exceed the peak physiologic range: 100–200 pg/mL. 3. For individuals on spironolactone, serum electrolytes, particularly potassium, should be monitored every 3 mo in the first year and annually thereafter. 4. Routine cancer screening is recommended, as in nontransgender individuals (all tissues present). 5. Consider BMD testing at baseline (160). In individuals at low risk, screening for osteoporosis should be conducted at age 60 years or in those who are not compliant with hormone therapy. This table presents strong recommendations and does not include lower level recommendations.Table 15.Monitoring of Transgender Persons on Gender-Affirming Hormone Therapy: Transgender Female 1. Evaluate patient every 3 mo in the first year and then one to two times per year to monitor for appropriate signs of feminization and for development of adverse reactions. 2. Measure serum testosterone and estradiol every 3 mo.  a. Serum testosterone levels should be <50 ng/dL.  b. Serum estradiol should not exceed the peak physiologic range: 100–200 pg/mL. 3. For individuals on spironolactone, serum electrolytes, particularly potassium, should be monitored every 3 mo in the first year and annually thereafter. 4. Routine cancer screening is recommended, as in nontransgender individuals (all tissues present). 5. Consider BMD testing at baseline (160). In individuals at low risk, screening for osteoporosis should be conducted at age 60 years or in those who are not compliant with hormone therapy. 1. Evaluate patient every 3 mo in the first year and then one to two times per year to monitor for appropriate signs of feminization and for development of adverse reactions. 2. Measure serum testosterone and estradiol every 3 mo.  a. Serum testosterone levels should be <50 ng/dL.  b. Serum estradiol should not exceed the peak physiologic range: 100–200 pg/mL. 3. For individuals on spironolactone, serum electrolytes, particularly potassium, should be monitored every 3 mo in the first year and annually thereafter. 4. Routine cancer screening is recommended, as in nontransgender individuals (all tissues present). 5. Consider BMD testing at baseline (160). In individuals at low risk, screening for osteoporosis should be conducted at age 60 years or in those who are not compliant with hormone therapy. This table presents strong recommendations and does not include lower level recommendations.VTE may be a serious complication. A study reported a 20-fold increase in venous thromboembolic disease in a large cohort of Dutch transgender subjects (161). This increase may have been associated with the use of the synthetic estrogen, ethinyl estradiol (149). The incidence decreased when clinicians stopped administering ethinyl estradiol (161). Thus, the use of synthetic estrogens and conjugated estrogens is undesirable because of the inability to regulate doses by measuring serum levels and the risk of thromboembolic disease. In a German gender clinic, deep vein thrombosis occurred in 1 of 60 of transgender females treated with a GnRH analog and oral estradiol (141). The patient who developed a deep vein thrombosis was found to have a homozygous C677 T mutation in the methylenetetrahydrofolate reductase gene. In an Austrian gender clinic, administering gender-affirming hormones to 162 transgender females and 89 transgender males was not associated with VTE, despite an 8.0% and 5.6% incidence of thrombophilia (159). A more recent multinational study reported only 10 cases of VTE from a cohort of 1073 subjects (168). Thrombophilia screening of transgender persons initiating hormone treatment should be restricted to those with a personal or family history of VTE (159). Monitoring D-dimer levels during treatment is not recommended (169).4.2. We suggest periodically monitoring prolactin levels in transgender females treated with estrogens. (2 |⊕⊕○○)                    Evidence\nEstrogen therapy can increase the growth of pituitary lactrotroph cells. There have been several reports of prolactinomas occurring after long-term, high-dose estrogen therapy (170–173). Up to 20% of transgender females treated with estrogens may have elevations in prolactin levels associated with enlargement of the pituitary gland (156). In most cases, the serum prolactin levels will return to the normal range with a reduction or discontinuation of the estrogen therapy or discontinuation of cyproterone acetate (157, 174, 175).The onset and time course of hyperprolactinemia during estrogen treatment are not known. Clinicians should measure prolactin levels at baseline and then at least annually during the transition period and every 2 years thereafter. Given that only a few case studies reported prolactinomas, and prolactinomas were not reported in large cohorts of estrogen-treated persons, the risk is likely to be very low. Because the major presenting findings of microprolactinomas (hypogonadism and sometimes gynecomastia) are not apparent in transgender females, clinicians may perform radiologic examinations of the pituitary in those patients whose prolactin levels persistently increase despite stable or reduced estrogen levels. Some transgender individuals receive psychotropic medications that can increase prolactin levels (174).4.3. We suggest that clinicians evaluate transgender persons treated with hormones for cardiovascular risk factors using fasting lipid profiles, diabetes screening, and/or other diagnostic tools. (2 |⊕⊕○○)                    Evidence\n                    Transgender males\nAdministering testosterone to transgender males results in a more atherogenic lipid profile with lowered high-density lipoprotein cholesterol and higher triglyceride and low-density lipoprotein cholesterol values (176–179). Studies of the effect of testosterone on insulin sensitivity have mixed results (178, 180). A randomized, open-label uncontrolled safety study of transgender males treated with testosterone undecanoate demonstrated no insulin resistance after 1 year (181, 182). Numerous studies have demonstrated the effects of sex hormone treatment on the cardiovascular system (160, 179, 183, 184). Long-term studies from The Netherlands found no increased risk for cardiovascular mortality (161). Likewise, a meta-analysis of 19 randomized trials in nontransgender males on testosterone replacement showed no increased incidence of cardiovascular events (185). A systematic review of the literature found that data were insufficient (due to very low–quality evidence) to allow a meaningful assessment of patient-important outcomes, such as death, stroke, myocardial infarction, or VTE in transgender males (176). Future research is needed to ascertain the potential harm of hormonal therapies (176). Clinicians should manage cardiovascular risk factors as they emerge according to established guidelines (186).                    Transgender females\nA prospective study of transgender females found favorable changes in lipid parameters with increased high-density lipoprotein and decreased low-density lipoprotein concentrations (178). However, increased weight, blood pressure, and markers of insulin resistance attenuated these favorable lipid changes. In a meta-analysis, only serum triglycerides were higher at ≥24 months without changes in other parameters (187). The largest cohort of transgender females (mean age 41 years, followed for a mean of 10 years) showed no increase in cardiovascular mortality despite a 32% rate of tobacco use (161).Thus, there is limited evidence to determine whether estrogen is protective or detrimental on lipid and glucose metabolism in transgender females (176). With aging, there is usually an increase of body weight. Therefore, as with nontransgender individuals, clinicians should monitor and manage glucose and lipid metabolism and blood pressure regularly according to established guidelines (186).4.4. We recommend that clinicians obtain BMD measurements when risk factors for osteoporosis exist, specifically in those who stop sex hormone therapy after gonadectomy. (1 |⊕⊕○○)                    Evidence\n                    Transgender males\nBaseline bone mineral measurements in transgender males are generally in the expected range for their pretreatment gender (188). However, adequate dosing of testosterone is important to maintain bone mass in transgender males (189, 190). In one study (190), serum LH levels were inversely related to BMD, suggesting that low levels of sex hormones were associated with bone loss. Thus, LH levels in the normal range may serve as an indicator of the adequacy of sex steroid administration to preserve bone mass. The protective effect of testosterone may be mediated by peripheral conversion to estradiol, both systemically and locally in the bone.                    Transgender females\nA baseline study of BMD reported T scores less than −2.5 in 16% of transgender females (191). In aging males, studies suggest that serum estradiol more positively correlates with BMD than does testosterone (192, 193) and is more important for peak bone mass (194). Estrogen preserves BMD in transgender females who continue on estrogen and antiandrogen therapies (188, 190, 191, 195, 196).Fracture data in transgender males and females are not available. Transgender persons who have undergone gonadectomy may choose not to continue consistent sex steroid treatment after hormonal and surgical sex reassignment, thereby becoming at risk for bone loss. There have been no studies to determine whether clinicians should use the sex assigned at birth or affirmed gender for assessing osteoporosis (e.g., when using the FRAX tool). Although some researchers use the sex assigned at birth (with the assumption that bone mass has usually peaked for transgender people who initiate hormones in early adulthood), this should be assessed on a case-by-case basis until there are more data available. This assumption will be further complicated by the increasing prevalence of transgender people who undergo hormonal transition at a pubertal age or soon after puberty. Sex for comparison within risk assessment tools may be based on the age at which hormones were initiated and the length of exposure to hormones. In some cases, it may be reasonable to assess risk using both the male and female calculators and using an intermediate value. Because all subjects underwent normal pubertal development, with known effects on bone size, reference values for birth sex were used for all participants (154).4.5. We suggest that transgender females with no known increased risk of breast cancer follow breast-screening guidelines recommended for those designated female at birth. (2 |⊕⊕○○)4.6. We suggest that transgender females treated with estrogens follow individualized screening according to personal risk for prostatic disease and prostate cancer. (2 |⊕○○○)                    Evidence\nStudies have reported a few cases of breast cancer in transgender females (197–200). A Dutch study of 1800 transgender females followed for a mean of 15 years (range of 1 30 years) found one case of breast cancer. The Women’s Health Initiative study reported that females taking conjugated equine estrogen without progesterone for 7 years did not have an increased risk of breast cancer as compared with females taking placebo (137).In transgender males, a large retrospective study conducted at the U.S. Veterans Affairs medical health system identified seven breast cancers (194). The authors reported that this was not above the expected rate of breast cancers in cisgender females in this cohort. Furthermore, they did report one breast cancer that developed in a transgender male patient after mastectomy, supporting the fact that breast cancer can occur even after mastectomy. Indeed, there have been case reports of breast cancer developing in subareolar tissue in transgender males, which occurred after mastectomy (201, 202).Women with primary hypogonadism (Turner syndrome) treated with estrogen replacement exhibited a significantly decreased incidence of breast cancer as compared with national standardized incidence ratios (203, 204). These studies suggest that estrogen therapy does not increase the risk of breast cancer in the short term (<20 to 30 years). We need long-term studies to determine the actual risk, as well as the role of screening mammograms. Regular examinations and gynecologic advice should determine monitoring for breast cancer.Prostate cancer is very rare before the age of 40, especially with androgen deprivation therapy (205). Childhood or pubertal castration results in regression of the prostate and adult castration reverses benign prostate hypertrophy (206). Although van Kesteren et al. (207) reported that estrogen therapy does not induce hypertrophy or premalignant changes in the prostates of transgender females, studies have reported cases of benign prostatic hyperplasia in transgender females treated with estrogens for 20 to 25 years (208, 209). Studies have also reported a few cases of prostate carcinoma in transgender females (210–214).Transgender females may feel uncomfortable scheduling regular prostate examinations. Gynecologists are not trained to screen for prostate cancer or to monitor prostate growth. Thus, it may be reasonable for transgender females who transitioned after age 20 years to have annual screening digital rectal examinations after age 50 years and prostate-specific antigen tests consistent with U.S. Preventive Services Task Force Guidelines (215).4.7. We advise that clinicians determine the medical necessity of including a total hysterectomy and oophorectomy as part of gender-affirming surgery. (Ungraded Good Practice Statement)                    Evidence\nAlthough aromatization of testosterone to estradiol in transgender males has been suggested as a risk factor for endometrial cancer (216), no cases have been reported. When transgender males undergo hysterectomy, the uterus is small and there is endometrial atrophy (217, 218). Studies have reported cases of ovarian cancer (219, 220). Although there is limited evidence for increased risk of reproductive tract cancers in transgender males, health care providers should determine the medical necessity of a laparoscopic total hysterectomy as part of a gender-affirming surgery to prevent reproductive tract cancer (221).                    Values\nGiven the discomfort that transgender males experience accessing gynecologic care, our recommendation for the medical necessity of total hysterectomy and oophorectomy places a high value on eliminating the risks of female reproductive tract disease and cancer and a lower value on avoiding the risks of these surgical procedures (related to the surgery and to the potential undesirable health consequences of oophorectomy) and their associated costs.                    Remarks\nThe sexual orientation and type of sexual practices will determine the need and types of gynecologic care required following transition. Additionally, in certain countries, the approval required to change the sex in a birth certificate for transgender males may be dependent on having a complete hysterectomy. Clinicians should help patients research nonmedical administrative criteria and provide counseling. If individuals decide not to undergo hysterectomy, screening for cervical cancer is the same as all other females.                    5.0 Surgery for Sex Reassignment and Gender Confirmation\nFor many transgender adults, genital gender-affirming surgery may be the necessary step toward achieving their ultimate goal of living successfully in their desired gender role. The type of surgery falls into two main categories: (1) those that directly affect fertility and (2) those that do not. Those that change fertility (previously called sex reassignment surgery) include genital surgery to remove the penis and gonads in the male and removal of the uterus and gonads in the female. The surgeries that effect fertility are often governed by the legal system of the state or country in which they are performed. Other gender-conforming surgeries that do not directly affect fertility are not so tightly governed.Gender-affirming surgical techniques have improved markedly during the past 10 years. Reconstructive genital surgery that preserves neurologic sensation is now the standard. The satisfaction rate with surgical reassignment of sex is now very high (187). Additionally, the mental health of the individual seems to be improved by participating in a treatment program that defines a pathway of gender-affirming treatment that includes hormones and surgery (130, 144) (Table 16).                    Table 16.Criteria for Gender-Affirming Surgery, Which Affects Fertility 1. Persistent, well-documented gender dysphoria 2. Legal age of majority in the given country 3. Having continuously and responsibly used gender-affirming hormones for 12 mo (if there is no medical contraindication to receiving such therapy) 4. Successful continuous full-time living in the new gender role for 12 mo 5. If significant medical or mental health concerns are present, they must be well controlled 6. Demonstrable knowledge of all practical aspects of surgery (e.g., cost, required lengths of hospitalizations, likely complications, postsurgical rehabilitation) 1. Persistent, well-documented gender dysphoria 2. Legal age of majority in the given country 3. Having continuously and responsibly used gender-affirming hormones for 12 mo (if there is no medical contraindication to receiving such therapy) 4. Successful continuous full-time living in the new gender role for 12 mo 5. If significant medical or mental health concerns are present, they must be well controlled 6. Demonstrable knowledge of all practical aspects of surgery (e.g., cost, required lengths of hospitalizations, likely complications, postsurgical rehabilitation) Table 16.Criteria for Gender-Affirming Surgery, Which Affects Fertility 1. Persistent, well-documented gender dysphoria 2. Legal age of majority in the given country 3. Having continuously and responsibly used gender-affirming hormones for 12 mo (if there is no medical contraindication to receiving such therapy) 4. Successful continuous full-time living in the new gender role for 12 mo 5. If significant medical or mental health concerns are present, they must be well controlled 6. Demonstrable knowledge of all practical aspects of surgery (e.g., cost, required lengths of hospitalizations, likely complications, postsurgical rehabilitation) 1. Persistent, well-documented gender dysphoria 2. Legal age of majority in the given country 3. Having continuously and responsibly used gender-affirming hormones for 12 mo (if there is no medical contraindication to receiving such therapy) 4. Successful continuous full-time living in the new gender role for 12 mo 5. If significant medical or mental health concerns are present, they must be well controlled 6. Demonstrable knowledge of all practical aspects of surgery (e.g., cost, required lengths of hospitalizations, likely complications, postsurgical rehabilitation) Surgery that affects fertility is irreversible. The World Professional Association for Transgender Health Standards of Care (222) emphasizes that the “threshold of 18 should not be seen as an indication in itself for active intervention.” If the social transition has not been satisfactory, if the person is not satisfied with or is ambivalent about the effects of sex hormone treatment, or if the person is ambivalent about surgery then the individual should not be referred for surgery (223, 224).Gender-affirming genital surgeries for transgender females that affect fertility include gonadectomy, penectomy, and creation of a neovagina (225, 226). Surgeons often invert the skin of the penis to form the wall of the vagina, and several literatures reviews have reported on outcomes (227). Sometimes there is inadequate tissue to form a full neovagina, so clinicians have revisited using intestine and found it to be successful (87, 228, 229). Some newer vaginoplasty techniques may involve autologuous oral epithelial cells (230, 231).The scrotum becomes the labia majora. Surgeons use reconstructive surgery to fashion the clitoris and its hood, preserving the neurovascular bundle at the tip of the penis as the neurosensory supply to the clitoris. Some surgeons are also creating a sensate pedicled-spot adding a G spot to the neovagina to increase sensation (232). Most recently, plastic surgeons have developed techniques to fashion labia minora. To further complete the feminization, uterine transplants have been proposed and even attempted (233).Neovaginal prolapse, rectovaginal fistula, delayed healing, vaginal stenosis, and other complications do sometimes occur (234, 235). Clinicians should strongly remind the transgender person to use their dilators to maintain the depth and width of the vagina throughout the postoperative period. Genital sexual responsivity and other aspects of sexual function are usually preserved following genital gender-affirming surgery (236, 237).Ancillary surgeries for more feminine or masculine appearance are not within the scope of this guideline. Voice therapy by a speech language pathologist is available to transform speech patterns to the affirmed gender (148). Spontaneous voice deepening occurs during testosterone treatment of transgender males (152, 238). No studies have compared the effectiveness of speech therapy, laryngeal surgery, or combined treatment.Breast surgery is a good example of gender-confirming surgery that does not affect fertility. In all females, breast size exhibits a very broad spectrum. For transgender females to make the best informed decision, clinicians should delay breast augmentation surgery until the patient has completed at least 2 years of estrogen therapy, because the breasts continue to grow during that time (141, 155).Another major procedure is the removal of facial and masculine-appearing body hair using either electrolysis or laser treatments. Other feminizing surgeries, such as that to feminize the face, are now becoming more popular (239–241).In transgender males, clinicians usually delay gender-affirming genital surgeries until after a few years of androgen therapy. Those surgeries that affect fertility in this group include oophorectomy, vaginectomy, and complete hysterectomy. Surgeons can safely perform them vaginally with laparoscopy. These are sometimes done in conjunction with the creation of a neopenis. The cosmetic appearance of a neopenis is now very good, but the surgery is multistage and very expensive (242, 243). Radial forearm flap seems to be the most satisfactory procedure (228, 244). Other flaps also exist (245). Surgeons can make neopenile erections possible by reinervation of the flap and subsequent contraction of the muscle, leading to stiffening of the neopenis (246, 247), but results are inconsistent (248). Surgeons can also stiffen the penis by imbedding some mechanical device (e.g., a rod or some inflatable apparatus) (249, 250). Because of these limitations, the creation of a neopenis has often been less than satisfactory. Recently, penis transplants are being proposed (233).In fact, most transgender males do not have any external genital surgery because of the lack of access, high cost, and significant potential complications. Some choose a metaoidioplasty that brings forward the clitoris, thereby allowing them to void in a standing position without wetting themselves (251, 252). Surgeons can create the scrotum from the labia majora with good cosmetic effect and can implant testicular prostheses (253).The most important masculinizing surgery for the transgender male is mastectomy, and it does not affect fertility. Breast size only partially regresses with androgen therapy (155). In adults, discussions about mastectomy usually take place after androgen therapy has started. Because some transgender male adolescents present after significant breast development has occurred, they may also consider mastectomy 2 years after they begin androgen therapy and before age 18 years. Clinicians should individualize treatment based on the physical and mental health status of the individual. There are now newer approaches to mastectomy with better outcomes (254, 255). These often involve chest contouring (256). Mastectomy is often necessary for living comfortably in the new gender (256).5.1. We recommend that a patient pursue genital gender-affirming surgery only after the MHP and the clinician responsible for endocrine transition therapy both agree that surgery is medically necessary and would benefit the patient’s overall health and/or well-being. (1 |⊕⊕○○)5.2. We advise that clinicians approve genital gender-affirming surgery only after completion of at least 1 year of consistent and compliant hormone treatment, unless hormone therapy is not desired or medically contraindicated. (Ungraded Good Practice Statement)5.3. We advise that the clinician responsible for endocrine treatment and the primary care provider ensure appropriate medical clearance of transgender individuals for genital gender-affirming surgery and collaborate with the surgeon regarding hormone use during and after surgery. (Ungraded Good Practice Statement)5.4. We recommend that clinicians refer hormone-treated transgender individuals for genital surgery when: (1) the individual has had a satisfactory social role change, (2) the individual is satisfied about the hormonal effects, and (3) the individual desires definitive surgical changes. (1 |⊕○○○)5.5. We suggest that clinicians delay gender-affirming genital surgery involving gonadectomy and/or hysterectomy until the patient is at least 18 years old or legal age of majority in his or her country. (2 |⊕⊕○○).5.6. We suggest that clinicians determine the timing of breast surgery for transgender males based upon the physical and mental health status of the individual. There is insufficient evidence to recommend a specific age requirement. (2 |⊕○○○)                    Evidence\nOwing to the lack of controlled studies, incomplete follow-up, and lack of valid assessment measures, evaluating various surgical approaches and techniques is difficult. However, one systematic review including a large numbers of studies reported satisfactory cosmetic and functional results for vaginoplasty/neovagina construction (257). For transgender males, the outcomes are less certain. However, the problems are now better understood (258). Several postoperative studies report significant long-term psychological and psychiatric pathology (259–261). One study showed satisfaction with breasts, genitals, and femininity increased significantly and showed the importance of surgical treatment as a key therapeutic option for transgender females (262). Another analysis demonstrated that, despite the young average age at death following surgery and the relatively larger number of individuals with somatic morbidity, the study does not allow for determination of causal relationships between, for example, specific types of hormonal or surgical treatment received and somatic morbidity and mortality (263). Reversal surgery in regretful male-to-female transsexuals after sexual reassignment surgery represents a complex, multistage procedure with satisfactory outcomes. Further insight into the characteristics of persons who regret their decision postoperatively would facilitate better future selection of applicants eligible for sexual reassignment surgery. We need more studies with appropriate controls that examine long-term quality of life, psychosocial outcomes, and psychiatric outcomes to determine the long-term benefits of surgical treatment.When a transgender individual decides to have gender-affirming surgery, both the hormone prescribing clinician and the MHP must certify that the patient satisfies criteria for gender-affirming surgery (Table 16).There is some concern that estrogen therapy may cause an increased risk for venous thrombosis during or following surgery (176). For this reason, the surgeon and the hormone-prescribing clinician should collaborate in making a decision about the use of hormones before and following surgery. One study suggests that preoperative factors (such as compliance) are less important for patient satisfaction than are the physical postoperative results (56). However, other studies and clinical experience dictate that individuals who do not follow medical instructions and do not work with their physicians toward a common goal do not achieve treatment goals (264) and experience higher rates of postoperative infections and other complications (265, 266). It is also important that the person requesting surgery feels comfortable with the anatomical changes that have occurred during hormone therapy. Dissatisfaction with social and physical outcomes during the hormone transition may be a contraindication to surgery (223).An endocrinologist or experienced medical provider should monitor transgender individuals after surgery. Those who undergo gonadectomy will require hormone replacement therapy, surveillance, or both to prevent adverse effects of chronic hormone deficiency.                    Financial Disclosures of the Task Force*\nWylie C. Hembree (chair)—financial or business/organizational interests: none declared, significant financial interest or leadership position: none declared. Peggy T. Cohen-Kettenis—financial or business/organizational interests: none declared, significant financial interest or leadership position: none declared. Louis Gooren—financial or business/organizational interests: none declared, significant financial interest or leadership position: none declared. Sabine E. Hannema—financial or business/organizational interests: none declared, significant financial interest or leadership position: Ferring Pharmaceuticals Inc. (lecture/conference), Pfizer (lecture). Walter J. Meyer—financial or business/organizational interests: none declared, significant financial interest or leadership position: none declared. M. Hassan Murad**—financial or business/organizational interests: Mayo Clinic, Evidence-based Practice Center, significant financial interest or leadership position: none declared. Stephen M.Rosenthal—financial or business/organizational interests: AbbVie (consultant), National Institutes of Health (grantee), significant financial interest or leadership position: Pediatric Endocrine Society (immediate past president). Joshua D. Safer, FACP—financial or business/organizational interests: none declared, significant financial interest or leadership position: none declared. Vin Tangpricha—financial or business/organizational interests: Cystic Fibrosis Foundation (grantee), National Institutes of Health (grantee), significant financial interest or leadership position, Elsevier Journal of Clinical and Translational Endocrinology (editor). Guy G. T’Sjoen—financial or business/organizational interests: none declared, significant financial interest or leadership position: none declared.* Financial, business, and organizational disclosures of the task force cover the year prior to publication. Disclosures prior to this time period are archived.**Evidence-based reviews for this guideline were prepared under contract with the Endocrine Society.                    Abbreviations\n BMD DSDdisorder/difference of sex development DSMDiagnostic and Statistical Manual of Mental Disorders GD GnRHgonadotropin-releasing hormone ICDInternational Statistical Classification of Diseases and Related Health Problems MHPmental health professional VTE                    Acknowledgments\nDisclosure Summary: See Financial Disclosures.                    References\n1.Atkins  D\n, \nBest  D\n, \nBriss  PA\n, \nEccles  M\n, \nFalck-Ytter  Y\n, \nFlottorp  S\n, \nGuyatt  GH\n, \nHarbour  RT\n, \nHaugh  MC\n, \nHenry  D\n, \nHill  S\n, \nJaeschke  R\n, \nLeng  G\n, \nLiberati  A\n, \nMagrini  N\n, \nMason  J\n, \nMiddleton  P\n, \nMrukowicz  J\n, \nO’Connell  D\n, \nOxman  AD\n, \nPhillips  B\n, \nSchünemann  HJ\n, \nEdejer  T\n, \nVaronen  H\n, \nVist  GE\n, \nWilliams  JW, Jr\n, \nZaza  S\n; GRADE Working Group\n. Grading quality of evidence and strength of recommendations. BMJ. 2004;328(7454):1490.2.Swiglo  BA\n, \nMurad  MH\n, \nSchünemann  HJ\n, \nKunz  R\n, \nVigersky  RA\n, \nGuyatt  GH\n, \nMontori  VM\n\n. A case for clarity, consistency, and helpfulness: state-of-the-art clinical practice guidelines in endocrinology using the grading of recommendations, assessment, development, and evaluation system. J Clin Endocrinol Metab. 2008;93(3):666–673.3.Bullough  VL\n\n. Transsexualism in history. Arch Sex Behav. 1975;4(5):561–571.4.Benjamin  H\n\n. The transsexual phenomenon. Trans N Y Acad Sci. 1967;29(4):428–430.5.Meyerowitz  J\n\n. How Sex Changed: A History of Transsexuality in the United States. Cambridge, MA: Harvard University Press; 2002.6.Hirschfeld  M.\n\n Was muss das Volk vom Dritten Geschlecht wissen. Verlag Max Spohr, Leipzig; 1901.\n7.Fisk  NM\n\n. Editorial: Gender dysphoria syndrome—the conceptualization that liberalizes indications for total gender reorientation and implies a broadly based multi-dimensional rehabilitative regimen. West J Med. 1974;120(5):386–391.8.Diamond  L\n\n. Transgender experience and identity. In: Schwartz SJ, Luyckx K, Vignoles VL, eds. Handbook of Identity Theory and Research. New York, NY: Springer; 2011:629–647.9.Queen  C\n, \nSchimel  L\n\n, eds. PoMoSexuals: Challenging Assumptions About Gender and Sexuality. San Francisco, CA: Cleis Press; 1997.10.Case  LK\n, \nRamachandran  VS\n\n. Alternating gender incongruity: a new neuropsychiatric syndrome providing insight into the dynamic plasticity of brain-sex. Med Hypotheses. 2012;78(5):626–631.11.Johnson  TW\n, \nWassersug  RJ\n\n. Gender identity disorder outside the binary: when gender identity disorder-not otherwise specified is not good enough. Arch Sex Behav. 2010;39(3):597–598.12.Wibowo  E\n, \nWassersug  R\n, \nWarkentin  K\n, \nWalker  L\n, \nRobinson  J\n, \nBrotto  L\n, \nJohnson  T\n\n. Impact of androgen deprivation therapy on sexual function: a response. Asian J Androl. 2012;14(5):793–794.14.American Psychiatric Association\n. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Arlington, VA: American Psychiatric Association Publishing.15.Drescher  J\n, \nCohen-Kettenis  P\n, \nWinter  S\n\n. Minding the body: situating gender identity diagnoses in the ICD-11. Int Rev Psychiatry. 2012;24(6):568–577.17.Kreukels  BP\n, \nHaraldsen  IR\n, \nDe Cuypere  G\n, \nRichter-Appelt  H\n, \nGijs  L\n, \nCohen-Kettenis  PT\n\n. A European network for the investigation of gender incongruence: the ENIGI initiative. Eur Psychiatry. 2012;27(6):445–450.18.Dekker  MJ\n, \nWierckx  K\n, \nVan Caenegem  E\n, \nKlaver  M\n, \nKreukels  BP\n, \nElaut  E\n, \nFisher  AD\n, \nvan Trotsenburg  MA\n, \nSchreiner  T\n, \nden Heijer  M\n, \nT’Sjoen  G\n\n. A European network for the investigation of gender incongruence: endocrine part. J Sex Med. 2016;13(6):994–999.19.Ruble  DN\n, \nMartin  CL\n, \nBerenbaum  SA\n\n. Gender development. In: \n\nDamon  WL\n, \nLerner  RM\n, \nEisenberg  N\n\n, eds. Handbook of Child Psychology: Social, Emotional, and Personality Development. Vol. 3. 6th ed. New York, NY: Wiley; 2006;858–931.20.Steensma  TD\n, \nKreukels  BP\n, \nde Vries  AL\n, \nCohen-Kettenis  PT\n\n. Gender identity development in adolescence. Horm Behav. 2013;64(2):288–297.21.Rosenthal  SM\n\n. Approach to the patient: transgender youth: endocrine considerations. J Clin Endocrinol Metab. 2014;99(12):4379–4389.22.Saraswat  A\n, \nWeinand  JD\n, \nSafer  JD\n\n. Evidence supporting the biologic nature of gender identity. Endocr Pract. 2015;21(2):199–204.23.Gooren  L\n\n. The biology of human psychosexual differentiation. Horm Behav. 2006;50(4):589–601.24.Berenbaum  SA\n, \nMeyer-Bahlburg  HF\n\n. Gender development and sexuality in disorders of sex development. Horm Metab Res. 2015;47(5):361–366.25.Dessens  AB\n, \nSlijper  FME\n, \nDrop  SLS\n\n. Gender dysphoria and gender change in chromosomal females with congenital adrenal hyperplasia. Arch Sex Behav. 2005;34(4):389–397.26.Meyer-Bahlburg  HFL\n, \nDolezal  C\n, \nBaker  SW\n, \nEhrhardt  AA\n, \nNew  MI\n\n. Gender development in women with congenital adrenal hyperplasia as a function of disorder severity. Arch Sex Behav. 2006;35(6):667–684.27.Frisén  L\n, \nNordenström  A\n, \nFalhammar  H\n, \nFilipsson  H\n, \nHolmdahl  G\n, \nJanson  PO\n, \nThorén  M\n, \nHagenfeldt  K\n, \nMöller  A\n, \nNordenskjöld  A\n\n. Gender role behavior, sexuality, and psychosocial adaptation in women with congenital adrenal hyperplasia due to CYP21A2 deficiency. J Clin Endocrinol Metab. 2009;94(9):3432–3439.28.Meyer-Bahlburg  HFL\n, \nDolezal  C\n, \nBaker  SW\n, \nCarlson  AD\n, \nObeid  JS\n, \nNew  MI\n\n. Prenatal androgenization affects gender-related behavior but not gender identity in 5–12-year-old girls with congenital adrenal hyperplasia. Arch Sex Behav. 2004;33(2):97–104.29.Cohen-Kettenis  PT\n\n. Gender change in 46,XY persons with 5α-reductase-2 deficiency and 17β-hydroxysteroid dehydrogenase-3 deficiency. Arch Sex Behav. 2005;34(4):399–410.30.Reiner  WG\n, \nGearhart  JP\n\n. Discordant sexual identity in some genetic males with cloacal exstrophy assigned to female sex at birth. N Engl J Med. 2004;350(4):333–341.31.Meyer-Bahlburg  HFL\n\n. Gender identity outcome in female-raised 46,XY persons with penile agenesis, cloacal exstrophy of the bladder, or penile ablation. Arch Sex Behav. 2005;34(4):423–438.32.Coolidge  FL\n, \nThede  LL\n, \nYoung  SE\n\n. The heritability of gender identity disorder in a child and adolescent twin sample. Behav Genet. 2002;32(4):251–257.33.Heylens  G\n, \nDe Cuypere  G\n, \nZucker  KJ\n, \nSchelfaut  C\n, \nElaut  E\n, \nVanden Bossche  H\n, \nDe Baere  E\n, \nT’Sjoen  G\n\n. Gender identity disorder in twins: a review of the case report literature. J Sex Med. 2012;9(3):751–757.34.Fernández  R\n, \nEsteva  I\n, \nGómez-Gil  E\n, \nRumbo  T\n, \nAlmaraz  MC\n, \nRoda  E\n, \nHaro-Mora  J-J\n, \nGuillamón  A\n, \nPásaro  E\n\n. Association study of ERβ, AR, and CYP19A1 genes and MtF transsexualism. J Sex Med. 2014;11(12):2986–2994.35.Henningsson  S\n, \nWestberg  L\n, \nNilsson  S\n, \nLundström  B\n, \nEkselius  L\n, \nBodlund  O\n, \nLindström  E\n, \nHellstrand  M\n, \nRosmond  R\n, \nEriksson  E\n, \nLandén  M\n\n. Sex steroid-related genes and male-to-female transsexualism. Psychoneuroendocrinology. 2005;30(7):657–664.36.Hare  L\n, \nBernard  P\n, \nSánchez  FJ\n, \nBaird  PN\n, \nVilain  E\n, \nKennedy  T\n, \nHarley  VR\n\n. Androgen receptor repeat length polymorphism associated with male-to-female transsexualism. Biol Psychiatry. 2009;65(1):93–96.37.Lombardo  F\n, \nToselli  L\n, \nGrassetti  D\n, \nPaoli  D\n, \nMasciandaro  P\n, \nValentini  F\n, \nLenzi  A\n, \nGandini  L\n\n. Hormone and genetic study in male to female transsexual patients. J Endocrinol Invest. 2013;36(8):550–557.38.Ujike  H\n, \nOtani  K\n, \nNakatsuka  M\n, \nIshii  K\n, \nSasaki  A\n, \nOishi  T\n, \nSato  T\n, \nOkahisa  Y\n, \nMatsumoto  Y\n, \nNamba  Y\n, \nKimata  Y\n, \nKuroda  S\n\n. Association study of gender identity disorder and sex hormone-related genes. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33(7):1241–1244.39.Kreukels  BP\n, \nGuillamon  A\n\n. Neuroimaging studies in people with gender incongruence. Int Rev Psychiatry. 2016;28(1):120–128.40.Steensma  TD\n, \nBiemond  R\n, \nde Boer  F\n, \nCohen-Kettenis  PT\n\n. Desisting and persisting gender dysphoria after childhood: a qualitative follow-up study. Clin Child Psychol Psychiatry. 2011;16(4):499–516.41.Wallien  MSC\n, \nCohen-Kettenis  PT\n\n. Psychosexual outcome of gender-dysphoric children. J Am Acad Child Adolesc Psychiatry. 2008;47(12):1413–1423.42.Steensma  TD\n, \nMcGuire  JK\n, \nKreukels  BPC\n, \nBeekman  AJ\n, \nCohen-Kettenis  PT\n\n. Factors associated with desistence and persistence of childhood gender dysphoria: a quantitative follow-up study. J Am Acad Child Adolesc Psychiatry. 2013;52(6):582–590.43.Cohen-Kettenis  PT\n, \nOwen  A\n, \nKaijser  VG\n, \nBradley  SJ\n, \nZucker  KJ\n\n. Demographic characteristics, social competence, and behavior problems in children with gender identity disorder: a cross-national, cross-clinic comparative analysis. J Abnorm Child Psychol. 2003;31(1):41–53.44.Dhejne  C\n, \nVan Vlerken  R\n, \nHeylens  G\n, \nArcelus  J\n\n. Mental health and gender dysphoria: a review of the literature. Int Rev Psychiatry. 2016;28(1):44–57.45.Pasterski  V\n, \nGilligan  L\n, \nCurtis  R\n\n. Traits of autism spectrum disorders in adults with gender dysphoria. Arch Sex Behav. 2014;43(2):387–393.46.Spack  NP\n, \nEdwards-Leeper  L\n, \nFeldman  HA\n, \nLeibowitz  S\n, \nMandel  F\n, \nDiamond  DA\n, \nVance  SR\n\n. Children and adolescents with gender identity disorder referred to a pediatric medical center. Pediatrics. 2012;129(3):418–425.47.Terada  S\n, \nMatsumoto  Y\n, \nSato  T\n, \nOkabe  N\n, \nKishimoto  Y\n, \nUchitomi  Y\n\n. Factors predicting psychiatric co-morbidity in gender-dysphoric adults. Psychiatry Res. 2012;200(2-3):469–474.48.VanderLaan  DP\n, \nLeef  JH\n, \nWood  H\n, \nHughes  SK\n, \nZucker  KJ\n\n. Autism spectrum disorder risk factors and autistic traits in gender dysphoric children. J Autism Dev Disord. 2015;45(6):1742–1750.49.de Vries  ALC\n, \nDoreleijers  TAH\n, \nSteensma  TD\n, \nCohen-Kettenis  PT\n\n. Psychiatric comorbidity in gender dysphoric adolescents. J Child Psychol Psychiatry. 2011;52(11):1195–1202.50.de Vries  ALC\n, \nNoens  ILJ\n, \nCohen-Kettenis  PT\n, \nvan Berckelaer-Onnes  IA\n, \nDoreleijers  TA\n\n. Autism spectrum disorders in gender dysphoric children and adolescents. J Autism Dev Disord. 2010;40(8):930–936.51.Wallien  MSC\n, \nSwaab  H\n, \nCohen-Kettenis  PT\n\n. Psychiatric comorbidity among children with gender identity disorder. J Am Acad Child Adolesc Psychiatry. 2007;46(10):1307–1314.52.Kuiper AJ, Cohen-Kettenis PT. Gender role reversal among postoperative transsexuals. Available at: https://www.atria.nl/ezines/web/IJT/97-03/numbers/symposion/ijtc0502.htm. Accessed 26 August 2016.53.Landén  M\n, \nWålinder  J\n, \nHambert  G\n, \nLundström  B\n\n. Factors predictive of regret in sex reassignment. Acta Psychiatr Scand. 1998;97(4):284–289.54.Olsson  S-E\n, \nMöller  A\n\n. Regret after sex reassignment surgery in a male-to-female transsexual: a long-term follow-up. Arch Sex Behav. 2006;35(4):501–506.55.Pfäfflin  F\n, \nJunge  A\n\n, eds. Geschlechtsumwandlung: Abhandlungen zur Transsexualität. Stuttgart, Germany: Schattauer; 1992.56.Lawrence  AA\n\n. Factors associated with satisfaction or regret following male-to-female sex reassignment surgery. Arch Sex Behav. 2003;32(4):299–315.57.Cohen-Kettenis  PT\n, \nPfäfflin  F\n\n. Transgenderism and Intersexuality in Childhood and Adolescence: Making Choices. Thousand Oaks, CA: SAGE Publications; 2003.59.Gijs  L\n, \nBrewaeys  A\n\n. Surgical treatment of gender dysphoria in adults and adolescents: recent developments, effectiveness, and challenges. Annu Rev Sex Res. 2007;18:178–224.60.Cohen-Kettenis  PT\n, \nvan Goozen  SHM\n\n. Sex reassignment of adolescent transsexuals: a follow-up study. J Am Acad Child Adolesc Psychiatry. 1997;36(2):263–271.61.Smith  YLS\n, \nvan Goozen  SHM\n, \nCohen-Kettenis  PT\n\n. Adolescents with gender identity disorder who were accepted or rejected for sex reassignment surgery: a prospective follow-up study. J Am Acad Child Adolesc Psychiatry. 2001;40(4):472–481.62.Smith  YLS\n, \nVan Goozen  SHM\n, \nKuiper  AJ\n, \nCohen-Kettenis  PT\n\n. Sex reassignment: outcomes and predictors of treatment for adolescent and adult transsexuals. Psychol Med. 2005;35(1):89–99.63.de Vries  ALC\n, \nMcGuire  JK\n, \nSteensma  TD\n, \nWagenaar  ECF\n, \nDoreleijers  TAH\n, \nCohen-Kettenis  PT\n\n. Young adult psychological outcome after puberty suppression and gender reassignment. Pediatrics. 2014;134(4):696–704.64.Cole  CM\n, \nO’Boyle  M\n, \nEmory  LE\n, \nMeyer  WJ III\n\n. Comorbidity of gender dysphoria and other major psychiatric diagnoses. Arch Sex Behav. 1997;26(1):13–26.65.Cohen-Kettenis  PT\n, \nSchagen  SEE\n, \nSteensma  TD\n, \nde Vries  ALC\n, \nDelemarre-van de Waal  HA\n\n. Puberty suppression in a gender-dysphoric adolescent: a 22-year follow-up. Arch Sex Behav. 2011;40(4):843–847.66.First  MB\n\n. Desire for amputation of a limb: paraphilia, psychosis, or a new type of identity disorder. Psychol Med. 2005;35(6):919–928.67.Wierckx  K\n, \nVan Caenegem  E\n, \nPennings  G\n, \nElaut  E\n, \nDedecker  D\n, \nVan de Peer  F\n, \nWeyers  S\n, \nDe Sutter  P\n, \nT’Sjoen  G\n\n. Reproductive wish in transsexual men. Hum Reprod. 2012;27(2):483–487.68.Wierckx  K\n, \nStuyver  I\n, \nWeyers  S\n, \nHamada  A\n, \nAgarwal  A\n, \nDe Sutter  P\n, \nT’Sjoen  G\n\n. Sperm freezing in transsexual women. Arch Sex Behav. 2012;41(5):1069–1071.69.Bertelloni  S\n, \nBaroncelli  GI\n, \nFerdeghini  M\n, \nMenchini-Fabris  F\n, \nSaggese  G\n\n. Final height, gonadal function and bone mineral density of adolescent males with central precocious puberty after therapy with gonadotropin-releasing hormone analogues. Eur J Pediatr. 2000;159(5):369–374.70.Büchter  D\n, \nBehre  HM\n, \nKliesch  S\n, \nNieschlag  E\n\n. Pulsatile GnRH or human chorionic gonadotropin/human menopausal gonadotropin as effective treatment for men with hypogonadotropic hypogonadism: a review of 42 cases. Eur J Endocrinol. 1998;139(3):298–303.71.Liu  PY\n, \nTurner  L\n, \nRushford  D\n, \nMcDonald  J\n, \nBaker  HW\n, \nConway  AJ\n, \nHandelsman  DJ\n\n. Efficacy and safety of recombinant human follicle stimulating hormone (Gonal-F) with urinary human chorionic gonadotrophin for induction of spermatogenesis and fertility in gonadotrophin-deficient men. Hum Reprod. 1999;14(6):1540–1545.72.Pasquino  AM\n, \nPucarelli  I\n, \nAccardo  F\n, \nDemiraj  V\n, \nSegni  M\n, \nDi Nardo  R\n\n. Long-term observation of 87 girls with idiopathic central precocious puberty treated with gonadotropin-releasing hormone analogs: impact on adult height, body mass index, bone mineral content, and reproductive function. J Clin Endocrinol Metab. 2008;93(1):190–195.73.Magiakou  MA\n, \nManousaki  D\n, \nPapadaki  M\n, \nHadjidakis  D\n, \nLevidou  G\n, \nVakaki  M\n, \nPapaefstathiou  A\n, \nLalioti  N\n, \nKanaka-Gantenbein  C\n, \nPiaditis  G\n, \nChrousos  GP\n, \nDacou-Voutetakis  C\n\n. The efficacy and safety of gonadotropin-releasing hormone analog treatment in childhood and adolescence: a single center, long-term follow-up study. J Clin Endocrinol Metab. 2010;95(1):109–117.74.Baba  T\n, \nEndo  T\n, \nHonnma  H\n, \nKitajima  Y\n, \nHayashi  T\n, \nIkeda  H\n, \nMasumori  N\n, \nKamiya  H\n, \nMoriwaka  O\n, \nSaito  T\n\n. Association between polycystic ovary syndrome and female-to-male transsexuality. Hum Reprod. 2007;22(4):1011–1016.75.Spinder  T\n, \nSpijkstra  JJ\n, \nvan den Tweel  JG\n, \nBurger  CW\n, \nvan Kessel  H\n, \nHompes  PGA\n, \nGooren  LJG\n\n. The effects of long term testosterone administration on pulsatile luteinizing hormone secretion and on ovarian histology in eugonadal female to male transsexual subjects. J Clin Endocrinol Metab. 1989;69(1):151–157.76.Baba  T\n, \nEndo  T\n, \nIkeda  K\n, \nShimizu  A\n, \nHonnma  H\n, \nIkeda  H\n, \nMasumori  N\n, \nOhmura  T\n, \nKiya  T\n, \nFujimoto  T\n, \nKoizumi  M\n, \nSaito  T\n\n. Distinctive features of female-to-male transsexualism and prevalence of gender identity disorder in Japan. J Sex Med. 2011;8(6):1686–1693.77.Vujovic  S\n, \nPopovic  S\n, \nSbutega-Milosevic  G\n, \nDjordjevic  M\n, \nGooren  L\n\n. Transsexualism in Serbia: a twenty-year follow-up study. J Sex Med. 2009;6(4):1018–1023.78.Ikeda  K\n, \nBaba  T\n, \nNoguchi  H\n, \nNagasawa  K\n, \nEndo  T\n, \nKiya  T\n, \nSaito  T\n\n. Excessive androgen exposure in female-to-male transsexual persons of reproductive age induces hyperplasia of the ovarian cortex and stroma but not polycystic ovary morphology. Hum Reprod. 2013;28(2):453–461.79.Trebay  G\n\n. He’s pregnant. You’re speechles. New York Times. 22 June 2008.80.Light  AD\n, \nObedin-Maliver  J\n, \nSevelius  JM\n, \nKerns  JL\n\n. Transgender men who experienced pregnancy after female-to-male gender transitioning. Obstet Gynecol. 2014;124(6):1120–1127.81.De Sutter  P\n\n. Donor inseminations in partners of female-to-male transsexuals: should the question be asked? Reprod Biomed Online. 2003;6(3):382, author reply 282–283.82.De Roo  C\n, \nTilleman  K\n, \nT’Sjoen  G\n, \nDe Sutter  P\n\n. Fertility options in transgender people. Int Rev Psychiatry. 2016;28(1):112–119.83.Wennink  JMB\n, \nDelemarre-van de Waal  HA\n, \nSchoemaker  R\n, \nSchoemaker  H\n, \nSchoemaker  J\n\n. Luteinizing hormone and follicle stimulating hormone secretion patterns in boys throughout puberty measured using highly sensitive immunoradiometric assays. Clin Endocrinol (Oxf). 1989;31(5):551–564.84.Cohen-Kettenis  PT\n, \nDelemarre-van de Waal  HA\n, \nGooren  LJG\n\n. The treatment of adolescent transsexuals: changing insights. J Sex Med. 2008;5(8):1892–1897.85.Delemarre-van de Waal  HA\n, \nCohen-Kettenis  PT\n\n. Clinical management of gender identity disorder in adolescents: a protocol on psychological and paediatric endocrinology aspects. Eur J Endocrinol. 2006;155:S131–S137.86.de Vries  ALC\n, \nSteensma  TD\n, \nDoreleijers  TAH\n, \nCohen-Kettenis  PT\n\n. Puberty suppression in adolescents with gender identity disorder: a prospective follow-up study. J Sex Med. 2011;8(8):2276–2283.87.Bouman  MB\n, \nvan Zeijl  MCT\n, \nBuncamper  ME\n, \nMeijerink  WJHJ\n, \nvan Bodegraven  AA\n, \nMullender  MG\n\n. Intestinal vaginoplasty revisited: a review of surgical techniques, complications, and sexual function. J Sex Med. 2014;11(7):1835–1847.88.Carel  JC\n, \nEugster  EA\n, \nRogol  A\n, \nGhizzoni  L\n, \nPalmert  MR\n, \nAntoniazzi  F\n, \nBerenbaum  S\n, \nBourguignon  JP\n, \nChrousos  GP\n, \nCoste  J\n, \nDeal  S\n, \nde Vries  L\n, \nFoster  C\n, \nHeger  S\n, \nHolland  J\n, \nJahnukainen  K\n, \nJuul  A\n, \nKaplowitz  P\n, \nLahlou  N\n, \nLee  MM\n, \nLee  P\n, \nMerke  DP\n, \nNeely  EK\n, \nOostdijk  W\n, \nPhillip  M\n, \nRosenfield  RL\n, \nShulman  D\n, \nStyne  D\n, \nTauber  M\n, \nWit  JM\n; ESPE-LWPES GnRH Analogs Consensus Conference Group\n. Consensus statement on the use of gonadotropin-releasing hormone analogs in children. Pediatrics. 2009;123(4):e752–e762.89.Roth  CL\n, \nBrendel  L\n, \nRückert  C\n, \nHartmann  K\n\n. Antagonistic and agonistic GnRH analogue treatment of precocious puberty: tracking gonadotropin concentrations in urine. Horm Res. 2005;63(5):257–262.90.Roth  C\n\n. Therapeutic potential of GnRH antagonists in the treatment of precocious puberty. Expert Opin Investig Drugs. 2002;11(9):1253–1259.91.Tuvemo  T\n\n. Treatment of central precocious puberty. Expert Opin Investig Drugs. 2006;15(5):495–505.92.Schagen  SE\n, \nCohen-Kettenis  PT\n, \nDelemarre-van de Waal  HA\n, \nHannema  SE\n\n. Efficacy and safety of gonadotropin-releasing hormone agonist treatment to suppress puberty in gender dysphoric adolescents. J Sex Med. 2016;13(7):1125–1132.93.Manasco  PK\n, \nPescovitz  OH\n, \nFeuillan  PP\n, \nHench  KD\n, \nBarnes  KM\n, \nJones  J\n, \nHill  SC\n, \nLoriaux  DL\n, \nCutler  GB, Jr\n\n. Resumption of puberty after long term luteinizing hormone-releasing hormone agonist treatment of central precocious puberty. J Clin Endocrinol Metab. 1988;67(2):368–372.94.Klink  D\n, \nCaris  M\n, \nHeijboer  A\n, \nvan Trotsenburg  M\n, \nRotteveel  J\n\n. Bone mass in young adulthood following gonadotropin-releasing hormone analog treatment and cross-sex hormone treatment in adolescents with gender dysphoria. J Clin Endocrinol Metab. 2015;100(2):E270–E275.95.Finkelstein  JS\n, \nKlibanski  A\n, \nNeer  RM\n\n. A longitudinal evaluation of bone mineral density in adult men with histories of delayed puberty. J Clin Endocrinol Metab. 1996;81(3):1152–1155.96.Bertelloni  S\n, \nBaroncelli  GI\n, \nFerdeghini  M\n, \nPerri  G\n, \nSaggese  G\n\n. Normal volumetric bone mineral density and bone turnover in young men with histories of constitutional delay of puberty. J Clin Endocrinol Metab. 1998;83(12):4280–4283.97.Darelid  A\n, \nOhlsson  C\n, \nNilsson  M\n, \nKindblom  JM\n, \nMellström  D\n, \nLorentzon  M\n\n. Catch up in bone acquisition in young adult men with late normal puberty. J Bone Miner Res. 2012;27(10):2198–2207.98.Mittan  D\n, \nLee  S\n, \nMiller  E\n, \nPerez  RC\n, \nBasler  JW\n, \nBruder  JM\n\n. Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs. J Clin Endocrinol Metab. 2002;87(8):3656–3661.99.Saggese  G\n, \nBertelloni  S\n, \nBaroncelli  GI\n, \nBattini  R\n, \nFranchi  G\n\n. Reduction of bone density: an effect of gonadotropin releasing hormone analogue treatment in central precocious puberty. Eur J Pediatr. 1993;152(9):717–720.100.Neely  EK\n, \nBachrach  LK\n, \nHintz  RL\n, \nHabiby  RL\n, \nSlemenda  CW\n, \nFeezle  L\n, \nPescovitz  OH\n\n. Bone mineral density during treatment of central precocious puberty. J Pediatr. 1995;127(5):819–822.101.Bertelloni  S\n, \nBaroncelli  GI\n, \nSorrentino  MC\n, \nPerri  G\n, \nSaggese  G\n\n. Effect of central precocious puberty and gonadotropin-releasing hormone analogue treatment on peak bone mass and final height in females. Eur J Pediatr. 1998;157(5):363–367.102.Thornton  P\n, \nSilverman  LA\n, \nGeffner  ME\n, \nNeely  EK\n, \nGould  E\n, \nDanoff  TM\n\n. Review of outcomes after cessation of gonadotropin-releasing hormone agonist treatment of girls with precocious puberty. Pediatr Endocrinol Rev. 2014;11(3):306–317.103.Lem  AJ\n, \nvan der Kaay  DC\n, \nHokken-Koelega  AC\n\n. Bone mineral density and body composition in short children born SGA during growth hormone and gonadotropin releasing hormone analog treatment. J Clin Endocrinol Metab. 2013;98(1):77–86.104.Antoniazzi  F\n, \nZamboni  G\n, \nBertoldo  F\n, \nLauriola  S\n, \nMengarda  F\n, \nPietrobelli  A\n, \nTatò  L\n\n. Bone mass at final height in precocious puberty after gonadotropin-releasing hormone agonist with and without calcium supplementation. J Clin Endocrinol Metab. 2003;88(3):1096–1101.105.Calcaterra  V\n, \nMannarino  S\n, \nCorana  G\n, \nCodazzi  AC\n, \nMazzola  A\n, \nBrambilla  P\n, \nLarizza  D\n\n. Hypertension during therapy with triptorelin in a girl with precocious puberty. Indian J Pediatr. 2013;80(10):884–885.106.Siomou  E\n, \nKosmeri  C\n, \nPavlou  M\n, \nVlahos  AP\n, \nArgyropoulou  MI\n, \nSiamopoulou  A\n\n. Arterial hypertension during treatment with triptorelin in a child with Williams-Beuren syndrome. Pediatr Nephrol. 2014;29(9):1633–1636.107.Staphorsius  AS\n, \nKreukels  BPC\n, \nCohen-Kettenis  PT\n, \nVeltman  DJ\n, \nBurke  SM\n, \nSchagen  SEE\n, \nWouters  FM\n, \nDelemarre-van de Waal  HA\n, \nBakker  J\n\n. Puberty suppression and executive functioning: an fMRI-study in adolescents with gender dysphoria. Psychoneuroendocrinology. 2015;56:190–199.108.Hough  D\n, \nBellingham  M\n, \nHaraldsen  IR\n, \nMcLaughlin  M\n, \nRennie  M\n, \nRobinson  JE\n, \nSolbakk  AK\n, \nEvans  NP\n\n. Spatial memory is impaired by peripubertal GnRH agonist treatment and testosterone replacement in sheep. Psychoneuroendocrinology. 2017;75:173–182.109.Collipp  PJ\n, \nKaplan  SA\n, \nBoyle  DC\n, \nPlachte  F\n, \nKogut  MD\n\n. Constitutional Isosexual Precocious Puberty. Am J Dis Child. 1964;108:399–405.110.Hahn  HB, Jr\n, \nHayles  AB\n, \nAlbert  A\n\n. Medroxyprogesterone and constitutional precocious puberty. Mayo Clin Proc. 1964;39:182–190.111.Kaplan  SA\n, \nLing  SM\n, \nIrani  NG\n\n. Idiopathic isosexual precocity. Am J Dis Child. 1968;116(6):591–598.112.Schoen  EJ\n\n. Treatment of idiopathic precocious puberty in boys. J Clin Endocrinol Metab. 1966;26(4):363–370.113.Gooren  L\n\n. Hormone treatment of the adult transsexual patient. Horm Res. 2005;64(Suppl 2):31–36.114.Moore  E\n, \nWisniewski  A\n, \nDobs  A\n\n. Endocrine treatment of transsexual people: a review of treatment regimens, outcomes, and adverse effects. J Clin Endocrinol Metab. 2003;88(8):3467–3473.115.Krueger  RB\n, \nHembree  W\n, \nHill  M\n\n. Prescription of medroxyprogesterone acetate to a patient with pedophilia, resulting in Cushing’s syndrome and adrenal insufficiency. Sex Abuse. 2006;18(2):227–228.116.Lynch  MM\n, \nKhandheria  MM\n, \nMeyer  WJ\n\n. Retrospective study of the management of childhood and adolescent gender identity disorder using medroxyprogesterone acetate. Int J Transgenderism. 2015;16:201–208.117.Tack  LJW\n, \nCraen  M\n, \nDhondt  K\n, \nVanden Bossche  H\n, \nLaridaen  J\n, \nCools  M\n\n. Consecutive lynestrenol and cross-sex hormone treatment in biological female adolescents with gender dysphoria: a retrospective analysis. Biol Sex Differ. 2016;7:14.118.Hembree  WC\n, \nCohen-Kettenis  P\n, \nDelemarre-van de Waal  HA\n, \nGooren  LJ\n, \nMeyer  WJ 3rd\n, \nSpack  NP\n, \nTangpricha  V\n, \nMontori  VM\n; Endocrine Society\n. Endocrine treatment of transsexual persons: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2009;94(9):3132–3154.119.Mann  L\n, \nHarmoni  R\n, \nPower  C\n\n. Adolescent decision-making: the development of competence. J Adolesc. 1989;12(3):265–278.120.Stultiëns  L\n, \nGoffin  T\n, \nBorry  P\n, \nDierickx  K\n, \nNys  H\n\n. Minors and informed consent: a comparative approach. Eur J Health Law. 2007;14(1):21–46.123.Ankarberg-Lindgren  C\n, \nKriström  B\n, \nNorjavaara  E\n\n. Physiological estrogen replacement therapy for puberty induction in girls: a clinical observational study. Horm Res Paediatr. 2014;81(4):239–244.124.Olson  J\n, \nSchrager  SM\n, \nClark  LF\n, \nDunlap  SL\n, \nBelzer  M\n\n. Subcutaneous testosterone: an effective delivery mechanism for masculinizing young transgender men. LGBT Health. 2014;1(3):165–167.125.Spratt  DI\n, \nStewart  I\n, \nSavage  C\n, \nCraig  W\n, \nSpack  NP\n, \nChandler  DW\n, \nSpratt  LV\n, \nEimicke  T\n, \nOlshan  JS\n\n. Subcutaneous injection of testosterone is an effective and preferred alternative to intramuscular injection: demonstration in female-to-male transgender patients. J Clin Endocrinol Metab. 2017. doi:10.1210/jc.2017-00359126.Eisenegger  C\n, \nvon Eckardstein  A\n, \nFehr  E\n, \nvon Eckardstein  S\n\n. Pharmacokinetics of testosterone and estradiol gel preparations in healthy young men. Psychoneuroendocrinology. 2013;38(2):171–178.127.de Ronde  W\n, \nten Kulve  J\n, \nWoerdeman  J\n, \nKaufman  J-M\n, \nde Jong  FH\n\n. Effects of oestradiol on gonadotrophin levels in normal and castrated men. Clin Endocrinol (Oxf). 2009;71(6):874–879.128.Money J, Ehrhardt A. Man & woman, boy & girl: differentiation and dimorphism of gender identity from conception to maturity. Baltimore, MD: Johns Hopkins University Press; 1972:202–206.129.Heylens  G\n, \nVerroken  C\n, \nDe Cock  S\n, \nT’Sjoen  G\n, \nDe Cuypere  G\n\n. Effects of different steps in gender reassignment therapy on psychopathology: a prospective study of persons with a gender identity disorder. J Sex Med. 2014;11(1):119–126.130.Costa  R\n, \nColizzi  M\n\n. The effect of cross-sex hormonal treatment on gender dysphoria individuals’ mental health: a systematic review. Neuropsychiatr Dis Treat. 2016;12:1953–1966.131.Gooren  LJG\n, \nGiltay  EJ\n\n. Review of studies of androgen treatment of female-to-male transsexuals: effects and risks of administration of androgens to females. J Sex Med. 2008;5(4):765–776.132.Levy  A\n, \nCrown  A\n, \nReid  R\n\n. Endocrine intervention for transsexuals. Clin Endocrinol (Oxf). 2003;59(4):409–418.133.Tangpricha  V\n, \nDucharme  SH\n, \nBarber  TW\n, \nChipkin  SR\n\n. Endocrinologic treatment of gender identity disorders. Endocr Pract. 2003;9(1):12–21.134.Meriggiola  MC\n, \nGava  G\n\n. Endocrine care of transpeople part I. A review of cross-sex hormonal treatments, outcomes and adverse effects in transmen. Clin Endocrinol (Oxf). 2015;83(5):597–606.135.Bhasin  S\n, \nCunningham  GR\n, \nHayes  FJ\n, \nMatsumoto  AM\n, \nSnyder  PJ\n, \nSwerdloff  RS\n, \nMontori  VM\n\n. Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2006;91(6):1995–2010.136.Pelusi  C\n, \nCostantino  A\n, \nMartelli  V\n, \nLambertini  M\n, \nBazzocchi  A\n, \nPonti  F\n, \nBattista  G\n, \nVenturoli  S\n, \nMeriggiola  MC\n\n. Effects of three different testosterone formulations in female-to-male transsexual persons. J Sex Med. 2014;11(12):3002–3011.137.Anderson  GL\n, \nLimacher  M\n, \nAssaf  AR\n, \nBassford  T\n, \nBeresford  SA\n, \nBlack  H\n, \nBonds  D\n, \nBrunner  R\n, \nBrzyski  R\n, \nCaan  B\n, \nChlebowski  R\n, \nCurb  D\n, \nGass  M\n, \nHays  J\n, \nHeiss  G\n, \nHendrix  S\n, \nHoward  BV\n, \nHsia  J\n, \nHubbell  A\n, \nJackson  R\n, \nJohnson  KC\n, \nJudd  H\n, \nKotchen  JM\n, \nKuller  L\n, \nLaCroix  AZ\n, \nLane  D\n, \nLanger  RD\n, \nLasser  N\n, \nLewis  CE\n, \nManson  J\n, \nMargolis  K\n, \nOckene  J\n, \nO’Sullivan  MJ\n, \nPhillips  L\n, \nPrentice  RL\n, \nRitenbaugh  C\n, \nRobbins  J\n, \nRossouw  JE\n, \nSarto  G\n, \nStefanick  ML\n, \nVan Horn  L\n, \nWactawski-Wende  J\n, \nWallace  R\n, \nWassertheil-Smoller  S\n; Women’s Health Initiative Steering Committee\n. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA. 2004;291(14):1701–1712.138.Dickersin  K\n, \nMunro  MG\n, \nClark  M\n, \nLangenberg  P\n, \nScherer  R\n, \nFrick  K\n, \nZhu  Q\n, \nHallock  L\n, \nNichols  J\n, \nYalcinkaya  TM\n; Surgical Treatments Outcomes Project for Dysfunctional Uterine Bleeding (STOP-DUB) Research Group\n. Hysterectomy compared with endometrial ablation for dysfunctional uterine bleeding: a randomized controlled trial. Obstet Gynecol. 2007;110(6):1279–1289.139.Gooren  LJ\n, \nGiltay  EJ\n, \nBunck  MC\n\n. Long-term treatment of transsexuals with cross-sex hormones: extensive personal experience. J Clin Endocrinol Metab. 2008;93(1):19–25.140.Prior  JC\n, \nVigna  YM\n, \nWatson  D\n\n. Spironolactone with physiological female steroids for presurgical therapy of male-to-female transsexualism. Arch Sex Behav. 1989;18(1):49–57.141.Dittrich  R\n, \nBinder  H\n, \nCupisti  S\n, \nHoffmann  I\n, \nBeckmann  MW\n, \nMueller  A\n\n. Endocrine treatment of male-to-female transsexuals using gonadotropin-releasing hormone agonist. Exp Clin Endocrinol Diabetes. 2005;113(10):586–592.142.Stripp  B\n, \nTaylor  AA\n, \nBartter  FC\n, \nGillette  JR\n, \nLoriaux  DL\n, \nEasley  R\n, \nMenard  RH\n\n. Effect of spironolactone on sex hormones in man. J Clin Endocrinol Metab. 1975;41(4):777–781.143.Levy  J\n, \nBurshell  A\n, \nMarbach  M\n, \nAfllalo  L\n, \nGlick  SM\n\n. Interaction of spironolactone with oestradiol receptors in cytosol. J Endocrinol. 1980;84(3):371–379.144.Wierckx  K\n, \nElaut  E\n, \nVan Hoorde  B\n, \nHeylens  G\n, \nDe Cuypere  G\n, \nMonstrey  S\n, \nWeyers  S\n, \nHoebeke  P\n, \nT’Sjoen  G\n\n. Sexual desire in trans persons: associations with sex reassignment treatment. J Sex Med. 2014;11(1):107–118.145.Chiriacò  G\n, \nCauci  S\n, \nMazzon  G\n, \nTrombetta  C\n\n. An observational retrospective evaluation of 79 young men with long-term adverse effects after use of finasteride against androgenetic alopecia. Andrology. 2016;4(2):245–250.146.Gava  G\n, \nCerpolini  S\n, \nMartelli  V\n, \nBattista  G\n, \nSeracchioli  R\n, \nMeriggiola  MC\n\n. Cyproterone acetate vs leuprolide acetate in combination with transdermal oestradiol in transwomen: a comparison of safety and effectiveness. Clin Endocrinol (Oxf). 2016;85(2):239–246.147.Casper  RF\n, \nYen  SS\n\n. Rapid absorption of micronized estradiol-17 beta following sublingual administration. Obstet Gynecol. 1981;57(1):62–64.148.Price  TM\n, \nBlauer  KL\n, \nHansen  M\n, \nStanczyk  F\n, \nLobo  R\n, \nBates  GW\n\n. Single-dose pharmacokinetics of sublingual versus oral administration of micronized 17β-estradiol. Obstet Gynecol. 1997;89(3):340–345.149.Toorians  AWFT\n, \nThomassen  MCLGD\n, \nZweegman  S\n, \nMagdeleyns  EJP\n, \nTans  G\n, \nGooren  LJG\n, \nRosing  J\n\n. Venous thrombosis and changes of hemostatic variables during cross-sex hormone treatment in transsexual people. J Clin Endocrinol Metab. 2003;88(12):5723–5729.150.Mepham  N\n, \nBouman  WP\n, \nArcelus  J\n, \nHayter  M\n, \nWylie  KR\n\n. People with gender dysphoria who self-prescribe cross-sex hormones: prevalence, sources, and side effects knowledge. J Sex Med. 2014;11(12):2995–3001.151.Richards  C\n, \nBouman  WP\n, \nSeal  L\n, \nBarker  MJ\n, \nNieder  TO\n, \nT’Sjoen  G\n\n. Non-binary or genderqueer genders. Int Rev Psychiatry. 2016;28(1):95–102.152.Cosyns  M\n, \nVan Borsel  J\n, \nWierckx  K\n, \nDedecker  D\n, \nVan de Peer  F\n, \nDaelman  T\n, \nLaenen  S\n, \nT’Sjoen  G\n\n. Voice in female-to-male transsexual persons after long-term androgen therapy. Laryngoscope. 2014;124(6):1409–1414.153.Deuster  D\n, \nMatulat  P\n, \nKnief  A\n, \nZitzmann  M\n, \nRosslau  K\n, \nSzukaj  M\n, \nam Zehnhoff-Dinnesen  A\n, \nSchmidt  CM\n\n. Voice deepening under testosterone treatment in female-to-male gender dysphoric individuals. Eur Arch Otorhinolaryngol. 2016;273(4):959–965.154.Lapauw  B\n, \nTaes  Y\n, \nSimoens  S\n, \nVan Caenegem  E\n, \nWeyers  S\n, \nGoemaere  S\n, \nToye  K\n, \nKaufman  J-M\n, \nT’Sjoen  GG\n\n. Body composition, volumetric and areal bone parameters in male-to-female transsexual persons. Bone. 2008;43(6):1016–1021.155.Meyer III WJ\n, \nWebb  A\n, \nStuart  CA\n, \nFinkelstein  JW\n, \nLawrence  B\n, \nWalker  PA\n\n. Physical and hormonal evaluation of transsexual patients: a longitudinal study. Arch Sex Behav. 1986;15(2):121–138.156.Asscheman  H\n, \nGooren  LJ\n, \nAssies  J\n, \nSmits  JP\n, \nde Slegte  R\n\n. Prolactin levels and pituitary enlargement in hormone-treated male-to-female transsexuals. Clin Endocrinol (Oxf). 1988;28(6):583–588.157.Gooren  LJ\n, \nHarmsen-Louman  W\n, \nvan Kessel  H\n\n. Follow-up of prolactin levels in long-term oestrogen-treated male-to-female transsexuals with regard to prolactinoma induction. Clin Endocrinol (Oxf). 1985;22(2):201–207.158.Wierckx  K\n, \nVan Caenegem  E\n, \nSchreiner  T\n, \nHaraldsen  I\n, \nFisher  AD\n, \nToye  K\n, \nKaufman  JM\n, \nT’Sjoen  G\n\n. Cross-sex hormone therapy in trans persons is safe and effective at short-time follow-up: results from the European network for the investigation of gender incongruence. J Sex Med. 2014;11(8):1999–2011.159.Ott  J\n, \nKaufmann  U\n, \nBentz  EK\n, \nHuber  JC\n, \nTempfer  CB\n\n. Incidence of thrombophilia and venous thrombosis in transsexuals under cross-sex hormone therapy. Fertil Steril. 2010;93(4):1267–1272.160.Giltay  EJ\n, \nHoogeveen  EK\n, \nElbers  JMH\n, \nGooren  LJG\n, \nAsscheman  H\n, \nStehouwer  CDA\n\n. Effects of sex steroids on plasma total homocysteine levels: a study in transsexual males and females. J Clin Endocrinol Metab. 1998;83(2):550–553.161.van Kesteren  PJM\n, \nAsscheman  H\n, \nMegens  JAJ\n, \nGooren  LJG\n\n. Mortality and morbidity in transsexual subjects treated with cross-sex hormones. Clin Endocrinol (Oxf). 1997;47(3):337–343.162.Wierckx  K\n, \nGooren  L\n, \nT’Sjoen  G\n\n. Clinical review: breast development in trans women receiving cross-sex hormones. J Sex Med. 2014;11(5):1240–1247.163.Bird  D\n, \nVowles  K\n, \nAnthony  PP\n\n. Spontaneous rupture of a liver cell adenoma after long term methyltestosterone: report of a case successfully treated by emergency right hepatic lobectomy. Br J Surg. 1979;66(3):212–213.164.Westaby  D\n, \nOgle  SJ\n, \nParadinas  FJ\n, \nRandell  JB\n, \nMurray-Lyon  IM\n\n. Liver damage from long-term methyltestosterone. Lancet. 1977;2(8032):262–263.165.Weinand  JD\n, \nSafer  JD\n\n. Hormone therapy in transgender adults is safe with provider supervision; a review of hormone therapy sequelae for transgender individuals. J Clin Transl Endocrinol. 2015;2(2):55–60.166.Roberts  TK\n, \nKraft  CS\n, \nFrench  D\n, \nJi  W\n, \nWu  AH\n, \nTangpricha  V\n, \nFantz  CR\n\n. Interpreting laboratory results in transgender patients on hormone therapy. Am J Med. 2014;127(2):159–162.167.Vesper  HW\n, \nBotelho  JC\n, \nWang  Y\n\n. Challenges and improvements in testosterone and estradiol testing. Asian J Androl. 2014;16(2):178–184.168.Asscheman  H\n, \nT’Sjoen  G\n, \nLemaire  A\n, \nMas  M\n, \nMeriggiola  MC\n, \nMueller  A\n, \nKuhn  A\n, \nDhejne  C\n, \nMorel-Journel  N\n, \nGooren  LJ\n\n. Venous thrombo-embolism as a complication of cross-sex hormone treatment of male-to-female transsexual subjects: a review. Andrologia. 2014;46(7):791–795.169.Righini  M\n, \nPerrier  A\n, \nDe Moerloose  P\n, \nBounameaux  H\n\n. D-dimer for venous thromboembolism diagnosis: 20 years later. J Thromb Haemost. 2008;6(7):1059–1071.170.Gooren  LJ\n, \nAssies  J\n, \nAsscheman  H\n, \nde Slegte  R\n, \nvan Kessel  H\n\n. Estrogen-induced prolactinoma in a man. J Clin Endocrinol Metab. 1988;66(2):444–446.171.Kovacs  K\n, \nStefaneanu  L\n, \nEzzat  S\n, \nSmyth  HS\n\n. Prolactin-producing pituitary adenoma in a male-to-female transsexual patient with protracted estrogen administration. A morphologic study. Arch Pathol Lab Med. 1994;118(5):562–565.172.Serri  O\n, \nNoiseux  D\n, \nRobert  F\n, \nHardy  J\n\n. Lactotroph hyperplasia in an estrogen treated male-to-female transsexual patient. J Clin Endocrinol Metab. 1996;81(9):3177–3179.173.Cunha  FS\n, \nDomenice  S\n, \nCâmara  VL\n, \nSircili  MH\n, \nGooren  LJ\n, \nMendonça  BB\n, \nCosta  EM\n\n. Diagnosis of prolactinoma in two male-to-female transsexual subjects following high-dose cross-sex hormone therapy. Andrologia. 2015;47(6):680–684.174.Nota  NM\n, \nDekker  MJHJ\n, \nKlaver  M\n, \nWiepjes  CM\n, \nvan Trotsenburg  MA\n, \nHeijboer  AC\n, \nden Heijer  M\n\n. Prolactin levels during short- and long-term cross-sex hormone treatment: an observational study in transgender persons. Andrologia. 2017;49(6).175.Bunck  MC\n, \nDebono  M\n, \nGiltay  EJ\n, \nVerheijen  AT\n, \nDiamant  M\n, \nGooren  LJ\n\n. Autonomous prolactin secretion in two male-to-female transgender patients using conventional oestrogen dosages. BMJ Case Rep. 2009;2009:bcr0220091589.176.Elamin  MB\n, \nGarcia  MZ\n, \nMurad  MH\n, \nErwin  PJ\n, \nMontori  VM\n\n. Effect of sex steroid use on cardiovascular risk in transsexual individuals: a systematic review and meta-analyses. Clin Endocrinol (Oxf). 2010;72(1):1–10.177.Berra  M\n, \nArmillotta  F\n, \nD’Emidio  L\n, \nCostantino  A\n, \nMartorana  G\n, \nPelusi  G\n, \nMeriggiola  MC\n\n. Testosterone decreases adiponectin levels in female to male transsexuals. Asian J Androl. 2006;8(6):725–729.178.Elbers  JMH\n, \nGiltay  EJ\n, \nTeerlink  T\n, \nScheffer  PG\n, \nAsscheman  H\n, \nSeidell  JC\n, \nGooren  LJG\n\n. Effects of sex steroids on components of the insulin resistance syndrome in transsexual subjects. Clin Endocrinol (Oxf). 2003;58(5):562–571.179.Giltay  EJ\n, \nLambert  J\n, \nGooren  LJG\n, \nElbers  JMH\n, \nSteyn  M\n, \nStehouwer  CDA\n\n. Sex steroids, insulin, and arterial stiffness in women and men. Hypertension. 1999;34(4 Pt 1):590–597.180.Polderman  KH\n, \nGooren  LJ\n, \nAsscheman  H\n, \nBakker  A\n, \nHeine  RJ\n\n. Induction of insulin resistance by androgens and estrogens. J Clin Endocrinol Metab. 1994;79(1):265–271.182.Meriggiola  MC\n, \nArmillotta  F\n, \nCostantino  A\n, \nAltieri  P\n, \nSaad  F\n, \nKalhorn  T\n, \nPerrone  AM\n, \nGhi  T\n, \nPelusi  C\n, \nPelusi  G\n\n. Effects of testosterone undecanoate administered alone or in combination with letrozole or dutasteride in female to male transsexuals. J Sex Med. 2008;5(10):2442–2453.183.Giltay  EJ\n, \nToorians  AW\n, \nSarabdjitsingh  AR\n, \nde Vries  NA\n, \nGooren  LJ\n\n. Established risk factors for coronary heart disease are unrelated to androgen-induced baldness in female-to-male transsexuals. J Endocrinol. 2004;180(1):107–112.184.Giltay  EJ\n, \nVerhoef  P\n, \nGooren  LJG\n, \nGeleijnse  JM\n, \nSchouten  EG\n, \nStehouwer  CDA\n\n. Oral and transdermal estrogens both lower plasma total homocysteine in male-to-female transsexuals. Atherosclerosis. 2003;168(1):139–146.185.Calof  OM\n, \nSingh  AB\n, \nLee  ML\n, \nKenny  AM\n, \nUrban  RJ\n, \nTenover  JL\n, \nBhasin  S\n\n. Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials. J Gerontol A Biol Sci Med Sci. 2005;60(11):1451–1457.186.Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults\n. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486–2497.187.Murad  MH\n, \nElamin  MB\n, \nGarcia  MZ\n, \nMullan  RJ\n, \nMurad  A\n, \nErwin  PJ\n, \nMontori  VM\n\n. Hormonal therapy and sex reassignment: a systematic review and meta-analysis of quality of life and psychosocial outcomes. Clin Endocrinol (Oxf). 2010;72(2):214–231.188.Van Caenegem  E\n, \nWierckx  K\n, \nTaes  Y\n, \nSchreiner  T\n, \nVandewalle  S\n, \nToye  K\n, \nLapauw  B\n, \nKaufman  JM\n, \nT’Sjoen  G\n\n. Body composition, bone turnover, and bone mass in trans men during testosterone treatment: 1-year follow-up data from a prospective case-controlled study (ENIGI). Eur J Endocrinol. 2015;172(2):163–171.189.Turner  A\n, \nChen  TC\n, \nBarber  TW\n, \nMalabanan  AO\n, \nHolick  MF\n, \nTangpricha  V\n\n. Testosterone increases bone mineral density in female-to-male transsexuals: a case series of 15 subjects. Clin Endocrinol (Oxf). 2004;61(5):560–566.190.van Kesteren  P\n, \nLips  P\n, \nGooren  LJG\n, \nAsscheman  H\n, \nMegens  J\n\n. Long-term follow-up of bone mineral density and bone metabolism in transsexuals treated with cross-sex hormones. Clin Endocrinol (Oxf). 1998;48(3):347–354.191.Van Caenegem  E\n, \nTaes  Y\n, \nWierckx  K\n, \nVandewalle  S\n, \nToye  K\n, \nKaufman  JM\n, \nSchreiner  T\n, \nHaraldsen  I\n, \nT’Sjoen  G\n\n. Low bone mass is prevalent in male-to-female transsexual persons before the start of cross-sex hormonal therapy and gonadectomy. Bone. 2013;54(1):92–97.192.Amin  S\n, \nZhang  Y\n, \nSawin  CT\n, \nEvans  SR\n, \nHannan  MT\n, \nKiel  DP\n, \nWilson  PW\n, \nFelson  DT\n\n. Association of hypogonadism and estradiol levels with bone mineral density in elderly men from the Framingham study. Ann Intern Med. 2000;133(12):951–963.193.Gennari  L\n, \nKhosla  S\n, \nBilezikian  JP\n\n. Estrogen and fracture risk in men. J Bone Miner Res. 2008;23(10):1548–1551.194.Khosla  S\n, \nMelton  LJ III\n, \nAtkinson  EJ\n, \nO’Fallon  WM\n, \nKlee  GG\n, \nRiggs  BL\n\n. Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: a key role for bioavailable estrogen. J Clin Endocrinol Metab. 1998;83(7):2266–2274.195.Mueller  A\n, \nDittrich  R\n, \nBinder  H\n, \nKuehnel  W\n, \nMaltaris  T\n, \nHoffmann  I\n, \nBeckmann  MW\n\n. High dose estrogen treatment increases bone mineral density in male-to-female transsexuals receiving gonadotropin-releasing hormone agonist in the absence of testosterone. Eur J Endocrinol. 2005;153(1):107–113.196.Ruetsche  AG\n, \nKneubuehl  R\n, \nBirkhaeuser  MH\n, \nLippuner  K\n\n. Cortical and trabecular bone mineral density in transsexuals after long-term cross-sex hormonal treatment: a cross-sectional study. Osteoporos Int. 2005;16(7):791–798.197.Ganly  I\n, \nTaylor  EW\n\n. Breast cancer in a trans-sexual man receiving hormone replacement therapy. Br J Surg. 1995;82(3):341.198.Pritchard  TJ\n, \nPankowsky  DA\n, \nCrowe  JP\n, \nAbdul-Karim  FW\n\n. Breast cancer in a male-to-female transsexual. A case report. JAMA. 1988;259(15):2278–2280.199.Symmers  WS\n\n. Carcinoma of breast in trans-sexual individuals after surgical and hormonal interference with the primary and secondary sex characteristics. BMJ. 1968;2(5597):83–85.200.Brown  GR\n\n. Breast cancer in transgender veterans: a ten-case series. LGBT Health. 2015;2(1):77–80.201.Shao  T\n, \nGrossbard  ML\n, \nKlein  P\n\n. Breast cancer in female-to-male transsexuals: two cases with a review of physiology and management. Clin Breast Cancer. 2011;11(6):417–419.202.Nikolic  DV\n, \nDjordjevic  ML\n, \nGranic  M\n, \nNikolic  AT\n, \nStanimirovic  VV\n, \nZdravkovic  D\n, \nJelic  S\n\n. Importance of revealing a rare case of breast cancer in a female to male transsexual after bilateral mastectomy. World J Surg Oncol. 2012;10:280.203.Bösze  P\n, \nTóth  A\n, \nTörök  M\n\n. Hormone replacement and the risk of breast cancer in Turner’s syndrome. N Engl J Med. 2006;355(24):2599–2600.204.Schoemaker  MJ\n, \nSwerdlow  AJ\n, \nHiggins  CD\n, \nWright  AF\n, \nJacobs  PA\n; UK Clinical Cytogenetics Group\n. Cancer incidence in women with Turner syndrome in Great Britain: a national cohort study. Lancet Oncol. 2008;9(3):239–246.205.Smith  RA\n, \nCokkinides  V\n, \nEyre  HJ\n\n. American Cancer Society guidelines for the early detection of cancer, 2006. CA Cancer J Clin. 2006;56(1):11–25, quiz 49–50.206.Wilson  JD\n, \nRoehrborn  C\n\n. Long-term consequences of castration in men: lessons from the Skoptzy and the eunuchs of the Chinese and Ottoman courts. J Clin Endocrinol Metab. 1999;84(12):4324–4331.207.van Kesteren  P\n, \nMeinhardt  W\n, \nvan der Valk  P\n, \nGeldof  A\n, \nMegens  J\n, \nGooren  L\n\n. Effects of estrogens only on the prostates of aging men. J Urol. 1996;156(4):1349–1353.208.Brown  JA\n, \nWilson  TM\n\n. Benign prostatic hyperplasia requiring transurethral resection of the prostate in a 60-year-old male-to-female transsexual. Br J Urol. 1997;80(6):956–957.209.Casella  R\n, \nBubendorf  L\n, \nSchaefer  DJ\n, \nBachmann  A\n, \nGasser  TC\n, \nSulser  T\n\n. Does the prostate really need androgens to grow? Transurethral resection of the prostate in a male-to-female transsexual 25 years after sex-changing operation. Urol Int. 2005;75(3):288–290.210.Dorff  TB\n, \nShazer  RL\n, \nNepomuceno  EM\n, \nTucker  SJ\n\n. Successful treatment of metastatic androgen-independent prostate carcinoma in a transsexual patient. Clin Genitourin Cancer. 2007;5(5):344–346.211.Thurston  AV\n\n. Carcinoma of the prostate in a transsexual. Br J Urol. 1994;73(2):217.212.van Harst EP, Newling DW, Gooren LJ, Asscheman H, Prenger DM.\n Metastatic prostatic carcinoma in a male-to-female transsexual. BJU Int. 1998;81:776.213.Turo  R\n, \nJallad  S\n, \nPrescott  S\n, \nCross  WR\n\n. Metastatic prostate cancer in transsexual diagnosed after three decades of estrogen therapy. Can Urol Assoc J. 2013;7(7–8):E544–E546.214.Miksad  RA\n, \nBubley  G\n, \nChurch  P\n, \nSanda  M\n, \nRofsky  N\n, \nKaplan  I\n, \nCooper  A\n\n. Prostate cancer in a transgender woman 41 years after initiation of feminization. JAMA. 2006;296(19):2316–2317.215.Moyer  VA\n; U.S. Preventive Services Task Force\n. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2012;157(2):120–134.216.Futterweit  W\n\n. Endocrine therapy of transsexualism and potential complications of long-term treatment. Arch Sex Behav. 1998;27(2):209–226.217.Miller  N\n, \nBédard  YC\n, \nCooter  NB\n, \nShaul  DL\n\n. Histological changes in the genital tract in transsexual women following androgen therapy. Histopathology. 1986;10(7):661–669.218.O’Hanlan  KA\n, \nDibble  SL\n, \nYoung-Spint  M\n\n. Total laparoscopic hysterectomy for female-to-male transsexuals. Obstet Gynecol. 2007;110(5):1096–1101.219.Dizon  DS\n, \nTejada-Berges  T\n, \nKoelliker  S\n, \nSteinhoff  M\n, \nGranai  CO\n\n. Ovarian cancer associated with testosterone supplementation in a female-to-male transsexual patient. Gynecol Obstet Invest. 2006;62(4):226–228.220.Hage  JJ\n, \nDekker  JJML\n, \nKarim  RB\n, \nVerheijen  RHM\n, \nBloemena  E\n\n. Ovarian cancer in female-to-male transsexuals: report of two cases. Gynecol Oncol. 2000;76(3):413–415.221.Mueller  A\n, \nGooren  L\n\n. Hormone-related tumors in transsexuals receiving treatment with cross-sex hormones. Eur J Endocrinol. 2008;159(3):197–202.222.Coleman  E\n, \nBockting  W\n, \nBotzer  M\n, \nCohen-Kettenis  P\n, \nDeCuypere  G\n, \nFeldman  J\n, \nFraser  L\n, \nGreen  J\n, \nKnudson  G\n, \nMeyer  WJ\n, \nMonstrey  S\n, \nAdler  RK\n, \nBrown  GR\n, \nDevor  AH\n, \nEhrbar  R\n, \nEttner  R\n, \nEyler  E\n, \nGarofalo  R\n, \nKarasic  DH\n, \nLev  AI\n, \nMayer  G\n, \nMeyer-Bahlburg  H\n, \nHall  BP\n, \nPfaefflin  F\n, \nRachlin  K\n, \nRobinson  B\n, \nSchechter  LS\n, \nTangpricha  V\n, \nvan Trotsenburg  M\n, \nVitale  A\n, \nWinter  S\n, \nWhittle  S\n, \nWylie  KR\n, \nZucker  K\n\n. Standards of care for the health of transsexual, transgender, and gender-nonconforming people, version 7. Int J Transgenderism. 2012;13:165–232.223.Colebunders  B\n, \nD’Arpa  S\n, \nWeijers  S\n, \nLumen  N\n, \nHoebeke  P\n, \nMonstrey  S\n\n. Female-to-male gender reassignment surgery. In: Ettner R, Monstrey S, Coleman E, eds. Principles of Transgender Medicine and Surgery. 2nd ed. New York, NY: Routledge Taylor & Francis Group; 2016:279–317.\n224.Monstrey  S\n, \nHoebeke  P\n, \nDhont  M\n, \nDe Cuypere  G\n, \nRubens  R\n, \nMoerman  M\n, \nHamdi  M\n, \nVan Landuyt  K\n, \nBlondeel  P\n\n. Surgical therapy in transsexual patients: a multi-disciplinary approach. Acta Chir Belg. 2001;101(5):200–209.225.Selvaggi  G\n, \nCeulemans  P\n, \nDe Cuypere  G\n, \nVanLanduyt  K\n, \nBlondeel  P\n, \nHamdi  M\n, \nBowman  C\n, \nMonstrey  S\n\n. Gender identity disorder: general overview and surgical treatment for vaginoplasty in male-to-female transsexuals. Plast Reconstr Surg. 2005;116(6):135e–145e.226.Tugnet  N\n, \nGoddard  JC\n, \nVickery  RM\n, \nKhoosal  D\n, \nTerry  TR\n\n. Current management of male-to-female gender identity disorder in the UK. Postgrad Med J. 2007;83(984):638–642.227.Horbach  SER\n, \nBouman  M-B\n, \nSmit  JM\n, \nÖzer  M\n, \nBuncamper  ME\n, \nMullender  MG\n\n. Outcome of vaginoplasty in male-to-female transgenders: a systematic review of surgical techniques. J Sex Med. 2015;12(6):1499–1512.228.Wroblewski  P\n, \nGustafsson  J\n, \nSelvaggi  G\n\n. Sex reassignment surgery for transsexuals. Curr Opin Endocrinol Diabetes Obes. 2013;20(6):570–574.229.Morrison  SD\n, \nSatterwhite  T\n, \nGrant  DW\n, \nKirby  J\n, \nLaub  DR, Sr\n, \nVanMaasdam  J\n\n. Long-term outcomes of rectosigmoid neocolporrhaphy in male-to-female gender reassignment surgery. Plast Reconstr Surg. 2015;136(2):386–394.230.Dessy  LA\n, \nMazzocchi  M\n, \nCorrias  F\n, \nCeccarelli  S\n, \nMarchese  C\n, \nScuderi  N\n\n. The use of cultured autologous oral epithelial cells for vaginoplasty in male-to-female transsexuals: a feasibility, safety, and advantageousness clinical pilot study. Plast Reconstr Surg. 2014;133(1):158–161.231.Li  FY\n, \nXu  YS\n, \nZhou  CD\n, \nZhou  Y\n, \nLi  SK\n, \nLi  Q\n\n. Long-term outcomes of vaginoplasty with autologous buccal micromucosa. Obstet Gynecol. 2014;123(5):951–956.232.Kanhai  RC\n\n. Sensate vagina pedicled-spot for male-to-female transsexuals: the experience in the first 50 patients. Aesthetic Plast Surg. 2016;40(2):284–287.233.Straayer  C\n\n. Transplants for transsexuals? Ambitions, concerns, ideology. Paper presented at: Trans*Studies: An International Transdisciplinary Conference on Gender, Embodiment, and Sexuality; 7–10 September 2016; University of Arizona, Tucson, AZ.\n234.Bucci  S\n, \nMazzon  G\n, \nLiguori  G\n, \nNapoli  R\n, \nPavan  N\n, \nBormioli  S\n, \nOllandini  G\n, \nDe Concilio  B\n, \nTrombetta  C.\nNeovaginal prolapse in male-to-female transsexuals: an 18-year-long experience. Biomed Res Int. 2014;2014:240761.235.Raigosa  M\n, \nAvvedimento  S\n, \nYoon  TS\n, \nCruz-Gimeno  J\n, \nRodriguez  G\n, \nFontdevila  J\n\n. Male-to-female genital reassignment surgery: a retrospective review of surgical technique and complications in 60 patients. J Sex Med. 2015;12(8):1837–1845.236.Green  R\n\n. Sexual functioning in post-operative transsexuals: male-to-female and female-to-male. Int J Impot Res. 1998;10(Suppl 1):S22–S24.237.Hess  J\n, \nRossi Neto  R\n, \nPanic  L\n, \nRübben  H\n, \nSenf  W\n\n. Satisfaction with male-to-female gender reassignment surgery. Dtsch Arztebl Int. 2014;111(47):795–801.238.Nygren  U\n, \nNordenskjold  A\n, \nArver  S\n, \nSodersten  M\n\n. Effects on voice fundamental frequency and satisfaction with voice in trans men during testosterone treatment—a longitudinal study. J Voice. 2016;30(6):766.e23-766.e34.239.Becking  AG\n, \nTuinzing  DB\n, \nHage  JJ\n, \nGooren  LJG\n\n. Transgender feminization of the facial skeleton. Clin Plast Surg. 2007;34(3):557–564.240.Giraldo  F\n, \nEsteva  I\n, \nBergero  T\n, \nCano  G\n, \nGonzález  C\n, \nSalinas  P\n, \nRivada  E\n, \nLara  JS\n, \nSoriguer  F\n; Andalusia Gender Team\n. Corona glans clitoroplasty and urethropreputial vestibuloplasty in male-to-female transsexuals: the vulval aesthetic refinement by the Andalusia Gender Team. Plast Reconstr Surg. 2004;114(6):1543–1550.241.Goddard  JC\n, \nVickery  RM\n, \nTerry  TR\n\n. Development of feminizing genitoplasty for gender dysphoria. J Sex Med. 2007;4(4 Pt 1):981–989.242.Hage  JJ\n, \nde Graaf  FH\n, \nBouman  FG\n, \nBloem  JJAM\n\n. Sculpturing the glans in phalloplasty. Plast Reconstr Surg. 1993;92(1):157–161, discussion 162.243.Thiagaraj  D\n, \nGunasegaram  R\n, \nLoganath  A\n, \nPeh  KL\n, \nKottegoda  SR\n, \nRatnam  SS\n\n. Histopathology of the testes from male transsexuals on oestrogen therapy. Ann Acad Med Singapore. 1987;16(2):347–348.244.Monstrey  SJ\n, \nCeulemans  P\n, \nHoebeke  P\n\n. Sex reassignment surgery in the female-to-male transsexual. Semin Plast Surg. 2011;25(3):229–244.245.Perovic  SV\n, \nDjinovic  R\n, \nBumbasirevic  M\n, \nDjordjevic  M\n, \nVukovic  P\n\n. Total phalloplasty using a musculocutaneous latissimus dorsi flap. BJU Int. 2007;100(4):899–905, discussion 905.246.Vesely  J\n, \nHyza  P\n, \nRanno  R\n, \nCigna  E\n, \nMonni  N\n, \nStupka  I\n, \nJustan  I\n, \nDvorak  Z\n, \nNovak  P\n, \nRanno  S\n\n. New technique of total phalloplasty with reinnervated latissimus dorsi myocutaneous free flap in female-to-male transsexuals. Ann Plast Surg. 2007;58(5):544–550.247.Ranno  R\n, \nVeselý  J\n, \nHýza  P\n, \nStupka  I\n, \nJustan  I\n, \nDvorák  Z\n, \nMonni  N\n, \nNovák  P\n, \nRanno  S\n\n. Neo-phalloplasty with re-innervated latissimus dorsi free flap: a functional study of a novel technique. Acta Chir Plast. 2007;49(1):3–7.248.Garcia  MM\n, \nChristopher  NA\n, \nDe Luca  F\n, \nSpilotros  M\n, \nRalph  DJ\n\n. Overall satisfaction, sexual function, and the durability of neophallus dimensions following staged female to male genital gender confirming surgery: the Institute of Urology, London U.K. experience. Transl Androl Urol. 2014;3(2):156–162.249.Chen  H-C\n, \nGedebou  TM\n, \nYazar  S\n, \nTang  Y-B\n\n. Prefabrication of the free fibula osteocutaneous flap to create a functional human penis using a controlled fistula method. J Reconstr Microsurg. 2007;23(3):151–154.250.Hoebeke  PB\n, \nDecaestecker  K\n, \nBeysens  M\n, \nOpdenakker  Y\n, \nLumen  N\n, \nMonstrey  SM\n\n. Erectile implants in female-to-male transsexuals: our experience in 129 patients. Eur Urol. 2010;57(2):334–341.251.Hage  JJ\n\n. Metaidoioplasty: an alternative phalloplasty technique in transsexuals. Plast Reconstr Surg. 1996;97(1):161–167.252.Cohanzad  S\n\n. Extensive metoidioplasty as a technique capable of creating a compatible analogue to a natural penis in female transsexuals. Aesthetic Plast Surg. 2016;40(1):130–138.253.Selvaggi  G\n, \nHoebeke  P\n, \nCeulemans  P\n, \nHamdi  M\n, \nVan Landuyt  K\n, \nBlondeel  P\n, \nDe Cuypere  G\n, \nMonstrey  S\n\n. Scrotal reconstruction in female-to-male transsexuals: a novel scrotoplasty. Plast Reconstr Surg. 2009;123(6):1710–1718.254.Bjerrome Ahlin  H\n, \nKölby  L\n, \nElander  A\n, \nSelvaggi  G\n\n. Improved results after implementation of the Ghent algorithm for subcutaneous mastectomy in female-to-male transsexuals. J Plast Surg Hand Surg. 2014;48(6):362–367.255.Wolter  A\n, \nDiedrichson  J\n, \nScholz  T\n, \nArens-Landwehr  A\n, \nLiebau  J\n\n. Sexual reassignment surgery in female-to-male transsexuals: an algorithm for subcutaneous mastectomy. J Plast Reconstr Aesthet Surg. 2015;68(2):184–191.256.Richards  C\n, \nBarrett  J\n\n. The case for bilateral mastectomy and male chest contouring for the female-to-male transsexual. Ann R Coll Surg Engl. 2013;95(2):93–95.257.Sutcliffe  PA\n, \nDixon  S\n, \nAkehurst  RL\n, \nWilkinson  A\n, \nShippam  A\n, \nWhite  S\n, \nRichards  R\n, \nCaddy  CM\n\n. Evaluation of surgical procedures for sex reassignment: a systematic review. J Plast Reconstr Aesthet Surg. 2009;62(3):294–306, discussion 306–308.258.Selvaggi  G\n, \nElander  A\n\n. Penile reconstruction/formation. Curr Opin Urol. 2008;18(6):589–597.259.Dhejne  C\n, \nLichtenstein  P\n, \nBoman  M\n, \nJohansson  ALV\n, \nLångström  N\n, \nLandén  M\n\n. Long-term follow-up of transsexual persons undergoing sex reassignment surgery: cohort study in Sweden. PLoS One. 2011;6(2):e16885.260.Kuhn  A\n, \nBodmer  C\n, \nStadlmayr  W\n, \nKuhn  P\n, \nMueller  MD\n, \nBirkhäuser  M\n\n. Quality of life 15 years after sex reassignment surgery for transsexualism. Fertil Steril. 2009;92(5):1685–1689.e3.261.Papadopulos  NA\n, \nLellé  JD\n, \nZavlin  D\n, \nHerschbach  P\n, \nHenrich  G\n, \nKovacs  L\n, \nEhrenberger  B\n, \nKluger  AK\n, \nMachens  HG\n, \nSchaff  J\n\n. Quality of life and patient satisfaction following male-to-female sex reassignment surgery. J Sex Med. 2017;14(5):721–730.262.Simonsen  RK\n, \nHald  GM\n, \nKristensen  E\n, \nGiraldi  A\n\n. Long-term follow-up of individuals undergoing sex-reassignment surgery: somatic morbidity and cause of death. Sex Med. 2016;4(1):e60–e68.263.Djordjevic  ML\n, \nBizic  MR\n, \nDuisin  D\n, \nBouman  MB\n, \nBuncamper  M\n\n. Reversal Surgery in regretful male-to-female transsexuals after sex reassignment surgery. J Sex Med. 2016;13(6):1000–1007.264.Liberopoulos  EN\n, \nFlorentin  M\n, \nMikhailidis  DP\n, \nElisaf  MS\n\n. Compliance with lipid-lowering therapy and its impact on cardiovascular morbidity and mortality. Expert Opin Drug Saf. 2008;7(6):717–725.265.Forbes  SS\n, \nStephen  WJ\n, \nHarper  WL\n, \nLoeb  M\n, \nSmith  R\n, \nChristoffersen  EP\n, \nMcLean  RF\n\n. Implementation of evidence-based practices for surgical site infection prophylaxis: results of a pre- and postintervention study. J Am Coll Surg. 2008;207(3):336–341.266.Davis  PJ\n, \nSpady  D\n, \nde Gara  C\n, \nForgie  SE\n\n. Practices and attitudes of surgeons toward the prevention of surgical site infections: a provincial survey in Alberta, Canada. Infect Control Hosp Epidemiol. 2008;29(12):1164–1166.    \n    \n\n\n\n        \n\n        \n                    Author notes\n*Cosponsoring Associations: American Association of Clinical Endocrinologists, American Society of Andrology, European Society for Pediatric Endocrinology, European Society of Endocrinology, Pediatric Endocrine Society, and World Professional Association for Transgender Health.Copyright © 2017 Endocrine SocietyCopyright © 2017 Endocrine Society\n\n        \n    \n    \n    \n\n                \n                \n    \n            \n            \n        \n        Supplementary data\n        \n \n    \n                    \n\n                \n            \n        \n\n    \n\n\n    \n            \n                Citations\n                    \n                            \n                    \n                Views\n                \n            \n                    \n                    Altmetric\n                    \n\n\n            \n                    \n    \n    \n        Email alerts\n                \n                \n                \n                    \n        \n    \n    \n    \n        See also\n                    \n                \n                        \n                                Companion Articles\n                            \n                                    \n                                        Effect of Sex Steroids on the Bone Health of Transgender Individuals: A Systematic Review and Meta-Analysis\n                                    \n                                    \n                                        Sex Steroids and Cardiovascular Outcomes in Transgender Individuals: A Systematic Review and Meta-Analysis\n                                    \n                                    \n                                        Letter to the Editor: “Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society Clinical Practice Guideline” \n                                    \n                            \n                        \n                \n            \n    \n    \n    \n    \n    Citing articles via\n    \n\n    \n            \n            \n                \n                    Latest\n                \n            \n            \n                \n                    Most Read\n                \n            \n            \n                \n                    Most Cited\n                \n            \n    \n        \n        \n        \n \n    \n    \n        More from Oxford Academic\n            \n            \n            \n\n            \n            \n    \n\n    \n\n","length":251721,"excerpt":"Gender affirmation is multidisciplinary treatment. Gender-dysphoric/gender-incongruent persons seek and/or are referred to endocrinologists to develop the physi","byline":"Hembree, Wylie C, Cohen-Kettenis, Peggy T, Gooren, Louis, Hannema, Sabine E, Meyer, Walter J, Murad, M Hassan, Rosenthal, Stephen M, Safer, Joshua D, Tangpricha, Vin, T’Sjoen, Guy G","dir":null,"siteName":"OUP Academic","lang":"en"},"finalizedMeta":{"title":"Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society* Clinical Practice Guideline","description":"Gender affirmation is multidisciplinary treatment. Gender-dysphoric/gender-incongruent persons seek and/or are referred to endocrinologists to develop the physi","author":"","creator":"","publisher":"","date":"2017-09-13","image":"https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/jcem/Issue/102/11/3/m_cover.jpeg?Expires=1722615010&Signature=1k7bdN9ysp1LbHC-WdBQCSB9w8IJRIodgVWnNGaQKp-lm55NjCUmXT-ebEQE8BKCj0sUH8aEsUBVOtouS8VC7sh7HG57Tbp2yIbki2yS~-gqF-1v4W3Z47djZeV7~dq0rcxoC0KNK8WANS~xjFZiksUkRE3VNS3is720fTWOzh-7TaPOTYIJAR1jIBaA6FOvhheUPLurGmssKN5Sq3FKiA2m689PMATqMf8vcthKlm6VYS5I3Be~7TQavbvcGzgTAWVqvhX1ikdnhh~ceGtNIDGAJZiLJCIaXjcSc4~HVWKslGdO6tJg71lTWN-8vZ4d~RhJV7hLXDiqXH5rw~06eA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA","topics":[]},"jsonLd":{"@type":"ScholarlyArticle","headline":"Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society* Clinical Practice Guideline","description":"Gender affirmation is multidisciplinary treatment. Gender-dysphoric/gender-incongruent persons seek and/or are referred to endocrinologists to develop the physi","image":"https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/jcem/Issue/102/11/3/m_cover.jpeg?Expires=1722615010&Signature=1k7bdN9ysp1LbHC-WdBQCSB9w8IJRIodgVWnNGaQKp-lm55NjCUmXT-ebEQE8BKCj0sUH8aEsUBVOtouS8VC7sh7HG57Tbp2yIbki2yS~-gqF-1v4W3Z47djZeV7~dq0rcxoC0KNK8WANS~xjFZiksUkRE3VNS3is720fTWOzh-7TaPOTYIJAR1jIBaA6FOvhheUPLurGmssKN5Sq3FKiA2m689PMATqMf8vcthKlm6VYS5I3Be~7TQavbvcGzgTAWVqvhX1ikdnhh~ceGtNIDGAJZiLJCIaXjcSc4~HVWKslGdO6tJg71lTWN-8vZ4d~RhJV7hLXDiqXH5rw~06eA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA","mainEntityOfPage":{"@type":false,"@id":false},"datePublished":"2017-09-13","dateModified":false,"isAccessibleForFree":false,"isPartOf":{"@id":"https://academic.oup.com/jcem/jcem/issue/102/11","@type":"PublicationIssue","issueNumber":"11","datePublished":"2017-11-01","isPartOf":{"@id":"https://academic.oup.com/jcem/jcem","@type":"Periodical","name":"The Journal of Clinical Endocrinology & Metabolism","issn":["1945-7197"]}},"discussionUrl":false,"license":false,"author":[{"name":"Hembree, Wylie C","affiliation":"1 New York Presbyterian Hospital, Columbia University Medical Center, New York, New York 10032 (Retired)","@type":"Person"},{"name":"Cohen-Kettenis, Peggy T","affiliation":"2 VU University Medical Center, 1007 MB Amsterdam, Netherlands (Retired)","@type":"Person"},{"name":"Gooren, Louis","affiliation":"3 VU University Medical Center, 1007 MB Amsterdam, Netherlands (Retired)","@type":"Person"},{"name":"Hannema, Sabine E","affiliation":"4 Leiden University Medical Center, 2300 RC Leiden, Netherlands","@type":"Person"},{"name":"Meyer, Walter J","affiliation":"5 University of Texas Medical Branch, Galveston, Texas 77555","@type":"Person"},{"name":"Murad, M Hassan","affiliation":"6 Mayo Clinic Evidence-Based Practice Center, Rochester, Minnesota 55905","@type":"Person"},{"name":"Rosenthal, Stephen M","affiliation":"7 University of California San Francisco, Benioff Children’s Hospital, San Francisco, California 94143","@type":"Person"},{"name":"Safer, Joshua D","affiliation":"8 Boston University School of Medicine, Boston, Massachusetts 02118","@type":"Person"},{"name":"Tangpricha, Vin","affiliation":"9 Emory University School of Medicine and the Atlanta VA Medical Center, Atlanta, Georgia 30322","@type":"Person"},{"name":"T’Sjoen, Guy G","affiliation":"10 Ghent University Hospital, 9000 Ghent, Belgium","@type":"Person"}],"publisher":"Oxford University Press","editor":{"@type":false,"name":false,"description":false,"sameAs":false,"image":{"@type":false,"url":false},"givenName":false,"familyName":false,"alternateName":false,"publishingPrinciples":false},"@context":"https://schema.org","@id":"https://academic.oup.com/jcem/article/102/11/3869/4157558","name":"Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society* Clinical Practice Guideline","url":"https://dx.doi.org/10.1210/jc.2017-01658","inLanguage":"en","copyrightHolder":"Oxford University Press","copyrightYear":"2022","sameAs":"","pageStart":"3869","pageEnd":"3903","siteName":"OUP Academic","thumbnailURL":"https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/jcem/Issue/102/11/3/m_cover.jpeg?Expires=1722615010&Signature=1k7bdN9ysp1LbHC-WdBQCSB9w8IJRIodgVWnNGaQKp-lm55NjCUmXT-ebEQE8BKCj0sUH8aEsUBVOtouS8VC7sh7HG57Tbp2yIbki2yS~-gqF-1v4W3Z47djZeV7~dq0rcxoC0KNK8WANS~xjFZiksUkRE3VNS3is720fTWOzh-7TaPOTYIJAR1jIBaA6FOvhheUPLurGmssKN5Sq3FKiA2m689PMATqMf8vcthKlm6VYS5I3Be~7TQavbvcGzgTAWVqvhX1ikdnhh~ceGtNIDGAJZiLJCIaXjcSc4~HVWKslGdO6tJg71lTWN-8vZ4d~RhJV7hLXDiqXH5rw~06eA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA","image:alt":"Issue Cover"},"twitterObj":false,"status":200,"metadata":{"author":false,"title":"Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society* Clinical Practice Guideline | The Journal of Clinical Endocrinology & Metabolism | Oxford Academic","description":"Gender affirmation is multidisciplinary treatment. Gender-dysphoric/gender-incongruent persons seek and/or are referred to endocrinologists to develop the physi","canonical":"https://academic.oup.com/jcem/article/102/11/3869/4157558","keywords":[],"image":"//oup.silverchair-cdn.com/UI/app/svg/umbrella/oxford-academic-logo.svg","firstParagraph":"Cosponsoring Associations: American Association of Clinical Endocrinologists, American Society of Andrology, European Society for Pediatric Endocrinology, European Society of Endocrinology, Pediatric Endocrine Society, and World Professional Association for Transgender Health."},"dublinCore":{},"opengraph":{"title":"Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society* Clinical Practice Guideline","description":"Gender affirmation is multidisciplinary treatment. Gender-dysphoric/gender-incongruent persons seek and/or are referred to endocrinologists to develop the physi","url":"https://academic.oup.com/jcem/article/102/11/3869/4157558","site_name":"OUP Academic","locale":false,"type":"article","typeObject":{"published_time":false,"modified_time":false,"author":false,"publisher":false,"section":false,"tag":[]},"image":"https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/jcem/Issue/102/11/3/m_cover.jpeg?Expires=1722615010&Signature=1k7bdN9ysp1LbHC-WdBQCSB9w8IJRIodgVWnNGaQKp-lm55NjCUmXT-ebEQE8BKCj0sUH8aEsUBVOtouS8VC7sh7HG57Tbp2yIbki2yS~-gqF-1v4W3Z47djZeV7~dq0rcxoC0KNK8WANS~xjFZiksUkRE3VNS3is720fTWOzh-7TaPOTYIJAR1jIBaA6FOvhheUPLurGmssKN5Sq3FKiA2m689PMATqMf8vcthKlm6VYS5I3Be~7TQavbvcGzgTAWVqvhX1ikdnhh~ceGtNIDGAJZiLJCIaXjcSc4~HVWKslGdO6tJg71lTWN-8vZ4d~RhJV7hLXDiqXH5rw~06eA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA","updated_time":"2017-09-13","image:url":"https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/jcem/Issue/102/11/3/m_cover.jpeg?Expires=1722615010&Signature=1k7bdN9ysp1LbHC-WdBQCSB9w8IJRIodgVWnNGaQKp-lm55NjCUmXT-ebEQE8BKCj0sUH8aEsUBVOtouS8VC7sh7HG57Tbp2yIbki2yS~-gqF-1v4W3Z47djZeV7~dq0rcxoC0KNK8WANS~xjFZiksUkRE3VNS3is720fTWOzh-7TaPOTYIJAR1jIBaA6FOvhheUPLurGmssKN5Sq3FKiA2m689PMATqMf8vcthKlm6VYS5I3Be~7TQavbvcGzgTAWVqvhX1ikdnhh~ceGtNIDGAJZiLJCIaXjcSc4~HVWKslGdO6tJg71lTWN-8vZ4d~RhJV7hLXDiqXH5rw~06eA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA","image:secure_url":"https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/jcem/Issue/102/11/3/m_cover.jpeg?Expires=1722615010&Signature=1k7bdN9ysp1LbHC-WdBQCSB9w8IJRIodgVWnNGaQKp-lm55NjCUmXT-ebEQE8BKCj0sUH8aEsUBVOtouS8VC7sh7HG57Tbp2yIbki2yS~-gqF-1v4W3Z47djZeV7~dq0rcxoC0KNK8WANS~xjFZiksUkRE3VNS3is720fTWOzh-7TaPOTYIJAR1jIBaA6FOvhheUPLurGmssKN5Sq3FKiA2m689PMATqMf8vcthKlm6VYS5I3Be~7TQavbvcGzgTAWVqvhX1ikdnhh~ceGtNIDGAJZiLJCIaXjcSc4~HVWKslGdO6tJg71lTWN-8vZ4d~RhJV7hLXDiqXH5rw~06eA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA","image:alt":"Issue Cover"},"twitter":{"site":false,"description":false,"card":false,"creator":false,"title":false,"image":false},"archivedData":{"link":false,"wayback":false}},"localImage":"/assets/images/contexter/httpsacademicoupcomHTTPHandlersSigmaLoginHandlerashxerrorlogin_requiredandstate997b234e-ba15-464c-af78-0244a94fea51redirecturlpercent3Dhttpszazjzjacademiczwoupzwcomzjjcemzjarticlezj102zj11zj3869zj4157558//Users/zuckerscharffa/Dev/context-center/_contexterCache/images/httpsacademicoupcomHTTPHandlersSigmaLoginHandlerashxerrorlogin_requiredandstate997b234e-ba15-464c-af78-0244a94fea51redirecturlpercent3Dhttpszazjzjacademiczwoupzwcomzjjcemzjarticlezj102zj11zj3869zj4157558/m_cover.jpeg"}